<SEC-DOCUMENT>0001664710-26-000018.txt : 20260304
<SEC-HEADER>0001664710-26-000018.hdr.sgml : 20260304
<ACCEPTANCE-DATETIME>20260304160404
ACCESSION NUMBER:		0001664710-26-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260304
DATE AS OF CHANGE:		20260304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Keros Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001664710
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811173868
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39264
		FILM NUMBER:		26721108

	BUSINESS ADDRESS:	
		STREET 1:		1050 WALTHAM STREET, SUITE 302
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-314-6297

	MAIL ADDRESS:	
		STREET 1:		1050 WALTHAM STREET, SUITE 302
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>kros-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f,d:2030eac40e414171a9c72c0ab0189734-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:kros="http://www.kerostx.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kros-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001664710</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-37">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-38">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-39">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-99">385</ix:nonNumeric><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-100">386</ix:nonNumeric><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-101">207</ix:nonNumeric><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-102">203</ix:nonNumeric><ix:nonNumeric contextRef="c-17" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-103">269</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-104">207</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" scale="0" id="f-394">1</ix:nonFraction><ix:nonNumeric contextRef="c-139" name="kros:LesseeOperatingLeasePeriodForImprovement" format="ixt-sec:durwordsen" id="f-780">8 years, 4 months</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="f-846">1</ix:nonFraction><ix:nonNumeric contextRef="c-185" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-852">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-186" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-853">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kros-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="financialinstitution"><xbrli:measure>kros:financialInstitution</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>kros:segment</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>kros:product</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>kros:vote</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="performanceobligation"><xbrli:measure>kros:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:KeithRegnanteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:KeithRegnanteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:LorenaLernerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:LorenaLernerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:NimaFarzanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:NimaFarzanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JuliusKnowlesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JuliusKnowlesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:AlpnaSethMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:AlpnaSethMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JeanJacquesBienaimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JeanJacquesBienaimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kros:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kros:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:TheGeneralHospitalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:TheGeneralHospitalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-05</xbrli:startDate><xbrli:endDate>2016-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DividendsAxis">kros:O2025Q1DividendsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-15</xbrli:startDate><xbrli:endDate>2025-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-20</xbrli:startDate><xbrli:endDate>2025-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:UnvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kros:TermLoanCreditAgreementThreeAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:EmployeeStockPurchasePlanTwentyTwentyMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:EmployeeStockPurchasePlanTwentyTwentyMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-15</xbrli:startDate><xbrli:endDate>2016-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:PhaseAPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:AccentTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-12</xbrli:startDate><xbrli:endDate>2021-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ManufacturingTechnologyTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:TechTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ManufacturingTechnologyTransferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:TechTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ClinicalProductSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ClinicalProductSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:SupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseAndKnowHowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:RinvaterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:RinvaterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:ElriterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:ElriterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:CiboterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:CiboterceptProgramExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:PreclinicalDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:PreclinicalDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:OtherExternalCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:OtherExternalCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001664710</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2030eac40e414171a9c72c0ab0189734_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">________________________________________</span></div><div style="margin-bottom:9.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">________________________________________</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2025</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39264</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">________________________________________</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">KEROS THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">________________________________________</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.568%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">81-1173868</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1050 Waltham Street,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 302</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02421</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">Lexington,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-14">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tel: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">314-6297</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">KROS</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">Preferred Share Purchase Rights</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:NoTradingSymbolFlag" format="ixt:fixed-true" id="f-21">N/A</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;None</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-23">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-24">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-25">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-26">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.555%"><tr><td style="width:1.0%"/><td style="width:36.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.902%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-27">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-28">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for&#160;complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-30">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-31">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrects are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#9744;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#9744;&#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-32">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30, 2025, the last business day of the registrant's most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-33">453.0</ix:nonFraction>&#160;million, based on a closing price of $13.35 per share of the registrant&#8217;s common stock as reported on the Nasdaq Global Market. The calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February 27, 2026, there were <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-34">19,717,533</ix:nonFraction> outstanding shares of the registrant's common stock, par value $0.0001 per share.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-35" escape="true"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2026 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2025.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_7"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.854%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART I. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_64">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_64">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 1B. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_88">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_88">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 1C.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_91">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_91">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_94">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_94">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_97">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_100">84</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART II. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_106">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_106">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_109">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_109">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_112">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_112">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_142">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_142">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_193">Financial Statements and Supplementary Data Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_145">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_148">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_148">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 9A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_151">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_151">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_154">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_154">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_160">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_154">99</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART III. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 10. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_166">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_166">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_169">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_169">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_172">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_172">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_175">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_175">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_178">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_178">100</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART IV. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_184">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_184">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_187">Form 10</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_187">-</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_187">K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_187">104</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_190">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_193">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_193">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_10"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including statements about:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the timing of initiation of a Phase 2 clinical trial of our lead product candidate, rinvatercept (KER-065), in patients with Duchenne muscular dystrophy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the timing of engagement with regulators on the planned Phase 2 clinical trial of rinvatercept in patients with amyotrophic lateral sclerosis; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">plans of Takeda Pharmaceuticals U.S.A., Inc., or Takeda, to advance elritercept (KER-050) into a Phase 3 clinical trial in patients with myelodysplastic syndromes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">risks associated with public health crises, which may adversely impact our business, preclinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to receive the required regulatory approvals and clearances to successfully market and sell our products, if approved in the United States and certain other countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully advance our pipeline of additional product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to develop sales and marketing capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the rate and degree of market acceptance of any products we are able to commercialize;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the effects of increased competition as well as innovations by new and existing competitors in our market;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to obtain funding for our operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the sufficiency of our existing capital resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to establish and maintain collaborations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to effectively manage our anticipated growth;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to maintain, protect and enhance our intellectual property rights and proprietary technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">costs associated with defending intellectual property infringement, product liability and other claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulatory developments in the United States, Australia, New Zealand, Europe, the United Kingdom and other foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to attract and retain qualified employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and stock performance; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the future trading prices of our common stock and the impact of securities analysts&#8217; reports on these prices.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">You should read the section titled &#8220;Risk Factors&#8221; set forth in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, &#8220;Keros,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Keros Therapeutics, Inc. and its subsidiaries.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING TRADEMARKS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_13"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i2030eac40e414171a9c72c0ab0189734_16"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div id="i2030eac40e414171a9c72c0ab0189734_19"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-&#223;, family of proteins. We are a leader in understanding the role of the TGF-&#223; family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of neuromuscular diseases. Our most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rinvatercept is designed to bind to and inhibit TGF-&#223; ligands, including myostatin (GDF8) and activin A, which are negative regulators of muscle and bone mass and strength. Through inhibition of these TGF-&#223; ligands, we believe that rinvatercept has the potential to increase skeletal muscle regeneration, increase muscle size and strength, reduce body fat, reduce fibrosis of the skeletal muscle and increase bone strength. We are developing rinvatercept for the treatment of Duchenne muscular dystrophy, or DMD and for the treatment of amyotrophic lateral sclerosis, or ALS.  In March 2025, we announced initial topline results from the Phase 1 clinical trial of rinvatercept in healthy adult volunteers. We expect to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026. We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-&#223; receptor known as activin receptor type IIA, or ActRIIA, that is fused to the portion of the human antibody known as the Fc domain. Elritercept is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-&#223; family of proteins to promote hematopoiesis. We believe elritercept has the potential to provide benefit to patients suffering from red blood cell and platelet differentiation and maturation defects occurring across the spectrum from early through terminal stages of hematopoiesis, and consequently may be effective for many patients that have limited treatment options or are refractory to available therapies. In July 2025, we announced that the first patient was dosed in the placebo-controlled Phase 3 RENEW clinical trial in patients with very low-, low-, or intermediate-risk MDS, which we refer to as lower-risk MDS. The dosing of the first patient triggered a $10 million milestone payment to us under the license agreement with Takeda.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our strategy focuses on the role of members of the TGF-&#223; family of proteins in the development of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. Aged and damaged cells are routinely replaced by new cells in normally functioning organs. These new cells are derived from stem cells that have the ability to differentiate into cells with specialized functions when appropriate signals are provided to maintain the homeostatic state of the tissue. Members of the TGF-&#223; family of proteins, including activins and bone morphogenic proteins (BMPs), provide the necessary signals for this process of self-renewal and repair.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We seek to address the limitations of current therapeutic approaches to treating diseases whose manifestations are linked to dysfunction of TGF-&#223; signaling pathways by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">leveraging our comprehensive insights into the TGF-&#223; signaling pathways to discover therapeutics to treat disorders that are linked to dysfunctional TGF-&#223; signaling;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">expanding our library of proprietary molecules that are engineered to induce desired biological effects, such as increased muscle mass and strength, increased muscle regeneration, improved muscle quality and reduced tissue fat, improved bone mineral density, reduced inflammation, reduced fibrosis and modulated blood cell production;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">engineering proprietary molecules to selectively target specific proteins in the TGF-&#223; signaling pathways to provide therapeutic benefit while potentially minimizing safety risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">developing product candidates for the treatment of diseases where targeting the TGF-&#223; signaling pathways has clinical validation or biological rationale to improve our probability of success in the clinic; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">targeting the TGF-&#223; family of proteins, which are highly conserved throughout evolution, permitting the use of animal models to potentially predict with high confidence the therapeutic benefit in patients.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are led by a highly experienced management team and scientific advisory board who have significant experience and expertise researching and developing therapeutics in targeting the TGF-&#223; family of proteins. Our team has collectively worked on marketed therapeutics such as Reblozyl and Winrevair, and led drug discovery at companies including Acceleron Pharma Inc. (which was acquired by Merck &amp; Co. Inc. in November 2021) and Wyeth Pharmaceuticals Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_22"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth our product candidates and their current development stages:</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g1.jpg" alt="pipeline.jpg" style="height:227px;margin-bottom:5pt;vertical-align:text-bottom;width:702px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%">[NTD:  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_25"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our mission is to deliver significant clinical benefit to patients suffering from </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">disorders that are linked to dysfunctional signaling of the TGF-&#223; family of proteins</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. With a focus on developing differentiated product candidates, we aim to target the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TGF-&#223; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">pathways critical for the growth, repair and maintenance of a number of tissue and organ systems. The key elements of our strategy include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Rapidly advance the clinical development of rinvatercept</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In March 2025, we announced initial topline results from the Phase 1 clinical trial of rinvatercept in healthy adult volunteers. We expect to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026. We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Pursue development and, if approved, commercialization of our product candidates in indications and regions where we believe we can maximize their value independently or through strategic collaborations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. We plan to independently advance our product candidates in indications and regions that we believe have clearly defined regulatory paths and commercialization strategies. We intend to also opportunistically evaluate strategic collaborations to maximize the potential commercial value of our product candidates and discovery programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Leverage our proprietary discovery approach and knowledge base to develop new therapeutics</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Our discovery efforts are focused on expanding our pipeline of wholly-owned assets for the treatment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">disorders that are linked to dysfunctional </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TGF-&#223; </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">signaling</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Accordingly, we intend to identify and develop product candidates to treat diseases where targeting the TGF-&#223; signaling pathways has clinical validation or biological rationale, including neuromuscular and neurodegenerative disorders, rare bone and fibrosis diseases, and obesity and frailty indications.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Maintain a dynamic, data-driven operating model</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. We manage our clinical programs dynamically, utilizing a data-driven approach to determine which product candidates and discovery-stage assets to develop, which includes considering the potential product profile and the most recent data. Our extensive knowledge of our assets and the process of drug development informs our decision-making process regarding when to advance the science and clinical path to pursue demonstrating proof-of-concept, balanced with the imperative of maintaining an efficient timeframe and cost-effective budget. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_31"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Neuromuscular Franchise</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rinvatercept</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from ActRIIA and ActRIIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of DMD and for the treatment of ALS. We expect to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026. We also plan to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuromuscular Disease</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Neuromuscular disease is a broad term that encompasses many diseases that either directly (via intrinsic muscle pathology) or indirectly (via nerve pathology) impair the functioning of muscles. Symptoms of neuromuscular disease include increasing generalized weakness and fatigue, dysphagia, dyspnea on exertion and at rest, sleepiness, morning headache, difficulties with concentration and mood changes. Most neuromuscular diseases are characterized by progressive muscular impairment </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">leading to loss of muscle function and can lead to loss of ambulation, being wheelchair-bound, swallowing difficulties, respiratory muscle weakness and death. Neuromuscular disorders can progress rapidly or slowly. Decline in muscle mass can also be associated with secondary osteoporosis and obesity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">One example of a rapidly progressive condition is Duchenne muscular dystrophy, or DMD, which is the most common form of muscular dystrophy and results in muscle degeneration and premature death. DMD results from the lack of functional dystrophin protein that helps promote myofiber stability, caused by a gene mutation. The lack of dystrophin, an important structural component of muscle cells, causes muscle cells to have increased susceptibility to damage and to progressively die. Additionally, the absence of dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and the replacement of muscle with fibrotic and fatty tissue. The replacement of muscle fibers with fatty and fibrotic tissue leads to progressive loss of muscle strength and function, leading to immobility and respiratory and cardiac complications. In DMD patients, heart muscle cells progressively die and are replaced with scar tissue. This cardiomyopathy eventually leads to heart failure, which is currently the leading cause of death among those with DMD. The National Organization for Rare Disorders estimates that approximately one in every 3,500 male births is affected by DMD worldwide. The symptoms of DMD typically manifest in the first few years of life. Patients experience progressive muscle weakness and muscle wasting and have difficulty standing up, climbing stairs, running, breathing and performing daily functions. As the disease progresses, the severity of damage to skeletal and cardiac muscles results in most patients experiencing total loss of ambulation in the pre-teenage or early teenage years. Progressive loss of upper extremity function is often observed in the mid-to-late teens followed by paralysis, respiratory and/or cardiac failure, resulting in early mortality in the third or fourth decade of life.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Reduced muscle strength, loss of ambulation and use of glucocorticoids in DMD contribute to the development of secondary osteoporosis. The most significant clinical complications are bone fragility and higher risk of bone fracture. Additionally, fracture can lead to premature loss of ambulation, which can have a detrimental effect on independent mobility and quality of life.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Decreased mobility, along with the use of glucocorticoids, is associated with increased risk of obesity and the associated negative health consequences, including type 2 diabetes and cardiovascular disease, in DMD patients.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Current Treatment Options for DMD</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Glucocorticoids have been the standard of care in DMD and help preserve muscle strength and function, leading to extension of independent ambulation for several years. While glucocorticoids help to maintain muscle function in DMD patients, long-term treatment with them can have significant negative side effects, including fluid retention, hyperglycemia, severe weight gain with fat deposits in the abdomen, face and neck, bone fragility, cataracts, high blood pressure and mood effects, leading many patients to forego long-term treatment. Additionally, glucocorticoid treatment is associated with lean mass loss, an effect mediated by myostatin.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are four therapies approved by U.S. Food and Drug Administration, or the FDA, related to phosphorodiamidate morpholino oligomers-based oligonucleotide skipping, each addressing a specific exon skipping mutation: casimersen (exon 45), eteplirsen (exon 51), golodirsen (exon 53) and viltolarsen (exon 53). These products have all been approved using the accelerated approval pathway on the basis of dystrophin production. However, the FDA-approved labels for all four drugs state that continued approval may be contingent upon the verification of a clinical benefit in confirmatory clinical trials. These therapies require weekly intravenous infusions. Additionally, in June 2023, the FDA accelerated approval of ELEVIDYS, an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients aged four through five years with DMD with a confirmed mutation in the DMD gene. In June 2024, the FDA granted ELEVIDYS full approval for the treatment of ambulatory individuals aged four years and older, and accelerated approval for the treatment of non-ambulatory individuals aged four years and older. This product was approved using the accelerated approval pathway on the basis of expression of ELEVIDYS micro-dystrophin in patients treated with ELEVIDYS. Following reports of fatal liver injury, the FDA removed the non-ambulatory indication from the official label in November 2025.   </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the European Union, neither ELEVIDYS nor any exon-skipping therapies currently hold marketing authorization for the treatment of Duchenne muscular dystrophy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2024, Italfarmaco S.p.A. announced that the FDA approved Duvyzat (givinostat), a histone deacetylase, or HDAC, inhibitor for the treatment of DMD in patients aged six years and older. HDAC inhibitors modulate the deregulated activity of HDACs in dystrophic muscle. However, Duvyzat can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Low platelet counts resulted in Duvyzat dose reduction in 28% of DMD patients in a randomized, double-blind, placebo-controlled 18-month trial.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Based on our preclinical data, we believe that rinvatercept has the potential to treat multiple pathophysiologies of DMD by improving muscle and bone strength and reducing fat mass and cardiac fibrosis.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyotrophic Lateral Sclerosis</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amyotrophic lateral sclerosis, or ALS, is a fatal, progressive, neurodegenerative disease that specifically targets motor neurons in the spinal cord and brain.These are specialized cells that are responsible for controlling voluntary muscle movement. Each muscle is made up of multiple motor units, which consists of a motor neuron that is connected and activates each muscle fiber via a neuromuscular junction. In ALS, the loss of motor neurons and neuromuscular junctions leads to atrophy and a subsequent loss of connected muscle fibers. However, healthy, connected adjacent muscle fibers and motor units remain.</span></div><div style="margin-bottom:9.5pt"><img src="kros-20251231_g2.jpg" alt="ALS - 1.jpg" style="height:251px;margin-bottom:5pt;vertical-align:text-bottom;width:702px" id="i-2"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Early symptoms of ALS include muscle twitching and weakness in a limb. As the disease progresses, patients with ALS lose the ability to move, speak, eat and breathe. This progressive loss of motor neurons leads to muscle weakness, loss of function and eventually paralysis. The majority of patients with ALS die from respiratory failure within three to five years of first symptom onset, and the patient&#8217;s quality of life is typically poor.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the United States alone, ALS has a prevalence of approximately 9.9 per 100,000 people, with approximately 33,000 people estimated to have been living with ALS in 2022. The biological mechanisms that cause ALS are only partially understood. While 10% of ALS cases are familial, linked to mutations in certain genes, the vast majority of ALS cases (approximately 90%) are sporadic with no known family history.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Current Treatment Options for ALS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is currently no cure for ALS, and currently approved therapies offer limited benefits, aiming to provide temporary relief of symptoms without treating underlying disease progression for the majority of patients with ALS. There are three therapies approved by FDA to treat ALS and its symptoms: riluzole, an anti-glutamatergic agent; edaravone, a free-radical scavenger; and tofersen, an antisense oligonucleotide treatment for ALS associated with superoxide dismutase 1 (SOD1) gene mutation. One additional therapeutic option, sodium phenylbutyrate and taurursodiol, was approved under an accelerated pathway by the FDA but subsequently withdrawn from the market following negative results from a confirmatory Phase 3 trial. These treatments have demonstrated only modest clinical efficacy. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Based on our preclinical data, we believe that rinvatercept has the potential to maximize the functional strength of healthy, connected muscle fibers, allowing them to compensate for atrophied fibers and motor units. This has the potential to lead to overall preservation of muscle strength and function and improved quality of life for patients with ALS.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g3.jpg" alt="ALS - 2.jpg" style="height:251px;margin-bottom:5pt;vertical-align:text-bottom;width:345px" id="i-3"/></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 Clinical Trial in Patients with DMD</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect to commence an open-label, multi-cohort Phase 2 basket clinical trial to evaluate rinvatercept in patients with DMD in the second quarter of 2026. The primary objective of this trial is to assess the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory patients with DMD. The key secondary objectives of this trial are to evaluate pharmacokinetics, anti-drug antibodies, body composition and comprehensive functional improvements (skeletal muscle, motor, cardiac and pulmonary), plus exploratory serum biomarkers.  The trial design is summarized in the figure below.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial Design</span></div><div style="margin-bottom:9.5pt"><img src="kros-20251231_g4.jpg" alt="dmd trial design.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:702px" id="i-4"/></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Rinvatercept is administered to patients subcutaneously once every four weeks, starting at a dose of 0.5 mg/kg. Based on individual titration rules, the dose may be escalated in 0.5 mg/kg increments after two doses, up to a maximum dose of 2.0 mg/kg.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Phase 1 Clinical Trial in Healthy Adult Volunteers</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We completed a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of rinvatercept in healthy adult male volunteers. The primary objectives of this trial were to assess safety, tolerability and pharmacokinetics of rinvatercept. Exploratory endpoints included assessments of the pharmacodynamic effect on bone, adipose, muscle, cardiac tissue and fibrosis. To aid in the assessment of adipose tissue, volunteers were required to have a BMI &#8805; 27 to &#8804; 35 kg/m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to be enrolled in Part 2 of this trial. The trial design is summarized in the figure below.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Phase 1 Clinical Trial Design</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g5.jpg" alt="Picture3.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:624px" id="i-5"/></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rinvatercept was generally well-tolerated, with no major safety signals observed in the trial. No serious adverse events or dose-limiting toxicities were reported. Additionally, we observed evidence for activin inhibition across tissues of interest, as rinvatercept elicited:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Increased lean muscle mass and thigh muscle volume;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Increases in bone specific alkaline phosphate, a biomarker of bone formation, demonstrating mobilization of osteoblasts;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Decreases in C-Terminal Telopeptide, a biomarker that reflects the rate of bone resorption;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Increases in whole body bone mineral density that was durable and sustained, suggesting a balance of osteoblast and osteoclast activity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Increases in adiponectin, a biomarker of fat mobilization, and decreases in leptin, a biomarker of fat mass; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Corresponding decreases in fat mass, both whole body and visceral fat mass.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Data</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have generated preclinical data that we believe demonstrated proof-of-mechanism of rinvatercept for the treatment of DMD and for the treatment of ALS. Specifically, in preclinical studies:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Rinvatercept showed high affinity for and potent inhibition of ligands involved in the regulation of muscle and bone homeostasis;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">RKER-065, the research form of rinvatercept, increased utrophin expression and muscle strength in a mouse model of DMD;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Co-treatment with prednisolone and RKER-065 increased both muscle mass and strength and trabecular bone and strength;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Co-treatment with an HDAC inhibitor and RKER-065 increased muscle mass and strength and reduced fibrosis;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">RKER-065 increased satellite cells in skeletal muscle; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Co-treatment with phosphorodiamidate morpholino oligomer, or PMO, therapy and RKER-065 improved grip strength and the efficiency of exon skipping; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">RKER-065 treatment reduced muscle wasting and preserved muscle function in a mouse model of ALS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KER-065 targeted ligands that signal through ActRIIA and ActRIIB to increase skeletal muscle and bone in preclinical studies</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">KER-065 is a modified ActRII ligand trap that contains sequences from both wild-type ActRIIB and wild-type ActRIIA. In preclinical studies, KER-065 bound to and inhibited multiple ligands that signal through these cell surface receptors, including activin A and myostatin (GDF8). These ligands are key negative regulators of muscle and bone growth. Consequently, we believe KER-065 has the potential to increase skeletal muscle and bone mass, increase fat metabolism and reduce fibrosis.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment with RKER-065 increased utrophin expression and muscle strength in a mouse model of DMD</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In preclinical studies conducted in the X-linked muscular dystrophy, or MDX, mouse model of DMD, twice weekly, intraperitoneal 10 mg/kg dosing of RKER-065 increased expression of utrophin in muscle fibers, potentially contributing to the observed increased strength.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Evoked Force Maximum Gastrocnemius</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g6.jpg" alt="Picture7.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:507px" id="i-6"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">***P value &lt;0.001</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-treatment with prednisolone and RKER-065 increased both muscle mass and strength and trabecular bone and strength</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">MDX mice were treated with vehicle (Veh) or 2-prednisolone (Pred), or co-treated with 10 mg/kg of prednisolone and RKER-065 twice weekly (Pred+065). Prednisolone-treated MDX mice had less muscle mass and strength than vehicle-treated mice, while co-treatment with prednisolone and RKER-065 increased both muscle mass and strength and trabecular bone and strength.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Lean Mass (Left) and Grip Strength (Right)</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g7.jpg" alt="Picture11.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:390px" id="i-7"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*P value &#8804;0.05; **P value &lt;0.01; ***P value &lt;0.001</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Bone Volume Fraction (BV/TV; Left) and Polar Mass Moment of Inertia (MMI; Right)</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g8.jpg" alt="Picture12.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:320px" id="i-8"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">**P value &lt;0.01; ****P value &lt; 0.0001</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment with RKER-065 increased satellite cells in skeletal muscle</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In young boys with DMD, muscle undergoes continuous rounds of degeneration and regeneration, but eventually the ability of the muscle to regenerate declines due to a decline in muscle progenitor cells known as satellite cells. To evaluate the activity of RKER-065 on satellite cells, wild-type mice were treated with a single 10 mg/kg dose of RKER-065 or vehicle. Muscles were dissected and processed to obtain single cell suspensions on day 1, day 2 and day 4. Treatment with RKER-065 increased the pool of satellite cells in wild-type mice, and observed relative expression of markers of satellite cell differentiation demonstrated the commitment and differentiation of satellite cells to muscle. </span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Satellite Cell Population</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g9.jpg" alt="Picture15.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:376px" id="i-9"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">****P value &lt; 0.0001; ns = not significant</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-treatment with PMO therapy and RKER-065 improved efficiency of exon skipping</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">MDX mice were treated with vehicle, 25 mg/kg of PMO therapy, or co-treated with 10 mg/kg of RKER-065 twice weekly and 25 mg/kg of PMO therapy once weekly. Co-treatment with PMO therapy and RKER-065 improved grip strength and the efficiency of PMO-driven exon skipping.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Grip Strength Measurement</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g10.jpg" alt="Picture18.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:453px" id="i-10"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">**P value &lt;0.01; ***P value &lt;0.001; ****P value &lt;0.0001; ns = not significant</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g11.jpg" alt="Picture16.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:607px" id="i-11"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">***P value &lt;0.001</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-treatment with an HDAC inhibitor and RKER-065 increased both muscle mass and strength and reduced fibrosis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">MDX mice were treated with vehicle or an HDAC inhibitor, or HDACi, or co-treated with 10 mg/kg HDACi daily and 3 mg/kg RKER-065 twice weekly. HDACi-treated MDX mice had less muscle mass and strength than vehicle-treated mice, while co-treatment with HDACi and RKER-065 increased both muscle mass and strength and reduced markers of fibrosis in the muscle tissue.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g12.jpg" alt="preclinical.jpg" style="height:172px;margin-bottom:5pt;vertical-align:text-bottom;width:702px" id="i-12"/></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">**P value &lt;0.01; **** P value &lt; 0.0001</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RKER-065 treatment reduced muscle wasting and preserved muscle function in a mouse model of ALS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a mouse model of ALS, ALS mice were treated with vehicle or 10 mg/kg RKER-065 twice weekly. RKER-065 treatment preserved both muscle mass and strength and neuromuscular transmission.</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g13.jpg" alt="ALS3.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:497px" id="i-13"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*P value &#8804;0.05; **P value &lt;0.01; ****P value &lt;0.0001</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_34"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Hematology Franchise</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept is designed to target TGF-&#223; signaling pathways to address diseases that arise from ineffective hematopoiesis.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hematopoiesis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The primary cellular components of blood are red blood cells, white blood cells and platelets. The function of red blood cells is to distribute oxygen to tissues throughout the body and to carry waste carbon dioxide back to the lungs. White blood cells are responsible for the immune response through coordinated surveillance and targeting of pathogens, infected or aberrant cells and cell debris. Platelets are a key component of the coagulation system and are responsible for stopping bleeding by forming a blood clot.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Hematopoiesis is the production of red blood cells, white blood cells and platelets from common progenitor stem cells, or progenitor cells, in the bone marrow. This process begins when a hematopoietic progenitor cell becomes committed to a specific cellular lineage. These cells progress through a series of intermediate stages before becoming a mature cell with a specialized function. At any given time, pools of each progenitor cell are maintained and primed to rapidly respond to a reduction of red blood cells, white blood cells and platelets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TGF-&#223; signaling pathways involving activins prevent differentiation in order to maintain progenitor cells in a quiescent state while others involving BMPs promote differentiation of progenitor cells. Homeostasis of this process is essential to ensure all cell types are properly replenished in the blood.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In many hematological disorders, there is abnormal proliferation and differentiation of the progenitor cells for red blood cells, platelets and neutrophils. This failure to produce fully mature cells is termed ineffective hematopoiesis, and may be due to single or multiple defects that can lead to hyperproliferation or a shortage of progenitor cells. These changes have clinical consequences: a lack of red blood cells leads to anemia, a lack of platelets hampers clotting, resulting in increased incidence of bleeding events, and a lack of neutrophils increases susceptibility to infection. The failure of progenitor cells to differentiate can also lead to a build-up of these cells, resulting in bone marrow failure and fibrotic disease.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elritercept:&#160;For the Treatment of Ineffective Hematopoiesis to Address Cytopenias</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept, our most advanced product candidate, is being developed for the treatment of cytopenias that occur due to ineffective hematopoiesis, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Elritercept is designed to benefit patients suffering from defects in red blood cell and platelet differentiation and maturation across the spectrum from early through terminal stages of hematopoiesis. Consequently, elritercept may be effective for many patients that have limited treatment options or are refractory to available therapies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myelodysplastic Syndromes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">MDS is a collection of bone marrow disorders characterized by ineffective hematopoiesis, often with a dramatic expansion of progenitor cells that are unable to mature into functioning blood cells. In the United States, there are 60,000 to 170,000 patients with MDS and 15,000 to 20,000 new cases of MDS reported each year. MDS predominantly affects older adults, with approximately 75% of patients aged 60 years or older at diagnosis. Median survival ranges from approximately nine years for very low-risk patients to less than a year for high-risk patients.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cytopenias in MDS are caused by defects occurring across the various stages of hematopoiesis, from the self-renewal of progenitor cells to differentiation in early through terminal stages. Anemia is the most frequent consequence of ineffective hematopoiesis in patients with MDS due to low red blood cell production, and impacts 90% of MDS patients, with approximately 40% becoming transfusion dependent. Another consequence is thrombocytopenia, a deficiency of platelets in the blood, which is impaired blood clotting that can cause bleeding. The prevalence of thrombocytopenia in patients with MDS has been reported at 40% to 65%. A deficiency of neutrophils in the blood, or neutropenia, also increases the risk of serious infections in patients with MDS and has been reported to affect approximately 20% of patients with MDS.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To guide decisions on risk stratification and the treatment of patients with MDS, clinicians typically use the International Prognostic Scoring System-Revised, or the IPSS-R. The IPSS-R incorporates information on bone marrow blast percentage, karyotype and presence and severity of cytopenias in order to classify patients with MDS into groups based on the risk of progression to acute myeloid leukemia, ranging from very low-risk to high-risk. Patients are further classified into high transfusion burden and low transfusion burden categories based on the number of units of transfused red blood cells they receive.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A second classification system is the World Health Organization, or WHO, system, which is based on a combination of morphology, immunophenotype, genetics and clinical features. The WHO classification system includes a subgroup of patients with MDS that show the presence of iron deposits around the mitochondria, known as ring sideroblasts. These patients are commonly referred to as RS positive and comprise approximately 15% of incident patients with MDS, and splicing factor mutations, such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">SF3B1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, are highly correlated with these patients. Patients with splicing factor mutations often have been observed to have defects in the differentiation of red blood cells at the terminal stage. The majority of patients with MDS that develop cytopenias lack ring sideroblasts or a single, defining splicing factor mutation and are termed non-RS. These non-RS patients have differentiation and maturation defects occurring across the spectrum from early through terminal stages of hematopoiesis.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Current Treatment Options for Cytopenias in Patients with MDS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Patients with MDS-associated anemia are generally treated with red blood cell transfusions and erythropoiesis-stimulating agents, or ESAs, which are not approved for such treatment. The current treatment of MDS-associated thrombocytopenia is platelet transfusions and platelet-stimulating agents.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Severe cytopenia and transfusion dependence are independent predictors of poor prognosis for patients with MDS and are inversely correlated with quality of life. Red blood cell and platelet transfusions provide temporary benefits to patients with MDS, but are associated with both acute and chronic health risks, including risk of bacterial infection and allergic reactions to the donor blood, and place a significant burden on both the patient and the healthcare system. Repeated red blood cell transfusions are also associated with iron overload, further exacerbating damage to the bone marrow and increasing the risk of acute myeloid leukemia progression and cardiovascular disease. Additionally, the benefit from a platelet transfusion is typically short-lived and availability is limited. Platelet-stimulating agents for the treatment of thrombocytopenia, which are not currently indicated for MDS, carry the risk of thromboembolic events and bone marrow fibrosis.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ESAs are a class of drugs that work on the proliferation stage of red blood cell development by expanding the pool of early-stage progenitor cells. While ESAs have been shown to alleviate anemia in a subset of patients with MDS, patients that have elevated endogenous erythropoietin levels are unlikely to respond. In two controlled Phase 3 clinical trials evaluating darbepoetin alfa (Aranesp) and epoetin alpha (Epogen/Procrit) for the treatment of MDS-associated anemia, 15% to 31% of </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">patients responded, respectively. However, this response was limited to patients with low endogenous erythropoietin levels at baseline and to patients who had a low transfusion burden at baseline. These treatment options also represent a significant burden to patients; epoetin alpha must be administered up to three times a week. Additionally, the effect of ESAs is limited to the red blood cell lineage and, therefore, ESAs only treat MDS-associated anemia and do not provide benefit to cytopenia of other cell lineages, including thrombocytopenia and neutropenia.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Reblozyl, a TGF-&#223;-based erythroid maturation agent, is designed to promote the terminal differentiation of red blood cells through inhibition of selected endogenous TGF-&#223; superfamily ligands. The characteristics of response were defined in a Phase 2 clinical trial of Reblozyl in patients with MDS. Consistent with the mechanism of Reblozyl on the terminal stages of erythropoiesis, the majority of responders were determined to have an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">SF3B1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> splicing factor mutation. Additionally, the responders were characterized as having increased erythroid progenitor cells in the bone marrow, while patients with fewer erythroid progenitor cells in the bone marrow did not achieve hematological improvement. We believe this indicates that Reblozyl is limited to its effect on terminal differentiation of erythropoiesis and does not affect the early stages of differentiation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Reblozyl received approval from the U.S. Food and Drug Administration, or the FDA, in April 2020 for the treatment of anemia in adult RS positive patients with very low- to intermediate-risk MDS that failed an erythropoiesis stimulating agent and required two or more units of red blood cells over eight weeks. The approval was based on a single Phase 3 clinical trial of Reblozyl that was conducted in RS positive, very low- to intermediate-risk patients with MDS. This trial included both patients with low transfusion dependence requiring fewer than four units of red blood cells over eight weeks and patients with high transfusion dependence requiring four or more units of red blood cells over eight weeks. In this trial, 37.9% of the RS positive patients treated with Reblozyl achieved the primary endpoint of transfusion independence, compared to 13.2% of patients that received placebo. The highest proportion of responders to Reblozyl were those with low transfusion dependence, while only a few high transfusion burden patients achieved transfusion independence despite being RS positive patients. The FDA also approved Reblozyl in August 2023 for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-na&#239;ve) in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, the FDA approved imetelstat (RYTELO) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe that additional treatment options will be needed to address anemia in the heterogeneous non-ring sideroblast MDS population, to provide clinical benefit to the RS positive population regardless of transfusion burden and to address other cytopenias, such as thrombocytopenia.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept is designed to alter TGF-&#223; signaling pathways at multiple stages of hematopoietic differentiation in both red blood cells and platelets. Consequently, we believe elritercept has the potential to provide therapeutic benefit in a broader subset of patients with MDS that have varying defects in commitment, differentiation and maturation of multiple cell types found in blood.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Myelofibrosis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Myelofibrosis is a group of rare cancers of the bone marrow in which the marrow is replaced by scar tissue and is not able to produce healthy blood cells. As a result, the spleen begins to produce cells to compensate for this ineffective hematopoiesis, which ultimately causes the spleen to enlarge. Myelofibrosis is characterized by ineffective hematopoiesis, an enlarged spleen, bone marrow fibrosis and shortened survival. Patients often experience multiple disease-associated and treatment-emergent cytopenias, including anemia and thrombocytopenia.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ineffective hematopoiesis in myelofibrosis is driven by molecular abnormalities in the Janus kinase 2, or JAK2, -signal transducers and activators of transcription, or JAK-STAT, signaling pathway of transcriptional activators. Specifically, JAK2 activation leads to proliferation of red blood cell progenitors and platelet progenitors, or megakaryocytes, that fail to mature to platelets. Additionally, megakaryocyte dysplasia/hyperplasia has been implicated in inducing bone marrow fibrosis in patients with myelofibrosis. The inability of megakaryocytes to fully differentiate leads to the release of pro-inflammatory and pro-fibrotic factors that results in scarring of the bone marrow, which further exacerbates the myelofibrosis-associated cytopenias.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Myelofibrosis is a relatively rare condition with an identified prevalence of 16,000 to 18,500 patients in the United States. Approximately 3,000 new patients are diagnosed with myelofibrosis each year, and the median age at diagnosis is approximately 60 years. Currently, there are limited therapeutic options to address the myelofibrosis-associated cytopenias. Within a year of diagnosis, 38% of patients with myelofibrosis are red blood cell transfusion dependent and eventually nearly all will develop transfusion dependence. Additionally, within a year of diagnosis, 26% of patients with myelofibrosis will develop thrombocytopenia and 51% will develop anemia.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Current Treatment Options for Cytopenias in Patients with Myelofibrosis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently approved products for the treatment of myelofibrosis, including JAK inhibitors ruxolitinib (Jakafi), fedratinib (Inrebic) and pacritinib (Vonjo), have been observed to exacerbate myelofibrosis-associated cytopenias. In a third-party Phase 3 clinical trial of Jakafi and a third-party Phase 3 clinical trial of Inrebic, treatment led to significant reductions in spleen volume </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">and improvement in total symptom scores. However, JAK inhibitors interfere with normal hematopoiesis and treatment with Jakafi and Inrebic also resulted in clinically significant anemia and thrombocytopenia in these Phase 3 trials. Approximately 45% of patients in the Phase 3 clinical trial of Jakafi developed treatment-related grade 3 or 4 anemia. Grade 3 or higher adverse events of anemia and thrombocytopenia were observed in approximately 34% and 12%, respectively, of patients evaluated in the Phase 3 clinical trial of Inrebic. The treatment-related cytopenias led to severe complications, dose reductions and reduced compliance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2023, momelotinib (Ojjaara) received approval from the FDA for the treatment of intermediate or high-risk myelofibrosis in adults with anemia. In a third-party Phase 3 clinical trial of Ojjaara versus danazol in patients with myelofibrosis who were symptomatic and anemic and had been previously treated with an approved JAK inhibitor, 25% in the Ojjaara arm achieved the primary endpoint of total symptom score reduction of at least 50%, compared to 9% in the danazol arm. Additionally, 31% in the Ojjaara arm achieved the secondary endpoint of transfusion independence, compared to 20% in the danazol arm. In a separate third-party Phase 3 clinical trial of Ojjaara versus ruxolitinib in JAK-na&#239;ve patients, in the subset of patients with anemia, a numerically lower percent of patients treated with Ojjaara (25%) achieved a total symptom score reduction of 50% or more at Week 24 compared with ruxolitinib (36%). In this trial, similar reductions in spleen volume reduction were observed with both Ojjaara (31%) and ruxolitinib (33%).</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe elritercept has the potential to not only ameliorate myelofibrosis-associated cytopenias, but also improve spleen volume and patient-reported outcomes, alone or in combination with approved products regardless of the underlying mechanism of action of such products, including JAK inhibitors and Ojjaara.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution:&#160;Elritercept</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept is a ligand trap comprised of a modified ligand-binding domain of ActRIIA that is fused to the portion of the human antibody known as the Fc domain. Elritercept is designed to bind to and inhibit the signaling of TGF-&#223; ligands involved in the regulation of hematopoiesis, including activin A, activin B and growth differentiation factor 11, that restrict blood cell progenitors from continuing through differentiation and developing into mature cells with specialized function. The elritercept-mediated inhibition of these regulators has been shown in preclinical studies to stimulate the progenitors to progress to maturation and, consequently, increase the number of mature cells in the blood. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Data from our Phase 1 clinical trial in healthy volunteers and our two ongoing Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, also demonstrate that treatment with elritercept increased red blood cell and platelet production. These data indicate that elritercept is differentiated from available therapies because it appears to have both sustained and rapid effects on multiple cellular lineages in the hematopoietic pathway. We believe elritercept&#8217;s promotion of differentiation of early- and terminal-stage progenitor cells contributes to these sustained and rapid effects, respectively, and consequently, elritercept may be effective for many patients that are refractory to available therapies and may potentially provide benefit in multiple cytopenias simultaneously.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Mechanism of Action of&#160;Elritercept</span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="kros-20251231_g14.jpg" alt="business4b.jpg" style="height:294px;margin-bottom:5pt;vertical-align:text-bottom;width:624px" id="i-14"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consistent with our preclinical studies, which showed improvement in bone health, we observed an increase in b</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">one-specific alkaline phosphatase, a biomarker of bone remodeling</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, in our Phase 1 clinical trial in healthy volunteers and our ongoing </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Phase 2 clinical trial in patients with MDS, following administration of elritercept. Based on these data, we believe elritercept also has the potential to regenerate a healthy bone marrow and slow disease progression.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Separately, in a preclinical study in wild type mice, treatment with ruxolitinib resulted in reductions in red blood cells, hemoglobin and hematocrit, recapitulating the anemia observed in myelofibrosis patients. Administration of RKER-050, a mouse version of elritercept, reversed the observed ruxolitinib-associated reductions in the red blood cell parameters, which we believe supports the potential of elritercept to mitigate the dose-limiting effects of ruxolitinib and enhance the duration of therapy in myelofibrosis patients.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We intend to develop elritercept for the treatment of both MDS- and myelofibrosis-associated cytopenias. We believe elritercept has the potential to overcome limitations of current treatment options for MDS- and myelofibrosis-associated cytopenias. We believe the potential advantages of elritercept compared to current treatment options include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Dual mechanism affecting both the early and terminal stages of erythropoiesis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Patients with MDS can have defects occurring anywhere along the differentiation and maturation spectrum of erythropoiesis, and often have multiple mutations that cause ineffective erythropoiesis. By acting on cell types throughout the erythropoiesis pathway, elritercept may lead to robust responses in RS positive patients who have a characteristic defect in terminal maturation, and may also address anemia in the broader MDS population, including non-RS patients, that has defects in earlier-stage erythroid cell development. Specifically related to red blood cells, we have demonstrated in multiple preclinical studies that administration of RKER-050 elicited increases in red blood cell production in healthy mice by stimulating multiple stages in the maturation of erythroid precursors. The rapid and sustained increase in red blood cells observed in these preclinical studies suggests that RKER-050 potentially stimulated both terminal maturation of late-stage erythroid precursors to rapidly increase red blood cells and maturation of early-stage precursor populations to increase the pool of progenitors that can be mobilized for a sustained upregulation of erythropoiesis. Additionally, by increasing the pool of early erythroid precursor cells and serum erythropoietin, we believe elritercept can potentially treat patients with MDS that have hypocellular bone marrow. We have also observed an increase in erythropoietin in healthy mice in preclinical studies of RKER-050, which we believe could contribute to the durability in red blood cell production and is supportive of the durability of the red blood cell increase we observed in our Phase 1 clinical trial of elritercept in healthy post-menopausal women.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Increased platelet counts in blood. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Ineffective hematopoiesis in patients with MDS and in patients with myelofibrosis can result in thrombocytopenia, which can lead to an increased risk of bleeding events. We believe treatment with elritercept has the potential to address the MDS- and myelofibrosis-associated thrombocytopenia. Additionally, by promoting thrombopoiesis, we believe elritercept has the potential to aid the differentiation of megakaryocytes to platelets in myelofibrosis patients and reactivate hematopoiesis in the bone marrow. We have demonstrated in preclinical studies that treatment with a single dose of RKER-050 resulted in rapid and sustained increases in platelets in healthy mice. We observed an increase in platelets 12 hours after administration of RKER-050, which we believe supports that elritercept can potentially promote production of platelets by blocking inhibitory TGF-&#223; ligands so that megakaryocytes can fully differentiate. Additionally, bone marrow analysis performed 24 hours post-dose demonstrated that administration of RKER-050 increased the megakaryocyte precursor population, and that these cells had increased ploidy, compared to vehicle. These data suggest that RKER-050 promoted the maturation of early megakaryocyte populations and primed megakaryocytes for proplatelet production.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Reduced accumulation of progenitor cells.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Ineffective hematopoiesis in patients with MDS and in patients with myelofibrosis can be caused by excessive production of blood cell progenitors that are unable to complete differentiation and ultimately become mature blood cells. We believe treatment with elritercept will stimulate these progenitors to progress to maturation, ameliorating the accumulation of these cells that lead to MDS- and myelofibrosis-associated cytopenias.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.68pt">Regeneration of the bone marrow microenvironment to potentially slow disease progression. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The bone marrow microenvironment is composed of bone cells, stromal cells, immune cells, blood vessels and nerves. Crosstalk in this osteo-hematopoietic niche determines the maintenance, self-renewal and eventual differentiation of hematopoietic stem cells and progenitor cells to blood cells. Accordingly, a disease-impacted bone marrow microenvironment contributes to ineffective hematopoiesis and bone loss. In a preclinical study, administration of RKER-050 in a mouse model of MDS prevented the anemia and bone loss observed in the vehicle-treated MDS mice. We believe these data support the potential of elritercept to alter the bone marrow microenvironment that is supportive of self-renewal and maintenance of normal hematopoietic stem cells and progenitor cells in patients with MDS and other hematological diseases, including myelofibrosis.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.64pt">Robust and sustained increase in red blood cells, hemoglobin and reticulocytes, supporting monthly or less frequent dosing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> ESAs can require dosing up to three times a week. We believe that treatment with elritercept has the potential to reduce the frequency of dosing to every four weeks or less frequently, thereby decreasing the burden on patients and potentially improving compliance.</span></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2024, we entered into an exclusive license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025. See the section titled &#8220;Business&#8212;Collaborations and License Agreement&#8212;2024 License Agreement with Takeda </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pharmaceuticals U.S.A., Inc.&#8221; set forth in Part I, Item 1 of this Annual Report on Form 10-K for additional information regarding our license agreement with Takeda.</span></div><div style="margin-bottom:2pt;margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Phase 3 Clinical Trial in Patients with Myelodysplastic Syndromes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2024, we initiated a global, multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of elritercept versus placebo in patients with transfusion-dependent anemia with lower-risk MDS, which we refer to as the RENEW trial. The primary endpoint is the proportion of patients achieving transfusion independence for at least eight weeks from baseline through week 24. A key secondary endpoint is the proportion of patients achieving transfusion independence for at least 24 weeks from baseline through week 48. The trial design is summarized in the figure below. </span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Phase 3 Clinical Trial Design</span></div><div style="margin-bottom:9.5pt"><img src="kros-20251231_g15.jpg" alt="RENEW trial design.jpg" style="height:190px;margin-bottom:5pt;vertical-align:text-bottom;width:702px" id="i-15"/></div><div id="i2030eac40e414171a9c72c0ab0189734_37"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Preclinical Pipeline</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Proprietary Discovery Approach</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe, based on our previous experience with ActRII ligand traps using endogenous and wild-type sequences, that observations in preclinical rodent models have the potential to translate to humans in the clinic. Specifically:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Wild-type ActRIIA-Fc was associated with increased bone growth and red blood cell production in rodents and non-human primates. In a third-party clinical trial of ActRIIA-Fc, increased bone mineral density and red blood cell production was reported in healthy post-menopausal women. In this clinical trial, it was also reported that lower doses elicited the effect on red blood cells compared to bone, and thus, the dominant effect on red blood cell production prevented development in diseases with bone loss.</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">In third-party preclinical studies in rodents and non-human primates, ActRIIB-Fc was associated with increased bone mineral density and lean muscle mass, but was not associated with changes in red blood cells. However, ActRIIB-Fc was also observed to cause nose and gum bleeding, which we believe is due to its effect of disrupting normal vascular remodeling. BMP9 signaling is required for normal vascular remodeling, but is not involved in regulation of muscle or bone tissues. ActRIIB-Fc potently inhibits BMP9 signaling, which is the mechanism behind the bleeding events observed with ActRIIB-Fc treatment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have developed a proprietary library of ActRII ligand traps by combining sequences from ActRIIA and ActRIIB. We have engineered molecules that are designed to have the therapeutic properties of either or both parent molecules without the dose-limiting effect on red blood cells observed with ActRIIA-Fc or the negative effect on blood vessels observed with wild-type ActRIIB-Fc. Our ActRII program has produced a broader pipeline of engineered ligand traps, and we currently have an expansive library of unique variants in preclinical development. These include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Molecules designed to increase bone mass without the dose-limiting effect on red blood cells observed with wild-type ActRIIA-Fc; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Molecules designed to increase muscle and bone mass with reduced BMP9 binding without impacting vascular remodeling that leads to weak blood vessels observed with the wild-type ActRIIB-Fc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our discovery approach has built on these initial observations to generate product candidates designed to target ActRII receptors that address certain downsides observed in third-party preclinical studies and clinical trials of ActRIIA-Fc and ActRIIB-Fc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe that we are well positioned to advance our product candidates and pursue commercial opportunities in diseases where muscle and bone loss result in a debilitating impact on survival and quality of life, if our product candidates are successfully developed and approved. Our deep knowledge and expertise of the TGF-&#223; family of proteins provides a streamlined approach to screen and develop novel product candidates for a broad range of indications, including neuromuscular and neurodegenerative disorders, rare bone and fibrosis diseases and obesity/frailty indication.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_40"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs, to produce our product candidates for preclinical and clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. We require that our CMOs produce bulk drug substances and finished drug products in accordance with current Good Manufacturing Practices, or cGMPs, and all other applicable laws and regulations. We have quality agreements in place with our key CMOs. We have also established an internal quality management organization, which audits and qualifies our CMOs. Additionally, we maintain agreements with our manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have engaged CMOs to manufacture supply for preclinical and clinical use. Additional CMOs are used to label, package and distribute drug product for preclinical and clinical use. We obtain our supplies from these CMOs on a purchase order basis and do not have any long-term supply arrangements in place. We do not currently have arrangements in place for redundant supply. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost, if needed. As our development programs expand and we build new process efficiencies, we expect to continually evaluate this strategy with the objective of satisfying demand for registration trials and, if approved, the manufacture, sale and distribution of commercial products.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_43"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary rights. While we believe that our product candidates, discovery programs, technology, knowledge, experience and scientific resources provide us with competitive advantages, we compete in the highly competitive markets and face significant competition from many sources, including pharmaceutical and biotechnology companies, as well as academic institutions, governmental agencies and private and public research institutions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We compete in the segments of the biotechnology, pharmaceutical and other related industries that develop and market therapies in our target indications. There are many other companies, including large biotechnology and pharmaceutical companies, that have commercialized and/or are developing therapies for the same therapeutic areas that our product candidates target. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc. and Agamree (vamorolone) is an FDA-approved corticosteroid marketed by Catalyst Pharmaceuticals in the United States. In addition, there are four FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are phosphorodiamidate morpholino oligomers, or PMOs, approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., or Sarepta, and VILTEPSO (vitolarsen), a PMO approved for the treatment of patients with DMD who are amenable to exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Additionally, in June 2023, Sarepta announced that the FDA accelerated approval of its product, ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. In June 2024, the FDA granted ELEVIDYS full approval for the treatment of ambulatory individuals aged four years and older, and accelerated approval for the treatment of non-ambulatory individuals aged four years and older. In July 2025, Sarepta announced its decision to voluntarily and temporarily pause all shipments of ELEVIDYS for patients with DMD in the United States, following reports of fatal liver injury. Subsequently, in July 2025, Sarepta announced that the FDA notified Sarepta that it may lift its voluntary pause on shipments of ELEVIDYS for ambulatory patients with DMD, and Sarepta resumed shipping to such patients immediately.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2024, Italfarmaco S.p.A. announced that the FDA approved Duvyzat (givinostat), a histone deacetylase inhibitor for the treatment of DMD in patients aged six years and older.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, several companies are developing gene therapies to treat DMD, including REGENXBIO Inc. and Solid Biosciences Inc. RNA-targeted treatments that are in clinical and preclinical development are also being pursued by several companies, including Avidity Biosciences, Inc., Wave Life Sciences Ltd., Dyne Therapeutics, Inc. and Sarepta. Edgewise Therapeutics, Inc. is developing sevasemten, a myosin ATPase inhibitor, for both DMD and Becker muscular dystrophy.  Satellos Bioscience Inc. is developing SAT-3277, an AAK1 inhibitor, for the treatment of DMD.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are three therapies approved by FDA to treat ALS and its symptoms: riluzole, an anti-glutamatergic agent; edaravone, a free-radical scavenger; and tofersen, an antisense oligonucleotide treatment of SOD1-ALS. One additional therapeutic, sodium phenylbutyrate and taurursodiol, was approved under an accelerated pathway by the FDA but subsequently withdrawn from the market following negative results from a confirmatory Phase 3 trial. To the best of our knowledge, there are no other companies developing product candidates to treat ALS by targeting skeletal muscle. However, several companies are developing product candidates to treat ALS through other mechanisms, including Otsuka Pharmaceutical Co., Ltd., Novartis AG and Genervon Biopharmaceuticals LLC.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Kyntra Bio Inc. (formerly FibroGen Inc.) and Astellas Pharma Inc. are developing product candidates for the treatment of anemia, and Merck &amp; Co. Inc., or Merck, Bristol-Myers Squibb Company and Disc Medicine are developing product candidates targeting diseases associated with MDS and myelofibrosis, including chronic anemia. Additionally, in April 2020, Merck and Bristol-Myers Squibb Company received FDA approval of its product, Reblozyl, for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. In June 2020, Merck further announced that the European Commission approved Reblozyl for the treatment of transfusion-dependent anemia in adult patients with MDS or beta thalassemia and in September 2020, Merck announced that Health Canada approved Reblozyl for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta thalassemia. In August 2023, Bristol-Myers Squibb Company announced that the FDA approved Reblozyl for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-na&#239;ve) in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions. In April 2024, Bristol-Myers Squibb Company further announced that the European Commission expanded approval of Reblozyl to include treatment of adult patients with and without ring sideroblasts with transfusion-dependent anemia due to lower-risk MDS. In June 2024, Geron Corporation announced that the FDA approved imetelstat (RYTELO) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2022, CTI BioPharma Corp. (which was acquired by Swedish Orphan Biovitrum AB in June 2023) received FDA accelerated approval of its product, pacritinib (Vonjo), for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 &#215; 109/L. In September 2023, GSK plc announced that the FDA approved its product, Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia. Additionally, MorphoSys AG (which was acquired by Novartis AG in July 2024) is also developing a product candidate as a treatment for myelofibrosis, and Incyte Corporation is developing an ALK2 inhibitor product candidate for the treatment of myelofibrosis. Geron Corporation is also developing imetelstat as a treatment for myelofibrosis. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other companies that are developing product candidates that are designed to target the TGF-&#223; signaling pathways include Scholar Rock Holding Corporation, Biogen Inc. and Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future, either alone or with their strategic collaborators, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies or universities and research institutions. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and enrolling patients for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products, if approved. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_46"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations and License Agreement</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 License Agreement with Takeda Pharmaceuticals U.S.A., Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2024, we entered into a license agreement with Takeda, which became effective on January 16, 2025. Under the terms of the license agreement with Takeda, or the Takeda Agreement, we granted to Takeda the exclusive right to develop, manufacture and commercialize elritercept and certain derivative compounds globally, excluding the territories of mainland China, Hong Kong and Macau, which we refer to collectively as the Takeda Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Agreement, we received a $200.0 million upfront payment in February 2025.  In July 2025, we announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept, which triggered a one-time $10.0 million milestone payment to us under the Takeda Agreement. We received the $10.0 million payment for the achievement of this development milestone in August 2025. In addition to the upfront payment and milestone payment, we are entitled to receive up to an aggregate of (i) $80.0 million upon the achievement of specified development milestones, (ii) $280.0 million upon the achievement of specified commercial milestone and (iii) $740.0 million upon the achievement of specified sales milestones. If a licensed product is approved for marketing in the Takeda Territory, we will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Takeda&#8217;s obligation to pay royalties for a given licensed product in a given country in the Takeda Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Takeda Agreement will continue in force until the expiration of the royalty term. Takeda may terminate the Takeda Agreement (i) in its entirety or on a country-by-country basis for convenience, with notice or (ii) if Takeda reasonably determines that the development, manufacture, and commercialization of the licensed compound or licensed product pose a safety or public health risk. We may terminate the Takeda Agreement in its entirety in the event that Takeda or its affiliates bring a patent challenge. Either party may terminate the Takeda Agreement in its entirety (i) if the other party materially breaches the Takeda Agreement and fails to cure such breach; or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2021, we entered into a license agreement with Hansoh (Shanghai) Healthtech Co., Ltd., or Hansoh.  Under the terms of the license agreement with Hansoh, or the Hansoh Agreement, we granted to Hansoh the exclusive right to develop, manufacture and commercialize elritercept and licensed products containing elritercept within the territories of mainland China, Hong Kong and Macau, which we refer to collectively as the Hansoh Territory. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from us, and the parties will also negotiate in good faith to enter into an agreement for commercial supply prior to any anticipated commercialization in the Hansoh Territory. In addition, Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Hansoh Agreement, we received a net $18.0 million upfront payment in January 2022. In addition to the upfront payment and development milestones achieved to date, we are entitled to receive up to an aggregate of (i) $23.5 million upon the achievement of specified development milestones and (ii) $144.0 million upon the achievement of specified net sales thresholds for all licensed products in the Hansoh Territory. If a licensed product is approved for marketing in the Hansoh Territory, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. We recognized $3.0 million as revenue and $0.3 million in withholding tax upon the achievement of a development milestone related to the Hansoh Agreement on our consolidated statement of operations for the year ended December 31, 2024, and a receivable, net of withholding tax, on our consolidated balance sheet as of December 31, 2024. Payment was received during the year ended December&#160;31, 2025.  No milestones were achieved during the year ended December&#160;31, 2025. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Hansoh&#8217;s obligation to pay royalties for a given licensed product in a given region in the Hansoh Territory will begin on the date of the first commercial sale for such licensed product in such region and continue until the latest of (i) ten years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents or joint patents, and (iii) expiration of regulatory exclusivity in such region. During the royalty term, neither party will directly or indirectly commercialize a competing product in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Hansoh Agreement will continue in force on a region-by-region basis until the expiration of the royalty term. Hansoh may terminate the Hansoh Agreement in its entirety for convenience, with notice. We may terminate the Hansoh Agreement in its entirety for a patent challenge brought by Hansoh or its affiliates or their sublicensees. Either party may terminate the Hansoh Agreement in its entirety (i) if the other party materially breaches the Hansoh Agreement and fails to cure such breach or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Exclusive Patent License Agreement with The General Hospital Corporation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2016, we entered into an exclusive patent license agreement with The General Hospital Corporation, or MGH, which was subsequently amended in May 2017 and February 2018. Under the license agreement with MGH, or the MGH Agreement, we obtained an exclusive, worldwide license, with the right to sublicense, under certain patents and technical information of MGH, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products and processes for use in the treatment, diagnosis, palliation and prevention of diseases and disorders in humans and animals. We are required to use commercially reasonable efforts to develop and commercialize licensed products and processes, and must achieve certain required diligence milestones.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the MGH Agreement, we made an initial license payment of $100,000 and reimbursed MGH approximately $280,000 of prior patent prosecution expenses related to the licensed patents. We also issued MGH an aggregate of 358,674 shares of our common stock. Additionally, we are required to pay a low-five digit to mid-five digit annual maintenance fee prior to the first commercial sale of our first product or process, a&#160;mid-five&#160;digit annual maintenance fee after the first commercial sale of our first product or process that is creditable against royalties, certain clinical and regulatory milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $8.6&#160;million in the aggregate, and certain commercial milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $18.0&#160;million in the aggregate. We made payments of $50,000 and $300,000 in 2020 and 2021, respectively, for the achievement of the clinical and regulatory milestones of (i) filing of an IND in the first </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">country and (ii) the completion of a Phase 1 clinical trial, respectively. We are also obligated to pay tiered royalties on net sales of licensed products ranging in the&#160;low-single&#160;digits to&#160;mid-single&#160;digits. The royalty rates are subject to up to a maximum 50% reduction for lack of a valid claim, in the event that it is necessary for us to obtain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed&#160;product-by-licensed&#160;product and&#160;country-by-country&#160;basis upon the later of expiry of the last valid claim of the licensed patents that cover such licensed product in such country and ten years from the first commercial sale of such product in such country. We are also obligated to pay a percentage of&#160;non-royalty&#160;related payments received by us from sublicensees ranging in the&#160;sub-teen&#160;double digits and a change of control fee equal to a&#160;low-single&#160;digit percentage of the payments received as part of any completed transaction up to a&#160;low-seven&#160;digit amount.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The MGH Agreement expires upon expiry of the last remaining royalty obligation for a licensed product or process. Under the MGH Agreement, MGH may terminate the agreement upon our uncured material breach or insolvency, a challenge by us of the licensed patents and certain other specified breaches of the MGH Agreement. We may terminate the agreement for any reason upon specified prior written notice to MGH.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_49"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We strive to protect the proprietary technology, inventions and improvements that we believe are commercially important to our business, including obtaining, maintaining, enforcing and defending our intellectual property rights, including patent rights, whether developed internally or licensed from third parties. We rely, in part, on trade secrets and know-how relating to our proprietary technology and drug candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely, in part, on data exclusivity, market exclusivity and patent term extensions if and when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we own or may obtain in the future; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other intellectual property rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of February 27, 2026, our patent portfolio consisted of 23 issued U.S. patents, 27 pending U.S. patent applications, 45 issued ex-U.S. patents and 102 pending ex-U.S. applications, with expected expiry dates not earlier than between March 13, 2029 and October 29, 2046. Of these, 28 issued patents and 83 patent applications relate to rinvatercept and elritercept, and 40 issued patents and 46 patent applications relate to other technologies, in each case as described in more detail below. Each of our pending international patent applications has been filed under the Patent Cooperation Treaty and has not yet entered any national jurisdictions. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that may be commercially important to the development of our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We seek U.S. and international patent protection for a variety of technologies, and own patent applications with claims directed to ActRIIA ligand traps, ActRIIB ligand traps, ActRII chimera ligand traps, GDNF fusion polypeptides, ALK2 antibodies, crystal forms of an ALK2 inhibitor, and uses thereof. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets, and that may be used to manufacture and develop novel products. We are a party to license agreements that give us rights to use specific technologies in our product candidates and in manufacturing our product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Patent applications directed to our most advanced programs are summarized below. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rinvatercept</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rinvatercept is a ligand trap comprised of a modified ligand-binding domain derived from ActRIIA and ActRIIB that is designed to bind to different TGF-&#223; ligands that signal through a TGF-&#223; signaling pathway. We own one issued U.S. patent, 11 pending U.S. patent applications, and 26 pending ex-U.S. applications that contain claims or supporting disclosure directed to ligand traps comprised of a modified ligand-binding domain derived from ActRIIA and ActRIIB and use thereof to treat muscle disease, bone disease, anemia, fibrosis, pulmonary hypertension, metabolic disease, thrombocytopenia, and neutropenia, among others. Any patents issuing from these applications will have expiration dates between March 19, 2041 and May 8, 2046, absent any patent term adjustments or extensions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elritercept </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Elritercept is a modified ActRIIA ligand trap that is designed to bind to different TGF-&#223; ligands that signal through a TGF-&#223; signaling pathway. We own six issued U.S. patents, 21 issued ex-U.S. patents, 10 pending U.S. patent applications and 58 pending ex-U.S. applications that contain claims or supporting disclosure directed to ActRIIA ligand traps and use thereof to treat muscle disease, bone disease, metabolic disease, anemia, fibrosis, pulmonary hypertension, thrombocytopenia, and neutropenia, among others. Any patents issuing from these applications will have expiration dates between November 9, 2037 and February 27, 2045, absent any patent term adjustments or extensions.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We plan to seek United States and international patent protection for a variety of additional technologies. We own nine issued U.S. patents, 18 issued ex-U.S. patents, 21 pending U.S. patent applications, and 46 pending ex-U.S. applications that contain claims or supporting disclosure directed to cibotercept, GDNF fusion polypeptides, ALK2 antibodies, crystal forms of an ALK2 inhibitor, ActRII chimera ligand traps, and uses of small molecule ALK2 inhibitors. Any patents issuing from these applications will have expiration dates between November 9, 2037 and November 9, 2043, absent any patent term adjustments or extensions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property Protection </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March 16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_52"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drug and biological products such as those we are developing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates are subject to regulation under the Food, Drug, and Cosmetic Act and the Public Health Service Act, and other federal, state, local and foreign statutes and regulations. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug and Biological Product Regulation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through either a New Drug Application, or NDA, or a Biologics License Application, or BLA. The process required by the FDA before biopharmaceutical product candidates may be marketed in the United States generally involves the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">submission to the FDA of an Investigational New Drug, or IND, application which must become effective before human clinical trials may begin; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the trial may be initiated; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational drug product for each proposed indication and to establish the safety, purity and potency of the investigational biologic product candidate for each proposed indication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">preparation of and submission to the FDA of an NDA for a small molecule product candidate or a BLA for a biologic after completion of all pivotal clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">payment of user fees for FDA review of the NDA or BLA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">a determination by the FDA within 60 days of its receipt of the NDA or BLA to file the application for review; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities at which the proposed product will be produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s continued identity, strength, quality and purity; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA or BLA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">FDA review and approval of an NDA or licensure of a BLA, including consideration of the views of any FDA Advisory Committee, prior to any commercial marketing or sale of the product for particular indications for use in the United States; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">compliance with any post-approval requirements, including the potential requirement to conduct post-approval studies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before testing any drug or biologic candidate in humans in the United States, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to beginning the first clinical trial with a product candidate, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The IND submission contains the general investigational plan and the protocol or protocols for preclinical studies and clinical trials, as well as results of in vitro and animal studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. These investigators are generally physicians who are not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used in monitoring subject safety and assessing efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the existing IND. Furthermore, each clinical trial must be reviewed and approved by an independent IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection, if deemed necessary, and the practice of medicine in the foreign country is consistent with the United States. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Human clinical trials in the United States are typically conducted in three sequential phases that may overlap or be combined: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Phase 2 clinical trials involve studies in a limited population of disease-affected patients to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">Phase 3 clinical trials generally involve a large number of patients at multiple geographically dispersed clinical trial sites and are designed to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">When these phases overlap or are combined, the trials may be referred to as Phase 1/2 or Phase 2/3. A Phase 1/2 clinical trial is a human trial that investigates both safety and preliminary efficacy of an investigational therapy. A Phase 2/3 clinical trial is a human trial that investigates both preliminary and confirmatory efficacy and safety to potentially support submission of a marketing application with the applicable regulatory authorities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies, are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition to FDA approval of an NDA or BLA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the chemistry and physical characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. FDA requires diversity plans to ensure that clinical trials aim to include broad racial and ethnic exposure data. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Review Process</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA or BLA. The NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results of preclinical studies and clinical trials, as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each submission of an NDA or BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product application also includes a non-orphan indication. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within sixty days of receipt. Such decision could include either issue a refusal to file letter or acceptance of the NDA or BLA for filing, indicating that it is sufficiently complete to permit substantive review. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Once an NDA or BLA has been accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review standard applications within ten months from the filing date, during which it will complete its initial review of a new molecular entity NDA or original BLA and respond to the applicant, or within six months from the filing date of a new molecular entity NDA or original BLA designated for priority review. In both standard and priority reviews, the FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews the application to determine, among other things, whether a product is safe and effective, or for a biologic, safe, pure and potent for its intended use, and whether the facility in which it is manufactured, processed, packed or held meets standards designed to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA generally accepts data from foreign clinical trials in support of an NDA or BLA if the trials were conducted under an IND, and the IND requirements, unless waived, were met. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA or BLA if the trial was conducted in accordance with GCPs and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical studies, the FDA may accept foreign data as the sole basis for marketing approval if (1) the foreign data are applicable to the U.S. population and U.S. medical practice, (2) the trials were performed by clinical investigators with recognized competence, and (3) the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of the advisory committee, but it considers such recommendations when making decisions on approval. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA will issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response letter usually describes all of the specific deficiencies that the FDA has identified in the NDA or BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests for additional information or clarification, which may include the potential requirement for additional clinical studies, including the potential requirement to conduct additional clinical trial(s) and/or to complete other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same product for the same indication for seven years, except in </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application fee. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to monitoring and record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, compliance with advertising and promotion requirements, which include restrictions on promoting the product for unapproved uses or patient populations, known as &#8220;off-label use,&#8221; and limitations on industry-sponsored scientific and educational activities. Further, after approval, if there are any changes or modifications to the approved product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA review and approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA will not approve the NDA or BLA without an approved REMS, if required. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">fines, warning or untitled letters or holds on post-approval clinical studies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">product seizure or detention, or refusal of the FDA to permit the import or export of products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Exclusivity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. To date, only a handful of biosimilars have been licensed under the BPCIA, although numerous biosimilars have been approved in the European Union. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products, if approved. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials in the EU</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Similar to the United States, the various phases of non-clinical and clinical research in the European Union, or the EU, are subject to significant regulatory controls. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on January 31, 2022 repealing and replacing the former Clinical Trials Directive 2001/20, or CTD.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the CTR, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The CTR foresaw a three-year transition period that ended on January 31, 2025. Since this date, all new or ongoing trials are subject to the provisions of the CTR.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In all cases, clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials, including ATMPs, must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility, which can be subject to GMP inspections.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">EU Review and Approval Process</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accelerated and Alternative Marketing Authorization Mechanisms</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development in the EU</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Regulation in the EU</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import.  The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Data and Market Exclusivity in the EU</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Orphan Designation in the EU</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i) the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii) either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b)  the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Regulation (EC) No 847/2000 sets out further provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product. An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10 year period if: (i) if the applicant consents to a second original orphan medicinal product application, (ii) if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii) if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Post-authorization Requirements in the EU</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other EU Compliance Requirements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, the civil False Claims Act, U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar foreign, federal and state fraud and abuse, transparency and privacy laws. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The U.S. federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value, including stock options. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and others on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly, and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the U.S. federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">actions, and civil monetary penalty laws prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent. For example, the civil False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">HIPAA created additional federal civil and criminal liability for, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose certain requirements on HIPAA covered entities, which include certain healthcare providers, healthcare clearing houses and health plans, and individuals and entities that provide services on their behalf that involve individually identifiable health information, known as business associates, as well as their covered subcontractors, relating to the privacy, security and transmission of individually identifiable health information. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other transfers of value made in the prior year to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor, state and foreign laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government, state and local laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws which require the reporting of information related to drug pricing, state and local laws requiring the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. For example, the U.S. Department of Health and Human Services, or HHS, imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source drugs that have been on the market for at least seven years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to 20 products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third party not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some EU Member States may approve a specific price for a product, or they may instead adopt a system of direct or indirect controls on the profitability of the </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. On January 12, 2025, Regulation No 2021/2282 on HTA entered into application through a phased implementation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Regulation initially applies to new active substances for oncology and ATMPs. It will be expanded to orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Select high-risk medical devices also came into scope in 2026. The Regulation initially applies to new active substances for oncology and ATMPs. It will be expanded to orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Select high-risk medical devices also came into scope in 2026. The HTA Regulation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products. The Regulation establishes a framework for EU-level joint clinical assessments, joint scientific consultations and the early identification of emerging health technologies. The Regulation permits EU Member States to use common HTA tools, methodologies, and procedures across the EU and requires them to rely on EU&#8209;level joint clinical assessment reports for the clinical components of their national HTA evaluations. Individual EU Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. Since its enactment, there have been judicial, Congressional and executive branch challenges and amendments to certain aspects of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.  The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional action is taken by Congress In addition, Congress is considering additional health reform measures as part of the other reform measures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform, U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. In June 2024, in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state, federal, and foreign healthcare reform measures will be adopted in the future.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Regulation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Foreign Corrupt Practices Act </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_55"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December 31, 2025, we had 78 full-time employees, including 27 who hold Ph.D. or M.D. degrees. Of these full-time employees, 59 employees are engaged in research and development and 19 employees are engaged in management or general and administrative activities. All of our employees are based in the United States. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At Keros, diversity means making a conscious effort to reflect the many experiences and identities of the world outside, while treating each other with fairness and without bias. Inclusion is the choice we make every day to foster an environment where people of all backgrounds not only belong but excel, so that together, as a company, we can succeed. Keros strives to foster an inclusive community, both inside and out of the office. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retention, Training and Development</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The development, attraction and retention of our employees is a critical success factor for Keros. We cultivate a culture of learning and offer formal and informal training and development opportunities for employees at all levels. We actively promote from within and continue to fill our team with strong and experienced management talent.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An important part of attracting and retaining key talent is competitive pay and benefits. To ensure our compensation and benefits programs are competitive, we engage a nationally recognized outside compensation and benefits consulting firm to independently evaluate the effectiveness of our programs and to provide benchmarking against our peers within the industry. Our pay for performance philosophy seeks to motivate and reward employees while accomplishing our short and long-term strategic goals. As part of our performance management process, employees are evaluated both on what they accomplished and on their experience managing and mentoring other employees. Annual salary increases and incentive bonuses are based on merit and include individual and corporate performance factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To encourage our employees to think like owners and share in the Company&#8217;s success, all employees are granted stock options and/or restricted stock units. All employees are eligible for health insurance, paid and unpaid leaves including paid parental leave, retirement plans with an employer contribution match and life and disability/accident coverage. Additionally, to continually develop and facilitate the growth of our employees, we also offer all full-time employees the option to participate in our education assistance program, where we reimburse employees for a portion of tuition fees and eligible expenses.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conduct and Ethics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At Keros, we are committed to fostering a culture of integrity and ensuring each of our employees is equipped with resources to help them do the right thing. We believe it is imperative that the board of directors and senior management strongly support a no-tolerance stance for workplace harassment, biases and unethical behavior. All employees are required to abide by, review and confirm compliance to the Company&#8217;s Code of Business Conduct and Ethics and Insider Trading policies upon hire and on an annual basis thereafter.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_58"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We were originally incorporated under the laws of the State of Delaware under the name Keros Therapeutics, Inc. in December 2015. Our principal executive office is located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421. Our telephone number is (617) 314-6297. We completed our initial public offering in April 2020 and our common stock is listed on the Nasdaq Global Market under the symbol &#8220;KROS.&#8221;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_61"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our website address is www.kerostx.com and our investor relations website address is https://ir.kerostx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available free of charge on our investor relations website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further corporate governance information, including our corporate governance guidelines and board committee charters, is also available on our investor relations website under the heading "Corporate Governance." The contents of our websites are not intended to be incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_64"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K as well as our other public filings with the Securities and Exchange Commission, or the SEC. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects and cause the trading price of our common stock to decline.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. Some of the more significant risks include the following:</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We have a limited operating history, have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We will need substantial additional funding in order to complete the development and commence commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, reduce or eliminate certain of our product development or research operations. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We are heavily dependent on the success of our product candidates, which are in clinical development. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">All of our product candidates are in preclinical or clinical development stages. Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of rinvatercept (KER-065), elritercept (KER-050) or any future product candidates. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and contract research organizations, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We are dependent on our existing third-party collaborations with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, and Hansoh (Shanghai) Healthtech Co., Ltd., or Hansoh, to commercial elritercept, and if Takeda and Hansoh are not successful in commercializing elritercept in their respective licensed territories, we will lose a significant source of potential revenue.</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Our current and future collaborations are and will be important to our business. If we are unable to enter into new collaborations, or if these or our current collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Public health crises could adversely impact our business, including the timing or results of our preclinical studies and clinical trials.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_67"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. Since our inception in 2015, we have invested most of our resources in developing our product candidates, building our intellectual property portfolio, developing our supply chain, conducting business planning, raising capital and providing general and administrative support for these operations. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing drug products. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have not yet demonstrated the ability to progress any product candidate through late-stage clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. While we were profitable in the year ended December 31, 2025, this was driven by the one-time upfront payment from our license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we have incurred losses in all fiscal years prior to the fiscal year ended December 31, 2025. For the years ended December&#160;31, 2025 and 2024, we reported a net income of $87.0 million and a net loss of $187.4 million, respectively.  As of December&#160;31, 2025, we had an accumulated deficit of $481.8 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our lead product candidate, rinvatercept, our most advanced product candidate, elritercept, and any future product candidates we may develop. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if, and as, we: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">commence a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy, or DMD;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">commence a Phase 2 clinical trial of rinvatercept in patients with amyotrophic lateral sclerosis, or ALS;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">continue the research and development of our other clinical- and preclinical-stage product candidates and discovery-stage programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">increase the amount of research and development activities to identify and develop product candidates using our proprietary discovery approach; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">make milestone, royalty or other payments under in-license or collaboration agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintain, expand and protect our intellectual property portfolio; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">invest in or in-license other technologies; and </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, manufacturing challenges, safety issues or other regulatory challenges. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To become and remain profitable, we, our collaborators and any potential future collaborators must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We, our collaborators and any potential future collaborators may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability.  Revenue we generate from our collaborations with Takeda and Hansoh (Shanghai) Healthech Co., Ltd., or Hansoh, and any future collaboration arrangements may not be sufficient to sustain our operations. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding in order to complete the development and commence commercialization of our product candidates. Failure to obtain this necessary capital when needed may force us to delay, reduce or eliminate certain of our product development or research operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have funded our operations primarily through private placements of our equity securities, upfront and expense reimbursement payments received from our collaborators, from our initial public offering, or IPO, in April 2020, from our public offerings of common stock in November 2020 and January 2024, and from our &#8220;at the market offering,&#8221; in connection with our Sales Agreement with Leerink Partners LLC, or Leerink, as agent, pursuant to which we may offer and sell, from time to time, shares of our common stock through Leerink, or the ATM Offering. We expect our expenses to increase in connection with our ongoing activities, particularly as we commence our two Phase 2 clinical trials of rinvatercept, one in patients with DMD and one in patients with ALS, and continue to research, develop and initiate clinical trials of any other future product candidates. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our product development programs or any future commercialization efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $287.4 million in cash and cash equivalents. Based on our current operating assumptions, we expect that our existing cash and cash equivalents as of December&#160;31, 2025 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2028. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements for rinvatercept, elritercept or our other preclinical programs will depend on many factors, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the progress, timing and completion of preclinical studies and clinical trials for our current or any future product candidates, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to public health crises or other causes; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the timing and amount of milestone and royalty payments we are required to make or are eligible to receive under our license agreements with each of The General Hospital Corporation, Takeda and Hansoh; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the number of potential new product candidates we identify and decide to develop; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the need for additional or expanded preclinical studies and clinical trials beyond those that we plan to conduct with respect to our current and future product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or any future product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the costs involved in filing patent applications, maintaining and enforcing patents or defending against infringement or other claims raised by third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the maintenance of our existing license and collaboration agreements and the entry into new license and collaboration agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the effect of competing technological and market developments; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the cost of manufacturing rinvatercept and future product candidates for clinical trials in preparation for marketing approval applications and in preparation for commercialization; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products, if approved, on our own; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our product candidates, if approved; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">market acceptance of any approved product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all.  Further, in the event that the license agreement we entered into with Takeda, or the Takeda Agreement, is terminated, we may not receive any additional fees or milestone payments under that agreement. Absent the funding support obtained under the Takeda  Agreement, our further development of elritercept would require significant additional capital from us, or the establishment of alternative collaborations with third parties, which may not be possible. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. Disruptions in the financial markets in general, geopolitical conflicts and economic instability, may make equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts, which would adversely affect our business prospects, or we may be unable to continue operations.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to holders of our common stock, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operations with our existing cash and cash equivalents and revenue from our collaborations. In order to further advance development of our product candidates, discover additional product candidates and pursue our other business objectives, we will need to seek additional funds. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We cannot guarantee that future financing will be available in sufficient amounts or on commercially reasonable terms, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our common stock and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional common stock or securities convertible or exchangeable into common stock would dilute all of our existing stockholders and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt or declare dividends, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for rinvatercept or any future product candidate at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Further, any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_70"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Regulatory Approval of our Product Candidates </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our product candidates, which are in clinical development. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. We are early in our product candidate development efforts, as rinvatercept and elritercept are still in clinical trials. If either of rinvatercept or </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">elritercept encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be significantly harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of rinvatercept, elritercept and any future product candidates we develop, which may never occur. Rinvatercept, elritercept and any future product candidates we develop will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions for specific indications for use, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales. The success of our current and future product candidates will depend on several factors, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">successful and timely completion of clinical trials and preclinical studies for which the U.S. Food and Drug Administration, or the FDA, or any comparable foreign regulatory authority agree with the design, endpoints or implementation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">receiving regulatory approvals or authorizations for conducting our planned clinical trials or future clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">commencement of and successful patient enrollment in, and completion of, additional clinical trials on a timely basis; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe and effective as a treatment for our targeted indications or, in the case of an applicable product candidate which is regulated as a biological product, that the applicable product candidate is safe, pure, and potent for our targeted indications; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates, both in the United States and internationally; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">successfully scaling a sales and marketing organization and launching commercial sales of our product candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">acceptance of our product candidates&#8217; benefits and uses, if approved, by patients, the medical community and third-party payors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintaining a continued acceptable safety profile of our product candidates following approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">effectively competing with companies developing and commercializing other therapies in the indications which our product candidates target; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">enforcing and defending intellectual property rights and claims. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize rinvatercept, elritercept or any future product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for our current and future product candidates, we may not be able to continue our operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">All of our product candidates are in preclinical or clinical development stages. Clinical trials are difficult to design and implement, and they involve a lengthy and expensive process with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of rinvatercept, elritercept or any future product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We cannot guarantee that any of our ongoing and planned clinical trials will be conducted as planned or completed on schedule, if at all. Moreover, even if these trials are initiated or conducted on a timely basis, issues may arise that could result in the suspension or termination of such clinical trials. For example, in January 2025, we announced the early termination of our Phase 2 clinical trial evaluating cibotercept in patients with pulmonary arterial hypertension, or PAH, which we refer to as the TROPOS trial, based on an ongoing safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have not completed any pivotal clinical trials required for the approval of any of our product candidates. Although we have completed our Phase 1 clinical trial of rinvatercept and our Phase 1 clinical trial of elritercept, both in healthy volunteers, we may experience delays in our ongoing clinical trials or preclinical studies and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, have sufficient drug supply for our product candidates on a timely basis or be completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. We also may experience numerous </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize rinvatercept, elritercept or any future product candidates, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in or failure to obtain regulatory authorizations to commence a trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in reaching a consensus with regulatory agencies as to the design or implementation of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in or failure to obtain institutional review board, or IRB, or positive ethics committee opinions at each site; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in or failure to recruit a sufficient number of suitable patients to participate in a trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure to have patients complete a trial or return for post-treatment follow-up, including disruptions in our ability to treat patients or conduct post-treatment follow-up due to public health crises;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">clinical sites deviating from trial protocol, missing data or dropping out of a trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in adding new clinical trial sites; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure to manufacture sufficient quantities of our product candidates for use in clinical trials in a timely manner; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or safety or tolerability concerns that could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure to perform clinical trials in accordance with the FDA&#8217;s or any comparable foreign regulatory authority&#8217;s good clinical practices, or GCP, requirements, or regulatory guidelines in other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in regulatory requirements, policies and guidelines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure of our third-party research contractors to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in establishing the appropriate dosage levels and frequency of dosing in clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the quality or stability of our product candidates falling below acceptable standards; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">business interruptions resulting from geopolitical actions, including war, such as the current Russia-Ukraine war and the war in the Middle East, and terrorism or the perception that such hostilities may be imminent, another outbreak of a contagious disease, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, public health crises may increase the likelihood that we encounter additional difficulties and delays in the future. We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or recommended for suspension or termination by the Safety Review Committee for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy or safety, purity and potency of our product candidates or any future product candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any of our product candidates, including rinvatercept, elritercept and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our investigational drug products are safe and effective for use in each targeted indication, and in the case of our product candidates regulated as biological products, such as rinvatercept and elritercept, that the product candidate is safe, pure and potent for use in its targeted indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">product candidates involved, as well as the target indications, patient population and regulatory agency. Prior to obtaining approval to commercialize rinvatercept, elritercept and any future product candidates in the United States or abroad, we, our collaborators or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications. For example, in January 2025, we announced the early termination of our TROPOS trial evaluating cibotercept in patients with PAH, based on an ongoing safety review due to the unanticipated observation of pericardial effusion adverse events in the trial. Consequently, we determined to deprioritize cibotercept, and pause all material, internal development activities associated with this asset.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in clinical trials. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, approval of rinvatercept, elritercept and any future product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later-stage trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The results of nonclinical and preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. For example, in a Phase 1 clinical trial evaluating cibotercept in healthy volunteers, cibotercept was generally well tolerated at doses up to 4.5 mg/kg, and there were no reported pericardial effusion adverse events. However, in January 2025, we announced the early termination of our TROPOS trial evaluating cibotercept in patients with PAH, based on an ongoing safety review due to the unanticipated observation of pericardial effusion adverse events in the trial. Furthermore, there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. Any such setbacks in our clinical development could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, some of the clinical trials we conduct may include open-label trials conducted at a limited number of clinical sites on a limited number of patients. For example, our ongoing Phase 2 clinical trials for elritercept, one in patients with lower-risk MDS and one in patients with myelofibrosis, are open-label trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved product or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. For example, in our ongoing Phase 2 clinical trial for elritercept in patients with lower-risk MDS, the dose levels for Cohorts 1, 2, 3, 4 and 5 of Part 1 of the trial were 0.75 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 3.75 mg/kg and 5.0 mg/kg, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Open-label clinical trials are also subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that two open-label Phase 2 clinical trials are ongoing for elritercept, one in patients with lower-risk MDS and one in patients with myelofibrosis, the results from these clinical trials may not be predictive of future clinical trial results with these or other product candidates for which we include an open-label clinical trial, when studied in a controlled environment with a placebo or active control. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may be associated with serious adverse, undesirable or unacceptable side effects or other properties or safety risks, which may delay or halt their clinical development, or prevent marketing approval. If such side effects are identified during the development of our product candidates or following approval we may suspend or abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. While rinvatercept and elritercept have generally been well tolerated in our preclinical studies and clinical trials to date, the results from future preclinical studies and clinical trials, including our other product candidates, may identify additional safety concerns or other undesirable properties of our product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The results of our ongoing Phase 2 clinical trials of elritercept, our ongoing Phase 1 clinical trial of rinvatercept and future clinical trials of these and other product candidates may show that our product candidates cause undesirable or unacceptable side effects or even death. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, if our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved. .</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, adverse developments in clinical trials of pharmaceutical and biopharmaceutical products conducted by others may cause the FDA or other foreign regulatory oversight bodies to suspend or terminate our clinical trials or to change the requirements for approval of any of our product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, if any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">regulatory authorities may withdraw approvals of such product and require us to take our approved product off the market; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be required to conduct additional clinical trials, which may lead to additional interactions with regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be subject to limitations on how we may promote the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">sales of the product may decrease significantly; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our reputation may suffer.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our product candidates, if approved. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with, or otherwise adversely affect, clinical trials of our product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of our clinical trials in accordance with their protocols depends, among other things, on our ability to recruit a </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">sufficient number of eligible patients to participate and remain in the trial until its conclusion. Patients may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches, competitive clinical trials for similar patient populations, the existence of current treatments or for other reasons, including public health crises. Any delays related to patient enrollment or difficulties related to patient retention could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by many factors, including the: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">size and nature of the patient population and process for identifying patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">proximity and availability of clinical trial sites for prospective patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">ability of patients to travel to clinical trial sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">eligibility and exclusion criteria for the trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">design of the clinical trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">safety profile, to date, of the product candidate under study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">perceived risks and benefits of the product candidate under study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">perceived risks and benefits of our approach; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">approval of competing product candidates currently under investigation for the treatment of similar diseases or conditions, or competing clinical trials for similar product candidates or targeting patient populations meeting our patient eligibility criteria; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">severity of the disease under investigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">degree of progression of the patient&#8217;s disease at the time of enrollment and throughout the clinical trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">ability to obtain and maintain patient consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">risk that enrolled patients will drop out before completion of the trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">patient referral practices of physicians; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">ability to adequately monitor patients during and after treatment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Enrollment risks are heightened with respect to indications that are rare or orphan diseases, which may limit the pool of patients that may be enrolled in our planned clinical trials. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Delays related to patient enrollment and difficulties related to patient retention may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical trials may change as more participant data become available. For example, in December 2024, we announced preliminary efficacy results from Parts 1 and 2 of our Phase 2 clinical trial evaluating elritercept for the treatment of anemia and thrombocytopenia in patients with lower-risk MDS. Preliminary or interim data from our clinical trials are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as enrollment continues, more trial data become available and we issue our final clinical trial report. Interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, if any, and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, if any, product candidate or our business. If the preliminary and interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before we can commence clinical trials for any product candidate, we must complete extensive preclinical studies that support any future Investigational New Drug, or IND, applications in the United States, or similar applications in other jurisdictions. All of our completed clinical trials have, to date, been conducted outside of the United States. However, we submitted and cleared an IND with the FDA for our Phase 2 clinical trial for elritercept in patients with MDS in October 2022 and submitted and cleared an IND with the FDA for our Phase 2 clinical trial for elritercept in patients with myelofibrosis in February 2025. Conducting preclinical testing is a lengthy, time-consuming and expensive process and delays associated with product candidates for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. While we are initially conducting a Phase 2 clinical trial for rinvatercept in patients with DMD outside of the United States, we cannot be certain of the timely completion or outcome of our preclinical testing and studies for our other product candidates and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and foreign clinical trials will ultimately support the further development of our other product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our research and development activities could be affected or delayed as a result of shortages in animal availability or possible restrictions on animal testing.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Failure to access or a significant delay in accessing animal research models that meet our needs or that fulfill regulatory requirements may materially adversely affect our ability to advance our preclinical and clinical programs and successfully develop our product candidates, and this could result in significant harm to our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, laws or regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective as a treatment for our targeted indications, or, in the case of a product candidate regulated as a biological product, that the product candidate is safe, pure and potent for its proposed indication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the population studied may not be sufficiently broad or representative to assure safety or efficacy in the population for which we seek approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the FDA or comparable foreign regulatory authorities may require additional preclinical studies or clinical trials beyond those that we currently anticipate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or a Biologics License Application, or BLA, as applicable, to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the approval policies or regulations of the FDA or any comparable foreign regulatory authorities or the laws they enforce may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, financial condition and results of operations. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. If global health concerns such as a pandemic prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if any, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The FDA and any comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The acceptance of trial data by the FDA or any comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice, (ii) the trials are performed by clinical investigators of recognized competence and pursuant to compliance with current GCP requirements and (iii) the FDA is able to validate the data through an on-site inspection or other appropriate mean. Similar requirements and limitations regarding the acceptability of foreign clinical trial data may apply in other countries. Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with such product candidate. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with current Good Manufacturing Practices, or cGMPs, and GCP requirements for any clinical trials that we conduct post-approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or BLA, other foreign marketing authorization application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may impose similar requirements to the FDA REMS program. As an example, the European Commission may require the implementation of a risk mitigation plan in order to collect additional information on a medicine&#8217;s safety profile which may include plans for pharmacovigilance activities and measures to minimize risks. In addition, if the FDA </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or a comparable foreign regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA or comparable foreign regulatory authorities may impose consent decrees, or similar requirements, or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program, or comparable foreign program. Other potential consequences include, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">restrictions or suspensions on operations including on the marketing or manufacturing of our products, if approved, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">fines, warning letters or holds on clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities strictly regulate marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies and comparable foreign regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA or comparable foreign regulatory authorities. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA and comparable foreign regulatory authorities do not govern the behavior of physicians in their choice of treatments. The FDA and comparable foreign regulatory authorities do, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. As an example, the United States federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other foreign regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s approved labeling.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The holder of an NDA or BLA and equivalent foreign applications must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to confirm the safety and efficacy of our products, if approved, in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products, if approved. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. As an example, the regulatory landscape related to clinical trials in the EU has evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, or CTD, became applicable on January 31, 2022. The CTR permits trial sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment of some elements of the application by all EU Member States in which the trial is to be conducted, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor through a centralized EU portal, the Clinical Trial Information System, or CTIS. In addition, the CTR requires the publication of certain data and documents in relation to the conduct of a clinical trial, which will take place in accordance with specific timelines. The timelines are established by the European Medicines Agency, or the EMA, and are determined based on the documents and the categorization of the clinical trial. The CTR provided a three-year transition period that ended on January 31, 2025. Since this date, all new or ongoing trials are subject to the provisions of the CTR. Our compliance with the CTR requirements and that of our third-party service providers, such as CROs, may impact our developments plans.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ollowing a public consultation that began in 2022, the United Kingdom government has enacted new legislation to overhaul the clinical trials regulatory framework. In April 2025, the UK adopted an amendment to the Medicines for Human </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Use (Clinical Trials) Regulations 2004 intended to support a more streamlined and flexible regulation of clinical trials, remove unnecessary administrative burdens on trial sponsors, and protect the interests of trial participants. It also intends to bring the UK regulatory framework for clinical trials into closer alignment with the CTR. The amendment will become applicable on April 28, 2026 following a one-year transition period. While these changes introduce efficiencies and align with some principles of the CTR, divergence between the United Kingdom and EU regulatory systems remains. Any significant divergence could affect the cost and complexity of conducting clinical trials in the United Kingdom and may impact the acceptability of United Kingdom-based trial data for seeking marketing authorizations in the EU, and vice versa.</span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">on December 11, 2025, the European Commission, the Parliament and the European Council reached a political agreement on a comprehensive overhaul of EU pharmaceutical legislation, or the Pharma Package. The reform has been under negotiation since the European Commission submitted its proposal in April 2023. This package - comprised of a new directive and regulation to replace existing legislation &#8211; aims to modernize the EU framework. The political agreement is currently subject to formal approval by the European Parliament and Council. If approved in the form proposed, the Pharma Package will, among other changes, reduce the baseline market protection period by one year, with limited opportunities for extensions, capped at a maximum of 11 years; reshape the incentives regime for orphan medicinal products, by introducing &#8220;breakthrough&#8221; orphan medicinal products &#8211; those addressing diseases with no available medicinal treatment &#8211; which will benefit from 11 years of market exclusivity; and expand the Bolar exemption to permit generic and biosimilar manufacturers to conduct preparatory activities for regulatory submissions, including pricing and reimbursement, and participate in procurement tenders while patent protection remains in force. A decrease in market exclusivity opportunities for our product candidates in the EU, combined with the expanded Bolar exemption, could open them to generic or biosimilar competition earlier than under the current regime, potentially impacting reimbursement status and the commercial prospects of our product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If approved, our investigational products regulated as biologics, including rinvatercept and elritercept, may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are developing rinvatercept for the treatment of DMD and for the treatment of ALS, and elritercept for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with MDS and myelofibrosis, both of which we anticipate will be regulated as a biological product. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our products, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The EU also provides opportunities for data and market exclusivity related to marketing authorizations. Upon receiving a marketing authorization, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial marketing authorization of the reference product in the EU. The overall 10-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also believe that our product candidates in the EU should benefit from this data and market exclusivity. As with the United States, however, if competitors obtain marketing authorization for their biosimilar products, our products may become subject to competition from these biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of biopharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of product candidates by us and our collaborators in clinical trials, and the potential sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients who use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">decreased demand for our products, if approved, due to negative public perception; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">injury to our reputation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">initiation of investigations by regulators; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">costs to defend or settle the related litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">a diversion of management&#8217;s time and our resources; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">substantial monetary awards to trial participants or patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">loss of revenues from product sales; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the inability to commercialize any of our product candidates, if approved.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we believe we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. For example, in August 2025, we announced the deprioritization of cibotercept, including our decision to discontinue all material, internal development activities related to this asset. This decision came after the termination of the development of cibotercept in PAH following the analysis of all available safety and efficacy data from the TROPOS Phase 2 clinical trial in patients with PAH. Additionally, in November 2023, we announced the deprioritization of our small molecule product candidate, KER-047, a potent and selective inhibitor of activin receptor-like kinase-2, a TGF-&#223; superfamily receptor, including our decision to pause all development activities associated with this asset. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular proprietary molecules in our library, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for rinvatercept and elritercept, our business, financial condition and results of operations could be materially adversely affected. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek Fast Track Designation by the FDA for product candidates that we develop, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may seek Fast Track Designation for product candidates we develop. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. We received Fast Track Designation for elritercept for the treatment of anemia in adults with lower-risk MDS, however we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug designation for product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As part of our business strategy, we may seek orphan drug designation for any product candidates we develop, which meets the related applicable criteria, and we may be unsuccessful. For example, in August 2025, we announced that the FDA granted orphan drug designation for rinvatercept for the treatment of DMD. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act in the United States, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards certain clinical trial costs, tax advantages and user-fee waivers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Generally in the United States, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for seven years, except in limited circumstances. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, the European Commission, on the basis of the opinion of the EMA Committee for Orphan Medicinal Products, grants orphan drug designation for medicines to be developed for the diagnosis, prevention or treatment of diseases that are life-threatening or chronically debilitating, for which either no satisfactory method of diagnosis, prevention, or treatment exists, or if such method exists, the medicine is of significant benefit to those affected by such condition. To benefit from such designation, either the prevalence of such condition must not be more than five in 10,000 people across the EU or, if more prevalent, it must be unlikely that the marketing of the medicine would generate sufficient returns to justify the investment needed for its development.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will benefit from those designations. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_73"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are successful in obtaining marketing approval from applicable regulatory authorities for rinvatercept, elritercept or any other product candidate, our ability to generate revenues from any such products will depend on our success in: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">launching commercial sales of such products, whether alone or in collaboration with others; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">receiving approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations that would impede our ability to market such products; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">creating market demand for such products through marketing, sales and promotion activities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">hiring, training, and deploying a sales force or contracting with third parties to commercialize such products in the United States; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">creating strategic collaborations with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">manufacturing such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintaining patent and trade secret protection and regulatory exclusivity for such products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">achieving market acceptance of such products by patients, the medical community, and third-party payors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">achieving coverage and adequate reimbursement from third-party payors for such products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">effectively competing with other therapies; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">maintaining a continued acceptable safety profile of such products following launch.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We compete in the segments of the biotechnology, pharmaceutical and other related industries that develop and market therapies in our target indications. There are many other companies, including large biotechnology and pharmaceutical companies, that have commercialized and/or are developing therapies for the same therapeutic areas that our product candidates target. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc. and Agamree (vamorolone) is an FDA-approved corticosteroid marketed by Catalyst Pharmaceuticals in the United States. In addition, there are four FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are phosphorodiamidate morpholino oligomers, or PMOs, approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc., or Sarepta, and VILTEPSO (vitolarsen), a PMO approved for the treatment of patients with DMD who are amenable to exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Additionally, in June 2023, Sarepta announced that the FDA accelerated approval of its product, ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. In June 2024, the FDA granted ELEVIDYS full approval for the treatment of ambulatory individuals aged four years and older, and accelerated approval for the treatment of non-ambulatory individuals aged four years and older. In July 2025, Sarepta announced its decision to voluntarily and temporarily pause all shipments of ELEVIDYS for patients with DMD in the United States. Subsequently, in July 2025, Sarepta announced that the FDA notified Sarepta that it may lift its voluntary pause on shipments of ELEVIDYS for ambulatory patients with DMD, and Sarepta resumed shipping to such patients immediately.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2024, Italfarmaco S.p.A. announced that the FDA approved Duvyzat (givinostat), a histone deacetylase inhibitor for the treatment of DMD in patients aged six years and older.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, several companies are developing gene therapies to treat DMD, including REGENXBIO Inc. and Solid Biosciences Inc. RNA-targeted treatments that are in clinical and preclinical development are also being pursued by several companies, including Avidity Biosciences, Inc., Wave Life Sciences Ltd., Dyne Therapeutics, Inc. and Sarepta. Edgewise Therapeutics, Inc. is developing sevasemten, a myosin ATPase inhibitor, for both DMD and Becker muscular dystrophy. Satellos Bioscience Inc. is developing SAT-3277, an AAK1 inhibitor, for the treatment of DMD.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are three therapies approved by FDA to treat ALS and its symptoms: riluzole, an anti-glutamatergic agent; edaravone, a free-radical scavenger; and tofersen, an antisense oligonucleotide treatment of SOD1-ALS. One additional therapeutic, sodium phenylbutyrate and taurursodiol, was approved under an accelerated pathway by the FDA but subsequently withdrawn from the market following negative results from a confirmatory Phase 3 trial. To the best of our knowledge, there are no other companies developing product candidates to treat ALS by targeting skeletal muscle. However, several companies are developing product candidates to treat ALS through other mechanisms, including Otsuka Pharmaceutical Co., Ltd., Novartis AG and Genervon Biopharmaceuticals LLC.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Kyntra Bio Inc. (formerly FibroGen Inc.) and Astellas Pharma Inc. are developing product candidates for the treatment of anemia, and Merck &amp; Co. Inc., or Merck, Bristol-Myers Squibb Company and Disc Medicine are developing product candidates targeting diseases associated with MDS and myelofibrosis, including chronic anemia. Additionally, in April 2020, Merck and Bristol-Myers Squibb Company received FDA approval of its product, Reblozyl, for the treatment of anemia failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. In June 2020, Merck further announced that the European Commission approved Reblozyl for the treatment of transfusion-dependent anemia in adult patients with MDS or beta thalassemia and in September 2020, Merck announced that Health Canada approved Reblozyl for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta thalassemia. In August 2023, Bristol-Myers Squibb Company announced that the FDA approved Reblozyl for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-na&#239;ve) in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions. In April 2024, Bristol-Myers Squibb Company further announced that the European Commission expanded approval of Reblozyl to include treatment of adult patients with and without ring sideroblasts with transfusion-dependent anemia due to lower-risk MDS. In June 2024, Geron Corporation announced that the FDA approved imetelstat (RYTELO) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2022, CTI BioPharma Corp. (which was acquired by Swedish Orphan Biovitrum AB in June 2023) received FDA accelerated approval of its product, pacritinib (Vonjo), for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 &#215; 10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">/L. In September 2023, GSK plc announced that the FDA approved its product, Ojjaara, for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anemia. Additionally, MorphoSys AG (which was acquired by Novartis AG in July 2024) is also developing a product candidate as a treatment for myelofibrosis, and Incyte Corporation is developing an ALK2 inhibitor product candidate for the treatment of myelofibrosis. Geron Corporation is also developing imetelstat as a treatment for myelofibrosis. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other companies that are developing product candidates that are designed to target the TGF-&#223; signaling pathways include Scholar Rock Holding Corporation, Biogen Inc. and Regeneron Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We anticipate that we will continue to face intense and increasing competition as new treatments enter the market and advanced technologies become available. There can be no assurance that our competitors are not currently developing, or will not in the future develop, products that are equally or more effective or are more economically attractive than any of our current or future product candidates. Competing products may gain faster or greater market acceptance than our products, if any, and medical advances or rapid technological development by competitors may result in our product candidates becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we or our product candidates do not compete effectively, it may have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of biopharmaceutical products. To achieve commercial success for any approved product, we must develop or acquire a sales and marketing organization, outsource these functions to third parties or enter into strategic collaborations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may decide to establish our own sales and marketing capabilities and promote our product candidates if and when regulatory approval has been obtained in the United States or in other jurisdictions. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. Even if we establish sales and marketing capabilities, we may fail to launch our products, if approved, effectively or to market our products effectively since we have no experience in the sales and marketing of biopharmaceutical products. In addition, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. In the event that any such launch is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">commercialization expenses, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Factors that may inhibit our efforts to commercialize our products, if approved, on our own include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the inability of sales personnel to obtain access to or educate adequate numbers of physicians on the benefits of our products, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">costs of marketing and promotion above those anticipated by us.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or the profitability of these product revenues to us could be lower than if we were to market and sell any products that we develop ourselves. Such collaborative arrangements with partners may place the commercialization of our products, if approved, outside of our control and would make us subject to a number of risks including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products, if any, or that our collaborator&#8217;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator&#8217;s business strategy. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products, if approved, or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention to sell and market our products, if any, effectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our products, if any, which in turn would have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. The revenues that we generate from their sales may be limited, and we may never become profitable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive marketing approval will depend on a number of factors, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the clinical indications for which our product candidates are approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">physicians, hospitals and patients considering our product candidates as a safe and effective treatment; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the potential and perceived advantages of our product candidates over alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the prevalence and severity of any side effects; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">product labeling or product insert requirements of the FDA or comparable foreign regulatory authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the timing of market introduction of our product candidates in relation to other potentially competitive products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the cost of our product candidates in relation to alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the amount of upfront costs or training required for physicians to administer our product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the availability of coverage and adequate reimbursement from third-party payors and government authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the willingness of patients to pay out-of-pocket in the absence of comprehensive coverage and reimbursement by third-party payors and government authorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the effectiveness of our sales and marketing efforts and distribution support; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the presence or perceived risk of potential product liability claims.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, Congressional and executive branch challenges and amendments to certain aspects of the ACA.  For example, on July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.  The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies. Other legislative changes have also been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act and the Consolidated Appropriations Act of 2023, will remain in effect until 2032, unless additional action is taken by Congress. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at the U.S. Department of Health and Human Services, or HHS, the FDA, the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform, U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks.  In June 2024, Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the EU provides options for EU Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">an adverse impact on reimbursement status. We expect that legislators, policymakers and healthcare insurance funds in the EU Member States will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. The Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. On January 12, 2025 Regulation No 2021/2282 on HTA entered into application through a phased implementation. The Regulation is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and establishes a framework for EU-level joint clinical assessments. The regulation permits EU Member States to use common HTA tools, methodologies, and procedures across the EU to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. The implementation of cost containment measures or other healthcare reforms may negatively impact our operations. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC and other government agencies or comparable regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, otherwise prevent new products and services from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory and policy changes, and other events that may otherwise affect the FDA&#8217;s or comparable foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies or comparable foreign regulatory authorities on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disruptions at the FDA, other agencies or comparable foreign regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved, which would adversely affect our business. For example, the U.S. government has shut down several times, including in October 2025, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities during such shutdowns. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may be subject to applicable healthcare regulatory laws, which could expose us to penalties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by private individuals on behalf of the government through civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal civil and criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information, as well as their covered subcontractors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to certain payments and other transfers of value made in the prior year to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">analogous U.S. state and foreign laws and regulations, including: anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government or foreign regulatory authorities, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; laws that require the registration of pharmaceutical sales representatives; and laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, our activities are also subject to certain federal, state consumer and foreign protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we believe they are, even assuming approval of a product candidate, our business may suffer. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our projections of both the number of people who are affected by disease within our potential target indications, as well as the subset of these people who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, healthcare utilization databases and market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the CMS. The CMS decide whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products, if approved, to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products, if any. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, obtaining coverage and adequate reimbursement for products administered under the supervision of a physician may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, HHS imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source drugs </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">that have been on the market for at least seven years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to 20 products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products, if approved, may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_76"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The patenting process is expensive and time-consuming, and we may not be able to file, prosecute and maintain all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue, obtain or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim, and we may be subject to a third-party preissuance submission of prior art to the USPTO. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products, if any, on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">others may independently develop similar or alternative technologies or duplicate any of our technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that our pending patent applications will not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that others may circumvent our owned or in-licensed patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products, if any, or technology similar to ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">we may not develop additional proprietary technologies for which we can obtain patent protection; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. See the section titled &#8220;Business&#8212;Collaborations and License Agreement&#8221; set forth in Part I, Item 1 of this Annual Report on Form 10-K for additional information regarding our license agreements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our right to sublicense patents and other rights to third parties under collaborative development relationships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, intellectual property license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our patent license with a third party, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a party to a license agreement pursuant to which we in-license key patent and patent applications for our product candidates. These existing licenses impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensor may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by our licensor have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to patent protection, we rely heavily upon know-how and to some extent trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to our product candidates and programs. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.  We are aware of issued patents, in the United States and abroad, relating to methods of treating DMD. If any such patent were to be asserted against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if these patents were asserted against us and our defenses to such an action were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and precluded from commercializing rinvatercept in certain indications, which could have a material adverse effect on our business, financial condition, cash flows or results of operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, if any; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the United States is protected under the Safe Harbor exemption as set forth in 35 U.S.C. &#167; 271. If and when rinvatercept, elritercept, or another one of our product candidates is approved by the FDA, that certain third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we do not believe that any claims of such patent that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Even if such a license is available, it may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Lastly, we may need to indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our product candidates, including rinvatercept and elritercept. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the product candidates or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products, if approved, or services. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the foreign patent offices. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products, if approved, or technology similar to ours. Any such patent application may </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, the patents included in our patent portfolio may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. For example, the patents related to novel ALK2 inhibitors in the patent family that we license from The General Hospital Corporation are expected to expire in April 2038, without taking into account any possible patent term adjustments or extensions. Upon the expiration of our current or future owned or licensed patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2037 through 2046, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the U.S. and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or in ex-U.S. jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc. v. Sanofi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, the Federal Circuit held that a well-characterized antigen is insufficient to satisfy the written description requirement of certain claims directed to a genus of antibodies that are solely defined by function; and in the case of Assoc. for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Molecular Pathology v. Myriad Genetics, Inc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Some of our in-licensed intellectual property that is discovered through government-funded programs may be subject to federal regulation such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements and limit our ability to contract with foreign manufacturers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">It is possible that patent filings we may choose to in-license in the future may be subject to the Bayh-Dole Act. In particular, under the Bayh-Dole Act, the federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. Intellectual property discovered under government-funded programs are also subject to certain reporting requirements, compliance with which may require us or our licensors to expend substantial resources. Such intellectual property is also subject to a preference for U.S. industry, which may limit our ability to contract with foreign product manufacturers for products covered by such intellectual property. Moreover, we sometimes collaborate with academic institutions to accelerate our preclinical research or development. While it is our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. Further, we may choose to license intellectual property in the future that may be subject to government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as do federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensing partners are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Also, competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may incur substantial costs as a result of litigation or other proceedings relating to patents, and we may be unable to protect our rights to our products, if approved, and technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we or our licensing partners choose to go to court to stop a third party from using the inventions claimed in our owned or in-licensed patents, that third party may ask the court to rule that the patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive and would consume time and other resources even if we or they, as the case may be, were successful in stopping the infringement of these patents. In addition, there is a risk that the court will decide that these patents are not valid and that we or they, as the case may be, do not have the right to stop others from using the inventions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party&#8217;s activities do not infringe our owned or in-licensed patents. In addition, the U.S. Supreme Court has recently changed some legal principles that affect patent applications, granted patents and assessment of the eligibility or validity of these patents. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Some of our owned or in-licensed patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which could also make it more difficult to obtain patents. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We, or our licensing partners, may not be able to detect infringement against our owned or in-licensed patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensing partners detect infringement by a third party of our owned or in-licensed patents, we or our licensing partners, as the case may be, may choose not to pursue litigation against or settlement with the third party. If we, or our licensing partners, later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us or our licensing partners to enforce our owned or in-licensed patents, as the case may be, against such third party. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If another party questions the patentability of any of our claims in our owned or in-licensed U.S. patents, the third-party can request that the USPTO review the patent claims such as in an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> review, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> re-exam or post-grant review proceedings. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in foreign patent offices, where either our owned or in-licensed foreign patents are challenged. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the future, we may be involved in similar proceedings challenging the patent rights of others, and the outcome of such proceedings is highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. Further, for our licensed patents, we may not have the right to control prosecution, including filing with the USPTO, of a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names or trademarks. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_79"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators and trial sites. If we, our investigators or any of our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP regulations. In addition, our clinical trials must be conducted with product, including biologic product, produced in compliance with applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat preclinical studies or clinical trials, which would delay the regulatory approval process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, these laboratories, investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Public health crises and government measures taken in response also impact our CROs, and may affect our ability to initiate and complete our preclinical studies and clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA or comparable foreign regulatory authorities. Any such delay or rejection could prevent us from commercializing our clinical-stage product candidate or any future product candidates. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply and manufacture our product candidates, and we expect to continue to rely on third parties to manufacture our products, if approved. The development of such product candidates and the commercialization of any products, if approved, could be stopped, delayed or made less profitable if any such third party fails to provide us with sufficient quantities of product candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or capability internally to manufacture our product candidates for use in the conduct of our preclinical studies and clinical trials or for commercial supply, if our products are approved. We rely on, and expect to continue to rely on, contract manufacturing organizations, or CMOs. Any replacement of our CMOs could require significant effort and expertise because there may be a limited number of qualified CMOs. This could be particularly problematic where we rely on a single-source supplier, as is currently the case for the manufacture of each of rinvatercept and elritercept.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Reliance on third-party providers may expose us to more risk than if we were to manufacture our product candidates ourselves. We are dependent on our CMOs for the production of our product candidates in accordance with relevant regulations, such as cGMP, which includes, among other things, quality control, quality assurance and the maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development activities that could harm our competitive position. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our product candidates, we could experience delays in our research or planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. Any changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around manufacturing and testing requirements generally or with respect to our technology in particular, could also limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if necessary, could significantly delay our clinical trials and the commercialization of our products, if approved, which could materially adversely affect our business, financial condition and results of operation. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In complying with the applicable manufacturing regulations of the FDA and comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. The facilities used by our contract manufacturers to manufacture our product candidates are subject to review by the FDA or comparable foreign regulatory authorities pursuant to inspections that will be conducted after we submit our NDA or BLA to the FDA, or similar applications to comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP requirements for manufacture of drug and biologic products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we will not be able to secure or maintain regulatory approval for our product candidates manufactured at these manufacturing facilities. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing partners may be found on regulatory inspection by the FDA or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if any regulatory authority withdraws its approval in the future, we and they may need to find alternative manufacturing facilities, which would negatively impact the ability to develop, obtain regulatory approval for or market our product candidates, if approved. The failure of our manufacturers to comply with regulatory requirements could also result in an enforcement action against us, including the seizure of products and shutting down of production. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant interruptions. We face risks inherent in relying on a single CMO, as any disruption, such as a fire, natural hazards or vandalism at the CMO could significantly interrupt our manufacturing capability. All of our CMOs currently do not have alternative production plans in place or disaster-recovery facilities available. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our existing third-party collaborations with Takeda and Hansoh to commercialize elritercept, and if Takeda and Hansoh are not successful in commercializing elritercept in their respective licensed territories, we will lose a significant source of potential revenue.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the Takeda Agreement, Takeda will pay us milestone payments upon the achievement of specified development, commercial and sales milestones. In addition, if a licensed product is approved for marketing within the Takeda Territory, which includes all countries globally other than the territories of mainland China, Hong Kong and Macau, we will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions. However, under the terms of the Takeda Agreement, Takeda may terminate the agreement in its entirety or on a country-by-country basis for convenience and without cause on written notice of a certain period. In addition, Takeda generally has control over the further clinical development of elritercept and any other licensed compounds in the Takeda Territory. Takeda&#8217;s decisions with respect to such development will affect the timing and availability of potential future payments under the Takeda Agreement, if any. If the Takeda Agreement is terminated early, or if Takeda&#8217;s development activities are terminated early or suspended for an extended period of time, or are otherwise unsuccessful, our business and business prospects would be materially and adversely affected.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Additionally, under the terms of the license agreement with Hansoh, Hansoh will pay us milestone payments upon the achievement of specified development and commercial milestones. In addition, if elritercept, or a licensed product containing elritercept, is approved for marketing within the territories of mainland China, Hong Kong and Macau, which we refer to collectively as the Hansoh Territory, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. We are relying on Hansoh to commercialize elritercept in the Hansoh Territory, and if Hansoh is not able to commercialize elritercept in those countries, or determines not to pursue development or commercialization of elritercept in those countries, we will not receive any milestone or royalty payments under the agreement.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our current and future collaborations are and will be important to our business. If we are unable to enter into new collaborations, or if these or our current collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into additional strategic collaborations in the future when strategically attractive, including potentially with major biotechnology or pharmaceutical companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. Other than our respective collaborations with Takeda and Hansoh for elritercept, we have no active collaborations for any of our product candidates. Our collaborations with Takeda and Hansoh and any future collaboration arrangements may not ultimately be successful, which could have a negative impact on our business, results of operations, financial condition and growth prospects. We do not maintain significant rights or control of future development and commercialization </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">activities under our collaboration with Takeda. This could lead to potential disputes in the future over the terms of the collaboration and the respective rights of the parties, and these risks and uncertainties could be present with respect to our potential future collaborations as well.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our product could change and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual property rights held by third parties, and the growth of our business may depend in part on our ability to acquire or in-license these intellectual property rights. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any future collaborations we enter into may pose a number of risks, including, but not limited to, the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators have significant discretion in determining the efforts and resources that they will apply; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may not perform their obligations as expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products, if approved, and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">if a collaborator of ours is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of any product candidate licensed to it by us; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our therapeutic collaborators. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborative partners. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon an assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such ownership regardless of the merits of the challenge) and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may evaluate various acquisition opportunities and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">increased operating expenses and cash requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the assumption of additional indebtedness or contingent liabilities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the issuance of our equity securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions or pursue collaborations in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_82"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Employee Matters, Managing Our Growth and Other Risks Relating to Our Operations </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, including our Chief Executive Officer and Chief Scientific Officer. If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management and particularly on the services of our scientific personnel including Jasbir Seehra, Ph.D., our Chief Executive Officer, and Lorena Lerner, Ph.D., our Chief Scientific Officer. We believe that their drug discovery and development experience and overall biopharmaceutical company management experience would be difficult to replace. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees. The loss of the services of our key personnel and any of our other executive officers, key employees, and scientific and medical advisors, and our inability to find suitable replacements, could result in delays in our research and development objectives and harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our corporate restructuring announced in May 2025 may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 29, 2025, we announced the implementation of a corporate restructuring, including a reduction in force of approximately 45% of our then-current employee base across all functions, or the 2025 Restructuring. We substantially completed the 2025 Restructuring at the end of July 2025. As a result of the 2025 Restructuring, we estimated that we will </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">realize average annualized cost savings of approximately $17 million. However, these estimates are subject to several assumptions, and actual results may differ. We may not realize, in full or in part, the anticipated benefits and savings from this plan due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected cost savings from the announced plan, our operating results and financial condition could be adversely affected. The workforce reduction may be disruptive to our operations and could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale, as well as result in weaknesses in our infrastructure and operations, and may increase the risk that we become unable to comply with legal and regulatory requirements. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical and/or manufacturing personnel. Any failure to attract or retain qualified personnel could prevent us from successfully developing rinvatercept or from supporting our ongoing collaborations.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December 31, 2025, we had 78 full-time employees, including 59 employees engaged in research and development and 19 employees engaged in management or general and administrative activities. As our clinical development and commercialization plans and strategies develop, we expect we will need additional managerial, operational, sales, marketing, financial, legal and other personnel. Future growth would impose significant added responsibilities on members of management, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">managing our development efforts effectively, including the clinical and FDA review process for rinvatercept, elritercept and any future product candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">improving our operational, financial and management controls, reporting systems and procedures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize rinvatercept, elritercept and any other product candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. The services include substantially all aspects of clinical trial management and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of rinvatercept, elritercept and our other product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize rinvatercept, elritercept and our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.  </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our internal computer systems, or those used by our contract research organizations, or other contractors or consultants with whom we work, fail, suffer security incidents, or are or were otherwise compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties with whom we work, collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, process), proprietary, confidential and sensitive data, including personal data (such as health-related data), intellectual property and trade secrets (collectively, sensitive information). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work are vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties with whom we work are subject to a variety of evolving </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">threats, including but not limited to social-engineering attacks (including through deep fakes, which are increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, attacks enhanced or facilitated by AI, and other similar threats. It may be difficult and/or costly to detect, investigate, mitigate, contain and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain and remediate a security incident could result in outages, data losses and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems. For example, threat actors may use an initial compromise of one part of our environment to gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain access to the networks or systems of third parties with whom we work, such as through phishing or supply chain attacks. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide products and services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business, particularly due to our hybrid work policies. Hybrid work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use third parties to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, encryption and authentication technology, employee email and other functions. We also work with third-party service providers to provide other products, services, parts or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities in our information systems, but we have not always been and may not in the future be able to detect and remediate all vulnerabilities on a timely basis because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited and result in a security incident, but may not be detected until after the security incident has occurred. Unremediated high risk or critical vulnerabilities pose material risks to our business. Further, we have at times experienced and may in the future experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats have in the past and may in the future cause a security incident or other interruption that have in the past and may in the future result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of or access to our sensitive information or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our business. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations have required us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The costs to respond to a security incident and/or to mitigate any security vulnerabilities that we identify could be significant, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity, and other harm to our business and our competitive position. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. Additionally, our sensitive information could be leaked, disclosed, or revealed as a result of or in connection with our employee&#8217;s, personnel&#8217;s, or vendor&#8217;s use of generative artificial intelligence, or AI, technologies, resulting in adverse consequences. In each case, these consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class action </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause individuals to stop conducting business with us or negatively impact our ability to grow and operate our business. For example, the loss of preclinical or clinical data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security incident affecting us, our current and future CROs, collaborators, contractors, consultants or other partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. Likewise, we use third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could face governmental reporting obligations, fines, incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Most jurisdictions have enacted laws requiring companies to notify individuals, regulatory authorities, and others of security incidents involving certain types of data. In addition, our agreements with collaborators may require us to notify them in the event of a security incident. Such mandatory disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences such as negative publicity, may cause our collaborators to lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources to respond to and/or alleviate problems caused by the actual or perceived security incident.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, any actual or perceived security incident could result in legal claims or proceedings, regulatory investigations or actions, and other types of liability under laws that protect the privacy and security of personal information, including federal, state and foreign data protection and privacy regulations, violations of which could result in significant penalties and fines in the EU, UK and United States notably. In addition, security incidents and other incidents of unauthorized access to our information technology systems and data can be difficult to detect and any delay in identifying such breaches or incidents may lead to increased harm and legal exposure of the type described above.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition to experiencing a security incident, third parties may gather, collect or infer sensitive information about us from public sources, data brokers or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to government enforcement actions, including administrative, civil or criminal fines or penalties, private litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; other liabilities and adverse publicity and could negatively affect our operating results and business. Compliance or the failure to comply with such laws and regulations could increase the costs of our products, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we process personal data and other sensitive information. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including federal and state health information privacy laws, state data breach notification laws, and federal and state consumer protection laws (including Section 5 of the Federal Trade Commission Act) and other similar laws (e.g., wiretapping laws), that govern the collection, use, disclosure and protection of health information and other personal information could apply to our operations or the operations of our collaborators. In addition, we obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, which imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. Depending on the facts and circumstances, we could be subject to civil, criminal and administrative penalties and fines if we violate HIPAA. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, certain state and foreign laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than U.S. federal law and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, or the CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines and allows private litigants affected by certain data breaches to recover significant statutory damages. The CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other laws and regulations also apply to our business model. We are subject to new laws governing the privacy of consumer health data. For example, Washington&#8217;s My Health My Data Act, or MHMD, broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states have passed, are considering, and may adopt similar laws. Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data. For example, some of our data processing practices may be challenged under wiretapping laws, if we obtain consumer information from third parties through various methods, including cookies, chatbot and session replay providers, or via third-party marketing pixels. These practices may be subject to increased challenges by class action plaintiffs. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demands.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the EU's General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR (collectively referred to as the GDPR), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais) (Law No. 13,709/2018), Turkey&#8217;s Personal Data Protection Law, South Korea&#8217;s Personal Information Protection Act, Taiwan&#8217;s Personal Data Protection Act, Peru&#8217;s Personal Data Protection Law, South Africa&#8217;s Protection of Personal Information Act, and China&#8217;s Personal Information Protection Law impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to &#8364;20 million under the EU GDPR, 17.5 million pounds sterling under the UK GDPR, or in each case,4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or the EEA, and the UK have significantly restricted the transfer of personal data to countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EU-U.S. Data Privacy Framework and the UK Extension to the EU-U.S. Data Privacy Framework, under which we have self-certified to allow for transfers from the EEA and/or UK to the United States, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Regulators in the United States, such as the Department of Justice, are also increasingly scrutinizing certain personal data transfers and have proposed and may enact certain data localization requirements, for example, the Biden Administration&#8217;s executive order Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered &#8220;foreign persons&#8221; and are majority owned by, organized under the laws of, a primary resident in, or a contractor of, a covered person or country of concern, as applicable) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to enter into certain transactions or agreements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Laws such as these give rise to an increasingly complex set of compliance obligations on us. These data protection rules continue to evolve and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions and increased costs of compliance. We strive to comply with these rules and obligations to the extent possible. Such compliance is a rigorous and time-consuming process.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials, whitepapers and other statements, such as statements related to compliance with certain certifications or self-regulatory principles, concerning data privacy and security. Although we endeavor to comply with our policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials, statements or documentation are found to be deficient, lacking in transparency, deceptive, unfair, misleading or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and individuals&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent and creating uncertainty. Additionally, these obligations are subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources. These obligations may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work on may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits and inspections); litigation (including class action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal information in AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions and lawsuits. If we are unable to use AI, it could make our business less efficient and result in competitive disadvantages.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our costs of legal compliance, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government investigations and/or enforcement actions (which could include civil, criminal and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and comparable foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal or comparable foreign healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Public health crises could adversely impact our business, including the timing or results of our preclinical studies and clinical trials.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result of any public health crises, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in local regulations as part of a response to public health crises, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">risk that participants enrolled in our clinical trials will acquire any contagious diseases while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">interruptions in preclinical studies due to restricted or limited operations at our research and development laboratory facility or delays in receiving the supplies and materials needed to conduct our preclinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">refusal of the FDA or comparable foreign regulatory authorities to accept data from clinical trials in these affected geographies; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">interruption or delays to our sourced discovery and clinical activities.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the extent a public health crises adversely affects our business, financial condition and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks are associated with operating our business internationally which could materially adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have conducted and conduct certain research and development and clinical operations in Australia, New Zealand, Europe, the United Kingdom and other foreign countries and may also conduct certain future clinical trials outside of the United States. Additionally, while we have not taken any steps to enter into any non-U.S. markets, we may do so in the future. Accordingly, we are subject to risks related to operating in foreign countries, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">different standards of care in various countries that could complicate the evaluation of our product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">different United States and foreign drug import and export rules; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">reduced protection for intellectual property rights in certain countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">compliance with the FCPA and other anti-corruption and anti-bribery laws; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">different payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">potential liability resulting from development work conducted by foreign partners; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">business interruptions resulting from natural disasters, outbreaks of contagious diseases and other public health crises, or geopolitical actions, including war and terrorism, or systems failure including cybersecurity breaches; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">compliance with evolving and expansive foreign regulatory requirements, including data privacy laws (such as the GDPR).</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, in connection with the ongoing war between Russia and Ukraine, the U.S. government and EU countries have imposed enhanced export controls on certain products and sanctions on certain industry sectors and parties in Russia. The U.S. government has also indicated it will consider imposing additional sanctions and other similar measures in the near </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">future. Although we do not currently conduct any clinical trials in Russia or Ukraine, further escalation of geopolitical tensions could have a broader impact that expands into other markets where we do business or conduct certain research and development operations, which could adversely affect our business, our supply chain for our product candidates, our collaborators or our ability to carry out our clinical trials.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are presently conducting clinical development in Australia, New Zealand, Europe, the United Kingdom and other foreign countries and may choose to conduct additional international clinical trials in the future. The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits companies and their employees and third-party intermediaries from paying, offering, promising or authorizing others to pay or offer anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls. The FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are owned and operated by the government, and doctors and other hospital employees are considered foreign officials. We can be held liable for the corrupt or other illegal activities of our employees, representatives, contractors, business partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities. Noncompliance with the FCPA and anti-corruption laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, our products, if approved, may be subject to export controls, trade sanctions laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act of 2017, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security, or CARES, Act was signed into law in March 2020. The CARES Act modifies certain of the changes made by the Tax Act. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the Tax Act, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition or results of operations. For example, the IRA, enacted in 2022, includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock, and the OBBBA, enacted in 2025, restores the current tax deductibility of domestic research and experimental expenses, which expenses had been required under the Tax Act to be capitalized and subsequently amortized over five years. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, as amended by the CARES Act, or newly enacted federal tax legislation such as the OBBBA.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss, or NOL, carryforwards and certain tax credit carryforwards may be subject to limitation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $159.1 million of U.S. federal, $27.9 million of state and no foreign NOL carryforwards. Under the Tax Act, as modified by the CARES Act, federal NOLs incurred in taxable years beginning after December 31, 2017 can be carried forward indefinitely, but the deductibility of federal NOLs in taxable years beginning after December 31, 2020, is limited.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our NOL and tax credit carryforwards are subject to review and possible adjustment by the U.S. and state tax authorities. In addition, under Sections 382 and 383 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL and research and development, or R&amp;D, tax credit carryforwards to offset its post-change taxable income and tax may be limited. This could limit the amount of NOLs or R&amp;D tax credit carryforwards that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs and R&amp;D tax credits carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Through November 21, 2025, we completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation. The results of this study indicated that we experienced ownership changes as defined by Section 382 of the Code in 2016, 2020 and 2025. These ownership changes have subjected and will continue to subject our NOL and tax credit carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset our taxable income and tax in periods following the ownership changes.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_85"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">An active, liquid and orderly trading market may not develop for our common stock and as a result it may be difficult for you to sell your shares of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to our IPO in April 2020, there was no public market for shares of our common stock. Although our common stock is currently listed on the Nasdaq Global Market, we cannot assure you that an active trading market for our shares will develop or be sustained. In the absence of an active trading market for our common stock, investors may not be able to sell their shares of common stock without depressing the market price for the common stock, or may not be able to sell the shares at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to enter into collaborations or acquire other companies or technologies using our shares as consideration. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">variations in the level of expense related to the ongoing development of our product candidates and preclinical and clinical development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">results of preclinical studies and ongoing and future clinical trials, or the addition or termination of clinical trials or funding support by us, or current or future collaborators or licensing partners; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">additions and departures of key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">strategic decisions by us, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">regulatory developments affecting our product candidates; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">general economic conditions, including as a result of bank failures, as well as economic conditions specifically affecting the biopharmaceutical industry.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and is likely to continue to be volatile and fluctuate substantially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The market price of our common stock has been and is likely to continue to be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways. The market price for our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this &#8220;Risk Factors&#8221; section: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">results of preclinical studies and clinical trials of rinvatercept, elritercept and any other product candidate we may develop or those of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">commencement or termination of collaboration, licensing or similar arrangements for our development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">failure or discontinuation of any of our development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">results of clinical trials of product candidates of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">regulatory or legal developments in the United States and other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the recruitment or departure of key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the level of expenses related to the development of rinvatercept, elritercept and any other product candidate we may develop; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">announcements or expectations of additional financing efforts by us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">sales of our common stock by us, our insiders or other stockholders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">recommendations and changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">changes in the structure of healthcare payment systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad,  such as potential future disruptions in access to bank deposits or lending commitments due to bank failures; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">investors&#8217; general perception of us and our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. In addition, the trading prices for common stock of other pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of public health crises, geopolitical tensions, a resulting global slowdown of economic activity, increased inflation, tariffs and other adverse effects or developments. The extent to which these factors may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may negatively affect the liquidity of our common stock. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against public companies following declines in the market prices of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business, operating results, financial condition and cash flows. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to our 2020 Equity Incentive Plan, or 2020 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2021 continuing through January 1, 2030, by 4.0% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by our board of directors. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">You should not rely on an investment in our common stock to provide dividend income. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur, as the only way to realize any return on their investment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our capital allocation strategy may not be effective at enhancing stockholder value, or providing other benefits we expect.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although our capital allocation strategy is intended to enhance stockholder value and demonstrate our commitment to return excess capital to stockholders while maintaining our ability to advance the clinical development of our product candidates, there can be no assurance it will be effective. We have taken significant steps intended to better align our existing capital structure with our go-forward capital allocation strategy. For example, in June 2025, following a strategic alternatives review process, our board of directors determined to initiate a process to return $375 million of excess capital to stockholders. Subsequently, on October 15, 2025, we entered into the ADAR1 Repurchase Agreement and the Pontifax Repurchase Agreement, each as described in more detail herein, to repurchase the shares of our common stock held by the ADAR1 Parties and the Pontifax Parties, respectively. Pursuant to the terms and conditions of the ADAR1 Repurchase Agreement and the Pontifax Repurchase Agreement, the ADAR1 Parties and the Pontifax Parties sold all of the shares of our common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to us at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 20, 2025 we announced the commencement of an issuer tender offer to repurchase shares of our common stock for an aggregate cash purchase price of up to $194.4 million, at a cash purchase price of $17.75 per share, the final results of which were announced on November 20, 2025. Returning excess capital, including via the ADAR1 Repurchase Agreement, the Pontifax Repurchase Agreement and the completed issuer tender offer, may reduce the market liquidity for our stock, potentially affecting its trading volatility and price, and diminished our cash reserves, which may impact our ability to advance the clinical development of our product candidates. Therefore, if we do not properly allocate our capital, we may fail to produce optimal financial results and experience a reduction in stockholder value.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly or indirectly compete with us. As a result of these relationships, conflicts may arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders, and members of our board of directors that are representatives of such principal stockholders may not be disinterested in such conflicts. Neither the principal stockholders nor the representatives of the principal stockholders on our board of directors, by the terms of our amended and restated certificate of incorporation, are required to offer us any transaction opportunity of which they become aware and could take any such opportunity for themselves or offer it their other affiliates, unless such opportunity is expressly offered to them solely in their capacity as members of our board of directors. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline. We are unable to predict the effect that such sales, particularly by our directors, executive officers and significant stockholders, may have on the prevailing market price of our common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to options, restricted stock units or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements on Form S-8 are available for sale in the public market subject to vesting arrangements and exercise of options and the restrictions of Rule 144 under the Securities Act in the case of our affiliates. In addition, certain holders of shares of our common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, the price of our stock would likely decline. If one or more of these analysts cease to cover our stock or fail to publish reports on us regularly, we could lose visibility in the market for our stock, which, in turn, could cause our stock price and trading volume to decline. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We will incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Stock Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We are evaluating these rules and regulations, and cannot predict or estimate the amount or timing of additional costs we may incur or the timing of such costs. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our services. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure requirements applicable to smaller reporting companies, our common stock may be less attractive to investors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company,&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies,&#8221; including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We are also a non-accelerated filer and are not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. Our internal controls over financial reporting will not receive the level of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to these requirements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer a &#8220;smaller reporting company.&#8221; We will remain a &#8220;smaller reporting company&#8221; until (a) the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day of our most recently completed second fiscal quarter is $250 million or more and we reported annual net revenues as of our most recently completed fiscal year of $100 million or more, or (b) the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day of our most recently completed second fiscal quarter is $700 million or more, regardless of annual revenue.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to assess the effectiveness of our internal control over financial reporting annually and disclosure controls and procedures quarterly. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. When we become an accelerated filer or large accelerated filer, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our stockholder rights plan and provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2025, our board of directors adopted a stockholder rights plan that would cause substantial dilution to, and substantially increase the costs paid by, a stockholder who attempts to acquire us on terms not approved by our board of directors. The intent of the stockholder rights plan is to protect our stockholders&#8217; interests by encouraging anyone seeking control of our company to negotiate with our board of directors. However, our stockholder rights plan could make it more difficult for a third party to acquire us without the consent of our board of directors, even if doing so may be beneficial to our stockholders. This plan may discourage, delay or prevent a third-party tender offer or takeover attempt, including offers or attempts that could result in a premium over the market price of our common stock. This plan could reduce the price that stockholders might be willing to pay for shares of our common stock in the future. Furthermore, the anti-takeover provisions of our stockholder rights plan may entrench management and make it more difficult to replace management even if the stockholders consider it beneficial to do so.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">establish a classified board of directors such that not all members of the board are elected at one time; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">limit the manner in which stockholders can remove directors from the board; </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">prohibit our stockholders from calling a special meeting of our stockholders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making third-pary tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any derivative action or proceeding brought on our behalf; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, unless we consent in writing to the selection of an alternative forum. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. For example, the Court of Chancery of the State of Delaware recently determined that a provision stating that U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act is not enforceable. However, on March 18, 2020, this decision was ultimately overturned by the Delaware Supreme Court. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business. </span></div><div id="i2030eac40e414171a9c72c0ab0189734_88"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_91"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. CYBERSECURITY</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-40" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data and information related to our product candidates, preclinical studies and clinical trials, which we refer to collectively as Information Systems and Data.  </span></div><div style="margin-bottom:9.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our information technology and security, or IT, management team, and legal, and risk management teams, together with our third-party service providers, help identify, assess and manage our cybersecurity threats and risks. In doing so, they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using a multi-faceted approach including use of manual and automated tools,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">internal and external IT audits, and IT security, governance, risk and compliance reviews, reviewing reports and using services that identify cybersecurity threats, conducting threat and vulnerability assessments, evaluating reported threats as well as the industry&#8217;s risk profile, and third-party-conducted red/blue team testing and tabletop incident response exercises.</span></ix:nonNumeric></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: maintaining an incident response plan and policy, incident detection and response, maintaining a vulnerability management policy, maintaining disaster recovery and business continuity plans, conducting risk assessments, implementing security standards and certifications, maintaining network security controls, access controls, and physical security measures, asset management, systems monitoring, conducting proactive privacy and cybersecurity reviews of systems and applications, performing penetration testing using external third-party tools and techniques to test security controls, conducting employee training, monitoring emerging laws and regulations related to data protection and information security and implement appropriate changes and encrypting Information Systems and Data. In addition, we maintain cybersecurity insurance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-42" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-43">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes</ix:nonNumeric>.  For example, our IT team works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. Additionally, our risk committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</ix:nonNumeric> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-44">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers and penetration testing firms</ix:nonNumeric>.   </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight of applicable third-party service providers when handling or processing our Information Systems and Data. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider, including completion of security questionnaires, review of the vendor&#8217;s written security program, review of security assessments and reports, audits, and security assessment calls with the vendor&#8217;s security personnel. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-45"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">If our internal computer systems, or those used by our contract research organizations, or other contractors or consultants with whom we work, fail, suffer security incidents, or are or were otherwise compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8221;</span></ix:nonNumeric></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-46" escape="true">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-48">audit committee</ix:nonNumeric> is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric> Members of our audit committee receive updates on a regular basis from senior management, including leaders from our IT and legal teams regarding matters of cybersecurity. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents (if any) and status on key information security initiatives.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-51" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-49" escape="true">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity.</ix:nonNumeric></ix:nonNumeric> These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to our audit committee on any appropriate items</ix:nonNumeric>.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Chief Financial Officer is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-54" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-53" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-52">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Financial Officer and General Counsel.</ix:nonNumeric> Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. Our Head of IT works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response plan includes reporting to our audit committee for certain cybersecurity incidents.</ix:nonNumeric></ix:nonNumeric> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_94"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2021, we entered into an indenture of lease for approximately 35,662 square feet of office and laboratory space located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, which terminates in February 2031. As of January 23, 2023, we moved our principal office to this property. Prior to that date, our principal office was located at 99 Hayden Avenue, Suite 120, Building E, Lexington, Massachusetts 02421, which provided approximately 15,622 square feet of office and laboratory space. The lease for the prior principal office expired on March 31, 2023. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2024, we entered into a sublease for approximately 20,000 square feet of office and laboratory space located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421, expanding our existing headquarters. The sublease expires in September 2029.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or substitute space will be available in the future on commercially reasonable terms to accommodate any such expansion of our operations. </span></div><div id="i2030eac40e414171a9c72c0ab0189734_97"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may become subject to arbitration, litigation or claims arising in the ordinary course of business. We are not currently a party to any material arbitration or legal proceedings. The results of any future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, and other factors.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_100"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_103"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i2030eac40e414171a9c72c0ab0189734_106"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock commenced trading on the Nasdaq Global Market on April 8, 2020 and trades under the symbol &#8220;KROS.&#8221; Prior to April 8, 2020, there was no public market for our common stock.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of February 27, 2026, there were 12 stockholders of record of our common stock, one of which is Cede &amp; Co., a nominee for Depository Trust Company, or DTC. All of the shares of common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are considered to be held of record by Cede &amp; Co. as one stockholder.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings for the operation and expansion of our business and, therefore, we do not anticipate declaring or paying cash dividends in the foreseeable future. The payment of dividends will be at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, any limitations on payment of dividends present in any future debt agreements and other factors that our board of directors may deem relevant.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our stock repurchase activity for each of the three months in the quarter ended December 31, 2025 was:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Period</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 1-31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,176,595(1)(2) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,176,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">November 1-30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,950,165(3)  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,950,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 1-31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,126,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,126,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;On October 15, 2025, we entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (collectively the &#8220;ADAR1 Parties&#8221;, and such stock purchase agreement, the &#8220;ADAR1 Repurchase Agreement&#8221;), and certain entities affiliated with Pontifax Venture Capital (collectively, the &#8220;Pontifax Parties&#8221;, and such stock purchase agreement, the &#8220;Pontifax Repurchase Agreement&#8221; and, together with the ADAR1 Repurchase Agreement, the &#8220;Repurchase Agreements&#8221;). Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to us at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;On October 20, 2025, we announced that our board of directors authorized the repurchase of up to $194.4 million shares of our common stock at a cash purchase price of $17.75 per share, through a tender offer, which we refer to as the Tender Offer. We launched the Tender Offer on October 20, 2025 and it was completed on November 21, 2025. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;On November 20, 2025, we disclosed that a total of 17,712,262 shares of our common stock were validly tendered and not validly withdrawn. In accordance with the terms and conditions of the Tender Offer, we accepted for purchase a total of 10,950,165 shares of common stock,  or the Tender Offer Shares, at a purchase price of $17.75 per share, for an aggregate purchase price of approximately $194.4 million, excluding fees and expenses of $9.6 million relating to the Repurchase Agreements and the Tender Offer. As a result of the Tender Offer, we had 19,543,706 shares of common stock outstanding immediately following the closing of the Tender Offer. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_109"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. [Reserved]</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_112"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS&#160;OF&#160;OPERATIONS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_115"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-&#223;, family of proteins. We are a leader in understanding the role of the TGF-&#223; family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Our most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. In December 2024, we entered into an exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, which became effective on January 16, 2025, to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception in 2015, we have devoted the majority of our efforts into business planning, research and development of our product candidates, including by conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. To date, we have not generated any revenue from product sales as none of our product candidates have been approved for commercialization. We have historically financed our operations primarily through the sale of convertible preferred stock and common stock and cash received from licensing agreements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Sales Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022, we filed a prospectus supplement to our registration statement on Form S-3ASR with the Securities and Exchange Commission, or the SEC, for the issuance and sale, if any, of up to $250.0 million of shares of our common stock pursuant to a sales agreement with Leerink Partners LLC, or Leerink, as sales agent, which we refer to as the ATM Sales Agreement, under which we may offer and sell, from time to time, shares of our common stock, or the ATM Shares, through Leerink, which we refer to as the ATM Offering. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2024, we filed a new registration statement on Form S-3ASR, which we refer to as the New Shelf Registration Statement, to replace the prior shelf registration statement that was set to expire, including a base prospectus, which became effective immediately upon filing, under which we could issue an unspecified amount of shares of our common stock, preferred stock, debt securities and warrants. In June 2024, we filed a prospectus supplement to the New Shelf Registration Statement for the issuance and sale, if any, of up to an additional </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$350.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> of shares of our common stock under the ATM Sales Agreement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the filing of our Annual Report on Form 10-K for the year ended December 31, 2024, we no longer qualified as a well-known seasoned issuer and therefore were not eligible to use the New Shelf Registration Statement as an automatic shelf registration statement, and no shares were sold during the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the ATM Sales Agreement, Leerink may sell the ATM Shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Exchange Act of 1934, as amended. We may sell the ATM Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the ATM Sales Agreement, but we have no obligation to sell any of the ATM Shares in the ATM Offering. As of December&#160;31, 2025, we have sold a total of 4,290,096 shares of our common stock pursuant to the ATM Offering for aggregate net proceeds of approximately $228.6 million after deducting sales agent commissions and estimated offering expenses.  As of December&#160;31, 2025, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">we may not offer and sell any ATM shares.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">January 2024 Public Offering of Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On January&#160;8, 2024, we closed an underwritten public offering in which we issued and sold 4,025,000 shares of common stock, which included 525,000 shares of common stock issued and sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $40.00 per share. The aggregate net proceeds to us from the public offering were approximately $151.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">October 2025 Share Repurchases</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 15, 2025, we entered into the Repurchase Agreements with the ADAR1 Parties and the Pontifax Parties. Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of our common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to us at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million. In addition, concurrently with the execution of the Pontifax Repurchase Agreement, each of Tomer Kariv and Ran Nussbaum resigned from our board of directors and all committees thereof.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Repurchase Agreements, each of the ADAR1 Parties and the Pontifax Parties agreed to customary standstill restrictions and voting commitments, which will remain in effect until immediately following the final certification of the voting results for our 2028 annual stockholder meeting. We and each of the ADAR1 Parties and the Pontifax Parties also agreed to customary mutual non-disparagement obligations to remain in effect during the same period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">November 2025 Issuer Tender Offer</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 20, 2025, we announced that our board of directors authorized the Tender Offer, which we launched on October 20, 2025 and completed on November&#160;21, 2025 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 20, 2025, we disclosed that a total of 17,712,262 shares of our common stock were validly tendered and not validly withdrawn. In accordance with the terms and conditions of the Tender Offer, we accepted for purchase a total of 10,950,165 Tender Offer Shares at a purchase price of $17.75 per share, for an aggregate purchase price of approximately $194.4 million. As a result of the Tender Offer, we had 19,543,706 shares of common stock outstanding immediately following the closing of the Tender Offer.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred recurring operating losses each fiscal year through December 31, 2024. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and commercialization of one or more of our product candidates. Our net income, which was primarily driven by revenue related to the Takeda Agreement, was $87.0 million for the year ended December&#160;31, 2025 compared to a net loss of $187.4 million for the year ended December&#160;31, 2024. As of December&#160;31, 2025, we had an accumulated deficit of $481.8 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future in connection with our ongoing activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We will not generate any revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operating activities through a combination of equity offerings, debt financings, and license and development agreements in connection with any future collaborations. Adequate funding may not be available to us on acceptable terms, or at all. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to obtain funding, we will be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had cash and cash equivalents of $287.4 million. Based on our current operating assumptions, we expect that our existing cash and cash equivalents as of December&#160;31, 2025 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2028. See &#8220;&#8212;Liquidity and Capital Resources.&#8221; </span></div><div id="i2030eac40e414171a9c72c0ab0189734_118"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Known Trends, Events and Uncertainties</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While recent trends towards rising inflation have eased, prices continue to rise, which may also materially affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to our preclinical studies, clinical trials, interest rates and overhead costs may adversely affect our operating results. Rising interest rates and implementation of tariffs also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Additionally, the general consensus among economists suggests that we should expect a higher recession risk to continue over the next year due in part to ongoing tariff and trade uncertainties, which, together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term, and could negatively affect our operations. Furthermore, such economic conditions have produced downward pressure on share prices. Although we do not believe that inflation, higher interest rates or tariffs have had a material impact on our financial position or results of operations to date, we may </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">experience increases in the near future (especially if inflation rates rise more quickly) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions, including as a result of bank failures, and employee availability and wage increases, which may result in additional stress on our working capital resources.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_121"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Exclusive Patent License Agreement with The General Hospital Corporation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2016, we entered into an exclusive patent license agreement with The General Hospital Corporation, or MGH, which was subsequently amended in May 2017 and February 2018. Under the license agreement with MGH, or the MGH Agreement, we obtained an exclusive, worldwide license, with the right to sublicense, under certain patents and technical information of MGH, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products and processes for use in the treatment, diagnosis, palliation and prevention of diseases and disorders in humans and animals. We are required to use commercially reasonable efforts to develop and commercialize licensed products and processes, and must achieve certain required diligence milestones. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the MGH Agreement, we made an initial license payment of $0.1 million in 2016 and reimbursed MGH approximately $0.3 million of prior patent prosecution expenses related to the licensed patents in 2017. We also issued MGH an aggregate of 358,674 shares of our common stock. Additionally, we are required to pay a nominal annual maintenance fee prior to the first commercial sale of our first product or process, a mid-five digit annual maintenance fee after the first commercial sale of our first product or process that is creditable against royalties, certain clinical and regulatory milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $8.6 million in the aggregate, and certain commercial milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $18.0 million in the aggregate. We made payments of $50,000 and $300,000 in 2020 and 2021, respectively, for the achievement of the clinical and regulatory milestones of (i) filing of an IND in the first country and (ii) the completion of a Phase 1 clinical trial, respectively. We are also obligated to pay tiered royalties on net sales of licensed products ranging in the low-single digits to mid-single digits. The royalty rates are subject to up to a maximum 50% reduction for lack of a valid claim, in the event that it is necessary for us to obtain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed product-by-licensed product and country-by-country basis upon the later of expiry of the last valid claim of the licensed patents that cover such licensed product in such country and ten years from the first commercial sale of such product in such country. We are also obligated to pay a percentage of non-royalty-related payments received by us from sublicensees ranging in the sub-teen double digits and a change of control fee equal to a low-single digit percentage of the payments received as part of any completed transaction up to a low-seven digit amount. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 12, 2021, we entered into a license agreement with Hansoh (Shanghai) Healthtech Co., Ltd., or Hansoh.  Under the terms of the license agreement with Hansoh, or the Hansoh Agreement, we granted to Hansoh the exclusive right to develop, manufacture and commercialize elritercept and licensed products containing elritercept within the territories of mainland China, Hong Kong and Macau, which we refer to collectively as the Hansoh Territory. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from us, and the parties will also negotiate in good faith to enter into an agreement for commercial supply prior to any anticipated commercialization in the Hansoh Territory. In addition, Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Hansoh Agreement, we received a net $18.0 million upfront payment in January 2022. We recognized $3.0 million as revenue and $0.3 million in withholding tax upon the achievement of a development milestone related to the Hansoh Agreement on our consolidated statement of operations for the year ended December 31, 2024, and a receivable, net of withholding tax, on our consolidated balance sheet as of December 31, 2024. In addition to the upfront payment and development milestones achieved to date, we are entitled to receive up to an aggregate of (i) $23.5 million upon the achievement of specified development milestones and (ii) $144.0 million upon the achievement of specified net sales thresholds for all licensed products in the Hansoh Territory. If a licensed product is approved for marketing in the Hansoh Territory, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. No milestones were achieved during the year ended December&#160;31, 2025. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Hansoh&#8217;s obligation to pay royalties for a given licensed product in a given region in the Hansoh Territory will begin on the date of the first commercial sale for such licensed product in such region and continue until the latest of (i) ten years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents or joint patents, and (iii) expiration of regulatory exclusivity in such region. During the royalty term, neither party will directly or indirectly commercialize a competing product in the Hansoh Territory.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective in June 2023, in connection with the Hansoh Agreement, we entered into a manufacturing technology transfer agreement, or the Tech Transfer Agreement, with Hansoh. The Tech Transfer Agreement governs the transfer to Hansoh of all documents and information required to complete the manufacturing technology transfer. Under the Tech Transfer Agreement, Hansoh is obligated to make certain payments to us, at the rates set forth in the Tech Transfer Agreement, as manufacturing technology transfer services are provided over the term of the Tech Transfer Agreement. We recognized $0.1 million and $0.1 million of service and other revenue for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective in February 2024, in connection with the Hansoh Agreement, we entered into a clinical product supply agreement with Hansoh, or the Supply Agreement. We recognized $0.1 million and $0.4 million of other revenue for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 License Agreement with Takeda Pharmaceuticals U.S.A., Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2024, we entered into a license agreement with Takeda, which became effective on January 16, 2025. Under the terms of the license agreement with Takeda, or the Takeda Agreement, we granted to Takeda the exclusive right to develop, manufacture and commercialize elritercept and certain derivative compounds globally, excluding the territories of mainland China, Hong Kong and Macau, which we refer to collectively as the Takeda Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Agreement, we received a $200.0 million upfront payment in February 2025. In July 2025, we announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept, which triggered a $10.0 million milestone payment to us under the Takeda Agreement. We received the $10.0 million payment for the achievement of this development milestone in August 2025. In addition to the upfront payment and milestone payment, we are entitled to receive up to an aggregate of (i) $80.0 million upon the achievement of specified development milestones, (ii) $280.0 million upon the achievement of specified commercial milestones and (iii) $740.0 million upon the achievement of specified sales milestones. If a licensed product is approved for marketing in the Takeda Territory, we will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Takeda&#8217;s obligation to pay royalties for a given licensed product in a given country in the Takeda Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_124"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have not generated any revenue, and do not expect to generate any revenue in the foreseeable future, from product sales. We have generated revenue solely from research collaborations or licensing of intellectual property. We may in the future generate revenue from other strategic collaborations. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the preclinical and clinical development of our current and potential future product candidates, and include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct research, preclinical and clinical activities on our behalf, as well as contract manufacturing organizations, or CMOs, that manufacture drug product for use in our preclinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">license fees incurred in connection with license agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">research and development supplies and services expenses; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">cost of outside consultants, including their fees and related travel expenses, engaged in research and development functions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">expenses related to regulatory affairs; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">fees related to our scientific advisory board.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue ongoing and initiate new clinical trials for our product candidates and continue to discover and develop additional product candidates. We expect research and development expenses to fluctuate from quarter to quarter depending on the timing of clinical trial activities, clinical manufacturing and other development activities. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful commercialization of any product candidates we may develop in the future, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development program and plans. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include professional fees for legal, patent, accounting, information technology, auditing, tax and consulting services, and travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential commercialization of our product candidates. We have incurred and expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services, director and officer insurance costs, and investor and public relations costs. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Incentive Income </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development incentive income includes payments received under the Research and Development Tax Incentive, or the R&amp;D Incentive, from the Australian government. The R&amp;D Incentive is one of the key elements of the Australian government&#8217;s support for Australia&#8217;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development in Australia.  Since July 1, 2021, the R&amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#8217;s aggregated revenue as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Refundable tax offset of up to 18.5% above a company&#8217;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Non-refundable tax offset of up to 16.5% above a company&#8217;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.</span></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have assessed our R&amp;D activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;D Incentive.  We estimate the refundable or non-refundable tax offset available to us based on available information at the time. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Income</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Dividend income consists of income earned on our money market funds that are recorded as cash equivalents on our consolidated balance sheets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other expense, net consists of unrealized and realized gains and losses on foreign currency and other taxes and fees. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax provision recorded for the year ended December&#160;31, 2025 resulted from income tax related to taxable income generated from the Takeda Agreement. We continue to maintain a full valuation allowance against our net deferred tax assets due to our history of losses and expected future losses.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_127"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison for the years ended December&#160;31, 2025 and 2024</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2025 and 2024 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.992%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.143%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">REVENUE:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">244,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(129,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(173,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(46,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(40,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(176,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(214,383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">INCOME (LOSS) FROM OPERATIONS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">67,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(210,833)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE), NET:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development incentive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognized $205.4 million of license revenue related to the upfront payment and achievement of a development milestone under the Takeda Agreement and $38.5 million of service and other revenue related to the transition services agreement with Takeda, or the TSA, for the year </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2025, compared to zero </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">year </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> December&#160;31, 2024. In connection with the Hansoh Agreement, we recognized $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> of service and other revenue for the year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2025, compared to $3.0 million of license revenue and $0.5 million of service and other revenue for the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the years ended December&#160;31, 2025 and 2024 (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.992%"><tr><td style="width:1.0%"/><td style="width:64.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.301%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ CHANGE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025 vs 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rinvatercept</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,009)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Elritercept</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">44,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cibotercept</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(17,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical and development fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel expenses (including stock-based compensation)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(8,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Facilities and supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">129,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">173,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(43,986)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses were $129.6 million for the year ended December&#160;31, 2025, compared to $173.6 million for the year ended December&#160;31, 2024. The decrease of $44.0 million was primarily due to a decrease in program-related costs, including (i) a $9.0 million decrease of rinvatercept-related expenses, which was driven by a net decrease of $7.8 million in manufacturing and preclinical activities and a $1.2 million decrease in clinical spend associated with our completed Phase 1 clinical trial; (ii) a net decrease of $6.3 million in elritercept-related expenses, primarily driven by a decrease of $8.4 million in clinical spend associated with our ongoing Phase 2 clinical trials, one in patients with MDS and </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">one in patients with myelofibrosis, and the advancement of the Phase 3 RENEW clinical trial, as clinical activities transitioned to Takeda during 2025, partially offset by an increase of $2.1 million in manufacturing activities; (iii) a $17.2 million decrease of cibotercept-related expenses, primarily driven by a $9.5 million decrease in clinical spend associated with our terminated Phase 2 clinical trial and a net decrease of $7.7 million in manufacturing and preclinical activities; (iv) a $5.2 million decrease in preclinical pipeline and development activities; and (v) a $8.3 million decrease in personnel costs, including a decrease of $5.0 million of stock-based compensation costs, driven by a reduction in headcount. These decreases were partially offset by (a) a $1.4 million increase in professional fees and (b) a net increase of $0.6 million in facilities and supplies and other expenses.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses were $46.8 million for the year ended December&#160;31, 2025, compared to $40.8 million for the year ended December&#160;31, 2024. The increase of $6.1 million was primarily due to (i) a $5.9 million increase in professional fees and (ii) a net $0.9 million increase in facilities, supplies and other expenses. These increases were partially offset by (a) a $0.6 million decrease in personnel expenses, which includes a decrease of $1.2 million of stock-based compensation costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">partially </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">offset by a net increase of $0.5 million in salaries and bonus, severance, benefits and other payroll costs and (b) a $0.1 million decrease in director and officer insurance premiums.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Other Income, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total other income, net was $24.3 million for the year ended December&#160;31, 2025, compared to $23.8 million for the year ended December&#160;31, 2024. The increase of $0.5 million was primarily related to (i) an increase of $1.4 million of dividend income and (ii) a decrease of $0.4 million in other expense, net, partially offset by a decrease of $1.2 million in R&amp;D Incentive income in Australia.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax provision was $4.9 million for the year ended December&#160;31, 2025, compared to $0.3 million for the year ended December&#160;31, 2024. The increase of $4.6 million in income tax provision is attributed to taxable income generated from the Takeda Agreement.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_130"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses each fiscal year through December 31, 2024. Our net income, which was primarily driven by the one-time upfront fee related to the Takeda Agreement, was $87.0 million for the year ended December&#160;31, 2025, compared to a net loss of $187.4 million for the year ended December&#160;31, 2024. As of December&#160;31, 2025 and December&#160;31, 2024, we had an accumulated deficit of $481.8 million and $568.8 million, respectively. To date, we have devoted the majority of our efforts into business planning, research and development of our product candidates, including conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. We expect to continue to incur substantial expenses in connection with our ongoing activities, particularly as we advance the preclinical studies and clinical trials of our product candidates. Furthermore, we expect to incur costs associated with operating as a public company, including significant legal, accounting, investor relations, director and officer insurance premiums and other expenses. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution and other commercial infrastructure to commercialize such products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently do not have any products approved for sale. We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. Since our inception, we have funded our operations primarily through equity financings, research collaborations or licensing of intellectual property. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022, we filed a prospectus supplement to a registration statement on Form S-3ASR, including a base prospectus and sales agreement prospectus, or the Prior Shelf Registration Statement, for the issuance and sale of up to $250.0 million of shares of our common stock. On May 3, 2024, we filed a new registration statement on Form S-3ASR, or the New Shelf Registration Statement, to replace the Prior Shelf Registration Statement that was set to expire, which became automatically effective upon filing, and which permits us to offer, from time to time, an unspecified amount of common stock, preferred stock, debt securities and warrants, including through an &#8220;at the market&#8221; program with Leerink, as sales agent, or the ATM Program. As of the filing of our Annual Report on Form 10-K for the year ended December 31, 2024, we no longer qualified as a well-known seasoned issuer and therefore were not eligible to use the New Shelf Registration Statement as an automatic shelf registration statement. As of December&#160;31, 2025, we have sold a total of 4,290,096 shares of our common stock pursuant to the ATM Program. As of December&#160;31, 2025, we were not eligible to offer and sell any shares of our common stock under the ATM Program and did not sell any shares during the year ended December&#160;31, 2025. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In October 2025, we entered into the Repurchase Agreements, pursuant to which the ADAR1 Parties and the Pontifax Parties sold all of the shares of our common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to us at a per share purchase price of $17.75 per share, for an aggregate purchase price of $180.6 million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2025, we completed our Tender Offer and accepted for purchase a total of 10,950,165 shares of our common stock at a purchase price of $17.75 per share, for an aggregate purchase price of approximately $194.4 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had cash and cash equivalents of $287.4 million. Based on our current operating assumptions, we believe that our existing cash and cash equivalents will be sufficient to fund our projected liquidity requirements into the first half of 2028. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Due to the numerous risks and uncertainties associated with the development of our product candidates and programs, and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future funding requirements, both near and long-term, will depend on many factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the progress, timing and completion of preclinical studies and clinical trials for our current or any future product candidates, as well as the associated costs, including any unforeseen costs we may incur as a result of preclinical study or clinical trial delays due to public health crises or other causes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the timing and amount of milestone and royalty payments we are required to make or are eligible to receive under our license agreements with each of The General Hospital Corporation, Hansoh and Takeda;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the number of potential new product candidates we identify and decide to develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the need for additional or expanded preclinical studies and clinical trials beyond those that we plan to conduct with respect to our current and future product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or any future product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the costs involved in filing patent applications, maintaining and enforcing patents or defending against infringement or other claims raised by third parties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the maintenance of our existing license and collaboration agreements and the entry into new license and collaboration agreements;</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the effect of competing technological and market developments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the costs of operating as a public company;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the cost of manufacturing rinvatercept and future product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products, if approved, on our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our product candidates, if approved; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.64pt">market acceptance of any approved product candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, implementation of tariffs, public health crises, bank failures, geopolitical tensions and resulting global slowdown of economic activity continue to rapidly evolve and have already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital when and if needed. If we are unable to obtain funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs and clinical development efforts, which would adversely affect our business prospects, or we may be unable to continue operations. We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. Adequate additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for each of the periods presented (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">107,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(160,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(378,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">391,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents, and restricted cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(272,516)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">229,021&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by (Used in) Operating Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $107.5 million for the year ended December&#160;31, 2025, which was driven by (i) a net income of $87.0 million and (ii) non-cash charges, including $28.7 million of stock-based compensation expense, $2.4 million in lease expenses and $1.5 million in depreciation, partially offset by $12.1 million net cash used by operating assets and liabilities. The $12.1 million of cash used by operating assets and liabilities was primarily comprised of (i) a $13.1 million decrease in accounts payable and accrued expenses primarily driven by the transition of activities to Takeda and reduction in other clinical spend; (ii) a $2.3 million increase in current income tax receivable; (iii) a $0.8 million increase in accounts receivable; and (iv) a $2.0 million change in operating lease liabilities; partially offset by a $6.1 million decrease in prepaid expenses and other assets due to timing of expense recognition for our research and development costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in operating activities was $160.9 million for the year ended December&#160;31, 2024, which was driven by a net loss of $187.4 million and $11.4 million net cash used by operating assets and liabilities, partially offset by non-cash charges, including $34.9 million of stock-based compensation expense, $1.8 million in lease expenses and $1.2 million in depreciation. The $11.4 million of cash used by operating assets and liabilities was primarily comprised of (i) a $10.2 million increase in prepaid expenses and other assets due to timing of expense recognition for our research and development costs; (ii) a $2.6 million increase in accounts receivable; and (iii) a $1.3 million change in operating lease liabilities, which was partially offset by a $2.7 million increase in accounts payable and accrued expenses to support the advancement of our programs.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Investing Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in investing activities was $1.6 million and $1.9 million for the years ended December&#160;31, 2025 and 2024, respectively. The cash used in investing activities in each period was due to purchases of property and equipment. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by (Used in) Financing Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in financing activities was $378.5 million for the year ended December&#160;31, 2025, which was primarily related to $375.0 million used to repurchase shares of common stock via the ADAR1 Repurchase Agreement, the Pontifax Repurchase Agreement and the Tender Offer and $3.9 million in cash paid for direct expenses associated with the Repurchase Agreements and the Tender Offer, which was partially offset by (i) proceeds from short-swing profit settlement of $0.1 million, (ii) proceeds of $0.1 million related to issuance of common stock under the employee stock purchase plan; and (iii) proceeds of $0.2 million related to exercises of options to purchase common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $391.8 million for the year ended December&#160;31, 2024, which was primarily related to (i) net proceeds of $151.1 million received from our public offering of common stock in January 2024, after deducting underwriting discounts, commissions and offering expenses; (ii) net proceeds of $228.6 million received from sales of our common stock under the ATM Program, after deducting sales agent commissions and offering expenses; and (iii) proceeds of $12.1 million related to exercises of options to purchase common stock.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_133"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may incur contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or royalty payments that we are required to make under the MGH Agreement pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and are excluded from the table below. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the MGH Agreement, we are obligated to pay MGH designated amounts when any licensed product achieves certain developmental milestones. Following the commencement of commercial sales of the licensed products, we will pay designated amounts when certain milestone events occur. The development milestones and commercial milestones range from $50,000 to $10.0 million depending upon the significance of the particular milestone. We are also required to pay MGH royalties on all sales of licensed products, with such royalties ranging from the low-single digits to mid-single digits of sales, as well as royalties ranging in the low-double digits of sublicense income depending on the stage of development of the relevant product or process when the sublicense is granted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In October 2025, we announced that we plan to distribute 25% of any net cash proceeds we receive on or before December&#160;31, 2028 from the Takeda Agreement to our stockholders.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lease commitments reflect payments due for our lease and sublease agreements for office and laboratory space in Lexington, Massachusetts that expire in 2031 and 2029, respectively. As of December&#160;31, 2025, our contractual commitments for our leases were $22.0 million, which will be paid over the term of such leases. For additional information on our leases and timing of future payments, please read Note 13, Leases, to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with contract manufacturing organizations for process development, raw material purchases and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancellable obligations of our service providers, up to the date of cancellation and, in the case of certain arrangements with contract manufacturing organizations, may include noncancellable fees. Under such agreements, the exact amounts owed by us in the event of termination will be based on the timing of the termination and the exact terms of the agreement.  As of December&#160;31, 2025, we have committed up to approximately $1.6 million under these agreements which are expected to be paid through 2029.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_136"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, our revenues have consisted solely of payments received related to research collaborations and licensing of intellectual property. We apply the revenue recognition guidance in accordance with Financial Accounting Standards Board, Accounting Standards Codification, or ASC, Subtopic 606, Revenue from Contracts with Customers, or ASC 606. Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect consideration we are entitled to in exchange for the goods or services we transfer to our customer. All variable consideration, including milestones and royalties, is constrained until the cumulative revenue related to the consideration is no longer probable of reversal. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. We must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For performance obligations which consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We receive payments from our customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until we satisfy our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Research and Development Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our external research and development expenses. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing research and development expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued and prepaid research and development expenses. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We account for all stock-based compensation awards granted to employees and non-employees as stock-based compensation expense at fair value. Our stock-based awards include stock options and restricted stock unit, or RSU, awards. The measurement date for awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Our Black-Scholes option-pricing model requires the input of subjective assumptions, including the expected volatility of the price of our common stock. We lack company-specific historical and implied volatility information. Therefore, we estimate our expected stock volatility based on the historical volatility of a group of publicly traded peer companies, weighted with our own historical volatility for the period during which our stock has been publicly traded. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and these assumptions either increase or decrease, our stock-based compensation expense could materially differ in the future. Stock-based compensation expense is classified in the accompanying statements of operations based on the function to which the related services are </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">provided. We recognize stock-based compensation expense for the portion of awards that have vested. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%;padding-left:34.79pt"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_139"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_142"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a "&#8221;smaller reporting company,&#8221; as defined in Item 10(f)(1) of Regulation S-K. As a result, pursuant to Item 305(e) of Regulation S-K, we are not required to provide the information required by this Item 7A.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_145"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 8 is contained beginning on page F-1 of this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_148"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_151"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2025. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (2013 framework) (COSO). Based on its assessment, management concludes that, as of December&#160;31, 2025, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the fiscal quarter ended December&#160;31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_154"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. <ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-56"><ix:nonNumeric contextRef="c-6" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-57">OTHER INFORMATION</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the three months ended December 31, 2025, the following directors and officers of the Company adopted a &#8220;Rule 10b5-1 trading arrangement&#8221; as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company&#8217;s Insider Trading Policy and all of which were intended to satisfy Rule 10b5-1(c):</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-7" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-59" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-7" name="ecd:TrdArrAdoptionDate" id="f-58">On December 11, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndName" id="f-60">Keith Regnante</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrIndTitle" id="f-61">Chief Financial Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-7" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-62">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-63">24,741</ix:nonFraction> shares of our common stock to be acquired upon the settlement of restricted stock units, or RSUs, vesting on February 17, 2026 and August 15, 2026, owned by Mr. Regnante. The plan will expire on <ix:nonNumeric contextRef="c-7" name="ecd:TrdArrExpirationDate" id="f-64">December 31, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan.</span></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-9" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-66" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-9" name="ecd:TrdArrAdoptionDate" id="f-65">On December 10, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndName" id="f-67">Lorena Lerner</ix:nonNumeric>, our <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrIndTitle" id="f-68">Chief Scientific Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-9" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-69">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-70">19,577</ix:nonFraction> shares of our common stock to be acquired upon the settlement of RSUs vesting on February 17, 2026 and August 15, 2026, owned by Dr. Lerner. The plan will expire on <ix:nonNumeric contextRef="c-9" name="ecd:TrdArrExpirationDate" id="f-71">December 31, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan.</span></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-11" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-73" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-11" name="ecd:TrdArrAdoptionDate" id="f-72">On December 5, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-11" name="ecd:TrdArrIndName" id="f-74">Nima Farzan</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-11" name="ecd:TrdArrIndTitle" id="f-75">member of our board of directors</ix:nonNumeric>, <ix:nonNumeric contextRef="c-11" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-76">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-77">7,875</ix:nonFraction> shares of our common stock to be acquired upon the exercise of stock options or settlement of RSUs. The plan will expire on <ix:nonNumeric contextRef="c-11" name="ecd:TrdArrExpirationDate" id="f-78">June 30, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan.</span></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-13" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-80" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-13" name="ecd:TrdArrAdoptionDate" id="f-79">On December 5, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-13" name="ecd:TrdArrIndName" id="f-81">Julius Knowles</ix:nonNumeric>, a member of our board of directors, <ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-82">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-83">2,625</ix:nonFraction> shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on <ix:nonNumeric contextRef="c-13" name="ecd:TrdArrExpirationDate" id="f-84">June 30, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan.</span></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-15" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-86" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-15" name="ecd:TrdArrAdoptionDate" id="f-85">On December 9, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-15" name="ecd:TrdArrIndName" id="f-87">Alpna Seth</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-15" name="ecd:TrdArrIndTitle" id="f-88">member of our board of directors</ix:nonNumeric>, <ix:nonNumeric contextRef="c-15" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-89">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-90">2,625</ix:nonFraction> shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on <ix:nonNumeric contextRef="c-15" name="ecd:TrdArrExpirationDate" id="f-91">June 30, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan.</span></ix:nonNumeric></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"><ix:nonNumeric contextRef="c-17" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-93" escape="true"><ix:nonNumeric contextRef="c-17" name="ecd:TrdArrAdoptionDate" id="f-92">On December 5, 2025</ix:nonNumeric>, <ix:nonNumeric contextRef="c-17" name="ecd:TrdArrIndName" id="f-94">Jean-Jacques Bienaim&#233;</ix:nonNumeric>, a <ix:nonNumeric contextRef="c-17" name="ecd:TrdArrIndTitle" id="f-95">member of our board of directors</ix:nonNumeric>, <ix:nonNumeric contextRef="c-17" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-96">adopted</ix:nonNumeric> a Rule 10b5-1 trading plan that provides for the purchase of up to <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-97">7,000</ix:nonFraction> shares of our common stock. The plan will expire on <ix:nonNumeric contextRef="c-17" name="ecd:TrdArrExpirationDate" id="f-98">August 31, 2026</ix:nonNumeric>, subject to early termination for certain specified events set forth in the plan</ix:nonNumeric>.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_160"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_163"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We will file a definitive Proxy Statement for our 2026 Annual Meeting of Stockholders, or our 2026 Proxy Statement, with the SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2026 Proxy Statement that specifically address the items set forth herein are incorporated by reference. </span></div><div id="i2030eac40e414171a9c72c0ab0189734_166"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 10 will be included under the headers &#8220;Proposal 1 - Election of Directors,&#8221; &#8220;Executive Officers&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our 2026 Proxy Statement and is incorporated herein by reference.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have adopted a written Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and directors, including our principal executive officer, principal financial officer and principal accounting officer. A current copy of the Code of Conduct is available on the Investors section of our website, www.kerostx.com, under "Corporate Governance." We intend to disclose on our website any amendments to, or waivers from, our Code of Conduct that are required to be disclosed pursuant to SEC rules.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-105">adopted</ix:nonNumeric> insider trading policies and procedures governing the purchase, sale, and/or other dispositions of our securities by directors, officers and employees, a copy of which is attached as an exhibit to this Annual Report on Form 10-K. In addition, it is our intent to comply with the applicable laws and regulations relating to insider trading.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_169"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 11 will be included under the header &#8220;Executive Compensation&#8221; in our 2026 Proxy Statement and is incorporated herein by reference.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_172"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND RELATED STOCKHOLDER MATTERS    </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 12 will be included under the header &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our 2026 Proxy Statement and is incorporated herein by reference.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_175"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 13 will be included under the header &#8220;Transactions with Related Persons and Indemnification&#8221; in our 2026 Proxy Statement and is incorporated herein by reference.</span></div><div id="i2030eac40e414171a9c72c0ab0189734_178"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The information required by this Item 14 will be included under the header &#8220;Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm&#8221; in our 2026 Proxy Statement and is incorporated herein by reference.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_181"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i2030eac40e414171a9c72c0ab0189734_184"></div><div style="-sec-extract:summary;margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Consolidated Financial Statements required to be filed by Item 8 of this Annual Report on Form 10-K, and filed in this Item 15, are as follows:</span></div><div style="margin-bottom:9.5pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.584%"><tr><td style="width:1.0%"/><td style="width:91.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.905%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_199">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-106">34</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_202">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_202">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_205">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_205">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders&#8217; Equity</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_208">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_211">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_211">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_214">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_214">9</a></span></div></td></tr></table></div><div style="margin-bottom:9.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The Consolidated Financial Statement Schedule have been omitted because they are either not applicable or the required information is included in the Consolidated Financial Statements or notes thereto listed in (a)(1) above.</span></div><div style="margin-bottom:9.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3) Exhibits are incorporated herein by reference or are filed with this Annual Report on Form 10-K as indicated below.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(b) Exhibits </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:8.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NO.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NO.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILING DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520105266/d891585dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 13, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/exhibit31.htm">Amended and Restated Bylaws of the Registrant.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 6, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/exhibit314925.htm">Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on April 9, 2025.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 10, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex41.htm">Amended and Restated Investors&#8217; Rights Agreement by and among the registrant and certain of its stockholders, dated as of March&#160;2, 2020.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex42.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.3&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/exhibit41492025.htm">Rights Agreement, dated as of April 9, 2025 between Registrant and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 10, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.4*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit4410-kfy2025.htm">Description of the Registrant&#8217;s Securities.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex101.htm">Form of Indemnity Agreement between the registrant and its directors and officers.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex102.htm">2017 Stock Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex103.htm">Form of Stock Option Grant Notice and Option Agreement for the 2017 Stock Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex104.htm">2020 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/exhibit105.htm">Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for the 2020 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 26, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex106.htm">2020 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.7*+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit107.htm">Amended and Restated Non-Employee Director Compensation Policy</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:8.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.8+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex107.htm">Offer Letter Agreement by and between the registrant and Jasbir Seehra, dated as of December&#160;14, 2015.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex1010.htm">Exclusive Patent License Agreement by and between the registrant and The General Hospital Corporation, d/b/a Massachusetts General Hospital, or MGH, dated as of April&#160;5, 2016, as amended by Amendment&#160;#1 by and between the registrant and The Brigham and Women&#8217;s Hospital, Inc. on May&#160;12, 2017 and by Amendment&#160;#2 by and between the registrant and MGH on February&#160;23, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471022000011/exhibit1010.htm">License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd., dated as of December 12, 2021, as amended by Amendment No. 1 by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd., dated as of February 10, 2022.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.11#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471023000021/exhibit1011.htm">Amendment No. 2, dated as of March 11, 2022, and Amendment No. 3, dated as of December 11, 2022, to License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.11</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 9, 2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471024000017/exhibit1012fy2023.htm">Amendment No. 4 dated as of April 12, 2023, to License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2024</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520074978/d855212dex1013.htm">Offer Letter Agreement by and between the registrant and Keith Regnante, dated as of February 7, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 16, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex1014.htm">Employment Agreement by and between the registrant and Jasbir Seehra, dated as of March 31, 2020, effective as of April 13, 2020.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1664710/000119312520093365/d855212dex1017.htm">Employment Agreement by and between the registrant and Keith Regnante, dated as of March 31, 2020, effective as of April 13, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">333-237212</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 1, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.16+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/exhibit101coo.htm">Employment Agreement by and between the registrant and Christopher Rovaldi, dated as of January 28, 2022 effective as of February 1, 2022.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">January 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/exhibit1028625.htm">Separation and Release Agreement by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/exhibit1028625.htm">the r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/exhibit1028625.htm">egistrant and Christopher Rovaldi, dated as of August 6, 2025.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">August 6, 2025</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.18+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471022000011/exhibit102110-kfy2021.htm">First Amendment to the Employment Agreement by and between the registrant and Keith Regnante, dated as of January 1, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.19+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/exhibit1018625.htm">Employment Agreement by and between the registrant and Lorena Lerner, dated as of August 6, 2025.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">August 6, 2025</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.20+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/exhibit1038625.htm">Employment Agreement by and between Registrant and Esther Cho, dated as of August 6, 2025.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">August 6, 2025</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.21</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471021000065/exhibit101q32021.htm">Indenture of Lease by and between the registrant and Revolution Labs Owner, LLC, dated September 7, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">November 4, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.22</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471023000030/exhibit10110-qxq12023.htm">First Amendment to Lease, by and between the registrant and Revolution Labs Owner, LLC, dated January 6, 2023.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">May 4, 2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.23#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/exhibit1024form10-kfy2024.htm">Exclusive License Agreement by and between the registrant and Takeda Pharmaceuticals U.S.A., Inc., dated as of December 3, 2024.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.24</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 26, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.24*#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1024.htm">Amendment No. 1, dated as of March 24, 2025,  Amendment No. 2, dated as of April 23, 2025, Amendment No. 3, dated as of June 5, 2025 and Amendment No. 4, dated as of June 13, 2025 to Exclusive License Agreement by and between the registrant and Takeda Pharmaceuticals U.S.A., Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:8.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.25</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000038/exhibit10141725.htm">Letter Agreement, dated April 17, 2025, by and between the registrant and Pontifax (Israel) IV, L.P.,  Pontifax (Cayman) IV, L.P., Pontifax (China) IV, L.P. and Pontifax Late Stage Fund L.P.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 18, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.26</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000110465925099512/tm2528773d1_ex2-1.htm">Stock Purchase Agreement, dated as of October 15, 2025, by and between the Registrant and certain entities affiliated with ADAR1 Capital Management.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 15, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.27*+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1027.htm">First Amendment to the Employment Agreement by and between the registrant and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1027.htm">Esther Cho</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1027.htm">, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1027.htm">February 24, 2026</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit1027.htm">.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.28</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000110465925099512/tm2528773d1_ex2-2.htm">Stock Purchase Agreement, dated as of October 15, 2025, by and between the Registrant and certain entities affiliated with Pontifax Venture Capital.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">October 15, 2025</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/exhibit1910-kfy2024.htm">Insider Trading Policy.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 26, 2025</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit21110-kfy2025.htm">Subsidiaries of Keros Therapeutics, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit23110-kfy2025.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit31110-kfy2025.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit31210-kfy2025.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit32110-kfy2025.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1664710/000166471025000018/exhibit9710-kfy2024.htm">Incentive Compensation Recoupment Policy.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">001-39264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">February 28, 2024</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;&#160;Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#x5E;&#160;&#160;&#160;&#160;Certain exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant will furnish supplementally a copy of any omitted exhibit to the SEC upon request. The Registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits so furnished.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;&#160;&#160;Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm to Keros Therapeutics, Inc. if publicly disclosed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The agreements and other documents filed as exhibits to this Annual Report on Form 10-K are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_187"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. FORM 10-K SUMMARY</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_190"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"/><td style="width:46.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.330%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Date: March 4, 2026</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">/s/ Jasbir Seehra</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Jasbir Seehra, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">POWER OF ATTORNEY AND SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jasbir Seehra, Ph.D., and Keith Regnante, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:31.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.288%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NAME</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jasbir Seehra</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jasbir Seehra, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Keith Regnante</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Keith Regnante</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jean-Jacques Bienaim&#233;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jean-Jacques Bienaim&#233;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Nima Farzan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nima Farzan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Carl Gordon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carl Gordon, Ph.D., C.F.A.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Mary Ann Gray</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mary Ann Gray, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Julius Knowles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Julius Knowles</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Alpna Seth</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 4, 2026</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alpna Seth, Ph.D.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_193"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_196"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:91.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_199">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: 34)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_199">F-2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_202">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_202">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_205">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_205">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_208">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_211">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_211">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_214">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2030eac40e414171a9c72c0ab0189734_214">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div id="i2030eac40e414171a9c72c0ab0189734_199"></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Keros Therapeutics, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Keros Therapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Revenue Recognition &#8212; Takeda License Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> &#8211; Refer to Notes 2 and 15 to the financial statements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). As described in Note 15 to the financial statements, the Company entered into a license agreement with Takeda (the &#8220;Takeda Agreement&#8221;), which became effective January 16, 2025, and concurrently entered into a separate transition services agreement with Takeda (the &#8220;TSA&#8221;), pursuant to which the Company will provide certain transitional services to Takeda, including, but not limited to, clinical trial and manufacturing services, during the term of the TSA (the "Transition Services"). Pursuant to the terms of the Takeda Agreement, the Company received a $200.0 million upfront payment in February 2025, which was included in the transaction price at inception. The transaction price also included estimated variable consideration of $51.4 million relating to Transition Services.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Takeda Agreement and the TSA as a single contract under ASC 606 and identified two performance obligations, which included the license to the Company&#8217;s intellectual property (&#8220;License and Know-How&#8221;) and the Transition Services. The Company determined that the License and Know-How were distinct from the Transition Services. The Company allocated $195.4 million of the upfront payment to the License and Know-How, which was recognized as revenue at a point in time when control of the License and Know-How was transferred to Takeda. The remaining transaction price was allocated to the Transition Services, which was recognized over time as services were provided. As of December 31, 2025, the Company recognized $38.5 million of service revenue for the Transition Services and such services are substantially complete.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We identified the revenue recognition for the Takeda Agreement and the TSA as a critical audit matter. Auditing the Company&#8217;s application of the relevant accounting guidance required significant auditor judgment, including the need to involve an internal subject matter expert.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our audit procedures related to the Company&#8217;s revenue recognition for the Takeda Agreement and the TSA included the following, among others:</span></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Agreed the $200 million upfront payment to cash received and verified cash receipt for all payments received by the Company from Takeda for Transition Services performed during the year.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Obtained and read the Company&#8217;s accounting position paper assessing the accounting treatment for the Takeda Agreement and the TSA pursuant to ASC 606.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Utilized the assistance of our professionals with specialized knowledge and skills in the relevant technical accounting guidance, to evaluate (1) the Company&#8217;s determination of performance obligations, (2) the timing of revenue recognition for the License and Know-How and (3) the determination of the transaction price.</span></div><div><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-107">Deloitte &amp; Touche LLP</ix:nonNumeric> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-108">Boston, MA</ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">March 4, 2026</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2019.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_202"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-109">287,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-110">559,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-111">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-112">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-113">22,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-114">26,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current income tax receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-115">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-117">315,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-118">588,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-119">16,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-120">19,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-121">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-122">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-123">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-124">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other long term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-126">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-127">338,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-128">615,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-129">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-130">4,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-131">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-132">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-133">16,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-134">20,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-135">20,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-136">27,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-137">14,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-138">16,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-139">34,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-140">44,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">COMMITMENTS AND CONTINGENCIES (Note 14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-19" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-141"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-20" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-142"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">STOCKHOLDERS&#8217; EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Preferred stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-143"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-144">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-145"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-146">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2025 and 2024; <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-147"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-149"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-150">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Series A junior participating preferred stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-153"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-154">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-155">500,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-156">no</ix:nonFraction> shares authorized as of December&#160;31, 2025 and December&#160;31, 2024, respectively; <ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-157"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-159"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-160">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-163"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-164">0.0001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-165"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-166">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-167">40,670,466</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">19,543,706</ix:nonFraction> shares outstanding as of December&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-169"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-170">40,554,705</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-171">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-172">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-173">21,126,760</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="3" id="f-174">no</ix:nonFraction> shares as of December&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-175">384,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:fixed-zero" scale="3" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-177">1,169,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-178">1,140,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-179">481,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-180">568,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">303,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">571,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">338,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">615,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_205"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">REVENUE:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-185">38,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-186">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-187">205,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-188">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-189">244,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-190">3,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPERATING EXPENSES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">129,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-192">173,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">46,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-194">40,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-195">176,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-196">214,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">INCOME (LOSS) FROM OPERATIONS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">67,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">210,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTHER INCOME (EXPENSE), NET:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development incentive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:ResearchAndDevelopmentIncentiveIncome" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:ResearchAndDevelopmentIncentiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-200">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DividendIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-201">24,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DividendIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-202">23,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-203">539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-204">954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-205">24,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-206">23,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">91,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-208">187,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-209">4,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-210">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-212">187,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders &#8212; basic and diluted (Note 11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-213"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-214">87,014</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-215"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-216">187,353</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding&#8212;basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-217">37,221,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-218">37,437,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding&#8212;diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-219">37,859,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-220">37,437,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock &#8212; basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-221">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-222">5.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-223">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-224">5.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_208"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.803%"><tr><td style="width:1.0%"/><td style="width:36.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COMMON STOCK</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-225">0.0001</ix:nonFraction> PAR VALUE</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TREASURY STOCK</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ADDITIONAL<br/>PAID-IN<br/>CAPITAL</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL STOCKHOLDERS&#8217;  EQUITY</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHARES</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">AMOUNT</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-226">31,841,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-227">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">713,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">381,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">332,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of underwriting discounts, commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-233">9,943</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-234">4,025,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-235">151,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-236">151,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under the ATM agreement, net of commissions and offering cost of $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-237">3,655</ix:nonFraction> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-238">4,290,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-239">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-240">228,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-241">228,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-242">398,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-243">12,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-244">12,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-245">34,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-246">34,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-247">187,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-248">187,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-249">40,554,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-250">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">1,140,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">568,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">571,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under the employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-256">11,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-257">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-258">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of treasury stock, including excise tax, direct fees and expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-259">9,558</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-260">21,126,760</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-261">384,558</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-262">384,558</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-swing profit settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="kros:ShortSwingProfitSettlement" scale="3" id="f-263">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:ShortSwingProfitSettlement" scale="3" id="f-264">139</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-265">73,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-266">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-267">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-268">30,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">28,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-270">28,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-272">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span id="i9a70f0176f014deea0e8813746651887_20-0-1-1-163929"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-273">40,670,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-274">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" sign="-" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-275">21,126,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-276">384,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-277">1,169,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-278">481,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-279">303,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_211"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:75.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.106%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">187,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-282">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-283">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gain on disposal of fixed asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-284">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-286">28,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-287">34,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-288">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-289">1,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-290">825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-291">2,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-292">4,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-293">10,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-294">2,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-296">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-297">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-298">3,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-299">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use assets and operating lease liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:RightToUseAssetsAndOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-300">1,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:RightToUseAssetsAndOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-301">1,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-302">10,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-303">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-304">107,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-305">160,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-306">1,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-307">1,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-308">1,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-309">1,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of underwriting discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-311">151,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payment of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:PaymentOfInitialPublicOfferingCosts" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:PaymentOfInitialPublicOfferingCosts" scale="3" id="f-313">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the ATM agreement, net of commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-315">228,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payment of issuance costs associated with issuance of common stock under the ATM agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-317">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-318">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchase of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-320">375,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payment of direct expenses associated with the treasury stock repurchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:PaymentOfStockRepurchaseCosts" format="ixt:num-dot-decimal" scale="3" id="f-322">3,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:PaymentOfStockRepurchaseCosts" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Short-swing profit settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:ProceedsFromShortSwingSettlementProfit" scale="3" id="f-324">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:ProceedsFromShortSwingSettlementProfit" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-326">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-327">12,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-328">378,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-329">391,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-330">272,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-331">229,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-332">561,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-333">332,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-334">288,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-335">561,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-336">7,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment purchases in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-338">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Treasury stock repurchase costs in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-340">5,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use&#160;assets obtained in exchange for operating lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-343">5,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the cash and cash equivalents and restricted cash as of each of the periods shown above:</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-344">287,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-345">559,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-346">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-347">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-348">288,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-349">561,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_214"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.</span></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i2030eac40e414171a9c72c0ab0189734_217"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-350" continuedAt="f-350-1" escape="true">NATURE OF BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="f-350-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Keros Therapeutics, Inc. (&#8220;Keros&#8221; or the &#8220;Company&#8221;) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (&#8220;TGF-&#223;&#8221;) family of proteins. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company's lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. The Company&#8217;s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (&#8220;cytopenias&#8221;), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (&#8220;MDS&#8221;) and in patients with myelofibrosis.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since its inception in 2015, the Company has devoted the majority of its resources to business planning, research and development of its product candidates, including conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-351">287.4</ix:nonFraction> million cash and cash equivalents as of December&#160;31, 2025 will allow the Company to continue its operations for at least the next 12 months from the date these consolidated financial statements are issued. In the absence of a significant source of recurring revenue, the continued viability of the Company is dependent on its ability to continue to raise additional capital to finance its operations. If the Company is unable to obtain additional funding, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-352" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiaries, Keros Therapeutics Australia Pty Ltd (&#8220;Keros Australia&#8221;) and Keros Security Corporation, a Massachusetts securities corporation.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_223"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-353" continuedAt="f-353-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-353-1" continuedAt="f-353-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-354" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, Keros Australia and Keros Security Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-355" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, useful lives assigned to property and equipment and accrued and prepaid research and development expenses. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-356" continuedAt="f-356-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-353-2" continuedAt="f-353-3"><ix:continuation id="f-356-1" continuedAt="f-356-2"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:9.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-356-2">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</ix:continuation> The Company had no financial instruments measured at level 3 as of December&#160;31, 2025 or 2024. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-357" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of standard checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had restricted cash in the form of certificates of deposit related to its operating leases in Lexington, Massachusetts of $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-358"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-359">1.4</ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-360" escape="true">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits.</ix:nonNumeric> As of December&#160;31, 2025 and 2024, the Company&#8217;s cash and cash equivalents were held with <ix:nonFraction unitRef="financialinstitution" contextRef="c-27" decimals="INF" name="kros:NumberOfFinancialInstitutions" format="ixt-sec:numwordsen" id="f-361"><ix:nonFraction unitRef="financialinstitution" contextRef="c-1" decimals="INF" name="kros:NumberOfFinancialInstitutions" format="ixt-sec:numwordsen" id="f-362">three</ix:nonFraction></ix:nonFraction> financial institutions. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-363" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are written off from the accounts, and any resulting gain or loss is included in the determination of net loss. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-364" continuedAt="f-364-1" escape="true">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:</ix:nonNumeric></span></div><ix:continuation id="f-364-1" continuedAt="f-364-2"><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"/><td style="width:52.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.329%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESTIMATED USEFUL LIFE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-365">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-366">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-56" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-367">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">lesser of useful life or remaining lease term</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-368" escape="true">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</ix:nonNumeric> To date, no impairments have been recognized for these assets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-369" continuedAt="f-369-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than 12 months are recognized on the balance sheet as right-of-use, or ROU, assets and current and non-current lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a </span></div></ix:nonNumeric></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-353-3" continuedAt="f-353-4"><ix:continuation id="f-369-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="f-370" escape="true">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</ix:nonNumeric> Through December&#160;31, 2025, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="kros:TreasuryStockPolicyTextBlock" id="f-371" escape="true">The Company records its repurchases of shares of common stock at cost. These shares are classified as treasury stock, which is a reduction of stockholders&#8217; equity.  Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock is included in shares authorized and issued but excluded from shares outstanding.</ix:nonNumeric>  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="f-372" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services with contract research organizations that conduct research, preclinical and clinical activities on the Company&#8217;s behalf, as well as contract manufacturing organizations that manufacture drug product for use in the Company&#8217;s preclinical studies and clinical trials, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-373" continuedAt="f-373-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development incentive income includes payments under the Research and Development Tax Incentive (the &#8220;R&amp;D Incentive&#8221;) from the Australian government. The R&amp;D Incentive is one of the key elements of the Australian government&#8217;s support for Australia&#8217;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development. Since July 1, 2021, the R&amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#8217;s aggregated revenue as follows:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Refundable tax offset of up to 18.5% above a company&#8217;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Non-refundable tax offset of up to 16.5% above a company&#8217;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has assessed its research and development (&#8220;R&amp;D&#8221;) activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;D Incentive. The Company estimates the refundable or non-refundable tax offset available to it based on available information at the time. This estimate is also reviewed by the Company&#8217;s external tax advisors on an annual basis.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-373-1" continuedAt="f-373-2">The Company&#8217;s estimate of the cash refund it expects to receive related to the R&amp;D Incentive is included in other assets in the accompanying consolidated balance sheet and such amounts are recorded as research and development incentive income in the statement of operations. The Company recognizes research and development incentive income when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.</ix:continuation> The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="kros:ResearchAndDevelopmentIncentiveIncome" format="ixt:fixed-zero" scale="6" id="f-374">not</ix:nonFraction> record other income from the R&amp;D Incentive for the year ended December&#160;31, 2025. The Company has received payments and has recorded other income from the R&amp;D Incentive of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="kros:ResearchAndDevelopmentIncentiveIncome" scale="6" id="f-375">1.2</ix:nonFraction> million for the year ended December&#160;31, 2024 related to the R&amp;D Incentive as defined above. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-376" continuedAt="f-376-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;606&#8221;). The Company enters into certain agreements that are within the scope of ASC 606, under which the Company licenses or grants an option to license rights to certain of the Company&#8217;s product candidates and may perform research and </span></div></ix:nonNumeric></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-376-1" continuedAt="f-376-2"><ix:continuation id="f-353-4" continuedAt="f-353-5"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s arrangements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance arrangements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For combined performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div></ix:continuation></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-353-5" continuedAt="f-353-6"><ix:continuation id="f-376-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If performance obligations are satisfied over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and the timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-377" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The functional currency for the Company&#8217;s wholly owned foreign subsidiary, Keros Australia, is the United States dollar. All foreign currency transaction gains and losses are recognized in the consolidated statement of operations.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-378" escape="true">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-379">one</ix:nonFraction> reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular concentration is focused on the discovery and development of novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-&#223; family of proteins.</ix:nonNumeric> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-380" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#8217;s stock-based awards include stock options and restricted stock unit ("RSU") awards. The measurement date for employee and non-employee awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Stock-based compensation expense is classified in the accompanying consolidated statement of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies weighted with its own volatility for the period in which its stock has been publicly traded. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div></ix:nonNumeric><ix:continuation id="f-373-2" continuedAt="f-373-3"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company </span></div></ix:continuation></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-353-6" continuedAt="f-353-7"><ix:continuation id="f-373-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for interest and penalties related to uncertain tax positions within the provision for income taxes. As of December&#160;31, 2025, there have been no interest or penalties recorded.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-381" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to net income (loss) for all periods presented.</span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-382" escape="true">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period, and if dilutive, the weighted-average number of potential shares of common shares. The Company&#8217;s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-383" continuedAt="f-383-1" escape="true">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div><ix:continuation id="f-383-1" continuedAt="f-383-2"><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-384">41,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-386">4,470,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-387">5,384,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-388">8,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-389">47,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-390">4,520,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-391">5,432,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-392" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2023-09&#8221;). ASU No. 2023-09 requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The new standard was effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU No. 2023-09 for its consolidated financial statements for the fiscal year ended December 31, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2024-03&#8221;), which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="kros:RisksAndUncertaintiesPolicyTextBlock" id="f-393" continuedAt="f-393-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. While recent trends towards rising inflation have eased, prices continue to rise, which may materially affect the Company&#8217;s business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to the Company&#8217;s preclinical studies and clinical trials, interest rates and overhead costs may adversely affect its operating results. Implementation of tariffs present a recent challenge impacting the U.S. economy and could make it more difficult for the Company to obtain traditional financing on acceptable terms, if at all, in the future. Although the Company does not believe that inflation, higher interest rates or tariffs have had a material impact on its financial position or results of operations to date, the Company may experience increases in the near future (especially if inflation rates rise more quickly) on its operating costs, including its labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company&#8217;s working capital resources. </span></div></ix:nonNumeric></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-393-1" continuedAt="f-393-2"><ix:continuation id="f-353-7" continuedAt="f-353-8"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-393-2"><ix:continuation id="f-353-8">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_229"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-395" continuedAt="f-395-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-396" escape="true"><ix:continuation id="f-395-1" continuedAt="f-395-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.145%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-397">270,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-398">270,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-401">270,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-402">270,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.153%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-405">556,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-406">556,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-409">556,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-410">556,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-395-2">There have been no transfers between fair value levels during the years ended December&#160;31, 2025 and 2024. The carrying values of prepaid expenses, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_232"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-413" continuedAt="f-413-1" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-414" escape="true"><ix:continuation id="f-413-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:PrepaidExternalRDCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-415">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:PrepaidExternalRDCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-416">15,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:PrepaidExternalManufacturingCostsCurrent" scale="3" id="f-417">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:PrepaidExternalManufacturingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-418">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid sales tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:SalesTaxReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:SalesTaxReceivableCurrent" scale="3" id="f-420">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-421">609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-422">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid subscriptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:PrepaidSubscriptionCurrent" scale="3" id="f-423">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:PrepaidSubscriptionCurrent" scale="3" id="f-424">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest and dividend receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DividendAndInterestReceivable" scale="3" id="f-425">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DividendAndInterestReceivable" format="ixt:num-dot-decimal" scale="3" id="f-426">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:PrepaidLegalAndConsultants" format="ixt:num-dot-decimal" scale="3" id="f-427">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:PrepaidLegalAndConsultants" scale="3" id="f-428">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Refunds due from contract research organizations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:RefundsDueFromContractResearchOrganizationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-429">14,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:RefundsDueFromContractResearchOrganizationsCurrent" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-431">2,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-432">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-433">22,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-434">26,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_235"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-435" continuedAt="f-435-1" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="f-435-1"><ix:continuation id="f-364-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-436">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-437">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-438">7,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-439">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-440">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-441">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-442">8,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-443">7,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-444">4,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-445">2,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-446">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-447">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationNonproduction" scale="6" id="f-448">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:DepreciationNonproduction" scale="6" id="f-449">1.2</ix:nonFraction> million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_238"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-450" continuedAt="f-450-1" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-451" escape="true"><ix:continuation id="f-450-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-452">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">5,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:AccruedManufacturingCostsCurrent" scale="3" id="f-454">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:AccruedManufacturingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-455">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-456">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-457">10,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-458">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-460">3,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-461">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-462">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-463">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-464">16,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-465">20,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_241"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="f-466" continuedAt="f-466-1" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-466-1" continuedAt="f-466-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts General Hospital</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 5, 2016, the Company entered into an exclusive patent license agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital (&#8220;MGH&#8221;). Under the license agreement with MGH (as amended in May 2017 and February 2018, the &#8220;MGH Agreement&#8221;), the Company obtained an exclusive, worldwide license, with the right to sublicense, under certain patents and technical information of MGH, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products and processes for use in the treatment, diagnosis, palliation and prevention of diseases and disorders in humans and animals. The Company is required to use commercially reasonable efforts to develop and commercialize licensed products and processes and must achieve certain required diligence milestones.</span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-466-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the MGH Agreement, the Company is required to pay a low-five digit to mid-five digit annual maintenance fee prior to the first commercial sale of its first product or process, a mid-five digit annual maintenance fee after the first commercial sale of its first product or process that is creditable against royalties, certain clinical and regulatory milestone payments for the first <ix:nonFraction unitRef="product" contextRef="c-74" decimals="INF" name="kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" format="ixt-sec:numwordsen" id="f-467">three</ix:nonFraction> products or indications to achieve such milestones, which milestone payments are $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="kros:ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" scale="6" id="f-468">8.6</ix:nonFraction>&#160;million in the aggregate, and certain commercial milestone payments for the first <ix:nonFraction unitRef="product" contextRef="c-74" decimals="INF" name="kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" format="ixt-sec:numwordsen" id="f-469">three</ix:nonFraction> products or indications to achieve such milestones, which milestone payments are $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="kros:ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" scale="6" id="f-470">18.0</ix:nonFraction>&#160;million in the aggregate. The Company made payments of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" format="ixt:num-dot-decimal" scale="0" id="f-471">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" format="ixt:num-dot-decimal" scale="0" id="f-472">300,000</ix:nonFraction> in 2020 and 2021, respectively, for the achievement of the clinical and regulatory milestones of (i) filing of an IND in the first country and (ii) the completion of a Phase 1 clinical trial, respectively.  The Company is also obligated to pay tiered royalties on net sales of licensed products ranging in the low-single digits to mid-single digits. The royalty rates are subject to up to a maximum <ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="kros:ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" scale="-2" id="f-473">50</ix:nonFraction>% reduction for lack of a valid claim, in the event that it is necessary for the Company to obtain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed product-by-licensed product and country-by-country basis upon the later of expiry of the last valid claim of the licensed patents that cover such licensed product in such country or <ix:nonNumeric contextRef="c-75" name="kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" format="ixt-sec:durwordsen" id="f-474">ten years</ix:nonNumeric> from the first commercial sale of such product in such country. The Company is also obligated to pay a percentage of non-royalty-related payments received by it from sublicensees ranging in the low-double digits and a change of control fee equal to a low-single digit percentage of the payments received as part of any completed transaction up to a low seven-digit amount.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The MGH Agreement expires upon expiry of the last remaining royalty obligation for a licensed product or process. Under the MGH Agreement, MGH may terminate the agreement upon the Company&#8217;s uncured material breach or insolvency, a challenge by the Company of the licensed patents and certain other specified breaches of the MGH Agreement. The Company may terminate the agreement for any reason upon specified prior written notice to MGH.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hansoh Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 12, 2021, the Company entered into a license agreement with Hansoh. Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;). Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.</span></div></ix:continuation><div id="i2030eac40e414171a9c72c0ab0189734_244"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-475" continuedAt="f-475-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-475-1" continuedAt="f-475-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-476">200,000,000</ix:nonFraction> shares of common stock at a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-477">0.0001</ix:nonFraction> per share. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-478">232.3</ix:nonFraction> million pursuant to the &#8220;at the market offering,&#8221; in connection with our Sales Agreement with Leerink Partners LLC, as agent (&#8220;ATM Offering&#8221;), pursuant to which we sold <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-479">4,290,096</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-480">54.14</ix:nonFraction> per share. The net proceeds from the ATM Offering for the year ended December&#160;31, 2024 were approximately $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-481">228.6</ix:nonFraction> million after deducting sales agent commissions of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="kros:SaleOfStockAgentCommissions" scale="6" id="f-482">3.5</ix:nonFraction> million and offering expenses of less than $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="kros:SaleOfStockStockIssuanceCosts" scale="6" id="f-483">0.2</ix:nonFraction> million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On January&#160;8, 2024, the Company closed an underwritten public offering in which <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-484">4,025,000</ix:nonFraction> shares of common stock were issued and sold, which included <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-485">525,000</ix:nonFraction> shares of common stock issued and sold pursuant to the exercise in full of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-486">40.00</ix:nonFraction> per share. The aggregate net proceeds from the public offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-487">151.1</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Stockholder Rights Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 9, 2025, the Company&#8217;s board of directors (the &#8220;Board&#8221;) declared a dividend of <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="kros:CommonStockDividendNumberOfRightsPerShare" format="ixt-sec:numwordsen" scale="3" id="f-488">one</ix:nonFraction> right (&#8220;Right&#8221;) to purchase one-thousandth of one share of the Company&#8217;s newly designated Series A Junior Participating Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-489">0.0001</ix:nonFraction> per share (each, a &#8220;Preferred Share&#8221; and collectively, the &#8220;Preferred Shares&#8221;), for each outstanding share of common stock to the stockholders of record as of the close of business on April 24, 2025. The Company also adopted a limited duration stockholder rights plan (the &#8220;Rights Plan&#8221;), effective immediately, as set forth in the Rights Agreement, dated as of April 9, 2025 (the &#8220;Rights Agreement&#8221;), by and between the Company and Computershare Trust Company, N.A., as Rights Agent. The Rights Agent currently serves as the Company&#8217;s transfer agent with respect to the common stock and also has been appointed transfer agent with respect to the Preferred Shares, if any, that may be issued pursuant to the exercise of rights under the Rights Agreement. The Rights will expire on April 9, 2026, unless the rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Plan.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In general terms, the Rights Plan is designed to impose a penalty upon any person or group that acquires beneficial ownership of <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="kros:CommonStockBeneficialOwnershipPenaltyThreshold" scale="-2" id="f-490">10</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="kros:CommonStockBeneficialOwnershipPenaltyThreshold" scale="-2" id="f-491">15</ix:nonFraction>% in the case of a passive institutional investor) or more of the outstanding shares of Common Stock without the approval of the Board. The Board adopted the Rights Plan in response to significant and rapid accumulations of </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-475-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">the common stock by a number of investors who have indicated a desire to influence the control of the Company. The Rights Plan is intended to protect the investment of the Company's stockholders during a period in which it believes shares of the Company do not reflect the Company&#8217;s intrinsic value. The Rights Plan will reduce the likelihood that any entity, person or group gains control of the Company through open-market accumulation without paying all stockholders an appropriate control premium. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a summary of the rights and privileges of the holders of common stock as of December&#160;31, 2025:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Preference: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Dividends: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. As of December&#160;31, 2025, <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="INF" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="f-492">no</ix:nonFraction> cash dividends have been declared or paid.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each holder of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="kros:CommonStockVotingRightsNumberOfVotes" format="ixt-sec:numwordsen" scale="0" id="f-493">one</ix:nonFraction> vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Rights and Preferences</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">: Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-494" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-495">716,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-497">3,901,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-498">5,384,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under the ESPP Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-499">1,641,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-500">1,247,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under 2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-501">3,146,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-502">861,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-503">9,406,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-504">7,494,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_1045"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:TreasuryStockTextBlock" id="f-505" continuedAt="f-505-1" escape="true">TREASURY STOCK</ix:nonNumeric></span></div><ix:continuation id="f-505-1" continuedAt="f-505-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board may authorize the repurchase of shares of the Company&#8217;s common stock, in the open market or through negotiated transactions, at such times and at such prices as management deems appropriate. For the year ended December&#160;31, 2024, the Company did not acquire any shares of its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 15, 2025, the Company entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (collectively, the &#8220;ADAR1 Parties&#8221;) and certain entities affiliated with Pontifax Venture Capital (collectively, the &#8220;Pontifax Parties&#8221;). Such stock purchase agreements for each of the Pontifax and ADAR1 Parties are collectively referred to as &#8220;Repurchase Agreements&#8221;. Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="0" id="f-506">10,176,595</ix:nonFraction> shares of common stock, to the Company at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-96" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-507">17.75</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-508">180.6</ix:nonFraction> million, excluding excise tax, direct fees and expenses related to the repurchases. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 20, 2025, the Company commenced a tender offer to repurchase shares of its common stock at a cash purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="kros:SharesAcquiredPricePerShareOnCommencementOfTenderOffer" scale="0" id="f-509">17.75</ix:nonFraction> per share  (the &#8220;Tender Offer&#8221;). The Tender Offer expired at 5:00 p.m. Eastern time on November 18, 2025, and following such expiration the Company accepted for purchase a total of <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-510">10,950,165</ix:nonFraction> shares, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-511">194.4</ix:nonFraction> million, excluding excise tax, direct fees and expenses related to the Tender Offer.  More than <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-512">10,950,165</ix:nonFraction> shares were tendered in the Tender Offer, and as such, shares were accepted for purchase on a pro rata basis, except for conditional tenders that were automatically regarded as withdrawn if the condition was not satisfied. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the accompanying consolidated balance sheets. </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="f-505-2">The completion of the Repurchase Agreements in October 2025 and the Tender Offer in November 2025 concluded the Company&#8217;s previously announced $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-513">375.0</ix:nonFraction> million capital return program.  In connection with the Repurchase Agreements and Tender Offer, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-514">9.6</ix:nonFraction> million in excise tax, direct fees and expenses that were included in the cost of treasury stock in the accompanying consolidated balance sheets as of December&#160;31, 2025.</ix:continuation> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_250"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-515" continuedAt="f-515-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board adopted the 2017 Stock Incentive Plan (the "2017 Plan") in February 2017, and the stockholders approved the 2017 Plan in March 2017. The 2017 Plan was most recently amended in March 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there were an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-516">412,099</ix:nonFraction> shares of common stock issuable upon the exercise of outstanding options under the 2017 Plan. Any options or awards outstanding under the 2017 Plan remain outstanding and effective.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2020, the 2020 Equity Incentive Plan (the "2020 Plan") became effective, and, as a result, no further awards will be made under the 2017 Plan. The 2020 Plan provides for the grant of stock options qualifying as incentive stock options ("ISOs"), to employees and for the grant of nonstatutory stock options ("NSOs"), restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to employees, consultants and directors. The 2020 Plan also provides for the grant of performance cash awards to employees, consultants and directors. Any previously granted awards under the 2017 Plan will remain outstanding in accordance with their respective terms. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the 2020 Plan, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by <ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" scale="-2" id="f-517">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. On January 1, 2024, the Company increased the number of shares available for future grant under the 2020 Plan by <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-518">1,273,643</ix:nonFraction> shares. On January 1, 2025, the Company increased the number of shares available for future grant under the 2020 Plan by <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-519">1,622,188</ix:nonFraction> shares. On January 1, 2026, the Company increased the number of shares available for future grant under the 2020 Plan by <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-520">781,748</ix:nonFraction> shares. The awards granted under the 2020 Plan typically vest over a <ix:nonNumeric contextRef="c-102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-521">four-year</ix:nonNumeric> period and have a <ix:nonNumeric contextRef="c-102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-522">10-year</ix:nonNumeric> contractual term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there were an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-523">3,489,607</ix:nonFraction> shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan. Additionally, there were an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-524">3,146,054</ix:nonFraction> shares reserved for future issuance under the 2020 Plan, including shares forfeited from the 2017 Plan.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-525" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of RSU award activity during the year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.074%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF UNITS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE GRANT-DATE FAIR VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-528">1,167,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-529">11.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-530">30,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-531">12.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-532">420,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-533">10.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-534">716,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-535">12.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The summary of RSU award activity includes <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-536">90,500</ix:nonFraction> performance-based awards granted during the year ended December&#160;31, 2025. The weighted-average grant date fair value of RSU awards granted during the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-537">11.71</ix:nonFraction> and <ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="3" id="f-538">zero</ix:nonFraction>, respectively. The aggregate fair value of RSU awards that vested during the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-539">0.5</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="3" id="f-540">zero</ix:nonFraction>, respectively. As of December&#160;31, 2025, there has been <ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-541">no</ix:nonFraction> expense recognized for the performance-based awards, for which the performance criteria was not deemed probable as of December&#160;31, 2025. As of December&#160;31, 2025, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-542">6.9</ix:nonFraction> million of unrecognized stock-based compensation expense related to RSU awards that are expected to vest, including $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-543">1.4</ix:nonFraction> million of unrecognized stock-based compensation expense related to performance-based awards for which the performance criteria is currently not deemed probable. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately <ix:nonNumeric contextRef="c-106" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-544">1.71</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-515-2" continuedAt="f-515-3"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-545" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December&#160;31, 2025 and 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-546">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-547">4.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-110" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-548">5.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-111" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-549">5.91</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-550">83.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-551">81.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-552">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-553">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-554" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of option activity during the year ended December&#160;31, 2025 is as follows (in thousands except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.870%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF<br/>OPTIONS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-<br/>AVERAGE<br/>EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (IN&#160;YEARS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE<br/>INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-555">5,384,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-556">42.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-557">7.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-558">7,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-559">84,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-560">14.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-561">73,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-562">2.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-563">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-564">783,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-565">54.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-566">709,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-567">49.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-568">3,901,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-569">38.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-570">5.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-571">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-572">3,091,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-573">34.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span id="id1d28d2136374e9b8448ed57bce695c6_8-5-1-1-163929"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-574">5.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-575">12,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-576">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-577">10.1</ix:nonFraction> million during the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during each of the years ended December&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-578">10.36</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-579">40.92</ix:nonFraction>, respectively. As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-580">22.9</ix:nonFraction> million of unrecognized stock-based compensation expense related to unvested service-based stock options and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-581">2.9</ix:nonFraction> million of unrecognized stock-based compensation expense related to performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of <ix:nonNumeric contextRef="c-110" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-582">1.49</ix:nonNumeric> years. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The summary of option activity includes <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-583">125,000</ix:nonFraction> performance-based options granted during the year ended December&#160;31, 2024. The options include performance-based and service-based vesting criteria. As of December&#160;31, 2025, the performance criteria was deemed probable for 50% of the performance-based options. Accordingly, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-584">2.0</ix:nonFraction> million stock-based compensation expense during the year end December&#160;31, 2025. Of the $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-585">2.9</ix:nonFraction> million of unrecognized stock-based compensation expense, $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" scale="6" id="f-586">0.4</ix:nonFraction> million is related to service-based vesting criteria that the Company expects to recognize and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" scale="6" id="f-587">2.5</ix:nonFraction> million is related to performance-based vesting criteria that are not considered probable as of December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2020, the Board adopted and the Company's stockholders approved the 2020 Employee Stock Purchase Plan ("ESPP"). The ESPP became effective on April 7, 2020. Under the ESPP, eligible employees can purchase shares of the Company's common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of the Company's common stock on the first trading day of the twenty-four month offering period, or on the applicable purchase date. Each offering under the ESPP consists of two twelve-month purchase periods.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the ESPP, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" scale="-2" id="f-588">1.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-589">455,852</ix:nonFraction> shares or (iii) or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-590">405,547</ix:nonFraction> shares. On January 1, 2026, the Company increased the number of shares available for future grant under the ESPP by <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-591">195,437</ix:nonFraction> shares.  </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-515-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-592">11,806</ix:nonFraction> shares of common stock were purchased under the ESPP. As of December&#160;31, 2025, there was an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-593">1,641,602</ix:nonFraction> shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-594" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December&#160;31, 2025 and 2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-595">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-596">18,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-597">15,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-598">16,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-599">28,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-600">34,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_1069"></div><div style="margin-bottom:4pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-601" continuedAt="f-601-1" escape="true">INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-601-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-602" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.579%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-603">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-604">187,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-605">37,221,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-606">37,437,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-607">419,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-611">218,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-613">637,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding used to compute diluted net income (loss)<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-615">37,859,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-616">37,437,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-617">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-618">5.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-619">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-620">5.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-383-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.281%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-621">41,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-623">4,470,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-624">5,384,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-625">8,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-626">47,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-627">4,520,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-628">5,432,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In periods where there is a net loss, zero incremental shares are included as the effect would be antidilutive.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_253"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-629" continuedAt="f-629-1" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="f-629-1" continuedAt="f-629-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-630" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"><tr><td style="width:1.0%"/><td style="width:65.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.164%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-631">74,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-632">189,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-633">17,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-634">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-635">91,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-636">187,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-637" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the provision for income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.283%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-642">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-643">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-644">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-645">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred income tax provision</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-648">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-649">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-650" continuedAt="f-650-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025 in accordance with the guidance in the ASU No. 2023-09, which the Company has elected to prospectively adopt:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-651">19,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-652">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-653">734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-654">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Difference between local tax rare and U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-655">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-656">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-657">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-658">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of changes in taw laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of cross-border tax laws</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" format="ixt:fixed-zero" scale="-2" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-663">13,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-664">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-665">33,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-666">36.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-667">5,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" scale="-2" id="f-668">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-669">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-670">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-671">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="-2" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="3" id="f-673">2,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-674">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-675">308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-676">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-677">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-678">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> State and local income tax, net of federal income tax effect, are not material and Massachusetts is the most significant state that the Company operates in.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-629-2" continuedAt="f-629-3"><ix:continuation id="f-650-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the year ended December&#160;31, 2024 prior to adoption of ASU No. 2023-09:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.681%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income at U.S. statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-679">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-680">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-681">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-682">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-683">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="f-684">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign withholding taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="kros:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" scale="-2" id="f-685">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-686">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-687">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-688">27.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-27" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-689">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:9.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-690" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The net deferred income tax asset balance as of December&#160;31, 2025 and 2024 related to the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-691">35,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-692">45,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-693">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-694">16,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" format="ixt:num-dot-decimal" scale="3" id="f-695">53,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" format="ixt:num-dot-decimal" scale="3" id="f-696">78,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-697">7,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-698">7,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-699">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-700">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-701">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-702">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-703">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-704">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-705">102,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-706">155,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-707">97,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-708">150,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-709">4,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-710">5,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-711">4,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-712">5,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-713">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-20" xsi:nil="true" name="us-gaap:DeferredTaxLiabilitiesOther" id="f-714"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-717">159.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-718">27.9</ix:nonFraction> million, respectively. The federal NOLs can be carried forward indefinitely. The state NOL carryforwards begin to expire in 2039.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had U.S. federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-719">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-720">0.1</ix:nonFraction> million, respectively. The federal research and development tax credits expire in 2045. The state research and development tax credits expire in 2040.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the NOL and tax credit carryforwards are subject to review and potential adjustments by the Internal Revenue Services and state tax authorities. Under Section 382 of the Code (&#8220;Section 382&#8221;), certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of NOL carryforwards or tax credits which could be used annually to offset future taxable income. Based on a previous Section 382 analysis that the Company performed, the Company determined that on April 15, 2016 and April 13, 2020, Section 382 ownership changes and limitations had occurred. Based on such analysis, the Company determined that $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="kros:OperatingLossCarryforwardWriteOff" scale="6" id="f-721">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="kros:OperatingLossCarryforwardWriteOff" scale="6" id="f-722">0.3</ix:nonFraction> million of its federal and state NOL carryforwards, respectively, were limited by Section 382 and therefore were previously written off. The Company had updated its analyses under Section 382 through November 21, 2025, and determined that, in addition to the previous Section 382 ownership changes and limitations on April 15, 2016 and April 13, 2020, a Section 382 ownership change occurred on November 21, 2025. As a result of the November 21, 2025 Section 382 </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-629-3" continuedAt="f-629-4"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ownership change and limitation, $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="kros:OperatingLossCarryforwardWriteOff" scale="6" id="f-723">14.0</ix:nonFraction> million of federal research and development tax credit carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="kros:OperatingLossCarryforwardWriteOff" scale="6" id="f-724">169.4</ix:nonFraction> million of state NOL carryforwards and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="kros:OperatingLossCarryforwardWriteOff" scale="6" id="f-725">5.9</ix:nonFraction> million of state research and development tax credit carryforwards have been written off. Though subject to a Section 382 limitation, federal NOL carryforwards have not been written off since they can be carried forward indefinitely. The remaining unused carryforwards remain available for future periods. The Company may also experience ownership changes in the future as a result of subsequent shifts in the Company&#8217;s stock ownership, some of which may be outside the Company&#8217;s control. As a result, its ability to use its pre-change NOLs or tax credits to offset U.S. federal taxable income or tax may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOLs and research and development credits. Under the applicable accounting standards, management has considered the Company&#8217;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance was maintained as of December&#160;31, 2025 and 2024. A decrease in the Company&#8217;s valuation allowance was recorded in 2025 in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-726">52.0</ix:nonFraction> million primarily due to the reduction of net deferred tax assets related to capitalized research and development expenses, research and development tax credits and net operating loss carryforwards. An increase in the Company&#8217;s valuation allowance was recorded in 2024 in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-727">50.6</ix:nonFraction> million, primarily due to the generation of additional net deferred tax assets related to capitalized research and development expenses, net operating loss carryforwards and research and development tax credits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research and development (&#8220;R&amp;D&#8221;) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five years and costs for foreign R&amp;D activities must be amortized over 15 years &#8211; both using a midyear convention.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 4, 2025, President Trump signed H.R. 1, the One Big Beautiful Bill Act into law. The legislation included several changes to the Internal Revenue Code. These changes are generally effective for tax years beginning after December 31, 2025 except for changes related to the expensing of U.S.-based R&amp;D expenditures which was retroactively effective and available for tax years beginning after December 31, 2024 and the reinstatement of 100% bonus depreciation for qualified assets/property placed in service after January 19, 2025. The changes that were retroactively effective were reflected in the year ended December&#8239;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in.  ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal and state research credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-728">3.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-729">2.0</ix:nonFraction> million relate to positions taken in prior years and $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-730">1.1</ix:nonFraction> million relate to current year positions. As of December&#160;31, 2025, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal research credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-731">0.1</ix:nonFraction> million, which relate to current year positions. The Company does not have any other material gross unrecognized tax benefits related to income tax reserves. The Company does not expect any of its unrecognized tax benefits related to income tax reserves, if recognized, to impact its effective tax rate due to full valuation allowance in the United States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December&#160;31, 2025 and 2024, the Company had no interest or penalties related to unrecognized tax benefits. For the year ended December&#160;31, 2025, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-732">7.2</ix:nonFraction> million of total income taxes, $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-733">4.9</ix:nonFraction> million related to Australia and $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="f-734">2.3</ix:nonFraction> million related to U.S. federal income taxes. For the year ended December&#160;31, 2024, the Company made <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="6" id="f-735">zero</ix:nonFraction> payments for income taxes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to income tax examination by federal, state and foreign jurisdictions, where applicable. The Company recently closed an income tax examination with the state of Massachusetts for the tax years ended December 31, 2021 and 2022, with no material impact to the Company's financial statements. The Company&#8217;s tax years are still open under statute for income tax examination by the Internal Revenue Service (&#8220;IRS&#8221;) from December 31, 2022 to the present. There are currently no pending income tax examinations with the IRS. To the extent the Company has tax attribute </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-629-4"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">carryforwards, the tax years in which the tax attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state and foreign tax authorities to the extent utilized in a future period.</span></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_256"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-736" continuedAt="f-736-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-736-1" continuedAt="f-736-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 7, 2021, the Company entered into an indenture of lease (the &#8220;1050 Waltham Lease&#8221;) with Revolution Labs Owner LLC (the &#8220;Landlord&#8221;), pursuant to which the Company is leasing approximately <ix:nonFraction unitRef="sqft" contextRef="c-138" decimals="0" name="kros:LesseeAreaOfSublease" format="ixt:num-dot-decimal" scale="0" id="f-737">35,662</ix:nonFraction> square feet of office, laboratory and vivarium space located at 1050 Waltham Street, Lexington, Massachusetts (the &#8220;Premises&#8221;) for its new principal executive office. Base rent was initially fixed at $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="kros:LesseeOperatingLeaseMonthlyBaseRent" scale="6" id="f-738">0.2</ix:nonFraction> million per month and will increase by approximately <ix:nonFraction unitRef="number" contextRef="c-139" decimals="INF" name="kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" scale="-2" id="f-739">3</ix:nonFraction>% per annum until the 1050 Waltham Lease expires on November&#160;30, 2031. The Company is obligated to reimburse the Landlord for certain variable costs, including its proportional share of taxes and operating expenses which are not included in the measurement of the 1050 Waltham Lease liability. In connection with its entry into the 1050 Waltham Lease, the Company has provided the Landlord a letter of credit in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-740">1.2</ix:nonFraction> million, which is recognized as restricted cash within other assets on the consolidated balance sheets. The Company has the option to extend the term of the 1050 Waltham Lease for a period of an additional <ix:nonNumeric contextRef="c-19" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="f-741">5</ix:nonNumeric> years. As of December&#160;31, 2025, the Company has no reasonable certainty that this option to extend will be exercised. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a sublease (the &#8220;Sublease Agreement&#8221;) with Accent Therapeutics, pursuant to which the Company has sublet approximately <ix:nonFraction unitRef="sqft" contextRef="c-141" decimals="-3" name="kros:LesseeAreaOfSublease" format="ixt:num-dot-decimal" scale="0" id="f-742">20,000</ix:nonFraction> square feet of office and laboratory space located at 1050 Waltham Street, Lexington, Massachusetts, expanding the Company's existing headquarters. Accordingly, the Sublease Agreement for the premises was determined to be classified as an operating lease. Upon commencement of the sublease, the Company recorded an ROU asset of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-743">5.7</ix:nonFraction> million and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-744">5.7</ix:nonFraction> million. The term of the sublease commenced on July 1, 2024 (the "Sublease Commencement Date"). The Sublease Agreement has a term of <ix:nonNumeric contextRef="c-143" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-745">5 years and 3 months</ix:nonNumeric>, measured from the Sublease Commencement Date. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s obligation for the payment of base rent for the premises began on the Sublease Commencement Date. Base rent was initially fixed at $<ix:nonFraction unitRef="sqft" contextRef="c-140" decimals="0" name="kros:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" scale="0" id="f-746">71.00</ix:nonFraction> per rentable square foot and the Company is only required to pay base rent on <ix:nonFraction unitRef="sqft" contextRef="c-140" decimals="0" name="kros:LesseeOperatingLeaseAreaOfRentalSpace" format="ixt:num-dot-decimal" scale="0" id="f-747">17,500</ix:nonFraction> square feet for the first year of the sublease. The Sublease Agreement also provides for three months of free rent. Base rent will increase by approximately <ix:nonFraction unitRef="number" contextRef="c-139" decimals="INF" name="kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" scale="-2" id="f-748">3</ix:nonFraction>% per annum until the Sublease Agreement expires on September&#160;30, 2029.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with its entry into the Sublease Agreement and as a security deposit, the Company provided Accent Therapeutics a letter of credit in the amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-749">0.2</ix:nonFraction> million on the Sublease Commencement Date.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-750" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the lease cost as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.283%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-751">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-752">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-753">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-755">2,047</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-756">1,554</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-757">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-758">5,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other information as of December&#160;31, 2025 and 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.283%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating leases </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-759">3,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-760">3,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-762">5,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate for the leases as of December&#160;31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.281%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-19" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-763">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-20" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-764">6.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-765">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-766">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-736-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-767" continuedAt="f-767-1" escape="true">Maturities of operating lease liabilities at December&#160;31, 2025 are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-767-1"><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.294%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">MATURITY OF LEASE LIABILITY</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-768">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-769">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-770">4,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-771">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-772">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="kros:LesseeOperatingLeaseLiabilityToBePaidYearSix" format="ixt:num-dot-decimal" scale="3" id="f-773">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-774">21,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-775">5,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-776">16,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Included in the consolidated balance sheet:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-777">2,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-778">14,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-779">16,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i2030eac40e414171a9c72c0ab0189734_1118"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-781" continuedAt="f-781-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-781-1"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into agreements in the normal course of business with contract manufacturing organizations for process development, raw material purchases and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancellable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancellable obligations of the Company&#8217;s service providers, up to the date of cancellation and, in the case of certain arrangements with contract manufacturing organizations, may include noncancellable fees. Under such agreements, the exact amounts owed by the Company in the event of termination will be based on the timing of the termination and the exact terms of the agreement.  As of December&#160;31, 2025, the Company has committed up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:PurchaseObligation" scale="6" id="f-782">1.6</ix:nonFraction> million under these agreements which are expected to be paid through 2029.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution of Proceeds</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to distribute <ix:nonFraction unitRef="number" contextRef="c-145" decimals="2" name="kros:LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" scale="-2" id="f-783">25</ix:nonFraction>% of any net cash proceeds it receives on or before December&#160;31, 2028 from the Takeda Agreement (as defined below) to its stockholders.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span><br/></span></div><div id="i2030eac40e414171a9c72c0ab0189734_262"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-784" continuedAt="f-784-1" escape="true">REVENUE FROM CONTRACTS WITH CUSTOMERS</ix:nonNumeric></span></div><ix:continuation id="f-784-1" continuedAt="f-784-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Hansoh License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a license agreement with Hansoh (the &#8220;Hansoh Agreement&#8221;). Under the Hansoh Agreement, the Company granted to Hansoh the exclusive right to develop, manufacture and commercialize elritercept and licensed products containing elritercept within the territories of mainland China, Hong Kong and Macau (the &#8220;Hansoh Territory&#8221;).</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from the Company, and the parties will also negotiate in good faith to enter into an agreement for commercial supply prior to any anticipated commercialization in the Hansoh Territory. In addition, Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Hansoh Agreement, the Company received a net one-time $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-785">18.0</ix:nonFraction> million upfront license payment in January 2022. In addition to the upfront payment and development milestones achieved to date, the Company will also be eligible to receive up to an aggregate of (i) $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="kros:RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" scale="6" id="f-786">23.5</ix:nonFraction> million upon the achievement of specified development milestones and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="kros:RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" scale="6" id="f-787">144.0</ix:nonFraction> million upon the achievement of specified net sales thresholds for all licensed products in the Hansoh Territory. If a licensed product is approved for marketing in the Hansoh Territory, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-784-2" continuedAt="f-784-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Hansoh&#8217;s obligation to pay royalties for a given licensed product in a given region in the Hansoh Territory will begin on the date of the first commercial sale for such licensed product in such region and continue until the latest of (i) <ix:nonNumeric contextRef="c-148" name="kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" format="ixt-sec:duryear" id="f-788">10</ix:nonNumeric> years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents or joint patents, and (iii) expiration of regulatory exclusivity in such region. During the royalty term, neither party will directly or indirectly commercialize a competing product in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Hansoh Agreement will continue in force on a region-by-region basis until the expiration of the royalty term. Hansoh may terminate the Agreement in its entirety for convenience, with notice. The Company may terminate the Hansoh Agreement in its entirety for a patent challenge brought by Hansoh or its affiliates or their sublicensees. Either party may terminate the Hansoh Agreement in its entirety (i) if the other party materially breaches the Hansoh Agreement and fails to cure such breach or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Hansoh Agreement and concluded that it was subject to ASC 606, as the Company viewed the Hansoh Agreement as a contract with a customer. As such, the Company assessed the terms of the Hansoh Agreement and identified a single performance obligation for the Company to provide Hansoh an exclusive license to develop, manufacture and commercialize elritercept and licensed products containing elritercept in the Hansoh Territory, including the underlying know-how related to such licenses. All other promised goods/services were deemed immaterial in the context of the Hansoh Agreement. Under the Hansoh Agreement, Hansoh was obligated to pay a one-time, net $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-789">18.0</ix:nonFraction> million payment to the Company, which was paid in the first quarter of 2022.  The Company recognized a gross upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-790">20.0</ix:nonFraction> million as revenue and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="kros:RevenueFromContractWithCustomerWithholdingTaxes" scale="6" id="f-791">2.0</ix:nonFraction> million in withholding tax on its consolidated statement of operations for the year ended December 31, 2021, and a receivable, net of withholding tax on its consolidated balance sheet as of December 31, 2021. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will recognize development milestone payments as revenue at the point in time when it is determined that it is probable such milestones will be achieved as all performance obligations will have been satisfied at the point which a milestone might occur (i.e., Hansoh will have assumed all responsibility for the activities under the Hansoh Agreement). The Company will recognize royalty payments and commercial milestone payments as the associated sales of licensed products are recorded by Hansoh, as they predominantly relate to the license granted with the Hansoh Agreement. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-792">3.0</ix:nonFraction> million as revenue and $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="kros:RevenueFromContractWithCustomerWithholdingTaxes" scale="6" id="f-793">0.3</ix:nonFraction> million in withholding tax upon the achievement of a development milestone related to the Hansoh Agreement on its consolidated statement of operations for the year ended December 31, 2024, and a receivable, net of withholding tax, on its consolidated balance sheet as of December 31, 2024. Payment was received during the year ended December&#160;31, 2025.  No milestones were achieved during the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, the Company entered into a manufacturing technology transfer agreement (the &#8220;Tech Transfer Agreement&#8221;) with Hansoh, effective in June 2023. The Tech Transfer Agreement governs the transfer to Hansoh, by the Company of all documents and information required to complete the manufacturing technology transfer. Under the Tech Transfer Agreement, Hansoh is obligated to make certain payments to the Company, at the rates set forth in the Tech Transfer Agreement, as manufacturing technology transfer services are provided over the term of the Tech Transfer Agreement. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="kros:ServiceAndOtherRevenue" scale="6" id="f-794">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="kros:ServiceAndOtherRevenue" scale="6" id="f-795">0.1</ix:nonFraction> million of service and other revenue for the years ended December&#160;31, 2025 and 2024,  respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, the Company entered into a clinical product supply agreement (the &#8220;Supply Agreement&#8221;) with Hansoh, effective February 2024. The Company evaluated the Supply Agreement and concluded that it was subject to ASC 606, as the Company viewed the Supply Agreement as a contract with a customer. As such, the Company assessed the terms of the Supply Agreement and identified a single performance obligation for the Company to supply Hansoh with clinical product supply. The Company recognizes revenue at a point in time when control transfers, which is deemed to be at the shipping point when the clinical product supply is ready for shipment. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-796">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-797">0.4</ix:nonFraction> million of other revenue for the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Takeda License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into a license agreement with Takeda, which became effective on January 16, 2025. Under the terms of the license agreement with Takeda (the "Takeda Agreement"), the Company granted to Takeda the exclusive right to develop, manufacture and commercialize elritercept and certain derivative compounds globally, excluding the territories of mainland China, Hong Kong and Macau (collectively, the "Takeda Territory"). Concurrent with the Takeda Agreement, the Company entered into a separate Transition Services Agreement with Takeda (&#8220;TSA&#8221;), pursuant to which the Company will provide certain transitional services to Takeda, including, but not limited to, clinical trial and manufacturing services, during the term of the TSA (the "Transition Services"). In January 2026, the initial <ix:nonNumeric contextRef="c-155" name="us-gaap:InvestmentCompanyFeeWaiverTerms" id="f-798">fifteen</ix:nonNumeric> month term of the TSA was extended for <ix:nonNumeric contextRef="c-156" name="us-gaap:InvestmentCompanyFeeWaiverTerms" id="f-799">six</ix:nonNumeric> months through October 2026. The Company will receive reimbursement of certain costs incurred by the Company in connection with providing the Transition Services. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="kros:LicenseAgreementUpfrontFee" scale="6" id="f-800">200.0</ix:nonFraction> million upfront payment in February 2025. In July 2025, a one-time $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-801">10.0</ix:nonFraction> million development milestone was achieved upon dosing of the first patient in the Phase 3 RENEW clinical trial of elritercept. In addition to the upfront and development milestone payments, the Company is entitled to receive up to an aggregate of (i) $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="kros:PotentialMilestonePaymentsDevelopmentBasedMilestones" scale="6" id="f-802">80.0</ix:nonFraction> million upon the achievement of specified development milestones; (ii) $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="kros:PotentialMilestonePaymentsCommercialBasedMilestones" scale="6" id="f-803">280.0</ix:nonFraction> million upon the achievement of specified commercial milestones; and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="kros:PotentialMilestonePaymentsSalesBasedMilestones" scale="6" id="f-804">740.0</ix:nonFraction> million upon the achievement of specified sales </span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-784-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">milestones. If a licensed product is approved for marketing in the Takeda Territory, the Company will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-805">10.0</ix:nonFraction> million as revenue upon the achievement of this development milestone related to the Takeda Agreement on its consolidated statement of operations for the year ended December&#160;31, 2025. Payment was received during the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Takeda&#8217;s obligation to pay royalties for a given licensed product in a given country in the Takeda Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) <ix:nonNumeric contextRef="c-161" name="kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" format="ixt-sec:duryear" id="f-806">10</ix:nonNumeric> years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Takeda Agreement will continue in force until the expiration of the royalty term. Takeda may terminate the Takeda Agreement (i) in its entirety or on a country-by-country basis for convenience, with notice or (ii) if Takeda reasonably determines that the development, manufacture, and commercialization of the licensed compound or licensed product pose a safety or public health risk. The Company may terminate the Takeda Agreement in its entirety in the event that Takeda or its affiliates bring a patent challenge. Either party may terminate the Takeda Agreement in its entirety (i) if the other party materially breaches the Takeda Agreement and fails to cure such breach; or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company assessed this arrangement in accordance with ASC 606 and concluded it is a contract with a customer as defined in ASC 606. As the Company entered into the Takeda Agreement and the TSA concurrently, they were evaluated as a single contract under ASC 606. The Company identified <ix:nonFraction unitRef="performanceobligation" contextRef="c-162" decimals="INF" name="kros:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-807">two</ix:nonFraction> performance obligations in the Takeda Agreement and TSA including the license to its intellectual property (&#8220;License and Know-How&#8221;) and the Transition Services. The Company determined that the License and Know-How were distinct from the Transition Services as Takeda is able to derive benefit from the License and Know-How upon delivery and the Transition Services do not modify the License and Know-How.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price at contract inception included fixed consideration consisting of the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-808">200.0</ix:nonFraction> million. The transaction price at inception also included estimated variable consideration of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:ReimbursementFromLimitedPartnershipInvestment" scale="6" id="f-809">51.4</ix:nonFraction> million relating to the Transition Services revenue that was not constrained. The transaction price has been allocated to the License and Know-How and the Transition Services on a relative standalone selling price basis. The Company allocated $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-810">195.4</ix:nonFraction> million of the transaction price to the License and Know-How, which was recognized at a point in time, when control of the License and Know-How was transferred to Takeda on the effective date of the Takeda Agreement. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-811">56.1</ix:nonFraction> million of the transaction price was allocated to the Transition Services, which will be recognized over time as services are provided using the input method, based on costs incurred to provide the Transition Services, as the level of costs incurred over-time best reflect the transfer of services. As of December&#160;31, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-812">38.5</ix:nonFraction> million of service revenue for the Transition Services and such services are substantially complete. Any remaining services to be performed pursuant to the TSA will be recognized as performed and based on rates agreed to in the TSA. The $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-813">10.0</ix:nonFraction> million development milestone was recognized as license revenue upon achievement in July 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The remaining $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="kros:PotentialMilestonePaymentsDevelopmentBasedMilestones" scale="6" id="f-814">80.0</ix:nonFraction> million of specified development milestones, $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="kros:PotentialMilestonePaymentsCommercialBasedMilestones" scale="6" id="f-815">280.0</ix:nonFraction> million of specified commercial milestones and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="kros:PotentialMilestonePaymentsSalesBasedMilestones" scale="6" id="f-816">740.0</ix:nonFraction> million of specified sales milestones were considered constrained at contract inception and excluded from the transaction price since the Company could not conclude it is probable that a significant revenue reversal in the amount recognized will not occur. The sales-based milestone payments and royalties will be recognized upon occurrence based on the sales and usage-based royalty exception. The Company will reevaluate the transaction price at the end of each reporting period and will adjust the estimate of the transaction price as uncertain events are resolved or other changes in circumstances occur. The Company determined that the Takeda Agreement and TSA did not contain a significant financing component.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable were $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-817">3.6</ix:nonFraction> million as of December&#160;31, 2025 and <ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-818">zero</ix:nonFraction> as of December&#160;31, 2024. Accounts receivable are amounts due from Takeda for the Transition Services.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-819" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue recognized from Takeda for the year ended December&#160;31, 2025 and  2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-820">205,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-822">38,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Takeda</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-824">243,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i2030eac40e414171a9c72c0ab0189734_265"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-826" continuedAt="f-826-1" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="f-826-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-827" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.854%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.797%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">REVENUE:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-828">244,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-829">3,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">LESS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rinvatercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-830">7,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-831">16,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Elritercept program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-832">38,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-833">44,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cibotercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-834">12,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-835">29,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical &amp; development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-836">6,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-837">12,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Compensation costs (excluding stock based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-838">45,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" format="ixt:num-dot-decimal" scale="3" id="f-839">48,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-840">35,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">26,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-842">12,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-843">13,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-844">87,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-845">187,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company manages operations on a consolidated basis as a single reportable and single operating segment focused on developing novel therapeutics. Segment revenue above is 100 percent attributed to the Company&#8217;s agreements with Takeda and Hansoh and is equal to consolidated total revenue. All revenues are derived in the United States where the agreements originated. The Company manages expenses on a program level. The significant expense categories outlined above align with the segment-level information that is regularly provided to the CODM to allocate resources, assess performance of the reportable segment, and make key operating decisions. On a quarterly basis, the CODM reviews financial information, including consolidated net income, clinical expenses by program, other company expenses and a long-range cash flow projection, to make resource decisions for the Company&#8217;s programs to achieve the approved corporate goals. No segment asset information is provided above as the CODM is focused on how expenses impact ending cash by period and overall cash runway.  Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. All long-lived assets are held in the United States.</span></div></ix:continuation><div id="i2030eac40e414171a9c72c0ab0189734_1079"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-847" continuedAt="f-847-1" escape="true">CORPORATE RESTRUCTURING</ix:nonNumeric></span></div><ix:continuation id="f-847-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2025, the Board formally approved a plan to reduce the overall workforce by approximately <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-848">45</ix:nonFraction>% (the "2025 Restructuring"). In connection with the 2025 Restructuring, the Company incurred one-time employee termination benefits, including severance, retention and benefits costs. The total costs associated with the 2025 Restructuring was $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-849">3.1</ix:nonFraction> million, including severance, retention and benefits costs, of which $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-850">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-851">0.5</ix:nonFraction> million were recognized as part of total <span style="-sec-ix-hidden:f-852">research and development</span> and <span style="-sec-ix-hidden:f-853">general and administrative expenses</span>, respectively, during the year ended December&#160;31, 2025. All costs have been incurred under the Company&#8217;s single reportable segment. The 2025 Restructuring was complete as of December&#160;31, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-854" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued compensation and benefits costs as of December&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"><tr><td style="width:1.0%"/><td style="width:77.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">RESTRUCTURING LIABILITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="kros:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="f-856">Expenses incurred</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-857">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-858">2,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-859">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other segment items include other expense, income tax provision, bank fees, research and development incentive income, depreciation expense, dividend income and stock-based compensation.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">F-29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>exhibit4410-kfy2025.htm
<DESCRIPTION>EX-4.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ibad057fe129c4aa59f1207bddd606e45_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.4</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">DESCRIPTION OF REGISTRANTS SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following description of the capital stock of Keros Therapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company&#8217;s amended and restated certificate of incorporation, or the certificate of incorporation, the amended and restated bylaws, or the bylaws, and certificate of designation of rights, preferences and privileges of Series A junior participating preferred stock,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">which are incorporated by reference as exhibits to the Company&#8217;s Annual Report on Form 10-K to which this description is also an exhibit. The Company encourages you to read that law and those documents carefully.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The certificate of incorporation authorizes the issuance of up to 200,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share, 500,000 of which have been designated as Series A Junior Participating Preferred Stock, $0.0001 par value per share, which shares are individually referred to as a &#8220;Preferred Share,&#8221; and collectively referred to as the &#8220;Preferred Shares.&#8221; All other shares of preferred stock are undesignated. For a description of the rights of our Preferred Shares, see below under the heading &#8220;Stockholder Rights Agreement.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Description of Common Stock</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Voting Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the certificate of incorporation and bylaws, common stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Dividends</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Liquidation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company&#8217;s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Rights and Preferences</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of Preferred Shares, upon issuance of any such shares, and shares of any series of preferred stock that the Company may designate in the future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Stockholder Rights Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2025, the Company&#8217;s board of directors, declared a dividend of one right, or Right, to purchase one-thousandth of one share of the Company&#8217;s newly designated Preferred Shares, for each outstanding share of common stock to the stockholders of record as of the close of business on April 24, 2025, or the Record Date, and adopted a limited duration stockholder rights plan, or the Rights Plan, effective immediately, as set forth in the Rights Agreement, dated as of April 9, 2025, or the Rights Agreement, by and between the Company and Computershare Trust Company, N.A., as Rights Agent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary description of the Rights and material terms and conditions of the Rights Agreement.</font></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Rights Agreement, the Rights will not be exercisable and will trade with shares of the Company&#8217;s common stock until the earlier to occur of (a) the tenth calendar day (or such later date as may be determined by the Company&#8217;s board of directors) after a person or group acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of outstanding common stock, an Acquiring Person, or, in the event that the Company&#8217;s board of directors determines on or before such tenth calendar day to effect an exchange and determines that a later date is advisable, such later date that is not more than twenty (20) calendar days after the date such shares of common stock are acquired, or (b) the tenth business day (or such later date as may be determined by action of the Company&#8217;s board of directors prior to such time as any person or entity becomes an Acquiring Person) following the date of commencement, or the first announcement, of an intention to commence, a tender offer or exchange offer, the consummation of which would result in any person or entity, or group of persons or entities acting in concert, becoming an Acquiring Person. The term &#8220;Acquiring Person&#8221; is subject to certain customary exceptions whereby certain stockholders that would have otherwise been an Acquiring Person are excluded from the definition of &#8220;Acquiring Person.&#8221; Any stockholders with beneficial ownership of common stock above the applicable threshold as of the first public announcement of the Rights Plan on April 10, 2025 are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights. Prior to exercise, the Rights do not give their holder any dividend, voting or liquidation rights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The date when the Rights separate from common stock and become exercisable is referred to herein as the &#8220;Distribution Date&#8221;. Unless and until the occurrence of such date, common stock certificates or, in the case of uncertificated shares, notations in the book-entry account system, will evidence the Rights, and any transfer of shares of common stock will constitute a transfer of the related Rights. After the Distribution Date, the Rights will be evidenced by separate book-entry credits or by Rights certificates that the Company will mail to all eligible, certificated holders of common stock. Any Rights held by an Acquiring Person will be null and void and may not be exercised.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise Price</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Rights Agreement, after the Distribution Date, each Right will entitle the holder thereof to purchase one-thousandth (1&#47;1,000th) of a Preferred Share for $165.00, subject to adjustment, or the Exercise Price. Each one-thousandth (1&#47;1,000th) of a Preferred Share has economic terms similar to that of one share of common stock. The Exercise Price payable, and the number of Preferred Shares or other securities or other property issuable upon exercise of the Rights, will be subject to adjustment from time to time to prevent dilution in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Preferred Shares. The exercise of Rights to purchase Preferred Shares will at all times be subject to the availability of a sufficient number of authorized but unissued Preferred Shares. Notwithstanding the foregoing, with certain exceptions, no adjustment in the Exercise Price will be required until cumulative adjustments require an adjustment of at least 1% in such Exercise Price. No fractional Preferred Shares will be issued (other than fractions which are integral multiples of the number of one one-thousandth (1&#47;1,000th) of a Preferred Share issuable upon the exercise of one Right, which may, at the Company&#8217;s election, be evidenced by depositary receipts), and in lieu thereof, an adjustment in cash will be made based on the market price of the Preferred Shares on the last trading day prior to the date of exercise.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Ownership</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Rights Agreement, certain synthetic interests in securities created by derivative positions &#8212; whether or not such interests are considered to be ownership of underlying shares of common stock or are reportable for purposes of Regulation 13D of the Securities Exchange Act of 1934, as amended &#8212; are treated as beneficial ownership of the number of shares of common stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of common stock are directly or indirectly held by counterparties to the derivatives contracts. Swaps dealers unassociated with any control intent or intent to evade the purposes of the Rights Agreement are excepted from such imputed beneficial ownership. In addition, shares held by affiliates and associates of an Acquiring Person, including shares that are subject of, or the reference securities for, or that underly, any derivative position of such persons, will be deemed to be beneficially owned by the Acquiring Person. In addition, any securities beneficially owned by a third party with whom the Acquiring Person has any agreement, arrangement or understanding (whether or not in writing) (i) for the purpose of acquiring, holding or voting securities of the Company or (ii) to cooperate in obtaining, changing or influencing control of the Company, will be deemed to be beneficially owned by the Acquiring Person.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consequences of a Person or Group Becoming an Acquiring Person</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Flip-In.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> If a person or group becomes an Acquiring Person, all holders of Rights except the Acquiring Person or its affiliates may, for the Exercise Price, purchase shares of common stock with a market value of twice the Exercise Price.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Exchange.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In lieu of the &#8220;flip-in&#8221; feature described above, the Company&#8217;s board of directors may, at its option at any time after a person or group becomes an Acquiring Person, exchange the Rights (other than Rights owned by the Acquiring Person or its affiliates), in whole or in part, for shares of common stock at an exchange ratio of one share of common stock per Right (subject to adjustment).</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">Flip-Over.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company is later acquired in a merger or similar transaction after the Distribution Date, all holders of Rights except the Acquiring Person or its affiliates may purchase, for the Exercise Price, a number of shares of the common stock of the Principal Party (as defined in the Rights Agreement) having a market value of twice the Exercise Price.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Preferred Share Provisions</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each Preferred Share, if issued&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">will not be redeemable&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">when, as and if any dividend is declared on common stock, entitle the holder to quarterly dividend payments in an amount per share equal to 1,000 times the aggregate per share amount of all cash dividends, and 1,000 times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions other than a dividend payable in common stock or a subdivision of the outstanding common stock (by reclassification or otherwise), declared on common stock since the immediately preceding quarterly dividend payment date or, with respect to the first date when quarterly dividends are payable in cash, since the first issuance of any share or fraction of a share of Series A Junior Participating Preferred Stock&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">will entitle the holder upon liquidation either to receive a preferential liquidation payment of the greater of (a) $1,000 per Preferred Share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment and (b) an aggregate amount per Preferred Share equal to 1,000 times the aggregate amount to be distributed per share to holders of common stock plus an amount equal to any accrued and unpaid dividends on such Preferred Shares&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">will have the same voting power as 1,000 shares of common stock&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">if shares of common stock are exchanged via merger, consolidation, or a similar transaction, will entitle the holder to a per share payment equal to the payment made on 1,000 shares of common stock&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">will rank junior to any other series of the Company&#8217;s preferred stock in the event such other preferred stock is issued by the Company, unless the terms of any such series provide otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The value of one one-thousandth (1&#47;1,000th) interest in a Preferred Share is intended to approximate the value of one share of common stock.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expiration</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Rights will expire on April 9, 2026, or the Final Expiration Date, unless the Rights are earlier redeemed or exchanged by the Company.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The board of directors may redeem the Rights for $0.001 per Right at any time prior to the earlier of (A) such time as any person or group becomes an Acquiring Person or (B) the close of business on the Final Expiration Date. Following the expiration of the above periods, the Rights become nonredeemable. If the board of directors redeems any Rights, it must redeem all of the Rights. Once the Rights are redeemed, the only right of the holders of Rights pursuant to the Rights Agreement will be to receive the redemption price of $0.001 per Right. The redemption price will be adjusted if the Company effects a stock split or stock dividend of common stock.</font></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Dilution Provisions</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Rights will have the benefit of certain anti-dilution provisions set forth in the Rights Agreement.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendments</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Rights Agreement may be amended by the board of directors without the consent of the holders of the Rights. After a person or group becomes an Acquiring Person, the board of directors may not amend the Rights Agreement in a way that adversely affects holders of the Rights.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Miscellaneous</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Rights Agreement does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future board to redeem the Rights. Until a Right is exercised, it does not entitle the holder thereof to any additional rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Anti-Takeover Provisions</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Anti-Takeover Statute</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The Company is subject to Section 203 of the DGCL, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66-2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In general, Section 203 defines a &#8220;business combination&#8221; to include the following&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Anti-Takeover Effects of Certain Provisions of the Certificate of Incorporation and Bylaws</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The certificate of incorporation provides for the Company&#8217;s board of directors to be divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because the Company&#8217;s stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of the shares of common stock outstanding will be able to elect all of the Company&#8217;s directors. The directors may be removed by the stockholders only for cause upon the vote of holders of 66 </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">2&#47;3% of the shares then entitled to vote at an election of directors. Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only be filled by a majority vote of the directors then serving on the board, even though less than a quorum. The certificate of incorporation and bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by a consent in writing. A special meeting of stockholders may be called only by a majority of the whole board of directors, the chair of the board of directors or (if the chair is unavailable) the Company&#8217;s chief executive officer or president. The bylaws also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#8217;s notice.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The certificate of incorporation further provides that the affirmative vote of holders of at least 66 2&#47;3% of the voting power of all of the then-outstanding shares of voting stock, voting as a single class, is required to amend certain provisions of the certificate of incorporation, including provisions relating to the structure of the board of directors, the size of the board, removal of directors, special meetings of stockholders, actions by written consent and cumulative voting. The affirmative vote of holders of at least 66 2&#47;3% of the voting power of all of the then-outstanding shares of voting stock, voting as a single class, is required to adopt, amend or repeal the bylaws, although the bylaws may be adopted, amended or repealed by a simple majority vote of the Company&#8217;s whole board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The foregoing provisions will make it more difficult for the Company&#8217;s existing stockholders to replace the board of directors as well as for another party to obtain control of the company by replacing the board of directors. Since the board of directors has the power to retain and discharge the Company&#8217;s officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for the board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of the company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">These provisions are intended to enhance the likelihood of continued stability in the composition of the board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of the company. These provisions are also designed to reduce the Company&#8217;s vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, such provisions could have the effect of discouraging others from making tender offers for the Company&#8217;s shares and may have the effect of deterring hostile takeovers or delaying changes in control of the company or management. As a consequence, these provisions also may inhibit fluctuations in the market price of the Company&#8217;s stock that could result from actual or rumored takeover attempts.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Choice of Forum</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for&#58; (1) any derivative action or proceeding brought on the Company&#8217;s behalf&#59; (2) any action or proceeding asserting a breach of fiduciary duty owed by any of the Company&#8217;s current or former directors, officers or employees to the Company or its stockholders&#59; (3) any action or proceeding asserting a claim against the Company or any of its current or former directors, officers or other employees, arising out of or pursuant to the Delaware General Corporation Law, the certificate of incorporation or the bylaws&#59; (4) any action or proceeding to interpret, apply, enforce or determine the validity of the certificate of incorporation or the by-laws&#59; or (5) any action or proceeding asserting a claim against the Company that is governed by the internal affairs doctrine, provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction&#59; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. It is possible that a court of law could rule that the choice of forum provision contained in the certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The transfer agent and registrar for the Company&#8217;s common stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall Street, Suite 101, Canton, Massachusetts 02021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:107%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:107%">The common stock is listed on the Nasdaq Global Market under the symbol &#8220;KROS.&#8221;</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>exhibit107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i7eb23174ad0a420f837b83493edbed92_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.6pt;padding-left:0.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:119%">Exhibit 10.7</font></div></div><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</font></div><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Amended and Restated Non-Employee Director Compensation Policy</font></div><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Each member of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) who is not also serving as an employee of or consultant to Keros Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or any of its subsidiaries (each such member, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Eligible Director</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for his or her Board service. An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This Policy first became effective commencing as of April 7, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), has been subsequently amended, most recently on February 24, 2026, and may be further amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Annual Cash Compensation</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Annual Board Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">All Eligible Directors&#58; $41,500</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Chairman of the Board Service Retainer (in addition to Eligible Director Service Retainer)&#58; $33,000</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Lead Independent Director (in addition to Eligible Director Service Retainer)&#58; $31,000</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Annual Committee Chair Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Chairman of the Audit Committee&#58; $17,000</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Chairman of the Compensation Committee&#58; $14,000</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Chairman of the Nominating and Corporate Governance Committee&#58; $10,000</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Annual Committee Member Service Retainer (not applicable to Committee Chairs)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Member of the Audit Committee&#58; $8,500</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9pt">Member of the Compensation Committee&#58; $7,000</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.68pt">Member of the Nominating and Corporate Governance Committee&#58; $5,000</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Equity Compensation</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The equity compensation set forth below will be granted under the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the approval of the Plan by the Company&#8217;s stockholders. All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.6pt;padding-left:0.5pt;text-align:right;text-indent:-0.5pt"><font><br></font></div></div><div style="padding-left:0.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">death, Disability or Cause (as each such term is defined in the Plan), the post-termination exercise period will be 12 months from the date of termination).</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director&#8217;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Appointment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Eligible Director will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted (i) a stock option to purchase a number of shares of Common Stock having a grant date fair value, as determined in accordance with Financial Accounting Standards Board ASC Topic 718, equal to $150,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Initial Option Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the number of shares of Common Stock subject to the Initial Option Grant will not exceed 0.075% of the number of shares of Common Stock outstanding as of the applicable grant date&#59; and (ii) a restricted stock unit award covering a number of shares of Common Stock having a grant date fair value, as determined in accordance with Financial Accounting Standards Board ASC Topic 718, equal to $150,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Initial RSU Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the number of shares of Common Stock subject to the Initial RSU Grant will not exceed 0.075% of the number of shares of Common Stock outstanding as of the applicable grant date. The shares subject to each Initial Option Grant will vest in equal quarterly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through each such vesting date. The Initial RSU Grant will vest over a three-year period, in twelve equal quarterly installments on each Quarterly Vesting Date (as defined below) that occurs on or following the Appointment Effective Date, subject to the Eligible Director&#8217;s Continuous Service through each such vesting date. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the 15</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;of each of February, May, August and November. Notwithstanding the foregoing, each Initial Option Grant and Initial RSU Grant will vest in full upon a Change in Control (as defined in the Plan). </font></div><div style="padding-left:36pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; On the date of each annual stockholder meeting of the Company held after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Annual Grant Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), each Eligible Director who continues to serve as a non-employee member of the Board following such stockholder meeting&#160;(other than a director receiving an Initial Option Grant and an Initial RSU Grant less than three (3) months prior to such stockholder meeting) will be automatically, and without further action by the Board or the Compensation Committee of the Board, granted (i) a stock option to purchase a number of shares of Common Stock having a grant date fair value, as determined in accordance with Financial Accounting Standards Board ASC Topic 718, equal to $75,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Annual Option Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the number of shares of Common Stock subject to the Annual Option Grant will not exceed 0.0375% of the number of shares of Common Stock outstanding as of the applicable grant date&#59; and (ii) a restricted stock unit award covering a number of shares of Common Stock having a grant date fair value, as determined in accordance with Financial Accounting Standards Board ASC Topic 718, equal to $75,000</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Annual RSU Grant</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the number of shares of Common Stock subject to the Annual RSU Grant will not exceed 0.0375% of the number of shares of Common Stock outstanding as of the applicable grant date. The shares subject to the Annual Option Grant will vest in equal quarterly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of the Company&#8217;s next annual stockholder meeting, subject to the Eligible Director&#8217;s Continuous Service through such vesting date. The Annual RSU Grant will fully vest on the earlier of (A) the first anniversary of the applicable Annual Grant Date and (B) the date of the Company&#8217;s next annual stockholder meeting following the applicable Annual Grant Date, subject to the Eligible Director&#8217;s Continuous Service through such vesting date. Notwithstanding the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.6pt;padding-left:0.5pt;text-align:right;text-indent:-0.5pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">foregoing, each Annual Option Grant and Annual RSU Grant will vest in full upon a Change in Control.</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Non-Employee Director Compensation Limit</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director (as defined in the Plan) shall in no event exceed the limits set forth in Section 3(d) of the Plan.</font></div><div style="margin-bottom:0.6pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>4
<FILENAME>exhibit1024.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i3743a2b7d0a64f6394fc61624ad62709_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. &#91;***&#93; INDICATES THAT INFORMATION HAS BEEN REDACTED.</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.24</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">This Amendment No. 1 to the Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into and effective as of March 24, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 1 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation, having a place of business at 1050 Waltham St., Suite 302, Lexington, MA 02421 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Keros</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation having a place of business at 500 Kendall Street, Cambridge, MA 02142 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Takeda</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Keros and Takeda are hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and singularly as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties entered into that certain Exclusive License Agreement dated as of December 3, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties now seek to amend section 4.2(d) of the Existing Agreement as further described herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual covenants contained below, the Parties agree as follows&#58; </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Capitalized terms used but not otherwise defined in this Amendment No. 1 shall have the meanings given to such terms in the Existing Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Payment for Prepaid Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Section 4.2(d) of the Existing Agreement is hereby amended by deleting the last sentence in its entirety and replacing it with the following sentence&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Takeda shall pay such expenses within &#91;***&#93; after receipt of such invoice.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Effectiveness of Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the changes expressly specified in this Amendment No. 1 all other terms and conditions of the Existing Agreement shall remain unchanged and continue to be in full force and effect on its terms.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment No. 1 may be executed in any number of counterparts (delivery of which may be by facsimile, via email as a portable document format (.pdf) or through the use of electronic signatures), each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS, WHEREOF, each Party hereto, intending to be legally bound hereby, have caused this Amendment No. 1 to be executed and delivered by its proper and duly authorized officer effective as of the Amendment No. 1 Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Keros Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Jasbir Seehra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Jasbir Seehra</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 3&#47;24&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Takeda Pharmaceuticals U.S.A., Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Phil McGurk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Phil McGurk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 3&#47;25&#47;2025</font></div><div id="i3743a2b7d0a64f6394fc61624ad62709_7"></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Signature Page to Amendment No. 1 to Exclusive License Agreement</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">This Amendment No. 2 to the Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 2</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into and effective as of April 23, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 2 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation, having a place of business at 1050 Waltham St., Suite 302, Lexington, MA 02421 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Keros</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation having a place of business at 500 Kendall Street, Cambridge, MA 02142 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Takeda</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Keros and Takeda are hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and singularly as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties entered into that certain Exclusive License Agreement dated as of December 3, 2024 as previously amended by Amendment No. 1 to Exclusive License Agreement, effective as of March 24, 2025, (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties now seek to amend section 4.2(d) of the Existing Agreement as further described herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual covenants contained below, the Parties agree as follows&#58; </font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Capitalized terms used but not otherwise defined in this Amendment No. 2 shall have the meanings given to such terms in the Existing Agreement.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Payment for Prepaid Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Section 4.2(d) of the Existing Agreement is hereby amended by deleting the last sentence in its entirety and replacing it with the following sentence&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Takeda shall pay such expenses within &#91;***&#93; after receipt of such invoice.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Effectiveness of Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the changes expressly specified in this Amendment No. 2 all other terms and conditions of the Existing Agreement shall remain unchanged and continue to be in full force and effect on its terms.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment No. 2 may be executed in any number of counterparts (delivery of which may be by facsimile, via email as a portable document format (.pdf) or through the use of electronic signatures), each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">.&#93;</font></div><div id="i3743a2b7d0a64f6394fc61624ad62709_13"></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS, WHEREOF, each Party hereto, intending to be legally bound hereby, have caused this Amendment No. 2 to be executed and delivered by its proper and duly authorized officer effective as of the Amendment No. 2 Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Keros Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Jasbir Seehra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Jasbir Seehra</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 4&#47;23&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Takeda Pharmaceuticals U.S.A., Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Phil McGurk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Phil McGurk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 4&#47;24&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Signature Page to Amendment No. 2 to Exclusive License Agreement</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 3 TO EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">This Amendment No. 3 to the Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 3</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into and effective as of June 5, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 3 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation, having a place of business at 1050 Waltham St., Suite 302, Lexington, MA 02421 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Keros</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation having a place of business at 500 Kendall Street, Cambridge, MA 02142 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Takeda</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Keros and Takeda are hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and singularly as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties entered into that certain Exclusive License Agreement dated as of December 3, 2024 as previously amended by Amendment No. 1 to Exclusive License Agreement, effective as of March 24, 2025, and Amendment No. 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">to Exclusive License Agreement, effective as of April 23, 2025, (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties now seek to amend section 4.2(d) of the Existing Agreement as further described herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual covenants contained below, the Parties agree as follows&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Capitalized terms used but not otherwise defined in this Amendment No. 3 shall have the meanings given to such terms in the Existing Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Payment for Prepaid Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Section 4.2(d) of the Existing Agreement is hereby amended by deleting the last sentence in its entirety and replacing it with the following sentence&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Takeda shall pay such expenses by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Effectiveness of Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the changes expressly specified in this Amendment No. 3 all other terms and conditions of the Existing Agreement shall remain unchanged and continue to be in full force and effect on its terms.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment No. 3 may be executed in any number of counterparts (delivery of which may be by facsimile, via email as a portable document format (.pdf) or through the use of electronic signatures), each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS, WHEREOF, each Party hereto, intending to be legally bound hereby, have caused this Amendment No. 3 to be executed and delivered by its proper and duly authorized officer effective as of the Amendment No. 3 Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Keros Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Jasbir Seehra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Jasbir Seehra</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 6&#47;5&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Takeda Pharmaceuticals U.S.A., Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Phil McGurk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Phil McGurk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 6&#47;5&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Signature Page to Amendment No. 3 to Exclusive License Agreement</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">This Amendment No. 4 to the Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 4</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into and effective as of June 13, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 4 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Keros Therapeutics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation, having a place of business at 1050 Waltham St., Suite 302, Lexington, MA 02421 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Keros</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation having a place of business at 500 Kendall Street, Cambridge, MA 02142 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Takeda</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Keros and Takeda are hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and singularly as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties entered into that certain Exclusive License Agreement dated as of December 3, 2024 as previously amended by Amendment No. 1 to Exclusive License Agreement, effective as of March 24, 2025, Amendment No. 2 to Exclusive License Agreement, effective as of April 23, 2025, and Amendment No. 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">to Exclusive License Agreement, effective as of June 5, 2025 (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Existing Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties now seek to amend Section 4.2(d) of the Existing Agreement as further described herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual covenants contained below, the Parties agree as follows&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Capitalized terms used but not otherwise defined in this Amendment No. 4 shall have the meanings given to such terms in the Existing Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Payment for Prepaid Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Section 4.2(d) of the Existing Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">With respect to and as applicable to any Keros CMO agreement or Keros Contractor agreement assigned to Takeda pursuant to Section 4.2(c), if (i) Keros has prepaid such Keros CMO or Keros Contractor for amounts that (A) are directly attributable to the Exploitation of the Licensed Compound in the Territory, and (B) are solely for services or other activities performed or completed or goods supplied after the Keros Contractor Assignment Date (as defined below) and do not relate to activities that have been performed, services rendered, or goods supplied prior to the Keros Contractor Assignment Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Prepaid Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) Takeda is issued a credit for, or otherwise receives the benefit of, such Prepaid Expenses as part of the assignment of such Keros CMO agreement or Keros Contractor agreement to Takeda, then Takeda shall reimburse Keros for the amount of the credit or benefit received by Takeda as part of such assignment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Prepaid Expenses Credit Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Takeda shall pay the Prepaid Expenses Credit Reimbursement within &#91;***&#93; after receipt of an invoice therefor.  For purposes of this Section 4.2(d), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Keros Contractor Assignment Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the effective date on which Keros&#8217;s existing applicable agreement with a Keros CMO or a Keros Contractor has been assigned to Takeda or its designee pursuant to a written assignment agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any language to the contrary, Takeda shall not be required to pay the amount previously invoiced by Keros under the original terms of Section 4.2(d) and such previous invoice shall become void upon Amendment No. 4 Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Deletion of Schedule 4.2(d).  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 4.2(d) of the Existing Agreement is hereby deleted in its entirety.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Effectiveness of Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the changes expressly specified in this Amendment No. 4 all other terms and conditions of the Existing Agreement shall remain unchanged and continue to be in full force and effect on its terms.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Amendment No. 4 may be executed in any number of counterparts (delivery of which may be by facsimile, via email as a portable document format (.pdf) or through the use of electronic signatures), each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i3743a2b7d0a64f6394fc61624ad62709_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS, WHEREOF, each Party hereto, intending to be legally bound hereby, have caused this Amendment No. 4 to be executed and delivered by its proper and duly authorized officer effective as of the Amendment No. 4 Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Keros Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Jasbir Seehra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Jasbir Seehra</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 6&#47;13&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:174%">Takeda Pharmaceuticals U.S.A., Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Phil McGurk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Name&#58; Phil McGurk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:174%">Date&#58; 6&#47;16&#47;2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Signature Page to Amendment No. 4 to Exclusive License Agreement</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>5
<FILENAME>exhibit1027.htm
<DESCRIPTION>EX-10.27
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib2c30414aa304d809c881a3e6073aecb_1"></div><div style="min-height:74.16pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.27</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-right:-1.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT TO </font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Amendment to Executive Employment Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is entered into by and between Keros Therapeutics, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Esther Cho (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (each herein referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as of February 24, 2026 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Company and Executive entered into that certain Executive Employment Agreement as of August 6, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Company and Executive desire to amend the Employment Agreement pursuant to the terms of this Amendment. In consideration of Executive&#8217;s continued engagement with the Company and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the Parties agree as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Definitions </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Capitalized terms used herein and not otherwise defined shall have the same meaning as set forth in the Employment Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties hereby agree that the Employment Agreement shall be amended as follows&#58;</font></div><div style="margin-bottom:11pt;padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.37pt">Section 1(a) (&#8220;Positions and Duties&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; This Section shall be amended to change Executive&#8217;s title from Senior Vice President, General Counsel to Chief Legal Officer. All other provisions in Section 1(a) shall remain the same.  </font></div><div style="margin-bottom:11pt;padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">Section 3(a) (&#8220;Base Salary&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#58; This Section shall be amended to increase Executive&#8217;s annual Base Salary to $485,000, less applicable withholdings and deductions. All other provisions in Section 3(a) shall remain the same.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Continuation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Except as set forth herein, all of the terms and conditions set forth in the Employment Agreement, including any exhibits, are unchanged and shall remain in full force and effect and are hereby ratified and confirmed by the Parties hereto. If any provision of this Amendment is inconsistent with the Employment Agreement, the Parties intend that the terms of this Amendment shall control solely to the extent required to make the Employment Agreement consistent with this Amendment. Nothing herein shall change the at-will nature of Executive&#8217;s employment. Executive agrees and confirms that nothing herein triggers the Good Reason provision contained in the Employment Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Construction of Terms</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Amendment constitutes the entire understanding between the Parties with respect to the subject matter hereof and supersedes any other agreements or promises made to Executive by anyone with respect to this subject matter, whether oral or written. No modification to this Amendment shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Governing Law</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be governed by the laws of the Commonwealth of Massachusetts, without regard to the conflicts of law provisions of any jurisdiction.</font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.361%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Counterparts</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, with the same force and effectiveness as though executed in a single document. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt">Effective Date</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The terms and conditions set forth in this Amendment shall be effective as of the Effective Date.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Effective Date.</font></div><div style="margin-bottom:12pt;margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">KEROS THERAPEUTICS, INC.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXECUTIVE</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jasbir Seehra&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Esther Cho&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Jasbir Seehra&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Esther Cho</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;padding-left:40.5pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>exhibit21110-kfy2025.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i03aa2f3f90c14066bcc15b31e95adf18_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Subsidiaries of Keros Therapeutics, Inc.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.062%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:125%;text-decoration:underline">Name of Subsidiary</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:125%;text-decoration:underline">Jurisdiction of Organization</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:125%">Keros Therapeutics Australia, Pty Ltd</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:125%">Australia</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:125%">Keros Security Corporation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:125%">Massachusetts</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exhibit23110-kfy2025.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i60f8a774969d4c12a67590804d9ca183_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:110%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We consent to the incorporation by reference in Registration Statement Nos. 333-237732, 333-252151, 333-263394, 333-270268, 333-277483 and 333-285271 on Form S-8 of our report dated March 4, 2026, relating to the financial statements of Keros Therapeutics, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">March 4, 2026</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exhibit31110-kfy2025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if2e963965519453cb1bd8cbcd471b22d_1"></div><div style="min-height:43.2pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Jasbir Seehra, Ph.D., certify that&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">I have reviewed this Annual Report on Form 10-K of Keros Therapeutics, Inc.&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="padding-left:27pt;text-indent:-33.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Date&#58; March 4, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Jasbir Seehra, Ph.D.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Jasbir Seehra, Ph.D.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exhibit31210-kfy2025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="iff64deacc11e4f11aa8b39c8bdd4cf67_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Keith Regnante, certify that&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">I have reviewed this Annual Report on Form 10-K of Keros Therapeutics, Inc.&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="padding-left:27pt;text-indent:-33.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Date&#58; March 4, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">By&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Keith Regnante</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Keith Regnante</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#160;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exhibit32110-kfy2025.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ie3c99926969042958364140febe1ad15_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Jasbir Seehra, Ph.D., Chief Executive Officer&#160;of Keros Therapeutics, Inc. (the &#8220;Company&#8221;) and&#160;Keith Regnante,&#160;Chief Financial Officer&#160;of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The Company&#8217;s Annual Report on Form 10-K for the period ended&#160;December 31, 2025, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</font></div></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div style="text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">In Witness Whereof</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">, the undersigned have set their hands hereto as of the&#160;4th&#160;day of&#160;March, 2026.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.902%"><tr><td style="width:1.0%"></td><td style="width:60.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.757%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#47;s&#47; Jasbir Seehra</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Jasbir Seehra, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">(Principal Executive Officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#47;s&#47; Keith Regnante</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Keith Regnante</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Keros Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>kros-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kros="http://www.kerostx.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.kerostx.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kros-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kros-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kros-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kros-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.kerostx.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.kerostx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATION" roleURI="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION">
        <link:definition>9952157 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952159 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETS" roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS">
        <link:definition>9952160 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNET" roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET">
        <link:definition>9952161 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>9952162 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.kerostx.com/role/LICENSEAGREEMENTS">
        <link:definition>9952163 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952164 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TREASURYSTOCK" roleURI="http://www.kerostx.com/role/TREASURYSTOCK">
        <link:definition>9952165 - Disclosure - TREASURY STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952166 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMELOSSPERSHARE" roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHARE">
        <link:definition>9952167 - Disclosure - INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.kerostx.com/role/INCOMETAXES">
        <link:definition>9952168 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.kerostx.com/role/LEASES">
        <link:definition>9952169 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEFROMCONTRACTSWITHCUSTOMERS" roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS">
        <link:definition>9952171 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.kerostx.com/role/SEGMENTREPORTING">
        <link:definition>9952172 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATERESTRUCTURING" roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURING">
        <link:definition>9952173 - Disclosure - CORPORATE RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9955513 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables">
        <link:definition>9955514 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables">
        <link:definition>9955515 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>9955516 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955517 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMELOSSPERSHARETables" roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHARETables">
        <link:definition>9955519 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.kerostx.com/role/INCOMETAXESTables">
        <link:definition>9955520 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.kerostx.com/role/LEASESTables">
        <link:definition>9955521 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEFROMCONTRACTSWITHCUSTOMERSTables" roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables">
        <link:definition>9955522 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGTables" roleURI="http://www.kerostx.com/role/SEGMENTREPORTINGTables">
        <link:definition>9955523 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATERESTRUCTURINGTables" roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables">
        <link:definition>9955524 - Disclosure - CORPORATE RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" roleURI="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
        <link:definition>9955525 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails">
        <link:definition>9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails" roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails">
        <link:definition>9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9955529 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails">
        <link:definition>9955530 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails">
        <link:definition>9955531 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>9955532 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>9955533 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSDetails" roleURI="http://www.kerostx.com/role/LICENSEAGREEMENTSDetails">
        <link:definition>9955534 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955535 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofPreferredStockDetails" roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails">
        <link:definition>9955536 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TREASURYSTOCKDetails" roleURI="http://www.kerostx.com/role/TREASURYSTOCKDetails">
        <link:definition>9955537 - Disclosure - TREASURY STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955538 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails">
        <link:definition>9955539 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails">
        <link:definition>9955540 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>9955541 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails">
        <link:definition>9955543 - Disclosure - INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails" roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails">
        <link:definition>9955544 - Disclosure - INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>9955545 - Disclosure - INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails" roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails">
        <link:definition>9955546 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>9955547 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails" roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails">
        <link:definition>9955548 - Disclosure - INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.kerostx.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9955549 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.kerostx.com/role/LEASESNarrativeDetails">
        <link:definition>9955550 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofLeaseCostsDetails" roleURI="http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails">
        <link:definition>9955551 - Disclosure - LEASES - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturityofLeaseLiabilityDetails" roleURI="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails">
        <link:definition>9955552 - Disclosure - LEASES - Schedule of Maturity of Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofMaturityofLeaseLiabilityDetails_1" roleURI="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1">
        <link:definition>9955552 - Disclosure - LEASES - Schedule of Maturity of Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955553 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails">
        <link:definition>9955554 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails" roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails">
        <link:definition>9955555 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955556 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.kerostx.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9955557 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATERESTRUCTURINGNarrativeDetails" roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails">
        <link:definition>9955558 - Disclosure - CORPORATE RESTRUCTURING - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails" roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails">
        <link:definition>9955559 - Disclosure - CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="kros_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentIncentiveIncome" abstract="false" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ShortSwingProfitSettlement" abstract="false" name="ShortSwingProfitSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" abstract="false" name="IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" abstract="false" name="RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_SecondaryOfferingMember" abstract="true" name="SecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_RightToUseAssetsAndOperatingLeaseLiabilities" abstract="false" name="RightToUseAssetsAndOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PaymentOfInitialPublicOfferingCosts" abstract="false" name="PaymentOfInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PaymentOfStockRepurchaseCosts" abstract="false" name="PaymentOfStockRepurchaseCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ProceedsFromShortSwingSettlementProfit" abstract="false" name="ProceedsFromShortSwingSettlementProfit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" abstract="false" name="TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_TreasuryStockPolicyTextBlock" abstract="false" name="TreasuryStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kros_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="kros_NumberOfFinancialInstitutions" abstract="false" name="NumberOfFinancialInstitutions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kros_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_PrepaidExternalRDCostsCurrent" abstract="false" name="PrepaidExternalRDCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PrepaidExternalManufacturingCostsCurrent" abstract="false" name="PrepaidExternalManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_SalesTaxReceivableCurrent" abstract="false" name="SalesTaxReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PrepaidSubscriptionCurrent" abstract="false" name="PrepaidSubscriptionCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PrepaidLegalAndConsultants" abstract="false" name="PrepaidLegalAndConsultants" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_RefundsDueFromContractResearchOrganizationsCurrent" abstract="false" name="RefundsDueFromContractResearchOrganizationsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_AccruedManufacturingCostsCurrent" abstract="false" name="AccruedManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_TheGeneralHospitalCorporationMember" abstract="true" name="TheGeneralHospitalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" abstract="false" name="NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" abstract="false" name="ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" abstract="false" name="ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" abstract="false" name="ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kros_O2025Q1DividendsMember" abstract="true" name="O2025Q1DividendsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_SaleOfStockAgentCommissions" abstract="false" name="SaleOfStockAgentCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_SaleOfStockStockIssuanceCosts" abstract="false" name="SaleOfStockStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_CommonStockDividendNumberOfRightsPerShare" abstract="false" name="CommonStockDividendNumberOfRightsPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="kros_CommonStockBeneficialOwnershipPenaltyThreshold" abstract="false" name="CommonStockBeneficialOwnershipPenaltyThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_CommonStockVotingRightsNumberOfVotes" abstract="false" name="CommonStockVotingRightsNumberOfVotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kros_A2020PlanMember" abstract="true" name="A2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" abstract="false" name="SharesAcquiredPricePerShareOnCommencementOfTenderOffer" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="kros_A2017StockIncentivePlanMember" abstract="true" name="A2017StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" abstract="true" name="EmployeeStockPurchasePlanTwentyTwentyMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_PerformanceBasedAwardsMember" abstract="true" name="PerformanceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_UnvestedStockOptionsMember" abstract="true" name="UnvestedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_PerformanceBasedStockOptionsMember" abstract="true" name="PerformanceBasedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_TermLoanCreditAgreementThreeAmendmentMember" abstract="true" name="TermLoanCreditAgreementThreeAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" abstract="false" name="ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" abstract="false" name="ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" abstract="false" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_OperatingLossCarryforwardWriteOff" abstract="false" name="OperatingLossCarryforwardWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PhaseAPremisesMember" abstract="true" name="PhaseAPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_WalthamLeaseMember" abstract="true" name="WalthamLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_AccentTherapeuticsIncMember" abstract="true" name="AccentTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_LesseeAreaOfSublease" abstract="false" name="LesseeAreaOfSublease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="kros_LesseeOperatingLeaseMonthlyBaseRent" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_LesseeOperatingLeasePeriodForImprovement" abstract="false" name="LesseeOperatingLeasePeriodForImprovement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" abstract="false" name="LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" abstract="false" name="LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="kros_LesseeOperatingLeaseAreaOfRentalSpace" abstract="false" name="LesseeOperatingLeaseAreaOfRentalSpace" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="kros_LesseeLeaseOtherInformationAbstract" abstract="true" name="LesseeLeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_TakedaPharmaceuticalsU.S.A.Inc.Member" abstract="true" name="TakedaPharmaceuticalsU.S.A.Inc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" abstract="false" name="LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="kros_HansohAgreementMember" abstract="true" name="HansohAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_TechTransferAgreementMember" abstract="true" name="TechTransferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_SupplyAgreementMember" abstract="true" name="SupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_HansohShanghaiHealthtechCoLtdMember" abstract="true" name="HansohShanghaiHealthtechCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ManufacturingTechnologyTransferAgreementMember" abstract="true" name="ManufacturingTechnologyTransferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ClinicalProductSupplyAgreementMember" abstract="true" name="ClinicalProductSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_LicenseAndKnowHowMember" abstract="true" name="LicenseAndKnowHowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_TransitionServicesMember" abstract="true" name="TransitionServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" abstract="false" name="RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" abstract="false" name="RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_RevenueFromContractWithCustomerWithholdingTaxes" abstract="false" name="RevenueFromContractWithCustomerWithholdingTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_ServiceAndOtherRevenue" abstract="false" name="ServiceAndOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" abstract="false" name="PotentialMilestonePaymentsDevelopmentBasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PotentialMilestonePaymentsCommercialBasedMilestones" abstract="false" name="PotentialMilestonePaymentsCommercialBasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_PotentialMilestonePaymentsSalesBasedMilestones" abstract="false" name="PotentialMilestonePaymentsSalesBasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="kros_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="kros_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_RinvaterceptProgramExpensesMember" abstract="true" name="RinvaterceptProgramExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_ElriterceptProgramExpensesMember" abstract="true" name="ElriterceptProgramExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_CiboterceptProgramExpensesMember" abstract="true" name="CiboterceptProgramExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_PreclinicalDevelopmentExpensesMember" abstract="true" name="PreclinicalDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_OtherExternalCostsMember" abstract="true" name="OtherExternalCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_A2025RestructuringMember" abstract="true" name="A2025RestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" abstract="false" name="RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="kros_KeithRegnanteMember" abstract="true" name="KeithRegnanteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_LorenaLernerMember" abstract="true" name="LorenaLernerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_NimaFarzanMember" abstract="true" name="NimaFarzanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_JuliusKnowlesMember" abstract="true" name="JuliusKnowlesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_AlpnaSethMember" abstract="true" name="AlpnaSethMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="kros_JeanJacquesBienaimeMember" abstract="true" name="JeanJacquesBienaimeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>kros-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0a978f5b-e884-419e-a6f5-e71f373818c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a04af42e-8e67-4d09-816a-b1aeec4d8872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0a978f5b-e884-419e-a6f5-e71f373818c8" xlink:to="loc_us-gaap_Liabilities_a04af42e-8e67-4d09-816a-b1aeec4d8872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e21a873c-5ec1-4cd2-a495-8607ad3927e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0a978f5b-e884-419e-a6f5-e71f373818c8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e21a873c-5ec1-4cd2-a495-8607ad3927e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_729e0e2b-ce96-4de3-8757-9cc30c831a13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0a978f5b-e884-419e-a6f5-e71f373818c8" xlink:to="loc_us-gaap_StockholdersEquity_729e0e2b-ce96-4de3-8757-9cc30c831a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f38dbcdf-8fd5-412b-b634-adac18d84fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4dec482-3ffc-4730-a74f-05aa2c768ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f38dbcdf-8fd5-412b-b634-adac18d84fc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_e4dec482-3ffc-4730-a74f-05aa2c768ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4d5b6a96-5ed4-4f0a-a138-05fe16bb7647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f38dbcdf-8fd5-412b-b634-adac18d84fc1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4d5b6a96-5ed4-4f0a-a138-05fe16bb7647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f52e36f8-9d7a-450f-b5b0-9ae60d7be8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dd73d76-3dd5-4e9e-ae66-beb56de3cf84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f52e36f8-9d7a-450f-b5b0-9ae60d7be8fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4dd73d76-3dd5-4e9e-ae66-beb56de3cf84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_98ff5279-dad0-42bc-849e-d8065883042d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f52e36f8-9d7a-450f-b5b0-9ae60d7be8fe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_98ff5279-dad0-42bc-849e-d8065883042d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a76382a-161b-4cf9-875b-b6326fd2abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f52e36f8-9d7a-450f-b5b0-9ae60d7be8fe" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a76382a-161b-4cf9-875b-b6326fd2abdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_019c6f88-2dd1-78ce-91a8-e5c8aec66f98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f52e36f8-9d7a-450f-b5b0-9ae60d7be8fe" xlink:to="loc_us-gaap_IncomeTaxesReceivable_019c6f88-2dd1-78ce-91a8-e5c8aec66f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_456436d6-d54d-4f3a-8545-98c9646c8c51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bc4721a6-fd9d-44f3-97c0-c59ef64b708c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_456436d6-d54d-4f3a-8545-98c9646c8c51" xlink:to="loc_us-gaap_AccountsPayableCurrent_bc4721a6-fd9d-44f3-97c0-c59ef64b708c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a857e5c-a087-43a5-b912-fbe9162991b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_456436d6-d54d-4f3a-8545-98c9646c8c51" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6a857e5c-a087-43a5-b912-fbe9162991b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c9a140ef-e57e-4827-9577-2adf61a852ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_456436d6-d54d-4f3a-8545-98c9646c8c51" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c9a140ef-e57e-4827-9577-2adf61a852ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_336a079d-5de4-4da5-813c-94c8a71ad08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:to="loc_us-gaap_AssetsCurrent_336a079d-5de4-4da5-813c-94c8a71ad08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a1ffb12-bf91-4241-b148-1996e533c774" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a1ffb12-bf91-4241-b148-1996e533c774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3e103b76-5335-45d0-872c-b6ea9b30d813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3e103b76-5335-45d0-872c-b6ea9b30d813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ebbd14ea-fd2c-40ea-acca-bfd6bc27df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ebbd14ea-fd2c-40ea-acca-bfd6bc27df6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_79895b54-d8c5-427a-b09f-d69e6260d077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ee74624e-e95f-4e01-a45d-35ac8415b0ac" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_79895b54-d8c5-427a-b09f-d69e6260d077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_08bc28a8-c9b0-456d-873c-8355990d17c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:to="loc_us-gaap_PreferredStockValue_08bc28a8-c9b0-456d-873c-8355990d17c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5b4a65bf-f185-4499-8d75-e4b486f113e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:to="loc_us-gaap_CommonStockValue_5b4a65bf-f185-4499-8d75-e4b486f113e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_a970420f-41b7-4a28-a6ff-dc66c9cd4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:to="loc_us-gaap_TreasuryStockCommonValue_a970420f-41b7-4a28-a6ff-dc66c9cd4f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c1d0e7c0-0139-4aeb-8d3d-1d73f9e38057" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c1d0e7c0-0139-4aeb-8d3d-1d73f9e38057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c055f-5670-7666-8bbf-1fdaae74b229" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c0376f4d-c01d-4d82-a704-3e3c0a9cd89a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019c055f-5670-7666-8bbf-1fdaae74b229" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ed65f2f2-9cdd-43de-baea-34658fb8dca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_96d25f67-5420-4597-aa09-89d0adc29b16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed65f2f2-9cdd-43de-baea-34658fb8dca2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_96d25f67-5420-4597-aa09-89d0adc29b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_15cb3eed-f1c1-47e1-9a80-4eed5f40966a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed65f2f2-9cdd-43de-baea-34658fb8dca2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_15cb3eed-f1c1-47e1-9a80-4eed5f40966a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aeaae940-3f1c-47b0-987f-08581096b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_831e0f21-3eb5-47c7-8541-1f2e8c7d027a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aeaae940-3f1c-47b0-987f-08581096b9b3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_831e0f21-3eb5-47c7-8541-1f2e8c7d027a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7f640250-2bc3-4eda-a59c-1c75ccfa0244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aeaae940-3f1c-47b0-987f-08581096b9b3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7f640250-2bc3-4eda-a59c-1c75ccfa0244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0db466ca-bac8-4d23-a9c4-42a4cf037927" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_496a946e-f993-41f5-9c8f-41a74107ac68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0db466ca-bac8-4d23-a9c4-42a4cf037927" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_496a946e-f993-41f5-9c8f-41a74107ac68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8bb3bd9-a698-4e14-a7b6-8b5940534a93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0db466ca-bac8-4d23-a9c4-42a4cf037927" xlink:to="loc_us-gaap_OperatingExpenses_b8bb3bd9-a698-4e14-a7b6-8b5940534a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7d422489-1f83-4e72-a94a-fe03185d105e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentIncentiveIncome_d8d92fb8-5485-410e-b871-cb1470572d5e" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentIncentiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7d422489-1f83-4e72-a94a-fe03185d105e" xlink:to="loc_kros_ResearchAndDevelopmentIncentiveIncome_d8d92fb8-5485-410e-b871-cb1470572d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendIncomeOperating_1ca78306-833a-4780-aae0-70fb4ea70159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7d422489-1f83-4e72-a94a-fe03185d105e" xlink:to="loc_us-gaap_DividendIncomeOperating_1ca78306-833a-4780-aae0-70fb4ea70159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3340e950-8f3b-43f9-853c-c53edbdd4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_7d422489-1f83-4e72-a94a-fe03185d105e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3340e950-8f3b-43f9-853c-c53edbdd4f45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a5e54c-dc3c-40e9-b6e0-d9e4a22d80e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ed6391d1-8ea5-4b76-a8f8-a3e43ddaba41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a5e54c-dc3c-40e9-b6e0-d9e4a22d80e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_ed6391d1-8ea5-4b76-a8f8-a3e43ddaba41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_483b73da-b667-4f9a-9fb4-a64fa3e5f179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8a5e54c-dc3c-40e9-b6e0-d9e4a22d80e3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_483b73da-b667-4f9a-9fb4-a64fa3e5f179" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64f5b8d2-453f-4181-ba07-4d05930d75aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8118c464-edfa-4a6a-b2d7-0a4cf88fc19a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64f5b8d2-453f-4181-ba07-4d05930d75aa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8118c464-edfa-4a6a-b2d7-0a4cf88fc19a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c0f89-af4b-7624-b064-07beb7cae276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c0f89-af4b-7ae0-bc33-5167f387e34d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c0f89-af4b-7624-b064-07beb7cae276" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019c0f89-af4b-7ae0-bc33-5167f387e34d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_019c0f89-af4b-7e08-a0b5-b03dbf841210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019c0f89-af4b-7624-b064-07beb7cae276" xlink:to="loc_us-gaap_RestrictedCash_019c0f89-af4b-7e08-a0b5-b03dbf841210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9825c681-09b1-4623-bbfd-b0e26625a2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_NetIncomeLoss_9825c681-09b1-4623-bbfd-b0e26625a2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_554c5882-d1ee-4321-a50e-2469276a9deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_Depreciation_554c5882-d1ee-4321-a50e-2469276a9deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00b85f90-67f6-48c0-bd7e-a8d8f88345f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_00b85f90-67f6-48c0-bd7e-a8d8f88345f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0a9b1930-e0af-4546-bc43-7a1f0533e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_ShareBasedCompensation_0a9b1930-e0af-4546-bc43-7a1f0533e4e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2302bd1f-59d9-4f1b-a18b-60b52879891c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2302bd1f-59d9-4f1b-a18b-60b52879891c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37bfe362-b3b9-445f-835b-e8ef9aefde98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37bfe362-b3b9-445f-835b-e8ef9aefde98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c8887b4-ee0c-48c7-899c-d69d9b64726a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c8887b4-ee0c-48c7-899c-d69d9b64726a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_985e7733-ae88-44ca-8226-331d23ee346c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_985e7733-ae88-44ca-8226-331d23ee346c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e7888cc2-7e32-4b4e-9e8b-58d93917e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e7888cc2-7e32-4b4e-9e8b-58d93917e7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_449a3b48-0c71-4ca4-8cfd-a44683ad19dc" xlink:href="kros-20251231.xsd#kros_RightToUseAssetsAndOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_449a3b48-0c71-4ca4-8cfd-a44683ad19dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019c0f89-0749-7a11-b6e4-dda86348088f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_019c0f89-0749-7a11-b6e4-dda86348088f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6fa0-f418-7014-b1f7-d1c0f028fc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb3d2121-29f4-4886-ad6b-f3a075e00807" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6fa0-f418-7014-b1f7-d1c0f028fc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5713bac-472d-4911-8d94-92df18a93d00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9acc8d26-9bba-468d-b23c-805a838980d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5713bac-472d-4911-8d94-92df18a93d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9acc8d26-9bba-468d-b23c-805a838980d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_273bc564-5394-4d55-b134-1bf173cdd6db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5713bac-472d-4911-8d94-92df18a93d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_273bc564-5394-4d55-b134-1bf173cdd6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_027c889a-e247-4fd0-95b1-76d437feb041" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d5713bac-472d-4911-8d94-92df18a93d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_027c889a-e247-4fd0-95b1-76d437feb041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cb595-28c0-7ac6-95cb-3607fc1e892e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cb595-28c0-7ac6-95cb-3607fc1e892e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfInitialPublicOfferingCosts_019cb595-28c0-7bf4-bf0b-094093b36216" xlink:href="kros-20251231.xsd#kros_PaymentOfInitialPublicOfferingCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_kros_PaymentOfInitialPublicOfferingCosts_019cb595-28c0-7bf4-bf0b-094093b36216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019cb595-28c0-77e7-9663-18d5b94e8586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019cb595-28c0-77e7-9663-18d5b94e8586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019cb595-28c0-7eeb-8351-534d175bbc75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019cb595-28c0-7eeb-8351-534d175bbc75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019cb595-28c0-7fd5-8535-cecb6cea4c21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019cb595-28c0-7fd5-8535-cecb6cea4c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfStockRepurchaseCosts_019cb595-28c0-7bd8-bbdd-937f28d041f6" xlink:href="kros-20251231.xsd#kros_PaymentOfStockRepurchaseCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_kros_PaymentOfStockRepurchaseCosts_019cb595-28c0-7bd8-bbdd-937f28d041f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ProceedsFromShortSwingSettlementProfit_019cb595-28c0-7321-b7ed-318ec41ad011" xlink:href="kros-20251231.xsd#kros_ProceedsFromShortSwingSettlementProfit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_kros_ProceedsFromShortSwingSettlementProfit_019cb595-28c0-7321-b7ed-318ec41ad011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_019cb595-28c0-7f26-b30b-e4c731ef04b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cb595-28c0-795a-88f8-805b82a24fe2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_019cb595-28c0-7f26-b30b-e4c731ef04b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2e9c5ca3-93ef-43de-9bce-0ea1060e50aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18f93eed-d02c-4cb9-aea2-95152fa05240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2e9c5ca3-93ef-43de-9bce-0ea1060e50aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18f93eed-d02c-4cb9-aea2-95152fa05240" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalRDCostsCurrent_8ef3bfa2-fec8-4026-8460-a466cd1d903b" xlink:href="kros-20251231.xsd#kros_PrepaidExternalRDCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_PrepaidExternalRDCostsCurrent_8ef3bfa2-fec8-4026-8460-a466cd1d903b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalManufacturingCostsCurrent_ef5060ff-d016-408b-bd11-0da13c27f16f" xlink:href="kros-20251231.xsd#kros_PrepaidExternalManufacturingCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_PrepaidExternalManufacturingCostsCurrent_ef5060ff-d016-408b-bd11-0da13c27f16f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SalesTaxReceivableCurrent_8f1fbf5b-8eb6-4a08-9e88-b031bc26a749" xlink:href="kros-20251231.xsd#kros_SalesTaxReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_SalesTaxReceivableCurrent_8f1fbf5b-8eb6-4a08-9e88-b031bc26a749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1bfe4ba4-c9ec-4e13-b1e0-06afca8da044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_us-gaap_PrepaidInsurance_1bfe4ba4-c9ec-4e13-b1e0-06afca8da044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidSubscriptionCurrent_4d798aea-9bfb-407c-a2b4-769c0af923e0" xlink:href="kros-20251231.xsd#kros_PrepaidSubscriptionCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_PrepaidSubscriptionCurrent_4d798aea-9bfb-407c-a2b4-769c0af923e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendAndInterestReceivable_42182800-3122-482e-8301-e0dbda3a9053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendAndInterestReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_us-gaap_DividendAndInterestReceivable_42182800-3122-482e-8301-e0dbda3a9053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidLegalAndConsultants_6c820886-3045-4cee-8401-1d274590f3b4" xlink:href="kros-20251231.xsd#kros_PrepaidLegalAndConsultants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_PrepaidLegalAndConsultants_6c820886-3045-4cee-8401-1d274590f3b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent_019c0f9a-679e-7a45-81d8-030fa1cac342" xlink:href="kros-20251231.xsd#kros_RefundsDueFromContractResearchOrganizationsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent_019c0f9a-679e-7a45-81d8-030fa1cac342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019c0f9a-679e-78a0-ad14-859513236737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccdc811f-3094-49e6-b694-89f8b0b2c9b7" xlink:to="loc_us-gaap_OtherAssetsCurrent_019c0f9a-679e-78a0-ad14-859513236737" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a66aed5b-8c14-432c-8056-6d0827018a60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_273a24f8-9a04-4f76-915c-cddfb32cfd15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a66aed5b-8c14-432c-8056-6d0827018a60" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_273a24f8-9a04-4f76-915c-cddfb32cfd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_791c0457-2cf5-46d0-9e5e-91011b277aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a66aed5b-8c14-432c-8056-6d0827018a60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_791c0457-2cf5-46d0-9e5e-91011b277aa1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedResearchAndDevelopmentCostsCurrent_0d216fcd-3636-4d91-a47d-e3fe0fa4015a" xlink:href="kros-20251231.xsd#kros_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_kros_AccruedResearchAndDevelopmentCostsCurrent_0d216fcd-3636-4d91-a47d-e3fe0fa4015a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedManufacturingCostsCurrent_79a9072e-1efc-4144-b3b9-21970fab00af" xlink:href="kros-20251231.xsd#kros_AccruedManufacturingCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_kros_AccruedManufacturingCostsCurrent_79a9072e-1efc-4144-b3b9-21970fab00af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a43b587-0627-45f9-9533-d3b1a3acd332" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9a43b587-0627-45f9-9533-d3b1a3acd332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_edc81efe-e6f8-4b45-b192-0e6af142ef6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_us-gaap_TaxesPayableCurrent_edc81efe-e6f8-4b45-b192-0e6af142ef6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a0def860-4d4c-4643-a3d6-0a6e0330d88e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a0def860-4d4c-4643-a3d6-0a6e0330d88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019c0f9b-cb55-7dd3-b528-89557d39dc40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ab7920e8-4d0b-4234-99c5-8c9841009c1a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019c0f9b-cb55-7dd3-b528-89557d39dc40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-729f-b925-92cc5765ff1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-79b4-9634-bbc97681c131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-729f-b925-92cc5765ff1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-79b4-9634-bbc97681c131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-7644-aeee-971a6c4bebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-729f-b925-92cc5765ff1d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-7644-aeee-971a6c4bebbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97ef15b7-3cb5-4763-beaf-3dca29cc537d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_75649731-fea0-4839-87c6-54e87d134732" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97ef15b7-3cb5-4763-beaf-3dca29cc537d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_75649731-fea0-4839-87c6-54e87d134732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_df682fe4-80cf-4cf5-8e91-d96e94aea11e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97ef15b7-3cb5-4763-beaf-3dca29cc537d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_df682fe4-80cf-4cf5-8e91-d96e94aea11e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e47ef781-3ed9-4e3b-81d8-4b14c0dde0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d7bf50cf-76b6-4a31-9553-982d3656db01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e47ef781-3ed9-4e3b-81d8-4b14c0dde0cb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d7bf50cf-76b6-4a31-9553-982d3656db01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f96d13cf-9c79-4dec-8348-a36dade64d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e47ef781-3ed9-4e3b-81d8-4b14c0dde0cb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f96d13cf-9c79-4dec-8348-a36dade64d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2044094a-d79a-45bc-9542-752d90ac4734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e47ef781-3ed9-4e3b-81d8-4b14c0dde0cb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2044094a-d79a-45bc-9542-752d90ac4734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59d0b7e3-e675-434a-8aee-93cd338e0a84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2aaabd8f-02d6-4d77-be30-b73cce587283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_59d0b7e3-e675-434a-8aee-93cd338e0a84" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2aaabd8f-02d6-4d77-be30-b73cce587283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3d0a078-861e-4ff4-b722-c283253164f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_59d0b7e3-e675-434a-8aee-93cd338e0a84" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3d0a078-861e-4ff4-b722-c283253164f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c700a-4f69-79fa-a95a-91201f23659d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c700a-4f69-79fa-a95a-91201f23659d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c700a-4f69-7721-bc79-da8dd3b84f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c700a-4f69-7721-bc79-da8dd3b84f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c700a-4f69-7ebd-98a6-68c3b12f54d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c700a-4f69-7ebd-98a6-68c3b12f54d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c700a-4f69-7412-83cd-302f5561f26b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c700a-4f69-7412-83cd-302f5561f26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c700a-4f6a-75f5-bcbb-f2535349dc77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c700a-4f6a-75f5-bcbb-f2535349dc77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c700a-4f6a-7b09-9f75-483a7a97850c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c700a-4f6a-7b09-9f75-483a7a97850c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c700a-4f6a-7f2f-b353-103e33c94380" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c700a-4f6a-7f2f-b353-103e33c94380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700a-4f6a-732e-bd6b-8bf30a15449e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700a-4f6a-732e-bd6b-8bf30a15449e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700a-4f6a-787b-8363-02459b2b9b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700a-4f6a-787b-8363-02459b2b9b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c700a-4f6a-71b3-8e39-aedbf32a9802" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c700a-4f6a-71b3-8e39-aedbf32a9802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c700a-4f6a-7d19-aba3-9ec359ec0ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c700a-4f6a-7d19-aba3-9ec359ec0ca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad4-d724-7313-a548-a2e94f0c81f3" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c700a-4f69-79fd-bb62-868bce36b7aa" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad4-d724-7313-a548-a2e94f0c81f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c7015-f973-741c-b595-8bf9fe1cbe10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c7015-f973-741c-b595-8bf9fe1cbe10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c7015-f973-7434-b55c-a9e812170587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c7015-f973-7434-b55c-a9e812170587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c7015-f973-7b38-80de-b00de19b13ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c7015-f973-7b38-80de-b00de19b13ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c7015-f973-7fdf-926c-ef143caf1aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c7015-f973-7fdf-926c-ef143caf1aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c7015-f973-71a0-97f9-fd10b8858fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c7015-f973-71a0-97f9-fd10b8858fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c7015-f973-7167-8076-accae4b05bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c7015-f973-7167-8076-accae4b05bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c7015-f973-7e03-a51f-c863d3ac657e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c7015-f973-7e03-a51f-c863d3ac657e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7015-f973-7c1b-9159-8f99be4969bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7015-f973-7c1b-9159-8f99be4969bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7015-f973-7f28-b84a-4f4d610af85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7015-f973-7f28-b84a-4f4d610af85b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c7015-f973-73ff-8355-ca6949c88e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c7015-f973-73ff-8355-ca6949c88e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c7015-f973-7ec0-9c6d-7bb773afe39f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c7015-f973-7ec0-9c6d-7bb773afe39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7016-af8f-7d9f-80aa-a7b99ade7201" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7016-af8f-7d9f-80aa-a7b99ade7201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7016-af8f-70ad-bbeb-ba719e4353cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7016-af8f-70ad-bbeb-ba719e4353cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7016-af8f-74ef-8551-1c0473a468f2" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7016-af8f-74ef-8551-1c0473a468f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7016-af8f-7375-b49e-81dbc38490e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7016-af8f-7375-b49e-81dbc38490e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad4-ac0f-791f-89bd-f6bff05d5f7c" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c7015-f973-72a7-a14a-caa7282fff39" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad4-ac0f-791f-89bd-f6bff05d5f7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_9e62c371-ab7e-4a1d-9b85-0e2dcf532b48" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_9e62c371-ab7e-4a1d-9b85-0e2dcf532b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10006aac-f2e7-41b9-96a2-0fef92e26a82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10006aac-f2e7-41b9-96a2-0fef92e26a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_972102ff-125c-4ac1-9192-58dce47bbb22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_972102ff-125c-4ac1-9192-58dce47bbb22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6b4110ef-347c-4e07-9d2f-edb9195543f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6b4110ef-347c-4e07-9d2f-edb9195543f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsOperatingLeaseLiability_e9cc377a-3c25-4d5f-a13e-baa2e77ca82e" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_kros_DeferredTaxAssetsOperatingLeaseLiability_e9cc377a-3c25-4d5f-a13e-baa2e77ca82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b179e8a3-b1b7-46c3-8f66-cd5484222a98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_b179e8a3-b1b7-46c3-8f66-cd5484222a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a51dd88a-c2b3-4003-b7b1-7a1de236fb47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_41e8c46a-42f0-404f-a4ac-ee6cb586d33c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a51dd88a-c2b3-4003-b7b1-7a1de236fb47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_75ccd4e7-f77d-41ca-96fc-8ca4694099d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_790df425-e819-49b2-8bf4-2fe88a0fbcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_75ccd4e7-f77d-41ca-96fc-8ca4694099d6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_790df425-e819-49b2-8bf4-2fe88a0fbcd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f6bbcd51-6446-4e1e-a822-31c28d7bbdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_75ccd4e7-f77d-41ca-96fc-8ca4694099d6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f6bbcd51-6446-4e1e-a822-31c28d7bbdfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c118d745-87da-401f-bee6-eab28cc3e313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4f6b9fd5-71c9-4588-929e-f9fb19ec5191" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c118d745-87da-401f-bee6-eab28cc3e313" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4f6b9fd5-71c9-4588-929e-f9fb19ec5191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0f8c3464-2171-4b24-a823-d65dd4709ee6" xlink:href="kros-20251231.xsd#kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c118d745-87da-401f-bee6-eab28cc3e313" xlink:to="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_0f8c3464-2171-4b24-a823-d65dd4709ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_019c7025-d072-7518-933a-377b67f24e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c118d745-87da-401f-bee6-eab28cc3e313" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_019c7025-d072-7518-933a-377b67f24e4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESScheduleofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5ab75f93-a40f-4c10-90f3-27f7ca467df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c2ef52e4-93b1-441f-9c84-4202a35a062e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5ab75f93-a40f-4c10-90f3-27f7ca467df3" xlink:to="loc_us-gaap_OperatingLeaseCost_c2ef52e4-93b1-441f-9c84-4202a35a062e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_832bd73a-8e6f-425a-a6ad-4bcf2555923b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5ab75f93-a40f-4c10-90f3-27f7ca467df3" xlink:to="loc_us-gaap_ShortTermLeaseCost_832bd73a-8e6f-425a-a6ad-4bcf2555923b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_019c46d0-eb34-79d6-9ddd-93266b0505bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5ab75f93-a40f-4c10-90f3-27f7ca467df3" xlink:to="loc_us-gaap_VariableLeaseCost_019c46d0-eb34-79d6-9ddd-93266b0505bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESScheduleofMaturityofLeaseLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12a64a2f-5adb-4858-8094-b67f10fb293c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_645a2888-fb04-48f4-a677-4ccc50b604c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12a64a2f-5adb-4858-8094-b67f10fb293c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_645a2888-fb04-48f4-a677-4ccc50b604c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c2ab38dc-1c73-4d66-8bc0-4b83af3fe978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_12a64a2f-5adb-4858-8094-b67f10fb293c" xlink:to="loc_us-gaap_OperatingLeaseLiability_c2ab38dc-1c73-4d66-8bc0-4b83af3fe978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6f27db28-ae11-4cc1-82cd-b272cb62764c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e24d56cc-a853-42ea-b9b1-f523de54932e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f27db28-ae11-4cc1-82cd-b272cb62764c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e24d56cc-a853-42ea-b9b1-f523de54932e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a1689f4-4347-4020-add2-ff1cc6270d39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f27db28-ae11-4cc1-82cd-b272cb62764c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a1689f4-4347-4020-add2-ff1cc6270d39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESScheduleofMaturityofLeaseLiabilityDetails_1"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45fff3d8-8f46-4009-8c88-8310cbac30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45fff3d8-8f46-4009-8c88-8310cbac30e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0b2dbfa6-4124-401e-a960-7238b2dd5ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0b2dbfa6-4124-401e-a960-7238b2dd5ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_b26d346f-cb00-41ff-8f89-ef0f5807f870" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseLiabilityToBePaidYearSix"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_b26d346f-cb00-41ff-8f89-ef0f5807f870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3441cff4-c51d-4331-b7b8-f9be0e1cbd85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3441cff4-c51d-4331-b7b8-f9be0e1cbd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_93461553-a028-4264-a901-6834138a5271" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_93461553-a028-4264-a901-6834138a5271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e45c25ae-5190-48c4-b6c2-253db173a8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a3df2800-592e-4eb8-8b09-c6439de7a1f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e45c25ae-5190-48c4-b6c2-253db173a8b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61c29765-c6b7-4b84-a87b-2317e0b0657f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6f905593-fdc5-4e65-b1e3-e563901e00fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61c29765-c6b7-4b84-a87b-2317e0b0657f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6f905593-fdc5-4e65-b1e3-e563901e00fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_439a136d-fa26-4c00-9760-f0713f74deed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61c29765-c6b7-4b84-a87b-2317e0b0657f" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_439a136d-fa26-4c00-9760-f0713f74deed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_01271f7f-b69d-45c8-b5db-a3e2deaab59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61c29765-c6b7-4b84-a87b-2317e0b0657f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_01271f7f-b69d-45c8-b5db-a3e2deaab59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_24a299cf-bd45-4c6d-ad18-6642464bcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_61c29765-c6b7-4b84-a87b-2317e0b0657f" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_24a299cf-bd45-4c6d-ad18-6642464bcd14" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>kros-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.kerostx.com/role/CoverPage" xlink:type="simple" xlink:href="kros-20251231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7998-9873-b21d7757ec54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:to="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7998-9873-b21d7757ec54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:to="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c954c-f326-7cb6-aef2-f1f79ba351e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:to="loc_us-gaap_CommonStockMember_019c954c-f326-7cb6-aef2-f1f79ba351e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019c954c-f326-7ba0-8d00-65d2eca157e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:to="loc_us-gaap_PreferredStockMember_019c954c-f326-7ba0-8d00-65d2eca157e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f98694cf-9071-436f-8b4e-674de9e81025" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentType_f98694cf-9071-436f-8b4e-674de9e81025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e818e45-75e2-41d3-8716-8398d78ee946" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentAnnualReport_6e818e45-75e2-41d3-8716-8398d78ee946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6dd58991-74c2-4231-ae7b-74e2c31fd848" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentPeriodEndDate_6dd58991-74c2-4231-ae7b-74e2c31fd848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_34bdc193-3d47-4e72-8114-e560b01927d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_CurrentFiscalYearEndDate_34bdc193-3d47-4e72-8114-e560b01927d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e6161688-5c52-4a83-8288-0c314fda7df6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentTransitionReport_e6161688-5c52-4a83-8288-0c314fda7df6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_282ef325-1987-49c3-9112-c3b0c2931854" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityFileNumber_282ef325-1987-49c3-9112-c3b0c2931854" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b867636-c7dd-4d7c-b73e-9a3d944c6bb2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityRegistrantName_2b867636-c7dd-4d7c-b73e-9a3d944c6bb2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1fe0c180-7ccf-428a-8801-b018c209e818" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1fe0c180-7ccf-428a-8801-b018c209e818" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_48135496-6dd0-4cc8-ae66-b6e124859fd2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityTaxIdentificationNumber_48135496-6dd0-4cc8-ae66-b6e124859fd2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3c436a79-4372-4fec-9622-70174b9832e1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressAddressLine1_3c436a79-4372-4fec-9622-70174b9832e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b4624d76-f8b9-45a1-ac24-e599a6da7238" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressAddressLine2_b4624d76-f8b9-45a1-ac24-e599a6da7238" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_68cb7b7a-ef0d-47b1-887c-3265031c3074" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressCityOrTown_68cb7b7a-ef0d-47b1-887c-3265031c3074" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8db3db43-9c81-4fb3-82aa-7274884e04ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressStateOrProvince_8db3db43-9c81-4fb3-82aa-7274884e04ba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0ffbc3c0-beea-4c91-ab5c-e09a9fd740e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressPostalZipCode_0ffbc3c0-beea-4c91-ab5c-e09a9fd740e3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_536c92d8-779c-4f9d-acd6-82e7a870c703" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_CityAreaCode_536c92d8-779c-4f9d-acd6-82e7a870c703" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5291939-8cd3-467b-bb30-9a43a0901af2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_LocalPhoneNumber_a5291939-8cd3-467b-bb30-9a43a0901af2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_062843cc-cd9d-4131-916e-2f59546d67b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_Security12bTitle_062843cc-cd9d-4131-916e-2f59546d67b4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ccfc5f64-3b57-429b-ba2f-a560aa09c7da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_TradingSymbol_ccfc5f64-3b57-429b-ba2f-a560aa09c7da" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3f671dea-971e-4190-b8dd-19fae59ba2b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_SecurityExchangeName_3f671dea-971e-4190-b8dd-19fae59ba2b1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_019cafde-bc01-78b0-9d41-98a454831c98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_NoTradingSymbolFlag_019cafde-bc01-78b0-9d41-98a454831c98" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a72c97bf-fed8-4d2f-98f9-66592d3c42ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a72c97bf-fed8-4d2f-98f9-66592d3c42ad" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_df68f8fe-0200-44ea-b8f5-b1ecd43b996d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityVoluntaryFilers_df68f8fe-0200-44ea-b8f5-b1ecd43b996d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3901db50-2e04-43d8-afd7-7d34a0f1cb8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCurrentReportingStatus_3901db50-2e04-43d8-afd7-7d34a0f1cb8a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_07f5dacd-09dd-4abc-85d5-06f94a50e5c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityInteractiveDataCurrent_07f5dacd-09dd-4abc-85d5-06f94a50e5c6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_354e8822-cff6-4393-b034-d9505bb34374" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityFilerCategory_354e8822-cff6-4393-b034-d9505bb34374" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c452611d-6095-457a-a371-17b3885dff98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntitySmallBusiness_c452611d-6095-457a-a371-17b3885dff98" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_51d29599-acd3-48b2-823e-5ca22a464344" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityEmergingGrowthCompany_51d29599-acd3-48b2-823e-5ca22a464344" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8beb38c2-28a6-4874-a520-5874743ee97f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8beb38c2-28a6-4874-a520-5874743ee97f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_762ad37b-1650-4ce8-901d-b0f151c15970" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_762ad37b-1650-4ce8-901d-b0f151c15970" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ef6b1c7e-e554-4f52-988c-37a2bd447483" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityShellCompany_ef6b1c7e-e554-4f52-988c-37a2bd447483" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4ee37626-a921-4189-bdac-d20d69bea4c8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityPublicFloat_4ee37626-a921-4189-bdac-d20d69bea4c8" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ee211126-2b6b-4cab-84f0-5bd67c3c3a01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ee211126-2b6b-4cab-84f0-5bd67c3c3a01" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_519724bb-2160-458d-8da2-a153f96499be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_519724bb-2160-458d-8da2-a153f96499be" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fef5d21c-5e51-4d98-a826-c0cd55da6299" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCentralIndexKey_fef5d21c-5e51-4d98-a826-c0cd55da6299" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1718d567-d935-42ef-a38c-6daa553ee7d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_AmendmentFlag_1718d567-d935-42ef-a38c-6daa553ee7d7" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e22d6d38-41e4-49ce-9a61-9e30afb011a8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e22d6d38-41e4-49ce-9a61-9e30afb011a8" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d8e831f8-d2d8-4844-9260-a6662c925beb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFiscalYearFocus_d8e831f8-d2d8-4844-9260-a6662c925beb" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:to="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b5ae22a7-b1b0-42bf-a601-b570731012cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:to="loc_us-gaap_ClassOfStockDomain_b5ae22a7-b1b0-42bf-a601-b570731012cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:to="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c7e75212-8c89-455e-8d85-772679c7351e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c7e75212-8c89-455e-8d85-772679c7351e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:to="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e072475f-67df-4e32-99ec-1f5adc35a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e072475f-67df-4e32-99ec-1f5adc35a7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e986647a-ab39-4dde-9df8-99c89e58d991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e986647a-ab39-4dde-9df8-99c89e58d991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd599ced-3500-4bc7-ae50-8bd47221c429" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd599ced-3500-4bc7-ae50-8bd47221c429" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_019c6f85-88c1-7529-ae2d-00529b3f8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_IncomeTaxesReceivable_019c6f85-88c1-7529-ae2d-00529b3f8e23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5835a10-4ab5-4717-8ebc-1a4da3e78633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_AssetsCurrent_b5835a10-4ab5-4717-8ebc-1a4da3e78633" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc89d89c-9a37-44ce-9269-41ff8d1c8209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc89d89c-9a37-44ce-9269-41ff8d1c8209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_43f12bcf-a4aa-4456-9c3e-24aa49dc07c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_43f12bcf-a4aa-4456-9c3e-24aa49dc07c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8c99838d-111e-473a-8714-0206f4df5350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8c99838d-111e-473a-8714-0206f4df5350" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c1dd7ca1-34dc-4fdf-831e-5eb7d7871762" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c1dd7ca1-34dc-4fdf-831e-5eb7d7871762" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_32240628-70f2-4a50-b9c8-7871e624d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_Assets_32240628-70f2-4a50-b9c8-7871e624d3c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed840214-c825-410e-a0fd-fa9a41bbce76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed840214-c825-410e-a0fd-fa9a41bbce76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc8c0428-afba-4032-affd-4d3538fab54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc8c0428-afba-4032-affd-4d3538fab54f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b420f31-8880-49a4-be00-631a062095fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0b420f31-8880-49a4-be00-631a062095fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5aa92e92-6a03-4dd6-afb4-8a80ee4ceaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_LiabilitiesCurrent_5aa92e92-6a03-4dd6-afb4-8a80ee4ceaaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5524784d-71da-4e69-830b-0254aac92a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5524784d-71da-4e69-830b-0254aac92a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe5205bd-7af8-44aa-9d94-0fac9b38bb46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_Liabilities_fe5205bd-7af8-44aa-9d94-0fac9b38bb46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2fed36d1-5811-4b5f-adbb-8d78b187c95e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2fed36d1-5811-4b5f-adbb-8d78b187c95e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8f6a8e7e-92e5-4fc7-b25b-099739a99191" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_PreferredStockValue_8f6a8e7e-92e5-4fc7-b25b-099739a99191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f00864d0-6d5c-49b8-927c-9aa4cdaaf66d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_CommonStockValue_f00864d0-6d5c-49b8-927c-9aa4cdaaf66d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019c055e-d9ed-76fe-9668-1aa479b74373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019c055e-d9ed-76fe-9668-1aa479b74373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9d3b530a-7dc2-4cab-8144-bfd75788dc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9d3b530a-7dc2-4cab-8144-bfd75788dc2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6f3daff-d584-47a9-ae33-92ed30630343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6f3daff-d584-47a9-ae33-92ed30630343" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5951cac0-715b-4ec9-ac16-6aec0a2c748e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_StockholdersEquity_5951cac0-715b-4ec9-ac16-6aec0a2c748e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_67b2ffdd-4702-435c-acff-da85382cefc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_67b2ffdd-4702-435c-acff-da85382cefc8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_39fa36b1-ae82-4d4d-971b-a60cf7711044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:to="loc_us-gaap_ClassOfStockDomain_39fa36b1-ae82-4d4d-971b-a60cf7711044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:to="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a41842ce-941a-47cc-90a1-44c6b3a305a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a41842ce-941a-47cc-90a1-44c6b3a305a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245becde-2ce9-45be-9652-7ab52b91d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245becde-2ce9-45be-9652-7ab52b91d5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08aca755-f02b-49e7-93ae-a9a6b5b18d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08aca755-f02b-49e7-93ae-a9a6b5b18d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_df8a7edb-9ffa-45b7-aa5e-679deb97872e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_df8a7edb-9ffa-45b7-aa5e-679deb97872e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f420c758-96f6-4dfa-85f6-9b719a7f9f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f420c758-96f6-4dfa-85f6-9b719a7f9f3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fcac3b1-46ec-4b41-92ee-8cd484802691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fcac3b1-46ec-4b41-92ee-8cd484802691" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f3684203-7557-4010-9088-8bf9bba622d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f3684203-7557-4010-9088-8bf9bba622d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1b7568ec-9a16-4301-828f-5dadbaab0879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_1b7568ec-9a16-4301-828f-5dadbaab0879" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_86d52024-a086-439f-8583-36bae5cffd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_86d52024-a086-439f-8583-36bae5cffd2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c055a-4091-780a-9f59-64dfe8abe0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c055a-4091-780a-9f59-64dfe8abe0d2" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:to="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_941c96b5-d99b-4ceb-8bad-9a0031f42db2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:to="loc_srt_ProductsAndServicesDomain_941c96b5-d99b-4ceb-8bad-9a0031f42db2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:to="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_8778ddb7-3ebc-4fdc-a9c9-110f5d911758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:to="loc_us-gaap_ServiceOtherMember_8778ddb7-3ebc-4fdc-a9c9-110f5d911758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e356967a-71f2-41a7-b881-d591379942ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:to="loc_us-gaap_LicenseMember_e356967a-71f2-41a7-b881-d591379942ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ae0d1a-580e-440b-86c5-705f18040fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ae0d1a-580e-440b-86c5-705f18040fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3f30ad7b-25a7-4690-aaa4-419e89d3de23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3f30ad7b-25a7-4690-aaa4-419e89d3de23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a002ea9-753e-4764-9fe2-0a4fd5d6de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a002ea9-753e-4764-9fe2-0a4fd5d6de5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d724de1e-e1b5-47a5-b285-e8037de55dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_OperatingExpenses_d724de1e-e1b5-47a5-b285-e8037de55dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74fccfc1-1d64-4681-ab0e-3a9ece6d0317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_OperatingIncomeLoss_74fccfc1-1d64-4681-ab0e-3a9ece6d0317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentIncentiveIncome_0438bd77-b3aa-4c53-9a79-3cad3de16792" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentIncentiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_kros_ResearchAndDevelopmentIncentiveIncome_0438bd77-b3aa-4c53-9a79-3cad3de16792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendIncomeOperating_130cdca1-0064-4235-879c-dc3095bbb9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_DividendIncomeOperating_130cdca1-0064-4235-879c-dc3095bbb9eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e347f88a-5991-4118-8931-a5b20a3e1b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e347f88a-5991-4118-8931-a5b20a3e1b8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2be8f355-d742-4188-b469-f12d46d3dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2be8f355-d742-4188-b469-f12d46d3dff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35ee3aef-7f69-4b54-b665-dbd6b39c3f86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35ee3aef-7f69-4b54-b665-dbd6b39c3f86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e8e966c7-fe74-4de2-9a03-613cffeaa85f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e8e966c7-fe74-4de2-9a03-613cffeaa85f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec993a56-1eb6-4137-b8ec-4930dc1e8382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLoss_ec993a56-1eb6-4137-b8ec-4930dc1e8382" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1eb0b504-9b1d-4efe-b865-38ac8c2d1083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1eb0b504-9b1d-4efe-b865-38ac8c2d1083" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba2f038c-6c66-405a-b8be-951f693c07b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba2f038c-6c66-405a-b8be-951f693c07b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b8b53f8-5815-4040-ba43-ca2e1db0f757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b8b53f8-5815-4040-ba43-ca2e1db0f757" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_186fde49-8758-47e1-a581-fb9d776b04ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_186fde49-8758-47e1-a581-fb9d776b04ec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5a3084e8-8407-4caf-80b0-d49a90900fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_EarningsPerShareBasic_5a3084e8-8407-4caf-80b0-d49a90900fae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5b57d011-f331-438a-b8b2-7342068de500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5b57d011-f331-438a-b8b2-7342068de500" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:to="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:to="loc_us-gaap_EquityComponentDomain_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:to="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72f861c4-34de-4dfd-85c2-db606b884e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_CommonStockMember_72f861c4-34de-4dfd-85c2-db606b884e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0f5c-cd42-7306-9056-061db57ffe45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0f5c-cd42-7306-9056-061db57ffe45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2b345b7b-2ce9-4cef-98e1-eef251b7a43b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2b345b7b-2ce9-4cef-98e1-eef251b7a43b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9a2ad634-387e-4b32-bc7e-23e265d9420f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_RetainedEarningsMember_9a2ad634-387e-4b32-bc7e-23e265d9420f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2574193e-0989-4dd0-8e8d-1cd0711be32e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2574193e-0989-4dd0-8e8d-1cd0711be32e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_76f027fa-42c6-45df-8c58-584645b9404a" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:to="loc_kros_AtTheMarketOfferingMember_76f027fa-42c6-45df-8c58-584645b9404a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0169971a-5b14-4971-a62f-02b29afb20ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_SharesOutstanding_0169971a-5b14-4971-a62f-02b29afb20ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d644be49-281d-4514-bb68-23a09115336d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockholdersEquity_d644be49-281d-4514-bb68-23a09115336d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c0f5c-0438-7c31-a58b-ca7cccffb713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c0f5c-0438-7c31-a58b-ca7cccffb713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbdf15e2-ed11-4723-81e2-2fa254ff096d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbdf15e2-ed11-4723-81e2-2fa254ff096d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aec3819b-b3a9-4834-b9ac-d274915ad731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aec3819b-b3a9-4834-b9ac-d274915ad731" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e072d0f4-884f-41ec-8b09-b07e33f3d8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e072d0f4-884f-41ec-8b09-b07e33f3d8eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3850d895-ebc4-43fe-9111-17a56ec8ebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3850d895-ebc4-43fe-9111-17a56ec8ebdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0f60-6466-7ad5-97da-315be94e24e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0f60-6466-7ad5-97da-315be94e24e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0f60-9bc5-7fc2-84ef-ad817409dcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0f60-9bc5-7fc2-84ef-ad817409dcaf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShortSwingProfitSettlement_019c0f69-28c3-7809-8221-d57dbe2639ed" xlink:href="kros-20251231.xsd#kros_ShortSwingProfitSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_kros_ShortSwingProfitSettlement_019c0f69-28c3-7809-8221-d57dbe2639ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0250e68b-51f2-45fa-bed6-2ccc043456c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0250e68b-51f2-45fa-bed6-2ccc043456c0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b2ad860-0b45-45f1-9496-85bf8c15cfac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b2ad860-0b45-45f1-9496-85bf8c15cfac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019c0f6a-f265-721d-b161-f02708dde5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019c0f6a-f265-721d-b161-f02708dde5f0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d640e12c-5c70-4617-835d-288c7df34d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d640e12c-5c70-4617-835d-288c7df34d25" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62d58823-a534-4355-b986-b56e20358303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_NetIncomeLoss_62d58823-a534-4355-b986-b56e20358303" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e8964a5f-0723-4da4-9158-1c81b96b92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bafa054-3309-40ae-bc39-64ef1bcc40f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c0f6c-49f0-7845-8bd6-8c3fb2dc9b84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_019c96dc-d1f3-7410-8c9b-70e188e2cf1b" xlink:href="kros-20251231.xsd#kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_019c96dc-d1f3-7410-8c9b-70e188e2cf1b" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_a879a048-abaa-4d4a-bd35-1e9f069a1d30" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:to="loc_kros_AtTheMarketOfferingMember_a879a048-abaa-4d4a-bd35-1e9f069a1d30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c98428c-a2f8-40b8-b2f3-55f13791e937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c98428c-a2f8-40b8-b2f3-55f13791e937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_80a04cb3-0b59-4691-9ec2-cd1d32b408b3" xlink:href="kros-20251231.xsd#kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_80a04cb3-0b59-4691-9ec2-cd1d32b408b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_019c96db-95fb-7843-94a9-bea01cc6d4b8" xlink:href="kros-20251231.xsd#kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_019c96db-95fb-7843-94a9-bea01cc6d4b8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SecondaryOfferingMember_31295533-4da5-470e-9c5f-1a86b0219c69" xlink:href="kros-20251231.xsd#kros_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:to="loc_kros_SecondaryOfferingMember_31295533-4da5-470e-9c5f-1a86b0219c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_749c3e91-61f7-4eb0-9309-867883c515d8" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:to="loc_kros_AtTheMarketOfferingMember_749c3e91-61f7-4eb0-9309-867883c515d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_984593ee-303e-420f-b6f5-30fe341f6d62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_NetIncomeLoss_984593ee-303e-420f-b6f5-30fe341f6d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4b0a5ae3-7ce7-4f0e-9ad2-61eafd15b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_Depreciation_4b0a5ae3-7ce7-4f0e-9ad2-61eafd15b2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8940351d-59c4-49e2-b4e2-395677f16f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8940351d-59c4-49e2-b4e2-395677f16f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_55fbd09d-15c4-4233-802b-930c8a58884a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_ShareBasedCompensation_55fbd09d-15c4-4233-802b-930c8a58884a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_671f6e16-0d38-4bfc-920b-fb050133c150" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_671f6e16-0d38-4bfc-920b-fb050133c150" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e28dff26-573d-4166-9501-cc0778dc71d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e28dff26-573d-4166-9501-cc0778dc71d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2ba8430f-f086-4c90-9b53-7656af636746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2ba8430f-f086-4c90-9b53-7656af636746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6f9f-798d-76c8-b7a1-43b296c7f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6f9f-798d-76c8-b7a1-43b296c7f26d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_736f3ea2-89aa-4712-8f5b-a9d2735bfc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_736f3ea2-89aa-4712-8f5b-a9d2735bfc5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_37df1a6e-db00-407e-95f5-2f3bad2445fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_37df1a6e-db00-407e-95f5-2f3bad2445fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_c5ebd775-b56a-4e4e-ac59-734a795acbf1" xlink:href="kros-20251231.xsd#kros_RightToUseAssetsAndOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_c5ebd775-b56a-4e4e-ac59-734a795acbf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_941238c7-73a2-43ae-9aaa-a962b2a87258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_941238c7-73a2-43ae-9aaa-a962b2a87258" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ea84c50-e039-4daa-b4aa-b251eb505d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ea84c50-e039-4daa-b4aa-b251eb505d26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_344430be-5ed5-474a-b41f-c774bdb86d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_344430be-5ed5-474a-b41f-c774bdb86d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_264f0f02-5a3b-4840-ae6b-7eefb11b97e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_264f0f02-5a3b-4840-ae6b-7eefb11b97e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e55d029-cf5f-4ea7-bde6-5bc61bbd5004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e55d029-cf5f-4ea7-bde6-5bc61bbd5004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfInitialPublicOfferingCosts_82c6c7ce-ae66-445e-8858-e88dfb54ad83" xlink:href="kros-20251231.xsd#kros_PaymentOfInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_PaymentOfInitialPublicOfferingCosts_82c6c7ce-ae66-445e-8858-e88dfb54ad83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6deb6096-c171-4f25-aa70-dad5d0b99e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6deb6096-c171-4f25-aa70-dad5d0b99e22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019c0f79-9a8e-7c78-9881-27cbcff5aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019c0f79-9a8e-7c78-9881-27cbcff5aec9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0f7b-c924-7a95-bc7c-b98bd395a698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0f7b-c924-7a95-bc7c-b98bd395a698" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfStockRepurchaseCosts_019c96f6-ccc9-79cd-9084-0aaac318445d" xlink:href="kros-20251231.xsd#kros_PaymentOfStockRepurchaseCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_PaymentOfStockRepurchaseCosts_019c96f6-ccc9-79cd-9084-0aaac318445d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ProceedsFromShortSwingSettlementProfit_019c9551-edef-702e-bbff-011dae4dfeaf" xlink:href="kros-20251231.xsd#kros_ProceedsFromShortSwingSettlementProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_ProceedsFromShortSwingSettlementProfit_019c9551-edef-702e-bbff-011dae4dfeaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1dc18265-3d0d-4a52-8a15-f9578b5ba756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1dc18265-3d0d-4a52-8a15-f9578b5ba756" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7afd6e96-70d3-4b28-91c9-052a53b76d97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7afd6e96-70d3-4b28-91c9-052a53b76d97" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_041775e8-ccbb-4711-9575-d997aa45c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_041775e8-ccbb-4711-9575-d997aa45c6c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f62c463-3cd0-48ef-86ce-b86ee7edea5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f62c463-3cd0-48ef-86ce-b86ee7edea5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8deee54-a73e-41d4-8449-2b36feef1008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c0f7f-e11a-7b44-9838-6b78b1e7f67f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c0f7f-e11a-7b44-9838-6b78b1e7f67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58e5f7b5-a97a-4fe6-8dd2-086c45f0c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58e5f7b5-a97a-4fe6-8dd2-086c45f0c2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_019c0f85-32d6-7835-94e6-6bc3b7e5ddc6" xlink:href="kros-20251231.xsd#kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_019c0f85-32d6-7835-94e6-6bc3b7e5ddc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_99ce6c64-3162-4996-a45d-e40935d1718d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_99ce6c64-3162-4996-a45d-e40935d1718d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8815b2c-1a43-425a-9cbc-01d81a212555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8815b2c-1a43-425a-9cbc-01d81a212555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_002c2f31-af0e-43d2-8ab8-5ecb94150d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:to="loc_us-gaap_RestrictedCash_002c2f31-af0e-43d2-8ab8-5ecb94150d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_710a669c-5caa-4488-a8db-bf1f112bdb83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d8a2037-4711-4a5a-b677-dc79cf7eea73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d8a2037-4711-4a5a-b677-dc79cf7eea73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ComputerEquipmentAndSoftwareMember_82e4fa0f-7718-4ac8-8616-f2dacd3cc891" xlink:href="kros-20251231.xsd#kros_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_kros_ComputerEquipmentAndSoftwareMember_82e4fa0f-7718-4ac8-8616-f2dacd3cc891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_939471b8-ab40-4fd8-adeb-237187d4e618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_939471b8-ab40-4fd8-adeb-237187d4e618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6c24bea0-24ca-4f1a-b7dd-741cdcbed01a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6c24bea0-24ca-4f1a-b7dd-741cdcbed01a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2ad3010c-4b0d-4b1f-87d6-32c5ea3518fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2ad3010c-4b0d-4b1f-87d6-32c5ea3518fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4aa6a08-a3f2-4840-827a-7e08ec23c74e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a4aa6a08-a3f2-4840-827a-7e08ec23c74e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0f95-2362-7f99-b3d9-5f01eea89ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0f95-2362-7f99-b3d9-5f01eea89ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ffe5b3b-8b31-4e18-9b6f-6ef9268c5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ffe5b3b-8b31-4e18-9b6f-6ef9268c5ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1ce20144-21b1-4bce-b168-35e92feed215" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_EmployeeStockMember_1ce20144-21b1-4bce-b168-35e92feed215" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77b55d00-1d15-4607-9e37-4ce25891eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77b55d00-1d15-4607-9e37-4ce25891eb3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ba7c381-341b-49f5-aba8-0ac1dc74fb93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ba7c381-341b-49f5-aba8-0ac1dc74fb93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d0cfc016-7eeb-4347-b4b3-518665c1b875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d0cfc016-7eeb-4347-b4b3-518665c1b875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a84dce82-b55b-4c04-8fb2-96dc30c82a81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a84dce82-b55b-4c04-8fb2-96dc30c82a81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2607011f-68d4-43cb-8913-362089ca61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2607011f-68d4-43cb-8913-362089ca61a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7661789b-0424-4f43-8485-490112cd5992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7661789b-0424-4f43-8485-490112cd5992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8807d446-c315-43c6-acae-a901906a2abd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8807d446-c315-43c6-acae-a901906a2abd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_855fab76-e1bd-4d8c-a0a3-b22b5e281c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_855fab76-e1bd-4d8c-a0a3-b22b5e281c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ccdc721-d9fe-4291-8e96-3fe84e95a943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ccdc721-d9fe-4291-8e96-3fe84e95a943" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84b856a0-236c-42a8-9991-8a48b09d70c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_84b856a0-236c-42a8-9991-8a48b09d70c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ComputerEquipmentAndSoftwareMember_d81d4ba1-a3ab-42eb-a800-76f477e93313" xlink:href="kros-20251231.xsd#kros_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_kros_ComputerEquipmentAndSoftwareMember_d81d4ba1-a3ab-42eb-a800-76f477e93313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e3659cce-7488-4a1e-8755-f5cfed4ced6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e3659cce-7488-4a1e-8755-f5cfed4ced6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3919a65b-06cf-494a-a248-7dd820c6f255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3919a65b-06cf-494a-a248-7dd820c6f255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_650c3b7e-ed57-45ed-9ff2-d31b2ff4012e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_650c3b7e-ed57-45ed-9ff2-d31b2ff4012e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f6a4302-fb32-4710-9730-c1b49f8bf8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f6a4302-fb32-4710-9730-c1b49f8bf8c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_230a7061-9578-40b8-a576-08e3b90030c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_230a7061-9578-40b8-a576-08e3b90030c0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LICENSEAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:to="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TheGeneralHospitalCorporationMember_d55826f7-ae97-4a66-b7a8-2fa75277db3e" xlink:href="kros-20251231.xsd#kros_TheGeneralHospitalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:to="loc_kros_TheGeneralHospitalCorporationMember_d55826f7-ae97-4a66-b7a8-2fa75277db3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140d78bf-41b3-47da-9e7f-4b0850ac9e42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_140d78bf-41b3-47da-9e7f-4b0850ac9e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_cf724682-fc7c-42d4-8736-4f214f339677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_cf724682-fc7c-42d4-8736-4f214f339677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_5babfa2d-55c6-4b2d-a1c1-93dded486820" xlink:href="kros-20251231.xsd#kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_5babfa2d-55c6-4b2d-a1c1-93dded486820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_b8128d4c-b498-4cb7-a773-56d152b8a1af" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_b8128d4c-b498-4cb7-a773-56d152b8a1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_ce528166-9f47-4fec-8c80-75d04003e112" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_ce528166-9f47-4fec-8c80-75d04003e112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_8bfa75fe-463c-43ea-a559-2e14b8074ac0" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_8bfa75fe-463c-43ea-a559-2e14b8074ac0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_19f10b56-7f17-4182-822e-bc4d8edee632" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_19f10b56-7f17-4182-822e-bc4d8edee632" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_3f77d33b-1c2b-4934-99e0-4317f6209d58" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_3f77d33b-1c2b-4934-99e0-4317f6209d58" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7573-9502-c33dfdc2b75b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:to="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7573-9502-c33dfdc2b75b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:to="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c4693-d551-78b9-bd7d-2863b00902c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:to="loc_us-gaap_CommonStockMember_019c4693-d551-78b9-bd7d-2863b00902c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-72a4-bb76-6436d24083c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-72a4-bb76-6436d24083c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019c4693-d551-7c8b-9834-7a7afd859ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019c4693-d551-7c8b-9834-7a7afd859ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_019c76db-0aa2-7764-8d9b-c046af806f74" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:to="loc_kros_AtTheMarketOfferingMember_019c76db-0aa2-7764-8d9b-c046af806f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c4693-d551-718e-aa02-6793143cf3e3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:to="loc_srt_RangeMember_019c4693-d551-718e-aa02-6793143cf3e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:to="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c4693-d551-7d4f-b7d6-ccba644817bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:to="loc_srt_MinimumMember_019c4693-d551-7d4f-b7d6-ccba644817bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c4693-d551-74a5-be3b-8959eeb9f377" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:to="loc_srt_MaximumMember_019c4693-d551-74a5-be3b-8959eeb9f377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019c4693-faf5-7b3c-872c-ece9fb105209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:to="loc_us-gaap_DividendsDomain_019c4693-faf5-7b3c-872c-ece9fb105209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:to="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_O2025Q1DividendsMember_019c4693-faf5-7397-a4da-355b873fe84a" xlink:href="kros-20251231.xsd#kros_O2025Q1DividendsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:to="loc_kros_O2025Q1DividendsMember_019c4693-faf5-7397-a4da-355b873fe84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019c4693-d551-7422-b391-7364f2753361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019c4693-d551-7422-b391-7364f2753361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c4693-d551-707d-ac9a-3b04a83a997c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c4693-d551-707d-ac9a-3b04a83a997c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019c76dc-56c0-7efb-993a-a38107332b47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019c76dc-56c0-7efb-993a-a38107332b47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019c4693-d551-707f-9e91-09724d73323e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019c4693-d551-707f-9e91-09724d73323e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019c4693-d551-7935-9495-056503593797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019c4693-d551-7935-9495-056503593797" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c4693-d551-73ec-9e02-bcaaaf408086" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c4693-d551-73ec-9e02-bcaaaf408086" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockAgentCommissions_019c76dc-56c0-7ad2-9666-c39fec234c8d" xlink:href="kros-20251231.xsd#kros_SaleOfStockAgentCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_SaleOfStockAgentCommissions_019c76dc-56c0-7ad2-9666-c39fec234c8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockStockIssuanceCosts_019c76dc-56c0-712b-8cff-d844fd2fc8b0" xlink:href="kros-20251231.xsd#kros_SaleOfStockStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_SaleOfStockStockIssuanceCosts_019c76dc-56c0-712b-8cff-d844fd2fc8b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockDividendNumberOfRightsPerShare_019c4693-d551-7e54-bb61-477888e34ae5" xlink:href="kros-20251231.xsd#kros_CommonStockDividendNumberOfRightsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockDividendNumberOfRightsPerShare_019c4693-d551-7e54-bb61-477888e34ae5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019c4693-d551-705a-a5e2-3bdfe591a5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019c4693-d551-705a-a5e2-3bdfe591a5ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold_019c4693-d551-72fc-96d8-94598e21b774" xlink:href="kros-20251231.xsd#kros_CommonStockBeneficialOwnershipPenaltyThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold_019c4693-d551-72fc-96d8-94598e21b774" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_019c4693-faf5-7188-bd8f-4a3708090c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_019c4693-faf5-7188-bd8f-4a3708090c16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockVotingRightsNumberOfVotes_019c4693-faf5-735e-ac05-f3bf077584a0" xlink:href="kros-20251231.xsd#kros_CommonStockVotingRightsNumberOfVotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockVotingRightsNumberOfVotes_019c4693-faf5-735e-ac05-f3bf077584a0" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:to="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7119-ada9-f0224f4e23c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7119-ada9-f0224f4e23c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c96e9-ceac-72fb-beb4-25068c913d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c96e9-ceac-72fb-beb4-25068c913d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c96e9-ceac-773b-9909-afd594471340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c96e9-ceac-773b-9909-afd594471340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c96e9-ceac-7e23-8186-e4e386b3c948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_EmployeeStockMember_019c96e9-ceac-7e23-8186-e4e386b3c948" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020PlanMember_019c96e9-ceac-78eb-8ea6-7bdeae0acf52" xlink:href="kros-20251231.xsd#kros_A2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_kros_A2020PlanMember_019c96e9-ceac-78eb-8ea6-7bdeae0acf52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c96e9-ceac-71da-83f1-47980278504d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c96e9-ceac-71da-83f1-47980278504d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/TREASURYSTOCKDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#TREASURYSTOCKDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/TREASURYSTOCKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-7452-ad2a-42bdc41513b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:to="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-7452-ad2a-42bdc41513b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:to="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0fb1-637a-76b3-8439-282d0b694ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0fb1-637a-76b3-8439-282d0b694ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_019c0fb1-3592-7a21-9f53-e392f8ca4de0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_019c0fb1-3592-7a21-9f53-e392f8ca4de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c0fb1-3592-7f49-a9c5-4c2e823f840a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c0fb1-3592-7f49-a9c5-4c2e823f840a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0fb1-3592-726b-b902-690d37ae8a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0fb1-3592-726b-b902-690d37ae8a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_019c0fb1-3592-754d-a041-e72ddeca3c49" xlink:href="kros-20251231.xsd#kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_019c0fb1-3592-754d-a041-e72ddeca3c49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0fb1-3592-71af-b8f0-2d2648e8d9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0fb1-3592-71af-b8f0-2d2648e8d9e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c0fb1-637a-7ba4-88f1-0dbc22ef60e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c0fb1-637a-7ba4-88f1-0dbc22ef60e2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019c98d4-b238-77b1-b7c5-f798580b126f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:to="loc_us-gaap_PlanNameDomain_019c98d4-b238-77b1-b7c5-f798580b126f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:to="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2017StockIncentivePlanMember_019c98d4-b238-7a36-bf8d-5fbe666f4bdb" xlink:href="kros-20251231.xsd#kros_A2017StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_A2017StockIncentivePlanMember_019c98d4-b238-7a36-bf8d-5fbe666f4bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020StockIncentivePlanMember_019c98d4-b238-7bbd-af57-bf9c9f5fd764" xlink:href="kros-20251231.xsd#kros_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_A2020StockIncentivePlanMember_019c98d4-b238-7bbd-af57-bf9c9f5fd764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_019c98d5-412a-7c72-8c11-be6b8898edea" xlink:href="kros-20251231.xsd#kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_019c98d5-412a-7c72-8c11-be6b8898edea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7c58-b0c0-acfe68a0bb47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7c58-b0c0-acfe68a0bb47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019c98d4-b238-7fc8-8728-4e36bee35a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:to="loc_us-gaap_SubsequentEventMember_019c98d4-b238-7fc8-8728-4e36bee35a37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7a28-993b-1b93db507b81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7a28-993b-1b93db507b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedAwardsMember_019c98d4-de4c-7b35-aed8-0598dd5adda6" xlink:href="kros-20251231.xsd#kros_PerformanceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_PerformanceBasedAwardsMember_019c98d4-de4c-7b35-aed8-0598dd5adda6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c98d4-de4c-797d-861d-9fc8d8e46ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c98d4-de4c-797d-861d-9fc8d8e46ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_UnvestedStockOptionsMember_019c98d5-1a01-7384-bf44-954b3fe1d842" xlink:href="kros-20251231.xsd#kros_UnvestedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_UnvestedStockOptionsMember_019c98d5-1a01-7384-bf44-954b3fe1d842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedStockOptionsMember_019c98d5-1a01-77e7-b0d2-83fc1dea9d0c" xlink:href="kros-20251231.xsd#kros_PerformanceBasedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_PerformanceBasedStockOptionsMember_019c98d5-1a01-77e7-b0d2-83fc1dea9d0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c98d5-1a01-79b1-b150-24ecd2b49ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c98d5-1a01-79b1-b150-24ecd2b49ebf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-72b7-beae-b78bf15cb6aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-72b7-beae-b78bf15cb6aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TermLoanCreditAgreementThreeAmendmentMember_019c98d5-1a01-765c-b953-e0861323df65" xlink:href="kros-20251231.xsd#kros_TermLoanCreditAgreementThreeAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:to="loc_kros_TermLoanCreditAgreementThreeAmendmentMember_019c98d5-1a01-765c-b953-e0861323df65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019c98d4-b238-74d6-a3bb-f8385979d86b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019c98d4-b238-74d6-a3bb-f8385979d86b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_019c98d4-b238-76be-a521-76d3d3dad497" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_019c98d4-b238-76be-a521-76d3d3dad497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019c98d4-b238-7349-a9d3-7232ecb7af38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019c98d4-b238-7349-a9d3-7232ecb7af38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019c98d4-b238-73ae-a882-14772e3f677c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019c98d4-b238-73ae-a882-14772e3f677c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019c98d4-b238-788c-8ee9-29373998126d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019c98d4-b238-788c-8ee9-29373998126d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019c98d4-b238-7a8f-ab9d-52ec134190b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019c98d4-b238-7a8f-ab9d-52ec134190b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c98d4-de4c-744d-aded-8195404d0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c98d4-de4c-744d-aded-8195404d0a87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d4-de4c-7a0a-8746-0fdd7c99acf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d4-de4c-7a0a-8746-0fdd7c99acf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c98d4-de4c-7095-a9ac-5d0fc72d3872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c98d4-de4c-7095-a9ac-5d0fc72d3872" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c98d4-de4c-7608-a42c-f77ec2465da4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c98d4-de4c-7608-a42c-f77ec2465da4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c98d4-de4c-7f39-971c-c55ba925272f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c98d4-de4c-7f39-971c-c55ba925272f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019c98d4-de4c-7ea0-b5e7-8837c441fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019c98d4-de4c-7ea0-b5e7-8837c441fa20" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019c98d5-1a01-735b-baa6-91d817d3ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019c98d5-1a01-735b-baa6-91d817d3ebe9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d5-1a01-78a9-b960-5fa34afd1c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d5-1a01-78a9-b960-5fa34afd1c24" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019c98d5-1a01-7503-935d-019355106618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019c98d5-1a01-7503-935d-019355106618" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_019c98d5-1a01-7e3c-8526-89e05954a156" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_019c98d5-1a01-7e3c-8526-89e05954a156" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_019c98d5-1a01-7443-92fe-85e2e52e4ea8" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_019c98d5-1a01-7443-92fe-85e2e52e4ea8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_019c98d5-1a01-7afa-8169-56a68cedde94" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_019c98d5-1a01-7afa-8169-56a68cedde94" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019c98d5-1a01-71b8-bbf8-538c2f126618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019c98d5-1a01-71b8-bbf8-538c2f126618" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019c98d5-412a-79fb-a8e2-0ad5622f4bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019c98d5-412a-79fb-a8e2-0ad5622f4bdc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c98d5-412a-73c5-a4c7-6eb3a8c2974b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c98d5-412a-73c5-a4c7-6eb3a8c2974b" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:to="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76c8-ab39-56d415c98f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76c8-ab39-56d415c98f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c1222-084d-7ec9-a64d-c7c611bc841e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c1222-084d-7ec9-a64d-c7c611bc841e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-79f5-a3c3-43dda07fc5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-79f5-a3c3-43dda07fc5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c0fba-8460-7563-bd26-a4918f1899fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c0fba-8460-7563-bd26-a4918f1899fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0fba-8460-7198-b18e-860c272e7f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0fba-8460-7198-b18e-860c272e7f83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c0fba-8460-7c4b-996f-2a73473fdf03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c0fba-8460-7c4b-996f-2a73473fdf03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-7e9f-9abb-6603436c1aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7912-b651-ce661bb1170e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7912-b651-ce661bb1170e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-789a-8715-31e8fc9f0b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-789a-8715-31e8fc9f0b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7c2e-9a8a-4150923b595d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7c2e-9a8a-4150923b595d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c0fba-8460-7106-8c9c-f83c031e7502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c0fba-8460-7106-8c9c-f83c031e7502" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7913-bf67-3e8f88c5c137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:to="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c7952d02-12ec-4180-97fc-2f7923d043aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c7952d02-12ec-4180-97fc-2f7923d043aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea071393-9d79-4ec8-b901-80538998b378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea071393-9d79-4ec8-b901-80538998b378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812a81ee-48be-484f-be8b-42f435fc4313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812a81ee-48be-484f-be8b-42f435fc4313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3186fba6-d09a-4bed-abc4-df8e7a087358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3186fba6-d09a-4bed-abc4-df8e7a087358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46360f43-fee1-4d50-b838-726cd09f2865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46360f43-fee1-4d50-b838-726cd09f2865" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86d076a8-4b79-4446-85c6-67fe736f27a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86d076a8-4b79-4446-85c6-67fe736f27a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa54af2b-f179-4813-aa63-1f18d8d44951" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa54af2b-f179-4813-aa63-1f18d8d44951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_163485c7-381b-488a-8aa1-87812c027cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_163485c7-381b-488a-8aa1-87812c027cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e76e1fc4-d6d1-4eb6-a0c1-eeaffe62926b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e76e1fc4-d6d1-4eb6-a0c1-eeaffe62926b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:to="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-796e-87d0-98240f062b5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-796e-87d0-98240f062b5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7106-873a-1a328663af39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7106-873a-1a328663af39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7b4b-83e9-dfe62af6416c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7b4b-83e9-dfe62af6416c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7ca2-a664-8bf535f832f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7ca2-a664-8bf535f832f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c0fcc-1cff-782f-a009-9ed980394b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:to="loc_us-gaap_NetIncomeLoss_019c0fcc-1cff-782f-a009-9ed980394b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-7740-96b8-25233ae2ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-7740-96b8-25233ae2ec37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-76fe-9875-3943da31ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-76fe-9875-3943da31ac43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-7bd5-a95e-fedd42f139f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-7bd5-a95e-fedd42f139f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c0fbe-e67d-7db2-b878-21d844f094c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c0fbe-e67d-7db2-b878-21d844f094c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c0fbe-e67d-727c-b884-2be9631df9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c0fbe-e67d-727c-b884-2be9631df9ab" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7518-88c6-37ac70aeae01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7518-88c6-37ac70aeae01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7b06-8b19-63eeac7ff758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7b06-8b19-63eeac7ff758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7acd-859a-ccda07fef579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7acd-859a-ccda07fef579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7da2-86d0-9899c57825c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7da2-86d0-9899c57825c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c0fbe-e67d-70b4-9fc1-615ea3bf7a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c0fbe-e67d-70b4-9fc1-615ea3bf7a80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-7a61-9a3b-9e612c85bb9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-7a61-9a3b-9e612c85bb9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_019c7008-f2b5-725b-b0ca-27e1a5d0b9a3" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:to="loc_country_AU_019c7008-f2b5-725b-b0ca-27e1a5d0b9a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c7008-f2b5-7ca3-92a7-49090d4d612f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c7008-f2b5-7ca3-92a7-49090d4d612f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c7008-f2b5-72e9-b4a7-60af09dc6050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c7008-f2b5-72e9-b4a7-60af09dc6050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c7008-f2b5-7b5c-b67f-19e89ff34f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c7008-f2b5-7b5c-b67f-19e89ff34f2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c7008-f2b5-70da-94f8-ffcd18b679ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c7008-f2b5-70da-94f8-ffcd18b679ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c7008-f2b5-71b6-aac6-e0bd5efe4f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c7008-f2b5-71b6-aac6-e0bd5efe4f1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c7008-f2b5-786a-8adc-0aa26449522d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c7008-f2b5-786a-8adc-0aa26449522d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c7008-f2b5-7bb0-aa48-0f837ff2c291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c7008-f2b5-7bb0-aa48-0f837ff2c291" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7008-f2b5-7b2b-aef9-ce49a946d0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7008-f2b5-7b2b-aef9-ce49a946d0c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad3-f077-7936-bed1-10c26fb812ac" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad3-f077-7936-bed1-10c26fb812ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7008-f2b5-7020-86f4-955516ea827b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7008-f2b5-7020-86f4-955516ea827b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c7008-f2b5-77ce-a908-807ac0fb5512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c7008-f2b5-77ce-a908-807ac0fb5512" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c7008-f2b5-7dfe-aeb2-ebff6fbdc1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c7008-f2b5-7dfe-aeb2-ebff6fbdc1ab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c7008-f2b5-7521-bcae-8659225756ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c7008-f2b5-7521-bcae-8659225756ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c700d-2379-7a91-add4-65427b5f79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c700d-2379-7a91-add4-65427b5f79c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c700d-2379-78f9-bb68-24a6c25a69c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c700d-2379-78f9-bb68-24a6c25a69c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c700d-2379-79ef-84c2-bdc9820b4c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c700d-2379-79ef-84c2-bdc9820b4c0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c700d-2379-7f8e-b7fb-97aaa8c8e627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c700d-2379-7f8e-b7fb-97aaa8c8e627" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c700d-2379-7b91-9a17-68ccdbfcf616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c700d-2379-7b91-9a17-68ccdbfcf616" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c700d-2379-7615-b982-cb12938852f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c700d-2379-7615-b982-cb12938852f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7013-0be3-70ff-acf7-cc57ed1b84ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7013-0be3-70ff-acf7-cc57ed1b84ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c700d-2379-7128-a293-0f4442bc8683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c700d-2379-7128-a293-0f4442bc8683" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7013-0be3-7d4b-99a9-c850c71bd3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7013-0be3-7d4b-99a9-c850c71bd3d9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7013-0be3-7154-a8ed-aa17d5c050ad" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7013-0be3-7154-a8ed-aa17d5c050ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad3-8da6-74fb-b14d-625c3e201938" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad3-8da6-74fb-b14d-625c3e201938" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700d-2379-7528-a733-728ef3cccfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700d-2379-7528-a733-728ef3cccfbc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c700d-2379-7376-b852-4f7dd97d015f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c700d-2379-7376-b852-4f7dd97d015f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7013-0be4-7b65-9635-8a7c7100e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7013-0be4-7b65-9635-8a7c7100e91a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700d-2379-75fe-a555-05446462e93d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700d-2379-75fe-a555-05446462e93d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c700d-2379-705c-800b-91dba540d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c700d-2379-705c-800b-91dba540d88b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c700d-2379-70ec-88d4-c36f6af0636f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c700d-2379-70ec-88d4-c36f6af0636f" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-7e0b-9943-dd3237b6f607_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-7e0b-9943-dd3237b6f607_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c7022-6e2c-7373-89fd-6e8b3a62e719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_us-gaap_DomesticCountryMember_019c7022-6e2c-7373-89fd-6e8b3a62e719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c7022-6e2c-7d3c-9c33-92a6d2eb2069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c7022-6e2c-7d3c-9c33-92a6d2eb2069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_019c98e8-f850-75f5-8b94-1b3bc482418d" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_country_AU_019c98e8-f850-75f5-8b94-1b3bc482418d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c98e8-f850-7ad4-8446-faf065fe5fab" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_country_US_019c98e8-f850-7ad4-8446-faf065fe5fab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-7a3b-90ea-b70298ee7303_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-7a3b-90ea-b70298ee7303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_019c7022-6e2c-771f-8be9-57ebd2b060fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:to="loc_us-gaap_ResearchMember_019c7022-6e2c-771f-8be9-57ebd2b060fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019c7022-6e2c-7b75-8c40-eff11f0d21c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019c7022-6e2c-7b75-8c40-eff11f0d21c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019c7022-6e2c-7950-836e-37eb0d86a2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019c7022-6e2c-7950-836e-37eb0d86a2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OperatingLossCarryforwardWriteOff_019c9716-34f9-71fd-b3fd-81041fef2603" xlink:href="kros-20251231.xsd#kros_OperatingLossCarryforwardWriteOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_kros_OperatingLossCarryforwardWriteOff_019c9716-34f9-71fd-b3fd-81041fef2603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019c7022-90bb-700b-94a2-253df2fc213e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019c7022-90bb-700b-94a2-253df2fc213e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019c7022-bc0e-77b4-a1ff-dcacc20da8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019c7022-bc0e-77b4-a1ff-dcacc20da8cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c7022-bc0e-7f2e-b1c5-a28cd1499468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c7022-bc0e-7f2e-b1c5-a28cd1499468" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019c7022-bc0e-78d3-ac4b-85b60bce9da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019c7022-bc0e-78d3-ac4b-85b60bce9da7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_019c98e8-f850-766c-bdac-2114b8492609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_IncomeTaxesPaid_019c98e8-f850-766c-bdac-2114b8492609" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7fd1-a8ef-738633f684ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:to="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7fd1-a8ef-738633f684ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:to="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PhaseAPremisesMember_019c6fa9-e60c-72fa-b12e-3722f160c3e1" xlink:href="kros-20251231.xsd#kros_PhaseAPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:to="loc_kros_PhaseAPremisesMember_019c6fa9-e60c-72fa-b12e-3722f160c3e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_WalthamLeaseMember_019c6fa9-e60c-732a-be19-9a8c6f6dda66" xlink:href="kros-20251231.xsd#kros_WalthamLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:to="loc_kros_WalthamLeaseMember_019c6fa9-e60c-732a-be19-9a8c6f6dda66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:to="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-7624-b941-9b7ed13dfb1d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-7624-b941-9b7ed13dfb1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccentTherapeuticsIncMember_019c6fa9-e60c-72e4-9564-1bd82bcafc2e" xlink:href="kros-20251231.xsd#kros_AccentTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:to="loc_kros_AccentTherapeuticsIncMember_019c6fa9-e60c-72e4-9564-1bd82bcafc2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeAreaOfSublease_019c6fa9-e60c-7cc9-9535-e92216a7f93f" xlink:href="kros-20251231.xsd#kros_LesseeAreaOfSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeAreaOfSublease_019c6fa9-e60c-7cc9-9535-e92216a7f93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRent_019c6fa9-e60c-7215-850a-6a564338c2aa" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseMonthlyBaseRent_019c6fa9-e60c-7215-850a-6a564338c2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeasePeriodForImprovement_019c6fad-3a67-71f6-9c73-930928c7bffa" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeasePeriodForImprovement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeasePeriodForImprovement_019c6fad-3a67-71f6-9c73-930928c7bffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_019c6fa9-e60c-701a-bfff-c589e2ad1b79" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_019c6fa9-e60c-701a-bfff-c589e2ad1b79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_019c6fa9-e60c-70fe-81b7-23ec8db3bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_019c6fa9-e60c-70fe-81b7-23ec8db3bfee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_019c6fa9-e60c-71dc-b36e-fcb03e6dc4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_019c6fa9-e60c-71dc-b36e-fcb03e6dc4e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c6fa9-e60c-794a-a847-dddda9299342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c6fa9-e60c-794a-a847-dddda9299342" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019c6fa9-e60c-7e67-8791-94ded9d5ce6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_OperatingLeaseLiability_019c6fa9-e60c-7e67-8791-94ded9d5ce6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019c6fa9-e60c-7b33-ad17-74574dae5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019c6fa9-e60c-7b33-ad17-74574dae5a76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_019c6fa9-e60c-7465-98c0-5afa565aa91b" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_019c6fa9-e60c-7465-98c0-5afa565aa91b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace_019c6fa9-e60c-7874-a30a-0323c0541f3a" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAreaOfRentalSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace_019c6fa9-e60c-7874-a30a-0323c0541f3a" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:to="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:to="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-756c-8a2e-548e5b610eea_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-756c-8a2e-548e5b610eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c46d8-cf98-7dbe-bc5b-3d9677698082" xlink:href="kros-20251231.xsd#kros_TakedaPharmaceuticalsU.S.A.Inc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:to="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c46d8-cf98-7dbe-bc5b-3d9677698082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_019c46d5-e8bf-7baf-bd15-639b8e2e832e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:to="loc_us-gaap_PurchaseObligation_019c46d5-e8bf-7baf-bd15-639b8e2e832e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_019c46d8-cf98-79a6-bdab-b97b2270d727" xlink:href="kros-20251231.xsd#kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:to="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_019c46d8-cf98-79a6-bdab-b97b2270d727" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7f63-a3a9-6faece36380f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7f63-a3a9-6faece36380f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohAgreementMember_019c0fdf-7403-7817-a25a-71266a0cedcc" xlink:href="kros-20251231.xsd#kros_HansohAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_HansohAgreementMember_019c0fdf-7403-7817-a25a-71266a0cedcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_019c0fdf-7403-7b2b-82e7-b43bfe6fe747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_019c0fdf-7403-7b2b-82e7-b43bfe6fe747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TechTransferAgreementMember_019c0fdf-7403-7238-91c6-215e05b62220" xlink:href="kros-20251231.xsd#kros_TechTransferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_TechTransferAgreementMember_019c0fdf-7403-7238-91c6-215e05b62220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SupplyAgreementMember_019c0fdf-7403-7e66-bb4a-7a7bcd96a17f" xlink:href="kros-20251231.xsd#kros_SupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_SupplyAgreementMember_019c0fdf-7403-7e66-bb4a-7a7bcd96a17f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7797-bac8-01c02e0dd3f1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7797-bac8-01c02e0dd3f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohShanghaiHealthtechCoLtdMember_019c0fdf-7403-78fa-a64a-6b43a23b3558" xlink:href="kros-20251231.xsd#kros_HansohShanghaiHealthtechCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_HansohShanghaiHealthtechCoLtdMember_019c0fdf-7403-78fa-a64a-6b43a23b3558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ManufacturingTechnologyTransferAgreementMember_019c0fdf-7403-7036-b16a-8c91a13215fd" xlink:href="kros-20251231.xsd#kros_ManufacturingTechnologyTransferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_ManufacturingTechnologyTransferAgreementMember_019c0fdf-7403-7036-b16a-8c91a13215fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ClinicalProductSupplyAgreementMember_019c0fdf-7403-7bd5-a24c-92701159c3e9" xlink:href="kros-20251231.xsd#kros_ClinicalProductSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_ClinicalProductSupplyAgreementMember_019c0fdf-7403-7bd5-a24c-92701159c3e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c0fdf-7403-705a-8b27-b067aa97eb28" xlink:href="kros-20251231.xsd#kros_TakedaPharmaceuticalsU.S.A.Inc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c0fdf-7403-705a-8b27-b067aa97eb28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7649-aba7-15b113f2280c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7649-aba7-15b113f2280c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019c0fdf-7403-76ee-bf99-4fb87882d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_us-gaap_LicenseMember_019c0fdf-7403-76ee-bf99-4fb87882d6ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAndKnowHowMember_019c0fdf-7403-7285-ba98-25a132ba578b" xlink:href="kros-20251231.xsd#kros_LicenseAndKnowHowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_kros_LicenseAndKnowHowMember_019c0fdf-7403-7285-ba98-25a132ba578b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TransitionServicesMember_019c0fdf-7403-7377-929b-53066a0f7cf0" xlink:href="kros-20251231.xsd#kros_TransitionServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_kros_TransitionServicesMember_019c0fdf-7403-7377-929b-53066a0f7cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c98fb-8326-71a7-aa6a-b3e011be1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_us-gaap_ServiceMember_019c98fb-8326-71a7-aa6a-b3e011be1bf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0fdf-7403-7560-a96f-a08e96ab4129_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:to="loc_srt_RangeMember_019c0fdf-7403-7560-a96f-a08e96ab4129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:to="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c0fdf-7403-7302-a5a5-84b3d2517637" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:to="loc_srt_MaximumMember_019c0fdf-7403-7302-a5a5-84b3d2517637" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c0fdf-7403-7b01-96a3-a18b1f3c35f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:to="loc_srt_MinimumMember_019c0fdf-7403-7b01-96a3-a18b1f3c35f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c0fdf-7403-7083-a283-bea939acbbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c0fdf-7403-7083-a283-bea939acbbb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_019c0fdf-7403-7de3-b4a6-503564ff6d22" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_019c0fdf-7403-7de3-b4a6-503564ff6d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_019c0fdf-7403-7074-8b35-79b4d48d3281" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_019c0fdf-7403-7074-8b35-79b4d48d3281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_019c0fdf-7403-7856-886e-74cd33b7167d" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_019c0fdf-7403-7856-886e-74cd33b7167d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c0fdf-7403-763e-868a-8c731568e64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c0fdf-7403-763e-868a-8c731568e64e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes_019c0fdf-7403-7e96-b7c8-c5a355537904" xlink:href="kros-20251231.xsd#kros_RevenueFromContractWithCustomerWithholdingTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes_019c0fdf-7403-7e96-b7c8-c5a355537904" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ServiceAndOtherRevenue_019c0fdf-7403-7e12-a810-cf6afd9022bf" xlink:href="kros-20251231.xsd#kros_ServiceAndOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_ServiceAndOtherRevenue_019c0fdf-7403-7e12-a810-cf6afd9022bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFeeWaiverTerms_019c0fdf-7403-7fe4-a490-e5daae1570ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeeWaiverTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_InvestmentCompanyFeeWaiverTerms_019c0fdf-7403-7fe4-a490-e5daae1570ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAgreementUpfrontFee_019c0fdf-7403-7f7e-b4b9-7bdca95a736a" xlink:href="kros-20251231.xsd#kros_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_LicenseAgreementUpfrontFee_019c0fdf-7403-7f7e-b4b9-7bdca95a736a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_019c0fdf-7403-71e9-ad88-5220700decbf" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsDevelopmentBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_019c0fdf-7403-71e9-ad88-5220700decbf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones_019c0fdf-7403-7366-9b4d-f95f3924f2cd" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsCommercialBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones_019c0fdf-7403-7366-9b4d-f95f3924f2cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones_019c0fdf-7403-7f9f-b45e-8edf1e481997" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones_019c0fdf-7403-7f9f-b45e-8edf1e481997" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfPerformanceObligations_019c0fdf-7403-7c1a-9d48-84cc384ee02d" xlink:href="kros-20251231.xsd#kros_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_NumberOfPerformanceObligations_019c0fdf-7403-7c1a-9d48-84cc384ee02d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_019c0fdf-7403-7216-a555-b61d73990fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_019c0fdf-7403-7216-a555-b61d73990fc0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019c0fdf-7403-7f6d-bce4-739ed0462047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019c0fdf-7403-7f6d-bce4-739ed0462047" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:to="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7f1f-9975-d68c85ec6b00_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7f1f-9975-d68c85ec6b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseRevenueMember_019c0fde-79c4-72f4-88fb-8ef5d152af36" xlink:href="kros-20251231.xsd#kros_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:to="loc_kros_LicenseRevenueMember_019c0fde-79c4-72f4-88fb-8ef5d152af36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c0fde-79c4-7c4f-a3f3-49bd687fc3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:to="loc_us-gaap_ServiceMember_019c0fde-79c4-7c4f-a3f3-49bd687fc3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c0fde-79c4-76d8-b2c7-9ada9f16bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:to="loc_us-gaap_Revenues_019c0fde-79c4-76d8-b2c7-9ada9f16bfc7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b1e60b67-0975-473e-8983-65d69bdd02fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:to="loc_us-gaap_SegmentDomain_b1e60b67-0975-473e-8983-65d69bdd02fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:to="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ReportableSegmentMember_d1549115-2b4b-4eff-a2cb-1649faeccf82" xlink:href="kros-20251231.xsd#kros_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:to="loc_kros_ReportableSegmentMember_d1549115-2b4b-4eff-a2cb-1649faeccf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:to="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_376291ee-55df-493a-8377-b9becadd9144_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:to="loc_srt_ProductsAndServicesDomain_376291ee-55df-493a-8377-b9becadd9144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:to="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RinvaterceptProgramExpensesMember_019c0fe4-4642-798a-9e51-19a8f9275ea1" xlink:href="kros-20251231.xsd#kros_RinvaterceptProgramExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_RinvaterceptProgramExpensesMember_019c0fe4-4642-798a-9e51-19a8f9275ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ElriterceptProgramExpensesMember_baa2da57-c219-4bf1-bf52-ea8125b60ed1" xlink:href="kros-20251231.xsd#kros_ElriterceptProgramExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_ElriterceptProgramExpensesMember_baa2da57-c219-4bf1-bf52-ea8125b60ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CiboterceptProgramExpensesMember_35427226-b474-4206-a55b-fc25ba995708" xlink:href="kros-20251231.xsd#kros_CiboterceptProgramExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_CiboterceptProgramExpensesMember_35427226-b474-4206-a55b-fc25ba995708" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PreclinicalDevelopmentExpensesMember_91742b3c-4324-4d36-9d53-d9365137b5de" xlink:href="kros-20251231.xsd#kros_PreclinicalDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_PreclinicalDevelopmentExpensesMember_91742b3c-4324-4d36-9d53-d9365137b5de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OtherExternalCostsMember_019c7b68-7d98-7b32-82d8-6ebcaa259238" xlink:href="kros-20251231.xsd#kros_OtherExternalCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_OtherExternalCostsMember_019c7b68-7d98-7b32-82d8-6ebcaa259238" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_72b2bf57-0f9a-4f43-b5f0-30afd1e28a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_72b2bf57-0f9a-4f43-b5f0-30afd1e28a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_051b437b-8f69-4bde-874c-670902e903d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_051b437b-8f69-4bde-874c-670902e903d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_7975a217-cf2c-455d-aae2-b5aef5ee47e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_7975a217-cf2c-455d-aae2-b5aef5ee47e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_9888dbe4-c45b-44e2-8755-d31f65b6e298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_9888dbe4-c45b-44e2-8755-d31f65b6e298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_edfb9ad9-2a1a-4104-9fb4-c679b61b4669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_NetIncomeLoss_edfb9ad9-2a1a-4104-9fb4-c679b61b4669" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURINGNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ad3-9243-cc77d325c521_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ad3-9243-cc77d325c521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2025RestructuringMember_019c0fe8-83c9-7248-91cf-e342768d8478" xlink:href="kros-20251231.xsd#kros_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:to="loc_kros_A2025RestructuringMember_019c0fe8-83c9-7248-91cf-e342768d8478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7045-81b9-6ed7db3b2563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7045-81b9-6ed7db3b2563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c0fe8-83c9-77ad-b4de-15bbd4300573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c0fe8-83c9-77ad-b4de-15bbd4300573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c0fe8-83c9-793c-80a7-7b266f223c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c0fe8-83c9-793c-80a7-7b266f223c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c0fe8-83c9-7ac1-b062-68bda3a229af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c0fe8-83c9-7ac1-b062-68bda3a229af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_019c0fe8-83c9-745d-bae7-c97de51210aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_019c0fe8-83c9-745d-bae7-c97de51210aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-71f1-8fe4-9127e6ae091f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-71f1-8fe4-9127e6ae091f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c0fff-6f56-7702-965b-3f1b621d2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c0fff-6f56-7702-965b-3f1b621d2fa1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"/>
  <link:definitionLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7aa2-946e-04b90d6a8709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7aa2-946e-04b90d6a8709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2025RestructuringMember_019c0fe8-83c9-719b-abb4-ce5e66e30577" xlink:href="kros-20251231.xsd#kros_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:to="loc_kros_A2025RestructuringMember_019c0fe8-83c9-719b-abb4-ce5e66e30577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-7737-8a11-53bf25f499fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-7737-8a11-53bf25f499fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-7a46-9f20-e54c977d738c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-7a46-9f20-e54c977d738c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_019c0fe8-83c9-7227-a152-b7bc42c3a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_PaymentsForRestructuring_019c0fe8-83c9-7227-a152-b7bc42c3a27e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-757f-9dad-8ea1824b21db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_019c0fff-c89f-7ada-a236-1838766719af" xlink:href="kros-20251231.xsd#kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_019c0fff-c89f-7ada-a236-1838766719af" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_KeithRegnanteMember_019c050d-ff2a-733d-8b2a-96afa8cc7134" xlink:href="kros-20251231.xsd#kros_KeithRegnanteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_KeithRegnanteMember_019c050d-ff2a-733d-8b2a-96afa8cc7134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LorenaLernerMember_019c0512-f8cf-7fd4-bc7f-7911b3902ece" xlink:href="kros-20251231.xsd#kros_LorenaLernerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_LorenaLernerMember_019c0512-f8cf-7fd4-bc7f-7911b3902ece" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NimaFarzanMember_019c0513-4afa-799e-8e84-bf906e2be717" xlink:href="kros-20251231.xsd#kros_NimaFarzanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_NimaFarzanMember_019c0513-4afa-799e-8e84-bf906e2be717" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JuliusKnowlesMember_019cafd4-f9d8-71e4-9e1c-eacbeae5355b" xlink:href="kros-20251231.xsd#kros_JuliusKnowlesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_JuliusKnowlesMember_019cafd4-f9d8-71e4-9e1c-eacbeae5355b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AlpnaSethMember_019c0514-0278-7d7b-98c4-10d3e8d9de85" xlink:href="kros-20251231.xsd#kros_AlpnaSethMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_AlpnaSethMember_019c0514-0278-7d7b-98c4-10d3e8d9de85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JeanJacquesBienaimeMember_019c0514-c808-71c8-b27f-b0d3234ed991" xlink:href="kros-20251231.xsd#kros_JeanJacquesBienaimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_JeanJacquesBienaimeMember_019c0514-c808-71c8-b27f-b0d3234ed991" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>kros-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_71e7de63-aa69-410b-884f-d2f540cfc94c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019c0fa1-22e8-7b69-815b-b9eb8968e362_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PerformanceBasedAwardsMember_019c0fbb-5d11-741e-859c-7c338de8ff41_terseLabel_en-US" xlink:label="lab_kros_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Awards</link:label>
    <link:label id="lab_kros_PerformanceBasedAwardsMember_label_en-US" xlink:label="lab_kros_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Awards [Member]</link:label>
    <link:label id="lab_kros_PerformanceBasedAwardsMember_documentation_en-US" xlink:label="lab_kros_PerformanceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedAwardsMember" xlink:href="kros-20251231.xsd#kros_PerformanceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PerformanceBasedAwardsMember" xlink:to="lab_kros_PerformanceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c0fdf-7403-717d-8798-71c3e16d3a00_terseLabel_en-US" xlink:label="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals U.S.A., Inc.</link:label>
    <link:label id="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_label_en-US" xlink:label="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals U.S.A., Inc. [Member]</link:label>
    <link:label id="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_documentation_en-US" xlink:label="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals U.S.A., Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:href="kros-20251231.xsd#kros_TakedaPharmaceuticalsU.S.A.Inc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:to="lab_kros_TakedaPharmaceuticalsU.S.A.Inc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_10b93abe-c900-4497-8f3a-53cae444f239_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_33712edc-62b8-4b50-8b97-369f5bc53cde_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADDITIONAL PAID-IN CAPITAL</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PreclinicalDevelopmentExpensesMember_00d5f478-5f97-4f36-8848-126b9a2898f5_terseLabel_en-US" xlink:label="lab_kros_PreclinicalDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical &amp; development expenses</link:label>
    <link:label id="lab_kros_PreclinicalDevelopmentExpensesMember_label_en-US" xlink:label="lab_kros_PreclinicalDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preclinical &amp; Development Expenses [Member]</link:label>
    <link:label id="lab_kros_PreclinicalDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_kros_PreclinicalDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical &amp; Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PreclinicalDevelopmentExpensesMember" xlink:href="kros-20251231.xsd#kros_PreclinicalDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PreclinicalDevelopmentExpensesMember" xlink:to="lab_kros_PreclinicalDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7a94b5a7-d217-4130-8353-7c266ff6ea22_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TechTransferAgreementMember_019c0fdf-7403-7f18-9223-9ecc2f723409_terseLabel_en-US" xlink:label="lab_kros_TechTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tech Transfer Agreement</link:label>
    <link:label id="lab_kros_TechTransferAgreementMember_label_en-US" xlink:label="lab_kros_TechTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tech Transfer Agreement [Member]</link:label>
    <link:label id="lab_kros_TechTransferAgreementMember_documentation_en-US" xlink:label="lab_kros_TechTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tech Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TechTransferAgreementMember" xlink:href="kros-20251231.xsd#kros_TechTransferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TechTransferAgreementMember" xlink:to="lab_kros_TechTransferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4333c3a8-6ccb-462a-87cd-c38335971c3e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, increase resulting from prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeLeaseOtherInformationAbstract_b4e3150a-ec11-4b23-895a-98f843c88301_terseLabel_en-US" xlink:label="lab_kros_LesseeLeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_kros_LesseeLeaseOtherInformationAbstract_label_en-US" xlink:label="lab_kros_LesseeLeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_kros_LesseeLeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_kros_LesseeLeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Other Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeLeaseOtherInformationAbstract" xlink:href="kros-20251231.xsd#kros_LesseeLeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeLeaseOtherInformationAbstract" xlink:to="lab_kros_LesseeLeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ab8fa2a5-7089-4e24-9f1a-a0e78a151589_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_14333905-108c-47cc-afb2-9220f846f8f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c96f2-d917-7975-9c87-ce87604c5b19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_24b67f88-d6a9-4685-a6c4-6500ddbb5bc7_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4de54d67-7b04-4bcf-b756-67f156e9a267_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share of common stock - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0048a46c-0b76-452b-830d-d0467df248ca_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bb9ab01e-6a37-4d5f-85ff-e998c4cb374b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_dfb8930d-0c26-461d-b227-0c3c438e31a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE FROM CONTRACTS WITH CUSTOMERS</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_22186c10-5663-44cb-b753-4b26a7a06423_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c7001-05e1-7cdc-8767-9c2fe47e31d1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2f482316-4d56-438b-8bc8-7ddccd40f65f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6e3c1ec8-d755-4efc-8570-045b7671a83c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent_019c0f99-9356-761d-b48c-c16a2e42d29d_terseLabel_en-US" xlink:label="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refunds due from contract research organizations</link:label>
    <link:label id="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent_label_en-US" xlink:label="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds Due From Contract Research Organizations Current</link:label>
    <link:label id="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent_documentation_en-US" xlink:label="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refunds Due From Contract Research Organizations Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:href="kros-20251231.xsd#kros_RefundsDueFromContractResearchOrganizationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:to="lab_kros_RefundsDueFromContractResearchOrganizationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8e0e1ec7-5209-496f-a868-a51ce94c2e69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019c0f6a-f265-7901-a198-3a376b5f19e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_afdbcea9-c364-443c-bef4-80f313a9b42f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under the employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d7632964-854e-4c97-ad96-f264431228f2_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current income tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRent_ba836cad-5517-415a-91cb-c4bf5fc71e1e_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, monthly base rent</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:to="lab_kros_LesseeOperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_CiboterceptProgramExpensesMember_dcd05ee0-b4be-4a4a-8cf7-d4865f89b258_terseLabel_en-US" xlink:label="lab_kros_CiboterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cibotercept program expenses</link:label>
    <link:label id="lab_kros_CiboterceptProgramExpensesMember_label_en-US" xlink:label="lab_kros_CiboterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cibotercept Program Expenses [Member]</link:label>
    <link:label id="lab_kros_CiboterceptProgramExpensesMember_documentation_en-US" xlink:label="lab_kros_CiboterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cibotercept Program Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CiboterceptProgramExpensesMember" xlink:href="kros-20251231.xsd#kros_CiboterceptProgramExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_CiboterceptProgramExpensesMember" xlink:to="lab_kros_CiboterceptProgramExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_17dfec94-f242-4111-a956-57ed627c6141_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f24c54e8-41c5-405c-b8c1-1d62aef42586_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ef671594-8773-4af8-b46d-52e2383bb74b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9b33f88e-43f6-4199-b892-09a555b275c5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_70331529-52d9-4539-bb29-9a4b9f1a3805_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7322-845c-a6deb46f30a1_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4ba32259-b308-4715-a3fd-f12b8120cc6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ad64dd6f-4177-4de5-873a-9a99c8c48b5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_019c98e8-f850-78ae-adcb-ea67e77fcd74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7f67-8d1b-448d798df0fc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dfbb32b7-13b6-4666-bca4-e5e90c716d63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_692060c5-e166-4adb-a586-696d78063646_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d5bc0751-6b5b-4754-99d3-9b138fc7d729_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e3e6f662-d3d9-4d2b-84fd-ce8226050e82_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a7ee6bfb-e0f1-46d3-94ea-b015f4b10a77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a2772ad6-8421-4bea-97df-83988c376af4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7aebd808-677f-42a5-a28b-06f8f8c94976_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Useful Lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_82201c1e-6898-4e2a-8061-db688c465cfd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_198e0906-6d94-4743-9424-bf092e4cb3e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PrepaidSubscriptionCurrent_ee3badd2-a4cf-46d5-ac1d-c1b8bf95ec1e_terseLabel_en-US" xlink:label="lab_kros_PrepaidSubscriptionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid subscriptions</link:label>
    <link:label id="lab_kros_PrepaidSubscriptionCurrent_label_en-US" xlink:label="lab_kros_PrepaidSubscriptionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Subscription, Current</link:label>
    <link:label id="lab_kros_PrepaidSubscriptionCurrent_documentation_en-US" xlink:label="lab_kros_PrepaidSubscriptionCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Subscription, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidSubscriptionCurrent" xlink:href="kros-20251231.xsd#kros_PrepaidSubscriptionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PrepaidSubscriptionCurrent" xlink:to="lab_kros_PrepaidSubscriptionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_cc531bb7-dbc1-4aec-9f11-27c2ec6cb3e8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb221f39-de8f-47d1-8d0e-95734601a05e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of underwriting discounts, commissions and offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b508c8e1-2de9-4d49-9fce-04598225be85_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_360b2a7e-2aea-43a0-93ae-a7630ffbd87b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_e12dc794-9956-4b8f-b37b-f536389e32bb_terseLabel_en-US" xlink:label="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions and offering cost</link:label>
    <link:label id="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_label_en-US" xlink:label="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock, Discounts, Commissions and Offering Costs</link:label>
    <link:label id="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_documentation_en-US" xlink:label="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock, Discounts, Commissions and Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:href="kros-20251231.xsd#kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:to="lab_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5fa1b0dd-e2e6-42d0-8511-6d3452cc38df_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_08802fbe-0fde-4d35-81e7-b6f8c6a05531_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bd8e1b9b-f06f-4c3d-bd35-20b3aad0d745_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5eacf2a6-bc46-4fdd-8556-d6fa1855225f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4807bd4e-f932-418b-afb0-abdc19b7def2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NUMBER OF OPTIONS</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_966f79a2-2f5f-4df9-86e3-cabff3790109_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e31f6615-7539-45c5-9766-00dee31ae8b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3e4f91cb-9898-4fab-be75-36a7a5df4528_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_9c295c7f-c718-4466-b2de-902b7b622635_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_68b281b2-263f-4767-8f63-5451e5f060ad_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3315150c-c593-4220-810f-50e01dca2375_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019c0fa1-22e8-7074-94d1-71bab39bad41_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_617de789-d88d-4610-abd4-8697ee2a6bd1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7c58b026-724b-42b6-9649-5e08f79d73ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_CommonStockVotingRightsNumberOfVotes_65d401fb-fe4e-4030-a393-e02a8be76122_terseLabel_en-US" xlink:label="lab_kros_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per common share held</link:label>
    <link:label id="lab_kros_CommonStockVotingRightsNumberOfVotes_label_en-US" xlink:label="lab_kros_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:label id="lab_kros_CommonStockVotingRightsNumberOfVotes_documentation_en-US" xlink:label="lab_kros_CommonStockVotingRightsNumberOfVotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Voting Rights, Number Of Votes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockVotingRightsNumberOfVotes" xlink:href="kros-20251231.xsd#kros_CommonStockVotingRightsNumberOfVotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_CommonStockVotingRightsNumberOfVotes" xlink:to="lab_kros_CommonStockVotingRightsNumberOfVotes" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_92e5ac5d-8aa1-4afe-83ae-593e2258de2f_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Expiration Period</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:to="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_431f8c00-f170-49a6-9067-3fc39e5faee3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_80224e49-85ff-49ce-850e-71c88f1d327d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3f920c9-7fb1-47ff-bd38-e289e28e6cc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_019c0f5c-cd42-7884-9e07-b8e369e5a3b1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TREASURY STOCK</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c1228-b6f6-7c36-ab75-20bc8811775a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of RSU awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LicenseAndKnowHowMember_019c0fdf-7403-70a4-8ef5-580bfd6f880f_terseLabel_en-US" xlink:label="lab_kros_LicenseAndKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Know-How</link:label>
    <link:label id="lab_kros_LicenseAndKnowHowMember_label_en-US" xlink:label="lab_kros_LicenseAndKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Know-How [Member]</link:label>
    <link:label id="lab_kros_LicenseAndKnowHowMember_documentation_en-US" xlink:label="lab_kros_LicenseAndKnowHowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and Know-How</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAndKnowHowMember" xlink:href="kros-20251231.xsd#kros_LicenseAndKnowHowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LicenseAndKnowHowMember" xlink:to="lab_kros_LicenseAndKnowHowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4e73880f-6e34-4782-bbf9-78c26886cc58_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b3d65e08-cf7e-4158-b92c-882227331ba8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_b9f10118-16c4-4de0-badf-f89cf0bd7608_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty rate, maximum reduction</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Royalty Rate, Maximum Reduction, Percentage</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Royalty Rate, Maximum Reduction, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:to="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6803d6a8-b989-4815-ad9d-dee81cff7a18_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_70685f5f-54e4-4067-8c6f-304d5241ac39_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_019c46d8-cf98-7b9f-8698-63e94356f10c_terseLabel_en-US" xlink:label="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses agreement, planned stockholder distribution from proceeds, percentage</link:label>
    <link:label id="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_label_en-US" xlink:label="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Agreement, Planned Stockholder Distribution from Proceeds, Percentage</link:label>
    <link:label id="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_documentation_en-US" xlink:label="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licenses Agreement, Planned Stockholder Distribution from Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:href="kros-20251231.xsd#kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:to="lab_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_A2020PlanMember_019c76df-9b38-74c5-8d08-c90bedd17df1_terseLabel_en-US" xlink:label="lab_kros_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available under 2020 Plan</link:label>
    <link:label id="lab_kros_A2020PlanMember_label_en-US" xlink:label="lab_kros_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Plan [Member]</link:label>
    <link:label id="lab_kros_A2020PlanMember_documentation_en-US" xlink:label="lab_kros_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020PlanMember" xlink:href="kros-20251231.xsd#kros_A2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_A2020PlanMember" xlink:to="lab_kros_A2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_366dfcf0-3980-49d6-9121-55fb6900b9ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_KeithRegnanteMember_label_en-US" xlink:label="lab_kros_KeithRegnanteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Keith Regnante [Member]</link:label>
    <link:label id="lab_kros_KeithRegnanteMember_documentation_en-US" xlink:label="lab_kros_KeithRegnanteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Keith Regnante</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_KeithRegnanteMember" xlink:href="kros-20251231.xsd#kros_KeithRegnanteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_KeithRegnanteMember" xlink:to="lab_kros_KeithRegnanteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_CommonStockDividendNumberOfRightsPerShare_019c0fa0-ee53-7962-b3d8-dfbf713205ce_terseLabel_en-US" xlink:label="lab_kros_CommonStockDividendNumberOfRightsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of rights (in USD per share)</link:label>
    <link:label id="lab_kros_CommonStockDividendNumberOfRightsPerShare_label_en-US" xlink:label="lab_kros_CommonStockDividendNumberOfRightsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Dividend Number Of Rights Per Share</link:label>
    <link:label id="lab_kros_CommonStockDividendNumberOfRightsPerShare_documentation_en-US" xlink:label="lab_kros_CommonStockDividendNumberOfRightsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Dividend Number Of Rights Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockDividendNumberOfRightsPerShare" xlink:href="kros-20251231.xsd#kros_CommonStockDividendNumberOfRightsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_CommonStockDividendNumberOfRightsPerShare" xlink:to="lab_kros_CommonStockDividendNumberOfRightsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4a601fba-8fd0-40ef-8129-b18b0b3a6092_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_348ef1c8-7958-46ce-af19-c57cfb83bb90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2bb1ed81-714c-49c4-9dd0-8fa34c620bf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_019b3629-cb7a-74d7-af85-1cb7ae01c7ed_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TREASURY STOCK</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_019c0fe8-83c9-7c2a-a82f-834ab2c3bf04_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_019c0fe8-83c9-7a8d-8421-cae3bf6b705b_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_17285f61-899a-4702-a02e-f6aa6b13739e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Before Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54274bb2-8948-4e83-a0e1-776e8121c3e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_28c162eb-9f1d-4b65-9870-db2dc8004dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6dfdb1fd-d986-4ac9-ac56-24abf077ddd7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ff2a6ff9-44f3-4bb6-a79d-8e5872552aa7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_86cc5936-4163-4444-addd-6073603c25f6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6e0ca314-94c0-4dfb-86e6-0ec51d20acdf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Period</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_c8932ab8-9299-45b3-9255-94c3cd82be41_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_c4043fba-b87d-457f-839d-e4838bae5dd9_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Office furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2a6e8000-0ad4-409d-adf1-54c67c60b5f2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ab149f3a-c480-4b8c-8afb-94d3642ece54_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_d4ac771d-f855-4e1d-b5d1-c7ba2fea8f8d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_45fbd561-2b04-490b-9f72-9db929342c96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_faf85ec1-d7c6-411d-a50a-72d683c0f601_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_560aa74c-a4a1-4a23-8539-536f4e2a34a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7870-9e8a-167e4e579b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_cb96b2fb-b40e-4855-a43e-bcbf34df84ca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_76260edf-4aa4-4bac-b069-1717232d7338_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Incentive and Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e6bc636d-d225-41f3-8520-1a602c7bdb4b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_46f869d7-961f-4390-b7a6-a7ed7f7204dd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SecondaryOfferingMember_33eb3f8e-176d-4375-9387-9361aa6ac1d3_terseLabel_en-US" xlink:label="lab_kros_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_kros_SecondaryOfferingMember_label_en-US" xlink:label="lab_kros_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:label id="lab_kros_SecondaryOfferingMember_documentation_en-US" xlink:label="lab_kros_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SecondaryOfferingMember" xlink:href="kros-20251231.xsd#kros_SecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SecondaryOfferingMember" xlink:to="lab_kros_SecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019cb58c-3cfb-7f6b-a8bb-11fc236bc406_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_02ba819c-6296-40c7-9308-bb39bca13059_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1f141e9a-eaef-4f21-aa80-a977c0feb338_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d4ebc9c4-7e9a-4fc8-bcec-9c3e3a3eff45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019c0f95-2362-7584-bbb3-1348a8187a22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested RSU awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1be13a18-4226-4fe5-af63-7c80d312079d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7722c782-7ca2-4583-b147-d0b42ec36a20_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_86245cde-d1b5-40c3-8ef2-1ef8211cb31b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_869d5a48-a603-4c55-b02b-fa2a1058a1a3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use&#160;assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_38e71750-c246-4be3-999c-aaa65cb7fb29_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3b4595fe-fc02-432a-84a6-f451af0b6aba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_886e1db0-805d-4356-810c-d5de2eca7c19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22dcba7b-b2c7-48a7-a0ad-c959bfe037b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d49512a3-8dbb-41ac-b5d5-531f4fae3c84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fee</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_02517daa-1c09-473d-9960-788082c95fa0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_f67b2803-88d5-4b4a-ab4b-87db66fab807_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AlpnaSethMember_label_en-US" xlink:label="lab_kros_AlpnaSethMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alpna Seth [Member]</link:label>
    <link:label id="lab_kros_AlpnaSethMember_documentation_en-US" xlink:label="lab_kros_AlpnaSethMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alpna Seth</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AlpnaSethMember" xlink:href="kros-20251231.xsd#kros_AlpnaSethMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AlpnaSethMember" xlink:to="lab_kros_AlpnaSethMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c7006-2d0c-7371-8936-15b778c1251d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-779e-a2b1-ba51f4f778bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1fa75df5-50f9-4e2d-970b-0bd0ab27fe2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MATURITY OF LEASE LIABILITY</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad3-8da6-732f-babb-bf1692609285_terseLabel_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_label_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_documentation_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:to="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a5a36082-c510-4887-99e9-8f6c7db3ec4c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f3dbfe87-f880-481f-8981-1e1e48e7d10d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_044916cd-37f6-421a-9d9f-177f6c77b69a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_dd71e7c3-8de7-4094-9dab-9fd2b8798261_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_019c954c-f326-7a9a-b806-9e775c473568_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_a3b311a9-90e2-4de7-815d-6c1029691fbf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_019c0fdc-3011-77c3-b360-c814a63b78fd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_4268b87f-ee3c-4b55-ba81-045c47868513_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, monthly base rent per square foot</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_label_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent Per Square Foot</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Rent Per Square Foot</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:to="lab_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_043f7c94-94f8-4735-872d-045ad3a6b2fb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3ca43b67-5655-49c3-b788-c34dc7f85609_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PaymentOfStockRepurchaseCosts_019cb594-7c4e-70af-9aaa-8693e8ad4ed9_negatedLabel_en-US" xlink:label="lab_kros_PaymentOfStockRepurchaseCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of direct expenses associated with the treasury stock repurchase</link:label>
    <link:label id="lab_kros_PaymentOfStockRepurchaseCosts_label_en-US" xlink:label="lab_kros_PaymentOfStockRepurchaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Stock Repurchase Costs</link:label>
    <link:label id="lab_kros_PaymentOfStockRepurchaseCosts_documentation_en-US" xlink:label="lab_kros_PaymentOfStockRepurchaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of Stock Repurchase Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfStockRepurchaseCosts" xlink:href="kros-20251231.xsd#kros_PaymentOfStockRepurchaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PaymentOfStockRepurchaseCosts" xlink:to="lab_kros_PaymentOfStockRepurchaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_019c98e8-f850-743b-ade8-16eb742f9c69_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc1b1f8-c4e3-4458-85db-1ccecbde050e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18367719-354b-4caa-a236-32a36f063aa4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7001-cad6-7385-bb14-115bc86c403e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f055b5bd-4c31-4986-9bfa-d5a8c5e99e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3a65d68c-a06f-4af2-9eff-aa21ac3ae9fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCUMULATED DEFICIT</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10b7dbe5-f6df-4b84-b0ad-e42bdf0a9aca_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18f01cf1-02cd-4974-b126-52645870282a_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9b2ee1fc-d31e-4374-a2c8-a859cd580b05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_77fd6418-0c74-43a7-8d1c-ddf4700c174d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3d58a369-88bb-4c38-a954-f777712858e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0dfdb8be-7aad-41d8-b99b-a09f9b7a75c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2f1b436-a753-4e44-b4f7-ec54fe9cf1c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aefe5c73-3d95-4697-9cb7-14fe7b7fc447_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f521ff20-c412-4bbd-95e7-83c5040dd909_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b72c5080-b972-4cac-b8ab-bf5b5f545ad4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c5f992e9-1efa-40ad-a3b1-799919a91376_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c26711c9-8e88-40ef-9013-36b541d1fc79_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2b965d2c-0e3b-404c-976b-30a9c58be17c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_85d2c40a-2645-45be-8179-bf0d95eb50a1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued excise tax</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_5dbe97be-2a64-43e7-957d-c114e517fdfb_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual increase in operating lease</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_label_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Increase In Monthly Base Payment, Percentage</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Increase In Monthly Base Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:to="lab_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_019c954c-f326-7a14-8cdf-4a4d5fcf4768_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6446b34a-9ba6-4769-9c90-fc4cd5413582_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ff6c25fb-f6ef-49d7-b7c2-d0a8c63553eb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfa8d06f-47eb-4ad3-80e2-29c631205c8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8c5e19c2-ae31-4f93-b0e3-07d518a3b47f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0ec38f52-bc05-4fa2-ab61-107715752b96_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c0fe8-83c9-7d6b-adf6-cd1a08b355fd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CORPORATE RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1be89e7c-4b91-48c4-a4d3-6cb3641e69cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_019b3669-9643-77e5-bcb3-acc3e526c7ec_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_368bbc18-5347-4fac-9b86-95505236877c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2cf8c1e1-3f6f-4490-8e1a-8ec2e5cee336_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_019b366a-87b0-7a6f-b786-d346235fb8a2_terseLabel_en-US" xlink:label="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired, price per share on commencement of tender offer (in USD per share)</link:label>
    <link:label id="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_label_en-US" xlink:label="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Price Per Share on Commencement of Tender Offer</link:label>
    <link:label id="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_documentation_en-US" xlink:label="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Acquired, Price Per Share on Commencement of Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:href="kros-20251231.xsd#kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:to="lab_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6bc041b5-ca83-4661-9ebb-32ba4882ec02_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_273517c1-e48c-497d-8ca7-a071c15e70b0_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-701e-a861-487a89bd3e67_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c7000-e633-7a57-bf4f-38edef017356_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_10b4ad23-e609-4835-a18f-bf474e133c62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9702374b-c74f-4a13-a2b5-442f2c7c94a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_154cc573-93b3-4a3e-8f5c-72025e4e44ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_251fc2d6-7f7c-4713-84ea-4fefb67b80a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e3e80d9-69a8-4c91-ae1b-b564afa5af69_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6ad6ba85-e44e-4280-9243-f7e1a041a167_negatedLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeasePeriodForImprovement_f7bf034b-b99d-4edc-922d-1a9949bf2245_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeasePeriodForImprovement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, period for improvement</link:label>
    <link:label id="lab_kros_LesseeOperatingLeasePeriodForImprovement_label_en-US" xlink:label="lab_kros_LesseeOperatingLeasePeriodForImprovement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period For Improvement</link:label>
    <link:label id="lab_kros_LesseeOperatingLeasePeriodForImprovement_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeasePeriodForImprovement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period For Improvement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeasePeriodForImprovement" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeasePeriodForImprovement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeasePeriodForImprovement" xlink:to="lab_kros_LesseeOperatingLeasePeriodForImprovement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1de114ea-6f16-49c0-ae99-8bb1e721bcc3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TransitionServicesMember_019c0fdf-7403-7a5c-9224-70db3a0513f1_terseLabel_en-US" xlink:label="lab_kros_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Services</link:label>
    <link:label id="lab_kros_TransitionServicesMember_label_en-US" xlink:label="lab_kros_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Services [Member]</link:label>
    <link:label id="lab_kros_TransitionServicesMember_documentation_en-US" xlink:label="lab_kros_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TransitionServicesMember" xlink:href="kros-20251231.xsd#kros_TransitionServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TransitionServicesMember" xlink:to="lab_kros_TransitionServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-7828-8438-629b1f7df77a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c09b9fb-a6f5-417f-a174-0a7462382199_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_24b60e93-6563-42e4-a65c-b785064e7890_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_23924adc-10a7-418d-83e6-c9e7915b84a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bf3470b5-76a9-44a5-bdc8-259656014e12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b1bc5f09-1cae-4a4e-a1f9-81eda98c45cd_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-7f33-b58e-9395c8f2edfa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b7d56395-d266-43ed-82d6-529310eca899_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f628d16d-7544-4dcf-a648-542d161b4d91_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_9ef16fcc-ea48-4fb1-965e-6179fd867bd9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c98d338e-4749-4a83-9749-0d17803511be_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ServiceAndOtherRevenue_a3abb299-d84d-48e9-b53c-771dcf88260a_terseLabel_en-US" xlink:label="lab_kros_ServiceAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_kros_ServiceAndOtherRevenue_label_en-US" xlink:label="lab_kros_ServiceAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service And Other Revenue</link:label>
    <link:label id="lab_kros_ServiceAndOtherRevenue_documentation_en-US" xlink:label="lab_kros_ServiceAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service And Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ServiceAndOtherRevenue" xlink:href="kros-20251231.xsd#kros_ServiceAndOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ServiceAndOtherRevenue" xlink:to="lab_kros_ServiceAndOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_08703359-3d1c-4fa1-8b18-2615c1d0cc73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_15aabc20-735d-42d8-9b37-381dc3a22049_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cc91e39c-4638-4781-b596-907d25da02ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AccentTherapeuticsIncMember_17ead11b-fdc4-4f63-ab80-2836739162d2_terseLabel_en-US" xlink:label="lab_kros_AccentTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accent Therapeutics, Inc</link:label>
    <link:label id="lab_kros_AccentTherapeuticsIncMember_label_en-US" xlink:label="lab_kros_AccentTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accent Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_kros_AccentTherapeuticsIncMember_documentation_en-US" xlink:label="lab_kros_AccentTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accent Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccentTherapeuticsIncMember" xlink:href="kros-20251231.xsd#kros_AccentTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AccentTherapeuticsIncMember" xlink:to="lab_kros_AccentTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_71a994fd-c56e-4734-a0d7-090a86f0d028_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_A2017StockIncentivePlanMember_cbe5b510-49fa-43c0-983c-6b7f85602b22_terseLabel_en-US" xlink:label="lab_kros_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_kros_A2017StockIncentivePlanMember_label_en-US" xlink:label="lab_kros_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_kros_A2017StockIncentivePlanMember_documentation_en-US" xlink:label="lab_kros_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2017StockIncentivePlanMember" xlink:href="kros-20251231.xsd#kros_A2017StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_A2017StockIncentivePlanMember" xlink:to="lab_kros_A2017StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_019c0f85-32d6-7ef0-9614-c471849f2797_terseLabel_en-US" xlink:label="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock repurchase costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Repurchase Costs Still In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock Repurchase Costs Still In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:href="kros-20251231.xsd#kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:to="lab_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_cf1f97a8-1b7e-492b-9a4c-2c432555077f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0bcf4ceb-21c5-4184-a7a7-6d39e8023f06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6cbbf704-048b-4668-81a0-e8d57520728f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7a17-a48d-e7a442d75349_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0921119e-14ac-47be-8b2e-950cfc4ac268_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WEIGHTED- AVERAGE EXERCISE PRICE</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d822a01a-2b67-4404-83b5-bbb88c5ae5af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_858d4fb7-0392-48cc-b4f8-517eee575d07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ee90ae51-79d2-47bf-b813-b58a6a5ffdbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PerformanceBasedStockOptionsMember_6e61e06c-6034-424d-bb3e-daf730a28937_terseLabel_en-US" xlink:label="lab_kros_PerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Stock Options</link:label>
    <link:label id="lab_kros_PerformanceBasedStockOptionsMember_label_en-US" xlink:label="lab_kros_PerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Stock Options [Member]</link:label>
    <link:label id="lab_kros_PerformanceBasedStockOptionsMember_documentation_en-US" xlink:label="lab_kros_PerformanceBasedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedStockOptionsMember" xlink:href="kros-20251231.xsd#kros_PerformanceBasedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PerformanceBasedStockOptionsMember" xlink:to="lab_kros_PerformanceBasedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_70db39b7-ebe6-44f5-8be2-bac37aa9901c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-71d8-aa3b-416e1c352719_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_54ce2646-1a09-494d-93be-e0e63dac2fc4_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_f432edb3-367a-4ab3-bbe4-69c6223869ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c0fe8-83c9-782b-82a6-51f1d6e9eba8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of positions eliminated (as a percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_019c0fdf-7403-789d-a796-df0192768e80_terseLabel_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone, development based milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_label_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Development Based Milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_documentation_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Development Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsDevelopmentBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:to="lab_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_da3fb8ad-9df4-490f-b732-d64db1ab5c7c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c08c3e5a-4885-47c2-bc59-d4bdbb90db8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_9f2bd359-ed46-4804-9480-0c527be53fe3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_9fa60cf4-9c5d-4355-be68-cf1a170f69b6_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6baaf939-89c7-4b60-a3dc-47f06af5b7de_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a28d0322-d3c1-4f35-94de-5f7f1a12b9a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f6e85fce-3300-4ce5-a337-6958fb5e7811_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6fc8463f-9aed-46d0-a3de-56d443e24bda_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_883d6ee8-d675-4cd3-a40c-903b66640971_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_70929d33-f958-4a96-afa6-21b1617d4c32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e6037a67-5d99-42d7-86d1-cbe9e9717df7_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1a03f4df-73eb-47f0-805b-9051dc4b99e1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyFeeWaiverTerms_019c0fdf-7403-7484-b3c7-beb4e406078e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFeeWaiverTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of the TSA</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyFeeWaiverTerms_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyFeeWaiverTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Company, Fee Waiver Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFeeWaiverTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeeWaiverTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyFeeWaiverTerms" xlink:to="lab_us-gaap_InvestmentCompanyFeeWaiverTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_0c37e16a-5078-430b-8a10-69c4b33f0e94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_08a6a313-83ec-422a-8f3a-e679c6104593_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8bef6278-12d3-452f-b3d8-c71e81afc844_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested award, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_40398cd8-7415-41a4-96cd-be970627a372_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a89e3f85-6cb0-41fa-843b-68a9f25265cd_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9fc12d2c-0eed-4ff9-8450-bfcbc07039f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_90da698d-28c7-4872-ad95-f17d400f23ba_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PhaseAPremisesMember_41ff7c7f-7a4e-4d9f-9388-b73970338166_terseLabel_en-US" xlink:label="lab_kros_PhaseAPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase A Premises</link:label>
    <link:label id="lab_kros_PhaseAPremisesMember_label_en-US" xlink:label="lab_kros_PhaseAPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase A Premises [Member]</link:label>
    <link:label id="lab_kros_PhaseAPremisesMember_documentation_en-US" xlink:label="lab_kros_PhaseAPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase A Premises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PhaseAPremisesMember" xlink:href="kros-20251231.xsd#kros_PhaseAPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PhaseAPremisesMember" xlink:to="lab_kros_PhaseAPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_60eae8d7-9b72-4f2f-8e1d-5f0c74897a62_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88f2f06a-4947-47ce-bd94-a31aec4e672a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7001-7b1d-74d2-a7b1-eb80095203f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_32cb4f70-9c77-477a-ad61-c8f27d2e100f_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_55668e5d-510b-44c2-a6ab-d9abd278b2f9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0a5ea109-0750-4a63-b9af-5b160a1f3331_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05e70305-daab-412d-85df-29c0921588b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_658fe340-d01b-42da-a474-b7741526ad2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SupplyAgreementMember_019c0fdf-7403-7ae4-b322-7a93a9d648aa_terseLabel_en-US" xlink:label="lab_kros_SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply Agreement</link:label>
    <link:label id="lab_kros_SupplyAgreementMember_label_en-US" xlink:label="lab_kros_SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Agreement [Member]</link:label>
    <link:label id="lab_kros_SupplyAgreementMember_documentation_en-US" xlink:label="lab_kros_SupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SupplyAgreementMember" xlink:href="kros-20251231.xsd#kros_SupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SupplyAgreementMember" xlink:to="lab_kros_SupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_0e4a32f4-99d7-4060-bf22-bd904e019d88_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SaleOfStockAgentCommissions_33c52b95-8fb7-4896-8702-edcb19e8541c_terseLabel_en-US" xlink:label="lab_kros_SaleOfStockAgentCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales agent commissions</link:label>
    <link:label id="lab_kros_SaleOfStockAgentCommissions_label_en-US" xlink:label="lab_kros_SaleOfStockAgentCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Agent Commissions</link:label>
    <link:label id="lab_kros_SaleOfStockAgentCommissions_documentation_en-US" xlink:label="lab_kros_SaleOfStockAgentCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Agent Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockAgentCommissions" xlink:href="kros-20251231.xsd#kros_SaleOfStockAgentCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SaleOfStockAgentCommissions" xlink:to="lab_kros_SaleOfStockAgentCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f541a132-f8ab-4b0c-860a-1eba3d776791_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ReportableSegmentMember_468e96bd-5ed8-4ff7-b084-e408b08a897f_terseLabel_en-US" xlink:label="lab_kros_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_kros_ReportableSegmentMember_label_en-US" xlink:label="lab_kros_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_kros_ReportableSegmentMember_documentation_en-US" xlink:label="lab_kros_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ReportableSegmentMember" xlink:href="kros-20251231.xsd#kros_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ReportableSegmentMember" xlink:to="lab_kros_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76b19aed-3fb0-4ddc-86cc-5f0f330bcd16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ManufacturingTechnologyTransferAgreementMember_019c0fdf-7403-7238-abf4-88497af7ba25_terseLabel_en-US" xlink:label="lab_kros_ManufacturingTechnologyTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Technology Transfer Agreement</link:label>
    <link:label id="lab_kros_ManufacturingTechnologyTransferAgreementMember_label_en-US" xlink:label="lab_kros_ManufacturingTechnologyTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Technology Transfer Agreement [Member]</link:label>
    <link:label id="lab_kros_ManufacturingTechnologyTransferAgreementMember_documentation_en-US" xlink:label="lab_kros_ManufacturingTechnologyTransferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ManufacturingTechnologyTransferAgreementMember" xlink:href="kros-20251231.xsd#kros_ManufacturingTechnologyTransferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ManufacturingTechnologyTransferAgreementMember" xlink:to="lab_kros_ManufacturingTechnologyTransferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_DeferredTaxAssetsOperatingLeaseLiability_aa571efb-31af-4193-82fe-f34fc42fd544_terseLabel_en-US" xlink:label="lab_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_kros_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Operating Lease Liability</link:label>
    <link:label id="lab_kros_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_kros_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_019c0fb1-3592-7ac5-96a8-f765d3f701c1_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized, number of shares repurchase</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b46d9fb-5b02-44f1-8c6b-1229bc17eab1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_aae88a20-56cc-48f8-9d0c-dd894c17c3a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c96f3-80a4-7d05-9a47-8956ceedb3fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f27dc10c-438d-43c6-b6b6-bc50405991eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6728865d-eaca-4662-9469-ee297686e025_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ComputerEquipmentAndSoftwareMember_4fd794c0-248b-47e2-855b-fb810c2d8e08_terseLabel_en-US" xlink:label="lab_kros_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_kros_ComputerEquipmentAndSoftwareMember_38310349-dd36-4e18-9327-1e6359bf2283_verboseLabel_en-US" xlink:label="lab_kros_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_kros_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_kros_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_kros_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_kros_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ComputerEquipmentAndSoftwareMember" xlink:href="kros-20251231.xsd#kros_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ComputerEquipmentAndSoftwareMember" xlink:to="lab_kros_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7c0bfeac-3e70-4088-87ea-30021557ac07_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_019c0fde-79c4-7f26-978f-c4a9b927a904_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue from Takeda</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_829933bc-7c51-48e1-b141-cac329a14e4a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of discounts and offering costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c7004-cfb4-70df-bb03-541d305d9310_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between local tax rare and U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e6775ff7-0dc8-4f21-8db9-9a5772d9d115_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_d0cced07-6f73-486a-904c-68f77e0cb6a5_terseLabel_en-US" xlink:label="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label id="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_label_en-US" xlink:label="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Cost</link:label>
    <link:label id="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_documentation_en-US" xlink:label="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:to="lab_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6092640c-d84d-4be8-8590-7d821d591536_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_728aafef-1824-4c37-a5b5-4957cf7e4a23_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace_760bf178-a7a2-489f-9b7b-02d76cf003d4_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, area of rental space</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace_label_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Rental Space</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Rental Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAreaOfRentalSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:to="lab_kros_LesseeOperatingLeaseAreaOfRentalSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_HansohShanghaiHealthtechCoLtdMember_0ff61eeb-fa4a-43de-98ce-b272b7bc9df5_terseLabel_en-US" xlink:label="lab_kros_HansohShanghaiHealthtechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hansoh Shanghai Healthtech Co Ltd</link:label>
    <link:label id="lab_kros_HansohShanghaiHealthtechCoLtdMember_label_en-US" xlink:label="lab_kros_HansohShanghaiHealthtechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hansoh Shanghai Healthtech Co Ltd [Member]</link:label>
    <link:label id="lab_kros_HansohShanghaiHealthtechCoLtdMember_documentation_en-US" xlink:label="lab_kros_HansohShanghaiHealthtechCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hansoh Shanghai Healthtech Co Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohShanghaiHealthtechCoLtdMember" xlink:href="kros-20251231.xsd#kros_HansohShanghaiHealthtechCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_HansohShanghaiHealthtechCoLtdMember" xlink:to="lab_kros_HansohShanghaiHealthtechCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c35c4af2-f44a-4026-bff1-11555f14f7e6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendIncomeOperating_8aec80b0-cfb6-49e4-8686-a19d68175b40_terseLabel_en-US" xlink:label="lab_us-gaap_DividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_DividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_DividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendIncomeOperating" xlink:to="lab_us-gaap_DividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8e5c756c-e21a-4688-977e-7203e648d735_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3118a041-cb68-415b-ac4c-d6ca67144ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9444384-78ab-4861-a5fe-0c5ebe65588f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8b707333-1200-4053-8dd3-4f5142f493c6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_99b4c518-f9f3-47a8-b734-7d229ca599bb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_JeanJacquesBienaimeMember_label_en-US" xlink:label="lab_kros_JeanJacquesBienaimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jean-Jacques Bienaim&#233; [Member]</link:label>
    <link:label id="lab_kros_JeanJacquesBienaimeMember_documentation_en-US" xlink:label="lab_kros_JeanJacquesBienaimeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jean-Jacques Bienaim&#233;</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JeanJacquesBienaimeMember" xlink:href="kros-20251231.xsd#kros_JeanJacquesBienaimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_JeanJacquesBienaimeMember" xlink:to="lab_kros_JeanJacquesBienaimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_019c0fe8-83c9-7509-8e54-3f821d39397e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related, expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_UnvestedStockOptionsMember_e1a30df6-bf48-4a75-99fd-a7666786a011_terseLabel_en-US" xlink:label="lab_kros_UnvestedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested Stock Options</link:label>
    <link:label id="lab_kros_UnvestedStockOptionsMember_label_en-US" xlink:label="lab_kros_UnvestedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Stock Options [Member]</link:label>
    <link:label id="lab_kros_UnvestedStockOptionsMember_documentation_en-US" xlink:label="lab_kros_UnvestedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_UnvestedStockOptionsMember" xlink:href="kros-20251231.xsd#kros_UnvestedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_UnvestedStockOptionsMember" xlink:to="lab_kros_UnvestedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_67c1cfec-6b27-48b6-9253-7530e69b13f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RinvaterceptProgramExpensesMember_019c0fe4-4642-7903-b1b2-d3d0af6f2523_terseLabel_en-US" xlink:label="lab_kros_RinvaterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rinvatercept program expenses</link:label>
    <link:label id="lab_kros_RinvaterceptProgramExpensesMember_label_en-US" xlink:label="lab_kros_RinvaterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rinvatercept Program Expenses [Member]</link:label>
    <link:label id="lab_kros_RinvaterceptProgramExpensesMember_documentation_en-US" xlink:label="lab_kros_RinvaterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rinvatercept Program Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RinvaterceptProgramExpensesMember" xlink:href="kros-20251231.xsd#kros_RinvaterceptProgramExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RinvaterceptProgramExpensesMember" xlink:to="lab_kros_RinvaterceptProgramExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e873cbab-b5f0-4345-9dc3-caa7a32c3b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c0fba-8460-7ae3-a70d-17780841c555_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4bec3e43-a954-4587-bc3d-222f2736f93f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f99469ec-4200-48ee-a752-ae8d81ffb76e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bdc5fa6d-b144-4e82-ac58-1dd35f0a5263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ElriterceptProgramExpensesMember_4d810977-19ed-45bd-bad9-9d6216335418_terseLabel_en-US" xlink:label="lab_kros_ElriterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elritercept program expenses</link:label>
    <link:label id="lab_kros_ElriterceptProgramExpensesMember_label_en-US" xlink:label="lab_kros_ElriterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elritercept Program Expenses [Member]</link:label>
    <link:label id="lab_kros_ElriterceptProgramExpensesMember_documentation_en-US" xlink:label="lab_kros_ElriterceptProgramExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elritercept Program Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ElriterceptProgramExpensesMember" xlink:href="kros-20251231.xsd#kros_ElriterceptProgramExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ElriterceptProgramExpensesMember" xlink:to="lab_kros_ElriterceptProgramExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1bd41dbd-533e-49d5-b7da-5b1e100b5307_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0f8c-28b5-78f2-962c-3d416c75e9e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of treasury stock, including excise tax, direct fees and expenses of $9,558</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f6f8cd1c-6d84-4ffe-8f50-06c3b5d2ba8d_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_00ad63f9-9746-4a2c-9bbf-ada076361fba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e7aebee5-0c5c-4a49-8808-1430b1628bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2aef3ef1-78d5-4465-9bbb-348fd85b0d25_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9eeea5f4-0623-4326-ac24-ea597489150e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_A2020StockIncentivePlanMember_d96c499f-6877-4f07-b1fd-50d676c019f7_terseLabel_en-US" xlink:label="lab_kros_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_kros_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_kros_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_kros_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_kros_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020StockIncentivePlanMember" xlink:href="kros-20251231.xsd#kros_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_A2020StockIncentivePlanMember" xlink:to="lab_kros_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_2bc3e587-6ac0-4eb3-a256-54bd8796dfb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_60b10923-e6ef-4cee-90b2-1438f867e69d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities_e134ce17-8a4f-46b4-ad72-03e6d78f7c51_negatedTerseLabel_en-US" xlink:label="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets and operating lease liabilities</link:label>
    <link:label id="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities_label_en-US" xlink:label="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-to-Use Assets and Operating Lease Liabilities</link:label>
    <link:label id="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-to-Use Assets and Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:href="kros-20251231.xsd#kros_RightToUseAssetsAndOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:to="lab_kros_RightToUseAssetsAndOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_0ba00803-3ee1-45a0-96b2-8935b93739d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation costs (excluding stock based compensation)</link:label>
    <link:label id="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_label_en-US" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_96990eff-37e2-4207-b33a-672df3b04411_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment_019c0fdf-7403-7e25-8b24-8f4745d99bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement from limited partnership investment</link:label>
    <link:label id="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment_label_en-US" xlink:label="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement from Limited Partnership Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:to="lab_us-gaap_ReimbursementFromLimitedPartnershipInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_019c7000-e633-7064-b6b4-087e8d9bfb13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_9985cdf3-031b-46c3-a5fd-3bba49f48a85_terseLabel_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase in shares authorized</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_label_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Authorized, Percentage</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:to="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LorenaLernerMember_label_en-US" xlink:label="lab_kros_LorenaLernerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lorena Lerner [Member]</link:label>
    <link:label id="lab_kros_LorenaLernerMember_documentation_en-US" xlink:label="lab_kros_LorenaLernerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lorena Lerner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LorenaLernerMember" xlink:href="kros-20251231.xsd#kros_LorenaLernerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LorenaLernerMember" xlink:to="lab_kros_LorenaLernerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_WalthamLeaseMember_79cc859d-f59c-47cc-a633-b71df0b6cf56_terseLabel_en-US" xlink:label="lab_kros_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Waltham Lease</link:label>
    <link:label id="lab_kros_WalthamLeaseMember_label_en-US" xlink:label="lab_kros_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Waltham Lease [Member]</link:label>
    <link:label id="lab_kros_WalthamLeaseMember_documentation_en-US" xlink:label="lab_kros_WalthamLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Waltham Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_WalthamLeaseMember" xlink:href="kros-20251231.xsd#kros_WalthamLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_WalthamLeaseMember" xlink:to="lab_kros_WalthamLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-7f68-b353-d3de909276ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationNonproduction_05d52248-65ff-4cbf-b108-9ec258f9af85_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationNonproduction_label_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction" xlink:to="lab_us-gaap_DepreciationNonproduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c0fba-8460-727d-9ace-cfab35704b01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c0fba-8460-7529-9098-bf037b0039e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_465f5619-478c-47a8-a101-a094e8a38b61_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_a94e303c-b3ce-43bf-8e0a-f7b36bc1df57_terseLabel_en-US" xlink:label="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products</link:label>
    <link:label id="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_label_en-US" xlink:label="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products Achieving Milestone to Trigger Maintenance Fee</link:label>
    <link:label id="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_documentation_en-US" xlink:label="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products Achieving Milestone to Trigger Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:href="kros-20251231.xsd#kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:to="lab_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4c548641-da54-4654-b8aa-ec147e7fba4a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_972ac6a7-1d9c-46d3-ac72-28deac6e20a0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7110ae85-f36f-477b-8706-b082b057c94c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_823989a6-6cf0-4ab8-a639-901f14f1baae_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_717fcc97-b858-486e-a9e5-863a98be29a1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f2f56db7-6010-4d64-89d5-0350110b8853_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_1ecd3d86-4d9b-4e8d-b0e5-dcf72b47892e_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_f2b173ec-42e2-410d-bca0-0a3d953f67ed_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7c2e-a10d-32eaeafa1d8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_98087361-2ecc-4fa9-b579-e1cfef70c877_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_HansohAgreementMember_f47eb056-ce49-44ea-af85-3bb41d08b30c_terseLabel_en-US" xlink:label="lab_kros_HansohAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hansoh Agreement</link:label>
    <link:label id="lab_kros_HansohAgreementMember_label_en-US" xlink:label="lab_kros_HansohAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hansoh Agreement [Member]</link:label>
    <link:label id="lab_kros_HansohAgreementMember_documentation_en-US" xlink:label="lab_kros_HansohAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hansoh Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohAgreementMember" xlink:href="kros-20251231.xsd#kros_HansohAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_HansohAgreementMember" xlink:to="lab_kros_HansohAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PrepaidLegalAndConsultants_019c0f98-d4ac-7af0-9d0f-93d6bc422b6f_terseLabel_en-US" xlink:label="lab_kros_PrepaidLegalAndConsultants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid legal and consultants</link:label>
    <link:label id="lab_kros_PrepaidLegalAndConsultants_label_en-US" xlink:label="lab_kros_PrepaidLegalAndConsultants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Legal And Consultants</link:label>
    <link:label id="lab_kros_PrepaidLegalAndConsultants_documentation_en-US" xlink:label="lab_kros_PrepaidLegalAndConsultants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Legal And Consultants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidLegalAndConsultants" xlink:href="kros-20251231.xsd#kros_PrepaidLegalAndConsultants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PrepaidLegalAndConsultants" xlink:to="lab_kros_PrepaidLegalAndConsultants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_c0158b66-d656-41c2-970a-073678a5f3a3_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e522b1cd-47b3-47d6-b872-7b816471e7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_019c0fe8-83c9-7d15-aa9e-3c57a2990642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Compensation and Benefits Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_270cc63f-1985-4437-9763-3c1ee90fc491_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9efee558-4785-40db-b834-2c978fffec0a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ae6d095e-1bfe-4968-ae40-b2257fcfb8ef_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c7003-7baf-7e27-93a0-939cd5d8ca99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in taw laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-7131-8cdc-3cd7c8829b3c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_180840c1-f04a-4002-9f82-1b1c388d8a4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_73d3d824-1a0b-41c1-bf74-66d2634cca7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c7002-fe7d-762d-a250-328fee5d1ac0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of cross-border tax laws</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5488ecbf-85e8-4901-9df9-82b97668ea94_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6543748a-8552-48bc-91eb-98640589ca27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87fbf037-1795-487d-8f0c-54dded4e481f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_8c1d0ff8-df9b-4fd6-b7b1-61bc20a8a618_terseLabel_en-US" xlink:label="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twenty Member</link:label>
    <link:label id="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_label_en-US" xlink:label="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twenty Member [Member]</link:label>
    <link:label id="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_documentation_en-US" xlink:label="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twenty Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:href="kros-20251231.xsd#kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:to="lab_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_6eb2e099-5c36-48db-b033-d1d37494cb2c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_fea24e2a-15f2-4b87-b2f8-106b2f846526_terseLabel_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign withholding taxes</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_label_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes, Percent</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_documentation_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:to="lab_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c7004-ea03-73f3-9c9b-67defdcf1373_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between local tax rare and U.S. federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_2bc4fc69-5e8f-48a9-9ffd-b9291456cdb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_019c0fe8-83c9-7968-a75b-ab36500688f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7745-9905-dd206c8ceda5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-770e-a300-bc9ed38691ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_7aef404f-95c8-4130-be76-9715eeeb6555_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_019c7008-f2b5-7e99-a019-9dcdd4b551af_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6cedb8bd-10fd-4bfc-91c9-ad7d32d03d43_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_48aa7f4f-d663-4029-b65a-f744d9a2b120_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available under the ESPP Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_019c0fbe-e67d-7ee9-94fb-38295c8998a0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_ca6ecd14-bd78-4b78-90b3-87e935d6aa5c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5bc68e9a-bd23-45f4-abab-8793e7750cb7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b7855a02-e98c-4eca-9faa-855959bd604f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87db855f-4a15-4475-9260-732cda2d68ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_a5123ad8-d943-4601-9f13-2363f4259006_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f008de3b-086f-4d6d-91ac-a4dbc766b115_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_eb3b07ce-5633-4039-84a1-4a362cac1115_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_64f49907-3721-471a-9217-7e7de89a29b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b92265a5-1fb9-483a-a93b-287ef0295271_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bf71614-e402-48bf-bcfa-515407f02e1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c7001-3d63-721f-9282-a3473546398b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RisksAndUncertaintiesPolicyTextBlock_019c9541-4860-7ca8-8a5a-54f4032ae00e_terseLabel_en-US" xlink:label="lab_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_kros_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_kros_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:href="kros-20251231.xsd#kros_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_kros_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019c0fa1-22e8-7c78-93be-7715bc87ef79_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_321c7f45-7b5c-4221-b7b9-3901cb8bb348_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1ff87071-f278-419c-bb69-c17f19f42b8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones_019c0fdf-7403-75fb-81df-9e89276ac3ee_terseLabel_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments, commercial-based milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones_label_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Commercial-based Milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones_documentation_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Commercial-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsCommercialBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:to="lab_kros_PotentialMilestonePaymentsCommercialBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_32b722fc-a810-4d7d-860e-4d21f00de436_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and regulatory milestone payments</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Clinical And Regulatory Milestone</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Clinical And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:to="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_NumberOfPerformanceObligations_019c0fdf-7403-7ac2-9984-c69e5bc37aad_terseLabel_en-US" xlink:label="lab_kros_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_kros_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_kros_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_kros_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_kros_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfPerformanceObligations" xlink:href="kros-20251231.xsd#kros_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_NumberOfPerformanceObligations" xlink:to="lab_kros_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ClinicalProductSupplyAgreementMember_019c0fdf-7403-7a48-a314-45627e53ebb0_terseLabel_en-US" xlink:label="lab_kros_ClinicalProductSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Product Supply Agreement</link:label>
    <link:label id="lab_kros_ClinicalProductSupplyAgreementMember_label_en-US" xlink:label="lab_kros_ClinicalProductSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Product Supply Agreement [Member]</link:label>
    <link:label id="lab_kros_ClinicalProductSupplyAgreementMember_documentation_en-US" xlink:label="lab_kros_ClinicalProductSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Product Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ClinicalProductSupplyAgreementMember" xlink:href="kros-20251231.xsd#kros_ClinicalProductSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ClinicalProductSupplyAgreementMember" xlink:to="lab_kros_ClinicalProductSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fe5ecadf-f506-40b0-ae4c-c1c76a3cdf32_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December&#160;31, 2025 and 2024; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_30c48060-c460-42f3-a894-ec0b37eb33a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a4da81b1-71ce-41e7-900a-383120d8d339_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_a0959c79-0294-468c-9edb-92bd37033ab1_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1e43ae0e-fb6f-4a3e-a619-73bc602893f9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d1b499db-2a55-4d6c-8de4-c56a469fb538_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ee9bcaf0-4632-4352-8209-ef686807e30d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; 40,670,466 shares issued and 19,543,706 shares outstanding as of December&#160;31, 2025 and 40,554,705 shares issued and outstanding as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_e670cd46-54dd-4f99-a581-51aeb279fe0c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7709-b392-827e8d61a0a1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27780903-df59-4e0c-9a6b-4259d1ca7b12_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SaleOfStockStockIssuanceCosts_e255b19e-3d27-4588-b77a-fee45114374a_terseLabel_en-US" xlink:label="lab_kros_SaleOfStockStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, stock issuance costs</link:label>
    <link:label id="lab_kros_SaleOfStockStockIssuanceCosts_label_en-US" xlink:label="lab_kros_SaleOfStockStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Issuance Costs</link:label>
    <link:label id="lab_kros_SaleOfStockStockIssuanceCosts_documentation_en-US" xlink:label="lab_kros_SaleOfStockStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockStockIssuanceCosts" xlink:href="kros-20251231.xsd#kros_SaleOfStockStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SaleOfStockStockIssuanceCosts" xlink:to="lab_kros_SaleOfStockStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_061800bc-bc3a-40f3-87bf-c34588cddfb5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common stock outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-753c-b70a-e68ef9c41a74_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used to compute diluted net loss (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_c494aae9-b2cd-4998-961e-2e3b8ee447c5_terseLabel_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, sales milestones, variable consideration amount</link:label>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_label_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Sales Milestones, Variable Consideration</link:label>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_documentation_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Sales Milestones, Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:to="lab_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_59183d82-dc10-4f4f-9365-62ef75e3cf88_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f68fee91-58ad-485e-8e78-259ac7116429_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShortSwingProfitSettlement_019c0f69-28c3-7221-aee1-1dbe2d337540_terseLabel_en-US" xlink:label="lab_kros_ShortSwingProfitSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-swing profit settlement</link:label>
    <link:label id="lab_kros_ShortSwingProfitSettlement_label_en-US" xlink:label="lab_kros_ShortSwingProfitSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Swing Profit Settlement</link:label>
    <link:label id="lab_kros_ShortSwingProfitSettlement_documentation_en-US" xlink:label="lab_kros_ShortSwingProfitSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Swing Profit Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShortSwingProfitSettlement" xlink:href="kros-20251231.xsd#kros_ShortSwingProfitSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShortSwingProfitSettlement" xlink:to="lab_kros_ShortSwingProfitSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_019cafde-bc01-7144-913a-5c51621ecf2f_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_61c1655c-cdda-4ed2-9c64-f5ab52a04861_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold_019c0fa1-22e8-7fda-9c2f-a4002fd717c3_terseLabel_en-US" xlink:label="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership (in percent)</link:label>
    <link:label id="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold_label_en-US" xlink:label="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Beneficial Ownership Penalty Threshold</link:label>
    <link:label id="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold_documentation_en-US" xlink:label="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Beneficial Ownership Penalty Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:href="kros-20251231.xsd#kros_CommonStockBeneficialOwnershipPenaltyThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:to="lab_kros_CommonStockBeneficialOwnershipPenaltyThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_c7cfb587-9ac0-4bd1-bcde-478cd01ec75f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs associated with issuance of common stock under the ATM agreement</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c19353eb-3cea-47a7-a71d-bd6de2c29c82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a8bacd93-30d9-441c-ba0d-9d7c171d4d41_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_475ee403-775f-4b7f-ab48-de7e7f6bd8e7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TermLoanCreditAgreementThreeAmendmentMember_715e4464-65bc-4362-ab83-84cfb48914f7_terseLabel_en-US" xlink:label="lab_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement Three Amendment</link:label>
    <link:label id="lab_kros_TermLoanCreditAgreementThreeAmendmentMember_label_en-US" xlink:label="lab_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement Three Amendment [Member]</link:label>
    <link:label id="lab_kros_TermLoanCreditAgreementThreeAmendmentMember_documentation_en-US" xlink:label="lab_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement Three Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:href="kros-20251231.xsd#kros_TermLoanCreditAgreementThreeAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:to="lab_kros_TermLoanCreditAgreementThreeAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_583e75f1-9231-4033-9e74-ed58134706fb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_A2025RestructuringMember_019c0fe8-83c9-7057-8d53-349a39fca73c_terseLabel_en-US" xlink:label="lab_kros_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:label id="lab_kros_A2025RestructuringMember_label_en-US" xlink:label="lab_kros_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Restructuring [Member]</link:label>
    <link:label id="lab_kros_A2025RestructuringMember_documentation_en-US" xlink:label="lab_kros_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2025RestructuringMember" xlink:href="kros-20251231.xsd#kros_A2025RestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_A2025RestructuringMember" xlink:to="lab_kros_A2025RestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1e4bb0e5-190c-4673-8501-622e24ee7a35_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ProceedsFromShortSwingSettlementProfit_019c9551-edef-7c03-a2d8-a03e794fee08_terseLabel_en-US" xlink:label="lab_kros_ProceedsFromShortSwingSettlementProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-swing profit settlement</link:label>
    <link:label id="lab_kros_ProceedsFromShortSwingSettlementProfit_label_en-US" xlink:label="lab_kros_ProceedsFromShortSwingSettlementProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short Swing Settlement Profit</link:label>
    <link:label id="lab_kros_ProceedsFromShortSwingSettlementProfit_documentation_en-US" xlink:label="lab_kros_ProceedsFromShortSwingSettlementProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Short Swing Settlement Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ProceedsFromShortSwingSettlementProfit" xlink:href="kros-20251231.xsd#kros_ProceedsFromShortSwingSettlementProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ProceedsFromShortSwingSettlementProfit" xlink:to="lab_kros_ProceedsFromShortSwingSettlementProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_13f4470e-c4f2-4e97-9bd1-3cb03d5a9101_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bbc1abab-34a6-4d91-abd1-08caf39cca79_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4a1dfcf7-9929-4c0b-9362-666a99fc4d09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TheGeneralHospitalCorporationMember_3ab7aafa-96c3-4c70-a29f-25a857cdcad3_terseLabel_en-US" xlink:label="lab_kros_TheGeneralHospitalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MGH</link:label>
    <link:label id="lab_kros_TheGeneralHospitalCorporationMember_label_en-US" xlink:label="lab_kros_TheGeneralHospitalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The General Hospital Corporation [Member]</link:label>
    <link:label id="lab_kros_TheGeneralHospitalCorporationMember_documentation_en-US" xlink:label="lab_kros_TheGeneralHospitalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The General Hospital Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TheGeneralHospitalCorporationMember" xlink:href="kros-20251231.xsd#kros_TheGeneralHospitalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TheGeneralHospitalCorporationMember" xlink:to="lab_kros_TheGeneralHospitalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2661253c-0a3a-469d-a64a-226f820133b7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d958bbc4-35e6-440a-9678-84414987cfed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_16d7a706-2d31-47b4-aeac-23216f18148f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_180a5786-1f15-4505-98c9-5f2b84a0881e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019b366a-4d1f-7dbc-ad8e-dd13ff9fab14_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired, average cost per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_eb093c9d-b8d3-4da2-bf38-2c32edde2072_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_019c96db-95fb-7a68-9cd3-df5945bfbd8f_terseLabel_en-US" xlink:label="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of treasury stock</link:label>
    <link:label id="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_label_en-US" xlink:label="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase of Treasury Stock, Excise Tax, Direct Fees and Expenses</link:label>
    <link:label id="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_documentation_en-US" xlink:label="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repurchase of Treasury Stock, Excise Tax, Direct Fees and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:href="kros-20251231.xsd#kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:to="lab_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4395034c-8991-40f5-82e0-66ae9a3cdc31_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_677209ab-bd4e-4dfc-8951-814da3c29a20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019c0fbe-e67d-7385-ab59-b83dd7161344_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_019c46d8-cf98-74e6-af08-bf3820123260_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d6fadd83-e011-4b57-a792-b52bd1b86477_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_783c373c-3c34-4a19-94fb-31ab4b9baa76_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones_019c0fdf-7403-719e-83fa-6869feb50b96_terseLabel_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments, sales-based milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones_label_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Sales-based Milestones</link:label>
    <link:label id="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones_documentation_en-US" xlink:label="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments, Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:to="lab_kros_PotentialMilestonePaymentsSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d02b1edd-eff4-4d12-be34-4acb27565027_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_603315ab-dabd-4bc8-8f2f-d2225da7188b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable payments</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc9fd098-c08d-48ec-a74c-3d43462feb82_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8217505f-02c5-494a-95ad-aa3ffeb3bd44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_JuliusKnowlesMember_label_en-US" xlink:label="lab_kros_JuliusKnowlesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Julius Knowles [Member]</link:label>
    <link:label id="lab_kros_JuliusKnowlesMember_documentation_en-US" xlink:label="lab_kros_JuliusKnowlesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Julius Knowles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JuliusKnowlesMember" xlink:href="kros-20251231.xsd#kros_JuliusKnowlesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_JuliusKnowlesMember" xlink:to="lab_kros_JuliusKnowlesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6f8dbd06-603d-4a51-8881-d726b3caea60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3e7e2af-a0e9-44e9-8dc0-9cd2370229a3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dcec1ea6-3405-436e-81bb-e764ef3eb627_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5946ecee-141e-454b-be97-8808a392591e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019c0fa1-22e8-773c-b654-7022a0bdf105_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeAreaOfSublease_c619e980-0aa4-4f2d-90c7-71f4e99fbaeb_terseLabel_en-US" xlink:label="lab_kros_LesseeAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, area of sublease</link:label>
    <link:label id="lab_kros_LesseeAreaOfSublease_label_en-US" xlink:label="lab_kros_LesseeAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Area of Sublease</link:label>
    <link:label id="lab_kros_LesseeAreaOfSublease_documentation_en-US" xlink:label="lab_kros_LesseeAreaOfSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Area of Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeAreaOfSublease" xlink:href="kros-20251231.xsd#kros_LesseeAreaOfSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeAreaOfSublease" xlink:to="lab_kros_LesseeAreaOfSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019b3669-9643-753a-bad6-de9a28f37d66_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, authorized, amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_e4501af0-ae20-4c9d-83ed-ab4cdc73d2be_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_d930e1c0-fa38-4e8e-ae57-feb931a9988d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9ec14e3c-d4dd-48bf-8ab2-b0eac3a540f3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_OtherExternalCostsMember_019c7b68-7d98-7dfd-bfb2-6d4bea960352_terseLabel_en-US" xlink:label="lab_kros_OtherExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other external costs</link:label>
    <link:label id="lab_kros_OtherExternalCostsMember_label_en-US" xlink:label="lab_kros_OtherExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other External Costs [Member]</link:label>
    <link:label id="lab_kros_OtherExternalCostsMember_documentation_en-US" xlink:label="lab_kros_OtherExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other External Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OtherExternalCostsMember" xlink:href="kros-20251231.xsd#kros_OtherExternalCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_OtherExternalCostsMember" xlink:to="lab_kros_OtherExternalCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d0e01dd0-fd31-41c6-9e60-cb43f0686f59_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ab78bda1-09d9-40bf-af63-56573fcfc733_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c6cba420-ba94-4d72-aa6e-525d2f1bbe8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM (IN&#160;YEARS)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AccruedResearchAndDevelopmentCostsCurrent_5256f001-19c6-4143-9192-89aa2c3b440d_terseLabel_en-US" xlink:label="lab_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued external R&amp;D costs</link:label>
    <link:label id="lab_kros_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:label id="lab_kros_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="kros-20251231.xsd#kros_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_kros_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_22f63c51-0ca4-4122-ad47-968ab5a47970_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_84575168-a2b2-4bd4-ae1c-4cb862821821_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_11c2b818-d2d1-4b17-9e3b-b8bfb06a1e26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QUOTED PRICES ACTIVE MARKETS FOR IDENTICAL ASSETS (LEVEL&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f6ca270d-8d23-430b-9592-3d2b837b0d98_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_6ae58042-55dc-4e53-8fb1-86efe2db738c_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_be8f095d-9050-4e47-a669-4bb2d7540384_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0d1bdeee-c333-4c14-a8b1-b4d6f79f998f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_NumberOfFinancialInstitutions_9b49a18f-7fc0-4b3e-8502-a1f5ec997309_terseLabel_en-US" xlink:label="lab_kros_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label id="lab_kros_NumberOfFinancialInstitutions_label_en-US" xlink:label="lab_kros_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions</link:label>
    <link:label id="lab_kros_NumberOfFinancialInstitutions_documentation_en-US" xlink:label="lab_kros_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfFinancialInstitutions" xlink:href="kros-20251231.xsd#kros_NumberOfFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_NumberOfFinancialInstitutions" xlink:to="lab_kros_NumberOfFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f4729e1e-c0cc-41dd-956b-73cbb7fb044b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share of common stock - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentIncentiveIncome_cee5f467-0bf2-4f7c-a4b9-efc576d3e21f_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentIncentiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentive income</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentIncentiveIncome_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentIncentiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Incentive, Income</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentIncentiveIncome_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentIncentiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Incentive, Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentIncentiveIncome" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentIncentiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentIncentiveIncome" xlink:to="lab_kros_ResearchAndDevelopmentIncentiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_019c98d5-1a01-7d24-9bf2-465c33906f64_terseLabel_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, cost not yet recognized, recognition not probable</link:label>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_label_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Not Probable</link:label>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_documentation_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Not Probable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:to="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9ee81414-d528-4639-a42e-8eb78acfda70_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6094457e-8311-4e1a-90b2-11ff888ddeae_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_20e64f1e-44ea-4091-bf59-76b0637677db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_cac536c2-b3d6-46e0-8a15-bd9dac2296c4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_8ec004e8-9f2d-4158-b31c-cfdd41fbcae2_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_07a0c851-ca31-4d40-9081-8b662944590d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsAxis_992239b0-f4fb-4258-9f4c-c4726c96ee23_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:label id="lab_us-gaap_DividendsAxis_label_en-US" xlink:label="lab_us-gaap_DividendsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAxis" xlink:to="lab_us-gaap_DividendsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c055a-4091-76b8-a31e-5218f41372f9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c0f6c-49f0-795e-89bb-709013bcad74_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3d6d9adb-003e-4a57-9a57-96a505699022_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7356-a5d4-fab0f3a411c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1a3daaf8-9b04-4cf5-973a-ed40cf3c648a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2195460b-c476-43fe-8f28-729b4a90a298_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e0a9e6ed-25ca-406a-862d-607300b827a5_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dd07c982-6e35-4ec5-b9e6-8df78605a55c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_144f1abc-b5be-46ec-920d-e7b0c0d88a57_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_981422a9-1896-429b-bb6c-7e5887c4a382_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_d6791f50-d118-4cd0-9ba3-cb549078cecd_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_97d38cdc-249a-4539-aa10-9b53a991f2da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_935e198a-66cf-4a80-bd7f-016011645653_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c7001-5c65-7826-85b8-6a111ea8d1a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_767cc947-7754-4fec-a3f4-599050826349_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019c0f8c-28b5-7d55-a16e-2b010f111cea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares, acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019b3669-9643-7900-82c2-8f1959c86b63_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares, acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_090e0108-fc67-475f-928e-471ff087aeb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad3-f077-7fc2-ba8b-dd877c568cc4_terseLabel_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_label_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:label id="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_documentation_en-US" xlink:label="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:to="lab_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10c6de95-00a3-47d5-85ff-ddff9ed61070_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7d6daba3-3195-457a-ac1e-1d2e4c0cdc5b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5290711a-94bd-4b79-833b-82f0240cf173_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f8a21447-2f6b-4cde-81a7-6310ecc03777_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AccruedManufacturingCostsCurrent_81ba6c7f-288c-4b05-a5e8-35dee841a4e2_terseLabel_en-US" xlink:label="lab_kros_AccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued external manufacturing costs</link:label>
    <link:label id="lab_kros_AccruedManufacturingCostsCurrent_label_en-US" xlink:label="lab_kros_AccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Costs, Current</link:label>
    <link:label id="lab_kros_AccruedManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_kros_AccruedManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedManufacturingCostsCurrent" xlink:href="kros-20251231.xsd#kros_AccruedManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AccruedManufacturingCostsCurrent" xlink:to="lab_kros_AccruedManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8e719e56-a16c-4eaf-89e7-a32b3d1709df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_NimaFarzanMember_label_en-US" xlink:label="lab_kros_NimaFarzanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nima Farzan [Member]</link:label>
    <link:label id="lab_kros_NimaFarzanMember_documentation_en-US" xlink:label="lab_kros_NimaFarzanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nima Farzan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NimaFarzanMember" xlink:href="kros-20251231.xsd#kros_NimaFarzanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_NimaFarzanMember" xlink:to="lab_kros_NimaFarzanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4a24b9a-f679-4e2f-a2e4-31935e62e2a1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_c975211a-6a57-4c12-89d7-95d87daf87d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Waltham lease for additional period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_76bfee4f-38ff-4b0e-a5b1-01cef1d6e350_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_edabc2b6-716d-48cb-9fc0-d5e9e73b8ac3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d8d30656-ab69-4f96-9d45-094f46fd2cec_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDomain_63d5b65c-f959-45fd-8b89-df84a1bffbac_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:label id="lab_us-gaap_DividendsDomain_label_en-US" xlink:label="lab_us-gaap_DividendsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDomain" xlink:to="lab_us-gaap_DividendsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_5c4048e0-9599-40c3-8c19-17222305e340_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Included in the consolidated balance sheet:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b275591f-cbc7-4459-9692-a5b7831d97bc_negatedTerseLabel_en-US" xlink:label="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Right of Use Asset</link:label>
    <link:label id="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Right of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="kros-20251231.xsd#kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PrepaidExternalRDCostsCurrent_d8bdfe40-4766-4bda-8d14-855c309fddfa_terseLabel_en-US" xlink:label="lab_kros_PrepaidExternalRDCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid external R&amp;D costs</link:label>
    <link:label id="lab_kros_PrepaidExternalRDCostsCurrent_label_en-US" xlink:label="lab_kros_PrepaidExternalRDCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid External R&amp;D Costs, Current</link:label>
    <link:label id="lab_kros_PrepaidExternalRDCostsCurrent_documentation_en-US" xlink:label="lab_kros_PrepaidExternalRDCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid External R&amp;D Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalRDCostsCurrent" xlink:href="kros-20251231.xsd#kros_PrepaidExternalRDCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PrepaidExternalRDCostsCurrent" xlink:to="lab_kros_PrepaidExternalRDCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fb161afe-fad3-44ae-8adb-fd4680a21b16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d89ab434-d941-465b-83e8-337e8e82ddc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_OperatingLossCarryforwardWriteOff_019c970f-2dd8-7a86-8a34-2d5f35878cef_terseLabel_en-US" xlink:label="lab_kros_OperatingLossCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforward, written off</link:label>
    <link:label id="lab_kros_OperatingLossCarryforwardWriteOff_label_en-US" xlink:label="lab_kros_OperatingLossCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Write Off</link:label>
    <link:label id="lab_kros_OperatingLossCarryforwardWriteOff_documentation_en-US" xlink:label="lab_kros_OperatingLossCarryforwardWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward, Write Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OperatingLossCarryforwardWriteOff" xlink:href="kros-20251231.xsd#kros_OperatingLossCarryforwardWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_OperatingLossCarryforwardWriteOff" xlink:to="lab_kros_OperatingLossCarryforwardWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_bf88713a-66e7-4404-bd1d-574c8173123d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_6f9f9a3d-f84b-4f96-88f6-6009984242d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_891e9150-011b-474b-bbcf-a5dd573d6174_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c2a1bc7e-10f4-43e0-8601-5888bf6a0a9d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_019c0fe8-83c9-71b4-b195-4a9e50b1df6e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_25944fff-a8a7-44ee-bcf3-ddffcd5d56b4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f5d90c5d-ba31-48a0-a5cf-eb58977bc579_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_TreasuryStockPolicyTextBlock_019c0f92-bf1b-7d08-b902-135793ebd266_terseLabel_en-US" xlink:label="lab_kros_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_kros_TreasuryStockPolicyTextBlock_label_en-US" xlink:label="lab_kros_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Policy Text Block]</link:label>
    <link:label id="lab_kros_TreasuryStockPolicyTextBlock_documentation_en-US" xlink:label="lab_kros_TreasuryStockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TreasuryStockPolicyTextBlock" xlink:href="kros-20251231.xsd#kros_TreasuryStockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_TreasuryStockPolicyTextBlock" xlink:to="lab_kros_TreasuryStockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0f97-4186-71d0-a99d-7e23f1684665_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019b366a-4d1f-7ab3-8dbb-bcde338bfc52_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3322c09d-a053-47c1-897e-035e120c2e23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7a1f-951e-555b9c4240dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019c0f79-9a8e-79b2-b24d-0bb17d4b0fad_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_3619312f-2a0b-48ec-8cda-7733371f06da_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_b3b6d154-cb97-4f32-8f4d-716a850103a0_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8faa06ff-d13d-4cc0-9917-efad87687b2e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_983cdff1-e8bd-41e0-97eb-5d5925daec03_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_6e1f6e05-72eb-4e66-9cc2-5a0bacafbf45_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3fd9e53c-76ac-4cc1-8500-dd89f9eb7140_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">INCOME (LOSS) FROM OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PrepaidExternalManufacturingCostsCurrent_774475e2-8406-4225-936b-674735fa1878_terseLabel_en-US" xlink:label="lab_kros_PrepaidExternalManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid external manufacturing costs</link:label>
    <link:label id="lab_kros_PrepaidExternalManufacturingCostsCurrent_label_en-US" xlink:label="lab_kros_PrepaidExternalManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid External Manufacturing Costs, Current</link:label>
    <link:label id="lab_kros_PrepaidExternalManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_kros_PrepaidExternalManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid External Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalManufacturingCostsCurrent" xlink:href="kros-20251231.xsd#kros_PrepaidExternalManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PrepaidExternalManufacturingCostsCurrent" xlink:to="lab_kros_PrepaidExternalManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ce452ad9-2406-45c9-8ad1-4afd033fac9c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LicenseAgreementUpfrontFee_019c0fdf-7403-774e-8f16-e3c49fadd0ee_terseLabel_en-US" xlink:label="lab_kros_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License agreement upfront fee</link:label>
    <link:label id="lab_kros_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_kros_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Upfront Fee</link:label>
    <link:label id="lab_kros_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_kros_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Upfront Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAgreementUpfrontFee" xlink:href="kros-20251231.xsd#kros_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LicenseAgreementUpfrontFee" xlink:to="lab_kros_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c7006-2d0c-72ac-b2d5-7000309aeb90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_be70de3b-24f8-4e4d-b552-71081b927a29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of fixed asset</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_37cb5ca0-5299-4c2d-b682-395159efda9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7001-9421-7c85-8825-b00f6ba85c2f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_176e20bc-4079-4b27-80ca-06f232f6af12_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9dd3f542-887e-46b5-b53c-5112d7aef7bf_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_86fa4a6b-a865-4d4b-956c-a9bc8134ded5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2c67b1cc-a79a-4641-91ab-cd7e9ae45795_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_16f529aa-756a-4f80-abcb-399ff0b0f6d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_5ea03ba9-07f0-46af-b74d-4f2feaa84d4a_terseLabel_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award, annual increase percent of shares outstanding</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_label_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Annual Increase Percent of Shares Outstanding</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_documentation_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Annual Increase Percent of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:to="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_15f8f277-727d-4a42-812e-51e095449e4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_4b051f9a-18d0-4a46-aeef-3c89a26c1929_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3a83b0d8-2a76-424a-a492-6d1791bc345c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_40d50f00-f648-4a28-8075-a8b2e8b51fe1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_254d3216-983b-4174-97d3-c64f6b082379_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e49b886f-0e86-4183-972d-8c4656b0cf7a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd6dc66d-a611-477d-8b53-8b0ff2bf8990_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_68524e65-8ae3-4fe7-a4c8-15da6acb4a8c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_ac68ae2a-e4c2-4955-b876-121cc632c52b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e8735a03-042a-4e4f-bd12-4b1330eb6f29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_2e365066-5961-4cf2-8cf3-8bd28fc0a19b_terseLabel_en-US" xlink:label="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2031</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_label_en-US" xlink:label="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Six</link:label>
    <link:label id="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_documentation_en-US" xlink:label="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseLiabilityToBePaidYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:to="lab_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c7003-91f9-7037-81b7-a17c4008d79e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in taw laws or rates enacted in the current period</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5c15dc5d-78f5-4e06-95ee-fc291bfe8261_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_429222b8-52f3-447a-bfe0-21a4bebcb929_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_d2c05c1c-e83b-4109-90e7-fadc378db3a7_terseLabel_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, development milestones, variable consideration</link:label>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_label_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Development Milestones, Variable Consideration</link:label>
    <link:label id="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_documentation_en-US" xlink:label="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Development Milestones, Variable Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:to="lab_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_543d12a6-f7fe-4e90-84e9-3c7c70a924e1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_f5b69908-9a05-4f2c-818a-a79948b5eb7b_terseLabel_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGGREGATE INTRINSIC VALUE</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_label_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:to="lab_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_85522574-fb62-455b-b03d-c1085e126983_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Commercial Milestone</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Agreement, Contract To Perform For Others, Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:to="lab_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ff90b778-00d4-492f-89f0-77c466e86fe0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_a7ed48e4-24ee-4bcf-9b48-ec78a7660b0a_terseLabel_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for achievement of clinical and regulatory milestones</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_label_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Payment For Achievement Of Clinical And Regulatory Milestone</link:label>
    <link:label id="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_documentation_en-US" xlink:label="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Payment For Achievement Of Clinical And Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:to="lab_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_73116e33-cec1-404a-824a-aff292c49a91_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b177b813-3105-4921-a106-e19b27795dc3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3aab3256-4e46-4262-9c13-2e8566926d74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_019c1002-84f6-7e20-b108-884fb68c3497_terseLabel_en-US" xlink:label="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:href="kros-20251231.xsd#kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_019cb58b-ae0e-730d-9ce2-5309566003bb_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 21,126,760 and no shares as of December&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_019c46cd-2992-7169-91ff-33939a8b139e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d646971f-0a70-4a09-b5d8-fbca644bf9a5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7931-b673-d36653a377bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_300d4d9a-d937-4a04-aafb-83ef8ab31619_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate &#8212; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_63712b46-a8d4-4af6-99ed-8911c89b8381_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6f8235d-e504-4a1f-99e6-57ce550274b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f38aa7e-a0c5-45df-a3d4-8d90628d94bd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common stock outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e0cd0a88-ac41-4904-b903-d626fe8e3fd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_O2025Q1DividendsMember_98e9ff72-ed56-48f6-be0f-7886475ca016_terseLabel_en-US" xlink:label="lab_kros_O2025Q1DividendsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">O2025Q1Dividends</link:label>
    <link:label id="lab_kros_O2025Q1DividendsMember_label_en-US" xlink:label="lab_kros_O2025Q1DividendsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">O 2025 Q1 Dividends [Member]</link:label>
    <link:label id="lab_kros_O2025Q1DividendsMember_documentation_en-US" xlink:label="lab_kros_O2025Q1DividendsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">O 2025 Q1 Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_O2025Q1DividendsMember" xlink:href="kros-20251231.xsd#kros_O2025Q1DividendsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_O2025Q1DividendsMember" xlink:to="lab_kros_O2025Q1DividendsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendAndInterestReceivable_51538795-9986-4851-a003-fdf27ef29f48_terseLabel_en-US" xlink:label="lab_us-gaap_DividendAndInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and dividend receivable</link:label>
    <link:label id="lab_us-gaap_DividendAndInterestReceivable_label_en-US" xlink:label="lab_us-gaap_DividendAndInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend and Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendAndInterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendAndInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendAndInterestReceivable" xlink:to="lab_us-gaap_DividendAndInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d0448223-927f-4e88-aa4b-9215e50c8f20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2c21e262-fc89-4fee-8219-815738b0dc51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_43739772-a97b-4d58-bd21-eb688e9c288b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_84bbce51-6d97-4f68-a741-c746fb073e98_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE), NET:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_245ef4ac-4eb1-42eb-9767-3326324ca623_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a7b33848-059a-4e7f-b2c9-a78d523cec27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_734f5cfb-38a2-4718-815f-6cf8fe748cd0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_175ffee5-a8b6-457d-8a14-7abe07ecb929_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe4317ec-841d-4d15-818c-23db30ba6fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_13720678-4e08-4f4e-868a-ffa19bcf7186_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d7d78c51-0416-468b-82e2-f4afa118aa97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes_a1af99ad-6324-4897-b8b7-c53eb521e5e6_terseLabel_en-US" xlink:label="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Withholding taxes from upfront fee</link:label>
    <link:label id="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes_label_en-US" xlink:label="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Withholding Taxes</link:label>
    <link:label id="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes_documentation_en-US" xlink:label="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Withholding Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:href="kros-20251231.xsd#kros_RevenueFromContractWithCustomerWithholdingTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:to="lab_kros_RevenueFromContractWithCustomerWithholdingTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_91556f83-952e-4739-b0fe-bdac8f44a69f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_27407cf1-b6a8-4664-896f-6aa2728cbdc3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term &#8212; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aa7831db-98e9-4f5d-aaea-b940728c3fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24617cb2-4687-437b-b30b-31d7a3088956_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AtTheMarketOfferingMember_89dbbfa5-f6b2-4950-95d1-aaf9fd4df18b_terseLabel_en-US" xlink:label="lab_kros_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_kros_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_kros_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_kros_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_kros_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AtTheMarketOfferingMember" xlink:to="lab_kros_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c7002-e4de-7f57-9f90-d65066f6842a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of cross-border tax laws</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_304d0ddd-4747-4226-a041-1828570a05c2_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_43c7d844-4c64-435c-b52a-6b546af4330f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0d8666e7-9288-47b6-8435-77a489996047_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7764-9870-81b0944cd0ab_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_08d0f9f8-f1ac-41f5-a7ee-fb06fc787302_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantees and Indemnifications</link:label>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_label_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_55c37a6f-c34d-49f3-a3e9-72d8cb2c0005_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_090a7519-536c-4617-a8ed-4847e0e78efd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled or forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_PaymentOfInitialPublicOfferingCosts_efd771b4-1de6-4991-808b-551eee73e159_negatedTerseLabel_en-US" xlink:label="lab_kros_PaymentOfInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs</link:label>
    <link:label id="lab_kros_PaymentOfInitialPublicOfferingCosts_label_en-US" xlink:label="lab_kros_PaymentOfInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Initial Public Offering Costs</link:label>
    <link:label id="lab_kros_PaymentOfInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_kros_PaymentOfInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfInitialPublicOfferingCosts" xlink:href="kros-20251231.xsd#kros_PaymentOfInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_PaymentOfInitialPublicOfferingCosts" xlink:to="lab_kros_PaymentOfInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_LicenseRevenueMember_9e0f947b-77b6-4004-afd8-eb3312222cfb_terseLabel_en-US" xlink:label="lab_kros_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_kros_LicenseRevenueMember_label_en-US" xlink:label="lab_kros_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License revenue [Member]</link:label>
    <link:label id="lab_kros_LicenseRevenueMember_documentation_en-US" xlink:label="lab_kros_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseRevenueMember" xlink:href="kros-20251231.xsd#kros_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_LicenseRevenueMember" xlink:to="lab_kros_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_362a6bfc-fc83-4b46-9020-ef28052b74a0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8685d685-1efd-4736-b6e6-1fc5eddb2eae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b064da74-73a0-457a-a9fd-5b8856f8910d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchases in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_95ff30c6-86ff-44f2-a3fa-87af670afc42_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, increase resulting from current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4b627e65-fd7f-4b40-ac8d-c8411f3be9f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a5670c3a-f77d-4a50-8bbb-2c1d6f0bab8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_584ee64d-b25c-499c-a809-e3e6cf5d9e9a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1969e76d-399c-4ce2-bd95-439663905abd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_019c98d5-1a01-716d-a5b6-2ede678670d3_terseLabel_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, cost not yet recognized, recognition expected</link:label>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_label_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Expected</link:label>
    <link:label id="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_documentation_en-US" xlink:label="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:to="lab_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b21b583-9af3-4aa5-a07a-b739c0e61ec0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_04283e01-b487-4e67-a156-d214efbd6a11_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c0fb5-6884-74a6-9192-1ac92281202d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c0fff-6f56-76c8-a6e0-8831d0984fc9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_783ee697-fe84-4778-9a46-078401dc1082_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Tax Credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_09b1d05c-bc7c-4745-affe-fa5ba5a35879_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_46887237-7749-4faa-b0e5-88f9803bd196_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_39c98d6a-b770-4908-95bb-0788e68eb243_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">COMMON STOCK</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0fba-8460-75d9-b06d-53e3d803c35a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_9a40efee-ca74-4701-ba3b-777e268e7c5f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_SalesTaxReceivableCurrent_30291bb4-fbc8-44fc-8a5c-b55e0c5f2d12_terseLabel_en-US" xlink:label="lab_kros_SalesTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid sales tax</link:label>
    <link:label id="lab_kros_SalesTaxReceivableCurrent_label_en-US" xlink:label="lab_kros_SalesTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Tax Receivable, Current</link:label>
    <link:label id="lab_kros_SalesTaxReceivableCurrent_documentation_en-US" xlink:label="lab_kros_SalesTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SalesTaxReceivableCurrent" xlink:href="kros-20251231.xsd#kros_SalesTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_SalesTaxReceivableCurrent" xlink:to="lab_kros_SalesTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_99115cac-1fc7-456c-a247-7ff8b2144704_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b33dc033-1a14-475a-94c0-67057ae287d5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_kros_AuditInformationAbstract_label_en-US" xlink:label="lab_kros_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_kros_AuditInformationAbstract_documentation_en-US" xlink:label="lab_kros_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AuditInformationAbstract" xlink:href="kros-20251231.xsd#kros_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_kros_AuditInformationAbstract" xlink:to="lab_kros_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_6528e4e4-126a-4caa-98a6-b52d527a6e1b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal and consultants</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bd3df161-8ec6-49e6-b16d-43391a511703_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>kros-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:edfce08a-e7b1-4838-a567-9c2308cf244f,g:8f9dd3c4-0a74-4e9d-9be2-9812ed7f125f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kerostx.com/role/CoverPage" xlink:type="simple" xlink:href="kros-20251231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7f707786-d59e-446a-8418-a7e13f6d9874" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7f707786-d59e-446a-8418-a7e13f6d9874" xlink:to="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c954c-f326-7998-9873-b21d7757ec54" xlink:to="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c954c-f326-7cb6-aef2-f1f79ba351e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:to="loc_us-gaap_CommonStockMember_019c954c-f326-7cb6-aef2-f1f79ba351e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_019c954c-f326-7ba0-8d00-65d2eca157e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c954c-f326-7082-bacc-18dfaba676f2" xlink:to="loc_us-gaap_PreferredStockMember_019c954c-f326-7ba0-8d00-65d2eca157e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019c954c-f326-76d8-81be-b0398c9e2ad5" xlink:to="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f98694cf-9071-436f-8b4e-674de9e81025" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentType_f98694cf-9071-436f-8b4e-674de9e81025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6e818e45-75e2-41d3-8716-8398d78ee946" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentAnnualReport_6e818e45-75e2-41d3-8716-8398d78ee946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6dd58991-74c2-4231-ae7b-74e2c31fd848" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentPeriodEndDate_6dd58991-74c2-4231-ae7b-74e2c31fd848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_34bdc193-3d47-4e72-8114-e560b01927d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_CurrentFiscalYearEndDate_34bdc193-3d47-4e72-8114-e560b01927d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e6161688-5c52-4a83-8288-0c314fda7df6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentTransitionReport_e6161688-5c52-4a83-8288-0c314fda7df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_282ef325-1987-49c3-9112-c3b0c2931854" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityFileNumber_282ef325-1987-49c3-9112-c3b0c2931854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b867636-c7dd-4d7c-b73e-9a3d944c6bb2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityRegistrantName_2b867636-c7dd-4d7c-b73e-9a3d944c6bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1fe0c180-7ccf-428a-8801-b018c209e818" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1fe0c180-7ccf-428a-8801-b018c209e818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_48135496-6dd0-4cc8-ae66-b6e124859fd2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityTaxIdentificationNumber_48135496-6dd0-4cc8-ae66-b6e124859fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3c436a79-4372-4fec-9622-70174b9832e1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressAddressLine1_3c436a79-4372-4fec-9622-70174b9832e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b4624d76-f8b9-45a1-ac24-e599a6da7238" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressAddressLine2_b4624d76-f8b9-45a1-ac24-e599a6da7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_68cb7b7a-ef0d-47b1-887c-3265031c3074" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressCityOrTown_68cb7b7a-ef0d-47b1-887c-3265031c3074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8db3db43-9c81-4fb3-82aa-7274884e04ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressStateOrProvince_8db3db43-9c81-4fb3-82aa-7274884e04ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0ffbc3c0-beea-4c91-ab5c-e09a9fd740e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityAddressPostalZipCode_0ffbc3c0-beea-4c91-ab5c-e09a9fd740e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_536c92d8-779c-4f9d-acd6-82e7a870c703" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_CityAreaCode_536c92d8-779c-4f9d-acd6-82e7a870c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5291939-8cd3-467b-bb30-9a43a0901af2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_LocalPhoneNumber_a5291939-8cd3-467b-bb30-9a43a0901af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_062843cc-cd9d-4131-916e-2f59546d67b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_Security12bTitle_062843cc-cd9d-4131-916e-2f59546d67b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ccfc5f64-3b57-429b-ba2f-a560aa09c7da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_TradingSymbol_ccfc5f64-3b57-429b-ba2f-a560aa09c7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3f671dea-971e-4190-b8dd-19fae59ba2b1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_SecurityExchangeName_3f671dea-971e-4190-b8dd-19fae59ba2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_019cafde-bc01-78b0-9d41-98a454831c98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_NoTradingSymbolFlag_019cafde-bc01-78b0-9d41-98a454831c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a72c97bf-fed8-4d2f-98f9-66592d3c42ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a72c97bf-fed8-4d2f-98f9-66592d3c42ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_df68f8fe-0200-44ea-b8f5-b1ecd43b996d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityVoluntaryFilers_df68f8fe-0200-44ea-b8f5-b1ecd43b996d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3901db50-2e04-43d8-afd7-7d34a0f1cb8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCurrentReportingStatus_3901db50-2e04-43d8-afd7-7d34a0f1cb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_07f5dacd-09dd-4abc-85d5-06f94a50e5c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityInteractiveDataCurrent_07f5dacd-09dd-4abc-85d5-06f94a50e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_354e8822-cff6-4393-b034-d9505bb34374" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityFilerCategory_354e8822-cff6-4393-b034-d9505bb34374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c452611d-6095-457a-a371-17b3885dff98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntitySmallBusiness_c452611d-6095-457a-a371-17b3885dff98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_51d29599-acd3-48b2-823e-5ca22a464344" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityEmergingGrowthCompany_51d29599-acd3-48b2-823e-5ca22a464344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8beb38c2-28a6-4874-a520-5874743ee97f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8beb38c2-28a6-4874-a520-5874743ee97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_762ad37b-1650-4ce8-901d-b0f151c15970" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_762ad37b-1650-4ce8-901d-b0f151c15970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ef6b1c7e-e554-4f52-988c-37a2bd447483" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityShellCompany_ef6b1c7e-e554-4f52-988c-37a2bd447483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4ee37626-a921-4189-bdac-d20d69bea4c8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityPublicFloat_4ee37626-a921-4189-bdac-d20d69bea4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ee211126-2b6b-4cab-84f0-5bd67c3c3a01" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ee211126-2b6b-4cab-84f0-5bd67c3c3a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_519724bb-2160-458d-8da2-a153f96499be" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_519724bb-2160-458d-8da2-a153f96499be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fef5d21c-5e51-4d98-a826-c0cd55da6299" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_EntityCentralIndexKey_fef5d21c-5e51-4d98-a826-c0cd55da6299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1718d567-d935-42ef-a38c-6daa553ee7d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_AmendmentFlag_1718d567-d935-42ef-a38c-6daa553ee7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e22d6d38-41e4-49ce-9a61-9e30afb011a8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e22d6d38-41e4-49ce-9a61-9e30afb011a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d8e831f8-d2d8-4844-9260-a6662c925beb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019c954c-f326-7a7d-bbce-1977a04ca161" xlink:to="loc_dei_DocumentFiscalYearFocus_d8e831f8-d2d8-4844-9260-a6662c925beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/AuditInformation" xlink:type="simple" xlink:href="kros-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_kros_AuditInformationAbstract_be211360-1572-47aa-97e7-51d69901e23f" xlink:href="kros-20251231.xsd#kros_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_4d72f8ca-de57-4c65-a186-53644e410c05" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_AuditInformationAbstract_be211360-1572-47aa-97e7-51d69901e23f" xlink:to="loc_dei_AuditorFirmId_4d72f8ca-de57-4c65-a186-53644e410c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_15093b64-c28b-4a8c-b6f4-aeba42d9d4d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_AuditInformationAbstract_be211360-1572-47aa-97e7-51d69901e23f" xlink:to="loc_dei_AuditorName_15093b64-c28b-4a8c-b6f4-aeba42d9d4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_34617750-fa71-4767-8434-6035df485eca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_AuditInformationAbstract_be211360-1572-47aa-97e7-51d69901e23f" xlink:to="loc_dei_AuditorLocation_34617750-fa71-4767-8434-6035df485eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f6eebffd-aff5-416e-8f35-215f9bf77e01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6eebffd-aff5-416e-8f35-215f9bf77e01" xlink:to="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b5ae22a7-b1b0-42bf-a601-b570731012cc" xlink:to="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c7e75212-8c89-455e-8d85-772679c7351e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_48835c98-e1e4-493a-b910-96637203ffaf" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c7e75212-8c89-455e-8d85-772679c7351e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25c892b4-f017-4a34-b8fa-73b36f95f92d" xlink:to="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:to="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e072475f-67df-4e32-99ec-1f5adc35a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e072475f-67df-4e32-99ec-1f5adc35a7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e986647a-ab39-4dde-9df8-99c89e58d991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e986647a-ab39-4dde-9df8-99c89e58d991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd599ced-3500-4bc7-ae50-8bd47221c429" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd599ced-3500-4bc7-ae50-8bd47221c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_019c6f85-88c1-7529-ae2d-00529b3f8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_IncomeTaxesReceivable_019c6f85-88c1-7529-ae2d-00529b3f8e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5835a10-4ab5-4717-8ebc-1a4da3e78633" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_797990a7-8eda-4e9f-9468-153dc7fac7f9" xlink:to="loc_us-gaap_AssetsCurrent_b5835a10-4ab5-4717-8ebc-1a4da3e78633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc89d89c-9a37-44ce-9269-41ff8d1c8209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc89d89c-9a37-44ce-9269-41ff8d1c8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_43f12bcf-a4aa-4456-9c3e-24aa49dc07c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_43f12bcf-a4aa-4456-9c3e-24aa49dc07c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8c99838d-111e-473a-8714-0206f4df5350" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8c99838d-111e-473a-8714-0206f4df5350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c1dd7ca1-34dc-4fdf-831e-5eb7d7871762" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c1dd7ca1-34dc-4fdf-831e-5eb7d7871762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_32240628-70f2-4a50-b9c8-7871e624d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_856ce08a-29b2-4531-a109-b81c4b390db3" xlink:to="loc_us-gaap_Assets_32240628-70f2-4a50-b9c8-7871e624d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7330b629-ec5c-49d2-8b93-fce98573c07b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed840214-c825-410e-a0fd-fa9a41bbce76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed840214-c825-410e-a0fd-fa9a41bbce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc8c0428-afba-4032-affd-4d3538fab54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cc8c0428-afba-4032-affd-4d3538fab54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0b420f31-8880-49a4-be00-631a062095fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0b420f31-8880-49a4-be00-631a062095fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5aa92e92-6a03-4dd6-afb4-8a80ee4ceaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9504c014-da14-4043-866c-d6250b5c934e" xlink:to="loc_us-gaap_LiabilitiesCurrent_5aa92e92-6a03-4dd6-afb4-8a80ee4ceaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5524784d-71da-4e69-830b-0254aac92a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5524784d-71da-4e69-830b-0254aac92a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe5205bd-7af8-44aa-9d94-0fac9b38bb46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_Liabilities_fe5205bd-7af8-44aa-9d94-0fac9b38bb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2fed36d1-5811-4b5f-adbb-8d78b187c95e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2fed36d1-5811-4b5f-adbb-8d78b187c95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8f6a8e7e-92e5-4fc7-b25b-099739a99191" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_PreferredStockValue_8f6a8e7e-92e5-4fc7-b25b-099739a99191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f00864d0-6d5c-49b8-927c-9aa4cdaaf66d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_CommonStockValue_f00864d0-6d5c-49b8-927c-9aa4cdaaf66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019c055e-d9ed-76fe-9668-1aa479b74373" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019c055e-d9ed-76fe-9668-1aa479b74373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9d3b530a-7dc2-4cab-8144-bfd75788dc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9d3b530a-7dc2-4cab-8144-bfd75788dc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6f3daff-d584-47a9-ae33-92ed30630343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e6f3daff-d584-47a9-ae33-92ed30630343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5951cac0-715b-4ec9-ac16-6aec0a2c748e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f5a3318c-aebe-4164-96ce-0acd0b0d82f0" xlink:to="loc_us-gaap_StockholdersEquity_5951cac0-715b-4ec9-ac16-6aec0a2c748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_67b2ffdd-4702-435c-acff-da85382cefc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3a695d40-e5dd-4f88-9519-868556e52024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_67b2ffdd-4702-435c-acff-da85382cefc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bed88f28-a375-4f44-af7c-92a116d200c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bed88f28-a375-4f44-af7c-92a116d200c0" xlink:to="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39fa36b1-ae82-4d4d-971b-a60cf7711044" xlink:to="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a41842ce-941a-47cc-90a1-44c6b3a305a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b16ecbbd-85d8-4de5-a0de-409242d1ba65" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a41842ce-941a-47cc-90a1-44c6b3a305a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38fce008-4e5a-49dd-b882-2eb9edfef85d" xlink:to="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245becde-2ce9-45be-9652-7ab52b91d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_245becde-2ce9-45be-9652-7ab52b91d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08aca755-f02b-49e7-93ae-a9a6b5b18d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08aca755-f02b-49e7-93ae-a9a6b5b18d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_df8a7edb-9ffa-45b7-aa5e-679deb97872e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_df8a7edb-9ffa-45b7-aa5e-679deb97872e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f420c758-96f6-4dfa-85f6-9b719a7f9f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f420c758-96f6-4dfa-85f6-9b719a7f9f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fcac3b1-46ec-4b41-92ee-8cd484802691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1fcac3b1-46ec-4b41-92ee-8cd484802691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f3684203-7557-4010-9088-8bf9bba622d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f3684203-7557-4010-9088-8bf9bba622d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1b7568ec-9a16-4301-828f-5dadbaab0879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_1b7568ec-9a16-4301-828f-5dadbaab0879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_86d52024-a086-439f-8583-36bae5cffd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_86d52024-a086-439f-8583-36bae5cffd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c055a-4091-780a-9f59-64dfe8abe0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45af51f1-b364-478a-a884-1c259505f6e2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c055a-4091-780a-9f59-64dfe8abe0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1f2e07bb-0b4b-4ed8-ae01-04068e471f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f2e07bb-0b4b-4ed8-ae01-04068e471f73" xlink:to="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:to="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_941c96b5-d99b-4ceb-8bad-9a0031f42db2" xlink:to="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_8778ddb7-3ebc-4fdc-a9c9-110f5d911758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:to="loc_us-gaap_ServiceOtherMember_8778ddb7-3ebc-4fdc-a9c9-110f5d911758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_e356967a-71f2-41a7-b881-d591379942ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0b8f531c-331e-4ba2-9aac-56340fa461ff" xlink:to="loc_us-gaap_LicenseMember_e356967a-71f2-41a7-b881-d591379942ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c172444f-a4dc-471f-8fe2-46341e510ed4" xlink:to="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ae0d1a-580e-440b-86c5-705f18040fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_74f13740-0924-41dd-8b18-5af65790fddf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1ae0d1a-580e-440b-86c5-705f18040fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3f30ad7b-25a7-4690-aaa4-419e89d3de23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3f30ad7b-25a7-4690-aaa4-419e89d3de23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5a002ea9-753e-4764-9fe2-0a4fd5d6de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5a002ea9-753e-4764-9fe2-0a4fd5d6de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d724de1e-e1b5-47a5-b285-e8037de55dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e1787f46-e409-42b8-ac34-bb0a3c0e349a" xlink:to="loc_us-gaap_OperatingExpenses_d724de1e-e1b5-47a5-b285-e8037de55dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74fccfc1-1d64-4681-ab0e-3a9ece6d0317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_OperatingIncomeLoss_74fccfc1-1d64-4681-ab0e-3a9ece6d0317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentIncentiveIncome_0438bd77-b3aa-4c53-9a79-3cad3de16792" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentIncentiveIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_kros_ResearchAndDevelopmentIncentiveIncome_0438bd77-b3aa-4c53-9a79-3cad3de16792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendIncomeOperating_130cdca1-0064-4235-879c-dc3095bbb9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendIncomeOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_DividendIncomeOperating_130cdca1-0064-4235-879c-dc3095bbb9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e347f88a-5991-4118-8931-a5b20a3e1b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e347f88a-5991-4118-8931-a5b20a3e1b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2be8f355-d742-4188-b469-f12d46d3dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_97c7f939-c730-4ef4-8f36-f037b159829d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2be8f355-d742-4188-b469-f12d46d3dff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35ee3aef-7f69-4b54-b665-dbd6b39c3f86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_35ee3aef-7f69-4b54-b665-dbd6b39c3f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e8e966c7-fe74-4de2-9a03-613cffeaa85f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e8e966c7-fe74-4de2-9a03-613cffeaa85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec993a56-1eb6-4137-b8ec-4930dc1e8382" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLoss_ec993a56-1eb6-4137-b8ec-4930dc1e8382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1eb0b504-9b1d-4efe-b865-38ac8c2d1083" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1eb0b504-9b1d-4efe-b865-38ac8c2d1083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba2f038c-6c66-405a-b8be-951f693c07b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ba2f038c-6c66-405a-b8be-951f693c07b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b8b53f8-5815-4040-ba43-ca2e1db0f757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b8b53f8-5815-4040-ba43-ca2e1db0f757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_186fde49-8758-47e1-a581-fb9d776b04ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_186fde49-8758-47e1-a581-fb9d776b04ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5a3084e8-8407-4caf-80b0-d49a90900fae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_EarningsPerShareBasic_5a3084e8-8407-4caf-80b0-d49a90900fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5b57d011-f331-438a-b8b2-7342068de500" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_73eceb96-acd2-444b-a56a-cb6270d62c76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5b57d011-f331-438a-b8b2-7342068de500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5207bcba-c96c-4f64-a182-93d740a86089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5207bcba-c96c-4f64-a182-93d740a86089" xlink:to="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_530ee5dc-6bb9-4ee1-bee4-b8f95dd3d455" xlink:to="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72f861c4-34de-4dfd-85c2-db606b884e78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_CommonStockMember_72f861c4-34de-4dfd-85c2-db606b884e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0f5c-cd42-7306-9056-061db57ffe45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0f5c-cd42-7306-9056-061db57ffe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2b345b7b-2ce9-4cef-98e1-eef251b7a43b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2b345b7b-2ce9-4cef-98e1-eef251b7a43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9a2ad634-387e-4b32-bc7e-23e265d9420f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d89a157-4610-4aa3-a2d8-febd671ac98d" xlink:to="loc_us-gaap_RetainedEarningsMember_9a2ad634-387e-4b32-bc7e-23e265d9420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2574193e-0989-4dd0-8e8d-1cd0711be32e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_76f027fa-42c6-45df-8c58-584645b9404a" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6051f309-9351-4334-baf1-23882caba220" xlink:to="loc_kros_AtTheMarketOfferingMember_76f027fa-42c6-45df-8c58-584645b9404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8107380a-f426-464e-ae7d-bd2aff5f9709" xlink:to="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e3c6d6fb-ce79-447f-87ec-78d169fb638e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0169971a-5b14-4971-a62f-02b29afb20ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_SharesOutstanding_0169971a-5b14-4971-a62f-02b29afb20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d644be49-281d-4514-bb68-23a09115336d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockholdersEquity_d644be49-281d-4514-bb68-23a09115336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c0f5c-0438-7c31-a58b-ca7cccffb713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c0f5c-0438-7c31-a58b-ca7cccffb713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbdf15e2-ed11-4723-81e2-2fa254ff096d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dbdf15e2-ed11-4723-81e2-2fa254ff096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aec3819b-b3a9-4834-b9ac-d274915ad731" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_aec3819b-b3a9-4834-b9ac-d274915ad731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e072d0f4-884f-41ec-8b09-b07e33f3d8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e072d0f4-884f-41ec-8b09-b07e33f3d8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3850d895-ebc4-43fe-9111-17a56ec8ebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3850d895-ebc4-43fe-9111-17a56ec8ebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0f60-6466-7ad5-97da-315be94e24e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0f60-6466-7ad5-97da-315be94e24e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0f60-9bc5-7fc2-84ef-ad817409dcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0f60-9bc5-7fc2-84ef-ad817409dcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShortSwingProfitSettlement_019c0f69-28c3-7809-8221-d57dbe2639ed" xlink:href="kros-20251231.xsd#kros_ShortSwingProfitSettlement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_kros_ShortSwingProfitSettlement_019c0f69-28c3-7809-8221-d57dbe2639ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0250e68b-51f2-45fa-bed6-2ccc043456c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0250e68b-51f2-45fa-bed6-2ccc043456c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b2ad860-0b45-45f1-9496-85bf8c15cfac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1b2ad860-0b45-45f1-9496-85bf8c15cfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019c0f6a-f265-721d-b161-f02708dde5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_019c0f6a-f265-721d-b161-f02708dde5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d640e12c-5c70-4617-835d-288c7df34d25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d640e12c-5c70-4617-835d-288c7df34d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62d58823-a534-4355-b986-b56e20358303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_NetIncomeLoss_62d58823-a534-4355-b986-b56e20358303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e8964a5f-0723-4da4-9158-1c81b96b92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_SharesOutstanding_e8964a5f-0723-4da4-9158-1c81b96b92d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bafa054-3309-40ae-bc39-64ef1bcc40f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_StockholdersEquity_2bafa054-3309-40ae-bc39-64ef1bcc40f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c0f6c-49f0-7845-8bd6-8c3fb2dc9b84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c0f6c-49f0-7845-8bd6-8c3fb2dc9b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_019c96dc-d1f3-7410-8c9b-70e188e2cf1b" xlink:href="kros-20251231.xsd#kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_acd18840-88a9-4aaa-84c4-c3f64797287a" xlink:to="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_019c96dc-d1f3-7410-8c9b-70e188e2cf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6ccf545-7a25-41b2-b625-63a66c76c367" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6ccf545-7a25-41b2-b625-63a66c76c367" xlink:to="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9580b7ec-b2d9-49b0-90ed-60bfed6cfdba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_a879a048-abaa-4d4a-bd35-1e9f069a1d30" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2e743c56-1ba1-4239-9067-01c998996448" xlink:to="loc_kros_AtTheMarketOfferingMember_a879a048-abaa-4d4a-bd35-1e9f069a1d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a6c69892-879c-40da-90ac-91c365cbf468" xlink:to="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c98428c-a2f8-40b8-b2f3-55f13791e937" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0c98428c-a2f8-40b8-b2f3-55f13791e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_80a04cb3-0b59-4691-9ec2-cd1d32b408b3" xlink:href="kros-20251231.xsd#kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts_80a04cb3-0b59-4691-9ec2-cd1d32b408b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_019c96db-95fb-7843-94a9-bea01cc6d4b8" xlink:href="kros-20251231.xsd#kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2414aaa2-fc61-48b7-b657-f94fb64303aa" xlink:to="loc_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses_019c96db-95fb-7843-94a9-bea01cc6d4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="kros-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bd1a162a-cb2d-4b5f-8b3a-c38842ff8be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd1a162a-cb2d-4b5f-8b3a-c38842ff8be2" xlink:to="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5ea9dbd9-6b46-41fa-9358-ac1dc3f53228" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SecondaryOfferingMember_31295533-4da5-470e-9c5f-1a86b0219c69" xlink:href="kros-20251231.xsd#kros_SecondaryOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:to="loc_kros_SecondaryOfferingMember_31295533-4da5-470e-9c5f-1a86b0219c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_749c3e91-61f7-4eb0-9309-867883c515d8" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70f91aa4-0e1b-4efb-a531-cc0407cdf803" xlink:to="loc_kros_AtTheMarketOfferingMember_749c3e91-61f7-4eb0-9309-867883c515d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3e4a28a-6954-49f0-8893-c71e2a550658" xlink:to="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_984593ee-303e-420f-b6f5-30fe341f6d62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_NetIncomeLoss_984593ee-303e-420f-b6f5-30fe341f6d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4b0a5ae3-7ce7-4f0e-9ad2-61eafd15b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_Depreciation_4b0a5ae3-7ce7-4f0e-9ad2-61eafd15b2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8940351d-59c4-49e2-b4e2-395677f16f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8940351d-59c4-49e2-b4e2-395677f16f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_55fbd09d-15c4-4233-802b-930c8a58884a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_ShareBasedCompensation_55fbd09d-15c4-4233-802b-930c8a58884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_671f6e16-0d38-4bfc-920b-fb050133c150" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_671f6e16-0d38-4bfc-920b-fb050133c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_601e8cf5-a0b9-4577-ae2e-2caf42528478" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e28dff26-573d-4166-9501-cc0778dc71d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e28dff26-573d-4166-9501-cc0778dc71d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2ba8430f-f086-4c90-9b53-7656af636746" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2ba8430f-f086-4c90-9b53-7656af636746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6f9f-798d-76c8-b7a1-43b296c7f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_019c6f9f-798d-76c8-b7a1-43b296c7f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_736f3ea2-89aa-4712-8f5b-a9d2735bfc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_736f3ea2-89aa-4712-8f5b-a9d2735bfc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_37df1a6e-db00-407e-95f5-2f3bad2445fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_37df1a6e-db00-407e-95f5-2f3bad2445fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_c5ebd775-b56a-4e4e-ac59-734a795acbf1" xlink:href="kros-20251231.xsd#kros_RightToUseAssetsAndOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_kros_RightToUseAssetsAndOperatingLeaseLiabilities_c5ebd775-b56a-4e4e-ac59-734a795acbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_941238c7-73a2-43ae-9aaa-a962b2a87258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03b432ad-0441-40de-b06f-1b7fa6bb8fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_941238c7-73a2-43ae-9aaa-a962b2a87258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ea84c50-e039-4daa-b4aa-b251eb505d26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d460978a-f190-4508-bb74-f03e7d53a7ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ea84c50-e039-4daa-b4aa-b251eb505d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_344430be-5ed5-474a-b41f-c774bdb86d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_344430be-5ed5-474a-b41f-c774bdb86d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_264f0f02-5a3b-4840-ae6b-7eefb11b97e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4177cd39-221b-4306-b48a-2376bf6bde76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_264f0f02-5a3b-4840-ae6b-7eefb11b97e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e55d029-cf5f-4ea7-bde6-5bc61bbd5004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e55d029-cf5f-4ea7-bde6-5bc61bbd5004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfInitialPublicOfferingCosts_82c6c7ce-ae66-445e-8858-e88dfb54ad83" xlink:href="kros-20251231.xsd#kros_PaymentOfInitialPublicOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_PaymentOfInitialPublicOfferingCosts_82c6c7ce-ae66-445e-8858-e88dfb54ad83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6deb6096-c171-4f25-aa70-dad5d0b99e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6deb6096-c171-4f25-aa70-dad5d0b99e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019c0f79-9a8e-7c78-9881-27cbcff5aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019c0f79-9a8e-7c78-9881-27cbcff5aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0f7b-c924-7a95-bc7c-b98bd395a698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0f7b-c924-7a95-bc7c-b98bd395a698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PaymentOfStockRepurchaseCosts_019c96f6-ccc9-79cd-9084-0aaac318445d" xlink:href="kros-20251231.xsd#kros_PaymentOfStockRepurchaseCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_PaymentOfStockRepurchaseCosts_019c96f6-ccc9-79cd-9084-0aaac318445d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ProceedsFromShortSwingSettlementProfit_019c9551-edef-702e-bbff-011dae4dfeaf" xlink:href="kros-20251231.xsd#kros_ProceedsFromShortSwingSettlementProfit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_kros_ProceedsFromShortSwingSettlementProfit_019c9551-edef-702e-bbff-011dae4dfeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1dc18265-3d0d-4a52-8a15-f9578b5ba756" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1dc18265-3d0d-4a52-8a15-f9578b5ba756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7afd6e96-70d3-4b28-91c9-052a53b76d97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f727123-1e57-40f4-b870-b903988dbcae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7afd6e96-70d3-4b28-91c9-052a53b76d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_041775e8-ccbb-4711-9575-d997aa45c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_041775e8-ccbb-4711-9575-d997aa45c6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f62c463-3cd0-48ef-86ce-b86ee7edea5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f62c463-3cd0-48ef-86ce-b86ee7edea5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8deee54-a73e-41d4-8449-2b36feef1008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8deee54-a73e-41d4-8449-2b36feef1008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c0f7f-e11a-7b44-9838-6b78b1e7f67f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c0f7f-e11a-7b44-9838-6b78b1e7f67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58e5f7b5-a97a-4fe6-8dd2-086c45f0c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58e5f7b5-a97a-4fe6-8dd2-086c45f0c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_019c0f85-32d6-7835-94e6-6bc3b7e5ddc6" xlink:href="kros-20251231.xsd#kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses_019c0f85-32d6-7835-94e6-6bc3b7e5ddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_99ce6c64-3162-4996-a45d-e40935d1718d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f37d2025-c077-4cf6-929e-20b9de7f4f65" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_99ce6c64-3162-4996-a45d-e40935d1718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_077fdc89-8bb1-407e-b922-9a90382136de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8815b2c-1a43-425a-9cbc-01d81a212555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8815b2c-1a43-425a-9cbc-01d81a212555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_002c2f31-af0e-43d2-8ab8-5ecb94150d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:to="loc_us-gaap_RestrictedCash_002c2f31-af0e-43d2-8ab8-5ecb94150d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_710a669c-5caa-4488-a8db-bf1f112bdb83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_54ea51a6-c77e-40da-959a-05b961a78f55" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_710a669c-5caa-4488-a8db-bf1f112bdb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="kros-20251231.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbd64026-af95-424c-9897-461f6e5be816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f1844c46-b9ef-4cef-88db-65469ba0c037" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbd64026-af95-424c-9897-461f6e5be816" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f1844c46-b9ef-4cef-88db-65469ba0c037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_70108710-82de-403b-b56c-99c314f8261a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4a4a1b69-4702-4935-b36f-d60a29d20735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70108710-82de-403b-b56c-99c314f8261a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4a4a1b69-4702-4935-b36f-d60a29d20735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="kros-20251231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52e718de-62fe-4ff5-aa03-6f3d8258c5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_97546172-78fe-4301-8a30-9d062d7adb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52e718de-62fe-4ff5-aa03-6f3d8258c5b4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_97546172-78fe-4301-8a30-9d062d7adb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="kros-20251231.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4860bfbd-0ef8-433b-a2aa-894cbf848bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_ce2af25d-e0d8-4922-9524-96f1eb756a51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4860bfbd-0ef8-433b-a2aa-894cbf848bcb" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_ce2af25d-e0d8-4922-9524-96f1eb756a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNET"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_01c44c7d-7d11-4d51-8242-22a3f01d1e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b8b4e894-623c-462d-8b6e-3971eb0a5235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_01c44c7d-7d11-4d51-8242-22a3f01d1e8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b8b4e894-623c-462d-8b6e-3971eb0a5235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="kros-20251231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_92849a6c-a8dc-4c7c-b10b-7ab5ee1293dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_c2affd42-8557-48fb-b82a-36c55334937d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_92849a6c-a8dc-4c7c-b10b-7ab5ee1293dd" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_c2affd42-8557-48fb-b82a-36c55334937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="kros-20251231.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_959060b0-3e4e-44ca-86ed-dec59ac7e545" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_8bce3c00-0b41-4eeb-9b25-0d7f0d932dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_959060b0-3e4e-44ca-86ed-dec59ac7e545" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_8bce3c00-0b41-4eeb-9b25-0d7f0d932dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7234c41e-5656-4de9-a6d4-f4823d6664c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b7f9b727-4dc8-49c3-a70a-7c288fcb67c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7234c41e-5656-4de9-a6d4-f4823d6664c2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b7f9b727-4dc8-49c3-a70a-7c288fcb67c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/TREASURYSTOCK" xlink:type="simple" xlink:href="kros-20251231.xsd#TREASURYSTOCK"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/TREASURYSTOCK" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b3629-21e3-7ce7-9646-75369a9b6680" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_019b3629-cb7a-7183-84df-187766af15ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b3629-21e3-7ce7-9646-75369a9b6680" xlink:to="loc_us-gaap_TreasuryStockTextBlock_019b3629-cb7a-7183-84df-187766af15ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b469fe0-c4af-4a0a-b45d-aec8f68e5869" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fd8d37dd-8470-4eae-89f3-f46b1dabce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b469fe0-c4af-4a0a-b45d-aec8f68e5869" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fd8d37dd-8470-4eae-89f3-f46b1dabce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHARE" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-7017-a978-0d82123c50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019c0fbe-e67d-76e1-a74f-e77fe498bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-7017-a978-0d82123c50d8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019c0fbe-e67d-76e1-a74f-e77fe498bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXES" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_67999e66-09f7-49ed-b4c7-3825a180b9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_61936a8e-c661-4836-9950-cb5d3b67a198" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_67999e66-09f7-49ed-b4c7-3825a180b9f0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_61936a8e-c661-4836-9950-cb5d3b67a198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASES" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019c46cd-ec18-770c-97a0-8a10af41e889" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_019c46cd-ec18-77f6-a980-cb9d0465ced4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019c46cd-ec18-770c-97a0-8a10af41e889" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_019c46cd-ec18-77f6-a980-cb9d0465ced4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="kros-20251231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c46d2-d9ce-71b1-8416-28e14af9806d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c46d3-5d54-7f64-b5d8-df8edb6f0fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c46d2-d9ce-71b1-8416-28e14af9806d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_019c46d3-5d54-7f64-b5d8-df8edb6f0fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERS"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f79ba698-f08a-4fd1-8f74-8792bf516233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9fe3e577-f03f-4222-b1cc-6467a2085e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f79ba698-f08a-4fd1-8f74-8792bf516233" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9fe3e577-f03f-4222-b1cc-6467a2085e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="kros-20251231.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_16ea09a1-d53a-43ea-85bf-050aae585878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_22bc3751-8b91-4e4f-85f3-084cb9ab3d12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_16ea09a1-d53a-43ea-85bf-050aae585878" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_22bc3751-8b91-4e4f-85f3-084cb9ab3d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURING" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-72b5-ba9f-5ba7cf33ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c0fe8-83c9-7324-af41-797e0ca8ef9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-72b5-ba9f-5ba7cf33ff4a" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c0fe8-83c9-7324-af41-797e0ca8ef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa3709f1-1e85-4831-8d37-4586ec8bddfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa3709f1-1e85-4831-8d37-4586ec8bddfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2e302360-7ca4-49fb-85d3-ab24b7268fde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2e302360-7ca4-49fb-85d3-ab24b7268fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_56b73685-48f1-40eb-9cb9-56b74b695203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_UseOfEstimates_56b73685-48f1-40eb-9cb9-56b74b695203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c39ec621-9fd2-45db-9625-7bd6343a7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c39ec621-9fd2-45db-9625-7bd6343a7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5a3bbe93-9900-4cc2-bda3-a5d0f5df37a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5a3bbe93-9900-4cc2-bda3-a5d0f5df37a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7974ea7d-2584-4bed-aa5d-547f915e9013" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7974ea7d-2584-4bed-aa5d-547f915e9013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_600eaaf3-5a86-4cfe-9e44-e30cc2167a70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_600eaaf3-5a86-4cfe-9e44-e30cc2167a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3cd2f97a-8eed-4d05-8964-ba49b4fe2f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3cd2f97a-8eed-4d05-8964-ba49b4fe2f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_463082cf-c30c-4401-bd97-6262211ac96c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_463082cf-c30c-4401-bd97-6262211ac96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_b64b9fd7-52ca-4900-936b-2e275d869ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_b64b9fd7-52ca-4900-936b-2e275d869ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TreasuryStockPolicyTextBlock_019c0f92-bf1b-75cb-adcd-1e2c87719d1a" xlink:href="kros-20251231.xsd#kros_TreasuryStockPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_kros_TreasuryStockPolicyTextBlock_019c0f92-bf1b-75cb-adcd-1e2c87719d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_46f69137-470e-424e-827c-8855e8e477cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_46f69137-470e-424e-827c-8855e8e477cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c9eac54d-72af-46e6-8140-a411b561d473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c9eac54d-72af-46e6-8140-a411b561d473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e2ab1f6f-6932-4f5a-81a3-a2c9f5873076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e2ab1f6f-6932-4f5a-81a3-a2c9f5873076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ab03943a-ee0f-418a-9f94-4e8d5afa8551" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ab03943a-ee0f-418a-9f94-4e8d5afa8551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b519be17-c193-4bd7-9f15-99025f261fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b519be17-c193-4bd7-9f15-99025f261fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5ec5d922-0ee3-442e-81dc-7a314f6a72af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5ec5d922-0ee3-442e-81dc-7a314f6a72af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1606fc04-5ba4-450e-ae90-8098ca4a9664" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1606fc04-5ba4-450e-ae90-8098ca4a9664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0fbf69f9-2b39-4a68-ba71-aa2be7ab977f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0fbf69f9-2b39-4a68-ba71-aa2be7ab977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5511bd04-4325-4e42-be40-c1797b9958ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5511bd04-4325-4e42-be40-c1797b9958ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RisksAndUncertaintiesPolicyTextBlock_019c9541-4860-70d4-8173-5dd67194d186" xlink:href="kros-20251231.xsd#kros_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27a83824-b418-463a-a201-8d20301ced38" xlink:to="loc_kros_RisksAndUncertaintiesPolicyTextBlock_019c9541-4860-70d4-8173-5dd67194d186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9144a432-a8c2-41c8-8b6a-afc09e41346a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_53b6dafa-79d5-4d59-ae7a-57dba396e2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9144a432-a8c2-41c8-8b6a-afc09e41346a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_53b6dafa-79d5-4d59-ae7a-57dba396e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1ffdf94d-ba56-48e0-adeb-4d9b8d26ba27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9144a432-a8c2-41c8-8b6a-afc09e41346a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1ffdf94d-ba56-48e0-adeb-4d9b8d26ba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="kros-20251231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0707c7ee-4d4a-48ec-8b48-1212e5c84acb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eca19fde-088c-4319-93e9-3aa2993f29f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0707c7ee-4d4a-48ec-8b48-1212e5c84acb" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_eca19fde-088c-4319-93e9-3aa2993f29f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="kros-20251231.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_80ed32e1-7e5b-4ce8-9e32-18db27db6f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_eb6de36c-cff1-4f62-8474-8e6b65b77eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_80ed32e1-7e5b-4ce8-9e32-18db27db6f4f" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_eb6de36c-cff1-4f62-8474-8e6b65b77eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNETTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f529eab9-bd8e-4fef-af7a-b52353d6fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_91b5bebc-585b-47d7-a8d2-824734684a72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f529eab9-bd8e-4fef-af7a-b52353d6fb69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_91b5bebc-585b-47d7-a8d2-824734684a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="kros-20251231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0313a1fc-964c-42fb-933f-a11ec01d3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_906e61be-6fb7-4a48-8dda-7463b7929f18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0313a1fc-964c-42fb-933f-a11ec01d3b23" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_906e61be-6fb7-4a48-8dda-7463b7929f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6afc060a-a23a-4468-9125-282234dcb82f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_b996bca3-ffae-451b-bdb3-79801427b570" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6afc060a-a23a-4468-9125-282234dcb82f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_b996bca3-ffae-451b-bdb3-79801427b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00bb38f5-7d4d-4a37-b11b-8cde46616d37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c0fb5-6884-7bbe-a63f-02cb16cfdccd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00bb38f5-7d4d-4a37-b11b-8cde46616d37" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_019c0fb5-6884-7bbe-a63f-02cb16cfdccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8dd52fd-9ba8-4619-b946-671fa74c8a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00bb38f5-7d4d-4a37-b11b-8cde46616d37" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8dd52fd-9ba8-4619-b946-671fa74c8a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8ccea859-a38b-495d-a915-9f5e94d23fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00bb38f5-7d4d-4a37-b11b-8cde46616d37" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8ccea859-a38b-495d-a915-9f5e94d23fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_20d3a17e-b21b-47e7-8add-368a0f1bd6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00bb38f5-7d4d-4a37-b11b-8cde46616d37" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_20d3a17e-b21b-47e7-8add-368a0f1bd6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHARETables" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-715e-981f-5ff643950a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019c0fbe-e67d-77fd-a71f-67ad3e34c8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-715e-981f-5ff643950a4d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_019c0fbe-e67d-77fd-a71f-67ad3e34c8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019c0fbe-e67d-7d9a-89db-d2e14507395b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-715e-981f-5ff643950a4d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019c0fbe-e67d-7d9a-89db-d2e14507395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b482677f-614d-4c9f-902f-e96a2e81bf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9cd14b26-4ed2-4aab-9624-00fe051a721c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b482677f-614d-4c9f-902f-e96a2e81bf9d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9cd14b26-4ed2-4aab-9624-00fe051a721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e40c2350-2a7a-4c1b-9443-d1c26d54a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b482677f-614d-4c9f-902f-e96a2e81bf9d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e40c2350-2a7a-4c1b-9443-d1c26d54a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d0ba591-7288-484f-bb11-6f604da26d37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b482677f-614d-4c9f-902f-e96a2e81bf9d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d0ba591-7288-484f-bb11-6f604da26d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f8cc1ca6-c59c-4564-8f82-8a74ec357938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b482677f-614d-4c9f-902f-e96a2e81bf9d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f8cc1ca6-c59c-4564-8f82-8a74ec357938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESTables" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d37eaa8-f950-4e77-86ba-e7d95a88483a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_edb5c43c-e3b7-43fa-8b14-ec97c3f2e040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d37eaa8-f950-4e77-86ba-e7d95a88483a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_edb5c43c-e3b7-43fa-8b14-ec97c3f2e040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_df291022-91e5-47e0-8900-0abd1b661f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d37eaa8-f950-4e77-86ba-e7d95a88483a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_df291022-91e5-47e0-8900-0abd1b661f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERSTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fdc-3011-7549-a752-35db22a4e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019c0fdc-3011-7e66-9c4f-feb9db76502a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fdc-3011-7549-a752-35db22a4e71a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019c0fdc-3011-7e66-9c4f-feb9db76502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SEGMENTREPORTINGTables" xlink:type="simple" xlink:href="kros-20251231.xsd#SEGMENTREPORTINGTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SEGMENTREPORTINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6d5b40c5-2c49-4824-a3c4-a8e2278b1933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58ceed59-7e47-4a39-82c8-e849789dc624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6d5b40c5-2c49-4824-a3c4-a8e2278b1933" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58ceed59-7e47-4a39-82c8-e849789dc624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURINGTables"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-7899-83ad-96f9f2126c57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_019c0fe8-83c9-7650-bb77-4df55e76b275" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-7899-83ad-96f9f2126c57" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_019c0fe8-83c9-7650-bb77-4df55e76b275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0cb3a87-d61b-44c9-b932-9bbc83119812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f499e65-7ddc-4bd5-b1ba-226153e380aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0cb3a87-d61b-44c9-b932-9bbc83119812" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f499e65-7ddc-4bd5-b1ba-226153e380aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3809e01e-7acf-4e16-848c-07d36ab1e2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3809e01e-7acf-4e16-848c-07d36ab1e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfFinancialInstitutions_038ab734-84a6-4ced-9d1b-be0d7d0c3b85" xlink:href="kros-20251231.xsd#kros_NumberOfFinancialInstitutions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:to="loc_kros_NumberOfFinancialInstitutions_038ab734-84a6-4ced-9d1b-be0d7d0c3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentIncentiveIncome_b6a7a91c-2ad9-4a27-ac27-5b84f2cfdb7b" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentIncentiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:to="loc_kros_ResearchAndDevelopmentIncentiveIncome_b6a7a91c-2ad9-4a27-ac27-5b84f2cfdb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6bee9074-a913-4faa-89b9-1c1afd1dfc11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:to="loc_us-gaap_NumberOfReportableSegments_6bee9074-a913-4faa-89b9-1c1afd1dfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_068666d3-c8df-484d-b8a9-e3d8dd723cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f4786a2-79cb-4dbf-bb14-837fbed196eb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_068666d3-c8df-484d-b8a9-e3d8dd723cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9c66194-ca8b-4a45-a631-4cbdda96d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9c66194-ca8b-4a45-a631-4cbdda96d6c8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3d8a2037-4711-4a5a-b677-dc79cf7eea73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ComputerEquipmentAndSoftwareMember_82e4fa0f-7718-4ac8-8616-f2dacd3cc891" xlink:href="kros-20251231.xsd#kros_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_kros_ComputerEquipmentAndSoftwareMember_82e4fa0f-7718-4ac8-8616-f2dacd3cc891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_939471b8-ab40-4fd8-adeb-237187d4e618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_939471b8-ab40-4fd8-adeb-237187d4e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6c24bea0-24ca-4f1a-b7dd-741cdcbed01a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f9948b93-3835-4569-ae76-af182eb91f5b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6c24bea0-24ca-4f1a-b7dd-741cdcbed01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0fb7263c-3e33-4cb6-9bfe-f7088e4bda53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2ad3010c-4b0d-4b1f-87d6-32c5ea3518fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb983c54-4b71-44a0-bc76-072657b6c6d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2ad3010c-4b0d-4b1f-87d6-32c5ea3518fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df061b72-9226-451f-a4d8-e4802e7ff21c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df061b72-9226-451f-a4d8-e4802e7ff21c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a4aa6a08-a3f2-4840-827a-7e08ec23c74e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0f95-2362-7f99-b3d9-5f01eea89ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0f95-2362-7f99-b3d9-5f01eea89ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ffe5b3b-8b31-4e18-9b6f-6ef9268c5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ffe5b3b-8b31-4e18-9b6f-6ef9268c5ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1ce20144-21b1-4bce-b168-35e92feed215" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ebfa19a-05b5-4dac-a2ba-fa574e46fc3c" xlink:to="loc_us-gaap_EmployeeStockMember_1ce20144-21b1-4bce-b168-35e92feed215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_789dd6cb-522c-4f3e-8dd4-5f94739e1bcb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77b55d00-1d15-4607-9e37-4ce25891eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_afad7f05-d4e4-4c58-a693-246404c11fee" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77b55d00-1d15-4607-9e37-4ce25891eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02667456-9945-4a94-9e17-2786bdd541e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02667456-9945-4a94-9e17-2786bdd541e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ba7c381-341b-49f5-aba8-0ac1dc74fb93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d0cfc016-7eeb-4347-b4b3-518665c1b875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ebddd2a7-f2d3-4c51-9b56-3fb97b33d16a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d0cfc016-7eeb-4347-b4b3-518665c1b875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a84dce82-b55b-4c04-8fb2-96dc30c82a81" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2607011f-68d4-43cb-8913-362089ca61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2607011f-68d4-43cb-8913-362089ca61a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7661789b-0424-4f43-8485-490112cd5992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7661789b-0424-4f43-8485-490112cd5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8807d446-c315-43c6-acae-a901906a2abd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d9e9951e-d149-46b2-b5d5-9470aae424bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8807d446-c315-43c6-acae-a901906a2abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b48cf45-d484-4879-98d7-95f4844a5000" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e30f79e-fcc8-44f0-8fd9-8235bbcf5ae0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_855fab76-e1bd-4d8c-a0a3-b22b5e281c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_855fab76-e1bd-4d8c-a0a3-b22b5e281c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ccdc721-d9fe-4291-8e96-3fe84e95a943" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_32792378-62f8-490b-b426-59a47197d0e3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ccdc721-d9fe-4291-8e96-3fe84e95a943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalRDCostsCurrent_61f8b6e3-f985-4610-8b34-87b3636f5a75" xlink:href="kros-20251231.xsd#kros_PrepaidExternalRDCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_PrepaidExternalRDCostsCurrent_61f8b6e3-f985-4610-8b34-87b3636f5a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidExternalManufacturingCostsCurrent_ea303ba0-da98-41f4-939b-c3709f1b5a68" xlink:href="kros-20251231.xsd#kros_PrepaidExternalManufacturingCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_PrepaidExternalManufacturingCostsCurrent_ea303ba0-da98-41f4-939b-c3709f1b5a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SalesTaxReceivableCurrent_d0f83f9f-44ea-4348-b4c6-0ce2c2e88c27" xlink:href="kros-20251231.xsd#kros_SalesTaxReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_SalesTaxReceivableCurrent_d0f83f9f-44ea-4348-b4c6-0ce2c2e88c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_577896dc-638c-4e1d-af8f-2e18c77db534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_us-gaap_PrepaidInsurance_577896dc-638c-4e1d-af8f-2e18c77db534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidSubscriptionCurrent_7bd7bdaf-5ac1-4e26-bb88-c3eccfed4d8e" xlink:href="kros-20251231.xsd#kros_PrepaidSubscriptionCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_PrepaidSubscriptionCurrent_7bd7bdaf-5ac1-4e26-bb88-c3eccfed4d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendAndInterestReceivable_dd05f6af-c171-47d0-8397-2c8678e6f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendAndInterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_us-gaap_DividendAndInterestReceivable_dd05f6af-c171-47d0-8397-2c8678e6f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PrepaidLegalAndConsultants_019c0f98-d4ac-7edb-b011-67d64b80c0c9" xlink:href="kros-20251231.xsd#kros_PrepaidLegalAndConsultants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_PrepaidLegalAndConsultants_019c0f98-d4ac-7edb-b011-67d64b80c0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent_019c9585-f903-7605-a81e-ed8cb52d6c1f" xlink:href="kros-20251231.xsd#kros_RefundsDueFromContractResearchOrganizationsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_kros_RefundsDueFromContractResearchOrganizationsCurrent_019c9585-f903-7605-a81e-ed8cb52d6c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6752f4f1-fb7f-4efd-aaff-13846c628528" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_us-gaap_OtherAssetsCurrent_6752f4f1-fb7f-4efd-aaff-13846c628528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_08188380-0949-4479-b84d-7d5ad1623925" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_13598640-d007-4f77-b55b-84b060ebed54" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_08188380-0949-4479-b84d-7d5ad1623925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f8e814b-eac2-4fd2-8a56-f529808c0ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f8e814b-eac2-4fd2-8a56-f529808c0ebb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_84b856a0-236c-42a8-9991-8a48b09d70c8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ComputerEquipmentAndSoftwareMember_d81d4ba1-a3ab-42eb-a800-76f477e93313" xlink:href="kros-20251231.xsd#kros_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_kros_ComputerEquipmentAndSoftwareMember_d81d4ba1-a3ab-42eb-a800-76f477e93313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e3659cce-7488-4a1e-8755-f5cfed4ced6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e3659cce-7488-4a1e-8755-f5cfed4ced6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3919a65b-06cf-494a-a248-7dd820c6f255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5661039e-b488-4172-9b0a-02df55b0c3d4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3919a65b-06cf-494a-a248-7dd820c6f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf113adb-7e52-4b01-8a87-1130ce7ffd09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_650c3b7e-ed57-45ed-9ff2-d31b2ff4012e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_650c3b7e-ed57-45ed-9ff2-d31b2ff4012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f6a4302-fb32-4710-9730-c1b49f8bf8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f6a4302-fb32-4710-9730-c1b49f8bf8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_230a7061-9578-40b8-a576-08e3b90030c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4701d01-afd5-41b7-ba9f-96a9d0936be7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_230a7061-9578-40b8-a576-08e3b90030c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ae8093-1cea-4b9f-9691-1ec4b47d1fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction_ec5b4d21-7135-4016-ab6f-3bd535eb1f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ae8093-1cea-4b9f-9691-1ec4b47d1fd8" xlink:to="loc_us-gaap_DepreciationNonproduction_ec5b4d21-7135-4016-ab6f-3bd535eb1f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedResearchAndDevelopmentCostsCurrent_01552aa4-d05c-4f45-844d-1a239791101d" xlink:href="kros-20251231.xsd#kros_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_kros_AccruedResearchAndDevelopmentCostsCurrent_01552aa4-d05c-4f45-844d-1a239791101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccruedManufacturingCostsCurrent_dc6a3fb6-367c-49c8-bf2b-5238b52bab11" xlink:href="kros-20251231.xsd#kros_AccruedManufacturingCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_kros_AccruedManufacturingCostsCurrent_dc6a3fb6-367c-49c8-bf2b-5238b52bab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5fe803b-6442-4ec9-88f4-879bc39629ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5fe803b-6442-4ec9-88f4-879bc39629ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_019c0f9b-9c64-7653-a1d4-500ef1704f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_us-gaap_TaxesPayableCurrent_019c0f9b-9c64-7653-a1d4-500ef1704f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d98c8594-5499-42a3-9ebc-d388be92b08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d98c8594-5499-42a3-9ebc-d388be92b08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_171d79a6-df23-47fe-a019-98c84f3f5543" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_171d79a6-df23-47fe-a019-98c84f3f5543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c46c5d80-1376-424f-bef4-72231158198f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_badbe772-1976-4470-af1f-44d35fd120a2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c46c5d80-1376-424f-bef4-72231158198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LICENSEAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_8062fa6c-64aa-4ca3-b572-162db77facc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_8062fa6c-64aa-4ca3-b572-162db77facc8" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:to="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1ae507f7-7b5c-49e0-8743-ee3df4e2fd7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TheGeneralHospitalCorporationMember_d55826f7-ae97-4a66-b7a8-2fa75277db3e" xlink:href="kros-20251231.xsd#kros_TheGeneralHospitalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92c841e3-fa23-45d9-a7c2-69aa785ae455" xlink:to="loc_kros_TheGeneralHospitalCorporationMember_d55826f7-ae97-4a66-b7a8-2fa75277db3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_140d78bf-41b3-47da-9e7f-4b0850ac9e42" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_cf724682-fc7c-42d4-8736-4f214f339677" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f320e332-32b2-4017-882d-e63d71249dc0" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_cf724682-fc7c-42d4-8736-4f214f339677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b5da6b3e-88b9-4688-bc99-471e5b4b59f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_5babfa2d-55c6-4b2d-a1c1-93dded486820" xlink:href="kros-20251231.xsd#kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee_5babfa2d-55c6-4b2d-a1c1-93dded486820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_b8128d4c-b498-4cb7-a773-56d152b8a1af" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone_b8128d4c-b498-4cb7-a773-56d152b8a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_ce528166-9f47-4fec-8c80-75d04003e112" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone_ce528166-9f47-4fec-8c80-75d04003e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_8bfa75fe-463c-43ea-a559-2e14b8074ac0" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone_8bfa75fe-463c-43ea-a559-2e14b8074ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_19f10b56-7f17-4182-822e-bc4d8edee632" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage_19f10b56-7f17-4182-822e-bc4d8edee632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_3f77d33b-1c2b-4934-99e0-4317f6209d58" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_741ff885-8ec8-4e13-b809-5143fd99faa9" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_3f77d33b-1c2b-4934-99e0-4317f6209d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8287fa57-574b-47cd-94f7-fa067b91b598" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8287fa57-574b-47cd-94f7-fa067b91b598" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c4693-d551-7573-9502-c33dfdc2b75b" xlink:to="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019c4693-d551-78b9-bd7d-2863b00902c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c4693-d551-7539-882f-5ee15831c629" xlink:to="loc_us-gaap_CommonStockMember_019c4693-d551-78b9-bd7d-2863b00902c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_019c4693-d551-72a4-bb76-6436d24083c6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_019c4693-d551-7c8b-9834-7a7afd859ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:to="loc_us-gaap_OverAllotmentOptionMember_019c4693-d551-7c8b-9834-7a7afd859ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AtTheMarketOfferingMember_019c76db-0aa2-7764-8d9b-c046af806f74" xlink:href="kros-20251231.xsd#kros_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_019c4693-d551-70a5-beaf-6977fe02c980" xlink:to="loc_kros_AtTheMarketOfferingMember_019c76db-0aa2-7764-8d9b-c046af806f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c4693-d551-718e-aa02-6793143cf3e3" xlink:to="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c4693-d551-7d4f-b7d6-ccba644817bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:to="loc_srt_MinimumMember_019c4693-d551-7d4f-b7d6-ccba644817bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c4693-d551-74a5-be3b-8959eeb9f377" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c4693-d551-76f7-aba6-3dfd07180366" xlink:to="loc_srt_MaximumMember_019c4693-d551-74a5-be3b-8959eeb9f377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAxis_019c4693-faf5-7b3c-872c-ece9fb105209" xlink:to="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_O2025Q1DividendsMember_019c4693-faf5-7397-a4da-355b873fe84a" xlink:href="kros-20251231.xsd#kros_O2025Q1DividendsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_019c4693-faf5-7984-b392-bb4e2909ccbc" xlink:to="loc_kros_O2025Q1DividendsMember_019c4693-faf5-7397-a4da-355b873fe84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_de34b22d-48c3-4f5d-b498-21e71ba24d76" xlink:to="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019c4693-d551-7422-b391-7364f2753361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019c4693-d551-7422-b391-7364f2753361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c4693-d551-707d-ac9a-3b04a83a997c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019c4693-d551-707d-ac9a-3b04a83a997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019c76dc-56c0-7efb-993a-a38107332b47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019c76dc-56c0-7efb-993a-a38107332b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019c4693-d551-707f-9e91-09724d73323e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019c4693-d551-707f-9e91-09724d73323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019c4693-d551-7935-9495-056503593797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019c4693-d551-7935-9495-056503593797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c4693-d551-73ec-9e02-bcaaaf408086" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019c4693-d551-73ec-9e02-bcaaaf408086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockAgentCommissions_019c76dc-56c0-7ad2-9666-c39fec234c8d" xlink:href="kros-20251231.xsd#kros_SaleOfStockAgentCommissions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_SaleOfStockAgentCommissions_019c76dc-56c0-7ad2-9666-c39fec234c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SaleOfStockStockIssuanceCosts_019c76dc-56c0-712b-8cff-d844fd2fc8b0" xlink:href="kros-20251231.xsd#kros_SaleOfStockStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_SaleOfStockStockIssuanceCosts_019c76dc-56c0-712b-8cff-d844fd2fc8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockDividendNumberOfRightsPerShare_019c4693-d551-7e54-bb61-477888e34ae5" xlink:href="kros-20251231.xsd#kros_CommonStockDividendNumberOfRightsPerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockDividendNumberOfRightsPerShare_019c4693-d551-7e54-bb61-477888e34ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019c4693-d551-705a-a5e2-3bdfe591a5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_019c4693-d551-705a-a5e2-3bdfe591a5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold_019c4693-d551-72fc-96d8-94598e21b774" xlink:href="kros-20251231.xsd#kros_CommonStockBeneficialOwnershipPenaltyThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockBeneficialOwnershipPenaltyThreshold_019c4693-d551-72fc-96d8-94598e21b774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_019c4693-faf5-7188-bd8f-4a3708090c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_019c4693-faf5-7188-bd8f-4a3708090c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CommonStockVotingRightsNumberOfVotes_019c4693-faf5-735e-ac05-f3bf077584a0" xlink:href="kros-20251231.xsd#kros_CommonStockVotingRightsNumberOfVotes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019c4693-d551-72a6-9e0b-0f33619b27de" xlink:to="loc_kros_CommonStockVotingRightsNumberOfVotes_019c4693-faf5-735e-ac05-f3bf077584a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5bd61821-8e5c-45e6-a96b-51ae14b31a18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5bd61821-8e5c-45e6-a96b-51ae14b31a18" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:to="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c96e9-8486-7119-ada9-f0224f4e23c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c96e9-ceac-72fb-beb4-25068c913d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c96e9-ceac-72fb-beb4-25068c913d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c96e9-ceac-773b-9909-afd594471340" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c96e9-ceac-773b-9909-afd594471340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c96e9-ceac-7e23-8186-e4e386b3c948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_us-gaap_EmployeeStockMember_019c96e9-ceac-7e23-8186-e4e386b3c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020PlanMember_019c96e9-ceac-78eb-8ea6-7bdeae0acf52" xlink:href="kros-20251231.xsd#kros_A2020PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c96e9-8486-7acb-907f-29456cc8eae0" xlink:to="loc_kros_A2020PlanMember_019c96e9-ceac-78eb-8ea6-7bdeae0acf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b8afd9a-d3c0-4ff7-b0ea-88dc1f920372" xlink:to="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c96e9-ceac-71da-83f1-47980278504d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ceab8163-c444-4008-8e6d-bb513a841352" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c96e9-ceac-71da-83f1-47980278504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/TREASURYSTOCKDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#TREASURYSTOCKDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/TREASURYSTOCKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_019b3634-a2ae-7027-90f3-74adcfba220b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_019b3634-a2ae-7027-90f3-74adcfba220b" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019c0fb1-637a-7452-ad2a-42bdc41513b7" xlink:to="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0fb1-637a-76b3-8439-282d0b694ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019c0fb1-637a-712e-b59a-372589ede8a4" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0fb1-637a-76b3-8439-282d0b694ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_019b3669-9643-7cf9-819d-4ebe8b21f6bd" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_019c0fb1-3592-7a21-9f53-e392f8ca4de0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_019c0fb1-3592-7a21-9f53-e392f8ca4de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c0fb1-3592-7f49-a9c5-4c2e823f840a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c0fb1-3592-7f49-a9c5-4c2e823f840a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0fb1-3592-726b-b902-690d37ae8a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0fb1-3592-726b-b902-690d37ae8a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_019c0fb1-3592-754d-a041-e72ddeca3c49" xlink:href="kros-20251231.xsd#kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer_019c0fb1-3592-754d-a041-e72ddeca3c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0fb1-3592-71af-b8f0-2d2648e8d9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0fb1-3592-71af-b8f0-2d2648e8d9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c0fb1-637a-7ba4-88f1-0dbc22ef60e2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_019c0fb1-3592-793c-9537-5f7f71df986d" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c0fb1-637a-7ba4-88f1-0dbc22ef60e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1ef28e2-4d85-4dcf-bb60-e0267e01fa87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1ef28e2-4d85-4dcf-bb60-e0267e01fa87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019c98d4-b238-77b1-b7c5-f798580b126f" xlink:to="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2017StockIncentivePlanMember_019c98d4-b238-7a36-bf8d-5fbe666f4bdb" xlink:href="kros-20251231.xsd#kros_A2017StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_A2017StockIncentivePlanMember_019c98d4-b238-7a36-bf8d-5fbe666f4bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2020StockIncentivePlanMember_019c98d4-b238-7bbd-af57-bf9c9f5fd764" xlink:href="kros-20251231.xsd#kros_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_A2020StockIncentivePlanMember_019c98d4-b238-7bbd-af57-bf9c9f5fd764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_019c98d5-412a-7c72-8c11-be6b8898edea" xlink:href="kros-20251231.xsd#kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019c98d4-b238-7540-b721-54f372bbbeb2" xlink:to="loc_kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember_019c98d5-412a-7c72-8c11-be6b8898edea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019c98d4-b238-7c58-b0c0-acfe68a0bb47" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019c98d4-b238-7fc8-8728-4e36bee35a37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019c98d4-b238-7a69-95e1-c441eb906dc3" xlink:to="loc_us-gaap_SubsequentEventMember_019c98d4-b238-7fc8-8728-4e36bee35a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c98d4-de4c-7a28-993b-1b93db507b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedAwardsMember_019c98d4-de4c-7b35-aed8-0598dd5adda6" xlink:href="kros-20251231.xsd#kros_PerformanceBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_PerformanceBasedAwardsMember_019c98d4-de4c-7b35-aed8-0598dd5adda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c98d4-de4c-797d-861d-9fc8d8e46ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c98d4-de4c-797d-861d-9fc8d8e46ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_UnvestedStockOptionsMember_019c98d5-1a01-7384-bf44-954b3fe1d842" xlink:href="kros-20251231.xsd#kros_UnvestedStockOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_UnvestedStockOptionsMember_019c98d5-1a01-7384-bf44-954b3fe1d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PerformanceBasedStockOptionsMember_019c98d5-1a01-77e7-b0d2-83fc1dea9d0c" xlink:href="kros-20251231.xsd#kros_PerformanceBasedStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_kros_PerformanceBasedStockOptionsMember_019c98d5-1a01-77e7-b0d2-83fc1dea9d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c98d5-1a01-79b1-b150-24ecd2b49ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c98d4-de4c-7bcd-99b2-cbbb92902e2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c98d5-1a01-79b1-b150-24ecd2b49ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019c98d5-1a01-72b7-beae-b78bf15cb6aa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TermLoanCreditAgreementThreeAmendmentMember_019c98d5-1a01-765c-b953-e0861323df65" xlink:href="kros-20251231.xsd#kros_TermLoanCreditAgreementThreeAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019c98d5-1a01-7b90-b16d-d37feabe4692" xlink:to="loc_kros_TermLoanCreditAgreementThreeAmendmentMember_019c98d5-1a01-765c-b953-e0861323df65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acad4e32-4025-41cb-8747-0eea9498d044" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019c98d4-b238-74d6-a3bb-f8385979d86b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_019c98d4-b238-74d6-a3bb-f8385979d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_019c98d4-b238-76be-a521-76d3d3dad497" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage_019c98d4-b238-76be-a521-76d3d3dad497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019c98d4-b238-7349-a9d3-7232ecb7af38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_019c98d4-b238-7349-a9d3-7232ecb7af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019c98d4-b238-73ae-a882-14772e3f677c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_019c98d4-b238-73ae-a882-14772e3f677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019c98d4-b238-788c-8ee9-29373998126d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_019c98d4-b238-788c-8ee9-29373998126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019c98d4-b238-7a8f-ab9d-52ec134190b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019c98d4-b238-7a8f-ab9d-52ec134190b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c98d4-de4c-744d-aded-8195404d0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c98d4-de4c-744d-aded-8195404d0a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d4-de4c-7a0a-8746-0fdd7c99acf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d4-de4c-7a0a-8746-0fdd7c99acf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c98d4-de4c-7095-a9ac-5d0fc72d3872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_019c98d4-de4c-7095-a9ac-5d0fc72d3872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c98d4-de4c-7608-a42c-f77ec2465da4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019c98d4-de4c-7608-a42c-f77ec2465da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c98d4-de4c-7f39-971c-c55ba925272f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_019c98d4-de4c-7f39-971c-c55ba925272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019c98d4-de4c-7ea0-b5e7-8837c441fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_019c98d4-de4c-7ea0-b5e7-8837c441fa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019c98d5-1a01-735b-baa6-91d817d3ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_019c98d5-1a01-735b-baa6-91d817d3ebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d5-1a01-78a9-b960-5fa34afd1c24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c98d5-1a01-78a9-b960-5fa34afd1c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019c98d5-1a01-7503-935d-019355106618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019c98d5-1a01-7503-935d-019355106618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_019c98d5-1a01-7e3c-8526-89e05954a156" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected_019c98d5-1a01-7e3c-8526-89e05954a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_019c98d5-1a01-7443-92fe-85e2e52e4ea8" xlink:href="kros-20251231.xsd#kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable_019c98d5-1a01-7443-92fe-85e2e52e4ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_019c98d5-1a01-7afa-8169-56a68cedde94" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding_019c98d5-1a01-7afa-8169-56a68cedde94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019c98d5-1a01-71b8-bbf8-538c2f126618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_019c98d5-1a01-71b8-bbf8-538c2f126618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019c98d5-412a-79fb-a8e2-0ad5622f4bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_019c98d5-412a-79fb-a8e2-0ad5622f4bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c98d5-412a-73c5-a4c7-6eb3a8c2974b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c98d4-b238-7fa3-95e4-1ec75c9e60ab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_019c98d5-412a-73c5-a4c7-6eb3a8c2974b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019c0fba-8460-7bde-8ea8-299ff4651d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019c0fba-8460-7bde-8ea8-299ff4651d0d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:to="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fba-8460-76c8-ab39-56d415c98f10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c1222-084d-7ec9-a64d-c7c611bc841e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fba-8460-76ca-b507-c648123b8fe8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c1222-084d-7ec9-a64d-c7c611bc841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019c0fba-8460-7830-ac3a-4d08f77918b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-79f5-a3c3-43dda07fc5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-79f5-a3c3-43dda07fc5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c0fba-8460-7563-bd26-a4918f1899fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_019c0fba-8460-7563-bd26-a4918f1899fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0fba-8460-7198-b18e-860c272e7f83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_019c0fba-8460-7198-b18e-860c272e7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c0fba-8460-7c4b-996f-2a73473fdf03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_019c0fba-8460-7c4b-996f-2a73473fdf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-7e9f-9abb-6603436c1aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_019c0fba-8460-742a-8059-c5632f0bfe2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019c0fba-8460-7e9f-9abb-6603436c1aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019c0fba-8460-7f2d-828d-4e99b475e112" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7912-b651-ce661bb1170e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7912-b651-ce661bb1170e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-789a-8715-31e8fc9f0b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-789a-8715-31e8fc9f0b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7c2e-9a8a-4150923b595d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_019c0fba-8460-7c2e-9a8a-4150923b595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c0fba-8460-7106-8c9c-f83c031e7502" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_019c0fba-8460-7106-8c9c-f83c031e7502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7913-bf67-3e8f88c5c137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_019c0fba-8460-7fec-b054-b56b41cd5d60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_019c0fba-8460-7913-bf67-3e8f88c5c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9cc2117-929e-44cf-9e8a-3ce3c7b0d311" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9cc2117-929e-44cf-9e8a-3ce3c7b0d311" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:to="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0ae363b2-6bd8-4ee7-9ac8-ca8786e24a92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c7952d02-12ec-4180-97fc-2f7923d043aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdf85a15-0f4c-4858-b88d-6b6fa879ef33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c7952d02-12ec-4180-97fc-2f7923d043aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c14fdba9-c0bf-4c03-933b-c3c53ccd7c9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea071393-9d79-4ec8-b901-80538998b378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ea071393-9d79-4ec8-b901-80538998b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812a81ee-48be-484f-be8b-42f435fc4313" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_812a81ee-48be-484f-be8b-42f435fc4313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3186fba6-d09a-4bed-abc4-df8e7a087358" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3186fba6-d09a-4bed-abc4-df8e7a087358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46360f43-fee1-4d50-b838-726cd09f2865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408bda52-b944-4a6b-8a18-0dee79bd0ece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46360f43-fee1-4d50-b838-726cd09f2865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec4e69d1-6239-400b-955f-b7489e11cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec4e69d1-6239-400b-955f-b7489e11cc30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5a558115-ecc3-40fa-a113-e890b7abfdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5a558115-ecc3-40fa-a113-e890b7abfdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01868b22-4351-4533-af89-1f06e05bd201" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_01868b22-4351-4533-af89-1f06e05bd201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21132a1e-a917-4f95-853d-cb5919ce0333" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21132a1e-a917-4f95-853d-cb5919ce0333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_efe32f1b-294b-4e35-9d22-12df7507ba98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_efe32f1b-294b-4e35-9d22-12df7507ba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3c8e73c9-0fae-4c40-8466-431eb0c1417d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3c8e73c9-0fae-4c40-8466-431eb0c1417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_849e2b3f-c6d5-4397-8d3b-a966790874de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_849e2b3f-c6d5-4397-8d3b-a966790874de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d91f0389-61c7-4b46-bb25-b99c9d1696f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70c32f4e-e968-4cc9-b592-c93e754d4ef4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d91f0389-61c7-4b46-bb25-b99c9d1696f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec4e69d1-6239-400b-955f-b7489e11cc30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f34cebc1-3712-4bff-a4e7-dcb33c882e89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f34cebc1-3712-4bff-a4e7-dcb33c882e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_37b9a4c8-8061-47ad-887b-9c4a138643b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_37b9a4c8-8061-47ad-887b-9c4a138643b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d810cf60-1b27-47a9-93e5-a350bf13dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d810cf60-1b27-47a9-93e5-a350bf13dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_de9327f1-363c-466e-93ec-667e65b16dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_de9327f1-363c-466e-93ec-667e65b16dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_42c80bf1-428b-4765-840f-d4e12c9d1a67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_42c80bf1-428b-4765-840f-d4e12c9d1a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66e26d7a-01ea-42bc-b27a-e08bc3de1536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66e26d7a-01ea-42bc-b27a-e08bc3de1536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9c080167-2209-4669-8745-89a4241357a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7e4118a4-7c97-4049-ab86-71816953c033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9c080167-2209-4669-8745-89a4241357a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18919180-5c2a-4881-9a36-baf83cc8d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec4e69d1-6239-400b-955f-b7489e11cc30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18919180-5c2a-4881-9a36-baf83cc8d24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99e79692-98fa-4428-9da7-a33cb8c000cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18919180-5c2a-4881-9a36-baf83cc8d24a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99e79692-98fa-4428-9da7-a33cb8c000cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b09db1b3-01cc-43ff-ba66-70b6d18a0565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18919180-5c2a-4881-9a36-baf83cc8d24a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b09db1b3-01cc-43ff-ba66-70b6d18a0565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a671459e-9a5b-4a30-ae78-8c943a4aee1f" xlink:href="kros-20251231.xsd#kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec4e69d1-6239-400b-955f-b7489e11cc30" xlink:to="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a671459e-9a5b-4a30-ae78-8c943a4aee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_45425533-98b9-4b51-9712-78e41a2b94f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a671459e-9a5b-4a30-ae78-8c943a4aee1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_45425533-98b9-4b51-9712-78e41a2b94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9c073a95-4103-4f2f-a1c7-ee80aaa909d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a671459e-9a5b-4a30-ae78-8c943a4aee1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9c073a95-4103-4f2f-a1c7-ee80aaa909d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c2aabf5e-de5a-4102-965f-c96dac01d0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a671459e-9a5b-4a30-ae78-8c943a4aee1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c2aabf5e-de5a-4102-965f-c96dac01d0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfd367c-a84c-4cef-9972-66f5a2ef957b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acfd367c-a84c-4cef-9972-66f5a2ef957b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_86d076a8-4b79-4446-85c6-67fe736f27a4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa54af2b-f179-4813-aa63-1f18d8d44951" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa54af2b-f179-4813-aa63-1f18d8d44951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_163485c7-381b-488a-8aa1-87812c027cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35f6c666-4d3c-489e-828e-bebee9909f6e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_163485c7-381b-488a-8aa1-87812c027cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_88058547-0251-414b-86ae-32a1bc551a3a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e76e1fc4-d6d1-4eb6-a0c1-eeaffe62926b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4661fc1f-d397-48fc-be4e-9bced0860be6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e76e1fc4-d6d1-4eb6-a0c1-eeaffe62926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-76d1-851b-2daf5b9893c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-76d1-851b-2daf5b9893c4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:to="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019c0fbe-e67d-796e-87d0-98240f062b5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7106-873a-1a328663af39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7106-873a-1a328663af39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7b4b-83e9-dfe62af6416c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7b4b-83e9-dfe62af6416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7ca2-a664-8bf535f832f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019c0fbe-e67d-7482-9936-a25388dd151e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7ca2-a664-8bf535f832f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7a72-a246-6a17832d9a46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019c0fcc-1cff-782f-a009-9ed980394b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_019c0fbe-e67d-7a6b-a3b5-42adabeca4b1" xlink:to="loc_us-gaap_NetIncomeLoss_019c0fcc-1cff-782f-a009-9ed980394b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-7740-96b8-25233ae2ec37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019c0fbe-e67d-7740-96b8-25233ae2ec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-76fe-9875-3943da31ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_019c0fbe-e67d-76fe-9875-3943da31ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-7bd5-a95e-fedd42f139f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c0fbe-e67d-7843-bf8b-71424f034d05" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019c0fbe-e67d-7bd5-a95e-fedd42f139f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019c0fbe-e67d-7db2-b878-21d844f094c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_EarningsPerShareBasic_019c0fbe-e67d-7db2-b878-21d844f094c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019c0fbe-e67d-727c-b884-2be9631df9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-747f-b969-e60c8f80df3c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019c0fbe-e67d-727c-b884-2be9631df9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-71d2-bdc0-30e292d9a436" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c0fbe-e67d-71d2-bdc0-30e292d9a436" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019c0fbe-e67d-7518-88c6-37ac70aeae01" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7b06-8b19-63eeac7ff758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019c0fbe-e67d-7b06-8b19-63eeac7ff758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7acd-859a-ccda07fef579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019c0fbe-e67d-7acd-859a-ccda07fef579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7da2-86d0-9899c57825c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019c0fbe-e67d-7017-b108-74f92ca5f1a0" xlink:to="loc_us-gaap_EmployeeStockMember_019c0fbe-e67d-7da2-86d0-9899c57825c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019c0fbe-e67d-7bae-9817-933864307a2a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c0fbe-e67d-70b4-9fc1-615ea3bf7a80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019c0fbe-e67d-7a39-aab6-af84f6daeb36" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019c0fbe-e67d-70b4-9fc1-615ea3bf7a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_55f6409b-a54a-4d54-a625-aa9224203e47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0a131306-62e8-4bb0-be6d-97545da8d3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55f6409b-a54a-4d54-a625-aa9224203e47" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0a131306-62e8-4bb0-be6d-97545da8d3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_26d116bc-c009-41db-8115-69b70263a332" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55f6409b-a54a-4d54-a625-aa9224203e47" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_26d116bc-c009-41db-8115-69b70263a332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37fbb971-9ec5-4a6e-aec6-fbaca8d14493" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55f6409b-a54a-4d54-a625-aa9224203e47" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37fbb971-9ec5-4a6e-aec6-fbaca8d14493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ada9b82-a39c-4fdb-b1cd-5dac8b2edcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ada9b82-a39c-4fdb-b1cd-5dac8b2edcb8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c6defc89-9229-47ec-9876-5abea8466247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c6defc89-9229-47ec-9876-5abea8466247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b8d4407d-5dfb-46a1-bf29-9241bbd94241" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b8d4407d-5dfb-46a1-bf29-9241bbd94241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_59ed6bed-520d-4efd-bfb7-329660a4d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_59ed6bed-520d-4efd-bfb7-329660a4d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d0c02953-fe2b-49eb-a244-59a256fa7e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_cbd6eb55-428a-4e0a-aeea-6e1cdcbdbd78" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d0c02953-fe2b-49eb-a244-59a256fa7e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad398b24-6996-445a-9a5d-a5d389bca364" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ada9b82-a39c-4fdb-b1cd-5dac8b2edcb8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad398b24-6996-445a-9a5d-a5d389bca364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_675d6c2b-bdad-4760-a08c-5eab76e03dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ada9b82-a39c-4fdb-b1cd-5dac8b2edcb8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_675d6c2b-bdad-4760-a08c-5eab76e03dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_083b4274-1f9a-4336-9b9e-37ba0b68e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_083b4274-1f9a-4336-9b9e-37ba0b68e9fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7008-f2b5-7a61-9a3b-9e612c85bb9b" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_019c7008-f2b5-725b-b0ca-27e1a5d0b9a3" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7008-f2b5-767d-9087-66f6d7ea35b3" xlink:to="loc_country_AU_019c7008-f2b5-725b-b0ca-27e1a5d0b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_019c7008-0af2-74c3-9962-495d378fa68b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c7008-f2b5-7ca3-92a7-49090d4d612f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c7008-f2b5-7ca3-92a7-49090d4d612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c7008-f2b5-72e9-b4a7-60af09dc6050" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c7008-f2b5-72e9-b4a7-60af09dc6050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c7008-f2b5-7b5c-b67f-19e89ff34f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_019c7008-f2b5-7b5c-b67f-19e89ff34f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c7008-f2b5-70da-94f8-ffcd18b679ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_019c7008-f2b5-70da-94f8-ffcd18b679ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c7008-f2b5-71b6-aac6-e0bd5efe4f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_019c7008-f2b5-71b6-aac6-e0bd5efe4f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c7008-f2b5-786a-8adc-0aa26449522d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_019c7008-f2b5-786a-8adc-0aa26449522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c7008-f2b5-7bb0-aa48-0f837ff2c291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c7008-f2b5-7bb0-aa48-0f837ff2c291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7008-f2b5-7b2b-aef9-ce49a946d0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c7008-f2b5-7b2b-aef9-ce49a946d0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad3-f077-7936-bed1-10c26fb812ac" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount_019c8ad3-f077-7936-bed1-10c26fb812ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7008-f2b5-7020-86f4-955516ea827b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c7008-f2b5-7020-86f4-955516ea827b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c7008-f2b5-77ce-a908-807ac0fb5512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c7008-f2b5-77ce-a908-807ac0fb5512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c7008-f2b5-7dfe-aeb2-ebff6fbdc1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_019c7008-f2b5-7dfe-aeb2-ebff6fbdc1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c7008-f2b5-7521-bcae-8659225756ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c700c-88db-7d40-9290-e0db55bd4235" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c7008-f2b5-7521-bcae-8659225756ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_019c7008-f2b5-778d-ad8d-c9d1baa4c655" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c700d-2379-7a91-add4-65427b5f79c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c700d-2379-7a91-add4-65427b5f79c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c700d-2379-78f9-bb68-24a6c25a69c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c700d-2379-78f9-bb68-24a6c25a69c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c700d-2379-79ef-84c2-bdc9820b4c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_019c700d-2379-79ef-84c2-bdc9820b4c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c700d-2379-7f8e-b7fb-97aaa8c8e627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_019c700d-2379-7f8e-b7fb-97aaa8c8e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c700d-2379-7b91-9a17-68ccdbfcf616" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_019c700d-2379-7b91-9a17-68ccdbfcf616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c700d-2379-7615-b982-cb12938852f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_019c700d-2379-7615-b982-cb12938852f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7013-0be3-70ff-acf7-cc57ed1b84ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_019c7013-0be3-70ff-acf7-cc57ed1b84ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c700d-2379-7128-a293-0f4442bc8683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c700d-2379-7128-a293-0f4442bc8683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7013-0be3-7d4b-99a9-c850c71bd3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_019c7013-0be3-7d4b-99a9-c850c71bd3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7013-0be3-7154-a8ed-aa17d5c050ad" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent_019c7013-0be3-7154-a8ed-aa17d5c050ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad3-8da6-74fb-b14d-625c3e201938" xlink:href="kros-20251231.xsd#kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_019c8ad3-8da6-74fb-b14d-625c3e201938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700d-2379-7528-a733-728ef3cccfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c700d-2379-7528-a733-728ef3cccfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c700d-2379-7376-b852-4f7dd97d015f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c700d-2379-7376-b852-4f7dd97d015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7013-0be4-7b65-9635-8a7c7100e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_019c7013-0be4-7b65-9635-8a7c7100e91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700d-2379-75fe-a555-05446462e93d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c700d-2379-75fe-a555-05446462e93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c700d-2379-705c-800b-91dba540d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_019c700d-2379-705c-800b-91dba540d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c700d-2379-70ec-88d4-c36f6af0636f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c700d-4a41-7836-863a-220d1d550b70" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c700d-2379-70ec-88d4-c36f6af0636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ba91cbdc-9c0a-4d6e-83c5-15e1a7a7809a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ba91cbdc-9c0a-4d6e-83c5-15e1a7a7809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50c57cb4-ac50-4f47-a464-072a75280176" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_50c57cb4-ac50-4f47-a464-072a75280176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_350071e8-94d5-4690-9337-5d42b4d83182" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost_350071e8-94d5-4690-9337-5d42b4d83182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e4a8d49c-02a6-4d27-860a-8ab148e5446c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_e4a8d49c-02a6-4d27-860a-8ab148e5446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxAssetsOperatingLeaseLiability_9ddaee35-60c2-43ce-b99d-463e37cf97bc" xlink:href="kros-20251231.xsd#kros_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_kros_DeferredTaxAssetsOperatingLeaseLiability_9ddaee35-60c2-43ce-b99d-463e37cf97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_dcbfc440-3c3d-4709-8761-429cee922338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_dcbfc440-3c3d-4709-8761-429cee922338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f271b50d-8770-417d-9759-cd474e11a52a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f271b50d-8770-417d-9759-cd474e11a52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_75e9e483-1644-4ea6-8448-c12134e4aa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_75e9e483-1644-4ea6-8448-c12134e4aa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_35f837f1-4597-43fd-843c-683856d5d915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_35f837f1-4597-43fd-843c-683856d5d915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6d118e89-e070-466c-8354-b8d9578bcbac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_6d118e89-e070-466c-8354-b8d9578bcbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c0fd527-b70d-43f7-9497-01a1c2f6f045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c0fd527-b70d-43f7-9497-01a1c2f6f045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_f5cefd92-212b-4436-a32b-bcb38efca01e" xlink:href="kros-20251231.xsd#kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c0fd527-b70d-43f7-9497-01a1c2f6f045" xlink:to="loc_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_f5cefd92-212b-4436-a32b-bcb38efca01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_019c7025-6c92-7ff4-b406-1144a18f3fba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2c0fd527-b70d-43f7-9497-01a1c2f6f045" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_019c7025-6c92-7ff4-b406-1144a18f3fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5169e6ae-8baa-4278-91a2-29764c26a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_46731326-8964-4f06-ad1c-b33e6d543276" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5169e6ae-8baa-4278-91a2-29764c26a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8ba881e2-dc37-41b8-8148-9dc442761cee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ba881e2-dc37-41b8-8148-9dc442761cee" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c7022-6e2c-7e0b-9943-dd3237b6f607" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019c7022-6e2c-7373-89fd-6e8b3a62e719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_us-gaap_DomesticCountryMember_019c7022-6e2c-7373-89fd-6e8b3a62e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c7022-6e2c-7d3c-9c33-92a6d2eb2069" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c7022-6e2c-7d3c-9c33-92a6d2eb2069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_019c98e8-f850-75f5-8b94-1b3bc482418d" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_country_AU_019c98e8-f850-75f5-8b94-1b3bc482418d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_019c98e8-f850-7ad4-8446-faf065fe5fab" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c7022-6e2c-756b-abe7-257b6e060d80" xlink:to="loc_country_US_019c98e8-f850-7ad4-8446-faf065fe5fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_019c7022-6e2c-7a3b-90ea-b70298ee7303" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_019c7022-6e2c-771f-8be9-57ebd2b060fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_019c7022-6e2c-769c-a0bf-f03177f021f8" xlink:to="loc_us-gaap_ResearchMember_019c7022-6e2c-771f-8be9-57ebd2b060fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7a1e0950-916c-4fef-b549-d9be1774c4f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_019c7022-6e2c-7b75-8c40-eff11f0d21c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_019c7022-6e2c-7b75-8c40-eff11f0d21c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_019c7022-6e2c-7950-836e-37eb0d86a2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_019c7022-6e2c-7950-836e-37eb0d86a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OperatingLossCarryforwardWriteOff_019c9716-34f9-71fd-b3fd-81041fef2603" xlink:href="kros-20251231.xsd#kros_OperatingLossCarryforwardWriteOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_kros_OperatingLossCarryforwardWriteOff_019c9716-34f9-71fd-b3fd-81041fef2603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019c7022-90bb-700b-94a2-253df2fc213e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_019c7022-90bb-700b-94a2-253df2fc213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_019c7022-bc0e-77b4-a1ff-dcacc20da8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_019c7022-bc0e-77b4-a1ff-dcacc20da8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c7022-bc0e-7f2e-b1c5-a28cd1499468" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_019c7022-bc0e-7f2e-b1c5-a28cd1499468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019c7022-bc0e-78d3-ac4b-85b60bce9da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019c7022-bc0e-78d3-ac4b-85b60bce9da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_019c98e8-f850-766c-bdac-2114b8492609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_019c7022-6e2c-7adc-b673-cf9a75f35c6d" xlink:to="loc_us-gaap_IncomeTaxesPaid_019c98e8-f850-766c-bdac-2114b8492609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b56b3cdd-8c03-4d08-ba73-aea139fe494f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b56b3cdd-8c03-4d08-ba73-aea139fe494f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_019c6fa9-e60c-7fd1-a8ef-738633f684ad" xlink:to="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PhaseAPremisesMember_019c6fa9-e60c-72fa-b12e-3722f160c3e1" xlink:href="kros-20251231.xsd#kros_PhaseAPremisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:to="loc_kros_PhaseAPremisesMember_019c6fa9-e60c-72fa-b12e-3722f160c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_WalthamLeaseMember_019c6fa9-e60c-732a-be19-9a8c6f6dda66" xlink:href="kros-20251231.xsd#kros_WalthamLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_019c6fa9-e60c-7a64-a83d-c2650e562c70" xlink:to="loc_kros_WalthamLeaseMember_019c6fa9-e60c-732a-be19-9a8c6f6dda66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:to="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019c6fa9-e60c-7624-b941-9b7ed13dfb1d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AccentTherapeuticsIncMember_019c6fa9-e60c-72e4-9564-1bd82bcafc2e" xlink:href="kros-20251231.xsd#kros_AccentTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019c6fa9-e60c-77e2-a772-2b006b305135" xlink:to="loc_kros_AccentTherapeuticsIncMember_019c6fa9-e60c-72e4-9564-1bd82bcafc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_28aa0a18-0112-4f1d-8d0f-03474231e22f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeAreaOfSublease_019c6fa9-e60c-7cc9-9535-e92216a7f93f" xlink:href="kros-20251231.xsd#kros_LesseeAreaOfSublease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeAreaOfSublease_019c6fa9-e60c-7cc9-9535-e92216a7f93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRent_019c6fa9-e60c-7215-850a-6a564338c2aa" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseMonthlyBaseRent_019c6fa9-e60c-7215-850a-6a564338c2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeasePeriodForImprovement_019c6fad-3a67-71f6-9c73-930928c7bffa" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeasePeriodForImprovement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeasePeriodForImprovement_019c6fad-3a67-71f6-9c73-930928c7bffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_019c6fa9-e60c-701a-bfff-c589e2ad1b79" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage_019c6fa9-e60c-701a-bfff-c589e2ad1b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_019c6fa9-e60c-70fe-81b7-23ec8db3bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_019c6fa9-e60c-70fe-81b7-23ec8db3bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_019c6fa9-e60c-71dc-b36e-fcb03e6dc4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_019c6fa9-e60c-71dc-b36e-fcb03e6dc4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c6fa9-e60c-794a-a847-dddda9299342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019c6fa9-e60c-794a-a847-dddda9299342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_019c6fa9-e60c-7e67-8791-94ded9d5ce6f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_OperatingLeaseLiability_019c6fa9-e60c-7e67-8791-94ded9d5ce6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019c6fa9-e60c-7b33-ad17-74574dae5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_019c6fa9-e60c-7b33-ad17-74574dae5a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_019c6fa9-e60c-7465-98c0-5afa565aa91b" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot_019c6fa9-e60c-7465-98c0-5afa565aa91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace_019c6fa9-e60c-7874-a30a-0323c0541f3a" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseAreaOfRentalSpace"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_019c6fa9-e60c-78a1-8d22-a0477d44df2a" xlink:to="loc_kros_LesseeOperatingLeaseAreaOfRentalSpace_019c6fa9-e60c-7874-a30a-0323c0541f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESScheduleofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_862e7564-c4f3-4a37-96b6-01f8b7a48306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:to="loc_us-gaap_OperatingLeaseCost_862e7564-c4f3-4a37-96b6-01f8b7a48306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_019c46d0-b795-76c4-826c-48f5b1bd9944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:to="loc_us-gaap_ShortTermLeaseCost_019c46d0-b795-76c4-826c-48f5b1bd9944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_48713117-f4d7-4416-aed9-8eed8501d9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:to="loc_us-gaap_VariableLeaseCost_48713117-f4d7-4416-aed9-8eed8501d9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8098258f-d8a4-4946-a059-ca756dd138b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:to="loc_us-gaap_LeaseCost_8098258f-d8a4-4946-a059-ca756dd138b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:href="kros-20251231.xsd#kros_LesseeLeaseOtherInformationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07bd3fc7-6e35-484f-b78f-be5857a454cc" xlink:to="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3cbc2c1a-91bb-46d3-890f-c87cd214402e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:to="loc_us-gaap_OperatingLeasePayments_3cbc2c1a-91bb-46d3-890f-c87cd214402e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0a790d1-7300-45eb-af47-284cf2dff1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e0a790d1-7300-45eb-af47-284cf2dff1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fb20a694-1fe4-43ad-97b2-d91155accb06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fb20a694-1fe4-43ad-97b2-d91155accb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_db6acff8-28b2-4afb-b7bb-c94c5c29962a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_kros_LesseeLeaseOtherInformationAbstract_64eb277c-4e26-45ef-ae34-e67a212c9884" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_db6acff8-28b2-4afb-b7bb-c94c5c29962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#LEASESScheduleofMaturityofLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9a1b48bc-80dd-4b9f-a754-c1aeb80b9fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a1b48bc-80dd-4b9f-a754-c1aeb80b9fd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3051de31-aba0-42ef-8cc0-aa02fcb2531b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3051de31-aba0-42ef-8cc0-aa02fcb2531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5eb05c3-fd5e-49be-bc85-7549ab4b6856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5eb05c3-fd5e-49be-bc85-7549ab4b6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a996119c-634c-4045-b50b-8a4b154949ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a996119c-634c-4045-b50b-8a4b154949ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6a7b14d6-2cd8-4d67-a63b-e488d221ab8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6a7b14d6-2cd8-4d67-a63b-e488d221ab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7b4ea4ef-2197-430a-8384-e4757869fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7b4ea4ef-2197-430a-8384-e4757869fd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_ab7a6299-8c98-4beb-99b8-c1ab081b23c3" xlink:href="kros-20251231.xsd#kros_LesseeOperatingLeaseLiabilityToBePaidYearSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix_ab7a6299-8c98-4beb-99b8-c1ab081b23c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94538284-9fc2-43bf-9291-ba6296b0d3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_94538284-9fc2-43bf-9291-ba6296b0d3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_156a4c05-5e87-42e1-baec-ee1a2fa50c03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_156a4c05-5e87-42e1-baec-ee1a2fa50c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f6a2c4a8-de53-4d8b-927a-cc0a98542d28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_68e22e69-b2ec-4ed5-9701-153dc0ebff7c" xlink:to="loc_us-gaap_OperatingLeaseLiability_f6a2c4a8-de53-4d8b-927a-cc0a98542d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_2d0315e5-bace-4bc3-8957-ecf70210b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9a1b48bc-80dd-4b9f-a754-c1aeb80b9fd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_2d0315e5-bace-4bc3-8957-ecf70210b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffd519ab-e538-4ed9-b24d-d30c8897ef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2d0315e5-bace-4bc3-8957-ecf70210b58a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffd519ab-e538-4ed9-b24d-d30c8897ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_edeeba97-8e40-4109-b7b3-7c0a6e533a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2d0315e5-bace-4bc3-8957-ecf70210b58a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_edeeba97-8e40-4109-b7b3-7c0a6e533a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46a2a670-8a38-45f6-8a6b-06c70ea75dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_2d0315e5-bace-4bc3-8957-ecf70210b58a" xlink:to="loc_us-gaap_OperatingLeaseLiability_46a2a670-8a38-45f6-8a6b-06c70ea75dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c46d2-d9ce-7108-828f-5559cf2be738" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_019c46d2-d9ce-7108-828f-5559cf2be738" xlink:to="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:to="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019c46d8-cf98-756c-8a2e-548e5b610eea" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c46d8-cf98-7dbe-bc5b-3d9677698082" xlink:href="kros-20251231.xsd#kros_TakedaPharmaceuticalsU.S.A.Inc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c46d8-cf98-7488-8889-e59b9df3ac44" xlink:to="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c46d8-cf98-7dbe-bc5b-3d9677698082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_019c46d8-cf98-77b6-9b04-3e51e0a2c0d9" xlink:to="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_019c46d5-e8bf-7baf-bd15-639b8e2e832e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:to="loc_us-gaap_PurchaseObligation_019c46d5-e8bf-7baf-bd15-639b8e2e832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_019c46d8-cf98-79a6-bdab-b97b2270d727" xlink:href="kros-20251231.xsd#kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_019c46d8-cf98-7892-91ad-1fa05b5f4cdf" xlink:to="loc_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage_019c46d8-cf98-79a6-bdab-b97b2270d727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fdf-7403-726e-822e-55b7fc4d337e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fdf-7403-726e-822e-55b7fc4d337e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_019c0fdf-7403-7f63-a3a9-6faece36380f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohAgreementMember_019c0fdf-7403-7817-a25a-71266a0cedcc" xlink:href="kros-20251231.xsd#kros_HansohAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_HansohAgreementMember_019c0fdf-7403-7817-a25a-71266a0cedcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_019c0fdf-7403-7b2b-82e7-b43bfe6fe747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_019c0fdf-7403-7b2b-82e7-b43bfe6fe747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TechTransferAgreementMember_019c0fdf-7403-7238-91c6-215e05b62220" xlink:href="kros-20251231.xsd#kros_TechTransferAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_TechTransferAgreementMember_019c0fdf-7403-7238-91c6-215e05b62220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_SupplyAgreementMember_019c0fdf-7403-7e66-bb4a-7a7bcd96a17f" xlink:href="kros-20251231.xsd#kros_SupplyAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_019c0fdf-7403-7ddd-b3ef-35689ff5655b" xlink:to="loc_kros_SupplyAgreementMember_019c0fdf-7403-7e66-bb4a-7a7bcd96a17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019c0fdf-7403-7797-bac8-01c02e0dd3f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_HansohShanghaiHealthtechCoLtdMember_019c0fdf-7403-78fa-a64a-6b43a23b3558" xlink:href="kros-20251231.xsd#kros_HansohShanghaiHealthtechCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_HansohShanghaiHealthtechCoLtdMember_019c0fdf-7403-78fa-a64a-6b43a23b3558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ManufacturingTechnologyTransferAgreementMember_019c0fdf-7403-7036-b16a-8c91a13215fd" xlink:href="kros-20251231.xsd#kros_ManufacturingTechnologyTransferAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_ManufacturingTechnologyTransferAgreementMember_019c0fdf-7403-7036-b16a-8c91a13215fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ClinicalProductSupplyAgreementMember_019c0fdf-7403-7bd5-a24c-92701159c3e9" xlink:href="kros-20251231.xsd#kros_ClinicalProductSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_ClinicalProductSupplyAgreementMember_019c0fdf-7403-7bd5-a24c-92701159c3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c0fdf-7403-705a-8b27-b067aa97eb28" xlink:href="kros-20251231.xsd#kros_TakedaPharmaceuticalsU.S.A.Inc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019c0fdf-7403-7571-85c8-e1698b19a0b5" xlink:to="loc_kros_TakedaPharmaceuticalsU.S.A.Inc.Member_019c0fdf-7403-705a-8b27-b067aa97eb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c0fdf-7403-7649-aba7-15b113f2280c" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019c0fdf-7403-76ee-bf99-4fb87882d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_us-gaap_LicenseMember_019c0fdf-7403-76ee-bf99-4fb87882d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAndKnowHowMember_019c0fdf-7403-7285-ba98-25a132ba578b" xlink:href="kros-20251231.xsd#kros_LicenseAndKnowHowMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_kros_LicenseAndKnowHowMember_019c0fdf-7403-7285-ba98-25a132ba578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_TransitionServicesMember_019c0fdf-7403-7377-929b-53066a0f7cf0" xlink:href="kros-20251231.xsd#kros_TransitionServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_kros_TransitionServicesMember_019c0fdf-7403-7377-929b-53066a0f7cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c98fb-8326-71a7-aa6a-b3e011be1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fdf-7403-7d04-b066-095855763e8a" xlink:to="loc_us-gaap_ServiceMember_019c98fb-8326-71a7-aa6a-b3e011be1bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019c0fdf-7403-7560-a96f-a08e96ab4129" xlink:to="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019c0fdf-7403-7302-a5a5-84b3d2517637" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:to="loc_srt_MaximumMember_019c0fdf-7403-7302-a5a5-84b3d2517637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019c0fdf-7403-7b01-96a3-a18b1f3c35f1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019c0fdf-7403-709f-b363-c3ee884fd7f2" xlink:to="loc_srt_MinimumMember_019c0fdf-7403-7b01-96a3-a18b1f3c35f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fdf-7403-7e01-b1c1-1affdd4ca7af" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c0fdf-7403-7083-a283-bea939acbbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019c0fdf-7403-7083-a283-bea939acbbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_019c0fdf-7403-7de3-b4a6-503564ff6d22" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration_019c0fdf-7403-7de3-b4a6-503564ff6d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_019c0fdf-7403-7074-8b35-79b4d48d3281" xlink:href="kros-20251231.xsd#kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration_019c0fdf-7403-7074-8b35-79b4d48d3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_019c0fdf-7403-7856-886e-74cd33b7167d" xlink:href="kros-20251231.xsd#kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod_019c0fdf-7403-7856-886e-74cd33b7167d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c0fdf-7403-763e-868a-8c731568e64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_019c0fdf-7403-763e-868a-8c731568e64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes_019c0fdf-7403-7e96-b7c8-c5a355537904" xlink:href="kros-20251231.xsd#kros_RevenueFromContractWithCustomerWithholdingTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_RevenueFromContractWithCustomerWithholdingTaxes_019c0fdf-7403-7e96-b7c8-c5a355537904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ServiceAndOtherRevenue_019c0fdf-7403-7e12-a810-cf6afd9022bf" xlink:href="kros-20251231.xsd#kros_ServiceAndOtherRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_ServiceAndOtherRevenue_019c0fdf-7403-7e12-a810-cf6afd9022bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyFeeWaiverTerms_019c0fdf-7403-7fe4-a490-e5daae1570ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyFeeWaiverTerms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_InvestmentCompanyFeeWaiverTerms_019c0fdf-7403-7fe4-a490-e5daae1570ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseAgreementUpfrontFee_019c0fdf-7403-7f7e-b4b9-7bdca95a736a" xlink:href="kros-20251231.xsd#kros_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_LicenseAgreementUpfrontFee_019c0fdf-7403-7f7e-b4b9-7bdca95a736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_019c0fdf-7403-71e9-ad88-5220700decbf" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsDevelopmentBasedMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones_019c0fdf-7403-71e9-ad88-5220700decbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones_019c0fdf-7403-7366-9b4d-f95f3924f2cd" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsCommercialBasedMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsCommercialBasedMilestones_019c0fdf-7403-7366-9b4d-f95f3924f2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones_019c0fdf-7403-7f9f-b45e-8edf1e481997" xlink:href="kros-20251231.xsd#kros_PotentialMilestonePaymentsSalesBasedMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_PotentialMilestonePaymentsSalesBasedMilestones_019c0fdf-7403-7f9f-b45e-8edf1e481997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NumberOfPerformanceObligations_019c0fdf-7403-7c1a-9d48-84cc384ee02d" xlink:href="kros-20251231.xsd#kros_NumberOfPerformanceObligations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_kros_NumberOfPerformanceObligations_019c0fdf-7403-7c1a-9d48-84cc384ee02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_019c0fdf-7403-7216-a555-b61d73990fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReimbursementFromLimitedPartnershipInvestment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_ReimbursementFromLimitedPartnershipInvestment_019c0fdf-7403-7216-a555-b61d73990fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019c0fdf-7403-7f6d-bce4-739ed0462047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fdf-7403-7c50-a49e-0c2c212a5744" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019c0fdf-7403-7f6d-bce4-739ed0462047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fde-79c4-761b-afab-8522881a3a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019c0fde-79c4-761b-afab-8522881a3a9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:to="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019c0fde-79c4-7f1f-9975-d68c85ec6b00" xlink:to="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LicenseRevenueMember_019c0fde-79c4-72f4-88fb-8ef5d152af36" xlink:href="kros-20251231.xsd#kros_LicenseRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:to="loc_kros_LicenseRevenueMember_019c0fde-79c4-72f4-88fb-8ef5d152af36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_019c0fde-79c4-7c4f-a3f3-49bd687fc3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019c0fde-79c4-7757-acf3-1009ce1e6777" xlink:to="loc_us-gaap_ServiceMember_019c0fde-79c4-7c4f-a3f3-49bd687fc3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019c0fde-79c4-731a-ab30-f17be4039b3d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019c0fde-79c4-76d8-b2c7-9ada9f16bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019c0fde-79c4-7307-9c75-71f361504a81" xlink:to="loc_us-gaap_Revenues_019c0fde-79c4-76d8-b2c7-9ada9f16bfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_636608a1-dceb-498b-8aa9-e78a59208c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_636608a1-dceb-498b-8aa9-e78a59208c6c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b1e60b67-0975-473e-8983-65d69bdd02fa" xlink:to="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ReportableSegmentMember_d1549115-2b4b-4eff-a2cb-1649faeccf82" xlink:href="kros-20251231.xsd#kros_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_185fe4c0-a090-4ccd-88fc-59682ed6e53f" xlink:to="loc_kros_ReportableSegmentMember_d1549115-2b4b-4eff-a2cb-1649faeccf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:to="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_376291ee-55df-493a-8377-b9becadd9144" xlink:to="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RinvaterceptProgramExpensesMember_019c0fe4-4642-798a-9e51-19a8f9275ea1" xlink:href="kros-20251231.xsd#kros_RinvaterceptProgramExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_RinvaterceptProgramExpensesMember_019c0fe4-4642-798a-9e51-19a8f9275ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_ElriterceptProgramExpensesMember_baa2da57-c219-4bf1-bf52-ea8125b60ed1" xlink:href="kros-20251231.xsd#kros_ElriterceptProgramExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_ElriterceptProgramExpensesMember_baa2da57-c219-4bf1-bf52-ea8125b60ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_CiboterceptProgramExpensesMember_35427226-b474-4206-a55b-fc25ba995708" xlink:href="kros-20251231.xsd#kros_CiboterceptProgramExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_CiboterceptProgramExpensesMember_35427226-b474-4206-a55b-fc25ba995708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_PreclinicalDevelopmentExpensesMember_91742b3c-4324-4d36-9d53-d9365137b5de" xlink:href="kros-20251231.xsd#kros_PreclinicalDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_PreclinicalDevelopmentExpensesMember_91742b3c-4324-4d36-9d53-d9365137b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_OtherExternalCostsMember_019c7b68-7d98-7b32-82d8-6ebcaa259238" xlink:href="kros-20251231.xsd#kros_OtherExternalCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49b0b479-34f1-4238-b0c8-985a48d88443" xlink:to="loc_kros_OtherExternalCostsMember_019c7b68-7d98-7b32-82d8-6ebcaa259238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3bfa5c71-a0b9-484f-81df-f5366322b221" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_72b2bf57-0f9a-4f43-b5f0-30afd1e28a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_72b2bf57-0f9a-4f43-b5f0-30afd1e28a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_051b437b-8f69-4bde-874c-670902e903d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_051b437b-8f69-4bde-874c-670902e903d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_7975a217-cf2c-455d-aae2-b5aef5ee47e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_7975a217-cf2c-455d-aae2-b5aef5ee47e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_9888dbe4-c45b-44e2-8755-d31f65b6e298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_9888dbe4-c45b-44e2-8755-d31f65b6e298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_edfb9ad9-2a1a-4104-9fb4-c679b61b4669" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9ec0dd40-dde4-4bcd-8ffd-a6ef4b284e0d" xlink:to="loc_us-gaap_NetIncomeLoss_edfb9ad9-2a1a-4104-9fb4-c679b61b4669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7baec08b-a175-4e1d-9f58-45b521d0179b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f73b2cfa-b9ae-4169-a140-6404b0a97f10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7baec08b-a175-4e1d-9f58-45b521d0179b" xlink:to="loc_us-gaap_NumberOfReportableSegments_f73b2cfa-b9ae-4169-a140-6404b0a97f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURINGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-745a-826e-3924d7ffa968" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-745a-826e-3924d7ffa968" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7ad3-9243-cc77d325c521" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2025RestructuringMember_019c0fe8-83c9-7248-91cf-e342768d8478" xlink:href="kros-20251231.xsd#kros_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7d7f-b606-b245b61e56b8" xlink:to="loc_kros_A2025RestructuringMember_019c0fe8-83c9-7248-91cf-e342768d8478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c0fe8-83c9-7045-81b9-6ed7db3b2563" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c0fe8-83c9-77ad-b4de-15bbd4300573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c0fe8-83c9-77ad-b4de-15bbd4300573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c0fe8-83c9-793c-80a7-7b266f223c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c0fe8-83c9-7ab0-b40d-d926f5fa1990" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c0fe8-83c9-793c-80a7-7b266f223c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7e28-9048-99f1f52e7984" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c0fe8-83c9-7ac1-b062-68bda3a229af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c0fe8-83c9-7ac1-b062-68bda3a229af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_019c0fe8-83c9-745d-bae7-c97de51210aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_019c0fe8-83c9-745d-bae7-c97de51210aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-71f1-8fe4-9127e6ae091f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-71f1-8fe4-9127e6ae091f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c0fff-6f56-7702-965b-3f1b621d2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-7fa9-a68c-c55896f07a7b" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c0fff-6f56-7702-965b-3f1b621d2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails" xlink:type="simple" xlink:href="kros-20251231.xsd#CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"/>
  <link:presentationLink xlink:role="http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-79f1-bb96-2a9187713af3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c0fe8-83c9-79f1-bb96-2a9187713af3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:to="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_019c0fe8-83c9-7aa2-946e-04b90d6a8709" xlink:to="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_A2025RestructuringMember_019c0fe8-83c9-719b-abb4-ce5e66e30577" xlink:href="kros-20251231.xsd#kros_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_019c0fe8-83c9-7ee5-8f5e-18e8dfed8675" xlink:to="loc_kros_A2025RestructuringMember_019c0fe8-83c9-719b-abb4-ce5e66e30577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c0fe8-83c9-7364-82aa-3f134ac46954" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c0fe8-83c9-763e-b8fd-92ca9c4c4fa5" xlink:to="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-7737-8a11-53bf25f499fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-7737-8a11-53bf25f499fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-7a46-9f20-e54c977d738c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_RestructuringCharges_019c0fe8-83c9-7a46-9f20-e54c977d738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_019c0fe8-83c9-7227-a152-b7bc42c3a27e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_PaymentsForRestructuring_019c0fe8-83c9-7227-a152-b7bc42c3a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-757f-9dad-8ea1824b21db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_us-gaap_RestructuringReserve_019c0fe8-83c9-757f-9dad-8ea1824b21db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_019c0fff-c89f-7ada-a236-1838766719af" xlink:href="kros-20251231.xsd#kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_019c0fe8-83c9-7162-9ce0-c01048b69e05" xlink:to="loc_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_019c0fff-c89f-7ada-a236-1838766719af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_KeithRegnanteMember" xlink:href="kros-20251231.xsd#kros_KeithRegnanteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_KeithRegnanteMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_LorenaLernerMember" xlink:href="kros-20251231.xsd#kros_LorenaLernerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_LorenaLernerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_NimaFarzanMember" xlink:href="kros-20251231.xsd#kros_NimaFarzanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_NimaFarzanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JuliusKnowlesMember" xlink:href="kros-20251231.xsd#kros_JuliusKnowlesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_JuliusKnowlesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_AlpnaSethMember" xlink:href="kros-20251231.xsd#kros_AlpnaSethMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_AlpnaSethMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_kros_JeanJacquesBienaimeMember" xlink:href="kros-20251231.xsd#kros_JeanJacquesBienaimeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_kros_JeanJacquesBienaimeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>kros-20251231_g1.jpg
<TEXT>
begin 644 kros-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %>!#<# 2(  A$! Q$!_\0
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;B49C,T+)O\ ]W(Y_"OL36ULM+_;9\ W'Q277(M"V$Q-XYU>TU(JP:?R&:2
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MRRWL:I&K%3)\J!V&T;.:S]L^6]NWXFGL];7/CR&*2XD2*&-YI7.$CB4LS'T
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M@\$M@ U]+?LP_%#P]\,?@)\0KW6]0UJ&=?$.D7%O8^&]52QU"XV;CP6Y:+.
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M_?V/_P")HW:1_P \]0_[^Q__ !-4** +^[2/^>>H?]_8_P#XFC=I'_//4/\
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M7[7_ ) >H_\ 7:W_ /:E)@4****8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %7_\ F7?^WW_VG5"K_P#S+O\ V^_^TZ0%"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%(>AH *6ON/P;I'@^;6_@#\.[KX5>&M?L/&_AB&ZU75$LF358I6:56N%N$8
M$!1&&.1Z\]*\MD_9"MI-<T:VM?%<DECJFA:WKL=RMB'$:6$S(L>=X#[P%._C
M&>AK!5H]=/Z_X!K[-]#YM9@JDDX ZDT9SR.17U=\*_@#X:^'_P 8/A!:^(?%
M*:IXQU:ZTW4Y_"O]CO)9"TN,D*URQV.P4Y*[<'&,U8UK]C6T\>>.K*]\*>-K
M:ZT76M6UM;Z1M--M_9C6<C-+'$C.!(HR%4DH.AX'0]M!/4/9RL?)5%?39_9!
M\-6MKXBU:^^*5K%X;TBQTV_>^L[*.^EC%U.\+0RI!.ZB5&3HCLIW Y !K8C_
M &%]+T[7]1TSQ!\1_P"RO)\6P^$[.6'1VG^URSVR3P/@2#83O ;/"X)R>*/;
M0[B]G(^3**^FX_V)9K'P=/JNO>.-+T2_FFU2+3H9S"EO/]BD:,[WDF20&1D;
M:(XY,<;L9K8_8=\"^!?&W@WXBIXVT:QO1<W&FZ/8ZA=PJ\FGS7GG1))&Q^Z?
M,,?([@4.M%1<EK8%3E=)GR917W)=?LS>'=*_9]T/P/J.G6=C\2Y/$.CVNKZ[
M]F62YLS?W$@6('()"Q+&VW(!W5Y7I?[(5G=30C4?'=MH-L_C74/"+76I6HBC
M M8FD$P9I -\A78J$@9(^:A5H.XW3D?-]%?1MW^R?I7A>/Q5K'C3Q9JW@WPI
MH=Y:::MQ>:!Y]_<7,Z!P!!#,R>6!R)!(P;MSQ57_ (9,2XMK>6+Q1*T-QX N
M_'"RC3\ >2Y46_+\;N#O/(SC;5>UAW%[.1\]JP894@CU%+7VS\1?V8+'XO?'
M6[M[>X?PCIOV'0[&WGL]/MQ9FZGLE?#%YHLL3@[8U=SDG'%>)>./V>=)^'/P
MAL_%FM^,FCUZ^O\ 4-,LM!M]-:19Y[2Y\F0^?OPB;06RRYR5 !R2%&K&5N[!
MTY(\2I:^S? <7A72?"O[.7ARX^%?AGQ:/'D5S%J]W<6#'4R!>&(2QSHP*[%.
M22.B]17,Z[^QKH\FL:MJ6B>,9'\$Z5>:]#K-]]D$KZ1]@):.(G>!*95*!3E>
M2>#2]M&]GH/V;MH?+%%?5GA']D/PQ_PE?PN_MCQ3J.N>&O%5U!;S:EHMC&]@
M9I(F<6BW"3,R2;E"-YB(1R0#BL36OV9?!;>'_$_B;3O']U;Z7!XKF\*Z/97&
MC,9;N\V QQ$^9E%$A*&1N-J;^IVT_;0O87LY'S=2,P526(4>IKZHNOV)=/DU
MW^Q](^(8U74-*\16'AOQ)&VCO MC-=$!'MV=\7"JQ((^7UKKO@C^S!X?\+_&
M+P3KEAXHM_'.D6?B^Z\*ZS8WVCM;(ETEM,XV+(6$R83DX&"!BDZT$KC5*5['
MQ517T_J/[(FCZY-IUYX;\>C5U\2:?K-[HT/]DM ;B_L9/WMD%9\@,"VQ\9.S
M[HR*Y*W_ &>['2?VD/ 'PRU#5I+^;4GTTZXJQ"$V<DZB66U4ACN*H0-W'+=!
MBJ56+%[.1X92U]A3>)_"_A;X.ZAXTLOA-X/UZ[U/XDWFA0Z;J&E>88K%(5,=
MO!L(*O\ +UY^9F."37K-K^SC\+;'5/BWX1_L&SAEU74;+3-"FNP)9]&O+O37
MGC@20Y9<3* !G^, UFZZCNBE2;V9^<E)7Z V/P'\$^&? /P<\/ZCX7TRY\66
MWC71],\47<UNKRSR7,#W,MK(W=562-2IX^45P?B/_A%/&7P_^,'B5OAIX7\-
M7_PSU^!=*OM)L3!::G&+QHFL[F)F*RDHO./[PZ=Q5D]D#IM=3YE^&?A.[\<>
M)GT>REAAN9[.?:]P2$&$[X!/>O0?^&3?%?\ T%-'_P"_DO\ \17>MX$TOX<_
MMF:SH^AP_9=&DLCJ%G:YS]FCN+:.<0_\ +E1[ 5[A7SF99E7P]91I/1I/8_5
M.%^&\!FF!E7Q2;DI-:.VB2_S/E+_ (9-\5_]!31_^_DO_P 11_PR;XK_ .@I
MH_\ W\E_^(KZMHKRO[:Q?=?<?7?ZDY/_ "R_\"9\I?\ #)OBO_H*:/\ ]_)?
M_B*/^&3?%?\ T%-'_P"_DO\ \17U;11_;6+[K[@_U)R?^67_ ($SY2_X9-\5
M_P#04T?_ +^2_P#Q%'_#)OBO_H*:/_W\E_\ B*^K:*/[:Q?=?<'^I.3_ ,LO
M_ F?*7_#)OBO_H*:/_W\E_\ B*/^&3?%?_04T?\ [^2__$5]6T4?VUB^Z^X/
M]2<G_EE_X$SY2_X9-\5_]!31_P#OY+_\11_PR;XK_P"@IH__ '\E_P#B*^K:
M*/[:Q?=?<'^I.3_RR_\  F?*7_#)OBO_ *"FC_\ ?R7_ .(H_P"&3?%?_04T
M?_OY+_\ $5]6T4?VUB^Z^X/]2<G_ )9?^!,^4O\ ADWQ7_T%-'_[^2__ !%'
M_#)OBO\ Z"FC_P#?R7_XBOJVBC^VL7W7W!_J3D_\LO\ P)GRE_PR;XK_ .@I
MH_\ W\E_^(H_X9-\5_\ 04T?_OY+_P#$5]6T4?VUB^Z^X/\ 4G)_Y9?^!,^4
MO^&3?%?_ $%-'_[^2_\ Q%!_9-\5_P#04T?_ +^2_P#Q%?5M%']M8ONON#_4
MG)_Y9?\ @3/ES4_V5_%%Y>&6/4])"[(T :23/RHJG^#U%5?^&3?%?_04T?\
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MK]2:*/K53R#ZO _+;_AW5\9_^?/P_P#^#A?_ (FC_AW5\9_^?/P__P"#A?\
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ML!AL1+FJQN]MV>_@<_S++:7L<+5Y8MWVB]7ZI]CZ+_X:^_ZE3_R?_P#L*/\
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M\G__ +"OG2BC^R<%_)^+_P P_P!;\[_Y_P#_ )+#_P"1/HO_ (:^_P"I4_\
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M+_X:^_ZE3_R?_P#L*/\ AK[_ *E3_P G_P#["OG2BC^R<%_)^+_S#_6_._\
MG_\ ^2P_^1/HO_AK[_J5/_)__P"PH_X:^_ZE3_R?_P#L*^=**/[)P7\GXO\
MS#_6_._^?_\ Y+#_ .1/HO\ X:^_ZE3_ ,G_ /["C_AK[_J5/_)__P"PKYTH
MH_LG!?R?B_\ ,/\ 6_._^?\ _P"2P_\ D3Z+_P"&OO\ J5/_ "?_ /L*/^&O
MO^I4_P#)_P#^PKYTHH_LG!?R?B_\P_UOSO\ Y_\ _DL/_D3Z+_X:^_ZE3_R?
M_P#L*/\ AK[_ *E3_P G_P#["OG2BC^R<%_)^+_S#_6_._\ G_\ ^2P_^1/H
MO_AK[_J5/_)__P"PJ]X=_;#GA\2:>R^"[&[B\P9AO+V0KN['Y5&0/0U\S5H>
M'O\ D.V'_79::RO!Q?,H?B_\S.IQ5G-:#IRKNS[**_%*Y]@_\/0_%W_0@^'_
M /P,N*/^'H7B[_H0?#__ (&7%?%M+7=["E_*?+^VGW/M'_AZ%XN_Z$'P_P#^
M!EQ1_P /0O%W_0@^'_\ P,N*^+J*/84OY1^VGW/M'_AZ%XN_Z$'P_P#^!EQ1
M_P /0O%W_0@^'_\ P,N*^+J*/84OY0]M/N?:/_#T+Q=_T(/A_P#\#+BC_AZ%
MXN_Z$'P__P"!EQ7Q=11["E_*'MI]S[1_X>A>+O\ H0?#_P#X&7%'_#T+Q=_T
M(/A__P #+BOBZBCV%+^4/;3[GVC_ ,/0O%W_ $(/A_\ \#+BC_AZ%XN_Z$'P
M_P#^!EQ7Q=11["E_*'MI]S[1_P"'H7B[_H0?#_\ X&7%'_#T+Q=_T(/A_P#\
M#+BOBZBCV%+^4/;3[GVC_P /0O%W_0@^'_\ P,N*/^'H7B[_ *$'P_\ ^!EQ
M7Q=11["E_*'MI]S[1_X>A>+O^A!\/_\ @9<4?\/0O%W_ $(/A_\ \#+BOBZB
MCV%+^4/;3[GVC_P]"\7?]"#X?_\  RXJS#_P4X\6R:?=7!\!Z"&A>- OVRXP
M=V[/_H/ZU\2U?M?^0'J/_7:W_P#:E'L*7\H>VGW/L+_AZ%XN_P"A!\/_ /@9
M<4?\/0O%W_0@^'__  ,N*^+J*/84OY0]M/N?:/\ P]"\7?\ 0@^'_P#P,N*/
M^'H7B[_H0?#_ /X&7%?%U%'L*7\H>VGW/M'_ (>A>+O^A!\/_P#@9<4?\/0O
M%W_0@^'_ /P,N*^+J*/84OY0]M/N?:/_  ]"\7?]"#X?_P# RXH_X>A>+O\
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M^&>?A]_T /\ R:F_^*KT;:?2C:?2CZYB?^?LOO8?V+EG_0-#_P  C_D><_\
M#//P^_Z '_DU-_\ %4?\,\_#[_H ?^34W_Q5>C;3Z4;3Z4?7,3_S]E][#^Q<
ML_Z!H?\ @$?\CSG_ (9Y^'W_ $ /_)J;_P"*H_X9Y^'W_0 _\FIO_BJ]&VGT
MHVGTH^N8G_G[+[V']BY9_P! T/\ P"/^1YS_ ,,\_#[_ * '_DU-_P#%4?\
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M^#=&_L>'47NI;I?M$LWF,@C"G]XQQ@,>GK7Z5[3Z&O@S_@J0"&^&^1CB^_\
M:5=&'G*51)LRJQBH-I'P?1117KGFA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%2VOV?S/]),PBQ_R
MP"EL_B>E6L:1_>U'_OB/_&D!0HJ_C2/[VH_]\1_XT8TC^]J/_?$?^- %"BK^
M-(_O:C_WQ'_C1C2/[VH_]\1_XT 4**OXTC^]J/\ WQ'_ (T8TC^]J/\ WQ'_
M (T 4**OXTC^]J/_ 'Q'_C1C2/[VH_\ ?$?^- %"BK^-(_O:C_WQ'_C1C2/[
MVH_]\1_XT 4**OXTC^]J/_?$?^-&-(_O:C_WQ'_C0!0HJ_C2/[VH_P#?$?\
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MV-+^1?<'UW%?\_I?^!/_ #-7_A9GB_\ Z&G6/_ Q_P#&C_A9GB__ *&G6/\
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M8TC^]J/_ 'Q'_C1C2/[VH_\ ?$?^-'+'L',^YV/_  T)\4O^BC>*/_!M-_\
M%4?\-"?%+_HHWBC_ ,&TW_Q5<=C2/[VH_P#?$?\ C1C2/[VH_P#?$?\ C1RQ
M[!S/N=C_ ,-"?%+_ **-XH_\&TW_ ,51_P -"?%+_HHWBC_P;3?_ !5<=C2/
M[VH_]\1_XT8TC^]J/_?$?^-'+'L',^YV/_#0GQ2_Z*-XH_\ !M-_\51_PT)\
M4O\ HHWBC_P;3?\ Q5<=C2/[VH_]\1_XT8TC^]J/_?$?^-'+'L',^YV/_#0G
MQ2_Z*-XH_P#!M-_\51_PT)\4O^BC>*/_  ;3?_%5QV-(_O:C_P!\1_XT8TC^
M]J/_ 'Q'_C1RQ[!S/N=C_P -"?%+_HHWBC_P;3?_ !5'_#0GQ2_Z*-XH_P#!
MM-_\57'8TC^]J/\ WQ'_ (T8TC^]J/\ WQ'_ (T<L>P<S[G8_P##0GQ2_P"B
MC>*/_!M-_P#%5F>+/'WB;QYH-K+XE\0ZGX@DM;QD@?4KIYS$K1@L%+$X!(&<
M>E8.-(_O:C_WQ'_C6AC2?^$=^]J&/MO]R/\ YY_6BR6R"[[F!15_&D?WM1_[
MXC_QHQI'][4?^^(_\:HDH45?QI'][4?^^(_\:,:1_>U'_OB/_&@"A15_&D?W
MM1_[XC_QHQI'][4?^^(_\: *%%7\:1_>U'_OB/\ QHQI'][4?^^(_P#&@"A1
M5_&D?WM1_P"^(_\ &C&D?WM1_P"^(_\ &@"A15_&D?WM1_[XC_QHQI'][4?^
M^(_\: *%%7\:1_>U'_OB/_&H;K[#L7[*UT7SSYZH!CVP>M %:BBBF 4444 %
M%%% !1110 4444 %%%% !1110 4AI:2@#Z%^(?[..B>"/V??#7CR$>,-0U'6
M-+M=0:[2SMSHMJ\LFPPR2[A*'_N@*<[ER>37G?Q2^&MIX \-_#C4[6]N+N3Q
M3H UB>.95"P.9GCV)@<KA,\\\UN>,/C_ &_CCX7Z'X2U+P/IIU#1=+ATFQ\0
MKJ%R)XHHWWY\@,(BQ)8?,#C=QT&(O$WQUL/%WPOT+PGJG@#2+C5-#TI=)T[Q
M,;VX%U;Q"0ON$0(C))+=0>M81YU:_?\  U?+T/5]#_8]\,ZI\!].\<7FO^(=
M)NKOPW-KS:E<6UM_8D$J.56U>0L)?,<@!0 <Y]>*\7L_A;9W7[..H?$DWMRF
MI6OB6'0EL-J^28WMS*7)QNW C'IBNET+]J;6M'TO0=&N-"L=4\.:?X;F\,7F
MC74\GD:E;O(T@E?'W)49LJR\C'7FN)M_BE>6WP7O?ANMA =.NM<CUTWS2,9E
MD2$Q"/'0K@YSUS2BJG5]?P!N'0],\9?"?X0Z+\"=*\?:5K_CBXO-:N+G3M.L
M[RRLUB%W H+^<5;*Q$G@J2WL*DU_]G#1=!_9GT/XD!/&-_J6J:=]M::SL[=M
M'LF^T>3LGE+"1<CI@-R17EFL?$Z\UCX2^&_ ,EC!'8Z'J5UJ45XKL997G #*
MR] !CC%=3K'Q^M_$/P@T/P-J7@?3;JYT33WT_3]?_M"Y2>%6E,A;R581,<G^
M(&CEFK:]?P'>.OH>J>!?V._#'BKX&:+XVU#7_$6CW&I:-?:K)JC6UL=$L&@D
M9%BGD+"0-)M&T*#G)]@?+_A?\(/#.I?"_4OB3\0M>U31/"<&I)HUI;:#:1W%
M]>WAC\Q@HD(1453DD]>>G>YX5_:HUSPOH_A'1CHEAJ6@:'H]]H=YI-U-)Y&K
MVUS(9&$P'W61B"K+R,>]8WPV^/#^!?!^L>#M5\):1XV\%ZC>+J T;6))4^S7
M*C:LL4T9#J=H"GUQVR<JU36_?\ O#0ZGX#_ 7PM\:/%GQ @M;SQ5J&A>'[,7
MVG1:-9P-JE_&TP15,4AV!\') 8#@\T[X3?L^^'_'WCOXH:9J(\96^G>#[66Z
MBT[3=/AFUJ?9.(O)>#E?-&>54]0>:YOX=?'R'X>Z]XXNH_!&DW^C>++?[)/H
M/VNXMK>UA$HD5(GC;S, @#KGCK53PG\>-0\ ZE\0+KPOI4>@#Q;8M8(MG?3A
M]+0R*X:"4G>S KU8YYZTVJFMO($X:7.X\1?L^^"/ 7[1EO\ #OQ)XA\1/I.I
M061L;G3[. 7T%Q=%-D-U&[;4VACNV\_=XYK@OV@? _A#X:_$C4O"OA+4=<U3
M^QYYK'49M;AAC_TF.0J?)\H_-'@=6 /M7(Z!XNOM$\;:9XHF9]5U&RU"'46:
M\E9VN)(Y%?YW)+')7!/6I?B'XRN/B+X^\1>*KNVCL[K6K^;4);>%BR1-(Q8J
MI/) SWJU&2:N^A#<;:(W?A;\.;3QII?C77-7O;BQT+PKH[:C<M:(K333.ZQ6
MT"[N!OD898]%4]\5Z7\%OV5K/XI?">V\>7VNW.CZ18ZM>1>(+E8U>.QT^WME
MF,L8QN:5F8(%Y'.<<5YU\*/B%IOA/0_'WAS7([IM%\6:-]A>:S4/);W44BS6
MTNTD!E\Q=K#(.UB1TP>@^%?[47B7X1^%="T+1["REMM-UFXU:?[2S,E_'/ (
M);29/NF(J <]00#VJ9\[ORE1Y-+FG^SS\"?#GQQUKQ\ROXLETK0+5+RPLM$M
M[>?4[R-YO+52C[8R^W#$ @=?2K7P5_9UT7XH>/OB5H]TGB]+3PK!)<6^FZ;:
M6[ZQ/MN/*\IXG;RQ( >0& R#S7,?#CX\6GPWU;QRUMX&TV_T#Q7"MO-H,VH7
M$45K$LOFJD<J$28#8 R<X &:S/#_ ,:KOPA-\0F\/Z1#HT/BZT^QK';W<V[2
MU$RRJ89"2S,&4<L<TFJEW;RL"<-+C_CQ\)[/X5?%S4_!V@:I-XGBM4B966$&
MYCD9 SP2+&6'F1G(;;^G(J]\%_A#HWC2Q\:^(/&FJ:GX?\*^$;6"74&TVU66
M]:6>80Q1JDA 'S$EB>@%9/Q&^-.K?$#Q[;>-8+9/"_B@6L45YJ.B7$D+W=PJ
M;&NOE(\N1UP&"G!Z]S5OX6_';4?AW>>*?[3TBS\<:7XHA2/6-.UV:4B[=)1+
M'*TBG?O#C.3G.>:KW^2W47N\WD=_H7[*-O)^TYXH^%VI:EJE_8:+87&I1W6A
MV\;7MY$L*2PK'&YV[W$BK@G&[N!S7.>&/@3IOBSX]:QX-$_B#PWX=T>UN=1O
MYM>L8TU2WMK>$22AH5)3S">%P2,$'FL2?XY3>(/B]K7Q \7>&[#Q7=:J6:33
M9+JXLX(CA1'L:%@X"*@4 D@CKS6K_P -1>)IOCM?_%"[T[3;R^O[=]/N='D5
MA:2V30B$VYYW8V ?-G.1GVJ;5/P_$KW/Q_ T/$OP+\)Z#\5_ASI<?B/5)O G
MCNPM+_3]6DMXTO;5;AC$@FCY4E)0-P7JI.#FO(_%WAF]\$^+-:\.ZD%&H:3>
MS6-QL^[YD;E"1[$C(^M>EW7QPL/'/QD\%>)/%.DKHOA/PO':6]GH.@(76"UM
M3YD=NAD8$[W^\['.&)QP!7G'C?Q9=^//&FO^)K]52]UB_GOYD4Y"M(Y?:/89
MQ^%7'F^T1+EZ&+1116I 4444 :&D_P"IU3_KS;_T-*SZOZ5_J-4_Z]#_ .C$
MJA2 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4U_NM]*=37^ZW
MTH T_$/_ "&+CZ)_Z M9U:/B'_D,W/\ P#_T!:SJ2V![A1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "K_A__D.Z=_U\1_\ H0JA5_0/^0[IW_7Q
M'_Z$*3!;E!OO'ZT4-]X_6BF 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5^U_Y >H_]=K?_P!J50J_:_\ (#U'_KM;_P#M2DP*%%%%, HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "K__ #+O_;[_ .TZH5?_ .9=
M_P"WW_VG2 H4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 6.-Y7"1HTCMT5%+$_0"E\F3:Y\J3$
M9PYV'Y#TPWI^->U?LC^$O'WB[XEWD/P_UVX\+W-OITD^IZS:6PN)[:S#*7$,
M>UF>1B%5549).,XS7T/XMM_$?Q<T?]IR+2O FO:=K-[!X<6#1KJPV:E=K',<
MW,L*CAY C2$#H![&L)5>65OZW-8PYE<^#XH9;AML44DS]=L:%C^0I$ADD5V2
M*1U3EF5"0OU(Z?C7TY^PYJ6H?"OXT>.M2OM/FM]2\-^$]5N;FQN(RLD;P&-G
MC=3R""I&#WKZ)U+POX=^%/PS^-FB:#Y5['XT\/:GXXB,?&S36,*6D7MDRW'T
MQ4SK<LN6PXT^97N?FQ5K3]*OM6DE2PLKF^>&)IY5M86E,<:\L[!0<*.['@5]
M=W7[+_PNN+/PQK-OJ=Y8>'_B'J6DV7A5Y=0#R6*/&6U$S9&'9'7REW8 9UZU
MZ#I?P1\*_!KQ;XK'AVSUO2;VX\$>)[>YL]4CN##)%$D?ES1231H7R& ;:"F<
M;3BAUX] 5)GY\?2K46EWL^GSZA%97,EA;NL<UVD+&&)F^ZK.!M4GL">:^Q_%
M'['?@;2_!=XL*:YHPL+#1[FW^(&H7L;Z3K$EV\:R1118&W8)"1@\;>>.3VOC
MGX4^"O@S\%_B#H=[X0\4Z/X+A\8:-;ZA>:I?AFU>V5PKWEJRJ"BX8G'()48Q
MR >WCI8?LGU/SZHK[/OOV4_AIX$\=:'X4\22ZUK%_JAU/58I]'>:>)-.$@BT
MWSQ CNB2$[GE521@#H>-CP[^QKX66&_75O OB#7M6M_&J^'Y]/\ "^O":&QL
MWMXG^T22L@++&9"Q)"MR%;&#D]O 7LI'Q#+I=[;Z?;W\MG<1V%P[1PW3PL(I
M67[RHY&&([@'CO5:ONZ;X"V/BGP/X!\!:>W_  DVA:+XF\6,C_:WA:Z@MV 4
MJ84=W;./EC4ECG&*K-^QOX"M_BAJ_AR+3M=O;J[T?3;_ $6PNYKJ&RCFF$AG
MAN+N.!VC8"(E/-4#KN)Q1[>/4/9/H?$6FZ;>:U?16.G6=QJ%[,=L5K:1-++(
M<9PJ*"3P#T':H&4HS*P*LIP588((Z@U][_#OX0^$-=\*_L^G2?">L:#?WFMZ
ME8:IXJT'5RDUO-%YBLLEQ&H),AC/ED$;55@,Y)KQWQA\!= \,_ 6P\5VOA?Q
M-XMU/5K*YU"X\56=\HTW19$N"@@GCP2[8&&+$$D\9Z!JM%NW]=?\@=-VN?-B
MPRR1M(D4CQ*<-(J$JOU.,"F5]U^$[/Q+XP_8]BT^.'7?A]IGAWPW/J%Q*(H3
MH'BRS9LLKS8WQW3C*CG()SZ8R;?]E;X6KXA\%3";4-0T'XBZW91>&(8]0*S0
M:=]D\Z\:4@<NLI$0SR*7MEK</9/2Q\559NM+O;&UM+FYLKFVMKQ#);330LB3
MJ#@M&Q&' /&1FOLGPW^RS\+_ !Y=>#=0T:V\26>G74GB"WN]&N-0CDN]4FTX
M@1QP/M 1I3DX X (Z@M7:^+/@WX2\5:+\.-+\4^&?$OA[0?#OP[UK6UT*:]'
M]HV;PW$;^4\FW#$!B/F4=5W#(-#KQO8/9.US\^**^SO 7[+OPY^('@+0]=MM
M#\36^G>)+#5-3;Q+'JD<EAX5$&XPVUR"@\UOE 9FVDYX'H[4/V=_@YH/A&YN
M]0TCQ5<:AIO@#3O&]W-9ZLB1W'F,5D@C5HSLWD'YCG:#P..7[:-[![*6Y\7T
M5]V:=^Q=\.V\<>.UV:[JVEZ2^D&TT.UDFEO8(+N!9996\B-Y)"N65?E"Y!W'
M%>=^*_V<?!5G\$?%GB#PS:ZSJ6K:#/=M=7_B!Y].$=NET8H'MT\KR;C*JRNO
MF!]^<#C%"K0?]=Q>RDCY:CMYI^8H991G;^[C+<^G Z^U"V\TDC(D$KNOWD6-
MBRXZY&.*^XOV;1)H5_\ LM6&DKBRU63Q!K5\T?2XU!$EA4/CJ8XE4 'H&/K7
ML/PW3P]I_C34?B+I:Q/=?&32Y;BWMT^]:K;:?))?#ZFZ$8J)5^5O3^K_ / +
MC2OU/R]:UG6'SFMYE@QGS3$VS'KNQBDCAEF1GCADD13AG1"RK]2!Q7Z*?"FZ
M^)ZZ?^S?;:)#<3?"N3PLI\5"]AC;21!YDAE,[2#:'$8! SGIQC-9>EV6I^,O
MV=]?T+PC_;OPW\+Z19ZSJ6GZ[;V\+Z#XETYYI0$N)"-\<VT;5YR ,^@#]OKM
M^(O9'Q-X!\&:MXRU#5=*TNW5[\6;,8IW$6 )$SG=T-=-_P ,T^/_ /H'6?\
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M/_P.C_QK[(HH_MS%=H_<_P#,/]0\J_FG]Z_^1/C?_AFGQ_\ ] ZS_P# Z/\
MQH_X9I\?_P#0.L__  .C_P :^R**/[<Q7:/W/_,/]0\J_FG]Z_\ D3XW_P"&
M:?'_ /T#K/\ \#H_\:1OV:?'Y4C^S;/I_P _T?\ C7V311_;F*[1^Y_YA_J'
ME7\T_O7_ ,B?(>L?LY>.[S4IYHM/M#&VW!-[&.B@>OM5/_AFGQ__ - ZS_\
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M/_&C_AFGQ_\ ] ZS_P# Z/\ QK[(HH_MS%=H_<_\P_U#RK^:?WK_ .1/C?\
MX9I\?_\ 0.L__ Z/_&C_ (9I\?\ _0.L_P#P.C_QK[(HH_MS%=H_<_\ ,/\
M4/*OYI_>O_D3XW_X9I\?_P#0.L__  .C_P :/^&:?'__ $#K/_P.C_QK[(HH
M_MS%=H_<_P#,/]0\J_FG]Z_^1/C?_AFGQ_\ ] ZS_P# Z/\ QH_X9I\?_P#0
M.L__  .C_P :^R**/[<Q7:/W/_,/]0\J_FG]Z_\ D3XW_P"&:?'_ /T#K/\
M\#H_\:MZ3^SCX\M-5LYY=.M!'',CL1>QG !!/>OKVBC^W,5VC]S_ ,P_U#RK
M^:?WK_Y$^.#^S3X_W'_B76?7_G^C_P :3_AFGQ__ - ZS_\  Z/_ !K[(HH_
MMS%=H_<_\P_U#RK^:?WK_P"1/C?_ (9I\?\ _0.L_P#P.C_QH_X9I\?_ /0.
ML_\ P.C_ ,:^R**/[<Q7:/W/_,/]0\J_FG]Z_P#D3XW_ .&:?'__ $#K/_P.
MC_QH_P"&:?'_ /T#K/\ \#H_\:^R**/[<Q7:/W/_ ##_ %#RK^:?WK_Y$^-_
M^&:?'_\ T#K/_P #H_\ &C_AFGQ__P! ZS_\#H_\:^R**/[<Q7:/W/\ S#_4
M/*OYI_>O_D3XW_X9I\?_ /0.L_\ P.C_ ,:/^&:?'_\ T#K/_P #H_\ &OLB
MBC^W,5VC]S_S#_4/*OYI_>O_ )$^-_\ AFGQ_P#] ZS_ / Z/_&C_AFGQ_\
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M_P# Z/\ QH_X9I\?_P#0.L__  .C_P :^R**/[<Q7:/W/_,/]0\J_FG]Z_\
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M]/\ A9GA#_H:='_\#$_QH_X69X0_Z&G1_P#P,3_&O@O:/2C:/2N/^P:7\[_
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M.!*NCQ_:I%3N< @?F:^']H]**N&0T(R3E)M&-;C['3IN-.E&+?75V/T]M_\
M@HO\&[6WB@B3Q(D42"-%_LH<*!@#_65)_P /'O@_Z>)?_!4/_CE?E_17M?5:
M9^<O$5&[L_4#_AX]\'_3Q+_X*A_\<H_X>/?!_P!/$O\ X*A_\<K\OZ*/JM,/
MK$S]0/\ AX]\'_3Q+_X*A_\ '*/^'CWP?]/$O_@J'_QROR_HH^JTP^L3/U _
MX>/?!_T\2_\ @J'_ ,<H_P"'CWP?]/$O_@J'_P <K\OZ*/JM,/K$S]0/^'CW
MP?\ 3Q+_ ."H?_'*^./VO/B]X?\ CA\0&\3^&A>#2S%;6G^G0>3)YD<;[OER
M>/F'.:\&J_\ \R[_ -OO_M.KA0A3?-$B564U9E"BBBNDQ"BBMSP3X'U[XC^*
M+'P[X:TR?5]9O&VPVMN,GW9CT51U+'  I;:L#")"@DG KU/X7_LR_$3XN6?]
MHZ-H1L] 7F37M8D%G8HO<^8^-V/]D&O;_#/PU^'W[/UY;6UU96WQ?^*K.J)8
MHIDT;3)R>(PHYNI0>,=,^F*^K_!?P$N_&UU:ZY\=O%$6H7BJLEMX/6Z2"RLE
MQ\H>-2 3C^$<>I:OGJV;QYW2PJYFMWT7S/O<-PI5IX>.-S6?L:<OAC:]2?\
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MH_X43X _Z%>S_P"^Y/\ XJN\HH^M8C_GY+[V']DY=_T#P_\  (_Y'!_\*)\
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M_P!]R?\ Q5=Y11]:Q'_/R7WL/[)R[_H'A_X!'_(X/_A1/@#_ *%>S_[[D_\
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M9_\ XY7M7V>7_GF__?)H^SR_\\W_ .^31[2?\S#DCV/%?^&-?@G_ -$ZTO\
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M)H^SR_\ /-_^^31[2?\ ,PY(]CQ7_AC7X)_]$ZTO_O[/_P#'*/\ AC7X)_\
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M ,!_X ?V1Q;_ #5/_!J_^3/-O^%_?$#_ *&2;_OQ#_\ $4?\+^^('_0R3?\
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M3_P /_Q='_#(,G_0UI_X '_XNCZWE7:/_@/_   _LCBW^:I_X-7_ ,F>;?\
M"_OB!_T,DW_?B'_XBC_A?WQ _P"ADF_[\0__ !%>D_\ #(,G_0UI_P" !_\
MBZ/^&09/^AK3_P  #_\ %T?6\J[1_P# ?^ ']D<6_P U3_P:O_DSS;_A?WQ
M_P"ADF_[\0__ !%'_"_OB!_T,DW_ 'XA_P#B*])_X9!D_P"AK3_P /\ \71_
MPR#)_P!#6G_@ ?\ XNCZWE7:/_@/_ #^R.+?YJG_ (-7_P F>;?\+^^('_0R
M3?\ ?B'_ .(H_P"%_?$#_H9)O^_$/_Q%>D_\,@R?]#6G_@ ?_BZ/^&09/^AK
M3_P /_Q='UO*NT?_  '_ ( ?V1Q;_-4_\&K_ .3/-O\ A?WQ _Z&2;_OQ#_\
M11_PO[X@?]#)-_WXA_\ B*])_P"&09/^AK3_ , #_P#%T?\ #(,G_0UI_P"
M!_\ BZ/K>5=H_P#@/_ #^R.+?YJG_@U?_)GFW_"_OB!_T,DW_?B'_P"(H_X7
M]\0/^ADF_P"_$/\ \17I/_#(,G_0UI_X '_XNC_AD&3_ *&M/_  _P#Q='UO
M*NT?_ ?^ ']D<6_S5/\ P:O_ ),\V_X7]\0/^ADF_P"_$/\ \11_PO[X@?\
M0R3?]^(?_B*])_X9!D_Z&M/_   /_P 71_PR#)_T-:?^ !_^+H^MY5VC_P"
M_P# #^R.+?YJG_@U?_)GFW_"_OB!_P!#)-_WXA_^(H_X7]\0/^ADF_[\0_\
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M])_X9!D_Z&M/_  __%U')^Q_=M+&L/BVT16;#R7%DX"#UPK$FFL5E3=K1_\
M ?\ @$2RKBR*<FZG_@R_Y2/.O^%_?$#_ *&2;_OQ#_\ $4?\+^^('_0R3?\
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M/^AZ\.?^ US_ /$T>VH]P]G4['R]_P +:\=_]#OXD_\ !O<?_%T?\+:\=_\
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M.L^+]=N]=U#&U'N&^2)<YVQH,*B^R@5R]%%=*22LCAWW"BBBF 4444 %%%%
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MY_\  Y?_ (BC^R<;_P ^_P 5_F'^MN2?]!'_ )++_P"1/H2BOGO_ (:^L_\
MH5+G_P #E_\ B*#^U_9@$_\ "*7/_@<O_P 11_9.-_Y]_BO\P_UMR3_H(_\
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MN2?]!'_DLO\ Y$^A**^>_P#AKZS_ .A4N?\ P.7_ .(H_P"&OK/_ *%2Y_\
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M['![>GW/T$HK\^_^'HVM_P#1.=+_ /!K+_\ &Z/^'HVM_P#1.=+_ /!K+_\
M&Z/JU7L'MZ?<_02BOS[_ .'HVM_]$YTO_P &LO\ \;H_X>C:W_T3G2__  :R
M_P#QNCZM5[![>GW/T$HK\^_^'HVM_P#1.=+_ /!K+_\ &ZLP_P#!3S6I-/N;
MC_A7>E@PO&@7^U)>=V[_ *9]MOZT?5JO8/;0[GWW17Y]_P##T;6_^B<Z7_X-
M9?\ XW1_P]&UO_HG.E_^#67_ .-T?5JO8/;T^Y^@E%?GW_P]&UO_ *)SI?\
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MNNZ/\0!"^CZ_;6TL2;'D$99X9,.N"1QW![5FYQ3LV4HMJ]CRC[/I?_/]=?\
M@(O_ ,<H^SZ7_P _UU_X"+_\<KU3XZ?LWR_!?PQIOB&W\56?BC2;S4;G26:.
MPN+":*Y@SYB^7, 73@C>OR_4$&H_C=^S_:?!32=/>?QG#K6MW*6TTFDP:/=0
MB&*:'S5;[0P,3D# VJV[GIP:%.+M9[C<6MT>7_9]+_Y_KK_P$7_XY1]GTO\
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MC[/I?_/]=?\ @(O_ ,<K/HH T/L^E_\ /]=?^ B__'*/L^E_\_UU_P" B_\
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M /'*SZ* -#[/I?\ S_77_@(O_P <H^SZ7_S_ %U_X"+_ /'*SZ* -#[/I?\
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M[/I?_/\ 77_@(O\ \<K/HH T/L^E_P#/]=?^ B__ !RC[/I?_/\ 77_@(O\
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M6?10!H?9]+_Y_KK_ ,!%_P#CE'V?2_\ G^NO_ 1?_CE9]% &A]GTO_G^NO\
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MIMKB:9\\K) (P!ZY#&JU% !1113 **** "BBB@ HHHH **** "BBB@ HHHH
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M/,**]/\ ^&7?C!_T3/Q+_P" )H_X9=^,'_1,_$O_ ( FCGCW#EEV/,**]/\
M^&7?C!_T3/Q+_P" )H_X9=^,'_1,_$O_ ( FCGCW#EEV/,**]/\ ^&7?C!_T
M3/Q+_P" )H_X9=^,'_1,_$O_ ( FCGCW#EEV/,**]/\ ^&7?C!_T3/Q+_P"
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MX>2?"/\ Y]_$_P#X+$_^.UY?L:G\IV^TAW/J>BOEC_AY)\(_^??Q/_X+$_\
MCM'_  \D^$?_ #[^)_\ P6)_\=H]C4_E#VD.Y]3T5\L?\/)/A'_S[^)__!8G
M_P =H_X>2?"/_GW\3_\ @L3_ ..T>QJ?RA[2'<^IZ*^6/^'DGPC_ .??Q/\
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M?_P6)_\ ':/8U/Y0]I#N?4]%?+'_  \D^$?_ #[^)_\ P6)_\=H_X>2?"/\
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MP01S.BLD Y.PEN<<\5X]6T>:WO;F<K7]T****LD**** "BBB@ HHHH ****
M/H?]F7X7^&OB!X3\02Z]I[7KQ7T4:$3O'A1'N ^4CNQKUS_AF?X<_P#0!?\
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M*^G:*/;5/YF'LX=CYB_X=R_!O_GEXC_\&_\ ]A1_P[E^#?\ SR\1_P#@W_\
ML*^G:*/;5/YF'LX=CYB_X=R_!O\ YY>(_P#P;_\ V%'_  [E^#?_ #R\1_\
M@W_^PKZ=HH]M4_F8>SAV/F+_ (=R_!O_ )Y>(_\ P;__ &%'_#N7X-_\\O$?
M_@W_ /L*^G:*/;5/YF'LX=CYB_X=R_!O_GEXC_\ !O\ _84?\.Y?@W_SR\1_
M^#?_ .PKZ=HH]M4_F8>SAV/F+_AW+\&_^>7B/_P;_P#V%2I_P3O^#T=M- (O
M$7ERLK-_Q-N<KG'\'^T:^F**/;5/Y@]G#L?,7_#N7X-_\\O$?_@W_P#L*/\
MAW+\&_\ GEXC_P#!O_\ 85].T4>VJ?S,/9P['S%_P[E^#?\ SR\1_P#@W_\
ML*/^'<OP;_YY>(__  ;_ /V%?3M%'MJG\S#V<.Q\Q?\ #N7X-_\ /+Q'_P"#
M?_["C_AW+\&_^>7B/_P;_P#V%?3M%'MJG\S#V<.Q\Q?\.Y?@W_SR\1_^#?\
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MK]F>\;[/'XC^)VG,3M%_<:=92Q?[QC4A@/;K7AMTD4=U.D$AF@61ECE9=I=
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M[9\9? 7PG\-_#_Q,U*;295T73[/0=2M])T[7+Z%+FVGOW1EO(I@'CD,8 V2
M[""RXS@=+\6/V>O!'Q,_:"\5^!-,\(CP3K]YINGZGX;U2*^(L=1@C:,79CA
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M5K_WX3_"C^S;/_GRM?\ OPG^%'UB'\B_KY![&?\ ,?D3_P -F_&O_HHVJ?\
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M_P"_"?X4?6(?R+^OD'L9_P Q^1/_  V;\:_^BC:I_P!^H/\ XW1_PV;\:_\
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MI$^(NJ*BS.JCRH. &( _U=0?\-F_&O\ Z*-JG_?J#_XW7Z[_ -G6?_/E:_\
M?A/\*3^S;/\ Y\K7_OPG^%'UB'\B_KY![&7\Q^1/_#9OQK_Z*-JG_?J#_P"-
MT?\ #9OQK_Z*-JG_ 'Z@_P#C=?KM_9MG_P ^5K_WX3_"C^S;/_GRM?\ OPG^
M%'UB'\B_KY![&?\ ,?D3_P -F_&O_HHVJ?\ ?J#_ .-T?\-F_&O_ **-JG_?
MJ#_XW7Z[?V;9_P#/E:_]^$_PH_LVS_Y\K7_OPG^%'UB'\B_KY![&?\Q^1/\
MPV;\:_\ HHVJ?]^H/_C='_#9OQK_ .BC:I_WZ@_^-U^NW]FV?_/E:_\ ?A/\
M*/[-L_\ GRM?^_"?X4?6(?R+^OD'L9_S'Y$_\-F_&O\ Z*-JG_?J#_XW1_PV
M;\:_^BC:I_WZ@_\ C=?KM_9MG_SY6O\ WX3_  H_LVS_ .?*U_[\)_A1]8A_
M(OZ^0>QG_,?D3_PV;\:_^BC:I_WZ@_\ C='_  V;\:_^BC:I_P!^H/\ XW7Z
M[?V;9_\ /E:_]^$_PH_LVS_Y\K7_ +\)_A1]8A_(OZ^0>QG_ #'Y$_\ #9OQ
MK_Z*-JG_ 'Z@_P#C='_#9OQK_P"BC:I_WZ@_^-U^NW]FV?\ SY6O_?A/\*/[
M-L_^?*U_[\)_A1]8A_(OZ^0>QG_,?D3_ ,-F_&O_ **-JG_?J#_XW1_PV;\:
M_P#HHVJ?]^H/_C=?KM_9MG_SY6O_ 'X3_"C^S;/_ )\K7_OPG^%'UB'\B_KY
M![&?\Q^1/_#9OQK_ .BC:I_WZ@_^-T?\-F_&O_HHVJ?]^H/_ (W7Z[?V;9_\
M^5K_ -^$_P */[-L_P#GRM?^_"?X4?6(?R+^OD'L9_S'Y$_\-F_&O_HHVJ?]
M^H/_ (W5VW_;&^-#:3?2GXB:H9(Y855O*@X!WY_Y9]\#\J_6G^S;/_GRM?\
MOPG^%+_9]GT^Q6N/^N"?X4?6(?R+^OD'L9?S'Y$?\-F_&O\ Z*-JG_?J#_XW
M1_PV;\:_^BC:I_WZ@_\ C=?KM_9MG_SY6O\ WX3_  H_LVS_ .?*U_[\)_A1
M]8A_(OZ^0>QG_,?D3_PV;\:_^BC:I_WZ@_\ C='_  V;\:_^BC:I_P!^H/\
MXW7Z[?V;9_\ /E:_]^$_PH_LVS_Y\K7_ +\)_A1]8A_(OZ^0>QG_ #'Y$_\
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M-AK&K:!H]U)!)J\FD3VZJJGAIE8'R&QC*.<C/-=/\&_@+K7Q6\9:9H]U'?\
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MT3_P)?\ ^-T?\,?^-/\ GOHG_@2__P ;J^>?\HK+N?5G_"<^&O\ H8](_P#
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M3[ID_:>^$,,CQR?$KPVCH2K*;T9!'44S_AJ+X/\ _13/#7_@<*^(-2_X)O\
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M **9X:_\#A7PO_P[8^+'_/\ ^%__  82_P#QFC_AVQ\6/^?_ ,+_ /@PE_\
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M\#A1_P -1?!__HIGAK_P.%?"_P#P[8^+'_/_ .%__!A+_P#&:/\ AVQ\6/\
MG_\ "_\ X,)?_C-'LJ/\X>TJ_P I]T?\-1?!_P#Z*9X:_P# X4?\-1?!_P#Z
M*9X:_P# X5\+_P##MCXL?\__ (7_ /!A+_\ &:/^';'Q8_Y__"__ (,)?_C-
M'LJ/\X>TJ_RGW1_PU%\'_P#HIGAK_P #A1_PU%\'_P#HIGAK_P #A7PO_P .
MV/BQ_P __A?_ ,&$O_QFC_AVQ\6/^?\ \+_^#"7_ .,T>RH_SA[2K_*?='_#
M47P?_P"BF>&O_ X4]?VG/A$T3R#XD^&S&A 9OMHP"<X'XX/Y5\*?\.V/BQ_S
M_P#A?_P82_\ QFK</_!.'XJQZ;=VYO\ PQOEDB9?]/EQA=^<_NO]H4>RH_SA
M[2K_ "GV[_PU%\'_ /HIGAK_ ,#A1_PU%\'_ /HIGAK_ ,#A7PO_ ,.V/BQ_
MS_\ A?\ \&$O_P 9H_X=L?%C_G_\+_\ @PE_^,T>RH_SA[2K_*?='_#47P?_
M .BF>&O_  .%'_#47P?_ .BF>&O_  .%?"__  [8^+'_ #_^%_\ P82__&:/
M^';'Q8_Y_P#PO_X,)?\ XS1[*C_.'M*O\I]T?\-1?!__ **9X:_\#A1_PU%\
M'_\ HIGAK_P.%?"__#MCXL?\_P#X7_\ !A+_ /&:/^';'Q8_Y_\ PO\ ^#"7
M_P",T>RH_P X>TJ_RGW1_P -1?!__HIGAK_P.%'_  U%\'_^BF>&O_ X5\+_
M /#MCXL?\_\ X7_\&$O_ ,9H_P"';'Q8_P"?_P +_P#@PE_^,T>RH_SA[2K_
M "GW1_PU%\'_ /HIGAK_ ,#A1_PU%\'_ /HIGAK_ ,#A7PO_ ,.V/BQ_S_\
MA?\ \&$O_P 9H_X=L?%C_G_\+_\ @PE_^,T>RH_SA[2K_*?='_#47P?_ .BF
M>&O_  .%'_#47P?_ .BF>&O_  .%?"__  [8^+'_ #_^%_\ P82__&:/^';'
MQ8_Y_P#PO_X,)?\ XS1[*C_.'M*O\I]T?\-1?!__ **9X:_\#A1_PU%\'_\
MHIGAK_P.%?"__#MCXL?\_P#X7_\ !A+_ /&:/^';'Q8_Y_\ PO\ ^#"7_P",
MT>RH_P X>TJ_RGW1_P -1?!__HIGAK_P.%'_  U%\'_^BF>&O_ X5\+_ /#M
MCXL?\_\ X7_\&$O_ ,9H_P"';'Q8_P"?_P +_P#@PE_^,T>RH_SA[2K_ "GW
M1_PU%\'_ /HIGAK_ ,#A1_PU%\'_ /HIGAK_ ,#A7PO_ ,.V/BQ_S_\ A?\
M\&$O_P 9H_X=L?%C_G_\+_\ @PE_^,T>RH_SA[2K_*?='_#47P?_ .BF>&O_
M  .%?,/_  4&^+G@CXC?"?PS;>%?%>E>(;BWUWS)8M/N!(R+]GD&2.PR1^=>
M:_\ #MCXL?\ /_X7_P#!A+_\9KS/XZ?LZ^*?V>=)T6U\43Z9/)JUQ+-;_P!F
MSM* L:*K;MR+@Y88ZUI3ITE-.,KLSG.HXM.)Y!1117HG&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M (/OI].\4:5/;DB7[0B8'\2L0"/R-?3+<,17YRZ'^W-X7\*>(A>Q>#M3UR.
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MC2_^B;7_ /X-X_\ XU1_P](TO_HFU_\ ^#>/_P"-4?5ZO8/;4^Y]QT5\.?\
M#TC2_P#HFU__ .#>/_XU3H?^"HFERS1Q_P#"M[\;V"Y_M>/C)Q_SRH^KU>P>
MVAW/N&BOB&Z_X*@:7:W4\!^'%^QBD:/=_:T?."1G_5>U1?\ #TC2_P#HFU__
M .#>/_XU1]7J]@]M#N?<=%?#G_#TC2_^B;7_ /X-X_\ XU1_P](TO_HFU_\
M^#>/_P"-4?5ZO8/;4^Y]QT5\.?\ #TC2_P#HFU__ .#>/_XU1_P](TO_ *)M
M?_\ @WC_ /C5'U>KV#VU/N?<=%?#G_#TC2_^B;7_ /X-X_\ XU1_P](TO_HF
MU_\ ^#>/_P"-4?5ZO8/;4^Y]QT5\.?\ #TC2_P#HFU__ .#>/_XU1_P](TO_
M *)M?_\ @WC_ /C5'U>KV#VU/N?<=%?#G_#TC2_^B;7_ /X-X_\ XU1_P](T
MO_HFU_\ ^#>/_P"-4?5ZO8/;4^Y]QT5\.?\ #TC2_P#HFU__ .#>/_XU1_P]
M(TO_ *)M?_\ @WC_ /C5'U>KV#VU/N?<=%?#G_#TC2_^B;7_ /X-X_\ XU1_
MP](TO_HFU_\ ^#>/_P"-4?5ZO8/;4^Y]QT5\.?\ #TC2_P#HFU__ .#>/_XU
M1_P](TO_ *)M?_\ @WC_ /C5'U>KV#VU/N?<=%?#G_#TC2_^B;7_ /X-X_\
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M_P"'7_P>_P"?KQ-_X'Q?_&:/KE+S#ZO,_)JBOUE_X=?_  >_Y^O$W_@?%_\
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MB;_P/B_^,T?7*7F'U>9^35%?K+_PZ_\ @]_S]>)O_ ^+_P",T?\ #K_X/?\
M/UXF_P# ^+_XS1]<I>8?5YGY-45^LO\ PZ_^#W_/UXF_\#XO_C-'_#K_ .#W
M_/UXF_\  ^+_ .,T?7*7F'U>9^35%?K+_P .O_@]_P _7B;_ ,#XO_C-'_#K
M_P"#W_/UXF_\#XO_ (S1]<I>8?5YGY-45^LO_#K_ .#W_/UXF_\  ^+_ .,T
M?\.O_@]_S]>)O_ ^+_XS1]<I>8?5YGY-45^LO_#K_P"#W_/UXF_\#XO_ (S1
M_P .O_@]_P _7B;_ ,#XO_C-'UREYA]7F?DU3X?]='_OC^=?K%_PZ_\ @]_S
M]>)O_ ^+_P",TJ_\$P?@\K!A=>)L@Y'^GQ?_ !FCZY2\Q_5YGY3:Y_R&M0_Z
M^9/_ $,U2K]:;C_@F+\(;JXEFDN_$QDD<NQ^WQ#DG)_Y8U'_ ,.O_@]_S]>)
MO_ ^+_XS1]<I!]7F?DU17ZR_\.O_ (/?\_7B;_P/B_\ C-'_  Z_^#W_ #]>
M)O\ P/B_^,T?7*7F+ZO,_)JBOUE_X=?_  >_Y^O$W_@?%_\ &:/^'7_P>_Y^
MO$W_ ('Q?_&:/KE+S#ZO,_)JBOUE_P"'7_P>_P"?KQ-_X'Q?_&:/^'7_ ,'O
M^?KQ-_X'Q?\ QFCZY2\P^KS/R:HK]9?^'7_P>_Y^O$W_ ('Q?_&:/^'7_P '
MO^?KQ-_X'Q?_ !FCZY2\P^KS/R:HK]9?^'7_ ,'O^?KQ-_X'Q?\ QFC_ (=?
M_![_ )^O$W_@?%_\9H^N4O,/J\S\FJ*_67_AU_\ ![_GZ\3?^!\7_P 9H_X=
M?_![_GZ\3?\ @?%_\9H^N4O,/J\S\FJ*_67_ (=?_![_ )^O$W_@?%_\9H_X
M=?\ P>_Y^O$W_@?%_P#&:/KE+S#ZO,_)JBOUE_X=?_![_GZ\3?\ @?%_\9H_
MX=?_  >_Y^O$W_@?%_\ &:/KE+S#ZO,_)JI+7_CZ@_ZZ+_,5^L/_  Z_^#W_
M #]>)O\ P/B_^,TZ/_@F#\'XY%<77B;*D,/]/B['_KC1]<I>8_J\S\H]7_Y"
MU]_U\2?^A&JE?K3<?\$Q?A!<W$LSW7B7?(Y=L7\6,DY/_+&H_P#AU_\ ![_G
MZ\3?^!\7_P 9H^N4@^KS/R:HK]9?^'7_ ,'O^?KQ-_X'Q?\ QFC_ (=?_![_
M )^O$W_@?%_\9H^N4O,7U>9^35%?K+_PZ_\ @]_S]>)O_ ^+_P",T?\ #K_X
M/?\ /UXF_P# ^+_XS1]<I>8?5YGY-45^LO\ PZ_^#W_/UXF_\#XO_C-'_#K_
M .#W_/UXF_\  ^+_ .,T?7*7F'U>9^35%?K+_P .O_@]_P _7B;_ ,#XO_C-
M'_#K_P"#W_/UXF_\#XO_ (S1]<I>8?5YGY-45^LO_#K_ .#W_/UXF_\  ^+_
M .,T?\.O_@]_S]>)O_ ^+_XS1]<I>8?5YGY-45^LO_#K_P"#W_/UXF_\#XO_
M (S1_P .O_@]_P _7B;_ ,#XO_C-'UREYA]7F?DU17ZR_P##K_X/?\_7B;_P
M/B_^,T?\.O\ X/?\_7B;_P #XO\ XS1]<I>8?5YGY-45^LO_  Z_^#W_ #]>
M)O\ P/B_^,T?\.O_ (/?\_7B;_P/B_\ C-'UREYA]7F?DU5^U_Y >H_]=K?_
M -J5^JW_  Z_^#W_ #]>)O\ P/B_^,U*O_!,?X0QV\L N_$OER,K,/MT7)7.
M/^6/^T:/KE(?U>9^2M%?K+_PZ_\ @]_S]>)O_ ^+_P",T?\ #K_X/?\ /UXF
M_P# ^+_XS1]<I>8OJ\S\FJ*_67_AU_\ ![_GZ\3?^!\7_P 9H_X=?_![_GZ\
M3?\ @?%_\9H^N4O,/J\S\FJ*_67_ (=?_![_ )^O$W_@?%_\9H_X=?\ P>_Y
M^O$W_@?%_P#&:/KE+S#ZO,_)JBOUE_X=?_![_GZ\3?\ @?%_\9H_X=?_  >_
MY^O$W_@?%_\ &:/KE+S#ZO,_)JBOUE_X=?\ P>_Y^O$W_@?%_P#&:/\ AU_\
M'O\ GZ\3?^!\7_QFCZY2\P^KS/R:HK]9?^'7_P 'O^?KQ-_X'Q?_ !FC_AU_
M\'O^?KQ-_P"!\7_QFCZY2\P^KS/R:HK]9?\ AU_\'O\ GZ\3?^!\7_QFC_AU
M_P#![_GZ\3?^!\7_ ,9H^N4O,/J\S\FJ*_67_AU_\'O^?KQ-_P"!\7_QFC_A
MU_\ ![_GZ\3?^!\7_P 9H^N4O,/J\S\FJ*_67_AU_P#![_GZ\3?^!\7_ ,9H
M_P"'7_P>_P"?KQ-_X'Q?_&:/KE+S#ZO,_)JK_P#S+O\ V^_^TZ_5;_AU_P#!
M[_GZ\3?^!\7_ ,9J;_AV1\(?L?V;[5XE\OS?-_X_XL[MN/\ GCZ4?7*0_J\S
M\E**_67_ (=?_![_ )^O$W_@?%_\9H_X=?\ P>_Y^O$W_@?%_P#&:/KE+S%]
M7F?DU17ZR_\ #K_X/?\ /UXF_P# ^+_XS1_PZ_\ @]_S]>)O_ ^+_P",T?7*
M7F'U>9^35%?K+_PZ_P#@]_S]>)O_  /B_P#C-'_#K_X/?\_7B;_P/B_^,T?7
M*7F'U>9^35%?K+_PZ_\ @]_S]>)O_ ^+_P",T?\ #K_X/?\ /UXF_P# ^+_X
MS1]<I>8?5YGY-45^LO\ PZ_^#W_/UXF_\#XO_C-'_#K_ .#W_/UXF_\  ^+_
M .,T?7*7F'U>9^35%?K+_P .O_@]_P _7B;_ ,#XO_C-'_#K_P"#W_/UXF_\
M#XO_ (S1]<I>8?5YGY-45^LO_#K_ .#W_/UXF_\  ^+_ .,T?\.O_@]_S]>)
MO_ ^+_XS1]<I>8?5YGY-45^LO_#K_P"#W_/UXF_\#XO_ (S1_P .O_@]_P _
M7B;_ ,#XO_C-'UREYA]7F?DU17ZR_P##K_X/?\_7B;_P/B_^,T?\.O\ X/?\
M_7B;_P #XO\ XS1]<I>8?5YGY-45^LO_  Z_^#W_ #]>)O\ P/B_^,T?\.O_
M (/?\_7B;_P/B_\ C-'UREYA]7F?DU17ZR_\.O\ X/?\_7B;_P #XO\ XS1_
MPZ_^#W_/UXF_\#XO_C-'UREYA]7F?DU17ZR_\.O_ (/?\_7B;_P/B_\ C-%'
)UREYA]7F?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>kros-20251231_g10.jpg
<TEXT>
begin 644 kros-20251231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+L17AI9@  34T *@    @ ! $[  (
M   +   !2H=I  0    !   !5IR=  $    6   "SNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M17-T:&5R($-H;P    60 P "    %    J20!  "    %    KB2D0 "
M SDV  "2D@ "     SDV  #J'  '   !#    9@     '.H    !
M
M
M
M
M
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MBB@ HHHH **** "DP*6B@!*6BB@ HHHH **** "BBB@ HHHH **** $HI:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%(QPI.<<=:\%^+O[<7P7^ _C27PIXX\8OHFO10I</:_
MV9>7 5'&5.Z*%QS]: />Z*^4/^'I?[,O_11V_P#!#J7_ ,CT?\/2_P!F7_HH
M[?\ @AU+_P"1Z /J^BOE#_AZ7^S+_P!%';_P0ZE_\CT?\/2_V9?^BCM_X(=2
M_P#D>@#ZN;&TYZ5'PO '7FOE7_AZ5^S+_P!%';_P0ZE_\CTA_P""I'[,QQCX
MCMG_ + .I?\ R/0!Z=\2/@7)X^^*_@;QDNL"S'AF61S9_9M_VC=C^+>-N,>A
MJNOP",7QRU[Q\NMR)%JVC'2#8QVYCDA'R#S$FW<$;,@;>_6O.?\ AZ-^S+V^
M(S>__$AU+_Y'IO\ P]%_9G)Y^(Y]O^)#J7_R/7-]7IMMO^NA[$<YQU.FJ2GH
MHN%K+X6^9K[PU']C?Q#XEM+'0/$'Q*N==\(VEV+M+>[TY6O7&2=C71D+'KC.
MVOJ>U@^SQHBC"J,#]*^61_P5$_9F&/\ BX[#'3&@ZE_\CTO_  ](_9D_Z*.W
M_@AU+_Y'JZ-"%!-0_JQ..S;&9C&,<3*_+M9)+7=V26Y]7"G5\H?\/2OV9?\
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M:Y222V;GY9%5B5)P>H'2@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ^_Z2O@'_AW'\;_^CSO'_P#WQ??_ "SH_P"'<?QO_P"CSO'_ /WQ??\ RSH
M^_MH/84!0.@Q7P#_ ,.X_C?_ -'G>/\ _OB^_P#EG1_P[C^-_P#T>=X__P"^
M+[_Y9T ??VT>E&T>@_*O@'_AW'\;_P#H\[Q__P!\7W_RSH_X=Q_&_P#Z/.\?
M_P#?%]_\LZ /O[:!T %&T<<5\ _\.X_C?_T>=X__ .^+[_Y9T?\ #N/XW_\
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M\ _\.X_C?_T>=X__ .^+[_Y9T?\ #N/XW_\ 1YWC_P#[XOO_ )9T ??VT>E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;(WEQLW]T9K\T?\
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M:1U+C[M?;O[<7Q,^*'P5\*Z/X\\#^*/"VFZ1H[2MJVA>)0(SJP8+LCBD)!+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I3&("L2<#%.?[IQU
MKR7]JGXF7?P?_9Y\>^+M.;9J6FZ9*UHYY"3L-D;'/8.ZG\*SJ2Y(N78J,>9J
M/<]4\P_*-W.>GK]*D;UYQCMUK\3-8^#6J_"G]E3P-^U-H_C7Q WQ.O\ 6([F
M^FGO-T,D4DLH4$8#M_JDW L00[@@@"OV2\!^)T\:^!?#^OHK1QZKIUO?JC=5
M$L:N!_X]6KCRQ;>ZW,U)-I+9WM\C;DF\M-S.!@XYQCW[^O'-.BG$D8='#IC(
M*G=D'H?RQ7YA?\%//'GQJ\6>&?'6C6WAW_A&?@[X;N;-+S5YW*RZ]+(8=BQY
M',:22 D*,93EL_+7USH/C(?#O]@G3/$;2!&TKX?0W*,3U=;!=GYMC\ZEOEIN
M;Z.Q;3C*,.Y]"^9E"0V>,]<\=L4JL68<^WXU^#7[/_@_X*?$33] M?'7QR\5
M^$_&NISN)K>.V<V4#&1O*#7#C&6&TD_=!;D\&OV>^('QR^'?P)LM$B\;^+M/
M\,Q7R.FGG4)"IN!$$WD8'.T/'D_[55RM1NR7)*?(CTNG5\]WG[?O[/-I:33O
M\6-!*1(TC")Y)'( R=JJI9C[ $GM7KWP]^(?A[XJ^$]/\4^$]5BUKP_?[S;W
MT.0D@5V1@ 0""&4CD \5/4?0Z:BBBF 44AZ&OA[X@?L&?&'QEX]\2:]I?[6?
MCCPYINK:E<WUMHUFMX8+".25G6",K?JNU P4 *HP!P,4 ?<5-VKZ"O@+_AW'
M\;_^CSO'_P#WQ??_ "SH_P"'<?QO_P"CSO'_ /WQ??\ RSH ^_MHZXHV@=!7
MP#_P[C^-_P#T>=X__P"^+[_Y9T?\.X_C?_T>=X__ .^+[_Y9T ??VT>@].E&
MT>@KX!_X=Q_&_P#Z/.\?_P#?%]_\LZ/^'<?QO_Z/.\?_ /?%]_\ +.@#[]VC
MT'I1M''%? 7_  [C^-__ $>=X_\ ^^+[_P"6='_#N/XW_P#1YWC_ /[XOO\
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M /?%]_\ +.C_ (=Q_&__ */.\?\ _?%]_P#+.@#[_HKX _X=Q_&__H\[Q_\
M]\7W_P LZ/\ AW'\;_\ H\[Q_P#]\7W_ ,LZ /O[:.F!CI1M&<XYKX!_X=Q_
M&_\ Z/.\?_\ ?%]_\LZ/^'<?QO\ ^CSO'_\ WQ??_+.@#[]V*.PI=H]*^ ?^
M'<?QO_Z/.\?_ /?%]_\ +.C_ (=Q_&__ */.\?\ _?%]_P#+.@#[^Q2U\ ?\
M.X_C?_T>=X__ .^+[_Y9T?\ #N/XW_\ 1YWC_P#[XOO_ )9T ??]%? '_#N/
MXW_]'G>/_P#OB^_^6=!_X)R?&\ G_AL[X@?]\7W_ ,LJ /O^BN:^'OAZ_P#!
M_@/PQH.J:S<>(]1TO3;:PN=8N]PFOY8XE1IY-S,=SE2Y)8G)/)KI: "BBB@
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M+5O^B/VG_A0/_P#(U'_#\+5?^B/VO_A0O_\ (U7[&IMR@?K!GM2U^=?[*?\
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MZNS_ .";7Q=UWXH>.O#]MXL^,?\ 9,GAG2UTC1_AI:VYMXKRV2 (DSLP"S,
MH<;2[]P57Y3]L_&?]EOPO\4O /Q"TG3;73O#'B+QK;I!J/B6WTY);A]I3#-\
MRLZXC V[AZY!YK:^&7[/_A;X=Z;X'DETS3]5\5>%M#AT*'Q*UDD=T\4<2QM@
M@DJ&VDA<M@%AGDY=%\D9<W7_ "%6][EY>A\)?\%(_B_XA^$_CK6XO"?QB.IW
M/B32GTG5_AI<6YN8K2V:W8-.A'RPN48OSM<Y!^9<"N#_ .";_P 7M<\=>,O
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MG/KU]:1V<<-L""(8+="5A3(!(!()&:^@*I_#&/9"^W)A1114E!1110 4444
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M!Z+@^GZ4;<=%'Y5\!?\ #E7X(_\ 0T^/_P#P86/_ ,AT?\.5?@C_ -#3X_\
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M_#EUJ%[HVD&?R9M2='G;S;B2=M[(BJ<-*P&%' &:]%H **** "BBB@ HHHH
M**** "BBB@!/?O12T4 )1@8QCBEHI60";1G..:6BBF 4FT>E+10 W:#VH"@=
M!3J* $VCTHV@=!2T4 (0&X/(I-B^E.HH ;L7.<#-+M'3'%+10 FT>@_*C:/2
MEHH ;L7CCITHV*.PIU% #=HZ8&*%15& H ]J=10 FT#H*6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,/VI/\ DV7X
MN_\ 8H:O_P"D4M>1?\$M_P#DQ;X;?[VI_P#ISNJ]=_:D_P"39?B[_P!BAJ__
M *12UY%_P2W_ .3%OAM_O:G_ .G.ZH ^K**** "D"A>@Q2T4 %%%% !1110
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M74?B3P'\./AS9.)?%'BKQ?8I86B_ZP1QDAYL<\*9$!S_ 'CZ5ZY^T9^T]:_
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M3VMQ"@OK?S"DB$,,Q[U.#R"1WI,#Z-P,\ 9SG\:\#_;8_P"2/:5[^+_#@/\
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M^UEX O\ Q?X8TW5-*T^SU232G@U98EE:5(H92P".PV[9U[YR#Q7M% !1110
M4444 %%%% !2-T/./>EHH X3XT?"G1_CE\,M;\#>(9[RWT?68TANI+&1$F4+
M(L@VEU8#YD'\)^E?(4'_  1C^!L*[7UWQS,2<[I-2M,_3Y;4#%?>^/:C ]*
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M_DV7XN?]BAJ__I%+7D7_  2W_P"3%OAM_O:G_P"G.ZKUG]J1_P#C&3XN=O\
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M*^<S/^*C]DX)_P!QGZ_H%>9?M,?\D-\5_P#7"/\ ]'QUZ;7F7[3'_)#?%?\
MUPC_ /1\=>=0_BQ/L<R_W*M_A9]0_P#!';_DT>7_ +&.]_\ 0(:^YZ^&/^".
MW_)H\O\ V,=[_P"@0U]SU]JS^:0HHHI %%%% !1110 4A&1@C(I:* $HVCTI
M:* $V@=J*6B@!-H]*6BB@ INT'J :5ONFHC)UYR<XX/0_P"?:@"7:!VI JKT
M %-.=N"=I]>M(S-N Z?A0!)M'I1@>E1F0<  GOW/ZBDW'H#E@!GG_/O0!+M&
M<XYHP/2H?,([EAC.,<GTYX%+YG3YLC^\.A_SUH DVCT%&Q?04TDL..,^_P#@
M::6.W[V> <_YQB@"7:#U _*C:.N.:8=W3//MTH#9( Z_7_/ZT /P/2C:/2AN
MAJ+S0P)!)7&1@CGZ<T 2X'I2;1Z"F!MR@JW7I@TGF' .1\W3^GZ4 2>6O/RC
M\J-H'0 4QF8*<'H><X_QH9BJGO@9_P ]Z6P$FT>E&!Z5&6P,D[?4GI3LGKR.
M>_:F ZEHI#T- "T4S=_]?%)OVY)/L?2@"2BHMQ'KCNQ_SBEW$D@=1U'4_P Z
M )**8K<9)'7%/H *:WW33J0CB@#PG]H/]C/X4_M*CS?&/A[_ (FX3RX]=TU_
ML]]& , %P"' ["0,!V%?,,O_  1]L+.X:/1_C5XNTS1R?ELC$'8+Z%ED0'_O
MBOT%U+4K72=/N+R\NH[*TMXFEEN9Y%2.) ,EV9N  !G)KYI\/_\ !2#X)^+?
MB%_PA_A_7-1UN]6&YN#>VNGO]D\N"!YY#O;#$!(VP54Y(J(VYN6)4F[79G_
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M0?\ ]M#_ "K6K)\-_P#(/_[:'^5:U?T7D7_(MH?X3S:GQ,*V?@]_R<9\-/\
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M%!QS_9"_^C'KZ /:O /V /\ DS/X4_\ 8(7_ -&/7OY[5\$?S]'H?B1\?O\
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M^V]_T-.K?]\:=_\ $4#X]?MO'.?%.K >R:=_\14?_#;W@/\ Z!GB#_P&A_\
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M93U;]4>C_LZ_#WPW\/? <4/A+Q=J_C31-0G-]!JVK:P-39U95 6.;&/+&W(
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MNHR,FN^\%? WP/\ #;PKKWAS0-"%EH>MW-S>:E:2W,TZW$MPNV8EI78C<.,
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M:'^$\VI\3"MGX/?\G&?#3_L8]+_]*XZQJV?@]_R<9\-/^QCTO_TKCKQ>,/\
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M'6-6S\'O^3C/AI_V,>E_^E<=>+QA_P BQ_XD71^(_I,7O]37)?&#_DDOC?\
M[ =]_P"B'KK5[_4UR7Q@_P"22^-_^P'??^B'K\-ZG<?SI_"G_CSO_P#>C_\
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MOM6?S2%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@\-^'/@[XK\>^'W^">AZK]OBFM5?[=)'EB$"F,'/[QP%9\*7)RP517V1\2/
M?Q<F^)GPQD^'7BK2O#WP[T=TC\0Z+=+^^O+=73"1?N&Y\M67!D3!-;R?,I6Z
MO]#!+17Z)_F?*_[$=C;^+OVSOVL+S6+:.[NOMEQI^V= W^CM=3(4P?X2L<8Q
MTPH]*Y'_ ()^_P#"4:Q^Q1\?_#?A*SEU74Y+R^M='M$E5-TD]JL?RLY"C'RG
MDCIUKU/XP?L<_&KP?\>O&/Q'^ /BS1-'B\<0&#6+'5]RO!(X&Z6,F.13\P+[
MN&4L0 P)%>B_!O\ 87L?AY^R/KGP@U#7)&U?Q );O4]:TW<NR[?;L>/.&*)Y
M: 9QO"MD#.*RCI"[VY4K>=]S>;YJC7G>_E;8^,O"\GQ\_89^#_A76O&GPI\%
M:C\/;2Z\F^L[JWBFU0>?(6#2RJS;6.=J_> ^4,O2ONSX\_%CXXGPG\/_ !!^
MSWX$T7QSI^N6;WU^VM3I#]FB=('M=F;F')<22YQNQL'3C/S ?V%?VF?B!X/T
M'X0>./B/X=?X2:/=1RBZL09;V6%"?+C ,2L2 QP'?:./O;0*_1[PMH-IX5\.
MZ7HVGQM#8Z?;16EO&QR5C1 JJ?< "M>;W&^MS/\ Y>:>9^=?QH^,'[<.H?!W
MQW:^*O@GX/TOPO-H-_%JM]:WT32V]HUO()Y$ U%R66,L0-K<CH>E?0/_  2W
M_P"3%_AK@YR=3S_X,[JO7/VH_P#DV7XN?]BAJ_\ Z12UY'_P2V_Y,7^&W^]J
M?_ISNJDH^K:_G"_:0_Y.Y^,/_8X:U_Z6S5_1[7\X7[2'_)W/QA_['#6O_2V:
MO:R7_D8T?\2(G\+.4HHHK^CNQYS,SQ%_R"S_ +XK]U?^"8/_ "8Q\,O]W4?_
M $Y75?A5XB_Y!9_WQ7[J_P#!,'_DQCX9?[NH_P#IRNJ_$>,?^1BO\*.VC\)]
M2MG:<<'%?G?^U/\ \%3=8_9Q_:"\3_#NW^'MGKUIHQM=M[)JCP23>;:Q3GY?
M*8#!EQ_P'WK]$&Z&OPH_X*20QC_@H%XM&Q1YB:66X^\?L-OU]>@_(5\90I>W
MJQI7M=I?B==.//44>Y[TW_!;W5\8_P"%.VH/K_PD+_\ R-7$?#G_ (*T7_PZ
MU[QWJD/PLBO3XLUPZY+&^NLOV=OLL%OY8/V?YAB -G_:]J^<_LL"@,$4-UX4
M4Q;6  #RD Z8VCZU^F_ZC3O_ !E]Q]<N')_\_$?8<W_!;[6/)8)\'[6.3'#/
MK[E1]1]F'\Z^R?V%_P!KB\_:]^'FN^)+_0+?PW/INK'3EM;>Z,P=?)CD#995
MY^<C_@-?B_XHMH5\/7Y$2 B(D$*,]#7Z8_\ !%-1_P ,U^,&Q\Q\6S G_MRM
M*^-SK*'E%6-)SYKJ^UCP<?@7@)J#E>Y^@S=#7X]?\%GO^3@/AU_V ?\ VZEK
M]A6^Z:_'G_@L_P#\G ?#K_L _P#MU+7@T_C1P4?XD?5?F<P/Z?U-% _I_4T5
M^AP^%']*P2Y5Z(BN_P#CUF_W&_E7IO\ P1&_Y&[XN_\ 7IIO_H=Q7F5W_P >
MLW^XW\J]-_X(C?\ (W?%W_KTTW_T.XKYO.?L'Y?QI\='YGZPL3M;!(..,5^=
M'_!8;XF?$+X::/\ "VZ\&>+=<\*V%S<:C%?RZ'J4MF9G"VY@#F-E9@!Y_M7Z
M,>M?FO\ \%NB1\,?AF <#^V+G_T0*^<9^:+5'REH?C[]K_5-"TZ[T[X@^)IM
M/N+6.:WFEUZ-F:-DRK$LY8DKC)/<\U#=7/[7%]K>G:Q<>+-8GU;3HIHK.^?5
MX#-;I+M\U4?=E0^Q-P'WMBYZ"O>OA3_R2WP;_P!@:S'_ )!3_ ?E755\[4S&
MI&;BEL?LE#A# U:4:LI.[2V/FP>+/VS2PSX\\1XS_P!!N'_XNNX_X)X_&KXT
M>*OVUM+\.>*O'?B;Q%IT":DNL:=J6MRW-M'Y<$@#+&TA3B;RP-HX!XXKUNO(
M/^"<9/\ P\6\6Y/RF+6@1Z_Z0#_,5W8+%3Q$FI(^7XCR/#Y31ISHMMR;6OH?
MLL,_K4E,],4^O4/@PHHHH&)7S=_P48_Y,I^*?_7A#_Z50U](U\W?\%&/^3*?
MBG_UX0_^E4-'5#/P3\-_\@__ +:'^5:U9/AO_D'_ /;0_P JUJ_HO(O^1;0_
MPGFU/B85L_![_DXSX:?]C'I?_I7'6-6S\'O^3C/AI_V,>E_^E<=>+QA_R+'_
M (D71^(_I,7O]37)?&#_ ))+XW_[ =]_Z(>NM7O]37)?&#_DDOC?_L!WW_HA
MZ_#>IW'\Z?PI_P"/._\ ]Z/_ -FKO*X/X4_\>=__ +T?_LU=Y7]"\+?\BFE\
M_P S]-R?_<X!7 ?%;_4V'_;3_P!EKOZX#XK?ZFP_[:?^RU'%?_(IJ_+\PSG_
M '1G]'GP\_Y)_P"&?^P9:_\ HI:Z!NU<_P##S_DG_AG_ +!EK_Z*6N@;M7\_
M=3\P^R?SW^#_ /DY[XE_]?VI?^E@KV6O&O!__)SWQ+_Z_M2_]+!7LM?9Y5_N
MR]6?MO"?_(N7JPKRG]I;_D0;?_L(1_\ H$M>K5Y3^TM_R(-O_P!A"/\ ] EK
MJQO^[U/0];//^1=6]&?L#^P!_P F9_"G_L$+_P"C'KW\]J\ _8 _Y,S^%/\
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MY+XP?\DE\;_]@.^_]$/76KW^IKDOC!_R27QO_P!@.^_]$/7X;U.X_G3^%/\
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M_P!(I:\B_P""6_\ R8M\-O\ >U/_ -.=U0!]65_.%^TA_P G<_&'_L<-:_\
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M#\NXT^.C\S]8O6OS7_X+=?\ ),OAE_V&+G_T2*_2CUK\U_\ @MU_R3+X9?\
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M?^/._P#]Z/\ ]FKO*X/X4_\ 'G?_ .]'_P"S5WE?T+PM_P BFE\_S/TW)_\
M<X!7 ?%;_4V'_;3_ -EKOZX#XK?ZFP_[:?\ LM1Q7_R*:OR_,,Y_W1G]'GP\
M_P"2?^&?^P9:_P#HI:Z!NU<_\//^2?\ AG_L&6O_ **6N@;M7\_=3\P^R?SW
M^#_^3GOB7_U_:E_Z6"O9:\:\'_\ )SWQ+_Z_M2_]+!7LM?9Y5_NR]6?MO"?_
M "+EZL*\I_:6_P"1!M_^PA'_ .@2UZM7E/[2W_(@V_\ V$(__0):ZL;_ +O4
M]#UL\_Y%U;T9^P/[ '_)F?PI_P"P0O\ Z,>O?SVKP#]@#_DS/X4_]@A?_1CU
M[^>U?!'\_1Z'XD?'[_E*7XI_Z_X__3:E?0%?/_Q^_P"4I?BG_K_C_P#3:E?0
M%?.9G_%1^R\$_P"XS]?T"O,OVF/^2&^*_P#KA'_Z/CKTVO,OVF/^2&^*_P#K
MA'_Z/CKSJ'\6)]CF7^Y5O\+/J'_@CM_R:/+_ -C'>_\ H$-?<]?#'_!';_DT
M>7_L8[W_ - AK[GK[5G\TA1112 **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#]J3_ )-E^+O_
M &*&K_\ I%+7D7_!+?\ Y,6^&W^]J?\ Z<[JO7?VI/\ DV7XN_\ 8H:O_P"D
M4M>1?\$M_P#DQ;X;?[VI_P#ISNJ /JROYPOVD/\ D[GXP_\ 8X:U_P"ELU?T
M>U_.%^TA_P G<_&'_L<-:_\ 2V:O:R7_ )&-'_$B)_"SE****_H[L><S,\1?
M\@L_[XK]U?\ @F#_ ,F,?#+_ '=1_P#3E=5^%7B+_D%G_?%?NK_P3!_Y,8^&
M7^[J/_IRNJ_$>,?^1BO\*.VC\)]2U^%/_!2;_E()XH_W-,_](H*_=:OPI_X*
M3?\ *03Q1_N:9_Z105\I@/\ >Z7^)?F=^'_C0]5^9YNW;Z4E*W;Z4E?U'(_8
M([F7XJ_Y%W4/^N/]#7Z7?\$4_P#DVKQA_P!C;-_Z16=?FCXJ_P"1=U#_ *X_
MT-?I=_P13_Y-J\8?]C;-_P"D5G7XMQQ_O=+T?YGP7$/\:'H?H*WW37X\_P#!
M9_\ Y. ^'7_8!_\ ;J6OV&;[IK\>?^"S_P#R<!\.O^P#_P"W4M?G5/XT?,T?
MXD?5?F<P/Z?U-% _I_4T5^AP^%']+1^%>B(KO_CUF_W&_E7IO_!$;_D;OB[_
M ->FF_\ H=Q7F5W_ ,>LW^XW\J]-_P""(W_(W?%W_KTTW_T.XKYO.OL'Y=QI
M\='YGZQ>M?FO_P %NO\ DF7PR_[#%S_Z)%?I1ZU^:_\ P6Z_Y)E\,O\ L,7/
M_HD5\YU/S2)PWPI_Y);X-_[ UG_Z)6NJKE?A3_R2WP;_ -@:S_\ 1*UU5?$5
M/C9_3V$_W>'HOR05X[_P3B_Y2,^+?^N6M?\ H\5[%7CO_!.+_E(SXM_ZY:U_
MZ/%>MEGQ3]#\_P"./]WH^K_(_9E>I^M25&O4_6I*^A/R-[A1110(2OF[_@HQ
M_P F4_%/_KPA_P#2J&OI&OF[_@HQ_P F4_%/_KPA_P#2J&CJAGX)^&_^0?\
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M ./6;_<;^5>F_P#!$;_D;OB[_P!>FF_^AW%?-YU]@_+N-/CH_,_6+UK\U_\
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M0;?_ +"$?_H$M>K5Y3^TM_R(-O\ ]A"/_P! EKJQO^[U/0];//\ D75O1G[
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MU-A_VT_]EKOZX#XK?ZFP_P"VG_LM1Q7_ ,BFK\OS#.?]T9_1Y\//^2?^&?\
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MQCO?_0(:^YZ^U9_-(4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'1XHS'$&E*Q%?N_-\SIPIZUU22LU'J]/N.?HK]$[_>?&WPW^$?AO]M#]L_\
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MFF7#>8,_+*O;L:_3/_A!?#9X/A_2_P#P"B_^)IW_  @_ASD_\(_I?_@%'_\
M$U\WF&8ULSK>WKVOY&D8J.Q\=-_P6$^ )4@-XHSV_P")2/\ XY7YC?MA?'3P
MS\</VK-<^(7AO[6= O!9B,WD/ES?NK:*-LKDXY0]Z_?T^!?#?_0OZ5_X!1?_
M !--_P"$%\-\?\4]I7_@%%_\37#1J.C4C4CNM32,G"2E'='\ZS_$G2%503+_
M -^QG^=,_P"%D:1ZS?\ ? _QK^BP^!_#?'_$@TL?]N4?_P 32_\ "#>'!_S
M-+_\ H__ (FOM'QGF?=?<?0?V]B[]#^<76_'VEZAI-W;Q>;YDJ%5R@QT^M?8
M_P#P3D_;L^&7[+?P;U_PQXU.M+J=[KTNHQ#3[(3)Y36]O&,MN7#9B;\"*_7/
M_A!_#G0Z!I9'_7E'_P#$TO\ P@OAOK_PCVE9SG_CRB_^)KY[,LUQ&:SC4Q%K
MI6T5CR\7C*N-DI5=T?'/_#W_ . N7&?% (X^;2ER#ZD>;QSCTK\_O^"B7[4G
M@O\ :>^*GA'Q#X-&H?V?I>E_8Y_[0MA#)O\ .=^!N.1AO6OM3]A7POHUU^V9
M^UG;3:18S6]MKD0@ADMD9(LW-V3M!&%R>>*^\?\ A!O#>?\ D7]+_P# */\
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M^$^ '][Q1_X*1_\ '*^P5\#^&O\ H7]+_P# */\ ^)IW_""^&_\ H7M*_P#
M*+_XFNH\'K='QY_P^$^ '][Q1_X*1_\ '*/^'PGP _O>*/\ P4C_ ..5]A_\
M(+X;_P"A>TK_ , HO_B:/^$%\-_]"]I7_@%%_P#$T ?'9_X+"? '!P?%&?\
ML%#_ ..5X]^UW_P4L^#GQJ_9S\;^"/#C>(#K.L6L<-M]LTX1Q96:.0Y;><<(
M:_27_A!?#?\ T+VE?^ 47_Q-)_P@WAS/_(OZ5G_KRC],?W?2EL!_,EH^K06-
MJT<@8G.>!_\ 7J[_ ,)):?[?_?/_ ->OZ8/^$'\-_P#0OZ7_ . 4?_Q-'_"#
M^'/^@!I?_@''_P#$U]?A>*,?A*$:%.UH^1BZ2;NS^9__ (2*T/'S_P#?/_UZ
MTOA[XQT_PW\7_!GB.]\Y=-TG6+*]N?*3<_E13H[[1GDX4X&:_I._X0?PY_T
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M?^&C/"7K??\ ?D?XU^\/_"#^',\:!I?_ (!1_P#Q-'_""^'?^@!I?_@''_\
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MW[0GA3Q=^VYK7Q3L/MQ\+W=VLR>9!MGVBS6'E2W]X>O2O5?^&T/AWZZI_P"
M8_\ BZ_97_A!O#62?^$?TO).?^/*/K_WS2?\(+X<_P"@!I?_ (!Q_P#Q-<E;
M"TZ[3F?19=GV+RNFZ="UGW5S\:_^&SOAXW ;5 ?^O,?_ !=<=\9/VH/!GCGX
M9ZYH>F+J!O;R*-8O-MP%X=&.?F_V3^=?N+_P@OAS_H :7_X!Q_\ Q-'_  @O
MAOG/A_2O_ *+_P")K&.!HPDI(]"MQ7F%>G*E-JSTV/RC_P""?7[?WPN_9I^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#.U-VYR<$8##!S@^=_%CPGKG@WQE\ M='P5T/X+Z5<:W:?V3)8ZF+K5+Y1)
MPDN75@>A4Y9 P);D9P?T4TK_ ()Z_#32OV=]:^#9N]>O_#6HZF=6%Y>7,)O;
M6Z*QJ'B=(50 "/H4/WW!X(KC+?\ X);?#RXL](&L^./'VMZSH]U%-I^K76K(
M\EI%%S';QH\3HD6=IQMW948(7BMU+]ZIO:Z?X:BDUR6CUN<=XFR?^"QGA'!_
MYE1\_P#@/<U^AM>*77[+?A;4/VDM+^-LNHZQ_P )98:?_9B6HFB^Q/$4=-S)
MY>[=B0\AP/:O:ZB%E3C%=+_FS/7G<O3\@HHHIEA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %)2T4 )M'I1@>E+10 FT>E)L7T%.HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>kros-20251231_g11.jpg
<TEXT>
begin 644 kros-20251231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+L17AI9@  34T *@    @ ! $[  (
M   +   !2H=I  0    !   !5IR=  $    6   "SNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M17-T:&5R($-H;P    60 P "    %    J20!  "    %    KB2D0 "
M S8T  "2D@ "     S8T  #J'  '   !#    9@     '.H    !
M
M
M
M
M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +?B1FK]%5?2Q-M4PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXW\U'D8]%8D?*W<"L/PUX;^*/PE&HZ)X>\-6/B;2[B<S6MRTZ(8R0!E@6!Z
M9'3(X-3'X8W_ )?QO^94OBE;^;\+#OAY\1];\3?!#QG'J6H2SZAHMI+Y&H*Q
M21T:-BC$\'<"IYZ].]8'@WPSXT\>?"*XUV\^(&JVT5BL[6MM'*Y,C)EB97W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <KXZ^'>A_$2QM+3Q#]I\J
MTE,L8MY=AR1CG@UI^&/"^D>#]"BTCP_:"UM(B6VY+%F/5F)Y)-:]%"TO;J#U
MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **\C^-'CWQ!X+L[R-M,@DT+4;%[6&]@N]ES!<LK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVA;-J_;\DST^BOGZTT/7_ O[0'A'1[CQMK>N6>HPSRR17MS(5^6.3@J7((R
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M:/[4U#_G^N?^_P W^-5:*/9P[!]:Q'\[^]EK^U-0_P"?ZY_[_-_C1_:FH?\
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M %S_ -_F_P :JT4>SAV#ZUB/YW][+7]J:A_S_7/_ '^;_&C^U-0_Y_KG_O\
M-_C56BCV<.P?6L1_._O9:_M34/\ G^N?^_S?XT?VIJ'_ #_7/_?YO\:JT4>S
MAV#ZUB/YW][+7]J:A_S_ %S_ -_F_P :/[4U#_G^N?\ O\W^-5:*/9P[!]:Q
M'\[^]EK^U-0Q_P ?US_W^;_&C^U-0_Y_KG_O\W^-5:*/9P[!]:Q'\[^]EO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<E>PU\YQ:QXOUC]I+P3)XW\/PZ'/'!<+!%%,)?,7RI<L2&/?C%?1E !1110
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M'#%1TH V1X4Q\K7D6?\ >I?^$1[B\B_[ZK*.E:H3D0S$?0TO]EZD.D,WTP:
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M6"%"P4,[' &3P.30!3HKT,_!#QB#@II0/_86M_\ XN@_!'QC_=TG_P &UO\
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MG_HF*N["[,^7SS^)#T/<****ZSY\**** "BBB@ HHHH **** "BBB@ HHHH
M*\=_:?\ ^20I_P!A*'_T%Z]BKQW]I_\ Y)"G_82A_P#07J)[?-?F=.&_B/\
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M?^/R'_KHO\ZW=_PY_P"@SXE_\%,'_P D4^*?X<Q3(_\ ;'B4[6!Q_94'./\
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MF?+YY_$AZ'N%%%%=9\^%%%% !1110 4444 %%%% !1110 4444 %>._M/_\
M)(4_["4/_H+U[%7CO[3_ /R2%/\ L)0_^@O43V^:_,Z<-_$?^&7_ *2SX^H!
MP:**LYA<Y/I6QH&FVFI2/'=SB(C[N:QJV?#^F0ZI,\4MP("!D9/6@#='A+2
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ML[;_ /!M?TO^'H"U:_KI>WK;^M3Q_P -^#=9\5V^ISZ/;J\.E6K75U([;51
M"<9[DX.![&N@E^#WB&*Y6S^WZ"VH.BNNG_VO"MPVY0R@(Q!R01Q7<>&]7T&U
MNM6\,>!KF6YT:/0M1O+BZEC*/<S-$=H(/.(T(4>IW'O7%?&5'D^*]TD*LTC6
MUF%51DD_9X\8]Z.J7]=?\@6S^?\ [;_F<]KW@G7/#5O8S:K9F-;UG2,+RRR(
MVUHV'57!QQ[@BJ?B'P_>^&-7;3-5\I;R-%:6.-PWE%AG:V.C 'D=J^EY)8]-
MO[9_&%Q:Q&XM["&S%Y&7VZRL.#,>1\J@H'/KM]*^9O$5KJ=EXDU"WU\2#4X[
MAQ=&0Y8R9Y.>^>N?>D])<OK_ %^OI;N"UC?T_K]/6YG4444P+>DZ9<:SK%GI
MED%-S>3I!$&. 68@#)[<FNNF^$?B(27$&GW6C:K>6V[S;+3]4BEN%V_>_=YW
M$C'0#-9/P[_Y*=X9_P"PK;?^C5K3$.HS_'65-%$AOO[?<P^5G((G)S] .OM5
M*-W&/>_Z?YDMV4GVM^O^14T;X:>)]=TV*^LK.".*X=H[875Y% ]RRG!6-78%
MB#QP.O%5]8\!>(-"\,6FOZG9&&QNIY+8$GYHY$8JRNO\)RK?D:] \1V::I\2
MM4\3Z[J$EOX2T74I$M7!^:X99"_D6X[DODD]%!R36QKGCFUU30/#9\4+Y&B>
M*(]0%\J*6^RDW1:.91W,;8/N-WK4)\T4UN_\KK[_ ,/0MKE;3Z?T_N_$\L\/
M_#OQ#XET-M7TVVC^Q"\BL1++)MW2R,%4#U ++D]LUHS?"/Q");B#3[K1M4O+
M;=YME8:I%+<+M^]^[!W$C!X )]J]0\#Z[9:E'?Z9H+-_86CZCHUM8[EVF7_2
M\O,P_O.V6^F!VKRP0ZC/\=94T42&^_M]S#Y6<@B<G/T Z^U6DI345U_^U_S)
M;Y8MOI_P?\C+O/ FO6?BFQ\/FU6:]U!8WM/)?<DRR#*L&].N3VP<]*Q=0LGT
MW4KBRDEBE>WD:-GA?<C$'!P>X]Z^FM=Y_MK3+&YMD\37[W\OAD%/WD=HS#S4
M5L\&3$ACXZ9P>:^7F5D=E<%64X((P0:S4KV_K^K;/S+:M_7];]/(2BBBJ)"K
M>D_\AFR_Z^$_]"%5*MZ3_P AFR_Z^$_]"%14^!G3A/\ >*?^)?F?HQ1115G,
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!R_BK6-$NM(US1;G7H=.GALM]VY57-M$_&]E8$$'..?6O(
M-.G\/Z58165A\>[N*VA4+''M1@BCH!G. /2O:_%-WI6@>'-6UW4;"&=(+5GG
M'E*6F51PA)'/.!S7FT'ASXC:C9QZO#HW@6S65!+'I,M@6;:1D*T@'WL>G&:E
M;O\ KN-[+^NQW_P_G@N?"44EKXF?Q1&97 U%P 7Y^[QQQTKIJYGX?:Y:^(?!
MMO?6>FQZ4V^2*XLHU $,R,5=>  >1UKIJTEN3'8****D84444 >/>-O^3GOA
M]_UZ77_HN2O8:\>\;?\ )SWP^_Z]+K_T7)7L- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?/?[6?_ "+_ (<_Z^IO_05KAK7_ (\X?^N:_P J
M[G]K/_D7_#G_ %]3?^@K7#6O_'G#_P!<U_E7?@]Y'T&2_%/Y?J2T445Z)]&%
M2? [_DXJ;_KWG_\ 014=2? [_DXJ;_KWG_\ 017%C/@1XF<_P8^OZ'UI1117
MF'RY\E^.?^3L]1^J?^D2UUM<EXY_Y.SU'ZI_Z1+76UY^)^,^MR7_ '=^OZ(*
M***YCVS-\2?\BKJW_7E-_P"@&NI_93_Y)EJG_88D_P#1,5<MXD_Y%75O^O*;
M_P! -=3^RG_R3+5/^PQ)_P"B8J[L+LSY?//XD/0]PHHHKK/GPHHHH **** "
MBBB@ HHHH **** "BBB@ KQW]I__ ))"G_82A_\ 07KV*O'?VGO^21)_V$H?
M_07J)[?-?F=.&_B/_#+_ -)9\?44459S!3D+@_)D'U%-K<\-7.F6UXW]KQEH
MR.U &1NF/5F_.G S8X9OSKT#^UO!:G"VC,/6GKJ_@HCFT8?A0!YXKSKR'<'V
M-$SS28,SL^./F.:]!^W^"9.MNRD]3CI6)XKFT!K:)-#!W?Q<4 <D>M%&** "
MBBB@!V1MZ<TVBB@ HHK2\.SV%MXETZ;6;9;K3UN$^TPL2 \>?F'!!Z9II7=A
M-V5S-K6UGQ/K/B&UTZVUF^:ZATRW%M:*R*OE1CMP!GH.3D\5Z??_  JTZUU+
M3_"\CI;ZAJ>HW=TEZ26:/3X5/EA5) )?#$$^@YJ*'X<>%[+2M5:^U"XN;:1=
M/DM+R"%6EA\Z61&7&\(PRH^8$C'3FDM4OE_7YK[QNRN_ZW_X9_<>:ZWXGUGQ
M%#I\6M7S72:;;+:VH9%7RXQT7@#/U.3[U!K6N:CXBU(ZAK%Q]HNC&D9DV*GR
MHH51A0!P !7INI?"RPLX8X[V\*0:7;ZA-=S6=KF>X6"Z\H8#/@DY!SP ,]>M
M)?\ POTZYU+PAI%A)/9C4(+R6YO+JV:*9UC9G&8F; ;8  ,@'@]*-]>__!U_
M!@]+^6GY:?D>245TGC;PS:>&=5M8M.OS?6MW:I<QR,H!4$D%25)5N5Z@X-<W
M2'L%%%%,05V=M\6O&=I9VMM!J=NJ6<*06[G3K9I(T484!S'NX'?.:XRM+P[<
M6%KXETZ;6;9;K3TN$-S"Q(#QY^8<<],U44V^43T5S:T[XH>+]+CODM]6$HU"
M83W9N[2&Y,S@8!)E1CQC@=!4.K?$/Q+K>EW&G7]Y;_9+G9YT4%A;P!]A)7)C
M13P2:[^_^%6FVNIV'A>1TM[_ %/4;NZCO2=S)I\*'RPJD@$OAB"?0<U'#\./
M"UEI.JM?7]Q<VTJZ?):7D$*O+#YTLB,N-X1AE1\P)&.G-2ES)?+^OEM\AO2_
M]=?Z?S/+=$UO4/#NKQ:GHUQ]FO(0PCEV*^-RE3PP(Z$CI726_P 6_&=K:6MO
M!JEN$LX4@@<Z=;-)&BC"@.8]W [YS74ZE\++"RBCBO;PK;Z7;ZA-=S6=KFXN
M%@NO*& SX)Y!SP ,]>M%_P#"_3;G4?!^D6$EQ9C4(;R6YO+JV:*9UC9G7,;-
M@-L&!R >#THO=+^N_P#DP:LW?I_P/^ >>ZYXOU[Q):V]OKFI2WD5N[R1B0+G
M>YRS,0,L3@<MDX '2J^K>(-3UV*Q35KG[2+"W%M;LT:AEB'12P +8[;B<5I>
M-_#-IX8U2UBTV_-]:WEJES'(R@%0205)4E6Y7J#@US=)6_K[AN_]?>%%%%,0
M5V[?&+QR2&&KPK*J!!.FG6RR@ 8&)!'NX QG.:XBBCR ZW3/BAXNTG3)-/M=
M3CDMI;AKF1;JR@N2\K=7+2HQ)]R:IZYX[\0^(M--AJMW ]H95F,,%E! I=00
M&_=HO.&(_P#U"MGX4:1INKZ[JPU>VL;B.UTB>YB&H-(L"2+MPSE"&VC)SBNP
MM- ^'.IMXF=!;Q6D=I8PB]MY)3!97<K,KO'O^8Q!MN=V>,XH:V7]>7Y?D"?7
M^O/\_P SR32-<U'09[B;2KCR)+BVDM93L5MT3C#+\P.,CN.:ZAOC%XY)##5X
M5E5 @G33K990 ,#$@CW< 8SG->AZCX.\':7\.X_$?A_18]?N+&V\H+*\ICNW
M^T&)[EE1@Q4;> "!AAFO-OB5HEAHVL:9)IUD=-_M'2X+V?3RS-]ED?.4&XE@
M. 0"<C-#?^7Y_P#!!+^ON_X!B:WXHUGQ&+0:W?R7?V.,QP;@!M!.XDX RQ)R
M6.23U)J+7/$&I^)+Y+S6KG[5<I"D(E,:JS*@PNXJ!N..-QR3ZUG44 %%%>L?
M#O1?"TGP_.K>*;;2#'_;0MKBXU&6X5A;^4&80^4?]9U(R"*=M&_ZWL*^MOZ[
MGF&G:A=:3JEMJ&GR^3=6LJS0R;0VQU.0<$$'D=ZZJ[^+?C:\AGC;6%@^T B:
M2TLH+>1P>N7C16Y^M=?!X9^'DO@G1;Z_F>P=KF[NA,[MOU"VBF*B#'02$%,$
M?[5=#XG\%>&O#_BO2=/TOP7'JMKKFHR03N99R;- RH(XRK@*P!WY;/7THLW:
M/?\ X']?+T&_=N_ZZ_U\_4\MM?BMXOM-)L]-BO[1[2QC\JWCFTNUE\M?0%XR
M?QSS6/X@\6ZSXH6U36KJ.9+3?Y"1VT4*Q[VW-@1JHY/-=5JW@3PY8>'==O8?
M$T#W%AJIM((3'*=R#S<(2$P6;8I# [1SDBN_\1^!O"27)M[32--+6NJZ; 5L
M)I_.BCFQO%R';;ALX4QYZC)%)>^U\OQM_F#]U??^!XKH?BS6O#<4T>BWOV9)
MYH9Y!Y2/N>%]\9^8'HW.._?-;ES\7?&US',IUB. SY\U[6QMX'?/7+QQJQSW
MYYKTZ/P'X5T[Q!=6RZ19WM@MCJ%\-1N?/>)9HY0H@V1MOQ$."/O,3GIBN?\
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MJ?V4_P#DF6J?]AB3_P!$Q5W879GR^>?Q(>A[A11176?/A1110 4444 %%%%
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M\^^C?^ C?_%T >4ZGJVHZU>M>:Q?7-_<L #-<RM(Y Z#+$FJE>P_\-.>.O\
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MX+U?2;I+;2-6OVBU"2ZMV4K&NW=@, 1CGG'-=IX1^(_AKQO=7=KX?O9)+FS
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M(]^W:N@JI$H^<?&'P6\8:/X9\3WVE^*Y]374I#<7.FV^G%Y;PE^%W!BQQG/
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M<5";-O[IH I8H*X%719MG[II]Q9-'#G;VH SAS2[34]M;F:3 ':KC:<Z]5H
MS,4F*T38MZ4B63%ONT >H^,/](_98\!SO]^+4+F(?3?-_P#$BCPA_H_[*WCN
M=/OS:C;0D^P>'_XHU@:_XOCNO@[HO@X6,B2Z;>27)N2X*N&,AP!U'^L_2J^B
M>-8;7X/ZUX)^PR/-J=['=+=!QM0*8SM*]3_J_P!: .%HJV]HRMC'Z4W[(^[H
M: *U%6C:..WZ5%+"T0&?Y4 145+#"TQ(4=*>]FZ=C0!7HJ4P/Z&G+;.>WZ4
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M::\G@/\ RR,KE]OU (S[UVM:2W,X[:!1114E!1110!X]XV_Y.>^'W_7I=?\
MHN2O8:\>\;?\G/?#[_KTNO\ T7)7L- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?/?[6?_(O^'/\ KZF_]!6N&M?^/.'_ *YK_*NY_:S_ .1?
M\.?]?4W_ *"M<-:_\></_7-?Y5WX/>1]!DOQ3^7ZDM%%%>B?1A4GP._Y.*F_
MZ]Y__014=2? [_DXJ;_KWG_]!%<6,^!'B9S_  8^OZ'UI1117F'RY\E^.?\
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M>(]77_4:IKEQ-;G^]&NV(,/8F,FNWI;I/R7Y:AU:\W^84444 %%%% !1110
M4444 %%%% !1110 4444 %%8/CG5+[1/ 6M:GI";[VTLY)81MW88+UQWQUQ[
M5Q&C_#/4]6T6SU&Y^)_BR66[@29GM+U4B)8 _*NTX'-"U;\OUO\ Y#V2_K^M
MSU6BLGPUH<GA[14L)M6U#5V5V;[5J,OF2G)Z%L#@=JUJ8@HHHI %%%% 'CWC
M;_DY[X??]>EU_P"BY*]AKQ[QM_R<]\/O^O2Z_P#1<E>PT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\]_M9_\B_X<_P"OJ;_T%:X:U_X\X?\
MKFO\J[G]K/\ Y%_PY_U]3?\ H*UPUK_QYP_]<U_E7?@]Y'T&2_%/Y?J2T445
MZ)]&%2? [_DXJ;_KWG_]!%1U)\#O^3BIO^O>?_T$5Q8SX$>)G/\ !CZ_H?6E
M%%%>8?+GR7XY_P"3L]1^J?\ I$M=;7)>.?\ D[/4?JG_ *1+76UY^)^,^MR7
M_=WZ_H@HHHKF/;,WQ)_R*NK?]>4W_H!KJ?V4_P#DF6J?]AB3_P!$Q5RWB3_D
M5=6_Z\IO_0#74_LI_P#),M4_[#$G_HF*N["[,^7SS^)#T/<****ZSY\****
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M/_WP:/:T_P"9!]1Q?_/J7_@+_P BC15[^Q=2_P"?&?\ [X-']BZE_P ^,_\
MWP:/:T_YD'U'%_\ /J7_ ("_\BC15[^Q=2_Y\9_^^#1_8NI?\^,__?!H]K3_
M )D'U'%_\^I?^ O_ "*-%7O[%U+_ )\9_P#O@T?V+J7_ #XS_P#?!H]K3_F0
M?4<7_P ^I?\ @+_R*-%7O[%U+_GQG_[X-']BZE_SXS_]\&CVM/\ F0?4<7_S
MZE_X"_\ (HT5>_L74O\ GQG_ .^#1_8NI?\ /C/_ -\&CVM/^9!]1Q?_ #ZE
M_P" O_(HT5>_L74O^?&?_O@U3DBDAD*3(R..JL,$549QELS*IAZU)7J0:]4T
M-JWI/_(9LO\ KX3_ -"%5*MZ3_R&;+_KX3_T(4JGP,K"?[Q3_P 2_,_1BBBB
MK.8K7FGVFH& WD"3&VF6>$L.8Y!G##T/)_.K-%% !1110 4444 5[_3[35=/
MFL=2MX[FUG7;+#*N5<>A%3JH50JC  P .U+10!6M-.L["6YDLK:.![N7SIV1
M<&5\ ;CZG  _"K-%% !39$66-HW&58%2,]0:=10!!965MIMC#9V$"6]M @CB
MBC&%11T %3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% &;XCM[*Z\
M-:A#JMU+9V30,9[B*4Q-&@&2P8<C@=:^<[;2_#4=G]KT'PG\1I] 7++>VUVR
M*Z=W2/.2O?/%?0/C;0YO$W@;6-&MI!'->VCQ1LQX#$<9]L]:X73OBO?:3HUO
MI.H?#[Q0-:MH5@^S6MAO@=E&,K*#C8<=<<#UJ>K^7Z_U\RNB_KM_7R.Q^'D.
MBQ>";*3PQ?75]IMP#-%-=S-+(<GD$MSP<C';%=-7(?"_0-0\.^!8+;68T@OK
MB>:[FMXSE8#+(7\L$>@./KFNOK26YG'8**\9\1>,?BI?Z]X@/A+2++3-'T$,
M?,U:!U>^"@DF,D8(.TD8P,8YYIU_\;[J/X):9XKM--B_MG5+C[%!;,28A,"P
M+=<E?ER!GN!FH3NKKR_'8MJSM_6FY[)17DO@GQYXPM?B5_P@_P 1X=/:]N;/
M[79W-@"%(P24.>O ;L.5/7.:]:JK:7)N>/>-O^3GOA]_UZ77_HN2O8:\>\;?
M\G/?#[_KTNO_ $7)7L-(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'SW^UG_R+_AS_ *^IO_05KAK7_CSA_P"N:_RKN?VL_P#D7_#G_7U-_P"@
MK7#6O_'G#_US7^5=^#WD?09+\4_E^I+1117HGT85)\#O^3BIO^O>?_T$5'4G
MP._Y.*F_Z]Y__017%C/@1XF<_P &/K^A]:4445YA\N?)?CG_ ).SU'ZI_P"D
M2UUM<EXY_P"3L]1^J?\ I$M=;7GXGXSZW)?]W?K^B"BBBN8]LS?$G_(JZM_U
MY3?^@&NI_93_ .29:I_V&)/_ $3%7+>)/^15U;_KRF_] -=3^RG_ ,DRU3_L
M,2?^B8J[L+LSY?//XD/0]PHHHKK/GPHHHH **** "BBB@ HHHH **** "BBB
M@ KQW]I__DD*?]A*'_T%Z]BKQW]I_P#Y)"G_ &$H?_07J)[?-?F=.&_B/_#+
M_P!)9\?44459S!2A2QX&:2KNF2Q0WBM/]V@"O]FFQGRV_*@VTP_Y9M^5=U_:
MFD>6" F?I0-4TCN$_*@#A1;3'_EFWY4CV\D?WT*CWKO1JFC[N53'TK+U[4--
MGMRMLJYQVH Y*BBB@ HHHH **** %Z"DHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "K&GPK<ZE;0R?<DE56^A-5ZN:/_ ,AJS_Z[)_.HJ-J#:.G"
M14L13C+9M?F,O;N6ZN7>1C@'"(.B#L .PJ**-I'VKFFO_K6^IKH/#%@EX[;\
M9IQ22LC.K4G4J.4G=LQ6M90> :3[-+[UZ#)H$0]*;_846.QJC.[.!%K*3T--
MEA:(\YKT$:%#W K&\0:;';H-H'6@+LY>*%Y>F:>;:0=FKH_#^G),I+ 5N/HD
M)/ % 79Y\8)!V-"VTA[&N_;0H5'.*:NC0=P* NSS^5&C;!S4UO9RSC*AL5MZ
MUI\<4X"<9KK?"?AZ.ZT\&3'UH"[/.I-/G7H#3!8SD=&KV9_"4#-P%(J-O!\!
M!PH!H"[/'UL)V'"G\JKR1O$VU\BO9D\)PA6X%<%XGTB.UO-JCO0%V<Q';RRC
M*@D>M-:&5>"#7HWAKP[%<:?N8 YK0D\'1,22@H"[/*-DGHU CD;H&KU$^#(S
M_ ,4B^#%16.T8H"[/+3N!YR#6@\C7>AEYR7DMYE1'/)VL"<9]B/UJ?Q%IO\
M9]\RKT]*JP_\@&Z_Z^(OY/6=39/S1V8.3O.'1QE?Y)M?<U<HU;TG_D,V7_7P
MG_H0K1C\$^*98UDB\.ZHZ. RLMHY!!Z'I5S3/!'BF/5K1Y/#NJ*JSH68VC@
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M%%6<P4444 &X^IHR?4T44 +N/J?SI,FBB@ HHHH **** "@<T44 !&**4TE
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M/L\7()&?X*X.K>D_\AFR_P"OA/\ T(4YZ19EA4I5X)[77YGZ#_V!IG_/J/\
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MH52",*,5SO@3P19> O#:Z/87$UU$L[S"2X"[@7ZC@"NEHH6CN 4444 %%%%
M!1110 4444 >-W/CGPYX)^//BF3Q1J2V"75A9+"6B=]Y ;/W%..HZUE^ /B]
MX%T;6/&$VI:\D$>H:U)<VK&WF/F1%% ;A#CD'@X->XRV-I/)OGM89'_O/&"?
MS-,_LO3_ /GQMO\ ORO^%$;K[FOO=PEK^'X*QP'P)N(KOX=37-N^^&;5;R2-
ML8W*920>?:O2:9%#%!'L@C2-/[J* /R%/IZ:)=$E]RL'5M]6_P 0HHHI %%%
M% 'CWC;_ ).>^'W_ %Z77_HN2O8:\>\;?\G/?#[_ *]+K_T7)7L- !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?/?[6?\ R+_AS_KZF_\ 05KA
MK7_CSA_ZYK_*NY_:S_Y%_P .?]?4W_H*UPUK_P ></\ US7^5=^#WD?09+\4
M_E^I+1117HGT85)\#O\ DXJ;_KWG_P#014=2? [_ ).*F_Z]Y_\ T$5Q8SX$
M>)G/\&/K^A]:4445YA\N?)?CG_D[/4?JG_I$M=;7)>.?^3L]1^J?^D2UUM>?
MB?C/K<E_W=^OZ(****YCVS-\2?\ (JZM_P!>4W_H!KJ?V4_^29:I_P!AB3_T
M3%7+>)/^15U;_KRF_P#0#74_LI_\DRU3_L,2?^B8J[L+LSY?//XD/0]PHHHK
MK/GPHHHH **** "BBB@ HHHH **** "BBB@ KQW]I_\ Y)"G_82A_P#07KV*
MO'?VG_\ DD*?]A*'_P!!>HGM\U^9TX;^(_\ #+_TEGQ]1115G,%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %&*** "BBB@ HHHH ****
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MI6I^#+RXTZ_T^ZOX-=@%Q%JBP,\L,@B -O<8'RJO1#P.W6O4Z*+:-=U;\_\
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M3_R&;+_KX3_T(5%3X&=.$_WBG_B7YGZ,44459S!1110 4444 %%%% !1110
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MW5NW?T,,1@Z=*DYIL_02BBBOG#RCY[_:S_Y%_P .?]?4W_H*UPUK_P ></\
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M_P"PE#_Z"]1/;YK\SIPW\1_X9?\ I+/CZBBBK.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JW
MI/\ R&;+_KX3_P!"%5*MZ3_R&;+_ *^$_P#0A45/@9TX3_>*?^)?F?HQ1115
MG,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7BG[0@^T:MX"L;@;K.XUE?.0_=;E!S^#
M-7M=<A\2/A_:_$/P['837<EA=VLPN+2\C7<89!WQD9'XCMZ4MFGV:?XCW37=
M/\C@5C2P_;"1+!%B2ZT7-PL8P"0IP3C_ '$K>\0ZS\98/$-[%X;\-:!<Z4LI
M%K-<3$2.G8L/-'/X"K/@'X77?AKQ/>^)_$_B"3Q!KMW"+<7#1>6L48QP!DY)
MP.>*]&JMHI?UNV3O)OT_)(^==6TCXVZM\0]%\4W'A31A>:1%(D CND$+!PP.
M\&;<3\W;':NI_M[X^?\ 0H^&?^_Y_P#C]>PT4AGCW]O?'S_H4?#/_?\ /_Q^
MO)-;^"7Q2U[Q-J&N7>B6*7-_.\\B17D8168Y( +DX_&OKRBJA.4)*479H#XY
M_P"%!?$W_H#6G_@;%_\ %5AZ[\,O&OAS5M'TW5=-MX[K69S;V:K<(P=P5&"0
MW'WQUK[BKR'XPP2R_$SX7O%$[K'J[ERJDA1OAZ^E=G]H8K^=D\J/%_\ A07Q
M-_Z UI_X&Q?_ !5,D_9_^)DD91M'M,'TO8O_ (JOLFBIECL3).+F[,.5'S[X
M'TOXV^ O"\6A:3X8T*>VBD>17N;D%R6.3RLH'Z5T/]O?'S_H4?#/_?\ /_Q^
MO8:*XRCPW7Y?CIXB\.ZAHUYX5\.QV]_;O;R/%<8=588)&9B,\^E>7V7P(^)]
MC 8HM%LV4MNRU['_ /%5]A45K2JSHRYJ;LRX3E!WB['R)_PI3XI_] 2Q_P#
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MU/SK_L'5O^@9=_\ ?EO\*/[!U;_H&7?_ 'Y;_"OT4HI6GW7W?\$OFP_\DO\
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MM_A7Z*446GW7W?\ !#FP_P#)+_P)?_(GYU_V#JW_ $#+O_ORW^%']@ZM_P!
MR[_[\M_A7Z*446GW7W?\$.;#_P DO_ E_P#(GYU_V#JW_0,N_P#ORW^%']@Z
MM_T#+O\ [\M_A7Z*446GW7W?\$.;#_R2_P# E_\ (GYU_P!@ZM_T#+O_ +\M
M_A1_8.K?] R[_P"_+?X5^BE%%I]U]W_!#FP_\DO_  )?_(GYU_V#JW_0,N_^
M_+?X4?V#JW_0,N_^_+?X5^BE%%I]U]W_  0YL/\ R2_\"7_R)^=?]@ZM_P!
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M7Z*446GW7W?\$.;#_P DO_ E_P#(GYU_V#JW_0,N_P#ORW^%']@ZM_T#+O\
M[\M_A7Z*446GW7W?\$.;#_R2_P# E_\ (GYU_P!@ZM_T#+O_ +\M_A1_8.K?
M] R[_P"_+?X5^BE%%I]U]W_!#FP_\DO_  )?_(GYU_V#JW_0,N_^_+?X4?V#
MJW_0,N_^_+?X5^BE%%I]U]W_  0YL/\ R2_\"7_R)^=?]@ZM_P! R[_[\M_A
M1_8.K?\ 0,N_^_+?X5^BE%%I]U]W_!#FP_\ )+_P)?\ R)^=?]@ZM_T#+O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9VC?[T8=V95/H0&'':NVJYI1DTB(MN*;"BBBI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$\GZ5\V?$'4O'WA3X^3WUK>M>F: R6%FX_=75J.6@"]"PP>.I(R.2 >K^/\
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M=I5MVV_KT\OZ1"5_3^OQ_IA1114E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'%=M5Z)67]=OFO\ @;$ZMW?]=']X4445(PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0EHWD4,ULSDG"GL0K!>/2NVK2RA>*UU?YW,[\UI>2_*P4445)04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+0?#?P
MM;^.I/%T6F1KJTB8+_P!N\@7H'(X+?XG/4T4=;ATL%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%0W<S6]E-,@!:-"P!Z<"@":BH+*9KFQAF< -(@8@=
M.:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>kros-20251231_g12.jpg
<TEXT>
begin 644 kros-20251231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $F!*L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'%>?_P#",WVG_LS^(-)_L?4)OAGX:^.DYU[2+&&1\:&CC*[%Y:%6*D@>Q]Z
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MB_5+AX;?Q;X(\?:>"]O)''LVQRR*#Y;*I.595[9; QY5\0+[P_\ &?\ 9@^
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M?XJ?%&;XD:QH5F]CH$/]EI9):JP=1)($;#.!(YX RQR2< #IOV5_V.X/V?\
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M:^UJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7'_"'XI:/\:OAKH'CC0([J+1]:M_M-LE]&L<P7<5^959@#E3T)KL* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^5?$
M'Q/^._C?]HSXD^ _AO>^ ]+T;P?;Z5*TGB:PO)IYFNX'DX:&51@&-NPX(ZT
M?55%?-/]C_M=_P#0S?![_P %&I__ !^C^Q_VN_\ H9O@]_X*-3_^/T ?2U%?
M-/\ 8_[7?_0S?![_ ,%&I_\ Q^C^Q_VN_P#H9O@]_P""C4__ (_0!Z1\3OV<
M? OQ8OH=1UG1H(]72\L;N35+6"(74XM)O-B@DD9&)BW9!7N">E;G_"FO ?\
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M_P#P[E_9T_Z)K;_^#.^_^/T?\.Y?V=/^B:V__@SOO_C] 'TB&#<@YI:^6O\
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MD#M0!RGPI_:-?XM? O4/B3I'A:Z>TCBEET^SFO[6*344C0'?GS"EON;<-LK
M@*"<9KRG]E']O:+]I;XH>)/"ECH,SQ6M]/-#=EH+<66GK$@C$JF9FGE:;S5)
MA!4 *2<'GZ0T[X0>"M+\+:MX<M_"VDQZ)K!9M3L5LXQ%?,R*CM,@4!V954$D
M<XK!\!_LW_#_ .'7B;4=?TGP_:?VM=:E-J<-U-;Q%[!Y88X7CMBJ Q1%(U&P
M'N: /G_]H#_@H2GP/^/6B> +KPQ<$M/,D\0FMI'U"-X0+-H9//"VY:<E7$X&
M%&[O7J7[47[3-S^SM\&8?&5SX=D>2[M73(NK>1-/NVAS LB>8IG0RD*WDDD
M%NE=-XL_9?\ AMXT\8V/B34O#&GO>PS7=Q=1+:0^3J;W%N()#=J4)FP@&,G@
MBMSQY\$?!?Q&\)P^'M9T"QEL;6RFL+!UMX_,TZ.2$PL;8LI$3",X! XP* ./
M_9/_ &B#^TM\,X/%4>CRZ=:J(K<74DT.+R<1CSV2)'=XD$NY563#$ '&#7M5
M<E\.?A3X6^%.D_8/#.CVNFAXH([FYA@1)KPPQ+$DDS*HWOM498BNMH *BNIG
M@M9I8XC,Z(66,,%+D#(&3P,^_%2U'<6\=U!)!-&LL,BE'C<95E(P01W!% 'Q
M=\)?^"B!^)O[1VH?#2+PG<+<LUK;Q67VFU5[&1/,%^\MP)S'.J?NMBP@LV6X
MXXW_ -L/]NB+]EOQ7X<T:]T298;Z]M)WU#,-PMQ8[F%VB1+*LD<JC9M9QL8D
M\\5ZWX=_95^&'A?QC<^(K#PIIL<[+8"UL_L</V73WL_,\F2V0(/*?]ZV6!R>
M*T?B-^SOX$^*&LV&L:UH=M_:]K?V=^VH001">Y^RLS10S.R$O#EVRG?- &+X
MJ_:(;P9\ ;/XIZIX3NX[)HH[J]TR'4;.2:TMF)S*)/-$4I"[6V(Y)W8&37!?
ML7?M@7G[47@6^U Z QO-)@87U]#+#!!/=%W*P10M*TBCRO+)D?"EBP!XKW-_
MA'X)D\)Z=X7;PGHS>&]-F6XLM):QC-K;RJQ=72,C:I#,2"!P36'\*?V=_ GP
M=T&/3-!T2W:06;:?-J5U#&UY=6YD>3RII%5=ZAI&P".!Q0!\Z_!W_@H=_P +
M4_:+U+X;0^%+A9V>U@AL_M%JKV#H)!?O+<"<QSJC>7L6$%F!;CCC[4KR7PW^
MRO\ #'PKXPNO$6G^%-.CN'%@;6T-G#]FTY[176&2U0(/*?\ >-E@>>*]:H *
M*** "BBB@ HHHH **** "BBB@ HHHH \G_:KF\+V_P"SYXT?QFNJ2^&_LBK<
MP:+*8KR<F1!'%$PZ,\A1?3YN>*\5_9*T_P#X1'XM:AX?\2:'\0O"7BR;0_M]
MEIOBKQD=?LKJQ\U$=T(.U)D<QJRD9 ?@D9KV/]H:/4_$G@_Q+X5D^&[^./#=
M]HCO/C68; 2S>:J_9PSD&-@N91+G ,8'7%>1?L?^!=>\.?$K7K[Q+X.\41:Q
M_9B67_"1>+/&]IK]S;P!U>.R2.$*8D;)DR1\Q49)XH ^O*9'#'#O\N-4WMN;
M: ,D]S[T^B@#YO\ VI_^2P?LU_\ 8[2?^FZYKZ0KYO\ VI_^2P?LU_\ 8[2?
M^FZYKZ0H Y7XJ>';CQ=\-_$VBVNFV.L7.H:?-;1V&IW$EO;3LR$!))(@713G
MDKR.U?"W[(_['_Q1^&W[0VL^(O%M\OB32-+U?RU_M6[U") S648%[9;W9;G8
M#]ES,"=L>0P(Q7Z)UYMXV_:4^%/PV\03:%XJ^(?AOP[K,**\EAJ6I10S(K#<
MI*L00"""* /ASX[?L5_%?QE^TQ;ZQHTMKI_AS5I]5NQI%K?ZDVF%!Y3.MY.K
MJ;=[T'#+" H\OHW->Q?MX?L\>-?BQ\&],A\'6-GIVH:%H=T)VTZ\O)+UE\E
M=.M8H]JSI-MV,9<\*N%R:]C_ .&T/@-_T5_P;_X.8/\ XJC_ (;0^ W_ $5_
MP;_X.8/_ (J@#S;X"_LY^+O ?[-'C'P?XAT_1O$_B'6[=F6ZU#4[Y#JQ>W55
M%Z6+26[)Q&1"2 $!&VO'_P!D']D'XH_#7]H#6?$?BZ_7Q+I6EZP\2MJUWJ$0
M#-91@7UEO=EN, BVS-D[8\A@017U3_PVA\!O^BO^#?\ P<P?_%5Z%XG^)7A3
MP5X17Q5K_B+3='\-LL3KJU[<K%;$28\L[R<8;(QZYH Z6BO&/^&T/@-_T5_P
M;_X.8/\ XJC_ (;0^ W_ $5_P;_X.8/_ (J@#C_V[/@CXL^-GPUMK3P?]FL]
M4TY+NY.J"ZNH[Z!?((,-K% 0)FG \HK(=N&Z$UR_[&W[._C+X6_ /Q'I'BO3
M]/UK5_$&CVYBDU&^O$N+@-:LJV-XC[OLZP[A"/)_AR=H(Y]8_P"&T/@-_P!%
M?\&_^#F#_P"*H_X;0^ W_17_  ;_ .#F#_XJ@#Y$_9M_8Q^*O@/]I6_UWQ)<
MP:WH6C7^GS?8[Z^U%+(;K<E);&1W;[2UH/W"B8$8/537Z15XQ_PVA\!O^BO^
M#?\ P<P?_%4?\-H? ;_HK_@W_P ','_Q5 'L]%>,?\-H? ;_ **_X-_\','_
M ,57;?#KXR>!?B['?R>"?%NC^*H[ HMTVDWB7 @+[M@?:3C.UL9]#0!V-%%%
M !7S?X!_Y/U^+7_8GZ%_Z.NZ^D*^;_ /_)^OQ:_[$_0O_1UW0!](4444 %%%
M% !7SU^V9X>E\6^!="@CTJW\8:;I>NVNH:UX0DU&*T;5K14E'E9D958ARD@C
M8@/Y1%?0M?*W[<2?#WP7X9TWQ)XK\#>&_$4>J:G%!J-UK\1,8AMK6[G7D'F7
M:LD<8_O3=^E '2_L7^%;GPQX)\52+H,7@S0=3U^:^T;PC'>Q77]CVS0PJ8R8
MF9$+RK+-Y:G"^;BOH2OEO_@GW>02?#3Q+9+X.\,^#[^QUA$O8?"<#PV4LLEE
M;7&"K,Q\V(3""3G[T)Z=*^I* "OF[]@[_DE/B[_L>_$7_I?+7TC7S=^P=_R2
MGQ=_V/?B+_TOEH ^D:\^^.'P3T'X]>!Y_#/B+[0UDV^1(X[B5(C+Y;*C2QHR
MB959@^QCM+*OI7H-<#\=OB9<_!WX3Z_XOL](77KS3DB\C36N?LXN)))DB53)
MM;;RXYP: .<^&?[,/A;X8_!VY^'>GW&J1Z3?VJ0WK6FHW$&9/*5)9+?$A-L)
M"I<K&0,NWK6;^SU^R+X._9SU36]1\."6"YU*ZNG,=O+-%;BWDE#PQ/"9&21X
M@-BRD;B"?6N<_P"%Q_M,?]&YZ)_X<"#_ .1J3_A<G[3'_1N>B?\ AP(/_D>@
M"[X/_8=\!^"_C7=?$>Q?4/[5=;>2*4WUR;K[0LDS3R37!E)G282HK1.-H$*_
M@>-OV'O ?CKXT6GQ&OGU#^U46X>>5;ZY%UY[-"8'@N!*#;K"(G"QH-I$S?C2
M_P"%R?M,?]&YZ)_X<"#_ .1ZV/AG\=OB=JWQ;TOP5\1/A58^!5U32KW4K*^L
M_$L>I^8;:2W1T*)"FW_CY0Y)[=* /?AP,4M?+^I?M-?%G6OBIX_\*?#[X-:?
MXML/"-_#I]QJ5WXLCT]I))+>.88B>!L<28X8]*L_\+D_:8_Z-ST3_P .!!_\
MCT ?2]?//Q8_8E\"?%_XJZ5XYUDWKZC;O*URQO+CS2# (X%MI!*/LOE./-'E
MCEB2>M9W_"Y/VF/^C<]$_P##@0?_ "/1_P +D_:8_P"C<]$_\.!!_P#(] '4
M_M%?LH>%OVC/#^G6&NS7+7&FB%;-[J>:X@0+-&\C-!YBJ\CI&T?F-E@)&Q7I
MO@'P+I?PU\)V/AO1/M0TJQ#+;1WEW+=/&A8L$#R,S;5SM4$\* !TKPG_ (7)
M^TQ_T;GHG_AP(/\ Y'H_X7)^TQ_T;GHG_AP(/_D>@#Z7HKYH_P"%R?M,?]&Y
MZ)_X<"#_ .1Z7_A<?[3'_1N>B?\ AP(/_D:@#Z6HK@O@3\3+CXQ?"?P]XPO-
M)70KO4HY&FTU;G[0+=TE>-E$FU=W*'G KO: "BBB@#YH_85_Y%CXN_\ 94/$
MG_I4*^EZ^:/V%?\ D6/B[_V5#Q)_Z5"OI>@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X9_:
M&_;2\7?"OX[:WX6.J:)X9TZS@EATS3M1TBZNKK5)&T\SP72NAPT37.+81Q@M
MN!R1D"OM+PMJ5YK'AG2+_4;)M-U"ZLX9[BR8Y-O(R!GC/^Z21^%?"GQF^+&F
M_P##0GQ"TKQM\<?''P[M]&N;6+1+#PKHK2VWV=[2)Y&:3[)*3+YK29Y QMP3
MT'W1X1FBN?">BS6]]<:I!)90O'?72[9KA3&I$CC PS#DC Y)X% &O1110!\]
M?\%!/^3,OBO_ -@C_P!JI7NV@_\ (#T[_KVC_P#017A/_!03_DS+XK_]@C_V
MJE>[:#_R ]._Z]H__010!?HHHH **** "OFW]FE0W[0?[3>0#_Q4^G]1_P!0
MR"OI*OF[]F?_ ).#_:;_ .QGT_\ ]-D% 'T=Y2?W%_*CRD_N+^5/HH 9Y2?W
M%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5/HH X/X[QJOP/^(A"J/\ BG-1[?\
M3K)7/?L@?\FI?!W_ +%'2O\ TDCKU74-/MM6L+FQO;>*[L[F)H9[>9 \<L;
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MO(M0NM TFWTZ6ZA4JDK1QA2R@\@''>N[H ^;_P#AEOXB?]'*_$#_ ,!=._\
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M/DENEG<:?;:E:VUO; LWVY7MK69]\DB-M(<;CD!L  U]U_LP?L<> /V2[?Q
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MQP>?8UT%5M1_Y!]S_P!<F_D: ,/1?B9X/\27T5EI/BO0]4O)@3';V6HPS2.
M,DA58D\<\5TM<I\)P/\ A5W@_C_F#V?_ *)2NKH **** /%?V-?^3;_"7^]>
M_P#I;/7M5>*_L:_\FW^$O]Z]_P#2V>O:J "BBB@#YH_85_Y%CXN_]E0\2?\
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M_P F1_%+_KTM?_2R"@#\-[7_ (]HO]P?RJ6HK7_CVB_W!_*I:_U(PG^[T_\
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M91G6"XDMY$=&#HZ21LK(RLH((/45XJ/V-;Z%A;6WQZ^+EOHX&T6']OQ.0O\
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M^=-_]+H:_!&@ K]?_P#@B'_R2KXE?]AJW_\ 1%?D!7Z__P#!$/\ Y)5\2O\
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M_P!-US7TA0 5\T?!O_D^7]HS_L%>%_\ TGNJ^EZ^:/@W_P GR_M&?]@KPO\
M^D]U0!]+T444 ?'_ /P3+_Y);\4/^RD:U_[0K[ KX_\ ^"9?_)+?BA_V4C6O
M_:%?8% 'QW\4?^4GOP6_[$_5/_:U?8E?'?Q1_P"4GOP6_P"Q/U3_ -K5]B4
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M_P#7SIO_ *70U^"- !7Z_P#_  1#_P"25?$K_L-6_P#Z(K\@*_7_ /X(A_\
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M_P"DF&6_'(^G?^"F?_)COQ/_ .N%E_Z7VU?G_P##7_DG?A?_ +!=M_Z*6OT
M_P""F?\ R8[\3_\ KA9?^E]M7Y__  U_Y)WX7_[!=M_Z*6O\]N./]WH^K_(^
M \1O]UP_^)_D=)7NG_!*O_D=OVAO^PQI_P#Z+N*\+KW3_@E7_P CM^T-_P!A
MC3__ $7<5XG!'^^U?\/ZH^>\._\ D85O\'_MR/T'HHHK]F/W\**** "BBB@
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MCOXH_P#*3WX+?]B?JG_M:OL2OCOXH_\ *3WX+?\ 8GZI_P"UJ^Q* /P%\/\
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M;C_>;ZUA^./^1)\1?]@VY_\ 135_+6'_ (T/5?F?Q]A/X]/U7YGZ*?\ !/\
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M_P#P1#_Y)5\2O^PU;_\ HBOR K]?_P#@B'_R2KXE?]AJW_\ 1% 'M7_!5_\
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M\GR_M&?]@KPO_P"D]U7TO5"UT'3+'5K[5;;3K2WU2^6-+N]B@59KA8P1&)'
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M?MZ_\E%_9=_[*9I_\Z^OZ "OC_\ X)E_\DN^*'_92-:_]H5]@5\?_P#!,O\
MY)=\4/\ LI&M?^T* &_\%8O^3+?$W_81T[_TJ2OSB7[H^E?H[_P5B_Y,M\3?
M]A'3O_2I*_.)?NCZ5\+Q/_RY_P"WOT/ZJ\#=LQ_[A?\ N06OMW_@D!_R(GQ<
M_P"QOD_]$I7Q%7V[_P $@/\ D1/BY_V-\G_HE*PX:_C5/3]3UO&[_D6X/_&_
M_23V?_@I5_R9#\4?^O6T_P#2VWK\.K;_ (]XO]P?RK]Q?^"E7_)D/Q1_Z];3
M_P!+;>OPZMO^/>+_ '!_*O[A\#O]XQ_I3_.9_$N9[0^9)7Z2?\$5?]7\:_\
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MQ=_[&6]_]&FO$Z]L_;:_Y.Z^+O\ V,M[_P"C37B= 'T5_P $[_\ D]+X5?\
M83?_ -$2U_0]7\\/_!.__D]+X5?]A-__ $1+7]#U 'Y\?L+_ +.'PO\ BYX=
M^+6L^,_ FA^)M5B^(VLVJ7FI6BRR+$IB8(">P+L<>YKZ7_X8?^ /_1(_"?\
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M7_\ 8AC_ -++>OF.#?\ D9_]NO\ 0^.X!_Y''_;DOT/T\HHHK]R/Z/"BBB@
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MYTOVVO\ D[KXN_\ 8RWO_HTUXG7MG[;7_)W7Q=_[&6]_]&FO$Z /HK_@G?\
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MWF^M8?CC_D2?$7_8-N?_ $4U?RUA_P"-#U7YG\?83^/3]5^9^BG_  3_ /\
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MO(P4<LQQU8Y8XXR:\;^$-O%;?MS?'U(8TB0:%X:^5% '^KNNPKZ8KYK^$_\
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M*?%W_8]^(O\ TOEKZ1KYN_8._P"24^+O^Q[\1?\ I?+0!\D?\%R?^0/\'?\
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M/T/L?]N#_DT/XN_]BY=_^BS7YH?#7_DG?A?_ +!=M_Z*6OTO_;@_Y-#^+O\
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M\-[7_CVB_P!P?RJ6HK7_ (]HO]P?RJ6O]5,)_N]/_"OR/R66[/UV_P""._\
MR:?J'_8T7W_HJ"E_X*W?\D4^'/\ V/NG?^B;FD_X([_\FGZA_P!C1??^BH*7
M_@K=_P D4^'/_8^Z=_Z)N:_RYS+XJ_\ V]^I]7B/]VG_ (7^1\TO]YOK6'XX
M_P"1)\1?]@VY_P#135N/]YOK6'XX_P"1)\1?]@VY_P#135_+6'_C0]5^9_'V
M$_CT_5?F?HI_P3__ .3-/A/_ -@=?_1CU]!5\^_\$_\ _DS3X3_]@=?_ $8]
M?05?U&?V8%%%% !1110 4444 %%%% !1110 5\U_"?\ Y/I^/O\ V O#7_HN
MZKZ4KYK^$_\ R?3\??\ L!>&O_1=U0!S/_!5G_DR#QO_ -?.F_\ I=#7X(U^
M]W_!5G_DR#QO_P!?.F_^ET-?@C0 5^O_ /P1#_Y)5\2O^PU;_P#HBOR K]?_
M /@B'_R2KXE?]AJW_P#1% 'M7_!5_P#Y,D\8?]?FG?\ I7%7T5\$O^2,^ ?^
MP!8?^DT=?.O_  5?_P"3)/&'_7YIW_I7%7T5\$O^2,^ ?^P!8?\ I-'0!VM?
M'_[!W_)4/VI?^RDWO\S7V!7Q_P#L'?\ )4/VI?\ LI-[_,T =7_P4B_Y,E^*
M7_7E;_\ I7!7Y4Z'_P @33_^O>/_ -!%?JM_P4B_Y,E^*7_7E;_^E<%?E3H?
M_($T_P#Z]X__ $$5\3Q-\%+U?Z']/>!W^\X__##\Y%VOJ[_@C;_R,7[0'_82
MT_\ ]"O:^4:^KO\ @C;_ ,C%^T!_V$M/_P#0KVN3AK^-4]/U/HO&[_D6X/\
MQO\ ])/I;_@I5_R9#\4?^O6T_P#2VWK\--+_ .09:?\ 7)?Y"OW+_P""E7_)
MD/Q1_P"O6T_]+;>OPTTO_D&6G_7)?Y"O[4\$?^1CC/\  O\ TH_B?,O@CZEJ
MOT?_ .")?_'K\:_^O[3?Y7=?G!7Z/_\ !$O_ (]?C7_U_:;_ "NZ^K\;_P#D
M7X/_ !R_]),,M^.1]._\%,_^3'?B?_UPLO\ TOMJ_/\ ^&O_ "3OPO\ ]@NV
M_P#12U^@'_!3/_DQWXG_ /7"R_\ 2^VK\_\ X:_\D[\+_P#8+MO_ $4M?Y[<
M<?[O1]7^1\!XC?[KA_\ $_R.DKW3_@E7_P CM^T-_P!AC3__ $7<5X77NG_!
M*O\ Y';]H;_L,:?_ .B[BO$X)_WVK_A_5'SWAW_R,*W^#_VY'Z#T445^S'[^
M%%%% !1110 4444 >!?M6>"=+;PW=>/=<^)_Q$\!Z1X?L6\^U\$ZHMLMT2XV
MYB,3EY69E1>1U ]Z\_\ V1;K['\3M5TG7-:^-%EXF_LC[9!X=^*&J07=O/9M
M*J_:H/)7;YBMM1E+;EWXQSD>H?'[Q%X7\::UI/P-U?2-5UJ[\;6<\UP=*<1'
M2[.$J?MKRDC;ME\L)@$ENW'/GO[.^BV7A?\ :8\::#XL\1^,O%7Q(TS18HM-
MU3Q6D"07&BM*I9[00*%/[X!9&<;R44^HH ^KZ*** /F_]J?_ )+!^S7_ -CM
M)_Z;KFOHZ3_5M]*^<?VI_P#DL'[-?_8[2?\ INN:^CI/]6WTH _EBU3_ )"5
MW_UV?_T(U6JSJG_(2N_^NS_^A&JU 'U__P $G_\ D]KPC_UY:C_Z22U^]-?@
MM_P2?_Y/:\(_]>6H_P#I)+7[TT ?'_\ P3+_ .26_%#_ +*1K7_M"OL"OC__
M ()E_P#)+?BA_P!E(UK_ -H5]@4 ?'?Q1_Y2>_!;_L3]4_\ :U?8E?'?Q1_Y
M2>_!;_L3]4_]K5]B4 ?@+X?_ .0YXV_[&74/_1M;E8?A_P#Y#GC;_L9=0_\
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M6I3%80W;',I! ). =J@LH+MA02.: /0*^;OV#O\ DE/B[_L>_$7_ *7RU](
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M;5(K:>UN"\231+(%8C@D!L'%?W/0\7>&:=*$).I=)+X/+U/@GE]9N^A]6?\
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M0_\ !.74/@)I>HZ=X!^.GC#PW9:A,L]U%;V-B_F2*NT-EXF(X]* -'_@J_\
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M!VMPZ_IRV6E7Z*UQ']U90TC;D]0"#[UZ+_8?[7'_ $-GPB_\$NH__'Z^E**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>kros-20251231_g13.jpg
<TEXT>
begin 644 kros-20251231_g13.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (6 WP# 2(  A$! Q$!_\0
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M-:R//NQ=^6$VF1<#Y\_A7[FV\$5K!'##&L4,:A$CC "JH&  !T %?@U^S/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_,[_@MUXTU+3?A_P##7PO;RR1Z;JU_=WETJD@2-;I$L:MZC]^QQZ@'
MM7Z8U\L_\%#/V2[S]J_X-V]CH,T4/B[0;EK_ $M9R%CN,KMD@9C]W<,$'IN1
M<\9- ' #XH>&?^"=/['_ ,+K[0/ \GBE=<CM5O&T^=8)9[B6V:=[B23RV+\@
MJ 1P" .!BMK]CG_@H3I'[6GQ2UCPY9_#V;PK?VNF&\FU":^2=I%214$9 B4\
M&0D9/'/K7RK\%_VZ?CY^RIX/LOAKX\^#&L>(3HR?8].N)H;BWG$8XCC+B-TF
M5>@9>P R<9KHO^"5OPM^(D/[17CSXD^)/!&J^&-"UJRNC'/J%N\"F:6ZCE\M
M!( S #=\V,<=: /+/@#\=OVK?VA?B-XX^'O@CQY<37,PD:35M7G"II-O'.06
MC8(2K.2J9"DX/&.H]*_:F^-'QO\ @3\9/V>O ES\0=1AOKC0]+C\0?8[@/%?
M71OI(I9&9ERVY5 R<<"M'_@DW\/?%/A']H+XN7FO>&=8T2UN;,K!<:C82VZ2
MG[63A6=0&XYXH_X*8?#[Q3XH_;4^#>I:-X:UC5].M;/3Q/>6-A+-#$1J4K$.
MZJ0N%()R>AS0!I?\%,/VCOBQ\(?VH/AUH/P\\37]A;7VDVDYT:!PL%[<->S(
M%<8_C"HAY'%<3^U'KG[7G[(DWAWXH>(?BQ#KMIJM\([G1[(,=/M)BID%N8&4
M*8RH90RX/R]<X-4_^"M=QJEG^V=\))]#A2YUJ+2+%[&&0X62X&HSF-3R."VT
M=>]4_P!K;XS?&?\ ;HN?#'PCTGX*:[X3O[#4!/J<=XLCI]I"M'N:4QJD<*@R
M'<2<Y&#QR ?JK\&_B-!\7OA1X2\:VT/V:+7=,@O_ ",Y\IG0%DSWPV1^%?F7
M^WE^SK\6?@W^U4/VB?AUH\GB73_/@U)C!;&Z:PN(XUC99H1\QB8+G<O3)R5(
M!/Z8_!7X<Q_"'X1^#_!<4PN!H6EV]@TRC D=$ =P.V6R?QKX_P#CE^WM\5OV
M<_CEXLT#6/@[J/B[P.DT<FC:M8Q36Y:(Q(6!E$<B2 .6[ CH: +'[+__  4F
MT#]JKSO &JV'_"!?$V\M)H],E9O-LIKGRWPT3'YD=?O;&'." Q/%? ^E?"?X
MNS?\%"KGP3!\2Q%\5%N)$;QGA\,PLBY.,;N8_DZ5ZQ\"_A1\1/VLOVZ--^,<
M/PUF^&'A*QU2#5+N22!X(B8 ORH61?-FE*C<57'+$^][]IJR\=?LM_\ !2!O
MC'%X'U/Q3X>NYTN[9K*%S'<(]J()8A(JL$D4EN"/0XP: .P_X*,?'#XR?LTQ
M_!/0],^(>HKJYT20:U=V+;%U*XC>)3(P*YY^;\Z]1\,?$#]H+]G/P)\2?CG\
M<=8M-4TJ[T:.?1O"%M='9I]Y+,JPPM'L"I@.H8JS'&<DFO$/^"FFF^,/CEJ'
MP"\6:7X#U]6O='>[N]/@L9KE[!I)87\J4JG# >H'0\5]^_ME? ^^_:(_9I\6
M^"-+DCCUFZ@CN+'SFVH]Q#(LJ(3V#%-N>V[- 'YFV/QZ^-GQ ^$NL_&.Z_:B
MT;PQX@A::ZLOA]#=11/+%&V"@AW84G!V(RN6 &3\U?0/C[]M+QI\2/\ @F7/
M\4]'U*3PQXZL]4M]*OKW2\(#,MQ&KL@.=H='4E>VXCI7RY\'9O!7P;\,'P7\
M8OV3->\4^-K*XF1-2MXIT>Z4L2%8#Y3MSM#IN!4#ZGZL_:.^&<<W_!,B>T\%
M?"F]\#WNM:A9ZI-X.L89[FYMY&N4!+*1O+>7&A/ QZ"@#QBW\3?M:_$O]C.#
MXQ6_Q5?1]"\/P7$JVMK*T>HZI%'.XEN)957!*G*JA.-L7J>?>_@7^WSX@C_X
M)Z^(_BMXM\G6O%_ANZDT:*1DV"^N#Y8MWE"X'_+9=VW&0A/!-6/A-X.U^S_X
M)&ZCX?GT/4H=?;P]JT8TJ2TD6Z+-<SE5$1&[)!! QSD5XE^SA^S#XS^*7_!-
M?XE>!O[$O]&\4R>(?[2T^QU2V>U>Y:%('" 2 ??"LH/3- #_ ((S?MD?%OX5
M:O\ 'O3/BI&MFHN[BT\,WX_<WT46X2^7$%\N, JZIT.4ZCK5W]B7XB_'3]JO
MX!_&+3(OBK?V7BNSNM-?3]:U!M_V6+]ZTZ+M7/SJH'X5S/[._P"U/\8OAO\
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M\?\ X0^(O -_J-QI-IK,2127EJBO)&%D5^ W!SLQ^->?^$/V-?#?AG]DN[^
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M110!\V_#G]A#P!\*?V??&'PN\.2WEN/%FGRV6J^()]LEY.SQ&/?C 4!0QVH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\O\
M[2'[9TOPG^,O@?X2^"O#4?C3Q_XDE4R6<MW]GAL86)"R2,%8YP'<CLJ$]Q7U
M!7YA?L1R?\+F_P""DWQS\?:GF>70_M5I8;SN$2^>+:/&>F(HF'']X^M 'Z73
M:U8V!2*^O[2VN-H+(\RK^(!.<5:M;N"]A$MO-'/$W22)@RG\17Y)_MZ>'_AO
MXF_X*.:!I_Q8U>;0O TWAN(WU_;R,CHP2X,0!5'/+A1]WOVZUO?\$Z_)\#_M
M+_%:Y^'NO:S??LXZ1ILTC:KK&];8NI1U=<JH++B?D*"4&2.10!^J=%?#K?\
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M?R[^)VK^.?AO^WO\:_BOX%4W,O@/4H]0U6P7/^DZ?)Y<4ZL!U3##=Z [OX:
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M ;1XOV6?^"E&L?!WP=<7=O\ #GQ)H7]HQ:'-<R316<ZQ&4,A<DYS'*,YR1(
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MW<*KGW8U[[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW&,\\"21R1P,( 3S7S=X"_9;U'X4:?K?@+XH?"+XR^)+\WLBVEW\/[W?HU]
MP"KO&-BY*Y+$DX894;>?VIHH _.#]M3]F_Q)H_[/O[/Z?#SP7KFM6'@34([N
MZT&-_MFHV\;B.38=@_>%75D)5>,@XQ3_ (ZV/C#XX?M8?LM?$33?ASXNTG1X
MG$FHPZEI4BRZ7MO",7.T%8N!N^8_=(-?HY10!^=WC?0_&_P._P""F6H?$\_#
MCQ/XQ\'^)-(ATZ&^\-V1NA;NT<$3-+CA K1'.XCY3D9Z5I_LF?"+Q%:?MI?M
M/W?B;PIJMEX6\1-/!;7M]8R16M]$]PVX1R,H5P5/8G@U]_44 ?CI\(_V5?B?
M=_'3PM\#_$GA/5S\)?!WC.^\0#7+FSF2SNX0J;%$I78P<1*  >LK^]>G_ML?
MLS>)[7]KY?BM+X2\9^-O &L:=%;7J_#^[,>JV4R1K%@* 6*':K8^Z<MD@CG]
M/** /D']@'X.>&O!:^,_%VB>!_B!X(GUJ6&WE3X@W2O>7JQAG\WRP-R8:1ER
MQ)-<?^S?\+-?M_V_/VD=4\0>%-1A\)Z]9_9[>]U"P=;._1GB#(CLNV0%=V0"
M>,U]W44 ?D%+^QU\1O@;^W9\-=*T?1]>\0_"?3O$D6KZ1?6]K)/;:9!-,K31
MR.JD1E2@SD@$!6[FMGX[_LP^(?A[^UUX_P#&7B'P/\1O&?@+Q9(;VSU#X97;
M+>03.0QCFC49*@AA@X&-I!/(K]9** /RQ^+'[-;Z=_P3]\2V7PZ^&OC[2]1\
M0>*+6_?P[KP-]JK+&=OGM'$N4#+R0<D=S7Z!?#;P-;ZE^S?X8\(:SIQM+:X\
M+6VF7MA+%Y;1AK58Y$9".",D$$<&O3** /Q\_9U_9C^*FK?'?P#\)_&WA+5H
M?AE\-?$6IZS'J]Y8RQV=^-Z&,+(1L<,\:$ $\2/[UW/[7/[,?B3P_P#MB:O\
M3;[P?XZ\;?#[Q%9QK(_P[NV34[*=8XX]K(H)*?N\XX4[NH*X/ZE44 ?)W[ 7
MP?\ #O@'0?%_B30_!7CKP1)K]Y&LUMX^NEDO;M8E++/Y8&4RTTB_,23MS5']
MK#X[_$7X?^-KOPR_[.UU\9_AK?V$3)-90M*1<'<)(Y%$4HP!C!**?FZFOK^B
M@#\H_P!FO]D'XI7'PQ_:3U-O \GP]L/'&BS6?A[P;=7!#^86:1!ASE0@/EJT
MF"=YX JO-IOQ \6_\$R]:^$3_"3QOI7BSPO-9+Y=UI$NW4@^H-(3; #<^Q>6
MXP.N2*_62B@#\O?B?\(_'5_KG[#<EKX-UZX3P[9VBZPT6G3,--(DM"1<$+^Z
M(VMG=C[I]*]5UKX<^*IO^"M6A>+U\-:L_A2+PVT#:X+*0V22?99EV&;&P-D@
M8SG)K[MHH _.[X1_!;QGJ7[77[6[7/A[4]*TOQ5HUY8:5J]_9R16ER\N$4I*
M1M<<Y^4G@&O$/"MG\8/"_P"PIXZ^ ,GP(\9R^((;F6235A:?Z$86N$D)B(^:
M:3*D!8@P(.[( -?L!10!^3_QB^#/C_4_@3^QCI]GX(\0W5]H-P&U:VATR9I-
M/'G6YS.H7,?"L?FQT-;GQX^'_P 2O%_[67CNU^(7@/XF?$+PI=1B/P9:^$]0
M:STB-2O N95(6-?[Q)W;@3ALBOU$HH _+K]EW]GWXAWG_!./XU> [GPEJNC^
M*M4O[B2PTK5;9[66X"QV[ () ,[O+90>A/>L+QCI_C_XB_\ !,VV^&47PF\;
MZ7XI\)7NG6SVUWH\N;]?-E8R6Z@;W51C<=O&X=>M?K%10!^;'Q1^#OQ*^&_Q
M(_9V^/'A_P $:GXTM/#'A.QTG7/#=DG_ !,+4I;LC,D+?,6Q,W &0R8. <CH
MOAWX+\??M2?MS^'?C=JGP_USX:>"/".F&SM8_$T0M[^_FVRKCR>H&9F)/3"#
MDDX'Z"T4 ?GC^P7\,?&/@_0?VGX]=\+:UHSZOJ-S)IRW]C+";Q2EU@Q!E&\'
M<O*Y^\/6L3]B_P")]Q^P[^Q+=ZS\2_"'B2PNKCQ<]I;:*UD8+V=IHX]K)',4
MROR-SGL:_2FN+^)7P<\'?&!="7QAHL>MQZ'J$>JV$<LTB)%=)G9(51@'QD\-
MD<]* .LL+EKRQMKAX)+9Y8UD,,N-\9(!VG'&1TK\M_V<_P!AN'XS77[2^F?$
M7P/>:%?:EK+OX;\0ZIILD,T#&:Y82V[L!N3/EE@N0PP#UK]4** /S-\'ZE\9
M/$G["_QB^#/CWP3XIN/&7AJP:QTB^DTRXE75[59E54BEVXF9-N!M)+(4(S@U
MWL'[(VJ?&G_@G=\-_#<UC=>&?B;X7T]=0T22\C:VN;2]1V;RGW ,@<  ],'8
MW\-?>M% 'YB_\$^]#^-/P;^"/QYU^;X?ZO/\09]0M;^QTO7;*2V.J2Y?SMN[
M9NX9CE3U(^E>9_M">%_B;^W#XH\-6VA_LOZG\+O&$%XKZCXPO1);JR="7=H8
M@0K$OG+OP-O4Y_8:B@"GH]I-I^DV5K<3FZGA@2.2=NLC!0"Q^I&?QKX?_; ^
M'?BKQ-^W;^S9K^D>&M6U30])N%;4-2L[*26WM!]I!S+(H*IQS\Q'%?=E% 'P
MW^W9\(?'&F_';X1_'KP+X9NO&C^#Y/L^K:'IHW7<EOO9@\:]6X>5< $@E3C&
M<4OV=_A]XW^.7[;.N_M#>*/!.K?#[PS9:2-)T+3/$$0AOYV*>6SO%U4 &4\\
M?.H!.":^\:* /D'_ (*G>!_$7Q!_92NM(\+Z%J7B+56UFSE%EI5J]S,44ON;
M8@)P.,G%:'Q<^"MA<_L*ZQ8:;X#M)?%S>"HX8[6UTA#?&Z^S("H4)O\ ,W9X
M'.:^KJ* /R/\8:O\9_!7[ /PW^#GA3X:^-AK&M6]TWB"[M-#N6DL[0W<O^CX
M"Y#RCD@X^3C^/CZ!^"OQM\,?!O\ 97\7^';3X5^._AMHOA#PU/='4_&>D"Q3
M5+QQLX8,=TTDKKQC@$ < "ON^N,^*GP=\(?&SP_;Z'XVT@:[H\%U'>BQDN)8
MXGE3.PNJ,N\#)^5LK[4 >$?\$Q?AY??#K]CGP;#J4307FK-<:N8GR"J32$Q<
M'IF,(?QKZJJ.&&.UACAAC6**-0B1HH"JH&  !T %24 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'RWH^M_&[XM?$KXI6GA?XB>'
M?"6A^%O$/]BVUG>>%CJ$KK]DMYR[2?:8^\Y&,?PUT7_"M?VCO^BW>%/_  @S
M_P#)U>L^#/AOHW@/5_%FI:6LXN?$VJ?VOJ'G2[P9_)BA^0?PKLA3CUS74T ?
M/O\ PK7]H[_HMWA3_P (,_\ R=1_PK7]H[_HMWA3_P (,_\ R=7T%10!\^_\
M*U_:._Z+=X4_\(,__)U'_"M?VCO^BW>%/_"#/_R=7T%10!\^_P#"M?VCO^BW
M>%/_  @S_P#)U'_"M?VCO^BW>%/_  @S_P#)U?05% 'S[_PK7]H[_HMWA3_P
M@S_\G4?\*U_:._Z+=X4_\(,__)U?05% 'S[_ ,*U_:._Z+=X4_\ "#/_ ,G4
M?\*U_:._Z+=X4_\ "#/_ ,G5]!44 ?/O_"M?VCO^BW>%/_"#/_R=7'_$;6/C
MW\%)O!>K:U\3?#/B?2=3\5Z1H5WI]OX1-G(T5U=)"[++]J?:0K''RU]95\]_
MMI?\B?\ #?\ [*/X9_\ 3C'0!]"4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17AW[8_P"T)=_LU_!>Y\3:3IL6K^(;R\@TK2;.
MX)$;W4Q(4OCDJ &.!UQC(SFO-?@;\>OBWX9_:17X+?&O_A']2U75=#_MW1]9
M\.0O%&=I(EMY%;N-KX; ^[WW# !]=T5XY^U)\1_B'\.?AY;R_"_P;+XR\7ZE
M?1:?;H8GDMK%7SNN9PO.Q< ?5@3P#7B?PN_:;^)_P[_:'UCX0_&J;P]K]Q'X
M;E\36NN^&('B6.*-69XI4?'9'P<#D#KNX /L^BOSDTO]N'XXV/A'PK\===TK
MPR/@KXD\0#2(]!MUD_M.TMFF:);@RDX9LQR<="1T .1^C2L&4$'(/((H 6BB
MB@ HHHH *^6=>_;RT#0?VAK;X7R^&]>.HO!-&U@NG2'4);H3(L/E(#L:!XC)
M+YFX85.<=*^IJ\&U7]B3X3:Q\24\8W/AFV>Z,4_G6VP;9KF6=)C=-)_K!*I3
M:I#@!69<8XH POVC/VVM _9Y\?>&O#&KZ5J,<VI7\,<EQ-92-%<6KQN6>T9,
M^;(L@BC*'',@[<U>_:1_:^L?V?OA79>*K[PUK%M<:G:+-91ZI9LD$,Y9/]&N
MF0L8I2I<@8(^0C-=!\6/V1?AM\9/%NG>)/$&@V]QJMO>PW5U-)$LOVZ..)XE
MMY-X;$6'W$)MRRJ>HI?BM^R/\./BUX%LO#.HZ,EM%IMA_9NEWD?[V;3X=R$B
M+S=R[B$"[F!;!//)H TK/]HC1-0^#LGQ,M]!\23>&U/F*JZ81=2VVX#[6D);
M<8=I\S/78"=M<I^R=^UMI?[46AWMSIVEWD<MC).MS>PVSC3UQ.ZPQK*^"TK1
M".0J!\H?K7>Q?L^_#N'X?S^!D\*6*^$)KK[9)HRAA;-)O#_<S@+N4?(/E[8Q
MQ61\"_V8? O[/L$[^&=,1-4N/.2XU(HL<LT<D[S!'5 J$(7"J=N0JJ,\4 >M
M4444 %>!?M9_M8:;^R[X7CO[_2KR>XNP@L[N6W<Z>TGG(KPR2IDI)Y9>101@
M[#S7OM>3?'?]F3P/^T+IOE>)]-5]2CA6WMM45%>:VC$R2LL8<,@W;-I.W.UB
M,\T 2O\ M$:)'\'1\2VT'Q*OAO/F%3IA^U"UW8^U^3NW>3M_>9Z[.=O:N9_9
M-_:LT[]J+PG)J5CI5Y;S6N];N[CMW&GB02NJ0QRO@O)Y8C=@!@;QS7<?\,^_
M#K_A %\#_P#")V)\(+=_;1HN&^S>;YGF?<SC;N_@^[CC&.*R?@/^S+X'_9YT
MUH?#&G*FHS1M#=:HRJDUTAF>51(J (2N_:&VYVJHSQ0!ZQ7SW^VE_P B?\-_
M^RC^&?\ TXQU]"5@^+_ NA>/;73[;7]/348-/U"WU6U1W9?+NH)!)#(-I&2K
M '!X/<&@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **^%O^"HEM\24^&JZKIGB:WT+X?:?=Z<+BPLU<7VI74EVJ;7D!&R%%*L
M.6;KT%=!^T!X?B^-G[7GA;X7^)+Z^'@NT\#7GB+^SK*^EM?.OC/Y"2NT3*6,
M:_,H)P#GCDT ?9-%?FOH]A\5_P!I_P#92_9^2#0[KX@6]IK5\_B-KK7/[*6^
M@M'F@MUFN%/F$.,99%8DQ\]<U[;\$?CMX?\  _[-]]J/@/X1>*9KS0_$-QH>
MK^!]%G?5;VROE;$["21R9(QA3N!_B' H ^NZ*\*_9K_:KM/VB]<\;:+_ ,(5
MXA\#ZQX3>TCO]/\ $4213AKA9&0; Q(PL>>0.&&*]UH **** "BBB@ HHHH
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M9(0?G;:BKN.3A0.U;ECJEEJBNUE=P7:H<,T$JN ?0X- '#_\*(\*?\]/$?\
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M_HH ^1OV5_\ D\[]K;_L(Z#_ .D<M?7-?(W[*_\ R>;^UM_V$=!_](Y:^N:
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M -E'\,_^G&.OH2OGO]M+_D3_ (;_ /91_#/_ *<8Z /H2BBB@ HHHH ****
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MF\)_"77)9=36P="\%CN.9%1MP";>000C+C#<C-;'P._9&^$'Q1\/VOASP_\
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M0 4444 =U_P3[_Y/ ^+O_8N:;_Z$*_1FOSF_X)]_\G@?%W_L7--_]"%?HS0
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MQKJ8L[:> &;82A(E )^7/3B@#Z&HHHH **** "OD;_@IY_R;GI7_ &-NC_\
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M(9KZ=5$DBQW4L:;L 9(55&>IQS7J'[0W_) ?B9_V+&I_^DLE>$?\$J?^3'_
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M^9NQGD1_\\T_[Y%5M9_Y!EQ]!_,5<JGK/_(,N/H/YBO%SJG"&4XSD5OW<_\
MTEFM)OVD?5']+/P[_P"2?^&?^P7:_P#HI:Z&N>^'?_)/_#/_ &"[7_T4M=#7
M\/'TH4444 %%%% !1110 4444 %%%% !1110 5\Q?\%']/U[4_V3_$T.AP7U
MU;K<6DFKV^FG_2)--693<JN.?NCGV![9KZ=KP3]M_P"+WBSX)?L]ZOXC\$PV
MY\0O=6MA!=7B!X;,32K&9W!^7"Y_B^4$@G(XH _+_P 4?$#X*>)/#/Q1\ ?"
M;3-2N-1UOQ)H-_\ #O3M.M;A9;>ZBM(8IIF9N00[7 .XDDMN''(_:_1X[J'2
M+&.^<2WJP1K.XZ-(%&X_GFOSY\/_ +(_[6VAZ@=:TGXJ?#C2=4N5S)>:?X;M
MHI6W<D>8EF"0?UK]"-+BNH-+LX[V59[Q(46>51@/(% 9@/0G)H M4444 %%%
M% 'R-^RO_P GF_M;?]A'0?\ TCEKZYKY&_97_P"3S?VMO^PCH/\ Z1RU]<T
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M,_V>?^1#U#_L.ZC_ .CJ],H **** .Z_X)]_\G@?%W_L7--_]"%?HS7YS?\
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MW_R3_P ,_P#8+M?_ $4M=#7\-GTP4444 %%%% !1110 4444 %%%% !1110
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MU*\T1YM!U/=]HM"MO.@5]R(<D*&Y4<,*^[J "BBB@ HHHH **** //\ QU\
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M!)))SR<]K\&O@UX=^!?@M/#?AM+I[=KB6]NKR_G,]U>W,K;I9YI#]YV/4\=
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M[-YVDV]C]FQG=CROO;LCKTV^]>@UQ5J<:51PA-37=7L_O2?X%)W6P5\AWO\
MRE6T[_LE+_\ IR-?7E?(=[_RE6T[_LE+_P#IR-8#/KRBBB@#S[]H;_D@/Q,_
M[%C4_P#TEDKPC_@E3_R8_P"!?^OC4O\ TNGKW?\ :&_Y(#\3/^Q8U/\ ])9*
M\(_X)4_\F/\ @7_KXU+_ -+IZ /KBBO@3]MK]IOXI_"'XJ^'M*L-/TZZT73M
M0B\1[/#^MS0W;Z7$OERKJD?E,([=I95.\97"8Y.<=K^T1\=OB_X+_9GTGQ-'
M:>#)=1\06<UC-_PC^MSK<&XNODL6TI]A\Z3#*Y'<K\O'- 'V-17R=^R5\:/B
MK\6O@;J^I2V7A>+4M'L4TO3X]4U>>XO3J4"%+C^U2(P8F+*&*@;AN/7@UX[^
MS=^UE\6OB%^T9K>B/8:&+#Q%?Q2V\VI^()I=,^R68^SWPT8>6//+2*\AP<#'
M.1DT ?HG17YU_M%?M9?%SX;_ +26CZ6;#06TWP_/.+A]-\0SPZ2(;[$-@=8S
M$?)=64N 3AMW&!S7WYX.GUJZ\*Z3-XCCT^+7I+:-KY-*D>2U$Q4%A$S@,4ST
M)YQ0!L4444 %?"W_  5,N(-2TWX,>%O$6KW&A?#G7_%B6_B2^AD\M5B55**[
M= ,&1N<@%-W\-?=-<I\3/A9X3^,GA&Z\,>--#M?$&AW!#/:W2G 8?==6!#(P
MR<,I!&3S0!^=OP_\"_#;]IC]M;Q6^H)INO\ P1^%'A6UT'33>77F:?N"J@8R
M%MK '[0=V>=B'G KU3_@E+):P^$?B_IOAVXENO %CXTN8_#TKL64P%1D*2>1
MM$9]\YZFO?8_V-_A18?!77_A7H_AI= \):X5:_CTZ5A<3,KJP9IGW,3E%').
M!P,5W_PM^%7A7X+^";#PGX-T>'1-"L@?+MX<DLQ.6=V.2[D]6))- '6T444
M%%%% !7R-_P4\_Y-STK_ +&W1_\ T?7US7R-_P %//\ DW/2O^QMT?\ ]'T
M?7-%%% 'XP?L\_\ (AZA_P!AW4?_ $=7IE>9_L\_\B'J'_8=U'_T=7IE !11
M10!W7_!/O_D\#XN_]BYIO_H0K]&:_.;_ ()]_P#)X'Q=_P"Q<TW_ -"%?HS0
M!X1^W9_R9]\6O^P#/_2OQ,3[B_05^V?[=G_)GWQ:_P"P#/\ TK\3$^XOT%?-
MYQ_R[^?Z'[7X;_\ ,7_VY_[>.HHHKYL_:A5^\/K7Z_?\$Q?^3,?!G_7WJG_I
MPN*_(%?O#ZU^OW_!,7_DS'P9_P!?>J?^G"XKZ')_CG\C\>\1_P"!AO67Y(^J
M:_,C_@M?_P >/P8_Z_-4_P#0+:OTWK\R/^"U_P#QX_!C_K\U3_T"VK]#R+_D
M;83_ *^0_P#2D?@]3X)>A^9%%%%?W(?,!5/6?^09<?0?S%7*IZS_ ,@RX^@_
MF*\//?\ D4XO_KW/_P!)9K2_B1]4?TL_#O\ Y)_X9_[!=K_Z*6NAKGOAW_R3
M_P ,_P#8+M?_ $4M=#7\-GTP4444 %%%% !1110 4444 %%%% !1110 5\M_
MMT?'7X'^$_ =U\//BS<7FIMXB@!CT/18C-?X#929.T9#J-K,>2.A&17U)7YP
MZ#\7?AA\,_\ @I!\>->^*FN:9I=Q;6>F6>AW6K1M(81]GC:58<*=IX7)&#R?
M4T > ?L]^$?V;_'_ ,8M*TOQ7\2OB2ZWM_!-:^'_ !O MM;:E/&%CMUFF1F#
M$#:B@[>!M!YQ7[.*H50JC '  K\U/^"CG[3_ ,"OC!^S?J-IX3\8Z'K_ (TM
M+ZSN=+^S1/\ :8F69=[(Y08^0MGG^E?HKX/NI;[PGHEQ.YEGFL8))';JS&-2
M3^= &O1110 4444 ?(W[*_\ R>;^UM_V$=!_](Y:^N:^1OV5_P#D\W]K;_L(
MZ#_Z1RU]<T %%%% !1110 4444 %%%% !1110!Y_\;HOARW@L3?%"+2I/#,-
MS&P;6$W0I,<JAZ=>6'XFOCKPA=?LLCXU?$-M37P;_P (LUMIO]D>=#^XW^7)
M]H\OCKNV[OPK[^O+&WU"$PW5O%<Q9SY<R!UR.AP:H_\ "*Z)T_L>PQ_UZI_A
M7'6HNI)25M.ZO^I]%E^:1P=&=*3J>]I[L^5+5.Z7*]=+7[,\3U']GV'0_LWC
M3X&:C:>#]5FMHY/[-1"=%UF':"@FA'W&*XQ*F&&><UU'PN_: LO&.M2>$O$^
MF3>"?B%:INGT#4&&)QWEM)?NSQGU7D=P*]7CC6*-410B*,*JC  '85QWQ0^$
M7ACXOZ*FG>([ S- _FV=_;N8KNRE'22"5?F1A[<''((J_9N&M+[NG_ ,%C:>
M*7L\==]I[S7K_,O)ZKHTM#LJ^;?''QZ^,G@2\TB*^^%&AM%K&JQZ18.GB@$R
M32;C'N'D_*"%.3VJY'\1O&O[.+K9_$MI_%_@13MM_'5C;EKFR7LNH0H"<#C]
M\@P?XADUY%\<?VW/A%XQO?AXVE>(;BX71O%EGJ=X?L$RA+>,2!W&5Y^\.!R<
MUSUL1%1^+E?;3]?T/7RS*:TJVE!5Z;^TN9K9_P K5GW4E?R/K#X9:YXWUS3[
MR3QOX6L/"UW'*%MX;#4_MRRICEBVQ=ISQCFNTKS;X-_M#>!_CW'JLG@S5)-2
M73&C6Y\RVDAV;]VW[X&<[&Z>E>DUVTY*44XRNNY\SC*=2E7E"K2]G+^6S5M/
M-M^>K"BBN \??'SX>_"W5HM+\6>+-/T+4)81<);W;D,T9) ;@=,@_E52E&*O
M)V,:-&KB)<E&+D^R5W^!W]%>8>%?VF_A9XX\06>AZ#XXTK5-6O&*V]I;R$O(
M0I8@<>@)_"O3Z49QFKQ=RJV'K8>7+6@XOS37YA3619%VLH8>A&:=15G.1?98
M/^>,?_?(J10%  & .PI:*8!1112 ^:_&G[&VH^/;Q)-6^-7CZ6W@U%=4M+43
M6OEVLZ.6B9/W.?D)XR3TKU7X3?#'5?AK:ZE%JGCWQ%XZ:[='CE\0/$S6P4$%
M4\M%X.<G.>@KOZ*]:OFF+Q%'V%62<>W+%?DK_P"9"A&+NADT*7$3Q2HLD;J5
M9'&0P/!!'<5X=XJ_9!\'W6LR^(/!-WJ7PL\4NV]M3\(S_9HYF_Z;VI!AE'KE
M,GUKW2BN;#8S$8-N5";C??L_)K9KR::'**EN?'GQH^.WQE_90^'>K:GXYLO#
M_C_0_*:TL/$NER?V?=I=.I$/VBT;*N-PR3$W0$X]/(?V ?VZ_"7ACX(P>"_&
M;ZFNLZ'/-Y#:?ID]X9K:20R!F\I6P0[LO..-M=?_ ,%*?A_!\6-6\)Z#JWQ<
M\(_#_2+&"2^32]?N'CFN9F8IYV #E0JE1Z$OZU\\_P#!/?X:P>#?BMX-\7:1
M\9/!T=_J;265YX1:Y?[=<0LS*8MF,%CL61?HIK]GP. RO&<,U,1BH6JR?.^2
M,HJ\5+E5^645=<UW%<JOK9ZGG2E.-9*+T/O63]O+X-6^U9]=U6VD*AC'+X>U
M ,,^H\BG_P##>GP+"CS/&S0L1DQRZ/?JP^H,%?0%,:&-VRR*Q]2,U^3>VRK_
M )\5/_!D?_E1WVGW7W?\$\*3]NKX$NJG_A8=DA89VR6MRC?B#$"*^2_"_P"W
M]X'C_;R\3:Y=WRP> +W1DT"WUH12."T#&59MBJ7VN[2(.,\H?6ON/X]^&_$N
MM?"CQ-9> ;'36\8WUJ;6RN+XK&D)?Y6DW;3\RJ6(XZ@5^0VD?\$[_C1#\6)_
M"ED^BP>)M+L8-;\Y=1(18WE9$97V?>WQGC':OT?A7!</8O#XJIBING>+C:52
M+:6C<E:$;6=DF[K?0XZ\JL7%15_D?IVW[=WPMN6VZ0/%'B)N@&D^&+^7=],Q
M#_)I_P#PU\]^,Z+\&?BKJH/W6?PX;16]P9G3CI^=>P_#EO$C>!-!_P"$PBMH
M?%"V<:ZDMG)YD)G"X=D; X)&?;.*Z.OSRI6RZC-PCAW*SMK4NG_X#&.AUI3?
M7\#Y\;]H3XJ7Y_XE/[.WB1E/1M6UNPLQ^(#N1^7I7YZ?\%%/VK/'7CSQ%IWP
M[UKP_:^")?#UPM_=V>G:R-09KED!BWRHB!616)V@9!?KP*_8ZORT_:*_9O\
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M*1^#U/@EZ'YD4445_<A\P%4]9_Y!EQ]!_,5<JGK/_(,N/H/YBO#SW_D4XO\
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MS_K[U3_TX7%?D"OWA]:_7[_@F+_R9CX,_P"OO5/_ $X7%?0Y/\<_D?CWB/\
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M@ HHHH **** "BBB@ HHHH *\K^+WQIM_ %Q+HLG@_QCX@ENK-G6Y\/Z,]Y
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MM&2005<8YSP>.*ZCPC[THHHH \^_:&_Y(#\3/^Q8U/\ ])9*\(_X)4_\F/\
M@7_KXU+_ -+IZJ?M,_MK>%--T'XE_#@>#_'M[KC:=?:.ES9^'I);-YI('C5E
ME#<IEA\P'2MW_@F3X;U;PG^QCX&T_6],N](OQ)?2FUO86BE"/>3.C%6 (!4@
MCV(H ^IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY&_X*>?\
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M&_97_P"3S?VMO^PCH/\ Z1RU]<U\C?LK_P#)YO[6W_81T'_TCEKZYH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\8>"
M]"^(&@S:+XCTJVUG29F5I+.\0/&Q4AE)'L0#6U12:35F7&<J<E.#LUU/(_\
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M4445J>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7\-GTP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?(W[*_\ R>;^UM_V$=!_](Y:^N:^1OV5_P#D\W]K;_L(Z#_Z1RU]<T %%%%
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MKW_$****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^8O\
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MEZC#<F(,EOM+[&.T'!QGT-?H.1M1S7"M[>TA_P"E(_#*GP2]#\ZZ*B^U0?\
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M?_HE_@S_ ,)^T_\ C=>B44 <!_PS[\+O^B;>$/\ P16O_P ;I?\ AG[X7?\
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M.T:;4)(M$DO9@S:E9C[D^W *G.0>H)'RDB@#L/\ AG[X7?\ 1-O"/_@BM?\
MXW1_PS]\+O\ HFWA'_P16O\ \;KOJ* /._\ AG/X3_\ 1,/!O_A/VG_QNC_A
MG/X3_P#1+_!G_A/VG_QNO1** ,/PGX'\-^ [*:S\,^']+\.VDTGFR6^DV4=K
M&[X W,L:@$X &3S@"MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYHKY&_X;'^,/_1J/C7_P9P?_ !%'_#8_QA_Z-1\:_P#@S@_^(H ^N:*^1O\
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M+WP3\-_&"[\%7OB&YO;9O".O6_B*P-I.L2M<PYV"7<IW(<\@8)]:]%K\P/\
M@IE\?D^(%WJO@71/%6EZ7H7@?4-.EUNTEO$2ZU>_EG4+;Q1[@S1V\>Z21L$!
MBH/*YH _3^BJ.AZQ8>(-'L]2TJ^MM3TVZB66WO+.99H9D(X9'4D,#Z@XJ]0
M4444 %%%% !117.?$C6[KPS\._%&KV.#>Z?I5U=P;AD>9'"S+QWY H YWP[\
M%?#?AWXV>+/B79W-X_B;Q%8VMA?6\DZ-;I%  (RB!=RD@#)+'/M7HM?EY^Q;
M?P>&O&7P)\9>,/!OEZU\0H-3M[3QM9^(;B:]U&\!9G.I6Y 1D901%@MLP,XX
MQ^H= !1110 4444 %%%% %?4+6*]L+FWF8K#-$T;L#@A2""<_2N)^!/P=\/_
M  #^%>B>!?"UQ>76A:7YWV::_F6:9O,F>5MS*J@_-(V, <8KQ#_@H\S7/P9\
M,Z3!<W$]]JWBW2[*W\.6[,@\1,TAW:>\@(\M'4,2[<#9S63_ ,$][?\ X1_4
M/C/X:GLG\(WNF^)@_P#P@(N#<P^'X9(0T0BFR5=91E_DPHQTH ^PZ*** "BB
MB@ HHHH *\[^-7P3\.?'[P[INA>(KB]BM=+U>VUB/^SIUCD\^ DH&)5OE^8Y
M& ?<5TOCZS\1ZAX,UBV\(W]GI7B6:V:/3[Z_A,L%O*>!(R#[P'7'?%?GY\&;
MCQ+\%_@W^VG,OB>\UWQ5H6HW;_\ "0W8"SS7(LLF; .%.XD@#I@#M0!^C\<T
M<I8(ZN5.UMIS@^AI]?G[\ /"6G?!K]H3]GRU\(">*U\=?#R:]\2>7<N\>HW*
M10S+>RJ6(,I=V&_KAL=*_0*@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBJ6M:?)JVCWUC%>W&FRW,#PI>6I F@+*0)$
M)!&Y<Y&0>10!8NFBCM9FGD$,(0EY&?:%7')SV^M?!7BSQI=_\$Z[_P /W?AO
M0KCQ9^S[KU]<7>O^(/[0?4;^VO;B7AP<[5C50H Y\PE]S;R,^%?$B3XB_"/Q
M1X4_9N^._BG4+KX-:UX@6XC\=K<.DU]8;9"+.:8D[5\YHMX8Y09.2NTCTJ]^
M"WC#]AWQY#H_A;0]0^+O[-_CRX33K_PJR_;)].DF.T%!T(.>'X5APQ#!7H 9
M\+;#XX?LL:IJTWP1\.6?QS^"'C&:36-!:WOTC?3Y)><,Q(( X5@1@[,Y1MPK
MZ<_87_9WUO\ 9Y^$^J6_BB2U7Q1XEUFX\0:E9:>0;:REF"@01$=0JH,D<9)
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M,1ED\IE#[M@//()(!P*^VO"GA31_ OAO3M \/Z;;Z1HNGPK!:V-H@2.%!T
M_P#UDDDU%X+\%Z)\._"NF>&O#>FP:1H>FPK;VEE;KA(D';U))R23R222236W
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!DG<.57)!Y#CH14GQO\ @AXV\5?MX_ CQ]I>B/=>$_#NGSPZIJ(FC MW99P
M5+;CG>O0'K6%X2_9G\;WW[4_[3^L:EI9TOPQXZT#^R])U>25&21V@2,G:I+
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M[5QOPS^'/[2/['N@^+OAGX#^'^D_$3PUJ>HW%YH'B5M6CM#8^<%'^DQ/RVW
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MOAUXJ^-<GQ%N/@3\+M%M+BZ\,:?:W+))?>46_?W4B.N,E=@Z_,<*O&7 -O\
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MTK2;'0=/AL--LK?3K& ;8K6UB6**,9SA54 #DGIZU;H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\N_:1\2?$SPG\
M++_4OA-X<L/%'BV%T9+#4)2BF$',A1<C>^!@+N7[V<G&" <5\=/V[/A3^SO\
M3]#\#^,M3NK74M2B^T37$%LTL%A&QQ&\Q'.&(;[H8C;DX&*^9_ASXOM/V/\
M]L F'7(=?^!_QHG:]TCQ +@7$5GJ3L"R&?)X+,JG)Y5HR>8S7DG[2WQR\%_M
M8^%=,\6OX>A\)?';X;OYVI^!_$\.%U:Q4YN;=-X'FA1N?80'"F3 .0:T?&W[
M!8^.WP"LO&G[-WB>>+PCX@V:M-\/=6N]\$%VA(9;>5L^7+&QD0AL$CC?@XH
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MK%=TUU<M@9/W44=68G@* 23T%;FJ:O8Z'8R7FI7MOI]G'C?<74JQ1KGIEF(
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MOH%FB?ZJP(-?'?Q3\(_M;#QEX@\(?#"U\!>$OAEJ!6VTS4[51%/I=N5"O($
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!SWQ"\"Z5\3O NO>$M<C>71]:LI;"Z6-MK^7(I4E3V(SD'U%?
MFG\0?V*_AO\  &;PC:_M!_M :[K/PZANFM?#WA>2.:.,*H+'?L=]B*" S(J_
M>4;ESBOU-KG/''PW\*?$S34T_P 6^&]*\2V*-O2WU6SCN$1O50X.#[B@#\^?
MV2?!?A#X@_MR7WQ%^!?AY_#?P=\.Z&^D76H10R06VK7C C;$C_,0 48Y&?W0
M8X+#/Z4UF^'O#>D^$='MM)T/3+/1]+M5V065C L,,2^BHH 'X5I4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>kros-20251231_g14.jpg
<TEXT>
begin 644 kros-20251231_g14.jpg
M_]C_X  02D9)1@ ! 0( .P [  #_X1GH17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "=!   %
M )T$   4    1TE-4" R+C$P+C(R   R,#(P.C$P.C(X(#(R.C(T.C,P  $
M : #  $    !          @   $$  $      0   0$$  $   !X     @$#
M  ,    , 0   P$#  $    &    !@$#  $    &    %0$#  $    #
M 0($  $    2 0   @($  $   #-&         @ "  ( /_8_^  $$I&248
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M)&<$_@ 1R,US^H^%]+T^^DMC96LFT*0PA R" 1QV.#TK/&I^.54*/#FI!0
M LG0<@?A43W?C*5V>3PM?.[')9HI"2?RI2PU=KW8O[QT<VRZ,FZLXM?X+?H6
M_P"Q-+_Z!]M_W[%']B:7_P! ^V_[]BJ7G^+_ /H4[S_OR_\ A1Y_B_\ Z%.\
M_P"_+_X5'U7$]F=7]M9-Y?\ @/\ P"[_ &)I?_0/MO\ OV*/[$TO_H'VW_?L
M52\_Q?\ ]"G>?]^7_P *//\ %_\ T*=Y_P!^7_PH^JXGLP_MK)O+_P !_P"
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M'_P(;_&JE+F^)MB2:V1]P45\/_\ "<>*O^A@U'_P(;_&C_A./%7_ $,&H_\
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M#!J/_@0W^->X_L]ZWJFLKKK:EJ%S=F,Q!/.D+;<[LXS2LK:%7=]3V^N0\?\
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M65H@!^0 "@ =  , %0 !86-S<$U31E0
M     /;6  $     TRUL8VUS
M                           -9&5S8P   2    ! 8W!R=    6     V
M=W1P=    9@    48VAA9    :P    L<EA96@   =@    48EA96@   >P
M   49UA96@   @     4<E120P   A0    @9U120P   A0    @8E120P
M A0    @8VAR;0   C0    D9&UN9    E@    D9&UD9    GP    D;6QU
M8P         !    #&5N55,    D    ' !' $D 30!0 "  8@!U &D ; !T
M "T :0!N "  <P!2 $< 0FUL=6,          0    QE;E53    &@   !P
M4 !U &( ; !I &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6  $
MTRUS9C,R       !#$(   7>___S)0  !Y,  /V0___[H?___:(   /<  #
M;EA96B        !OH   ./4   .06%E:(        "2?   /A   ML1865H@
M        8I<  +>'   8V7!A<F$       ,    "9F8  /*G   -60  $]
M  I;8VAR;0       P    "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P
M       !    #&5N55,    (    ' !' $D 30!0;6QU8P         !
M#&5N55,    (    ' !S %( 1P!"_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\( $0@"I06; P$1  (1 0,1 ?_$
M !X  0 !! ,! 0             '!08("0(#! $*_\0 '0$!  $% 0$!
M          8" P0%!P$("?_:  P# 0 "$ ,0   !W^
M                                                     &%<LA\\
MZ7>2WK=H                                   !^9?YK_;@
M                                           ?IH^E/Q'UN3_G$);G
M1;-><]0EO6[0                                   ?F7^:_P!N
M                                               !^FCZ4_$?6Y/^
M<9W0R<ZQNB<RV)P'H\MZW:                                   ?F7
M^:_VX                      V"S_Y$]]>)3K>90K&UJUW7WGF1O!N$_4<
M::V;;)NC?%MFX<CO?.C&.T>[%)VR@]\9T7UK\X^U
M  /TT?2GXCZW)_SC/>%3RX\?(U-=.Y/L3@/1Y;UNT
M               'YE_FO]N                      -X7;/R]Q1BO?)!V
M$1QRCO9<C9%QJ]LV,:[^>_8=>R-3DC(N,77EQ^.-=,ZK=P+ZSHMT4W=5/+?O
M4                     #]-'TI^(^MR?\ .,]X5/+LQ<OS54:FNG<GV)P'
MH\MZW:                                  ?F7^:_VX
M          V8=)^):Y>U=)M;"+]9.9"V$0@#0=:]5=F!M%U;9#T7XQC#63BQ
M<&52_M^=<?*JG=PM7O,ON8                     #]-'TI^(^MR?\XSWA
M4\NS%RQYJJ-373N3[$X#T>6];M                                 !
M^9?YK_;@                                                   ?
MIH^E/Q'UN3_G&>\*GEV8N6!YJJ-373N3[$X#T>6];M
M               /S+_-?[<
M              #]-'TI^(^MR?\ .,]X5/+LQ<L >:JC4UT[D^Q. ]'EO6[0
M
M                        #6Y/^<9[PJ>79BY8 'FJHU-=.Y/L3@/1Y;UN
MT
M                         &MR?\XSWA4\NS%RP !YJJ-373N3[$X#T>6]
M;M                               (;VNGP&FT#J%NZ
M                                      ("WL>W0\D[+=.-E@  >:JC
M4UT[D^Q. ]'EO6[0                              8HR>)#*Z,2T
M                                                     >:JC4UT
M[D^Q. ]'EO6[0                             #%&3Q(971B6@
M  #7F9'$_ QI(8,_0  #&PR3!2"&R>P83$7&1Y!)039 >\  QI.1DH8TG,R3
M   !@$9^FJ$RL/294F-9DH #&DYF28 ,/"]3(X &-ADF             >:J
MC4UT[D^Q. ]'EO6[0                             8HR>)#*Z,2T
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M>)#*Z,2T
M      >:JC4UT[D^Q. ]'EO6[0     4_P JH%-Z[Z\<
M    #%&3Q(971B6@        ?#Z      4CVBC^T^+VGM\7G3>['H      Z
MWGD]I]7E7:]                               'FJHU-=.Y/L3@/1Y;U
MNT    'PT91GM]B47]J&[YEESG18                    8HR>)#*Z,2T
M     #X617CQ'=QK2OTU&U3?%J[--K.]ZH   #S/,4<[!PUDNNL;;6>TOK5W
M,MH[G9=ZS9>I4    !2*O,-M]YCOO/+AQ[63T<Q)8Q*[\M9E5\N
M   4ZFYBKKIE>MW F?+T%?KQP               !YJJ-373N3[$X#T>6];M
M  /-Y[\/5[X.H_,Y"?IZ_,G1^I5^A26?/ON]I                    Q1D
M\2&5T8EH\JF+[]FQ+]N6L6_?5N[]   !$]W$U_2O50O(L7AFT5#%KD'0Y&5D
M5S,I\/8W!Y=   ^&&&?K,$)_K/1L;'HN>>QYYJ*J9B7,OH1L,U-'L[MIO
M 6O51JYFRQI%D^N]7YO?.W"MYS<_U%_8E,K6,^YJ;P    IOE5.\K]GMNK>^
M?0    8M8,GP%U70(/PY'+5_3[9)#R"4;^L                'FJHU-=.Y
M/L3@/1Y;UNT'D\]U>:3J.N_2],X&;^V@.V+?<DN"JUH.BO>HPL[+K]IWBR7B
M,_Y6C                    Q1D\2&5T8EO!YK^W^JPYFFMY7Z/F'7F="=I
MFIJ=C<]-8  \JG7WOM)B/T/75BX]'M/RCWP8ER5HEEY8QW*R(L[*YZ+@  L"
MJQJDFVCM&5XE?N>=SSD\^4U4JCWHU5[./G^QR*LY\HV,@   :XI!9Q?G.36<
MV[[[?OSQ<^CPI"U5K,B+X-'\KEJWG7'1>   &'&]DV(4BF-[Z?79 1F/3;8T
M\M7L+N    ,7<"58,:F?V1C[N_Z\;-38PS*+;\[]=5L    "F6\G&70]9H%G
M9922#D-T9&I         \U5&IKIW)]B<!Z/+>MVFM33=(U+QSLO4\/3S81NN
M:;D)%Q[!36S/3?&>XRMF1;;WO^5959L9                    Q1D\2&5T
M8EL*7<;5-T^/5;-M]GOGFHKHVLN9T0/:YR:_9@ "S*[&L69Z.-I?AU"KW[[0
MM^TSSV0HIEY>1+,O.G(R'QM@  ,7<O!U@=(T5T;*W[[GG;X^O%-752HN!<SF
MYIL[FJOY;X>Q   X&E.>6Z?),FL9%?;X]5KWVZ^QL6YMIJ<]J'OG0KGG%V?8
M]  &&N\W^!W3.F75F7*EJK&3O+8AVZ[$DVC3Y#7M5ZO?   !#>OET3V-ITJZ
MA35[O+GK\KF/9P:]LC5    >"F]K<@_U+&FNE]5N8DC9D<V03OY3Y
M  'FJHTN=<XON.Y-V;2A$N]8=:R:]?ET<5N2\C6?I-FGS-T^>ZOM-TJCTW]H
M^ZYE6*K8                   &*,GB0RNC$MP?S=9@MU+2W!72J\Z+==K8
M_NQ/E^YS%Q]G]  (INX>K.?Z3Q[FQW9?OWSS[1Y;/BYM#?SJ@N?/F/L9 HR
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MZ70FT,BSL A,\'3XUI:?I&O+2]-\/ES)/-B^XB1\9O.YB
M       #%&3Q(971B6Q_7CZ^9/J8*E&)Y<RBG6?<SN;[+,O"V5^T7P !YU.*
M&?J<&YYK_?ZM+86ZEC>Y00C-O+"NWYCWLA[.PJ7E8  M.JWKLWNGQ\Z!K^Z_
M1[_'=YYY7MPQ_(R)B>;2\9GQA;>XZ:P  /A .1K(!WMS#*8[&3]'BSKI<>9M
M1C^SQPK4-5=E&1D/CYP  &N233#%OHG0KER/.6DQ)2A4?DF):RE>7,]<J%UV
MJ@  #X8X:;I-L54>_P!I\M-79XM[&WEQY6AR-V<'K]W#   '5Y[KQAGTO"FH
MZ%(N;&=@4S^:KWR]         ,+I=";0R+.P"$SP #K\=;W&_'W6K31]0M^U
MG[ =K ,^]I!>_P!\                     Q1D\2&5T8EOQY$-S&QIS,7A
M>INJQ5)>+?R"M9OT  'PQLR=;WK/<\J#WD6^\DJWF25:S?H   ,0LK5PYM<:
M&)%C5"CVU\ZBYM=<R.B67?UN[.N/FWQ3?    LNO'L6]@1-?]KEFFI4O4][3
M[[X\OS+9R[DIO   6AY7CY7*XRV6QJL>HOOW!Y>VYLR(_?\ 7B\@   0YKIE
M'V+N?/<M>6W>\2OV/./MO*;;\[J==D   #X4FWEU*O&[?:0       !A=+H3
M:&19V 0F>   1O:S/SOQ'Z(MJUL/+3<&VZ0\>V4[GG
M   &*,GB0RNC$M       %.JM697CTSVWY"_[>5<=-\   #X\M.JU#%W#M6J
MWXO%/>=7J;:+\U6<[TJ@   !YU,47]?0:[7HI<O5;\=9VTY,IV<WL>@   6Q
M1?C.UL[1\R;L]2[>T-8JM    "CT9$&ZN;VY;RO%Z]7M--MYDP["(3!FQOZ
M             872Z$VAD6=@$)G@   P!U4[TVQOMO5Y3PIN\*K<TY.F_1?,
M?G'F                   :?36^;=B?I/$AE=&):               .+R-
M+F/3*O/?2^>>RA1D\@     <'EDW<2V*[''RKN]IJ%-V2+.;V/0    .!;I<
MH     !XZ:X<QMY;&/M+EOZR[+F-(F1J/H   +:+E!1#W'M       !A=+H3
M:&19V 0F>    8MX<CT*Q#Z'Z[ECIHO==5K*7,C>_66?/_(
M     Z35,:92RC]B9C9)XD,KHQ+?R3F:I43)TS,-()^A(O4   TJEH'E,C#*
MTTX&_4D0    'X]#=H7,2,8/&?!FH     6*?E#-_P"8ZDHGO>2F]UEGZ @
M  #\UIE(9 F#QLM,<"[3:&   #2P=14B"C+EYW/<D#5T;@3(0 'X^C=X0R6:
M9L%7,52]2\3H/*1P6D;D"ZP   #"Z70FT,BSL A,\    '$UIZ?HNJR/=CH_
ME<JY&IW?R?A&0N7H0                 ,$#0B;$S=:40O@Q1D\2&5T8ENG
M@D@S',#38:8'&R8N@   UJG:9?&O4V$F$!L8+O    !A4?"/2]BP#*HG<
M  MLU %[E2+1)R)W,=392    85E0(M(Q*@2R2299    UIGN)%,9#(\A R;
M(%,Y"3P :B"O$G$*DQE'([+S/0208&&<!BX;@RO    PNET)M#(L[ (3/
M   +#MY448^XG;*T5=JM                 #',_/B2\;[R30 8HR>)#*Z,
M2T                                 "CG<5(                M8N
MD    &%TNA-H9%G8!"9X                        !'9H0(3/T#&3(  ,
M6I)%L!9M!)2UFU
M     %/NV-HG..H5FU>   &%TNA-H9%G8!"9X
M **:736L;[C/<
M         &MR?\XSWA4\NS%RP  ,+I=";0R+.P"$SP
M     #B:N#2J;AC;,=X
M               !K<G_ #C/>%3R[,7+  &%TNA-H9%G8!"9X
M             -/Y#!O#+D
M                    -;D_YQGO"IY=F+E@ 872Z$VAD6=@$)G@
M
M                &MR?\XSWA4\NS%RP!A=+H3:&19V 0F>
M     <2,+GD&9'MM7/;TM4Y%8WMUT@
M                                 -;D_P"<9[PJ>79BY8&%TNA-H9%G
M8!"9X                 !U&(N:Q[SLCT55]+WQJ>^U:S%U^-.F/5[50
M                                                           &
MMR?\XSWA4\NS%RQA=+H3:&19V 0F>                  #'3)HQ%V>96UW
MO5<3@MTU33Z+.0F#K)[L9LEVZ@
M                           !K<G_ #C/>%3R[,7+PNET)M#(L[ (3/
M                !:5=G!S95V5E9UPT7/CT?%'DJM6WY[(V!J\A\>YD19O@
M
M #6Y/^<9[PJ>8M22*6AD6=@$)G@                  $07L/#;99WAO9=0
MIJ^O1RKM^6FBUO?;VP=7F1A7)8HO
M                              #6Y/\ G%S6+W"F[L A,\
M         $57</$G-R+2S<^IT7 J\^W+?DH\M*CRC6\78UJ;,MTY
M                                                       UPSWG
M57LY&P>$3T                   "WJK6#&>L#-SJYY<[:_.-+H4T'Q2K>)
M<MBSL'UU5[>70
M              !;EZS<=F\                    .#R"[V-B5GY=IW[UP
M*^FKRF4W:.Q[XP]=?%JK.S$R/:]
M                                                   'C4X[9&#C
MYDY$1963UJZM1;N_'QKCIHG"Q[E!8R_H
M                                  (5V^EEK5[:H47
M        *?[1#=S%MFNJUU5+]IE^RO\ \O7G3<[7H
M                                           &OJ=<[Q5DL6W/\C[3
M4*+@                     '!YU'H>@          "S\.1:KN7?>(
M                                              O#,CDF?1?YERYJ
M]QA!,(1MXY9U^H47                                  !&6LF_YY/G
M[]@0                                                  !)NRA&
MQ;Z\_#K*Z,2WM\JUD]$YCMXY9U^H47
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M0Q?!=A"Q>1<A'1#)DX>PKY+0        !&6LF_YY/G[]@0
M                                    !)NRA&Q;Z\_#K*Z,2V5]9MP
M(MV6JUD]$YCMXY9U^H47                -*!)1=!CN5 QA,RBVCX7V8S&
M\4D@         IEK.QXC_8
M             !4[F# /6_EO*Z,2V5]9MP !%NRU6LGHG,=O'+.OU"BX
M            !#YC@9W@            C[.UT);G1@
M                                 8=RR&;&^?\ 297UFW   BW9:K63
MT3F.WCEG7ZA1<                       &"!9!LF     !KZG7.ZM:O2#
M@[$                                                   #)B.R>
MK6KP   BW9:K63T3F.WCEG7ZA1<                       LPT.F)1^@X
MR\    !KZG7.\KHQ+97UFW        '60&=).15  ",B^2J  $-$R@$-DR M
M<LT\@+3)E+L  !#1,H(;)D   !#I,1&9>Q0B\P  "-RZRN@%/+-)"
M        (MV6JUD]$YCMXY9U^H47    !K#,<C9H1N7,748ZF1!BX92F1H
M           ()/SZ%1/T#DT@   U]3KG>5T8ELKZS;@       #K-#1.Q8A,
M9Z2I%D%JD<ET&5)32%"0RPR\"\BTB6C$TRR+T,73O,5SUEL&<!\+'*(2"5XP
M+,]BW##LR?)Q/$0,9F%ZF/ABT3T:W3]*Y^3PVID1DUF+AGX>XQ.,HS!$G4E$
M\I;Y.! I>9%I(A9!,QB,2N=I)!;Q:1+QL5          (MV6JUD]$YCMXY9U
M^H47    -.Y>)1R BZCPEH%<,B"$3>2              ##$_/X9I&],NP
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MVO7CTJJCM+CHO5RF^             ,;#),Z7E!KL=)4*:ZOY<YO0
M     (MV6JUD]$YCMXY9U^H47   !Q><GH                   %)-,)K"
M-\!L1.)R-?4ZYWE=&);*^LVX                        MZJQ$M[ ICSM
M]\[?/>9?5&1?UK-]*H            <7EHUXT3Y.CI/MF5Z,_P!GE7C\KORQ
ML_7Y=             BW9:K63T3F.WCEG7ZA1< %G5>1?<4+WR5*:9(M5\GH
M 'F]\]'GOT                 CXT,&.1>9^G0P(G7.\KHQ+97UFW
M  '$I%5'6\JU-?>]             I7MN"[^K\*GT>U]==JS]IJKOP-A6<?*
MJ--<J6L^K4W0          /A&5S#LRNQ3O;7N>^M34???7YYV%XV\ZZ+>6
M           (MV6JUD]$YCMXY9U^H47!UO,6,CWQ5+0>UQ3E[C>>[RH"U*[<
M<7/;8]JD>W1>]/M9IJY/0                -,!^?@WO&8<ZYWE=&);*^LV
MX%(JIL&Y:Z7MQTU7A;K]#T   <'EE7*+!N6[.N><_/*Y3[+-F]=]%8
M     '%Y!-_5T*JWV^>=7K&+H_./N^CW=BY>4_*>LU&S>Y/9.M9]QT9
M      MFJSC?>UO0>WU5_'L*E[Y4/'M+VMYUT6\L             "+=EJM9
M/1.8[>.6=?J%%P0Y=\A^\YO+GHIR-L>^SRL"V*J,5K][V^^4[VB:[5,S6:N;
MT                 #X:^YUSO*Z,2V5]9M_A&]VSC?L;6'TUM4#)\R$BUS*
MR.W)YQ\BH>>@ #I>0MDV,>MC8P+Z!I8GD.!ZK=>0$3V6><%V^0&'?D.U=
M        % JLP3>UG+WVV\W L+:ZK'V8120]CJJE<L3ORWJE^:K;]!WO93LY
M];HR         !;E6-#EW7VQZM]5W^^5@J+SV%3\5-[?=O,O"WF
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MJK%C>>^JJB+-C!?-O>.5:O&H%K/[O+TKQ_M=\X4MDJC+O:UF@
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MD]$YCMXY9U^H47 (TKIB.Y[XGLGTT3):K^@ %%]IQ?O^VS77YWF7MBU==NX
M                !KZG7.\KHQ+97UFWZWD#7[,+;2WB9.[-UZ^K(2)79TUM
M<Y6+W8]  $?W*(2O6<*.@Z6 >B:.X+WGE\>'67\L.:;_ #5B.QFS'O\ I5
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MP-9M[I(%,DSSE[D9E +Z/*3  ".#'$C,RB/&3N8?'D)?*>9(@
M& AER=Y12ME-,<S)P[3S'02.          #&HODNDNPH9<8
M!%NRU6LGHG,=O'+.OU"BX                            !KZG7.\KHQ+
M=7>LV]J%3)9+))D,!2+2HF_$G8 &H V^&A(R3*,9*&FLI1.9M2,Q@
M    #\M1E.5DQB,GC$LELR-(<+Y,*C]3X          /S(D^$A'@+))]*F0Z
M9TF;P           (MV6JUD]$YCMXY9U^H47
M     !KZG7.ZM:O8J8.Q["6B'B^B9S"@DHJQ53+  $6F/!+);QT&29A^58D
MI!DL            1@7(=!3RJ%NE1/AR+C+,).          !AP164<DHMDB
M S#(],GB3P      9,1V3U:U>   $6[+5:R>B<QV\<LZ_4*+@
M                  $?9VNA+<Z,
M                   ##N60S8WS_I,KZS;@  1;LM5K)Z)S';QRSK]0HN
M
M                     #7U.N=Y71B6ROK-N  (MV6JUD]$YCMXY9U^H47
M
M                       -?4ZYWE=&);*^LVX $6[+5:R>B<QV\<LZ_4*+
M@
M                         U]3KG>5T8ELKZS;@"+=EJM9/1.8[>.6=?J%
M%P
M                          #7U.N=Y71B6ROK-N!%NRU6LGHG,=O'+.OU
M"BX
M                            -?4ZYWE=&);*^LVXBW9:K63T3F.WCEG7
MZA1<
M                              U]3KG>5T8ELKZS;Q;LM5K)Z)S';QRS
MK]0HN
M                               #7U.N=Y71B6]OE6LGHG,=O'+.OU"B
MX
M                           !KZG7.Y<U>XP@F$(V\<LZ_4*+@
M
M                    U]3KG>*LEBVY_D?::A1<
M
M        @W<:28M5MZA1<                 __Q  X$   !00! 08$!00"
M P$!   #! 4&!P ! A<(&!$2(#9 4! 3,#<4%18A8"(Q-7 R,R0T02,X_]H
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MZ9+K=,EUNF2ZD!U/V04]#QOBB>,8$(P$[6DNP\NLQYH[W1_?IO\ M?"'VO\
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M$X4E_/\ DKY:0?\ !RI*@+.!BN*QDP;V=;$N(:6<;_F!;]L/!E_50_[7;*J
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MZ;UV8GRI1&?DAGL=KNZ<&>FQC&<MMQ]L5IRW'#Y48,=!TREMB78U>2JQ>1:
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M<)0V6/%O J+)=*HX[\#0'ZYN$02E KE:W[^*XN%K^R.9J-UY)4G\.% G>/\
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M(S V0%)@A*&U\#,T8G!TL<'1X20W=H*S\4-3<I(7)5=CHE18@Y.4EM+7_]H
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MD>ZZ7./5&952Z1-/3\PP[+L)=6F>D9IE@?RCG)RC;"<YU8.<E+:4:*?=6_\
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MR,U)5UJ_N'X!70?,88-T^.!&</X_Q]3XX5UWZQ"O"5YS_?XHZ>GU&QG&WE_
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M4K5U6_CKAQ](!UW,:[W\_J 723XO\8E@.=^ PN2[)I Z4IU^DPM5]701^V#
M&L^3JBJM9]/F+@YS-GD'K"D&YMYQ"%'.<LDE"D6<%O<JZ_B-C#$T9%3F<C."
MD*2$'K4-:#\7[>B'G5/.K<6;J4HG_3XOP,JGD*6SF:EJ918]=UBYMZ80 E-O
MX\__ '@^6+B#_I#$N\^K-;22#;.5U1-R]/7(JE'BG.+90,WP\\^+XX>:++KK
M*O":<6V;=%T**?\ #\#DRGQ)8LDTK=0TU.-ORJL_-&>XMI7<[84KH4M_,2D
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M\A"<VY+2++5XQ#S'*IY5PN.*Z<\JSE>F$L:PM3B<WJZC\?\ W,3RY>794?\
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M.8<JJ5"XY!'Q'EVCJ][,<_BM5/U+]XRD8&_%:E_KO[QF_>)<NDZT\T_L]'5
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M@F%ZKD]0-HE]:2KQF_Z?Y24+<I-/;;2I:UU5I"$(!4M:U2TT$I2D7*E*)
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M[-QWH^3?;>-_E*@_9N.]'R;[;QO\I4'[-QWH^3?;>-_E*@_9N.]'R;[;QO\
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MU$- BTW-BRW%@M-$.!2I5MMMEM#32$---(2VVVVD(0VA S4H0E-@E*0   +
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MJ(:!%IN;%EN+!::(<"E2K;;;+:&FD(:::0EMMMM(0AM"!FI0A*;!*4@   6
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M+2QU$- BTW-BRW%@M-$.!2I5MMMEM#32$---(2VVVVD(0VA S4H0E-@E*0
M + :A_5=E+]HI3X68^AS\4#VBHOP33OH;/J5BL2=$DUSDXNP'-::3;E9AVW-
M::3UD^Z5X*$W4H@"*72ZACBH>O-9SV:0RLIEY=)4D/!*M<M+'40T"+3<V++<
M6"TT0X%*E6VVV6T--(0TTTA+;;;:0A#:$#-2A"4V"4I    L!J']5^4OVBE/
MA9CZ'/Q0/:*B_!-.^ALQ6*Q)T237.3B[ <UII-N5F';<UII/63[I7@H3=2B
M(I=+J&.*AZ\UG/9I#*RF7ETE20\$JURTL=1#0(M-S8LMQ8+31#@4J5;;;9;0
MTTA#332$MMMMI"$-H0,U*$)38)2D   "P&H?U892_:*4^%F/H<_#%8DZ)A6D
M3DXNP%)IR6FDVY68=[B9S6FD]9/NE>"A-U*( BETNH8XJ'KS6<]FD,K*9>72
M5)#P2K7+2QU$- BTW-BRW%@M-$.!2I5MMMEM#32$---(2VVVVD(0VA S4H0E
M-@E*0   + :A_5CE+]HI3X68^AS\8=H,_BI<I.5=;B:-3F&9.6;%V^Z42J$M
M<C+V-TMDM_[9-#G+<NRRH+"E2K;;;+:&FD(:::0EMMMM(0AM"!FI0A*;!*4@
M   6 U#^K*N467KC4G*S:EB78GVYMUM&I3X:EYEOD,\$%I*RZ"M:;KS$J0@H
M6H.H;;;9;0TTA#332$MMMMI"$-H0,U*$)38)2D   "P&H>\G_\0 7!$  0(#
M P<%"0D/ P,# @<! 0(#  01!086$B$Q056DU!,B,E:3%#515&%QD;33!Q 5
M(# T4'6!(R0S-D!"4F!P=(2AL<'P0[/1<N'Q8G.R4Y(E8X*#E,+5HO_:  @!
M @$!/P']A]U+*EK8?M"3F:@&2Y1IQ/29>2\V$.I&@T"E)*3F4E2AFK46K94W
M8\VJ5FDT(YS3J:\F^W7,XV=8.L=)"JI4 1^S/W/>^<[^X'UAB)>?D+THF+#M
M7):GV'GQ)S H%+Y-2DI6U7_6"4CEV.B\@9::4/)6K94W8\VJ5FDT(YS3J:\F
M^W7,XV=8.L=)"JI4 1^S+W/>^<[^X'UAB)M2D3\RM"E(6B<>4A:24J2I+RBE
M25#."#G!&<&+-M*2O;)? ]L9+=I-I)E9H !3J@/PK6@!X ?=V,R'D@K0!0AJ
MU;*F['FU2LTFA'.:=37DWVZYG&SK!UCI(55*@"/UUG;$LQJZ35IMRU)Y3$FX
M7^6?-5//-)<^YETLYTJ(S-YM6>)"P++L^Q5VK>!E:UN +9E^5=:6E*A]Q:"6
MG&R7W^D0LT;13*",ATQ=&Q;+M9N?=G97E>3?;2RCEYA"6DJ2M1 +3B%*U"JR
MK,D:#6O=UQ=C6EVKG_\ JQ<ZQ+-M1F=<GY<OJ:=:0W]V>:"04*4K\"XW4DTZ
M1.@4IGK9TK<VVW%R<I)3DI,%M2D%QUX*(2,ZFSW7--536M'$Y_T2*Q:]G_!=
MI34CE\H&%IR5TH5(<;0\WE#1E9#B0JF;*K3-[QL.P+!LZ7F+=0]-S4P1]R96
MXFBB I2&DMNL52RDCE'''.<KH@926XO!=^SF[,9MJQRM,JH-%QI:EK')O')0
MX@N$NI6EQ26W&U*5IJ,DH5ERME7>E;NRMK6E(O3*E)275-//AQ2G7U(11L34
MNT @%*=1H*G*56MJ35UG912+*LV=EIS*1D.O.++80%<\$&>F!G3F'W/3K$6)
M8%FBRG+<MLK,K11:80I:.8ESD@M91D.*<==YC*$*2FA"BI66.3-A6%;=E/SM
MA-ORS\OE_<G%N**G&T!SD7$O// <HDC(<;=R0HYR<E2?H_W/>^<[^X'UAB)[
MY[.?O4Q_NKA*E(4E:%*0M"@I"TDI4E235*DJ&<$'.",X,6;:4E>V2^![8R6[
M2;23*S0 "G5 ?A6M #P ^[L9D/)!6@"A#5JV5-V/-JE9I-".<TZFO)OMUS.-
MG6#K'20JJ5 $?KI)"3-V[)$_3N;D[-RLKH<IRS7(9?\ ^7R_)Y=>;DUR^;6+
M_)GNZ)12S6SL@AD)J$IF?]3E=1<4BG)D_F!02*APJ]S[YK:/[PS_ +:HFI.Y
MJ9:85*VM:#DTEETR[:VUY#CX02TA=;-; 2I= H\HB@/2$>Y]\UM']X9_VU1=
M^S;!8#]H6(\]:3[:%-@/N!"T%0Z 06)?DR[DT2XXV:BN2:5AYNTKQVO.+:E:
MS:RIQ<OEMM\BVQR; 05/J:!4V VA6A2E5.2,X";O6M9\S(OSTGR4N9^4:*N7
MEG,ZWDT24M/+5GH<]*>6/="Z=D_],[_65B7S^Y^JN?[WFM.?HVD[D^B@IX*"
MD2=XK"-AR=E6G+3;X0G)>0R*(!;>*VU\H)B7<H1DJHBM"%)-<Q5:EW+'F;&-
ML6(5-);:6_D*<=<;=:;)#R3RREN-NM9*J<[)JDH4GG!:;6S7&E*>*V7_ #+)
M_KGCW/\ YI:(U=T,YO\ ]M7T?[GO?.=_<#ZPQ$]\]G/WJ8_W5^\E2D*2M"E(
M6A04A:24J2I)JE25#."#G!&<&+-M*2O;)? ]L9+=I-I)E9H !3J@/PK6@!X
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M!^%:T / #[NQF0\D%: *$-6K94W8\VJ5FDT(YS3J:\F^W7,XV=8.L=)"JI4
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M_79*E(4E:%*0M"@I"TDI4E235*DJ&<$'.",X,6;:4E>V2^![8R6[2;23*S0
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M)-4J2H9P0<X(S@Q9MI25[9+X'MC);M)M),K-  *=4!^%:T / #[NQF0\D%:
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M!^%:T / #[NQF0\D%: *$-6K94W8\VJ5FDT(YS3J:\F^W7,XV=8.L=)"JI4
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M;RIFT_!5E48LM@!LEL9'=.1F"4@4R99-.8C_ %.FO\U(^/,S3<JD*<KSCDI
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M%IR3#C2FSGK3PZHHE0IG_P _M'-3F$ &"C/51&;5K]$,,@A*UII3.A)_J?\
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MZRDZAFR9<'.E.EP\]?YJ1]$I-#$N$U\"H$'TP% :85IJ(J3K@GTPMU*<Q_\
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M<62I:UJ-5*4HYR2<Y)^,%D05YHRS\2IBI^B?<^[\S/U8]ZU)1;??FU_K.?\
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MK]%7_-80M"QE((SYQGTQEJT4@J.O-$Y:TA(I*G7T90U!0RJ^01;=Y7;1"F&
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M<1BI&/)#&BPVY$:$DHACE5Z-Y*NV/XNM_P#GQ_\ 8)&*+_--._L8?9( XQF
M8;Q&"5C2"*(C5:09!N16O8]JJUS7(K7-545,L>W>R-H6VRD1M3ICE>0<,9'[
MX<Q-[B4TCE]YS-Y815:,CM6S)('5:43)4R'-A$5.,T^3EFX!VIU=83)XLX^4
MW?J:W_9;;_\ /C_[!(Q1?YIIW]C#[@@#C&8!AO$8)6-((HB-5I!D&Y%:]CVJ
MK7-<BM<U514RQ[=[(VA;;*1&U.F.5Y!PQD?OAS$WN)32.7WG,WEA%5HR.U;,
MD@=5I1,E3(<V$14XS3Y.6;@':G5UA,GBSCY3=^IK?]EEO_SX_P#L$C%%_FFG
M?V,/N2 .,9@&&\1@E8T@BB(U6D&0;D5KV/:JM<UR*US55%3+'MWLC:%MLI$;
M4Z8Y7D'#&1^^',3>XE-(Y?><S>6$56C([5LR2!U6E$R5,AS81%3C-/DY9N =
MJ=76$R>+./E-WZFM_P!E=O\ \^/_ +!(Q1?YIIW]C#[H@#C&8!AO$8)6-((H
MB-5I!D&Y%:]CVJK7-<BM<U514RQ[=[(VA;;*1&U.F.5Y!PQD?OAS$WN)32.7
MWG,WEA%5HR.U;,D@=5I1,E3(<V$14XS3Y.6;@':G5UA,GBSCY3=^IK?]E5O_
M ,^/_L$C%%_FFG?V,/NR .,9@&&\1@E8T@BB(U6D&0;D5KV/:JM<UR*US55%
M3+'MWLC:%MLI$;4Z8Y7D'#&1^^',3>XE-(Y?><S>6$56C([5LR2!U6E$R5,A
MS81%3C-/DY9N =J=76$R>+./E-WZFM_']6N*+&#+/3N(:(\ASVB)QNIPX+M2
MCR>FEDESVY?A-3/=GADJ%P?\<C%U;.1%B5J0 FA[AOT&$QXWZ",<QVERZ7M<
MU=Z+CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J
M?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U
M6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z
M-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/
M)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_
M %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_
MHVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58
M\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HV
MO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\F
MI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\
M58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR:G^C
M:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_]5CR
M:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G^C:_
M]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5CR:G
M^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K_P!5
MCR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J?Z-K
M_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U6/)J
M?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58\FI_HVO_58\FI_HVO_ %6/)J?Z-K_U
M6/)J?Z-K_P!5CR:G^C:_]5CR:G^C:_\ 58@T^=8E1@,@S%F,?%I59>][E"\.
MAVU J:<GJN[?GBCM<BM<VET]KFN3)6JD02*BHN]%1=RHOV@@#C&8!AO$8)6-
M((HB-5I!D&Y%:]CVJK7-<BM<U514RQ[=[(VA;;*1&U.F.5Y!PQD?OAS$WN)3
M2.7WG,WEA%5HR.U;,D@=5I1,E3(<V$14XS3Y.6;@':G5UA,GBSCY3=^IK?Q]
M<_\ 4O\ >&DXMC^NO[PU;_7,@#C&8!AO$8)6-((HB-5I!D&Y%:]CVJK7-<BM
M<U514RQ[=[(VA;;*1&U.F.5Y!PQD?OAS$WN)32.7WG,WEA%5HR.U;,D@=5I1
M,E3(<V$14XS3Y.6;@':G5UA,GBSCY3=^IK?Q[<_]2_WAI.+8_KK^\-6^]:5P
M8VSP>K>=<J]';5HG_I7"MU'Y#JD@\=./TN3%380Z4>1M33@[3[B,:DT;2I^W
M7@[]H*Q5A^#4]MM'NGPJAN-<;7.DA#Q'B6RC?=]7&>-^+RV#\_8LNBUN-5SR
MKZJ9*527TV-%/'CG%)I<5Y:BZ1.B$$#:5>+OC"EE5J%79<A$?P4T6CP:1+BW
MU7Y%+JQ*D*821'C GVY$1U.=%FQ1B.YE9.[7)%+'J$+Q.6M'>[IE+B6Y1'\%
MY*64M5N0DQOAL-42-.<*/'B^%!$V:RV0 JWP/)9L2F-QYCO%"]B:2G '*J X
MDE\&,8NQ#(F-"]T8!39+LAE,C!O+DNS:Y79;L-D\)E#I-O7,LV4QU.HQV2(B
M0&Z.*&5PZK66-,7QFMC:@7DHQRM$YRC;[%JLBVNMTS;KJ<BF1(OAH=$:(H4B
MHS.02G5!CE.68(;4>T V<I[S(B98IP^%G@LK-@4JJRN)QJ_%K],N^EA.K4>B
M3BTH .+\G6_9LV\E1C(04<J"+L[*3@]M^@U^W:E.:MW52?/$U].H[S0-G*I;
M?"M.VSB0RSC,*$=6U.$%.*:512VGP4<'M,MF1<EQTN16"U&[25):/%C"'5C(
M!14@HIC3;"B33/?XW<2*Q@';1SVVKP56;1[.?=U2ML==KLZXSU9]!B2$BS#R
M84)*844]&-X@78R#-.\B2(R.CL:A#XCK,:)DM0!64P"N<!LE1MV[0J_E*)":
MD&KN4K,L]_NKSHU$C5<$NQJF.E5=U2C10!.<LBIQ6%I[XTZ6XP%+2)>^0R*5
M&[)5%R^3>0+WMNB46W8=0V=E3:;,9)F56G\9FM4]01M4FJUZQ602\N#27(0I
M6<67+Q>+*M6KQJN6HWY464NCE@1HIH<>02;!@,=42&G1C!$Z14 )JC1Y;D;M
M'*Q-*9V9$LVW*)5;5FSFLO:JU&8T4VDP.-Q6O+3@+5(#GE;#669FB)5=J9HQ
M. !J:B_:.":U*7!I$JGWY70TNK&GBF/F1@&K%&INNG/CS8X1%:RI%)G)CRV.
M<P::$35GB#:$RS)% AU:IU>CTJO.KC9X9%2I8D.D4T3P1"V#Y R1F^+ER=C(
MF11JCQD4[(56?22U^I56JQZ12*("6D(DV05KRE>LGBLUPA $/G9$.Y\@L8&E
MNVVK/;4VC.H*MJDVED@.GI4T1\1H"(5DM(<#6T@Y(^2Z*-6/1[>6B(]V)/!4
MV-5TN*+24J[Y3HT7P.X#HX)6Q9(2<LSC.QD,=DZ T.YS=OJR1WN*=6;EC5>3
M$J5392@MH\:+),P[HYY6U,R7.@M0#11WZE&\A=6E&B=GNI;^"^W*)<=3-5&"
MJ@:Y,;%!%I>Q(KI M54I&LFVV;5<V0=XV9Z8,G5F+W%O6]!H,Z[;QNHKA4.W
M8$@,+:HCT$AID\["LA@(==FPFP-N'(*]&"CD?BJ0;NX.JK8<^G#B'&IJK!N"
MDU 4I\EFF%6:<,48DF/Q='28NC6%IQ.<N3FZO<4*1<,>K2!W!5FTB)X)C19"
MA.K-:FE)*G0M,9B9:E#MS;^0!V_[\( XQF 8;Q&"5C2"*(C5:09!N16O8]JJ
MUS7(K7-545,L>W>R-H6VRD1M3ICE>0<,9'[X<Q-[B4TCE]YS-Y815:,CM6S)
M('5:43)4R'-A$5.,T^3EFX!VIU=83)XLX^4W?J:W\>7/_4O]X:3BV/ZZ_O#5
MOO6RO:5[7_;-[3R>#?;1X1\!?%5X\<X]X)^R'Q?QKBVP_P#7.+[7Q.TQPH?Y
M1O:;X7]KEP<3]I/AOP=X-6DIIXUX=]\\=XQQG5LO$*#8Y<O:9TZ]Z[<M>EU&
MNV[==JP:<0PG4BD49756V(X!!>-\E7Q3QO"H=C)CQD,K&.B/>TARW=P72U>V
M\:3=SN#X<%%61(\'UB9-F2QM;O<]$=3[@I":=31(^&UBIM!,3^#I0R0-I-K1
M(UNW>?CLY4JK8$JT8Y1L:V5LH0]I5JKH?3DC%5LA%>8A!B(W^#M9=L-E6]1Q
M7%<4*GK!FRRS:8M3KUGG-*ASIYY<OC0I<PTJ.0IB;$NG1D-C6)P71;*D52%
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M?XQ<JCP@\'O"!4>#VO5T"1Z^P=#@7'3:DB,$Q2MI\^1&  []B(CR$25D=''
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ME#J$60]$STC*QRY>?<O-Z?Q9<_\ 4O\ >&DXMC^NO[PU;\1>^) Q?Q57-_\
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M?TJN!GC2WRA,5%?'.]7ZF^9KG9N:N7-U>? YX$V94Y$D#MSA%3G3Y/T^;/\
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MQEQY1A[,F7)"C<T7)J<_.G.J8BL,U6!BDXP]G^F(GP-7H;U)Z<-E/V8([4T
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MZ6$,MVW=37'Y3I,ESL]I529[UWI#1=#/':G,]SRFHORHBXS08T7SHQN?Z<L
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M6\)E'X3Z%3(5S<&U'CUTJVP>6M'N"#,:)(B4]:GM)$9Q9$RF@:\Q"YNF.UB
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M"2F-F5"WH%8)=59A4E1<6#+9.""E1BKL1OVT31I.UI"-DC1X"0YL^SK8J,^
M"''AU&HT&ESZB -/:UL)HY\J*64WBJ-;L,B^*5,V9+CA"O*Q97!<:%?$R&;8
M7::ZWRHX8(W[)-E1X0!"*KS&VGOJ6US$'IT+J3%.]L7@SP]Q,'A?P+QKP3X0
MT)QGP=Q[WYQ/::MAQGQVC+:<K[1<U[\$-;M(0;V>V7<ELWL"J^"UJ;7F*ZHQ
M)-$8Z6I'GDRI",<H-!9DI'DD">,8>#8M>N"UY=;M6_8]TUHD<$ZF4YE*$>.]
M*;1!,B3#RC1QA5!OJ3XRR'/\=(8B)BO6=/D$B K448TE":CWQ9,64"?!D;-5
M:A6@FQ8Y2!ULVPVN%K9JU)!X,;HO"P@V+$;2H<BJT>G5DEV5*ET4L4L"-)!+
M&&DC>QT.,_:@*TBE QQBR6J5A*;X0LZV:L>D4^#2X$VKT*EU.?'@TUB,A 9-
MF1#2$9'3E#1'HC7N<]J(YRXOR_K#E<&18=Y-IH>+W<:ZG20!@0X@ON-&A"$,
MJR DW\<DM<'0N0WJY$I_MH\$>V#B[?"O@'CG@?C>:Z_!_A#W[Q?++3QGQF>>
M?VMULUZ93)L]];J-34M()*+$0,H<00F;29$A&4B)&5Q/>Z-:K]+7/RU+;/"@
M*72VT*B69(MV3#>67X6).*:OO:0 6PW0UBZ*N'41\YA4<,B(!4TN6O<(W!76
M+09)NVFPX-P46]H]66 T\$( !G0)-&:25K4<83M@1&#:9TA[W2&&&*/58-\B
MHM^UBY;GEWC7Y%5H\2;3%KDMI![2!"J I#6; 9Y2-E.8R0]TR7D@0E0#."RI
M<%H+&H#.#:HURIQZ15@S:71%-4I5&FA;'@V[32)LGRH$LTYK'07/)(VC2.(0
MCFU#_*5[1-OM(_@GVC^V#9;+27C?A#P]R]IKV'%^+<G3M=IOT?;*K3Q.8PLZ
MFSH8G$S0;228Q0L<_2CG:$<]%=I:Y<L\D5=V(W ]4:_P8TZRD<1LNJ4P-S52
MYW@-72W 02-G1Z;2R(LTRHFAD,B &,>VU;0CZ=7;3_R?5VE1[,HMF-I?"A29
MM=%18]%C A J%'B@ :+(F;".TS>.*(223S-:$:?-C;/HU4X/:K,]L]8J-0IU
MSTVH52UJ]19T2+'BQY[4A,J$26 L5)+Q1F%#F_9NDG8WE5&B'N*DTVZBWVSA
M HZT:'*6U:#40!='%2HD28O&GTU0D>W;.$THME!1P938;FRK8OCA8K=HE]HX
M9Z6Y1+*!5TAEG5$3!'J=1/66C,PRH,3W C->)Y(T72H1L*,UY4NS[5M"VJU<
MMH7#;(:E3Z%3J1\<4XL<8IDJEP$E\0XWQ8\@;6&^X,(@2$&-,6O:4PW!%(L^
MBD0$PT8EY%N1]-+,-*E+&(6-#I;IOCR)'VL80-S$(B[W+]IX2[^F3*82DWC'
MHP:7%C%E/J(5@1HXI*U 98@8P>6#Q/%Y4O:,=J?L530MLSJ#5H]&NJRK@BW'
M;LR<!TFG/E1R!*L:<P>96A>:-%-M1L,J.C[-P'M*JL!PA\*%9M4U7HMO5&@V
MS1K.#5VT:$ZIQY4654I!ZOIEND%!-DB*)!D:[6-S2,;'&+%W6+>M1I"EC0+A
MKKJC3B2CT^)(BO\ "]+*PDN'"E/<.1# AF-C,>1'OCBVFM%=-K-TQA5N3PC5
M*94ZJRLQQSDG4R*]:; CS12VE9* Y8TJ<%IFN9LYR:6Z<L5&S>#VDVC:<FH5
M:EU(NS@#H5-.L F;GR? E+.0A]ER!.=%)^0KV-WX''OY>"Y;>!3E"%;0]MGA
ME9HM@R*I/#2)"XKL4/M]*(7:;+9HC=?VFZKSX(J[:3(U\'2=<-LWO'J_@YM3
MUF,^H1)=%VDQQ'R94V0T?O5@UF&&3C(V@0/")=MXU^GUSA&ORW*E;C)$(,B)
M;U#@2J>R*"%#8\;I3@H6/#VLAP$*D>,U&A><DHLI."FN5"'QZ30;MHDVHTE3
MR8@DN:;6RM-%XY'A&,L8%59FA0!U%&YJ<C)RU7@HJ]7L(G$UM^/:$R$ZO 18
M--K!:A/)<,@M/,O&B XJ&$.GP'"9L7)(*1Q%D8X$*U%FTID3@S6I>&V2"RV2
M)B2Z?18HO!3!PS#*J$IA5(DLT/2QXU:KW:FI>\#@SN:RPVK?E4GU:3[9HE72
MNV[)JC5%*=17TP1(<IXANTQGSUT(@(^86DVQRVW:58H-!N[VO1Y2,J%P4&FU
M$CI=2E.G5,T9D\,Q809,I^;0#(ND(@,>\KA:UIW"+P:$X/(T>G6=&M6/2[I=
M7@1P#&67J:"%0(&AD<0"1QQ-$T;6:7L6-H:S,?M]]K'MAVY]K[4?"O@;BVKW
MKL_#/OW;Z/N^KQ>K[GN]S5N#2NS:$6Y'5R9<- JT$DTD&G5'1#2$KI)Z='FB
M:9L8L6>X,,BLC2G[)#$8W'!]=IY%@5:_K5MQMN7!3KLI\ROV5<H0\9V,HVU@
M#G,/M)4F8]4I['I+DY@*%(R+(ORVJX/@\MVJWK"XFUG!U:@J+1*:D<!$A[<B
MCCU.M(DHI".6=I> 1"CBJS:O7%.X-JU5[#;/M^HVX"ARJ>^O"AK;U I9Z:U:
MD8U.,<M7(A!KICPA1%:/>]KW*N*APG\%]8M,%0N*BQJ+<5*O*/5'P7I$9$""
M=$-2&OD*9H($)&A=Q=C7@>KRG'(40K)X1[=NBTY5\42VS6Q<27!3ZA$H%2BG
MD5"7MXD:DM+*9L"5,S11U?'5_%HI22\]L,G#71JE<=O5:M\)T^E5&%5=,ZGQ
MN,QY:SI[JC%% D>#V.,0@X@8/A%J":/4H\]#>"FZK+K=N1K[X.['I=E3@5X-
M0/;5:APZ6L,GCX0V5((VGDU!PU2,TIAR0OU0R1U:;A,JO"17J;,N[A*I$>BE
M?;D>4E$MV' 8%8#*<RH*.5+:.5#I\@C3MCJY(FG:.+(-)6A4"ZKALB39ML4Q
M*3"%0Z?4W5VLQ(L)8-+'53U!@H<)L%B )G3F/(=0-$<A&O(]W"(2',X_;/!K
M/K4:W1;WQJ95;HDO">-%S\6-\"'$J5-EH)K=9F-+DW-=5PWQ;=5M8EJWN^A+
M=$*LBJGAZ&*CQV >.A\49Q A)&DFD\TS&B')5BQB$CL.6K4JW(/ G7;;J-4D
MS856OVS"UB[Z#%DZ4;#AJD0L*<R(UJ;)DZ3L2%UE049IG!;3J:/8(RGP8D%B
M18@8$9&1(XP-XO!C(D:$#(?BHD=$#''I")$8QOVGP)1=$Z[)S&M"%K=NVEM/
MN'(D#3/:2B9IQ*%DJD56F,W8;,<GVYWGKG73.>Z6$,MVW=37'Y3I,ESL]I52
M9[UWI#1=#/':G,^V[6=2H1RY9;5\<6TR3F17Z<U3#Z@*D9G(I7*TT@QHZ*9<
MWZ8Y'."SGY"-:FA-S<DPT,"("*-N>EH1,8B9\_P43GZ_Q*DFZ:P*/)*QSH=)
MC^^:M.R_^SPAYD0>>3723;**-5369JJF;K=L>)-MRES"DCQ85#21,NFK,7:9
M--+BM4PE()$>Z'21,<-=H-\R8+E8!6N$V>2CQ'D9)=0(;T/69J/R*]M1G:G"
MIVMRJTS1)*ENS?XR*72_ :-:U'B4B %J)HCM53'<G_BRY1%?)F'=SN-)*4CE
M5>5[FY_ZE_O#2<6Q_77]X:M_J-(IU4A1*E3Y8U#+@SXP9D.2)><4B-(80)AK
MDF;",<U?-B/!@18T&%$"R/$APP#C18P!-1@@1XX6L$$(VHC6#&QK&-1$:B)^
M(IJT>CTNDK4I9)]16F4^) 6?.+]UFS5BB%QJ67_Q))]9G_A/7[7X$HNB==DY
MC6A"UNW;2VGW#D2!IGM)1,TXE"R52*K3&;L-F.3[<[SUSKIG/=+"&6[;NIKC
M\ITF2YV>TJI,]Z[TAHNAGCM3F?C,E6N:LP*-!&B^-FG8)3/3_P *,)5VLD[O
MP0@80CNIN)%)X,H;J1#S>-;EJ8A$J9VHKV:Z?3W;6/!8_DD$:6LB2K'9.BQ"
MICVSWI*E6]3*D1LV34ZQJE7#5D(YBN=&@$(A0ZQ9M')J+@M'XI0Q9(N2C(]M
M4D?'=GLY5>G-#)KD[K=QB=LAZ!N5,^*Q61XC5^ !%W^[N4(!$.5_@?2(+'$(
M[37Z4Y=+&(KER:BN7)-R(J\R8IMN#L>5/93N.92GOG <7C<^5.7,3:<5&Z%D
MJ/X:YHS5NSR3R=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8
M\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G
M9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_
M6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:
MAW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW
M5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5C
MR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=
MG]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]
M9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J
M'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=
M6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/
M)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V
M?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?U
MFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH
M=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U
M8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U8\
MG9_6:AW5CR=G]9J'=6/)V?UFH=U8\G9_6:AW5CR=G]9J'=6/)V?UFH=U81TJ
MQ.+-<NEKI$^6%KG<^2*2F-15RWY)B#,<U&.EPXTES&[T:IPL*K45=^35=DF?
MVGP)1=$Z[)S&M"%K=NVEM/N'(D#3/:2B9IQ*%DJD56F,W8;,<GVYWGKG73.>
MZ6$,MVW=37'Y3I,ESL]I529[UWI#1=#/':G,_&4BHU2;$IU/B"<:5-G2!18L
M<3$U/(8YG,&-C43-5<Y$Q)I/!M#;7IK4<-;BGM*&C@)RFJL*&]HY525CDW%)
MQ6([<\3I0US5M=JLF>6"145UT7*IHU)$%7L:05%BB"@S;D<]L:DQ10MJ-6R#
MQGO1RQYXXBW!<@N5X>K#!E?'+I<U5ID/+BU/1$>Y&D:TDS2N3Y;TR1/]<K?_
M )\?_8)&*+_--._L8?M'@2BZ)UV3F-:$+6[=M+:?<.1(&F>TE$S3B4+)5(JM
M,9NPV8Y/MSO/7.NF<]TL(9;MNZFN/RG29+G9[2JDSWKO2&BZ&>.U.9^,5551
M$1,U5=R(B<ZJO4B8E4RVU'>-RA51*"&;3181D?I)QZJ,:]IGAR?JC0$.]2M2
M.8L17.(-0"9/JD)AFYQ(>NF6=1-XLW&<4JQ4(-KT-[Y/-JQ6:N+H?)!XC5:\
M2LO"O"<,X@$&\- @&:B[APE>JU-S7.^ZU',*J,9!P0/155@A,8(0VHP8QM1@
MV,:F36L8U$:UJ)N1$1$1/]=+?_GQ_P#8)&*+_--._L8?=^!*+HG79.8UH0M;
MMVTMI]PY$@:9[243-.)0LE4BJTQF[#9CD^W.\]<ZZ9SW2PAENV[J:X_*=)DN
M=GM*J3/>N](:+H9X[4YGXRMV'9$FK5"@5DQ*+6;;I0VL(2<]A9,67,D#$PG@
ML\84B/*X[+%  48$>CUF)HBUCA/G<:,U1F;:U)+E$:J*Y=E5JFB;24F6SUQZ
M=Q9C2-<WCTD*Y.!2Z)385*IT5NB/"I\846,)/XH@M:W->=SLM3ES<Y55<_\
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MWX&U>Y$UHQS/Q5DO,N-GI50N7DN_T3M_-NW-YL^=5557Y',(U6Y_ *GP'_\
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M)#5 TYIAI+B/*FW/)>Y5(_%@<(=S1YQK"I5KUZF.GQ:-)JL:UJ^9\@Q*O-2
M"3+ RHPB1X;#,COV:Q7.;R5.]G\)?A%M^D5&/9=Q<'\&!2ZF6/,IS;IJ$.AR
M.-UN)!J8(IQPX;","5[8Z"E,:0P2.E2)316?,JO")9$JH65;\^@6I;]L42ZK
M;EU4-2I\<)755]R,B1YYH<>%(5*52FS(8BL%4&*)^E,<)EBW3PEU>P?;C>EU
M&]J[>"(UZDO2#4FA^R]*KL8#I/OH#M#(T22)8#A)+&4,F271P4TZ;MZJZA\
M5/C"J54@;&4^93YM8ANFO"8LQ8-0V9\CC26<T;C2A=((A-1/X7(8X& %[8#G
MV8AH,>UD4:GRI)=+41NLQ2O.5V6;WO4CLU=GC^"3>]>#,AVQ:%L+%N:IMA2I
M*44U9LNVX5/2;%BB--9MI,<X>3'?I(/9.R*\3"1.%6ZVU*+8%>X)XE/H=Q/H
M-8D@@5"35X$X<.;&C0#U&DRRQB'=LIL2.9'3N+N:C]LQG\)*[X5+J%(M2\;H
MM&H6O2YE/-3S'%3KCI"5FY602L8<$>O%(R6FW $FSBJ4C43FMJ'$C"AQXU!I
M(11PB:%@FM@AY",:B:<E5RKN^$KE7>J_>DNGS![:).C'ARA:WCVL:2)P3CUB
M<PC-8WN;K&]CVYYL<UV2XZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KU
MWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N
M]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUW
MO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]
MYXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO
M/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]Y
MXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/
M'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YX
MZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'
M1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ
M.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1
MWM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.
M]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1W
MM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]
MKUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM>N]YXZ.]KUWO/'1WM
M>N]YXB5"'0=C+@R03(I?"E9)LI,8K3 )H+47C?H(QKM!&/8[+)[7-S3%*_.N
M#^Z*[BS/S4MW]T0_=FI%7#FU<R190T3C4"5DJ,DQGJFYR<SV+XLP\QE16KA;
M3NQ"S+3F%<6)+$U[Q@&]^^ITQ-[MEJ7[*4O>01%4P44R^_@381Q2HDH3#QY
M'M($P2-U,(-[<VN:YJYHJ?B2KVC4Y4V%"K @C+)IQ6BE"6/)#+$K%>UXWLVH
M&(81&.882O&[<[-+<K5]<(]1O8=FSW3[5I;;9MVVXD$B1W1@+/)3 $DU)\9N
MS(-S2PF*< WN%HU#=]]"J5PSO!\(TMD$1N+3)>J40)SL%LX,>25,Q1C.UN8@
MTT9*Y'.:B])^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z
M<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[
MIQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'
MNG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X
M>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;
MA[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%
MN'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L
M6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^
MQ;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG
M[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2
M?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=
M)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQ
MTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG
M'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z
M<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[IQTG[%N'NG'2?L6X>Z<=)^Q;A[
MIQTG[%N'NG'2?L6X>Z<4^FV]6/"$T-P19Q0^#ZI$TQ1TZJ@>7:3H482Y%DA;
MH:]2+KS1JM:Y4LS\U+=_=$/[0:D5<.;5S)%E#1.-0)62HR3&>J;G)S/8OBS#
MS&5%:N%M.[$+,M.85Q8DL37O& ;W[ZG3$WNV6I?LI2]Y!$53!13+[^!-A'%*
MB2A,/'D >T@3!(W4P@WMS:YKFKFBI^,8LNGBB3+FK4SBM$@S=3XNSC;,U1G3
M BD1I)(<<+AQUXN5I.-38K=3&JXC8]-JAV6A<Q-D/P;5I#&T^=(>HAHRE59V
MSCF>4Y6C!#E<5GE<N0 2$:XGVVE?G7!_=%=Q;-2G6[MIM0M^C3I9O"]='M94
MNG1CR"[,538)FLKW.T"8P;<\F-:U$3'1CMJX>]L=&.VKA[VQT8[:N'O;'1CM
MJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.
MVKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8
M[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1
MCMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=
M&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQ
MT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;
M'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]
ML=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[
MVQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'
MO;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX
M>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VK
MA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:
MN'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CM
MJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;'1CMJX>]L=&.
MVKA[VQT8[:N'O;'1CMJX>]L=&.VKA[VQT8[:N'O;$.FP1;&%3XD>#$#K(391
M8@6 CBVA7/*_0)C6ZRO>1V6;W.<JK]I-2*N'-JYDBRAHG&H$K)49)C/5-SDY
MGL7Q9AYC*BM7"VG=B%F6G,*XL26)KWC -[]]3IB;W;+4OV4I>\@B*I@HIE]_
M FPCBE1)0F'CR /:0)@D;J80;VYM<US5S14_&$BC7%2H58I<I$0T.<%IA+I5
M',>W/E"*-[6O$83F&$]K7C>U[47$FL<%LSC043:.M.K'1)3<D*YZ4FL%5!R,
M_$L##J>Q>U-H]]5.Y6!Q[5+@B2*K2Z/IA&M2X]M#GTMC!JX(:;4'")*@CT$"
MX S!GP.)[-(D9C'C,@VT.I<2K6DJGMJK*&+6A;%?&$"%ABAG1M*M*V1!,=&C
M>WC+8QT* ?VJE?G7!_=%=Q9GYJ6[^Z(?WFY[W-8QC5<][E1K6M:F;G.<NY&H
MF]57<B8\I=@?_P"Y6[WCB;<YKSH4NA4Z3%A3JA1)B7&R+*G.TQ &%;Z5.0PA
MLE5J;+X#7$7)C7.2)4(14/#GQ038AVHY&FC2A-. K4>C7HA!/:]$<UKDSWHB
M[O=%N&ZJDE*I 3 CDE\5FS<C2G[,#$CTZ-+E/5[^M@'(U,W/5K45<1*A"*AX
M<^*";$.U'(TT:4)IP%:CT:]$()[7HCFM<F>]$7=[JW;<KU:' K5V2F0Z!!6+
M/D/G2"2 1!L4D2*<$1"29(0C).+&$1[E1CUV9-/LU&59]:%6H]*FK3IQA1IT
M=@I2,0FEBS8L;C G,74.3&VT4J?<S.R7V5J-?J]+HE/:1@EG5>?$IL-"EW#$
MLF84(4(1470S7J?ER47"0J)>EIUF8[X,2E7'1ZA)=GGS B3#%7F7F;U+B'4+
MQK0Z+$J$Q($,CXL^8II6S>72@J?%EF:QHV*XAR#;'%R4(5JO8CH]1O&NQJ+&
MEE<"+M!2Y4B41B(XB1X4"/*FG02.8IGBCN8'6S:N;K;G1[OJUT18=OW Q"46
M6Z+4B'J+,M2NC4P,(E5<@T5NWSA)Q?4S;[/6W.GUZB2TG4FJQF2X$M!'"AXY
M/@OV4D89 ^9<V&$-[5W.:GNZQ8M-K0Y5U4&+QRK4ID6>U8D='0V.?QPD5E/.
MHWSXC"CC2S%$\V@C&N:1&^Q2G796A4A*W.\'4O7&G2G2I>355NB!%E/$)FMF
MUDG:**%2#0IF*1F?VB)4[PK#:-!G36TZ*=T.H3$),>(IT$K*=$ED&FR"1[BE
M8P+$;RB)FF>'6Z"[+9/<##%COH0:[2R5ED@".4X'4QDI9K3!1CE*-0:QHURO
M1,EQ(J%2F1:? AB<>7.G2!1(<4+-[S2))WC"$3$^$0CVM;UK@DNW*[1J_%"7
M8&DT6IPJK'$?2U^Q(:"<XV%T/:_9N<C]+FNRR5/M$BXKIJ3*51XQ "++<"7*
M7:R2M" ;(T$$F69[WN3DA 16M1Q'Z1L>YM/K%,.DJFU6#$J5/E-:1C9,*< <
MJ(=K"M&5B& 5A$:1C"-1V3VM=FGN"RYLF/#B ;K/)E&''CA9S:RF*Y@QMS5$
MU/<B8,EN7-;UP+'3,Z42LTZJJ!-V\R09)]FG*;\/+X2>=/Q :D5<.;5S)%E#
M1.-0)62HR3&>J;G)S/8OBS#S&5%:N%M.[$+,M.85Q8DL37O& ;W[ZG3$WNV6
MI?LI2]Y!$53!13+[^!-A'%*B2A,/'D >T@3!(W4P@WMS:YKFKFBI]K=P=6AP
M@I8]+!P>ANAS_:G0;DVTQM8= *Q4J8QR![9D@/*;,V0TC9-C*\KR8X<X<R8M
M/NW@UN.E6VV[+=&:D!J()5X HQC0E;),2)/V$68V1Q8C-A&FPB!>TKU<ENU&
M][FATET^C0CCXX0TBH5![(<5THL>%&')J$U6/,Q3O!'+I<5FM<WIG5^$&V*_
M2:NQC"0**K@5&5'+<I83Y=.I-4AQF@J%/(5$8\XIW@YP1N;MC1];'8'=1:O3
M@&I--ANO1^PG4JET.K^#@S*F!#5=&HL.*YQ-,ADN8!!HGOPJ\I9-)M6[*=5:
ME%<9'PFME19!4C_=C0QSH\5:A%9S\;@<9BJWE(96[\<+E3NFX))X="X5;R"V
M=7*F4D:CT6 " 9 #/-,HJ?2X3%*1H&.%$C-5[FL8BNP:AVU=]+JE5 KTXD/C
M "'V;-H1\!98([*D,;.4\M/?)&Q$74Y-*Y7399ZC36T[CM,@\'YHM(N 4ZN&
MXI*)7F5$LAA8P%AR -9'=(C4ACV:M"R\T(GM'B7=2Y-T:BB\&AXP1JR /<,T
M)M0:!:8^H">QZ$IS9BSF:'JL?)CE3[\XC=M#BU'9L>R)/1-A5:=K<PCE@5(6
MF5&1Q!C<02/6/(T(R2$P\V*M=X/I$NZJ3#<V8!L1W%[NI1(VN0A6Q@()M04#
MA"6-(H[O"!)#T1E*$@D,\-"X08DJZJ7$7BSIZJ@[K@-"CAN&=\EPQ5@C'M:U
MR5$D:=JVCCU KLF)X3M&MQ:J%BZ9($UQZA"?FK=$VG26BF1=2M79/*%!2&^,
MCD*)4>OVBE?G7!_=%=Q9GYJ6[^Z(?WFYCVM>Q[5:]CD1S7-<F3FN:NY6JFY4
M7<J8X!HE%M.V:/%K%U3H]6C4NA4NGQZI';5[+&T%1#$BB'-"T<J2-HY+2,1D
M@[43(I$=6 VW;U#MX4JX+>)*%0Z3 I(Y)!R'M8\[($<#3/8U5:QQ$<K4541<
MEQP9W!<]I6K'X.*K&MZ@[.-/J4J[HH/!37 J,LV8J2)\VGPSU.-3Q19+FM&L
M*5*C'7:)0;!M.UJ9=#[@M<$^##(V:RIDK<VHUN"%.,CFCB,ID8=,'*E-)%:[
M9I(5\^(+QP.#^UY]G4A>&>^9%2$^@\;V5NT6/$JLV'&J,HL>I5(Q@2880RVC
MCU(B.&R<7C0U"*,:W^#GA9HEJ!+=L=24"X++/5?!G&<R,'"E1ZT]\I2/.)8S
MR,V6S.>'I$8!7''PC<']G6S9DF5:E3*.G5>LGJT*GPZ;#D2HQ?#(H\N1)J50
MGEXH. E.;3@@5LHDI'"TN%7YEL6-:$.LV5Q[VU2J[4*CX+DR(C"%2F4*F1)#
M)GA!1 .I>/5;B05:-%EN4Z(QMV+!;399KCID*H0ADVP0SH-0>(BQR+RU 9FR
MD#:5-H)"[)RDT;8G!W=-P6;:[>#F9"H%%6+%G5.1><:.E,8D:HRROXM2 +48
MD4DV)#9&D:%TPYDJ,4C28MW@WX,J32*]=MPTKPZL^O'E M^DTIXC2 'EMAJ.
M8=Q8\<IU&P@7C8^(C&R#2FB83@EX3Z-;T"Y9%-=5:)5K4//=1*L%@#2WB''J
MKGSAN2+&EN0KWM7:P)+'1V-43UO2E6?:=D/J%IUJHA?5:P:LQ*0ZGB*05,IC
M(<>9(E3*_/6+,5TCCM.I@&L"I6#0N;:_PAU^D<2J]KS_  )4J#$*[3,K!N+I
M3TA//K)'BS'2?';;;F@I%G*O&4"-QZ5PDW59UB/L>I/II2TFD3JTR[:7 J^S
M?!/-D2R$I2O<PC!JP0'/228(SBB^,T\ *TZVK2N"#?E1II85;KU'X[6J/"J]
M1M\<:9;LU)#/!DI05-LE7Z#HI0AW)IS6J<&7!/1;:F52VZ>.?<=>O$]1918C
MBMC/;"CAI#V2RFREQQ:T>Y>,J=BQVBB%D+PF5JYK9%&O#@KJ$:CURB4^27P?
M,FU&H^!Z;*C'.TA@035!DC;9NEO9$C+($0^V&W%*K5Q4[@\DVC7J:L^+.LZJ
MU$M1HAGB%(C4ZMQZ@8X3R]!-A*;3W^]9"+MFL3-J<+%[/LBU*2EHW$.."EV?
M3/ 0*M(J4B)3XDBK>-E;62DJ4)9L]J(Y8J.T1];$1]*K5Q4[@\DVC7J:L^+.
MLZJU$M1HAGB%(C4ZMQZ@8X3R]!-A*;3W^]9"+MFL3-J<(U'NJT? - MRL<4M
M&K<0J43P]3^-U$+97&9AB1:EM(T:)+VU-8$(.-;$K%?I7 ?SNHW]DJN#U2E6
MQ1:#<E'LX5QTRLT*G0Z/.=4J72$J6F2>".-QELUPWA,Z5M%8XJ26JTX1O;P9
M7;6K<M2]:J:XCT20MZ4KPV%W@?PP$%4"W;1W"K!(\ #"3G/*]Q'R"O:]Q=W!
M7& EFOV=5"?@_'+;6'!0Q)=,V[KOT)J^-(R*'P-\&$P:_P"<ZL<#,2JLX.EK
M0SP#VN*"RX/ 25DIJ2M5?7$D)QWB/AZ.]T#B'OA*:T#C>_=HN(G!19%$LF9?
M=(MZ)5[ZK-3-6!V52IA00C28],CQ7,K)@.+4(Z!(5SI*.EC86,[8RC,X6TK=
M!I=*X0N">'.).A"=,DV_42#CS'PID=KC"FI#*:$36#CJD=&=',.4G&-(0WA<
M-D4JC\%\"A5J77KHC.+Q@M0H<"3)DEI,656-MQ!\N.Z ,7$Z@G&&N$ZJ(='B
M%)X7*?9-FIP;1I15;294^KK>DJE J"TT]2')"O@D01R$<TJOAN*- F,R.>,C
M3NX(26=0(%P4_A.A<9%3YRFB54QYW@H5'@Q)J2QPH!7RJFP,LDR)-&W+DZ-*
MN6D\&7";0K4C+=-+-4[?J=HGJI@!V8IYTBSWU1ZNDD^QLJ*5X8T/9R=@1K"Q
M3H5O""V"[@]]N'@-BW(R8ZYEM;P.P]HH[P)L<JHM48-]/0*STXJBOJ/,C@XX
M1[+]JUHP4I5NMG>V:GTCBUUU11NM9O%ZQ5=N[CT;[*JHQ[ >SXK&Y3M.)]]U
M*SN#:GVW2W1B3K<)5ZU5+K#%D2@Q=7A*$\% <K7R!ZW!:96(TCV@,F28X(KH
MIXZ/#M2NEI%9HT<Q*A[8HUQRHKI!!U%XLJ<M*CQR1AA)$]^K(22_<)PTQP?2
M+[M;@KN>XY]Y/CF:VD52K4.G1V(CXLNB>&#@G0JQLU1'S';1@W)XL3DYJ?P5
M<&M%HU6N\]-6L52HW+(E!H%#A:5(-)(J>]D^09XM!'[)S-FDF$@V27'(D>I\
M$W"51:'3;JC4[PK3*I;!YI*%6(R#9(>P :FY\X3^+/4HWO>NOBLT9@QGB&A;
MXIUGVE8Q9MH5FH!=4ZJ>L1J>2"(I!4ZE#IP)IYDVO3>*37K*X[3Z8-K1-(P2
MO36*Y30!4VHQJC*HU6BQWO?$;/B"BR=I$<7,NP/$FQ#H,CGO \CP*4^SVQ*;
M"X.J!;,Y\MDM]0K=V523&I5(4*@2,%]-IK5JLY\S:&>A(JH,"1E:7>8>+MX*
M^$"CT&'=5KTX=7\(6L2>ZB381'4Q>0*ID+,&Y0UJF&"]S\R->="@C/$C7U^X
M[;L^PM=K+,/4YE0/6A1:@P$5)K:11:2&>:4ZJCB^-+*G56- )M@"&UI$=G%X
M5STA$J<R6^A1Z$DC*.2XFEDCV:27)M.(\7B&J:Y,=(XJQP/NJ*1+/3A&MNV:
M?&J=6%6J;4+8E5!6PB.I4MO@&MPZB^2HZIL97&DD1)A(;V!,(>L@R[/'#GPD
MT=/LQP9<--+K W>,R\'SKLO0$H3D&N:C+/!1^,(O)6*TZ.Y*KGP2\'5O2'N#
MPLU.D5V<\2^,%:$,8:F9Y&Y9(]%?QUJ<Z%HQ1N:BXX6"6Y2&5FJ0KE5*31GS
MA4X<PPXBL!&?/DZAQV99:BDSY+<L\USQ;-0X1+=X/CVM<=:#1W#M277GUNE$
M/D3WP:I/2#)*R.TY6MC1U"=P%&Z1%U,<ZRTISK,2O>!">TM);J]X&\!/?=J,
M]M&PRF>%GZ:GM_!7O-42G(F>4C'!7P<3X=M$2[+=X[=$J&&J.4-8!$J:RVT
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MFUY1HM2K+&G8K(0H\I%J$LR<;XL4^MRJN."*O0Z)5I5#IM$J JC6(].EFI<
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MG<YRI^G_ )XSVZ*W=^%GC>Y%<GF_Z816O1S=VI'>;Y>OY%\VY6IC6GR+\O\
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M)KTL<J5>'[8*)QRWX_'*]%\*P.,T2)L>,<:JX-OM:;'XOX_;3&A'L?&:M&_
MH%*N6@5.=(@)5 0Z?6:=-E&ICE8UM1%'C2"%) <X@T26QBQU5[$0G*3!:+3K
MIMR?60:T/285;IDJIA4?PT+ !)?*'H_#UB33U_>Z\'OMF"V[TE<1\%/@58;>
M.;!)*1FU)\!M*<9PE32QLY5>7Q#<S^+P.M7A6!T:G&EC@A,^/-F/-+*PA6!%
M%I\:7+*NS"4CE8!S1L8KB.:W?BGW#0)K:A1ZH'C$&8T1P(82/>)5V,H0)(G-
M(-['C,$9&.:J.:BX>4KV"$)CB%*1R,&,;$5SWO>Y4:QC&HKG.<J(U$557+ J
MG0ZI3JS33J1H:A2IL:HP3."1PBH*7$(8!%$5CQ$1KUT$:YCLG(J??QJO5S9-
M3,<2(-4XU/E99LC1F+SN7G>]?%A'F0BHU,+=EV*6):D0KA1(@G/&,XQOWTRF
M+N<@D<GV4JFXA2(H0JAD]X@A0@"BQ(HF CQP,:,(0C;I8,;&Y-:UK4R1$_'E
M*_.N#^Z*[BS/S4MW]T0\<$\^VK=]ME;!:-=XE;_A>'0N/[6)=09'V5GL)$B\
M5B$/-\:Q=OQ?B[,B&8N/X0D6Z:6:T[^KU*E5LUI-'&)2XM'##EO21#JT608-
M4E/)5X[Y16#CA)M>-1MOMI(X-HT6F<%WA:TBUJ<&1>OMVH<'BL6573^$IGM<
M/'=4C>"MH;WNPJ$G<7\0K=JW'\(9,TS6;;RHG7DB3LUR\R9IG\J>?'#16)KE
M#3:7P;Q)<^5LRE;' "D\'<HCE8%A"O5 1CD:,;'E(@W(-CG;L<*L.S+@\,R:
M;8]8DS1^"JW3]B$T0XAOUU6FP6$U/14TB<]R<[FHF_'!_79Y6P;3X4N"Y25,
MSN3'#7[4&8KY3DW-1S84<#,T7QAZR9Q&:EVF.!GA.JHU95>%#AX2M-1[40L>
MA0+@H$"C057G<./E-6.[)J.C% Y$7[H_^$(^WAF'"GI:%,NFK0\R5"C6[,AP
M12Y$.-F)"+)>X4$I721;$<A6IEMN-1+;@V2X9;;6F@E0)C,E?4$EM0Y:A*?D
MBNF2B/<22CT:X1,P:!-$T3/<<#@:EI]K9+_ M<;(W0%8U\!K>.*NY&I )54W
MJGB5D833EIR3++FRZLLNKS8N7VA_Y-?:W_E'K/A+VV^VCPYQWB5#XYQ'P/[P
MXKQ#B?%MOXWC?&=KXG98FH1="R>"]K(^K=MG-/$(J#S^'DR.=RY?Z(GY*XX,
MG!R>D'@[GEE:51=BUT;A!"W6G4JOF1MW/D5KO@KGBY:3_DZX4[5TVM79GA.\
MK1\!TEVQAN9Q5LSPA)SF%VVL(=GRV",[4FC?P#<+>KB])D5:Z;"N\R<D24Z?
M6ZJ> >0J?#;%VM1GO5<G_8N,Q%>B(ULWA?FM?M^$+AYH@*-M<U<"UK<I%TTZ
MEB3/X+T=M8DA$56.\'!<B-^"G""*RB[.J_Y'4=*8QCG3)-%;*IZUF-37-<FS
MG%@[79KI(0@D-'C-;+, PK7?9($B4L$3BLV(YS7S(U<$C5J[*B1K![:8^4Y9
M'&%&-),<T>0(8XY L;]\U?\ _P EC_93,?P;Z53+;IT"!<$^33:Z"*+8K68D
M<ML*C:H=BI)GE*VI312)$HQ9$@)E$0KF(B)P_6];T")1Z)(X$:G5%I5."R'3
MQ3!TRA-1\>''0<8+<Y\PFE@D1KY!5'H0CT6!>;*' 2ZCU;C!*_L46J*H[UFT
M%@6S'9F'$2FB&'B8G,C*1B2%$LC,B_P5YMK4>#1I58-(BU:1"%L3U-I(]MB>
M:H'9D:;*>RMU%I),HA2D8;9D<X36CQPLDIUJ\#=M)%N2L1IC[HD5*5PM5:J>
M$M4BHVYJ<XL9Q96T<2*T8Z;"12Q'>) YSOX(5>N2%2%ITR##@W55JO$B/BRZ
M?'CVFV%&K\N4-S)$&,!T]0LJ#WQXX'3'IH&IUQP#W*.91:18?M/K<*EU8!(4
M*VQ =2[@B1613B4<"/"9X5IC6/8K(HQ2@N1R#WI_"ZK-$FBJ-+E\&=52+.CY
MJ"2D:V9$,I /5$VH=N B".S,1QHTP7O$]CW5"ZK2HP&7U5;1KY)%> #77B12
MU(L:HQXTUB<<$$5'A918D9[1,,!AV#XTYY7\&3Z9<G\'JUZA3:W;LRGS*1*N
M./PIRJDIF ; N$08%2-*.:8=CY"<6;3QR0B=#EQZ9JU_>W\("[Z/R*_P<799
M-X4PZ)F1C(9I@YJ=7B1L(.HF;FW4E.;D[\%TT]-=MK7X/. ^ZKYF-W.8ESW1
M:<AU-@'\TJG!+"EC5=2AD1)P<A.U:^"MT7A"MK@Y!.CUADVM5BCR+CK"A!4Y
MSFMMR@"84=0.QY,YG&!.8)CXZ-5'%R=PP6<'A!AUKP'0PU"WN$0%G1Z;(EP7
M.5]3C2+:E,AQF),BC+36.(%AX3RFEC+*TQE2XKUIMYY0(M&N!]N6[[7*0O@&
MJ@KQ&FJGA8R2#53C"H=W$IT5T8.WR:CD$W'!'>--K21[BN>L6=%KE0\&TDW'
M05.A5:;/9Q0\$D*-QB3$"171(P'"TJP"B8Y6XN3@PLZ[J=;5'AVQ3JVLZ9;]
M-K!Z2) 4M9)X 3B&Z=,F3ZE&C.%4)+XH(A#F"-IA,SK-DKPG4[@RIUI0(,4U
M>)8TB[IUTW$L4!9Z)!%"F1Z73V%(]J.1HB,T;07&D/LHBUNLLC>%:96Y] FR
MH87QHE1?#!"F!G@CDY0-O%J$="CY*<8&96""Q6A9]\&J]7-DU,QQ(@U3C4^5
MEFR-&8O.Y>=[U\6$>9"*C4PMV78I8EJ1"N%$B"<\8SC&_?3*8NYR"1R?92J;
MB%(BA"J&3WB"%" *+$BB8"/' QHPA"-NE@QL;DUK6M3)$3\>TK\ZX/[HKN+9
MILZXMC-I]OT:#+#X(KI-E*B4Z,"0+:"ICQ/T%8YNL3WC=EFQSFJBXMKA MGA
ME]I5<MBDRJ7#)_D\JEQY\<\(#D'T3QQHB:XE2D1MF6'(TY[8;V$1JMNNZ;DX
M5)]XWO=M%-09=Q2[3JU,CPJ>6.("BI]%A4Y8P$58\97(A].B.P04!M)+CTVS
MO;[X;\'GJ)O"/M7N&F[;C\^1-T\3XK/V>RV^RSXT37IU\C5H;+X0;!X8JAP>
M7-588H5=("S*E<-+JPP-$,1CTFH0(\=).S %KB.<5BN$TS!#D/D%/7Z_.X1*
MC=UY7249*]<U4H-=CD.P.6SB0X(:80,&&QW*:!I"JUK0@:](\:,$5QVM[<_!
M_M@H\^D\>]KMPRN*<=CO!QCBW$(VWV6K5LN,!UY:=JS/4EF\'9>$QT299C@K
M"N1MF5\_&&H$X987TI6C489:%&32VIJX98H'*\K4<QW! *GW^M'@\$E5I-0B
M1?:G7YKJN"DNI+F12&2/#XF4W@I-K+V4Q5>=Y%"YR<KA)NVIWN*LT_A'IT.E
MS;<D6E< PQHH(@H<@99NP-QYLM@UW)#AJ%'Y(YZHC\5.W4X4#7#0"5,LZWH<
MJT[@B2*!'D/(^1 68@9:3Q$<HC(YL: UDGC9T#[\5HND_8MP]TXZ3]BW#W3C
MI/V+</=..D_8MP]TXD6Y=%694:9(<PNA:/<8C1Y(L]C+AR!TI"QI0M3VM*)R
M*HR%"_6$I1OI527A3X1KA%02;6@T:Y:G<\^A4<C1O")T&FQ[?A#38!?LPL,X
MPVM:W-BJF>*G1J!>%4E1:K7IMQ2'U:FU>0=DV?'A1BB"Z);D%C8K1P [)CQD
M*CE(KS/S1&TNK5*[:U1;AHC7#I=S6P"XJ17H87J]R@9,\!R&.$CR$>-" >X#
MBGV#A\8/M*C7XMWUVX;GJHFQYUTW:*XZW7C1FZ?>_'%H<=@QKLPM)L@,(9@
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M4S%' CW "I21AW$ECBTRJLXGM=371VF<=-H9B.(@VN8+9D>TP@0H0!18D43
M1XX&-&$(1MTL&-C<FM:UJ9(B?B3_Q  L$ $  @(! P$'! ,!       !$2$
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M:YL+8B46#W!I-X"I0DYU3 >V[[2#51;ZA*F(]# "9<Q$I[4!BM06 2E: )+
M6V'(N(OU<O:GL;&9@RB#[9Q)Z'JBKIWVV%I:U,5FZ-0@/[9]4L0Z"_,.Y_5,
M63E3H-"+"R,#\=$EEN039*_L N2-0RE<#1@9=[4+Z;UY]S74R4C?H+W<^Q#6
MZ=8E]:(Y?BR26M\YH$Q"/^;QF/K;:C#P@8OL6#H3R0FD'9N9#],8HMKW2#[6
M4O.'3\(\*SDS&UGZ<_:8U7/WG\-8K;I+M![J4E*_2BQX9RFQF3=!!A\6E]20
MA:_F 9)E'U&=TEA$^*__ %%ZMV K)H.#_%/A@UMH<;%9";F" '%S+2 X/LR
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M6]"29AJE<ZJQ"6(!LK:9.>:[ZL#(/$PJ$CB+SBTD4AA!T4'QU1%;4>:0EG>
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MR=M"X.V*0#US*!(<P-30X]!RYNSW:$Y)'=0]S(IE7%#OC$C70M,QL;NZ9?\
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MMO >CP\^<H%GB>OG%T ^D34Z/V(.7\/85 5P8:2,3$0&IV3E%NF"D)Q(B 0
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M_P#)@)RI[*F=$=HD<9-EQ^7DU\N,0(=G7/(.6=MS1;NHQ8Q%$LFYB3H(3DS
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M"'>5I*.38I@-R4#*JPTND=$B;D9U#E?;4@Z!FO;>/, Z5!DMBPIJ;,!-50J
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M,M&-NEE!IH;D>3MC0QM+QPG7(9F-=LW41ERH&0?F,,WLYK+:B;Q!<TB0RDU
M3H&9K"6Y;4$^QH443EX96ZB2?27N'3X<:6@:=QXFX_-1D_Y#^<?3(*7BBCQ<
M'T<FIS!^1VQPCU-\8804@E$  +JYUDJHPT@(DZ1QD5&? +!Z$>Y%H>*04!'J
M8UQ@MO*UU?(80H(8)4)(UNJPUU*#)?15(!%A(?%.4^I1/TR#X.OI'A0?WL^
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M#^]GP!@OH0Q<L-[74">X 41DT F:0LHE1$Y#/PAG0HJ>AYW17R<5=XH$#2X
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M$I$V.3B3<=\+,@D#?)W2$&-0"X"^1/#N$5E))SS);LC K4X(D$<D &MFP8
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MI81<49HQ@N%IFII#.P'\PY# P$@#W-)H/\.%!,-")%@Y"K.,5W/ GYE+U*J
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MV0"O 8BSG.',KI D[HAN'*@+%!:,9#;RXR^,RNQ_YP0::+D<=CQQ>>)\,,
M+93&1R8JRB^_@,FR(RKT2HZF4Z(KI0V^)=+L*88:+U'[%N2.&%7L71Z><B;*
M_E90))N1Q7DZ2<$:V+*T"37K BE6Q,]<IQOJ/SZWGFV[BMYL>+T)1C$+Q?'&
M&ET:[OY],.2#(E]YD2Q.IQ)I1A8+M*(2R:,(BG12_A1*(2;[*WK3JT88<BR5
MXL@1MD[1#!%,O=9T32_#>!)UZ'11N;[8Z6_'\_G'/7IY>AV\^3)-$=+^W?\
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M8&X%37BO3"O_ "6?VP4(D@&*^P\QM5'X<  #]%@)8PA(E"^<K6"!]NXZ"PD
M(K(. ERD)(M"!$$",AB$%X.O'=NH2-X8M0!&1%9 IT'OG%=!VU&)BG&G+&P
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ML2S8NP$-.*QB2 FK/3A@XQE?.G^\V1=1?#SA*KW73#$;,\H]+8P$5<PW!"O
M"R)UH ^#84DJP8W19P+#,-.#HQE:'ZJ 4K03SB[$/5\K;T)@-9$0-3&IJSD[
M?3>:6Y;\\<=L/Z_/^Y G53<$$1@5KO*E>I/K.-RZ"H3R'+J89_-=<##9F12-
M4HF++W!A<N4H!7:8YD_'6!N!4UXKTPK_ ,EG]L%")(!BOL/,;51^'   _12
MD'=: +5X"W"HG4Z_G!U"#8!3R;]PH-F #X"R^F*?(4+>$(-34N8P,O0##F1$
M10I0LXA:JBA3O\IU*D)0V4+?T3#$A808&\X253 [)*ZG76(L"$Q/CH*,J&LA
MPMZ2>;P2&QT?8WD\+UIM$K?3*8FH [">JHBQVD2%S71/)0G4_K@4#6CJFB'B
MRTZ1E6T6:07*@G8(R/LV&F@O1!#WP[_^Y/V4!75ES<&L2R"N9<]<<S!''<,
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M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,%G<J\+V0HZJP-P*FO%>F%?\
MDL_M@H1) ,5]AYC:J/PX  '[8ZE5@;@5->*],*_\EG]L%")(!BOL/,;51^'
M  _;'4JL#<"IKQ7IA7_DL_M@H1) ,5]AYC:J/PX  '[8ZE5@;@5->*],*_\
M)9_;!0B2 8K[#S&U4?AP  /VQU*K W J:\5Z85_Y+/[8*$20#%?8>8VJC\.
M !^V.I58&X%37BO3"O\ R6?VP4(D@&*^P\QM5'X<  #]L=2JP-P*FO%>F%?^
M2S^V"A$D Q7V'F-JH_#@  ?MCJ56!N!4UXKTPK_R6?VP4(D@&*^P\QM5'X<
M #]L=4@;P*D>*],*_P#)9_;!0B2 8K[#S&U4?AP  /VRU7J.&F8CE:JLV \Q
MM5'X<  #]LAJ1_5$.1&EPX/,;51^'   ^2?_V@ , P$  @ #    $
M
M    !>
M                                  !;P
M
M    !;.
M     ;:W G!H                      !19P
M                                   : *H[;2
M    !0+.
M    !^J.",K@                      !0!9P
M
M    !0 +.
M                                  !0 !9P
M
M    !0  +.
M                                  !0  !9P
M           !BDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDE&   +.
M                                       !9P
M                      !(      !  (    )!    !!)!  (  !
M          +.                                         ((  ( (
M)(  )!()((!((!)!() ((!) ()!)            !9P   !)(
M                      ! !) (! !(  ())))!( ) (! )! )   ! ( )
M           +.     )
M                                         !9P     #
M                      (      &3Z      !C@
M            +.    !*X                             )1)T    $&
MVZP    !$<#@           !X                 !9P  D!,'@
M              [W     6H'P   '/B4^    &9% "    !E8    !LQ@
M             +.!Q("!9@                     +B)$   OY>"(   Z+
MV\00   "6@!E    *P&0   !EG4     &JP        !9P506#?0
M             !;A*  !JE"\B   2(+$S0  !,#9C3*  !(H4D   !$W(@
M !:PZ         *5I(2>TP                     #621   ^8W]<  !2?
M,NR    Y"O@AJ  !.$Z&    9*W0   !/TP         .10"
M             *ZJ"  !"7:'4   .9[-#@  !@8*HS    U@-<   "_/=N
M  - H        !R YZD                         JOZ   ^TI0J  !&D
MV%%   !!V,>,    ;U+^    @3\<   !R^0        .0 !T-4@
M             "L!X   ++^S    .&A8N     &>W=P   D$WP    /^7D
M  *<        !R   /DO@                             !3)0    6&
MG>P    /1ID.    %%\     +^&H              .0   $#'*
M          (                  :,H      <4BP     (      /&[
M  !(       !R    "L$(                  (!( ))((    !!(    !(
M!      ! (1     !)!    ! *!(  )  (!)(    .0    )_P 8
M          "20 " 2"   "0""     222      0 "0    0 2     2 22
M 0 0 "22    <@      H                  20
M                  "                      #D
M        2"   2))))))))))))))))))))))))))))))))))))))))))))))
M))))))?    <@                        0
M                                    4   #D
M      " 0
M      4   <@                        "
M                                    4  #D
M
M      4  <@                 "/*@
M                                    4 #D                  3-
M::\
M      4 <@                  6,@Y8
M                                    4#D                  "B&
M35)
M      4<@                   N T]1
M                                    7D                   "^&
M@AE@
M      =                     J HLQ@
M                                    4                     I?
M-*R@
M                            (:-(L
M                                     @                     F
M:TT
M      -D                      7@           -))))))))))))))))
M)))))))))))))))))))))))))))))))))))(L\@
M             (
M     !-KD                                  (
M      "QQP$N78                     !-C<@                   "
M    2        (                      >^7\<B,@
M     !-@;D               "00"2"0"02        (
M      =7P]BY-@                     !-@#<@
M "0          (                      &1-<94_@
M     !-@ ;D                 2 "0 0         (
M                                   !-@ #<@                 2
M"""0         (
M     #M@  ;D                 2             (
M                                    5@  #<@
M             -
M      "@   ;D                              -@        2   "
M     020    0     2    0 "               #<@     "2 2
M       00    -@        2 0"0 0 200 "  " "" "  2" 222 ""2"0"
M00          ;D    000 "               0"   -@          """
M2"  "02020"2" 022 2"""00"2  2000          #<@
M        "0"  -@                        #K#@              (#T
M             ;D    @                     00-@
M         :89=             7)P;@            #<@ "DT  2
M           0"-@        0!             !7!EA            2AKWD
M@             ;D#W\D >MV@                 "-@"%!@   $.&P
M        75&,*&           7\K3X              #<@>TT 9<Q@
M            "-B5!N@  !CIQ$@           %0N65B0         !M8RSM
M@              ;D50N[+8D                   -A4-#P   J^XR8
M        -RYN2YM         (^'C R               #<@ 5;!$8
M             -@GR0F  1++> ,          ":KZ?C_ '8        "_<QE
M2                7( :^'+^                   #8B5AG@ 'YOL6#
M         GHBS2:,X        ! ^8(GH              "Y  GF8\,
M              #8?<:9  !D?("R            !VAZ3]         !;'.?
M/@              7( ?(   /O                  #8K0E=   MJJ@Q
M         %:"$@\X         !7%@E<              "Y ':4  !5J
M              #8-["S   &J:VO            "2AV<          $+27Y
ML              7( "X6  ACH                  #8$HPX   $^*YH
M        H  F-A^           '2+SH             "Y  %M\  'YH
M              #8   @    [V1               #JP            FZX
M              7(   \H                       #<$$@D@  $ @$
M             @$@           $@              "Y
M              #<$@D$@  D@ @@             D$ D@          $D D
M$            7(                             #0DD $@  @$$
M          @DD@D            @ DD       H   "Y
M              "
M       %8   7(
M                                     #8  "Y
M
M       #8  7(
M                                     #8 "Y
M
M       #8 7(
M                                     #8"Y
M
M       #87(
M                                     #:Y
M
M       #/(
M                                     #1
M
M        (                 __Q  L$0$  @(! P($!@,!       !$2$
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MR4PL@-BDD( (Q %F&X*7]Q=9$4NA*%J[1E"(CDE!6;:O/A'AX/(80)H!$?\
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M)":)XI;E)4DPL9.1^#T>HV?F0$MNCK]=\APIMO(9T<2$]3%X!6BU?37^K9Q
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M@HQ4TE\]>]GU41E$;(LYKG>OC?N*$O0RWT/G>O.$U35"X2OXJ0/_ "R,N-P
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M0'3(YV," KV(U!X^3$%L8/ ]*$*S_&>=0&<I#'$CIP1_Y:I_W,%B@<CQ0O9
M3O#4$AOPO;'[E4V?;^R& $(#:A)4L@3AA,^[?V!])CP&55)5/($1/\QJ('GH
M/P)76Z "ZV+4;E;D=BDP98)'EA*$* _\5"@D6/B#@4=LN&.;9FRC01;-_P#L
M'M."^ _F)#).)"<1 $1< &%OI$4=4JECK^DE!D',!+X+;1 IB8")J3'01_$$
M*N1E"(BF!F\AF\J41<!/W2IL^W]D, (0&U"2I9 G#"9]V_L#Z3'@,JJ2J>0(
MB?QG4J;/M_9# "$!M0DJ60)PPF?=O[ ^DQX#*JDJGD"(G\9N+D6IP,O1&&&&
M&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
M&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%'R#4X&7HFS[?V0P A ;
M4)*ED"<,)GW;^P/I,> RJI*IY B)_@'9KV;HR!P7'_*B?_\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ -X?5VK '%4_R2?;^R& $(#:A)4L@3AA,^[?V!])CP&55)5/
M($1/\ V>>)0DI 'K# ?Y3_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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M/7\;6:-3K5.*HRE0(]WGCXE4X,@]?Q13+$3UXB>(Y/1,W^^[/JA:P=7%HCN
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M@5T24=R0ZUKKUU]=,(*B6?59/@ *AKJCIXE]=_IYD,>6O:>"\L]+N#UCKJC
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MS!H1Q_ODR!Z]AEGK\IV2X"CH;<?7/C]@O[(8 0@-J$E2R!&";/-.;<R/A,>
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M(2@E*4@2R5.F$S[M_8'TF/ 95$A4\   _"8GOS7RL\3/7G)+%/7?FZYC?I6
MLGJ$[?M.+90N.&OZ]]:;E*%_U/>./'X=X2,%P!NEDU<RKRRQH2A47''P]:P2
M#!P?4\^,X@T2)=W9$>VXO/HK_7[7L^I+"3T8\1X]LZ"FX6]UR^WG&<2Z[/=N
M\XRN\$3UT\X $&NWY,)B'F.G+'%LMIN>F,I2[Z)CKQ7QT9"I2*D$^8W?SR7
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M_'\:"R@O5"<"*F2(ON;"->D8DH2P!,5U".]S Y!N">L?N&SZ4!T_*0H@^<>
M'BLX!0^N9G(=7J'IJ/KISW/T"^_;P>>V1+P)*I2;]G]@*@WH!/9QL5AJ)\$0
M^IC02+O >H1!Z48HH)W!OS^K2%BB).PENY8*QEF3+T'@""AUP- JBLFQ*\A2
M*D-AE5Q L0P*#T5S8F:U^MO[)9(2@E*4@2R5.F$S[M_8'TF/ 95$A4\   _&
MDTY ("/%:\9L(W\S4=(P 1'O<QU_B?9]O[)9(2@E*4@2R5.F$S[M_8'TF/ 9
M5$A4\   _C'9]O[)9(2@E*4@2R5.F$S[M_8'TF/ 95$A4\   _?MGCB4)*0!
MZRP7^4__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#^0[<TI('K#$?D7]DLD)02E*0)
M9*G3"9]V_L#Z3'@,JB0J>   ?OW=KV;HR!Q7/_*B?_\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ -H?5VK '!4?R2?;^R62$H)2E($LE3IA,^[?V!])CP&51(5/   /
MXQV?;^R62$H)2E($LE3IA,^[?V!])CP&51(5/   /XQV?;^R62$H)2E($LE3
MIA,^[?V!])CP&51(5/   /XQV?;^R62$H)2E($LE3IA,^[?V!])CP&51(5/
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M^%"'@%@/VSP#*(?,LD ,1'!0:6#P FH?"A#P"P'[98%_ S.X0<+ !$0='4@
M&,1@19HP L'@!-0^%"'@%@/^T70S4L5& L 48"=3JW"\379GUK]!CD!$F4;G
M?D$CT8F)XKD]?R>SH/B/*] ;%%*$5+T*C3.I,)C80+"A=<ZX1P%#44$! _\
M"!ZS4TU\M6,UH4XE3SM0"50C0_;RV FE +7PM$,!QE"SS-D"&JX$8$;( "+*
MS"T>7Q'#1PI?Q4H_U# "/L#,XP@X6 "(@Z.I  ,8C BS1@!8/ ":A\*$/ +
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M<P&5I>5'YAJS"J#VU(ST8"#QF&:)I_4V $?8&9QA!PL $1!T=2  8Q&!%FC
M"P> $U#X4(> 6 _;+ "/L#,XP@X6 "(@Z.I  ,8C BS1@!8/ ":A\*$/ + ?
MME@!'V!F<80<+ !$0='4@ &,1@19HP L'@!-0^%"'@%@/VRP C[ S.,(.%@
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M(.CJ0 #&(P(LT8 6#P FH?"A#P"P'[9$$'V!F<80<+ !$0='4@ &,1@19HP
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MV$]?0TH"B3AF)0!6%Q@(KF30O-*2*BVD"IGHWO$:)^*Y!9@T4 ))R)=,V.0
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MHJ1N6N'20L RF\0Y-JS6/!HT0,'<X=+VXVC\=(S%:51*@GB3LNV@(!(V"0
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M$(2,E  #OD@"F1)-((B2-(Z;NY:7#<$*0D0K):)T"R40%*HEE99$DF@Y!@
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M4P3H!6!0@*%"U\%^D@MN:\"T8  -$^<$_F(DGB@4 1^V1P GZ2"VYKP+1@
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M0;XJ&14)!5"W04!&$0/L2TWFN[2*@CE,J:4-3!,NMHQ+)@AQ1-) >)J($P#
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M*<Y2ZWC)"1B*(,Q4=JC=@F73(06@5IE1M!&7?B0YH5$D3%,0%A!%(]?SM \
M H#QL0<HH ""HYG#R >6Z !PW\T3:KE!557\!9D'$;_=_>"0(3KGK8X_KR$"
MC<3OB(&\.UL,!I)G ? ;;PKOO&]?C4 &XVQ,7[Z-AYFX5J%2Y,U%$C)H $3J
MSM7G;E[:85!<L3LQ XFR]F8TW8@3B)]Y)_2?R\89,EF@!*%4- V9=Y>_O)YC
MELCN6)M#,SM>D0,$F#\LIC+QX=&T=DT$4$"!RC#+N:J"S0E42<#R1&\<CLB(
M!5%BO<>,^=*K+:_CM@)R8AV_CYZ%.(!+P$(C)-X:;VJ9G&EI@= 4"8 ,W9*
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M7*"JJOP $19,,LFK)E/?C2B57V]BOVG_ "^@>  4!XV(.44 !!4<SAY /+=
M X;^:)M5R@JJK^V/Y?0/  * \;$'**  @J.9P\@'EN@ <-_-$VJY0555_7OW
M>QGTQFE60Q#_ *D@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
M@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@C
ML\B:;S2K)8+\"@>  4!XV(.44 !!4<SAY /+=  X;^:)M5R@JJK^O;5F,R\F
M8BBHA_ZH0000000000000000000000000000000000000000000000000000
M00000000000000000000000000000000000000000000000000001NP)3(R8
MF*KFGX)?0/  * \;$'**  @J.9P\@'EN@ <-_-$VJY0555_;'\OH'@ % >-B
M#E%  05',X>0#RW0 .&_FB;5<H*JJ_MC^7T#P "@/&Q!RB@ (*CF</(!Y;H
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MOM([X%"_O*_S&PS($J:#M\!GB-/$GUA,074ZP1Q/1.9"\M,PZ[W2KKZ"7C!
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M^-$NEPT^LHK48B0E']0IHHK.K>U6<=/[+ZMO+^:Y^+^E&H//\7:+Q?4<41<
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M?0H;CY"&25*RG,0C;N2SGPQAQ\=MO=_C]P_9.8:\;@H;SZ,>-F"N*(2I4/K
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MU]N$S^@RZHT\\LU6G7$EUU9U[^C/#LT4OE9CO,N"G$3U"?Y5:UF&? _.SW1
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MA0* !56 '*O08%B>T +Z.8Z,X.,]JHDAIX-#"K_ J!PY. R7[X'GHF8@ *A
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M)3<$A=K$HJO8M%X?)&A\O0P"XM^ G5H!2D"ZQ11.882UO#JY:_)![JB<;5"
M4P0"")1$1'A$TCY/EC=!P$6A%!PKC,)YGU4:C2:;:B. KD9'EA"I3HFM8T24
M3,;)0"D0RW'<<+#@DN$@#[&(K48B0E']0IHHK.K>U6<=/[+ZMO+^:Y^+U:AU
M1SWBV!0@4KRA4:#L/3%Q],.V/HFGJ5[%.;5TB^0D4A,$>PXQ8?#V'TW"\S48
MI,&U+M:L0B(HCZ;6,GM$TH0[R8*QNCE.XNWG-?XPB"(!HB)(G$AND]H8NKL
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MD1X%;M6-W15FD<&JDBL6/FCB4HM[!0D>I,>7D&VI-%\E4+QH&/=*J+@G)QC
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M\?)#XE0_++0%@H0Q5<3NF^X]A)A-" .J[%<:)H_\Q(O/JZ09!(G(>16G"H
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M14U(L30BC8GAT5T EE)X-:2!/R/."$,XE[47D P'@XU)FQ4@FD( =,A(?(J
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M)LTL>'%!B-@I5B<-HRA$>P,0F@H #M-AHWN<+1N',B4DB,0-) '9AJU$TF^
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MWNCYB2V4H4&3A8BT(T"8&I"[Z6%NRRE&E 0291J8*YQC9X%6@"BRAF!)O/Q
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M T0'9^'8_A8* =-2C((  ! " '0  >/KN\)'BAY7,GK#WH \<XH_@!_))>5
M0$[N'!G#2 #IZ;J0]R[WQ7$4: 5O8\?MXQ-"-O\ 9.<&SYK^_P#UWC%.U5XN
M$D%FP)%G>5/RI_N_:$ B6?CITZ;RJ>N@%Y0%0=#6V0!J<_O]C(R</'B>>%<)
M9J,JQ (BB)CP"6I=VM4J$4TP*Y(-< /X@HG;07+J8,H8T" A5#5%F)(D1 H7
MK((4QI#V T,@  -  !Q\T&CNU<@?(N&:T!&5 ,:T^4)B=P6Y$MZ(' FJ!G#N
M]97D,12VH14HB' P-R'8BB!3$64D#;(2>23*G7(=H0=]H[1>PJ_,!>"V",$#
M%,%/G>3/XK0\?LO9!( F@4<910**A'!!^EPAE8'+*CL9*PGG[\3S$#;'I$0?
MZ(H#!73\7 :H$H!("8.8(  ! " '0  >/DCU68R5!B,AM]3T.M6#/^/4?HA?
M#[QS#$0@]#O"1XH>5S)ZP]Z /'.*/X ?RBZXE-CD%J%N(8.%DN"&*")6"CCF
M2(;=#<-]MI5USDTAAOI?R-^<Z 5BC8]Q3?\ #[X8'#HK2%M5G\PB%P;^ #_'
MV9S?:C02[\XH1['##1R7A!@!8>H"WT5 ^!N*&^QM4N-4X;0$.!4_<90:/AEQ
MYX:%K_H5C(S=3ST*> 4VD&"H)6M!;B(PK0AA)&*1OW2T+9Z0&?G)[LC,]DOH
ML["JXR*YX<Y)R16^L*?DE7T;>C*SOS!N]SW-"'&!^]T02=Q]>A+IS=(NU*U5
M_P!F0<9O+@R44J/@Z?\ 6R)PY7R1R@0MDU%%(,Y9A%<WRX GKV3<VE*US@#@
MZ>EF<Z;>JO\ W3:?JA*0L%);OUQQ6:'M-&K4@\Q>_OS:NLPQZ^<5PJP><[Y=
M (H!!$01N- HG#_+#-".GP@.4EL/JT"RJY5K$N+"/6N\>-$_C)G5@,X";?\
M2TB_;8(T U/F]7P?X/$FS:\?75&OE68B3; '4X+ 34<6:PDRL%A]87(;1>IO
MC]+$XQ<V\^.9<<.Q<!4CE5VA<IKB 2Z9:!W0EM,2:.QTN^2BI:X:7 ?#+B")
M@/A(J(4?0!CN?Z;R@STP3<+Q++OMC79QXD$1 -T?EMLTB>^CMQ-Y@9/D%@1N
MPTK+.PN([?('HJY'FM@DB.$(J>':P0 3/BG*Z*,6O8BZV"U-I>E@#'D#-8A_
M:0DI669#GJ\\'^!)&8G9(&,GSE-,>M+'"6TUTHSPQ+.CDV$0<=#8A8VBE(3X
M],N_7TF#OIG#O6M;F,+H/.:F5M+<0+$NP4RTD'6. ]VV]Y!>G$?/I*!SC-Y'
M&0OM"L&J ;UM\KO"1XH>5S)ZP]Z /'.*/X ?RR0(\57 =B(GAR9FL&AU[:]E
M3!ZA*G82.-MII@1839X<C:FFCV.*31I$.=S!M'IN"7#&B43S%#]F@LE3'GSW
M(S)'!VV+6(\E$C:,S88FM/X+- B"%S<7CJ9 41[E1_AJ06VV_P#GGEHUH2];
M)\&J72@=;'81M<';T?L'YH5S0)WK6CDJQGG&"$:#D!'\BN*N,F_+YLUV:PWK
MY1?=IM(VM?,GGSZ>EVD]E .M.]&&D CUBLG!F"#'TA9VEF>MZU<ZM8Q:@(Q&
MFOAK3!(? ]R#^_-IWGXSI<JL!Z<2Q(?$FED[N%<T]XXS"N-'"8R9=;"Z4C\*
M7/SK_P!"N6G(S9'?+$^-(U5%)OE+7?7VN@F 8S)HANKU,XZOI]S-Y7GO.Y=)
MJD9U!8@UG@@*VU"0) !],_.U^TIXYXKP9H;I+8L*)B%U9ZFATEC9HQ^5Q:/>
M0-?49B6_ ,CF?-UX,UVI;D[%J.[);+AE2*DI/*X9"3?_ -73L6<_+$5WZP-
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M<R>L/>@#QSBC^ ']I+Z7B)4CKI? % 5T&CC212)XZ!6WKB[K;%:"H[\<\/\
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M3Y;>%>I_XHQ>#3_/*ONJOP7QUJ^T4Y/5W_665OZFF6O*DAS]%/PBZBI4&*2
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M%#\N<0H+HMN;# 3Z(*S55Z98PPU</IV/!'.U!Z%^SY^8/L8!52);4LU1^/\
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MW!V8QRV?HXK:40.U#=9@^0L3#"_T!OIV=7V3:H#<EP4YG@=E,.+1BK"#SA\
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MD4""<6O,'1HT1+*41!6&@+1%AN'=IP_<,1 JTJ#8$V&^XH!-NF:*DQYX.:'
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M 6HWC5:"(1^J_1278170T2CN:BL)-B054!%!]E*ZV3$?(K'=EJ.R<TO(3!#
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MBO$X_5KDG)#'@(P *'&:<L\AB6P!@1P[[; IM0PX/*JAY5*O/IQ"!@<./?\
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MX:Y$L%!@/,$^PG>YC!8)"'# TJZ&QN]2;'!2M0$DS$"(0T"X+^UM < 51"$
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M>=\9!*(N"JA$-:;YO*G.TD"<<;S3&^,J?H "ZI17 TJ@?L !85 SY @_C %
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MAR/#5T ZFT< -;&1ZCWR(^IR**&1/2:8J,$-82A9FGPO(H1FQ$OJE6/EB#J
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AG3[$#GA%*(_ JOZ8IZ0-2$QCF:V?8@<\(I1'X%5^Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>kros-20251231_g15.jpg
<TEXT>
begin 644 kros-20251231_g15.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0 #KL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MLWQ!XDTCPGI<NIZYJEEHVFQ8\R\U"X2"%,G R[D ?G5'PG\0O"WCZ.XD\,>)
M='\1QVY F;2;^*Z$9.<!C&QQG!Z^E4HMJZ6@;;G04445(!17-^+/B7X0\ O
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MW\5T(R>@8QL<9P>OI5*+:NEH&VYT%%%%2 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45F>(O%&C>#]+DU/7M
M6L=$TZ,A7O-1N4MX5)Z NY &?K53PGX^\,>/;>>?PSXCTGQ'! P6632;Z*Z6
M,GH&,;'!X[U7*VKI:!MN;U%%%2 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !16%XV\<:%\./#%]XA\2ZG#I&CV2;YKJ<G [  #)9B>
M H!))P!7Q3XQ_P""LGAG3=2>'PSX#U+7;16*BZO[]+'?CNJB.4X/O@^PKHHX
M>KB':E&X/179]YT5\C_!#_@I%X!^*WB"P\/ZSIE]X.UF^E6"W^T2+<6DDC'"
MIYJA2"20!N0#WKZXHK8>KAW:K&Q$91EL%%%%<Y84444 %%%% !1110 4444
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M=S:[OX(K@.2@]@\;M]7-;_[;G[<4WP+O!X+\%QV]QXQDA$MU>W"^9%IR,,H
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M3Z.HKX%_;8_;WUCX?^*KSP!\-Y8K;5+(A-3UQXUE:*0C)AA5@5R 1N8@X)P
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M##_KIJ/\K:JG_!)OP3JL-]XX\62V\D6C300Z=!,RD+-*&+OM]=HVY_WQ5O\
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MYLL"5YQQ7J__  4(\<?&CPRVFV'P\M-5E\)7NDW2ZW+IVC+>Q@'Y6$LAB<Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU\6?]@B[_P#1+U^,/[(&NZ;X9_:4\!ZIK&H6NE:;;7S//>7TZPPQ+Y3C+.Q
M49(ZGO7T>2_\OO2/_MQEBO\ =U_V]^2/W$KXB_X*NZA##\&?"EFSXN)]=$B)
MW*I!*&/X%U_.OH;7OVKO@YX;TZ2]N_B7X9FAC&2EAJ45Y*?I'"6<_@*_+O\
M;,_::;]ISXC6(T6UN8?#.DJUMI=O*O[V=W8;Y2HS@N0H"\D!1W)%<. PM6IB
M(/E=D[M^ANI*"<F^C_%6/H'_ ()(Z?-]N^)=]MQ (["$-ZMF<X_+^=?)7Q4N
MKGXH_M.^(A>R-YNK>)Y+3=G)1#<>4@'^ZH4#Z5^HW["WP'O/@3\$;:VUF VW
MB/6ICJ5_"WWH-RA8XC[J@&1V9F%?E_\ M#>&]0^$/[3'BV"2)HY[/7'U&U+C
MAXWD\Z)O<%67]:]_#UJ=7-9M/[-ONY;_ (G$HR>%FUNW?\&E^A^WVDZ5:Z%I
M5GIMC MM96<*6\$,8PJ1JH55 ]  *_*O_@J1X7M-%_: TS4[:)(I-7T:*:XV
MC!>1))(]Q]]JH/\ @-?I;\,_BQX;^*O@.P\5Z)JEK<:=/ LLQ$JYM6VY:.7G
MY&4Y!!]*_*3_ (*!?&'2?C%\?)'\/7<>I:/HUE'ID-W V^*>0,[R,A'!7<^W
M(Z[<C(Q7BY=3J_7DFM5>_P!S_6QU0<?82:VLK?>OT/NS]CS7I_$'[#FDR7#L
M\EKIFH689O[L;S*@_!0H_"OSJ_8E_P"3J?AU_P!A!O\ T3)7ZE?LU_"^[\ ?
MLL^&O"=]"T>HOI,KW,#D@I+<%Y60^A!DVGZ5^3G[,_BBS^&/[1O@K5M=<65G
MI^K+%=R2_*( VZ-F;/0+NR?8&O6P4HSQF+Y.MOSD<<D_J4?G^*5OP/V^\2?\
MB[JG_7K+_P"@&OQ/_8Y_Y.@^&_\ V%H_Y-7ZN?M+?M#>&?@E\)[_ %J[O;:]
MO=0M6CTFPBF4M>R.N%*X_P"68R"SC@#W(!_*/]CG_DZ#X;_]A:/^35QY-"25
M:;6C27S7-?\ -&^+?^SI?XOR1^B7_!33_DU^Z_["]G_-J^=?^"4/A72]4^(7
MC37+JT2?4]*LH([*9^3#YS2"0J.Q(0#/7!([FOHK_@II_P FOW7_ &%[/^;5
M\A_\$W_CIX>^$?Q0U?2/$D\>G67B6"&WBU*9]L4$T;,45R> K;R-Q. 0,\'(
M>71E+ 5XPWN_RC^@8K:#?E_Z4S[S_;F\,VOB?]EKQW'<QJ[6=JM_"S=4DBD5
M@1[X!'_ C7P5_P $P=8FT_\ :5:TC9A#?Z-=0R+V.TQR _FGZU]B?\%#_C%H
M_@C]GW5O#POX7UWQ,B6EI:1R R&$NK2RD#^#:"N>A+"OEK_@E;X(N=6^,VO>
M)C$?L.CZ4T'F$<>=,ZA0#Z[$DI9<G'!XB4OA=_OM;_)>H8GX(+K=?==?\'\R
MS_P5@_Y+!X0_[ ?_ +7DKZN_8$N_L'[&_A2Y(W"%=0DQZXNYS_2OE'_@K!_R
M6#PA_P!@/_VO)7UC_P $_K9;S]CWPA;O]R7[?&WT-Y.#652_]B+EWYG^<S2K
M;ZS#FVT_])/RA\-_$1=-^+UCXXUO3O\ A(3%JXU>YL9)O*%T_F^85+E6P"W7
M@U]OG_@KIG@_"?(_[&/_ .Y*^-]'LK7X+_M"6UGXOTJ'4-.\/ZZ(=2L+RW6:
M.:!)=KYC8$,"F2 1SD5^OWA?X0_ GQMH4&LZ#X%^'^KZ5.F^.[M-%LI(R/<B
M/@CN#R,<UZ>.GAE2IRJ4^:%M+.R6WYF+YO;S3^+\]7_7S/R(^$_B8W7[37A3
M7-+M!I27/BNWN(+.-]P@22Z4B($ 9 5MN<#(["OTF_:H_;PC_9I^(5GX57P2
M_B22;3X[YKIM4^R!=SNH4#R7W?<SG(Z]*[G1IOV=/#OQ0T;P[H>E^ K;QU-(
MYLH='TJV:YBD1"[9DBC/DL%#$;F4GMFO2_%GPI\$^/+Z*\\3>#M \17D4?E1
MW&K:7!=2(F2=H:120,DG'N:\O$XNE6=+GIODC?YK9:^31I&/OSE)ZM+\_P#A
MSX6'_!77GGX4<?\ 8Q__ ')7L?\ P40U%=8_9!NK]$,:75UI\X1CDJ&=6Q^M
M>UC]G'X3 Y'PO\& _P#8OVG_ ,;KQW_@I)&L7[*>K(BA$6_L@JJ,  2C@5S.
MIAIU:2H4^5\T>M^J+IJ7,VWI9_D?FS^SS^S5XG_:6UO5M+\,7VDV%QIMNMS,
MVK32QHRLVT!3'&Y)SZ@5W'QB_8#^*GP7\*W/B2_BTG7=(LU\R[FT.Y>5K=.[
MNDD:,5'<J#CJ<#)KO_\ @F+X^\,> ?B!XSN/$_B/2?#EO<:9%'#+JU]%:I(P
MER54R, 3CG K[!_:0_:Z^%7AOX0^)X+/Q?HGBC4]1T^>RM--TB]CO6EDDC9!
MO\MB$09R2Q' .,G KW,=C,50KJ%&-UITW,,/&-234]K_ (61X1_P3]_;,O\
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M=V7O#N57V%-QLE=OKO\ E^IGB.9X:3;T?3Y,_5[]M+_DUKXC?]@P_P#HQ*^
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M^U)X:6U3RXK7QA;I'&IQA5O% 7\ABOV?^-'_ "1_QS_V [[_ -$/7XO^$O\
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M5A8SCE59RV>J]+Q_6X8JUZ:ZJU__  +_ "/T8HHHKYHV"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMR ,[@,UECL!5Q6(56E9QE;6ZLM+?=UT,J7[I2C/2S?XZGO?_!5#_DW;1_\
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MII?9]N@Z/L_;P2WW_+_,_)']B7_DZGX=?]A!O_1,E?M+XD_Y%W5/^O67_P!
M-?C!^Q'9W#?M6^ $$$A>&^=I%"'* 129+#MCWK]H/$"-)H.I*JEF:VE 51DD
M[#Q6O$&T?1DX33$?^ _FS\3OV.?^3H/AO_V%H_Y-7Z)?\%-/^37[K_L+V?\
M-J_/3]CBQN?^&IOA[#]GE\V'55:2/8=R!5;<6';'?/2OT/\ ^"E]O+<?LOWI
MBB>01ZI:.^Q2=J[F&3Z#D<^]=>:?[SA_5?\ I2)P_P#%G_A_21X/_P $D?\
MD8/B3_UZV/\ Z'-7(?\ !5K_ )+QX:_[%R+_ -*;BNS_ ."25M,-7^)$YB<0
M&"Q02[3M+;ICC/3..U<C_P %6[:9?CAX8N#$X@;P_&BRE3M+"XG) /3(!''N
M*JM_R-X>G_MK*P_\.M_76)]E_L#?\FF^ _\ KG<_^E4U?'G_  5@_P"2P>$/
M^P'_ .UY*^Q_V#;::U_91\!I/$\+^3<-MD4J<&YE(.#V((/XU\>?\%8+>5?B
MQX.G,3B!M%*"7:=I83R$C/3."./<5PP_Y&[_ ,4ORD+#?[L_3]4?5W_!/VXB
ML_V/O"$\[K%!%]O>1V. JB\G))]L5^9T6EZKXV_:%UR]^!FGZMOM[VXU/24M
M'"W,,*,277I@<\+R<,%^8GG]*/V']&CNOV*/#VG:KOL;6ZM=12:27]V4BDN9
M\OD]!M.<],<U^8?@W6/%?PI^,UQ'\)==NM:UF"XFLM/O]$LVG:_BY^[ R-O!
M SM*D<9&< UWX?7,,4T]=;=MWO\ A\KV(C_NJ\WKZ:_\'\#USQ=X:_:O_:8E
ML/#_ (IT+Q5?6MO)OCCU/2UTJT5L8WNQCB1B 3@G)Y..M?H7^R%^SBO[-?PM
M&BW5U#?Z_J$_VW4[FWSY?F%0JQH3@E5 QD@9)8X&<5\&ZK^U=^USX)LVO_$%
MOKMA8PD-+/JWA&.WB ST9OLZ@#\17TE^QG^WM>?'3Q8/!/C/3;.P\0S0O+8W
MVG!DANMB[FC:-BQ5]H+9!P0#PN!G+%4\3*A*--14%J^7[_\ @B;2DI3OIM_7
MS/M&BBBOE3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:]H\7
MB#0]1TN=F2"^MI+:1H_O!74J2/?!K\_9/^"1:&1C'\5F5,G:K>'<D#L"?M0S
M^5?HC1730Q-7#-ND[7W^7KZ@_>7*S\]=/_X)&VD=RK7WQ1GN+?/S1V^A")R/
M9C<,!^5?1/P/_8=^%_P+U"+5M.T^XU[7X3F+5-;=9I(3ZQ(JJB'T8+N']ZOH
M&BMZF88JJN64]/N_(S]G'L%>!_M0?L>>%?VF;2VNKNYDT'Q/9Q^5;:S;1"0E
M,D^7*A(\Q 22.002<'D@^^45Q0G*G)3@[-&J=C\LM0_X)0_$R.^9++Q5X3N+
M//RRW$US%(1ZE! P!_X%7OO[.?\ P39\/?"SQ!9^)?&>KIXNUBS99K6QB@,=
ME!*#D.<DM*01D9"CU4\8^T**]*>:8J<>7F,73B]T%?"?[3'_  35_P"%D^--
M0\5^ -;L=$N]2E,]WI.IHZVWG,<O)')&K%=QY*[#R200.!]V45PT:U3#S]I3
M=F;=''H?G[\"?^"6\?A_Q!!JWQ.UNQUJ"V</'HNC^88)B#D>;*ZHQ7U0*,_W
ML9![_P %?\$[;+P9^T!!\2HO&SRVT&K2ZK%HL>DK&%+LS"/S?.(VJ6QP@X':
MOL.BNN68XF4N;FZ6,?9QY7%[,\J_:6^!,?[17PNN/![ZTV@&2ZANEO5MA<;2
MA)P4WKD')_B%?.-O_P $L_#"?"^ZT&Y\52W/B@7CW=IXBBT\0^6K(J^1)#YC
M;X\KN^\""3C&2#]QT5STL56HP<*<K)N_ST_R-7JTWT_K]3\N]+_X)/?$"76E
MCU+QAX:M=)W8:ZM?M$T^WU$31HN?;S/QK] /@5\#?#?[/O@.W\,>&XW:(.9K
MJ\GP9KN8@ R.1[   <  "O1**VKX^OB(\DY:&?LXWYCY@_:P_8DB_:@\4:-K
M@\8/X9GT^S-F8_[-%VLB[RX/^MC*G+'U[5ZY\ ?A##\!_A/H?@B#4WUE--$I
M-[)"(3*TDKR$[ 3M&7( R>G6O0Z*Y_K%7V*P]_<3O;SU_P V7)*4E)[K_ACY
MD_:B_85\+_M%:E_PD%KJ$GA?Q=Y:QR7\4(FANE48431Y!+ # <,#CJ&P /DJ
MX_X)1_%!;IE@\3^$9+;=\LDEQ=(Y'J5%N0#[;J_5"BNBAC\1AX\D):>822GN
M?&G[,7_!.VU^!_CS3?&NN^*VUW6=/#FVL[.U\FWC=T9"S,Q+28#''"8.#S7V
M7116%?$5<3)2JN[1,8*.P5YG^T5\$K?]H3X5ZEX,N-5DT7[5)%-'?1PB;RWC
M<,,H2NX'!&-PZ]:],HKGBW%J2W6OW&B;6Q^=G_#HG_JJ_P#Y;G_W76IX?_X)
M):-;WJMK?Q(OM0M,_-%I^E):2'Z.\LH'_?-??]%>G_:>+_G_  7^1E[.)YY\
M&?@)X*^ ?A]]*\'Z2MD)MK75Y,WF7-TP'!DD/)[X4849. ,UP'[6W[)4/[4U
MCX;B;Q._AF?19)V206(NEE$H3(*^8F"/+&#GN>*^@J*X?;5/:JMS>\NOX&D?
M<5HGD'[+O[/4/[-/PXF\*Q:X_B%IKZ2^DO&M1;C<RHNT)O?  0?Q'J:\-^/'
M_!-ZW^-7Q:UOQLOQ DT4:K)')+8G2!<;"L:H=LGGIU"9Y7C/>OM&BM8XNM&L
MZZE[STOIY?+HB8Q48\BV_K_,P[;PK#;>"8O#8GD:WCTX:=YV!O*B+R]V.F<<
MU\C?!'_@FQ;_  ;^+&A>-#\09-8329VGCL!HX@+DHR@-)Y[=-W9><=J^U:*5
M/%5J+E*$K.6_X_YL3A%P5-K1$%_:+?V-Q:LQ59HVC++U ((S^M?%GP;_ .":
M-M\)?BMH/C+_ (6%+JL6D77VJ.P_L<0LY (4-)Y[>O.%Y]J^VJ*FCB*N'YO9
M.U]_Z^94DIQY);&!X\\#Z-\2O"&J>&?$%HM]I&I0F">$G!P>0RGLP(!![$ U
M^<_C7_@D_P"+X=<F_P"$1\8:)>:.S$Q_VUYUO<1KGA3Y<<BL0/XOESZ#I7Z;
MT5>'Q57"MND[7&_>7*SX;^'7_!+OP[H/@?7;;Q)KXU7Q7J=HUM;ZA%:YMM,)
MQ\\<;,#(_&-S%>#P%/->J_LD?L=Q_LLW7B2X_P"$L;Q/+K*01_\ (/%HL*QE
MST\V3<3O]1TKZ/HK2ICL144E*6DM_P"NAG[.-DOF%%%%<!H<=\8/AS#\7/AE
MXB\'3WLFFQ:Q:FV-W'&':+D$-M)&>0.,CZU\[?LR_P#!/^']G7XG1^,6\<R>
M(9(K66VCM!I0M1^\ !8MYSYP.V!7UU1713Q%6C&4(.REN*45-)2Z:_U]P5\P
M?M8?L21?M0>*-&UP>,'\,SZ?9FS,?]FB[61=Y<'_ %L94Y8^O:OI^BLZ=25&
M:J0=FO\ ABKZ-=SSSX _"&'X#_"?0_!$&IOK*::)2;V2$0F5I)7D)V G:,N0
M!D].M>@31)<1/%*BR1NI5D89# \$$>E/HI5)RK3<YZM[D1BH*T3X(^-G_!+3
M3?$FMW>K_#KQ##X>6X<R'1=2B9[:-B<D1RIED7_9*MCUQ@5Y7I/_  2A^),U
MXBZGXL\*V=IGYI;22YGD'T1H4!_[Z%?J717HT\RQ-*/(I77F$HJ3NSP[]E;]
ME?2?V7O#>J65GK%QKVI:K)'+>7LT*PH=@8(J1@DJ!N;JS9)KRO\ :N_X)\6/
MQS\47'C#PMK,/AWQ+=*!>6]W$S6MVZC D)7YHVP "0&!P. <D_8M%<WUJM[;
MZQS>]W'&*A%Q6S/S;^%__!*/6E\00S_$+Q5IG]CPN&>S\/M+)+<#^Z9)(T\L
M>X5CCTZCUGPG_P $W=(\%_';3_'^D^,&M=)T_51J5KX?32_]4JMN6$3F8Y4=
M,[,X]^:^RZ*Z99EBI2YN:W0S=.+BXO9E+6M'L_$.CWVEZA MU87T#VUQ X^6
M2-U*LI]B"17YM_$#_@E#XI3Q!</X)\6Z-<:*[EHH]<::">)2>$)CCD#X_O?+
MGT%?IC17+A\35PLG*D[7-7[T>5GSS^QG^S'J7[,_@76=+UC6K;5]1U6[6ZD^
MPJXAA"H%"J6P6)Y).!V&.*\E^'?_  3'M/ /Q6T3Q@/B'-?6VEZDFHQZ?_8X
MC=]C[U0R^<1U R=GX"ON"BM/KU=595E*TI6OMTV,_9Q]FZ71_P!?J07UHM_8
MW%JY*I-&T99>H!!&?UKXL^#?_!-&V^$OQ6T'QE_PL*758M(NOM4=A_8XA9R
M0H:3SV]><+S[5]M45C1Q%7#\WLG;FW_KYER2G'DEL9_B+1X_$7A_4]*ED:**
M^M9;5Y%'*AT*DCW&:^/O@/\ \$WX/@G\6=$\:M\0)-:&E/))'8KI M]Y:-D&
MZ3SWX ;/"\X[5]HT44<15P_-[)VYM'^/^822G'EEL<W\1/AWH/Q5\':CX7\2
MV*ZAI%^FR6(G#*0<JZL.592 01T(K\^/'W_!)S7X=1E?P3XTTV[L&8E(=?CD
M@EC7L"\2.'/OM7Z5^E=%5A\55PK;I.UQOWE9GYC^$_\ @DWXPNKH?\)-XWT/
M3;8'DZ3#->.1Z?O%B ^O-?H3\)OAGIGP>^'.B>#='EGGT_2X3$DUR09)"6+,
MS8 &2S$\"NOHK3$8VOBH\E5Z=C-4XQ?-U/A[PE_P3&M/"WQ;TOQG_P +#FN;
M;3]7CU9-._L<([%)1*L9E\\CJ "=GX"ON&BBLJN(JUU&-1W4=B[+F<^K/A[2
M/^"8UII?Q<M?&9^(<TMK;ZPNK#3O['"N=LWFB/SO.(ZC&[9^%?;[HLB,C*&5
MA@J1D$>E.HI5<14K1C"H[J.P6]YSZL_.;XR?\$K]5U3Q;?:E\._$FDVNDWDS
M3+IFM>;$;3<<[$DC1]ZC)QE00,#GK7N'[$?[(&N?LR/XDO\ Q#KMCJ=_K$<,
M(MM,$AAB6,N<EW"EB=W]T8P>N:^J:*Z7F&(E1]BY76WG8F<5.7,PK@OCM\)X
M?CA\*=?\$SZC)I,>JI&OVV.(2F(I*D@.PD;AE ",C@]:[VBO/6C373]#2,G%
MW1\J_LJ_L*1?LR^/+_Q0?&C^)9[G3WT];<:8+145I(W+$^=)D_NP.W4U]544
M5O6Q%3$2YZKNS.,5&]NH5Y!^T=^S'X4_:5\-0:?KWFV&IV19K#5[0#SK<MC*
MD'AT.!E3Z<$'FO7Z*QC)PDI1=FC1-H_+G7O^"3_Q#M[]TT7Q?X9O[+/RS7YN
M+60_5%BD _[Z-=M\+/\ @E-/I^L6.H^./&EO-#;RK*^FZ);LPEVG.WSI,8''
M/[L]>HK]$**]7^UL7:W-\[(QE2C+1K0X?XU?"^'XR_"SQ!X+FOWTJ+5H!#]L
MCB$AB(=7!V$C(RHXR/K7AO[*G["L/[,OCS4/%#>-'\2SW.GOIZVXTP6BHK21
MN6)\V0D_NP.W4U]545P4\15HPE"#LI;FDHJ247LOZ_0*^+OCQ_P3>M_C5\6M
M;\;+\0)-%&JR1R2V)T@7&PK&J';)YZ=0F>5XSWK[1HJ:-:IAY^TI.SV_K[AO
M5<KV,_P]HZ>'?#^F:5%(TL=C:Q6JR.,%@B!03[G%?''[17_!-71/B=XDOO$W
M@G68_"NJ7KM-=:=<0&2SEE/)=2IW1$G)( 8$G@"OM>BJIXBK2J>UA*TA12C'
MD6Q^6FF?\$H?B5-J")J/BOPK:V);YYK66YFD ]0C0H"?;<*^U/V9/V0?"7[,
M]A//I\DFM^)KR,1W>MW2!&*<'RXD!(C3(SC)).,L<#'N]%=5;,<37CR2EIY$
M>SC>YSGQ"^'^B?%+P;JGA?Q%:"]TC4HC%-'G##NKJ>S*0&![$"OSI\8_\$G_
M !E#K<H\*^,-"O='9B8VUCSK>X1<\*1''(K$#OD9]!7Z<T5AA\55PK;I/<T?
MO*S/ASP'_P $N_#>B_#_ %ZQU_Q!_:7B[5+;R(-4CM,V^F?,K%HHBP+L<8+,
M1P< +R3ZU^R/^R''^RNOB9AXJ;Q/+K?V<,W]GBT6$1>9@ >8^2?,/.1T%?1-
M%:5,=B*BE&4M);_+\OD9^SC9+MJ%%%%<!H%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 R:%+B-XY462-QM9'&00>Q%<-<? /X8WEXUW
M/\./"4]VS;C/)H=JTA/KN,><UWE%5&4HN\78/(@L;&VTVUBM;.WBM+:(;8X8
M$"(@] HX J>BBI P?%7@'PQXZACA\2^'-)\0Q1G*1ZK8Q7*K] ZG%+X5\">&
MO UO)!X;\/:5X?@D.7BTJRBME8^X10#6[15<TK<M] WW"BBBI *BNK6&^MY(
M+B&.X@D&UXI5#*P]"#P14M% ' G]G_X7-=_:C\-O")N=V[SO["M=^?7=Y><U
MV]G8VVFVL=M:6\5K;QC"0PH$11Z #@5/15N<I:-B\PKE_%'PL\%^.+A9_$?A
M#0?$$ZC"RZIID%RP'H"ZDUU%%2FXNZ&<[X6^'/A/P/O_ .$;\,:-X?W_ 'O[
M+T^*VS]=BBNBHHH<G)W;%L%%%%(84444 %%%% !1110!Y=^U!H&M^*?V?/'N
ME>'$DEUBZTN5(881EY1P7C4=RR!E'UK\G/V1_C]8?LT_%>?Q#K6@3:Q;2V<E
MA*D)5;BV+.C%T#<$_)M*DKPQY[']M*\L^(7[+OPI^*E])>^)O ^EWU_*=TMY
M"K6UQ*>F7DA9&8_4FO4P6+CAU.%2-XRW[BJ152"B^CO^7^1\G_&#_@J%X,\2
M?#W7-&\+>%-<GU/4K.6S#:U'!#;Q"1"A8A)9"^ 3\N!GU%>+_P#!-OX-ZWXO
M^.5AXT%I-#X<\.+-))?,I$<MP\31I"I[M\^XXZ!><9&?O#1?V$?@1H-\EW;?
M#VTEE0Y"WMY=74?XI+*RG\17M^DZ/8:#IMOI^F65OIUA;KLAM;2)8HHU]%50
M !["NE8W#X>G..%@[R5KO^O-F4XSJ)0D]"Y1117A&P4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445B>*_''ASP'9
MQ7?B7Q!I?AVTFD\J.?5KV.UC=\9VAI& )P#P/2FDV[(#;HID,R7$22Q.LD3J
M&5T.0P/((/<4^D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%8?B+QSX;\'SV$.O>(-+T2;4)/)LX]1O8[=KE\@;8P
M[#>?F7@9/(]::3;L@-RBBBD 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5#$5(QV3?YG-0=Z4'Y+\@HHHKE-PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7V_[)=50>T(]:^BIV^KT<5+:G%I>J=HKY:OY&=9N-2:6\E%?>O>?W?BSAO\
M@GM8P^!?VE_C;X,@7R+>VDD6&'=G"07;QJ/?"R"L[XR!OVP/VZ=$\"VC?:_!
M_@[C4&7F,B-@]T3[L^R#ZBO//B3\8+G]F/\ ;*^-&L6$+/J&H6,UM8@8*K/<
M"WE61O93N;WQCO7UQ^P+^SY<_"'X9S>)/$,4G_"9>*RM[>&XR98(3EHXFSR&
M.XNW?+8/W:T<G35/'S>O)&WG)K]%^9-1<LJM*/VI/Y1TO]^R,W_@I-\5KGX<
M_ 6/0M+E-M>>)KG^SV:,X*VJJ6F ^HV)]'->(?LZ_M">.?@/\,-.\*>'_P!F
M?Q1J%P<SW.J*+E6OIFY,I469XQ@ ;CA0.:[/_@K!X3U+4/ _@;Q%;0O+IVE7
MMQ!=LH)$9F6/RV;T&8BN?5AZU[M\-/VSOA!XN\#Z9J4WC;1M!N?LT?VG3=2N
M5MIK>0*-R!7QN .0"N0>,5RT+1P-^3FYI/FWTMMM]_8TJ_%37D_OO_D?-/BS
MX3?'O]N+Q1X?;Q[X;MOAKX%TV5I%BERMQAB-_P"[9C(TA  !940?7.?5/^"B
MWQ(D^$_[.]EX7T-S9RZ_*NDKL.&2SC3,@'U 1#[.:]@^&G[5'P^^,7C^\\)^
M#=1N=>NK.R>]N+Z&U=+2-5D1-F]]I9B7!&T%2 >:^:_^"L'A/4M0\#^!O$5M
M"\NG:5>W$%VR@D1F98_+9O09B*Y]6'K41DZE>C0JPY(7O;_.^KNU8JG\<I7N
MTG\M+_+N<9^SK^T)XY^ _P ,-.\*>'_V9_%&H7!S/<ZHHN5:^F;DRE19GC&
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MBO?:W* 9[UL9!)'W4&?E0<#W))/!?M]?!+Q'\;_@G%9>%HS>:KI-^FI#3U8
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MPFT $G:S$#M79BY26)?+0NT]'KLMG;8QI2:@YWMO?]=?Z\CH?A%\.M._9O\
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M]GOP[^SCX$3P]H1>[N)G\^_U.=0);N;&-Q ^ZH'"J.@]223\%:]\/X?VKO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^?\
M^V59MX(_;<^"7C-LI9WDMI:R2'( ,5UA^?\ <G6OT KAOBA\$_!7QGATJ+QE
MHBZRNESFYLS]HF@:*0@9(:)U)!P."2.!Q7<#CBNN=93H4Z?6/-]S=T3)7JNI
MW27W7%K@/BQ\!_ OQQATR+QOH7]N1Z;(\EJANYX!&S !B?*==V=H^]FN_HKF
MC)PDI1=FBB.WMX[2WB@A01PQ*$1%Z*H& !^%<]X\^&OA7XH:/_9?BS0+#7[$
M$LD5]"'\MB,;D;JC8[J0:Z6BE=WOU!>[L?/UI^P-\!;*\6YC^'\+2*VX+-J5
MY(G7/*-,5(]L8KVOPQX3T3P5H\6E>'](LM$TR+E+33[=(8E)ZG:H R>Y[UK4
M5K.M5J*TY-^K)Y5>]@HHHK$H\W^+7[.GP[^.EQIT_CCPXNMS:<KI;2?:Y[=H
MU8@L,Q2)D$@=<UVWASP[IOA'0=/T71[./3]*L(5M[:UA'RQQJ,!1^'<\UI45
M?M)\BIW]U=.@/5W>YY5XH_9;^%WC3XBIX[UOPG!J/BE7BD^VRW,^UFB $9:(
M2>6V JCE3T&:]5HHH<Y2BHMZ+;R] ZWZE35M)L=>TVYT[4K.WU"PN4,4]K=1
M+)%*AZJRL""#Z&O#+_\ 8+^ VI7[WDOP^MTE=MQ6WO[N&//M&DP4#V Q7OU%
M.%2=)WIR:]- W5F<G\/_ (3^#?A38R6GA'PUIOA^*4*)396ZH\V,X\Q_O/C)
MQN)ZUT.K:38Z]IMSIVI6=OJ%A<H8I[6ZB62*5#U5E8$$'T-6Z*F4I3=Y.[$O
M=V/ ;_\ 8+^ VI7[WDOP^MTE=MQ6WO[N&//M&DP4#V Q7J7P_P#A/X-^%-C)
M:>$?#6F^'XI0HE-E;JCS8SCS'^\^,G&XGK7645K*O5E'EE-M>K#E5[V//?BI
M\ ? 7QLN-(G\:Z NN2:2SM9[[J>(1EBI;(C=0P.Q>&!'%>@JH50H& !@"EHK
M+FERJ%]%T]=Q[N[/-- _9O\ AQX6^)EW\0=)\,Q6/BZZ:5YM0BN9P&:08D/E
M;_+!;)SA>I)ZU'\3/V9/A=\8+XWWBWP9I^IZ@V ]]&7MKAP!@!I8F1V ' R3
MBO3Z*OVM2Z?,[K1:[+L@ZM]]_,\O^&?[,7PM^#]\+[PGX,T_3=07.V]D+W-P
MF1@[99F=UR/0BO4***4ZDZCO-MOS$DEL@HHHK,84444 %9_B#0;#Q5H.HZ-J
MMN+O3-0MY+6ZMV8J)(G4JRY!!&03R"#6A10--IW1\Z_\.]_@!_T(/_E9U#_Y
M(I1_P3X^  (/_" _^5C4/_C]?1-%=?UO$?\ /R7WLCE78X#XF? ?P-\8/#^F
M:'XMT0ZGI&FN'M;..\N+:.-@NP'$,B9PO SG&3CK76>&?#.E^#?#]AHFB6,.
MFZ381+!;6L PD:#H!_B>2<DUIT5SN<W'E;TW^?<=EIY:'F_Q+_9U^'?Q@\0:
M5KGBWPXFJZMI:A;2[6ZGMWC ;> ?*D7< W(W9QD^IKT62%)H6BD19(V4JR.,
MA@>"#GK3Z*3E)Q4&]%T]=Q]>;J>%M^P[\#&\0?VS_P *\L/MGF^;Y8N+@6^[
M.?\ CW\SRL?[.S'M7N21K'&J*JJBC:%48 'IBG454ZDZB2G)M+N*RO?J>(^+
MOV*?@EXXU:74M5\ 6/VR5BTCV,\]DKL3DL5@D1223R<9-=/\-_V<_AI\([E;
MKPEX-TS2;Y056^$9FN5!&"!-(6< CJ U>CT57MZO+R<SMVOH#2D[LY3XF?"W
MPQ\8?"TGASQ=IG]K:-)*DS6WVB6#+H<J=T;*W!]ZU/"/A+2? ?AG3?#^@V2Z
M?H^G0K;VMJC,PC0=!EB2?J22>]:]%9\TN7DOIO;S[CW=V>>_$[X ^ ?C+J6B
MW_C+0%UJZT=F:Q9[J>(1%BK'*QNH8$HO# ]*[;5M'L-?TNYTW4[&WU'3KE#%
M/:742RQ2H>JLC @CV-7**.:3BH-Z+9>NX=>;J>!WG[!_P(OM3:_D^'MJLY;=
MMAO;J*+/_7)90F/;;BO9/"O@_0_ NBPZ1X=TBRT32X<E+2P@6&,$]3M4#D]S
MU-;%%:2K5)KEE)M>HK*]['GOB7X > ?&'Q(TGQ]K'A];[Q9I0C%G?O=3@1>6
MS,G[H.(R06)R5//T%>A445FY2DE%O1#ZWZGD7Q#_ &2OA%\5-8DU7Q+X'L+S
M4I6W2W=M)+:22M_>=H70N?=LFMCX8_L\_#CX-.TO@[PCI^C73*4-X TUR5/5
M?.D+/CVW8KT6BM/;5%#V?,^7M?032D[L;)&LL;(PRK @\XX-<!\)_@'X"^!Z
MZH/!.@+HAU1T>\;[3-.TI3=MYE=B -S<# Y->@T5G&4HII.R>_GZC>JLS"\<
M>"-%^)'A74?#?B*R_M'1=001W-KYKQ>8H(;&Y&5AR!T(JO\ #OX;^'/A/X3M
M?#7A33%TG1+5G:*U6627!9BS$L[,Q))/4FNEHH4I*+BGHPWM?H%<Q\1OAKX<
M^+7A.Y\->*]._M71+ED>6U\^6'<48,OS1LK<$ ]>U=/123:::Z#O;8P/ ?@/
M0?AEX4L/#7AG3UTK1+%66WM4=W";F+-\SDL268G))/-;]%%.4G)N4G=LE)15
MD4==T2R\2Z)J&D:E#]HT^_MY+6YAWLF^-U*NNY2",@D9!!KF?A7\&_!WP2T&
M?1?!6BKHFFSSFZEB6>68O(5"EB\K,W10,9QQ7:44*4HIQ3T>_F-ZVOT.4^)G
MPM\+_&+PO)X<\7Z9_:^C22I.UM]HE@RZ'*G=&RMQ]:U/"/A+2? ?AG3?#^@V
M2Z?H^G0K;VMJC,PC0=!EB2?J22>]:]%'-+EY+Z;V\^X;N[///BK^S[\//C:M
MM_PFOA>TUN6V&V&X9I(9T7.=HEB97VYYVYQ[5'X#_9T^&WPQT>_TWPQX2L=(
M@OX'M;J6(NUQ-$P(9&G9C*1S_>X[5Z/15>TGR>SYGR]NGW!NT^J.-^%GP?\
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M?&/4-&O?&6@KKLVCNSV2S74Z11DE2<QHX1\[5^^#P,=*[U%6-555"JHP%48
M'I6T*T:="5./Q2W?DMDO7=_=J*:YG%=%KZO_ "73SU'4445QE!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^0O@Y\5OVG?C=\-](\:Z%;_  EM-*U3SO)AU!-42=?+F>%MP1F4?-&Q&&/!
M'TKZ]KYU_P"">_\ R:#X!_[B'_IPN:[*34*,I\J;NEKZ2_R)>X?\99_]48_\
MJU'_ !EG_P!48_\ *M7T514_6/[D?N"Q\Z_\99_]48_\JU'_ !EG_P!48_\
M*M7T511]8_N1^X+'SK_QEG_U1C_RK4?\99_]48_\JU?15%'UC^Y'[@L?.O\
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M "K4?\99_P#5&/\ RK5]%44?6/[D?N"Q\Z_\99_]48_\JU'_ !EG_P!48_\
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M%'UC^Y'[@L?.O_&6?_5&/_*M1_QEG_U1C_RK5]%44?6/[D?N"Q\Z_P#&6?\
MU1C_ ,JU'_&6?_5&/_*M7T511]8_N1^X+'SK_P 99_\ 5&/_ "K4?\99_P#5
M&/\ RK5]%44?6/[D?N"Q\Z_\99_]48_\JU'_ !EG_P!48_\ *M7T511]8_N1
M^X+'SK_QEG_U1C_RK4?\99_]48_\JU?15%'UC^Y'[@L?.O\ QEG_ -48_P#*
MM1_QEG_U1C_RK5]%44?6/[D?N"Q\Z_\ &6?_ %1C_P JU<9\'/BM^T[\;OAO
MI'C70K?X2VFE:IYWDPZ@FJ).OES/"VX(S*/FC8C#'@CZ5]>U\Z_\$]_^30?
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M_P",L_\ JC'_ )5J/^,L_P#JC'_E6KZ*HH^L?W(_<%CYU_XRS_ZHQ_Y5J/\
MC+/_ *HQ_P"5:OHJBCZQ_<C]P6/G7_C+/_JC'_E6H_XRS_ZHQ_Y5J^BJ*/K'
M]R/W!8^=?^,L_P#JC'_E6H_XRS_ZHQ_Y5J^BJ*/K']R/W!8^=?\ C+/_ *HQ
M_P"5:C_C+/\ ZHQ_Y5J^BJ*/K']R/W!8^=?^,L_^J,?^5:C_ (RS_P"J,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SK_P3W_Y-!\
M_P#<0_\ 3A<U]%5\Z_\ !/?_ )-!\ _]Q#_TX7-=4?\ =Y_XH_E(GJ?15%%%
M<I04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'G7[1__ ";S\4?^Q6U3_P!)):/V</\ DWGX
M7?\ 8K:7_P"DD5'[1_\ R;S\4?\ L5M4_P#226C]G#_DWGX7?]BMI?\ Z215
MU?\ ,/\ ]O?H3U/1:***Y2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=?
M^">__)H/@'_N(?\ IPN:^BJ^=?\ @GO_ ,F@^ ?^XA_Z<+FNJ/\ N\_\4?RD
M3U/HJBBBN4H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#YU^-W_ "=]^S5_W,O_ *;XZ^BJ^=?C=_R=
M]^S5_P!S+_Z;XZ^BJZJWP4O\/_MTB5NPHHHKE*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#SWQI\(X_&/Q:^''CEM3:UD\&_VELLA"&%U]KMUA.7W#9MVYZ'.<<5Z
M%1152DY))]/^'_4 HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 1ONGZ5^!6HZ?J?Q$^+<^GF[\[5M:UHVHNKV1B#++
M-L#.V"<9(S@'CM7[Z/\ =;Z5^$GP[_Y..\-?]C5;?^E:U]%D2OB)W[+\R*S<
M</)KO^C/;?%G_!-_XS_#G0[KQ!87FBZQ+8H9FM]!OI_M>U>24#Q1[B ,X!R<
M< FM3]CG]N7QAX,\>:1X5\;ZW=>(O">ISI:"?4I3+<6$CD*DBRMEBF2 58D
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M42>TC2]L9FBF17N$5MKK@KD$C(.>:,3@9X>I"%[J;23]6E^I%.7/*46K-?\
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M-["&ZA9$# 'W&<'W%+%8-4(1K4Y<T)=3-2:G[.:LS<HHHKS#4**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"%)/VBM69T5FC\.7#(S#)4^?;C(]#@D?B:^Z/VYO^34OB#_UZ1?^CXZ^&O\
M@E;_ ,G$:U_V+=Q_Z46U++/]TQ/S_P#20Q/\.'^+]8GV7_P4.4-^R;XOR <2
MV9&1T/VJ*ODG_@E!#&_QD\72-&K2)H7R,0"5S<19P>U?6_\ P4-_Y--\8?\
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M22Z:?F_U/3OVP_V\H_V?]<'A'PKIEKK?BP1+-=2WS-]FL@PRBLJD,[E><;E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 -?[K?2OP7\+Z-9^(_CII.DZC#]HT^^\1Q6MQ#N9=\;W(5
MERI!&02,@@U^]#?=;Z5^!5GXB/@SXN0Z\;;[6=*UP7OV;?Y?F>5/OV;L';G;
MC.#C/2OHLB_WB=^R_,FM=X>2CO?]&?K;_P .]_@!_P!"#_Y6=0_^2*]>^&7P
MK\*_!OPNOAWP?I*Z-HZS//\ 9UFDF)D;&YB\C,Q)P.I["OAC_A[M_P!4H_\
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M?^2D>.O^P3#_ .CJ\R_X*1R3-^U5K@E+%%L;,1[NFWR0>/;);]:]-_X),_\
M)2/'7_8)A_\ 1U=/_P %1/@%JFI7VE_%'1K22\L[>U%AK"PJ6,"JQ,4Q _A^
M<J3VPOK6U:I&GFD'+9JWW_U;YD8?6-5+?_\ 9/KW]E?[/_PS;\-/LW^J_L"S
MSC'WO*7?_P"/9KYX_P""KGD?\*5\*[]OVC^WU\OUQ]GEW?TKQ?\ 9)_X*&:7
M\%_AS;^"_&VBZIJ5CIK/_9U]I(CDE$;,6\ITD=!@$G#!NA QQD^8?M:_M2:C
M^UMXRT+3- T2\M-%L7:+3=-_UMU=3R$ NRID;C@*JKG'/)S7/]1KO,.>WN\W
M-?RO?_@%8>:ITO>Z*WX6_P"#_P $^D?^"24=P/#OQ'<_\>IN[)5X_C"2[OT*
MU\?_ +8G_)T7Q'_["\G\A7ZC?L4_ >Y^ 7P1LM*U6-8_$.IS-J6I(#GRI'50
ML6?]A%4''&[=BORY_;$_Y.B^(_\ V%Y/Y"NK"U8ULWG*&W+;[N5$TXN.&=^K
MO]_,?MAX;_Y%W2_^O6+_ - %?BQ^VQ_R=1\1?^P@/_125^T_AO\ Y%W2_P#K
MUB_] %?BQ^VQ_P G4?$7_L(#_P!%)7GY7_O\O27_ *5$N/\ NR_[=_)G[/\
M@MB_@[0F8EF-A 23U/[M:V:Q?!/_ ")F@?\ 8/M__1:UM5XV(_C3]7^8J/\
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M&@@U$:G,UW>:!+(L,J3,<N\+,0C*Q)8JQ!!)QG( [;_@E!_R1GQ;_P!AX_\
MI/%6+X?_ ."IMGH?B+6M'\>>#+A?L5[/;QWGA]U8LJ2,JAH9F7!  RPDY/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDO83;B19!(!@0[RNX=-^?>OJNBMJ5:I0;E3E9BDN:+B]@HHHK$9YI\?/V?\
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M!4U%.MBJV(M[65R%",7=(****Y2PHHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\/HTDYO88U@G52@)B99&8_?4_,J\&O6*N4)02<ENKKT8NKCU04445 PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO
MGS6OVM8G_:2T_P"$'A3PPWBF^&#J^J+?>1#IJCYI,KY;[RBXR,K\S!<YSCV'
M4/B-X3TGQ-;>'+[Q/HUEXANMOD:3<:A#'=R[L[=D1;>V<'&!S@ULZ-2*C)KX
MM5Z=Q-I-Q?3<Z*BBBL1A17-Z-\2O"/B+Q!=Z%I/BK1=3UNTW?:--L]1AFN8=
MI"MOB5BRX) .1P3724VFMT'D%%%%( HHHH **I:MK6G:!9F[U._M=.M0P4SW
M<RQ)D]!N8@9JU#-'<0I+$ZRQ2*&1T(*L",@@CJ* 'T444 %%%>-^)_VJ?"/A
M?X[Z/\)9K+6+SQ/J0C*36D$36L.\,P\QC(&&%7<<*>"*N%.527+!78GHG)[(
M]DHHHJ!A17D?[0W[3GA/]FG2]'O?%%MJE[_:LSPV\&DPQR2?( 68AY$&T;E'
M7N.*]3TV^74M.M;Q(Y(5N(EE$<P =0P!PP!.",\\UI[.7(JEM'I<'HTGU+-%
M%%9@%%%% !1110 4444 %%%% !1110 45YO\;/VA/!'[/^B0:CXQU0VK719;
M2RMXS+<7)49(1!V&1EF(49&3R*\^^!?[='P\_: \:KX5T"RU^PU9X9)XQJEG
M&D;J@RV&CE?''][%;PH5:D'4A%M+J*34;<W4^B:***P&%%%% !1110 4444
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M33R6Z1ZI$D<I*'#-A'<8SQU[&O0*J<)4Y.$U9HB,E)704445!04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%<S\3/'%K\-?A[XB\57O-OI%C->%?[Y1254>['
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG ^G_P!EGX!>-/@#-XFTC7/'4OB_PI(T)T2&X+^;; !O,RK$A <J J,5."<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M33P6*8(# @8^53M0=OF8_,0:_3^2QT[QYX3BAUK1X+O3]2MHY+C2]3@29,,
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M_ /2*\,_:'_9 \'_ +2^KZ1J'BC5=?L9-+@>W@CTFYACC(9@Q+"2)^>!R,<
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MUC$NDP7LI7^*691*Y/K\SFLO]L+X S_M%?!VY\/Z=/#;ZY9W":AISW!(C:5
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M*YL#/EJSKR>L8R:_Q/1?J5425!QCU:7R;U_(^Z9)$AB9W(1$!8D\  5^>/\
MP3RC;XD?M*?%[XC2@NK&58G;H#=7+2 #Z+#C\:^VOC??:II_P=\:3Z'8W6I:
MR-(N5L[2RB:6:29HV5 B*"6.2.!SQ7S]_P $U_A+K?PR^#NMW/B/1;[0M8U;
M5FD^RZC;/;SB&.-50LC@,!N,A&1WJ<*U3HUZC>MDE\WK^"'5^"$%UE_Z2KGC
M/[:G_%S_ -N+X8>!+U@^D0_88I(6.5/G7!:7\614'X"OT<55C4*H"JHP !@
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MK-2E[1ZMO7O]Q]4_"?X/^%/@EX3B\.^$=+73=/5C)(Q8O+/(0 9)'/+,<#Z
M    "NSJAH%O?VNA:=!JETM[J<=M&EU<H@19I@H#N%   +9. !UJ_7S=24I3
M;D[ON7"W*K*P4445F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\M?\%(_!K^*OV8M3O(8C)-HE];ZC\O4+N,3GZ!
M92?PKZEJIJNDV6NZ;<Z?J5G;ZA87*&*>UNHEEBE0\%61@0P/H15PDZ<XS71I
M_<[EQERO7^KZ'F/[)_B*/Q3^S;\.;^.028T:WMG8?WXE\IA_WTAKI?$'P4^'
MGBW5IM4USP'X9UK4Y\>;>ZAH]O/-)@ #<[H6.  .3T%='X?\.:3X3TF#2M#T
MNST;2X,^39:?;I!#'DECM1 %&22>!U)K1K6M5YZTZL-+MO[V84XN$%!]#SK_
M (9P^$O_ $2[P7_X3]I_\;K8\+?"/P+X'U)M0\-^"_#OA^_:,Q&ZTO2H+:4H
M2"5WH@."0.,]A76T5'M:CT<G]Y=D%)2T5D,Y_P +?#WPKX&DNY/#?AG1_#[W
MA#7+:7816QG(S@N44;B,GKZFN@HHIN3EJV 50US0=,\3Z5<:7K&G6FK:;<#;
M-9WT"S0R@$'#(P((R >1VJ_12 Q?"O@GP]X%T]['PUH.F>'K*20RO;:59QVT
M;.0 6*QJ 3@#GVIGBSP'X:\>VL-KXF\.Z3XBMH7\R*'5K&*Z2-L8W*LBD X[
MBMVBJYI-\S>H+38JZ9I=GHNGV]AI]I!86-N@CAMK6-8XHE'1550  /05:HHI
M-MN[ Y;Q3\*O!7CBZ6Y\2>#] \07*C:LVJ:9!<N!Z NI-7O#/@?PYX)MV@\/
M>']+T&%OO1Z991VRGZA%%;=%/FE;EOH&^X5R_BKX6^#/'5PD_B3PCH/B"=!M
M675=,AN64>@+J2*ZBBDFXNZ PO"_@/PUX)A:+P[X=TG0(F^]'I=C%;*?J$45
M=U[P]I7BK2;C2M;TRSUC3+@ 365_ D\,H!! 9'!4X(!Y'4"M"BAR;=V]06FQ
MGZ#X?TOPKI-OI>BZ;9Z1IEN"(;*P@2"&,$DD*B@*.23P.]9OBCX<^$_'%S:7
M'B/POHNOW%G_ ,>TNJ:?#<O#D@G874E>0.GI7144^:7-S7U%;2Q3U31[#7-/
MEL=2LK?4+*4;9+:ZB66-QZ%6!!KF_#WP=\ ^$=2&H:%X'\-Z+J Z76GZ3;P2
MC_@:(#^M=A10I2CLQ^1C^,/%NE^ _"VJ>(=:NEL]*TVW>YN)F_A11GCU)Z =
MR0*^&_V.?!FJ?M'?'GQ+^T'XKMFCTZ&Y>#0;6;) <#8I7L5BCPN>[L3U4U]U
M^(/#ND^+-)GTO7-+L]9TR?'FV6H6Z3PR8((W(X*G! /(ZBGZ+H>F^&]+M],T
MC3[72M-MUV0V=E"L,,2YSA44  9/85TT*RH1FTO>:LGV77YO8F:YHJ'2^OGV
M7^9>HHHKD*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ ILD:RQLC@,K#!![@TZBDU=68'P7_ ,$]M/E^
M&?QU^-OPZN5>-[2X2:!&S@QQ32(&_%98C]*^]***ZL17>(DIR6MDGYV5KDV]
MZ4N[OZ7"BBBN8H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OSY^.TU]^VM^U-I?PMT5YE\!^#IFEUN^C!"&4'$QSTW<>2GN7/(K
M]!J*Z</6]A4]K:[5[>3[^=NP2NX.*TOU\NI5TO2[71-,M-.L($M;*TB2""",
M86.-0%50/0  5:HHKG;;=V)))604444AA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5\4^(/ACXF\%_\%'=$\::9X<U2_P##
M&OV>V^U*TLY)+:V<V[PL)9%!5/FCC;YB/O5]K45O0K.A-S2O=-/T:%)<T'!]
M?T=[A1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /-_CY\2/$GPK\!_VYX5\%7WCW5!=1PG2=/#
MF3RVR6D^1'; P!PIY(KXYM_A?\6OVU_C?X<\3_$?P;<> / /A]@4TV^1XY9%
M#!VC"2!79I"%#/M50J\<CG]#J*[,/B/JWO1BN;H^VEO0F:YX\FR>C\Q  H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC!4'_@)'%%6E1EAO;TDTU+EU=[Z7N.[A4BI:IJ_W.Q^;?[7?[6'A/]HWXB>
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M_P!Z.&-F/_C[1US2PZOAZ2WFHM_]O/5?<=-.5J\_[GYI7^XZ?_@FGX0'AO\
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M+AX[>*-Q_$J &NJ4Z-/!TXN#]YM[]5HGMU%5O*LXI[)6_P"WM?P)Z**^6_\
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MD?8WQ<^-W@SX&^'TUCQEK4>E6\K%+>(*TDUPX&2L<:@LW;)Q@9&2*\$\-_\
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MI7IT9/T2^?\ 3/T/=T@C9W98XT&2S' 4#O["OF/XC?\ !1CX.?#W6)=-CO\
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M!@ 8 I:**\$W/SI_;HND\;?MG?!_P;=X73H6L?,W=#]HO,/^:QJ*_16OF_\
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M[:2<_1 >]&!_=.>+?V%I_B>WW*[?DRJJM2]FOMZ?+K_P#[8I:**\LT"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBL+Q%X\\,^$65==\1:3HK,,J-1OHK<GZ;V%5&,IOEBKLF4
ME%<TG9&[16/X=\9:!XOBDET'7--UN*/AWTZ[CN OU*$XK8HE&4'RR5F$91FN
M:+N@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBN5U?XK>"?#]\UGJGC'0--O%.&M[S5((I
M?0JS U<*<ZCM!7?D1.I&FN:;LO,ZJBJNFZI9:U9QWFGW<%]:2#*7%M*LD;#V
M920:M5+33LRDTU=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7GGQW^+T7P1^'MSXHDTQ]8,<T<"6BS"'<SG&2^UL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[/\ :T^/FM_ 7PQHE]H-AI][=ZA=M W]HJ[HBJF[A493D\=_PKY9_P""=_\
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M-CJSM<KJ%Z]_J4C9^>-<RR GMNQM_P"!"OUG@@CM88X88UBAC4(D:#"JH&
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ML9VAF\J-"2 RD$ LR=/2MO\ 8KUO7=1^!,FO>*-;U#6)+B^N9X[G4KEYW2!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?"URJ#:9%TR34F_[_B.0GZ[J^+=2OM"TCX[K>^"9V?08-;BGTR7:Z$1B564
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M.4:E2IOSW]U?\#YGSE;,J^89=7JPE3ITM5R6]Y]?O?=+S/:O^"?#27?P)U:
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M-?$W[&W[17P]^%/PGNM&\4^(/[+U)]5FN5@^Q7$V8VCB ;='&PZJW&<\4_\
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MFK\HC\2/U^/Q(_-?]AW_ ).2\-?]<;S_ -)I*_46OR<_96\=:'\-_C=H>O\
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M8_"_A/6M8E8+'86<UR2?]A"W]*_+_P#9O_:.E_9YOM>GC\/Q:\NJPQ1E6N3
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M91IQLVW;HE^A\YD^>83"XO%8FO=RJ2NDE?2[=OQ7W'J__!0KXL6EGX9T_P
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M@*[FO@,RK4Z^,JU:/PN3M_7GN??951JX? T:-?XE%7_R^6Q\0?\ !23Q,?\
MBB_#ZGC]_?R#_OE$_P#9Z]8_8/\ #/\ 8/[/MA=L,2:O>W%Z?7 81#](@?QK
MY4_;TUR;5?C]=6KB18M/L+>WCW@@'*F0E?;+D9]J3P7^W%X]\$>#]*\,:/H_
MAT6>GVRVL$C6D[3$*/O']]M+'DGY<9)XK]!CEF(Q604,/ADKR?,[NVCN_P!5
M]Q^?5LTPV%XBK8C$M\L5RJROK9)_^W?>?>?QT^*EC\'_ (:ZMK]U*BW2Q-%8
MP,?FFN&!"*!WYY/H 37Y[?L>^ [KXC_'S2+N56EM-(E.KWDQ'&Y#F/)]3(5X
M] WI5YO 'QP_:K\26]]J]G?R6PXCO-3B-G8VR$\F-< 'MG8&8X&<]:^[_@+\
M"M&^ _@_^RM/;[9J-P1+J&I.FU[B0#C _A1<D*N>,D\DDUP<U#AW U:2J*>(
MJ:::\J_X%V_-]+*YWR5?B3&TJGLW##TG?WM.9^GR2\E?6[L?'O\ P45\3#4?
MBEH6BH25TW3?,;TWRN2?_'47\Z^PO@!X1BT'X ^$-%FC*K)I,;SIT.Z93(X_
M.0U^?_Q^^U_%+]JO6M.@62:2YU:+2X5"DD*NV+./3@G]:^U?VLOBAXD^"?PU
MT?4O","ATU"&":22W\V*.!48[7'8,55<Y!YX(.*684)2R[ 9=3?O3U^;_P#V
MF:8&O%9MF&93O:DN7_P'33_P!?>?'/Q6_9M^(?[._B67Q%H/VRXT:SE::TUW
M2V/F6Z<_ZT+\R8'!)^4YZ\XKZ"_9'_:\U?XF^(H_!?C%(9]7DA>2RU2!!&9R
M@+,DB#Y0VT,0R@#Y<8SR> UC_@HUJVJ>%;K3T\$V4.IW%NT+7C7S/""RD%O)
M,><<]"_YU#^P3\$M:NO'$?Q U"SELM$L8)$L9)E*_:Y9%*$H#U159LMTS@#.
M#CUL73K5<MJRSJG%3@O<E=7;Z;>=O7MH>)AZM"EF=%9%4DXS?OQL^5*ZONNU
M_2V^IS/_  4 \4SZS\<%TEG)MM'L(8DC[!Y!YC'\0R_E75^#O!O[6'AWPGI^
M@:'#_9.A0Q;;>..32U*(Q+9W9,F26)))SD^M8G[?GPUU?2/BH?%XM9)=$U:W
MA3[4BDI%,BA"C'^$D*I&>N3CH:WO"?\ P4:U31?#5CI^J^#(=6U"VA6)KZ+4
MC;B7:  QC\I\$XYPV,] .E51C7JY1AHX&C"K9>\I6=GUM=I7O<,3+#T<ZQ,L
M?6G2O;E<;JZTTT3=K)?<='\,/V%->U/QC'XH^*>O1:G+YRW,MC!,]Q+=.#G$
MTK 8' R%W9'&17*_\%&_%4MUXZ\,^'4D(MK*P:[:,'C?(Y4''LL?ZFO=/V7O
MVCO%7[0'B#7I+WP]9:1X<T^!1'-!YCR-<,W"&0G:?E#$@*"./6O$/^"BO@*_
MM_&6A^+X[>233+BS%A-.HRL<J.S*#Z;E<X_W37FX*MBI9Y2IYBTI13LE:RO'
M;3K;]#U<70PD<BQ%7+4VIVO)WO*TE=ZZVW^5_,^FOV2O"-OX/_9_\)10QJLM
M_:C4IW'5WF^<$_12B_117Q9^W=XVB\6_'.>QM9A-;Z):1V!V]!+DO(/J"X4^
MZUO>!?VS/&__  K?1/AUX6\+QW/B6*W73;34H7:5RBC:A6 +PZJ!\Q8CC)%>
M3^&/AGJ=Y^T+I/@[5BU[J3:Q#%J3 F0[MZM<$M_%CY\MWQFO3R[+:F%S.OCL
M:TG[S2O=M7UEY*VGS\CR,QS2GB,GHX'!)N_)&3LTD[7Y?-MJ^E]O,_230?A9
M:W?[/^G^ KPM;PS:%'I\[H/F1S$ S >NXDU^?'B[X4_%3]E/Q/\ VW:-=V,$
M3F.'7M,.^VE0D860<@ G'R2#!([XS7UY^U]\?/%WP,OO!]QX=M(9=/N'G-[]
MJMR\,NT*$B+#!4\LPP0>.X!%>!?%3]O:_P#B1\/M5\,0>#;;2VU* VT]W)?&
MX 0_>V)Y:X/H23BO*R.&9_[Q3A&=*LWS)M=VF]?^#==#V<\EE45'"5ZDJ=6B
MERM)]DUM\NJL^NY] ?LC_M177QPBOM"\06T,'B33H!<?:+9=L=W#D*7V_P +
M E<@<'=D =*^/?VH=4U'XC?M+>(;*V5KJY%^FCV4&0N2A$:H"3@9<GK_ 'J^
MBOV ?@GK7A4:MXXURSETX:A;"ST^WG4K))$6#O*5/(4E4"^HR>F"?!?VJ/!?
MB#X4?M :EXA6"2&WO=1&KZ9?["8V<L),9Z;E?.5] #T->AE\,'0SZM#"V7NZ
M=N;2Z7]=SR\?4QV(X=IU,4F_?5WUY;.S?SMKUT9ZO9^$_P!KN;2;;0UE_LC3
M(85MHO(GTR#RHU 50&A^<8 '3FNU_9__ &(;CP3XPM?&'CK5X-7UBUF^TV]E
M:,TD8FZB661P"[ G. /O ')Z5QEK_P %*KY--C2X\ V\M^$ >>/562)F[D1F
M$D#VW'ZU[[^RW\:/$_QR\/ZUKNNZ+9Z1IL=TL&G?95DS* I,A+,QW8)49  S
MD=J\S,)9QA<-4G.C"C%Z-QLF[Z=VST\OCDV+Q%*G&M.M):I3<FHV5^R73S/;
M:Q/&GB[3_ ?A35/$&JR^38:? T\K=S@<*/<G 'N16W7PW_P4*^+TTEUIOPZT
M]F6(!+_42!_K&/\ JH_<#EC[[?2OC\LP,LQQ<,/'9[OLEO\ \#S/MLRQT,NP
ML\5/7E6B[OHOO_#4^5O%7Q$D\>?$ZY\6^)+5M3CNKU;BXL5F\K?"&&(%?!VC
M8 N<''6OI?Q%_P %"K?Q!X3U+0/^%<+;6MY9267RZR"(U9"G"_9QT!Z>U>I?
MLE_LP:#H?PO@U7QGX9TW5];UDBZ\G5K&.<VD./W: .IVD@[FZ'Y@#]VO;/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8[$5<3]<G/\ >73OINMO+H<E' 8;#X;ZG3A:G9JVKT=[[ZZW9X'^S;^RW/\
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M]C29$L_[-$&?,C9,E_-;H&/:N[_:2_9U3]H72=&LSK[: ^FS22K(+3[0'WJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8G&UD< JP/8@]:?10!R$/P?\!VU\+V'P3X<BO VX7":3;B0-Z[@F<UUP 4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRL P(*D<@=*VZJ<)4Y.$U9K=,F$XU(J<'=/9K9A1114%A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45Y_\ &CXU:'\"_#=MK>O6NH7=
MI<7(M4338DD<.59LG>Z@#"GO72>"?%UGX]\(Z3XBT^.>*QU*W6YA2Y0+(%89
M 8 D _0FNAX>JJ*KN/N-VOY]C#ZQ2]M[#F]^U[>6US<HHHKG-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHKS_XT?&K0_@7X;MM;UZUU"[M+BY%JB:;$DCARK-D
M[W4 84]ZUI4IUIJG35Y/9&=2I"C!U*CM%:M^1Z!16'X)\76?CWPCI/B+3XYX
MK'4K=;F%+E L@5AD!@"0#]":W*F<)4Y.$U9K1CA.-2*G!W3U04445!84444
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M:]_KKQ&$KX1I5X.+>JN<>'QF'Q?,\/-2Y79V"BBBN0[ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP/;Z:_9%\!_%/X5^/=<\->,3?2>&ET[SK.0SFXL_.$J >4Y^X2I?*?*3C)'
MKIQN1TL'3G?$Q=2*NX[?<[Z_<<N"SZKC*D''"R5*3LI_AJK:*_F?6%%?GM^V
M%\</%WBCXMW/P]T&_N=,TJTFBLOL]M-Y)O)W"Y,C C*Y8  G'&36/=_L9_&G
MX9VX\0Z%?6UQJ$(\PQ^']0E6[7N?O(FX^RDD^AJJ.00]A3K8K$1INHKQ3ZKS
M=U;=!7S^HL34P^$PTJOLW:371]DK.^S[;'Z0T5Y%\2/$/B#2_P!EW4M9FN+G
M3O$T?AQ)YIE!AFAN3"I<X&-C!B>F,&OAOX4_'/XQ^)K?4/!'AS6-7UW6M<DC
M$=[=WDD\UG&H;S/+=R?*!W+E\C&WCDYKDP.1U<=3JU(32Y'9WV\W?LEJ=6-S
MVC@9T8U(2?M%=66NVBMW;T]3]0:*_*CXN?!CXC_LZZMIFO:MJW^EWTC&'6-)
MOI6<3 9*L[!7#8Y]#SR:]-T[XF?&;]KS3=/\)^'G72;2PM576=465K>*XDY
M:5U&0& '[M <G<<8'R^C/AM>SCB*.(C*D]Y;)?B[]N]['G0XFM5EAL1AY1J?
M9CNY7^2MW[63UNK'Z%45^2^J6_Q!_9/^)WV4:@VFZO;[)]UI,SVMY$>FX'&]
M#@C# $$'H17ZC>#_ !E:^*O .D>*>+:TOM/COV#'(B5HP[ G_9Y'X5YF:9.\
MNITZ].HJE.>S6G^9Z659S_:-6IAJE)TZD-T]?T7Y==#HJ*_-#XC?&7X@_M4_
M$X^&/"=Q=0:-/*T5EI=M,88VB7.9KAN,\#<=W Z 9ZYGQ _9P^*7[-FFP^+%
MU6&&".14DOO#]]*'@9CA0^50X)XXR/7K7IT^&TE"&)Q$:=2>T;7>NU]5Z>IY
MM7B5N526$P\JE.%[R3LM-[:.ZZ]--3]0J*\*_9#^.EY\;?AW.^LM&_B+2)A;
M7DD:A1.K+F.7:. 6PP('&4)& <#Y'^('[17COX?_ +1WB:Y@\0ZK?Z?IVKW4
M4.C37TOV-E!9$0Q9V[1P< 9XZ@\UYV'R+$XC%U<'=*<%?UVM;UN>CB,^PU#!
M4L=9N$VEZ;WOZ6>Q^EM%?FWXX_9U^./Q*\,W7Q"\47"W<PB:\&E75TPNHX@-
MW[N$+LC 7G9N#>V:ZS]@WXZZZWC<> =8U&?4M*O;>1[!;J0NUM+&NXJA/(0H
M&^7H"!C&3GKJ</6PM2O0KQG*G\273OK?7[EL<4.(_P#:J="OAY0A4=HR?7Y=
M-UU>Z/IW]I[XO:M\$_ABWB+1;2SO+[[9%;+'?J[1 -N))"LI)^7UK$_9+^/6
MM_'KPKK5_KUCI]E=Z?>+ O\ 9RND;JR!N5=F.0<]_P *^9OVVO"?Q0M?%6OZ
MUJ=UJ$OPZFO(5LHSJ8:U5_+  %MYF5;(?G9ZG/->7_!+P/\ &3Q5I.I3?#.Y
MUB"PBG5+L:;K2V*F0KD;E,J;CCO@U[&$R7"5LG=252"FVGSM_#>WNO7?I\SR
M,=GF+H9RJ4*4W"*:Y4OCLY>\M-5Y^1^G'Q,\/ZQXJ\ ZWH^@:HNBZO>VS0P7
MS D1$XR>.1D9&1R,Y[5^;GQ9UCQW\-?!=Q\*?%VHZ9K^G1SQW%C+:Z@ES+9,
MA^Z,'>J%68;)%7'5> 0?T!D\ ZWXP^ -MX3UW4[JQ\17.BPVUW?QSEI4NA&N
MYF=3\_SCYL'Y@3SS7QG\;_V9=)_9]^ Z7M_,-:\8:GJ$-N]ZBGR+6,!G98@?
M7: 7;D]  "0>/AZK0H570JR4KS5ERW;=])*71+\O4[^(*>(Q.'C7HQ<;0DV^
M:UDUK%QL[M[=+->1)\,8/BC^T==^%XM"\2Z7X6T+PI%;I96B:@IEB\E53S6@
M0F1W..L@52"0" 3G]$%SM&XY;') Q7Q)X?\ V-=-^)'AWX=>-O#&JR>%YKJT
MM)]6MX]RG(1?,EMRO*2$@\?=YR,8P?MM5VJ ,D 8Y.37!Q!7H5IPC0:M%R3C
MRV<7?6[UYKO6_P#F=7#N'KT82G73?,HM2YKIJVB4=.6RTM^:%HHHKY,^P"BB
MB@ HHHH **** "O@?_@I!XF^T^+O"6@I)D6EG+>21@]&D<*I/X1G\Z^^*_++
M]LKQ"_BK]HKQ&D0,@LFAT^)4Y)*(,@>^]FK[#A6C[7,XS_D3?Z?J?(<5U_8Y
M5./\[4?QO^46?27[-_[)/PZ\6?!?PWK?BKPX=1UK48GN9)S?7,7R-(WEC;'(
MJ_<V]N]>O^&?V3?A3X/U^PUK2?":VVIV,HGMYGO[J4(XZ-M>4J2.HR.O-?&V
MA?$?]J+PSHMAI&FZ1XIM=.L8$MK>$>$D81QHH55R;8DX ').:^Q_V7=6^(6O
M?#1M0^)/VI=<FO9?)BO;)+29+<!54-&J)C+!R,C)!';%=N<4\QH>TQ+Q:<)-
MVC&<MGTMM:QY>2U,MK^RPJP;4XQ5Y2A'=+5WWU9<A_:=^&4_C5?"4?BB-]?:
M\_L\6HM+C:9]VS9YGE[/O<9W8]Z]1+!023@#K7Y3_%Q1X!_:LUFXC7RULO$:
M7ZCI@&59A_.OT$_:<^)2?##X+Z_JD<H2^N8?L-EZF:4%01_NC<W_  &O,S')
MX4(X1X9MNLEO;=V[)::GLY;G$\16QE/$VBJ#>U]DY:N[_N^0[P_^U!\,?%7B
MR#PSI7BA+S6KB9H(K=+.X"NXSD"0QA.QYW8KMO&?CK0/AYH<NK^(]5M])T^/
M@S7#?>/]U5'+-[*":^$_^">_PU.M>/-4\;7D>+'0X3!;R-P#<2+@D'_9CW9_
MZZ+7G_QP^)ES^T=\<H[*36+;2?#D=Y]@L)[Z98K:U@W8:=R2!EL%CSSP/2O3
MGP[0GF+PE";Y(13FW9V\E9=5^O8\JGQ)7AEOUW$4US3DXPBKZ^;N^FNWEM<^
MK+[_ (*&?#&UOG@BLO$5Y$IP+J"RB$;>X#RJV/JM>U_#'XO>%?C!HLFI>%M4
M6_BA(2>%E,<T#$9 =&Y'0X/0X."<5\?_ !'^&?[-/@7X6:A%9^(;?7?%"VCB
MTO=/U5KJ>6XV_+F.)C$J[L9RHP.^:Q/^"=.DZM-\4M<U&W$BZ-!I;0W3_P#+
M-I&D0QK_ +WRN?H#ZU6(RG+ZN!JXG#*<'3ZST4O3^EKT(HYQF5''4<-BG3FJ
MG2&KCZ_T]$]3[1^)'QT\#_"*XLK?Q;KJZ3/>*SP1_9IIF=0<$XC1L#/KBN/^
M)W[7WPZ^%LUI;WEY=ZO>W$4=P+328!))'&ZAD9][(%R"#M)W<CBOCK]O3Q/_
M &Y\>KBR27S(M)L8+7;V5B#(W_HP?E7IOPK_ &#QX^\(CQ)X^UW5++7=6474
M5M:;,PJW(,V]3N8@@[1MV]/89TLGR_#X.AC<=4:YULNM]K:7VU9M7SG,*^.K
MX# 4TW"UF^FGO7UMOHE;UV/H74_VLOAAH%CH\^L>(7TJ35;&+48+::QGDE$,
M@RA81HX4GZUZII.K6FO:59ZE83K<V-Y"EQ!,N<21NH96&?4$5^?7[?W@2T\'
M^(O K:?$8[)=&&FQYY^6W8!<GUVN/RKZE_9I\;6L?[+OAC7=1G$5IIFFRI/(
MQ^ZENSI_Z#&*\['99AZ>74L?AFWSR:L[>=NGD>C@LSQ,\TJ9;B4O=BG=7U=H
MWZV^T;?C;]IOX9_#OQ)/H/B#Q1'8ZM!M\VW6TN)MFX @%HXV4'!!QGO7IEO.
MEU!'-$V^.10ZMZ@C(-?EI\+=!N_VEOVF4N;Z)I;6^U!]5U!6&0EJC;MA]B-D
M8_WA7ZG !0 !@"LLYRVCE:HTHR;J.-Y;67IIWN:Y/FE;-)UZG*E2C*T7K=^N
MO:W3J+7S7I_["G@J\\5:QK_BS4-0\4W>HWLUV8"YM85$CEMIV'>2,XSO /H*
M^E*Y/XG?$[0OA+X3NO$'B"Z$%K",1Q*09+B3'$<8[L<?AU. *\G!XG%4).&$
MDU*>FF[\EU^X]C%X7#8F">*BG&.NNR\WTV[GY[_MI_!OPG\'?&FAVWA2"2QM
M[^S:::Q>=YA&5?:&!<EL-SU)^[7O?_!.&VO(_AOXIGD+?8)-5585/3>(E\PC
M\"GY5\K:C-XN_:X^-TLEI;;[_49 $CY,-A:J< LV.%4'D]R>!E@*_2/PCX;\
M.?L[_"2&R-RMMHVB6K375Y* IE?[SR'_ &F8\#W ':OT#.L1/"Y32R_$2YZT
MK7ZO>_\ ]JNY^=9-AZ>,SJIF&$AR4(:+2R;Y>73UUEY:7(?CM\9M,^!_@.ZU
MV^VSWK_N;"QW -<3$<#_ '1U8]@/7%?FMXB\,^(?''@SQ#\6O%%TY%]J"6EI
M(_!N[ACE]H[1QQJPX[[0.AKU*UM_$/[=7QV::47&G>#]-^]C!%E:YX4'IYTI
M'OW/(2NT_P""@UQI_A7PS\/O!&D6T=EIUJLMREO$,*B(JQIQ_P "?GOS3RJC
M'*:U'"+7$57>7]V*][E]7;7_ (8O-:[SBC7Q3_W:BFH_WYOW5+T3>G_!:5K_
M ()M>&?D\:^(77J;>PB;_OIY!_Z+K[>KY[_83\,_\(_^S[IMTR;)-6N[B^;U
MQN\I?_'8@?QKZ$KY#B"O[?,ZTNSM]RM^:/J^&Z'U?*J*[J_WNZ_"QR?Q;L1J
M7PK\86I7=YND7:@<]?);'3WK\]_V"YEB_:%L5.<R:?=*,>NP'^0-?I!XJM_M
MGAC5[?&?-LYDY]T(K\TOV&IFA_:0T! !^\M[M&S_ ->[G^8%>WD#OEN/C_=_
M27^1X_$GNX_+9]YV_P#)H?YGW3^U!\4A\)_@[K6J12^7J=TGV&PYY\Z0$;A_
MNKN;_@-?DY(K\.X;YQN#-_%R1GWY!_*OJ_\ ;@\=WGQ.^,FD^ -$W72Z8Z6H
MA0\2WLQ (_ %%]B6KA?VOOAS:?"WQEX5\/V0'DVGAVVB9U7'FR"27S)/JSEC
M^-?1\-TX9?0I1G_$KWE_VZEI_G\_(^<XHJ3S"M5=-_N\.DG_ (I-)_Y/_#YG
MZ5^#;Q;GP7H=TSKLDT^"4OT&#&IS]*_-'XC:C??M2?M.O9:8[/;7UZNG64@&
M1%:1DYE^FT/)^-?5GQD^+9^'O[('AZ>VGVZOKFBV>GVK#@@O;KYCCZ)N_$BN
M#_X)W_"?RK;6/B#?0_-+G3M-+#^$$&:0?4[4!']UQ7@97%9;2Q6:36J;A#UO
M_P -\KGN9I-YF\'E=-_&E.?E%+_A_G8^Q-)TS3/!7AFTT^W\NPTC2[584,C!
M4BBC4 $L?0#DFO"O%W[>/PM\+ZB]I;SZIXA*$JTVD6JM$"/1I'0-]5R/>O(?
M^"@7QLO/[4MOASI=PT%HD276JF,X,K-S'$3Z 88CN2OI5'X0_!?X!:'\/;75
MOB'XOT76=;NH%GFLX=; ^QY&1&L<#AV< _-G// ''/+@\IH+"K'YAS2YW[L8
MJ[?F_7Y>NMCMQN;5_K3RW+>6+@M92=HKR7]/TTN?3'PC_:H\ ?&;4!IFC7UQ
M9:PRETTW4XA%-( ,DH061B!DX#$X!.,"O7))%C1G=@B*,EF. !ZFOR6\"Z/#
MJ_[1VCVGP^-Y)8#7HY--DD!\U+=)0V]N^ @).>PYKZG_ &_OC9=^&]+L? 6D
M7+6\^J0FYU*2-L-]GR56+V#$,3[+CH358_A^$<90P^$;7M5>TMX][_Y=U:Y.
M7<03EA,17QJ3]B[7CM+HK?/KV:=CT7QU^W!\+O ^I26*7U]XBN(F*2?V+ LL
M:$=O,=T5O^ DUI_"S]K[X=?%C6(=(L+R[TG5IVVP6>KPB)ICZ(RLR$_[.[)[
M U\Q?L^_!KX)+X$@\0_$KQ=HMYJ=XAE71_[:6$VD?\(9(G$AD(&2.V0,9%>&
M^*]'T?5/C3)IOPM-W<Z;-J$4>CGY_,WG;@J6^; ?)!;G R:]6ED.65YU,+#G
M4H+6;7NW_K\$]>IX];B#-*%.&-G[/DFU:";<[/\ K[VM.A^H7QR\3'P?\'_&
M&KJ<26^F3>7_ +[*57_QYA7PW_P3U\,_VM\:+[573,>DZ7(ZMZ22,L8_\=,G
MY5]#_M[>)3H?P%&G&7%QJU]!;';_ !*F9&_#*#\Z^7?V?OCE8? 'X6^+=2LQ
M%>^,-;NH[2QM6Y6".)"3/)_LYEP!_$5] 37-DN&JO)\0Z*O.H^5>FB_5_<=>
M>8BD\WPD:SM"FG-WZ=?O]U?>K'WI\1/VA/A[\*=4BTWQ1XDATV_D02"V6":>
M0*>A81(VW/;.,UT6D_$+P[K7@J+Q=:ZK"/#<D+7 U"X#01B,$@L=X!49!Z@5
M\+?LY_LOZU\=M>;Q_P#$26Z;0[J8W(6=BL^J/GKG^&+MD8R.%P.1Z-_P4-O[
MCP[\-O!_A[2XEL=#GNG62"W4)&!$B^5'@<!1N) _V1Z5Y=7*,(L51R^E5<JK
M?O/3E6EVEI>_S_%Z>K0SC%SP];,*M)1HQ3<%KS2[-ZV2?I]Z6O7Z]_P4"^%V
MC:A);6T>N:U&AQ]JL+-!$WT\V1&_2O3?@S\?_"GQUM-0F\-O>)+8&/[3;WT'
MEO'OW;3D$J<[&Z$]*^1_V2?AA\#OB5X42P\3LM[XYDFD#V5W?S6IVY.SR CJ
M)/E )^\P.> ,5]>?!_X#^%O@?'K,?AE+M4U29)91=S"4H$!"HIP#M&YCSDY8
M\T\VPN5X*,\/3C-58[-VL]=7Z6O;1$91B\UQ\H8F<J;HRW2O=:?G>U]6>BUY
MQ^T9XE/A+X'^--25Q'*NG20QL?[\@\M?U>O1Z^7_ /@H1XE&D_!6TTM3^\U7
M4HD(_P!B,-(?U"5\_EU#ZSC*5'HY*_I?7\#Z;'5_JN$JU^L8MKU2T_$^7_V,
M_@_H?Q@^)6H6GB73SJ.B6.G/</#YTD0,I=%3YHV5NA8]>U?5/C_]@KX<:]H-
MQ'X:M+CPUJRH3;SQW<L\1?' D65FRN?[I!KCO^";OAG[/X4\8>(&7F[O(;%#
M[1(7;_T</RK[&=UC1G<A549+'@ >M?5\09MBJ.9RCAZKBH66CTO:[TVZ]3XW
MAO*<)6RR,\12C)S;>J5[7MONMNC/R9^ _C;5O@O\<=*<RM;"/4!IFJ6X;Y7B
M,GER*>QVGYA[J#7ZB^/OB)X=^&'A]M;\3ZDNE:8LBP^<T;R9=LX4*BEB>#T'
M:ORILX5\=?M"1I9?/'JWB?,17GY9+K(/Y'-?5/\ P4B\3"'0O!WA]7.Z>XFO
MI%'HBA%S^+M^5>QG>#CF&.P=.2M*HGS6WLK/_,\G(\6\MPF/G!WA3?NWVN[I
M??[I]2?#GXJ^%OBUI-QJ7A/51JUE;S?9Y9/(EAVR8#;<2*IZ$=N]9_Q(^.G@
M;X17%G;^+=>729[Q#)!']FFF9E!P3B-&P,^M><_L*^&?^$?_ &>]+N67;)JU
MW<7S>N-_E+_X[$#^-?*'[>'B,^(OV@+BPB<R+I=E;V80=G(,A _[^#\J^:PN
M3T,5F\\#&3]G&^NE]-.UM_(^FQ.<U\+DL<QG%>TDE9:\NKOWO\.NY^C6@^+-
M)\3>&;7Q#IMXMQHUU!]IBNBC(&CQG=A@".!W%<'X?_:@^%_BB/5Y-.\602Q:
M3;FZO));:>%(XPP7=N=%#99@ %)))&*R_B?(/A%^RGJ5K&XAETWP]'IT;?\
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MO"-J-17L]]D_UU#)<RQF(Q6(P>-2<J?6.W]=MGW-FBBBOD3[ **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ5ZC^P_\#_&?P>'B^7Q=IBZ5_:/V5;:'[5%,6\OS2S?NV8 ?.HY.>M>?R?\
M!2RZ-J%C^'T*W..9&U<E,^NWR0<?\"KZ _97^-6L_';P+JFO:UI]GI\MOJ<E
MG#'9*X0QB.-@268Y;+D$C X'%>?F4LTH8"I3K8:G2IR:ORI)MW7:3[+IL=N7
M1RG$8^E.CBJE6HKVYFVEH[[Q7X,^$/&G_)W^H?\ 8XC_ -*Q7ZD:Y_R!-0_Z
M]Y/_ $$U^7GC2UF_X;$O8_)D\QO&"LJ[3D@W0(('ICFOU$UI6DT>_5069H)
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M?PXMMJ5['';1V=H3($1>/,EDP.F>7(   ]*]'"X7%8BG]7S>E&5*,=*EU?\
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M_P!\JD9_6OH+X^?$[Q;X/_9]L_&/AZ(6VM[;*YN4^S>:D:.%,JE6!PO.TGJ
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M65M<\>NSRS^L=+^TM\:KO]H+Q1X4\->'5EO;.UA@BBBC'-U?2JH<@>Q.P?\
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M+[[+[C\H_C^L6O?M1>)H-4N&M[2;6UMII\@&.$,J;@3P,*/TKZZL_P#@G?\
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MH>SE>_(K;)OT5VK2M\M6,TC_ ()\?#"\M+2]CUOQ)>6\T:RH1>6^QU8 @@K
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M1:;J^AVNE?9H;:*.]FF69%4'=\JQ,#\S,1\W>OH;5_A7IFM?"$^ +D+)I_\
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M*@I+F3Z*5]KZ6ZLZL%B,?A<JC#$89SE%\KCI=PL];:WMI&W4\?\ VH/V;/\
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M,;IIX=/BDQR BEW ^N^/\JQ_^"D?B8R:MX-\/(_$4,U](F>[,$0_^.O7TO\
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M=>;97BH8/ RH0YG0M>*W?POYZQUMW/M/XJ?$33?A9X$U;Q'J<Z11VL+&*-B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMVD)]=Q3.:Z^BIA4G3=X-KT'.G"HK32:\R.WMXK."."")((8U"I'&H55 Z
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M"_BZ19-=\-Z1K4BC"MJ-C%<$#T!=35KP_P"$]$\)VS6VAZ-I^C6['+0Z?:I
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M52?5VT79:*RV7H@HHHKQSV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O"_P!K;X1>+OC!X)TO3_"5[!;W%E>_;)89IVA,V%(3:P!&03GG
M ]^*]THKIPV(GA:T:]/>+NKG/B*$,32E1J;25F?G+_PH?]J.6'[ ]YXA%D1L
M*MXJ0Q;?]W[1T_"O7?V</V'Y_ 7B>T\5^.+VUO\ 4K-Q-9Z;9DO''+U$DCL!
MN93R% P" <GI7U[17T.(XDQE:E*E",8*6_*K-_BSYNAPS@J-2-6<I5''5*3N
ME\K(****^5/K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MD_\ X*3?M'>,OV8?@;H?BGP//9P:M>>(X-,E:]MA.GDO:W4A 4G@[H4Y^OK7
M"_\ !,']KSXA_M5?\+*_X3VYT^X_L'^S/L7V&S6WQY_VOS-V#S_J4QZ<^M97
M_!:O_DUGPM_V.=K_ .D-]7E7_!#'_FMG_<$_]OZ /U4HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVMY:Z_A^)V4LTE6S6IE\8^["*;?F[:?C^!ZQ1117SQ]"%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\ ?\ !:O_ )-9\+?]CG:_^D-]7E7_  0Q_P":V?\
M<$_]OZ]5_P""U?\ R:SX6_['.U_](;ZO*O\ @AC_ ,UL_P"X)_[?T ?JI111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7\UG[6/_)TWQD_['/6?_2Z:OZ4Z_FL_:Q_Y
M.F^,G_8YZS_Z734 ?TIT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\U
MG[6/_)TWQD_['/6?_2Z:OZ4Z_FL_:Q_Y.F^,G_8YZS_Z735_2G0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R_Q0\2+X0^&_B?6F;;]ATZ>=3_M"
M,[1^>*_.;]A_PV?$G[1&C7$BF2/3(+B_DSSR$**3_P #D4U]A_MQ>)CX>_9[
MUB%'"2ZG<06*YZD%][#_ +Y0U\)?!/X;?%;Q:=1U3X9IJ4+V^VVNKK3M42Q;
M#?,$+&1"P^4' R.!GM7Z3P[02RO%5)34.?W;O1+3_P"V/S3B:NWF6#HQ@Y\G
MO\JU;UV_\D^X^]?VSO'FF>$/@7KMC=S1F_UF,6-I;%AO<E@68#T503GUQZBO
MFK_@G5X3N[_XFZYXAV,+#3].-L9,<&65U*K_ -\HY_+UJ#0_V(_BY\2-<6]\
M=:JNF#(66[U2_P#[0NBO^R%9@?HSK7VW\.?AOX=^!O@$:1HL316%HCW-Q<2D
M&6=PN7D<\9)"CT   & *Y*V(PF49;4P5"JJM2INULE_PWYG72P^,SK,Z6,K4
M72ITMD]V_3UM\D?G%^UWXFC\4?M&>)WD=C:V<\=@#'R0L2*KX'KNWUV?B[X@
M?'KQYX)D\6:);ZMX6^'NF0A;9=)N/L@CMT&T-N#++*  ,L,KP>F*\\^$/A1?
MCU^T/8V>H;FM-5U&:_O>3DQ M,ZY[;@-N>VZOT#_ &J-6M/!_P"SCXM2...W
M@>Q73X(8U"JOF%8U50.@ /3VKW<=B:>6_4L"J2G42BM=4KV6W=M;]/F>'@,-
M/-*F.QWM7"DW+X=&[7:5_P"5*UUUT['B'["?Q^\5^./$FJ^$/$VISZY%%8F^
MM+N\;?/'MD1&1G/+@^8#\Q)&WWKU']J[]IE?@7HMMIVD)#=^*]10O DPW1VT
M0.#*X[G/"CN0<\#!\!_X)O\ APW7CKQ9KI!V66GQV8/;=+)N_E#^M>4_'#4K
MGXS?M1:E8K*VVZUF/1;8]?+19!",#ZY;\37+6RO"XK/9P<4J<(J4DM%?_@WN
MS?#9MBL'P^JW,W4E)QBWJTN^O:S2[.W0Z#P[?_M*_$73)O&NC:GXIO=.C9I/
M-@OA##)M//EV^Y1( 01A$(R"*G\0?MS_ !3U:VT6STV^CT;4;:(P7SQ64$GV
MR;>0'VR(VPXP"JX&<G@$ ?HUI>FZ?X1\/VUC:1I9:7IMLL4:]%CB1<#\@*_+
M;X?VT7Q8_:JTYX84^R:EXC:^\N- J^2LK3$8'^PIK3+,9A<UJ59UL-!4Z2NM
M.FNCZ/37LK$9K@\7E-"E['%3=6J^5Z[O1W756=EO=I[GWU\>?C7/\!?A);:O
M=I%J7B.X6.T@C<;8Y;DIEW8#HHPS8&.PXS7QGH.K?M)?'R*Z\0:!JGB">Q24
MQE]/U)--MPPY*HOF1AL9'3)]3FOJW]L[X+ZU\8OAS9CP\@N=5TBY-TEF2%-P
MA0JRJ3QNZ$9ZX(KXY^#O[2WCG]FVZF\.7>F_:=)CG+W&AZI$T$T+G&XHV-R$
MX'#!E[XR<UQY%1A4P,ZN$A">(OM+HO)=/P7GH=W$%:I2QE*CBISAAN7>/66N
M[^[37NEJ?5O['-O\6[.Z\56GQ)EUDVMJ($LUUDF1FD)<NT<IR74 +G#$<BLK
M]J_]L&?X7ZD_A+P;Y$WB)4!O+^51(EED95%4\-)@YYR!D<$GCW#P?\9-$\=_
M">3QWI);[!':37$L,V \+Q*2\;X[C'X@@]Z_+GPGK'B?Q-\4U\2:;H,GC#Q
MMXVJO8?9);M9&#[MSQQG<5#$=P.@]JQRW!QS3'UL3C*2BJ=KQ6BYMM?+1M_+
MH;9EC7E.74:&"JN;JM\LGJ^7?3SU27SMJ>JZGI_[3=QX;G\:7>H>+K;25B-U
M)(NJFW*Q@9+?9ED5@N.?N8QSTKW']BG]IOQ'\2M:O?!WBRX_M.\AM3=V>I%
MLC*K*K1R;0 Q^8$-UX.2<BN)\3?$C]IOXQZ/=>'H_ L^@VM]&T%P8-+DLO,C
M8893)<N0H(]"#SUKUS]D7]E>\^"<E[XB\27$$WB.]M_LR6MLV^.TB)#,"W\3
MDJN<<#;P3FNO,*V'^H58XV--3^PH:M>O])6.#+Z.(^OT9X&=64/^7CGI%^E]
M_P 7>VI],4445^8GZF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ? '_!:O_DUGPM_V.=K_P"D-]7E7_!#'_FM
MG_<$_P#;^O5?^"U?_)K/A;_L<[7_ -(;ZO*O^"&/_-;/^X)_[?T ?JI1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7\UG[6/\ R=-\9/\ L<]9_P#2Z:OZ4Z_FL_:Q
M_P"3IOC)_P!CGK/_ *734 ?TIT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '\UG[6/\ R=-\9/\ L<]9_P#2Z:OZ4Z_FL_:Q_P"3IOC)_P!CGK/_ *73
M5_2G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\3_P#!23Q,%L?!
MGA]>LDD]_)S_ '0$7_T)Z]'_ &!?#/\ 8?P%BOV7#ZOJ%Q=9QSM4B$#\XB?Q
MKW+Q)\/_  OXRFAE\0>&](UR6%=L3ZE817#(#R0I=3@?2M;3=,L]&L8++3[2
M"QLH%V16]M&L<<:^BJH  ^E?1SS2']E1RZ$6G>[??5O_ "^X^<653>;O,IR7
M+RV2ZK1+?[_O+->9?M+^)CX1^!/C/4%E\J4V#VT;=]\N(QCW^>O3:HZUH6F^
M)-.ET_5]/M=4L)<>9:WL"S1/@Y&58$'FO"HRC3JPG-72:;7E?4]^HI2A)0=G
M9V]>A\"?\$Y_#/\ :'Q,\1:VR[H]-TP0*<='FD&#_P!\QO\ G7K'_!17Q.=-
M^%^A:(C8;4]2\QQW*1(3_P"A.E?3'AOP;X?\&PS0Z!H6FZ'#,P:6/3;..W5R
M.A8(!D_6D\2>"?#OC)($\0:!I>NI 28EU*SCN!&3U*[U.,X'3TKZ3$9S#$9K
M#'S@^6-M.NG_  =3Y?"9+4PF55,OC-<T^;7IKI^1\Z?\$\O#/]E?!O4=7=-L
MFJZI(5;^]'&JH/\ Q[S*^//'8O?@Y^TGJ-[=VAEFTGQ!_:*0N2HFC$WFI@XZ
M,N.?>OU<TG1[#0-/AL-,L;;3;"$8BM;2)8HHQG.%50 .2>GK7(_$3X&^!?BQ
M+!-XJ\.6VJ7$*[4N-[PS!?[OF1LK%>O!..375A,_A2S&MBJT&X5-&ENET[=-
M.ARXOAZ5;*Z."I32G3=T^C>M_P 7YGR7\8OVQ+[XV>'[GP?\.M%U&PCO+>1]
M3U"^"+)';*I,H 1F"IC.YR<XX R:XS_@GSX7_MCXV7.JNF8](TV656QTDD*Q
M@?\ ?+2?E7WAX-^#W@KX?Z-=:5H/AK3[&QNT\NYC\KS6N$Y^65WRSCD\,2.3
M6KX:\"^&_!?G_P#"/^'M*T+[1CSO[-LHK?S,9QNV*,XR>OK3>=X3#X2M@\'1
M<8S5DV]==[_+1)?J)Y'C,5BJ&+QM92E!W:2TTLU;YZMOR['S?XZ_;FM_AI\9
M/$7A;6O#DEWHFGR)#%=Z>X^TAM@9RR.0K EN,%< =\\?/7[67[2'AKX^#0X/
M#_AZ[LY;%W+ZAJ$<:W#JPP(@$9OESSRW7M7WIX_^!/@'XHW N?$WABSU*[ "
M_:ANAG('0&2,JQ ]":I>"?V;_AI\.]02_P!!\(V5M?1MNCN;AI+F2-O5&E9B
MI]UQ4X',LIP:IUU1E[:*Z/W6[6OOU]"\?EN;XQU:"KQ]C-O=>\E>]MM;=[W]
M#SW]G7X/ZQX9_97U#P[J$+6FLZ];7DYMI1AH3/%LC5@>AVJA(/0D@]*^)?@+
M\5+C]G7XM-JNIZ3-.(8Y=.O['A)D4L-VW/&Y60<'K@C(SFOUFKS[Q[\ /A[\
M3KS[9XD\+6=_>GAKI"\$SXX&Z2-E9L>Y-3@<]A"KB'C*?-"MO;=;[?)]RL=D
M$YT,-'!U.6=#X6]GMO\ -7V[GAVI?\%'/ L5N6T_PWXBN9\<)<I!"O\ WTLK
MG]*^A_A7XVF^)'P]T/Q/-IC:.^J0?:!9-+YIC4L=IW;5SE0&Z#[U<=H/[)GP
MC\.W0N+3P18RR#D"^DENU_[YF=A^E>LPPQV\*11(L44:A41  J@#   Z"O*Q
M]7+904<#3DG?5R?3M9-H]3+Z.:1FY8^K%JVT5U[W:3_X<?1117AGO!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'P!_P %J_\ DUGPM_V.=K_Z0WU>5?\ !#'_ )K9_P!P3_V_KU7_ (+5_P#)
MK/A;_L<[7_TAOJ\J_P""&/\ S6S_ +@G_M_0!^JE%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?S6?M8_\G3?&3_L<]9_]+IJ_I3K^:S]K'_DZ;XR?]CGK/_I=-0!_
M2G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?S6?M8_\G3?&3_L<]9_]
M+IJ_I3K^:S]K'_DZ;XR?]CGK/_I=-7]*= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'P!_P6K_Y-9\+?]CG:_P#I#?5Y5_P0Q_YK9_W!/_;^O5?^"U?_
M ":SX6_['.U_](;ZO*O^"&/_ #6S_N"?^W] 'ZJ4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5_-9^UC_R=-\9/^QSUG_TNFK^E.OYK/VL?^3IOC)_V.>L_P#I=-0!
M_2G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S6?M8_\G3?&3_L<]9_
M]+IJ_I3K^:S]K'_DZ;XR?]CGK/\ Z735_2G0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\ ?\%J_^36?"W_8YVO_ *0WU>5?\$,?^:V?]P3_ -OZ]5_X
M+5_\FL^%O^QSM?\ TAOJ\J_X(8_\UL_[@G_M_0!^JE%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?S6?M8_P#)TWQD_P"QSUG_ -+IJ_I3K^:S]K'_ ).F^,G_ &.>
ML_\ I=-0!_2G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S6?M8_P#)
MTWQD_P"QSUG_ -+IJ_I3K^:S]K'_ ).F^,G_ &.>L_\ I=-7]*= !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17.>*_B1X2\
M!F(>)O%.B^'3,,QC5M0AM=X]O,89_"K_ (<\5:+XPTX:AH.L6&MV#':+K3;E
M+B(D=MR$C/XU7*[<UM VT-2BBBI **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@#
M_@M7_P FL^%O^QSM?_2&^KRK_@AC_P UL_[@G_M_7JO_  6K_P"36?"W_8YV
MO_I#?5Y5_P $,?\ FMG_ '!/_;^@#]5**** "BBB@ HI.G)K\W/VO/\ @HGJ
MDFLZAX.^%5Y_9]E:R-!=^)8L-+<,.&6WZA4!R/,ZG&5P.6Z\-A:F*GR4R924
M=S]"?$?C?PYX/5&U[7]+T17&Y3J5Y';AAZC>PS7*_P##1WPF'!^*'@S_ ,*"
MT_\ CE?BMH/P[\>_%JZFU*QTO5/$$LC'S-0N&)5V[YFD(!/XYKI?^&3?BM_T
M*O\ Y4;3_P".U] LEII>]4U.:6)A%V;2^9^PG_#1_P )?^BH^"__  H+3_XY
M1_PT?\)?^BH^"_\ PH+3_P".5^/?_#)OQ6_Z%7_RHVG_ ,=H_P"&3?BM_P!"
MK_Y4;3_X[3_L>C_S\_(GZU3_ )E]Y^PG_#1_PE_Z*CX+_P#"@M/_ (Y1_P -
M'_"7_HJ/@O\ \*"T_P#CE?CW_P ,F_%;_H5?_*C:?_':/^&3?BM_T*O_ )4;
M3_X[1_8]'_GY^0?6J?\ ,OO/V$_X:/\ A+_T5'P7_P"%!:?_ !RC_AH_X2_]
M%1\%_P#A06G_ ,<K\>_^&3?BM_T*O_E1M/\ X[1_PR;\5O\ H5?_ "HVG_QV
MC^QZ/_/S\@^M4_YE]Y^PG_#1_P )?^BH^"__  H+3_XY1_PT?\)?^BH^"_\
MPH+3_P".5^/?_#)OQ6_Z%7_RHVG_ ,=H_P"&3?BM_P!"K_Y4;3_X[1_8]'_G
MY^0?6J?\R^\_83_AH_X2_P#14?!?_A06G_QRC_AH_P"$O_14?!?_ (4%I_\
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M$O\ T5'P7_X4%I_\<K\>_P#ADWXK?]"K_P"5&T_^.T?\,F_%;_H5?_*C:?\
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MPT?\)?\ HJ/@O_PH+3_XY7X]_P##)OQ6_P"A5_\ *C:?_':/^&3?BM_T*O\
MY4;3_P".T?V/1_Y^?D'UJG_,OO/V$_X:/^$O_14?!?\ X4%I_P#'*/\ AH_X
M2_\ 14?!?_A06G_QROQ[_P"&3?BM_P!"K_Y4;3_X[1_PR;\5O^A5_P#*C:?_
M !VC^QZ/_/S\@^M4_P"9?>?L)_PT?\)?^BH^"_\ PH+3_P".4?\ #1_PE_Z*
MCX+_ /"@M/\ XY7X]_\ #)OQ6_Z%7_RHVG_QVC_ADWXK?]"K_P"5&T_^.T?V
M/1_Y^?D'UJG_ #+[S]A/^&C_ (2_]%1\%_\ A06G_P <H_X:/^$O_14?!?\
MX4%I_P#'*_'O_ADWXK?]"K_Y4;3_ ..T?\,F_%;_ *%7_P J-I_\=H_L>C_S
M\_(/K5/^9?>?L)_PT?\ "7_HJ/@O_P *"T_^.4?\-'_"7_HJ/@O_ ,*"T_\
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M&C_A+_T5'P7_ .%!:?\ QRC_ (:/^$O_ $5'P7_X4%I_\<K\>_\ ADWXK?\
M0J_^5&T_^.T?\,F_%;_H5?\ RHVG_P =H_L>C_S\_(/K5/\ F7WG["?\-'_"
M7_HJ/@O_ ,*"T_\ CE'_  T?\)?^BH^"_P#PH+3_ ..5^/?_  R;\5O^A5_\
MJ-I_\=H_X9-^*W_0J_\ E1M/_CM']CT?^?GY!]:I_P R^\_83_AH_P"$O_14
M?!?_ (4%I_\ '*/^&C_A+_T5'P7_ .%!:?\ QROQ[_X9-^*W_0J_^5&T_P#C
MM'_#)OQ6_P"A5_\ *C:?_':/['H_\_/R#ZU3_F7WG["?\-'_  E_Z*CX+_\
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MQ_Y.F^,G_8YZS_Z735_2G0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"Z$*?O952?ES@ YKH*Q:<=T,****0'P!_P %J_\ DUGPM_V.=K_Z0WU>5?\
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M:[ZOE']O;_D$^#_^N]S_ .@QTNJ7=G7A:<:M50EMK^1T?_#=/@/_ *!'B/\
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M:=VOZL=U17YI_"+QI8>%_C9I?B'4[^2UTR.\EDGNMKN=C*XY"@L<Y'&*^_\
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M3K^:S]K'_DZ;XR?]CGK/_I=-7]*= !1110 4444 %%%% !117R#^WM^U]=?
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M"/@!_P!#]_Y1M0_^1Z_.[_AA;Q[_ -!?PY_X$W'_ ,8H_P"&%O'O_07\.?\
M@3<?_&*/[)PO\S^]?Y!]<I_S(_1'_AX1\ /^A^_\HVH?_(]'_#PCX ?]#]_Y
M1M0_^1Z_.[_AA;Q[_P!!?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBC^R<+_,
M_O7^0?7*?\R/T1_X>$? #_H?O_*-J'_R/1_P\(^ '_0_?^4;4/\ Y'K\[O\
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M$W'_ ,8H_LG"_P S^]?Y!]<I_P R/T1_X>$? #_H?O\ RC:A_P#(]'_#PCX
M?]#]_P"4;4/_ )'K\[O^&%O'O_07\.?^!-Q_\8H_X86\>_\ 07\.?^!-Q_\
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M]!?PY_X$W'_QBC^R<+_,_O7^0?7*?\R/T1_X>$? #_H?O_*-J'_R/1_P\(^
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M?PY_X$W'_P 8H_X86\>_]!?PY_X$W'_QBC^R<+_,_O7^0?7*?\R/T1_X>$?
M#_H?O_*-J'_R/1_P\(^ '_0_?^4;4/\ Y'K\[O\ AA;Q[_T%_#G_ ($W'_QB
MC_AA;Q[_ -!?PY_X$W'_ ,8H_LG"_P S^]?Y!]<I_P R/T1_X>$? #_H?O\
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MBC^R<+_,_O7^0?7*?\R/T1_X>$? #_H?O_*-J'_R/1_P\(^ '_0_?^4;4/\
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M_P#(];_A;]M+X)>,KV.TT[XAZ8D\AP@U!9;($^FZ=$&?;/-?F?\ \,+>/?\
MH+^'/_ FX_\ C%<YXT_9'^(/@W39;\VMGK5O"I>7^RIFD=% Y.QE5C_P$&C^
MR,,]IO\ #_(:QE-NW,C]NX9DN(DEB=9(W4,KH<A@>00>XI]?C_\ L9_MF:U\
M"_$]EX?\07LVH^ +V58IH)W+G32Q $T1)^51U9!P1D@9Z_K[#,EQ$DL3K)&Z
MAE=#D,#R"#W%?/8S!SP<^66J>S.Z,N9#Z***X"@HHHH **** "BBB@ HHHH
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MI-\4O!?C*.S^(QC\1Z0MQY-_#-I\=I>VH!PQ3RU0;E/574YQC*]1]A_\$^/
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MI=7<MGXJL[B<>;<!G*!)_,=_F.-IW$XQS7ZJU])R+ 24J$[MK4XZDVSG-/\
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M!.D^ /\ @M7_ ,FL^%O^QSM?_2&^KRK_ ((8_P#-;/\ N"?^W]>J_P#!:O\
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M"@EJ]?F?+/[>G_(L^$_^OR;_ - 6NQ_8Q_Y(E;_]?UQ_,5QW[>G_ "+/A/\
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MR44\9&_9_A<Y_P#9:_9Q\/>/_"UQXF\56\FH02S-;VEFLSQ)A<;I&*$,3G(
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M>]S_ .A1UZQX'_9&\&> ?%6GZ_97VM75Y8OYD4=Y<1&/=@@$A8E)QGUKR?\
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M)<^$?CE:Z5%<+-9:EYUC/Y3;HY-JLR.,<'YE&#Z,?6NM_;Q_Y'3PS_V#W_\
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MPH****\\H_FL_:Q_Y.F^,G_8YZS_ .ETU?TIU_-9^UC_ ,G3?&3_ +'/6?\
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M&P?E/L:UZ6VYD%%%%(04444 %%%% !17*_%'QY'\,_ FJ>)9;-K];%4/V9)
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M99OC?@'=YGEE_+\OIGG&ZO<O%?B[2/ ^B3ZOKE]'IVG0X#S2 GDG   !))]
M":=GRJ?1FTZ,X2Y)+4UZ*Y3P'\5/"OQ-ANI/#.KQZF+4J)E$<D3IG."5=5.#
M@\XQP:ZNAIK1F333LPHHHI""BBB@ HKR'X]_M I\#VT=#H3:T^HB4C_2_($8
M3;WV-G.[]*[+X5^/X_BAX#TSQ+%9-IZWHDS;/()"A21D(W8&1E?04U%N/.MC
M65.4(J<EH]CK****1D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>G[7'@NS\&
M_&*Z^P1+!;ZI;1ZCY*#"HS,Z/@>[1LW_  *OU3_8M\4W/C+]ESX>:C=R&6==
M/:R+GJ1;RO;KGU.(ASWK\S_VZ/\ DK>D?]@.'_THN*_1'_@GO_R:#X!_[B'_
M *<+FO/S=7PT'Y_HSZS!MNG&_8^BJ***^/.\**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R/%_AFU\:>$]:\/WK.EG
MJME-8S-&<,$D0HQ!]<,:_,GQ!_P3O^./PGUZ:_\ AOX@75$R5ANM)U,Z7>E/
M1PS*H_"0U^IM%=>'Q53"R;I]=T^H2]Z/*]C\GU_86_:4^+NK6X\<WLL20\)>
M^)O$(O\ RU)Y""-YF_#@'UK[X_9A_9>\/?LR^$Y[#39FU76[\J^HZO-&$:<J
M#M15R=D:Y.%R3DDDGM[116]?,*U>'L]%'LM#+V:O=ZGP3^V1_P $_-;^)GCB
M^\=?#R>TDO\ 4 )-0T:\E\DR3!0/,A<_+EL#*L1SDYYP/+/ _P"PS^T1\0EL
MO#7CSQ!J'AOP3:LFZUO]=^WQJB]!!;QRNF1VW;0/TK]2:*JCF-:C35)6:6UU
MMZ>A<X^T?,]S\]?!_P#P37\4> _V@M$\3Z1KNB'P9I.L07T$5Q<3M?F&-U;:
MRB'87..H8#G/'2OMCXR>![GXE?"GQ;X4L[B*TN]8TR>RBGG!,:.Z%06QSC)[
M5V5%<U?%5<0HJH[\HX)4Y^TCO_D?"W['_P"P?XX^ /QBA\7^(];\/W=C!9SV
MZP:7-/+*[2  9WQ( !UZFOMO6]%L?$FCWVE:G:QWNG7L+V]Q;S+E)(V!5E(]
M"":O44L3B*F*DI5=[6%"*IMN/J?F%\7O^"8?C;PWXBFU/X8ZG;ZSI@E\ZUL[
MJY^RWUL<Y50YPCX[/N4^W>L2/]E?]K[Q=%_9&LZKKT&ER#8ZZMXP6:VV^A1)
MY"1_P$U^K%%=L<TKJ*C)*5NZU%**;NM/0^=?V+?V7=1_9C\&ZU::SK%KJVKZ
MQ<1SSBQ5Q! $4JJJS8+_ 'F);:O88XJE^VU^R?<?M+>%=*N-#N[:Q\5:*TAM
M3>$K#<1/C?$S $J<JI#8/((.,Y'TO17%/$U9UOK#?O?TORT*II4URK;_ #/R
M5\'_ +%O[4>@K-H&E_;_  QHEW)FY-OXFBBLWZ N\<,Q9N /X">*_5_2;66Q
MTNSMYYOM$\,*1R3'^-@H!;\3S5NBML5C:F*24TE;LB(TU%W1^2G_  4V\"Z7
MX5_:"BU73[J(W/B#3X[V\LT'S0R*3%O/LX0'ZJWK7TA_P2S^&(\._"?6_&ES
M#MNO$-YY%NY'/V:#*Y'UD:3_ +X%?+/[2GPK^,GQP_:)\4:JGPX\4M#<7QL[
M&232YEMUMXSY<1\TKY84J-Q.[&6)S7ZJ_"?P';?"_P"&OAKPG:X,6DV$5J67
M^-PHWO\ \";<WXUZM6M['+*=+FO*5ODM[?+1$UES8BW1?FE;\7K\CK****^:
M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH;V,PW.H6]SJ90C!"3,S1D_6/8?QK\QOV5O^3H/AS_V,%O\ ^C!7[?R6,?\
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M9I-6O_7^9=_X=[_ #_H0?_*SJ'_R17I/PD^ ?@/X%6^I0>!] 70X]19'NO\
M2I[@R% 0O,KN0!N;@8'->@T5Y$L16G%QE-M/S9MRQWL<S\3O^2:^+/\ L$7?
M_HEZ_&3]CG_DZ#X;_P#86C_DU?M9XLT=_$7A;6-)CD6%[ZSFM5D89"%T*@D>
MV:^ O@#_ ,$X_B#\+?C1X7\6:OX@\-3Z5H]X+ITLIKAYY  < *T*J"<C^+CW
MKU,KKTZ/M?:.UTK?^3?YD8E.=#ECOK^*1^B5?E]_P5>\+W%G\5O"/B#8WV2_
MTAK0/CCS(969A_WS,M?J#7F'[0WP!T#]HOX?3>&=;9K25'^T6.HPH&DM)P"
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M9?\ A)J/P-^!_AWP7J]Y:W^HZ?Y[33V6XPDR3R2X4L 2 ' R0.G2OG[]M/\
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M,:HMRT\N5+$EV(QW&,$]^E?/7[97_)<+[_KSM_\ T"OT"KY!_:8_9_\ '7Q
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MQERHX/0@YX'2O:_V9_ ?C[PC;Z]=^/+^YNKJ^,*P0W=^;N2,)OW$MN8#.X<
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M;1Q52,%!=#Y)TG]C'6O#/Q.T35],U?3Y=!T^\M;H_:I)!=/Y91G^41[<EE;
MW< BOH?XJ_#33OBQX-NM!U%C#O(DM[E5RT$HSM<#OU(([@D5U]%*4G.*C+H9
MRKSE-3OJCX.;]EWXP^ M8E;PQ(\FX;/MVCZJMJ67/1MSHWX<CZUZO^SS^S]X
MT\)^/6\9>,M122[-N\(@DN6N;AV8 9=^1@#T8_A7TU15^UE8NIB9U(N+2U/!
M?VB/V94^+5U'KFBW4.G^(8XQ%(+C(ANE'W=Q )5ATS@Y& >F:\)T_P"!7Q]\
M,P_V?I$FJ6EBI.U-/U](8>3R0OG+_*OO"BIC)P5EL5'%5(Q479V[GS+^SO\
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M2XN) B(-TG4GBO<OVJ/^3?\ Q+_N6_\ Z415\;? CX0ZE\9/$5QI,-Z^GZ+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\!AG'1(^3C/K7Z8? #X*Z7\ ?A?I7@_3)FN_L^Z6ZO'7:US<.<O(1V'0 9.
MH&3C->BT4L1CIUX*DDHQ71&?L_>YI.["BBBO--0HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWNK?G<^-/@?^S%!\9_"<VLQ^+%TN:&Y:VEL_L'G%<!2&W>:O4-Z=J]#_ .&
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MDEOE(FO;,6EO'GJV=J)GCKR3CO7V1\#?A3#\'_ EOHXD6XOY7-Q>W"9VO*0
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M3W_Y-!\ _P#<0_\ 3A<U^=W[='_)6](_[ </_I1<5^B/_!/?_DT'P#_W$/\
MTX7->?F_^ZP]5^3/JL'_  X^A]%4445\>>B%%%% !17GGQ#^/W@;X3^*M"T'
MQ?K<6@7&M1R/975X"MLQ1E#*\OW8S\X.7POOGBN^MKF&\MXKBWE2>"5!)'+&
MP974C(8$<$$=ZMPE%*36C EHHHJ "BBB@ KX8^+'_!4"W^&WQ)\2>%;;X<R:
MM'HU]+8->R:T+<RO&Q5CY8MWP-P./F/&.G2ON>OPE_:7_P"3BOB7_P!C'?\
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M]*;BOKC_ ()R_P#)I_AG_KZO?_2F2O;>&I?V<L1;WK[_ #:(K-PK1C'9V_\
M2;GTU7PU<_\ !4"SMOBG+X2/PZG:UCU8Z6=0_MA=_$OE^9Y7D8Z\[=_XU]RU
M^$6J?\G'W?\ V-C_ /I8:G*L/2Q-=PJJZM^J)KR<*$IQW7^3/W=HK&\9>*['
MP+X3UGQ'J?F?V=I5I+>W'DKN?RXU+-M'<X'%>#_#/]OSX6?$K3O$NH"35?#5
MAH%LMU=W&NP11JRLVU1&(Y9"S$X 7&3G@&O+A2G43E!72W-7HDWUT/I&BO@7
MQ)_P5JT"SUAX="^'E_JNF*<"[OM32TD;W$:Q2#\V_*OIO]G7]J#P=^TIH=S=
M^'GFLM3LMOVW2+X 3P9Z,,$AD)!PP_$ \5T5,%B*</:3A9$.<4[7/7Z***XB
MSXQ_: _X*/VOP1^*NL^"K;P%+K[Z68TFO9-6%H&D:-7PJ>3)D ,.21SGBO/$
M_P""NBEAO^%)5<\E?$63^7V6OF/]NK_D[#XA?]?4'_I-%7Z:_#?]F[X4^)?@
M_P"$SJ/PX\+SS7FAV;SW*Z1!'.[- A9O-50X8DD[@<YYS7T?L<)0P=*O5I\S
MDEU>[5^YG4E:NZ2TW_!V.<^!/_!0#X<?&S6[70)!>>%/$-TPCM[35-IAN'/1
M(YE."Q[!@I).!DU]-U^&/[3WPPM?@;\?/$_A;1IY18:?<1SV3LY\R*.2-)47
M=U)7>!GK\N:_8C]G/QI>?$3X%^!O$6H/YNH7VE0O<R'^.4+M=OQ92?QKGQN$
MHQH0Q5#X96T?FKHF\H572G_7]7/1J*^3?CE_P4<^'WPCUR[T'1[*Z\:ZU:,8
M[@6,JQ6D3@X*&<ALL.^U6 Z9R"*\\\'_ /!6;PWJ6J1P>)? 6H:%9.P4W5AJ
M"WQ3/=D,<1P/8D^@-<=/ XFK#GA#0TE)0TD?>M%8O@WQEHOQ \,Z?XA\/:A#
MJFCW\8EM[J$G:Z].AY!!!!! ((((!%>%_$W]O'X=?"GXJS> =7L?$$^K02PP
MS7-G:1/;1M*JLN2TJL<!QG"GVS7/"C4J5/90BW+MU#F7(ZE]%U/HZO#/VP_V
MA;_]FWX4Q>(])TRWU35+N_CL+>.\W^0A9'<NX4@D 1D8!')'/%>6_'K_ (*3
M^%/A'XVN/#.@^'I?&EU8R&*_NHK];6WBD'WD1O+<R,IX/  /&3SCO?C/\5OA
MEXG_ &7-+\;_ !'\-W>J>#M8BM+I=)B4/<K+*,H%8.F&&3\P9>,^N*UCAJD5
M3JSA[K:^>NWSZ&D6E/D>]G_7R.*_8A_;.\2?M*>(O$.A>)]%TNPN]/M%O8;G
M25ECC9-X1D9)'<YRP((/KQ7U[7RI^P_XN^!GB;_A)XOA!X0U'PM=6XA.H?VL
MI>:5&+;,2&>8[05;Y=PY[5]%>//'_A_X8^%[WQ%XGU2'2-'M%S+<3$]3T50.
M68G@* 2>PK7'1C&O:$'';1_TSGI<SOK?4Z&BO@KQ=_P5F\-Z?J3Q>&_ .HZW
M9JQ N=0U!+$M[A%CEX^I!]A72_"K_@J)X \::K;Z=XJT6^\$S7#A$O'F6[LT
M)X&^0*C*,]]F!U) H_L[%<O-R/\ 7[MRY3C'=GVA14<$\=U#'-#(LL,BATDC
M8,K*1D$$=017AO[2'[87@G]FQ8+/5A<:QXCN8_-@T:PV^8$Y >5SQ&I(('4G
MG .#7#&$IR4(J[9:UU1[M7Y6?&#]NKXS>%/V@/%.A:9XH@M]#TW7I[&#3SIE
MJZ>3',4"L[1F0Y Y.[/IBO9? ?\ P5>\+:WKT5GXI\%WOAC39&V_VC:WPOA'
MD_>>/RHV"^NW<?8U\)?&K5[+Q!^T3XSU/3;J*^T^\\27-Q;W,#!DEC:X9E92
M.H((-?1Y;@)PQ:CB:>C76S6Z,JLX^PGRO73\F?NQ$Q>-&/4@&GU';_ZB/_='
M\JDKYI[E0=XIL****184444 %%%% !16'XX\8Z?\/?!^K^)=6,HTS2K9[NY,
M*;W$:#+$+WP.U4/AS\5O"/Q<T,:QX/\ $%EK]AP':U?YX2>0LD9P\;8YVN ?
M:KY)<O/;0#JZ***@ HHHH **YKXE>.+?X:_#_P 1>*[JWDN[?1K&:^>WB(#2
M"-"VT$],XQFOA'_A[M_U2C_RX_\ [DKJH86MB;^RC>WI^H2]U)L_1.BOSL_X
M>[?]4H_\N/\ ^Y*^ROV=_C-'\?OA/I'C:/26T3[>TR-8M/Y_EF.5HSA]J[@=
MN?NCKBM*V!Q&'A[2I&R]5_F9^TC=*YZ31117":!117SO^W7\8/%/P3^!_P#;
M_A"_CTW5Y-3@M!=/;QS;$97+85P5S\HZ@U<(N<XP6[:7WNQ48\W]=M3Z(HKX
MR_X)V?M&>/OCPOCF#QQK,>M-I/V-[686<-NZ^;YVX'RD4$?NUZC/6N+_ &_?
MVKOB=\%?BYI?A[P7X@CT337TF.\D46%O.TDC2RJ23+&^!A!P,5W2P-6.)6%;
M7-^&US.$E.,I+[/_  /\S] :*\K_ &7/'VL_%#X!>#?%'B">.YUG4;5GN9HX
MEC5V65TSM7@9"CH,5ZI7'5INC4E3ENFU]PH352*FMGJ%%%%9%A1110 4444
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M:5JNC^"+2RU"QF2[MYTN9R8Y8W#(P!D(X(!YXXKTBOR-^"O_  LK_A=7P_\
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MD^:;F]V?*7[67[%/_"[-8_X2OPK>VNE^)VC6.[@O-RP7H4 *Q902C@#&<$$
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ML3D]2G[U%\R_'_@D1J+J:/\ P5V_YI1_W%O_ &SKE/V%_P#DDFK_ /8<F_\
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MJ%(R% &>3T%>M5X'^Q/_ ,D9;_L)S_\ H*5[Y5U4E-I'E3TG)+N_S"BBBL2
MKYT_;H_Y))I'_8<A_P#2>XKZ+KYT_;H_Y))I'_8<A_\ 2>XJX?$CIP_\6)U?
M_!(G_FJ__<)_]O*_1.OS*_X)<_$CPE\/_P#A9G_"4^*-%\-?:_[,^S?VOJ$-
MKYVS[7OV>8PW;=RYQTW#UK[P_P"&C_A+_P!%1\%_^%!:?_'*^5S*G.6+FU%]
M/R1]=!^Z>BU_-9^UC_R=-\9/^QSUG_TNFK^@[_AH_P"$O_14?!?_ (4%I_\
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M,UL"(KE1]X;23M<#GK@C/3&*G_::^/NO?!>\T&WT6QTZZ_M!)I)6OTD?&PJ
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M,C]4J***W/C0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^%_VZ/^2MZ1_P!@.'_THN*_1'_@GO\ \F@^ ?\ N(?^G"YK\[OVZ/\
MDK>D?]@.'_THN*T/@Y^SU^T5XY^&^D:WX$U'4X/"EUYWV..W\1BT0;9G23$7
MFKM_>*_;GKWK''48UL/&,IJ.N[]&?4X1VIQ]#]BZ*_*?_ADW]KG_ *"^M?\
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MJ<,K*9,@@@@@]*N>'/C1\/O&&K1:7H/COPUK>IRAC'9:;J]O<3. ,DA$<L<
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MHK0BL-+RT_!_Y'[JV_\ J(_]T?RJ2H[?_41_[H_E4E?,/<JG\""BBOSH^/\
M\ ?VH/''QF\6ZAX8U'78?"CWK/I:#Q2L$(B('^KB$^8QD="JUU8>C&O)J4U'
MU&W8_1>BORG_ .&3?VN?^@OK7_A7#_X]1_PR;^US_P!!?6O_  KA_P#'J[_[
M/I?\_P"/]?,GF?8_5BBORG_X86_:9_Z#7_EQO_C1_P ,+?M,_P#0:_\ +C?_
M !H^HT/^@B/]?,.9]C]$?VDHTF_9W^*"NBNO_"+ZFV&&1D6LA!^H(!_"OPX\
M*>,-<\"ZW!K'A[5;O1M3@(*75E*T;C!!P2.HR!D'@XY%?3OC;]A_X]:-X-U[
M7_$>L6LFEZ+87%]<1SZW).S0QQL\@1<$$[4Z$C/%?)5>_EM"G2IRC&:FF93;
M?0^[/@=_P5$UWPS;P:9\2-)?Q)9Q(J+JFG!4O, 1K\ZL0KG D8G()9AT%??/
MPC^/G@/XY:6;WP;XBM=4=$#SV))CN[?M^\A;#*,\;L;21P37X-5]-_LT?L6_
M%CXFZUIGB"P:]^'ND1N)8O$EQOAN%XX>WC#+(Y]&!5?]JL,;E^%Y74OR?E]W
M^0XREL?L716'X)\/WWA;PQ8:7J.OWWB>\MXPDFJ:DD2S3'U(B15^F06Q]YF.
M2=ROCGH[(Z#RG]JW_DVOXF?]@"[_ /11K\KOV$_#.C^+_P!ISPKI6NZ58ZWI
MDT=V9;+4;9+B%\6TA&Y'!4X(!&1U%?JC^U;_ ,FU_$S_ + %W_Z*-?CQ^SQ\
M8O\ A0OQ9T?QM_9']N_V>LR_8?M/V?S/,B:/[^Q\8W9^Z<XKZ7*$Y4JZCNUI
MZVE8RQ*;HQ2[O_VT_9C_ (9P^$O_ $2[P7_X3]I_\;KM=!\.Z5X5TFWTO1-,
ML]'TRW!$-E86Z00QY))VH@"C))/ ZDU^?G_#W;_JE'_EQ_\ W)7U+KG[0V?V
M3;OXN6UA_9L\VAF_M[*:3S!%.XV1H6VC</,*\X&1V&:\G$8;%T8<U9.U[;IZ
M].I<'&<U!;LQ?V@_VY/A[^S_ *E)HETUSXB\3( 9-+TO:?L^1D>=(Q"H2/X1
MN;D$K@@U\_6?_!7*R>^5;KX7SPV>[YI8=<620#U"&W4$^VZOEO\ 9)^$2?M+
M?M"6NG>)9[B]L")M7UB0R'S;A58%@7ZY>1T!/7#'!S7Z>>/OV,?A'XV\$WF@
MP>!]%T*=X2EMJ6EV4=O=028^5_,4!GP<$AB0>]>E6H83+U&%>+G)J[M^FQ"E
M[2;C#1+K_7]>IM? 3]IKP-^T9I-Q<^%;V5+ZU -WI-^@CNK<'@,5!(93_>4D
M=C@\5XU_P5"_Y-K@_P"PY:_^@2U^?'[._C'5/@;^TIX=G64QR6FL#2M01"=L
MD+R>3,I'<8)(SW4'M7Z#_P#!4+_DVN#_ +#EK_Z!+6>(PD,-B*$Z3O&4HV^]
M?YHNA*7/.G+=)_D_\CR/_@D;_P ?/Q1_W--_G<UYS_P5._Y.&TG_ +%^W_\
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M^5?@Y\5/^2]^,/\ L9KS_P!*GK]X[?\ U$?^Z/Y5]!F7^Z8;T?Y1,9?[W/\
MKJSPS]N;_DU+X@_]>D7_ */CKX._X)<_\G)7?_8!NO\ T9#7WC^W-_R:E\0?
M^O2+_P!'QU\'?\$N?^3DKO\ [ -U_P"C(:65_P"Z8GT?_I)6(_AP_P 7ZQ/T
M0_:%_:5\*_LU:'I>J>*+75+V+4KAK>"'28(Y)-RKN).^1  !COGGI7">(_V_
M/A?X=^%&B>-Y)-1D.MK*UAH0BC^WN(Y&B9G4.51 R'YBV#VR>*\>_P""M'_(
MA> /^PG<?^BEKR'_ ()W_LMZ'\:+_4O&7C"./5M!T.<6=KH\Q)2:X*B0M(.\
M:A@=O1BQSP"#AAL)0J85UZK:Y7K;MV^;:*JR]FX65[_YO_(]6T'_ (*U:'=:
MTD.L?#J^T[2F;#7=GJB7,RCU\HQ1@_\ ??YU]P>"?&VB_$7PKIWB/P[?QZGH
MVH1>;;W,6<,.A!!Y# @@@\@@@U\!_P#!2;]F?PCX+\%Z-X[\(:#8^'9([U=/
MO[72[=8+>1'5BDGEJ JL&7;D 9WC/2M7_@DYX]NKS1?''@ZXE9[:RE@U*T1C
MG9Y@9)0/092,X]2:NIA\/B,)+$8=.+CNM_ZWN9S<J<HW>C_X;\]#] ZYGXG?
M\DU\6?\ 8(N__1+UTU<S\3O^2:^+/^P1=_\ HEZ^=J? SMH_Q(^J/QA_9 T+
M3?$W[2G@/2]8T^UU73;F^9)[.^@6:&5?*<X9&!##('4=J_4#XX?L;?"WQW\.
M=:M+#P;HGAK5HK626RU'1K".T>*95)4MY84.N1@JV>#V."/RQ_9;\;:+\.?C
M_P""_$GB*\_L_1=/O&ENKKRGE\M?+=<[45F/)'0&OT"^/7_!1[X:67P[U>T\
M!:I<>)?$=];26UL5L9[>&V9U*^8[3(A.T'("@Y( XZU]CFT,1.4/JZ=]=N_0
MXL-95KSVT_6Y\#?LE^/+_P"'G[1'@74;&9HEN-3AT^Y12<203N(G4CN,-GZJ
M#VK]M?$_BC2?!>@7VMZYJ$&EZ38QF6XN[E]J1J.Y/Z #DD@#FOQ\_8+^#.I?
M%3X_:!J*6LAT+PW<QZI?W>T[$:,[H8\_WF<+QUP&/:O?O^"K?Q4O$O\ PI\/
M;6=HK)H#J]]&IQYK%FCA#>PVR''J0>PI9I36(Q%&A'XG>_DM_P!'_3)PZO*<
MGLDOZ_%'5^./^"L'A32-4DM_"W@G4?$=HC%?ME[>K8*^/XD41R-@_P"T%/L*
M[#X)?\%*O 7Q1UZST+7]+NO!.IWCB*WDN9UN+-W)PJ&8!2I)/5D"^I%>6?L4
M> ?V>?#_ ,);'7?'^M^ ]2\7:L9))[/Q)J-G(;*,.52,02MA&(4,25W?-C.
M*\$_;N\%_"[PW\0M(U/X5ZOH5YI>JVKO>6&@7T5S#:SHP&0(V81AU887@?(V
M!6:PN#=;ZKR2OMS>:_#\"E*52#G%V_K^OD?L'J-_#I>GW5[<$B"VB::0J,D*
MH)/'T%?-WPS_ ."A7PL^)VL:K8VZ:UH<>FV$VHSWVLVT,4'DQXW$%)7;/S#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >9_M)?$S5/@[\%?$7B_18+.ZU+3OLWE17Z.\+>9
M<Q1-N"LI/RR$C!'('TK\VO OAOXB_ME?%_Q#_85[8Z;K=Q;R:O<0?:IK:T1
M\<;",?.0=TBG!]^:_5?QIX+T7XA>&KSP_P"(;!-3T>\V>?:R,RJ^QU=>5(/#
M*IX/:I/A#^SE\./A'?G7?"/A>WT75KFT:TEN8II7+1,ZN5P[D?>C0],\5VT\
M9#"TI6C[[V9M37,S\^_^'8?QJUK_ (__ !!X97R_N?;-3N9.O7;B!L=!Z=J/
M^'4WQ:_Z&'P7_P"!MW_\BU^K%%<_]KXGR^XZ?9H_"W]M3]B7QE^S?\)-+\3^
M)M8T*^@NM<BTU+?299I&#-;SR!B9(D&,1,/Q'X<U^P?^R?XB_:@_X3C^P=8T
MS2O[#^P^=_:1D_>>=]HV[=BMT\ELY]17WQ_P6K_Y-9\+?]CG:_\ I#?5Y5_P
M0Q_YK9_W!/\ V_KC>,K.LL1?WD5RJUC:M_\ @DSXR:%3/XYT*.7NL=O,ZCGL
M2!G\J\C_ &FOV*=9_9E\(Z7KVJ>);'6H[^^%BD-I Z%3Y;ON)8_[&,>]?LM7
MR!_P4F^'_B3XF?#OP5H?A71KO7=5EU[<+:SC+%5%O*"['HJ@D99B ,C)KU,+
MF6(J5XQJ2]U[[&<H*VA^3%=7\.?A5XN^+FN#1_!_A^]UZ_X+K:I\D(/ :20X
M2-<\;G('O7W1\"?^"6?_ ![ZI\5=7]'_ + T>3_QV6X_F(Q]'K[P\"_#OPS\
M,=#CT;PKH=EH6FISY-G$%WG^\[=7;_:8D^]>CB<WI4_=H^\_P)C3;W/QP_:/
M_93UG]F?P[X(N/$.JVMYK7B'[8T]E9*6BLQ#Y&U?,.-['SCG"@ C +#D^Z?L
M+_\ ))-7_P"PY-_Z3V]=7_P5V_YI1_W%O_;.N4_87_Y))J__ &')O_2>WKKP
MU:=?"QJ3W=_S9YV/5J;2\CZ+HHHJCYT**** /SF_:FD:3X]^)MQSAX!^ @CK
M]$K!5CL;=4.Y%C4*<YR,#%? O[9&D-IGQNO+C;A;ZTM[A3ZX7RS^L=?<O@75
MEUSP3H.HH=RW5A!,,?[4:FMH_P"[1\OZ_0]/':JD_+](G(?&+X!^'/C):H]^
MKV&KPIL@U.V WJ.NUP>'7/8\CG!&37Q7\7OV=O%'P=Q>W7EZEHK.$34K3("L
M>@=3RA/XCWS7T3X/_;4T9M2OM-\8V$FCSP7$D:7EG&TL)4,0-ZY+JV,=-P/M
MTK#_ &COVF_!_BSX=7WASPU<RZO<Z@45YS;211PHKAB?W@4ECM &!W/-1'GA
M9PV?Z_D;X?V].HJ4UI^7S-O]C?XQZIXTL=1\,:Y=/?7>FQ+/:W4S;I'A)VLK
M$\G:2N"><-[5X%\?O^3D]<_["%O_ .@1UZQ^PKX)O8KK7?%<\+164D(L;9V!
M E;<&<CU VJ,^I/H:\K_ &IM.N_#_P >]:NI$VBX:"\MV(X9?+49_!E(_"NG
M2.)B_+]5^@J44ZE:$/Z_IGZ(5^<OP@_Y.4T;_L-2?^A/7TAKW[:7@^V\#B]T
MHSWGB.2$!-,D@=1#*1U=R-I4'^Z23[=OF;X'+=K^T!X9-_&\-ZVI[YDD38P8
M@DY';KTK.C"2JW?3_@&=*G*&&JN2M=?DG_F?1?[=W_)/?#W_ &%/_:+T?L,^
M&].A\!ZKKBVRG5)[YK5KAAEA$J(0@]!EB3Z\>@H_;N_Y)[X>_P"PI_[1>O-/
MV6_VA=+^%MC=>'O$R26NDW4INX-0CB9_+<@*P95!)4[!@J#@@_@J.L)I?UL.
M4)3PD%'^M6=)^WGH=K'<^%-72-5O)EGMI' Y=%V,N3[%F_.M?X0^);RS_8V\
M1W$4C+-8QWL$+YY4-@Y'T,AKR;]JCXV:;\6O$6F6V@O)-HVF1OLN)$*>?(^-
MS!2 0 % &0#UXKZ/^&?PGO(/V89/"MTA@U/5;"XE:.08,<DN60'T(&S/T-19
MQPTN;K<TJ/DA0C/=-?=K^5T>!_L2^';76/BI>7US$DK:;8-- &&=LC.J!A[@
M%OSK[DU+2[+6K-[34+.WOK5\%H+F)9$;!R,JP(/-?G9\!/B0/@A\4)+G6K6=
M+5HY-/OXE7]Y#\P.=IZE609'IFOJ/Q9^V=X!T73?-T:6Y\1WS?<MHH)+=0?]
MMY%&!] WTK>LG+E<=?\ ASGQ%&K*NVD9'[=/'PRT4#_H*K_Z*DJY^P__ ,DB
MO?\ L*S?^BXZ;^VAIMQKGP:L=1MXV,=I?0W,RXSM1D9<_@SJ/QKS']E'X_>&
M/AKX9U70O$UU+IZM=&\M[A8'E5MR*K)A 2#\@(XQR>:SI?!476_^14HNIA*?
M(KV?^?\ F6/V]/\ D9O"?_7G-_Z&M>__ +,__)"_"/\ U[/_ .C7KXU_:)^+
M,OQD\3QZK:6,MMX?L ;.SDD3#.3\S%CT#'@[<\ "OLK]F?\ Y(7X1_Z]G_\
M1KT13C0L^_YW8L5%QITT_P"MCXOM_P#DZ*'_ +&Y?_2ROT>K\U_$]]_PA/[1
M5_J&H1/Y>G^)#=RHH^8HMQYG'U7I]:^[? /QM\(?$_5+FP\-ZD]_/;P"XEW6
MTD052VW'SJ,G)'3UHWH4[=OT1681;J\]M/\ @G%?$[]HSP'\(/$5_;0Z=_:7
MB6;:;T:="B'<%&T32G&3C''S$>U>#_%S]KB+XI^!=1\-GPA]@^U&-DNVU#S3
M&4=6SL\H<D CKWKSS3M1T_PQ\>I;SQE9O>6-MK$S7\$D>\L=[<E3]X!B&QW
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MV/ ==JD$?BI'X&NC2.)B_+_+]":44ZE:$/Z_IGZ)O]UOI7YS? /_ ).,\/\
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MOM68D#99V,BGZ_O0@J;]K+P7<^-O@]=/80M<7>FS)J"1(,LR*"KX'LK$_P#
M:B;Y::7+977YZ_F3&IS5J2G'EM=+[K?Y'"?L(^&[2/PGX@UXQ*U]->BR$A'S
M+&B*^!Z E^?7 ]*Z[]LKP_9ZI\&KK4)HE-WIMS#+!+CYEW.$89]"&Z>P]*\(
M_93^/FC_  K&JZ-XC>2VTN]D6XBNXXVD$4@&U@RJ"Q! 7D X(]^.@_:@_:4\
M/>//":>&/"L\M_#/,DUW>/"\2;5.510X#$[L$G ''?/&F(C*4TX^7X6N*G3J
M+%<S6E]_+^M#6_8)U29H/&&G,Q,"-;7"+V#,)%8_B%7\J\@N?^3L#_V. _\
M2P5]%_L4^ ;KPSX!O]<O86@EUR9'@5AAC!&"$;'N6<CVP>]?-7Q5:Z^'W[16
ML:A/"S26NM_VG&OW=Z&03+@^X(YK6Z^MQ]/\BJ=JCKJ/7_)K\S]$M:_Y U__
M ->\G_H)K\_/V1_^2\:!_P!<[C_T0]>_?$;]L3PL_@R2+PFT^J>(+^+R8[:2
MV=!;,PQE\C#$9X"ELGOBO!?V3[>6T_: T6":-HIHQ=(\;C!5A"X((]0:SH1<
M93;73\K_ .9E&$H86?,K'J7[:WPKUK5-7L/%^FVDU_8Q6GV6\6%2S0;69@Y
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M7FNX_:T^,W@[XF^&-"M/#6L?VE<6UXTLJ?99HMJE" <R(H//I7I/_#"W@/\
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M2VJAYH_(EB95)P#B15R,^E=E3::W!IQ=F%%%%(04444 %%%% !1110 4444
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M>HHKDE+F;D^I,8\L5'L?G)^WS^Q7XDUKQI>_$CP#I<VMPZ@ ^K:39ION(Y@
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MV:?W:G33:C.,GT/RN_X);ZU;:;^T5J%G.RK+J&A7$,&[JSK+%(5'_ 48_P#
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M_9[;/D?A\D(_&N6M_P#C%_\ ;H4'_1M/TCQ)M] +&<XS_P!^9OTKZ4_X)D_
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M!&?KY:(WZU[]12C)QV+5:HERJ3L8[?V1X!\+2M'##IFC:7;M)Y<*A4BC4$G
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MB5&+HSLO>B_P_I,^Z_BM\1+7X5^![_Q'=6YO!;[%CME?8979@H7=@XZYS@\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X+_P""
MM'_(A> /^PG<?^BEK6_X)0?\D9\6_P#8>/\ Z3Q5]B>*O!/AWQU8I9>)-!TS
MQ#9H_F);ZK9QW,:MTW!74@'WI_ACPAH/@G3?[.\.Z)IV@Z?O,GV72[2.VBW'
M&6V( ,\#G':O3IXQ0P<\-;5O?[O\B*D>>4'_ "_\'_,UZ***\PL**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /QY^$O[8/QA\8?%_P-I6L>-[N^T^^URQM+B![: "2*2X
M174D1@\@D<<\U^I%<G?:%\(X-:TY](T[P5'?K(K6[64%F)1*&&PIM&=V<8QS
MG&*ZROH*]:%;E<(<IP3WL%%%%<AF%%%% 'R7_P %'/B1_P (O\(;'PO;S;+S
MQ%=@2*#S]GBP[_FYC'YU\]_L=_M0> /V=_"NN0:[I>O7NN:I=J[S:;;0/&(4
M7$:Y>9#G<TA/&.16%^W)XZN/BA^T;=:+I^ZYAT?R]&M8D.=\V<R8'KYCE?\
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M+$+"R4%[G4WI;ZGU/1117@'8? '_  6K_P"36?"W_8YVO_I#?5Y5_P $,?\
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MEU V37%NDJRHK'$4A9G*D'*$_*.#VKZAJN5\JET9K4IRI2Y9!1114F04444
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MOZ4Z "BBB@ HHHH **** "OP>_:/_P"3AOBC_P!C3JG_ *5RU^\-?@]^T?\
M\G#?%'_L:=4_]*Y:^DR3^)/T,:FR/TNHHHKW#XH**** "BBB@ HHHH ****
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M4UC@3'S+%D*I/IA!D^F#7TA^W-X6GN?!?AO5K>-FM],N'MY=HX19%7:3[9C
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M^*/#\'A'P]=PZRYG6ZNKVU</#&%!VJK#AB<Y)'  ]3QN?L&_\BGXI_Z_8O\
MT6:[7PK^R3X-\.>$M4T>:2[OKS5(1#<:H2J3*H8-MB&"$&5![D]R:[/X2_!O
M0_@WI=]8Z)/?7,=Y,)I9+Z1'?(& !M50!^'>B+C",HKK_P #_(*M6FZ*IPZ,
MY2\^+WPC^*2W^A>(KK3T:SGDA>VUY5@VLK%2\<C':,XX*L&P>0*^//CUX>\%
M^&/'7D>!=474=+:%97$,_GQP29.423^(8 /4XSUKZ8\>_L2Z%XIUR\U/2=?N
M]$DNYFGEAE@6YC#,<G:-R$#)/!)J7P#^Q/X8\+ZI#?ZYJ=QXEDA8.ENT(@MR
M1TWIN8M]-V/4&E3Y8VDW9]3>G6HT;N$FUV/5O#'B2YT7X-:9KVMI)+=6FAQW
MMVO_ "T9E@#MU_B.#^->=_!;]JN#XO>,CX?;PW)H\C0/-%,+P3AMN,@CRUQP
M??I73?M,>-K?P/\ ![6RVPW&I1'3;>)N-S2J58_\!3<?P%>1?L2_"BYL$N_'
M.H1F)+F)K33XV&"R;@7D^F5"CZ-[4XVJ2G.6WZZ_\ Y%3A'#<\E[S>GX?\$^
ML:\Q_:4\,W'BSX+>)+.TC:6YBB6Z2-1DMY;JY '<[5->G45SR5UH84Y^SFI]
MC\^?V7O%7@71?$.IZ?XZTW2[FTODC^S7FJ6:3I!(I.5)93L#!NO3Y1FOJ&]O
MO@%86YFE7X?L@&<0P6<K?]\H"?TK!^(G[&/A3QAJ4^HZ1?7'AJZG<O)%#&)K
M?<3DD1D@KGT#8] *Y"R_8&M8Y@;OQK-/%GE8=-$;?F96_E74YJIJW9GH3E0J
M2<^=J_0^C?AW?>%]4\)VE[X.ALX= G9VA%C:_9HR0Q5CLVK@[E/;M7QA^V7X
M-;PO\5DUJW7R[?685N R\8F3"O\ CPC?\"K[1^'O@6P^&O@_3_#FF23S6=F&
MVR7#!I&+.78D@ =6/05E?%;X/:#\8M)M+#7#=1"UE,L,]G(J2(2,$996&#QQ
MCL*R;Y:BE'I^7]:G/AJRI5&Y;.__  #X0U#5]2_:'^,&CI.&2?4#:V1 Y\M$
M11(P]N)'_&OT+\1>&XM3\$:GH%L@BAGT^2QB0<!5,90#^5>>_#/]E[PA\*_$
MR:]IEQJE[?QQM'$=0FC=8]PP6 2-><9'/J:]>JJKC*'LX["K5E*I&4-HVM_7
MW'YI_!C6-!\"_%&)?&^DV]YI2^;9WD-]:K.+=\XWE"#RK+@X&<$U]D_:O@']
MF$^WX?;"-V/*LM__ 'SC.?;%-^+7[+7A7XIZE+JWFW&B:U*/WEU: ,DQQ@&2
M,]3[@@GOFO+XOV!8EF!D\<.\6>572@K8^OG'^57SJHES:-'34J4*KY^=KR/?
M?A9JW@'6K/49O 4&EQ6L<XANFTRQ%LK2 9&<(N[@\$9'/6OAWXJ?\G+:O_V'
M4_\ 0UK[=^#OP=TOX,Z!<Z9IEW=7OVJ?[1--=%<EMH7 "@8&![GGK7+:_P#L
MI^#_ !'X\F\67-YK"7\UTMX\$5Q&(2X(/0QEL9']ZIA*,*RG?1+_ ",*=6%/
MVB[['LU>8_M(> ?^%A?"76+.*+S+^S3[=:8&3YD>20/=EW+^->G4V5D2-VD(
M6, EBW0#OFN>6QS4ING-370_*RS\::E9>"]1\,1RXTR^NXKR5>^^-6 'T.5)
M_P!Q:^Z/V0_!'_")?"&TO)8]EYK4AOGSUV'Y8Q]-HW?\"KXO7P_9^/OB^VD>
M'HF@TW4M6:*U7.2D+2'YNG0+D^P%?IKI]C!I>GVUE;1B*VMXUAB1>BJH  _(
M5W3E^[YK6<O\E_P/N/1Q\E%JDO7^OQ+%>9_';X*I\;/#^GZ<=6.C26=S]H6?
M[/YX8%2I7;O7U!SGM7IE%<9YL)RIRYH[GR-_PP'_ -3W_P"4?_[?7SU\7OAQ
M_P *I\>7GAO^T?[4^SI&_P!J\CR=V] V-NYL8SZU^GU>/?$;]EOPE\3O%TOB
M+5;S5X+V5422.SGC6-@@ '#1L>@[&MHU)<ZYGH>A0QC3?M7=6_$7]GCX$I\&
M;'4YAK3:Q)JRP.?]&\@1! Q QO;)^<\\=*]@ID$*V\,<2?<C4*,^@&*?43ES
MRN>8Y2D^:6[/*/VH?!__  F'P9UQ$3?<Z>HU"'C)!CY;'_ "X_&O@>T\<7UG
M\/\ 4/":_P#'C>7\-\QST9$92/QRA_X!7ZE75M'>6TMO,@DAE0QNC=&4C!'Y
M5X O[#_P_6]$_P!MUXQA]_V<W47EXSG;_JMV/QS[TZ346U+9V^]?\,CT\/B8
M4Z?+/H]/Z_K<XOXE?"<V'[('AW;#B^TD1:I*,?-^^)\P'Z>8/^^*^:]:\;7W
MB+PCX9\.2!FAT8SK#SG=YKAL8]NE?IUK?A^Q\0>'[W1;R'?I]W;M;21J<?(R
M[2!Z<5XOH'[&'@3P_KUEJD=YK=T]I.LZ6]S<1&)F4@@,%B!(R/6M(S7/)SV;
MO^GY!1Q484DI_$K_ (_\.SU'X6^$U\#?#SP_H84*]G:(LN.\A&Z0_BQ:O@'Q
MYIZ_#7X^:C_:VG)>V5KK'VM[2>,.EQ;M)Y@&&X(*''/&:_2>O.OBU\"/#'QB
MAA;5XIK;48%V0ZA9L%E5<YVG((9<]B..<$9-9JHU5]H88:M&FI0J;,YK2=6^
M .L:;%>Q0^ X(Y%W>7=VUI!*OL4=0P/X5O?#O6OA3J7BBYM/!5OH UFW@,DL
MFDZ>D9$1(!Q*J $9(X#&O%I/V!8C,2GCAUBSPK:4"V/KYP_E7J_P5_9OT?X+
MZC=:E;:I>:IJ-S!]G=YE5(PNX,=JCG.5'4FK]SN%3V2@^6;;/E?]KSPW<>'_
M (V:C>O&?LVJ1Q7<+L,JV$",/P9#Q[BOHGP-XH^!'BWP[9WTVG>"=)NVC7[1
M9ZC:6EO)')CYAAU&X9[C(->G?$KX5^'OBQHBZ;K]JTBQL7@N86V30,1@E&P?
MR((.!D<5\^7W[ UK)<NUGXUF@M\_+'/IHE<#W82J#^0J:<ER*G+IL=#JTJT8
M\\G%H]7\,ZY\%Y/&6GZ;X=M_"[^(9"SVK:7I\18%5+$B5$VJ=H/\0KRS]O;_
M )!/@_\ Z[W/_H,==M\)/V2]&^%WBJS\0MKEYJNI6@?RE\I88AN0H25^8GAC
M_%7<_%OX*Z#\9K/3[?6Y[ZV%B[/%)82HC?, "#N1@1P.U3*UXM.]C*G4ITJZ
MFFVK?HSYH\-_!D?%']E?3;W3X=WB'2;B[EMMH^:>/S"7B]\XR/<>YJM^Q_\
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MUB>>>:3A8XU!9F/L ":)1E!)R5KJ_P N_H"U?*MRS17!_";XY>"/CEIU_?\
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M:***\\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBN3^*GQ*T?X0_#_6O%NNR^7I^F
M0&5E4@-*_1(US_$S$*/<T#BG)V1UE%?,?[$OQ ^*7QFT37O'WCG5%3P[J5RT
M6@Z+'9PQK#&K'?()%0.Z@_(-S'.UB>U>F?&']ICX<? GRX_%_B.&RU"5/,BT
MVW1I[IU['RT!*J<'#-@'!YKIJ8>=*I['>79:_+U1$9*=W';^M3U"BOC[3_\
M@J3\'KW4TM9K#Q580,VTWMQI\)B4?WB$F9\?12?:OJKPEXNT;QYX<L-?\/ZC
M!JNCWT?FV]W;ME'7I]00000>0000"**N&K45S5(M(.:-[7U->BBBN8H****
M"BBB@ HHHH **Y?XG?$;2/A+X#UGQ=KIF&E:7#YTRVZ!Y6RP550$@%BS #)
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M%% !1110!^-?P?\ V5_BSX5^,7@/4M6\":K8V%GKMC=7$\J*%CB2X1G<\]
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M\L9B:Z::6>782"5#2NQ4' SC&<4?$']G/X;?%*]:]\3>$+#4+YOOWD>^WG?
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M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\Z?MT?\DDTC_L.0_P#I/<5]%U\Z?MT?\DDTC_L.0_\ I/<5</B1TX?^+$ZO
M_@D3_P U7_[A/_MY7Z)U^=G_  2)_P":K_\ <)_]O*_1.OD<T_WN?R_)'U\/
MA05_-9^UC_R=-\9/^QSUG_TNFK^E.ORD^,__  1_^(/Q,^,/CKQA9>./#5I9
M^(->O]6@MYTN/,BCGN'E56PF-P#@''&17E%GZMT444 %%%% !1110!\8_P#!
M5G_DWGP]_P!C3;_^DEW7S#^P'_S/?_;A_P"W%?3W_!5G_DWGP]_V--O_ .DE
MW7S#^P'_ ,SW_P!N'_MQ7VF6_P"Y_,\K'?PI?+\SZYHHHKL/F0HHHH ****
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MW_\ ]MZUI_&CLPG\:/\ 70^GO^"4W_)O/B'_ +&FX_\ 22TK[.KXQ_X)3?\
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M_P#C]'_#=/CW_H$>'/\ P&N/_C]'LI!]3JGW117PO_PW3X]_Z!'AS_P&N/\
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MT^/?^@1X<_\  :X_^/T>RD'U.J?=%%?"_P#PW3X]_P"@1X<_\!KC_P"/T?\
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MKC_X_1[*0?4ZI]T45\+_ /#=/CW_ *!'AS_P&N/_ (_1_P -T^/?^@1X<_\
M :X_^/T>RD'U.J?=%%?"_P#PW3X]_P"@1X<_\!KC_P"/T?\ #=/CW_H$>'/_
M  &N/_C]'LI!]3JGW117PO\ \-T^/?\ H$>'/_ :X_\ C]'_  W3X]_Z!'AS
M_P !KC_X_1[*0?4ZI]T45\+_ /#=/CW_ *!'AS_P&N/_ (_1_P -T^/?^@1X
M<_\  :X_^/T>RD'U.J?=%%?"_P#PW3X]_P"@1X<_\!KC_P"/T?\ #=/CW_H$
M>'/_  &N/_C]'LI!]3JGW117PO\ \-T^/?\ H$>'/_ :X_\ C]'_  W3X]_Z
M!'AS_P !KC_X_1[*0?4ZI]T45\+_ /#=/CW_ *!'AS_P&N/_ (_1_P -T^/?
M^@1X<_\  :X_^/T>RD'U.J?<LRM)"ZH_ENRD*^,[3ZXKP;X4_LHVOP[\>_\
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M)/\ @I'KGB3X;_"SPQ?>'_$.HZ'<SZR(9)M*NY+9W3R)3M9D()&0#CV%4/\
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MO&[311R*[QII6PL <D!O.."?7!^E>9>'X/CW\(H9-(T?3?$%M:AB?)M]/%_
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M9U#_ .2*^BJ*/K>(_P"?DOO8<J['SK_P[W^ '_0@_P#E9U#_ .2*/^'>_P
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M4/\ Y(H_X=[_   _Z$'_ ,K.H?\ R17T511];Q'_ #\E][#E78^=?^'>_P
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MSJ'_ ,D5]%44?6\1_P _)?>PY5V/G7_AWO\  #_H0?\ RLZA_P#)%'_#O?X
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M(_Y^2^]ARKL?.O\ P[W^ '_0@_\ E9U#_P"2*/\ AWO\ /\ H0?_ "LZA_\
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MJDE:_P""6R"BBBN T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]].A_"OMJO /VQ/V73^T[X(TVQLM5CT?7=)G>XLIKA6:"3>NUXY-O(!PIW
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M1117EEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO^"=7P4\97C746AWGAN9\[_[$O#$A/J(W#HOT4 5Q?\ PZG^$O\ T,/C,?\
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M#;3_ .1:/^'4WPE_Z&'QI_X&VG_R+1_:6#\P^HTOY?Q9\P_\-^?]2)_Y6/\
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MVE@_,/J-+^7\6?,/_#?G_4B?^5C_ .T4?\-^?]2)_P"5C_[17T]_PZF^$O\
MT,/C3_P-M/\ Y%H_X=3?"7_H8?&G_@;:?_(M']I8/S#ZC2_E_%GS#_PWY_U(
MG_E8_P#M%'_#?G_4B?\ E8_^T5]/?\.IOA+_ -##XT_\#;3_ .1:/^'4WPE_
MZ&'QI_X&VG_R+1_:6#\P^HTOY?Q9\P_\-^?]2)_Y6/\ [11_PWY_U(G_ )6/
M_M%?3W_#J;X2_P#0P^-/_ VT_P#D6C_AU-\)?^AA\:?^!MI_\BT?VE@_,/J-
M+^7\6?,/_#?G_4B?^5C_ .T4?\-^?]2)_P"5C_[17T]_PZF^$O\ T,/C3_P-
MM/\ Y%H_X=3?"7_H8?&G_@;:?_(M']I8/S#ZC2_E_%GS#_PWY_U(G_E8_P#M
M%'_#?G_4B?\ E8_^T5]/?\.IOA+_ -##XT_\#;3_ .1:/^'4WPE_Z&'QI_X&
MVG_R+1_:6#\P^HTOY?Q9\P_\-^?]2)_Y6/\ [11_PWY_U(G_ )6/_M%?3W_#
MJ;X2_P#0P^-/_ VT_P#D6C_AU-\)?^AA\:?^!MI_\BT?VE@_,/J-+^7\6?FY
M\1/B0?B5\2+CQ1J=@1;331DZ>L_2% !Y8DV]P#\VWJ2<5]!1?M\)#&D<?@()
M&@"JJZO@ #H/]17U#_PZF^$O_0P^-/\ P-M/_D6C_AU-\)?^AA\:?^!MI_\
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M83%SPD^:.J>Z)E%2/Q+^&?[7'C'X?V,.FW8A\1Z9" L4=\S":-0,!5E'./\
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MTOY?Q9\P_P##?G_4B?\ E8_^T4?\-^?]2)_Y6/\ [17T]_PZF^$O_0P^-/\
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M55\!A548 &K\ ?\ ?BOJ#_AU-\)?^AA\:?\ @;:?_(M'_#J;X2_]##XT_P#
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MA+_T,/C3_P #;3_Y%H_M+!^8?4:7\OXL^8?^&_/^I$_\K'_VBC_AOS_J1/\
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MA+_T,/C3_P #;3_Y%H_M+!^8?4:7\OXL^8?^&_/^I$_\K'_VBC_AOS_J1/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R:))X
MGBD4-&ZE64]"#P17S?\ L?\ [-/B3]F[4O']GJ&HZ7>^&]7ODN=)CLI)6FB5
M3(/WH9% )0QCY2W*GFOI.BM85)4XRC':2L_D[H4O>23Z.X4445D,**** "BB
MB@ HHHH **** "BBB@ HHHH **** /*?VE/"/Q%\>_#:Y\/?#?5=)T/4M1;R
M+S4-3GEB:*V(.X0F.-R';@9., G'.",W]E?]FO2?V:_AZFDPF&^\0WA$VK:K
M&I'GR<X1<\B- 2%''<X!8U[116\:TXTY4H[/?S_X'D*2YK7Z!1116 PHHHH
M**** "BBB@ HHHH *;)O$;; I?!VAC@$]LFG44 ?+7P'_91\2>'_ (Y>)OBW
M\4-4TG7/%5Z[#3(=+>22"R1AM)!DC0@K'B-0!PN[DD\?4M%%;5:TJMN;HK+R
M2%;5RZL****Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIV;:4GS)+=ZJVEK[GWY17 ? ?XCR?%GX3>'O$\\:Q7EY"5N4C&%$T;M&Y [
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MD*R[63<N1ACW%=%\)OA]'\*_AWHGA2*^DU)--B:/[5(FPR$NSD[<G RQP,G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)2O?FOOM_6AO?MN?L^:%-H'B3XH-J&I?VVBVT8M-Z?9L!DBZ;-W3G[W6N1^
M'[%7A#XL?";0O%6IZSK=K?7XF,D-I)"(UV3.@QNC)Z*.]>_?MK?\FX^*/]ZV
M_P#1Z5+^Q?\ \FU^$/I<_P#I3+54,RQ=').>G4:<:BBO*/)>Q.*RW!UL]C"I
M334J;D_-\]K_ ''-_MS6HTO]FQ[.%Y#%#>6<(9VRS*I(&X]SP*[C]D^1I/V=
MO Y=BQ^Q,,L<\"5P!^5<;^WQ_P F]W?_ &$;7_T(UV'[)?\ R;KX'_Z\V_\
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M2-&^'A$>O:W?7=D]Y(,BT@$X9I<G(7 4#=@D9P!N(KZT_8O_ .3:_"'TN?\
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MV"?$7BJ.&+7/C-JNLP0MO2._L))@AZ$J'NC@X[U[]\8M/72?@#XLL4=I$MM
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M(58A2=JJ,\GK?\:?L-S_  Y\/WGB/X=>--;M-?T^%KCRYI0AG"@EE5XPI4D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ)^_\H,"RXE&XY7(^6+.>XKW;XRZ;=ZS\)O&%C8V\EW>7&E7,4,$*EGD<QL
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MBBO'D[MNQZT5RI*]PHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=!X'_;2^&WQ+NY=(@N;[0K^=&CMX]:A2)9F(.%5T=U!/8,1D\#)KRC_@F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'CY57"JZEVFG)6?2S5MNR]#YOZAC,;ET:$94E2:3349776Z?-H^[]3F/VK/
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M:\/W_BBVO41CI=S"\\L#*VX.$.6 (4Y/3\:^G_@SJ5]XD^ OA*Z,S?VE<Z%
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M7NHSVZR37$F!O)9@2%SG"C@"OG/_ (*->&[N*X\%>*8HM]I;F6SE;!PKY61
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>kros-20251231_g2.jpg
<TEXT>
begin 644 kros-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C ^ # 2(  A$! Q$!_\0
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M./\ Y2[+_P",T?\ #:7QE_Z''_REV7_QFO$:*/K>(_Y^2^]A_JWDG_0#2_\
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M_P"AQ_\ *79?_&:/^&TOC+_T./\ Y2[+_P",UXC14?6\1_S\E][.W_5O)/\
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M &+VG_\ I-'7;U^ATFW3BWV1_#>81C#&5HQ5DI2_-A1116IP'Y ?\+R^(_\
MT4#Q3_X.KG_XNC_A>7Q'_P"B@>*?_!U<_P#Q=<117YE[:I_,_O/]!/[-P/\
MSXA_X"O\CM_^%Y?$?_HH'BG_ ,'5S_\ %T?\+R^(_P#T4#Q3_P"#JY_^+KB*
M*/;5/YG]X?V;@?\ GQ#_ ,!7^1V__"\OB/\ ]% \4_\ @ZN?_BZ/^%Y?$?\
MZ*!XI_\ !U<__%UQ%%'MJG\S^\/[-P/_ #XA_P" K_([?_A>7Q'_ .B@>*?_
M  =7/_Q='_"\OB/_ -% \4_^#JY_^+KB**/;5/YG]X?V;@?^?$/_  %?Y';_
M /"\OB/_ -% \4_^#JY_^+H_X7E\1_\ HH'BG_P=7/\ \77$44>VJ?S/[P_L
MW _\^(?^ K_([?\ X7E\1_\ HH'BG_P=7/\ \71_PO+XC_\ 10/%/_@ZN?\
MXNN(HH]M4_F?WA_9N!_Y\0_\!7^1V_\ PO+XC_\ 10/%/_@ZN?\ XNC_ (7E
M\1_^B@>*?_!U<_\ Q=<111[:I_,_O#^S<#_SXA_X"O\ ([?_ (7E\1_^B@>*
M?_!U<_\ Q='_  O+XC_]% \4_P#@ZN?_ (NN(HH]M4_F?WA_9N!_Y\0_\!7^
M1V__  O+XC_]% \4_P#@ZN?_ (NC_A>7Q'_Z*!XI_P#!U<__ !=<111[:I_,
M_O#^S<#_ ,^(?^ K_([?_A>7Q'_Z*!XI_P#!U<__ !='_"\OB/\ ]% \4_\
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MPO+XC_\ 10/%/_@ZN?\ XNN(HH]M4_F?WA_9N!_Y\0_\!7^1V_\ PO+XC_\
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M_=KU<D]14/AW]HSP[\0_VPK#7WU*WT?PIIFE3Z?:7NJ3+;)+PS&0[R-NYFP
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M_$FBBBORP_T5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "ON#_@G?\/6M]/\ $WCF>V+R2?\ $LL<K@E5P\I4GC!/
MEKGU5A7P_7V9K7[17@OX>?LMV7@SP!XGEE\6"WBA>:SMKFW:*1W\RYE61T7'
M)=00<_,,=./5R]TZ=5UJC^%7]7Y'YYQO3QN-P$,LP,&Y5YQC)I-J,;W;DULM
MO57/;/A-X#\:^*/A+XZ\*_$G26T>?6;R]EMV6ZAGVQW.7.TH[X*2LQ&0.J\&
MOF[]@W2[K0_VA]<TV]B,%[9Z5=V\\3=4D2XA5E_ @UB?LT_M0:QX/^)T$_CO
MQ=K.H>&KFVEMYVU&[N+Q+=L!DD$?S'.Y ORC.'->@^%_C/\ "WPI^UKX@\;6
MGB0#PSK&CL7N187("7C21;X]GE;SGRR^[&,N><UZ4:U&JZ-52LXNSNU>W<^
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7;_ W_DM?P_\
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MQ%]_] '_ )5_^YGY&T5^N7_#./PF_P"B7^#/_"?M/_C='_#./PF_Z)?X,_\
M"?M/_C=']A1_Y^_^2_\ VP?\1??_ $ ?^5?_ +F?D;17ZY?\,X_";_HE_@S_
M ,)^T_\ C='_  SC\)O^B7^#/_"?M/\ XW1_84?^?O\ Y+_]L'_$7W_T ?\
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M)^T_^-T?\,X_";_HE_@S_P )^T_^-T?V%'_G[_Y+_P#;!_Q%]_\ 0!_Y5_\
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M_:?_ !NC_AG'X3?]$O\ !G_A/VG_ ,;H_L*/_/W_ ,E_^V#_ (B^_P#H _\
M*O\ ]S/R-HK]<O\ AG'X3?\ 1+_!G_A/VG_QNC_AG'X3?]$O\&?^$_:?_&Z/
M["C_ ,_?_)?_ +8/^(OO_H _\J__ ',_(VBOUR_X9Q^$W_1+_!G_ (3]I_\
M&Z/^&<?A-_T2_P &?^$_:?\ QNC^PH_\_?\ R7_[8/\ B+[_ .@#_P J_P#W
M,_(VBOUR_P"&<?A-_P!$O\&?^$_:?_&Z/^&<?A-_T2_P9_X3]I_\;H_L*/\
MS]_\E_\ M@_XB^_^@#_RK_\ <S\C:*_7+_AG'X3?]$O\&?\ A/VG_P ;H_X9
MQ^$W_1+_  9_X3]I_P#&Z/["C_S]_P#)?_M@_P"(OO\ Z /_ "K_ /<S\C:*
M_7+_ (9Q^$W_ $2_P9_X3]I_\;H_X9Q^$W_1+_!G_A/VG_QNC^PH_P#/W_R7
M_P"V#_B+[_Z /_*O_P!S/R-HK]<O^&<?A-_T2_P9_P"$_:?_ !NC_AG'X3?]
M$O\ !G_A/VG_ ,;H_L*/_/W_ ,E_^V#_ (B^_P#H _\ *O\ ]S/R-HK]<O\
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M_?\ R7_[8/\ B+[_ .@#_P J_P#W,E_9_P!2M-5^!O@&:RNH;R%=#LX&DMY
MZB2.%8Y$)!^\KHRL.H92#R#7?U\[_P#!/G_DT/P%_P!O_P#Z<+FOHBOI_9^R
M_=WO;3[C^?:]?ZU5G7M;G;=NUW<*SO$GB#3_  CX=U37-6N/LFE:9:RWMW<;
M&?RX8T+NVU06.%4G !)QP*T:\[_:._Y-Y^*'_8K:I_Z22U45=I'.]%<_(#^W
M-._Z"%K_ -_E_P :/[<T[_H(6O\ W^7_ !K]?_V<?^3>?A?_ -BMI?\ Z215
MZ)7SKR.BFUS/\#]X7BWCVK_58??(_#S^W-._Z"%K_P!_E_QH_MS3O^@A:_\
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M *!8??(_#S^W-._Z"%K_ -_E_P :/[<T[_H(6O\ W^7_ !K]PZ*/[%H_S/\
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M??(_#S^W-._Z"%K_ -_E_P :/[<T[_H(6O\ W^7_ !K]PZ*/[%H_S/\  /\
MB+6/_P"@6'WR/P\_MS3O^@A:_P#?Y?\ &C^W-._Z"%K_ -_E_P :_<.BC^Q:
M/\S_  #_ (BUC_\ H%A]\C\//[<T[_H(6O\ W^7_ !H_MS3O^@A:_P#?Y?\
M&OW#HH_L6C_,_P  _P"(M8__ *!8??(_#S^W-._Z"%K_ -_E_P :/[<T[_H(
M6O\ W^7_ !K]PZ*/[%H_S/\  /\ B+6/_P"@6'WR/P\_MS3O^@A:_P#?Y?\
M&C^W-._Z"%K_ -_E_P :_<.BC^Q:/\S_  #_ (BUC_\ H%A]\C\//[<T[_H(
M6O\ W^7_ !H_MS3O^@A:_P#?Y?\ &OW#HH_L6C_,_P  _P"(M8__ *!8??(_
M#S^W-._Z"%K_ -_E_P :/[<T[_H(6O\ W^7_ !K]PZ*/[%H_S/\  /\ B+6/
M_P"@6'WR/P\_MS3O^@A:_P#?Y?\ &C^W-._Z"%K_ -_E_P :_<.BC^Q:/\S_
M  #_ (BUC_\ H%A]\C\//[<T[_H(6O\ W^7_ !H_MS3O^@A:_P#?Y?\ &OW#
MHH_L6C_,_P  _P"(M8__ *!8??(_#S^W-._Z"%K_ -_E_P :/[<T[_H(6O\
MW^7_ !K]PZ*/[%H_S/\  /\ B+6/_P"@6'WR/P\_MS3O^@A:_P#?Y?\ &C^W
M-._Z"%K_ -_E_P :_<.BC^Q:/\S_  #_ (BUC_\ H%A]\C\//[<T[_H(6O\
MW^7_ !KI_A;XYT#PO\3?".LZGJMM;Z;IVL6=Y=3*WF%(HYD=V"KEFPH)PH)/
M8&OV<KYW_P""@W_)H?CW_MP_].%M6M+):/M(^\]UV.7%>*V.K4*E)X:'O)K=
M]4'[&_\ S7'_ +*EKG_M"OHBOG?]C?\ YKC_ -E2US_VA7T17T-7XV?AM/X4
M%%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV%/X4%%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^=_^"?/_)H?@+_M_P#_ $X7-?1%?.__  3Y_P"30_ 7_;__ .G"YKZ(
MK6M_$EZLSI_ O0*\[_:._P"3>?BA_P!BMJG_ *22UZ)7G?[1W_)O/Q0_[%;5
M/_226IA\2*ELP_9Q_P"3>?A?_P!BMI?_ *215Z)7G?[./_)O/PO_ .Q6TO\
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MV;^POO6&FR97[9_TUD[^7Z#^+J>.OVII^FVFDVJ6UC:PV=L@PL-O&(T7Z #
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MRCS6T-I1Y78NT4451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?.__  4&_P"30_'O_;A_Z<+:OHBOG?\ X*#?\FA^/?\ MP_]
M.%M6M'^)'U1G4^!^@?L;_P#-<?\ LJ6N?^T*^B*^=_V-_P#FN/\ V5+7/_:%
M?1%%7XV%/X4%%%%9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_)O/PO\ ^Q6TO_TDBKT2B?Q,(_"@HHHJ"@HHHH **** "BBB@ HHHH ****
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M4W*[?R.N!# $'(I:X#X*^)]3USP;%8>(;=[/Q/H[?8-2A<$9D08$BG^)'7#
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MH]4N/*TUTCEL(A^[9%+$%CGDEG!QVQ7KOQ3\6+X8\/OSB28$#W]OQ_D#7#_
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MDO)[GPGXM\%S>&8O$=KI*:OOCOS=0O:1RRBVC%[;BZD620J1;O)(-NQ8)GR
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M[RJY890;2TD:OTUO\6/!%YK&LZ3;^,O#\^JZ*,ZG8QZI T]B-P7]^@?='\Q
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MM?FNA]CZYX#A\0>,_#OB"[U34#'H+R7%II*>2+7[2\,L'VACY?FEQ%/,@7S
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M %%%% !1110 4444 %%%% !7SO\ \%!O^30_'O\ VX?^G"VKZ(KYW_X*#?\
M)H?CW_MP_P#3A;5K1_B1]49U/@?H'[&__-<?^RI:Y_[0KZ(KYW_8W_YKC_V5
M+7/_ &A7T115^-A3^%!11161H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?.OQ:/VKXF6:?P^9&O_D0 _P J^BJ^
M7OVNO$EW\-=>\*:[900R6]U)(MUYBY(V-&QV^A*E^?45=/#U,54C2I[O_)C]
MI&FG*1]&^&5 T&R(&-T8;\^:U*I:/=6MYI%G<V;H]G+"CQ,ARI4@$$'Z5G:]
MX\\.^%XRVJZU96/;;+,H8GT SDUE\"M+H7&,JLK05V^QO45XYKW[4OA'39/*
ML$O-6F(RODPF-#_P)\?IFO.-<_:P\07TDUOI>EV>E-MRCW#-.V/[P VC^=<T
M\71A]JY[F'R',,1JJ?*O/3_@_@?5)8*,DX%<KXE^*GA7PEO74M:M8YU&3;QO
MYDO_ 'PN37QIKWQ,\6>,8Y8M2U^\\U3S#&_E1>V53&5/O7*#-U;F:!!%>1$A
ME]6'53Z@^OT-<,\P_DC]Y]-AN$>N)J_*/^;_ ,CZ2\6_M<1^3=1^&M*R\0.;
MK5&\M5([[!SC'J17RE\0?VCO%7Q!EO)Y=1+:=:IG,YVP-(3A5$2\'/)!))P,
M]*P_B-KT=W]DL+=G0W$/F7!C^\\9)Q'CUR"3Z 'UKS*:8>9;VTS-':==WE?>
M?^^1NY(/&0>W KV\#@9XJC]8Q&J>R7:^]EJ[O1=.KZ7QQ53"977^K8.-I+>3
MM\5OAYI:*R?-*VNR75KHH_B1JEKJ5I>M?&Y<#%S9R1*B;<<A'!YYSC->EVGC
M#2[ZWMM5BNXH8I"(Y!+(%)4]#SW!_G7C$@BFO'CEGO[V7<JQ!9!%N+>BDECG
M\*Z_X?>';._77H+S1[>:.#"1375JK%7&00-P."< G![USYC@J,:/M%'DE'IW
M5[=D]'W5WKO8]7*\PQ$J_LN;GC+K_*[7W3DG==G9:;71WT/Q T3PSXAM[Z/7
MM/A=76X!^TH,2QL"#U[C^5?=$?[2'PQ^SQL_CS02Y4$JE\C'./8U\_?";]F'
M_A++[3]3U31+72-#A=9MK6B)+=#'W57&0I[L>W2OL&STJRT]0MM:06Z@8 BC
M5?Y"N+ TW"+;5KGS_$V*IXBK3IQDFXWO;Y:7/-F_:>^&>[;%XH@NF]+:&27_
M -!4U,W[1'A#R_,@77+T=OLF@WLI/TVQ&O3:9-,EO$\LKK'&@+,[G 4#J2>P
MKTSXH\O3]H/3+@XM?"7C>Y]U\+WB#\VC%;'PS^,&E?%*ZUZUT^PU2PN-%N%M
M;N/4K1H")"H;:,]2 >1U!ZURUQXFUGX[7$FG^$;NXT3P*C&.]\4P_+/J.#AH
MK'/1.H-QTZA,GYAZ=X5\*:3X)T*UT;0[&+3M-MEQ'!"..>2Q)Y9B>2QR2222
M30!K4444 %%%% !1110 4444 %%%% !1110 4444 ?.__!/G_DT/P%_V_P#_
M *<+FOHBOG?_ ()\_P#)H?@+_M__ /3A<U]$5K6_B2]69T_@7H%>=_M'?\F\
M_%#_ +%;5/\ TDEKT2O._P!H[_DWGXH?]BMJG_I)+4P^)%2V8?LX_P#)O/PO
M_P"Q6TO_ -)(J]$KSO\ 9Q_Y-Y^%_P#V*VE_^DD5>B43^)A'X4%%%%04%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M****R- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV*VJ?^DDM>B5YW^T=_R;S\4/^Q6U3_TDEJ8?$BI;,/V<?^3>?A?_ -BMI?\
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M MC;>V[''^^O4?0C^=?4O[(_B9]2\-:KI;.6CM94N(0?X4E!) _X$K'\:]+
MUFI>R>S/C.*,OA.E]=C\4;)^:_X<]]HHHKW3\N"BBB@ HHHH **** "BBB@
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MUT<GA.PE@O(;A&GN&0L[SMN5Q@C.W@?ID8K&^%\LZ>!;22,[3'/)#@_=*[R
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MY-#\>_\ ;A_Z<+:OHBOG?_@H-_R:'X]_[</_ $X6U:T?XD?5&=3X'Z!^QO\
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MYM&$<?65/;F?]?>%%%%=!Y(4444 %%%% !1110 4444 %%%% !1110!\[_\
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MS^F:1=T]5L2VJB'4+N/^"3;,%]SP?U&?QKBO%*?\3#PW;GI%+,%)_P!D\?\
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MGM+.\B!Q&A(4E@2"?K7T3\/_ -F_Q-XPN(+_ %CR_#^F!#M$BE[A\XY"<8'
MY;'TKLO@_P#L6^'_  #-)=:Y=+K\IN$N(K5K=5BC9/N$GDL1UZ@9[&OH_IP.
M!1+ 8>,O=;:7?K\K:>EWZGSF)XIQ4HN-)*+?EMY7;L_6R]#PZQ_9)\,P^8UU
MJVJ7$DGWC&T<8Z8X^4UK0_LN^!X1$&BOIEC((62Z.#]< 5ZY16BP]%?91\_+
M.,PGO6E]]OR*^GV%OI=C!9VD*V]K @CCBC&%50, "K%%%=)Y#;;NPHHHH$%%
M%% !1110 4444 %%%% !1110 4444 ?._P#P3Y_Y-#\!?]O_ /Z<+FOHBOG?
M_@GS_P FA^ O^W__ -.%S7T16M;^)+U9G3^!>@5YW^T=_P F\_%#_L5M4_\
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M_P"T*^B**OQL*?PH****R- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWGX7_P#8K:7_ .DD5>B43^)A'X4%%%%04%%%% !1110 4444 %%%% !1110
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MKA\+4H-M3:;[??O\CXS,.)J6)2A3H)I;<VO2VR\GW/CO2_V,-#^'?AK4-?\
M%6J-=VVF6LETUG;'.[8I8KO<=3C&-M>R_L]_!'P_\._A[HA.BVJZW-"+NZN9
M4$DGG2'>V">F,XXQTK3^-9.O#POX.CW$Z]J:&Y"C.+2W(FE/TW+$OT>O2U4(
MH51A0, #M79&C"+O;7ON?*XC,L7BDHU)Z+HM%;T0M%%%;'F!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SO_ ,%!
MO^30_'O_ &X?^G"VKZ(KYW_X*#?\FA^/?^W#_P!.%M6M'^)'U1G4^!^@?L;_
M /-<?^RI:Y_[0KZ(KYW_ &-_^:X_]E2US_VA7T115^-A3^%!11161H%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5Y?^TUH$OB3X%^+;2!/,F2U
M^T*O_7-@Y_137J%175K%?6LUM.@D@F1HY$;HRD8(_(U$X\\7'N=&&K/#UH5E
M]EI_<[GXT@G@@X/4'TKTKQ0&U[P5I]^HS*442>^!G^8/YU3^-_PMO?A+\0-3
MT>XC?['YAELYR.)(6.5.?7''X5TWAFS-OX1TJ"=?G9E)0^A)./R-?'N+BW%G
M]%1K0K4X5J;NGJCQQ9&A8.IPZG<#Z$<U[OI\_P!JEM;C',UHK-^?_P!<U@C]
MGGQ1XEU4#P_H][>6DISO$+!4!/\ >/'ZU[]X7_91\8ZA&@U">ST"!(UB1?,\
MZ7:._P O&?;(K:G1J3^&)P8O,\%AU^]JI/UU^Y:GS;XZ\*M?:7=W@9)KF"=I
M85;[Y^;D#U]<=\5S&B?#'7=>>P72[1KO4K@^<\4]L<HV>.Q+YST ZBOT1\*_
MLH>$=$6)M4>XUR="&/FGRHV8=\*<]?\ :KUG1?#>E>&[?R=+TZVL(^XMX@N[
MZD<G\:^@P?UG#0<8M*_E=V:VUTM^I^=YIG.7XF?-&$IM;:\JNG=/35OUZ>I\
M->!_V-O&WB*\74M4-OX=E0%8Y=BHX&,9"@%OS KW[P/^QQX)\*[)M0$^MW60
MS-(QC1FQU(!SW_O8]J]YHJH86G'?7U/"Q.?8[$749<B?\NGX[_B9NB^'-*\-
MVX@TO3[:PB QMMX@F?J1U_&M*BBNK;1'S\I.3YI.["BBBF2%<?\ $_X?)\0?
M#Z0P7)TS7+&47FDZJ@R]G=*#M?W4@E67^)68>A'844 <?\+?&EWXT\.RMJM@
MVE>(--N6T[5;(\K%<HJL=A_B1E='5NZNM=A35C2-G9552YW,0,;C@#)]> !^
M%.H **^?_$'QLUWP#\9O%MIJ;_VIX7DM[:QT73HXTCE&K&#SH[99 ,L;H,ZC
M>2%:!<8W&HO _P ?=:T3P=JT/BM(-;UO0[>VEN-2C=;2.^DN-8OK (D80A G
MV1".6+>:H.#\S 'T+17AB_M >*)M4OM#C\%:;;>)Y=>.C:/I>I:W<6GGQB*Z
MG%S<.]CA$:&SE9#;"[1W5T#_ +N1DY7Q)^U)XC^'U[<:9-X3O/&.NSZGJ3+8
M:3;WMP+>TM%LQ)'$UI8S-))ONU"&9(D;G?+'\H8 ^G:*\#_:2\=^-_#AT2;P
MS</I6C1Z3JFM:G-!=P6]^RVUL'6%4N+&ZCY+Y/W#D#G (;*@_:.\0>$=6\5W
M6O:/#JO@W3=;DTT:A%J,8U*-ETR.\\N*S6$+*N-Q+-*CY8D1E%#$ ^D:*^=_
M!/[3GBOQK_8=G%\-);#5=6U3['$=3N-0T^R%N+5[EIQ)=Z=#+(P6)TV) R[V
MC_>;69DZKXA?'#6/!GQ"N=#L_"<&J:-IUKH]YJ>JR:KY$D27][<6BK#!Y+>:
MZ-;[R&= 58_," & /7J*\/U#]I@6>DZ--%X?CEU#5M,DNK:TDU(1JMT=1M=/
M@@E<Q_(CS7:[I=I*!&PCGBL#QG^T-XM^&FN:M!K7AZ#4=8FM]'M['P_I$MW?
M6L5U.VI/,QGM[![IT,-F#\MJV&51M52T@ /H^BO%?#O[1TFM:/#=W?A.\T:\
M?5-*THZ;J$CV]P'O$C8GRY8D<;"[X5E4L$R=F2%ZOX,_$35OB1X<O;W7="M_
M#&JVMZ]K+I$=U<3S6X"(P$WG6UN5<[CPBO&R['2617!H [^BBB@ HHHH ***
M* "BBB@ HHHH ^=_^"?/_)H?@+_M_P#_ $X7-?1%?.__  3Y_P"30_ 7_;__
M .G"YKZ(K6M_$EZLSI_ O0*\[_:._P"3>?BA_P!BMJG_ *22UZ)7G?[1W_)O
M/Q0_[%;5/_226IA\2*ELP_9Q_P"3>?A?_P!BMI?_ *215Z)7G?[./_)O/PO_
M .Q6TO\ ])(J]$HG\3"/PH****@H**** "BBB@ HHHH **** "BBB@ HHHH
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M].%M6M'^)'U1G4^!^@?L;_\ -<?^RI:Y_P"T*^B*^=_V-_\ FN/_ &5+7/\
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M"%_Y6-0_^/T?\.^?@#_T(7_E8U#_ ./T44>VJ?S/[P]G#L@_X=\_ '_H0O\
MRL:A_P#'Z/\ AWS\ ?\ H0O_ "L:A_\ 'Z**/;5/YG]X>SAV0?\ #OGX _\
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M\K&H?_'Z/^'?/P!_Z$+_ ,K&H?\ Q^BBCVU3^9_>'LX=D'_#OGX _P#0A?\
ME8U#_P"/T?\ #OGX _\ 0A?^5C4/_C]%%'MJG\S^\/9P[(/^'?/P!_Z$+_RL
M:A_\?H_X=\_ '_H0O_*QJ'_Q^BBCVU3^9_>'LX=D'_#OGX _]"%_Y6-0_P#C
M]'_#OGX _P#0A?\ E8U#_P"/T44>VJ?S/[P]G#L@_P"'?/P!_P"A"_\ *QJ'
M_P ?H_X=\_ '_H0O_*QJ'_Q^BBCVU3^9_>'LX=D'_#OGX _]"%_Y6-0_^/T?
M\.^?@#_T(7_E8U#_ ./T44>VJ?S/[P]G#L@_X=\_ '_H0O\ RL:A_P#'Z/\
MAWS\ ?\ H0O_ "L:A_\ 'Z**/;5/YG]X>SAV0?\ #OGX _\ 0A?^5C4/_C]'
M_#OGX _]"%_Y6-0_^/T44>VJ?S/[P]G#L@_X=\_ '_H0O_*QJ'_Q^C_AWS\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>kros-20251231_g3.jpg
<TEXT>
begin 644 kros-20251231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C ><# 2(  A$! Q$!_\0
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M6_ SXAZ=H.@Z=HMW9W&EQWSOJ,$SR!VFF0@%)4&,1KVSDGFO&/\ AXE\1_\
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M)X6_\!+G_P"2*/\ AXE\1_\ H">%O_ 2Y_\ DBOENBCZ_BO^?C#_ %,X>_Z
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M$\+?^ ES_P#)%?+=%'U_%?\ /QA_J9P]_P! </Q_S/J3_AXE\1_^@)X6_P#
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M-G\'?]OG_I;/17W>&DY4(2ENTOR/XZSVC3PV;8NA1C:,:DTEV2DTE\D?+?\
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M_P#B*/\ A1OPX_Z)_P"%O_!+;?\ Q%']B5/YT'_$6\#_ - L_O1^0%%?K_\
M\*-^''_1/_"W_@EMO_B*/^%&_#C_ *)_X6_\$MM_\11_8E3^=!_Q%O _] L_
MO1^0%%?K_P#\*-^''_1/_"W_ ();;_XBC_A1OPX_Z)_X6_\ !+;?_$4?V)4_
MG0?\1;P/_0+/[T?D!17Z_P#_  HWX<?]$_\ "W_@EMO_ (BC_A1OPX_Z)_X6
M_P#!+;?_ !%']B5/YT'_ !%O _\ 0+/[T?D!17Z__P#"C?AQ_P!$_P#"W_@E
MMO\ XBC_ (4;\./^B?\ A;_P2VW_ ,11_8E3^=!_Q%O _P#0+/[T?D!17Z__
M /"C?AQ_T3_PM_X);;_XBC_A1OPX_P"B?^%O_!+;?_$4?V)4_G0?\1;P/_0+
M/[T?D!17Z_\ _"C?AQ_T3_PM_P""6V_^(H_X4;\./^B?^%O_  2VW_Q%']B5
M/YT'_$6\#_T"S^]'Y 45^O\ _P *-^''_1/_  M_X);;_P"(H_X4;\./^B?^
M%O\ P2VW_P 11_8E3^=!_P 1;P/_ $"S^]'QM\9/CIX'\5?LH>$_!NE:W]J\
M26-KID=Q9?9)TV-% %D&]D"'!&.&.>V:^2:_7_\ X4;\./\ HG_A;_P2VW_Q
M%'_"C?AQ_P!$_P#"W_@EMO\ XBNBOE=;$24I36BMLSPLG\0LJR6C.AA\-4:E
M*4WS2C>\M]DM#\@**_7_ /X4;\./^B?^%O\ P2VW_P 11_PHWX<?]$_\+?\
M@EMO_B*Y_P"Q*G\Z/=_XBW@?^@6?WH_("BOU_P#^%&_#C_HG_A;_ ,$MM_\
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M*-^''_1/_"W_ ();;_XBC^Q*G\Z#_B+>!_Z!9_>C\@**_7__ (4;\./^B?\
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M\#^=<RQD<QQU?&Q5E4G*27;FDW;\27X)_P#)WG[2G_<M?^F^2OHBOG?X)_\
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M*Y.!&9%_UQ]AT]17OOC#X-^"I5N=:\;ZCJ6LV$;^8Z:QJ+_9(<GKY:;4P/\
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M_P"RI:Y_[0HK6K\;,Z?PH/@G_P G>?M*?]RU_P"F^2OHBOG?X)_\G>?M*?\
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M_P!E2US_ -H44?L;_P#-<?\ LJ6N?^T**UJ_&S.G\*#X)_\ )WG[2G_<M?\
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M2J?,%C+WZ'\15&9'M(TXKGYK=^#]#_@:K[4TO5EE VPSKC/H.OZ']#5W8/\
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MUW5_U1YLN)*E3F5&E;M=J_SL^YY%8_#Z>\O)H-0U1;.0+NEM;6W=W5>F2Y
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M1FXF\]Q-(H@ +*D:L69@JDG-33_@'XDT^:XGB\8:=$8_$46O:;8QZ1<M8V8
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MCTK=T7X?O-J%K>^(YXKY\%K>RMUVVT!Z].Y_SDU7TWQ!X:^'MB]A;W'VR>4
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MB6-?R %5]6\2:=H=_HUE>W'DW.L7;6-BFQF\Z98);@ID A?W5O*V6P/EQG)
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M(^'-S;7.N3VJ^')-:DO]-L;R.>*:?_2+F?3U"2+# S%;9;M"SQJLC!MX]7^
MWB[5O'/PUM=9UQD;4IM0U*)UC9&6-8K^XBCC#( K!415W ?-MR>3F@#T&BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=_V-_P#FN/\ V5+7/_:%
M%'[&_P#S7'_LJ6N?^T**UJ_&S.G\*#X)_P#)WG[2G_<M?^F^2OHBOG?X)_\
M)WG[2G_<M?\ IODKZ(HJ_%\E^2"&WS?YA11161H%%%% !1110 4444 %%%%
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M.^$W_14/!G_A06G_ ,<H_P"&COA-_P!%0\&?^%!:?_'*.278.9=ST2BO._\
MAH[X3?\ 14/!G_A06G_QRC_AH[X3?]%0\&?^%!:?_'*.278.9=ST2BO._P#A
MH[X3?]%0\&?^%!:?_'*/^&COA-_T5#P9_P"%!:?_ !RCDEV#F7<]$HKSK_AH
MWX3?]%0\&?\ A06G_P <H_X:-^$W_14/!G_A06G_ ,<HY)=@YEW/1:*\Z_X:
M-^$W_14/!G_A06G_ ,<H_P"&C?A-_P!%0\&?^%!:?_'*.278.9=ST6BO.O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>kros-20251231_g4.jpg
<TEXT>
begin 644 kros-20251231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &B!2$# 2(  A$! Q$!_\0
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MQ;P2IDL57=&<*>'<#.!G) K[+TW4;?5].M;^SE$]I=1+/#* 0'1@&4\^H(H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5HH _+;]E.R\9_$>;X[_  R^'7C+Q)X]^!%]X.O=-T#Q!XM@EC\K4)X!%'%
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MM?V:?V?]"M?A_HGB?XOV4<Q@TBWL;Q+^XF2>6296>Y8A1;QAM@D.=JB,<]:
M/<:Y;Q9\5?!7@'4+&P\3^,- \.7]^0+2UU;4X+66X).T"-9&!?)XXSS7SOX'
M_;?\0K\>/#OPI^*_P@O_ (6:[XD@:;1K@:W!JUO<8#G:[PHH0DH1@%B"5R "
M#7QIX+UKQE\7_P#@IAXYN/&'P&T_Q;K":7!;7?@_5==LYXO#MNIL8S?1SR(8
MY616WA(P&S<M@@@T ?KY17RCXX_;AUBX^+'BCX?_  ?^$VI_%[5O":_\5!<P
M:K#IEM9/D@Q*\B-YD@*LNP $E6"[MIKQW]IW]MS6OBQ^P?J_CSX3Z3K.B%KV
M/3=>U:'5TL+[PO,EU;8&%.^;SO,6,&,@A9=S8P5H _1"BOSV\(_MQ?%7X-?L
M:^&/B#XV^#UUK6G6T&E6<.NW7B^&6;6(9H9-U](%AD>([TA!63YF-P.?E.?=
MOVDOVTM.^!_@7X:Z[X>\.GQWJ'Q O;>WT72X[\6;3PS1!Q,'\N3.#) NW'/F
MCGCD ^DZ*S/%#%/#6K,I*L+28@C@CY#7Y4_\$P?V-/@]^T7\ _$'B7XA^$/^
M$AUNV\3W&GQ71U2\MML"VMI(J;89D4_-+(<D9^;K@# !^M-%?-7QI_:OL_@A
MXY\,?"#P!X$U'XD?$&[L%EM?#MA>+:Q6MHBD*T]S*&"?*C8R#PN6(W+N=\ ?
MVRQ\5/BQKOPI\:^!=0^&/Q,TBV^V/HMY>QWT,\/RDM%<1A5<A71NF"&)!.UL
M 'L%G\:OA[J'A/4?%-KX\\,W/AG39?(O=:AUBW>RM9,J-DLP?8C9=!AB#\R^
MHKI](UBP\0:7::GI=[;ZEIMY$L]M>6<JRPSQL,JZ.I(92"""#@@U^)WP3_Y1
M*?M#?]C/IO\ Z4Z;7W)X(_:KT3]FO]CW]GVSDT:_\6>,/%&AV-CH7AK2R!/>
MR^5&"2QX10SQKG!.7& >< 'VS17RAX$_;BU>/XT>'_AA\7OA1J'PD\1^)(]^
MBROK$&JVEV>@0RQ*H1R05V\X.T'&X5;^#'[=6G?$SPO\:]2UWPN?"6H?"R:Z
M74]-.HBZ:6*%93O#>4FTEH)5VX;! Y.<4 ?4E%?(GPE_X*':+\3?V4?'GQGG
M\,'1I?"4DT%QX?.IB8RR!(V@ G\I<"5I53.PX(;@XKWC]GWXI7GQM^#/A3QW
M?:!_PC$^O6GVU=+^U_:O*B9F\H^;L3=N0(_W1C?CG&2 >AT5^>?[6$SQ_P#!
M43]FS8[+_H./E..#+<@_F.*O?\%J'9/V6?"Q5BI_X3.TZ''_ "Y7U 'W]17R
M7\:/VYK7]G?XF?#CX?7G@G4_%#^)=#2[ANM*N UT;@ATAMTMRGSF21%7<9%"
M[\D'%7?@_P#MNWOBSX_2_!OXC_#2^^%?C>:U-[IEO<:K#J,-]$$+\21JJAMB
MN<+O'[MP6!&* /J>BBB@ HHHH **** "BBB@ HHHH **** /SE_:Q_:2_9C^
M.W@'Q-H/BKPSJQ^*D%G<VFBZ5?>&KF'6H[L!A"(YD0J$\Q0=IDVD Y4]*\8\
M:?!#XI_#[]C']G3Q3X@\-ZMJ<W@/Q--K%_H?E-+>66GR3I+$'3JJ@0\J?N>:
MH;;@@?L#10!\I77[8WPY_:4^%_Q*T7X>3:QKAA\%ZI?7.H-I$]O:6S"#8+9Y
M)%7,S&7(5 P(C<[N!GAO^"7&@S:]^P0VF1M]FDU*ZU:WCF=3@%R4#>X!]/2O
MN:B@#\3O@/H?@/X6^"]>^''QP^*7QK^$7BF&^N;9_"GAV[N$TS4X7 4F**.V
ME5R_S*Q)VN-I!(->H_M4?LYIX=_9M_9LU[X?Z;\0/^$ \%ZE=WE\LJ"+Q+96
MUY=0W'V@!%"Q2*8GV,$PI>,GN3^L%% 'YK? /0?@)\5_VA_AYJOACXM?&[XO
M>)]%GFNK6;Q'--=:?I!6!Y&%U+/:QF-6**F(V.YVC'(-;/\ P2[@EC^/O[6[
M/&R*?%$"AF4@$BZU,D?D1^8K]$** /Q<\!PR-_P3$_:B 1B1XUM<C'I>:>3^
M0KK/CE:SGP3_ ,$Z5$,A8&W&-ISDR:40/Q /Y5^N]% 'P/\ M>*Q_P""C'[+
M1"DC_2>WHQS7R1#KWBIOB-^T5I>DWGQ%T#PQK7B>^@\26'PS\)0>(M,:V9W#
M%KI[E#:R,IEW%!R#C "[!^U]?$WAW_@GKXU^%,?B31?A3^T#J_@7P1K]W)=W
M>AS>';;4)0T@"OY=R[JR'8JJ&50?E&22* /9_P!BOQ-\-O$/[.7A2#X4W]U?
M^$=)B.FH=07;=QS(=T@G7&!(2^\X^7YP5X(KXFUGX$^#/V@/^"N7Q6\-^/\
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M[QM^T]H7C?\ X)HK\&]'T#7+CQ[I.G6MGKMC'I<L<.CPV5U',]U<2LNP!U@
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M*74/_CU0T5P_6\1_S\E][/I_['RW_H&A_P" 1_R)O[6UW_H;O%G_ (4NH?\
MQZC^UM=_Z&[Q9_X4NH?_ !ZLW63C1[XC@^1)_P"@FO"_V&R?^%!6/_7]<_\
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M<.&4[=RL.JD'O6W7.\5B4[>T?WL]Z&4Y74BIQPT+/^Y'_(F_M;7?^AN\6?\
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MLX4[($ # ?\  MQ_&O.*^LHTU"*?4_&:DG)V"O6?A+^T!K/@34(+34[F;4]
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M"K]HJ2RE^(7@VS\0W5FGE07AEEMKA$SNV>="Z.4R2=I;&23CDUTG_"Y/ _\
MT-.E_P#@0M._X7#X(_Z&K2O_  *7_&CDEV'S+N<1??L:_!;4?A5;_#>?X?Z8
MW@VWN3>0Z>K2J\<Y&#*)@XE#D<%M^2."<<56^'7[$OP2^$OBKP_XE\(^ K31
M-=T$3BPOH;NY:1/.C,4F\M*?-)1F4&3=MR<8KT'_ (6]X)/_ #-6D_\ @6G^
M-._X6YX*/_,UZ1_X&)_C2Y9=@YEW.5\-_LK_  J\)P^/H=-\&VBP>/)?.\20
MW,TUS'J#;I&RRRNP3#32$! H!;(Z#'!Z;_P3A_9QTFWDAM?AE9Q[[F.Z\UM0
MO7E61#E=LC3%U7/5%(4X&0<5[/\ \+9\%'_F:]'_ / V/_&G?\+6\%_]#9HO
M_@?%_P#%4<LNP<R[G+_&[]F'X8?M&Q::GQ$\)6_B)M.W?9)C<36TT0;&Y1)"
MZ-M.!\I...E)IG[+_P ,-&^(7A7QS9>%8K;Q1X7TE-#T>^2ZN,6EDD3PI$L?
MF>6<1R.NYE+8;K75?\+4\&?]#9HG_@PB_P#BJ=_PM'P:?^9LT/\ \&,/_P 5
M1RR[!='EOQ*_83^!'Q>\82^*?%7P[L;_ %Z9_,GNX+FYM//?CYI4AD19&.!D
ML"3WKLO$_P"SK\./%_PE'PQU'PG9KX# C"Z)8L]G$NQQ(I!A9&!WC<2#DG).
M<FNA_P"%G>#C_P S9H?_ (,H?_BJ=_PLKP@>GBK1/_!C#_\ %4<LNP71RWCS
M]FSX;_$SX5Z/\-_$GAM=0\%:0ELECI:WEQ"(5MX_+A DCD60[4XY8Y[YKTBU
MMX[.WBMX5V0Q($1?10, ?E6#_P +(\)'IXHT4_\ <0A_^*IW_"Q/"AZ>)]&/
M_;_%_P#%4<K[!='0T5S_ /PL+PL>GB71_P#P/B_^*IW_  GWA@]/$>DG_M^B
M_P#BJ.5]@NC>HK"_X3OPT>GB'2C_ -OL7_Q5.'CCPX>FOZ6?^WV/_P"*HY7V
M"Z-NBL;_ (33P\>FNZ9_X&1__%4O_"9:!_T'--_\"X_\:5GV"Z-BBLG_ (2[
M0CTUK3S_ -O4?^-+_P )7HA_YC&G_P#@4G^-%GV"YJT5F?\ "4:,>FK6)_[>
M4_QI?^$DT@]-5LC_ -O"?XT687-*BL__ (2'2O\ H)V?_?\ 3_&E&O:8>FHV
MA_[;K_C19C+]%4O[;TX]+^U/_;9?\:7^V+ ]+ZV/_;5?\:+,"Y157^U+(]+R
MW_[^K_C2_P!I6AZ74)_[:#_&@"S14'VZV/2XB_[[%+]K@/2:/_OH4@)J*C^T
M1'I(G_?0I?-0]'7\Z 'T4FX'H:6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** *.O7TFF:'J-Y$%,MO;R2H'&5RJDC/MQ7C
MWP__ &IM \2>5:Z]'_8-\<#S6):W<_[W5?Q_.O5_&!QX1UL_].,__HMJ_.>N
MRA3C43N85)N+5C]*[>YBO($F@E2>%QE9(V#*P]01UJ6OS\\#_%3Q+\/9@VD:
MBZ6^<M:3?/"WU4]/J,&OI3X?_M3Z!XB\NUUZ/^P;X\>:26MV/^]U7\?SJ:F'
ME'5:H<:JEN>WT5%;W,-Y DT$J3PN,K)&P96'J".M2URFQ\5:]\9/B,_BKQ-'
M;^.+^RM;;6]1M(+:&PL"D445W+%&H+VS,<*B\DDFJ?\ PN#XE_\ 10M4_P#!
M?IO_ ,BUSVK?\C9XN_[&35__ $X3U#7A8C%UH5IQB]$WT7?T/W/*\BRVM@*%
M6I13E*$6WKJW%7ZG3_\ "X/B7_T4+5/_  7Z;_\ (M'_  N#XE_]%"U3_P %
M^F__ "+7,45S_7:_\WX+_(]/_5[*O^?"_'_,Z?\ X7!\2_\ HH6J?^"_3?\
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M  O_ &;+SXC>%4UN76/[(CEE9(8GM#)YB# WYWKP3D=.U=;_ ,,9S=O%L?\
MX+S_ /'*^DM*TNUT33;73[*%8+2VC6**->BJ!@"K=>7+$5+Z,ZU2C;4^8/\
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MRB?)'_#'OBCMK&D?]]2__$4W_AC[Q5VU?1_^^Y?_ (W7US11]9J![*)\B_\
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M+_S*FN#_ +ATW_Q-?H511]:EV#V*[GYZ_P#"N?&2_P#,KZX/^X?-_P#$T?\
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MZ7X@TC4;>\UNVM+6+Q!:VMI<00V6HO CS0IYR_,JL6 *LXP!\QZUT_QF^/\
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M\K,V0ID*EABOUS^)FJ:CHGPW\5ZCI&D+X@U:STF[N+/2'7<M],D+M' 1W#L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_P3_P"A*_\ *K>__'J/J</YW]W_  0]LNQ]X45\'_\ ##_P3_Z$K_RJWO\
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M6]_^/4?\,/\ P3_Z$K_RJWO_ ,>H^IP_G?W?\$/;+L?>%%?!_P#PP_\ !/\
MZ$K_ ,JM[_\ 'J/^&'_@G_T)7_E5O?\ X]1]3A_._N_X(>V78^\**^#_ /AA
M_P""?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J/J</YW]W_!#VR['WA17P
M?_PP_P#!/_H2O_*K>_\ QZC_ (8?^"?_ $)7_E5O?_CU'U.'\[^[_@A[9=C[
MPHKX/_X8?^"?_0E?^56]_P#CU'_##_P3_P"A*_\ *K>__'J/J</YW]W_  0]
MLNQ]X45\'_\ ##_P3_Z$K_RJWO\ \>H_X8?^"?\ T)7_ )5;W_X]1]3A_._N
M_P""'MEV/O"BO@__ (8?^"?_ $)7_E5O?_CU'_##_P $_P#H2O\ RJWO_P >
MH^IP_G?W?\$/;+L?>%%?!_\ PP_\$_\ H2O_ "JWO_QZC_AA_P""?_0E?^56
M]_\ CU'U.'\[^[_@A[9=C[PHKX/_ .&'_@G_ -"5_P"56]_^/4?\,/\ P3_Z
M$K_RJWO_ ,>H^IP_G?W?\$/;+L?>%%?!_P#PP_\ !/\ Z$K_ ,JM[_\ 'J/^
M&'_@G_T)7_E5O?\ X]1]3A_._N_X(>V78^\**^#_ /AA_P""?_0E?^56]_\
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MG?W?\$/;+L?>%%?!_P#PP_\ !/\ Z$K_ ,JM[_\ 'J/^&'_@G_T)7_E5O?\
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M?_CU'_##_P $_P#H2O\ RJWO_P >H^IP_G?W?\$/;+L?>%%?!_\ PP_\$_\
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M_(>+HX_$>UC-2<4XR6RVDKI+K97:=_57/9=0\13>$/ ,^N>(_L_VG3=--WJ
ML-WE&1(]T@BW<[2P(7//(SS7R'\:?B3\2/B1^SI>>(-7\/Z'9>#]6GA-M]DN
M)?MMLJSC:\@;Y75BN!MP>0<8KZZU3PS-XN^'UQH'B&2%KK4=--G?RV2D1^8\
M6V1HPW(&XDKGGI7SKJ/[-OQ6U3X2O\.KCQ5X<;0+%MUC(L,PN+D"3<D<S$$1
MHN<C8&/R@9QS6>'E"+O*U[K[O([<YI8NM3=*BI.#A):6^+2W-?I:^WYV.NO_
M (P>)V\1>'/AUX TS2[S7UT.#4+V^UN21;6VCV* "L?S$G*]/[R]><9UO^U!
MXAT/PS\1(?$GAFU/B_P<(6EM]-E8VMRDKJ@D7.655W!CDGY3VYQK^(O@?XOT
M7QUI'CCP'JVCV^OQZ3'I.H66LI*;2Y1%4;MT8W_PIQ@?<7GJ*3PG\#?&GA^U
M\9>(Y/$FE2_$/Q)+"\DWV,OI\44;#,&UAN*LN5+8R!C'()-?N;:VZ=[WOK\C
M)K,_:-1YE\7\KCR\ONV3WES6_&^@>!/CUKK^ =?\7^*F\+ZEHUA8"]BF\+7C
MNRR'I;3)(24D)(&>F<UQ&F?M>>(+.3P[K&N?\(7<>']:NHX#I>BZFTVK:>DG
M(>=-Q' '( '. =I-;?A/]E74[W4/&VH>+)]!TEO$FEG3#IOA.WD2TB8NCB?$
MF/G#1J<8YRW/-0>#?V:_%NA2:1I=[8?#232-/EBW:PGA\2ZI<1HP.&WIL#,!
M@ODGG.2:O]QJ<S_MEJFES):]FV^;=KLUT>VMWL?3M%%%>8?>A1110 4444 %
M%%% !7V9\ _^2%_#G_L6]-_])8Z^,Z^S/@'_ ,D+^'/_ &+>F_\ I+'7O9;\
M%3U7ZGY1QU\6%_[?_P#;#O****]4_+@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#_V
M*?\ 3/V?=(UN7YM1UR^O]1OYL<RSM=RH7/OMC4?A7NM>%?L/_P#)KO@K_M]_
M]+9Z]UKZ2I\;/.ENPHHHK,D**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X/_8?_ .37?!7_ &^_^EL]
M>ZUX5^P__P FN^"O^WW_ -+9Z]UKZ2I\;]3SI;L****S)"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=/B]^R GQD_
M:"\)_$;6/%LBZ5X>%OY/AU=/#+(8I6EYF\S@,Y&[Y"<#&>F/HNBBI45&[74I
MML****HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "L;_@G)_P F9_#W_N(_^G&YK9K&_P""<G_)F?P]_P"XC_Z<;FN?$_P?
MFOR9TT=V?2E%%%>.=04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<HH^IT>P?VE5_E7X_P"9]1_\/$-6_P"B5?\ EQ)_\CT?\/$-6_Z)5_Y<2?\
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MC_AXAJW_ $2K_P N)/\ Y'KY<HH^IT>P?VE5_E7X_P"9]1_\/$-6_P"B5?\
MEQ)_\CT?\/$-6_Z)5_Y<2?\ R/7RY11]3H]@_M*K_*OQ_P SZC_X>(:M_P!$
MJ_\ +B3_ .1Z/^'B&K?]$J_\N)/_ )'KY<HH^IT>P?VE5_E7X_YGU'_P\0U;
M_HE7_EQ)_P#(]'_#Q#5O^B5?^7$G_P CU\N44?4Z/8/[2J_RK\?\SZC_ .'B
M&K?]$J_\N)/_ )'H_P"'B&K?]$J_\N)/_D>OERBCZG1[!_:57^5?C_F?4?\
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MJ/\ \D4<M'^9_<O\PU/I2BOFO_AW)^SO_P!$]_\ *WJ/_P D4?\ #N3]G?\
MZ)[_ .5O4?\ Y(HY:/\ ,_N7_P D&I]*45\U_P##N3]G?_HGO_E;U'_Y(H_X
M=R?L[_\ 1/?_ "MZC_\ )%'+1_F?W+_Y(-3Z4HKYK_X=R?L[_P#1/?\ RMZC
M_P#)%'_#N3]G?_HGO_E;U'_Y(HY:/\S^Y?\ R0:GTI17S7_P[D_9W_Z)[_Y6
M]1_^2*/^'<G[._\ T3W_ ,K>H_\ R11RT?YG]R_^2#4^E**^:_\ AW)^SO\
M]$]_\K>H_P#R11_P[D_9W_Z)[_Y6]1_^2*.6C_,_N7_R0:GTI17S7_P[D_9W
M_P"B>_\ E;U'_P"2*/\ AW)^SO\ ]$]_\K>H_P#R11RT?YG]R_\ D@U/I2BO
MFO\ X=R?L[_]$]_\K>H__)%'_#N3]G?_ *)[_P"5O4?_ )(HY:/\S^Y?_)!J
M?2E%?-?_  [D_9W_ .B>_P#E;U'_ .2*/^'<G[.__1/?_*WJ/_R11RT?YG]R
M_P#D@U/I2BOFO_AW)^SO_P!$]_\ *WJ/_P D4?\ #N3]G?\ Z)[_ .5O4?\
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M\0PZ9-J.D:UX8LOLGEO&5 21 <R??!.3@@'@'!JO\-YOA_\ #W]CFQ\=>(?
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M;Z.ZW2NM7^9\TT5]!_MU>%M&\'_M":CIV@Z39:+IZV-JZVFGVZ01!C'R0B
M$]^.:]D^*W[/?AGQM^V9X&\&6.CV6A>';C0(;_4+?2H$M5D5#.S\(!\S[$0L
M.<'/:M/K<%&,VM&F_N,OJLG*4$]4TOO/ABBOI+QA^TGX"FU+7="LO@IX-E\)
M[9K2PN;: V^I8&52<W0!.3PV-N>VX]:VK.S\)?LU_ #P7XGU#P7HOC;QUXU$
MUU!_PD,7VJRLK5"NW$7 )(>,]CEF^;"@57UB22O!W>RT_K07L(MNTU9;O4^4
MZ*^IOB+H_A#XU_LRWGQ3T7PGIG@?Q-X=U2/3M3L]%C\JTNXWV ,L0.$.9E.>
M3\K D\$;_P 8M>\&_LF:GH/@#2_AIX4\8ZG#8076MZQXELOM4L\L@.Y(LG]U
MPN0<D#</EX),K%<UHJ+YM=/3_AT-X:UY.7NZ:^O_  S/CJBOJKX3Z'\/]3T?
MXH_''6?!%NOAO1)(8=)\(?:FEMOMDNU2')490.Z$ C: [?*=BUN_"35O!O[7
M$'B?P3J?PX\+>#/$,.F3:CI&M>&++[)Y;QE0$D0',GWP3DX(!X!P:)8KEN^5
MV6^VG^=NH1PO-9<RN]M]?^'/CBNI\"_"_P 3_$S^V/\ A&M*;4_[(LWU"]VR
MQQ^5 O5OG8;C_LKECV%?2WPWF^'_ ,/?V.;'QUXA\"Z3XI\0KXCFM-/^VVRD
M2S&)MJSMC+PJ@D;RSP65>AP1V_['WQC7QE>?%2:'P1X0T".'0FO_ "=)TI85
M9EB5&B;GF%F0OY9[NW)K.KBIQA.4(?"[:^IK3PL)3A&<OB5]/0^0/A'\/-.^
M)7B*\TW4_%VD^#((+&2[2^UB18XI75E A4EA\S;B1ST4\&N(KZR_9@U/1_CE
M\;M?NM?\$>$K2VM_"5T8],TW1XXK-9$DC*S>4VX>9\Y&_KC%8WP7\.^$_AC^
MSSK?Q>\3>&K#Q?JUQJJZ)H>EZL-]H'V;GD=.C' ?@CI'QC=FK>(<924EKIIY
MNYFL.I1BT]-=?)6/F:BO?[/7-&_:D\<>!?"-MX \/^!]9NM2\J]U3PTOV6&6
MU(RX%O@J'558ABQR>. :[?QU\>/AS\+_ (F7_@S2/@QX0U7PCH=V^FW5UJ-D
M)]3N6C;9(Z3L3M^8-C.[. <C/%NO)-14/>WM=?UJ0J$;<SG[NU]?ZT/GOX2^
M =/^)/C&+1=3\5:5X-M&ADE;5-8D"0@J,A,D@;B>F2._4X!Y2^MEL[ZXMUFC
MN%BD:,31'*2 $C<I]#U%?<_A']GOP=X-_;FM/#D>EV>L^$=2T635[33=2@6Y
MBA5T8!")-V[#(Q4GD CN,GRO]GGPOX6\&_ GQQ\8?$GANS\876F7T6D:7I6I
M)OM5F81EI)%/#C$R<$<;3CELC)8N+O)7:M&R];FKPK5HNRUE=^ECC/@G\%M%
M^)7PI^+?B;4KN_M[_P (Z?!=V,=K(BQ2NXG)$H9"2/W2XVE>IKQBON[X6_$S
MP_\ $[]FWX[7FG^!])\&:[;Z)%%J7]@QF"RNT*W)A9(<D1LO[T'KG*\G  P?
MASX-CLOV<?"WB+X:?#;PI\3M;>:X/B@:Y:+?WELZM\D<<)8%1M_N<D;2 =Q-
M9QQ4H2GSKJE:ZTT[FCPT91AR/HWUUU['Q?170_$*_L]3\;:S<V'A[_A$[:2X
M;&B>8TGV-AP\>6 /#!N"!CIVKT7X'_ T>.WTG7CX^\"Z (M21#I6O:S]FO9-
MCJ<K%L.0V<+SR<UZ$JBA#GEH<$:;G+ECJ>,T5]?_ +9GP-_M+XM>/?&'_"P/
M MIM2.Y_L"YUK9JIV6T8\L0;/OMMRJ[N0R^M?(%30K1KP4T56HRHS<&>S_&7
M]F?5/AE\6-!\ Z-?2>+=5UBRM[JW\FT^SG=*[KLV[WX'EDEB0 ,DX K6UC]E
MVQT_X]>&?A7:>.(=2UB_ 75+J'3SY.FS;"YB'[W,K *?[G5>AR!]O?&"Q&FZ
MAXQ\4>"%BU#XOV'A.TCL[:=0SVEB9)=\]NN/GE.9!WY1!C#8?X2_8]NI[[]J
M;P1<W,TEQ<37TTDLTK%G=C#*2S$\DDG))KS*.(JU:,JE_A7WNU[^GYGI5L/2
MI58PM\3^Y7V]?R-WQ!^S_P#!OPKKVI:+JG[0'V74]-N9;.Z@_P"$,O'\N6-R
MCKN60@X8$9!(..#63\&?V;]&^*'A'QMXJU;QXOACPWX9F2-[[^R)+LS(V[]Y
MY:NK*,!> &/S'ICGK/CG\+_A'<?$KX@ZC<_&S[+KKZOJ%Q)HO_"*7;^7<&:1
MC;^<&VG#_)O P<9Z5U'[).EZ3K7[+7QILM=UK_A'-(FDMUN=4^R/=?9EV_>\
MI"&?G P/6JE6G&ASJ;O[NZ[O6WNJ_P"),:4)5N1P5M=GV77WG;\#S3Q=^RWI
MP^%^I>/OAY\0++XA:'I+8U*--/EL+FV7(&[RG9B1SDYV\#(R,X\!K[2\4:#H
M7[.?[*>N3^!-0G^(-I\0'33[WQ0L2PVEHB;\1F#<71R'E'S=">2"%4^&^&?V
M1?BYXQ\/Z?K>C^#IKW2[^%;BVN!>6RB2-AD-AI 1^(KHH8A<LG4EI>R;LG^A
MA7H/FBJ<=;7:5VOU)OA-^SFGCCP+J7CKQ5XKM/ 7@FSG^RKJEW:O<R7,V =D
M,*D%\>H.<@@ X.'?&#]G!?A_X%TCQUX8\5VGCOP3J4OV9=4M;5[:2";!.R6)
MBQ3[I')R#P0.,^B?':U32?V*?@=9V^Z.&:YN[F5,_>E+2$D^X+L/;.*@^&K"
M;_@G[\6XY&^6'7[*6)3C[[2VBDC_ ("/TK+VU32KS:<UK>5[>M^II[*FKT[:
M\M[^=K^ENAQGA_\ 9MTRQ\ Z1XO^(_CVS^'VFZVOF:3:_P!GRZA>W<?_ #U\
ME"I5,%2&R>&&<9&<S1?@?X?\8?&SPWX%\+^/8-?TO6D##78],DB\AMLC%&@=
M@=P"#C</O"OI']LRT^#=C\6-/L_'-YXT>\M-*M[2VL?#<-M'!:6R[BI+3 [R
M2S_<&!C!Y'/F=QX.\/?LF_'[X:>-(-5O->^'^J6ZZM8W@B7[4(7C*D,GR@E?
M,1N@X;&,C%33Q$ZD.:[YI)V5E;Y:%5*$*<^6RLFKN^OSU.>UWX%?!GP_?ZAI
M]U\?MNHV,LD$MO\ \(9>G$J$JR;@Y'W@1D'%?/E?5>C?#/X,?M+>,=7LO!_B
MCQ5X>\;ZM-<7MI;>);2W-I/(2TKQKY)) QNQEL@#.&Q@_,6O:+=^&]<U'2+^
M,17UA<R6MQ&#D+(C%6&>^"#77AYWO&4FWV:2_)(Y*\+6E&*2\FW^;91HHHKL
M.0**** "BBB@ HHHH **** "BBB@ HHHH *_0#]A_P#Y-=\%?]OO_I;/7Y_U
M^@'[#_\ R:[X*_[??_2V>O,Q_P "]3W,MVG\OU/=:QO^"<G_ "9G\/?^XC_Z
M<;FMFL;_ ()R?\F9_#W_ +B/_IQN:^=Q/\'YK\F?14=V?2E%%%>.=04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 97BKQ%:^$/"^L:]?;OL6EV<U]/MQGRXT+MC/LIKYU
M_9.^&S?$"WC^//CZ"/5?'/BE?M6EI/\ O8=#TXL3;P6P(^4E"&+]3NZ\L6]5
M_::_Y-O^*_\ V*>K?^D<M'[,O_)M_P */^Q3TG_TCBKIB^6DVMV["ZGI5%%%
M<PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!DT,=Q"\4J++%(I5T<95@1@@CN*^4KOP]'^R;^T9X5?PPOV/X:?$J^
M;2[[08SB#3M6*[H9[=,802;2K(#CKQPH'UA7S7^VM_Q\? /_ +*KH?\ *>NF
M@_>Y.C$SZ4HHHKF&?!_[#_\ R:[X*_[??_2V>O=:\*_8?_Y-=\%?]OO_ *6S
MU[K7TE3XWZGG2W9^.7A+_D7[3_@?_H;5L5C^$O\ D7[3_@?_ *&U;%?3Q^%'
MR&(_C3]7^844451SA1110 4444 %%%% !1110 4444 %26]Q+9W$4\$KPSQ,
M'CDC8JR,#D$$="#WJ.B@#ZU\>?$+X._M2Z3I6O>-?$U[\-/B%:6R65Y<1Z9+
MJ%G>*IR'"1\CJV,E2,D'< IKB?\ A8/PT^!_C_P)JWPS&I>)KW0[MKG5=<U)
M6MUOXW4(T,,)(V (9/F89RPSN KP"BN..%C%<O,^7MT_S_$ZY8F4GS67-WZ_
MY?@?5_B'3_V:_%_Q$N/'ES\0M8L[&^NFU.\\(OH<S3O,[>8\0G ,:J6)&.>I
MPPX-:'P]_:M\/ZY^UEXB^(GBFZD\/^'[G2)M-T^.6%YVB0!!$A$2L<MM9CU
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M.PRQK.HK:G15.3FVVWU?_ L95*SG%1222[?\&X4445N8!1110 4444 %%%%
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MWX]>#=*T;PA\5-:^$U]9WXNY=4T02F6XC$;IY+>7/"=N7#<L1E1QW'Y?>(/
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M!^OM%?-G[#/[3=Y^T)^S)9>.O&#VFFZGILUQ8ZO?,5@MG: !C<'.%C!1E+=
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M]1_PP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_/^'_  3\_P"BOT _X8?^"?\
MT)7_ )5;W_X]1_PP_P#!/_H2O_*K>_\ QZCZ_#LP_LU?S_A_P3\_Z*_0#_AA
M_P""?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J/K\.S#^S5_/^'_!/S_HK
M] /^&'_@G_T)7_E5O?\ X]1_PP_\$_\ H2O_ "JWO_QZCZ_#LP_LU?S_ (?\
M$_/^BOT _P"&'_@G_P!"5_Y5;W_X]1_PP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#
M^S5_/^'_  3\_P"BOT _X8?^"?\ T)7_ )5;W_X]1_PP_P#!/_H2O_*K>_\
MQZCZ_#LP_LU?S_A_P3\_Z*_0#_AA_P""?_0E?^56]_\ CU'_  P_\$_^A*_\
MJM[_ /'J/K\.S#^S5_/^'_!/S_HK] /^&'_@G_T)7_E5O?\ X]1_PP_\$_\
MH2O_ "JWO_QZCZ_#LP_LU?S_ (?\$_/^BOT _P"&'_@G_P!"5_Y5;W_X]1_P
MP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_/^'_  3\_P"BOT _X8?^"?\ T)7_
M )5;W_X]1_PP_P#!/_H2O_*K>_\ QZCZ_#LP_LU?S_A_P3\_Z*_0#_AA_P""
M?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J/K\.S#^S5_/^'_!/S_HK] /^
M&'_@G_T)7_E5O?\ X]1_PP_\$_\ H2O_ "JWO_QZCZ_#LP_LU?S_ (?\$_/^
MBOT _P"&'_@G_P!"5_Y5;W_X]1_PP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_
M/^'_  3\_P"BOT _X8?^"?\ T)7_ )5;W_X]1_PP_P#!/_H2O_*K>_\ QZCZ
M_#LP_LU?S_A_P3\_Z*_0#_AA_P""?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_
M /'J/K\.S#^S5_/^'_!/S_HK] /^&'_@G_T)7_E5O?\ X]1_PP_\$_\ H2O_
M "JWO_QZCZ_#LP_LU?S_ (?\$_/^BOT _P"&'_@G_P!"5_Y5;W_X]1_PP_\
M!/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_/^'_  3\_P"BOT _X8?^"?\ T)7_ )5;
MW_X]1_PP_P#!/_H2O_*K>_\ QZCZ_#LP_LU?S_A_P3\_Z*_0#_AA_P""?_0E
M?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J/K\.S#^S5_/^'_!/S_HK] /^&'_@
MG_T)7_E5O?\ X]1_PP_\$_\ H2O_ "JWO_QZCZ_#LP_LU?S_ (?\$_/^BOT
M_P"&'_@G_P!"5_Y5;W_X]1_PP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_/^'_
M  3\_P"BOT _X8?^"?\ T)7_ )5;W_X]1_PP_P#!/_H2O_*K>_\ QZCZ_#LP
M_LU?S_A_P3\_Z*_0#_AA_P""?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J
M/K\.S#^S5_/^'_!/S_HK] /^&'_@G_T)7_E5O?\ X]1_PP_\$_\ H2O_ "JW
MO_QZCZ_#LP_LU?S_ (?\$_/^BOT _P"&'_@G_P!"5_Y5;W_X]1_PP_\ !/\
MZ$K_ ,JM[_\ 'J/K\.S#^S5_/^'_  3\_P"BOT _X8?^"?\ T)7_ )5;W_X]
M1_PP_P#!/_H2O_*K>_\ QZCZ_#LP_LU?S_A_P3\_Z*_0#_AA_P""?_0E?^56
M]_\ CU'_  P_\$_^A*_\JM[_ /'J/K\.S#^S5_/^'_!/S_HK] /^&'_@G_T)
M7_E5O?\ X]1_PP_\$_\ H2O_ "JWO_QZCZ_#LP_LU?S_ (?\$_/^BOT _P"&
M'_@G_P!"5_Y5;W_X]1_PP_\ !/\ Z$K_ ,JM[_\ 'J/K\.S#^S5_/^'_  3\
M_P"BOT _X8?^"?\ T)7_ )5;W_X]1_PP_P#!/_H2O_*K>_\ QZCZ_#LP_LU?
MS_A_P3\_Z*_0#_AA_P""?_0E?^56]_\ CU'_  P_\$_^A*_\JM[_ /'J/K\.
MS#^S5_/^'_!/S_HK] /^&'_@G_T)7_E5O?\ X]1_PP_\$_\ H2O_ "JWO_QZ
MCZ_#LP_LU?S_ (?\$_/^BOT _P"&'_@G_P!"5_Y5;W_X]1_PP_\ !/\ Z$K_
M ,JM[_\ 'J/K\.S#^S5_/^'_  3\_P"BOT _X8?^"?\ T)7_ )5;W_X]1_PP
M_P#!/_H2O_*K>_\ QZCZ_#LP_LU?S_A_P3\_Z*_0#_AA_P""?_0E?^56]_\
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M[./[0-@TK&T@C$\<797>SG5V^I$:?]\BO2/^")G_ ";_ ..?^QG;_P!)(*]
M_8G_ &'?%G[,7@+XN>&];UO1M3'BH^5ID]A)*VR-8IHU:</&NUCYJDA=P&#R
M:ZC_ ()X?LI>*_V2?A;XB\.>+M2T;4K_ %+6#J$;Z)-++$L?DQ1X8R11G=E#
MT&,8YH X+_@L?_R:+;?]C+9?^BIZ^:OAWX1_;!_:$_91\)_##0O"_AGP[\*K
M[3HXH?$;7L<=Q=VBON"RXN)) "1R%A4D#!X)!^[_ -O;]FWQ#^U1\"!X,\+Z
MCIFFZO'JMOJ"2:N\B0,L:R*REHT=@<29'RGICC.:]#_9K^%^H?!?X#^!_ ^K
M75M>ZGH>FQVES/9EC"\@R6V%@"5R>"0"?04 ?GE^W1\*)OV.O^">_@OX7:'J
MSW:ZIXB7^W=05/*-](8I9F&T'A-Z1  Y.V)<GK7MWB+]B3X*V'[!=^(O"6BK
MJEKX,?64\6&VC^WFZ2S,XN#<??*%QDINV;3C %?1G[5'[-VA_M5?!_4/ ^MW
M,FG.TJ7FGZE%&)&L[M P27:2-PP[JRY&5=@"#@CXM_X8(_:QO? "_">]^.^@
MK\*4B6R6".*1KO[*,8B(^SJ^P 8\O[05P O3B@#QSX;>)]4\0?\ !%_XM6FH
MW,EQ;Z/XFM]/L%D)/E6YO=+GV#V\R>4_\"KVO]EO]CWX2^)O^"=\WB+6_"NG
MWWB37=#U"_N/$%[$LEW:21F98F@D89A5!$G"X!P=V<FNT_:^^ WA_P#9K_X)
M=^-/ ?AMII[.Q&G237EQCS;J=]5M&DE?' )/0#H H[5\^_L__L@_M!?$+]DO
MP[:?#;XQV6C_  \\:6LLNL>'=8#QM;YF>*5()$BD;8X3+(K1!MQ#9R20#SCX
M+^(-1U#_ ()-?M Z5<S/+IVG>(-+:T5\D1F2\L3(JGL,J&P.[$]Z^OOV:?\
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M4G_QBC_A@?2_^BT_&/\ \*I/_C%'MZ/\WX![%G445R__  P/I?\ T6GXQ_\
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M:?C'_P"%4G_QBC_A@?2_^BT_&/\ \*I/_C%'MZ/\WX![%G445R__  P/I?\
MT6GXQ_\ A5)_\8H_X8'TO_HM/QC_ /"J3_XQ1[>C_-^ >Q9U%%<O_P ,#Z7_
M -%I^,?_ (52?_&*/^&!]+_Z+3\8_P#PJD_^,4>WH_S?@'L6=117+_\ # ^E
M_P#1:?C'_P"%4G_QBC_A@?2_^BT_&/\ \*I/_C%'MZ/\WX![%G445R__  P/
MI?\ T6GXQ_\ A5)_\8H_X8'TO_HM/QC_ /"J3_XQ1[>C_-^ >Q9U%%<O_P ,
M#Z7_ -%I^,?_ (52?_&*/^&!]+_Z+3\8_P#PJD_^,4>WH_S?@'L6=117+_\
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M%G445R__  P/I?\ T6GXQ_\ A5)_\8H_X8'TO_HM/QC_ /"J3_XQ1[>C_-^
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MJD_^,4>WH_S?@'L6=117+_\ # ^E_P#1:?C'_P"%4G_QBC_A@?2_^BT_&/\
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M/^&!]+_Z+3\8_P#PJD_^,4>WH_S?@'L6=12,PC4LQ"JHR23@ 5S'_# ^E_\
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MS7EQH^BP-!;S:A(LD[@NSDNRJJDEF/10/:NUHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^:_VUO\ CX^ ?_95=#_E/7TI7S7^VM_Q\? /_LJNA_RGKHH?
MQ$)GTI1117.,RO$_BK1O!6BW.L>(-5L]%TJW&Z:\OYUAB3TRS$#)[#O7A6I?
M\%"OV?-)O'MI_B+ \B=6MM-O9T_!XX64_@:\BT71X_VN_BAX@\=>,E.I> _#
MVJ3:1X7\-3-NM)# =LM[-'G;(SL2 #V!!! %?0>G:99Z/:K:V%I!96R_=AMX
MUC0?0 8K2<J5%\LDV_)VM^#/2HX&=:/.W9,X_P#X>-_L[_\ 10O_ "B:C_\
M(]'_  \;_9W_ .BA?^434?\ Y'KN:*S]O1_D?_@2_P#D3H_LU_S_ (?\$X;_
M (>-_L[_ /10O_*)J/\ \CT?\/&_V=_^BA?^434?_D>NYHH]O1_D?_@2_P#D
M0_LU_P _X?\ !.&_X>-_L[_]%"_\HFH__(]'_#QO]G?_ **%_P"434?_ )'K
MN:*/;T?Y'_X$O_D0_LU_S_A_P3AO^'C?[.__ $4+_P HFH__ "/1_P /&_V=
M_P#HH7_E$U'_ .1Z[FBCV]'^1_\ @2_^1#^S7_/^'_!.&_X>-_L[_P#10O\
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M-_L[_P#10O\ RB:C_P#(]'_#QO\ 9W_Z*%_Y1-1_^1Z[FBCV]'^1_P#@2_\
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M^'C?[.__ $4+_P HFH__ "/1_P /&_V=_P#HH7_E$U'_ .1Z[FBCV]'^1_\
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M1-1_^1Z[FBCV]'^1_P#@2_\ D0_LU_S_ (?\$X;_ (>-_L[_ /10O_*)J/\
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M%_&OXLT  _$UVE17-K#>6[P7$4<\+C#QR*&5AZ$'K1[>C_(__ E_\B']FO\
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M%%%<XSXG_81^;]E?P7(>9)&OG=CU9OMUQR3W/ KWVO OV#_^34O _P#V_?\
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ML\UM=:6^[;F-RHD3=SL8<CDCT)'->B5F=L9<RN@HHHH&%%%% !1110 4444
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M//$GP@L?'GP'N?AKXAD8V=]H2Z-=3VC8*GR0GF1DCJK ,,CL,CM7SO)^S_\
MM,ZY\+A\']9\?> U\"/8C1;GQ59V=V=>N-.""-H_);]PLC1Y0OO/!SR>:^RZ
M* /F_P".'[+^K:KX"^$]E\*K_3-%UWX8:A:7>AQ:_P":]G<0PPF$P3M$-XW)
MC+J"3@]-V1F_%+X"_%3Q]XB^$?Q&$_@6[^(7@Q;];O0[]+K^Q+C[4 N^&3:\
MJ/&JKARAR><*.*^HJ* /F_X1_ OXE:/^TWK_ ,6?'NM^'+X:OX7BT5=/T*.:
M,64B71D$:>8N9(P@!\UF#,[L-BJ%K:_8F^ ^N_LU_L[Z#X"\27NG7^KV%Q=R
MRSZ5)(]N1+</(NTNB-G:PSE1SGKUKW:B@#Q?5?@OK5]^UYH7Q5CN[ >'['PA
M<>'Y;5I'^U&=[I9E=5V;2FT$$E@<]CUKR?\ :H_8AU;XP_'/P#\2?!FL:?HM
MS8ZE82^)K*_>5(]2M[2=989$V(P,R .@W 9# ;E"X/V!10!#>6<&H6D]K=01
MW-M.C12PS('21&&&5E/!!!((-</_ ,,__"__ *)OX1_\$5K_ /&Z[ZB@"MIN
MF6>BZ?;6&GVD%C8VT:Q06MM&L<42 8"JJ@!0!T JS110!Y;^TOX5^)'C;X/:
MUH7PIU[3?#/B^_V01ZIJ4DD:P0D_O2CQH[)(5R%8*<9R,'!'C?P#^%?[0?P/
M\/\ AOP=I7ASX-:5X-LIXQ>_V??ZJ][+&6'GS;G@ DG9<G+$ G X  'UM10!
MY/XD_95^$&O0ZI-)\)_ LVJ7JRNUY/X<LVD:9P29&?RBQ8L<ENN>:Q/V./V<
MK?\ 9I^"6A>&KO3= B\6K!LUO5M#MPO]H2++*T;/*8TDEV+)M!<9&2!Q7N=%
M !1110 4444 %%%% !7S7^VM_P ?'P#_ .RJZ'_*>OI2OFO]M;_CX^ ?_95=
M#_E/710_B(3/I2BBBN<9\3_L'_\ )J7@?_M^_P#2ZXKWVO OV#_^34O _P#V
M_?\ I=<5[[6.*_WBIZO\SZ[#_P &'HOR"BBBN4W"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _+G_@HU_9O_#<?PI_MK[+_ &/_ &9I/VW[?M^S
M^1_:=SYGF[OEV;<YW<8SFOMCX=ZO^S?I/BJU_P"$$O?A99>);K-M;_\ ".RZ
M;'>2[NL:>2=[9Q]T=<5K_%[]E?X6_'G6K+5_'7A5-<U*SM_LD-P+VYMF6+<6
MV'R9$W ,S$9SC<?6N;\&_L)_ WX?^*M+\1Z#X'%CK.F3K<VER=5OI?*D4Y5M
MKSLIQ[@UIS)I(X8T:D*DI))IOYGR!\2?C=XZ^-G[4OCKP#J'QLC^ _A/P[/<
M6]K.9_LGG^3*$!\P21%WD&9,&0#;P!UKE_V%8XX?V^M7CA\8S?$&-+*^0>)K
M@/OU'"H/-.]W8^F2QR!G.*_07XH?LE_"/XS:^NN>,/!5GJFKX4->QSS6TD@4
M87S#"Z;\  ?-G@ 5;\$_LP?"[X<>-HO%WACP?9Z'KT5G]@2XLY94C6' ! BW
M^7DX&6V[B<DDDFJYE:QE]6J.HI-WL[]?^&/CW]DV-)/^"FGQR9D5F2TU1E)&
M2I^WV@R/0X)'XFG?\%B/^17^&/\ U^7W_H$-?:'A/]G_ , ^!_B7KWQ T3P^
MMCXOUU)(]0U$74[^<KNDCCRV<HN6C0_*HZ4?%_\ 9_\  /QZM=+MO'?A]=>A
MTR5YK16NIX/+9@ QS$Z[@0HX.1Q2YES)FCP\G1E3OJW^I\T_\%4OA3)XH^"^
ME>.=.1EU7PC?*[S0@B06LQ5&((Y^600MGL-QKQO]E/Q'J'[8W[;-M\2=9M=E
MCX2T"V?RFY1;D0B(*/K/)<3+T^Z*^U/VR_&&F>"?V8?B)J&JVL=[;3:7)8I;
M2!BLDL^(8P<<@!Y%.01C'45XO_P2M^%K^"_V?[SQ/=P&&^\57[7"%T*L;6$&
M.+.>HW><P/3#BFG[A%2GS8E);;OY;'VA7YT?\$_[&WU+]J3]HVSNX4N+6XN;
MJ*6&1=RNC7TP92.X()%?HO7G_@'X!^ OA=XM\2>)O"_A]-*USQ%(9M3NEN9I
M//8NSDA'<JF69CA HY]A6:=DSJJ4W.<)+H?DS^T;I&H?LPW'Q3^"4R3/X5UR
M]L_$&@2-RJJLAQUY/R;HV;^];CCG->O?MR>'=1OOV)?V;=9M[=Y=.T_1K&&Z
MD4$B-I=/@\LMZ ^6PR>Y [U]_P#Q@_9Q^''Q\_LX^//#$.NR:?N^S3?:)K>6
M,-U7?"Z,5[[22,\XS74M\/\ PW)X'A\&RZ+9W/A:&RCTY-)N8Q+!]GC4*D95
MLY "KC// /6M.?8Y/JC]^-]'M]]SY5_:7_:[^$GBC]D?Q+_9/BG2+_4-?T;[
M)9Z!;W"->12RJ%"O"/FC\O.26 'R<<XKYU\1>%=2\*_\$G=,&IV[6LFH:Y'J
M$,<@PWDR7#>6Q'^TH##V8&OMC2/V#?@+H>N+J]K\.-/:\5_,"W-S<7$ .<_Z
MF21H\>VW%>G?$SX3^%/C#X/D\*^+M(75M!D>.1K,32P#<ARA#1,K#!]#2YDM
M$7*A4J7<VKVL?,VO?\HM8O\ L1;;_P!%I7+_ +)_PL\0?&#]@/PIH/AKQ[J?
MPYU(:M=7']LZ2)#,46YF!B^26(X;<#][^$<&OL"X^$?A*Z^%_P#PKJ72%;P;
M]@73/[,\^4#[.%"A/,W>9P /FW9]ZG^&OPR\-?!_P?:>%O".F#2-"M&=X;03
MR3;2[EV.^1F8Y9B>3WI<VEC7V#YDY;6L?/W@'X4^+?V1?#WCGQ_XX^-7B#XG
MZ78Z)-+'INLB=8XY$PZLIDN91N8KL& /O]:^0_V/?A+^TAXVTGQ-\4?AGXS\
M.^%G\2ZC*E_/K4(DFO)$<R,ZAK28*F^5QP025.1P*_4+XB?#SP_\5O!NH^%?
M%-A_:F@Z@$%U:>?)#Y@219%^>-E889%/!'3'2E^'WP]\/?"OP?IWA;PKIJ:1
MH.GJRVUG&[N$W.78EG)9B69B2222:.;0F6&YI1L[17F[W/R^^'%MXZ_9%_;Z
MT#_A9&J:9>ZAXTR-3O\ 2 5MKE;V5E#X\J(*1<QHS80 ;2>^:]1UC_E,1H7_
M %YM_P"F6:OL;XM?LV_#GXY:GI.H^-?#@UB_TD,ME<I>W%J\0+!B,PR)GD C
M.<<XQDU:F_9_\ W'Q@@^*4GA]6\>01>3'JWVJ<%5\EH<>5O\O/ELRYVYYI\Z
M,UAI1]U/123_ ,SX:_;9_P"4D/P$_P"X!_Z>)ZD_X*O?\E*^"_\ O77_ *.M
MJ^WO&7[//P]^(/Q&T#QYX@\.IJ/BS0?)_L[4&NIT\CRI6EC_ ':N$;:[,PW*
M>31\5/V>?A]\;-3T+4/&OAU=;O-$=GL)&NIX?*+,K'(C=0X)1>&!''N:%):#
MGAY2C-)_$T?#/_!13Q18>!_VR/@CXCU7S/[+T=;'4+ORDWOY,6HM(^U>YVJ>
M.]1?\%-_CQX$^+G@/P'X<\$>(;'Q9JDVI?;]FDR"<Q1F)HU1@O*NS2#Y#\WR
M\@<5]X>,_@'X!^(?CG1_&'B3PY!K'B#2(&MK.XN993&D3;MR-"&\N0'>_P!]
M6ZUS7@S]CGX,_#[QDOBK0/ .G6.NI)YT5PTDLR0/G(:**1VCC(/0HH([8H4E
MIY"GAZDG-)JTCX@_X*0^&[WP/H/[.3:C$PBTC36L;J2,;@DL2VFY?3G:V.>=
MI]*T_P#@J!^T!\/OB=\-_!N@^$?%%AXEOQJ(U27^S)1,D$/DN@\QAPCDR#Y#
M\PP<@<9_0CXD?"_PK\7?#,GA_P 8:);:]I$CB3[/<@C:XZ.C*0R,,D94@X)'
M>O-[/]B/X(V'@N_\*V_@&SBT:_DCENE6ZN?/E*-N0&X\SSMH/.W?CVH4EI?H
M%3#U&YJ#5I6_ ^//^"B7_)I/P"_Z][7_ -($KM/VWOVA/'/@WQK\+OAMX:\5
M1_#S1]<TZVN+_P 4.-OEAY#$09,918PF\[<$[QE@*^M_B-^SC\.OBUX5T+PU
MXK\-IJFB:'M_LZU%W<0"#;'Y:@-'(K$;0!AB>E7/B=\!_ /QFT*ST?QGX9M-
M=L;,8MA*726#@ [)4977( SAAG STH4EI<<L/4;DXNU[?@?D?\9=%3P_\>/A
MM9#XYS?'*9;VU:34&N)+B.Q)N4_=)(T\RMG&3M88P,BOHK_@K2#8^./@UJ$X
M,=E&UYNFQD#;+;,WZ'-?5UC^PW\#--M](BM?A]9V_P#95V+ZUFCNKD3"8$%2
M\GF[Y0"HPLA91SQR<^B?%+X/^#?C5X=&A>-M MM?TQ9/.2.<LC1/@C<DB$.A
MP2,J1P:?.KHA86?)..FMN_0^1O\ @I)X@TCXS?LHIK/@76M.\5:7H/B6UN-2
MNM(NDN8X$-O-'ABA(!#7,.0>F[GI70^'_P!KSX26G[%MD9?%&CIJ-OX272F\
M,_:$^V&Y2T\DP"#[Q4N,!]NW!!Z5]&?#CX$^ OA+X-O?"?A;PS:Z?X>OG>2[
ML96>Y2X+J$?S#,SEP54+AB1@8KSW_A@?X!#6SJO_  K>P^U%M_E_:KG[/G_K
MAYOEX]MN*GFC:S-72J\SG&UVK,^//V<_"FI:#_P3-^,FI7UNUO;:Q)<W%GO!
M!DB2.&,N/8NC@?[IKZ;_ ."9L:1_LA^&&554O>7[,0,;C]ID&3Z\ #\*^AO$
MGP^\.^+? ]YX.U/2H9?#-W:_8I=-AW01^3@ (OEE2@  QM(QCBH/AK\,O#7P
M?\'VGA;PCI@TC0K1G>&T$\DVTNY=COD9F.68GD]Z'*Z95.@Z<XN^B5C\]/VN
M-0N_V0?VW_#_ ,7M+LVFTCQ'9R/=6R?*DTJQ^1<)[\&"7KRQKU'_ ()5_#VY
MM?ACXI^)&K%I]7\7ZHX6YDY:2&%F#/[%IGFSC^X*YS_@K?KUMJ'AWX<^"K33
M3J'B/4=2EO+=HT9I414$7EKCJ9'E7CG_ %7TK[3^#?P]A^%'PI\)^$(-K#1]
M-@M))%&!)*J#S'_X$^YOQJF_<1A3I_[3*VRU^;/'O^"C?_)F?Q"_[AW_ *<;
M:O+_ -@?X_\ PU^&O[)?A^T\4>//#VBZA:SWTDVGW6HQ"[53<R,I\C=YAR""
M,+SD8K[#\?> = ^*'A#4O"_BC3DU;0=118[JS=W02 ,'7YD(92&52""""!7B
M-K_P3M_9ZL[A)H_AW&SH<@2ZM?R+^*M.0?Q%2FN6S-ZE.I[7VL+;6U/EWX 7
M=Q^U;_P40UCXL:)9W$7@KP\"4NY(]F\+:FV@4YZ-(=TNWJ%!!Q5[X+*&_P""
MK?Q!!&08[X$'_KE%7Z$>$/!>@?#_ $.'1O#6C6.A:5"24L]/@6&,$]6PHY)[
MD\FN5T?]GOX?Z!\5]1^)6G^'4M_&VH(T=SJ@N9SO#!0W[HN8P2$7D*#U]33Y
MD0L-)<KOK>[/R,^,UQXB_9K^('QK^#6B0.NC>*KRV6&.)2&^S^:)[=8QWS'+
MY9QUP1[5[S_P4"^%\'P9_9,^"7@V%55]+N6CN&7&'N&@+SOQ_>D9S^-?>/C3
M]FGX:_$3XBZ1X[\1>%H=2\5:5Y/V2_>YG0+Y3EX]T:N(WVL2?G4^G2M#XO?
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MI_[,O_)M_P */^Q3TG_TCBKS#]H+_D@OQ)_[%K4O_262O3_V9?\ DV_X4?\
M8IZ3_P"D<5>C2_@?/]#P,R^./H>E4444CR0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <#^T%_R07XD_P#8M:E_Z2R5Z?\ LR_\FW_"C_L4])_](XJ\P_:"_P"2"_$G
M_L6M2_\ 262O3_V9?^3;_A1_V*>D_P#I'%7HTOX'S_0\#,OCCZ'I5%%%(\D*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JKJ&EV6KVYM[ZT@O8#UBN(ED4_@1BK
M5% ' WO[/_POU)F:[^&_A&Z9CDF;0K5R?SCJG_PS/\'_ /HE/@C_ ,)RS_\
MC=>E45?M)]P/-?\ AF?X/_\ 1*?!'_A.6?\ \;H_X9G^#_\ T2GP1_X3EG_\
M;KTJBG[2?=@>:_\ #,_P?_Z)3X(_\)RS_P#C='_#,_P?_P"B4^"/_"<L_P#X
MW7I5%'M)]V!YK_PS/\'_ /HE/@C_ ,)RS_\ C='_  S/\'_^B4^"/_"<L_\
MXW7I5%'M)]V!YK_PS/\ !_\ Z)3X(_\ "<L__C='_#,_P?\ ^B4^"/\ PG+/
M_P"-UZ511[2?=@>:_P##,_P?_P"B4^"/_"<L_P#XW1_PS/\ !_\ Z)3X(_\
M"<L__C=>E44>TGW8'FO_  S/\'_^B4^"/_"<L_\ XW1_PS/\'_\ HE/@C_PG
M+/\ ^-UZ511[2?=@>:_\,S_!_P#Z)3X(_P#"<L__ (W1_P ,S_!__HE/@C_P
MG+/_ .-UZ511[2?=@>:_\,S_  ?_ .B4^"/_  G+/_XW1_PS/\'_ /HE/@C_
M ,)RS_\ C=>E44>TGW8'FO\ PS/\'_\ HE/@C_PG+/\ ^-T?\,S_  ?_ .B4
M^"/_  G+/_XW7I5%'M)]V!YK_P ,S_!__HE/@C_PG+/_ .-TO_#,_P (!R/A
M3X(!_P"Q=L__ (W7I-%'M)]V!QFE_!;X>Z',LNF^!/#.GRKT>UT>WB8?0J@K
ML(XDAC6.-%C11A548 'L*?14.3>[ ****0!1110!\3_L'_\ )J7@?_M^_P#2
MZXKWVO OV#_^34O _P#V_?\ I=<5[[6.*_WBIZO\SZ[#_P &'HOR/#OC]^UU
MX,^ -S%IE\MQK?B*11(-)T_;OB0]&E<\(#V')/7&.:^?I/\ @J.X=MGPN9DS
M\I;Q  2/<?9CBOBWQAXLN_'GC#6_$E_+)-=ZI>2W3M(<D!F.U?HHP .P %9%
M<M?$0P]1THP3MHV[[]=FCZS 9(L7AXXBK4:YE=*-MGMNGK;T/NC_ (>D2_\
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M_)O_ )(/]7*'_/V?_DO_ ,@?='_#TB7_ *);_P"7"/\ Y&H_X>D2_P#1+?\
MRX1_\C5\+T4?7E_SZC_Y-_\ )!_JY0_Y^S_\E_\ D#[H_P"'I$O_ $2W_P N
M$?\ R-1_P](E_P"B6_\ EPC_ .1J^%Z*/KR_Y]1_\F_^2#_5RA_S]G_Y+_\
M('W1_P /2)?^B6_^7"/_ )&H_P"'I$O_ $2W_P N$?\ R-7PO11]>7_/J/\
MY-_\D'^KE#_G[/\ \E_^0/NC_AZ1+_T2W_RX1_\ (U'_  ](E_Z);_Y<(_\
MD:OA>BCZ\O\ GU'_ ,F_^2#_ %<H?\_9_P#DO_R!]T?\/2)?^B6_^7"/_D:C
M_AZ1+_T2W_RX1_\ (U?"]%'UY?\ /J/_ )-_\D'^KE#_ )^S_P#)?_D#[H_X
M>D2_]$M_\N$?_(U'_#TB7_HEO_EPC_Y&KX7HH^O+_GU'_P F_P#D@_U<H?\
M/V?_ )+_ /('W1_P](E_Z);_ .7"/_D:C_AZ1+_T2W_RX1_\C5\+T4?7E_SZ
MC_Y-_P#)!_JY0_Y^S_\ )?\ Y ^Z/^'I$O\ T2W_ ,N$?_(U'_#TB7_HEO\
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M?_+A'_R-7PO11]>7_/J/_DW_ ,D'^KE#_G[/_P E_P#D#[H_X>D2_P#1+?\
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M\C5\+T4?7E_SZC_Y-_\ )!_JY0_Y^S_\E_\ D#[H_P"'I$O_ $2W_P N$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#XG_8/_Y-2\#_ /;]_P"EUQ7OM>!?L'_\FI>!_P#M
M^_\ 2ZXKWVL<5_O%3U?YGUV'_@P]%^1^#UG_ ,>Z?C_.IJAL_P#CW3\?YU-7
MCX[_ 'JK_BE^;/U3*_\ <,/_ ((_^DH****XCTPHHHH **** "BBB@ HHHH
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MFO/J^J/&7PUTK5_V0_V>9-*T?3;/Q-XBUO4;"XU1;9$GN";V6.(2R@;F51M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWPHDT/XI?"SQ-8ZIX5^%GBR_%_H]S:AKJYTIXV4QF7EF?(BAZ;L%2#D'(O\
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MO^QGN/\ TEM:];!?PZOR_,^.XB_Y<^K_ "/>OV@O^2"_$G_L6M2_])9*]/\
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M_ S_ *$?_P JU]_\?K'ZIA_^?C_\!7_R1W?ZQ5O^?"_\#?\ \@?E#17ZO?\
M#!_P,_Z$?_RK7W_Q^C_A@_X&?]"/_P"5:^_^/T?5,/\ \_'_ . K_P"2#_6*
MM_SX7_@;_P#D#\H:*_5[_A@_X&?]"/\ ^5:^_P#C]'_#!_P,_P"A'_\ *M??
M_'Z/JF'_ .?C_P# 5_\ )!_K%6_Y\+_P-_\ R!^4-%?J]_PP?\#/^A'_ /*M
M??\ Q^C_ (8/^!G_ $(__E6OO_C]'U3#_P#/Q_\ @*_^2#_6*M_SX7_@;_\
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M ,JU]_\ 'Z/^&#_@9_T(_P#Y5K[_ ./T?5,/_P _'_X"O_D@_P!8JW_/A?\
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M_A@_X&?]"/\ ^5:^_P#C]'_#!_P,_P"A'_\ *M??_'Z/JF'_ .?C_P# 5_\
M)!_K%6_Y\+_P-_\ R!^4-%?J]_PP?\#/^A'_ /*M??\ Q^C_ (8/^!G_ $(_
M_E6OO_C]'U3#_P#/Q_\ @*_^2#_6*M_SX7_@;_\ D#\H:*_5[_A@_P"!G_0C
M_P#E6OO_ (_1_P ,'_ S_H1__*M??_'Z/JF'_P"?C_\  5_\D'^L5;_GPO\
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MD%^)/_8M:E_Z2R5Z?^S+_P FW_"C_L4])_\ 2.*O,/V@O^2"_$G_ +%K4O\
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M;.A>--!MM<T\-OC\X%9('QC?%(I#(WNI&1P>*\4/[ ?A:U8II7Q)^*.@V?\
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M*\\_X8,TC_HL7Q@_\*L?_&:/^&#-(_Z+%\8/_"K'_P 9H^KT_P"?\ _M*/\
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M_P"%6/\ XS1]7I_S_@']I1_E/0Z*\\_X8,TC_HL7Q@_\*L?_ !FC_A@S2/\
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M!_:4?Y3T.BO//^&#-(_Z+%\8/_"K'_QFC_A@S2/^BQ?&#_PJQ_\ &:/J]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>kros-20251231_g5.jpg
<TEXT>
begin 644 kros-20251231_g5.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4D"60# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHJ@"BBB@ HHHH **** "BBB@ HHHH *0M2TA6@!-U+NI M+2N M)NI:0BF
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MG'7BC.1D<CUJ'(+-@^8#P5IGENK!D?*+QY=3)N(7+E%(.@I: "BBB@ HHHH
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M##82-"#^%?L1X^^ _@;XG>(+35?$V@Q:I?VH40RR$_+@Y%?FM_P4;T>Q\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF2Q'[@*UY>,PG[Q*/4:FDM3ZZI *_+"_\;?MFZI;MK-@=1@TDC><(N%%:7P
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MA:W/3CAZL-&/S3/ISX!?';P-\9_#MSJ_A*U@L[Q$+31M&$E+@<G'7&:_*_\
M:*9_%W[4'B9]4DE$+7:97/7D=*]J_P""7.FZAJ?Q:U>9$E&CM8.!/SMW_P!W
MZUYG^VAX$\0> ?V@M9U22&22P>X5X;@+A<#&:VPRAA\3*FB;L_7'X76=CH/P
MS\-P6UI';V[6,*^7"@&<H.3[UNZ?X=TK1=0DFL-+M;2>Y_ULT,05GX_B(ZU\
MT_!7]N?X6ZC\.=,CUKQ!:Z'J-A:)$UK<,=TA50,CCOBNH^!?[8>B?';QEKNC
M:+IK^3I^-EX&RLV?3BO G0KJ<VXZ&Z[GY1_&C6M0NOCUXCO;K;=W^GZR[6L/
MWE=5?(4CW]*^F(_^"A7QSTW2[&*T^%\,-MMV>3'I[A2 ,=/>O#OVC_ NH_"/
MX_WFIWEH[)/J?]HC(XV[\XK]&/A9^W-\)_$WA.QN->UW3="O@@4V]PO((&/2
MOI<0X>QA+V2E8SL?F3>6?C[X@?%O3M?/@^_TK4;K48YW$-FZ1#+Y.>.E?HS^
MWM:SW'P!TO[<WEWRQ?.(3QNV"M&/]O+P3JWQ%M?#&@V46OK.V!?6X 4<XZ8I
M/^"AGS?!5)4^3AF!]. :X/:RJ8NFJD>4(K>Q\P_\$Q])LM5\;RW5[9V\LUON
M1'= 6Z=:^H?^"A6@6VH?!TN8XP\.]E9ASTZ5\U?\$LT2X\4WCD^:06.[WQ7T
MY_P4.W_\*8_=PM,VY^AZ<4J]7EQ\;,NVA\O?\$M[J23Q=>)&_E0H["2-3@,V
M.M<#_P %,=4GN?VBM8M'E?R(;")O*S[=0/6N[_X)@1K:^,KB.2+8TCELD]\5
MD_\ !3SX?WMC\8)/%0B;R;ZWCM8'QQO KJ?)'')^1+7NGW?^QKX:TS0_V<_!
M<]A:+ U]IZ2SL5VLY.1\U?#W_!3;P?I7A_Q]%JFGVRV\US&B2+$@"=.3QWKV
MW]D[]M?P1HOP;T_0?%^J0Z-J6C6X@5)CS/@=J^.OVOOVAI/CUXPFN;&S>TT.
M$[(BW(<CC<#[T\OC*..E*IMJ9O8^[/\ @G/_ ,D=N_\ =7^1KX(_:/)_X:97
M_KZ'_H5??7_!.J-H_@_<97Y613G\#7P/^T@T?_#4'E(=Y%P#_P"/4J3_ .%*
M<EL#O9'Z+?$Q2O[%=THRS26*XSVY_P#K5\#?L+Z);ZQ\?GMKJUM;BVC3S K@
M'#@U]_?$AFC_ &+;IR,G[ I ].:^"_\ @G]##_PT?<1PKYF8"Y(/?-:X&44J
M\O-EO6Q^DG[6-A!)^SWXI)MH7>&U'E?+G9TZ>E?FI^P'OTG]HS[3:2>7,\)5
MU!QP3S7Z;_M5?)^S]XO*)\WV7I^(K\R/V#EB7]H]=PRQC)/MS7!ETE4H5(2!
MQUN>]_\ !5CPE/<VWA36&N/W<3LRQ[OIGBJ/[._[>_@#X6?"P^']?M[F"[\H
MA4ABX<E<9K._X*@1^*9O$FB(T<C:#O\ W)_AQ@9KQGPS^T!\$+/0+.W\0_!>
M;7M=M46(W"W#+N '+8%=M&C*>$45#F6GD3)V>A3\$PZC\??VIM)U30-*N;*P
MDO T=Q#$41?=B.E?LOHEG<:?I=E9SR"1H8@COG)) ZU\#? ?]NCX2>%VMM/T
M[P8O@RWG.QYII-VP?E7WOX=U:Q\0:/:ZGITRW-I=QB6.93PP/0UYV:NJ^7GA
MRHTB:!VLI [\"O@?_@J?G_A%].S_ '!_.OOCRR N#]TY^M? W_!51@OA73R/
MF?:/D_X%7+E?^]1'4^$M_P#!+G_D4;__ *Y?UK[M9P@W$X51DU^;G_!/?XW^
M ?ACX7O(?$_B>TT>9X\!;@D=Z]H^-/\ P4(\">&_"VH'PO=Q>([D@Q(;=L=1
MC-:XRC*6)DDC*+T/B?\ X*":@GB_]I;6YK-A(GV..%=O.2!C%?;VJ:E>^%_^
M"?\ HDUJ6@NX=+B3T(R3FOA3X%_";Q7^TE\9;?5IHY8[&.Y%S<2NN0\9.=M?
MJ-\9/A:WB+X$WW@[1_D:* +'M'0*"<5VXFI3BJ,%TL6C\S_V$?#>F^(/CK/=
M:S$+FY1O-$8&Y<[NOUK]>M=TJTUG0KNRN+:.:V>%@(9%RO3CBOQ:^ 'Q&'[.
M/QREFURU:&)KC[/),^0  W6OTC\??MW?##P]X-EU*QUZVU._EA.RSC;Y@2*K
M,X3Q%6%2CL)(_,B_MX_"?[25HT">5!#K.Y%C&,$/TK[E_;S^"OB+XX?#?PUX
MMTM!(VD6Y>2%<^8=WH*^,?@5X%UOX_?M 6VHP[VL8=3^WO)MX:/?G97Z<?'_
M /:;\/\ [-^K>%-$U32O,T_658>;GY( O'(JLPJ^TJTU35VA*)^?G[./[8WB
M_P#9KTG_ (1._P! 6+0S.7-Q?0LLQD/4<]J^_P#]G3]H'P%\;I[F72+&WL/$
M-N ;K;$J&1B.Q[UXI^T9\2OV=/B9X O;DZCINI^(F@)MHH25=),''0=C7S/_
M ,$[+'6[WXY6<EF)9+2UF/VIESA0<XS4U:,:]%UN6S%JG8?_ ,%#M6O;S]H&
M.UNY&G5+;<D;'*\'@5I?"W]MCXR_#?P/9^'O#GP[AN+.!=MM<I8N1+[L16K_
M ,%*OASJN@_%ZV\4I!)+HCP!3=A?E64G[OUKW#]D7]M;X>:7\,M)\.>*]0M=
M&O-/CV-<W &V3GKC%;U))X:+5/F0E>Y\4_'+QQ\0_CQXXT[Q%JG@*[TG5HHU
M@86%@ZQL<_>/')K]8?V1;'4M-^ ?AFWU:.2*^6-O,24$,.>^:\Q^(_[?_P -
M/"]]86N@26OBU[F5(MMH,;2QQGD5],^$=<3Q)X?L]22'[.MP@<1^E>3B\5*K
M0C2Y.5)FD-S9HHHKQ#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!OK24^F4KVT
M&ALG!#$X4#FH[6XBN8M\#J\>2,J<BHM89ETF]93AE@<@_P# 37E'[+>M7>O_
M  G6ZO)3).;^X3<?0-Q6B6ES*_O'L &#BI:C53QSG%25+-6%%%%(04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F,T
MVE:E(S0 R1MJ9QFN"^/+.OP=\8LO7^SWQ7?-G:0*\^^/,;#X+^+U4Y;[ _XU
MI2LI+U$?BGX!\>:K\-/B2^O^']/;4=8CD.V-8R^<GT%>[>/_ -H[X[_M"6R^
M'-3\+76CV4BA8VM+9T60GL_M7&?LDMM_:<TV$LLL+[R\+*#SFOVCM[6'[/%B
M&,#:.-@]*^MQF,C1]G+DYF8QB?"7[#O[%.J?#77H/&?C".+^TE4_9(8^5"L.
M=P]:]3_:J_:<\#? 9Q%?:7!JWB5L%$:$2,H/3/?%?3<BLJ%4(7LN!TK\??\
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M7[-]A\0]1M&OXXX2)=IQP@QFN,7]I[X ?';P>UWXHO\ 3K24Q'_1[@D...Q
MY->;A?;4(RC*%XO1V';4R/@S^W-\/_C-XCTS2_$FFPIXE#J+>:2$;(Y/]ECT
MK@/^"J>L/);>'](,KBWNK9I"T9^0D'UKX[OK;2;W]H*Q@\$H3I<]X$LYH2<,
MV>U?:7[>WPH\1:Q\%O"VII;23G3+)8KO R0Y]:]&6&HX?$4Y7T?^1=W8U/\
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M=N*^X?@'I3_LT_LTG6KS3WO7G\N>6U7@].35UY<E&FG\2L1?4_/CP[J/C?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O\
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MI6?M?:J[W"R0ZBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7E#[#@ Y[GWKZ,?G([5&Q>,9 WKTVUS4\3*$[0T*Y3R'X>?LR^&_A_\ "U_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW\S#,,=J^EI87VV"<XK5&'-[Q^IP?*[L\TY7\S!%?#ND_P#!5CP!K&M):?\
M"-:G;(S[1<RR+L^O2OKOX=_$/1?B5H,>JZ)?0WD+@%A$V?+)_A/O7C2P]2G#
MFE'0H_.'_@HA\9O'G@KXN7=AX>\5:CH]HJ1D16LI4#(%?:_[,WB35?$'[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3=0
MU)CFE:D]@/GK]NR:6#]GG6'AD,3^8GS+U[U\+_\ !-&%)OBAJEQ<#?<<<GJ.
M>M?>'[;VCRZY\ ]6@A^^KJ_X#-? _P#P3CUZ+3?C-J-G(N/.81K]<U]/E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C4P?>I[4P?>I]!]"G
MK7_()U#_ *]Y/_037C7['_\ R1]?^PG<_P#H=>RZU_R"=0_Z]Y/_ $$UXU^Q
M_P#\D?7_ +"=S_Z'753_ ($O5?J<\OB/<UIU-6G5QHW"BBBF 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<F&X/2I
M*BESCCK30T,52S;B<'IMK\K?^"HUW)>_$SPW$S[XX493[<]*_57Y58.>O2OR
MV_X*GZ"VA_$7PM>;M\=]&\I [8->GD[MBM#*1];?L V-O9_L^Z>MI$MM&9V8
MQ(,#/&3^-7OV^E_XQ7\994/^[0C/^\*Q_P#@G;KD6N?LZ6-Q'U%U)&1],5L_
MM]1LW[*_C%%."T:<_P# A5UF_P"T7?\ F+B?$7_!*F0'X^:P%9E7^Q^(\<9X
MYK]66N5CD 8D"ORJ_P""5?G3?'?5S-MDV:1@.@P.U?J3JVL67A^WENM5NX;:
M  E?,('056>4W+&KV?D9ZV/SQ_X*EV]N+RUDFC4GRU..^/6NZ_X)_>)F\,?
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MM2XKT_[7Q$4[):^0N5'DOCSP'K&N? '5/#%K&'U>:S\E(RV-S<<9KX#^&?\
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M+S7TWS25S2S"M*I&H]UL/E/B7_@G[^SGX^^"<ET_C+38[$R(P!64/U^E<?\
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M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $:F#[U/:F#[U/H/H4]:_P"03J'_
M %[R?^@FO&OV/_\ DCZ_]A.Y_P#0Z]EUK_D$ZA_U[R?^@FO&OV/_ /DCZ_\
M83N?_0ZZJ?\  EZK]3GE\1[FM.IJTZN-&X4444P"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHI* %HI-U&: %HI** %HHHH **3=10 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)
M10 M%)10 M%)10 M%)10 M%)10 M%)030 M%-W4;J8QU%-W4N:0A:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;1MHNP#/O1GWHVT;:+L S[T9]Z-M&VB[ ,^]&?>C;1MHNP#/O1GWHVT;:+L
MS[T9]Z-M&VB[ ,^]&?>C;1MHNP#/O1GWHVT;:+L S[T9]Z-M&VB[ ,^]&?>C
M;1MHO( S[T9]Z-M&VB[ ,^]&?>C;1MHNP#/O1U[T;:7&*+L!-M&VC-+GZ5=P
M$VTN/6C/K06I7 *6D!W4M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!&I@^]3VI@^]3Z#Z%/6O\ D$ZA
M_P!>\G_H)KQK]C__ )(^O_83N?\ T.O9=:_Y!.H?]>\G_H)KQK]C_P#Y(^O_
M &$[G_T.NJG_  )>J_4YY?$>YK3J:M.KC1N%%%%, HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I*6DH %Z4C4JTC4GJ"(FVKRQP?6FF1EZCS ?2DDD5M^2 5&?FX4
M5\__ !\_;-\!? ^QEAU#4?.UA0?+M[;#KN]R*Z:=-S=HHQJ5.4^@MP('&/:N
M<\4?$?PWX-CW:UK%MIP_Z:M7Y$?&3_@I'\0/'MQ-#I:)HUHV5CDM'*MM['ZU
M\WZW\2_&WB:7S]5\37]\K<[)YRPKW*.3U*B4F>7+&6>A^Z-Y^UI\)--^:\\=
M:7;1] TCD#/Y55_X;,^"G_11]&_[^'_"OP4OII-0DQ<R-,O7:W(SZU7^Q6__
M #R7\J[?[!D^I/UT_?+_ (;,^"G_ $4?1O\ OX?\*/\ ALSX*?\ 11]&_P"_
MI_PK\#?L5O\ \\E_*F_8K?\ YY+^5']@OJV+Z\?OI_PV9\%/^BCZ-_W]/^%'
M_#9GP4_Z*/HW_?T_X5^!?V*W_P">:_E1]BM_^>2_E1_8/]YB^OG[Z?\ #9GP
M4_Z*/HW_ ']/^%'_  V9\%/^BCZ-_P!_3_A7X%_8K?\ YY+^5)]BM_\ GFOY
M4_[!_O,?UX_?7_ALSX*?]%'T;_OZ?\*/^&S/@I_T4?1O^_I_PK\"_L5O_P \
MU_*C[%;_ //)?RI?V#_>8OKY^^G_  V9\%/^BCZ-_P!_3_A1_P -F?!3_HH^
MC?\ ?T_X5^!?V*W_ .>:_E1]BM_^>:_E3_L'^\Q_7C]]/^&S/@I_T4?1O^_I
M_P */^&S/@I_T4?1O^_I_P *_ O[%;_\\U_*C[%;_P#/)?RI?V#_ 'F+Z^?O
MI_PV9\%/^BCZ-_W]/^%'_#9GP4_Z*/HW_?T_X5^!?V*W_P">2_E1]BM_^>:_
ME3_L'^\Q_7C]]/\ ALSX*?\ 11]&_P"_I_PH_P"&S/@I_P!%'T;_ +^G_"OP
M+^Q6_P#SS7\J/L5O_P \E_*E_8/]YB^OG[Z?\-F?!3_HH^C?]_3_ (4?\-F?
M!3_HH^C?]_3_ (5^!?V*W_YY+^5'V*W_ .>:_E3_ +!_O,?UX_?3_ALSX*?]
M%'T;_OZ?\*/^&S/@I_T4?1O^_I_PK\"_L5O_ ,\U_*C[%;_\\E_*E_8/]YB^
MOG[Z?\-F?!3_ **/HW_?T_X4?\-F?!3_ **/HW_?T_X5^!?V*W_YYK^5)]BM
M_P#GFOY4_P"P?[S']>/WU_X;,^"G_11]&_[^G_"C_ALSX*?]%'T;_OZ?\*_
MO[%;_P#/)?RH^Q6__/)?RI?V#_>8?7C]]/\ ALSX*?\ 11]&_P"_I_PH_P"&
MS/@I_P!%'T;_ +^G_"OP+^Q6_P#SS7\J/L5O_P \U_*G_8/]YA]>/WT_X;,^
M"G_11]&_[^G_  H_X;,^"G_11]&_[^G_  K\"_L5O_SR7\J/L5O_ ,\E_*E_
M8/\ >8?7C]]/^&S/@I_T4?1O^_I_PH_X;,^"G_11]&_[^G_"OP+^Q6__ #S7
M\J3[%;_\\U_*G_8/]YB^O'[Z_P##9GP4_P"BCZ-_W]/^%'_#9GP4_P"BCZ-_
MW]/^%?@7]BM_^>2_E1]BM_\ GDOY4O[!_O,?UX_?3_ALSX*?]%'T;_OZ?\*/
M^&S/@I_T4?1O^_I_PK\"OL5O_P \U_*E^Q6__/-?RH_L'^\Q?7C]]/\ ALSX
M*?\ 11]&_P"_I_PH_P"&S/@I_P!%'T;_ +^G_"OP+^Q6_P#SR7\J/L5O_P \
MU_*G_8/]YC^O'[Z?\-F?!3_HH^C?]_3_ (4?\-F?!/\ Z*1HW_?T_P"%?@7]
MBM_^>:_E3H[&W:0#RD/U%+^P?[S#Z^?OO!^V%\&[T[+?Q_I-PW]V.0Y_E72^
M'OCKX(\32%+#Q!:3^FUNM?ST6\8T^<M&OE^Z"M?3_&'B#2K@26&N7MJ ?^6<
MA%']@M+<;QZ/Z.(YXI8U?S5='Y0@]13W8YP%R/6OPG^%_P"VS\3/AG?13?VG
M-KD,9XBOIBPQ]*^__P!G7_@I-X?^)TL>G>*DCT?4GPJB,87=]37CXC*ZM+S.
MVCC(SW/MN$;>V*DJAH^I6FK6275C=)=V\@W*\;!A^E7Q7CN/*['??FU$'6G4
M44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 1J8/O4]J8/O4^@^A3UK_D$ZA_U[R?^@FO&OV/_ /DCZ_\ 83N?
M_0Z]EUK_ )!.H?\ 7O)_Z":\:_8__P"2/K_V$[G_ -#KJI_P)>J_4YY?$>YK
M3J:M.KC1N%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I&Z&EI&H _(+_@J-X@DU'XJ+HLTV5LRLJPYZ9'6O
MB6OJS_@IG*7_ &K-;0_P6EO^JU\IU^H9=%1PT'W1\GBY7JM!1117IG&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 =5\*_%TO@7XA:#K4<IB%K=(9&'9"<-^A-?T)>'9I)O#NDO+DR/!&Q_%17
M\X=?T%?LT^*O^$V_9]^'.N2/YD]UH%GYS]<RK$JR?^/JU?(<04_=A/Y'MY;.
MSE$]*_B]#3Z;C+!NU/KXP]T****0!1110 4444 %%%% !1110 4444 %%%%
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MZ]^2T?\ #W[X8_\ 0LZ]^2U^3_-'-']A8;LP^O3/U@_X>_?#'_H6=>_):/\
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M %%%% !1110 4444 %%%% !1110 C4P?>I[4P?>I]!]"GK7_ ""=0_Z]Y/\
MT$UXU^Q__P D?7_L)W/_ *'7LNM?\@G4/^O>3_T$UXU^Q_\ \D?7_L)W/_H=
M=5/^!+U7ZG/+XCW-:=35IU<:-PHHHI@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(U+2'M0)['XH?\%,/^3LM?\ ^O2V_P#037RO7U1_P4P_Y.PU_P#Z]+;_ -!-
M?*]?JF _W6GZ(^0Q'\67J%%%%=YSA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7[B_P#!/6X?4/V-_AP^>5BO
M(_P2^N$_]EK\.J_<#_@F_P#\F8_#O_N(_P#IQNJ^:S[_ ':/^+]&>IE_\5^G
MZH^E"O[L+WIXII[FG5\"?1BT444#"BBB@ HHHH **** "BBB@ HHHH ****
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M5IU<:-PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(>U+2'M0)GXH?\ !3#_
M ).PU[_KTMO_ $$U\KU]4?\ !3#_ ).PU[_KTMO_ $$U\KU^J8#_ '6GZ(^0
MQ'\67J%%%%=YSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7[@?\ !-__ ),Q^'?_ '$?_3C=5^']?N!_P3?_
M .3,?AW_ -Q'_P!.-U7S>??[M'_$OR9ZF7?Q7Z?JCZ5;O]:=36[_ %IU? =#
MZ,6BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVZ7%U(66)L]>?2O.>6RIP<H[V^\VHUELS]+OCSXZ^/7ASQ$L7@"S\)76G/\
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M !1110 4444 %?N!_P $W_\ DS'X=_\ <1_].-U7X?U^X'_!-_\ Y,Q^'?\
MW$?_ $XW5?-Y]_NT?\2_)GJ9=_%?I^J/I5N_UIU-;O\ 6G5\!T/HQ:***!A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M44UJ2@!QZ4QI=JC/6GDX'I42MN; D!]J40',V,=R:7=V(.:\6^)'C[7_  _X
MJDLK&X B4!MNWUKFF^+7BO<?].C7V\L5TJC*2NB')(^C]P]#^5&X>A_*OF__
M (6UXK_Y_P"/_OW1_P +:\5_\_\ '_W[I^PD1[1'TAN]C^5&[V/Y5\W?\+;\
M5?\ /_'_ -^Z7_A;7BO_ )_X_P#OW1["0>T1](;AZ'\J-WL?RKYO_P"%M>*_
M^?\ C_[]TG_"V_%?_/\ Q_\ ?NCV$@]HCZ1W?7\J-WL?RKYO_P"%M>*_^?\
MC_[]T?\ "VO%?_/_ !_]^Z/82#VB/I#</0_E1N'O^5?-_P#PMKQ7_P _\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $:FTK4'[M*X"GE?6HU4*>%
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MISR^(]S6G4U:=7&C<****8!1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2-2TC4 >,?M ?\ 'QH_^ZU>3_PUZQ^T!_Q\:/\ [K5Y
M/_#7K8;X#EJ!1116RW.;J%%%%4QA1112$%%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -:@_=%#4'[M+J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0<9K]*O^"7?_  F=QH'BSQ)XEU&[GT>]VR6TVH2,RJ.<[2>@KXP_;D\<Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 ?>7_  1]_P"2P>./^P9'_P"ABOUA[&OR>_X(^_\ )8/''_8,C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[FM.IJTZN-&X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:/\ B7Y,]3+OXK]/U1](MW^M.IK=_K3J^ Z'T8M%%% PHHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN*2C[.3/ QM)WYD<-10>.#17UQXX4444 %%%% !1110 4444 %%%% !1110
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MK0ZU%;[E8'&1)\S>U6=HZU\9)MNY[D?=5AC&GCI1MI:+W)2UN%%%%!04444
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MCJ:<O6F1YWMD<=J?TKBW.A[B>].IM.I%"T444""BBB@ HHHH **** "BBB@
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M_<:N-KLOA'_R/%O_ +C5-3X6:0W/HW^&BC^&BO%ZG?T%HHHI@%%%% !1110
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M#_[\?_7H_P"&0?@S_P!$YT/_ +\?_7H_MZ/\K#ZAYGX!?;K?_GJOYT?;K?\
MYZK^=?O[_P ,@_!G_HG.A_\ ?C_Z]'_#(/P9_P"B<Z'_ -^/_KT?V]'^1A]0
M\S\ OMUO_P ]5_.C[=;_ //5?SK]_?\ AD'X,_\ 1.=#_P"_'_UZ/^&0?@S_
M -$YT/\ [\?_ %Z/[>C_ "L/J'F?@%]NM_\ GJOYT?;K?_GJOYU^_O\ PR#\
M&?\ HG.A_P#?C_Z]'_#(/P9_Z)SH?_?C_P"O1_;T?Y&'U!]S\ OMUO\ \]5_
M.C[=;_\ /5?SK]_?^&0?@S_T3G0_^_'_ ->C_AD'X,_]$YT/_OQ_]>C^WH_R
ML/J'F?@%]NM_^>J_G1]NM_\ GJOYU^_O_#(/P9_Z)SH?_?C_ .O1_P ,@_!G
M_HG.A_\ ?C_Z]']O1_D8?4/,_ +[=;_\]5_.C[=;_P#/5?SK]_?^&0?@S_T3
MG0_^_'_UZ/\ AD'X,_\ 1.=#_P"_'_UZ/[>C_(P^H>9^ 7VZW_YZK^='VZW_
M .>J_G7[^_\ #(/P9_Z)SH?_ 'X_^O1_PR#\&?\ HG.A_P#?C_Z]']O1_E8?
M4/,_ +[=;_\ /5?SH^W6_P#SU7\Z_?W_ (9!^#/_ $3G0_\ OQ_]>C_AD'X,
M_P#1.=#_ ._'_P!>C^WH_P C#Z@^Y^ 7VZW_ .>J_G1]NM_^>J_G7[^_\,@_
M!G_HG.A_]^/_ *]'_#(/P9_Z)SH?_?C_ .O1_;T?Y6'U#S/P"^W6_P#SU7\Z
M/MUO_P ]5_.OW]_X9!^#/_1.=#_[\?\ UZ/^&0?@S_T3G0_^_'_UZ/[>C_(P
M^H>9^ 7VZW_YZK^='VZW_P">J_G7[^_\,@_!G_HG.A_]^/\ Z]'_  R#\&?^
MB<Z'_P!^/_KT?V]'^5A]0\S\ OMUO_SU7\Z!?6Z\^<H_&OW]_P"&0?@S_P!$
MYT/_ +\?_7H_X9!^#/3_ (5SHG_?C_Z]+^WH_P K#ZAYGX#VOE7TA"!IV]$-
M;>E^"?$FK3@:;X=OKD'IL0FOWBM_V3_A%9G-OX!TB!O5(<?UKH-!^"?@[PW+
MOL-#M8/153I4/.TUHB_J9^-'PT_8A^*/Q'NX4GT:XT.VE((ENH2!CUS7W[^S
MY_P3;\(_#"2WU?Q1MUK78B'26)B(E;W4]:^TXXQ'&J(-B*,  =!Z4%5VE3R#
MVKQ:V85JW6QV4\+%&79Z796-@EO%#':6B8&(P$!/;I5YXSYFY^8D&44>M/:V
M29=KC='_ '3TI\<.Q0&8O]:\MR;=V=RBHJR$@4_,W9N0/2IJ3%+4C"BBBD 4
M444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***2@!:*3-(LBLN0>.E #J*:9 *6E= +1110 4444 %%%% !1113 ****
M0!1113 ****0!1110 444C,%&33 6DI&Y7(K)F\2:?::C%9S3[+B4X53WII-
M[ ;%%(&##(.106 7/:D M%)GC-&X9Q0 M%%% ",<"OA/_@JYK4FA_"S0(TD*
M)?W;0,,]>/\ Z]?=<@RM?GO_ ,%B_P#DEO@0DX U=L_]\"N_ _[Q Y\1_#9^
M64<8MMRISMXH8TJE=TA!R":;7ZJY<M-6/D+7D%%%%3'X;@]&%%%%,04444 %
M%%% !10HW9QVI54NI8=!Q0 E%=]\*_@-XZ^-EW<6W@W17U22W ,A)VJ ?>NW
M\5?L-_&KP3I,NIZOX4\BRA&YY$E#8'T%<LL51A+DE)7-53DUS):'A5%"J6D>
M/!#H2K \8(IT,9N-^P9V]<UU+5<RV,[,;138Y!(I9<D#KQ3H_P!ZC,OW5.#4
MW3'ROL%%(S!9"A^]C-"G?*L8^\W2M'%I78K,6E600MN.,>]&T[B.XZTL<'VH
M$?P]ZR4D]$PMKJ)YTT2_N]D>3G,@XIK20RR([/YMTO14/!_"O4_V8?A/>?'+
MXR:1HL%O]KM[69)KNW;[ODAN37UM^V5\#?AQ=?%[P'\/O!>DV?AR]NB\=]?6
M:_.IP,9'K7FU\5&%14WN_P #L5-VN?GWY3R*9))8WQ_"O4>U1KMN6^1MI'8F
MOJ?]K;]B>P_9DT.PU6T\1SZNMT%!62,+EC7RS&IF&/+$,HZ[:Z<+6C67-%Z$
M2I\KU!F9CAA@CBDIN['5R_.W/O3F^281'[YZ5V-JYSN+N%%*RE#@]:2D2%%%
M%,=@HHHH$%%%%%K@%%%%9R5MA[A1116D)/J/E1]-_P#!._6Y++]I;PUID4A1
M;V1MX!ZX%?MP"!E1UK\+/V 5Q^V!X"93_')G_ODU^Z:KAF]<U^=YXN6O;R/I
M,%\ Y<[>>M% I=IKYZ.VIZ;%%+2+2TT(****8!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U,'
MWJ>U,'WJ?0?0IZU_R"=0_P"O>3_T$UXU^Q__ ,D?7_L)W/\ Z'7LNM?\@G4/
M^O>3_P!!->-?L?\ _)'U_P"PG<_^AUU4_P"!+U7ZG/+XCW-:=35IU<:-PHHH
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2-2TC4 >,?M ?\?&C_[K5Y/_  UZQ^T!
M_P ?&C_[K5Y/_#7K8;X#EJ!1116RW.<****I@%%%%(04445+W *[+X1_\CQ;
M_P"XU<;79?"/_D>+?_<:IJ?"S2&Y]&_PT4?PT5XO4[^@M%%%, HHHH ****
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M^='U=B]HCZ(S]*,_2OG?_A;FL?[7YT?\+<UC_:_.CZNQ^T1]$9^E&?I7SO\
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M '6.;^),]#Z5UB!5.5Z&N)JQT#E)YS2YIM%2,<>E?GI_P6._Y)/X'_["S_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD UNE?/?QL_Y
M'H?]<5KZ$:OGOXV?\CV/^N*UT4?B,JCT.$9CYC\]Z7FFM]]_K3J]F5K(X;W8
M4445G=##FBBBG= %%%%*Z ****=T 4444KH HHHIW0!1112N@"BBBBZ *.?6
MBBGHP0=>O-)2T56Q$A*6BBC<J(^WF;3Y1,DKQR#D",XS7JO@/XP-^[L]3X'1
M6KR=E6SYG^=FY6@,@822\'^&L)T58V534^M;6\BOH!-;.)%(SP:E52R[APU?
M-WA7X@ZGX4D'FR-):,<A2>U>Z>%O&5GXJLUE@=4?NF:\Z=-Q.F,[F\FX\O\
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M\@G4/^O>3_T$UXU^Q_\ \D?7_L)W/_H=>RZU_P @G4/^O>3_ -!->-?L?_\
M)'U_["=S_P"AUU4_X$O5?J<\OB/<UIU-6G5QHW"BBBF 4444 %%%% !1110
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MMCP9_P!#;HO_ ('1?_%4?\+8\&?]#;HO_@=%_P#%5_.C]G;_ )[3_P#?UO\
M&C[._P#SVG_[^M_C1_JZ_P#GY^ ?7XG]%W_"V/!G_0VZ+_X'1?\ Q5'_  MC
MP9_T-NB_^!T7_P 57\Z/V=_^>T__ '];_&C[.W_/:?\ [^M_C3_U=?\ S\_
M/K\3^B[_ (6QX,_Z&W1?_ Z+_P"*H_X6QX,_Z&W1?_ Z+_XJOYT?L[_\]I_^
M_K?XTGV=_P#GM/\ ]_6_QI?ZNO\ Y^?@'U^)_1?_ ,+8\&?]#;HO_@=%_P#%
M4C?%CP7_ -#;HO\ X'1__%5_.E]G;_GM/_W];_&E6%^<2SD_]=F_QI_ZNO\
MY^?@+Z_$_>WXH:MX<\:?9)++QAH*-;@@>9?)W^AKBO\ A'-*,:X\;^&M_?\
MT]/\:_$>-KFWRK2S@'_IJW^-"VY4EWO)AGH/-;_&M8Y#**LJAD\6I;G[<?\
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MP6QP/%NBLWHM]&?ZU_.CY#=3+.1Z><W/ZT^W\RWE%Q;+<0L._G-_C2_U=?\
M.'U^)_1G;_$7PW>3"*WUNRG8]/+F4UO17"3*'1U=#T93D5_.QH7Q/\:Z!,L^
MG:W/;A.@W$UZSX0_;R^+?A.ZB>[\337.F1D;+4J/F]1FL:V12IQO&5QQQJDS
M]T!(<\]*;)*RC<,,HZXZU^>/P9_X*LZ1K$MMIWC/1SHZMA?M\LF0WOBON;P9
M\0M!\>:1!J6A7\5W:2C*,C#YO:OGZV!K47[R.R%>,NIU"7 D7<!CV/6E$A7
M;J3VJ&%GN)-[Q^5LX />EBS]H:5C@,,!:X7-0=I'8G<MT4450@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****7
M4!K=*^>_C9_R/0_ZXK7T(W2OGOXV?\CT/^N*UTT/C,JFQP;?ZQ_K3J:W^L?Z
MTZO7Z'#U"BBBI *0G'-+2;PF,KNW<8HO;4>XY%WQEP1@4U6W#(JPVDWB8VVS
ME6I_]G70&U;1ZGVB'R,J9HS5G^S+K_GT>D_LRZ_Y]'H]J@Y"OFC-6?[+NO\
MGU>C^R[K_GU>JYHE<A6S1FK/]EW7_/J]']EW7_/J]%XCY"MFC-6?[+NO^?5Z
M/[+NO^?5Z+Q%R,K9HS5G^R[K_GU>C^R[K_GU>B\1\A6S2]B:L?V7=?\ /J]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J8/O4]J8/O4^@^A3UK_D$Z
MA_U[R?\ H)KQK]C_ /Y(^O\ V$[G_P!#KV76O^03J'_7O)_Z":\:_8__ .2/
MK_V$[G_T.NJG_ EZK]3GE\1[FM.IJTZN-&X4444P"BBB@ HHHH **** "BBB
M@ HHHH ***3^*D 'VIA($B@CYL4YB=IQS4/+LI[8YI7UL'2YD>,/$UEX+\.Z
MCKEXX6&UA:1LGT%?A)^U-\<-6^-WQ8U6^-RTNF03,MKEN$3T%?H5_P %0/C=
M<>!?AS9>'M)G_P!(U*<P7*J>1&PK\EEA^S_N\YV]_6OM,FPG+^]?4\'&8B_N
MCU*B-H9>%7Y@XZDTH'[M#V/YTRBOK5&QXKU"BBBM="D[*P4444M"0HHHHT *
M***GE0:A1111RH-0HHHHY4&H4444<J#4****.5!J%%%%5H 4444] "BBBEH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHI=0&MTKY[^-G_(]#_KBM?0C=*^>_C9_P CT/\
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MQ("BBBH;N[@%%%%( HHHH **** "BBB@ HHHH **** /H'_@G_\ \G>>!O\
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M"L+D?]\FKC'FDB).R/QM_P""D_C)]8_:6U/3(I_/TN*SC,?.5$G?%?)JJRJ
MQRPZFO0OCUKK>)/BAK5R\GFLEQ(FXG)X8\5Y_7ZK@Z*IT(V/D\1*\V%%%%=I
MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %)M+< X)I:*+7T ^D_\ @GWXPD\._M,>&K&6?R-/F5_/.<!CCC-?MXS>
M='&\9RIYR.XK^=[X1ZRWA_XB:1?*YC:.555LXQDBOZ"O!-P]QX/T:4G+26L;
M$_517PN>T5"HI'T6!EH;XPR\=*.]+2?X5\L>L%+2+TI:F.P!1115 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112Z@-;I7SW\;/\
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MC/Q!C@#4KCC_ (&:SV^\<<5^O8>ZH13/CJOQL2BBBM3(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHI7 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 444J_>&>E-;@
M/LY&BO[%T.'%U%_Z$*_HS\ C9X'\/?\ 8.MS_P"0UK^<NS&W5[(G[K747'_
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MFG:4XET/37S#.G(D/0@'O7#@Y.-=J,FUUOW'63Y5>Q\O1@(0EO\ O7 ^>-N
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M44 %*OWA24J_>% F/M_^0I8?]?47_H0K^C7P+_R)/A[_ +!UO_Z+6OYRK?\
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M9?C%X+C=5)_M6W8.3QMWCFOO'_@L8RW"_"_8\<L8DDW;7!XXY^E?G)%)]GA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&I@^]3VI@^]3Z#Z%/6O\
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M([U%YT/V@AG8A3AD#?,*E)5CE 0G;/6J3N-JP4445=B HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !2K]X4E*OWA0)C[?\ Y"=A_P!?47_H0K^C
M7P+_ ,B3X>_[!UO_ .BUK^<FW_Y"EA_U]1?^A"OZ-O O_(D^'O\ L'6__HM:
M^,XDVI_,][+=C<I1]TTE*/NFOCNQ[@+3J:M.IB"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_6K\X=M&VC^R,%_)^(?7JA^CW_#Y*;_HFK?^!7_UJ/\ A\E-_P!$U;_P*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>$_VB-/8ZI;1V^I;<)=[>0<<'BO>JCW!?E/6MZ52=%\T'J3.*FK,_%;XP?\
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M  !C_P */[>G_(']GKN?SL_:D]'_ ._;?X4?:D]'_P"_;?X5_1-_PI'X?_\
M0EZ'_P" ,?\ A1_PI'X?_P#0EZ'_ . ,?^%']O3_ ) _L]=S^=G[4GH__?MO
M\*/M2>C_ /?MO\*_HF_X4C\/_P#H2]#_ / &/_"C_A2/P_\ ^A+T/_P!C_PH
M_MZ?\@?V>NY_.S]J3T?_ +]M_A1]J3T?_OVW^%?T3?\ "D?A_P#]"7H?_@#'
M_A1_PI'X?_\ 0EZ'_P" ,?\ A1_;T_Y _L]=S^=G[4GH_P#W[;_"C[4GH_\
MW[;_  K^B;_A2/P__P"A+T/_ , 8_P#"C_A2/P__ .A+T/\ \ 8_\*/[>G_(
M']GKN?SL_:D]'_[]M_A1]J3T?_OVW^%?T3?\*1^'_P#T)>A_^ ,?^%'_  I'
MX?\ _0EZ'_X Q_X4?V]/^0/[/7<_G9^U)Z/_ -^V_P */M2>C_\ ?MO\*_HF
M_P"%(_#_ /Z$O0__  !C_P */^%(_#__ *$O0_\ P!C_ ,*/[>G_ "!_9Z[G
M\[/VI/1_^_;?X4?:D]'_ ._;?X5_1-_PI'X?_P#0EZ'_ . ,?^%'_"D?A_\
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M0/[/7<_G9^U)Z/\ ]^V_PH^U)Z/_ -^V_P *_HF_X4C\/_\ H2]#_P# &/\
MPH_X4C\/_P#H2]#_ / &/_"C^WI_R!_9Z[G\[/VI/1_^_;?X4?:T#+\K\_[#
M?X5_1-_PI'X?_P#0EZ'_ . ,?^%)_P *2^'X_P"9+T/_ , 8_P#"D\^G_*']
MGQ[G\^-EHNHZTR1V%E+.[< *A_PKUCP%^QS\5/'T]N+7PG=_8YF"O<]HU/\
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M %%%% !1110 4444 %%%% !1110 C4P?>I[4P?>I]!]"GK7_ ""=0_Z]Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (U,'WJ>U,'WJ?0?0IZU_R"=0_P"O>3_T$UXU^Q__ ,D?7_L)W/\ Z'7L
MNM?\@G4/^O>3_P!!->-?L?\ _)'U_P"PG<_^AUU4_P"!+U7ZG/+XCW-:=35I
MU<:-PHHHI@%%%% !1110 4444 %%%% !1110 UJ7^&D:E_AI,!/XJHZW_P @
M74/^O:3_ -!-7OXJHZW_ ,@74/\ KVD_]!-/[2"6Q_.5XH_Y'+Q#_P!A*X_]
M#-9K?>-:7BC_ )'+Q#_V$KC_ -#-9K?>-?L,?@CZ'Q=7XV)1115&84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%%)C0444#J*<12"@C%/60P,[,NZ-
MNF!388T=7<E@.O-1*HH@HMA2U&RNBH^05;[@'4_6G33+'<HVY?.VX\O/RX_Q
MIQJTYZ4]RO9L=14;7$?F;PP+=USQ3Y&@6)#"YENI& $8Y'/;ZTJDITU>;T$H
M-B45]%?#7]@+XP_%CP['KNBZ?96UC<#*+J$OE2?D:YSXT_LC_$?]G^QBU'Q5
M;62VF I:"3<,FN:GC*$Y<D'J='L6HW9XQ12_);JK@^8TYVD==M!7;QZ5WIJ2
MT,)*PE%%%0+H%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5?O"
MDI5^\*!,?;_\A.P_Z^HO_0A7]&O@7_D2?#W_ &#K?_T6M?SE6_\ R$[#_KZB
M_P#0A7]&O@7_ )$GP]_V#K?_ -%K7QG$FU/YGO9;L;E*/NFDI1]TU\=V/<!:
M=35IU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%/VC?L!^:FLK0N!)C;ZK51BY;"$HH;&X[>4[&BI?NZ, HHHH **** "BBB@
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MBF 4444 %%%% !1110 4444 %%%% #6I?X:1J7M28"?Q51UO_D"ZA_U[2?\
MH)J]_%5'6_\ D"ZA_P!>TG_H)I_:02V/YR?$_P#R.7B'_L)7'_H9K.;[QK1\
M3_\ (Y>(?^PE<?\ H9K.;[QK]AC\$?0^+J_Q&)1115&84444 %%%% !1110
M4444 %%%% !1110 4444 %%%%&XPI0-W&,YXQ24A!;A3ANQI2]U:B^)F]X/\
M-R>-/%.F>'8KM-,:Y?8'E&17VC'_ ,$F_&>I"PFM_&EI]EN(U<_N3P#7R/\
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M@3'6_P#R%+#_ *^HO_0A7]&W@7_D2?#W_8.M_P#T6M?SDV__ "%+#_KZB_\
M0A7]&W@7_D2?#W_8.M__ $6M?&<2;4_F>]ENQN4H^Z:2G=J^.['N"+3J:M.I
MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\]:]>G#E1QRES"44453W'T"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "E7[PI*5?O"@3'6_P#R%+#_ *^HO_0A7]&W@7_D2?#W_8.M_P#T6M?S
ME6__ "$[#_KZB_\ 0A7]&O@7_D2?#W_8.M__ $6M?&<2;4_F>]ENQN4H^Z:2
ME'W37QW8]P%IU-6G4Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:F#
M[U/:F#[U/H/H4]:_Y!.H?]>\G_H)KQK]C_\ Y(^O_83N?_0Z]EUK_D$ZA_U[
MR?\ H)KQK]C_ /Y(^O\ V$[G_P!#KJI_P)>J_4YY?$>YK3J:M.KC1N%%%%,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.M;&W60"UE!,A*=:_3'XF:#IO[1W[-$FK>)]$M["[N+3[0%DZQ$#.,FO)_V
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M1]TU\=V/<!:=35IU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1\4?\CEXA_["5Q_Z&:SF^\:_88_!'T/BZO\ $8E%%%49A1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 A[5^!_[:_\ R=K\1?\ K_/\J_?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<]PHHHKOD[G,%%%%"V ****8!1110 4444 %%%% !1110 4444GL-;GZS_\
M!(/_ )(!X@_[##?^@U]VKVKX2_X)!_\ ) /$'_88;_T&ONU>U?E.,_C3]3Z[
M#_ O04=_K2K2#O\ 6E6N-;&_4.QIU-[&G4%!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 (U,'WJ>U,'WJ?0?0IZU_R"=0_Z]Y/_ $$UXU^Q_P#\D?7_ +"=S_Z'7LNM
M?\@G4/\ KWD_]!->-?L?_P#)'U_["=S_ .AUU4_X$O5?J<\OB/<UIU-6G5QH
MW"BBBF 4444 %%%% !1110 4444 %%%% #6I?X:1J7^&DP$_BJCK?_(%U#_K
MVD_]!-7OXJHZW_R!=0_Z]I/_ $$T_M();'\Y7BC_ )'+Q#_V$KC_ -#-9K?>
M-:7BC_D<O$/_ &$KC_T,UFM]XU^PQ^"/H?%U?C8E%%%49A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*OWA24J_>%
MF/M_^0G8?]?47_H0K^C7P+_R)/A[_L'6_P#Z+6OYRK?_ )"=A_U]1?\ H0K^
MC7P+_P B3X>_[!UO_P"BUKXSB3:G\SWLMV-RE'W324H^Z:^.['N M.IJTZF(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $/:OP/_ &U_^3M/B+_U_G^5?O@>U?@?^VO_ ,G:?$7_
M *_S_*OI\@_WE^AYN,^ \97[II*5?NFDK[R'Q,^86X4445$1O<****L HHI5
M5I#M098]* $HIQRTBHD>67AA2LH5L$8)Z+2>BN RBGLI>(E$PZGI2C_2F/EQ
M&( 4^M@6JN1T4$%3M88(_6BL]KR[%;:!1114REL^X7"BEI57<I+?)75I?E1%
MQM%)(IC YR#WIS1F/ +;LC-<\9\S:70H2BBEJG/E29(;:2C)HH:;5T""BBBH
MC>]BTKA112UT2BH]27H)14BQM)E43>QZ8INY5S&/FF'WE]*%%6O<!M%/6-F7
M>4VQ_P!^F-B%MW^M0UES)[,=@HI=HD4MNV'LM-7..>M4 M%%%3?6P@HHHJ@"
MBBBD]AK<_6?_ ()!_P#) /$'_88;_P!!K[M7M7PE_P $@_\ D@'B#_L,-_Z#
M7W:O:ORG&?QI^I]=A_@7H*._UI5I!W^M*M<:V-^H=C3J;V-.H*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6OGTG2[J_=>)OL\)<@_A7V-\:O\ @F+XA^#?P_U+Q4_C6TU.&QB:62W2$J6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB*.].I%Z4M" ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (U,'WJ>U,'WJ?0?0IZU
M_P @G4/^O>3_ -!->-?L?_\ )'U_["=S_P"AU[+K7_()U#_KWD_]!->-?L?_
M /)'U_["=S_Z'753_@2]5^ISR^(]S6G4U:=7&C<****8!1110 4444 %%%%
M!1110 4444 )1WI:3^*EU #W%1+N;=NX X J4CK4$FX2* VWBIO[P/8_'G_@
MI]X#N=$^/EUXK:/R[*^MH[:''0N!7QHH=5 D_P!9WK]E_P#@HU\"6^+7PE74
MK91]KT9VNQ@<M@=*_&IO-\QEG0QS@X=&Z@U^CY3B%4I*-]CY?%0:E>PE%#_N
M_O<48)56_A;H:]ZZ//"BBBF,****!!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%'8GL.M( HVLW"?>/2D7]Y]WFE<2QXV(3*?N*.I/I4
MRDDFQI7=CZK_ ."<_@2Y\0?M$:%XAAC\ZVTD/'<@\@,1Q7[3[@J@@<'C%?$W
M_!,WX$O\./AK=>)+V/\ TS72ESM8?,G'2OM@?-(1GMTK\US6O[:JVNA]/@XN
M,=2;^'BCO2*NU *7O7D+8] *6BBA %%%%, HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $:F#[U/:F#[U/H/H4]:_Y!.H?]>\G_ *":\:_8_P#^2/K_
M -A.Y_\ 0Z]EUK_D$ZA_U[R?^@FO&OV/_P#DCZ_]A.Y_]#KJI_P)>J_4YY?$
M>YK3J:M.KC1N%%%%, HHHH **** "BBB@ HHHH **** "BBB@ I H7.!2T4
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MMAO^?GXA]5F<#\WH*/F]!7??\,[_ !8_Z)UKW_@,:/\ AG?XL?\ 1.M>_P#
M8T>VPW_/S\0^K3.!^;T%'S>@KOO^&=_BQ_T3K7O_  &-'_#._P 6/^B=:]_X
M#&CVV&_Y^?B'U:9P/S>@H^;T%=]_PSO\6/\ HG6O?^ QH_X9W^+'_1.M>_\
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M6O?^ QH]MAO^?GXA]6F<#\WH*/F]!7??\,[_ !8_Z)UKW_@,:/\ AG?XL?\
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M_P"B=:]_X#&E[;#?\_/Q#ZM,X+YO04XJ%7?(=H_V>:[O_AG?XL'@_#K7L?\
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M?-?'UJE2M*]SV80446Z0J&ZBEHH+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J8/O4]J8/O4
M^@^A3UK_ )!.H?\ 7O)_Z":\:_8__P"2/K_V$[G_ -#KV76O^03J'_7O)_Z"
M:\:_8_\ ^2/K_P!A.Y_]#KJI_P "7JOU.>7Q'N:TZFK3JXT;A1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HO)^8D<>OO4M% $;0*RX897TI%AV
MD;3A1_#4M%2XI[@-V4AC^8'.*?15+07*B#['%YGF>6N_^]CFI=I[&G44]Q<J
M6PW!]:,'UIU%(=AN#ZT8/K3J* L-P?6C!]:=10%AN#ZT8/K3J* L-P?6C!]:
M=10%AN#ZT8/K3J* L-P?6C!]:=10%AN#ZT8/K3J* L-P?6C!]:=10%AN#ZT8
M/K3J* L-P?6C!]:=10%AN#ZT8/K3J* L-P?6C!]:=10%AN#ZT8/K3J* L-P?
M6C!]:=10%AN#ZT8/K3J* L-P?6C!]:=10%AN#ZT8/K3J* L-P?6EVGUI:* L
M0R6D4C!F16/J13Q&%Z=*?13NQ<J(Q" V<<TGDD_Q<>E2T5#BGN/8B6W6-LH-
MH/4#O1Y WY/([#TJ6BJ6FPPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BG4L
MO'4<U"T)N%'F#"]T]:LM2@47MJ/=6/EK]LG]CW3_ -HOPK<W,;_9O$EE&9;:
MY1 6F*CY8C[&OQH\:>!]?^&^NR:-XETZ33=2C8JT3 D<>]?T<LM>&_M"_LH>
M#OVBM)>#6[/[/=H#Y5U;@(^?<]Z]S Y@Z+M)Z'C8C"\VJ/P>W?-M[TG5C7U+
M\>O^"?GCOX5W3RPVS:YI2G-LNFH7EQ_"&KYRU;P?XFT.0_VEX?O[*0<,DT)4
MK]:^[H8ZE7CN>/*A*!C;AG'>BG73?9U#,/);TDXJ-[Y&C0R30GTV,,UT^UI=
MR/9S'T5!]K@_YZI_WU1]K@_YZI_WT*/:TNX>SGV)Z*@^UP?\]4_[Z%'VN#_G
MJG_?5'M:7</9S[$]%0?:X/\ GJG_ 'T*/M<'_/5/^^A1[6EW#V<^Q/14'VN#
M_GJG_?0H^UP?\]4_[ZH]K2[A[.?8GHJ#[7!_SU3_ +ZH^UP?\]4_[Z%'M:7<
M/9S[$]%0?:X/^>J?]]4?:X/^>J?]]"CVM+N'LY]B>BH/M<'_ #U3_OH4?:X/
M^>J?]]"CVM+N'LY]B>BH/M<'_/5/^^A1]K@_YZI_WT*/:TNX>SGV)Z*@^UP?
M\]4_[ZH^UP?\]4_[Z%'M:7</9S[$]%0?:X/^>J?]]"C[7!_SU3_OJCVM+N'L
MY]B>BH/M<'_/5/\ OH4?:X/^>J?]]"CVM+N'LY]B>BH/M<'_ #U3_OH4?:X/
M^>J?]]4>UI=P]G/L3T5!]K@_YZI_WT*/M<'_ #U3_OH4>UI=P]G/L3T$%5R>
ME0?:X/\ GJO_ 'U2K/'U\^/;Z;A1[6EW#V<^Q*&!Z4;AR?2F?V@C$*LD7YU<
MM].O+TA;2+[3,WW?+&0/K4RKTXJZ8U3D]"#.4W#I3/,616;)VCKQS7=^$_@7
MXZ\<WL-G8>'-16ZD( N&@;R1GU-?=O[/?_!+IE^QZQ\0YXY;J/#I#:-A?HPK
MCK9I3IQU9TT\*VSYS_8__8UU_P#:&\4VMWK<$NG^$K5A,;XK_K&4Y\O![&OV
M9\%^%-,\">';+0M)MTM-/MD"0I&,#WI/!OAW2O"FD0:3I=DEC:VZA!M0*&([
MUN?,LC E1G_5@U^?9AC)5Y-K8]ZC14$65^Z*6FKG:,]>].KS3K"BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C4P?>I[4P?>I]!]"GK7_ ""=0_Z]Y/\
MT$UXU^Q__P D?7_L)W/_ *'7LNM?\@G4/^O>3_T$UXU^Q_\ \D?7_L)W/_H=
M=5/^!+U7ZG/+XCW-:=35IU<:-PHHHI@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQI?^&%?@9_T3O3?R;_&O?**/;5/YG]X>RCV/ O\ AA;X&?\ 1.],_)O\:/\
MAA;X&?\ 1.],_)O\:]]HH]M4_F?WA[*/8\#_ .&%?@9_T3O3?R;_ !H_X85^
M!G_1.]-_)O\ &O?**/;5/YG]X>RCV/ O^&%O@9_T3O3/R;_&C_AA;X&?]$[T
MS\F_QKWVBCVU3^9_>'LH]CP/_AA7X&?]$[TW\F_QIO\ PPG\"U^8_#W3?R;_
M !KWZDI^VJ?S/[P]E'L>"+^PO\#%^9?A[IH_!O\ &M+3?V1?A-H,F_3O!%E;
M/G.Y,_XU[31UH5:I_,P]G'L8OA_POI?AFT6WT^QBM(QP%516DR 9XP/6K%!
M/45C.4I:W+44BIN>4A'CVH.0U.F4/M9H\RIRE6<45,;K<H1"2H)&#WIU%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J8/O4]J8/O4^@^A3UK_D$Z
MA_U[R?\ H)KQK]C_ /Y(^O\ V$[G_P!#KV76O^03J'_7O)_Z":\:_8__ .2/
MK_V$[G_T.NJG_ EZK]3GE\1[FM.IJTZN-&X4444P"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:F#[U/:F#[U/H/H
M4]:_Y!.H?]>\G_H)KQK]C_\ Y(^O_83N?_0Z]EUK_D$ZA_U[R?\ H)KQK]C_
M /Y(^O\ V$[G_P!#KJI_P)>J_4YY?$>YK3J:M.KC1N%%%%, HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BD)I-U #J*;NI: %HHHH **** "BBDS0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44FZ@!:*3-+0 4444 %%%% !1129H 6BBB@ HI*3=0 ZBBD- "T4E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 C4P?>I[4P?>I]!]"GK7_ ""=0_Z]Y/\ T$UXU^Q__P D?7_L)W/_
M *'7LNM?\@G4/^O>3_T$UXU^Q_\ \D?7_L)W/_H==5/^!+U7ZG/+XCW-:=35
MIU<:-PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E)NH
M =13=U+0 M%%% !1110 444F: %HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDW4 +129I: "BBB@
M HHHH ***2@!:*3-% "T4F:-U "T4E%*X"T4F:6F 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)13-U%KC';J./
M2DW9I:S?.M@#CTI:;FE5JM7Z@.HHHIB"BBB@!*,4M%*X!1114-@%%)[TM5$
MHHHJ@"BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "
MBDSR12U" *:5IU%6 BTM%%( HHI,U-P%HI-P]:3^*J5P%Q1BEI"<47L M(U
MH;%3J]@$W4<4E%%I+08N31NI,BBERRWN ZEI%I:H044E&?6E<!:*3-+5( HH
MHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
MU,'WJ>U,'WJ?0?0IZU_R"=0_Z]Y/_037C7['_P#R1]?^PG<_^AU[+K7_ ""=
M0_Z]Y/\ T$UXU^Q__P D?7_L)W/_ *'753_@2]5^ISR^(]S6G4U:=7&C<***
M*8!1110 4444 %%%% !1110 4444 %%%% !1110 4E+4>[FBUP';J./2DW9H
MK-\ZV&+QZ4HIN10&JDI=0'T4450@HHHH 2C%+12N 4445+8!124M$0"BBBK
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS\V*
M6H3 *:5IU%6 U:=112 ***2IY@%HI,BC-->8"TFT4M%.X";11TI:3UHN F:2
MBEX]:>B&&:,T<4<=^*0@6G4F,4M !1249]>*FX"T4F:6J0!1113 **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWL9K[_M9?.MHI",%T#8^HS6]6E*G;FZ@2T445@ 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 C4P?>I[4P?>I]!]"GK7_()U#_
M *]Y/_037C7['_\ R1]?^PG<_P#H=>RZU_R"=0_Z]Y/_ $$UXU^Q_P#\D?7_
M +"=S_Z'753_ ($O5?J<\OB/<UIU-6G5QHW"BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5Y&"9PN[Z58JLS [\'&WJ:F7-]D3=A RJ?-8^7GCF
MIM^XKAN#^M?/GQ._;D^$OPC\3/X?\3:K<07\:[RJ6Y<?SKF5_P""E7P*E:-%
MUR]R_P!W%F?\:ZX86O-7Y6R>9'U(HV#:$(&<\U*K#=@?C7RFW_!2KX%6[,S>
M(;XD=C:D_P!:]Z^%OQ:\._&+P]!KGAFX>YT^8;@\B;3CZ5-2A5I_$K!S';44
M45@6%%%% !1124K -D8(N2<>],7<N=S!O0"G2?,O0-[&J]Q=006_FW$T=L@_
MBD<*!^)II 3(Q;("E#[U-5"WU2UOH\V5W;W;?],I5?\ D:O#H,TP%HHHI %%
M%% !1110 4444 %%%% #6^[R.*A;.X;) J]P:F92<$'I6?<:KIT$GES7UI#-
MV1YE!_(F@"_G:PP,Y[T^H(92Z@Y4J>C(<@U/0 4444 %%%% !1110 4444 1
MG:6W?Q>E,:4!E+-L]C0I=MP90K]J\9^+W[6WPV^".J6VF>+M2FMKV8[46. R
M#/US51CV ]I1RW.,4^N>\$>--)\?Z!!K&BSM<6$P#([#!Y&>E= M*2Z#%&:6
MBBLUL(0U&LA8X,9 ]:DK(UZ^;2]-N;]&9VC0LL9Z$BJA&[ OQLF]@!R*F7M7
MP+X/_P""B/BSQ%\;KOP5+X7T^&RBN6@%RLC;\ XSC-?>UJQDMXG/5E#?F*Z*
ME*5-)R6XR>HIG*;<(7Y[5+4<SF.,N/X>:YFKL1$T@0>8#P/O+2EB5WA2&;BJ
MUW?P6-HUW</'#:A=SR2' %>!>-/V\O@_\/[PP:QKLZ3;O+VP0^8,_@:WA3<O
MA5QGT*K+(P&<2KP*2.-]N)6WL#D$<5X1X%_;:^$GQ O8[;1M:D>X<X430[,_
MF:]V6=98XY$8/#* 5=>>M95Z,TU=6$/63#']VP)[T;@P_>C !R*Y[QYXYTCX
M=^&[G6->NFM=.MQEI5Y:O"K/_@H?\%M2URUT:#6KN6]GD$2*;8@%CP.<UM&C
M-QND!]-1[CDELJ>E252TN_BU.T2ZMSFWD 9"1CBKM8-<N@#6SM)'6H=X9-TH
MVX/%6*JPQMM82G=EN,T174!Z@89\?>[5,OW17P;\<O\ @H)XA^$_QZO_  );
M:%9W<%K(J>9(QS@XK[;\(:T_B+POI6J21B*2\MDG9%Z L,XKHJ4I4TF^HS8H
MHHK 04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )5:\M8
M[RW:&09C;@@<5:IC 4M5)-!IU/G/Q5^P#\&?&7B*_P!=U30+B?4;QM\TGVD@
M$^PQ7Y?_ !R\ :'X#^-G_".Z-:-!I+3>40YR=N[&,U^Y<GW&^AK\5?VIUEF_
M:,5.%@^UY+9Y^]7T>63K5)22D[(RE8^X/A7_ ,$_?@MXD^'^D:A?>'[B>ZN(
MP\D@N".>M>[^$_'GPN^'<</@_2?$FGV\UL!$EBUQNE7''-:7P%4+\*/#H1RZ
M>1R6^E?CU\=]0N;;]H369+(&UU&6^D@@EB/S%BW _.L*=*>+JRC.3LAW25S]
MCM0^./@/2=7BTB\\6Z;!J<AVI;O* Q/TKJ+C6[2PL1>7-[%%9D;Q<,<)MK\]
M_@[_ ,$\]3\0+I/CWQMXAO6UY3YQM6^8#'3]*Y;]N+X_:ZWB70OA]X7OW@L$
MC2VFE1]N7SC!IT\NC7GRTI7MN+F/OJ;]H[X:0W1MY/&VDPR X^:<?,?05V.A
M^+-)\56!N]&U.WU"W!P9H&W+7YS>%_\ @F3I'B_PM;:YK'CJ2T\22Q^:NGQS
M(85;&0"<YYKSO]EGXT>(/@7^T/=^#]4OGN_#MO</9M'YFY&?. PH>7TYQE[*
M=W$.8_675_$&G^'[-KS4[R*QM5ZRS-M6N%?]I+X8PS&*3QSHX;/_ #W&![5X
M9^UU\%?B7\9]8TBW\-:BUGX;9E>Y_?A%V$<\&O'-:_X)>^%X/#-W?CQU*^L1
M1-.]N94V;E&2,YKEIT*+2<Y[]@YF?H'X=\8:1XMLQ/HFIV^K1'_EK;L"HKX4
M_P""EGQ(T74M#CT;2?$T3ZG;C;<V=G.1*K ]#CH:\*_89^+/B'P9\:8]#_M*
M:?19[G[&L!?*##8)%=3_ ,%!_P!F;0/AOKFI^.X-7NIK_6)C<M;NORH2>@/I
M7?3PM*GBHP<KIAS:'J?_  3O^,7A7PO\,U3Q/XK@TN^>1D6VU*X/F'GCK7VQ
MJWQ,\,:%I,.JZCKEG8Z9,NZ*YF?"2+Z@^E?E_P#LE_L/^'_VC_"\'BK5_$-[
MIT\3_+;6Z@CCOS7LW_!03PNG@OX-^&O#4=S(]EIUIY*3G[S@'J:VQ&#H8C&>
MQI2M<.;2Y]J0_%GPA<^'5\00^)M/?1"Y3[<LH,18=1FJFB_'3P!XDO8[72_%
M^EWMPW"Q0S LWTK\M/V2_P!GCQ?^T%X?&C?V_>:;\.5<L&A?K+_%\M<G^TI\
M ]0_9"\:6\6B:Y>/'<MNM+MN'P*B.5TG5]CSZASG[%>*OB5X8\$J&UW7[+2%
M*[@;J0+QZU6\+_%OPAXX=(O#WB.PU>1NGV60-7YS_!G]E[Q7^V-X=7Q-XT\6
M:A!IBQ?9X8U;<'91W%>(VMGK?[*/[1$FE:9JMPMGIER(S$6VJX)[UG_9D')T
MXSO)"YC]KX+DS1NQ4Q[20=WM7%:[\<O 7A2^>SUGQ?I>GW0.##/,%8&O#_VO
MOVAKKX5_ /3=2L9?*UG5+>/[IY173[X]Z^./V<_V43^U78WGB#QQXKDM(%.^
M&[:9?.ER>X)KEH8&+@ZM5M1'S:GZD^%/BEX3\;,4T+Q%8ZNW_3K(&K7\0>*-
M+\*Z;+?ZO?0Z?9QC<\TS84"OQ]^,?PUU;]BKXH:6OA;QA<W-@VR<K'*,,N>A
MP:^P_P!H;X@/\3?V)QKXPMWJ-H1& >&(X/-5+ KVD%%W4@YCZAT7XP>#?$.C
MS:MIOB6PO]+A;9)=PR@QHWH3ZUEV_P"T+\-[V\6UM_'&CR7&<&)9P2?:OR._
M95^$WCSXN2#PQX;U6XT[P[(V_4$ADPN_^(X[\5W/[5G[&:_LSQ:;KVC:Q<7\
M5R_[V>7AHR.21^-=CRNA&JJ3J:AS'ZQ^(/%6D:)X>EU34-2@LM-:/(NY&PF"
M..:_&_XQ>-XKS]JA]3T[7[B\T2*=6^TV]RWDJ,\D\U]>_LJ->?M8?LMZWH?B
M;4IXH+*[6WAN$.YMJKQ7P=\3/A3I_@'XW3> K'4)Y[*XD$;W#+A@#WJL+@\/
M[25.I*[3!R/V)^$'QH\%^*M%T72-)\5:?JNL-:AC9PS!I3@<\>U>H[V#-E@?
M]FOC_P#99_8+\-?!GQ/H7Q!T_P 07U[?_82AMI4 C.\<\YKZ[5E=G=.6]Z\7
M%TZ*J.-*3:-8[:F-XJ^(7ASP+:?:/$6LVFCPGG?=/M%4D^+G@V3PO%XE7Q-I
MY\/RL8TU#S1Y3,.H!KXZ_P""HK-)X)LXIHU6-D!+ \]:^;_V6?@7XN_:"\-P
M>''U6YL?AY&Q9(XFX1S]Y@OK7;2RZ$\-[7G,W+6Q^HND?'SX>:]>1VVG>,M*
MNYWX6.*8$M]*[E)F88!SN&5?L:_&;]IC]FS5?V1_$5C_ ,(_J%Q>6<Y\V*_D
M.)$ /2OO#X _M)OXI_93N_%U[,#JNFP2*JN?OLB\45,O4:<:E*5[CYCZ(\3?
M$KPOX):./7]?L=*E8<"YDVYK(TCX^?#O7KM;73_&.E75RQVK''."Q-?E/\.]
M%UW]N#XIWW_"2>(YM+T6:8EY3* ;7T"9/.:ZS]HC]BZ+]FOPS:>*/!OC"35;
M@3!,O,H9<=^#6CP%*-HSD^9^1/,S]8S<*L/G&11"!DOVQZUQ^D_&WP'X@U:Z
MTO3O%FF7FHVP8S6\,P+Q@=21[5\R?L>_'34OB]\"?$>GWMV\VIZ' (Y;AS\Q
M)![U^<OAV+6C\8=9T;PO/-!K^H7\D+7,9(9D9L8)]*BAE_M7)7V#F/VRTKXS
M^!?$.NKH6G^+=-O-4)*&SBE!D8XZ 5\-?M&?LJ^'O'GQTM-;G^*GA_P](LJC
M^RKYOW[MNZ"N\^ ?_!/-?AIX]\+_ ! O?$-W/XCLRTU]8O@QEB.!GO7R#^U=
M/%J?[4]DTZ8NQ?J57L!OK?#X.E4J2C3GHBN8_7CX=Z''X4\%Z?I<$RWBVT84
M21G(?W%1^)?BUX.\%N$U[Q%8:3(?X;F4*:\;^,'QBE^#O[.9U*U(.K&T_=;C
M@YP.E? _[/WP7\4_MM>*KV^\5:Y>1Z-O9S.K;BC=0HKGIX*,W.=25D@YC]2-
M)^/WP[URZ%MI_C+2KRX;@013 L?PKN+>9Y%#9WI(-R..F*_)K]H[]AF^_9LT
M\>*O"?B&]NT'S23/\K1 =Q7TS_P3Y_:'U7XB?#_4;'7KM[S4]/1FA,K9W(BY
MY-:5\LIPH+$4)\R%S:V/K3Q!XZT/P7:F77]8M=/4<EIFVC%<N/C5X$\7:'K$
M.A^*-.U2?[),3';S!B/D-?EO\>OB1XF_:*_:!C\-PWTEO!J-R+2&S@?,0(..
MM>R:[_P3AUKX3^#9=9\"^*M1F\2?9R]W8DA8^GSC/TI4L%2]WVTN5L7,?//[
M)\6W]IFPEAS=(^L-DISL^<\FOV6\4^.] \$V_GZ[JEOI</\ STN'VBOQF_8]
MANK#]H+0X'Q#/_: 2?8<@G=S^M?HE^W1\"/%OQN\')9>$XUENT 'EM)L!Y[F
MM<TC3]NH1V2'&5SZ(\,>.-"\;6OVG0=6M=5M_P#GI;/N%:_F!FY4Y%?+'["O
MP!\8_!+PG);>+0MO=-D"".0.O7KFOJ63]S^]+$_[->%42AMJ:GS_ /M/?LSZ
MA^T%)I\,.MBQTZ*13/!N8%U[CBO*/B=_P3A^&FG_  NO#HEC-#XCM8LI>RSE
MEW#D\5]K+&%D:0,5WC 7^M?/_P"V5\<M/^#_ ,*M03[0IU2YCQ$@.6/8UUX.
M=1U(J/<B3/RE^#OBK6?AS\9M%;3KF43C54L;J%6/S1!L$XK]-OV[OB=?>'?@
M'<II,$]O_:4 (NU./)Z=2*^!/V/_ (,ZM\9OC/;ZA%$QMK6Z&I37+<!ANR5S
M7ZO_ !R^'.A?$KX8ZKX?U>2.RL)(L+,<#R\#MFO>QM6G'%4FU=]C)'YQ?L-_
MLO\ @S]H.TN;WQA=G6'1B[VZ3$-]:Q/VYOV>_#7[.?C#P]=>"[GR+263+V*2
MDR18QP:\PL?&^N?L\_$S4E\":A=&&W+1;;4$AP#UXK3\$>)K3XZ?&C3M0^*>
MOWMA93S F.1<@?@:[W3JRKRJR^%+85T?J;^Q_P"(-1\0?!G3KG49_.E"J$/H
MNT8%>UF1HXV8\U@>!]%T;0/"NG6VA)$FEB%/*:'&'7'#'W-;RK\[%CE:^(KR
MC*HWM<Z5L9OB#Q5I7A>Q-SJU]%90@9+RM@ >M<GHOQV^'?B.]BM]-\9Z5?W6
M2JK#.#S@U^:?[;7QZUSQ]\7E\':9?S6VG&7[&WDMU<MC!%>AZ#_P3-U+PY\/
M;;7?#_B*]@\8M'YOV($*FXC(^:O6C@:<(1E5G:YC*3Z'S=>R!OVOM:DB7=$^
MN%MXZ-^\ZCVK]K+>[%OI=M-)*L4$<"O)*WW<;:_#+X=V.IZ5\=%T[57:;5;7
M4UBNF<Y^</SS7ZP?M1>!?'OC[X;:9IG@*\:RNB@^T!91&&0J, FNC,J,(NDD
M]&13DW<[K4OVA/AOI%T8+WQOI%M*#S'). :W/#/Q1\*>-.-!U^RU4]A;2;LU
M\#Z+_P $P=,\3:3]O\=>-IK'7BI/DQ3(RYQ_$2?6OFS1[K6_V:_VBM+\/Z;K
MLSVT%TH=(GS&Z9]16<,#AZ]XTYMM>1KS'Z]^)/C9X%\'Z@MAK?BO3=,OG;:M
MO<2A7SZ8KK;'5+?5(8Y[299[>0!DE0Y5A[5^7G_!1+X92W$_A'XA6T/F6TUJ
M)KF5N LA.0*^IOV"_B^OC/X'VJ:G*O\ :&GEVF^;.V,=#7)+!I4G.#NT',>[
M^+/C%X)\"W26OB'Q/I^D7$G"174H5C]!6F?&FBKHJ:P=4M_[*?[MWN^3ZYK\
M@/VB=:G^/O[55SHUDOVV.VO]ENK'J@;DUZ9^W;XIU_X?ZAH_@31+ZXL-%M["
M":=8R54DJ-PIQP>J4W9LE3/T+L_VBOAG?:C]@@\<:/->YV^2LXW9^E=Y:ZA#
MJ%NL]K.DT)Y$BG((K\N_A/\ L">$?B1\-['QGX>\=7">+KB(3&U+JN'STZYK
M[L_9@\%^*OA[\+X]&\7R?:=1BG;;(S[RT?;FN>M1C3^%EIW/8U8.H*G(I:9'
MMV#:,+V%/KB*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1J8/O4]J8/O4^
M@^A3UK_D$ZA_U[R?^@FO&OV/_P#DCZ_]A.Y_]#KV76O^03J'_7O)_P"@FO&O
MV/\ _DCZ_P#83N?_ $.NJG_ EZK]3GE\1[FM.IJTZN-&X4444P"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J&:-98V4CAN#BIJ:W0TM;IH/4\#^(7[#
M_P )?BGXHD\0>(=#GN]3D78TBW!48^F*_-+]L?X2^&?@O\3TTGPK8/:V/F[,
M2-NP/K7[4CM7Y#?\%&1-)\9-D8&PS_,Q/(Y%>_EM2M4J\JD]C.5D?1'[./["
M_P (?B!\,+/6-:T.>\OKC_6.LY4<BOHWP=J'PD_9[MXO!VFZ[8Z,\?R)87%Q
MF7Z5E_L9QB/X(Z4(Y#)\PSGZ"OSH_;VU#[#^TEJ]SL$3PW&(YT/S FE[.>*Q
M$J<I.R$FDKGZK:U\</ GAF:"'5?%FFV4UQ@Q)+* 6STQ73P:Y:3Z>-0CO8I;
M"0;EN5/R8]<U^:7P3_8'U[XUZ/IWC#QUXAOH9$99+2WSN!C'*FNA_;<^-FI_
M"7P5H'P^\*WTD;Q@P74RMM=>F*4<NC6J>SI2O;<.8^V=0_:&^'&F736MUXST
MJWE7AB\P !]/K73>&_'>@>,[=Y-"UJTU14&6>W<,!]:_-GX5_P#!.[3_ (Q>
M#K7Q'XN\;S:5J=THEBM8)D97R,AFR<C->;^$?%WB3]DC]IR+PJNJ->:#9SJM
MUMEW)(AZ9QUJO[.I2YH0G[T>@<Q^P5YJ=OIMFUU>3I;VZ#+2R'"BN"NOVCOA
MG8W#13^-](1P<%3./E^M>1_M4>"/B!\;_ NCCP!>-9VE\D<TN)A& AY/7VKP
MNU_X)<^']5TM[C5_'4L&NR)EK=94*;O0G-<5.A2Y;U)6] YF?>?ACXA>'?&<
M;/H.M6FLKGK:N& KYA_X*#?$;0[/X=3:!'XDM[77\-YEC'-MFVD<<#I7P]\$
M?&GB#X%_M#2:%IVK2RZ587GV*2-7RDAW8S7TA_P4'_9KT&^CG^*T^KW4>HW=
MN@^R;?D!50<BNWZK2I5X+FNF'-H<K_P3;^*F@>$;75G\6>)UTC;-MB75+@GS
M..V37Z*W7Q0\*V?AM-?GUVSAT:0D)>-)\C8]#7Y)_L@_LEZ+^U-;7-QK&N7>
ME+8R;42W4'?CG/-?2_[;'PU@^$/[,OAGPC8:C<75K:W;DSR<,X(Z&NO&87#5
M<3&E2E9L%+0^S+/XP>#=0T=M8MO$^GRZ7%Q).L@VJ3TR:I:5\?/AYK^H+8Z=
MXQTNZNR<"*.8$D^@K\I?V4?@9XM_:-L]1T33];NM,\(V\HCOI87Y#=ABJ?[2
MO[.-Q^RGXKM[C0-<O)T7:RWDGRMN]JSAE5*53V7M-1<Y^P7B#XC>&O"<*RZU
MK=IID;#(:XD"Y%9WA7XQ^"_'DQ3P]XIT[5'4X9+>4,:_-WX&_L[^,?VQM%^W
M>+O%VI66DVJ[4D1MQ<$<9%>.>)/"VL_LJ_M#:;X=T34[B%(;A)9.=HFCS_%]
M:E973G*5.$[M#YC]M%N#)(5"''9NU<;XD^-G@7PA=&WUSQ5INE3@X,5U,%:O
M%/VD?VBI_ ?[-<6OV<@MM:U"V5H/+;IV.#7Q1^S]^S?=?M@)<>(O&?BB2WM&
M<_OI9AY@/H 37%0P',I3JNT45S'ZD^&/BWX0\8S-'H7B2PUF4_=BM9 S5O:Q
MXAL- TU[_4KZ'3[6/[\TQPJ^QK\@OC]\&-5_8I\:Z#?^#?&-Q=V-V^Y&249P
M",@@'BOL#XA?&"'XG?L<G7;E"C,!:R,N3ODV<D_6G/ KFBZ;O&0<Q]/Z!\8/
M!GBK3K_4-'\2Z?J-C8#-W/;RAE@'JQ[5EK^T1\-7NEME\:Z29V. HG&2?2OR
M#_99^'/C;XF>(KWPOX5U2XTO1[I]FKK;O@.N>,^M>G_M6?L,I^S?X)C\::1X
MBO-7D$JQNEQP(Y#W'TKLGE=&G-4YU-63S'ZMWWBK2M-T.76KR_AM](C3S'NY
M&PBKZDU^.'[5'CI=>^/=IJFC^(IKW2UNU)FL[AA$$W]\'TKZK_8MUJ\_:6_9
MX\2?#SQ)J-P$DM?)-X.9%!/;-?#_ ,8O@_IOPD^*,7@ZRU2>]M6F$)ED7!ZX
MS6F'P.'C5G2J2U6WH#EH?KO\%_C7X$UCPYH^DZ=XLL-0U%HU46B3;I=V.E>Q
M;N/?TKXE_9@_8#\-_#O4](\>VGB"]NK_ .6<6LB 1@^E?:?EL7+%BK$?=[5X
MN,I48U'&G(TCJM3(\4>.M!\#V O?$.K6VC6S' ENWVBJ6G_%CPAJFAR:Q:>(
M["YTN,X>ZCE!0?C7RS_P4Z8CX1Z.KQ+-ON'#!CVP*^-OV8_@[XV_: L6T+3M
M9N]%\%QN$O9+5^CCH,5UX7+H5<.ZCGL0Y:GZK:3^T%\.M:U5;&P\;:3?7DC;
M([2&8%RWI7?+<@J&)PI_2OQR_:H_98N/V1]<TW6_#^I75S:S.H@U%AB028R>
ME?=?[%WQYF^(WP1U+4=6G^TW&BILFGE.3(P4G)]^*FKE\8T%5A*]Q\Q]%>)O
M'GA[P7"LNO:S::6C'"M<N%!KF;+]HKX9ZA="VMO&^CS3DX$:SC)-?EGKWBSQ
M7^VI\=+G39-1_LW0EN#;2Q^<%2",-CS%SWKT/XV_\$^='^"_P_N?%?A7QE)J
MM_8[3MEE4%CGKP:U6!IQ252339/,?J-#>)=VZS02K)"PW"1>A%<E_P +J\"M
MXF/AT>*M-.NJ2IL/.'FY'48KX\_X)Z_'S6?'&CZWX)UB\DO-2T^T:<32-DJO
M0#-?$?Q:NK_1_P!ICQ&^F2RCQ#<7F+>Z3.Y,\'!IT,N]M.4;[!SG[,/\;_ 4
M>N1Z*?&&EKJKN%%J91O8DXV@>M?'O[;7[->@_%3QU87UW\2M#\&M#)EK?5&^
M:3..E9GPD_X)R7>HW7AKQUXF\2WL7BF&[BOFM@0R/&"&&3[UXW_P4LN(K[XP
M6T-VF&295C4<CC K6C@Z4JSA3G>R*YC]*O@!X*MOA[\-]/TBUU&'5HTC5EN;
M<Y23@<CZUTWB3XD>&?!<2R:_K5IHX/\ S]2;<5XEX*^("_#/]F"VU=\&YAT\
M>3N.!D)QS7Y\_#?1?&O[<'Q4NK;6-7NH]&:;$X5\B!<]JQC@8U)S<Y6BNH<Q
M^J=C^T1\-=2NEM[7QMI$TS<+$LXR?I7<V^I17T*S6TBRP.,I*IRK_2OS ^.W
M_!.9?@SX=?Q5X7\1WU]<6R[660;=H'4UW7_!-W]H#6_$&H:IX2U_4)-12 !+
M*2X?)![_ $I5,MA*BZM&=T+FULS[V\1>,]%\'V?VC6]3M],B_O7#;17#ZC\=
M?A]XHTG4;+2?%NEW]\(B!;PS OGTQ7YC?M4?%OQ'\;/CE<>'[+4ITLK6\.FO
M9HWR9W8W8KV'5O\ @FS>_#GP)_PD_AGQ)?2^)Q#YTT!P!TSC-$<%3HQ@YSU8
MN8\ ^&NZ/]K:_"1-<S27[,/+[#=7[&ZIXJTKPKH<%YJU]#86JQ*6EF;"CBOQ
M<_9U@U:W_:0MXKIO^)K',5N"S?Q;N>:_4G]JGX5:]\6/A*=&\.@-?F'Y5+[0
MQ*C@FNG-(TU.G%;#C(]2\)_$KPQXZ#_\(_KMGJVSAOLS[L5T$C;F\MOE![GO
M7Q+^P;^R]X_^"-Y>S^+XULU9R4CAE#AACJ:^V)(]V6//]/>O K*,*G)%W7<T
M/DG_ (*,?$C4?!OP?N-,TZ.6-;D*6N(SC;@],U\V_L*_LK>"OC_X:F\0^,@^
MH.S,OV$S$2*0?O'VK[W_ &D/AGX>^*?PLU/1_$5V-.LV7S/MPQO0KR ,^M?D
M+X;^)7B#X$>.M1A\%:QJ%Y:QL8_)B!VE0>IQ7T6$2J89PBK2[F,FTST3]L[X
M%Z#^SC\4= B\(W96WO#Y@@CD):#!Z-7Z9?LLZYJ&O?!_2;C4YO-N@NW)_N@#
M%?E;\*]2TOXZ?'K3KCXG:_=V2RRETBD7*K[<U^I'Q<\>:+\#_@Y<7NF?9[>V
M6T\NS:-@-[A>*K'TGRTJ.\GU!2ZGR5_P4(^-UQXV\16?PU\+W6YR6BU"%>6=
ML\8QTKXUN/ K_#SXN^%M*N(6N+KSX9C(HZ9(X/O7T_\ L,_#6_\ C;\:-4^)
M^OV:S0VLK-(LG*L6!QCUKR'X[GR_VI[**.9LKJ"[%[ ;^%KT\+3ITY2P^]E^
M8<W4_8/X?R-)X-TMV&TF%>/3BMX,P!).17/> ?,'@O2O.7;)Y(W#\*WPI,@.
M?EQ7PU1*,FF^IO'8J:IKMEHM@;N_N$MH0,EI#BN'L_C_ /#;4[Y;.#QKI-Q=
MK(%\E)QN#9Z$5\)?\%&OVAM7LO&$7@_1KV6U@A?RKAH3R,^U5OA-_P $V)M>
M^'<?BX^(KZP\37BBYMH8\;9,C()/8DUZ]/ PC352I*R9E*78\>_;$NH[K]LC
M7+BV*W$3S1YE3D,,#I7ZW_#6Y6V^&?AIY'$:?V?$2[= -HK\2O&'AKQ'X*^-
MEWH?BB5[C7K691,TC;N,C'/TK]5?C!X-\<>//V8O#VD> KEK36I8;8M,LOED
M1A?FYKMQ]&G&%%)Z/J9TY-MW/3]:_:!^''AJZ-OJGC32;&;./+FG"G-:7AOX
ML>$/%]P(]%\3:?JCD9$=M(&)KX3T3_@F7IWBR.2[\>^-Y?[:QGR_.1L-[\U\
MPZWINM?LP_&JTTS0=9DGBCO51&CDR&CW=\5SQP6&J/EA-W]#7F/V#\2_&?P5
MX+NC;^(?$VGZ-<_\^]U*%<5T^E:Q;ZW8V][87"7=G<J)(9XCE64]Q7YI_P#!
M13X>S^+_  OX4^(4,.9+XJMTHZ(%4<U[O_P3O^+S>,/A3=V-_/\ O-&(@@CS
MG,:CK7$\%RPE-.[0<W0^E?%WQ:\'^ 9Q'XC\3:?HTC=([N4(:T+'QMH^HZ&=
M:@OX9-(QE;Q6_=L/4'TK\C_VQO$G_"\?VI5T.!VELKEX[:V5>0)!P:]L_;6U
MSQ%\$_@W\/O!6E32Z=9?V8JWTL!YWCUJUA%%J-3=B4S[=?\ :,^&4&H"PD\<
M:.MZ3CR3<#=],5W&FZU9ZU;"?3[N*[A;D21'(Q7Y1?L\?L4^"OV@/ 7_  ED
MOCBYLO%F6V6Y95^8=,Y.>:^Y?V0?A7XR^$?AW6M*\5737T)F4V,K2AR4 K*M
MAXTF[/[RD[GT+'()%R#GZ4^HX0H7Y%VBI*X"@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ J(R?.4QTYS4M0?>F8'TI (SY4@#.5//X5^+/[42I_PT=YCA@WVG &>/
MO5^U&S;&RKR<'%?F'\=OV,_BGXY^.L>N:1I"7.@BX$C7+2@,/FR1BO=RBO&@
MY<[W1A-,^_/@*I/PA\/C&";>OR'^*^V+]J*V*KYA_P"$@3*]?^6O6OV,^&.A
MS^%O!.CZ;=L5N(8MK)[XK\YO'W[%OQ:U;X_1^(['0(I-'_M=;II_.&?+WY)Q
M]*K!8A4YU=;-A9M'Z?6>U8;?'W3$N<=/NU^*'[5WAN^TWXX:E87<C6LNH:@S
MP/(<;59N&^@K]L(U2WM[>!OE;8%'X"OE[]KO]CBQ^/31:[:3M8:]:IY4(B7E
M\=.:RRS$?5ZK<GN.4;GRYX?_ ."<'Q'\6:-9:GIWQ5@ECE4-F&XD( QTXK1\
M _\ !/?5_"7Q(T^35/B5H-U<QS+*]H7)G<AL]^]8VG_LY_M;^"89-.\-ZA<V
MVG'Y5$=VH^7Z9KV7]G7]CCQ[I_Q LO&'Q!UV[>^A3+QNP8%NM>E+$5/8S3K*
MW;2Y/+Y'!_MY?M/>*-#^))^&^B7GV"&RBCR5^5I,J!P17%:#^P?\4?&W@QO&
MMU\0AID$MNUP(IYY!E-N2IKZ"_;2_8OU3XQ^(_\ A+_"<2R:Z0JDY"D[1@<U
MXGX:_9K_ &K=4L1H&M:O=6&@JOEB..Z5EV^F,UKAZU&-"$8247UN'+KJ>*?L
M?VT-M\>-#MH7WQV^I;,L<EG#8)_&OL;_ (*CEF\)6 *YC\OYCCH<\5YM\#_V
M'?B5\,?CEI6I2:8LFA6UPD\EXTHSURQQ7V3^U?\  E/CS\-[W1[9BFHY!BD4
M<C':LL3B*#QM.7,F@Y=+'B7_  3#F5OA"QE/EW,;.TI/ "9X-5/^"G=T9_A]
M8-"/-A:+(D7D'FO!O"'[)/[3/PXUQ+'0+FXL] D?RY3%< ;D[Y&:^D_VJ?V>
M/'_Q%^!OAS1=$A_M/7;.U$4\4D@&6[\T>VI+,55<U8.5VL8__!+W]Y\)VA8_
M<F=QMXYKSS_@K:5C\0?#J0X$HBE_'YJ^@/V"_@?XM^"OP[DLO%M@ECJ+.Q\I
M'##GIR*XC_@H7^SAX]^/6L>"[GPEI$=\NFHXGWRA=I)S7'[2G]?]IS>Z/ETL
M>A_\$\(UC_9YLPF1F[<G/X5\!_M^+&_[0VM*<J[7B9*G'<5^E7[(?PWUSX5_
M"&UT/Q%:K9:@DQ<QHVX<X[U\A_M=?L<_$WXG?&J_\0>&]&COM/FN5D#22A>
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ML;!T!'2G5\V;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME9Y/@Z7=E*MLVJO4#'>OD'_@I%NB_:JBB0!5:PA;Y1R217W9^QG\*?$7P?\
MAW_97B*S6TNF"EE5LX(KYO\ VU/V2_B/\8?VAH/%?AC3A>:,EI%%YID"_.O4
M8IX3$0I8V52^@^70YW]KS0[V\_90^&>HHDGV:RL,3L<X&3QFO&?V>_V4_%W[
M0FA_:= \?6NAPH,"Q69D?([X6OTTL_@=#XT_9UTOP'XLC$$WV013\!MC#/\
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M[]*C7<,[5^7^&E>^PB96#=#FEJMN2.3 ;!Q]VIHW+*"1@^E5+0!])FC.:-M
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M<KMD\Q]*'-"^]0MY@AR.6ZXI@D9E5V/E[?O+7E^S2FM1\Q(TFUF5@ <9W8X
MKFY/B5X3AU(Z2WB734U/./LS7*^9GZ9K7U>4MHNH2J=C+;R$-]%)K\9;B9KW
M]L.POI'=Y6O@&&X\X->AA<.ZTW$7,?LKJGB+3-!LA<ZKJ=K86W7SII BG\31
MH'BK1O%,'G:+JMIJD*_>>UE$@_,5\7?\%);J<? /3DMYF@9ECSM)''I47_!+
M>01^!]0B *HD>22Q/\5:SPO[EU;AS:GW4I=IN&4Q]_6GU'#LY9.AY-+YOWF
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M** "H0JK)YF?:IJ@=5 ^[\HYI:7U&?E+_P %-O#.L-X]M+^.%XHS(62=AA<
M^M>Y?LB_MJ>!F\&:=X4NPUAJENJI+*P"P$  $D^M?5_Q6^#_ (=^,WAV33->
MLX[I=I$,S#E*_/KX_?\ !.'5_!]K=:OX(O9+^WCC+RV,2[=J@9)S7U%"O0Q%
M)4:NAS24D[H_1S0/^$:UA?[6T6#3+M6^;[5:(K-_WT!7A'[5'[7]I\!=6@\/
M6ME<7FO7$(GA6--R\] :^)/V'?V@_$WPY^+VD>!;ZYE_LF]F\J2V<Y$0%?9/
M[4GQ9^#7@+Q-::IXDTBUU_QA'$OV>W=B&$?8UY\\'.-50@N9,TYERGS->?\
M!0S]H"%99G\$I;6:\BXEL&"8]<U]'_LJ_MO1?'*ZN- UB)+7Q'';O,/+7;&2
MHZ?G7SU\0O\ @IUHWBCP[J7A ?#W:ES%Y,)!.U??I7D'[$%S)=?M00SQ0&&.
M:%W-OG[O->O/!)T-:7+(SYEW.@_;B^-WQ!^('BZ+PYXGTA=+\,Z7.9+6X:$Q
M_:2>" 3][H*B_9G_ &F/C%\-+.VT#POX6&J:!=W\8,Z6C2>6I(!Y'3BO>O\
M@K5#'-X+\ _*I$=V[*H&/X17HG_!.*XEB^ ^KR@ 213[EX'9"<?I4^VHK+[<
MBNW^H[ZV.P_:=_;&T?\ 9]T2"W*?:_$L\*L+6-0VQBN?F%?)C_\ !0SX^E([
M^/P;%/I,O[Q)H;%B%3W->(?M+>/I-:_:.U/7M7M&N CJ'M&/WE4]*]T\/_\
M!3+2=#\%CPW;?"YOL:6QMV8,=K?+C/2B.5M48S4.9LSYG?<^D?V9_P!M;3?C
MM#>:;>J++Q+:Q;MA 2-V_N@=S7PW^V5\:/'OQ&\>ZGI/C#1/[,LM)F:#3F6
MQF:+.=V3UKC?V=_%+2_M)>%+W2[273K74-67?"%;"@MGGBOK#_@JR#]O\,E$
M"2K:OMN .5&XY%1[&&'KQ@H[A=M7/&_V5_VG/B_\/=#T/PCX2\+/J7A1[P[[
M^2T:3;N/S8:O9?CE^W+\8/A7XRTO2DT_28;6]8%#=0X?9GFO9_\ @FO="X_9
M7T9HPLR_;9E)Q[C)KB/^"F'PA36O"5IXR@MLR:3&4,BC[NXUA>C5Q7)4C;]3
M17M<^L_A/X_M?B5X+T_7('1A+&HE:/[OF8^;]:^)_P!I#]OKQ]X%^+EYX.\$
M6NF7;6UR(&:ZCW9Y[53_ &#/CD-*^!/BCPW=RXN=,M9[V.1FY)QTKP?]F7PO
M/\<_VKK?6;M&GL)+AY+B0\A2,XJI8%495)55[JV#GV/UN\&W6H:MX7TG4=3"
M+J5S:QR2I'P@8J"<"O"/VU/C-\0?@YX5L[KP-I"ZHTZ,+K$!D*=LC'2OI&WM
MUM+6.&/A(4"*/8# KG_B%((_!&JR?*F86SN /:O"H<D:RE:ZN7K8_#CP#\0O
M%O@[XAW'BGPY9I>^)+B9IY;:6,OAR<D;?7-?JO\ LJ_M >-/B1X-UO6?B3I*
M^'?[/C#LTD)@7]:_/3]F6'S?VHK]3&"@OV<2$<9W^E?>_P#P4&\877AWX'7E
MC;R^3_:,.V78,%L8[BOI\S]E4J4X1CN9JYXW\2O^"D6MWGB:_P!*^&^E'4;F
MT=H\30;Q)M/48ZUQ.E_\%(OC%I$PF\6>%H=*M\\I-9F-B/;-:_\ P2[^'.F:
MR]UXDOK=+JXA9HT9QG!'2OIW]NCX<Z)XD^!'BC6[BRC;5-*M3+;S8 (.0/ZU
MS3CAJ>+C3E#0/>L=/\$?CUIOQ_\ A;?ZS9.JS1Q-'-#D @[>>*_,"X5/^&RM
M/DB'[H7P^7\:]9_X)BZQ=VWBC5=,=FCLYM/FF:'.0[;>M>32@K^V58L%V!;X
M?N?7FO1PV&C2Q52,=K7(<CZ\_P""E1W? ?3L<2,(L?2E_P""7L;?\(3J4;C
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M<Q^N:]#_ ."B7P \4>,+#3-3T#3I-4BMU5)%C_Y9JJXS7D_P+_;O/PI\/Q>
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M_P#^2/K_ -A.Y_\ 0ZZJ?\"7JOU.>7Q'N:TZFK3JXT;A1113 **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M49N%*N5([5]&V'[%7P<TW5#J5IX/A2^5MXFWD\_G7L^DZ/:Z+816EG L$"*
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MPQX'UC6]0MG@DO8)+6)+I2'VNN.A[5\G^*]&UC]EC]I!M7DMIHH+&Z\\':1
M<G/RFOVGALUM[>*&WC%ND("(JCC:.U<9\2/@AX,^+5LL7BG1(]3C7^!N"?Q%
M90S*\Y.:T8K'QG\0/^"D&G>// )T;X?Z=>WGB*[A\NZ,\!,:[AA\$?C7S-^R
M+I\MA^TQH=G>;(+E+T3-&IP,L<U^HO@S]E/X7_#^0R:%X6ALV8$'DG@]N:FT
MO]E[X:Z'XRB\4V7AF*+7%<.+I6.01WQFM/KE"$'"E%JXG%LYC]L#]H#5/V?_
M (?SZWI%K%-=JZJIG7*<^M<O^Q1^U-XA_:*T^^3Q'96UO>VR;V>R7]T03Q@^
MM>\_$/X6^'OBMH<NB>+-.35M,D8,8GX''3I57X9_!CPC\'=--CX0T:/2K9^"
MJ$G^=>2Y0Y4DM2UN=K]W"K7R9_P4$_:-U#X-_#U=*T7RX[_6"UK)<2\>6K#J
MI]:^LG5VPF/^!5P/Q5^ O@?XTP6T/C+0TUB.!]\:NQ&T^O!JJ$J<*BE45T6]
M4?C?\!?&/P[\+?$*RU[XFO=WZ1DLWV<"02MZMGK7Z VO_!4'X(:1''8VT.HP
M6\*#8([8! !TQSUKTT_L%_!':8V\%PNAZ9D;Y?UH;]@OX(26XMF\$P^6IW!C
M(W7\Z]?$8[!8EJ+4M#)1:/"/V]+6Z^-GP2\.?$+PQ!+=Z%]F,@B1"9R&/&%%
M>6?L6_MG>&/V;_ ;^#_&5O=6Z^:URC+'F4%NS ]J_2K0/ VB^&?"]KX<L-.6
M'1[*/RH+=OF 7TYKS+Q%^Q?\(/%NJ2ZGJWA&"[O91AY2Q&1] :YZ>-POLWAZ
MD6'*[W/SO_;"_:6M_P!JCQ%HD/@W3+B>#3&9$+1$[MQZU][?L)_"V_\ A3\#
M+?3-2C\N>YF:[*D8(W@5V7@W]E?X8^ 9HI="\,P631\C!)_G7JR1B&(1J!L4
M8"@8P*Y\5BH3IJG35DBHK4C=/*5=B@QX(;UK\B/VY_AAJWPL^/EMXAM;.XEM
MI +N.>%"8E?=D;CVK]?%!C4@#(["N<\9_#_1/B%HKZ;X@L8]0M'.2C#G'IFL
M<+B/9.Y35T?#?A'_ (*::-I_PMMM--E=:KX^AAV>7!%YD1?H.17Q+KU]J^O?
M&S1-8\31-8:AJ&KPW26P&UMK2 _=/:OUW\(?L<?"3P3JR:IHOA*&QO V[=N)
MY_&KWB3]E+X;>,?%UEXGUOP[#>ZY9$?9[K)7RP#D# XKU\-F%'#\[Y=69<K9
M\D_\%2/"NO:OH?@K4K.*6YTV+!VH"1'\HSN]*\X_9Q_:3^"WPT\ 75GXDT :
MKKY.P*]JLGS8QQGWK]0/$7A+2_&&DS:9J]FEYI\B;# P[5Y!;_L,_!6WO_ML
M?@NW6XW;]Q=NOYUCA\QI1P[I23^0^36Y^4^M>*+3Q;^T)I&JPZ6-"TV:[4Q1
MQQ>4",^E?L7'X9M?&'P9ATV^1);>73_W8'()V\&LC5/V4?A=KUW:W%YX4A>6
MT;="^2-I_"O3;6SL]'TM+*&'RK.TBPD>> JBGC<PCB>3E5K"4+'X4>+K76?@
MCXT\3Z%%++:M>[DD7)7Y"QQ7W1_P2W^$XTOP[K?B74$+WLEP#;R.,_*1ZU\P
M_M@ZM9_%#]J"\M='MMYNBEN GJ.*_53]GGP3;^ OA+X;TZ*V\B<6B>?Z[L=Z
M]',,5?#1CU8*.IX;^T;^UQK/P0^)QT;4]'6Y\)%$9[D0EB<]1GI7RM^U3^TS
M\&_C9X+EL_"/A^6S\2# $R6BQ[SWY'6OTV\?_"GPM\3-/%EXDTB/4[?/W6X/
MYUYUIO[$WP<TBZCN+?PA")8SE#O)VUX^&Q4*-I6U'RL\(_X)>^$]>T?P'<W6
MH6LEI83;ECCD4J<YZXK[HCC3R_+Z@=JH:7HEMX?L4M=.A6WM(EPD"#%7H^(_
M,$95VY*UP5)^TDY=S4F7@4M,C5E7YFW&GUS(!JTZBBJ **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@+MI:0=*6FF(****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "-3!]ZGM3!]ZGT'T*>M?\@G4/\ KWD_]!->-?L?_P#)'U_["=S_
M .AU[+K7_()U#_KWD_\ 037C7['_ /R1]?\ L)W/_H==5/\ @2]5^ISR^(]S
M6G4U:=7&C<****8!1110 4444 %%%% !1110 4444 %%%% !1110 4TYS3J3
MO0 @-+FBAJ6H!^%'X4VBBS&.[T44M,044E&?:H=P$-)SVIV:3'O1=K;484E*
MHHZ4:OR .15'5+3^T+6YM)',*3IL$B'##/I5Y@3FH&C^0&3]XZ'*U49.XF?*
MFF?\$YOAYI_Q$N_%[ZKJMWJ-Q/\ :)(YW!0MG-?56GPFULXH2% B4(NW^Z!@
M4K%6CWR)L'<&I(\*HP,"M95')6;N%B2F]>*7=25C:ZU&+MXHV"CBBIY8B#/Y
M44<48]:K3<!10111FGY@+28I:2D -2;J6DIZ+<8E+P:-M)BAQBP#:/6G 4VE
M%+EBM@'4F*,T&CK808HI,F@FA^Z E&T'FE-(*(I[W&9>O:2-?TW4-+G^2TO+
M=X'D7[P# @X_.OG3X1_L'^!?@MXQ'BG2M3U*YO(9#*J2D%037TW*NYN3A?2H
MX8/+R5X]<UI1JU*<)I2W'96)5D#*".-PS[T]:;M!;=CG&*=G:,5C"[W9%M0-
M>??&?X,Z-\;_  K)H>MS36]LX(,EN?F&?2O0?O"H9(RN[YLQ_P!VKI\T)W3*
M/%_V=_V4_"_[-MG=0>';Z]O5N'WL;Q@2/I7MRM\M0JH7"J=H(^[4L:A4P.E7
M4J2G+WM25N+2YXI"*7%8)N^Q0@)I:,T;:N5^P"8I:7VIM/XEJ [%-IW:CZ5+
M5]!"-1[TM%/EUNP&[O:ES10,55T &DI]-S[5'+K= )FC-+DT;J.5@&ZAJ7=0
M:33L VBAOO49'3%-\L4KC$W4NWFDV\TZB<4[#%]J;0II12DMD(,TI:F9YH;-
M%1N$;H+#LT9I*7BJT:38A.*7-&VBERQB,*CDWB2/:%(SSGK^%2<>E17"C9N[
MKR*3LE?L!\I^)O\ @G?X \6?$"Y\57VLZM)?37GVPQLP*JV[.T>U?4]A9Q:;
M9P6MNBI%"@0*.. ,"E:/?L8GY",D>]*(BL@(?YOXO<5O5JRE!786+':A:2E]
M:R5^4!=M+2"EH3$%%%%4 4444 %%%% !1110 4444 %%%% !1110 44E+0 4
M44E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "5#)\RG+%=O/%3U REF!*]^M2^PS"\4>,],\'Z+<:IJUY#:6T2[AY
MCA68>P/6OG35?^"E?P3T?4C87&JZ@9U;:2EL2N?KFOES_@IE\0-4U;QYIFAQ
MW,AL;1S&R0L5!!/?%>N_LT_L-_"_QW\*[?5-<LO[8O+E>)XY2/+8CH?<5]#'
M+\-0H*M6D[OL92;O9'U3\,/C[X2^,-F;CPU??:#C(23"L?PK!^-'[6GP^^ >
ML6VE>+;V>#4+B(2I'!%O^4]^M>=? _\ 8I/P,^(TFNZ;KBMI!DW1Z=\VX#TS
M7GG[=W[-OA?XM_$S2M9U3XDZ5X+U..T6!;;4,EI$SU KS91I2J\M/X1IL^Q_
MA]X^TGXF>$K'Q'HLKRZ;J S"S#!XKH6:9;A5P/)QRV><UY3\ _#FD?"#X$Z/
MIL&N6^H:781,3JD9_=$9Y:N@\-?&[P#XVGGL]%\5:?JUS;@F:.WDRR =2?I6
M$Z+E=115SN'S'EE;<S< =J="S]),!O05YA<?M*?"VUO&TW_A.=*AO5.T1M+S
MGTKO=(UJPUVUBOK"ZCOHBN!/$<KS4RI225T%S4YZ]ZADN$WA3NS["LKQ%XRT
M;P9I_P!KU[5;?3K<<^;.VT5P8_:J^$4K%4^(6BY7J/._^M2C3J.5U%V'S(]6
M7+8':O@CX^?\%"/%_P +OC ?"6D:!IUY9)=BV>>X8AAEL>M?7'A?X_?#CQAJ
MR:?HGC#3-2OW.!!!+EC^E?DQ^U^N_P#:2U ,X4C5E_'YQ7J8#"QJU)JHNA$I
M'[,:1?M?Z;8W4@VRW%M',RKT!903BKVY6&>,'KFLCPMF3POHC [#]BASG_<%
M<_XL^-'@+P;-+!K_ (GT_29(SAEN)-I%>7[+F;Y4V4F=PK'/;'M28*YP=U<'
MX3^-_P /O&$R6_A_Q7IVJRN<*EO+N)-=VRE$8C[QI<CI[JWJ,48W;\^V*-S>
MG%,,BQ;5QEF/2N;\6?$KPOX#;=XA\0V>E(>@N&Q4<LIZ1$=*&$S?*6!':E8E
MF'9A^5<!X;^/WPZ\77PM]%\8Z9J=RQVB&WDRV:Z?Q9XRT/P3I,FI^(-4M])T
M^,9>XN&PH'N:)TYOW.5W'<V&9E'3BFMPH8DX7DURW@CXM>#_ (D*Q\+^(+/6
M@HR?LK[JL^+OB)X<^']JD_B36[71XI/NM<MM!IJ$OX?*[A<T]4U)M/TV^G0;
MI8;=YU#=, 9KX.\$_P#!1+Q;XN_:*T+X?#0; :7J%[]EENU)\Q5]17V39_$/
MPW\1/ >O:CX7U6WUNRCMIHWGM6W+NV'BOR*^!LBI^V%X-:+%LW]K-OW_ %->
MUE^#C6A4NK\J%<_:S;Y;#!/XTTR!I%5BP93VZ5Y]XB_:(^&GAG4GT_5O&6EV
M-VC;&CEEP0WI74>&_%NC^,+%+K0]4M]2M>K20G((KR/9SC=R0&V2[/@X">H-
M,9YA,W"^3C@YYJ"ZN[73;.6YNIUAM5Y9V. *\ZNOVD_A78WS:=<^-=+M;I3C
MR9)<-FG&,IKF2T"YZ:JC>&WL<C.*7<YQM QGG-8_A_QGH?B;39+W1M3M]3M8
M1\\L#9 '6N6TG]H3X:^(=8_LFP\8:9=ZCYGE_9XY26WYQMZ=:E4YM.R'<[\S
MKN;[WRG'2G&558 YR:IZSJUGH-B]_?7<=E8Q#,DTGW1]:Y'PQ\=OA]XXU*?3
M]#\5:?JEW ,R1V\F2M32HRE&UKA<Z^^U2RTW(O=0M[,/ROGS*GY9-366I6VI
M0^;9W,-U".!)"X=<_45^<W_!3KXB^'M<@T>PT+Q"D^L6BLDUI:3$.IST..]=
MK_P3S^.G@WPI\!K32?%7C"SL-=DOI,6M[,?-P<;<9Z]Z[Y8.4:"J6?W$\R/N
MK+LH!P#WQ4?F!09,G/W0#TS63<^+-'L]/CU"74(;>SF7='<NWRD>M<+=_M0?
M">QO?L=WX^T=;E3_ *MI<'/Y5Q/#MS4K,?,>I0M)P)=H<]E-+\RL2YP*P/#?
MC70/&EG+>^'M3M]611DM;OD"J'C;XJ>$? ,,<GB?7[/0\X/^E/MHY:E[6#F.
MLR?O=5'YU(I!7/:N.G^,'@BQ\-6WB6;Q+8Q:'=C,-^TG[J0#K@U1\-_'_P"'
M/C*\%IHGB_3=3N&/$<$N31R3EIRCYCNMX[%OFX'M4GS!<'_Z]-^=I 58"/KT
MZUR7BGXO>"_!,Q_M_P 0V6E%>OVB3 JHPE-Z+4.9'7QL -H)-(T:LP;=P.H%
M>?\ AGX_?#SQI=>1H7C+3=5E)P(K>3))]*[R,K%@QH3YG/6B4)0UDK"YB19
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML[<S+))"ZQ_)@OVR:XGXN^.+GX>^!=3\06D(N+FUA9UAD^Z2!FI_%GQ8\&>
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M&E6,L60X.[I53P_XCT[Q5I4>HZ3=1WMC)]R:(Y#54\1>*-(\+6;7&MZE;Z7
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M!PK=:UPN&C6ISNM4*5TS]C""DF_)/&,5(KD[?>HX9Q.R.G,;KN!I\;EIG!'
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MB@NU5DOK/_5N!W%>X-EE&Q@ASSGO7R%?EYWRLV187!7(IU-0844ZN<84444
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M8/2O0H4N6:C.KT^&Q%W8_2+]G[XA7GQ"_93U/4K^XDFGALYH3(YRWRI7Y?\
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M7T*ZI*S8MBWS $<'%?4RQ%2ABX4X[&70\9_X)6X5?$*A1NFD)BD[CCC-=/\
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M^"/#T3=5L8@?P05T0KPJEDW<W6PZBBBH **** "BBB@ HHHH **** "BBB@
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MG-??%%*GCJM*N\1&W,PY5L>,?"7X/W-O^SS9^!/%L"++);M!=1*0XP37Q?\
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M4YY?$>YK3J:M.KC1N%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:RBH.*:7=$N"9\"_LP_!K]I?PY\3!=?$C7KC4/#+0&-[>2\$BDGVS2_M1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 (U,'WJ>U,'WJ?0?0IZU_R"=0_P"O>3_T
M$UXU^Q__ ,D?7_L)W/\ Z'7LNM?\@G4/^O>3_P!!->-?L?\ _)'U_P"PG<_^
MAUU4_P"!+U7ZG/+XCW-:=35IU<:-PHHHI@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 -9@I]Z;P%+$\4X]:6@"%H]B?NQDGD4;3(H1QO'\6:F
MYHI<P#=BA0N.!T%/I*6F 4444 %%%% !1110 4444 %%%% $;*?,5NP'-1PR
M%][?\L_6K%)@=,<4 0AW9TVKE/[_ 'IK8FSA<HO(^M6.U(OTI<UF!55?.DCD
M'R%?O+5O=2$ =!2"J8#J6D/2@=*B^H"T4450!24M% $#NR^867" <-38U8 ,
MIW*PSS4W7WIQ'%*,K@,CVJN$&%J2F4ZA@%+2+2T( HHHI@%5VCW7 9&V[?O#
MUJQ28'6@".-EP2.!G%,D5F#Y7 ['UJ? ]*.:7-9@1*P*X!Z"EC8NJ'\ZDQ[4
M4[W 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+
M10 T4ZDI: "BBBI: 3=1GVHQ13 6D)I:2F 4M)2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U,'WJ?2!:8RCK7
M_()U#_KWD_\ 037C7['_ /R1]?\ L)W/_H=>U:I;M<:;>1I]^2%T'U*D5YQ^
MSOX+N_ GPY33+X;;C[;/+T[,V16T)J-.4'U:,7%W/4%IU-P=PQ]WO3JYS4**
M**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$XI:3&: $W4
MZDVT4 )NIU)BEJ5< HHHJ@"BBB@ HHHH **** "BBB@ HHHH 2BBC% "TF,4
MM% !1110 4444 %%%% "<4M)MI: $Q2T44 %%%% !1110 4444@$I-U+1MI@
M%+24M( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ,926&#BFE2TFXGY?2EF#
MLG[O ;/>A0_F'.-F./6@!<'>"#Q3Z8JE6]J?0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>kros-20251231_g6.jpg
<TEXT>
begin 644 kros-20251231_g6.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -H!S,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>)7U6R-ZLUO?) (P)&3:04;/W<_C7UI7X\_\%M?E^,'P^Y_Y@+\_]O$E '[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM7F6+4?$+0Z/9QM@ER[AY>/3RHY.?<5Q/_!'KX?W?A#]EFXUF[4H?$NM7%_
MK+M/DHJ0+UZY:)SGT8?6@#XJ_;B\7:UX#_X*>:KXA\.:5_;FNZ9>Z/<V6FB*
M27[3(MA;$1[$.XY_V:]U_P"'E'[4G_1N-Q_X(=4KSSX_<?\ !932O?7-"_\
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M+BX:VN(=[$DJ0LF"V2 PZXS7Z/?\% OWG[&GQ0;_ *AJ'_R/%7PG_P %4O\
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M9^T1JGP>^".E^%?#]ZUAJ_C*>:VFN(\[ULHE!F52#\I<R1K[J7'T^<OV[/\
ME*-\)?\ L(>'O_2U:U/^"WUE<+KWPKNV'^BR6U]$O7&Y6B+?HZ_G0![Q^QS_
M ,$S_AIX$^&>D:Q\0?#MGXT\::G;+<W0U:,R6MF'4$01P$[#M[R,"Q.2-H.!
MR/[?7_!/3X?:=\)=;^)'PST:/P5XI\-Q_P!HR0:6S16US"A!?$8.V)T'SJR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSU5%"H#QD)G S7OE-V^].H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /P!_X)<_\GU_#/\ [B?_ *:[NOW^K\ ?^"7/_)]?
MPS_[B?\ Z:[NOW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /P!_X)<_\ )]?PS_[B?_IKNZ_?ZOP!
M_P""7/\ R?7\,_\ N)_^FN[K]_J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4456U"\^PV%S<^6TODQ-)L3JV 3@>_%
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M*_ OP;\</VE?B+JS:5X3^(7Q6\4:HL33M9:+K>I7DPC4@%]D;EMH+ $XQR*
M/Z,J*_ +_C-[_JX#_P KE0:A??MIZ587-]>W?QYL[.VB::>XN)-:2.*-02SL
MQ. H ))/  H _H#WG.,9IU?CG_P2I^.OQ)^(O[44FD^*_B#XJ\3:8-!NIOL6
ML:U<W<'F"2$!_+D<KN )P<9Y-?L90 4444 %%%% !7G'[0OQLT_]G?X.^(/B
M%JFG7.JV&C+ 9+.T95ED\V>.$;2W'!D!Y[ UZ/7RW_P4XX_8;^)QS_RSL/\
MTX6U '@7_#[?P!U_X5SXEQ_U\V_^-26W_!;7X=23*)_A[XHCBZLT<UL[#CLI
M<9Y]^F36U_P2%\&Z!KO[+-U=:EH>FZA<_P#"072^==6<<KX"18&Y@3BOM/4_
M@[X#UJR>SU'P5X=O[1^'M[K2H)(VX(Y5D(/![T >6?LZ_MV?"/\ :;O/[,\*
MZW-8^(A'YK:#K4'V:[V]]O+1R$=Q&[$=\5] [O:OR-_X*/\ [%.G?L[/I/QJ
M^$$4GA>TM;^,7]C8N533YRV8;F#GY$+#:4Z E<#!P/T%_8W^/1_:0_9Y\*^,
M[@)'K$T1M=4BC 4+=Q$I(0N3M5RN\#^ZX[T 7_VA/VL/AM^S#HUO>^.=<^S7
M5TI-GI5G&9[RZQU*1CHO^VY5<\;LU\D_\/L_AA_:&S_A _%IL=W^NS:^;C'7
MR_-QG/;=7E>A_LR^-/VK/^"B'BK4_C'X4U[3O!%C)<75NE]:306MY:02+%:6
MT<WW2"'5VV'G;)TW9'Z4O^S[\,I/#)\.M\/O"YT,IY?]G_V1!Y.WT"[<#Z]<
M\]>: ,;]GO\ :F^'7[3OA^;5/ NMB\DM=HO--ND\F\LRP.T21GL<'#*2IVG!
M.#7K5?C3K?@.+]AG_@IQX-TGP%-)#X;\0WEC;II\DS2>59WTHADMW8Y9E1P7
M7=D_(F22,G]EJ "BBN#\;_';P!\-O$VC^'?$_BO3=$UO6"@L+&[EVR7.]_+7
M8.^7^7ZT =Y17SU\:/V]_@G\!=?DT'Q1XN1M=A.)]-TNWDO)8#Z2%%*H?]EF
M#>U=)\!_VMOA7^TFMTG@/Q3#J>H6B"2YTRXB>VNXE./F\J10649 +)N4$@$Y
MXH ]AHKYM^+O_!0[X%?!7Q-/X>UWQA]KUNV?R[FST>UEO#;,"05D=%V*P(.4
MW;AW%=_\#?VGOAI^T=IUU=?#_P 46VMO:X^TV91X+J#/ +PR!6"D@X;&TX.#
M0!ZG14,]U';0O-*ZQPQC<\CL%"J.I)/ %?+/C3_@I]^SMX*UV;29?&SZO<0O
MLEET>PGNH%/?$JKL<#U0L/?/% 'H/[6'[46D?LF_#>R\8ZUHU]KEI=:G'IBV
MU@Z+('>*60,=YQC$)_,5V7P3^*UG\;?A9X;\<:?8S:?9ZW:K=16MPZM)&I)X
M8KQGCM7P-_P4^^.'@?X]?L6:#X@\!^([7Q#I@\86D<C0962%_LEV=DL;@,C8
MYPP&1C''-?4/[#^M67AW]B7X<ZIJ5P+73[+01<7$[ LL42AF9VP#@  D^U '
MTC17GWPQ_: ^'7QHFU"'P-XPTKQ1-IX1KJ/3YP[1!R0I8>A*GGVKN+[4+?3+
M2>ZO)H[6U@C::::9PJ1HHRS,3T  SF@"S17FWPU_:.^&GQBU:[TSP3XQTSQ-
M?6D?G3Q:?(9/*3(4%CC R3@<\UZ30!Y!^U!^T1;?LQ?#%_'%_P"';_Q%IL-W
M';7,6GR(DD"OD+*V\XV[@J\<Y=>.N'?LP_M)^'_VI?A;!XV\/VEQIT)N9;.X
ML;ME:6WEC8?*Q4D<J4<>S"NB^-_PQL_C-\(_%W@J^"^3K>GRVJNPSY<A7,3X
M_P!F0*W_  &OS#_X) _$B[^'/QJ\=?!_7F:TEOU:X@M9L9CO;9BDR#_:,9R?
M^N% 'Z[U%-<1VT+RRNL42 L\CL J@=R3TJ6OEO\ X*1?&[_A27[*_B::UN#!
MK7B ?V'IY4D$-,#YK<=,0B7![,5H J_LV_\ !0;PY^U!\6M7\%^%?".M16VF
MP37,NN731BW\M) B' Y#.6!"GG@^AKZNKX5_X)&_ S_A6_[/,OC+4+?R]:\9
MW'VP.ZX<6<>5@&>X.7D'M)7UK\5/C/X(^"/AMM>\=>)+'PUI>2J2WCG?,P&2
ML4:@O(V/X44GVH [6BOD"R_X*N?LXWFJ)9GQ;?VT;-M%Y/HUT(?8G"%@/JOU
MKZC\'^-M!^('A^TUWPUJ]EKNCW:[X+ZPG66*0=\,IZ@\$=CQ0!YC^UA^U#I'
M[)OPWL_&.M:-?:Y:7.IQZ6MM8.B2!WCED#'><8Q"?S%=C\$_BM9_&[X6>&_'
M&GV,VG6>MVJW45K<.K21J2>&*\9X[5\A?\%GOE_92T/_ +&VT_\ 26[K=_9U
M_:D^&'[./[&'PDE\?^*[;1I[G1HS;6**]Q=3+EOF6&,,VW@_,0%SQG- 'VS1
M7S-\+?\ @HY\ _BYXDM?#^D^,Q8:Q>2"*UM]8M);-9W)P$61U\O<20 I8$D@
M &OI<,?2@#YA^#?[>7ASXR_M%^)?A#8>&=4L-5T,W@EU&XEB,$GV>98FV@'=
MR6!&:^H*\E\%_%GX/>)_B9J7ASPMK7AV\\<VGG_;+.P2,7B;'"R[R%SPV-W/
M6O4-0U*UTFSGO+VXAL[.WC:6:XN)!''$BC)9F/  '))Z4 6J*^4/&7_!4/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?\=>/O#_PQ\*W_ (F\4ZK;Z)H-B$-S?W1(CBWNJ+G [LZCZFO'
M_P#AOS]GG_HK'A__ +^O_P#$U[!XZ\ ^'_B=X5O_  SXITJWUO0;X(+FPN@3
M'+L=77.#V9%/U%>/_P## ?[//_1)_#__ 'Z?_P"*H X?XZ?MQ? ?Q)\$?B%I
M.F?$[0[S4K_P[J%K:VT<C;I97MI%1!\O4L0/QK\TO^"7/Q8\(?!W]I#4-=\:
MZ_:^'-'D\/75JMY>,0C2M-;LJ< \D(W_ 'S7Z6_'3]AWX#^&_@C\0M6TSX8Z
M'9ZE8>'=0NK6YCC;=%*EM(R./FZA@#^%?FE_P2W^$_A'XR?M(:AH7C70+3Q'
MI$?AZZNEL[Q24$JS6ZA^"#D!V_.@#]9/^&_/V>?^BL>'_P#OZ_\ \37'?&/]
MN/X#:]\(_&^F:=\4-"NKZ\T.^M[>W21RTDCV\BH@^7J20/QKL?\ A@/]GG_H
MD_A__OT__P 57'_&+]AOX#:%\(_'&IZ?\+]"M;^ST*^N+>XCC?='(EO(R,/F
MZ@@&@#\P_P#@F'\5/"7P?_:9E\0>,]=M?#NC'0[JV%Y>$A/,9XBJ\ \D*?RK
M];?^&_/V>?\ HK'A_P#[^O\ _$U^27_!,/X5^$OC!^TS+X?\9Z%:^(M&&B75
MP+.\!*>8KQ!6X(Y 8_G7ZV_\,!_L\_\ 1)_#_P#WZ?\ ^*H V/!_[9GP3^('
MB;3_  [X=^(VC:OK=_)Y5K96\CEY6P3A<KUP#^5>T5XOX/\ V,_@G\/_ !-I
M_B+P[\.=&TC6["3S;6]MXW#Q-@C*Y;K@G\Z]HH **** "OEO_@IQ_P F,_$_
M_KG8?^G&VKZDKY;_ ."G'_)C/Q/_ .N=A_Z<;:@#SC_@C?\ \FG7?_8PW?\
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M>7,WBJR+KG.&^R7>17HG[,OQ$M_A'_P3F\,^,[I/.BT3PNUZ(2<>:RJVQ/\
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M.42V]C;02C($D<*JW/N!0!\"_P#!5+]BW7_CMI>D?$;P)8/J_BC0K5K&^TJ
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M 4444 %%%% !1110 4444 18Z=Q7P)^V"W_&Q;]EXYX_>GV_UC5/_P %#O\
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M4HS CS/+\SH!\_%?26FZM9ZU8Q7FGW4-]:2C='/;2"1'&<<,#@\BO@/]G_\
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M\6:GX0U+P+>74LT;:+JV[[1%LD9 QW(APP7</EZ&O2Z "BBB@ HHHH ****
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M#BLN^\*Z+JE]%>WFD6-W>Q8\NYGMD>1,'(PQ&1@\T :<?^K7Z5^1W[3GS?\
M!7KP,?\ I_T;_P!%I7ZY5E7'A/1;S5%U*?2+";44*E;R2U1IE(Z$.1D8[>E
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M=6#B&[A65 P! .U@1G!//O4MCIUMI=K':V=O%:6T8VI# @1%'H%' H ^0O\
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M17Z-TW9[TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _ '_@ES_P GU_#/_N)_^FN[K]_J_ '_ ()<_P#)]?PS_P"XG_Z:
M[NOW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 5_L,'V/[)Y,?V79Y7D;!Y>S&-NWIC'&.E1Z?I-GI%OY%C:PV4 Z16\8C4<
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M5\/:5X:T\MO-KI%E':QEL?>*H "??K6_MH 39[YYS7$^*?@9\.?'%Y->>)/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ '
M_@ES_P GU_#/_N)_^FN[K]_J_ '_ ()<_P#)]?PS_P"XG_Z:[NOW^H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***;N]J %W4@?)XY^E>*?M7_M(K^S
M+\.8->A\+:IXQU?4+U--TW2=-C8^9<.K,OF.%;8N$(X5B20 #R1QW['/_#0_
MB*X\1>,OC?>6.D6&LI"^C^#;:V1)-,4;LLY +)D%?D=W;KNV$;: /-OC]^T-
M\>OB;\7-9^#?P&\&W/AZ72Y1#JWCO7(-EO &4-F(LI500W#8=VY*J,;J^P_A
M_I&LZ!X&T#3?$>L?\)%KUG8PP7^K>4(OM<ZH \NP<+N8$X'K71;1Q1M]Z (K
MRQ@U"UFMKJ&.YMID,<L,R!D=",%6!X((Z@U\_:Y_P3U_9V\1:Q)J5W\*]'2Y
MD;<4LWGM81](8I%C ]@H%?1%% '/>"?A[X9^&V@QZ+X4T'3O#FDQMO%GIELD
M$>X\%B% RQQRQY/<UT-%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PO&7@7P_\1/#
MMSH/BC1K'7]&N1^]L=0@6:)B.APP.".H8<@\@YKYFF_X)7?LX3:I]K_X0JY2
M'O9)J]V(3R#_ ,]-_;LW<U];44 <K\._A=X4^$OAV#0?!V@6'AS2(>1;6$ 0
M,V -S'J[8 RS$DXY)KJJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *3=^-&:_.GXW?\%5->^$OQ@\7^"[3X;6&JP:#J$EBM[-K#Q-,%Q\Q4
M0G&?3)KTLORW%YK6^KX*FYSM>RWT)E)05Y,_1;=1NK\M/^'RWB;_ *)1I?\
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M?.#\I+*^T?I=^RC\<X/VC?@/X5\=(BP7E];F.^@CX$5U&VR95']W>K$>Q!H
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M_HC?P_\ _"7L?_C5 'S1H?\ P63^ ^K7P@N]/\8Z)%G!N;_3(&C'U$,\C?\
MCO>OKWX7_%KPC\:/"-KXG\%:[:^(-$N<[+BV)!5AU5T8!D8<95@",]*\L^)'
M[!OP(^)/AF]TB?X:>']!>>%HXM0\/:=#I]S;,>CHT2KD@\X8,IQ@@CBOSU_X
M)HZYK?P'_;:\8?!Z34'OM)GDOM-N8T($3W5HYVSXR<':DB\=F'7 H _8RBBB
M@!N[K@9KY:^.G_!2KX(_ 77KK0M2UB^\2Z]9N8KK3O#5NMRUNX."CR.Z1!@<
MY7?N7!! /%:?_!0CX\7O[/O[,?B'7-(N/LOB#4I(]'TV<=8I90Q9Q_M+&LA!
M[$ ^U?-/_!-/]A#P)J7P@T[XF_$7PS:>*M>\0[YK.RUJ%9[6UM=Y"-Y+91WD
MP'W,#A64#!W9 /H+X%?\%*O@E\>]>M=!T[5K_P -:]=OY=KI_B2W6V:=L@!4
MD1WB+'(PN_<>PKZF#9QQ7YN_\%(OV"O MG\(]2^)WPY\/VOA#Q#X="W-U9:)
M"(+:[MMP#$0KA8Y(R=X9 ,@-D$[2/HS_ ()Y_'JZ_:"_9E\/ZQJMS]J\0Z6S
M:/J<I;+231 8D8_WGC:-S[L: /=?'GQ$\-?"_P +W?B/Q9K5IH&B6@!FO;V0
M(BD]%'<L>@4 DG@#-?'6O?\ !8[X#:/K1L;6T\7:U;;@/[1L=+B6#&<;L331
MR8[_ '*^;/VN]2\0_MS?MW:=\$M'U*2U\)>';EK.=H^4A>-0U[<LO0N"#$N<
MC*KTW&OOOPG^P=\ _"/@^#P]'\,/#NIP)#Y4E]JUA'=7LI(Y<W#@N&/7Y2 /
MX0!0!UWP+_::^''[2&AS:EX"\1P:O]FV_:K)P8;NUSD RPN R@X.&QM.#@G!
MKU'-?E_X;_87^*/[,/[;^C^+_@YX?GU+X6SW,:7;2:O;1M;V4Y"W,#K+(LDB
MQ?ZQ1M8GRX\DL*_2'QYXHB\#^!_$/B.Y(%OI&G7&H2;O[L4;2']%- 'Q_P"/
M?^"O/P:^'OC;7O#%[H'C6]O-'OIK":XL;&T:"5HW*%HRUTK%21D$J#CJ!6!_
MP^J^"'_0K?$#_P %]C_\F5XI_P $E_@3X7^,,GQ1\;^._#&C^,+>2]AL[5==
MT^*\6.;YY9G E5@"0\7/7UZU^B?_  RC\$.<?!OX?G_N5['_ .-4 2?LY_M$
M^'/VG?AQ%XU\+66J6&E27$ELL.KQ11S[D."<1R.N/3YL^PKU.L'PAX(\.?#[
M1ETGPMX?TOPWI:NT@L='LH[2 ,QR6\N-0,D]3BMZ@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /P!_X)<_\GU_#/\ [B?_ *:[NOW^K\ ?^"7/_)]?PS_[B?\
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M:7GPGT"+XHQ::WC2:T(UB'3ES;;V9ODQRI.PJ&QE2V['&* /E?X"_M2?&_\
M:P^,FEZYX-\&0>#_ ("V4TBW6H:]%FZU1 & \L@_?W8XCRB$$,[<*?N P(TB
MN5!=00K$<C.,\_@/RI(+6*UACBA1888QM2.-0JJ.P '85+0 SRQS[^U/HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA^(7A#_A(-8L_$LUA#<_VG>6VV!;:V<+MAF13\TCG)&>>O KZS_X==_LQ_\
M1,\?]Q[4_P#Y)K_-#B/_ )'.+_QR_-GV-'^''T/9?#_[2'PF\6:U:Z1H?Q0\
M&:SJUV_EV]AI_B"TGGF;KM1$D+,< \ 5Z-7SKX _X)\? +X6^,]*\5^%_ ?]
MEZ_I<OGVEW_;&H2^4^TKG9)<,IX)Z@]:^BJ^>-@HHHH *^6_^"G'_)C/Q/\
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M;W2X+VQ&HZ6)'\^2W9VDADM\GEUXX# \.H))!-?MEX(A2/P=H:HJHJV4("J
M /D%?E=_P6#^7]I'X1=_] C_ /2QJ /?_@O_ ,$J?AC_ ,(;!JOQ<M]0\?\
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M^$C8/#<V>0);EG^6.*(GI*7*[#_"<-Q@D?A+^RQ>>#_!G[07@#Q)\1]%NV\
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MU52=6)/H!FKOF<$XX^HH ?15:YU*ULVC2>YA@>0X19) I;Z9ZU/NH =1110
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M];9KK^W+:"(.)_-V;/*FDSCR6SG'48SSCXE_X+A<ZE\).W[K4O\ T*WK],/
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MF:[J46MQ6\5NNAV\,K(8WE+;Q++'C.\8QGO7V]_P^J^"'_0K?$#_ ,%]C_\
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MTA_P5"U/]HWPW+\,?@;X+U^*_P#$:&RN+R]B1KYX7&UXH887D W#@R%^%+<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'OO%?@R+4HM,L]1DTR1=4MUAE\U(HI"0%9@5VS)SG/7CBO6: %HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF[J6@!:*:&]J=0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT ?H)1N_.O@'_C89_P!4_P#_ "#4#:M_P4-TNZ4C1/ FKQD<KOMU1?KF5&H
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MHHH **** "BBB@ HHHH ***JZEJ=MI&GW-]>S1VUG;1M-//(VU(T4$LQ/8
MT <7\</^$[_X5;KO_"L?L/\ PG>R/^S/[2V^1N\Y/,W9_P"F?F?CBOSNU/\
M:._;9TGX]:7\'[B;P8/&>I6!U*WB6VC,!A D))DS@'$3<?2ON3_AM+X#G'_%
MW/")'_86B/\ 6OBKQE^T%\-KS_@J5X(\;P>.="E\(6OAF2UGUM+U#:Q2F*Z
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M_B5XNU+Q/XE\ VFJ:[J4GFW=X]W<HTK;0N2$E Z =!6'_P .Y?V<O^B8V/\
MX'7G_P >K^B>'_%F&1Y91R]X1SY%:_-:_P K,\BK@75FY\VY^'"\=:_5/_@C
MB"/@_P#$ GK_ ,)+^/\ QZ05[G_P[D_9RS_R3&Q_\#KS_P"/5ZI\(?@/X%^
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MT&LW!)]CO9JY_4/^"./P%O#,8KKQ=8^8,*+?5(CY?&,C?"WUYS0!]S;O;/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'S;^VU^QS_PV+X/\.Z%_P )=_PB/]D7S7OV
MC^S?MOF[HRFS;YT>W&<YR?I7Q[_PXQ_ZK9_Y:G_W;7ZJ5S'Q,^(VA_"/P#KO
MC'Q+<_8]$T:U:[N9 ,L5'15'=V)"J.Y8#O0!^:3?\$->/^2U\?\ 8I_7_I]H
M_P"'&7_5;/\ RU/_ +MK@OB!_P %IOB7J6O7'_"&^$O#>BZ&'(@35HIKR[90
M3@NZRH@R-ORA>""-QZURW_#Y;X\?] WP7_X+)_\ Y(H ]F_X<9?]5L_\M3_[
MMK]/_#>CCP]X>TO2O-^TFQM(;8S;=N_8@7=C)QG;TR:_%K_A\M\>/^@;X+_\
M%D__ ,D5^S_@W5IM<\(Z+J5QM^T7EE!<2;!M4,\:L<#L,F@#;HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /P!_X)<_\GU_#/_N)_P#IKNZ_?ZOP
M!_X)<_\ )]?PS_[B?_IKNZ_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $KPNV_:V\,:E^U._P #-+T[4-5UVUT][[4=
M4M0C6EBP0.(I#G=G:R#(& TB+USCW!V9E95;:V.&QG!KYP_8\_8_3]FE/&&M
MZWXA_P"$T\>>*M1DN]1\026_E,\>]F5 "S$99FD?!Y9@.=BF@#Z16/;WI]%%
M !1110 4444 %%%% !1110 44W=[4V298HV=SM51DLW  ]<T 24WS!_2ODSX
M[_\ !3#X1?!^ZDT71+N;XD>+R_DQ:/X9Q,GF'@*]QR@YXPF]@>-M>.-X8_;"
M_;0R==OX_P!GKX=7/_+A;*ZZI/%Z.N5F)QD$.T"GNAH ^F?V@/VZ/@_^SBEQ
M;^)O$T=]K\61_P (_HV+J^W?W74';%_VT9?;-?,W_"Y_VL_VS?W7PP\*Q_!+
MX?7&5'B37"1>SQ'^*-BF[D=/)CP#QYO>O?\ ]G__ ()X_!O]G^2WU&RT'_A*
M/$\>&_M[Q'MNIU?KNB0@1Q'.<%5#8X+&OI8)ZG- 'QK\%_\ @E[\-/ NK#Q+
M\0+N^^+WC2603SZCXD8O;-+G[WD%FWY[^<TE?8MC86^F6<-I9P16EK"H2*"%
M B1J!@*JC  'H*GQ2T ?)EU_P2Z_9[O+F:XE\,:D9)I&D?&MW8R6.3_RT]2:
MB_X=9?L\_P#0L:I_X/+O_P".5];XHV^]=\<QQL(J,:TK+97?^9')'>Q\D?\
M#K/]GCI_PC&J?^#R[_\ CE?1'PI^%?A[X+> =*\&^$[22QT#2Q(+6WEF>9DW
MR-(WSN2Q^9V/)[UU^*-M85L57Q%O;3<K;7;8XQ4=D+1117.4%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<3\:/E^#WCO!QG0K[_TGDKMJ9)"LJ%'
M 96!!5AD$'L1WIIV=P/YF;34K5;6)3/'D* 1N'85-_:EI_S\1_\ ?5?TF_\
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MFK>'?$_A&_\ [07QCIFU-1NG=MTP8G*@,<8!#!0,8()S]?T4 <OX^\%S^./
M>K^&X?$.J>'Y]0M&M?[9TMT2\AR,%T8J0">>0 1D[2IP1\T0?\$T? 6E^ _A
M[I&AZYJWAWQ/X1O_ .T%\8Z9L34;IW;=,&)RH#'& 0P4#&""<_7]% $,%N88
MHU:1I648,CXW/QU.,#/'85-110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?(O_!5'3=2U+]BGQF-/221(+FQN+M(P26@6ZCW' SPK%&/8!<]J^NJX3XV>
M*/"/@OX2^+=9\>B&7P=;:?+_ &I#<1B19X6788=A^\9"P0+QDL!QF@#\R?\
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M;?>N<\#?#7PM\,M)GTSPGX?TWPYI\]S)>2VNEVR01O,^-TA50 6.%&?10.@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P ><'_7-?\ T$5_0_@YA</B\=BHXBFI)16ZOU/)S"3C&+BP^PV__/O%GO\
M(/\ "HY[&W6%\6\6=O\ <%6L5'<?ZE_]T_RK^IL7E&7+#U+4(;/[*/$C4G?X
MC]#_ ((_M1?M#_%SX-^"/AY\ OAN-)M-#T:STF]\=:]M-LLD4*QR-%O C&&4
MG'[UB,?(*]>^'/\ P2[L/$'B*/QC^T#XYU;XN>+'PS6LES+'81=]@8D22(#T
M \M,<;,5]'_L>H/^&4_A!Z?\(IIO'_;LE>P;>,5_FM4^-^I]@C'\)^"]"\!Z
M'!HWAO1['0=(MQB*QTVV2WA3U(1 !DXZ]:V"N>].HK,84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  ]'_9B_Z*9_Y0=4_P#D:C_AZ/\ LQ?]%,_\H.J?_(U?*W_#C+_JMG_EJ?\
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MMEINK0W4DTC<*JB-FR2>W;J:_/;_ ()<_M$?#[]G7XG>,=8^(?B#_A']/O\
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M "@ZG_\ (U>J?\,G?!'_ *(Y\/\ _P )>Q_^-4?\,G?!'_HCGP__ /"7L?\
MXU0!YM8_\%,OV:=0W^5\3K==N,^?I5_#U]-\ S^%6O\ AY#^S=_T5+3_ /P"
MN_\ XS763?L6_ >>9Y&^$7@X,Y+$)HT"+SZ * !]!2?\,4_ 7_HD/@__ ,%$
M/_Q- '*?\/(?V;O^BI:?_P" 5W_\9KEOBI_P4*_9ZU[X8^+],L/B78W%]>Z/
M>6T$*V5V"\CPNJKDQ8&20.:]4_X8I^ O_1(?!_\ X*(?_B:Y'XM?L<_ _2?A
M5XTO;+X4^$[6\MM$O9H;B'2XE>-U@<JRD#(8$ @CH: /RD_X)D_%+PI\(?VG
M4\0>,M=M?#VC#1[N#[;>$A/,<Q[5X!Y.#^5?KE_PWY^SS_T5CP__ -_7_P#B
M:_(W_@F3\+?"GQ>_:<3P_P",M"M?$.C'1[N?[%> E/,0Q[6X(Y&3^=?KE_PP
M'^SS_P!$G\/_ /?I_P#XJ@#.\?\ [9OP+USX;>)8+'XK^%9KBZTFZCAA.I1K
M([M$P5=I(.23C!&:_*C_ ()8^*=%\&_M;Z;J6OZQ8:'IW]EWL9N]2NH[>(,R
M#:N]R!D^F:_3;XF?\$^/V>K+P+XIU*V^&.FV]]!IEU/%)#<W*"-Q$Q4A1( ,
M$9X%?E'_ ,$]?@KX2_: _:2LO"'C6PEU+0I=.NIVAAN9(&WHH*G>A!_#- '[
MM6?QM^'FI1N]GX\\,W:IPS0:Q;N![$A^*W+3QIH&H1QR6NMZ;<QR?<:&[C<-
M]"#S7R;??\$D_P!G6Z96BT'6;+ Y$&LSG/O\Y:L.[_X(X_ 2YDD:.X\76H;H
ML.JQD)]-T)_7- 'W-FDW>U? 7_#F#X0V?[S2_&WC^PNN@F^WV9X[CY;53^M+
M_P .C='T_C1_C5X_TU&YD7[2C;CZ_+L_K0!]^;J7<._!KX"_X==^,+/Y-,_:
MA^(%C G^HCWS'R_^^;I?T IG_#O'X]:;^^L?VR/&T\R\".\CO/+Q^-^X_2@#
M[_W4NZOS_P#^&*_VJ]*RNG?M67UTC\NU]!,2#Z#<[_TH_P"&9?VW[$>79?M'
MZ'/%'_JVNK3YV_WB;5C^9- 'Z 9I-WM7P#_PJO\ X*%Z;^^'QC\ :J!Q]G^Q
MPC/X_P!FI_Z%2?V3_P %"])X_MOP!K0?G?LA41_^0H_ZT ??^X4N?PKX _X2
MK_@H7I_[O_A#? &I^7_RV\Z%?-_\F4_D*/\ A>7[?^G_ +V^^ G@FXM^A2TO
M8_,/Y:FY_2@#[_W4;J_/_P#X:K_;.TOY=1_9HL;IW^9#8W3$ >^V9_UQ1_PW
M/^TW8?)>_LE:W/+'_K&M9KC:W^[B!OT)H _0&BO@#_AY1\7K/$FJ?L>?$"QM
M>\VZ\.#V&&T]1^M'_#U36=/XUG]G#Q_ICMS&OEN=P]?FA3^M 'W_ $5\ ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:4;X@:5HOQ.U3X=^&;0:>=<@TDR>;J8?[3Y*$+(@VKLEY;<!O'RFOTG^%_\
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M-]OLS@=_NVJG]:/^'1>BZ?QHWQH\?Z8K_P"M'VA#O_[YV?KFOO\ HH ^ /\
MAUOXMLU\K3?VGO'UC;+_ *J'=,=G_?-RHZ^@%-/_  3Q^/.GXFLOVR/&T\ZG
MY8[M+WRS]<W[#]*_0&DQ0!^?_P#PQ5^U7I1QIW[5M_=+(/G-]!,<?3<[_P!*
M!^S)^V[8+Y5E^T?HL\,?^K>ZM/G;_>)M6/YDU^@&*3;0!\ GX5?\%"]-Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M/_!+G_D^OX9_]Q/_ --=W7[_ %?@#_P2Y_Y/K^&?_<3_ /37=U^_U !1110
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MR,TUM'.OE/',6&UP1U1>U?F"?^"KW[22XSXOT_\ \$EI_P#&Z /WFHK\%_\
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ME_M8?#*V\&:MK5WH-M!J46I"ZLHED<LB2(%PW&")3^5>U44 ?FM_PY#\$?\
M12_$'_@#!_C2?\.0_!'_ $4OQ!_X P?XU^E5% 'YK?\ #D3P1_T4OQ!C_KQ@
M_P :^KOV0?V1](_9#\&ZUX>T?7[WQ!#J=_\ ;WFO84C9&\M$VC;VP@KWNB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 ?@#_P2Y_Y/K^&?_<3_ /37=U^_U?@#_P $N?\
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M7[3GB+4/$5A^SK\&V:^^)_B@"#4;RU?!TBU=<D%Q_JY&C)8MU2/+=64CW_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO]7X _\ !+G_ )/K^&?_ '$__37=U^_U !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!D>*?".C>.-"N]$\0Z79ZWH]VNRXL-0@6:&5>N&1@0>>?RKYIOO\
M@ES^S7?ZI)>O\/FC\QR[V\.LWT<.2<\*LPVCG@+@#H!7U;10!S'P^^&/A3X4
M^'8M!\'^']/\-Z1&V\6FG0+$K,>KMCEF.!ECD\=:Z3RQSW!I]% 'S7\0/^"<
M_P"SY\2?$%QK>J_#ZWMM2N&+SR:5=W%BDK$DEC'#(J9)))(4$]R:]4^#_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M^ /_  2Y_P"3Z_AG_P!Q/_TUW=?O]7X _P#!+G_D^OX9_P#<3_\ 37=U^_U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#\ ?^"7/_ "?7\,_^XG_Z:[NO
MW^K\ ?\ @ES_ ,GU_#/_ +B?_IKNZ_?Z@ HHHH **** "BBB@ HHHH ****
M"OS5_P""W7_)*_AK_P!AFX_]$"OTJKAOBE\#_ GQLT^QL?'/AFQ\36EC*TUM
M#>J2L3D8)&".<4 ?BY^RW_P4O\3?LM_"FW\"Z5X,TG6[2&[FNQ=WEU*DA,A!
M*X7C Q7KO_#[OQQ_T37P_P#^!T]??_\ PP'^SU_T2CP__P!^W_\ BJ/^& _V
M>O\ HE'A_P#[]O\ _%4 ?D'^U_\ \% /$'[7WA+0]!UCPGIGA^+2KYKY)K&X
MDD:1C&R8.[MAJ_1'_@C?Q^R3>#_J9KS_ -$V]>U_\,!_L]?]$H\/_P#?M_\
MXJO4OAK\)_"/P=\.MH/@O0;3P[H[3M=&SLU(3S6 #/R3R0J_E0!UU%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!^ /\ P2Y_Y/K^&?\ W$__ $UW=?O]7X _\$N?
M^3Z_AG_W$_\ TUW=?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'X _\$N?^3Z_AG_W$_P#TUW=?
MO]7X _\ !+G_ )/K^&?_ '$__37=U^_U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !29I:\?_:F_:.T/]ESX0:GXVUF(7LT;+;:=
MIBRB-[Z[<$I$&P=HP&9FP=JHQP< $ ]?W4FZOQ(MOVY?VQ_V@-3U76/ $>JC
M2[$,\MGX4\.QW-O:CAMI=XI&9L8PI8L<<"OH;]@W_@IUX@^)7Q T_P"&?Q?6
MU.KZE)]ETSQ!# MLTMUT$%Q$N$#.<A60+\Q52O.0 ?IG124M !1110!^ /\
MP2Y_Y/K^&?\ W$__ $UW=?O]7X _\$N?^3Z_AG_W$_\ TUW=?O\ 4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DO\ \%N_&ER_
MB;X8>$5E86D%I=ZK+'GAWD=(HR?=1%)C_?:OUHK\=/\ @MI#(/C7\/Y2C")O
M#[*KX^5B+F0D ]\9'TR/6@#[E_X)G^!X/!7[%_P_$<,<5UJJ7&K74L:!3,\T
M[E&;!.2(A$F?1!TK\JO^"B&AGX1_MU>,[WPZR:7+]LL]=M)+8 -%<20Q3/)C
M& QG\Q_Q]Z_7S]@N>.X_8[^$[1.LBC1(UW*<C<K,K#Z@@@^G2OR9_P""K]Q%
M-^VMXK2.17>*RT]) K<HWV6-L'T.TJ?H10!^Z7AO6$\1>'M,U5%*1WUK%<JI
M(X5U# ''UK1W>U<=\&]/DTGX1^"+*8AIK70[&!V'3*VZ*?U%?CK^T%_P3D_:
M(\<?'SXE^)-$^'OVW1M8\3ZGJ%C<_P!M:<GFP2W<KQOM>X#+E6!PP!&>0#0!
M^WF:,U^ 7_#KG]IW_HF?_E?TO_Y)H_X=<_M._P#1,_\ ROZ7_P#)- "_\$N>
M/VZOAG_W$_\ TUW=?OYFOYA?A;\+?$_QG\=:9X-\&Z;_ &QXCU(2_9;+SXH!
M)Y<3RO\ /*RH,)&YY8?=P,G KWW_ (=<_M._]$S_ /*_I?\ \DT ?O[FC-?@
M%_PZY_:=_P"B9_\ E?TO_P"2:Y7XH?L%_'7X,>!=3\8^,O _]C>&]-\K[5>_
MVO8S^7YDJ1)\D4[.<O(@X4XW9.!DT ?T3YHS7\UOP-_9<^)W[2?]M_\ "N/#
M7_"1_P!B^3]O_P")A:VOD^=YGE?Z^5-V[RI/NYQMYQD9]5_X=<_M._\ 1,__
M "OZ7_\ )- '[^YHS7X!?\.N?VG?^B9_^5_2_P#Y)KROXY_LN?$_]FO^Q/\
MA8_AK_A'/[:\[[!_Q,+6Z\[R?+\S_42OMQYL?WL9W<9P< ']*.:,U_.Q\+_V
M"_CK\:/ NF>,?!O@C^V?#FI>;]EO?[7L(/,\N5XG^26=7&'C<<J,XR,C!KJO
M^'7/[3O_ $3/_P K^E__ "30!^_N:,U^ 7_#KG]IW_HF?_E?TO\ ^2:\!^*7
MPL\3_!?QUJ?@WQEIO]C^(]-\K[59^?%/Y?F1)*GSQ,R'*2(>&/7!P<B@#^GO
M-&:_ +_AUS^T[_T3/_ROZ7_\DT?\.N?VG?\ HF?_ )7]+_\ DF@#]_<T9K\
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MS^,/[0_A:Z\1_#[PC_PD&C6MX^GS7/\ :=G;;9U1)&3;-,C'"RQG(&/FZ\'
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M@BO5/"/_  3C_:(\=>%=&\2:'\/OMNBZQ9PZA97/]M:='YL$J!XWVO<!ERK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV<2Q0P1(H5(T10 J@  *.  *NT )BOP#U+_E*-(/^JP#_P!/(K]_:_ +4O\
ME*/)_P!E@'_IY% '[^T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'P!^RY_P2E_X9K^.WAGXC_\ "T?^
M$C_L7[3_ ,2S_A'OLOG>=:RP?ZW[4^W'F[ONG.W'&<C[_HHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2;V?F GRW.6/+JW08Q7J5% 'Y#?\%M8(K/QU\+(88TBBCTFZ2..-0JHHE0
M=A]*^S/^"6O_ "8M\-?KJ?\ Z<[JOC;_ (+??\E!^%__ &"[O_T:E?9/_!+7
M_DQ;X:_74_\ TYW5 'Q)_P %M)Y&^,GP^B+,84T"1U3L&-RX8_CM7\A7Z#_L
M"VL5K^QS\*4A01HVC1R$#^\S,S'\6)-?"G_!;SPK/%XN^%_B41R&WN;&\TYI
M #M5HI(Y ">@)$S8]=I]*^R_^":OC.U\8?L7_#UX)EEFTV";3+F-3S$\,SJJ
MMZ$IY;?1@>] 'Y>_\%888X?VU/%#)&JO)8Z>[E5P7;[+& 3ZG  Y[ 5]*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M; !WQV4!511DX51DDY)]HVT;?>@!U%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YR?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO5K_ ,/7?B9KR"_B\O9)#YP;>,OG&/:OVLB!6- >H44_;[TM 'P/_P %!O\
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M6<:;O7;+))*I*M*5+( A*JI;YFW?+^AFVD\L4 /HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO'_V
MGOVH/"W[)_@&P\7>+M/UC4--O-3CTJ.+188I9A*\4LH8B22,!=L+#.<Y(XZD
M 'L%%? /_#ZCX(XS_P (MX_Q_P!@^Q_^3*3_ (?5?!#_ *%;X@?^"^Q_^3*
M/O\ HKY9_9H_X*+?#?\ :H^(<W@WPGHGBG3M3BL)=1:;6;2VBA\M'C4@&.XD
M;=F1<#;C@\U]34 %%%% !1110 4444 %%%% !1110 445YG^T'^T)X2_9G^&
M]UXT\92W TZ.:.UAM;)%>YNIGSMBB5F4,V%=N6 "HQSQ0!Z917E7[.'[1&B?
MM.?#E/&WAS1=<T;19;J2UM_[=AABDN/+(5I$$4L@*;MR9)!W(W&,$_.WQ#_X
M*Y?"#X:>/O$OA#5/#7CB?4M U.YTJZDM+"S:)Y8)6C=D+72DH2A() .,9 H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@#_@
MM-^[_99\+L#S_P )E:_^D5]7W_7P#_P6I_Y-7\,?]CE:_P#I%?4 ?#__  3E
M_8X\&?M@:MX[M?&.J:]ID>A0V<ML=#N(8BYE:8-O\V&3('EKC&.IK[?_ .'*
MOP0_Z&GX@?\ @PL?_D.OSY_8;_;7/[&.H>+[S_A#/^$Q_P"$@BM8MG]J?8?(
M\DR'.?)EW;O,]L8[YX^L?^'YO_5$_P#RZ_\ [BH ^KOV:/\ @G3\-_V5_B'-
MXR\)ZWXIU'4Y;"73FAUF[MI8?+=XV) CMXVW9C7!W8Y/%>Y>-OC5\/OAI?6]
MEXO\=>&O"EY<1^=#;ZYJ]O922QY*[U65U)7((R..*\J_8G_:Y_X;$^'NM^*/
M^$4_X1'^S=4;3?LO]I?;?,Q%')OW>5'C_68Q@],YYK\^_P#@MH<?&[P#_P!B
MZW_I3+0!^G/Q _:F^$WPO\$Z;XN\1>/=&M_#NI[OL%]:3_;%O=IPQ@6 .TH4
M\$H"!D9K3^#WQ_\ A[\?M&N-4\ >*;'Q+:VY47"VY9)H"P)7S(G"R1YVMC<H
MSM..AK\;OV3?V)_&W[=GA8:KJWC8>&/"/A6-=!TN26Q-X<C,[Q11"2,!09MS
M.6))E YQQ^@O@GX<:+_P2_\ V-_&VK&^C\4:M;/)J$M\UN;=;V[E98+2+9N<
MK&"8@1N.,R-WQ0!]#_%C]HGX:_ RWBE\=^,]*\-M,I>*VNILW,JCJR0J#(P'
MJ%(Y'K7!> _V_OV??B3JD6G:)\3M)^VS.(XHM3CGT_S&) "J;F.,,Q)  !R3
MP*_'[]F/X$^+_P#@H/\ M"ZJ_BCQ1>;?+;5=?UZ9?-F\LN%6&)>%5F)VHHPB
M*I(4A I^@?VU?^"5VA_ SX0W_C_X=^(]:U6'15$NJ:9KGE32/ SJIFBDB2/&
MPG+*5.5).X;<, ?L!Y@(!'.>E1W5]!86LUS=31VUM"C22S3,$1%4$LS$\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(W9&WS-J[NG7:/I7X;_M<>?^T#_P4 \8:3I+[KK6/%$/ARWD"[AOB,5D&QW
M,>?H* /W,^!,4EO\$?A]%*CI*GA_3U=) 0RM]G3((/.<YZUW=5-,TV#2=.M;
M&V01VUM$L,<:@ *J@   >PJW0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7.>-/ASX6^)&EQ:9XN\-Z1XITV*87,=GK5A
M%>0I*%91($D5@&"NR[NN&([G/1T4 <CX'^$/@7X8R7DG@[P7X>\)O>*JW+:'
MI4%D9PN=H?RE7=C<<9Z9-==110 5QGC;X*_#[XE7MO>>+_ OAKQ7>6\?DPW&
MN:1;WLD4>2VQ6E1B%R2<#CFNSHH Q?"?@O0/ >AP:+X9T33O#VCP,S1:?I5I
M';6\99BS%8XP%!)))P.236SBEHH R?$'A/1O%FGO8:YI5CK5BYW-:ZA;)/$3
M[JX(KG/"7P)^&W@'4?[0\,?#[PMX<O\ &/M6DZ+;6LN.>-\: ]SW[FNYHH ;
MY8Q@<4;>3S]*=10!P>H_ /X9ZQXA_M[4/AWX3O\ 7-_F#4[G1+:2YW<G=YK(
M6SR><U\!?\%NE6+P/\*$10B+?WX4+P /*AK].:\(_:F_8Y\&?M=:7H%AXQU3
M7M-AT6:6>W;0[B&)G:15#;_-BDR,(,8QU- 'S)_P1/\ E_9]\;YZ_P#"4-_Z
M26]?HE7B_P"R]^RGX3_9+\'ZKX;\(:CK.HV&I7QU"636IH995D,:1X4Q11C;
MB,<$$Y)YKVB@!*_%+_@J%\'=3^ /[5&F?%3P] ;?3?$%Q%K%M<K'F*#5(&5I
M4. .6*I-R<L7?T-?M=7F/[0W[/'A+]IKX<3^#/&,5Q_9[SQW4-W8NJ75K,A.
M)(G96"MM+J<J<J[#O0!T/PJ^(VF_%KX;>&O&6D-G3];L(KV)2<M'O4$HW^TK
M94^X-8&K?LQ_!_7M5O=3U3X5>"-1U*]F>XNKR[\.6<LT\KL6>1W:,EF9B26/
M))YS4'[./[/.B_LR_#>+P1X=UK7-9T6WNI;FV_MR:&62W\PAFC0Q11C9NW-R
M"<R-SC 'J= $<<*PQK'&JHBC:JJ. !T K,\4>$=$\;Z%=:)XCT>P\0:-=;?M
M&G:I:I<V\VU@Z[XW!5L,JL,C@@'J*UZ* .#\(? 7X:?#W6!JWA7X>>%/#.JB
M-HA?:/HEM:3A&^\OF1HK8.!D9[4GBSX _#'Q[K<FL^)OASX3\1:Q(JJ^H:MH
M=K=7#*H 4&22,L0 ,#G@5WM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_
M *(W\/\ _P )>Q_^-5ZK10!YC\5O&WAO]F7X$^(?$4%C8Z-H/AG3));33;2%
M+>#>!M@@1% 5=\C(@  Y85^5W_!)7X'W_P 6/V@M6^*VNH]UIOADO,ES."PN
M=3N P'/0E$:1SSPS1GO7ZB?M*?LVZ%^U%\/X_!OB77=>T;11>)>3+H,\,+W#
M(&VI(9(I R!FW8P/F53V%:WP&^ WA7]G+X:Z=X(\(0SII5HSR//>,KW%S*Y)
M:65U50S'IP       * /1*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>kros-20251231_g7.jpg
<TEXT>
begin 644 kros-20251231_g7.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,@!.0# 2(  A$! Q$!_\0
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M=:_)'_A]5\;_ /H5O '_ (+[[_Y,H _:FDS7XK_\/JOC?_T*W@#_ ,%]]_\
M)E=K\$?^"N7Q@^)'QH\ ^$=3\-^"(--\0>(+#2KJ2UL;Q94BGN8XG9"UVP#
M.<$J1D#@]* /UTHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3(
MH 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\(?!7_  4$
M_;'^)6JRZ9X1\3ZQXJU**$W,EGHOA&PO)DB#*ID*1VC$*&=!NQC+ =Q7[O5^
M*W_!%?\ Y.G\4_\ 8F77_I=8T '_  TM_P %#/\ H$?$#_PW$/\ \@T?\-+?
M\%#/^@1\0/\ PW$/_P @U^U-% 'XK?\ #2W_  4,_P"@1\0/_#<0_P#R#1_P
MTM_P4,_Z!'Q _P##<0__ "#7[4T4 ?BM_P -+?\ !0S_ *!'Q _\-Q#_ /(-
M'_#2W_!0S_H$?$#_ ,-Q#_\ (-?M310!^*W_  TM_P %#/\ H$?$#_PW$/\
M\@T?\-+?\%#/^@1\0/\ PW$/_P @U^U-% 'XK?\ #2W_  4,_P"@1\0/_#<0
M_P#R#1_PTM_P4,_Z!'Q _P##<0__ "#7[4T4 ?BM_P -+?\ !0S_ *!'Q _\
M-Q#_ /(-'_#2W_!0S_H$?$#_ ,-Q#_\ (-?M310!^*W_  TM_P %#/\ H$?$
M#_PW$/\ \@T?\-+?\%#/^@1\0/\ PW$/_P @U^U-% 'XK?\ #2W_  4,_P"@
M1\0/_#<0_P#R#1_PTM_P4,_Z!'Q _P##<0__ "#7[4T4 ?BM_P -+?\ !0S_
M *!'Q _\-Q#_ /(-'_#2W_!0S_H$?$#_ ,-Q#_\ (-?M310!^*W_  TM_P %
M#/\ H$?$#_PW$/\ \@T?\-+?\%#/^@1\0/\ PW$/_P @U^U-% 'XK?\ #2W_
M  4,_P"@1\0/_#<0_P#R#7?_ +&_[8W[2'C#]LWP?\,OBIXAU""UN/MG]I:#
MJGAZTT^X&W3I[B+>!;QRIRL3C!&1CJ#S^M5?E6W_ "G6'^?^98H _52BBB@
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M^#% 'ZJ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7XK?M+?\IDM'_['/PG_P"B
M=.K]J:_%;]I;_E,EH_\ V.?A/_T3IU '[4T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?BO^TQ_RF0T?_L<O"?\ Z)T^OVHK\5_VF/\ E,AH_P#V
M.7A/_P!$Z?0!^U%%%% !1110 4444 %%%% 'Y5_\%S?N_!3ZZW_[85]^_LF_
M\FL_!O\ [$W1_P#TBAKX"_X+F_=^"GUUO_VPK[]_9-.?V6?@Y_V)NC_^D4-
M'J]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %1X8=!BI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IG.>]/HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\5OV
MEO\ E,EH_P#V.?A/_P!$Z=7[4;AZU^*_[2O_ "F1T@]O^$S\)_\ HG3J /VI
MHHHH **** "BBB@ HHHH ***3(H 6BBB@ HHI,T +1129H 6BBDH 6BBDS0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%/Q*_X)PGX
MB?MC6GQX_P"%A?V?]GUG2=7_ .$?_L3S=WV)+=?+\_[0/O\ V?[WE_+OZ''/
MVM10 4444 %%%% !1110 4444 ?*G[<W[#9_;0_X0H?\)H?!W_"-_;O^83]N
M^T_:/(_Z;Q[-OV?WSN[8Y]\^$_@4_"_X7>#O!OVS^TAX=T:STC[=Y/E?:/L\
M*1>9LW-MW;-VW)QG&3UKKZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\:[W,@(PR-G@XH ]RHI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!7<6.PDL>* /NW]CWXT_M/\ [3GQNL_B+JVDV_AKX,^1-;C3+A&@MYHWP5>
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M"3Z'[1T9K\7?^'S_ ,<^O_")> O_  77W_R97V;_ ,$X?VT_&_[7_P#PL/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_X?4?!#_H5?B!_X+K'_ .3*^J?^&3_@C_T1OX?_ /A+V/\ \:H_X9/^"/\
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MH *_%;]I;_E,CI![?\)GX3_]$Z=7;?&[_@D9\8/B5\9_'OB[3?$?@B'3M?\
M$&H:K:Q7=]>+,D4]S)*BN%M& 8*XSAB,YY/6OF'P3\%=;_9W_;]^''P]\1W6
MGWNM:/XR\/\ VB?2I'>W;S9[69=K.B,?DE4'*CG/7J0#^A&BBB@ HHHH ***
M* "BBB@ KRG]K'_DUGXQ_P#8F:S_ .D,U>K5SGQ \$V7Q)\ ^)?".J2W$&FZ
M_IESI5U):,JS)%/$T3LA964, YP2I&>H(XH _GV^!?Q&\.>$_!\]EJNHK9W+
M7KRA#"[_ "E$ .54CJI]Z]%_X7?X)_Z#B_\ @--_\17W1_PY5^"'_0T^/_\
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M9&"1WKLO@7^S_P"$OV=?#^N:+X,MI[32]7UB?6Y;65P4AFE2-"D055"1A8E
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M110 4444 %%%% !1110 4444 %?G_P#\%JO^36?"W_8YVO\ Z0WU?H!7Y_\
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MOVPO@38?#75+#Q?>^#Y]0UK7/$&ASK<VVFV4EL8EA>>,E&,TF%V!B1M!( -
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7Y__P#!:K_DUGPM_P!CG:_^D-]7Z 5^?_\ P6J_Y-9\+?\ 8YVO_I#?4 >J
M_P#!+G_DQ/X9?]Q/_P!.EW7U77RI_P $N?\ DQ/X9?\ <3_].EW7U70 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD1AM96!((((()!XJ_10!Y/\ \,G_  1_Z(WX _\ "7L?_C5'_#)_P2_Z(WX
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MSDG R36W10 5B>*O!F@>/-'?2?$VA:;XBTN0@O8ZM9QW4#$="4D4J3^%;=%
M&1X;\+Z1X.T>WTC0-)L=#TFW7;!8Z=;);P1#T6- %4?05B:A\'_ FK>+H/%=
M]X)\.W?BB AHM;GTFWDO4(X!6<IO& 3W[UV5% %'5M'L=?TVYT[5+&WU+3[E
M#'/:W<*RQ2I_=9&R&'L163X,^'7A7X<:?)8>$_#&C^%[&1_,>VT6PBLXG;^\
M5C503[XKI** "BBB@ HHHH **** "BBB@#\K/^"YG_-%/KK?_MA7YX?"7_5Z
ME]8__9J_0_\ X+F?\T4^NM_^V%?GA\)?]7J7UC_]FKZOA;_D;4?G^3/:R?\
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MH_\ V.?A/_T3IU '[4T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/\/Z+:[?M&HZI=);6\.Y@B[Y'(5<LRJ,GDL!U- &M17E/_#6'P2_Z+'X _\
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M_#ZGXWG_ )E;P!_X+K[_ .3*/^'U'QN_Z%;P!_X+[[_Y,H ^I/%W_!4OQAX
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M'/\ L3='_P#2*&OYZOCC_P ED\<?]AN]_P#1[U_0K^R9_P FL_!S_L3='_\
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M_")_8=9BU?[:-;^V;]D$\7E[/L\>,F?=NS_#C'.0 ?I/_P $N?\ DQ/X9?\
M<3_].EW7U77RI_P2Y_Y,3^&7_<3_ /3I=U]5T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5\J_P#!4;_DQ3XF_P#<,_\
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MJS'"@L2!DG@5YM_PVI\!/^BO>$/_  ;Q?_%4 >U9HS7BO_#:GP%_Z*]X0_\
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M^9;+_@EK^SE8^)(]63P3/(L<@E73Y]5NI+7<"",J9,L,C[I)!Z$$<4 >:?\
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M_P#)BWPT_P"XG_Z<[NOR?_;]_P"2M:)_V!(O_1\]?K!_P2Y_Y,6^&G_<3_\
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M]5U\J?\ !+G_ ),3^&7_ '$__3I=U]5T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\J_\%1O^3%/B;_W#/\ TYVE?55?
M*O\ P5&_Y,4^)O\ W#/_ $YVE 'Y.?L!?\E9UG_L"2_^CX*^]Z^"/V O^2LZ
MS_V!)?\ T?!7WO7\U>(/_(X_[=7ZG]"\$_\ (J7^)A1117YB?H 4444 ?!7[
M?O\ R5K1/^P)%_Z/GK]8/^"7/_)BWPT_[B?_ *<[NOR?_;]_Y*UHG_8$B_\
M1\]?K!_P2Y_Y,6^&G_<3_P#3G=U_7W#?_(GPO^%'\O<1?\C7$?XCZKHHHKZ4
M^;"BBB@ HHHH **** "BBB@ HHHH **** "O$/VM/V5] _:U^&<?A37-2OM&
MEL[H7^GW]B QAN!&Z NC<2)B0Y7*D]F7K7M]% 'X=>./^"?_ .T[^ROK5SK7
MP^N-3UJS4\:IX%O94NF13E5DMU*RDD=5177J-Q[\N/\ @HI^U5\,;[^S=:\6
MZA;SQCFS\0:%;"7IW,D D_6OWLZYXJ*YM8;R$Q3PQSQ'JDBAE/X&@#\')O\
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M !AX[&D>(]-9!=V?]D7\_E%XUD7YXX&1LJZGACC..H-<U_P]&_9C_P"BF?\
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M"Y,;C:<$8Z<BOJG_ (>C?LQ?]%,_\H&J?_(U?C7_ ,,<_%K_ *%E?_!C:_\
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MB@ HHHH **** "BBB@ K\_\ _@M5_P FL^%O^QSM?_2&^K] *_/_ /X+5?\
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M* "BBB@ K\__ /@M5_R:SX6_['.U_P#2&^K] *_/_P#X+5?\FL^%O^QSM?\
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M/A?\*/Y>XB_Y&N(_Q'U71117TI\V%%%% !1110 4444 %%%% !1110 4444
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M7$-[XBO;F35-8N+<DQ?:9%1?+C)YVHB(F> 2K-@;L4 ?0]%%% !7Y4?ML?\
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M]7X\>$O#:^);V2 S>2(T+[MN[N!ZCUK]B/\ @M1_R:WX6_['*U_](;ZOR/\
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M_P!CG=?^D-C7]?<-_P#(GPO^%'\O<1?\C7$?XC[_ ****^E/FPHHHH ****
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M%% !1110 4444 %%%% !1110 5\J_P#!4;_DQ3XF_P#<,_\ 3G:5]55\J_\
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M^P)+_P"CX*^]Z^"/V O^2LZS_P!@27_T?!7WO7\U>(/_ "./^W5^I_0O!/\
MR*E_B84445^8GZ %%%% 'P5^W[_R5K1/^P)%_P"CYZ_6#_@ES_R8M\-/^XG_
M .G.[K\G_P!OW_DK6B?]@2+_ -'SU^L'_!+G_DQ;X:?]Q/\ ].=W7]?<-_\
M(GPO^%'\O<1?\C7$?XCZKHHHKZ4^;"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#X6_X*O?LQ^(OCQ\)= \1>$-,FUKQ!X1N)Y'TVV!:>XLYU3SA$@'[R
M16AA8*.2-^,G /Y8WUQ\;?VP_B%X?\+Z@-:\9^)=+MXM'M+>:U$?V&!6P#-M
M0! ,Y>63YC@;F.T5_1+X@\0Z7X5T6\UC6M1M=)TFSB,US?7TRPPPQCJSNQ
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M.?A/_P!$Z=0!^U%%%% 'P!_P6H_Y-;\+?]CE:_\ I#?5^1_PI_Y#5W_UP/\
MZ$M?KA_P6H_Y-;\+?]CE:_\ I#?5^1_PI_Y#5W_UP/\ Z$M>_D'_ ",Z'^(]
M++O][I^IZ?1117](GZL%4M<_Y M__P!>\G_H)J[5+7/^0+?_ /7O)_Z":XL=
M_NM3_"_R.;$?P)^C.:_91_Y.H^#O_8Z:/_Z70U_2E7\UO[*/_)U'P=_['31_
M_2Z&OZ4J_EU[GY %>5?M8?\ )K/QD_[$S6?_ $AFKU6O*OVL/^36?C)_V)FL
M_P#I#-2 _G0^&_\ R4#P[_V$(/\ T8M?:U?%/PW_ .2@>'?^PA!_Z,6OM:OJ
M<G^"9^K\%_P:WJ@HHHKZ(_1@KXI^)'_)0/$7_80G_P#1C5]K5\4_$C_DH'B+
M_L(3_P#HQJ^=SCX(>I^<\9_P:/JS^B[]D[_DUGX.?]B9HW_I##7JU>4_LG?\
MFL_!S_L3-&_](8:]6KY8_* K^:W]J[_DZGXQ?]CIK/\ Z735_2E7\UO[5W_)
MU/QB_P"QTUG_ -+IJ!QW1^AOP?\ ^22^"/\ L!V/_HA*Z_N*Y#X/_P#))?!'
M_8#L?_1"5U_<5_&69_[_ %_\4OS9_6F7_P"Z4O\ "OR"BBBO)/0/@K]OW_DK
M6B?]@2+_ -'SU^AG_!%;_DUKQ3_V.=U_Z0V-?GG^W[_R5K1/^P)%_P"CYZ_0
MS_@BM_R:UXI_['.Z_P#2&QK^ON&_^1/A?\*/Y>XB_P"1KB/\1]_T445]*?-A
M1110 4444 %%%% 'Y6?\%S/^:*?76_\ VPK\\/A+_J]2^L?_ +-7Z'_\%S/^
M:*?76_\ VPK\\/A+_J]2^L?_ +-7U?"W_(VH_/\ )GM9/_OU/Y_D>A4445_0
MI^G!6!X\_P"12O\ Z)_Z&M;]8'CS_D4K_P"B?^AK7D9M_P B^O\ X9?DSAQW
M^ZU/\+_(^E?^"*O_ "=/XH_[$VZ_]+;&OVJK\5?^"*O_ "=/XH_[$VZ_]+;&
MOVJK^9C\E"OE7_@J)_R8I\3?IIG_ *<[2OJJOE7_ (*B?\F*?$WZ:9_Z<[2@
M#\0_@-_R531OI-_Z)>OKBOD?X#?\E4T;Z3?^B7KZXKZ_)_X,O7]$?L7!O^XS
M_P 3_)!1117N'W85\$S?ZR3_ 'C7WM7P3-_K)/\ >-?,9QO3^?Z'YCQKO0^?
MZ']42?=7Z4ZFI]U?I3J^;/S :*_F3^"?_)9O!/\ V'+/_P!'I7]-@K^9/X)_
M\EF\$_\ 8<L__1Z5R8K_ '>IZ/\ ([,%_O-/_$OS/U8HHHK^*9;L_KB.R"BB
MBB.Z"6S/RF^./_)9/''_ &&[W_T>]?T*_LF?\FL_!S_L3='_ /2*&OYZOCC_
M ,ED\<?]AN]_]'O7]"O[)G_)K/P<_P"Q-T?_ -(H:_M7"?[M3]%^2/Y(QW^\
MU/5_F>LTM)2UV'$%%%% !1110 4444 %%%% !1110!Q_Q@\%2?$CX3>-?"44
MODR:]HE[I2R9 VF>!XL\@_WZ_'K_ ()X_MC:5^QOXJ\9^ ?B;IMYINDWU[B>
M\AA\R;3+Z#=%(DT:_,RG&TE<E63[I#$K^VF:^5OVIO\ @GG\*_VG-:77M4-S
MX5\83[8FUG2&17O-J$*LT;@K*0J\$8?" ;MJ@4 ?!?[)?[7'PP^$?[8/Q]^(
M?B/79[?PSXDN=2GTB6"PGEDO5EU$SQ@($RA,?/[S:.QP:S/AOX\U']O+_@II
MX6\8Z=I,VFZ-I>H6^IQ0OAGM;"P(DC>9EXW22*@/4!I@N2 #7M-M_P $1]#T
MV^>[UCXQW#Z,C9:./0H[>0+NX!E:X9<]L[,9[=J^XOV;OV3_ (>?LK^')],\
M$Z5(EU>;3?ZQ?N)KV]*X"[WP %')"(%0$DXR2: /9J*** *&O1//H>H11J7D
M>VD5549))4@ "OR2_P""(=Q$GQ-^)D+2*)I-'M76,L-S*)V!('H"RC\1ZU^O
ME?CA\=_V1/CY^R+^T%K7Q#^ UEK&HZ+J<LTMI<>';-;V>UCFDW/9S6NQRZ*V
MW!V,N%0Y# X )_\ @I%_Q,/^"COPTMK8B:<0:'$8T/(<WTI"GW(93^(K]AZ_
M)C]C#]CWXR_%W]IBR^.'QTT_4M/CTVX34E.O0K#>ZA>(H$ 6WP#"D15'RRJ!
ML14!Y*^^?\%%/BA^TG\/?%O@Z'X%V/B.[TVYLIY-2.A^&$U9!*)%";V:WEV'
M;G R,T >$_\ !<:)_P"W/@_)M/EM;:JH;'!(:UR,^HR/SK[/_:!U"VD_X)]^
M+[I;B-K>;P YCE# J^ZS 7![Y)&/7(K _;U_9/U/]K/X#Z7:Z2T</CC0V&H:
M>MUB-;AFBQ-;LQ^X7^4@G@,BYP,D?FO>>!?VUO%G@:V^!EWX8\;3>$;41V\>
MG7&F)#9[(R#'&;\HJM&I"X4S%!M&.@P ?3G_  2(\56OPY_9=^,OC'5$D.E:
M+?2ZC<-&,LT=O9"60*.YV_S%?//P9_9OUK_@IS\6?B)XZ^UZ%\+=*MIXWDBT
MG2A,&FF,C*OEJ\>]R%9GF8@LS9P>@_2_]F?]C^Q^#O[)=S\(]<FCN[GQ!97B
M>(KBRRJRS7<1BE$;<$A(]D88X)\L-@9P/SZ\#?#7]K/_ ()T^//$EMX&\$S?
M$#PWJKB(26>E3:G97H3)BN##;N)H) &92&*CD@[P$:@#9_8I\4:K^P_^VKJ_
MP$\1:;HNLQZW?1:<^OV=OMNT>6%)K1ED(W&)E>,/"?NLY8-\IW_<'_!0?]F'
MQ5^UC\&=&\(^$K_2-.U&S\00ZK)+K4TL4)B2VN8BJM''(=Q:9<?*!@'GH#\E
M_LB_LD_&?XQ?M51_M _&S2IO#B0W(U-+6]B%O<W=PL8CMXEM\[H8H56/_6 ,
M1&J_-EF7]5: /Q7_ .'*OQO_ .AI^'__ (,;[_Y#KR#]I[_@GO\ $3]DWP#8
M>+?%^L^&-1TV]U./24BT6ZN99A*\4LH8B2WC7;MA;/S$Y(XZD?T#U^?_ /P6
MJ_Y-9\+?]CG:_P#I#?4 >J_\$N?^3$_AE_W$_P#TZ7=?5=?*G_!+G_DQ/X9?
M]Q/_ -.EW7U70 5^?_\ P6F&/V6_"V1@'QG:]_\ IQOJ_0"OS_\ ^"U7_)K/
MA;_L<[7_ -(;Z@#\8;+2[S4M_P!EM9KG9C=Y2%L9Z9Q5G_A%]8_Z!EW_ -^6
M_P *[3X2?ZO5/]Z/^35Z#7Z3D_"E',L%#%3JM.5]++HVCZK Y-#%T(UG-JYX
M5_PB^L?] R[_ ._+?X5)_P (SJ__ $#+O_ORW^%>XT5[/^HN'_Y_R^Y'H?ZN
MT_\ GX_N/"O^$7UC_H&7?_?EO\*/^$7UC_H&7?\ WY;_  KW6BC_ %%P_P#S
M_E]R#_5VG_S\?W'SY=6LUE,T-Q$\,J]4D4@COTK^J.OY??B)_P C9>_[L?\
MZ M?U -7Y3C*"PN)J4$[J+:^YV/C*]/V-65-=&T.HHHKC, HHHH **** "BB
MB@ HHHH **** "OE7_@J-_R8I\3?^X9_Z<[2OJJOE7_@J-_R8I\3?^X9_P"G
M.TH _)S]@+_DK.L_]@27_P!'P5][U\$?L!?\E9UG_L"2_P#H^"OO>OYJ\0?^
M1Q_VZOU/Z%X)_P"14O\ $PHHHK\Q/T **** /@K]OW_DK6B?]@2+_P!'SU^L
M'_!+G_DQ;X:?]Q/_ -.=W7Y/_M^_\E:T3_L"1?\ H^>OU@_X)<_\F+?#3_N)
M_P#ISNZ_K[AO_D3X7_"C^7N(O^1KB/\ $?5=%%%?2GS84444 %%%% !1110
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M2?[QK[VKX)F_UDG^\:^8SC>G\_T/S'C7>A\_T/ZHD^ZOTIU-3[J_2G5\V?F
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M_FM_:N_Y.I^,7_8Z:S_Z734#CNC]#?@__P DE\$?]@.Q_P#1"5U_<5R'P?\
M^22^"/\ L!V/_HA*Z_N*_C+,_P#?Z_\ BE^;/ZTR_P#W2E_A7Y!1117DGH'P
M5^W[_P E:T3_ + D7_H^>OT,_P""*W_)K7BG_L<[K_TAL:_//]OW_DK6B?\
M8$B_]'SU^AG_  16_P"36O%/_8YW7_I#8U_7W#?_ ")\+_A1_+W$7_(UQ'^(
M^_Z***^E/FPHHHH **** "BBB@#\K/\ @N9_S13ZZW_[85^>'PE_U>I?6/\
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M>G\_T/S'C7>A\_T/ZHD^ZOTIU-3[J_2G5\V?F T5_,G\$_\ DLW@G_L.6?\
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M<_\ )BWPT_[B?_ISNZ_K[AO_ )$^%_PH_E[B+_D:XC_$?5=%%%?2GS84444
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M?M37XK?M+?\ *9+1_P#L<_"?_HG3J /VIHHHH ^ /^"U'_)K?A;_ +'*U_\
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M_P!.=I7U57RK_P %1/\ DQ3XF_33/_3G:4 ?B'\!O^2J:-])O_1+U]<5\C_
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MI, 2QYX)P""5W ;ER ?2=%%% !1110 4444 %%%% !1110 4444 %?G_ /\
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ME]8__9J_0_\ X+F?\T4^NM_^V%?GA\)?]7J7UC_]FKZOA;_D;4?G^3/:R?\
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MVKA/]VI^B_)'\D8[_>:GJ_S/6:6DI:[#B"BBB@ HHHH **** "BBB@ HHHH
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M"(3[#?\ 7-8'_!.'X+^./VE/VH)/CIXT-U=Z3I=[+JD^K7D>U=1U!@RQQ1<
M8C)W?(-J"-$P 0  ?LW1110 4444 %%%% !1110 4444 %%%% !7Y_\ _!:K
M_DUGPM_V.=K_ .D-]7Z 5^?_ /P6J_Y-9\+?]CG:_P#I#?4 >J_\$N?^3$_A
ME_W$_P#TZ7=?5=?*G_!+G_DQ/X9?]Q/_ -.EW7U70 5^?_\ P6J_Y-9\+?\
M8YVO_I#?5^@%?G__ ,%JO^36?"W_ &.=K_Z0WU 'Y/?"3_5ZI_O1_P FKT&O
M/OA)_J]4_P!Z/^35Z#7]!\*_\BBC\_\ TIGZ9DW^Y0^?YA1117UI[@4444 >
M._$3_D;+W_=C_P#0%K^H!J_E_P#B)_R-E[_NQ_\ H"U_4 U?S)FW^_U_\4OS
M/R/&?[S4_P 3_,=1117E'&%%)2T %%%% 'R3\#?^4AG[3'_8+\-_^D=?6U?)
M/P-_Y2&?M,?]@OPW_P"D=?6U !1110 44FX>M+0 5\J_\%1O^3%/B;_W#/\
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M>V?\/J/@A_T*OQ _\%UC_P#)E?FU_P ,LP_]#&W_ (!?_;*3_AEF'_H8V_\
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M_EU[GY %>5?M8?\ )K/QD_[$S6?_ $AFKU6O*OVL/^36?C)_V)FL_P#I#-2
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M4 %%%% 'Y6?\%S/^:*?76_\ VPK\\/A+_J]2^L?_ +-7Z'_\%S/^:*?76_\
MVPK\\/A+_J]2^L?_ +-7U?"W_(VH_/\ )GM9/_OU/Y_D>A4445_0I^G!6!X\
M_P"12O\ Z)_Z&M;]8'CS_D4K_P"B?^AK7D9M_P B^O\ X9?DSAQW^ZU/\+_(
M^E?^"*O_ "=/XH_[$VZ_]+;&OVJK\5?^"*O_ "=/XH_[$VZ_]+;&OVJK^9C\
ME"OE7_@J)_R8I\3?IIG_ *<[2OJJOE7_ (*B?\F*?$WZ:9_Z<[2@#\0_@-_R
M531OI-_Z)>OKBOD?X#?\E4T;Z3?^B7KZXKZ_)_X,O7]$?L7!O^XS_P 3_)!1
M117N'W85\$S?ZR3_ 'C7WM7P3-_K)/\ >-?,9QO3^?Z'YCQKO0^?Z']42?=7
MZ4ZFI]U?I3J^;/S :*_F3^"?_)9O!/\ V'+/_P!'I7]-@K^9/X)_\EF\$_\
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ML^*7Q>\$^#9/AOI5I%X@UNSTN2XAOYG>%)ITC:0 K@[58GGTK]1LB@!:_/\
M_P""U7_)K/A;_L<[7_TAOJ_0"OS_ /\ @M5_R:SX6_['.U_](;Z@#U7_ ()<
M_P#)B?PR_P"XG_Z=+NOJNOE3_@ES_P F)_#+_N)_^G2[KZKH *_/_P#X+5?\
MFL^%O^QSM?\ TAOJ_0"OS_\ ^"U7_)K/A;_L<[7_ -(;Z@#\GOA)_J]4_P!Z
M/^35Z#7GWPD_U>J?[T?\FKT&OZ#X5_Y%%'Y_^E,_3,F_W*'S_,****^M/<"B
MBB@#QWXB?\C9>_[L?_H"U_4 U?R__$3_ )&R]_W8_P#T!:_J :OYDS;_ '^O
M_BE^9^1XS_>:G^)_F.HHHKRCC/E7_@J+_P F*_$S_N&?^G.TK\@?V5_]5XE^
MMM_[5K]?O^"HW_)BGQ-_[AG_ *<[2OR"_97_ -5XE_WK;^4M>GEO^]0^?Y'T
M_#7_ "-:/S_)GO-%%%?;G[OJ%%%% :A7R/\ 'K_DJFL_2#_T2E?7%?(WQZ_Y
M*IK'T@_]$I7B9Q?V,?7_ #/@^,?]QA_B7Y,_H1_9._Y-9^#G_8F:-_Z0PUZM
M7E/[)W_)K/P<_P"Q,T;_ -(8:]6KY _'0KY5_P""HW_)BGQ-_P"X9_Z<[2OJ
MJOE7_@J-_P F*?$W_N&?^G.TH _)S]@+_DK.L_\ 8$E_]'P5][U\$?L!?\E9
MUG_L"2_^CX*^]Z_FKQ!_Y''_ &ZOU/Z%X)_Y%2_Q,****_,3] "BBB@#X*_;
M]_Y*UHG_ &!(O_1\]?K!_P $N?\ DQ;X:?\ <3_].=W7Y/\ [?O_ "5K1/\
ML"1?^CYZ_6#_ ()<_P#)BWPT_P"XG_Z<[NOZ^X;_ .1/A?\ "C^7N(O^1KB/
M\1]5T445]*?-A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?BM^TM_RF2T?_L<_"?\ Z)TZOU?U;]IK
MX/:#JEYIFI_%?P/IVI64SVUU9W?B.SBF@E1BKQNC2 JRL""I&000:_(OXV>+
M-#\<?\%=/#VM^'-9T_Q!HMUXS\*^1J.EW27-O+MCL$;9(A*MAE93@\%2.HH
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MS'Y*%?*O_!43_DQ3XF_33/\ TYVE?55?*O\ P5$_Y,4^)OTTS_TYVE 'XA_
M;_DJFC?2;_T2]?7%?(_P&_Y*IHWTF_\ 1+U]<5]?D_\ !EZ_HC]BX-_W&?\
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M?S6_M7?\G4_&+_L=-9_]+IJ!QW1^AOP?_P"22^"/^P'8_P#HA*Z_N*Y#X/\
M_))?!'_8#L?_ $0E=?W%?QEF?^_U_P#%+\V?UIE_^Z4O\*_(****\D] ^"OV
M_?\ DK6B?]@2+_T?/7Z&?\$5O^36O%/_ &.=U_Z0V-?GG^W[_P E:T3_ + D
M7_H^>OT,_P""*W_)K7BG_L<[K_TAL:_K[AO_ )$^%_PH_E[B+_D:XC_$??\
M1117TI\V%%%% !1110 4444 ?E9_P7,_YHI]=;_]L*_/#X2_ZO4OK'_[-7Z'
M_P#!<S_FBGUUO_VPK\\/A+_J]2^L?_LU?5\+?\C:C\_R9[63_P"_4_G^1Z%1
M117]"GZ<%8'CS_D4K_Z)_P"AK6_6!X\_Y%*_^B?^AK7D9M_R+Z_^&7Y,X<=_
MNM3_  O\CZ5_X(J_\G3^*/\ L3;K_P!+;&OVJK\5?^"*O_)T_BC_ +$VZ_\
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M^\U/5_F>LTM)2UV'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *0WU 'JO_!+G_DQ/X9?]Q/_ -.EW7U77RI_P2Y_Y,3^&7_<3_\ 3I=U]5T
M%?G_ /\ !:K_ )-9\+?]CG:_^D-]7Z 5^?\ _P %JO\ DUGPM_V.=K_Z0WU
M'Y/?"3_5ZI_O1_R:O0:\^^$G^KU3_>C_ )-7H-?T'PK_ ,BBC\__ $IGZ9DW
M^Y0^?YA1117UI[@4444 >._$3_D;+W_=C_\ 0%K^H!J_E_\ B)_R-E[_ +L?
M_H"U_4 U?S)FW^_U_P#%+\S\CQG^\U/\3_,=1117E'&?*O\ P5&_Y,4^)O\
MW#/_ $YVE?D%^RO_ *KQ+_O6W\I:_7W_ (*C?\F*?$W_ +AG_ISM*_(+]E?_
M %7B7_>MOY2UZ67?[U#Y_D?3\-?\C6C\_P F>\T445]R?NP4444 %?(WQZ_Y
M*IK'T@_]$I7US7R-\>O^2J:Q](/_ $2E>'G'\&/K^C/A.,?]QA_B7Y,_H1_9
M._Y-9^#G_8F:-_Z0PUZM7E/[)W_)K/P<_P"Q,T;_ -(8:]6KY _'0KY5_P""
MHW_)BGQ-_P"X9_Z<[2OJJOE7_@J-_P F*?$W_N&?^G.TH _)S]@+_DK.L_\
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MD_[$S6?_ $AFKU6O*OVL/^36?C)_V)FL_P#I#-2 _G0^&_\ R4#P[_V$(/\
MT8M?:U?%/PW_ .2@>'?^PA!_Z,6OM:OJ<G^"9^K\%_P:WJ@HHHKZ(_1@KXI^
M)'_)0/$7_80G_P#1C5]K5\4_$C_DH'B+_L(3_P#HQJ^=SCX(>I^<\9_P:/JS
M^B[]D[_DUGX.?]B9HW_I##7JU>4_LG?\FL_!S_L3-&_](8:]6KY8_* K^:W]
MJ[_DZGXQ?]CIK/\ Z735_2E7\UO[5W_)U/QB_P"QTUG_ -+IJ!QW1^AOP?\
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M3^"?_)9O!/\ V'+/_P!'I7]-@K^9/X)_\EF\$_\ 8<L__1Z5R8K_ '>IZ/\
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M-A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\*/Y>XB_P"1KB/\1]_T445]*?-A1110 4444 %%%% 'Y6?\%S/^:*?76_\
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M110!X[\1/^1LO?\ =C_] 6OZ@&K^7_XB?\C9>_[L?_H"U_4 U?S)FW^_U_\
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MKZG)_@F?J_!?\&MZH****^B/T8*^*?B1_P E \1?]A"?_P!&-7VM7Q3\2/\
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M[K^ON&_^1/A?\*/Y>XB_Y&N(_P 1]5T445]*?-A1110 4444 %%%% !1110
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M "BDR*,B@!:*3(]:6@ K\_\ _@M5_P FL^%O^QSM?_2&^K] *_/_ /X+5?\
M)K/A;_L<[7_TAOJ /5?^"7/_ "8G\,O^XG_Z=+NOJNOE3_@ES_R8G\,O^XG_
M .G2[KZKH *_/_\ X+5?\FL^%O\ L<[7_P!(;ZOT K\__P#@M5_R:SX6_P"Q
MSM?_ $AOJ /R>^$G^KU3_>C_ )-7H->??"3_ %>J?[T?\FKT&OZ#X5_Y%%'Y
M_P#I3/TS)O\ <H?/\PHHHKZT]P**** /'?B)_P C9>_[L?\ Z M?U -7\O\
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M3IU>J?\ #\[_ *HG_P"79_\ <5?%OQ*_:L'Q#_;&M/CQ_P (Q]@\C6=)U?\
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M9_K5E/\ S]_!GWW]LX+^?\&=_5/7/^0+?_\ 7O)_Z":XW_A;47_0-;_O]_\
M8U!?_%".\LIX%L"#*C)N\W[N01Z>]<V+XFRNIAYPC4U::V9C6S?!SI2BI=.S
M-/\ 91!_X:H^#W'3QGHW_I=#7]*5?S"_"GQX/AC\4O!_C+[%_:7_  CNM66K
M_8?.\K[1]GG27R]^UMN[9MW8.,YP>E?I+_P_._ZHG_Y=G_W%7X,]S\Y/U5KR
MK]K C_AEGXQ_]B9K/_I#-7Y__P##\[_JB?\ Y=G_ -Q5ROQ8_P""R ^)_P +
M/&7@[_A47]FGQ%HU[I'VW_A)?-\@7$#Q>9L^QKNV[\[<C..HZT@/S[^&P/\
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M )%'4/HG_H:U@?\ "V8NVG,?^VW_ -C6?K_Q#CUO1Y[);(Q&7 #M+NVX(/\
M='I7G9AQ)EM?!U:5.?O.+2T\CDQ6;82K0G",M6GT?4^Q?^"*_'[4_BC/'_%&
MW7_I;8U^U-?SL?L7_M5#]D#XIZIXR_X1C_A+?MNC2Z1]B.H?8]F^:"7S-_E2
M9QY&W;C^+.>,'[2_X?G?]43_ /+L_P#N*OPT_/3]5:^5?^"HG_)BGQ-_[AG_
M *<[2OE3_A^=_P!43_\ +L_^XJ\L_:@_X*L#]I#X%^)OAQ_PJ_\ X1S^VOLW
M_$R_X2#[5Y/E7,4_^K^RINW>5M^\,;L\XP0#Y!^ W_)5-&^DW_HEZ^N:^*?
M/BL>"_%EEK)M_M8M]^8?,V;MR%/O8/\ >].U>O?\-2P_]"VW_@:/_C=?1Y=C
M*.'IN-1ZL_2.&\XP>7X65/$2L^:^W2R/>**\(_X:DA_Z%QO_  -_^UT?\-20
M_P#0N-_X&_\ VNO4_M+"_P WX,^M_P!9LL_Y^?@SW>O@B;_6R?[QKW__ (:F
MA_Z%QO\ P-'_ ,;KY_D;=(Q/<YKP\RQ%/$.'LWL?"<3YGA<Q]E]6E?EO?\#^
MJ./[J_2G5^50_P""YF,#_A2?_EV?_<5'_#\[_JB?_EV?_<5>(?"GZIBOYD_@
MGG_A<W@G_L.6?_H]*_1D?\%S,_\ -$__ "Z__N*OS-\#^)1X0\9:'KQ@^U#3
M+Z&\^S[]GF>7(K[=V#C.W&<'&>E85Z<JE&<([M,ZL+)4Z\)RV31^N-%?'G_#
MPZ'_ *$1O_!O_P#:*/\ AX=#_P!"(W_@W_\ M%?S&^!L\O\ PE_X%'_,_HA<
M79.E;VOX,^PZ*^//^'AT/_0B-_X-_P#[12?\/#H?^A$;_P &_P#]HH7 V>77
M[I?^!1_S!\79/;^+^#/FOXY _P#"Y/'''_,;O?\ T>]?T*?LF?\ )K/P<_[$
MW1__ $AAK^=+QQXE'C#QEKNO+!]D&I7TUY]GW[_+\R1GV[L#.,XS@9QTK]"/
MA/\ \%CE^%_PK\'>#O\ A40U(^'='L](^V_\)+Y7G_9X4B\S9]C;;NV;MN3C
M/4]:_IO#PE3HPA+=)'\[XJ2J5YSCLVS]?J6ORJ_X?G?]43_\NS_[BH_X?G?]
M43_\NS_[BKH.4_53(I:^5/V&_P!N;_ALX^-/^*)_X0\>'/L7_,6^W?:?M'VC
M_IA%LV_9_?.[MCGZKH **** "BBB@ HHHH **** "BBB@ HHHH **** $S7X
M@?$7Q!\6O^"G7[3'B7PGX,UF./PAIK32Z?97EY)#I=O90R+&EQ($5MTDC%6S
MM9@7P/E7(_:[Q YCT#4G4E66VD((X((4D5^37_!$, _$;XGG W#2K, XY_US
MYY_ 4 <Y^R;\1OBA^PW^V%I7P6\?:M)<>&]6NH-,FT_[4]Q9(UP +:ZM2P&P
M>8ZAC@94N&&5!7]FJ_'?_@I4?+_X*+?#-T.QQ:Z(VY>#G[?-@_7I7[#T ?&'
M_!43]I_6OV=?@IING^$]0;2_%GBNZ>SM[Z-L36MM$H:XEB]'^>) PP1YN000
M#7YN:Q^QS\?_  #\';?]HE]9:U$MO#JLEQ9ZO<+KD4$NW9<.0HXPR$XD+@')
M P<?1_\ P7$8G7OA N25%MJAQV&6M03^GZ5]K_M!(H_8%\:+@;1X!FX Z?Z%
MQ0!C_L%?M03_ +0'[+T'BSQ5=Q'7?#[SZ=KMWM"+(T*+)YY4# W1/&S8&-V_
M  &!^:FHZU\<?^"IWQLU[2] U+^S_"]HK7$&EWUU);Z5IEH'Q#YJQA]\[G&6
MVLQ;=C:B@+ZY_P $\[B6'_@GW^U(\<CQM'IFIR(5."K#2GY'H>!S[5\M_LF_
MM!?%GX1Z;XK\-_!7P[<:GXO\1-;3W&H:?I;:G=V]M;B0!8[<(Z@%I\L[*P^Z
M,9YH ^F_V _&7Q>_9E_:RF^!_BV/4=1\-/</IEY;J\ES:6$WE>;;W,#8PB.K
M1<?+E9E+ , *_7S(]:_+?]C3_@I3\1KSXU:?\*/CI9@W^J7:Z=!J5QIPT^^M
M+QR!'%<0A57:Y*J,(I4L,[@>/J?_ (*#>-OC'X ^#&BZA\$+;6+KQ9)X@AM[
ME=&T1=5F%D;:Y9R8FAEPOF+#\^.I S\V" ?45?G_ /\ !:KG]EKPMCG_ (K.
MU_\ 2&^KY6_X:6_X*&?] CX@?^&XA_\ D&N!^-.M?MG_ +0WA>T\.?$#P5X^
M\0:+:WBZA#:_\((UOMG5'C#[H;1&^[*XQG'/3@&@#]//^"7/_)B?PS_[B?\
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M:CO*"L['XYFN+ACL;5Q-/:3N?NE17XK?\-+?\%"_^@1\0/\ PW$/_P @T?\
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M,_\ ROZG_P#)-?5=% 'RI_PZY_9C_P"B9_\ E>U/_P"2:/\ AUS^S'_T3/\
M\KVI_P#R37U710!\J#_@EU^S&?\ FF?_ )7]3_\ DFC_ (=<_LQ_]$S_ /*_
MJ?\ \DU]5T4:@?*G_#KG]F+_ *)E_P"5_5/_ ))H_P"'7/[,7_1,O_*_JG_R
M37U710!\J?\ #KG]F+_HF7_E?U3_ .2:/^'7/[,7_1,O_*_JG_R37U710!\J
M?\.N?V8O^B9?^5_5/_DFC_AUS^S%_P!$R_\ *_JG_P DU]5T4 ?*G_#KG]F+
M_HF7_E?U3_Y)H_X=<_LQ?]$R_P#*_JG_ ,DU]5T4 ?*G_#KG]F/_ *)E_P"5
M[4__ ))I/^'7?[,F3_Q;/_ROZI_\DU]644 ?*G_#KG]F/_HF?_E?U/\ ^2:/
M^'7/[,?_ $3/_P K^I__ "37U710!\J?\.NOV9.WPS_\K^J?_)-)_P .N_V8
M_P#HF7_E>U/_ .2:^K** /E3_AUS^S%_T3+_ ,K^J?\ R31_PZY_9B_Z)E_Y
M7]4_^2:^JZ* /E3_ (=<_LQ?]$R_\K^J?_)-'_#KG]F+_HF7_E?U3_Y)KZKH
MH ^4_P#AUS^S'_T3+_ROZI_\DTI_X)=_LR8_Y)E_Y7]3_P#DFOJNB@#\6/\
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M %\K[<>;)]W&<\YP,>KT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[%I;7""Y>!6"M*(\[B@9U!8# ) S6IF@!:*** "BBB@ HHHH **** "BBB@
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M@[LPJ.O<T =C^R;\6/&7QL^#EGXG\=^%6\&>(IKJ>"32FMIK<HB-A&V2_/\
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M-BT^&"6YN3&20)&CB5F1"0P#, &*G&<&NZ^&/Q2\*?&;P?9>*O!>MVVOZ#>
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M;?4+.&*6XD&&EN XC5VC"[54EB&)?NN2 ?$'[3G_ "EB/_8YZ#_Z#9U]F?\
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M?\%'/VHM3_9@^!*W?AQ8?^$J\0W9TRPGN(A*EJ-C-+.4;Y795 55;(W.I(8
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M8V<8?7+SP[J=Q=7NY.9_/!R"_P!X>6P49PF  !V/_!-/P'\2/AU^V9H-_>>
M/$OACPYJUOJ%C>27VE745O#"8'FCC:61,?ZV&$ L>3CO7)_"G_@JU\8OA1\)
M[/P/:VN@:PNFVJV6F:MJ=M*]S;0J-JJVV15DV+M"Y7C:-V_I7UU_P2U^)G[0
MGQNUG5_$OCKQ;?ZI\-+*V:VMO[0LX U]>E@!Y<OEARL:A]QW8RR#!YP ?#G[
M;GB+4/'7[>OC5YM&E\5-;:]%IT&A*9G^UQ6ZQQBV41$2 .$.?+(;+L1AN:Z/
MXD:EXL^(7@BZ\/0?L;67A>XDC M]8T+PQJ4%Y;L",,&Q\_3!#[@0>>>:[3_@
MIS\&?%WP'_:D7XP>'5NK72-;NK?5;+6+1"RV.HPA R.V,*Q=!(H;AMQ SL;'
M/_$#_@KE\</&W@JWT.T_L/PK?AE:XUO1+>5;J3:P90HDD=4SCYL+SG V@D$
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MPJ&!;:K8&0%RS 4 ?T#44@Z#-+0 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]BA:33[IAB:5E49,,N2S-SAF?=@$5S>F_MW:[\4/V<M+_9R^%?P:M]-UG5;
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MAW_P4$U6/]F>U^ ?PV^$-O#XJU2QDT8WNFS/<?:C+'LFN1;+'N:=U+G)<A2
M3E1L'Z0?L _LS7W[+7[/]IX?UMD?Q/JEV^K:LL+!T@F=$1858<,$2- 2.-Q;
M&1S7T!9>&=)TR^FOK/2K.UO)L^9<0VZ)(^>?F8#)YYYK6H **** "BBB@ HI
M* P.<$&@#\??VIHK#X]?\%4-)^'/Q/U2YT_P'8S6NF6ENESY2A9+);A%#'@&
M>X=(V888AE7.5!%C]MG_ ()IW?P)LQ\4/@=/JZZ;I)^TWVE17+O>:8$Y%S;2
M@^8R+R6!)9.6R5SL]J_X*J?L;ZG\5=+L_BQX%M)+KQ;X>MO*U6QMB?.N;)"S
MI-&HY,L3%N!RRGCE #)_P3P_X*-6'Q8TO3_AS\3M3BLO'%NJP:?J]VRQQ:N@
M "HSD\7/Y;\#&6R" <W^SI\7O!__  4Z^#-Y\)?B_#%!\1]%@%Q9ZS:JL<]P
MH 7[9",;4D!*B6/[K!@0 #A/&K?]AG]L+]EWQ-J-A\(]7N=4T74&P;[0=5@M
M89N<*TUO<.NR3 ^\-P7H'-+^TE\-]._93_X*5?#C4/AK*EE_;FI6.IMH]HP)
MM7N;I[>XMU7^".9"^%R,"5@NT!:_96@#XO\ V ?V&M5_9PDUSQU\0-477?B=
MXA5X[F19C<+:1-)YCCS6^:661P'=\XR !GEF^T*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9>:YD-O&V/F52S9;H69L<8KWNBB@ HHHH **** "OR#_ ."Q'PK^*K>.-/\
M'%]?3:Y\+8T2VL(+5"L>BSL%#K,H/)E89$W?(0XVIG]?*QO%/A72O''AS4M
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MC?Q598;3H(872ULYL8\YF=BTK@<+D*J_>P6"E?O2BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>kros-20251231_g8.jpg
<TEXT>
begin 644 kros-20251231_g8.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +; ZL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6OV[/B)H/C_Q3\8;?0=%\$W4,UCX;T.>,W<)BPJD6G*Q(PW+YTP=F&5VLIX
M/UNHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC.T\4#1EU8!A;/&5)!'3@CBOGSX=_P#!%O2-/\4V5YX^^)=YXLT*RVA=)L;
MV32HK B-IC-(4C/S J@#8;Y74\U^DVG:;;:186UC901VME:Q+#!;PJ%2*-0%
M55 Z  8 ':@#X*_X<J_!#_H:?B!_X,+'_P"0ZXOXW?\ !(SX/_#3X+^/O%VF
M>)?'$^I:!X?U#5;6*[OK-H7E@MI)45PMJI*DH 0"#C.".M?IG7E/[6/_ ":S
M\9/^Q,UG_P!(9J /E7_@BO\ -^RSXI[#_A,[K_TAL:_0"OS_ /\ @BK_ ,FL
M^*?^QSNO_2&QK] * "BBB@ HHHH **** "F[J=7E'[6"A?V6?C'_ -B9K/\
MZ0S4 >K9HS7X6?L5?\$W_P#AL'X6ZKXR_P"%B?\ ")?8=9ETC[%_8GVW?L@@
ME\S?]HCQGS\;=I^[G/.!] ?\.,?^JV_^6I_]VT ?JGFC-?E9_P .,?\ JMO_
M ):G_P!VT?\ #C'_ *K;_P"6I_\ =M 'ZIYHS7Y6?\.,?^JV_P#EJ?\ W;1_
MPXQ_ZK;_ .6I_P#=M 'ZIYHS7Y6?\.,?^JV_^6I_]VT?\.,?^JV_^6I_]VT
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MD[[V1$4_-*P&%' '4Y)_92ORK_YSK_Y_Z%B@#]5**** "BBB@ HHHH ****
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MUK\P/V@/^"D'A?XZ?LO_ !,^'WBGPYJ?P\^(WEK;II%]$\D4SI<QDH'VAHY
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M!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y3^UC_P FL_&3_L3-9_\
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MY-5DEUJ:*682O%%$5!CCC&W;"AQC.2>>@'L-% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKRG]K'_DUGXR?]B9K/\ Z0S5ZM7E/[6/_)K/QD_[$S6?_2&:@#Y5_P""*O\
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M#\K/^'YW_5$O_+K_ /N*C_A^=_U1+_RZ_P#[BK]4Z* /RL_X?G?]42_\NO\
M^XJ7_A^8>?\ BR?_ )=?_P!Q5^J5? /_  6H^7]EGPOC_H<K4?\ DC?4 ?:G
MPG\=?\+0^%G@WQE]A_LS_A(M&L]7^Q>;YOV?[1 DOE[]J[MN_&[:,XS@=*ZN
MO*?V3O\ DUGX.?\ 8F:-_P"D,->K4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %-W?X4ZOR;^(G[4W[0O[8'[2WB
M/X8? C5E\)^']#DN$-S!*D!DA@D$374]P5+A6D("I'V=<AL%@ ?K$&S1N]J_
M*'X/_M4?M ?LL_M4>'_A!\<=6_X2_2]=N;6U6>25+B2);F3RX;J"<!79/,.&
M20$[5;"@]?<O^"EW[9?BOX#KX7^'GPSD6+QYXE7SY+I8%GGM;8OY<8BC8$>9
M+(' 8@X$;8&2"H!]V;O_ *W-.K\=_&GQ5_; _82\0>$/%/Q+\3_\)=X8U>XV
MW.FW-ZE[#(0H,ELSE-T,NTDAHSMRO5P"#^MWA#Q;I_CCPEHGB329#/I6L64.
MH6DI&"T,L:R(3_P%AQ0!M5Y3^UC_ ,FL_&3_ +$S6?\ TAFKU:O)_P!K!P?V
M6?C&.G_%&:S_ .D,U 'RO_P15_Y-9\4_]CG=?^D-C7Z 5^?_ /P15_Y-9\4_
M]CG=?^D-C7Z 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?FO\6/^"R'_"K_ (I>,O!O_"H?[3_X1W6;S2/MW_"3>5]H\B=XO,V?9&V;
MMF=NXXSU/6N2_P"'Y7;_ (4I_P"77_\ <5?%OQ<T>S\1?MX>.=*U&'[187OQ
M'O[:>+<5WQOJ;JRY4@C()Y!S7UA_PR+\)?\ H4E_\&%W_P#':^4SKB7!Y#*$
M,4I/GVLD]O5H^HR?AW%9U"53#RBN7NW^B9T/_#\HY_Y(I_Y=?_W%2_\ #\P_
M]$3_ /+K_P#N*N=_X9#^$G_0I+_X,+O_ ..T?\,A_"3_ *%)?_!A=_\ QVOF
M/^(BY1_)4^Y?_)'T7^H>9_SP^]_Y&OJW_!;PZII5Y9?\*6\O[3 \._\ X2G.
MW<I&<?8N>M>=?LS_ /!6 _LZ_ _PQ\/#\+3XA_L1)D_M+_A(?LWG>9<23?ZO
M[*^W'F;?O'.W/&<5UW_#(?PD_P"A27_P87?_ ,=H_P"&0_A)_P!"DO\ X,+O
M_P".T?\ $1<H_DJ?<O\ Y(/]0\S_ )X?>_\ (Z+_ (?F'_HB?_EU_P#W%2?\
M/RL8_P"+)G_PJ_\ [BKGO^&0_A)_T*2_^#"[_P#CM'_#(?PD_P"A27_P87?_
M ,=H_P"(BY1_)4^Y?_)!_J'F?\\/O?\ D='_ ,/S/^J)_P#EU_\ W%2_\/R#
M_P!$4_\ +K_^XJYO_AD3X2_]"BO_ (,+O_X[7R-^U]\-_#GPO^(FF:9X9TW^
MS;*;2X[EXO.DES(99E)R[,>B+QG'%>YD_%V SK$?5<-&2E:^J5OP;/'S3A;&
M93A_K-:47';1N_Y'] OPF\=?\+0^%?@WQE]A_LS_ (2+1K+5_L7F^;]G^T0)
M+Y>_:N[;OQNVC.,X'2NKKRG]D[_DUGX.?]B9HW_I##7JU?;'QH4444 %%%%
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MYWD_:_,_U$K[<>;'][&=W&<' !^@%%%% !1110 4444 %%%% !1110 4444
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MWO\ HW+_ ,L;7/\ X_7*?%C]M?\ ; \6?"OQCHGB?X"_V/X;U+1KRRU/4/\
MA#M8@^RVLD#K--YDDQ1-J%FW,"HQDC%?K]7E/[6"X_99^,>#Q_PANL\8_P"G
M&:@#Y6_X(J_\FL^*?^QSNO\ TAL:_0"OS_\ ^"*O_)K/BG_L<[K_ -(;&OT
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M*]CKUQ)%>G[0CQA%%RA\P[E9^)QN^7C'.?N?;1M_SB@!U%%% !1110 4444
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M(Z@@@_C0!H;O:C=7Y\?'#_@I5/\ \+^\#> OA3;_ &W1'\3V^A^(?$-]8O\
M9Y)6N$BDMK<L%^9 6)<\'*[01\Q^D_VB_$GQMM]>\&^'/@[X>TETU>>4:OXK
MUXF6VTB)!E<0JZN[M\V#@K\H4CY\J >Z;N^*=7RS^QK^TOXL^,/BKXJ> /'5
MMI,_BGX>ZHNG7&L:"'2SOU+S1YV,24<- V1D [N@VFOJ:@ K\J_^<Z_^?^A8
MK]5*_*O_ )SK_P"?^A8H _52BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KQGX_\ [7GPR_9CO-&M?B!K-QI4VL)+)9B&QFN-ZQE0
MY)C4XP77KZU[-3=G/6@#Y"_X>O\ [-W_ $-VH?\ @DN__C='_#U[]F__ *&[
M4/\ P27?_P ;KZ^VBOE__@IDH'[#WQ/_ .N-D?\ RH6QH P?^'KW[-P_YF[4
M,_\ 8$N__C='_#U_]F[_ *&[4/\ P27?_P ;KZG\)_\ (JZ-_P!>4)_\<6M?
M:* . ^"?QT\(?M"^"AXL\$7\NI:)]HDM?/FMI+=O,3&X;74'N.<5Z!3=N.E.
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIN[VHW4 .HINZC
M?0 ZBF[J=0 4444 %%%% !1110 5Y3^UC_R:S\9/^Q,UG_TAFKU:O*?VL?\
MDUGXR?\ 8F:S_P"D,U 'RK_P15_Y-9\4_P#8YW7_ *0V-?H!7Y__ /!%7_DU
MGQ3_ -CG=?\ I#8U^@% !1110 44E-\SVH ?3=U+NKSKXV>%_B'XJ\-V=K\-
MO&UGX$UB.[66?4+[2EU%)(-C QA'( )8JV[_ &<=\T >BT5\J_\ "F_VKO\
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MFH66C:QY_P!GM]4CC2X7RO#\D#;UC=U&6B8C#'@CH>!]T_\ #KC]F+_HF?\
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M_P",XOB$,?\ -0]1_34I*J,>:5C6E#VE2,.YV7_#T']I_P#Z*4W_ (3^F?\
MR+1_P] _:?\ ^BDM_P"$_IG_ ,C5Z;17T?\ 8W]_\/\ @GZ2N"VU_'_\E_X)
MYE_P] _:?_Z*2W_A/Z9_\C5'=?\ !3C]IJ\MI;>;XC-)#*A1T.@:9AE(P1_Q
M[>AKU&BC^QG_ ,_/P_X(?ZE/_G__ .2_\$\/^'?[?GQ\^$_@W3O"GA/QJNC>
M'M.#K:V,6AZ>ZQ!G:1L%[<L<L['DGK71_P##T#]I_P#Z*2W_ (3^F?\ R-7I
MM%']C/\ Y^?A_P $/]2G_P __P#R7_@GF7_#T#]I_P#Z*4W_ (3^F?\ R-1_
MP] _:?\ ^BDM_P"$_IG_ ,C5Z;11_8W]_P##_@A_J4_^?_\ Y+_P3S-O^"GW
M[3RG!^)6/^X#IG_R-7[;_L]^)]4\<? 3X:^(];N_MNM:QX9TS4+ZY\M8_.GE
MM8Y)'VH JY9B<* !V K\ /VG#CQIIQQS_9Z<_P#;26OWK_9/7/[+/P<YX_X0
MS1O_ $AAKP*U/V-25.^Q^?X[#?4\1/#WORGJ]%%%8G"%%%% '\\GQ!_Y2%>+
M/^RG7G_IU>OT%K\^OB#_ ,I"O%G_ &4Z\_\ 3J]?H+7X-XE?QL-Z/\T?MO '
M^[UO5?D%%%%?BI^L!1110 4444 %?!7[?O\ R5K1/^P)%_Z/GK[UKX*_;]_Y
M*UHG_8$B_P#1\]?IOA[_ ,CC_MU_H?G_ !M_R*G_ (D?MK^R=_R:S\'/^Q,T
M;_TAAKU:O*?V3O\ DUGX.?\ 8F:-_P"D,->K5_2Q_/04444 %%%% !1110!\
MB_MP?LF_!;XR7.F>/?B]XWU7P5::1:#38KFVU*UM8&W2-( ?.AD+.2QP%/0=
M.*^+/^&;?V ^0/C[XK_\"8O_ )75Z#_P5U\-ZUX\^.?P)\(7.I_V/X4UN8V,
M=],";>WNI;J**69UR-VR-X6ZCC=R,FNX@_X(H_"M88Q/XY\8/-@;FC:T56/<
MA3"<#VR: .>_93^!_P"Q[X5_:"\(:K\-OB_XB\2^-[>68Z;I=Y/&T4[&WD5P
MP%E&>$+M]]?N_@?TUKXK^!/_  2S^'?P"^+'A[Q]HOBKQ/J&IZ+)))!;7[VQ
MA<O$\1W!85;@2$\$<@5]J4 >*?M+?LC^!OVK=/T*R\;OJBP:-++-:_V9<K =
MT@4-N)5L\(*]7LO#UK8>'(-$B,GV*&U6S7<<OY80(,G'7 ZUJ44 >&?LR?L<
M^ ?V3?\ A)/^$'?5F_M_[-]L_M2Z6?\ U'F^7MPBX_U[Y_#TKDOC5_P3?^"'
MQT\67/B;6=!N])UV\?S+R[T.[-M]J;NSIADW$\E@H8D9)/-?4%% 'E_P)_9I
M^'7[-N@W.E^ /#T.CI=LKWEVSM-=73+G;YDSDLP7<V%R%7<V ,FO3MOIQ3J*
M &>6*?110!X-:?L7_#VR_:8;XZQMJ_\ PFYD>0J;M?LF7M#:G]WLS_JV/\77
MGVKV?Q!X;TSQ9H=_HVLV%OJFDW\+6]U9W<8DBFC889&4\$$5I44 ?'-G_P $
MFOV=[/Q.NK#P_JLUJKAUT>;5IFM.,'!Y\PCCH7.<\YKZ[TO2K/1=-M=/L+6&
MRL;6)88+:WB6.**-1A55% "@     #%6Z* "BBB@ HHHH *_*O\ YSK_ .?^
MA8K]5*_*O_G.O_G_ *%B@#]5**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 9QSZ5_+SX-\&ZO\ $#Q'::#H5K]MU6ZW^5!YBQ[MJ,[?,Q"C
M"JQY/:OZAMN*_G"_8^;=^T1X6],7?_I+-7!C\1/"8.MB86O",I*_=*^IWY?0
MCBL72H3T4I)/YL7_ (8]^+?_ $*R?^#.T_\ CM'_  Q[\6_^A67_ ,&=I_\
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MQ_;S_"3Q[!+]GN-)\0DQ0&;."JSNJA&SCY)0AR<#=UKZ8^*'Q4\*?!KP7?\
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MR2Y*",$\1D<'O7WG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7Y5_P#.=?\ S_T+%?JI7Y5_\YU_\_\ 0L4 ?JI1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "-TK^;_P#8]_Y.(\+?2[_])9J_I ;I7\W_
M .Q[_P G$>%OI=_^DLU>-G7_ "+,5_U[G_Z2SV,F_P"1EA_\<?S1^E=%%%?Q
MJ?U:%%%% !1110 4445I3^->I$_A9\,_\$O_ /D_'X;?[VJ?^FR[K]_*_ /_
M ()?_P#)^/PV_P![5/\ TV7=?OY7]O+8_C^7Q,****9(4444 %%%% !1110
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M*_;]_P"2M:)_V!(O_1\]?>M?!7[?O_)6M$_[ D7_ */GK]-\/?\ D<?]NO\
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MHH **** "BBBM*?QKU(G\+/AG_@E_P#\GX_#;_>U3_TV7=?OY7X!_P#!+_\
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M0 4444 %%%% !1110 4444 %%%% !7Y5_P#.=?\ S_T+%?JI7Y5_\YU_\_\
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MW\@8H =13/,]!FGT %?E7_SG7_S_ -"Q7ZJ5^5?_ #G7_P _]"Q0!^JE%%%
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M LX(9E;RTQN;+H!QD=Z /8J*** "BBB@ HHHH **** "O*?VL?\ DUGXR?\
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M (2GQ'>>*+_[99WDF+RYV>8(\70VI^[7"G)'/)K9_P"$'\-_]"_I7_@%%_\
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MZ_?ROP#_ ."7_P#R?C\-O][5/_39=U^_E?V\MC^/Y?$PHHHIDA1110 4444
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M*_;]_P"2M:)_V!(O_1\]?>M?!7[?O_)6M$_[ D7_ */GK]-\/?\ D<?]NO\
M0_/^-O\ D5/_ !(_;7]D[_DUGX.?]B9HW_I##7JU>4_LG?\ )K/P<_[$S1O_
M $AAKU:OZ6/YZ"BBB@ HHHH *XWXI_%_P?\ !/PR/$7C?7(/#^BF=+87EPKL
MOF,&*KA%)R0K=NU=E7D?[3G[-NA?M3?#5?!7B+4]1TK3UO8K[[1I9C$NZ,,
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M+< = (US_?%?>/[,O[?'PL_:DU-=$\-7&I:7XI^SM<OHNK6A238O#LLB%HV
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M %%%% !1110 5^5?_.=?_/\ T+%?JI7Y5_\ .=?_ #_T+% 'ZJ4444 %%%%
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MNT_X+<^-8[=5N?AIH,T_.YX[Z:->O&%(.,#'?M0!M?\ #CW5NO\ PMZS)_[
M#_\ R17O?[%G_!-N_P#V2_B]=>-;CQ];^)HIM*GTW['#I;6I!DDB??O,K=/+
M(QCOUKY=@_X*I_M)_&"ZETWX=_#S2GN&&U?[%T:[U*ZC/KGS&3TZI7U!^Q%\
M-/VI+CXI7/Q#^/'B:Y_LF72I;2U\/W5X@83221LLWV6 "",A4<9.'^8#&,X
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MQ[_R<1X6^EW_ .DLU?T@-TK^;_\ 8]_Y.(\+?2[_ /26:O&SK_D68K_KW/\
M])9[&3?\C+#_ ../YH_2NBBBOXU/ZM"BBB@ HHHH ****TI_&O4B?PL^&?\
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MW>MZK\@HHHK\5/U@**** "BBB@ KX*_;]_Y*UHG_ &!(O_1\]?>M?!7[?O\
MR5K1/^P)%_Z/GK]-\/?^1Q_VZ_T/S_C;_D5/_$C]M?V3O^36?@Y_V)FC?^D,
M->K5Y3^R=_R:S\'/^Q,T;_TAAKU:OZ6/YZ"BBB@ HHHH *;MR,4ZN;\=_$CP
MO\+]$&L^+]?T_P -:295@%]JEPL$/F-DJFYB!DA3Q[4 =%M[YK"N?A_X7O)O
M-N/#>D3R_P#/22PB9OS*UYQ_PV=\!_\ HK_@S_P=0?\ Q5'_  V=\!_^BO\
M@S_P=0?_ !5 'L$%K%:PK##&L,2\"-%P!] .E/6/:<YKS+PG^U!\(_'GB"ST
M+PY\2?"^MZS>,RV]A8:I#+-*54L0J*V3@*3^%>H4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^5?_.=?_/\ T+%?JI7Y5_\ .=?_ #_T+% '
MZJ4444 %%%% 'XK_ /!:;_DZ;PI_V)MI_P"EU]7/>!_^1)\/_P#8.M__ $6M
M=#_P6F_Y.F\*?]B;:?\ I=?5SW@?_D2?#_\ V#K?_P!%K7T&3_Q)>A^A\&_[
MS5]/U-NBBBOJS]:"BBB@ HHHH *^:?VG?^1TT[_L'I_Z,DKZ6KYI_:=_Y'33
MO^P>G_HR2O&S;_=_FCXWBS_D7?-'[W?LG?\ )K/P<_[$S1O_ $AAKU:O*?V3
MO^36?@Y_V)FC?^D,->K5\:?B@4444 (W2OYO_P!CW_DXCPM]+O\ ])9J_I ;
MI7\W_P"Q[_R<1X6^EW_Z2S5XV=?\BS%?]>Y_^DL]C)O^1EA_\<?S1^E=%%%?
MQJ?U:%%%% !1110 4445I3^->I$_A9\,_P#!+_\ Y/Q^&W^]JG_ILNZ_?ROP
M#_X)?_\ )^/PV_WM4_\ 39=U^_E?V\MC^/Y?$PHHHIDA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E/[6/\ R:S\
M9/\ L3-9_P#2&:O5J\I_:Q_Y-9^,G_8F:S_Z0S4 ?*O_  15_P"36?%/_8YW
M7_I#8U^@%?G_ /\ !%7_ )-9\4_]CG=?^D-C7Z 4 %%%% #6ZU_.G\:/^3Y/
MB%_V4/4O_3E)7]%C=:_G3^-'_)\GQ"_[*'J7_IRDK2G\:]4=6%_CP]5^9] 4
M445^C+8_I*.R"BBBF,**** "BBB@#YJ_:>_Y'/3O^P>G_HR2OWM_9._Y-9^#
MG_8F:-_Z0PU^"7[3W_(YZ=_V#T_]&25^]O[)W_)K/P<_[$S1O_2&&O@,;_O$
M_4_G[._^1C6]3U:BBBN,\,**** /YY/B#_RD*\6?]E.O/_3J]?H+7Y]?$'_E
M(5XL_P"RG7G_ *=7K]!:_!O$K^-AO1_FC]MX _W>MZK\@HHHK\5/U@**** "
MBBB@ KX*_;]_Y*UHG_8$B_\ 1\]?>M?!7[?O_)6M$_[ D7_H^>OTWP]_Y''_
M &Z_T/S_ (V_Y%3_ ,2/VU_9._Y-9^#G_8F:-_Z0PUZM7E/[)W_)K/P<_P"Q
M,T;_ -(8:]6K^EC^>@HHHH **** "O%/VMOV:;/]JWX5KX'O=>G\.PC4(;_[
M9;VZSMF-7&W:67J'/.>U>UU\:_\ !5C3/$>K?LKE/"]IJEYJ$6MVDLBZ3%))
M*L027<Q$8)"C(R>G(H \0_X<>^&_^BKZI_X)XO\ X[1_PX]\-_\ 15]4_P#!
M/%_\=K\V/ .HIXGOOL_B#XI7W@Y-P_TJ[BN[J';QD_N"SYZ\;/3GT^M/AW^P
MQ;_%EXXO"7[6?AC6;F096SBN)TN?^_+RB0?]\T ?7'[._P#P2GT7]GWXS>&O
MB!:?$/4-9N-%EED2QFTR.)9=\,D1!<2$C D)X':OO2OS[_9K_P""9OB_X&_&
M;PKXZU;XO2>(K?29)))M(^Q3*LY>"2/&]IB."X;E>W05^@E !1110 4W>/\
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M#^UE\=-%^%-S--\ K&&#[#"UQ+/;PZANC&;9I"?D<B].0?F58CD@ U^BHD%
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M][5/_39=U^_E?V\MC^/Y?$PHHHIDA1110 4444 %%%% !1110 4444 %%%%
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M%^*/QD\*^$_&_P %7\-:%J$DD=]K"Z)J-LD 6!W!!E)5 615^8G[W7T_06@
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MC)O^1EA_\<?S1^E=%%%?QJ?U:%%%% !1110 4445I3^->I$_A9\,_P#!+_\
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M21BL7+9C4#.3AEK])8;:.VACAAC2*&-0J1QJ%50!@ #L!0!\"_\ #E7X(?\
M0T_$#_P86/\ \AUQ7QN_X)%_!_X:_!?Q_P"+M,\2>-Y]1T#P_J&JVL-W?6;0
MO+!;22HKA;525+( 0"#@G!'6OTTKRG]K'_DUGXR?]B9K/_I#-0!\J_\ !%7_
M )-9\4_]CG=?^D-C7Z 5^?\ _P $5?\ DUGQ3_V.=U_Z0V-?H!0 4444 -;K
M7\Z?QH_Y/D^(7_90]2_].4E?T6-UK^=/XT?\GR?$+_LH>I?^G*2M*?QKU1U8
M7^/#U7YGT!1117Z,MC^DH[(****8PHHHH **** /FK]I[_D<]._[!Z?^C)*_
M>W]D[_DUGX.?]B9HW_I##7X)?M/?\CGIW_8/3_T9)7[V_LG?\FL_!S_L3-&_
M](8:^ QO^\3]3^?L[_Y&-;U/5J***XSPPHHHH _GD^(/_*0KQ9_V4Z\_].KU
M^@M?GU\0?^4A7BS_ +*=>?\ IU>OT%K\&\2OXV&]'^:/VW@#_=ZWJOR"BBBO
MQ4_6 HHHH **** "O@K]OW_DK6B?]@2+_P!'SU]ZU\%?M^_\E:T3_L"1?^CY
MZ_3?#W_D<?\ ;K_0_/\ C;_D5/\ Q(_;7]D[_DUGX.?]B9HW_I##7JU>4_LG
M?\FL_!S_ +$S1O\ TAAKU:OZ6/YZ"BBB@ HHHH *\;_:G_:3TK]E7X8KXUUG
M2+S6[1K^&P%K8.JR;I Y#?-Q@;/UKV2O%_VM/V9[']JWX2R>![_7+CP\GVR*
M^BOK>!9BLD8< ,A(W+\YX!!X'- 'R-_P^V^'_P#T3KQ+_P"!-O\ _%4G_#[C
MX?\ _1.O$O\ X$6__P 57C.L?\$N_CS\#;R74?A_-X&^(]LK!UM]4T>RDNGQ
MC(\J_A>-1QQMESUQ@\F.7]K?Q_\  6X^S_&C]D_PB]I&XB%]'X;73 Y]IS'+
M#)_P  9XH ^JO@#_ ,%4O!WQ^^+GAWX?Z9X)US3+[6I)(XKN[GA,<92)Y22%
M.<8CQQZBON*OAG]E?]O[X%?&WQ]H7@_0_ =QX+\77FY;&-]*MO(++&[LL<T)
MRN$1OO*@/3O7W-0 4444 %-V>].HH ;MYSFG444 %%%% #=M&WG.:=10 W;S
MFD6/;T/-/HH **** "BBB@ K\J_^<Z_^?^A8K]5*_*O_ )SK_P"?^A8H _52
MBBB@ HHHH _%?_@M-_R=-X4_[$VT_P#2Z^KGO __ ")/A_\ [!UO_P"BUKH?
M^"TW_)TWA3_L3;3_ -+KZN>\#_\ (D^'_P#L'6__ *+6OH,G_B2]#]#X-_WF
MKZ?J;=%%%?5GZT%%%% !1110 5\T_M._\CIIW_8/3_T9)7TM7S3^T[_R.FG?
M]@]/_1DE>-FW^[_-'QO%G_(N^:/WN_9._P"36?@Y_P!B9HW_ *0PUZM7E/[)
MW_)K/P<_[$S1O_2&&O5J^-/Q0**** $;I7\W_P"Q[_R<1X6^EW_Z2S5_2 W2
MOYO_ -CW_DXCPM]+O_TEFKQLZ_Y%F*_Z]S_])9[&3?\ (RP_^./YH_2NBBBO
MXU/ZM"BBB@ HHHH ****TI_&O4B?PL^&?^"7_P#R?C\-O][5/_39=U^_E?@'
M_P $O_\ D_'X;?[VJ?\ ILNZ_?RO[>6Q_'\OB84444R0HHHH **** "BBB@
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M?@Y_V)FC?^D,->K5_2Q_/04444 %%%% !7BG[7'[3%K^RC\(9?'%UH$WB/\
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M -"Q7ZJ5^5?_ #G7_P _]"Q0!^JE%%% !1110!^*_P#P6F_Y.F\*?]B;:?\
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M?_I+/8R;_D98?_''\T?I71117\:G]6A1110 4444 %%%%:4_C7J1/X6?#/\
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M;3_TNOJY[P/_ ,B3X?\ ^P=;_P#HM:Z'_@M-_P G3>%/^Q-M/_2Z^KGO _\
MR)/A_P#[!UO_ .BUKZ#)_P")+T/T/@W_ 'FKZ?J;=%%%?5GZT%%%% !1110
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MG]6A1110 4444 %%%%:4_C7J1/X6?#/_  2__P"3\?AM_O:I_P"FR[K]_*_
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M\'/^Q,T;_P!(8:_!+]IW_D<M/[_\2]>G_7645^]?[)\@'[+/P<'?_A#-&_\
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M'\[/9_MO,?\ G\S^;S_AISQ'_P! W2_^_<G_ ,<I?^&G/$?_ $#M+_[]R?\
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M<#I7<&3VS7RW_P $PXYXOV&?ABMPLB/LU%@) 0=IU*Z*'GL5((]B*Y#]M/\
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M !LY_P _\(Q1_P ;.?\ /_",4 ?JB?NU_.'^Q^"O[1/A4^UU_P"DDU?=>/\
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M &FV* TC =&=LL<<9/%==Y?N:=2T )BC%+10 F*,4M% "8HQ2T4 )BC%+10
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M;SZEH'A_3]*N9;1F:%Y8+:.)V0LJDJ60D$@'&,@=*[>@!,48I:* $Q1BEHH
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M[\-Z=X@\/ZC;ZOHNHPK<6E[:ONCEC;H0?T(Z@C! /% &Q1110 4444 %%%%
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M@K1&.L7,?DSZYJ<@N+Z2/()02$ (I(!*HJ@E02"0, 'N5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5E^*/$EEX/\-:MKVIR>3INEVDM]=2
M<?)%&A=V_!5-<W\7OC5X+^ _@^7Q/XZUZVT#2$<1))/EGFD()$<4:@M(Y"L=
MJ@G )Z U\\^$_P#@H)^SS^TM_:GPZD\07&E_V_;S:2(-=M3:1WJ3*8BB2DE
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M) !( .WW\XQ6'XW\=:%\-_">J>)O$VIP:/H6F0F>ZO;EL)&H_4DDA0H&22
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M?L8_MJZ3X/D^#B^.M-T;X83;[:XN8KZ*6);9SF18F\H76Q@SCR_D4Y(; )-
M'U9^R3\5O"?[=WP;UU_$?PYTD>%M"UK^R=+TG5HUU$"WCMH6B>1I0<R_.<D=
M!CDG+'Z-\ ?";P7\*;&XLO!OA71_"UK<.))X](L8K82L.C/L4;B/?-<S^S?^
MSWX>_9E^$^E>!O#C27$%L6GN[Z90LE[<OCS)G Z$X  R<*JCG&3ZE0 4444
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M.OQV\;^/OBYXA;XJV^HW$C:5!J8)=XY$P9;S "F1 3&BQX0! X"_*D8!Q_\
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M >[^6/PI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+]I+X6_"?6(M(\8^/O#_ (=U615<6-]?HDX5ONLR9W*IYPQ ''6@#QW]N?\
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M^4I2+S7 R^U20,]*_,+_ ()4_L>^+-/O_#?QR?Q=<:+X=O[6YB_L.U1EEO\
M;*\02;<"K0?('!^]N QMP&/ZM4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5QOQ9^+GA;X(> ]2\8>,=3CTG1+%<O(_+R.?NQ1KU=V/ 4?R!- %;XT?&SPG
M\ ?A[J7C+QCJ*Z?I%F-JJ,&6YF(.R"%<C?(V#A?8DX4$C\M5T+X\_P#!6#Q5
M?ZH+\_#[X.64IBMX)I'>TWJ00!$I7[7/D@EVPJ<@%3A6^I/VROV==(_X*$?
MWPYXZ^&/B?\ M#4]/@DNM%47+"ROT? D@=&($,X9-NX@,K*4<#JGSU_P3Q_;
MPN/@WJ<'P(^,2-H-G83M8Z7J5]'Y#:9,'.;6Z!QA"Y.'/*DX;Y2"@!YAX^^#
M/[17_!,+7K7Q9X6\3MJ_@B2X19;NS$CZ?*<C$5]:,2(R_*A@3][Y9%8\?J'^
MR3^U#X<_:X^$L7BC2X!9:E _V+6=&D.YK2XV@E<X&^-E.5;&""0<,K*/5_%G
MAC1?&_A75="U^SM]3T+4K9[>\M;@ QRPL"&!_ YR.G!'-?E7_P $A[>;P_\
MM1?%_0/#M\VK^ X-/E5=0&TK<M#?*EE(2.,M$]PPP,=: ,W_ ()JQS?!?]O_
M .)/PVQ,E@T.J:4L6PD%K6Z5H9&8C./+20!LX/F#KQ7Z_P"WWS7#>#?@EX/\
M!^.O%_C+2-)CA\2^*KA+C4]1<;I'V1H@12?NI\FXJ.K,2>V.[H ;M]Z=110
M4444 %%%% !1110 4FZN5^)WQ1\,_!SP/JGB[Q=JD6CZ%IT?F37$IY)SA41>
MK.QP%4<DGBOSNC_X+>>'V\:"%_A;J0\)^9M-^NJQF_"==_V?RPF>VSSL?[?:
M@#])/%GBK3O!/A76/$>KS?9M)TFSFU"\FP3Y<,2-([8[X52?PKX)UC]H"[_X
M*1?L<_'30O"'A:^T#6--D@^P6LCF<ZA!%+%<HH=551,X@D4Q*6V[TY;=FJO_
M  4,T+QU^T;\$?"OQ7^"7C2[U[P%9V4US=:'I#-&\\;J\<MP0N'D*H9(I()!
ME0'&,F05I?\ !)/]ICPOXN^#MC\)93;Z3XO\."9X;880:E;/*\IF3U=2Y#CD
MX"MSN;: ?(?[/?QX\7_'[X;^!_V5U\1:3\+_  M$;H:YXCN+H07.HV9F:7['
M&K!0')D=2H),H W$ 2!_>?%OBX^$?VPO@-\!OV?/$2_\(!H%W9WVN:?H4B.D
MTR3R->M=W"$^>_V9"65N%9A_%@)]!_M#?\$N_A'\>O%5QXHA.H^"=?O':6\E
MT'RA;WDC-EI)(70CS"<Y9"N226#$YKT?]F#]B/X:_LHVMS+X5M+G4-?NXS%<
M^(-69);QXR0?*4JJJD>54[549VC<6(!H ]^VTA3WIU% !1110 4444 %%%%
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M(N,MCL,D#\S4<U];VTEO'+-'%)</Y4*.P5I7VLY50>IVHS8'92>QJ;;G@G-
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M&?\ P4H^%.B?$'P)K=K8>)/+"66OB+)* Y>TO(QSE23C/*'D95B& /F/X_\
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MR%O^"4GQ/^)GPQUKXE^/?'?V7XE:A#)JSZ+J5L9W?"%MEQ<>8/+D8;1@(P3
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MH_;J^$'[7G[.2:1I46N:'XQTO5;?4;*QU6R $W#Q2H)8F=<!)6;YBN=@[\4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '&?%SXO>%O@?X#U+QAXPU./2]$L5):1B#)*_.V*->KNQ& H_0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC%Y7'?;N)5<_PJO>O7-H^M&WWIU !1110 4444 %%%% !1110 4444 %%%%
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M_9K\(?LO_#NW\*>$;8\D2WVI7 !N;^?&#)(P_(*.%' ]:]7H **** "BBB@
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M  X '% %G;VS3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;4Y.^/!$8)X\HD1_K?4<D*2(RLH96&"I'!H ^ O@[_P5L\ :Q\ =1\1>._\
MB6>/]$B6.?P_: @ZM*1A)+7/ 1B/F#']WSG(VEN-_P""</PM\8?&KX]>+OVI
M?&MHFFV>L&ZBT:T4?ZUY&",Z$\B**-#""1ER2<_+SVWB3_@D7\.]<_:*@\8V
MMU_9OP]D)O+[P=!&4#70(/EQ2 C9;MDDH.5P54A6'E_>6FZ39Z+IUKI^GVT-
MC8VL206]M;QB..*-  B*HX50!@ <"@"SL[]Z=110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 SRP.G%/HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>kros-20251231_g9.jpg
<TEXT>
begin 644 kros-20251231_g9.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,?!+8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\<Z'%]D2\5H[O3VE$LEC<IQ)"[ #.#R#@94J<#.*]2H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'P-\%?#']O+1?AUH&D"U\(_;]%M9+*6>24RK-Y/F[G9BQ+[F)YXSQCBOI/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!\2/C)\>;SX1?"?5=0TK0K/4QH42:+.8+G6;[S/+?=*I!$?F915#;6 W$G<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9?\ @#H?@V=X9=<=FU#6+BWQLDO90-^TX&X(JQQ@GJ(P<#-?DE^TE\)?&W[
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M^F\N_=]H]L;>^>/W]K\K/^"YW_-$_P#N-_\ MA0!]4_\$N1_Q@K\,S_V$_\
MTYW=?5=?*O\ P2Y_Y,4^&?\ W$__ $YW=?55 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5^ ?_  5)_P"3ZOB5]-,_]-EI7[]U^ G_  5'^;]NCXE-_#C3,'_N
M&6E '[\Q_=7Z4^F1G@#':GT %%%% !1110 4444 )7X W'_*4D_]EC_]S=?O
MZS!5)/2OP$G7/_!4@GK_ ,7D[?\ 8;H _?Q:6F*V:?0 4444 %%%% !1110
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M*?LOVRU^Q_:OM7VG9L^S;_*W\;=^=O&[/-?7]% #0N.^:=110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 E?E9_P7._YHG_W&_\ VPK]4Z_*S_@N=_S1/_N-_P#M
MA0!]5?\ !+G_ ),4^&?_ '$__3G=U]55\J_\$N?^3%/AG_W$_P#TYW=?55 !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )7Y6?\%SO^:)_]QO\ ]L*_5.OR
ML_X+G?\ -$_^XW_[84 ?57_!+G_DQ3X9_P#<3_\ 3G=U]55\J_\ !+G_ ),4
M^&?_ '$__3G=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 E?E9_P7._YHG_W&_\ VPK]4Z_*S_@N=_S1/_N-_P#MA0!]
M5?\ !+G_ ),4^&?_ '$__3G=U]55\J_\$N?^3%/AG_W$_P#TYW=?55 !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T5\__ !1_;T^!
M7P7\=:GX.\9^./[&\2:;Y7VJR_LB_G\OS(DE3YXH&0Y21#PQQG!P017*?\/1
M_P!F+_HIG_E!U3_Y&H ^JJ_/;XO?\IE/@M_V*MQ_Z3:K7K__  ]&_9C/ ^)F
M?^X#J?\ \C5\<_$;]L;X0:]_P4N^&'Q7L?%_G> =&\/S65]JW]F7B^3,T&H(
M%\HPB5OFGB&50CYO8X /UPI:^5/^'HW[,7_13?\ R@:I_P#(U'_#T?\ 9B_Z
M*9_Y0=4_^1J /JNBOFGPI_P4@_9U\;>*-'\.Z+\0_MNLZO>0Z?96W]B:C'YL
M\KB.--SVX5<LP&6( SR0*^E%;=CC&: '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 C':,FD+=L9-+UK\.OB)^W]\?='_:/\3>&K/XB7<&B6OBNZTV
M&U%C:$);K>-&J9,.>% &<Y]Z /W%S2TU5QWIU !1110 4444 %%%% !1110
M4444 %%%% "5^5G_  7._P":)_\ <;_]L*_5.ORL_P""YW_-$_\ N-_^V% '
MU5_P2Y_Y,4^&?_<3_P#3G=U]55\J_P#!+G_DQ3X9_P#<3_\ 3G=U]54 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'D8I:* /P#_X*C_\
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M_93X_:B^#_?_ (K'1_\ TNAK^E-:_:#\A%HHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%)0 M%(&SVI: $)Q7X+_$C]C_XUZG^TUXHURU^&/B6?2+CQ?=7L5XE@
MYB>!KUW60-C[I7!SZ&OWH-)M';C\* %4YI:;C;S1N.>E #J*** "BBD/'-
M3BF^9SBL/QQXYT3X<^#M7\4>(;^/3=#TJV>[N[N0\1QJ,].Y/ "C))( R2!7
MX_6__!5KXQ^.OCQ86FA7MEHG@[5-?M[:VTN7389)HK1YE0*\A!)<H<DYZDXX
M H _9[=C.:-_.,<TA^5?7'MS7YY?MU_\%0)_@/XVN?AY\-M-L=7\3V 4:KJN
MHAI+:SD(#"&.-2/,D"G+,6VH<*0S!@H!^AS-BC=7XMZ?_P %2/VF?A?K&EWG
MCO0+6[TN^ EBL=9T-].^TP@C<8)%"G^(?-AP,C@]_P!5_P!G/X_>&_VEOA7I
M7CCPP72VNBT-U9S$&:RN4QYD,F.XR"#W5E;O0!Z?1110 E?E9_P7._YHG_W&
M_P#VPK]4Z_*S_@N=_P T3_[C?_MA0!]5?\$N?^3%/AG_ -Q/_P!.=W7U57RK
M_P $N?\ DQ3X9_\ <3_].=W7U50 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'X"?\ !4?_ )/J^)7TTS_TV6M>B_L2QWLOP"\2)IKH
MFHMJ=TMLT@^593;0;">.F[%><_\ !4C_ )/J^)7TTS_TV6M>J?L$_P#)'-4S
MT_MN;_T1!7P7&\N3)IRM>TH[[;GW/!L>;-8J]M'MZ"MH/[2S-_R,7ATCG'[F
M//\ Z)KE;[X+?'K4OB!I_C2XUG07\06$!MX+@%0JH0X(V>5M/$C]1WKZZV__
M *Z,5^)4^*J]&_LL/25U9^Y:Z>ZWV9^P5.':5:W/7J.SNO>V9\X?V'^TQ_T,
M?AWU_P!5'_\ &:T?V@(=>M_V2M<C\47$%SKRQ6PNI;8 1LWVR,C&%';';M7O
M]>/?M=<_L[^+L==MK_Z50UME^;RQ^982#HTX6J0=XQL]U^!EC<M6#P.)FJDY
MWA+XG=;'Q'^RKS^U%\'CC_F<M'_]+8:_I26OYK?V5/\ DZ#X/?\ 8Y:/_P"E
MT-?TI+7]2N^[/YK%HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(V-ISTI:2@#XA_
MX*H?'3XB? /X8>#M8^'NOW/AZYN]8>VO+F&VCF#1^2S*I\Q& Y'MTK\T?^'D
MO[2G&/BE>D_]@ZR_^,5^_FN>'],\3:/>Z3K&GVNJZ7>Q&"YL;V%989XR,%'1
M@0RGN"*_$#_@H;^QV_[(OQ.TGQAX*B*>!=6NA-IZSJLXTZ]0^8;9@X(=, ,F
M_.5#*<[<L <$W_!2;]I0*#_PM*]Q_P!@ZR_^,TW_ (>4?M*?]%2O/_!=9?\
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MMQV@Z%,/SQBOS;_X(KZ?+)^TIXQO<KY4/A.:!AGYMSWEH1@8_P"F;9/KCUH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *0\#IFEKQK]L#XY3?LY_LZ^,/'5I ESJEC D-A%(-R&Y
MFD6*)F&1E59P[#()"D"@#V-7#?\ ZJ6OYI[ZX^+O[2VL:QJDD?B[XD7\!^U7
MTEK!<:@+8,6(+*@98D_UFT *H&0, 5S?@;X4^-OB<UZ/!W@_7_%AL@ANAH>F
M3WOD!]VPOY2MMW;6QG&=IQT- ']%?Q4^&OP:U"2?Q1\2/"O@6ZEA@"RZSXIT
MVSD9(EZ;IIUR%&>YQS74_#+4/">I^!=$N? RZ>OA&2W!TQ=*A6&U\@$@>4@
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MNWBW_=M?_2J&O8:\>_:[_P"3=O%O^[:_^E4->]P__P C?"?]?(?^E(\;.O\
MD6XC_!+\F?$/[*G_ "=%\'?^QRT?_P!+H:_I46OYJ_V5/^3HO@[_ -CEH_\
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MO_?0_P */^$:M/[TO_?0_P */]4<R[+[P]M ^@?^'HW[3O\ T4W_ ,H&F?\
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M&>,E0*]%#;N:=GU0KHDHI!2T#"BBB@ HHHH **** "BBB@ HHHH 0]*^0?\
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M$X-:_:(\9Q_$?X;W%C'XGEMDM]6TN_D\E;X1KMBECEVD"7:%C*N0I5$Y&#N
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MV% 'U5_P2Y_Y,4^&?_<3_P#3G=U]55\J_P#!+G_DQ3X9_P#<3_\ 3G=U]54
M%%%% !1110 4E+24 ?DY_P %QCCQ%\(#_P!.VJ?^AVM?I]\-_#]IX5^'?A;1
M;!!#9:;I=K9P(@P%CCB5%&/H!7Y@?\%QO^1@^$/_ %ZZI_Z':U^J?AO_ )%[
M2_\ KUC_ /0!0!^=7_!;>WC_ .%2?#B8HIE76YT60CYE4P$D ^AVC\AZ5]*?
M";P!;?'#_@GSX+\&WDK6,&N> +'3//C^8PDV2(L@'?#*K8[XQ7S?_P %N/\
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M$W_!);]GS5?!L^E:7H6I:)K!AV0Z]'JUS+.),'#M'(YB(SC("#@<%>M?+O\
MP2%\6>(OAW^T-\2/@_J<YET^.UN;J>W60M%%?VEQ' [IGH&5RI/?RX_08_7!
MAQUK\>_V#IGC_P""HWQ+5695DNO$2N ?O+]LS@_B!^5 &U_P5H\;W_B_]I3X
M:?"?5]>7PYX#:WLKRZNY,B.)[FZDADNI<D K%&F0.WS\\\?5&@_\$L?V:/\
MA&[2)/"EUK+/ A76&UV[,DXP/W@\N41'/7Y4QSQVKI?VUOV&?#O[86@Z;)+J
M3^&O&&DADL-:C@\]&B8[GAFCW+O0GD$$%221D%E;\^I/V+OVROV6KQI_AWK-
M_JFDPEI,^$]9W0$9S\]G,5+L>3@1OSGD\9 /;O@1_P $^?BW^S'^V,OB/P'J
M-I/\+8;E89Y]4U 1SWNGRHOFPO%&K;Y(F8[<A0S1*?DW<?IH/O9K\J/V:O\
M@J9\0_#OQ1TWX>?'[1!!]HN(;&75I;!M.O["5\!7NH"%4H=R$X5"JDMAN!7Z
MJJ>1_*@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /P#_ ."I/_)]7Q*^FF?^FRTKU3]@G_DCFJ?]AN;_ -$05Y7_
M ,%2?^3ZOB5]-,_]-EI7JG[!/_)'-5_[#<W_ *(@K\^X[_Y$=3UC^9]WP7_R
M-X^C/I*BBBOY>/Z*6P5X]^UW_P F[>+?]VU_]*H:]AKQ[]KO_DW;Q;_NVO\
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ME"Y;U->'F_$D\UPZHNGRJ]]RX4N5W/V!_P""(\J'X1_$:(.ID77(69,\@&W
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M(]*WJ)5ZL+?#+WGZ=?Q,Z=Z"G?>.B^>Q]U_L1?!%?@'^S7X0\,RPB'5Y+?\
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M:+\2: OAGX*^"KB:UUCQ6@EU&2U<I-);O(8HK92.@E</NY&0@7HQ!])^ _\
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M'K5I"L,<WF2LY 599!P21D,>G:K@_<E%ZZ_=Y&=3XHO^F>X@TM%%04%%%%,
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M'ZR:YH&G>)M'O=(U:R@U/2[Z%K:ZL[J)9(9HF!#(Z,,,I!.01B@#\M?V4/\
M@K]JUYXFTWPU\:K:P;3;IU@7Q981?9V@<\!KF(?(4SU9 NWKM/4?JQ&RR!60
M[E(X(.1]:_$'_@JK^S/X$_9]^)GA2\\!V2:+9^)+.XGN=%AD+16\D;H/,C!)
M*(_F8VCY08SMXX'ZN?L9Z]=^)OV5?A/J-\[RW3^'+.-Y)6+.^R((&)/4D*"3
M[T >ST444 %%%% !1110 4444 %%%% !1110 E?E9_P7._YHG_W&_P#VPK]4
MZ_*S_@N=_P T3_[C?_MA0!]5?\$N?^3%/AG_ -Q/_P!.=W7U57RK_P $N?\
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M-HR,41=IN;ZJP6_=JGYK\!3]T]Z_(_\ X)I_\I#/C"?^G36/_3E!7ZX>U-"
M8H@^2?/Y-?>.6L.7S3^X_*S_ (+=?\?GP?/MJG\[6OTJOO"NF^.?AK-X<UB
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MF/NQKN&CW#KQ2JN.<U=TH\J(:<I*3Z"@4M)2TB@HHHH **** "BBB@ HHHH
M**** $(SQ7E7[4?P1C_:)^ WB[P"UPEI<:I;*;2XD!VQ7,3K+"QQSMWHH..Q
M->JL=HS320W!Q@^] '\[OPU^-_QK_8-^(6M:+8&X\+ZF)?+U7P]K%L);:X*Y
M"L4/4=UEC8;AC#%3S[K=?\%G/CE=6IACT#P+:N5P)X=-NBX]P&NF7\P:_7;X
MF_!'P#\9;%+7QQX1TGQ/'$"L4FHVJR20@]?+DQN3_@)%>#WW_!//]E3PKJ"7
M^H^!-+T^5W9D74-=O!$S'/ CDN-A[\;>,<=* /R,\-Z#\7_^"AGQ\C%S>7'B
M'Q!?%%N]3FCVVFE6BG@D*-L42Y8A%P68G&YG.?Z OAYX+T_X;^!?#GA/20PT
MS0].@TVVW_>,<,:QJ3[D*"??-5OAWX!\'?#SPY%IW@G0M(T'0V^=8='MXXHI
M#W<E!AB<<L<D^M=2JX[8]J 'T444 %%%% !1110 4444 %%%% !1110 E?E9
M_P %SO\ FB?_ '&__;"OU3K\K/\ @N=_S1/_ +C?_MA0!]5?\$N?^3%/AG_W
M$_\ TYW=?55?*O\ P2Y_Y,4^&?\ W$__ $YW=?55 !1110 444C-M4D]!0 M
M%>9ZM^TY\']!U:\TS5/BKX(TW4K*=[:ZL[OQ'9Q302HQ5XW1I 596!!4C((Y
MJM_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM 'JM%>5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM 'JM%>?^%OVA/A9XXUZUT3PW\2_!_B#6KK=Y&G:7KUK<W$VU2[
M;(TD+-A59C@<!2>@KT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#\ _^"I/_)]7Q*^FF?\ ILM*]4_8)_Y(
MYJG_ &&YO_1$%>5_\%2?^3ZOB5]-,_\ 39:5ZI^P3_R1S5?^PW-_Z(@K\^X[
M_P"1'4]8_F?=\%_\C>/HSZ2HHHK^7C^BEL%>/?M=_P#)NWBW_=M?_2J&O8:\
M>_:[_P"3=O%O^[:_^E4->]P__P C?"?]?(?^E(\;.O\ D6XC_!+\F?$/[*G_
M "=%\'?^QRT?_P!+H:_I46OYJ_V5/^3HO@[_ -CEH_\ Z70U_2HM?V(?RF+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 E%+10 4E+10 4444 )2;>>M.HH 04A7CK3J* &[?>EQ2T4O(!*6B
MBF E&#ZTM% "4?C2T4 %%%% !1110 4444 %%%% !1110 4444 %)2TC=* /
M"OVR?VH-/_92^"M_XNEMX]0UJ>46.CZ=*3MN+I@2"^"#Y:!6=L$'"X!!85^4
M/[.'[5/QC^.7[:'PWN?$?C36]3M[C7H3+I-K.Z6$4))#!;=#Y84(Q&X@G R2
M2,U[=_P6^UZZ;Q%\*-%#N+2*UU"\V!OE>1W@0$@=2 A /^T<8SS]6_\ !,/X
M/Z'\-_V4/">LVEC;C7_$T+:IJ6I)&/-FWR-Y49;KM2,( N<;MQQEC0!9_P""
MBW[6UQ^RS\%XW\/3Q1^.O$4K66D-(JN;957,UUL8881AD !!&^1,@@$5^)V@
M^%OB;^T]\0+O^S++7?B#XLN@;BZF^>XE"YY>1VX1 2 "Q &0!V%?3/\ P5W^
M*3^./VJI/#<5PS:?X2TV"Q$?&P7$J^?*X]R)(D/_ %R]J^S?^"./PGB\)_LX
MZGXUE@4:CXMU.4QS@?,;2V)A1?PE%R?Q% 'YJ_!_X\?%[]AOXI_9@FK:(]K,
M!JWA#5A)%;W:$C(:)AA6('RS*"1G()4D']_OAG\0-)^*G@#P]XOT*4S:3K=C
M%?6Y8895=0=K#LP.5([%2*_-O_@MSX%TL:7\,_&4<,,6LF>ZTF>90!)/!M66
M,,<9(C;S,<\&5O6OHK_@D_JT^I_L4^%(9FW"QOM0MH\G/R_:7DQ^<AH ^P:*
M** "BBB@ HHHH **** "BBB@ HHHH 2ORL_X+G?\T3_[C?\ [85^J=?E9_P7
M._YHG_W&_P#VPH ^JO\ @ES_ ,F*?#/_ +B?_ISNZ^JJ^5?^"7/_ "8I\,_^
MXG_Z<[NOJJ@ HHHH *1ONFEI* /YSOC?X,O?B1^W%X_\(:9+;P:EK_Q&U#2K
M::\=EA26?4Y(D:0JK$*&<$D D#H#TKZ(_P"'*_QN/_,T_#_\=0OO_D.O*S_R
ME,_[K+_[FZ_?Q4"X- 'XL?\ #E7XW_\ 0T_#_P#\&%]_\AT?\.5?C?\ ]#3\
M/_\ P87W_P AU^U-% 'XK?\ #E7XW_\ 0T_#_P#\&%]_\AT?\.5?C?\ ]#3\
M/_\ P87W_P AU^U-% 'XK?\ #E7XW_\ 0T_#_P#\&%]_\AT?\.5?C?\ ]#3\
M/_\ P87W_P AU^U-% 'XK?\ #E7XW_\ 0T_#_P#\&%]_\AT'_@BK\;QR?%/P
M_P ?]A"^_P#D.OVII#TH _ 3_@ERI'[=7PS/_83_ /39=U^_E?@'_P $N6_X
MSJ^&? _YB?\ Z;+NOW\H **** "BBB@ HHHH **** "BBB@ HHHH *0\<TM(
M>GI0!X_^T]^U#X6_9.\!V'BWQ=I^L:AIM[J<>E1Q:+#%+,)7BEE#$22QC;MA
M8$YSDKQW'S%_P^H^"/7_ (17Q_C_ +!]C_\ )E-_X+4*$_9:\+$#_F<[3_TA
MOJ^8?^">O_!/?X=?M9_!C6O%WB[6O%&G:C9>()]*CBT6ZMHH3$EM;2AB)+>0
M[MTS D'& ..N0#Z?_P"'U7P0_P"A6^('_@OL?_DRC_A]5\$/^A6^('_@OL?_
M ),H_P"'*OP0_P"AI^('_@PL?_D.C_ARK\$/^AI^('_@PL?_ )#H /\ A]5\
M$/\ H5OB!_X+['_Y,H_X?5?!#_H5OB!_X+['_P"3*/\ ARK\$/\ H:?B!_X,
M+'_Y#H_X<J_!#_H:?B!_X,+'_P"0Z #_ (?5?!#_ *%;X@?^"^Q_^3*/^'U7
MP0_Z%;X@?^"^Q_\ DRC_ (<J_!#_ *&GX@?^#"Q_^0Z/^'*OP0_Z&GX@?^#"
MQ_\ D.@ _P"'U7P0_P"A6^('_@OL?_DR@?\ !:KX(?\ 0K>/Q_W#['_Y,H_X
M<J_!#_H:?B!_X,+'_P"0Z/\ ARK\$/\ H:OB!_X,+'_Y#H 7_A]1\$N_A7Q^
M/^X?8_\ R97T[^S!^U#X6_:R\!ZAXM\(Z?K&G:=9:G)I4D6M0Q13&5(HI2P$
M<L@V[9EP20<@\=,_F'_P4)_X)[?#K]DWX+Z-XN\(ZUXGU'4;SQ!!I4D.M75O
M+"(GM[F4L!'!&=VZ%0#G&">.X^G?^"*WS?LN^*6/4>,KK_TAL: /T HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P#_ ."I
M/_)]7Q*^FF?^FRTKU3]@G_DCFJ?]AN;_ -$05Y7_ ,%2?^3ZOB5]-,_]-EI7
MJG[!/_)'-5_[#<W_ *(@K\^X[_Y$=3UC^9]WP7_R-X^C/I*BBBOY>/Z*6P5X
M]^UW_P F[>+?]VU_]*H:]AKQ[]KO_DW;Q;_NVO\ Z50U[W#_ /R-\)_U\A_Z
M4CQLZ_Y%N(_P2_)GQ#^RI_R=%\'?^QRT?_TNAK^E1:_FK_94_P"3HO@[_P!C
MEH__ *70U_2HM?V(?RF+1110 4444 %%%% !1110 4444 %%%)TH 6BL/Q=X
MZ\.?#_1VU?Q3K^E^&M)5UC:_UB]BM8 [?=4R2,%R>PSS7#?\-8_!#_HLGP__
M /"HL?\ X[0!ZK17E7_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#P
MJ+'_ ..T >JT5Y5_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?#_\ \*BQ
M_P#CM 'JM%>5?\-8_!#_ *+)\/\ _P *BQ_^.TA_:R^" !/_  N/P ?^YHL?
M_CM 'JU%<QX'^)_@[XFVMS<^#_%>A^*[:U<1SS:'J4-XD3D9"L8F8*2.<'M7
M3T %%%% "4M(:0/DXZ4M@'44F:0GO3 7-&:3<&(%(S!1R<"D [/-+3%;YJ<>
M* "D+4GF 9R*-WS'O0 ZEIBMV_6G4P%I*#3=W)% #LTM1JX) I] "T4F:;NW
M$4 .S2T44 (:*&.%)IK2>E #J6FL^WZ4N[VH 6BD8X6F^8![T .I:;N]J7=2
M 6BF[\]*,^E #J*;N&X#O3J8!2'I2TE 'YC_ /!;3X97VJ>$OAUX]M(&DL]*
MN;G2K]U4DIYXC>!CCHNZ*1<GNZCO7%_L6_\ !3_P5\#_ -FN#P5XVTW5[G7O
M#BS)I0L8E=-1A>1Y(T+EAY;*SE"2" @4@L<K7ZF^.O N@_$KPAJOACQ/IL.L
MZ#JD#6]W97 )61#[CD$'!# AE(!!! -?FE\0_P#@B3#<^()Y_!/Q*^P:/*Y*
M6.M:>9I8 >WFQN!)CW1?<F@#\VO$6M>(_CU\7+[43;MJ/BGQ?K+2):PG_6W-
MS-\L4>X\#<ZJH)Z8]*_H,T"X\'?L9_LW^'K3Q3K46E>&_"NFVUC<ZD89'$DN
M K.$168F20D@ $Y;%>0?L?\ _!-?P3^R[KB>*[_4Y?&OCA$:.#4KFW$%M9!L
M@F"'<Q#E3M+LS'&=NW<0?4_VU?@EK'[0W[-?BWP)X?>UCUS4C9M:27KE(5:*
M[AE;<P!(&Q''0]>AH _(7_@HE^VA:_M:>/\ 1[?PY:W-GX)\.1RI8_;$"37<
MTA'FW#*"0JE8T"*>0 2<%MH_6#_@GO\ #&]^$O[(?P]T74X6M]4N+1]4N8I$
M*/&US(TZHZGD,J2(I!Y!4\#I7S9^RI_P2&TOX:^*-.\5?%37+/Q;J-@ZS6^@
MZ;"W]GK,IR&F>0!IP#@A=B#*\[@<5^CH7&.<T .HHHH *9)*L2,[D(BC)9C@
M >M./2O)_P!J;X<^+OBY\!?%_@SP/JUCH>OZW:?8DO=09UB6%F7SD)168!X]
M\>0IQOS0!\Y_%S_@KU\&?ASX@GT?0K;5_'DMNQ26^T=(TLMP)!"2R,#)T^\B
ME2",,:ZW]G7_ (*;_"/]H7Q1:^%XCJ7A'Q)>-Y=I9ZXD:QW<G]R*5&92Q[*V
MTD\#)XKQ+]CG_@E#8?#W5O$>I?'#3M$\87"F.'2+.RGEELU7#>;*ZLL99CE0
MJLN!@GDD;?A+]O[X=^!_@S^U-KVA_#1UL](M8[:=[2UNFE6QNRN7B1B2PP0&
MVDG:6(&,   _H0W_ /UN:\$_::_;<^&/[*<-K!XMOKJ^UZ[C$UOH&CQI->-&
M6V^8P9E6-,Y^9V&=K;=Q!%>B_!W5-:O/@SX)U#Q8K6WB*70+&?5A(3E+HVT;
M3YY/1R_<].M?A=X-M[G]O+]NZRB\07]PUEXLUZ:>3<</%IL*/*+=/[N+>'RU
M/;@G)SD _0;P=_P6>^$>MZY#9:[X:\3>&K.5@O\ :,D45S%%UYD2-O,QQ_ K
MG)Z5]X>'?$NE^+M#T_6M%O[?5-)U"%;BUO;60/%-&PRKJPZ@BOSJ_P""B?[!
M/PN\&_LTZCXR^'OA2W\,:WX6:"5OL4LA%U:M(L4B2!V(9E#A]Y^;Y",G.*K?
M\$5?C!?ZWX'\;?#B^E::VT&>+4],W-G9%.7$T8'91(BO[F9J /TQHIH?/:ES
M0 5^5G_!<[_FB?\ W&__ &PK]4F8*I)Z8K\K?^"YN2/@H<<#^V__ &PH ^JO
M^"7/_)BGPS_[B?\ Z<[NOJJOE7_@ES_R8I\,_P#N)_\ ISNZ^JJ "BBB@ I*
M6DH _ +_ )RG?]UF_P#<Y7[^U^ 7_.4[_NLW_N<K]_: %HHHH **** "BBB@
M I*6DH _ /\ X)<_\GV?#/\ [B?_ *;+NOW]K\ O^"7/_)]GPS_[B?\ Z;+N
MOW]H **** "BBB@ HHHH **** "BBB@ HHHH *2EI* /@'_@M5_R:SX6_P"Q
MSM?_ $AOJ3_@BK_R:WXJ_P"QSNO_ $AL:7_@M5_R:SX6_P"QSM?_ $AOJ3_@
MBK_R:WXJ_P"QSNO_ $AL: /T HHHH **** "BBB@ HHHH ^ ?^"U/_)K/A?_
M +'*T_\ 2*^IO_!%3_DUKQ5_V.5U_P"D-C3O^"U/_)K/A?\ ['*T_P#2*^IO
M_!%3_DUKQ5_V.5U_Z0V- 'Z 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'X!_\ !4G_ )/J^)7TTS_TV6E>J?L$_P#)'-4_
M[#<W_HB"O*_^"I/_ "?5\2OIIG_ILM*]4_8)_P"2.:K_ -AN;_T1!7Y]QW_R
M(ZGK'\S[O@O_ )&\?1GTE1117\O']%+8*\>_:[_Y-V\6_P"[:_\ I5#7L->/
M?M=_\F[>+?\ =M?_ $JAKWN'_P#D;X3_ *^0_P#2D>-G7_(MQ'^"7Y,^(?V5
M/^3HO@[_ -CEH_\ Z70U_2HM?S5_LJ?\G1?!W_L<M'_]+H:_I46O[$/Y3%HH
MHH **** "BBB@ HHHH **** "D;I2TAH ^'O^"P5TUM^R"Z(%(N-?L8WR,X
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MELF_S&?M&?ME?$O]L#XV:9\*OV<M1UC2M)M[ABVLZ3=2V4MZ5X>XDE0AHK5
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M77B:WT^:Z^R6]SN@:UNY&3;-&ZC+1(<@9^7K@D5^87_#T;]IW_HIG_E TO\
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M_D6XC_!+\F?$/[*G_)T7P=_['+1__2Z&OZ5%K^:O]E3_ ).B^#O_ &.6C_\
MI=#7]*BU_8A_*8M%%% !1110 4444 %%%% !1110 4E+2&@#XS_X*W?\F7ZY
M_P!A73__ $<*_$[X6^,(O /Q T/Q#/;O=1:=<K.T,;!6<#L">E?OC^WS\#O$
M_P"T5^S?JW@WP@EI)K<UY:7,<=Y/Y*,L<H+#=@@'&3SZ5^5W_#I/]HH7P@_L
M#1_*/_+U_;,'E],],[O;[M9U:<:U.5*>S33]&;4:DJ-2-2&Z=T;7_#P+0.O_
M  BFH?\ @3'_ (4?\/!/#_\ T*NH?^!*?X52/_!(?]H3MI_A[_P;K_\ $T?\
M.A_VA/\ GP\/?^#=?_B:^'?!&1MW]E_Y,_\ ,^P7&.;K_EXON7^1=_X>">'_
M /H5=0_\"4_PH_X>">'_ /H5=0_\"4_PJE_PZ'_:$_Y\/#W_ (-U_P#B:/\
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MG2C[EN/,RW&6(5><[6]K^,_P%\=?\$OOBYX$^(/A/69M?T69(X9KV2,Q137
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MQU!6(EM3G[HD(.!TWCUDJZ4N;FAM+\T8U5:*GTZ^7]?UL?IK\8?C?X*_9_\
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MP/E+(/RK]5O@#\"_#7[.?PQTGP/X6BD&GV2EY;BX(,UW.QS)-(1U9C^  4#
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M=O/6EVTM% "8HVBEHH 3:*-HI:* $VTTIN[_ *"GT4 -5=O0\4ZBB@ HHHH
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M+B:6,.+>YN%^[,'C8/!*>,NFX'&=NXEC]R4F*AQ5T^I2=KKN?F!=_P#!-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ /_@J3
M_P GU?$KZ:9_Z;+2O5/V"?\ DCFJ?]AN;_T1!7E?_!4G_D^KXE?33/\ TV6E
M>J?L$_\ )'-5_P"PW-_Z(@K\^X[_ .1'4]8_F?=\%_\ (WCZ,^DJ***_EX_H
MI;!7CW[7?_)NWBW_ ';7_P!*H:]AKQ[]KO\ Y-V\6_[MK_Z50U[W#_\ R-\)
M_P!?(?\ I2/&SK_D6XC_  2_)GQ#^RI_R=%\'?\ L<M'_P#2Z&OZ5%K^:O\
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M_P""7/\ R8I\,_\ N)_^G.[KZJKY5_X)<_\ )BGPS_[B?_ISNZ^JJ "BBB@
MHHHH **** "BBB@ HHHH **** "BJ&N:]IOAG2KC4]8U"UTK3;< S7E].L,,
M8) !9V( Y(')ZD5QO_#0OPMSC_A9/A#_ ,'UK_\ '* /0:*\^_X:&^%?_12_
M!_\ X/K3_P".4']H;X6#_FI?@_\ \'UK_P#'* /0:*@LKZWU*T@NK6>.YM9T
M$D4T+ATD0C(92."",'(]:GH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** $K\K/^"YW_-$_P#N-_\ MA7ZIU^5G_!<[_FB?_<;_P#;"@#ZJ_X)<_\
M)BGPS_[B?_ISNZ^JJ^5?^"7/_)BGPS_[B?\ Z<[NOJJ@ HHHH **** "BBB@
M HHHH **** "BBB@#D/BU\+="^-7P[UKP3XE2>30]7C6*Z6VE,4A575QAAT^
M9!7RU_PZ'_9Z_P"@=X@_\&[_ .%?:E% 'X^?#O\ 86^%GB;_ (*)?%#X-WUK
MJC>"O#_AR'4[&)+YEG$S1Z<Q+28Y&;J;C'<>E?5W_#H?]GG_ *!WB#_P;O\
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M45D^*?%FA^!]!NM;\2:SI_A_1;7;]HU'5+I+:WAW,$7?(Y"KEF51D\E@.IH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "DZTM)0!^?_P#P6>\87>A_LV^'=#M;AX(];\0Q+=*O EAAAEDV
M-[>9Y+?5!7GG_!&W]G+PY?>%-:^+^LZ='J&OQ:G)I6C272AULHTC1I9HQT$C
MM(4W=0(R!@.V>B_X+;9_X5#\.>?^8]-^?V=L5Z/_ ,$E]6TZQ_8YT=)KRUMY
M?[5OBRR2*C<R=3G'8#\J /MC9SG.:22%)(VC=0Z,"K*PSD'J#FJ7_"2:3_T%
M++_P(3_&D;Q)I.#_ ,32R_\  A/\: /P[_X*L? G0O@M^T9;WGAJPATK1?%&
MG)J9L+9 D4-R)'CF"*!M4':CX'=VP ,"OV#_ &6_&EW\1?V<OAIXDU"4SZAJ
M'A^SENI3U><1*LC?BX8_C7YI_P#!;+4+6_\ B'\,C;7,5R%TJ[W>4X;&9DQG
M%?H+^P>/^,/?A*?^H##_ %H ]ZHHHH ***0G ]: %HKB/'GQO^'OPMECB\8>
M-_#WAB>4;HX-6U.&WED'JJ.P8CZ"I/ ?QG\!?%+S?^$.\::!XG:+F2/2=2AN
M7C&<9948E?Q% '9T4SS,X]:S?$GBK1O!NCW&KZ_JUCH>E6XW37VI7*6\$8]6
M=R%'XF@#5HKS;P?^TI\*/B!K2:/X;^)'A77-6D.([&QUBWEGEZ_<0/ENG;->
MC[OFQB@!U%%% "5^5G_!<[_FB?\ W&__ &PK]4Z_*S_@N=_S1/\ [C?_ +84
M ?57_!+G_DQ3X9_]Q/\ ].=W7U57RK_P2Y_Y,4^&?_<3_P#3G=U]54 %%%%
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MAKT^'>+HY_BIX94.3ECS7YK]4NR[GFY[PO\ V)AHXCVW/=VM:W2_=]C]/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<5# GZ9_X+?-<CQI\*$;=]B6POVC! QO,D._] GZ>M?7_P#P2[T?2M,_8G\
MRZ;M=[UKZYNY0N"\_P!KF1LCU4(J9[A!VYH ^K0<]>O\J^)/^"G7[+?Q-_:<
M\&^%H? ,FGW5GX?DNKVZT6YN?)FOIF5%B,1*[-RJ)<;F4?O#SGK]N;?Q].*&
M7\: /YU_V;/VA?'/[%WQN6Z,6H6EO;W?V+Q)X8N 4^TQJQ5T:-N%F3YBC<%6
MXSM+ _T-:#K-EXBT73]5TVX6[T^^MX[JVN(SE98W4,K ^A!!S[U^+/\ P62\
M,Z-H?[4FE7^G".'4=7\.6]WJ4<:8+R+--"DK-_$6CB1?7$0]17ZC?L0W%S=_
MLC_".2[SYJ^'+2,;ACY%C"Q_AL"T >X4444 )45Q<1V\,DLKK%%&I=Y)&"JH
M')))Z# _*I6^[7Q/_P %8/BIK_@G]G%/#/ABWO)M0\87?]G7,EG$SLEBJ%IQ
M\H.-_P"[C.>JNXH ^//^"@7_  4!U7]H#Q%+\*?A/+=OX/:Y%C<76GAFN/$$
MY;8(XPO)A+8"J.9"02,8%?2?[ ?_  31M/@RVF_$+XH6\.H^/% FL=%;;+;Z
M02!AF(R))QZ@E4/W<D!A^4_PSUGXD_![QA:^*?"%AJ>D:_:*ZV]]_90F:'<I
M5B@DC8 E21G&<$CO7MW_  WA^UKS_P 5AX@'UT.V_P#D>@#]VO%FE2:[X6UG
M38FVRWME-;*Q'1GC90>WJ*_"7_@E[JX\,_MQ>![>[3R6NEU"Q?S,J8Y#9S%0
M1CKN4+C_ &J_5G_@GG\1_&WQ8_9HTWQ!\0K^ZU+Q)+?W<4D]Y;K!(8UDP@*J
MJ@#'M7P%^W%^PW\2O@O\=KOXM?"?2]1UC0KK5/[<@DT6$W%WHM[YGFL&B4%C
M&) 75PI51\K8P"P!^A7_  4-\16WAW]C#XI7-T=JS::MF@SR7FGCA4<9_B<5
M\%?\$2?"SWGQ<^(OB,1EH[#0X=/,O/RFXN X'IS]E)_X#]:\@^*GQ^_:@_;>
MT_2?A_=^&=0OK6*X2673]"T66W6XF'"R7+G(55)8\E8P>2/E!'ZE?L"_LJ/^
MRC\%4T;5)(KCQ;K$_P#:.LS0,&C20J%2W1NZQJ.O=F<C@C !ZM\:O@'X$_:(
M\+6OASXA:'_PD&BVMZNH0VWVN>VV3JCQJ^Z&1&/RRN,$XYZ9 ->+?\.N/V8O
M^B9_^5_5/_DFOJJB@#Y5_P"'7/[,0_YIG_Y7]3_^2:^ /^"K7[+OPQ_9K_X5
M?_PKGPS_ ,(]_;7]J?;_ /B875UYWD_9/+_U\K[<>;)]W&=W.<#'[45^5G_!
M<[_FB?\ W&__ &PH ^JO^"7/_)BGPS_[B?\ Z<[NOJJOE7_@ES_R8I\,_P#N
M)_\ ISNZ^JJ "BBB@ HHHH **** "BBB@ HHHH 1NE?S7_M8?\G3?&/_ +'/
M6?\ TNFK^E!NE?S7_M8?\G3?&3_L<]9_]+IJ /K?X"^*;KP5^R)HFMV6D3:[
M=6D=PR:?;L5>;-[(I (5CP"3T/2L9OVN_%W_ $1C6_\ P(E_^1J[O]D/_DW7
MPE]+K_TKFKV+<?K^-?R[C\=@,-F>+ABL(JLO:3U<I+2^VA_26"PF,Q& PTL/
MB'37)'3E3Z;ZGPSH7Q:\8:+\<_$7Q$_X5=K4PU>Q2R_LW]ZOE;5A&[S/)^;_
M %/3:/O=>.?25_:\\7;@#\&-; ]?M,O_ ,C5].[CWI<FGB>(LMQCBZ^ 3Y4H
MKWY:):):=A8?),=A5)4L8U=N3]V.[W/E[]MC4I-7_9]\-WTUJ]E-=:E:SO;2
M'+1,UM,2A) Y!)'0=*\W_P""7'_)]GPR_P"XG_Z:[NO5OV]?^2,Z;_V'(3_Y
M GKRG_@EQ_R?9\,O^XG_ .FN[K]CX(E&630<%9<TM.VI^4<9)QS1IN[LM?D?
MO]1117WQ\*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\K?\%1
M/^3%?B9_W#/_ $YVE?5-?*W_  5$_P"3%?B9_P!PS_TYVE 'X;_ _P#Y+)X'
M_P"PW9?^CTK]6\\U^4GP/_Y+)X'_ .PW9?\ H]*_5O\ BK\%\2OX^&])?FC]
ML\/_ /=Z_J@HH[FBOQ=GZP%?FK^V)_R<5XI^EG_Z20U^E5?FK^V)_P G%>*?
MI9_^DD-?J_AQ_P C2K_U[?\ Z5$_-N/?^1=3_P :_)GZ?_\ !%7_ )-=\5?]
MCE=?^D-C7Z U^?W_  15_P"37?%7_8Y77_I#8U^@-?T6?@@4444 %%%% !11
M10 4C=#2TC=#0!^+/_!:K_DZ3PK_ -B;:_\ I=?5\0>%?N70_P!T?SK[?_X+
M5_\ )TGA7_L3;7_TMOJ^(/"OW;KZK_6OJN&/^1K2^?\ Z2S.I\!H?V+9'K#_
M ./'_&D_L.R_YX?^/-_C5^BOVIY7@'O0C_X"C@YI=RC_ &)9?\\/_'F_QI\U
MO';:?.D:[5$;8'7M5NH+W_CSG_ZYM_*LJV!PN'H5)4::B[/9)=!J3;29Q#5_
M5''_ *M?H*_E<:OZHX_]6OT%?SB]STA]%%%(#\ _^"I/_)]7Q*^FF?\ ILM*
M]4_8)_Y(YJG_ &&YO_1$%>5_\%2?^3ZOB5]-,_\ 39:5ZI^P3_R1S5?^PW-_
MZ(@K\^X[_P"1'4]8_F?=\%_\C>/HSZ2HHHK^7C^BEL%>/?M=_P#)NWBW_=M?
M_2J&O8:\>_:[_P"3=O%O^[:_^E4->]P__P C?"?]?(?^E(\;.O\ D6XC_!+\
MF?$/[*G_ "=%\'?^QRT?_P!+H:_I46OYJ_V5/^3HO@[_ -CEH_\ Z70U_2HM
M?V(?RF+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW:+?Z/JMK)97EJS,HEAD4JZ$J01D$C@]Z\ /_!-_]F\]?A=IYYS_ ,?MW_\
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M!5#X4_M"?MT_&KP#I/C/PGX1\!W_ (?U02-;7$GEQ,P21HVRCW0889&'([4
M?I6&S3J^2OV=_$?[7>H?%"R@^+_A7PEI7@EH)C<7&D21M.L@3,0&)W.-V >#
MW^M?6M !1110 5\K?\%1/^3%?B9_W#/_ $YVE?5-?*W_  5$_P"3%?B9_P!P
MS_TYVE 'X;_ _P#Y+)X'_P"PW9?^CTK]6_XJ_*3X'_\ )9/ _P#V&[+_ -'I
M7ZM_Q5^"^)7\?#>DOS1^V^'_ / K^J#N:*.YHK\79^L!7YJ_MB?\G%>*?I9_
M^DD-?I57YJ_MB?\ )Q7BGZ6?_I)#7ZOX<?\ (SJ_]>W_ .E1/S7CW_D74_\
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M_P BW$?X)?DSXA_94_Y.B^#O_8Y:/_Z70U_2HM?S5_LJ?\G1?!W_ +'+1_\
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MX7KX.\-^)OM?V+^QOWWVOR=GVCS^PVAM\'UV^U?5'_#"?[/O_1)O#7_@+_\
M7H _*X?\%@/V@O\ GX\,_P#@I_\ LZ_7C]ESXB:O\6?V?/ 7C#7FA?6=:TN.
M[NC;Q^6F]LYVKG@5S/\ PPC^S]T_X5+X;_\  7_Z]>R>%/">D>!O#MAH.@Z?
M#I6C6$0AM;.W7;'"@Z*H]* -:BBB@ HHHH **** "BBB@ HHHH **** $K\K
M/^"YW_-$_P#N-_\ MA7ZIU^5G_!<[_FB?_<;_P#;"@#ZJ_X)<_\ )BGPS_[B
M?_ISNZ^JJ^5?^"7/_)BGPS_[B?\ Z<[NOJJ@ HHHH **** /@#6/^4R.A?\
M8F-_Z)FK[_KX UC_ )3(Z%_V)C?^B9J^_P"@ HHHH **** $;I7\U_[6'_)T
MWQC_ .QSUG_TNFK^E!NE?S7_ +6'_)TWQD_['/6?_2Z:@#[9_9#_ .3=O"/T
MNO\ TKFKV*O'?V0_^3=O"/TNO_2N:O8J_CSB#_D;XO\ Z^2_]*9_5F2_\BS#
M?X(_D@H7I10O2O Z'LGS;^WK_P D9TS_ +#</_HB>O*?^"7'_)]GPR_[B?\
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M/_US;^53U!>_\><__7-OY5R8S_=JGH_R''XD<0U?U1Q_ZM?H*_E<:OZHX_\
M5K]!7\QO<]0?1112 _ /_@J3_P GU?$KZ:9_Z;+2O5/V"?\ DCFJ?]AN;_T1
M!7E?_!4G_D^KXE?33/\ TV6E>J?L$_\ )'-5_P"PW-_Z(@K\^X[_ .1'4]8_
MF?=\%_\ (WCZ,^DJ***_EX_HI;!7CW[7?_)NWBW_ ';7_P!*H:]AKQ[]KO\
MY-V\6_[MK_Z50U[W#_\ R-\)_P!?(?\ I2/&SK_D6XC_  2_)GQ#^RI_R=%\
M'?\ L<M'_P#2Z&OZ5%K^:O\ 94_Y.B^#O_8Y:/\ ^ET-?TJ+7]B'\IBT444
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M=\5?]CE=?^D-C7Z U^?W_!%7_DUWQ5_V.5U_Z0V-?H#7]%GX(%%%% !1110
M4444 %(W0TM(W0T ?BS_ ,%J_P#DZ3PK_P!B;:_^EM]7Q!X5^[=?5?ZU]O\
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MX[[/PH ^*/CM\;?'O[?W[0&C&'2%BU"\,>D:%X=LG:2.UC+EOF8CYCEF9Y"
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M?\A:;_@/\J^ XT_W"'^)?DSHH?$S]EO^"*G_ ":UXJ_['*Z_](;&OT K\_\
M_@BI_P FM>*O^QRNO_2&QK] *_%CM"OE;_@J)_R8K\3/^X9_Z<[2OJFOE;_@
MJ)_R8K\3/^X9_P"G.TH _#?X'_\ )9/ _P#V&[+_ -'I7ZM_Q5^4GP/_ .2R
M>!_^PW9?^CTK]6_XJ_!?$K^/AO27YH_;?#_^!7]4'<T4=S17XNS]8"OS5_;$
M_P"3BO%/TL__ $DAK]*J_-7]L3_DXKQ3]+/_ -)(:_5_#C_D9U?^O;_]*B?F
MO'O_ "+J?^-?DS]/_P#@BK_R:[XJ_P"QRNO_ $AL:_0&OS^_X(J_\FN^*O\
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M_P!E3_DZ+X._]CEH_P#Z70U_2HM?V(?RF+1110 4444 %%%% !1110 4444
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MM9?!G1O"/A'4-'T[4;/7X-5>76YI8H3$EM<Q%0T44AW;IT(&,8#<]!7Y\?\
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M_@EQ_P GV?#+_N)_^FN[KU;]O7_DC.F?]AN'_P!$3UY3_P $N/\ D^SX9?\
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M]"*@7  P!T&*  ( V[O3J** $;IZ5^5?_!<P;?\ A2G_ '&__;"OU4K\K/\
M@N=_S1/_ +C?_MA0!]5?\$N?^3%/AG_W$_\ TYW=?55?*O\ P2Y_Y,4^&?\
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MQO<]0?1112 _ /\ X*D_\GU?$KZ:9_Z;+2O5/V"?^2.:I_V&YO\ T1!7E?\
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M*_ +_@J-_P GU?$W_N&?^FRTK]_:_ +_ (*C?\GU?$W_ +AG_ILM*74#Y_\
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M^ XT_P!PA_B7Y,Z*'Q'[+?\ !%3_ )-:\5?]CE=?^D-C7Z 5^?\ _P $5/\
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M "?5\3?^X9_Z;+2EU ^?_#/_ "#V_P!_^@K6K)\,_P#(/;_?_H*UJ_HCA_\
MY%E'T/-J?$PHHHKZ$@H:[_R"9_H/YBND_9._Y.F^#?\ V.>C?^ET-<WKO_()
MG^@_F*Z3]D[_ ).F^#?_ &.>C?\ I=#7XMQI_O\ #_"OS9VT?A/Z4J6DI:^
M.@1NE?S7_M8?\G3?&/\ ['/6?_2Z:OZ4&Z5_-?\ M8?\G3?&3_L<]9_]+IJ
M/MG]D/\ Y-V\(_2Z_P#2N:O8J\=_9#_Y-V\(_2Z_]*YJ]BK^/.(/^1OB_P#K
MY+_TIG]69+_R+,-_@C^2"A>E%"]*\#H>R?-O[>O_ "1G3/\ L-P_^B)Z\I_X
M)<?\GV?#+_N)_P#IKNZ]6_;U_P"2,Z9_V&X?_1$]>4_\$N/^3[/AE_W$_P#T
MUW=?U#P)_P B2GZR_,_G;C3_ )&TO1'[_4445^@GP84444 %%%% !1110 5\
MK?\ !47_ ),5^)G_ '#/_3G:5]4U\K?\%1?^3%?B9_W#/_3G:4 ?@5I?_(0M
M_P#?7^==MVKB=+_Y"%O_ +Z_SKMNU?KW!/\ N];U1QU]PHHHK]*.8*Y'Q!_R
M%IO^ _RKKJY'Q!_R%IO^ _RKX#C3_<(?XE^3.BA\1^RW_!%3_DUKQ5_V.5U_
MZ0V-?H!7Y_\ _!%3_DUKQ5_V.5U_Z0V-?H!7XL=H5\K?\%1/^3%?B9_W#/\
MTYVE?5-?*W_!43_DQ7XF?]PS_P!.=I0!^&_P/_Y+)X'_ .PW9?\ H]*_5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\X*@O?\ CSG_ .N;?RJ>H+W_ (\Y_P#KFW\JY,9_NU3T?Y#C\2.(:OZHX_\
M5K]!7\KC5_5''_JU^@K^8WN>H/HHHI ?@'_P5)_Y/J^)7TTS_P!-EI7JG[!/
M_)'-4_[#<W_HB"O*_P#@J3_R?5\2OIIG_ILM*]4_8)_Y(YJO_8;F_P#1$%?G
MW'?_ "(ZGK'\S[O@O_D;Q]&?25%%%?R\?T4M@KQ[]KO_ )-V\6_[MK_Z50U[
M#7CW[7?_ ";MXM_W;7_TJAKWN'_^1OA/^OD/_2D>-G7_ "+<1_@E^3/B']E3
M_DZ+X._]CEH__I=#7]*BU_-7^RI_R=%\'?\ L<M'_P#2Z&OZ5%K^Q#^4Q:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX-_]CGHW_I=#7XMQI_O\/\*_-G;1^$_I2I:2EKX Z!&Z5_-?^UA_R=-\8_\
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M +'+1_\ TNAK^E1:_L0_E,6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_TZ7=?55 !7X!?\%1O^3ZOB9_W#/_39:5^_I/%?@'_P5%&?VZOB9G_J&?\
MIKM* /G[PU_R#V_W_P"@K6K)\-?\@]N_SG^0K6K^B,A:_LVCKT/.J?$PHHHK
MW[Q,RAKO_()G^@_F*Z3]D[_DZ;X-_P#8YZ-_Z70US>N_\@F?Z#^8KI/V3_\
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M-=\4_P#8Y77_ *0V-?H#7Y_?\$5\?\,N^*<?]#E=?^D-C7Z 5_1)^#"T4E%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A-7_P#\:H_X9C^/7_1(_B)_X35__P#&J_I(HKI^N8G_ )^/[V3RKL?S;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",NX8-?
M&_[6G_!,GP%^TUXCF\66.JW'@?QA. +N^M+=;BVO2  'F@+*2^ !N5US_%N.
M*^R:2@#\ROAI_P $3?#^D^(H+SQQ\1;OQ%I4+AVTS2M/^PF;!!P\QED(4X((
M50V#PP/(_27P[X=TWPGH=AHVC6,&F:380);6EE:QA(H(E "HJCH  *T *6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2OP"_YRG?\ =9O_ '.5^_K?
M=-?D"?V"_CK_ ,-\?\+('@?/@W_A9G_"0?VE_:]C_P >/]J?:/.\OS_,_P!5
M\VW;N[;<\4 ?K]2TT-[4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O@'_@M3_R:SX7_ .QRM/\ TBOJ^_:^0/\ @I]\
M!_'7[1'P#T'PW\/]"_M[6;7Q-;ZA-;?:X+;; MK=1L^Z:1%.&E08!SSTP":
M//\ _@BI_P FM>*O^QRNO_2&QK] *^/O^"7_ ,!?'7[._P !=?\ #?Q!T/\
ML#6KKQ-<:A#;?;(+G= UK:1J^Z&1U&6B<8)S\O3!&?L&@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:0]#0!^ 4W_*4
MH_\ 99/_ '-U^_HK\@9?V"_CJW[>Y^(X\#9\&_\ "R_^$@_M(:O8?\>/]J?:
M/-\OS_,_U7S;=N[MC/%?KXK9QQUH ?1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX.<TZFJV[M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI*\)^/\
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MMKFH%Q] \[+^8-?EA^V-^S-K7["_QWT=O#6MWDNDS!-5\.:V^U;F)HW&4<J
MIDC;:20 &#J<#)4?T MC!STK\P/^"X%C WACX2WA3-S%>:C"LF3\JO';EA^:
M+^7UR ?;7[(/QT;]HW]GGPAXYN(UBU6[MS;ZE$B[56[B8Q2E1DX1F4NHR<*X
MS5+]H3]M3X3_ +,MQ;V/C7Q"4UNYB\Z+1M/@:YNS'V=E7B-200"Y7.#C.#CY
MN_X(LZA-<?LS^*[20NT5OXLG,;,25 :TM257TP03Q_?)KD/B-_P2A\1?$O\
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M 5W@+NRS#Y!C'.0#W>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!%%I;3?VE:7/F2^>C[=L,KD?*I.2 .* /TKKRK]K#_ )-9^,?_ &)FL_\
MI#-7JM>?_M">%]3\<? /XE>'-%M?MNLZQX9U+3[*V\Q8_.GEM9(XTW,0JY9@
M,L0!GD@4 ?BY_P $FU_XS4\,?]@_4,_^ SU^\);BOP>\)_\ !.W]KSP'K46L
M>&?"&I>'=8A5ECU#2?%5A:W"!@0P$B788 @D'!Y!([UVUQ^RC^WYKT9L=3U/
MQM)8S?+*+WXA121;?]I?MK9'X&@"+_@L%\9])^(WQ_TGPMHMW'?V_@_3VMKN
M:%]R+>3/OEC!'!VHL(;!X;<IP5-??'['^B7'[+/_  3WL=:UNPEDO],T'4/%
ME[8@;)2&66Z2(AONOY7EJ0>C U\Z?LF_\$@[GPOXJT[Q3\9-2T[4$T^9;BV\
M,Z6S30RNN"IN9&4 J&R?*0%6P,L1E3^F/B+PWIWBSP[JF@ZK;)>:3J5K+975
MK)]V2&1"CH?8JQ'XT ?A)\)8/''_  4H_:4A\/\ Q"^(5U8V\\=QJ/EY+06T
M<8SY%I;EMBG#8]=H9F+'.?H#]M[]@OX*?LI?LOZCK6F7&K7_ (UNKVUM-,O-
M8U -([F0-*%BC5$(\I9.JG''.<&N!^)W_!*+XZ?"WQ\VH?"N5?%.FP77FZ9J
M.GZM%I^HVBCE3)YKQ!9%SC=&QS]["YP.UM?^"6_QO^*'A#Q'XH^+?C6_UGQE
M:Z3,?#^B3:P=0N9KI5S'%-<S,8XT)&W"L02P)90#D Z/_@AI\K?&OG_H"?\
MM_7JW_!8CX'GQU\!=+\>V,&_4_!MWFX89W-8W#)')P.NV00-ST&\UA_\$L_V
M;?C+^S/XR\=6?Q \#-H>A>(+*UDCU!=4LKD)<6[R!(RD4SO\RW$ASC *C/45
M]^>./!^F?$+P;KOAC6(?M&E:S936%U'D9:.5&1L>AP>#V.* /PMT7]KR73?^
M">.M?!<7)36I/$,<$"J2C+I4A:ZEP>_^D1E&'&5GP??[L_X(Y?!7_A"_@1J_
MC^]@V:CXPO=ENS9XL[8M&O!/&Z4SGW"H?2OR4M?A;?ZO\8D^'FCSPZMJ4VN?
MV%;7-N<Q7$AG\E9%()^0_>SZ5_27\._ NG?#/P#X=\(Z0ICTW0]/AT^VSG)2
M*-4#'GDG&3[DT >)?M;^*/V<-?T&7P/\;_$.@1A=EY'I]S=LM];,<[)8Q$?-
M0G!Y'WAD'()!^/-9_P""//@SXE>'-,\5_"/XK7(T'5;5;VP76K$7*RQNH9")
M4,3)UQAHRPZ'!&*^GOV[?V!]*_:ZTVPUK3-3A\.>/=)MVMK;4)XRUO=P9+""
M?;\P4,S%77.W>WRMG _/_3?V%_VU_A/'-H?@NZURVT=FW'_A&?&D=E:2,2<G
MRVN(FSZY0=: /!O$5A\2?V!?VC+K2[#Q%:VOBSP^\+O<:1<M+:W,<D:2B.12
M%)1E<;D=0><_W2?Z&_#&K-KWAW2=3:+[.U[:Q7)AY^0N@;;SZ9K\K_V<_P#@
MDAXSU?XB6WBKXXZO9MI\=RM[/I-O=F]NM2D#;BMQ*1M",1\Q#.S D?+UK]88
MXA$JJN%51@*HP![#VH DHHHH **** "BBB@!&^Z:_&#_ (*>? _XJ_$;]K+6
M=4\._#[QCXGT1-.L8+:\TS1;J[MAMA!=(W1&7 =G)4'J6)YK]GSS2*NW\\\4
M ?S]BW_;1LM.%L(/CQ;V$,7E^5MUI8DB QMQ]T*!QCI@5X7\,?\ A./^$[TW
M_A77_"0?\)G^\^P?\(OY_P#:&?*?S?*\C]YGR_,W;?X=V>,U_39KEN]UHM_#
M$I>22WD15! ))4@#)X_.OR/_ &#_ -@OXZ?!?]K'P/XS\8^!AI'AO33??:KW
M^UK&;R_,L;B),)%.SG+N@X7C// )H ^_/V"_^$W_ .&4_ __  L;_A(/^$R_
MT[[=_P )1Y_]H?\ ']<>7YOG_O/]7Y>W=_#MQ\N*^@J3%% 'XZ?\%MO^2W>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KEROS THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1173868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1050 Waltham Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">314-6297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,717,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2026 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2025.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001664710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Year Period</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KROS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred Share Purchase Rights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, MA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 287,415<span></span>
</td>
<td class="nump">$ 559,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">22,202<span></span>
</td>
<td class="nump">26,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Current income tax receivable</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">315,434<span></span>
</td>
<td class="nump">588,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">16,841<span></span>
</td>
<td class="nump">19,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">338,021<span></span>
</td>
<td class="nump">615,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">16,039<span></span>
</td>
<td class="nump">20,870<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,414<span></span>
</td>
<td class="nump">27,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">14,475<span></span>
</td>
<td class="nump">16,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,889<span></span>
</td>
<td class="nump">44,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December&#160;31, 2025 and 2024; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; 40,670,466 shares issued and 19,543,706 shares outstanding as of December&#160;31, 2025 and 40,554,705 shares issued and outstanding as of December&#160;31, 2024</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 21,126,760 and no shares as of December&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="num">(384,558)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,169,451<span></span>
</td>
<td class="nump">1,140,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(481,765)<span></span>
</td>
<td class="num">(568,779)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">303,132<span></span>
</td>
<td class="nump">571,553<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">338,021<span></span>
</td>
<td class="nump">615,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December&#160;31, 2025 and 2024; no shares issued and outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">40,670,466<span></span>
</td>
<td class="nump">40,554,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">19,543,706<span></span>
</td>
<td class="nump">40,554,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares)</a></td>
<td class="nump">21,126,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 244,061<span></span>
</td>
<td class="nump">$ 3,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(129,643)<span></span>
</td>
<td class="num">(173,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(46,849)<span></span>
</td>
<td class="num">(40,754)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(176,492)<span></span>
</td>
<td class="num">(214,383)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME (LOSS) FROM OPERATIONS</a></td>
<td class="nump">67,569<span></span>
</td>
<td class="num">(210,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE), NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendIncomeOperating', window );">Dividend income</a></td>
<td class="nump">24,867<span></span>
</td>
<td class="nump">23,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(539)<span></span>
</td>
<td class="num">(954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">24,328<span></span>
</td>
<td class="nump">23,780<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">91,897<span></span>
</td>
<td class="num">(187,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(4,883)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">87,014<span></span>
</td>
<td class="num">(187,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders - basic</a></td>
<td class="nump">87,014<span></span>
</td>
<td class="num">(187,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common stockholders - diluted</a></td>
<td class="nump">$ 87,014<span></span>
</td>
<td class="num">$ (187,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding - basic (in shares)</a></td>
<td class="nump">37,221,211<span></span>
</td>
<td class="nump">37,437,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding - diluted (in shares)</a></td>
<td class="nump">37,859,106<span></span>
</td>
<td class="nump">37,437,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share of common stock - basic (in dollars per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share of common stock - diluted (in dollars per share)</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,706<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 205,355<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Incentive, Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating dividend income on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th"><div>COMMON STOCK</div></th>
<th class="th">
<div>COMMON STOCK </div>
<div>At The Market Offering</div>
</th>
<th class="th"><div>TREASURY STOCK</div></th>
<th class="th"><div>ADDITIONAL PAID-IN CAPITAL</div></th>
<th class="th">
<div>ADDITIONAL PAID-IN CAPITAL </div>
<div>At The Market Offering</div>
</th>
<th class="th"><div>ACCUMULATED DEFICIT</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,841,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 332,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 713,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (381,426)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,841,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">332,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">713,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of underwriting discounts, commissions and offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025,000<span></span>
</td>
<td class="nump">4,290,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">151,057<span></span>
</td>
<td class="nump">$ 228,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,057<span></span>
</td>
<td class="nump">$ 228,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">12,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">34,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (187,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187,353)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts', window );">Commissions and offering cost</a></td>
<td class="nump">$ 9,943<span></span>
</td>
<td class="nump">$ 3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,554,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 571,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,140,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(568,779)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,554,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">571,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,140,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(568,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares, acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,126,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of treasury stock, including excise tax, direct fees and expenses of $9,558</a></td>
<td class="num">(384,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (384,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShortSwingProfitSettlement', window );">Short-swing profit settlement</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">73,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 87,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,014<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">21,126,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,126,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares)</a></td>
<td class="nump">21,126,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,126,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,670,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 303,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (384,558)<span></span>
</td>
<td class="nump">$ 1,169,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (481,765)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock, Discounts, Commissions and Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShortSwingProfitSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Swing Profit Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShortSwingProfitSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses', window );">Repurchase of treasury stock | $</a></td>
<td class="nump">$ 9,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of Treasury Stock, Excise Tax, Direct Fees and Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 87,014<span></span>
</td>
<td class="num">$ (187,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of fixed asset</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">28,696<span></span>
</td>
<td class="nump">34,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(825)<span></span>
</td>
<td class="num">(2,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,018<span></span>
</td>
<td class="num">(10,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Current income tax receivable</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,001)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RightToUseAssetsAndOperatingLeaseLiabilities', window );">Right-of-use assets and operating lease liabilities</a></td>
<td class="num">(1,978)<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(10,131)<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">107,505<span></span>
</td>
<td class="num">(160,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,551)<span></span>
</td>
<td class="num">(1,931)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,551)<span></span>
</td>
<td class="num">(1,931)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PaymentOfInitialPublicOfferingCosts', window );">Payment of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with issuance of common stock under the ATM agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of treasury stock</a></td>
<td class="num">(375,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PaymentOfStockRepurchaseCosts', window );">Payment of direct expenses associated with the treasury stock repurchase</a></td>
<td class="num">(3,897)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ProceedsFromShortSwingSettlementProfit', window );">Short-swing profit settlement</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">12,141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(378,470)<span></span>
</td>
<td class="nump">391,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="num">(272,516)<span></span>
</td>
<td class="nump">229,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">561,380<span></span>
</td>
<td class="nump">332,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">288,864<span></span>
</td>
<td class="nump">561,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">7,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases in accounts payable and accrued expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses', window );">Treasury stock repurchase costs in accounts payable and accrued expenses</a></td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use&#160;assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">287,415<span></span>
</td>
<td class="nump">559,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">288,864<span></span>
</td>
<td class="nump">561,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kros_SecondaryOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 228,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PaymentOfInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PaymentOfInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PaymentOfStockRepurchaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Stock Repurchase Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PaymentOfStockRepurchaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ProceedsFromShortSwingSettlementProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Short Swing Settlement Profit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ProceedsFromShortSwingSettlementProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RightToUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-to-Use Assets and Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RightToUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Repurchase Costs Still In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kros_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kros_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Keros Therapeutics, Inc. (&#8220;Keros&#8221; or the &#8220;Company&#8221;) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (&#8220;TGF-&#223;&#8221;) family of proteins. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company's lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. The Company&#8217;s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (&#8220;cytopenias&#8221;), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (&#8220;MDS&#8221;) and in patients with myelofibrosis.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since its inception in 2015, the Company has devoted the majority of its resources to business planning, research and development of its product candidates, including conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#8217;s $287.4 million cash and cash equivalents as of December&#160;31, 2025 will allow the Company to continue its operations for at least the next 12 months from the date these consolidated financial statements are issued. In the absence of a significant source of recurring revenue, the continued viability of the Company is dependent on its ability to continue to raise additional capital to finance its operations. If the Company is unable to obtain additional funding, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiaries, Keros Therapeutics Australia Pty Ltd (&#8220;Keros Australia&#8221;) and Keros Security Corporation, a Massachusetts securities corporation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, Keros Australia and Keros Security Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, useful lives assigned to property and equipment and accrued and prepaid research and development expenses. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:9.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company had no financial instruments measured at level 3 as of December&#160;31, 2025 or 2024. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of standard checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had restricted cash in the form of certificates of deposit related to its operating leases in Lexington, Massachusetts of $1.4 million as of December&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December&#160;31, 2025 and 2024, the Company&#8217;s cash and cash equivalents were held with three financial institutions. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are written off from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:52.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.329%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESTIMATED USEFUL LIFE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">lesser of useful life or remaining lease term</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than 12 months are recognized on the balance sheet as right-of-use, or ROU, assets and current and non-current lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2025, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records its repurchases of shares of common stock at cost. These shares are classified as treasury stock, which is a reduction of stockholders&#8217; equity.  Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock is included in shares authorized and issued but excluded from shares outstanding.  </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services with contract research organizations that conduct research, preclinical and clinical activities on the Company&#8217;s behalf, as well as contract manufacturing organizations that manufacture drug product for use in the Company&#8217;s preclinical studies and clinical trials, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Incentive</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development incentive income includes payments under the Research and Development Tax Incentive (the &#8220;R&amp;D Incentive&#8221;) from the Australian government. The R&amp;D Incentive is one of the key elements of the Australian government&#8217;s support for Australia&#8217;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development. Since July 1, 2021, the R&amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#8217;s aggregated revenue as follows:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Refundable tax offset of up to 18.5% above a company&#8217;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Non-refundable tax offset of up to 16.5% above a company&#8217;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has assessed its research and development (&#8220;R&amp;D&#8221;) activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;D Incentive. The Company estimates the refundable or non-refundable tax offset available to it based on available information at the time. This estimate is also reviewed by the Company&#8217;s external tax advisors on an annual basis.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s estimate of the cash refund it expects to receive related to the R&amp;D Incentive is included in other assets in the accompanying consolidated balance sheet and such amounts are recorded as research and development incentive income in the statement of operations. The Company recognizes research and development incentive income when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The Company did not record other income from the R&amp;D Incentive for the year ended December&#160;31, 2025. The Company has received payments and has recorded other income from the R&amp;D Incentive of $1.2 million for the year ended December&#160;31, 2024 related to the R&amp;D Incentive as defined above. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;606&#8221;). The Company enters into certain agreements that are within the scope of ASC 606, under which the Company licenses or grants an option to license rights to certain of the Company&#8217;s product candidates and may perform research and </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s arrangements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance arrangements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For combined performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If performance obligations are satisfied over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and the timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The functional currency for the Company&#8217;s wholly owned foreign subsidiary, Keros Australia, is the United States dollar. All foreign currency transaction gains and losses are recognized in the consolidated statement of operations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular concentration is focused on the discovery and development of novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-&#223; family of proteins. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Compensation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#8217;s stock-based awards include stock options and restricted stock unit ("RSU") awards. The measurement date for employee and non-employee awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Stock-based compensation expense is classified in the accompanying consolidated statement of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies weighted with its own volatility for the period in which its stock has been publicly traded. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for interest and penalties related to uncertain tax positions within the provision for income taxes. As of December&#160;31, 2025, there have been no interest or penalties recorded.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to net income (loss) for all periods presented.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period, and if dilutive, the weighted-average number of potential shares of common shares. The Company&#8217;s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2023-09&#8221;). ASU No. 2023-09 requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The new standard was effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU No. 2023-09 for its consolidated financial statements for the fiscal year ended December 31, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2024-03&#8221;), which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. While recent trends towards rising inflation have eased, prices continue to rise, which may materially affect the Company&#8217;s business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to the Company&#8217;s preclinical studies and clinical trials, interest rates and overhead costs may adversely affect its operating results. Implementation of tariffs present a recent challenge impacting the U.S. economy and could make it more difficult for the Company to obtain traditional financing on acceptable terms, if at all, in the future. Although the Company does not believe that inflation, higher interest rates or tariffs have had a material impact on its financial position or results of operations to date, the Company may experience increases in the near future (especially if inflation rates rise more quickly) on its operating costs, including its labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company&#8217;s working capital resources. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s financial statements.</span></div>In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.145%"><tr><td style="width:1.0%"></td><td style="width:43.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.153%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>There have been no transfers between fair value levels during the years ended December&#160;31, 2025 and 2024. The carrying values of prepaid expenses, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid sales tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid subscriptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest and dividend receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Refunds due from contract research organizations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation expense was $1.5 million and $1.2 million for the years ended December&#160;31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts General Hospital</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 5, 2016, the Company entered into an exclusive patent license agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital (&#8220;MGH&#8221;). Under the license agreement with MGH (as amended in May 2017 and February 2018, the &#8220;MGH Agreement&#8221;), the Company obtained an exclusive, worldwide license, with the right to sublicense, under certain patents and technical information of MGH, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products and processes for use in the treatment, diagnosis, palliation and prevention of diseases and disorders in humans and animals. The Company is required to use commercially reasonable efforts to develop and commercialize licensed products and processes and must achieve certain required diligence milestones.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the MGH Agreement, the Company is required to pay a low-five digit to mid-five digit annual maintenance fee prior to the first commercial sale of its first product or process, a mid-five digit annual maintenance fee after the first commercial sale of its first product or process that is creditable against royalties, certain clinical and regulatory milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $8.6&#160;million in the aggregate, and certain commercial milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $18.0&#160;million in the aggregate. The Company made payments of $50,000 and $300,000 in 2020 and 2021, respectively, for the achievement of the clinical and regulatory milestones of (i) filing of an IND in the first country and (ii) the completion of a Phase 1 clinical trial, respectively.  The Company is also obligated to pay tiered royalties on net sales of licensed products ranging in the low-single digits to mid-single digits. The royalty rates are subject to up to a maximum 50% reduction for lack of a valid claim, in the event that it is necessary for the Company to obtain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed product-by-licensed product and country-by-country basis upon the later of expiry of the last valid claim of the licensed patents that cover such licensed product in such country or ten years from the first commercial sale of such product in such country. The Company is also obligated to pay a percentage of non-royalty-related payments received by it from sublicensees ranging in the low-double digits and a change of control fee equal to a low-single digit percentage of the payments received as part of any completed transaction up to a low seven-digit amount.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The MGH Agreement expires upon expiry of the last remaining royalty obligation for a licensed product or process. Under the MGH Agreement, MGH may terminate the agreement upon the Company&#8217;s uncured material breach or insolvency, a challenge by the Company of the licensed patents and certain other specified breaches of the MGH Agreement. The Company may terminate the agreement for any reason upon specified prior written notice to MGH.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hansoh Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 12, 2021, the Company entered into a license agreement with Hansoh. Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;). Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock at a par value of $0.0001 per share. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company raised gross proceeds of $232.3 million pursuant to the &#8220;at the market offering,&#8221; in connection with our Sales Agreement with Leerink Partners LLC, as agent (&#8220;ATM Offering&#8221;), pursuant to which we sold 4,290,096 shares of common stock at a weighted average price of $54.14 per share. The net proceeds from the ATM Offering for the year ended December&#160;31, 2024 were approximately $228.6 million after deducting sales agent commissions of $3.5 million and offering expenses of less than $0.2 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On January&#160;8, 2024, the Company closed an underwritten public offering in which 4,025,000 shares of common stock were issued and sold, which included 525,000 shares of common stock issued and sold pursuant to the exercise in full of the underwriters&#8217; option to purchase additional shares, at a public offering price of $40.00 per share. The aggregate net proceeds from the public offering were approximately $151.1 million, after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Stockholder Rights Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 9, 2025, the Company&#8217;s board of directors (the &#8220;Board&#8221;) declared a dividend of one right (&#8220;Right&#8221;) to purchase one-thousandth of one share of the Company&#8217;s newly designated Series A Junior Participating Preferred Stock, par value $0.0001 per share (each, a &#8220;Preferred Share&#8221; and collectively, the &#8220;Preferred Shares&#8221;), for each outstanding share of common stock to the stockholders of record as of the close of business on April 24, 2025. The Company also adopted a limited duration stockholder rights plan (the &#8220;Rights Plan&#8221;), effective immediately, as set forth in the Rights Agreement, dated as of April 9, 2025 (the &#8220;Rights Agreement&#8221;), by and between the Company and Computershare Trust Company, N.A., as Rights Agent. The Rights Agent currently serves as the Company&#8217;s transfer agent with respect to the common stock and also has been appointed transfer agent with respect to the Preferred Shares, if any, that may be issued pursuant to the exercise of rights under the Rights Agreement. The Rights will expire on April 9, 2026, unless the rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Plan.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In general terms, the Rights Plan is designed to impose a penalty upon any person or group that acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of the outstanding shares of Common Stock without the approval of the Board. The Board adopted the Rights Plan in response to significant and rapid accumulations of </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">the common stock by a number of investors who have indicated a desire to influence the control of the Company. The Rights Plan is intended to protect the investment of the Company's stockholders during a period in which it believes shares of the Company do not reflect the Company&#8217;s intrinsic value. The Rights Plan will reduce the likelihood that any entity, person or group gains control of the Company through open-market accumulation without paying all stockholders an appropriate control premium. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a summary of the rights and privileges of the holders of common stock as of December&#160;31, 2025:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Preference: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Dividends: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. As of December&#160;31, 2025, no cash dividends have been declared or paid.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Rights and Preferences</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">: Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">716,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,901,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under the ESPP Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,641,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,247,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under 2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,146,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">861,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,406,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,494,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY STOCK<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">TREASURY STOCK</a></td>
<td class="text">TREASURY STOCK<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board may authorize the repurchase of shares of the Company&#8217;s common stock, in the open market or through negotiated transactions, at such times and at such prices as management deems appropriate. For the year ended December&#160;31, 2024, the Company did not acquire any shares of its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 15, 2025, the Company entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (collectively, the &#8220;ADAR1 Parties&#8221;) and certain entities affiliated with Pontifax Venture Capital (collectively, the &#8220;Pontifax Parties&#8221;). Such stock purchase agreements for each of the Pontifax and ADAR1 Parties are collectively referred to as &#8220;Repurchase Agreements&#8221;. Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to the Company at a price of $17.75 per share for an aggregate purchase price of $180.6 million, excluding excise tax, direct fees and expenses related to the repurchases. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 20, 2025, the Company commenced a tender offer to repurchase shares of its common stock at a cash purchase price of $17.75 per share  (the &#8220;Tender Offer&#8221;). The Tender Offer expired at 5:00 p.m. Eastern time on November 18, 2025, and following such expiration the Company accepted for purchase a total of 10,950,165 shares, for an aggregate purchase price of approximately $194.4 million, excluding excise tax, direct fees and expenses related to the Tender Offer.  More than 10,950,165 shares were tendered in the Tender Offer, and as such, shares were accepted for purchase on a pro rata basis, except for conditional tenders that were automatically regarded as withdrawn if the condition was not satisfied. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the accompanying consolidated balance sheets. </span></div>The completion of the Repurchase Agreements in October 2025 and the Tender Offer in November 2025 concluded the Company&#8217;s previously announced $375.0 million capital return program.  In connection with the Repurchase Agreements and Tender Offer, the Company incurred $9.6 million in excise tax, direct fees and expenses that were included in the cost of treasury stock in the accompanying consolidated balance sheets as of December&#160;31, 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board adopted the 2017 Stock Incentive Plan (the "2017 Plan") in February 2017, and the stockholders approved the 2017 Plan in March 2017. The 2017 Plan was most recently amended in March 2020.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there were an aggregate of 412,099 shares of common stock issuable upon the exercise of outstanding options under the 2017 Plan. Any options or awards outstanding under the 2017 Plan remain outstanding and effective.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2020, the 2020 Equity Incentive Plan (the "2020 Plan") became effective, and, as a result, no further awards will be made under the 2017 Plan. The 2020 Plan provides for the grant of stock options qualifying as incentive stock options ("ISOs"), to employees and for the grant of nonstatutory stock options ("NSOs"), restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to employees, consultants and directors. The 2020 Plan also provides for the grant of performance cash awards to employees, consultants and directors. Any previously granted awards under the 2017 Plan will remain outstanding in accordance with their respective terms. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the 2020 Plan, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. On January 1, 2024, the Company increased the number of shares available for future grant under the 2020 Plan by 1,273,643 shares. On January 1, 2025, the Company increased the number of shares available for future grant under the 2020 Plan by 1,622,188 shares. On January 1, 2026, the Company increased the number of shares available for future grant under the 2020 Plan by 781,748 shares. The awards granted under the 2020 Plan typically vest over a four-year period and have a 10-year contractual term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there were an aggregate of 3,489,607 shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan. Additionally, there were an aggregate of 3,146,054 shares reserved for future issuance under the 2020 Plan, including shares forfeited from the 2017 Plan.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of RSU award activity during the year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF UNITS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE GRANT-DATE FAIR VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,167,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(30,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">716,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The summary of RSU award activity includes 90,500 performance-based awards granted during the year ended December&#160;31, 2025. The weighted-average grant date fair value of RSU awards granted during the years ended December&#160;31, 2025 and 2024 was $11.71 and zero, respectively. The aggregate fair value of RSU awards that vested during the years ended December&#160;31, 2025 and 2024 was $0.5 million and zero, respectively. As of December&#160;31, 2025, there has been no expense recognized for the performance-based awards, for which the performance criteria was not deemed probable as of December&#160;31, 2025. As of December&#160;31, 2025, there was approximately $6.9 million of unrecognized stock-based compensation expense related to RSU awards that are expected to vest, including $1.4 million of unrecognized stock-based compensation expense related to performance-based awards for which the performance criteria is currently not deemed probable. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.71 years. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Valuation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December&#160;31, 2025 and 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">83.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">81.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of option activity during the year ended December&#160;31, 2025 is as follows (in thousands except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.870%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF<br/>OPTIONS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-<br/>AVERAGE<br/>EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (IN&#160;YEARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE<br/>INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(73,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(783,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(709,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,901,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38.52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,091,868&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">34.77&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span id="id1d28d2136374e9b8448ed57bce695c6_8-5-1-1-163929"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total intrinsic value of stock options exercised was $0.7 million and $10.1 million during the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during each of the years ended December&#160;31, 2025 and 2024 was $10.36 and $40.92, respectively. As of December&#160;31, 2025, there was $22.9 million of unrecognized stock-based compensation expense related to unvested service-based stock options and $2.9 million of unrecognized stock-based compensation expense related to performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 1.49 years. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The summary of option activity includes 125,000 performance-based options granted during the year ended December&#160;31, 2024. The options include performance-based and service-based vesting criteria. As of December&#160;31, 2025, the performance criteria was deemed probable for 50% of the performance-based options. Accordingly, the Company recorded $2.0 million stock-based compensation expense during the year end December&#160;31, 2025. Of the $2.9 million of unrecognized stock-based compensation expense, $0.4 million is related to service-based vesting criteria that the Company expects to recognize and $2.5 million is related to performance-based vesting criteria that are not considered probable as of December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2020, the Board adopted and the Company's stockholders approved the 2020 Employee Stock Purchase Plan ("ESPP"). The ESPP became effective on April 7, 2020. Under the ESPP, eligible employees can purchase shares of the Company's common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of the Company's common stock on the first trading day of the twenty-four month offering period, or on the applicable purchase date. Each offering under the ESPP consists of two twelve-month purchase periods.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the ESPP, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by the lesser of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 455,852 shares or (iii) or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by 405,547 shares. On January 1, 2026, the Company increased the number of shares available for future grant under the ESPP by 195,437 shares.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, 11,806 shares of common stock were purchased under the ESPP. As of December&#160;31, 2025, there was an aggregate of 1,641,602 shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December&#160;31, 2025 and 2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">34,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">INCOME (LOSS) PER SHARE</a></td>
<td class="text">INCOME (LOSS) PER SHARE<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.579%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,221,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,437,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">419,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">218,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">637,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding used to compute diluted net income (loss)<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,859,106&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,437,652&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"><tr><td style="width:1.0%"></td><td style="width:65.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">74,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(189,315)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,053)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the provision for income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred income tax provision</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025 in accordance with the guidance in the ASU No. 2023-09, which the Company has elected to prospectively adopt:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Difference between local tax rare and U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of changes in taw laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of cross-border tax laws</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(36.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the year ended December&#160;31, 2024 prior to adoption of ASU No. 2023-09:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.681%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income at U.S. statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign withholding taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The net deferred income tax asset balance as of December&#160;31, 2025 and 2024 related to the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">78,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">155,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(150,037)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $159.1 million and $27.9 million, respectively. The federal NOLs can be carried forward indefinitely. The state NOL carryforwards begin to expire in 2039.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had U.S. federal and state research and development tax credit carryforwards of $0.3 million and $0.1 million, respectively. The federal research and development tax credits expire in 2045. The state research and development tax credits expire in 2040.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the NOL and tax credit carryforwards are subject to review and potential adjustments by the Internal Revenue Services and state tax authorities. Under Section 382 of the Code (&#8220;Section 382&#8221;), certain substantial changes in the Company&#8217;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of NOL carryforwards or tax credits which could be used annually to offset future taxable income. Based on a previous Section 382 analysis that the Company performed, the Company determined that on April 15, 2016 and April 13, 2020, Section 382 ownership changes and limitations had occurred. Based on such analysis, the Company determined that $0.3 million and $0.3 million of its federal and state NOL carryforwards, respectively, were limited by Section 382 and therefore were previously written off. The Company had updated its analyses under Section 382 through November 21, 2025, and determined that, in addition to the previous Section 382 ownership changes and limitations on April 15, 2016 and April 13, 2020, a Section 382 ownership change occurred on November 21, 2025. As a result of the November 21, 2025 Section 382 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ownership change and limitation, $14.0 million of federal research and development tax credit carryforwards, $169.4 million of state NOL carryforwards and $5.9 million of state research and development tax credit carryforwards have been written off. Though subject to a Section 382 limitation, federal NOL carryforwards have not been written off since they can be carried forward indefinitely. The remaining unused carryforwards remain available for future periods. The Company may also experience ownership changes in the future as a result of subsequent shifts in the Company&#8217;s stock ownership, some of which may be outside the Company&#8217;s control. As a result, its ability to use its pre-change NOLs or tax credits to offset U.S. federal taxable income or tax may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOLs and research and development credits. Under the applicable accounting standards, management has considered the Company&#8217;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance was maintained as of December&#160;31, 2025 and 2024. A decrease in the Company&#8217;s valuation allowance was recorded in 2025 in the amount of $52.0 million primarily due to the reduction of net deferred tax assets related to capitalized research and development expenses, research and development tax credits and net operating loss carryforwards. An increase in the Company&#8217;s valuation allowance was recorded in 2024 in the amount of $50.6 million, primarily due to the generation of additional net deferred tax assets related to capitalized research and development expenses, net operating loss carryforwards and research and development tax credits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research and development (&#8220;R&amp;D&#8221;) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;D activities must be amortized over five years and costs for foreign R&amp;D activities must be amortized over 15 years &#8211; both using a midyear convention.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 4, 2025, President Trump signed H.R. 1, the One Big Beautiful Bill Act into law. The legislation included several changes to the Internal Revenue Code. These changes are generally effective for tax years beginning after December 31, 2025 except for changes related to the expensing of U.S.-based R&amp;D expenditures which was retroactively effective and available for tax years beginning after December 31, 2024 and the reinstatement of 100% bonus depreciation for qualified assets/property placed in service after January 19, 2025. The changes that were retroactively effective were reflected in the year ended December&#8239;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in.  ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal and state research credit carryforwards of $3.1 million, of which $2.0 million relate to positions taken in prior years and $1.1 million relate to current year positions. As of December&#160;31, 2025, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal research credit carryforwards of $0.1 million, which relate to current year positions. The Company does not have any other material gross unrecognized tax benefits related to income tax reserves. The Company does not expect any of its unrecognized tax benefits related to income tax reserves, if recognized, to impact its effective tax rate due to full valuation allowance in the United States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December&#160;31, 2025 and 2024, the Company had no interest or penalties related to unrecognized tax benefits. For the year ended December&#160;31, 2025, the Company paid $7.2 million of total income taxes, $4.9 million related to Australia and $2.3 million related to U.S. federal income taxes. For the year ended December&#160;31, 2024, the Company made zero payments for income taxes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to income tax examination by federal, state and foreign jurisdictions, where applicable. The Company recently closed an income tax examination with the state of Massachusetts for the tax years ended December 31, 2021 and 2022, with no material impact to the Company's financial statements. The Company&#8217;s tax years are still open under statute for income tax examination by the Internal Revenue Service (&#8220;IRS&#8221;) from December 31, 2022 to the present. There are currently no pending income tax examinations with the IRS. To the extent the Company has tax attribute </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">carryforwards, the tax years in which the tax attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state and foreign tax authorities to the extent utilized in a future period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 7, 2021, the Company entered into an indenture of lease (the &#8220;1050 Waltham Lease&#8221;) with Revolution Labs Owner LLC (the &#8220;Landlord&#8221;), pursuant to which the Company is leasing approximately 35,662 square feet of office, laboratory and vivarium space located at 1050 Waltham Street, Lexington, Massachusetts (the &#8220;Premises&#8221;) for its new principal executive office. Base rent was initially fixed at $0.2 million per month and will increase by approximately 3% per annum until the 1050 Waltham Lease expires on November&#160;30, 2031. The Company is obligated to reimburse the Landlord for certain variable costs, including its proportional share of taxes and operating expenses which are not included in the measurement of the 1050 Waltham Lease liability. In connection with its entry into the 1050 Waltham Lease, the Company has provided the Landlord a letter of credit in the amount of approximately $1.2 million, which is recognized as restricted cash within other assets on the consolidated balance sheets. The Company has the option to extend the term of the 1050 Waltham Lease for a period of an additional 5 years. As of December&#160;31, 2025, the Company has no reasonable certainty that this option to extend will be exercised. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a sublease (the &#8220;Sublease Agreement&#8221;) with Accent Therapeutics, pursuant to which the Company has sublet approximately 20,000 square feet of office and laboratory space located at 1050 Waltham Street, Lexington, Massachusetts, expanding the Company's existing headquarters. Accordingly, the Sublease Agreement for the premises was determined to be classified as an operating lease. Upon commencement of the sublease, the Company recorded an ROU asset of $5.7 million and a lease liability of $5.7 million. The term of the sublease commenced on July 1, 2024 (the "Sublease Commencement Date"). The Sublease Agreement has a term of 5 years and 3 months, measured from the Sublease Commencement Date. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s obligation for the payment of base rent for the premises began on the Sublease Commencement Date. Base rent was initially fixed at $71.00 per rentable square foot and the Company is only required to pay base rent on 17,500 square feet for the first year of the sublease. The Sublease Agreement also provides for three months of free rent. Base rent will increase by approximately 3% per annum until the Sublease Agreement expires on September&#160;30, 2029.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with its entry into the Sublease Agreement and as a security deposit, the Company provided Accent Therapeutics a letter of credit in the amount of approximately $0.2 million on the Sublease Commencement Date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the lease cost as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other information as of December&#160;31, 2025 and 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating leases </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate for the leases as of December&#160;31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Maturities of operating lease liabilities at December&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">MATURITY OF LEASE LIABILITY</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Included in the consolidated balance sheet:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into agreements in the normal course of business with contract manufacturing organizations for process development, raw material purchases and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancellable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancellable obligations of the Company&#8217;s service providers, up to the date of cancellation and, in the case of certain arrangements with contract manufacturing organizations, may include noncancellable fees. Under such agreements, the exact amounts owed by the Company in the event of termination will be based on the timing of the termination and the exact terms of the agreement.  As of December&#160;31, 2025, the Company has committed up to approximately $1.6 million under these agreements which are expected to be paid through 2029.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution of Proceeds</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to distribute 25% of any net cash proceeds it receives on or before December&#160;31, 2028 from the Takeda Agreement (as defined below) to its stockholders.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE FROM CONTRACTS WITH CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE FROM CONTRACTS WITH CUSTOMERS</a></td>
<td class="text">REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Hansoh License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a license agreement with Hansoh (the &#8220;Hansoh Agreement&#8221;). Under the Hansoh Agreement, the Company granted to Hansoh the exclusive right to develop, manufacture and commercialize elritercept and licensed products containing elritercept within the territories of mainland China, Hong Kong and Macau (the &#8220;Hansoh Territory&#8221;).</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from the Company, and the parties will also negotiate in good faith to enter into an agreement for commercial supply prior to any anticipated commercialization in the Hansoh Territory. In addition, Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Hansoh Agreement, the Company received a net one-time $18.0 million upfront license payment in January 2022. In addition to the upfront payment and development milestones achieved to date, the Company will also be eligible to receive up to an aggregate of (i) $23.5 million upon the achievement of specified development milestones and (ii) $144.0 million upon the achievement of specified net sales thresholds for all licensed products in the Hansoh Territory. If a licensed product is approved for marketing in the Hansoh Territory, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Hansoh&#8217;s obligation to pay royalties for a given licensed product in a given region in the Hansoh Territory will begin on the date of the first commercial sale for such licensed product in such region and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents or joint patents, and (iii) expiration of regulatory exclusivity in such region. During the royalty term, neither party will directly or indirectly commercialize a competing product in the Hansoh Territory.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Hansoh Agreement will continue in force on a region-by-region basis until the expiration of the royalty term. Hansoh may terminate the Agreement in its entirety for convenience, with notice. The Company may terminate the Hansoh Agreement in its entirety for a patent challenge brought by Hansoh or its affiliates or their sublicensees. Either party may terminate the Hansoh Agreement in its entirety (i) if the other party materially breaches the Hansoh Agreement and fails to cure such breach or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Hansoh Agreement and concluded that it was subject to ASC 606, as the Company viewed the Hansoh Agreement as a contract with a customer. As such, the Company assessed the terms of the Hansoh Agreement and identified a single performance obligation for the Company to provide Hansoh an exclusive license to develop, manufacture and commercialize elritercept and licensed products containing elritercept in the Hansoh Territory, including the underlying know-how related to such licenses. All other promised goods/services were deemed immaterial in the context of the Hansoh Agreement. Under the Hansoh Agreement, Hansoh was obligated to pay a one-time, net $18.0 million payment to the Company, which was paid in the first quarter of 2022.  The Company recognized a gross upfront fee of $20.0 million as revenue and $2.0 million in withholding tax on its consolidated statement of operations for the year ended December 31, 2021, and a receivable, net of withholding tax on its consolidated balance sheet as of December 31, 2021. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will recognize development milestone payments as revenue at the point in time when it is determined that it is probable such milestones will be achieved as all performance obligations will have been satisfied at the point which a milestone might occur (i.e., Hansoh will have assumed all responsibility for the activities under the Hansoh Agreement). The Company will recognize royalty payments and commercial milestone payments as the associated sales of licensed products are recorded by Hansoh, as they predominantly relate to the license granted with the Hansoh Agreement. The Company recognized $3.0 million as revenue and $0.3 million in withholding tax upon the achievement of a development milestone related to the Hansoh Agreement on its consolidated statement of operations for the year ended December 31, 2024, and a receivable, net of withholding tax, on its consolidated balance sheet as of December 31, 2024. Payment was received during the year ended December&#160;31, 2025.  No milestones were achieved during the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, the Company entered into a manufacturing technology transfer agreement (the &#8220;Tech Transfer Agreement&#8221;) with Hansoh, effective in June 2023. The Tech Transfer Agreement governs the transfer to Hansoh, by the Company of all documents and information required to complete the manufacturing technology transfer. Under the Tech Transfer Agreement, Hansoh is obligated to make certain payments to the Company, at the rates set forth in the Tech Transfer Agreement, as manufacturing technology transfer services are provided over the term of the Tech Transfer Agreement. The Company recognized $0.1 million and $0.1 million of service and other revenue for the years ended December&#160;31, 2025 and 2024,  respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Hansoh Agreement, the Company entered into a clinical product supply agreement (the &#8220;Supply Agreement&#8221;) with Hansoh, effective February 2024. The Company evaluated the Supply Agreement and concluded that it was subject to ASC 606, as the Company viewed the Supply Agreement as a contract with a customer. As such, the Company assessed the terms of the Supply Agreement and identified a single performance obligation for the Company to supply Hansoh with clinical product supply. The Company recognizes revenue at a point in time when control transfers, which is deemed to be at the shipping point when the clinical product supply is ready for shipment. The Company recognized $0.1 million and $0.4 million of other revenue for the years ended December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Takeda License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 3, 2024, the Company entered into a license agreement with Takeda, which became effective on January 16, 2025. Under the terms of the license agreement with Takeda (the "Takeda Agreement"), the Company granted to Takeda the exclusive right to develop, manufacture and commercialize elritercept and certain derivative compounds globally, excluding the territories of mainland China, Hong Kong and Macau (collectively, the "Takeda Territory"). Concurrent with the Takeda Agreement, the Company entered into a separate Transition Services Agreement with Takeda (&#8220;TSA&#8221;), pursuant to which the Company will provide certain transitional services to Takeda, including, but not limited to, clinical trial and manufacturing services, during the term of the TSA (the "Transition Services"). In January 2026, the initial fifteen month term of the TSA was extended for six months through October 2026. The Company will receive reimbursement of certain costs incurred by the Company in connection with providing the Transition Services. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the terms of the Takeda Agreement, the Company received a $200.0 million upfront payment in February 2025. In July 2025, a one-time $10.0 million development milestone was achieved upon dosing of the first patient in the Phase 3 RENEW clinical trial of elritercept. In addition to the upfront and development milestone payments, the Company is entitled to receive up to an aggregate of (i) $80.0 million upon the achievement of specified development milestones; (ii) $280.0 million upon the achievement of specified commercial milestones; and (iii) $740.0 million upon the achievement of specified sales </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">milestones. If a licensed product is approved for marketing in the Takeda Territory, the Company will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions.  The Company recognized $10.0 million as revenue upon the achievement of this development milestone related to the Takeda Agreement on its consolidated statement of operations for the year ended December&#160;31, 2025. Payment was received during the year ended December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Takeda&#8217;s obligation to pay royalties for a given licensed product in a given country in the Takeda Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Takeda Agreement will continue in force until the expiration of the royalty term. Takeda may terminate the Takeda Agreement (i) in its entirety or on a country-by-country basis for convenience, with notice or (ii) if Takeda reasonably determines that the development, manufacture, and commercialization of the licensed compound or licensed product pose a safety or public health risk. The Company may terminate the Takeda Agreement in its entirety in the event that Takeda or its affiliates bring a patent challenge. Either party may terminate the Takeda Agreement in its entirety (i) if the other party materially breaches the Takeda Agreement and fails to cure such breach; or (ii) upon the bankruptcy of the other party.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company assessed this arrangement in accordance with ASC 606 and concluded it is a contract with a customer as defined in ASC 606. As the Company entered into the Takeda Agreement and the TSA concurrently, they were evaluated as a single contract under ASC 606. The Company identified two performance obligations in the Takeda Agreement and TSA including the license to its intellectual property (&#8220;License and Know-How&#8221;) and the Transition Services. The Company determined that the License and Know-How were distinct from the Transition Services as Takeda is able to derive benefit from the License and Know-How upon delivery and the Transition Services do not modify the License and Know-How.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price at contract inception included fixed consideration consisting of the upfront fee of $200.0 million. The transaction price at inception also included estimated variable consideration of $51.4 million relating to the Transition Services revenue that was not constrained. The transaction price has been allocated to the License and Know-How and the Transition Services on a relative standalone selling price basis. The Company allocated $195.4 million of the transaction price to the License and Know-How, which was recognized at a point in time, when control of the License and Know-How was transferred to Takeda on the effective date of the Takeda Agreement. The remaining $56.1 million of the transaction price was allocated to the Transition Services, which will be recognized over time as services are provided using the input method, based on costs incurred to provide the Transition Services, as the level of costs incurred over-time best reflect the transfer of services. As of December&#160;31, 2025, the Company recognized $38.5 million of service revenue for the Transition Services and such services are substantially complete. Any remaining services to be performed pursuant to the TSA will be recognized as performed and based on rates agreed to in the TSA. The $10.0 million development milestone was recognized as license revenue upon achievement in July 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The remaining $80.0 million of specified development milestones, $280.0 million of specified commercial milestones and $740.0 million of specified sales milestones were considered constrained at contract inception and excluded from the transaction price since the Company could not conclude it is probable that a significant revenue reversal in the amount recognized will not occur. The sales-based milestone payments and royalties will be recognized upon occurrence based on the sales and usage-based royalty exception. The Company will reevaluate the transaction price at the end of each reporting period and will adjust the estimate of the transaction price as uncertain events are resolved or other changes in circumstances occur. The Company determined that the Takeda Agreement and TSA did not contain a significant financing component.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable were $3.6 million as of December&#160;31, 2025 and zero as of December&#160;31, 2024. Accounts receivable are amounts due from Takeda for the Transition Services.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue recognized from Takeda for the year ended December&#160;31, 2025 and  2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Takeda</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">243,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">REVENUE:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">244,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">LESS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rinvatercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Elritercept program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(38,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cibotercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical &amp; development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Compensation costs (excluding stock based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(48,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(35,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(13,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company manages operations on a consolidated basis as a single reportable and single operating segment focused on developing novel therapeutics. Segment revenue above is 100 percent attributed to the Company&#8217;s agreements with Takeda and Hansoh and is equal to consolidated total revenue. All revenues are derived in the United States where the agreements originated. The Company manages expenses on a program level. The significant expense categories outlined above align with the segment-level information that is regularly provided to the CODM to allocate resources, assess performance of the reportable segment, and make key operating decisions. On a quarterly basis, the CODM reviews financial information, including consolidated net income, clinical expenses by program, other company expenses and a long-range cash flow projection, to make resource decisions for the Company&#8217;s programs to achieve the approved corporate goals. No segment asset information is provided above as the CODM is focused on how expenses impact ending cash by period and overall cash runway.  Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. All long-lived assets are held in the United States.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">CORPORATE RESTRUCTURING</a></td>
<td class="text">CORPORATE RESTRUCTURING<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2025, the Board formally approved a plan to reduce the overall workforce by approximately 45% (the "2025 Restructuring"). In connection with the 2025 Restructuring, the Company incurred one-time employee termination benefits, including severance, retention and benefits costs. The total costs associated with the 2025 Restructuring was $3.1 million, including severance, retention and benefits costs, of which $2.5 million and $0.5 million were recognized as part of total <span style="-sec-ix-hidden:f-852">research and development</span> and <span style="-sec-ix-hidden:f-853">general and administrative expenses</span>, respectively, during the year ended December&#160;31, 2025. All costs have been incurred under the Company&#8217;s single reportable segment. The 2025 Restructuring was complete as of December&#160;31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued compensation and benefits costs as of December&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"><tr><td style="width:1.0%"></td><td style="width:77.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">RESTRUCTURING LIABILITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_KeithRegnanteMember', window );">Keith Regnante [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">On December 11, 2025, Keith Regnante, our Chief Financial Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 24,741 shares of our common stock to be acquired upon the settlement of restricted stock units, or RSUs, vesting on February 17, 2026 and August 15, 2026, owned by Mr. Regnante. The plan will expire on December 31, 2026, subject to early termination for certain specified events set forth in the plan.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Keith Regnante<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 11, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">385 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">24,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_LorenaLernerMember', window );">Lorena Lerner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">On December 10, 2025, Lorena Lerner, our Chief Scientific Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 19,577 shares of our common stock to be acquired upon the settlement of RSUs vesting on February 17, 2026 and August 15, 2026, owned by Dr. Lerner. The plan will expire on December 31, 2026, subject to early termination for certain specified events set forth in the plan.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Lorena Lerner<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 10, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">386 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">19,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_NimaFarzanMember', window );">Nima Farzan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">On December 5, 2025, Nima Farzan, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 7,875 shares of our common stock to be acquired upon the exercise of stock options or settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Nima Farzan<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our board of directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 5, 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 30, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">207 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">7,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_JuliusKnowlesMember', window );">Julius Knowles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">On December 5, 2025, Julius Knowles, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 2,625 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Julius Knowles<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 5, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 30, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">207 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_AlpnaSethMember', window );">Alpna Seth [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">On December 9, 2025, Alpna Seth, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 2,625 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Alpna Seth<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our board of directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 9, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 30, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">203 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=kros_JeanJacquesBienaimeMember', window );">Jean-Jacques Bienaim&#233; [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">On December 5, 2025, Jean-Jacques Bienaim&#233;, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the purchase of up to 7,000 shares of our common stock. The plan will expire on August 31, 2026, subject to early termination for certain specified events set forth in the plan<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jean-Jacques Bienaim&#233;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">member of our board of directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">On December 5, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">August 31, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">269 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_KeithRegnanteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_KeithRegnanteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_LorenaLernerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_LorenaLernerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_NimaFarzanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_NimaFarzanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_JuliusKnowlesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_JuliusKnowlesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_AlpnaSethMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_AlpnaSethMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=kros_JeanJacquesBienaimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=kros_JeanJacquesBienaimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data and information related to our product candidates, preclinical studies and clinical trials, which we refer to collectively as Information Systems and Data.  </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our information technology and security, or IT, management team, and legal, and risk management teams, together with our third-party service providers, help identify, assess and manage our cybersecurity threats and risks. In doing so, they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using a multi-faceted approach including use of manual and automated tools,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">internal and external IT audits, and IT security, governance, risk and compliance reviews, reviewing reports and using services that identify cybersecurity threats, conducting threat and vulnerability assessments, evaluating reported threats as well as the industry&#8217;s risk profile, and third-party-conducted red/blue team testing and tabletop incident response exercises.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: maintaining an incident response plan and policy, incident detection and response, maintaining a vulnerability management policy, maintaining disaster recovery and business continuity plans, conducting risk assessments, implementing security standards and certifications, maintaining network security controls, access controls, and physical security measures, asset management, systems monitoring, conducting proactive privacy and cybersecurity reviews of systems and applications, performing penetration testing using external third-party tools and techniques to test security controls, conducting employee training, monitoring emerging laws and regulations related to data protection and information security and implement appropriate changes and encrypting Information Systems and Data. In addition, we maintain cybersecurity insurance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes.  For example, our IT team works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. Additionally, our risk committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers and penetration testing firms.   </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight of applicable third-party service providers when handling or processing our Information Systems and Data. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider, including completion of security questionnaires, review of the vendor&#8217;s written security program, review of security assessments and reports, audits, and security assessment calls with the vendor&#8217;s security personnel. </span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, including under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">If our internal computer systems, or those used by our contract research organizations, or other contractors or consultants with whom we work, fail, suffer security incidents, or are or were otherwise compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes.  For example, our IT team works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. Additionally, our risk committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. Our audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. Our audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Financial Officer and General Counsel. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. Our Head of IT works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response plan includes reporting to our audit committee for certain cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity. These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to our audit committee on any appropriate items<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Financial Officer and General Counsel. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. Our Head of IT works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response plan includes reporting to our audit committee for certain cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiaries, Keros Therapeutics Australia Pty Ltd (&#8220;Keros Australia&#8221;) and Keros Security Corporation, a Massachusetts securities corporation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, Keros Australia and Keros Security Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, useful lives assigned to property and equipment and accrued and prepaid research and development expenses. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:9.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div>To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of standard checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are written off from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:52.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.329%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESTIMATED USEFUL LIFE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">lesser of useful life or remaining lease term</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for its leases under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than 12 months are recognized on the balance sheet as right-of-use, or ROU, assets and current and non-current lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and Indemnifications</a></td>
<td class="text">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_TreasuryStockPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text">The Company records its repurchases of shares of common stock at cost. These shares are classified as treasury stock, which is a reduction of stockholders&#8217; equity.  Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock is included in shares authorized and issued but excluded from shares outstanding.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services with contract research organizations that conduct research, preclinical and clinical activities on the Company&#8217;s behalf, as well as contract manufacturing organizations that manufacture drug product for use in the Company&#8217;s preclinical studies and clinical trials, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Research and Development Incentive and Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development incentive income includes payments under the Research and Development Tax Incentive (the &#8220;R&amp;D Incentive&#8221;) from the Australian government. The R&amp;D Incentive is one of the key elements of the Australian government&#8217;s support for Australia&#8217;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development. Since July 1, 2021, the R&amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#8217;s aggregated revenue as follows:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Refundable tax offset of up to 18.5% above a company&#8217;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt">Non-refundable tax offset of up to 16.5% above a company&#8217;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has assessed its research and development (&#8220;R&amp;D&#8221;) activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;D Incentive. The Company estimates the refundable or non-refundable tax offset available to it based on available information at the time. This estimate is also reviewed by the Company&#8217;s external tax advisors on an annual basis.</span></div>The Company&#8217;s estimate of the cash refund it expects to receive related to the R&amp;D Incentive is included in other assets in the accompanying consolidated balance sheet and such amounts are recorded as research and development incentive income in the statement of operations. The Company recognizes research and development incentive income when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for interest and penalties related to uncertain tax positions within the provision for income taxes. As of December&#160;31, 2025, there have been no interest or penalties recorded.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASC&#160;606&#8221;). The Company enters into certain agreements that are within the scope of ASC 606, under which the Company licenses or grants an option to license rights to certain of the Company&#8217;s product candidates and may perform research and </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s arrangements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance arrangements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For combined performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If performance obligations are satisfied over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and the timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The functional currency for the Company&#8217;s wholly owned foreign subsidiary, Keros Australia, is the United States dollar. All foreign currency transaction gains and losses are recognized in the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular concentration is focused on the discovery and development of novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-&#223; family of proteins.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#8217;s stock-based awards include stock options and restricted stock unit ("RSU") awards. The measurement date for employee and non-employee awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Stock-based compensation expense is classified in the accompanying consolidated statement of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies weighted with its own volatility for the period in which its stock has been publicly traded. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to net income (loss) for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period, and if dilutive, the weighted-average number of potential shares of common shares. The Company&#8217;s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2023-09&#8221;). ASU No. 2023-09 requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The new standard was effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU No. 2023-09 for its consolidated financial statements for the fiscal year ended December 31, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (&#8220;ASU No. 2024-03&#8221;), which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. While recent trends towards rising inflation have eased, prices continue to rise, which may materially affect the Company&#8217;s business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to the Company&#8217;s preclinical studies and clinical trials, interest rates and overhead costs may adversely affect its operating results. Implementation of tariffs present a recent challenge impacting the U.S. economy and could make it more difficult for the Company to obtain traditional financing on acceptable terms, if at all, in the future. Although the Company does not believe that inflation, higher interest rates or tariffs have had a material impact on its financial position or results of operations to date, the Company may experience increases in the near future (especially if inflation rates rise more quickly) on its operating costs, including its labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company&#8217;s working capital resources. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#8217;s financial statements.</span></div>In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_TreasuryStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_TreasuryStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:52.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.329%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESTIMATED USEFUL LIFE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">lesser of useful life or remaining lease term</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.145%"><tr><td style="width:1.0%"></td><td style="width:43.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">270,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.153%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUOTED PRICES<br/>ACTIVE MARKETS<br/>FOR IDENTICAL<br/>ASSETS (LEVEL&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNIFICANT OTHER<br/>OBSERVABLE<br/>INPUTS (LEVEL&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556,064&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid sales tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid subscriptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest and dividend receivable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Refunds due from contract research organizations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:52.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.329%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESTIMATED USEFUL LIFE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">lesser of useful life or remaining lease term</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external R&amp;D costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued external manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued excise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued legal and consultants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and 2024, the Company has reserved the following shares of common stock for future issuance:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">716,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,901,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under the ESPP Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,641,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,247,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Available under 2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,146,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">861,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,406,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,494,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of RSU award activity during the year ended December&#160;31, 2025 is as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF UNITS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE GRANT-DATE FAIR VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,167,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(30,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(420,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding RSU awards as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">716,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December&#160;31, 2025 and 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.91</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">83.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">81.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A summary of option activity during the year ended December&#160;31, 2025 is as follows (in thousands except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.870%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NUMBER OF<br/>OPTIONS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-<br/>AVERAGE<br/>EXERCISE PRICE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WEIGHTED-AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>TERM (IN&#160;YEARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGGREGATE<br/>INTRINSIC VALUE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(73,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(783,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(709,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,901,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38.52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,091,868&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">34.77&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span id="id1d28d2136374e9b8448ed57bce695c6_8-5-1-1-163929"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December&#160;31, 2025 and 2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">34,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.579%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,221,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,437,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">419,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of potentially dilutive restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">218,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total potentially dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">637,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding used to compute diluted net income (loss)<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">1</span></span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,859,106&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,437,652&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.00)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Unvested RSU awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,470,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,384,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,520,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,432,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Provision For (Benefit From) Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"><tr><td style="width:1.0%"></td><td style="width:65.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.164%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">74,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(189,315)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,053)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the provision for income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current income tax provision</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred income tax provision</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025 in accordance with the guidance in the ASU No. 2023-09, which the Company has elected to prospectively adopt:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S Federal statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State and local income tax, net of federal income tax effect<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">2</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Difference between local tax rare and U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of changes in taw laws or rates enacted in the current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of cross-border tax laws</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(36.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nontaxable or nondeductible items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following is a reconciliation of the Company&#8217;s U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the year ended December&#160;31, 2024 prior to adoption of ASU No. 2023-09:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.681%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income at U.S. statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign withholding taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The net deferred income tax asset balance as of December&#160;31, 2025 and 2024 related to the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">78,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,840&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">155,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(97,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(150,037)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The components of the lease cost as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,554</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,075&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other information as of December&#160;31, 2025 and 2024 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities<br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating leases </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate for the leases as of December&#160;31, 2025 and 2024 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liability</a></td>
<td class="text">Maturities of operating lease liabilities at December&#160;31, 2025 are as follows (in thousands):<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">MATURITY OF LEASE LIABILITY</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2030</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2031</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Included in the consolidated balance sheet:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue recognized from Takeda for the year ended December&#160;31, 2025 and  2024 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenue from Takeda</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">243,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">REVENUE:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">244,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">LESS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rinvatercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Elritercept program expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(38,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cibotercept program expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preclinical &amp; development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Compensation costs (excluding stock based compensation)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(45,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(48,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(35,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(26,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items<span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline">3</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(12,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(13,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(187,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE RESTRUCTURING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Accrued Compensation and Benefits Costs</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued compensation and benefits costs as of December&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"><tr><td style="width:1.0%"></td><td style="width:77.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">RESTRUCTURING LIABILITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of January 1, 2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expenses incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of December 31, 2025</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 287,415<span></span>
</td>
<td class="nump">$ 559,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>financialInstitution</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash | $</a></td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="nump">$ 1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_NumberOfFinancialInstitutions', window );">Number of financial institutions | financialInstitution</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_NumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financial Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_NumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Incentive, Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,520,042<span></span>
</td>
<td class="nump">5,432,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">41,207<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,470,286<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Available under the ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,549<span></span>
</td>
<td class="nump">47,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 270,713<span></span>
</td>
<td class="nump">$ 556,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">270,713<span></span>
</td>
<td class="nump">556,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">QUOTED PRICES ACTIVE MARKETS FOR IDENTICAL ASSETS (LEVEL&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">270,713<span></span>
</td>
<td class="nump">556,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">270,713<span></span>
</td>
<td class="nump">556,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PrepaidExternalRDCostsCurrent', window );">Prepaid external R&amp;D costs</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 15,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PrepaidExternalManufacturingCostsCurrent', window );">Prepaid external manufacturing costs</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">5,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_SalesTaxReceivableCurrent', window );">Prepaid sales tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PrepaidSubscriptionCurrent', window );">Prepaid subscriptions</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendAndInterestReceivable', window );">Interest and dividend receivable</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PrepaidLegalAndConsultants', window );">Prepaid legal and consultants</a></td>
<td class="nump">1,207<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RefundsDueFromContractResearchOrganizationsCurrent', window );">Refunds due from contract research organizations</a></td>
<td class="nump">14,480<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">2,397<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 22,202<span></span>
</td>
<td class="nump">$ 26,220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PrepaidExternalManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid External Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PrepaidExternalManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PrepaidExternalRDCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid External R&amp;D Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PrepaidExternalRDCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PrepaidLegalAndConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Legal And Consultants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PrepaidLegalAndConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PrepaidSubscriptionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Subscription, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PrepaidSubscriptionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RefundsDueFromContractResearchOrganizationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refunds Due From Contract Research Organizations Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RefundsDueFromContractResearchOrganizationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_SalesTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Tax Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_SalesTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendAndInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend and interest receivable from investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendAndInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 8,732<span></span>
</td>
<td class="nump">$ 7,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(4,435)<span></span>
</td>
<td class="num">(2,949)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,264<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=kros_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation expense</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued external R&amp;D costs</a></td>
<td class="nump">$ 2,662<span></span>
</td>
<td class="nump">$ 5,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_AccruedManufacturingCostsCurrent', window );">Accrued external manufacturing costs</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">4,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">10,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued excise tax</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and consultants</a></td>
<td class="nump">3,484<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 16,039<span></span>
</td>
<td class="nump">$ 20,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_AccruedManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_AccruedManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone', window );">Payment for achievement of clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kros_TheGeneralHospitalCorporationMember', window );">MGH | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee', window );">Number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone', window );">Clinical and regulatory milestone payments</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone', window );">Commercial milestone payments</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage', window );">Royalty rate, maximum reduction</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products Achieving Milestone to Trigger Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Agreement, Contract To Perform For Others, Clinical And Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Agreement, Contract To Perform For Others, Commercial Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Agreement, Contract To Perform For Others, Royalty Rate, Maximum Reduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Payment For Achievement Of Clinical And Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=kros_TheGeneralHospitalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=kros_TheGeneralHospitalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 08, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 09, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_CommonStockDividendNumberOfRightsPerShare', window );">Number of rights (in USD per share) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_CommonStockVotingRightsNumberOfVotes', window );">Number of votes per common share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_CommonStockBeneficialOwnershipPenaltyThreshold', window );">Beneficial ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_CommonStockBeneficialOwnershipPenaltyThreshold', window );">Beneficial ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 228,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_SaleOfStockStockIssuanceCosts', window );">Sale of stock, stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">4,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share) | $ / shares</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 151,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | O2025Q1Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from initial public offering, net of discounts and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_SaleOfStockAgentCommissions', window );">Sales agent commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_CommonStockBeneficialOwnershipPenaltyThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Beneficial Ownership Penalty Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_CommonStockBeneficialOwnershipPenaltyThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_CommonStockDividendNumberOfRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Dividend Number Of Rights Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_CommonStockDividendNumberOfRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_CommonStockVotingRightsNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number Of Votes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_CommonStockVotingRightsNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_SaleOfStockAgentCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Agent Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_SaleOfStockAgentCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_SaleOfStockStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_SaleOfStockStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=kros_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=kros_O2025Q1DividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=kros_O2025Q1DividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">9,406,212<span></span>
</td>
<td class="nump">7,494,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">716,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,901,706<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Available under the ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">1,641,602<span></span>
</td>
<td class="nump">1,247,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kros_A2020PlanMember', window );">Available under 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,146,054<span></span>
</td>
<td class="nump">861,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kros_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kros_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY STOCK (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2025</div></th>
<th class="th"><div>Oct. 15, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Authorized, number of shares repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,176,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares acquired, average cost per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of treasury stock</a></td>
<td class="nump">$ 194,400<span></span>
</td>
<td class="nump">$ 180,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer', window );">Shares acquired, price per share on commencement of tender offer (in USD per share)</a></td>
<td class="nump">$ 17.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares, acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,950,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized, amount</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember', window );">TREASURY STOCK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Acquired, Price Per Share on Commencement of Tender Offer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,696<span></span>
</td>
<td class="nump">$ 34,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="nump">$ 40.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,706<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,406,212<span></span>
</td>
<td class="nump">7,494,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=kros_TermLoanCreditAgreementThreeAmendmentMember', window );">Term Loan Credit Agreement Three Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding', window );">Share based compensation arrangement by share based payment award, annual increase percent of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kros_PerformanceBasedAwardsMember', window );">Performance Based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.71<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of RSU awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested award, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kros_UnvestedStockOptionsMember', window );">Unvested Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=kros_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, recognition expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, recognition not probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested award, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,706<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kros_A2017StockIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kros_A2020StockIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage', window );">Annual percentage increase in shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,188<span></span>
</td>
<td class="nump">1,273,643<span></span>
</td>
<td class="nump">3,146,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,489,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kros_A2020StockIncentivePlanMember', window );">2020 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">781,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="nump">195,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember', window );">Employee Stock Purchase Plan Twenty Twenty Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,641,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award, Annual Increase Percent of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Not Probable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=kros_TermLoanCreditAgreementThreeAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=kros_TermLoanCreditAgreementThreeAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kros_PerformanceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kros_PerformanceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kros_UnvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kros_UnvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=kros_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=kros_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kros_A2017StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kros_A2017StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kros_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kros_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) - Unvested RSU awards - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of beginning of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,167,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(30,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(420,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of end of period (in shares)</a></td>
<td class="nump">716,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding as of beginning of period (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">11.71<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="nump">12.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding as of end of period (in USD per share)</a></td>
<td class="nump">$ 12.37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 25 days<span></span>
</td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.59%<span></span>
</td>
<td class="nump">81.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>NUMBER OF OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of beginning of period (in shares)</a></td>
<td class="nump">5,384,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(73,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(783,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in USD per share)</a></td>
<td class="num">(709,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of end of period (in shares)</a></td>
<td class="nump">3,901,706<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">3,091,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED- AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of beginning of period (in USD per share)</a></td>
<td class="nump">$ 42.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">14.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in USD per share)</a></td>
<td class="nump">54.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">49.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of end of period (in USD per share)</a></td>
<td class="nump">38.52<span></span>
</td>
<td class="nump">$ 42.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in USD per share)</a></td>
<td class="nump">$ 34.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM (IN&#160;YEARS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>AGGREGATE INTRINSIC VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 12,209<span></span>
</td>
<td class="nump">$ 7,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 12,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 28,696<span></span>
</td>
<td class="nump">$ 34,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">18,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,408<span></span>
</td>
<td class="nump">$ 16,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 87,014<span></span>
</td>
<td class="num">$ (187,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding - basic (in shares)</a></td>
<td class="nump">37,221,211<span></span>
</td>
<td class="nump">37,437,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)</a></td>
<td class="nump">637,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding used to compute diluted net loss (in shares)</a></td>
<td class="nump">37,859,106<span></span>
</td>
<td class="nump">37,437,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share of common stock - basic (in dollars per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share of common stock - diluted (in dollars per share)</a></td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)</a></td>
<td class="nump">419,367<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Available under the ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)</a></td>
<td class="nump">218,528<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,520,042<span></span>
</td>
<td class="nump">5,432,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">41,207<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,470,286<span></span>
</td>
<td class="nump">5,384,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">8,549<span></span>
</td>
<td class="nump">47,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 74,804<span></span>
</td>
<td class="num">$ (189,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">17,093<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 91,897<span></span>
</td>
<td class="num">$ (187,053)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 4,883<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory tax rate</a></td>
<td class="nump">$ 19,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal income tax effect</a></td>
<td class="nump">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effect of changes in taw laws or rates enacted in the current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of cross-border tax laws</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">13,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(33,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount', window );">Nondeductible executive compensation</a></td>
<td class="nump">5,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="num">(2,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 4,883<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal income tax effect</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(3.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of changes in taw laws or rates enacted in the current period</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent', window );">Effect of cross-border tax laws</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Other permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(14.90%)<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Impact of foreign operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent', window );">Foreign withholding taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent', window );">Nondeductible executive compensation</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(36.30%)<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Changes in unrecognized tax benefits</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Difference between local tax rare and U.S. federal statutory tax rate</a></td>
<td class="nump">$ 1,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">$ (245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Difference between local tax rare and U.S. federal statutory tax rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 35,141<span></span>
</td>
<td class="nump">$ 45,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">16,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost', window );">Capitalized research and development expenses</a></td>
<td class="nump">53,477<span></span>
</td>
<td class="nump">78,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">7,667<span></span>
</td>
<td class="nump">7,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">2,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">102,840<span></span>
</td>
<td class="nump">155,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(97,991)<span></span>
</td>
<td class="num">(150,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">4,849<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="num">(4,608)<span></span>
</td>
<td class="num">(5,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Operating Lease Right of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Apr. 15, 2016</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52.0)<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, increase resulting from prior period tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Unrecognized tax benefits, increase resulting from current period tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_OperatingLossCarryforwardWriteOff', window );">Operating loss carryforward, written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_OperatingLossCarryforwardWriteOff', window );">Operating loss carryforward, written off</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_OperatingLossCarryforwardWriteOff', window );">Operating loss carryforward, written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_OperatingLossCarryforwardWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Write Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_OperatingLossCarryforwardWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2024 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeAreaOfSublease', window );">Lessee, area of sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Waltham lease for additional period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 16,841<span></span>
</td>
<td class="nump">$ 19,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">16,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=kros_AccentTherapeuticsIncMember', window );">Accent Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kros_PhaseAPremisesMember', window );">Phase A Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeAreaOfSublease', window );">Lessee, area of sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=kros_WalthamLeaseMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeaseMonthlyBaseRent', window );">Lessee, operating lease, monthly base rent</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeasePeriodForImprovement', window );">Operating lease, period for improvement</a></td>
<td class="text">8 years 4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage', window );">Percentage of annual increase in operating lease</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot', window );">Lessee, operating lease, monthly base rent per square foot | ft&#178;</a></td>
<td class="nump">71.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeaseAreaOfRentalSpace', window );">Lessee, operating lease, area of rental space | ft&#178;</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeAreaOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Area of Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeAreaOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Increase In Monthly Base Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeaseAreaOfRentalSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Rental Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeaseAreaOfRentalSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Base Rent Per Square Foot</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeasePeriodForImprovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Period For Improvement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeasePeriodForImprovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=kros_AccentTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=kros_AccentTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kros_PhaseAPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kros_PhaseAPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=kros_WalthamLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=kros_WalthamLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,231<span></span>
</td>
<td class="nump">$ 3,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable payments</a></td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">6,559<span></span>
</td>
<td class="nump">5,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeLeaseOtherInformationAbstract', window );"><strong>Lessee, Lease, Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8212; operating leases</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8212; operating leases</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeLeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Lease, Other Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeLeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Maturity of Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>MATURITY OF LEASE LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 4,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">4,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">3,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix', window );">2031</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">21,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">16,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Included in the consolidated balance sheet:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">$ 1,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">14,475<span></span>
</td>
<td class="nump">$ 16,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 16,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LesseeOperatingLeaseLiabilityToBePaidYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LesseeOperatingLeaseLiabilityToBePaidYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member', window );">Takeda Pharmaceuticals U.S.A., Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage', window );">Licenses agreement, planned stockholder distribution from proceeds, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licenses Agreement, Planned Stockholder Distribution from Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 03, 2024 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,061<span></span>
</td>
<td class="nump">$ 3,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,355<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member', window );">Takeda Pharmaceuticals U.S.A., Inc. | License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront license fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment', window );">Reimbursement from limited partnership investment</a></td>
<td class="nump">51,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member', window );">Takeda Pharmaceuticals U.S.A., Inc. | License and Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront license fee</a></td>
<td class="nump">195,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member', window );">Takeda Pharmaceuticals U.S.A., Inc. | Transition Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront license fee</a></td>
<td class="nump">$ 56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_HansohAgreementMember', window );">Hansoh Agreement | Hansoh Shanghai Healthtech Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration', window );">Revenue, remaining performance obligation, development milestones, variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration', window );">Revenue, remaining performance obligation, sales milestones, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RevenueFromContractWithCustomerWithholdingTaxes', window );">Withholding taxes from upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFeeWaiverTerms', window );">Term of the TSA</a></td>
<td class="text">fifteen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFeeWaiverTerms', window );">Term of the TSA</a></td>
<td class="text">six<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Hansoh Shanghai Healthtech Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Takeda Pharmaceuticals U.S.A., Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_LicenseAgreementUpfrontFee', window );">License agreement upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones', window );">Potential milestone, development based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PotentialMilestonePaymentsCommercialBasedMilestones', window );">Potential milestone payments, commercial-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_PotentialMilestonePaymentsSalesBasedMilestones', window );">Potential milestone payments, sales-based milestones</a></td>
<td class="nump">$ 740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_TechTransferAgreementMember', window );">Tech Transfer Agreement | Manufacturing Technology Transfer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_ServiceAndOtherRevenue', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_SupplyAgreementMember', window );">Supply Agreement | Clinical Product Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Upfront Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PotentialMilestonePaymentsCommercialBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments, Commercial-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PotentialMilestonePaymentsCommercialBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PotentialMilestonePaymentsDevelopmentBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments, Development Based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PotentialMilestonePaymentsDevelopmentBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_PotentialMilestonePaymentsSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments, Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_PotentialMilestonePaymentsSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RevenueFromContractWithCustomerWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Withholding Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RevenueFromContractWithCustomerWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Development Milestones, Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Sales Milestones, Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_ServiceAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service And Other Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_ServiceAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFeeWaiverTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of term of contractual and voluntary fee waiver agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFeeWaiverTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementFromLimitedPartnershipInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReimbursementFromLimitedPartnershipInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kros_TakedaPharmaceuticalsU.S.A.Inc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_LicenseAndKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_LicenseAndKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_TransitionServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_TransitionServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_HansohAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_HansohAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kros_HansohShanghaiHealthtechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kros_HansohShanghaiHealthtechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_TechTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_TechTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kros_ManufacturingTechnologyTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kros_ManufacturingTechnologyTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=kros_SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=kros_ClinicalProductSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=kros_ClinicalProductSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue from Takeda</a></td>
<td class="nump">$ 243,864<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=kros_LicenseRevenueMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue from Takeda</a></td>
<td class="nump">205,355<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue from Takeda</a></td>
<td class="nump">$ 38,509<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 244,061<span></span>
</td>
<td class="nump">$ 3,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(129,643)<span></span>
</td>
<td class="num">(173,629)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">87,014<span></span>
</td>
<td class="num">(187,353)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">244,061<span></span>
</td>
<td class="nump">3,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Compensation costs (excluding stock based compensation)</a></td>
<td class="num">(45,331)<span></span>
</td>
<td class="num">(48,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(12,101)<span></span>
</td>
<td class="num">(13,917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">87,014<span></span>
</td>
<td class="num">(187,353)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment | Rinvatercept program expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(7,081)<span></span>
</td>
<td class="num">(16,090)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment | Elritercept program expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(38,030)<span></span>
</td>
<td class="num">(44,319)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment | Cibotercept program expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(12,562)<span></span>
</td>
<td class="num">(29,777)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment | Preclinical &amp; development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(6,847)<span></span>
</td>
<td class="num">(12,008)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember', window );">Reportable Segment | Other external costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (35,095)<span></span>
</td>
<td class="num">$ (26,708)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=kros_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_RinvaterceptProgramExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_RinvaterceptProgramExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_ElriterceptProgramExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_ElriterceptProgramExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_CiboterceptProgramExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_CiboterceptProgramExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_PreclinicalDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_PreclinicalDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=kros_OtherExternalCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=kros_OtherExternalCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE RESTRUCTURING - Narrative (Details) - 2025 Restructuring<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated (as a percent)</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring and related, expected cost</a></td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">3,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and Development Expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">General and Administrative Expense<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Expenses incurred<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses incurred</a></td>
<td class="nump">3,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(2,909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>kros_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=kros_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>187</ContextCount>
  <ElementCount>414</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - TREASURY STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/TREASURYSTOCK</Role>
      <ShortName>TREASURY STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMELOSSPERSHARE</Role>
      <ShortName>INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS</Role>
      <ShortName>REVENUE FROM CONTRACTS WITH CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - CORPORATE RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/CORPORATERESTRUCTURING</Role>
      <ShortName>CORPORATE RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMELOSSPERSHARETables</Role>
      <ShortName>INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/INCOMELOSSPERSHARE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/INCOMETAXES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/LEASES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables</Role>
      <ShortName>REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SEGMENTREPORTINGTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/SEGMENTREPORTING</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - CORPORATE RESTRUCTURING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables</Role>
      <ShortName>CORPORATE RESTRUCTURING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/CORPORATERESTRUCTURING</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LICENSEAGREEMENTSDetails</Role>
      <ShortName>LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/LICENSEAGREEMENTS</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - TREASURY STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/TREASURYSTOCKDetails</Role>
      <ShortName>TREASURY STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/TREASURYSTOCK</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails</Role>
      <ShortName>INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/INCOMELOSSPERSHARETables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails</Role>
      <ShortName>INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/INCOMELOSSPERSHARETables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - LEASES - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails</Role>
      <ShortName>LEASES - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - LEASES - Schedule of Maturity of Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails</Role>
      <ShortName>LEASES - Schedule of Maturity of Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails</Role>
      <ShortName>REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails</Role>
      <ShortName>REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - CORPORATE RESTRUCTURING - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails</Role>
      <ShortName>CORPORATE RESTRUCTURING - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="kros-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails</Role>
      <ShortName>CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="kros-20251231.htm">kros-20251231.htm</File>
    <File>kros-20251231.xsd</File>
    <File>kros-20251231_cal.xml</File>
    <File>kros-20251231_def.xml</File>
    <File>kros-20251231_lab.xml</File>
    <File>kros-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>kros-20251231_g1.jpg</File>
    <File>kros-20251231_g10.jpg</File>
    <File>kros-20251231_g11.jpg</File>
    <File>kros-20251231_g12.jpg</File>
    <File>kros-20251231_g13.jpg</File>
    <File>kros-20251231_g14.jpg</File>
    <File>kros-20251231_g15.jpg</File>
    <File>kros-20251231_g2.jpg</File>
    <File>kros-20251231_g3.jpg</File>
    <File>kros-20251231_g4.jpg</File>
    <File>kros-20251231_g5.jpg</File>
    <File>kros-20251231_g6.jpg</File>
    <File>kros-20251231_g7.jpg</File>
    <File>kros-20251231_g8.jpg</File>
    <File>kros-20251231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="650">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="51">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kros-20251231.htm": {
   "nsprefix": "kros",
   "nsuri": "http://www.kerostx.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "kros-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "kros-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "kros-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "kros-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "kros-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kros-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 353,
   "keyCustom": 61,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 39,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/ecd/2025": 6,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://www.kerostx.com/20251231": 1
   },
   "contextCount": 187,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 715,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 650,
    "http://xbrl.sec.gov/ecd/2025": 51,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://fasb.org/srt/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://www.kerostx.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.kerostx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:IncomeTaxesReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kros:RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION",
     "longName": "9952157 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952159 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS",
     "longName": "9952160 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET",
     "longName": "9952161 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "longName": "9952162 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.kerostx.com/role/LICENSEAGREEMENTS",
     "longName": "9952163 - Disclosure - LICENSE AGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.kerostx.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952164 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.kerostx.com/role/TREASURYSTOCK",
     "longName": "9952165 - Disclosure - TREASURY STOCK",
     "shortName": "TREASURY STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952166 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.kerostx.com/role/INCOMELOSSPERSHARE",
     "longName": "9952167 - Disclosure - INCOME (LOSS) PER SHARE",
     "shortName": "INCOME (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.kerostx.com/role/INCOMETAXES",
     "longName": "9952168 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.kerostx.com/role/LEASES",
     "longName": "9952169 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS",
     "longName": "9952171 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS",
     "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.kerostx.com/role/SEGMENTREPORTING",
     "longName": "9952172 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.kerostx.com/role/CORPORATERESTRUCTURING",
     "longName": "9952173 - Disclosure - CORPORATE RESTRUCTURING",
     "shortName": "CORPORATE RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9955513 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables",
     "longName": "9955514 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables",
     "longName": "9955515 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "longName": "9955516 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955517 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9955518 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.kerostx.com/role/INCOMELOSSPERSHARETables",
     "longName": "9955519 - Disclosure - INCOME (LOSS) PER SHARE (Tables)",
     "shortName": "INCOME (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.kerostx.com/role/INCOMETAXESTables",
     "longName": "9955520 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.kerostx.com/role/LEASESTables",
     "longName": "9955521 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables",
     "longName": "9955522 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)",
     "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.kerostx.com/role/SEGMENTREPORTINGTables",
     "longName": "9955523 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables",
     "longName": "9955524 - Disclosure - CORPORATE RESTRUCTURING (Tables)",
     "shortName": "CORPORATE RESTRUCTURING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
     "longName": "9955525 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9955526 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kros:NumberOfFinancialInstitutions",
      "unitRef": "financialinstitution",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "kros:NumberOfFinancialInstitutions",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails",
     "longName": "9955527 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails",
     "longName": "9955528 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9955529 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails",
     "longName": "9955530 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "kros:PrepaidExternalRDCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "kros:PrepaidExternalRDCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
     "longName": "9955531 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "9955532 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "longName": "9955533 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "kros:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "kros:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails",
     "longName": "9955534 - Disclosure - LICENSE AGREEMENTS (Details)",
     "shortName": "LICENSE AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955535 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "kros:CommonStockDividendNumberOfRightsPerShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
     "longName": "9955536 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Preferred Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.kerostx.com/role/TREASURYSTOCKDetails",
     "longName": "9955537 - Disclosure - TREASURY STOCK (Details)",
     "shortName": "TREASURY STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-95",
      "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955538 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
     "longName": "9955539 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails",
     "longName": "9955540 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Valuation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "longName": "9955541 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
     "longName": "9955543 - Disclosure - INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details)",
     "shortName": "INCOME (LOSS) PER SHARE - Basic and Diluted Loss Per Share Calculation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
     "longName": "9955544 - Disclosure - INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "longName": "9955545 - Disclosure - INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "shortName": "INCOME TAXES - Schedule of Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails",
     "longName": "9955546 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Details)",
     "shortName": "INCOME TAXES - Schedule of Components of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
     "longName": "9955547 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails",
     "longName": "9955548 - Disclosure - INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details)",
     "shortName": "INCOME TAXES - Schedule of Net Deferred Income Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9955549 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.kerostx.com/role/LEASESNarrativeDetails",
     "longName": "9955550 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "kros:LesseeAreaOfSublease",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "kros:LesseeAreaOfSublease",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails",
     "longName": "9955551 - Disclosure - LEASES - Schedule of Lease Costs (Details)",
     "shortName": "LEASES - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails",
     "longName": "9955552 - Disclosure - LEASES - Schedule of Maturity of Lease Liability (Details)",
     "shortName": "LEASES - Schedule of Maturity of Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955553 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
     "longName": "9955554 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)",
     "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails",
     "longName": "9955555 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955556 - Disclosure - Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.kerostx.com/role/SegmentReportingNarrativeDetails",
     "longName": "9955557 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
     "longName": "9955558 - Disclosure - CORPORATE RESTRUCTURING - Narrative (Details)",
     "shortName": "CORPORATE RESTRUCTURING - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails",
     "longName": "9955559 - Disclosure - CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)",
     "shortName": "CORPORATE RESTRUCTURING - Schedule of Accrued Compensation and Benefits Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "kros:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "kros:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kros-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "kros_A2017StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "A2017StockIncentivePlanMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan",
        "label": "2017 Stock Incentive Plan [Member]",
        "documentation": "2017 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "kros_A2020PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "A2020PlanMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available under 2020 Plan",
        "label": "2020 Plan [Member]",
        "documentation": "2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "kros_A2020StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "A2020StockIncentivePlanMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "kros_A2025RestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "A2025RestructuringMember",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Restructuring",
        "label": "2025 Restructuring [Member]",
        "documentation": "2025 Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "AU",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia",
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "kros_AccentTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AccentTherapeuticsIncMember",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accent Therapeutics, Inc",
        "label": "Accent Therapeutics, Inc [Member]",
        "documentation": "Accent Therapeutics, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r814"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "kros_AccruedManufacturingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AccruedManufacturingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued external manufacturing costs",
        "label": "Accrued Manufacturing Costs, Current",
        "documentation": "Accrued Manufacturing Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and consultants",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "kros_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued external R&amp;D costs",
        "label": "Accrued Research And Development Costs, Current",
        "documentation": "Accrued Research And Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r138",
      "r598"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r814",
      "r1171"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADDITIONAL PAID-IN CAPITAL",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1114",
      "r1173"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r875",
      "r885",
      "r918"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r910",
      "r919",
      "r923",
      "r931"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r425",
      "r434"
     ]
    },
    "kros_AlpnaSethMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AlpnaSethMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpna Seth [Member]",
        "documentation": "Alpna Seth"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r95",
      "r140",
      "r163",
      "r164",
      "r165",
      "r210",
      "r222",
      "r247",
      "r251",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r494",
      "r496",
      "r541",
      "r585",
      "r586",
      "r591",
      "r682",
      "r762",
      "r763",
      "r777",
      "r814",
      "r822",
      "r824",
      "r839",
      "r1058",
      "r1059",
      "r1127"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r145",
      "r163",
      "r164",
      "r165",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r494",
      "r496",
      "r541",
      "r814",
      "r1058",
      "r1059",
      "r1127"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r805"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "kros_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.kerostx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.kerostx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.kerostx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment purchases in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r136",
      "r740"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r62",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r62"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "kros_CiboterceptProgramExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "CiboterceptProgramExpensesMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cibotercept program expenses",
        "label": "Cibotercept Program Expenses [Member]",
        "documentation": "Cibotercept Program Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/CoverPage",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r141",
      "r142",
      "r143",
      "r163",
      "r165",
      "r191",
      "r195",
      "r202",
      "r204",
      "r212",
      "r213",
      "r260",
      "r298",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r325",
      "r326",
      "r328",
      "r329",
      "r331",
      "r334",
      "r337",
      "r338",
      "r341",
      "r344",
      "r351",
      "r541",
      "r638",
      "r639",
      "r640",
      "r641",
      "r646",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r669",
      "r690",
      "r709",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r953",
      "r1024",
      "r1026",
      "r1035"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r212",
      "r328",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r502",
      "r638",
      "r639",
      "r640",
      "r641",
      "r778",
      "r953",
      "r1022",
      "r1024"
     ]
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36"
     ]
    },
    "kros_ClinicalProductSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ClinicalProductSupplyAgreementMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Product Supply Agreement",
        "label": "Clinical Product Supply Agreement [Member]",
        "documentation": "Clinical Product Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 14)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r87",
      "r592",
      "r668"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r289",
      "r290",
      "r732",
      "r1047",
      "r1053"
     ]
    },
    "kros_CommonStockBeneficialOwnershipPenaltyThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "CommonStockBeneficialOwnershipPenaltyThreshold",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial ownership (in percent)",
        "label": "Common Stock, Beneficial Ownership Penalty Threshold",
        "documentation": "Common Stock, Beneficial Ownership Penalty Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "kros_CommonStockDividendNumberOfRightsPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "CommonStockDividendNumberOfRightsPerShare",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of rights (in USD per share)",
        "label": "Common Stock Dividend Number Of Rights Per Share",
        "documentation": "Common Stock Dividend Number Of Rights Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/CoverPage",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "COMMON STOCK",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1031",
      "r1032",
      "r1034",
      "r1114",
      "r1170",
      "r1173"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r669",
      "r688",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December\u00a031, 2025 and December\u00a031, 2024; 40,670,466 shares issued and 19,543,706 shares outstanding as of December\u00a031, 2025 and 40,554,705 shares issued and outstanding as of December\u00a031, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r326",
      "r333",
      "r594",
      "r814"
     ]
    },
    "kros_CommonStockVotingRightsNumberOfVotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "CommonStockVotingRightsNumberOfVotes",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per common share held",
        "label": "Common Stock, Voting Rights, Number Of Votes",
        "documentation": "Common Stock, Voting Rights, Number Of Votes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Compensation costs (excluding stock based compensation)",
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r975"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "kros_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "verboseLabel": "Computer equipment and software",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer Equipment And Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r752"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails",
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r163",
      "r169",
      "r170",
      "r310",
      "r339",
      "r573",
      "r580",
      "r590",
      "r742",
      "r743",
      "r744",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r1110",
      "r1111",
      "r1112",
      "r1113"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1022",
      "r1028",
      "r1107"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1022",
      "r1028"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1022",
      "r1028"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1022",
      "r1028",
      "r1107"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r946"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r944"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r945"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r943"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r940"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r41",
      "r42",
      "r84",
      "r86",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r812",
      "r1022",
      "r1023",
      "r1025",
      "r1030",
      "r1048",
      "r1049",
      "r1050",
      "r1122",
      "r1123",
      "r1137"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r812",
      "r1022",
      "r1023",
      "r1025",
      "r1030",
      "r1048",
      "r1049",
      "r1050",
      "r1122",
      "r1123",
      "r1137"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred income tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r103",
      "r1022",
      "r1028"
     ]
    },
    "kros_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development expenses",
        "label": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Cost",
        "documentation": "Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "kros_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "documentation": "Deferred Tax Assets Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use asset",
        "label": "Deferred Tax Liabilities Operating Lease Right of Use Asset",
        "documentation": "Deferred Tax Liabilities Operating Lease Right of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofNetDeferredIncomeTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24",
      "r157",
      "r745",
      "r746",
      "r748",
      "r750"
     ]
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r389",
      "r420",
      "r421",
      "r423",
      "r793"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendAndInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendAndInterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and dividend receivable",
        "label": "Dividend and Interest Receivable",
        "documentation": "Amount of dividend and interest receivable from investment."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r714",
      "r839"
     ]
    },
    "us-gaap_DividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend income",
        "label": "Dividend Income, Operating",
        "documentation": "Amount of operating dividend income on securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r645",
      "r691",
      "r720",
      "r721",
      "r836",
      "r837",
      "r1175"
     ]
    },
    "us-gaap_DividendsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsAxis",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends [Axis]",
        "label": "Dividends [Axis]",
        "documentation": "Information by event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1064"
     ]
    },
    "us-gaap_DividendsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsDomain",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends [Domain]",
        "label": "Dividends [Domain]",
        "documentation": "Event wherein earnings are distributed to shareholder."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1064"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends payable",
        "label": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r85",
      "r835",
      "r1138"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868",
      "r911"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Period",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share of common stock - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r153",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r188",
      "r191",
      "r202",
      "r203",
      "r204",
      "r209",
      "r324",
      "r424",
      "r488",
      "r493",
      "r515",
      "r516",
      "r584",
      "r603",
      "r753"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share of common stock - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r153",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r191",
      "r202",
      "r203",
      "r204",
      "r209",
      "r324",
      "r424",
      "r488",
      "r493",
      "r515",
      "r516",
      "r584",
      "r603",
      "r753"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r206"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME (LOSS) PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r207",
      "r208"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r797"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r167",
      "r446",
      "r479",
      "r797"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r797",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of changes in taw laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r797",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of cross-border tax laws",
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of cross-border tax laws",
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between local tax rare and U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r450",
      "r797",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "kros_EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign withholding taxes",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Withholding Taxes, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Line Items]",
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r797"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r457",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "kros_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1022",
      "r1029",
      "r1098",
      "r1100"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1022",
      "r1029",
      "r1098",
      "r1100"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1022",
      "r1029",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of foreign operations",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1029",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r797",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation [Table]",
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r797"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r797",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r457",
      "r1022",
      "r1029",
      "r1098"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1022",
      "r1029",
      "r1098",
      "r1100"
     ]
    },
    "kros_ElriterceptProgramExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ElriterceptProgramExpensesMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elritercept program expenses",
        "label": "Elritercept Program Expenses [Member]",
        "documentation": "Elritercept Program Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense related to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested award, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available under the ESPP Plan",
        "verboseLabel": "Employee stock purchase plan shares",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Stock Options",
        "netLabel": "Options to purchase common stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "kros_EmployeeStockPurchasePlanTwentyTwentyMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "EmployeeStockPurchasePlanTwentyTwentyMemberMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan Twenty Twenty Member",
        "label": "Employee Stock Purchase Plan Twenty Twenty Member [Member]",
        "documentation": "Employee Stock Purchase Plan Twenty Twenty Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r126",
      "r127",
      "r128",
      "r149",
      "r150",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r184",
      "r186",
      "r211",
      "r261",
      "r262",
      "r273",
      "r323",
      "r352",
      "r424",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r555",
      "r572",
      "r602",
      "r627",
      "r628",
      "r629",
      "r646",
      "r709"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r879",
      "r912"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r529",
      "r805"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r529",
      "r805"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r528",
      "r529",
      "r531",
      "r536",
      "r575",
      "r576",
      "r577",
      "r738",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r805",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r522",
      "r805",
      "r1118",
      "r1120"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r524",
      "r526",
      "r527",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r583",
      "r805",
      "r808"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QUOTED PRICES ACTIVE MARKETS FOR IDENTICAL ASSETS (LEVEL\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r374",
      "r379",
      "r380",
      "r519",
      "r529",
      "r536",
      "r575",
      "r738",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r805",
      "r811"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r374",
      "r379",
      "r380",
      "r382",
      "r519",
      "r520",
      "r529",
      "r536",
      "r576",
      "r738",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r805",
      "r811"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r519",
      "r520",
      "r521",
      "r522",
      "r529",
      "r536",
      "r577",
      "r738",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r805",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r522",
      "r805",
      "r1118",
      "r1120"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r528",
      "r529",
      "r531",
      "r536",
      "r575",
      "r576",
      "r577",
      "r738",
      "r773",
      "r774",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r805",
      "r807",
      "r811"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r919"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture",
        "verboseLabel": "Office furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on disposal of fixed asset",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees and Indemnifications",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "kros_HansohAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "HansohAgreementMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hansoh Agreement",
        "label": "Hansoh Agreement [Member]",
        "documentation": "Hansoh Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "kros_HansohShanghaiHealthtechCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "HansohShanghaiHealthtechCoLtdMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hansoh Shanghai Healthtech Co Ltd",
        "label": "Hansoh Shanghai Healthtech Co Ltd [Member]",
        "documentation": "Hansoh Shanghai Healthtech Co Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r868"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r69"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r445"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r89",
      "r94",
      "r585",
      "r587",
      "r600",
      "r747",
      "r749",
      "r751",
      "r756",
      "r762",
      "r1037",
      "r1039",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r166",
      "r445"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r276",
      "r281",
      "r498",
      "r499",
      "r500",
      "r501",
      "r523",
      "r525",
      "r530",
      "r542",
      "r543",
      "r544",
      "r624",
      "r626",
      "r694",
      "r736",
      "r738",
      "r798",
      "r799",
      "r803",
      "r804",
      "r806",
      "r811",
      "r1108",
      "r1109",
      "r1141"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r281",
      "r498",
      "r499",
      "r500",
      "r501",
      "r523",
      "r525",
      "r530",
      "r542",
      "r543",
      "r544",
      "r624",
      "r626",
      "r694",
      "r736",
      "r738",
      "r798",
      "r799",
      "r803",
      "r804",
      "r806",
      "r811",
      "r1108",
      "r1109",
      "r1141"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r446",
      "r447",
      "r461",
      "r473",
      "r797",
      "r1104"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r446",
      "r447",
      "r461",
      "r473",
      "r797",
      "r1104"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r167",
      "r439",
      "r446",
      "r458",
      "r459",
      "r460",
      "r465",
      "r471",
      "r480",
      "r482",
      "r483",
      "r484",
      "r589",
      "r633",
      "r643",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseDetails",
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r104",
      "r163",
      "r185",
      "r186",
      "r210",
      "r230",
      "r251",
      "r444",
      "r446",
      "r481",
      "r604",
      "r747",
      "r749",
      "r751",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Incentive and Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r442",
      "r443",
      "r465",
      "r466",
      "r470",
      "r475",
      "r637"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r797",
      "r1098"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of changes in taw laws or rates enacted in the current period",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r446",
      "r451",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference between local tax rare and U.S. federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r450",
      "r797",
      "r1098"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r797"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1098",
      "r1100"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1098",
      "r1100"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income tax, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r797",
      "r1098"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r797",
      "r1098"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESScheduleofReconciliationofStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r1098",
      "r1100"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r64",
      "r1019",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r159",
      "r472",
      "r473"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r964"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current income tax receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of options and awards granted under the employee stock purchase plan (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r204",
      "r388"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r910",
      "r919",
      "r923",
      "r931"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "us-gaap_InvestmentCompanyFeeWaiverTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentCompanyFeeWaiverTerms",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of the TSA",
        "label": "Investment Company, Fee Waiver Terms",
        "documentation": "Description of term of contractual and voluntary fee waiver agreement."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "kros_IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions and offering cost",
        "label": "Issuance of Common Stock, Discounts, Commissions and Offering Costs",
        "documentation": "Issuance of Common Stock, Discounts, Commissions and Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "kros_JeanJacquesBienaimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "JeanJacquesBienaimeMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jean-Jacques Bienaim\u00e9 [Member]",
        "documentation": "Jean-Jacques Bienaim\u00e9"
       }
      }
     },
     "auth_ref": []
    },
    "kros_JuliusKnowlesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "JuliusKnowlesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Julius Knowles [Member]",
        "documentation": "Julius Knowles"
       }
      }
     },
     "auth_ref": []
    },
    "kros_KeithRegnanteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "KeithRegnanteMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Keith Regnante [Member]",
        "documentation": "Keith Regnante"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r957"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r957"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r813"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LesseeAreaOfSublease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeAreaOfSublease",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, area of sublease",
        "label": "Lessee, Area of Sublease",
        "documentation": "Lessee, Area of Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571"
     ]
    },
    "kros_LesseeLeaseOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeLeaseOtherInformationAbstract",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Other Information [Abstract]",
        "label": "Lessee, Lease, Other Information [Abstract]",
        "documentation": "Lessee, Lease, Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "kros_LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual increase in operating lease",
        "label": "Lessee, Operating Lease, Annual Increase In Monthly Base Payment, Percentage",
        "documentation": "Lessee, Operating Lease, Annual Increase In Monthly Base Payment, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LesseeOperatingLeaseAreaOfRentalSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeaseAreaOfRentalSpace",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, area of rental space",
        "label": "Lessee, Operating Lease, Area of Rental Space",
        "documentation": "Lessee, Operating Lease, Area of Rental Space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Lease Liability",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "kros_LesseeOperatingLeaseLiabilityToBePaidYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearSix",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Six",
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Year Six"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "kros_LesseeOperatingLeaseMonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeaseMonthlyBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, monthly base rent",
        "label": "Lessee, Operating Lease, Monthly Base Rent",
        "documentation": "Lessee, Operating Lease, Monthly Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, monthly base rent per square foot",
        "label": "Lessee, Operating Lease, Monthly Base Rent Per Square Foot",
        "documentation": "Lessee, Operating Lease, Monthly Base Rent Per Square Foot"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LesseeOperatingLeasePeriodForImprovement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LesseeOperatingLeasePeriodForImprovement",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, period for improvement",
        "label": "Lessee, Operating Lease, Period For Improvement",
        "documentation": "Lessee, Operating Lease, Period For Improvement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waltham lease for additional period",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding, amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r825"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r163",
      "r164",
      "r165",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r495",
      "r496",
      "r497",
      "r541",
      "r667",
      "r755",
      "r777",
      "r839",
      "r1058",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r88",
      "r596",
      "r814",
      "r822",
      "r824",
      "r1022",
      "r1027",
      "r1044",
      "r1121"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r135",
      "r163",
      "r164",
      "r165",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r495",
      "r496",
      "r497",
      "r541",
      "r814",
      "r1058",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "kros_LicenseAgreementUpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LicenseAgreementUpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement upfront fee",
        "label": "License Agreement Upfront Fee",
        "documentation": "License Agreement Upfront Fee"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LicenseAndKnowHowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LicenseAndKnowHowMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Know-How",
        "label": "License and Know-How [Member]",
        "documentation": "License and Know-How"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1067"
     ]
    },
    "kros_LicenseRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LicenseRevenueMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License revenue [Member]",
        "documentation": "License revenue"
       }
      }
     },
     "auth_ref": []
    },
    "kros_LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses agreement, planned stockholder distribution from proceeds, percentage",
        "label": "Licenses Agreement, Planned Stockholder Distribution from Proceeds, Percentage",
        "documentation": "Licenses Agreement, Planned Stockholder Distribution from Proceeds, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "kros_LorenaLernerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "LorenaLernerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lorena Lerner [Member]",
        "documentation": "Lorena Lerner"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r291",
      "r292",
      "r293",
      "r297",
      "r435",
      "r771",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r291",
      "r292",
      "r293",
      "r297",
      "r435",
      "r771",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "verboseLabel": "Laboratory equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r779",
      "r782",
      "r816",
      "r820",
      "r1140",
      "r1142",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "kros_ManufacturingTechnologyTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ManufacturingTechnologyTransferAgreementMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Technology Transfer Agreement",
        "label": "Manufacturing Technology Transfer Agreement [Member]",
        "documentation": "Manufacturing Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r217",
      "r292",
      "r293",
      "r294",
      "r295",
      "r383",
      "r415",
      "r416",
      "r417",
      "r435",
      "r522",
      "r581",
      "r623",
      "r625",
      "r632",
      "r659",
      "r660",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r768",
      "r778",
      "r792",
      "r798",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809",
      "r810",
      "r817",
      "r1060",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r217",
      "r292",
      "r293",
      "r294",
      "r295",
      "r383",
      "r415",
      "r416",
      "r417",
      "r435",
      "r522",
      "r581",
      "r623",
      "r625",
      "r632",
      "r659",
      "r660",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r768",
      "r778",
      "r792",
      "r798",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809",
      "r817",
      "r1060",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r779",
      "r782",
      "r816",
      "r820",
      "r1140",
      "r1142",
      "r1143",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r65",
      "r91",
      "r128",
      "r133",
      "r146",
      "r147",
      "r151",
      "r163",
      "r164",
      "r165",
      "r168",
      "r174",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r200",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r324",
      "r327",
      "r330",
      "r335",
      "r424",
      "r488",
      "r493",
      "r516",
      "r541",
      "r601",
      "r689",
      "r707",
      "r708",
      "r747",
      "r749",
      "r751",
      "r837",
      "r1058"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) attributable to common stockholders - basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r154",
      "r178",
      "r179",
      "r180",
      "r181",
      "r188",
      "r189",
      "r201",
      "r204",
      "r327",
      "r330",
      "r335",
      "r493"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to common stockholders - diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r190",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r204"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "kros_NimaFarzanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "NimaFarzanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nima Farzan [Member]",
        "documentation": "Nima Farzan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r876",
      "r886",
      "r910",
      "r919"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE), NET:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions",
        "label": "Number Of Financial Institutions",
        "documentation": "Number Of Financial Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r1038"
     ]
    },
    "kros_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations",
        "documentation": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "kros_NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products",
        "label": "Number of Products Achieving Milestone to Trigger Maintenance Fee",
        "documentation": "Number of Products Achieving Milestone to Trigger Maintenance Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.kerostx.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r1038"
     ]
    },
    "kros_O2025Q1DividendsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "O2025Q1DividendsMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "O2025Q1Dividends",
        "label": "O 2025 Q1 Dividends [Member]",
        "documentation": "O 2025 Q1 Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME (LOSS) FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r747",
      "r751",
      "r756",
      "r1037",
      "r1039",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r813"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MATURITY OF LEASE LIABILITY",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails",
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Included in the consolidated balance sheet:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/LEASESScheduleofMaturityofLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r565"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate \u2014 operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r813"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term \u2014 operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r813"
     ]
    },
    "kros_OperatingLossCarryforwardWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "OperatingLossCarryforwardWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforward, written off",
        "label": "Operating Loss Carryforward, Write Off",
        "documentation": "Operating Loss Carryforward, Write Off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r129",
      "r130",
      "r131",
      "r634",
      "r635"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r814"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "kros_OtherExternalCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "OtherExternalCostsMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other external costs",
        "label": "Other External Costs [Member]",
        "documentation": "Other External Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r814"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r802"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r874",
      "r884",
      "r917"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r877",
      "r887",
      "r920"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r877",
      "r887",
      "r920"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PaymentOfInitialPublicOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PaymentOfInitialPublicOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of issuance costs",
        "label": "Payment Of Initial Public Offering Costs",
        "documentation": "Payment Of Initial Public Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PaymentOfStockRepurchaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PaymentOfStockRepurchaseCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of direct expenses associated with the treasury stock repurchase",
        "label": "Payment of Stock Repurchase Costs",
        "documentation": "Payment of Stock Repurchase Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of treasury stock",
        "terseLabel": "Repurchase of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r1017"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of issuance costs associated with issuance of common stock under the ATM agreement",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "kros_PerformanceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PerformanceBasedAwardsMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Awards",
        "label": "Performance Based Awards [Member]",
        "documentation": "Performance Based Awards"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Stock Options",
        "label": "Performance Based Stock Options [Member]",
        "documentation": "Performance Based Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PhaseAPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PhaseAPremisesMember",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase A Premises",
        "label": "Phase A Premises [Member]",
        "documentation": "Phase A Premises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "kros_PotentialMilestonePaymentsCommercialBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PotentialMilestonePaymentsCommercialBasedMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments, commercial-based milestones",
        "label": "Potential Milestone Payments, Commercial-based Milestones",
        "documentation": "Potential Milestone Payments, Commercial-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PotentialMilestonePaymentsDevelopmentBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PotentialMilestonePaymentsDevelopmentBasedMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone, development based milestones",
        "label": "Potential Milestone Payments, Development Based Milestones",
        "documentation": "Potential Milestone Payments, Development Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PotentialMilestonePaymentsSalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PotentialMilestonePaymentsSalesBasedMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments, sales-based milestones",
        "label": "Potential Milestone Payments, Sales-based Milestones",
        "documentation": "Potential Milestone Payments, Sales-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PreclinicalDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PreclinicalDevelopmentExpensesMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical &amp; development expenses",
        "label": "Preclinical &amp; Development Expenses [Member]",
        "documentation": "Preclinical &amp; Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1170",
      "r1173"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r669"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r337"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r669",
      "r688",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December\u00a031, 2025 and 2024; no shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r326",
      "r332",
      "r593",
      "r814"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "kros_PrepaidExternalManufacturingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PrepaidExternalManufacturingCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid external manufacturing costs",
        "label": "Prepaid External Manufacturing Costs, Current",
        "documentation": "Prepaid External Manufacturing Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PrepaidExternalRDCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PrepaidExternalRDCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid external R&amp;D costs",
        "label": "Prepaid External R&amp;D Costs, Current",
        "documentation": "Prepaid External R&amp;D Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r769",
      "r1045"
     ]
    },
    "kros_PrepaidLegalAndConsultants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PrepaidLegalAndConsultants",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid legal and consultants",
        "label": "Prepaid Legal And Consultants",
        "documentation": "Prepaid Legal And Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "kros_PrepaidSubscriptionCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "PrepaidSubscriptionCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid subscriptions",
        "label": "Prepaid Subscription, Current",
        "documentation": "Prepaid Subscription, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9"
     ]
    },
    "kros_ProceedsFromShortSwingSettlementProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ProceedsFromShortSwingSettlementProfit",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-swing profit settlement",
        "label": "Proceeds from Short Swing Settlement Profit",
        "documentation": "Proceeds from Short Swing Settlement Profit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails",
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r123",
      "r255",
      "r582",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r739",
      "r746",
      "r749",
      "r751",
      "r779",
      "r780",
      "r815",
      "r817",
      "r818",
      "r821",
      "r826",
      "r956",
      "r959",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1056",
      "r1057",
      "r1140",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails",
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r123",
      "r255",
      "r582",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r739",
      "r746",
      "r749",
      "r751",
      "r779",
      "r780",
      "r815",
      "r817",
      "r818",
      "r821",
      "r826",
      "r956",
      "r959",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1056",
      "r1057",
      "r1140",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r570"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r137",
      "r599"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r570",
      "r588",
      "r599",
      "r814"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r100",
      "r101",
      "r597"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETTables",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives",
        "verboseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r570"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1030",
      "r1137"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r217",
      "r292",
      "r293",
      "r294",
      "r295",
      "r373",
      "r383",
      "r415",
      "r416",
      "r417",
      "r423",
      "r435",
      "r522",
      "r578",
      "r579",
      "r581",
      "r623",
      "r625",
      "r632",
      "r659",
      "r660",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r768",
      "r778",
      "r792",
      "r798",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809",
      "r810",
      "r817",
      "r829",
      "r1051",
      "r1060",
      "r1118",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r217",
      "r292",
      "r293",
      "r294",
      "r295",
      "r373",
      "r383",
      "r415",
      "r416",
      "r417",
      "r423",
      "r435",
      "r522",
      "r578",
      "r579",
      "r581",
      "r623",
      "r625",
      "r632",
      "r659",
      "r660",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r768",
      "r778",
      "r792",
      "r798",
      "r800",
      "r801",
      "r807",
      "r808",
      "r809",
      "r810",
      "r817",
      "r829",
      "r1051",
      "r1060",
      "r1118",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r879",
      "r912"
     ]
    },
    "kros_RefundsDueFromContractResearchOrganizationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RefundsDueFromContractResearchOrganizationsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refunds due from contract research organizations",
        "label": "Refunds Due From Contract Research Organizations Current",
        "documentation": "Refunds Due From Contract Research Organizations Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReimbursementFromLimitedPartnershipInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReimbursementFromLimitedPartnershipInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement from limited partnership investment",
        "label": "Reimbursement from Limited Partnership Investment",
        "documentation": "A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "kros_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails",
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r163",
      "r169",
      "r170",
      "r310",
      "r339",
      "r573",
      "r580",
      "r590",
      "r742",
      "r743",
      "r744",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r1110",
      "r1111",
      "r1112",
      "r1113"
     ]
    },
    "kros_RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of treasury stock",
        "label": "Repurchase of Treasury Stock, Excise Tax, Direct Fees and Expenses",
        "documentation": "Repurchase of Treasury Stock, Excise Tax, Direct Fees and Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and regulatory milestone payments",
        "label": "Research And Development Agreement, Contract To Perform For Others, Clinical And Regulatory Milestone",
        "documentation": "Research And Development Agreement, Contract To Perform For Others, Clinical And Regulatory Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "kros_ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments",
        "label": "Research And Development Agreement, Contract To Perform For Others, Commercial Milestone",
        "documentation": "Research And Development Agreement, Contract To Perform For Others, Commercial Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "kros_ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rate, maximum reduction",
        "label": "Research And Development Agreement, Contract To Perform For Others, Royalty Rate, Maximum Reduction, Percentage",
        "documentation": "Research And Development Agreement, Contract To Perform For Others, Royalty Rate, Maximum Reduction, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1097"
     ]
    },
    "kros_ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Expiration Period",
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1097"
     ]
    },
    "kros_ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for achievement of clinical and regulatory milestones",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Payment For Achievement Of Clinical And Regulatory Milestone",
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Payment For Achievement Of Clinical And Regulatory Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1097"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development",
        "negatedTerseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r736",
      "r747",
      "r748",
      "r762",
      "r1135"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "kros_ResearchAndDevelopmentIncentiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentive income",
        "label": "Research And Development Incentive, Income",
        "documentation": "Research And Development Incentive, Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LICENSE AGREEMENTS",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r735"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1096",
      "r1176"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Credit",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r878",
      "r888",
      "r921"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1020",
      "r1136",
      "r1139"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r961",
      "r1020"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested RSU awards",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CORPORATE RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r283",
      "r288"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related, expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r282",
      "r285",
      "r287"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of positions eliminated (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses incurred",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r155",
      "r156",
      "r284",
      "r285",
      "r748",
      "r1052"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r955"
     ]
    },
    "kros_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "documentation": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r286"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r76",
      "r595",
      "r630",
      "r631",
      "r642",
      "r670",
      "r814"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCUMULATED DEFICIT",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r184",
      "r186",
      "r261",
      "r262",
      "r273",
      "r323",
      "r424",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r503",
      "r505",
      "r506",
      "r508",
      "r514",
      "r553",
      "r555",
      "r627",
      "r629",
      "r646",
      "r1173"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r210",
      "r223",
      "r224",
      "r245",
      "r251",
      "r255",
      "r257",
      "r258",
      "r369",
      "r370",
      "r371",
      "r582",
      "r747",
      "r751"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license fee",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r210",
      "r223",
      "r224",
      "r245",
      "r251",
      "r255",
      "r257",
      "r258",
      "r369",
      "r370",
      "r371",
      "r582"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r737"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE FROM CONTRACTS WITH CUSTOMERS",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r371",
      "r372"
     ]
    },
    "kros_RevenueFromContractWithCustomerWithholdingTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RevenueFromContractWithCustomerWithholdingTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withholding taxes from upfront fee",
        "label": "Revenue From Contract With Customer, Withholding Taxes",
        "documentation": "Revenue From Contract With Customer, Withholding Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "kros_RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, development milestones, variable consideration",
        "label": "Revenue, Remaining Performance Obligation, Development Milestones, Variable Consideration",
        "documentation": "Revenue, Remaining Performance Obligation, Development Milestones, Variable Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "kros_RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, sales milestones, variable consideration amount",
        "label": "Revenue, Remaining Performance Obligation, Sales Milestones, Variable Consideration",
        "documentation": "Revenue, Remaining Performance Obligation, Sales Milestones, Variable Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue from Takeda",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r152",
      "r163",
      "r164",
      "r165",
      "r210",
      "r223",
      "r224",
      "r245",
      "r251",
      "r255",
      "r257",
      "r258",
      "r260",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r541",
      "r585",
      "r587",
      "r762",
      "r802",
      "r822",
      "r824",
      "r1058"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use\u00a0assets obtained in exchange for operating lease obligation",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r813"
     ]
    },
    "kros_RightToUseAssetsAndOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RightToUseAssetsAndOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets and operating lease liabilities",
        "label": "Right-to-Use Assets and Operating Lease Liabilities",
        "documentation": "Right-to-Use Assets and Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "kros_RinvaterceptProgramExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RinvaterceptProgramExpensesMember",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rinvatercept program expenses",
        "label": "Rinvatercept Program Expenses [Member]",
        "documentation": "Rinvatercept Program Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "kros_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "documentation": "Risks and Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "kros_SaleOfStockAgentCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SaleOfStockAgentCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agent commissions",
        "label": "Sale of Stock, Agent Commissions",
        "documentation": "Sale of Stock, Agent Commissions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from initial public offering, net of discounts and offering costs",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "kros_SaleOfStockStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SaleOfStockStockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, stock issuance costs",
        "label": "Sale of Stock, Stock Issuance Costs",
        "documentation": "Sale of Stock, Stock Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "kros_SalesTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SalesTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid sales tax",
        "label": "Sales Tax Receivable, Current",
        "documentation": "Sales Tax Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedFromComputationofDilutedNetLossPerShareDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHARETables",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Loss Per Share Calculation",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r797",
      "r1098"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Provision For (Benefit From) Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1028"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.kerostx.com/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentNetDetails",
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r1097"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGNarrativeDetails",
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGScheduleofAccruedCompensationandBenefitsCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/CORPORATERESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Compensation and Benefits Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r70",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r423"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r74",
      "r75",
      "r76",
      "r141",
      "r142",
      "r143",
      "r212",
      "r337",
      "r338",
      "r339",
      "r341",
      "r344",
      "r349",
      "r351",
      "r502",
      "r638",
      "r639",
      "r640",
      "r641",
      "r778",
      "r953",
      "r1022",
      "r1024"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Preferred Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r48",
      "r49",
      "r74",
      "r75",
      "r76"
     ]
    },
    "kros_SecondaryOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SecondaryOfferingMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secondary Offering",
        "label": "Secondary Offering [Member]",
        "documentation": "Secondary Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r210",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r258",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r282",
      "r287",
      "r490",
      "r491",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r759",
      "r762",
      "r763",
      "r770",
      "r819",
      "r1140",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r210",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r234",
      "r236",
      "r237",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r757",
      "r760",
      "r761",
      "r762",
      "r764",
      "r766",
      "r767"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r236",
      "r237",
      "r251",
      "r762"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r254",
      "r257",
      "r758",
      "r759",
      "r765"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r963",
      "r1061",
      "r1063"
     ]
    },
    "kros_ServiceAndOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ServiceAndOtherRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service revenue",
        "label": "Service And Other Revenue",
        "documentation": "Service And Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSScheduleofDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service revenue",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r751",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceOtherMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service and other revenue",
        "label": "Service, Other [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage increase in shares authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Authorized, Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Shares Authorized, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award, annual increase percent of shares outstanding",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Annual Increase Percent of Shares Outstanding",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Annual Increase Percent of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "periodStartLabel": "Outstanding as of beginning of period (in shares)",
        "periodEndLabel": "Outstanding as of end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of beginning of period (in USD per share)",
        "periodEndLabel": "Outstanding as of end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of RSU awards vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED-AVERAGE REMAINING CONTRACTUAL TERM (IN\u00a0YEARS)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled or forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted in period (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of stock (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "kros_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGGREGATE INTRINSIC VALUE",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "periodStartLabel": "Outstanding as of beginning of period (in shares)",
        "periodEndLabel": "Outstanding as of end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NUMBER OF OPTIONS",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of beginning of period (in USD per share)",
        "periodEndLabel": "Outstanding as of end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED- AVERAGE EXERCISE PRICE",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYScheduleofPreferredStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled or forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r393",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, recognition expected",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Expected",
        "documentation": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Expected"
       }
      }
     },
     "auth_ref": []
    },
    "kros_ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, recognition not probable",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Not Probable",
        "documentation": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Recognition Not Probable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant-Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "kros_SharesAcquiredPricePerShareOnCommencementOfTenderOffer": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SharesAcquiredPricePerShareOnCommencementOfTenderOffer",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares acquired, price per share on commencement of tender offer (in USD per share)",
        "label": "Shares Acquired, Price Per Share on Commencement of Tender Offer",
        "documentation": "Shares Acquired, Price Per Share on Commencement of Tender Offer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "kros_ShortSwingProfitSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "ShortSwingProfitSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-swing profit settlement",
        "label": "Short Swing Profit Settlement",
        "documentation": "Short Swing Profit Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r813"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.kerostx.com/role/SegmentReportingScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r132",
      "r210",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r258",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r282",
      "r287",
      "r490",
      "r491",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r759",
      "r762",
      "r763",
      "r770",
      "r819",
      "r1140",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/CoverPage",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r141",
      "r142",
      "r143",
      "r163",
      "r165",
      "r191",
      "r195",
      "r202",
      "r204",
      "r212",
      "r213",
      "r260",
      "r298",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r325",
      "r326",
      "r328",
      "r329",
      "r331",
      "r334",
      "r337",
      "r338",
      "r341",
      "r344",
      "r351",
      "r541",
      "r638",
      "r639",
      "r640",
      "r641",
      "r646",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r669",
      "r690",
      "r709",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r953",
      "r1024",
      "r1026",
      "r1035"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r52",
      "r53",
      "r126",
      "r127",
      "r128",
      "r149",
      "r150",
      "r151",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r184",
      "r186",
      "r211",
      "r261",
      "r262",
      "r273",
      "r323",
      "r352",
      "r424",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r493",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r555",
      "r572",
      "r602",
      "r627",
      "r628",
      "r629",
      "r646",
      "r709"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r211",
      "r325",
      "r326",
      "r328",
      "r331",
      "r555",
      "r582",
      "r636",
      "r647",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r749",
      "r751",
      "r830",
      "r1172"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r211",
      "r259",
      "r325",
      "r326",
      "r328",
      "r331",
      "r555",
      "r582",
      "r636",
      "r647",
      "r658",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r709",
      "r749",
      "r751",
      "r830",
      "r1172"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r873",
      "r883",
      "r916"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of underwriting discounts, commissions and offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76",
      "r638",
      "r709",
      "r723"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of common stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76",
      "r399"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under the employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of underwriting discounts, commissions and offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r49",
      "r76",
      "r646",
      "r709",
      "r723",
      "r838"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r52",
      "r53",
      "r76"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, authorized, amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized, number of shares repurchase",
        "label": "Share Repurchase Program, Authorized, Number of Shares",
        "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r66",
      "r671",
      "r688",
      "r710",
      "r711",
      "r814",
      "r839",
      "r1022",
      "r1026",
      "r1027",
      "r1044",
      "r1121",
      "r1173"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r352",
      "r502",
      "r513",
      "r712",
      "r713",
      "r727"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r574"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r574"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r574"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.kerostx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "kros_SupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "SupplyAgreementMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Agreement",
        "label": "Supply Agreement [Member]",
        "documentation": "Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "kros_TakedaPharmaceuticalsU.S.A.Inc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TakedaPharmaceuticalsU.S.A.Inc.Member",
     "presentation": [
      "http://www.kerostx.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Pharmaceuticals U.S.A., Inc.",
        "label": "Takeda Pharmaceuticals U.S.A., Inc. [Member]",
        "documentation": "Takeda Pharmaceuticals U.S.A., Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued excise tax",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "kros_TechTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TechTransferAgreementMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tech Transfer Agreement",
        "label": "Tech Transfer Agreement [Member]",
        "documentation": "Tech Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "kros_TermLoanCreditAgreementThreeAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TermLoanCreditAgreementThreeAmendmentMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Credit Agreement Three Amendment",
        "label": "Term Loan Credit Agreement Three Amendment [Member]",
        "documentation": "Term Loan Credit Agreement Three Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "kros_TheGeneralHospitalCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TheGeneralHospitalCorporationMember",
     "presentation": [
      "http://www.kerostx.com/role/LICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MGH",
        "label": "The General Hospital Corporation [Member]",
        "documentation": "The General Hospital Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.kerostx.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "kros_TransitionServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TransitionServicesMember",
     "presentation": [
      "http://www.kerostx.com/role/REVENUEFROMCONTRACTSWITHCUSTOMERSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition Services",
        "label": "Transition Services [Member]",
        "documentation": "Transition Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares acquired, average cost per share (in USD per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TREASURY STOCK",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost; 21,126,760 and no shares as of December\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r52"
     ]
    },
    "kros_TreasuryStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TreasuryStockPolicyTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock [Policy Text Block]",
        "documentation": "Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "kros_TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock repurchase costs in accounts payable and accrued expenses",
        "label": "Treasury Stock Repurchase Costs Still In Accounts Payable And Accrued Expenses",
        "documentation": "Treasury Stock Repurchase Costs Still In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.kerostx.com/role/TREASURYSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, shares, acquired (in shares)",
        "terseLabel": "Treasury stock, shares, acquired (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r49",
      "r76"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://www.kerostx.com/role/TREASURYSTOCK"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TREASURY STOCK",
        "label": "Treasury Stock [Text Block]",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of treasury stock, including excise tax, direct fees and expenses of $9,558",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33",
      "r76"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r462",
      "r796"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, increase resulting from current period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r796"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, increase resulting from prior period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r796"
     ]
    },
    "kros_UnvestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "UnvestedStockOptionsMember",
     "presentation": [
      "http://www.kerostx.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Stock Options",
        "label": "Unvested Stock Options [Member]",
        "documentation": "Unvested Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.kerostx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r214",
      "r215",
      "r216",
      "r217",
      "r585",
      "r587",
      "r754"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.kerostx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/LEASESScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable payments",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r813"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "kros_WalthamLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.kerostx.com/20251231",
     "localname": "WalthamLeaseMember",
     "presentation": [
      "http://www.kerostx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waltham Lease",
        "label": "Waltham Lease [Member]",
        "documentation": "Waltham Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common stock outstanding - diluted (in shares)",
        "totalLabel": "Weighted-average shares of common stock outstanding used to compute diluted net loss (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.kerostx.com/role/ConsolidatedStatementsofOperations",
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common stock outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.kerostx.com/role/INCOMELOSSPERSHAREBasicandDilutedLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505-30/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/460/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-9"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-15"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/730/tableOfContent"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001664710-26-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001664710-26-000018-xbrl.zip
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MIQBZ??"HN =%$ ^TLX.H$/MG>/PH I\[) *841G#SMPM$$9AV.GX>B_U<'-
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MO[UZ^>*HW6X-%II_>7EM9WUNP%3!)N!:"/_U)/J_%K3V\ ??$S"DQ2B$2R[
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M<P X$+O:LQ#Y$7@@2P8Q%5-6D=WM^BV)E$SA?<&A9/J%!X!9Q3!E"],@;YB
MU)U IL^%9@GV-HPYB\A;3+OD"I,W4QXY@T$= \B4O./:V@FBW8HEG6R*I;2(
M@Q@H/?)9>6-7 #VI!:"/BF"XF(;.,J!_H)#";F@"!=]NX)@+W+G054BF0N2
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MB9=]>W:QN^1Y:.?1\_-0\.#YW\[_WNFP%\I/YR*VS->"6Q&PU,AXQOX(A/G
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M8I4G/@*4_W9?)-JU7T+Z/U!+ P04    " " @&1<H/1^&.P(  "92   &
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M8D-@.,AR\!H2)I3*I- /N8^&*#J91*N0,_C:D&U(?,8!27QVM^_" 8W[G+2
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M-:+C7$'[0-]0&0O?X*DVT&(@8N2O%"IA4+J](!P!M /W?227F1D"X+I=:MS
M=N=,O"T[WI(!-?<5/[)F]RC@S)43SON,ZD^(%+=<9EO6C^0+WQ"0'/CS':'U
MY_%>OB/TS(Z0.X/&IE!7F)$RY(CST#/C9P@AKUB,6%@F!+MHRH15VMQ7_NX+
M4#8<"FLY7\IZ>XIJ1RV9 )M<]VV )B"9!DDL_(^+E%,,Y7^E DQVJ)G&H=O$
MWLDW>W):^1X2>=-HY09M]K2D)+B\*@"(<1\:=[1#P0$VLZK]?M-ES.DMEN%^
M>=,5XFYAUITJG![,>1489_LC_A3 $C9'&70T_)[,+0'N;"$7A &# ?8*?A7
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M,,5 DL&]']%D J3G*TUV6EZ]2J@D%)D%B-K[>L*[O6/7M3NK@\TCIW. @Y-
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MSD9IU^X#+ON"/'674^@8.X-,K4]YX@KA_#N_S7AH;E'^"U!+ P04    " "
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M*B^/QHNM=JH@Y+Y[Y.L"/B"Z#JWG20L\DP?'!(X?,[,Z>M'0Y ?6TJ(7LX'
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MOO^''#0N&$P-B@BZ7)0E"J*BM;ZX]9(H%P[P9%E(BQ.>NFAO'0S/RMU<.KA
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MKQ)\P1A#CSS@V1CNLL$@;@6\6,4?,C0^=-*;1W9CGY/0F'US-XB[H0^7Y_O
M6-^P\%#\"Q[EH-L]"NGI\'J?LN_X:CM+;>9V1$S I0#.)%7X$2(Q!1*3I>@,
MLL)1,34[893B?3%F62%Q@0+AXB;H^&&]0P&+!>Z(]A$\5R 2#H$ B(S]$'4+
M(L^(B!AT%1_4]J@/KPS W-*L!..9YM#,X5OKGP, /QP2.<#]ACQI,T#-,B&R
MQ,N (O$ADK>#0('UPCTQ.K8(?.G4TQ\C0Y^)(/X%LD\!AZ&"SFCN7.ND?AK
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M_M@=ZM"UQ3\*&B72Y.*XQ&%!6BRQB"C()<Q=%'_AJ#DW)2+LLMZD%9HK";K
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MIAY%.5L6K1:LG!0S+2\^&4FF6UY45Y9=A*@S">RMR[J)!K/-'A%DW/<$0+5
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M,T-#&M0&U+27R&FB'V0^32#%Z"UN=PA$$@^"B8O-5FN\%=1.\-R= :Y3:\/
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MHZ=M6@M030#YEP&BNI[;AJWRB$'HX*:8+8WR0R[AQ]E0J.86(TFFYUF.46K
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MYF=CU^=>D0C;&9D!*\JUB@$%?Z0B2J:OLL1<+M1C8C2]*.7>R !$'AHRKF<
M$)('$VL<0,Z++2_+O4R3R$P%!Q1O+(T.H,O"F'A$='I\N%K>$1B(0?;O"%F!
M*H^I#\"X$$@,,79)$.A]?NM(#WCZ+0_K '8M99UH@S12=!4/9/Q6)9GUR;-O
MGI?0N)3I^$'N]U 0F<T%S8!? 5EZ) B1OJFYS*OKBP^MU].)=IBH*(Q[NM"Q
ME@?B@#2,/#\;.>.A#"=!+TLGZ,WD)8LLSF+\/0*>4O2 TMP7W(GE -5^S][$
M^(7@>9;VABU580M>+.XL7R/[U:SVA5;%CY6?*(J^>SU'A_T2VG.O3T\%./+B
M1O(-4+J*A_E-QCM ]8K"G2Q<!O(27!N%?AYVHS7MK:!Q3#/J<T%KQD0(W6X2
M([5<.S0&I$;TH< .VVC<0+]$SU8*5^D*=2)*1#'G0(>U37#GONBV76 UDVQ"
M*YOE&UOW1"GF=5^&>V*IMJ2=&7NMO5)[K=/=S>VUS@+V6N4<?;H0[T3SH1L]
MO.Q23!4"5I>ISJEZI)8)89W"7C5VJM3=:!C%J:D_[(D$Y=54&2)FTNA>2M]<
M'WE#*:*@>6-V8.]//;$6*W;1/./C9D<)FK]JWAY/I6!E V5R/JY@>D'H-;-#
M@&2GDHT^%1N<67G>*]'*7]0K3*:62&J8=2YJ.GGT!:"!G85JK%A1YP-5@4P%
M.%2)3#G_S#MUKRMK_I EM12K9['_:F:2&DF<FG&S4\9P%H!> $O'>5U!1KF[
M0:1,;$ H4(? 5".]!%U*M&7>D:I'];&UZ@@N(->>298>H"8-B!/=+64S/Q^7
M+Z^?GT//'VBO*_*"=2VNZHV\PG&6-WWNK, =UBVPU^?B+ZW=LG)_E7VDYR59
M/7I[+NCKH8RRA++[@0UQ;C^E)6#J"<Y.2M$;@+ZQ%!-N(\XZ;39VG='@S9=!
MPS%*8I[=X*2^KOR,<8 .6_P>3UCC89I@I'#\$G#8/(P359F>2*([Z5U$]\$C
M,LKO$ZQ# J'HI;0;3;6438U?G6!J-0UYT T[9P7<KZI!YS$UZ/RG:=!9:3GG
MFHTM%_RM(=SKZ(::U\+49NZ8$Z-"GR86(1+@9ZIE1<+BX?Z6IU3(8O<]+96$
MTW+F3K*@4<*0!6&M* 6)[T_)G^GU-)Q32Q# RL>1SV%S<E1[Z@6F13"9+>J9
MJHN1E?\^-<)3RR,MB*QNQ";TZ]S )GPC4?+7D>.2GZ1NK%G'Q >@DM5RAZ1P
MWG\Z=_[VP\%!<_>MT][''^A3]ZW3V76^#-Z,5M@0:J_1VE]H^L^,#87D7^\T
M.NU9_HZI;_@$JX+Z&6D'#PRY9*B2(4C#!6IH%_&OL5(%X?NV.'=?L,7Y["K=
MC 1;7J5;RG3>M92\2Y_*BCIEREVG^TC;>:_=S96[W37:SH]J^H0>5-4.!#VA
M,@CJ+*)2E+4ZFD(.;FW,Z;G!TU5]BN]\QHF(L8_YR,*[1?\RAQMIS#GEIY&?
MGOWR7WW7Y\X@+"TP;U1ZT^G+=S)_F;Q5T\[(G:>:,^E)]VB6J6'O/,^:ZT=0
MP<5.);#7@J@'-NYBQ&#;0G\!$5G:Z_'<E(]Q+<?4[-24RD[4MZ@;C.1V-N6W
MGC6%33F33Q=OB."+H/X=7"@""(ZA'^,OR LN<;@ZAUB*/1:YE-!JJX[EG[U
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M15K3I3!ZZ':A&L2N1Y> Z@GE/:,#E_T]I.\9/Y!MFLY4HEH:BVIX67(&23:
MM6B'C]FZ[<LQSEU5K5N"/=1Y#<OJID&:;\(>:6:6_?^S]Z[-;1S)MNA?0>PS
M=X<4 =(D)?DQ^D1+LJTSDL60Y#UGWR\W&D"#[!'0C=V-)HWY]3=S96955C]
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M48[1-;>V7EG_7K)%N 24VSS0#GP2PXI;8C?;O#I*,39D0ETY(D6M_LP0=<^
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M&]<Y2 =[Y"A]4$T<V+0["@[[UE#49<-8GOW#X6D%?H-;X3F!K2(=T90K2+%
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M\ZK9P@B5!JCH EBU=9((T-A0(W&<A<5YV!=:2*>GNF(K5< @G! 4#KR\?T\
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M'6JAK5>\,CN-3P/>^)DT9W6K)PPE\+S!C&&D=W9X^$,\")P;6X:GTS!?LDZ
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M*3R8Z=$TOV/!1_8YN>$+EY>:=?+D=*K9!"&QD0UF#3G%9M&3.E.9#KY[EJW
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MAF? 'A75Q'O%G!H%[,F,*\JW-]P!5\BW3I]@BM_A1>_FVPI W._XET^_)CT
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M:<_RP=^29\8];[+.'W]\^?,/$Z$E9/G8;>@D<<_KJ9" ,3)X5BTDKU#OFJU
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MVL5!-P^,*0X_=D %_&9*,WE+.+N9L5W>ARTE^!,NMP"5)2,9!\IT'7(O&_R
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M DIIG>4] +@\_0X5E2=?1R<_&+#D?\BI'/0RU:Q@@A]M/;:]2CLG2:HXJ27
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MCTLQO>P1>Y.YS#-A;=L#^\ZXJE8J".- W5=Z3#Q?U$7X-NGHY*Z4+^,NM"B
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MF(%=1:*EMVJ&,>SI!A6 004QK .^)%7_TE@*1682&NW;M?V?/+/^S4-F_?.
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M0/EN5.T,ARA3?GX!U:8P"\U6]SO8>>!M4>ZS[&17:;$E9ZU),N[ AG:/VC8
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M&,_)VCSZ6S'_-,OFGZ#-VJW63 $Z/_F!5 XW0LR*=3,YYQA7\GV1B,EKYJ"
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MVK<Z[OL/.S%VU49'A ]RR"SW+D"_(6HP"M( -A(XM-D :8HO$@%;.54$!\Y
MX,@Z<+3>G]IZ-U"F5M=PL7/ U4(%"3(.PE0HL*?\X,#QT:/EJA9UZ=8-! \K
M] <0APOU]=''FAS7O[D@N[D(Y\ _E'^/GX@5NK"NHA/=[KJE72=UF!'L<0MF
M\NB$?Z/%EOHM>1-6*35([42(F)^)UOZRX]XS(G8L=I&J>%GD2U3^LHDU;-)6
M ]>&^9^:GKLT%3O(66B^C2514][OHW_SV^V0P09@SQ<ZT$SH8[17D^D),7;3
MVVST)A-7IAVX4GW&)1?IDYS5BC$($^MI=SF1AG,N>WJ+S"V[74T@TXR]<(9Y
M;*AK%U2X2N=%)%Y\/3R(UQDEC\V3!5.63L3405% +_!W@HI8U^<X6[/Q0%.Z
M1J\9MC>5V9EO:<L/HMH,W)G&/V5-=_=#150@J%Q< @Q+_4$MMWCL_4:.,-+C
M?OLMTH!)^@\P9U74]6*WU%_.ITDDJ'B??RB6^>Q-$EHP8<GY*8,<$5CR]WA7
M_B6\1GTY^^(=%6DO\_)+(2<B5V7VK X_^'&WY)_Q5^5,TOWCDQ.B0K'2!W'7
M5QR&(X'C5(IM0X"[7:*CU%:H!I(8P#^LP\*M0#5?-$W)YVAF)9,U@;!2[6FA
M5:)=I)1]RCY[3 %^:E_;F%.ISX>S4KU5F@LP7#,4L9=24#"1L&HLW8)@D1$Z
M)+F57AQ+M%2W1TBA]9%&GB-=C=F$FS%6G#TNG$^X<-XPBD1)&IF>DH<_CKU*
M8R;5]Y1J;5=N1&#)5]_OX#+_=P,P?_/@H5UO@6-X*Y2<85.3$?G!,!5O),F$
MV?J)JK$4.3@*0N7=N5__^]>_)S1L? #^.^(+?O<6$9PIMIM/4$(:4=A2[6MN
M?)T><!5I2D<2HI9G2I.$":$8G\KM1&(JIB8VG5%RGB,21=".147SKEP;Q'8T
MYX3^TU6]+NNL?T&)P!;!9ZLR31* <EX/,>KTK5"F:G+0G1M>0*B'0_Q!GQY@
M2](F-E%8I(,U)>$569'U/@Y-58/Z)ER9O#P'@$)S&%<_Z#!7)H'DX.4G*Z*
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M2[%>-] 0%N!U7BV5J!#KG,G%V&)?="&HJ$A6',9*]D1\L*&Y!AC*=BR[1JV
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M3QR%0?PS&E@Z7S[U '2JP7Q->RAU"<9.&>\F9&I(]7@+SUH('MY\1P^2OVA
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MO-NA)*V$4=4NORBIU+\L6R);AQT.7G5'M$OAL_ ,!0"T^F[A?-A=AI7\ ;6
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M8%R5RTX]T&"^=\5&R_YML'('GG2."@,O23HRUL&8MJX;,.XHL=UMH5B'"DB
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M) N&?_$AO^ T1OAI?D$0=(I]=Y+<8$UGMNK$0X4/Z?!NEB<?BF*+_U;Z0:(
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M3>=N2-&$W;E<S1BIU'0Z_N'F(5Z:(%L;O#H:RTBIGR_S[4Z(RL1]BR:YSV4
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MQ85MM\N/0_I10YJV__<X"WQSPTR""-A/2<:&T*CIF(Z)HN'ACXX3\Q%KO51
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MV &5HGW8JLPG.R4665:"@00F.Y3FI("L"2LI_Y4"QO!#H-L%F=V<K(H0].<
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M! BLN:'DTI!SMOH372=_A:[ ]]&W?+&KN^I/W(*W:;='O2YPNI=/;B7;T$V
MN9SL@;DP%<C>5#"%I\?YN*RW":)B*C%T)-TIP\BFB!6MC=V/;6P8Q5F8H#,<
M<)K60XC-Z[&I))*HT4A*V7!U'3M][E'1VJ)Y.*@K&>Z+8(@V0BM8\DZSNTC
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M[DN&P-E*Y.Z 4I/L9[(/1*O.$]@FB(XYJY4_&A>,L>3V#M[MC(>O;MN^42A
M '3-7G*HDBRGINJ1X)0-4B. ./:4'O?OJF5PPTI5[C!@WSF!C[@G73-'F%/#
M9]QG;K5,[EY3":I#*#!1[<:V\)/5N>1F-),:3HXW0&R3MT25=Z@%#"MP((*1
M"H\2E["R@I1;#%T!V2TOFQ ,Q:K4MXH&C\ 4@YL'TU?=R_;=LN_LR*:WM#NC
M>;2.10+&>5D^C_(8_/PVH:O&KNF)!7<=:][&0DM7.74"("@,4]SR=7?HQ*L"
M;>C#-0-+-U8&U[K7\L 1I"P__*")>3^:C+^5K 0C8#3JH:W+S@+E_R(?M/CU
MW)Z346+?!DH$@,/M-T(CCE>@$20Q,T$?XKSX31/.Q\_!+D6X% (_*847L1V:
M6]43IZAG;'T<OZM:T?$[Q/(0M:8=U83A]L=&SM$87)GX;VY3AL@5MSW]$+T"
MO0$[IJ@3[7JTXW@<DWR(E;K,4USP$.(]:A>!UK_+G*YTP5)1^[#6%%BK'Z;J
M$B(G+H+STHY5^9GVAJB%\;6:%B\=_N0]W%CB5KB+2S-TK*YIWPLF0 Q9J<IT
M9Z[IL"NY(:+2D*BP1CAAX)U47\VY$^X.T&X<,DF'BQWEJ*1^[%H2XT%;UX '
M)&EEJAHTP\[^D9H3DVZU//3Y8+WQG[W_YJX)AJP* #%VCBJ=#?F\IB)//0U$
MUP\?)84Q;+7%B[IS" :YH^ZX(CNQ<>TFBB8Z$H7Z2RK>*R5P#I V=A*YVAZE
MMH5T<S:_HR8D;:Q-&-Z$;/O#O8+NN4QSL8%_Z2HQDCZ9Y8NAKS>[HU^M[5 ?
MI/_HXC#.&T*X/YEZ3EP#JXESCO)O]$L&U,*AC_/DFT"2*;%> ]O*FCU^+(R7
M"^.?/A;&[S]KEFT5'R"[-KPW=16\0- >L^==R9U515T-X_=8ZI-/)$)$X49:
MMAZE$-^=]"/I/3\/?L#9W]KUZPL" KS4YC\ML/60L2S"R"L)NU4%V'F*K[O^
MADNS2 :VNQTG\4?D,2> 5]'$@__'#-F1<_--*\VTY+=='SI-TGSD^KS"O[V6
M05?!)+?$&D"^H7GM%V$C?5P)!(H%:14$A;XZ:EC@/Z_E_Z,>OZY)_ACB)J];
M0J^B+P)X18B"WM0#B];@1R!)$IQ04T@!HHV@X8,R0_BJ)CZI\E$&]4?;1B4N
M&WX$^3%"M')JBFL8E\C2;^NUH.1;@+P&S;M5KBIBG0#L8ES7&^YJO;GJ66B\
MY6)Y)9)$"V0$!1RG13Y)\Z/V4SU9G<N>L"UQC!H*7</U27:H*3FQPT;9-9M+
M0T)*]RE>3 NS*&["0WK3]COT9TR)DXLGTJ2U$WKNY'.0D7NT%._+4JS#-N;M
M$0+6:]2!M\'1:H0*2+S3M&N8O_,=/O:,/P9F O%A.5TH[49(%\8.'#TU2 !=
M-%?U;JN;Q(54ZNWP#X7'CM.NN3!TTS\.[6JBKB^-3C%\?#;8LX;%*=5MYCM&
M;5[9Y"7C6C9[$2W"9JEF@#8G/^0?&[8NLWF.;U?IU*)8JJG,(2O#L#(6S3"Y
MB>2*'G;X<AP.UWTK@8G/!D0& A6L$9EZ>1K9H0'Y>I@#L2@2!4/8K?"K/.**
M_YA,B=2>]5OQF?2H-WU+K>J-M,G *G?K!N;(::@ICQ^MW?&6R<M2F]F^0=9J
M!*TS3R(/W&>% *%)*AN<,T5C((K'T<X8D/O6JY5=?""OQU-3R&M^&"CR,"1/
M^3@]&KGW9^0$HO;<4)HOJ-PF*1G:#.=K8*CT3\)E\/3++__,"+;G+\[/S;ZA
MRWKCH74GC&GD5H.?4+(^2WZ5M(V+M2$UN^O]).>;_PVD2N/ZBEK;T!.B,6O"
MY:,MA7+=XVE+OTD[M]T>\:-R6-6XT#'CYER?.-O6C$570] =[=_D<<XJL#-&
M-9VUUY:C1I%="%*'(_PB9Q8Q9_-7&2LYR-%3(LU,X8$H69 %A[A^]&S^;SGT
M<D:I#';-J#E%!>KAI\H;VW6'506<S<,UGRDX2[YGO":??"FVX-6WS[ZOM#K0
M#BD;D,L#67WI&HDFC6(21=%X,W&W&T,YNFF0#0>M3&$7(%"9)!5)+^7R4 _F
MDL'#HC[ED4MZQ]C )PGP%(M)*7G&R[4N-4F82ILD^LW^,"7B<)*'%UE9="2]
M =S17*:LZ#8<J(RC\87\RG['FC$.XQW")3(NX0='*:+H=*7QBE#IQ,FW;)II
M5+,_9YK4.IL],_#4Z9"/["AH759_U)R#MGO3[][H+!_X5G=MDO><5.S/&Z1,
M1GD!'4Z8.#?41T/P3K?_=V+VOT-X3:W+?&"?]>-U,X63[N*56](AC.0Z4,N#
M(>#"D4)O@Y3240.MK*E76FM%IFW38"<]+NB[NW,ON%PFAEDH>NZYE(E:!4#:
M+=B D!L1"!.#YTM-VLI:Y=8ZC*CIQH91!%H_9+!I/>D7'U?_/:R^"B.L7BB]
MVLL#E4>ZQDC*"&!^VW6L3$1JZU,BHGB<Y> NG6OIIW9"UHJ2ANWG')PFU"K+
MIEFJ\-E5N]L,3:1^F0<IZJ\SS9*ZE\WO!(02,E:P[E'C5-UU? .%/SW[\65R
MDRLWA..E-(:Z6-6"L["5.7A3[PZ20FBUI[0-(R>L$>+UJ%+Q40@[E"M2.8@V
MO4#"<!V.="#[/17?IH'_:]]OVEK_ ]?]54M>!M]^'U?%IO-8!UQ]I"Z%#80<
M@!;DIOQ2'?IO\42$:0T>"\>A(?0JBAK2>I]<R_U-YT"3;:3$@Z%HJ!GMJMG!
MO<0@O!:J\PEIGT"B%P>$^+XNFF%\9#Q_[P:B#ANBOPR.(YL)MN324  <2:E&
MFTAP4B/!F18>^*OS%"@;#VD1YW.6@$MYIZTS5JO@/U,L*?K4X4N5JZ%Y2ORJ
M2* _JPK+D*);ZIM0\Y X]FTP:+,KL&1D?",)G^]7/'4)?]LRRQLW'8:9L:@^
M^RQ57,(+'\WB^=X;X_NY/+24#>@:.TX@P2*QPOQC^#_4[7/87=93C/@6<H=(
MR)W$%F6X9*,TB'R>"A35_"I%\TL!2B9Q%4M((JK[57%GIM-=ILK;M@"7[R&N
MP"5^3@L9DY-V[L2ME$0AR4TXDNE?(WUSV6Z3.R&IU/$%*RV(?$'("V_F\^!L
M-;->32*9,M]2O,27D4*,1 K2K<-GP_HUF3Z.;2F>QXN<!<.2YI5X.'90^:NQ
MC?0XZW98'ZY':/\"(L*BQCQ51#7?2/:;K@^9'PH5G5XRH0EX]M!MJ7T;>R),
MW,L&E3S%='4893^O:V'@L<TMNAD/&'.:9.$!<(LH1Q00@1V-N0"=9#F5U4H=
M;J&>\_8Z[)Y)$H0,P]W6[1"%7/HNL<B*W)$CI-053$7L1P4,N?TG>^>.ZPR$
M0#J>!PVV^I;,,^_UFC$;\$RZA$K6PZUBCF2&NTH;C;P!+^/6BA8+'9!\)36>
M8IY;]Y^LGD_@B.U';HC$L%,R>0?OU'9*=B3M%>?WK,J(^T$KUJPWZG])T(Y5
M>OL+!Z;=(JB>,6;+7:XGT&"E=K0R&.SY-L>XH[;7'YB_!D1,:<U)+ ]WI-^
M5&Q-8 CZ[?Z-M;#E2'RJ-BQ>*(GC<DAX ]PQ]<;,*JC>14"%HXKE#4Q(V@_H
MOK>IKVMT7%" ,!*)8GC.:&Q@<>AGA.MO$DJ-1Z1;&>GVV2/2[?ZSIDB7ZC34
M!<ZS5)$,'&.]X)%KJY^IHI %OF0_@X#DH*7D<TA.&O*$,>TO=%DPE\1^HG^F
M/E%J#W>MG"%$N.R'2ZV>71/+9:\P E<GL),6?O P&7M$353)FQ;G\ZI13L[H
M60=[&:[EG7K'<'C!!2^9S4(+K3-.+O(U<^CH[AV0 L;YYBJ<>:<4TY,%=W>3
M,XIDU]DP.J\HOY;8"PB_>KS%DJFUJJ1 .^]A#IMKG<>%T5J-N;E:S<U5HBN4
MKI.'=KN6%]<2P%/<+/4<$"VI2%$0;_ X81%X)RNI(8-NZ,(%/V][W0BO;XP$
MCN9QIV9>N^QH2R(P 8 9O=5A!U)+B70GHR\Z<IV&U;G#R'S(= %8SV0?IGMH
MUJ%YP31-Q&3S 3<N/-\Z'K6PP&0&#IW BI;Y$#'%UV04A'[\AHK>._1:8Z?7
MMB;UJ*OK1:OF#RU,\7B@:.8A^[@_\_3\UD1U#6@038GDR[[I]SMBP.PYZ' =
MJL%P G1$1J,54DF+Q"?B^9E0N5N;1Y@4YEA90XF'*)$8?PKE>^XHM ?VAK)@
M.G\5H62CM02(!J0!9##:<$1+O1V5@ 4LFM9/8']P_?DDZ$+]UPI=BEVY<I9S
M[-ZX;KE"N5X%ZT-FYT [REFR$'+OM,)+G%$T0)^7<@DLM2LB5R7.[+H?")#K
M#!@U"H[38:.=A=)F2N/1EP(A&55/A?%V:,*.5@577@)94J&6<;M 50#HT0#O
M4MF:1^.(_%7KY\GJA_9U0PF>*EU% L-L-L1$R@0HTDBR[_?*D0&^?43_BYK:
M8L$TX0=DS%'O,T(F*(G#7;<(I;*I&]N_)#BS,K)8$\-+N'"(3@ Z5"H!=8]>
MS&7JVP4]M0_66)]WQ]):WC1&4.-FW3D9E)I0OAR?63VA,>S2Q,[B:,HN"1P?
MKG4&\8!7SH:],H*9NXAH%QF;%R@$)&^7"0TD>5M-75M+K(Q 4]F5$.IOF"U]
MWAQFE>*<1)I4PL91[#P(3(FBQFM0T\%6CAA*W(G$S9BJ$3]9O402,\;W"Q9$
M<J-0;2U)4R)!POB65,^OXBNR2,3#I2RA;505!^%ZS0G8IBLE75P>I')(*WHE
MV>B;\NHB?$AW0<M0.^,6Y"8,3Q39=YRR4(.JW!&.B\;-?T(N=1?QSB>K;\6_
MC5O&"(<W@OY0DI.,?QC<XWX45^&(A)@'T'6H4E/O//<7&IL:WPC"WV/*"0>R
MW:VLPM!H1Z\_/'RQ=9+OTZ(DZ04LVAKP"#OB?V/CCOTJS# OS2BSZ4DYN1;5
M4K&P)VR>\1?%5<U)@N^[YB<6^MW>Y$$;71;F]-&;%WAR9?[9X3NU/$Q/M3O&
MC:[4+T#;SXQ)ICL4]E!'-&P[S\]X02[8G/8TY1>BVL]Q+PS2**=) >_9CR_9
MR2,D SUU0YYWPWP6G"&X88%)9ISTS[W--.7 #&8/X-NCI"& 2LZVQUD.P['B
M97Q9T@)D).:)249KA<^-;QK2T7JR^CYXJ."-[;O" -S/,=]_[)@04G3[3? ,
M%G:^ 9IKIMCGE#HG:_@=,6/,Z5UZ*!N*[+%/5N>1<$8$@?1+Z5@=>2I/9B$Y
MP7D+T1/0+XB((*<L3-,9XW-1#%?%!;,KNO(V;&3J4T;;I T5"!IX]/,3,Y+2
M'-16!('3]3R%-?.GUM.='!W=CDA<-1O6X1PG)INA1( RK*E<83N,$^C?6;7T
MX1JDYR[\*/7B"RB*UL^J5:(.IJ !7<_PXM<\R42YH](6&R>3A@ W7*"3DOQC
MRH?&M'9<\9?^.?QY('?/*.<=P:F+3!G!$X>;,A"7'EW!\K56;-:',V.'.L-,
M3>)YEE<SGN5L6(E7PL9>@DG@OCE ];9?N$9:9>F[Q0*)_?5V'D@WG+I\Z< 5
M2-=O?"*Y5YF"1*+DT<%AT4?34G%K2\?45%1S)UX98U^[1I*<#).BQL(;$AW,
M63H^-6RFU.WR-F!L9_9'T]S!P*('+DB"_LQ(F343@8Z9:^9FF)H3BUE>OKE1
MZ8(%^XD:$*^:'>+G$SD"<1E5E;<Q8.'NZ,A?<''['\<+"^<G$MY#R10M6*!$
MILR[2<K/FCM2&[S7LJ=6\36,0B7X@&>4\_+;#]F,B2VX1K9[X20MV'9'=SM:
M>(K%/"A+(UU)!,?2%HS:(1;E>,>=G:1Q+AKP1&JQA8(+U%=$XF3B%##W/&P$
M(TK63 YU*MBGEUGA!?SUWDYC0QVY_->8HN+W%-+SUK,MVC=%A]H'97Z;*'A.
MXI$X"2[=F#5WRC4!K<+ZL@OG(!S>"0!,P_ N[WI[8ZP?6.1-:?46*ZF-&?KS
M&1B)E UFT'#7?Y:JO]W%-E>^K 5T[1U^4%26K:A?FJZ'#"&R.YCD1;E':A2*
M!]PF &!9F?8%+>#7KEJK?_LFT2H ^(",%T>V*M$W*I!DVM=KIHX7M 7?6@!/
M4RJ^#>M(XX'DK:F1-V%T-XU(*W2B?M<D$71L'2+?H3GC]+O<8(]8AC*6X?-'
M+,/]9PT[V3$T>\$FOMDGL(],X$;LA!Y4H^$T_)V)U=Y1[7'U+<5,: 8X[.E0
M?/I)/(;J;X2KQ,IQ=*;TLKGSC[S0)V9-A7=6!1X:J_IPTS1I5J&H5">>M$G
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M_W)A55IU"E7+3G*DN#&LI9.+7TPMP!^B2TQ3KPE,+--.4^RU(%0Q':.!JQ-
MFJ4DG^ $NPT-L8)P@PNS3[/)>L)P[R94@TSZF]"]XD$TR'X0)5<T$)3+'ZV>
M,S+]A_T""NFFX22'G MVG<,%(^(<0B^I2,W8G8O[1J8D]ON59>_0'-HD&TL>
MYG=.7BVA-$8DD(H@055G8)AML ;6)S%[)/_P1O%/T5$DG7=J:.3:D?8\]H-*
M"GC!O+1:DS@\;GS:ST)C RITS7CE'GH2NNO=AK@#FL8$TU)X9,&C>LC6Z)4M
M#0?3!E.(Q4/,90)7.&61J2T;,=\(<KYT7U%Q,RGL;9JQ'=S^]6JA$'*I?7"
M) B3_&:R6EG5Q UM'Y;X8$6M%'DVVY(R1.NU-Q%<OLX8'I*T<-Z(*[T-07 J
MP(F'8]A.OY*E.1:4>R@S?Z#)I! 3?'D4Q_:KG<;;%^5A/UDEPLN<%D@;N=V$
M&'(?1D4R!(AZ.>_#)2-,8UA+O7-T0;4U?;Y:C*=SPGSQU.-*$.9$=RIU I4]
M"%8V/$3_6S%<40-0X YA?5I:'O%,^/,]MUO)E[,&GNQV0#7,;32WCVWG)B96
MI-Q$PRW"5V((?-&,GATEDUU[Z"9@#'=M=SE=Q;4U9="+MG=KAKV05N:V+3'!
M2.NS]$\WOY-@IG)N1Z#2/P[4ZV!B%-RP9?@]QKN5+(%N%<@ D0$XTTU"2Z>'
MCX%8-/!V#(=^8Z_"?=%,&^(NR(6[F?F"6<ZZ ;E=(<G!9HA3/IH2LG14C$'=
M(:!.O\1YP2"K;(]+4,N>"KZ.^Q[$Z';?BWC0(%>L#-27F.-4"+J'A\#BA5T]
M#/T-A?IAU>CIM;1I@-/GT#F_PF!"UTDCG+9AT=KI8.6^]H>LM)2FGBE)$'!*
MWQ)/:#<,K"2-1EPRNCXNV2\>T#8)AP'K#&<'^S=<()N)DS%^ET>K;P0>@KPL
MC9H\L7ZWF9%0+KMWTQ4X<CM,LPI";6C-ZTWC,I4B0+7;U1?]P"P8^)&#@'/$
MK>*T"#_RI+>RA+AQ@"_N9&PZ[-=F\" JS)]/$TMRB8I&_0;.'*6U1<3+B6?0
MVVD*J#PG[+W.+]T;U1V6_.)#MI4O6]#M%#;(8L<!6B7R6@Q >WVW97=!FBKJ
M?):Y>,"W,.[P"'K22KLY(8V0R#!T4OEQX+G.1NM1TK=L%C[V-+KLS;)WYYU
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M;43JBN1PN;LN=F98'A'Y'=,7VP$GW"G;E"8P8NX@+9%?(DWIX %9V8E"ZU2
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M/SHGU-,YQ$)+Y+)?G"Y'/#JZG>=X)(0\?Y7U1"XRYRN,$['S@P!NKSQI_Q\
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MPHC6C<'PX$Q\V:J(W"TV]QLF;9(2L_]1>7_RQ5H1A=6?2)!<D0[ +*',H%2
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M:?+&TOZ@:XS5Y/KT%!N#\BT@[O&FH18^^/GAI.JZZN;DR_:.>S/C7J,(LQE
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M:FU,40#7HF3"_]7C-!QB[WJ]5U\*!KJ#I[6\!_/NWT-4=C#TQKT@#AH5N?"
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M;,52R81\R)7-8DJZ^;T=IYR@.(Q.D"[PX&"F7M6OFPUW^7T?AM9?S:F876F
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MX,@OR?$'ER9UGX!?AHR6&K;I1OO]V3-JJ%FA0\8D8)A[4A?N1,^UKQ!?.-2
MN,,EEU+UG&'J+M*52YPA>=B"H5NK%:<61:H,R5IGDL^KIEK6*K4GKR$"!\$=
M(W6VV6)@$!YU[88'#]Z2+\H6KA?>:=ISJC<+"-719'BZ^_SX ;Q-I"?AV"YB
M5G0@QNTF2B]]L-F$O)?KMGO/)C):34DBJJ <HU7=??5,YXOO:B(N#>_FQI3\
ME^J? X5\GH4M.*;\6.?5KFWXC1HZ%;?AH9P(1#&+^)RD^BV1S*+<G6S;DP7I
MFZ>/Q,#3Z/.3=U>N."8D.E[Z?SQTK\/V9I267IE:@TNUKQ+JNGH^9_,=JD][
MO<SRGE?!XONI]FPMJ^I"7.>]@LGD<&3F)%&8M !MF@S)>ZPQ%O>Y#^<]2XUD
M)*,:_5R0K4:O7&^&MI-]WK$\\08%&@ 1L:9S[%58R=1&K^H8Q!','T8*77-[
M(2!I&:/G"PZ?K]K%+RKX(>A@I/R1=$!'LN04NHL05BFR&MT5E3:@:UIEO$G6
MFCB&"6/JX(<<Q;_ P?%=-:_0__3DS#F%E^5B]NP;V'&I^\0X*7I]7WWK$CT,
MW%VP<NB>I ?]?+;G2RYW%5:B=-M(PH"H:9&618^:@;[AKP'CF]/VRD=@+/SI
M\:J5X?39L</1$'5A:)DXZ)Q/:9J50GZ38/9%#'Q=M%8X(R25\[C-O^=*F%!-
M7VMQBF@.?,$L/$*UF-*PT,F!^=/^+K,Y1\3J/2!6%S#;.TQG9UFOPB/ "H.E
M:#[,UROBPK%%?X2HW'D^S,3"(?&9<B&LYL0))+_&"!1_[D(//)R1-8'WNA9%
M7LI:^?.PR"H#JO!>AN;H^K)>5>)ZU")HELB]DQ/M"9V%_[>3-M-H'1+ZDR.P
MY?ZW]1H\M^K@>"L>_7EV.^U,$M$7",VH>]3O^FT5%12"#TSM2P_YS"=/5Y9P
M?%.A'"^MSC0I+CJ]MINWB)QP4^36M4$BTDYRBQ*GY4:WGV4R_"[D,S/6;-QT
M64>N-OX)V30DN]$?WF'*M\"@#(S00$!J^-*2B*G@$;O0QW6<@19KP5J#0MM9
M)J+=\<+:7N-<1 K%Y<SW#LW#73K!;XX*ZQT,+ )@2<Q)D"[\X"PB5D/(5QC.
M$8&S64Y&2>4S-$/O2(43-YPB0:T<"2N I>N=(I=>1I/_''%;*4#[^-.$88D@
MU?")(P[K4>$Y"=B0 IE3OF"+Q$EX[5T[1(IA7X.XRYM-QG!/CV+2,,OR;>2Y
M$M$.)H@#92IDH9890T=?S)PJ?4YE_*8;$C9TV#*5PV+<6\I)5-R/&=E*$FLO
MY[M)K5=F$!1"?@AJIMX-&['N34MV)Y(X1>K_2T5*DBFJ-UNHADU".+5( KM1
M/4\ 8)DR%I1,#MG 6)/.]W1&E=LPZ]P@DM1]]R\HIU6JS^GFP "THT(6)CQJ
MV &=C0G#=ADY(,EWFY2L>BQ"E+1@/US#E<*,<@LYA'PV<6Y?TD*\Y ;%N%^H
MW\.A&[AJ5#8&A0HV?=BP%1G5O=U0?R0\"17IDH!G345_IR;)3 OQ.."]Z; ^
MN%!!V55ZL41]7J6V_=C:YT6+JO/GBY 3.B[0N#:"NAFH.BA^H)A:)BCT1.+"
M_VIID9'Q5YN0;$;NRG/G "4'+H,S<LWY8Z[8%T!6TR,PM!=94D2M?535[L)W
M$G5M9TX=#YM'&TD=.DTIQWAJ*MSDDZMAT5&10<,<V'S\\WE"KKF$HB]\YRH,
M)\<ZFO\6LI\$F!>3PL_IV!JVXK4C-_O<ROX*3F><+E49XM_F0Q_65L7CBXS-
M<Q=WY5[[05LV86ZA+4HV(1((I["!:P=L\:%E;E7-636[4-XV"'L0I%SBY,*Z
M  I:Y04W?2RIOD1 MC#05<$P#P9/$RH<7][BJEBG3'R.%%>[E"NL!?G17]*:
M_6+NQ+OMWE\6GL\5B(TEIV@D7NNIN1Q)PF#$RD2G%@DWRA"&/\R^T.K(9146
MWN5))Z!@^N.7ASH(PZ,N@*/O".4^>LIX=\<T^^5#7D O=^=5=Q)"GG+^'KG+
M8 C1Z<\VKMJ>L)B0^'0["M'H*KQGEDO\>]F5@_A2O(V4R,AY@MM+ "D4\!2G
M#1?E;!K^B2"2_5L. A7)F1M;Z?.+/SMDE-ED7OF\UFZS!4YG;VEQ\!-SD93*
M*<%6V,GF(AK0E97H@4!U"F=E"K0D<35:^G(J:M<,6!4J?D.A04M25F&E&5V)
M'C0"I+P,TT4 1T52\K/.U+=PGZ()Z+?QDW+R4+6PJ\D-7HV_'$M)MDG")]KA
M HU?RRUS-?9AZX>-TK>;2W(ZY]@]S/Q*A<6MPBWY5R?XU8D4EG@]@6?M+0V'
M''A->ZWD'U@$G:O2>J4LR&8J1\@\7<!Q^&A:@X_+)Q0_EW\6O>D2I89VTZX$
M/<@^KG:0TEW_(1@4T0F@5<FVM@G+?RZ^'<BQ^[0V\1U7]"@PP]ES779ND[!.
MMEWE8XPTQN9J6)$95OCAC/=U195=U$9;55//# [5#U<U']:C$72-.XI*PWJ.
M,">?]/)E6II=PMY<AKA)]G',X["#28<)ZL%>RX =R8NV74A9Q@+W7SYN1!R4
M(=E<%7$5TVL?L3EY;,ZW1VS.QX^:G \W>,5H3UR= .1:58(]PU:;?>'+$VQ@
M%U6U"6[]^\AY/CE9IHRI6J,B2TW?%4VL8)<OW>V^]*?[O U.C)GWJ[H;M*,O
M;*:U?/8:?IB#^*70.,E=,/8 7(];/4K"<1ZN2%;A2XH+&QJ!=GDB&SL:I/!:
MZKSU6VH0C8^;_#%XA%>LW^:/IS6U330J?5)U'1%-DR?9KO'H=B4V3"<P3.ZW
M[7*+SYT/! VEAX-57CG,H7TFW" \Q +_%DA&^+,&%7 I+8C;XX]P8R1E^N@J
M1%ZTJH2AUG#3=F5=(U5SR8-,:9QRCK-'2+9?_)!SN615GLY^V$9$D2X6 9P0
MY&FU\YY)#-C(=Z_U7W3D8LP ;Z%6B9)SW.-8DQ$T6H-3[CV?X(B)C=/9"P'7
M4'=KPT3MBNZ\R<S?XS-/P,#!6P@FCG!E-)TTM[(G#H2DE%QVWE.L.ERDW:,\
M2<&?IK>08TZ/43*F -EJ3*XWR7W\E BG@U]44FZH2'TWD]TH&R&_6(VOVE22
M;I<NG2;L_;992UMV]J'I\WWF"T@OK"I%)AYZ_C8Z#=.[T+3G/CE6@<C%JF,'
MU8P>7<>Y([J?D-^.?6,%0QZKC-6 X06LC"Z76.!1,! &6^5R/%P# 90M&P&Z
M):BVQ#E"Z2)*$#HWJ'#M##ZX%0^5 HIBF@TI9.4Z/A6P$9[.7GW8<NDKDJOS
MJ@US6:L,0U-=,-:&NJ3G;.^GH\0"WI+)/*<J 66G9?QCR0#) "87UCLRM+.
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M$KT-2E5ZY"O?F3&7Q-4=@K>N740D[MP"2\M'-8[A;NJ0TPMIV=N-=S_OAC
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M_W:SJH[+Y,[N1K4<^G+E@4[YLNO^_#!IJ&RVCJ5O[)O4RB%H2@\7%15N-Y<
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M12$.B>&45\\/T%C$-Y,.><A.AS>2EM<E>)>3X(/68M,KLWX_=(B:,8174.?
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M:=85Z>P-1;,K /VPG6:K<"33!KO1=IZJG?C%&A_68.FX]<'&M_ZB_)(7MF$
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M0EHH?UZR L04(77I9MQ)Q]!29+)87+,*KZ0)(=G0;*_,,B;$#ZW22_$&^.?
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M?53O%#'R<+F@]JB$J3(39+PIUDQ,I^&=PHU%HJ+*N?5W;;A"OSCL1#N3\/=
MV(G>OL%.E &0H5.S_I]+CP"KQ__O WA\WK)W.#2GL1^X%4>(6W'6_WWP:6"
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MR4M(UA?=G7!$W>U";&CZU9N&<]62)X%_]/^+GP5@UTP)R\&=TRC<XYEZ\+K
M&L9 VXAE@#<'&R8D/C#@3^3=-!I<P_2^"'KU*E8=HY"3 MVZ4T.AQ5Z.L0";
M6S=1> ?C\;4^''H+EV[.]>_O#__ZET:C^1;;Z.%NTARP5;T?)&B#KG3>0"9
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M4JYZSN+52[.->G 9U4Z43L+D9>8^U-]R58*"5.6MB3,ER";<#K!%FM@B)&/
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M7P9X%L1!, %MLV!8OTI!AN:"_";W\=/O'PR)N][K(FGX>"B@=F-=&EW0V\F
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MBW$[SFZ<^ZBY7YP[O;YBUGW42+/N]H,X=][;,JS["+20,[CNUGLW^J\;K+_
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MN-MN-YS&V/O6VN1+U5TN% [!)<X05-R;R.,"N.&*GG!GH;0TB+3#E;Y0W8U
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M=/7'LO!?>(>J\&KU_+-]_AEKIHW_7:FFSUPUS5:G.'7)XVO4G2/)WCL-4([
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M]H1MA9'UZ?</.;VK6-]MD[K;,<$L<'(4\,"9\J_^XFPYXW<1[+P[HW__&<(
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M#ILR:B FSC>9RPSE;C:PS*'2&0YA9WR,)EV9[D1::_F\M-;R^2-\_EBM=?6
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M=NU*;KAK5Z>'M&\U*4*%V(KZG CUL1-'6'/K=LKXP%*8BKR#];T+TWK_=D_
M807S]GUG^&/L6%C]'WL2:LTO2O?/F>F_2D8N(B.W3LX;TBH482LT;:5@7>C>
M6+FRG&=I%8J\@TTI3(78BAHUG6)4[3<A55%EATB^I$05>!O;JR4J>[ATCVWK
MEQSM;'H^T-[N?&#9\43> WWLKFU7I]KA]X9]_V+]]]V[V_L'K-:/!TYW7?CC
MYD&Y[_[2ZS]T[[N7RMWWK]>]"Z5S<7'[_>:A=_.+<M6[_U;<TMH/O**V-]9=
M)APB44H]K:(#_F.S+E!%ZEMU.S5MZM[*"W*GV];WGWSZ!OV+\?[ ^LPP?6:(
MUJC8ZU>WJ<#\,(X;!B+,Z5&8<]5VT2YCT7C3,'47:Y9_PJ%/+OC()Y]%H]5+
M-F23 7.5JD:9/'5Z$/X2]N*SZ,V):7@)I\ )0T4J?!-YWO^E,/*Y>:7[(;H.
M(W0=5.JN$&L.H+Q2JPCXFZU0GUXUY-'@]3;!J$]X(HOM#)ZP.2T8<.:ZO*NO
M3H\K)Z-P\Z,YGGRF[KG.S(6I$JOPI:7]5A$==15L1FO!U+'#@V5%S9E%^U]O
M?HC >@1+$G3>@,K14KV9Q2E*S>)#JO(:]/!11$+1'SB-<KSI [91P-X*U.E!
MCPZHIKQXF 7$?&0VO(':Q@^';(I4%H7NO]MFZ/K1?#H36/Q0+[ .^*I[)J>*
MT 9%F.K29M?>$N;#?M6"%::P\>; M' 3DRSU7]C9V09#CL^4E%M@Z[G?F^1P
ML!?D9>2>@.T##1D-E#J+@>[QAIHH,:27O)(">@IGIXNVXG&>PMX7HF4"'8N&
MW47$^6@@"O%R=4_4EW/L"R/T*<%RG\7QZ6?>+L,-.T(8HL&%&3N/36O*';P1
MA1=>ZAJD-)-=3T;,0/97O*BQA*4_1]8QZA2LN#-+]'R 5<XL/=;_G6W0/24<
MDA95""%::HM =1BS(6Y%M/G+R @L8QNP>R$I^/K &%$KH/!;L7F\+\HS4Z9@
MPQ+M7HC<^"K</V?@Z_!"P*B>8Q/Y=<^;N?1J?>#,8(@Q$SW95XC1R&745CQ4
MW+@9P4_4< QC1DU3P(Y@.W07'H.)X!)B3.2)]NP1"Z+%5N%3EW<FAS4Q^Q$D
MDC>8YZM"Q2Y6)30ZMIYQ;9@*=E!W'4MQ0 IB*^#-2T \2DK'HV;O9%W#?5#Q
M1?/2(,@%[^+-;I'J*&'XSDW?IPR JKC&P*J(QC@XB- B)K6ZF5<D;#3BUMA&
M1;.@IK(LF/@+_HHV%^DIE)?M (A!H,!?7&#AN8W+R]":@3$.6($;7F?(C)G+
M@T' TK@ZTO6F]\-;RJD!4=/X? T7JW$9FY\"BB*W&@97FKC=-)62TD>"QWX<
M+H>] +UL&$I%!M 54-4^6@L3IL*>3%#'0^J=H]-.<K&>H,KGJM$PO:'E>&+,
MI<OB)DV04K<\)S:!)]V:Z7XX>"JNH3[1A'[!BS1'H,.!C#!3<T)P9J(;U!PI
MLJ'4).J987\N;_X5R+&(_P0LU.,0+WWRH$0'S#+9DU!X,3T*-$4J >5BVFT0
M(I<80"T$GZ<CK0LT=D.L/DNZ[9ON^RN*Z[Z[6*(F'P93YNIX0E,&I329S&S>
MM4ETB(*-T(.OP6DBK3=R'6ZAP,R[L,6G(%&F8T2J?:D9XO8.>"KQ)L>=1S.)
MKP6"X:/C-R;,A@D( >-]TCX+IX@K$BX"U#0L+E_T6[05H581 Z<;3!C]4^4S
M"-J38ST)XT^0RB0' 2 -^%WV(XD^.)7_X5I?Y5W2)B!V+\I_9L:C$ &B>;@H
M(3&IF^ IAL.X?=4MI+IHJ/>LO\;%(; WZ5K0UW^ ^Z/CWCV#ZREZ!0I;"4.K
M*.ZQ^0C13N<*8@15B"I9/4"(8(MU;,.6G$WZ "C(=EP]+>Z- _,T0<>:?K"5
M!9;W>]!D-MB7>S9T0)_2=M*9>N6+\@"4-W3EVAPR&^Q'YQ% %VY*L)I\ITD#
MI1723I\XGZ7V!68^0K3H*/PLID+LH=572<2[;L?2=2[)@TA3R,HE\X _IW[1
M7>$09KN<O_YBZ#!PEDOQ.SK]"^4!Y'"H-,H-5=DSHZ6O(I 0LA07"'7U(4@]
MS?=BY@%M650L=X_453ZA!%3*7Y!H0"[ZE_;E,[D7!O''@ =]4##62(2:<*PI
M-$_/H@U2+*$ ]$ !\,4+]4"!1S$5\5&H*8(YJ4(E#M@0^ZJ&CH7R3]V>87D0
MK<$#9VK0<5.88VMA,J&ZQ@:.(B@')'R".7J;S+#?B28UC76FY!.,4^'9)&3(
M0=V0N>2)16^EX()X+SS/WZ4*-$NF-/"[+'/"@[^.J@QA(TF<?3+;N%J JC/L
M'CIST2 %8ZH ^]W F $%)@$8@16(8.]#1(&^> J#H?/]-O'AT'V;WZ'DQH.4
M,A,1@J[\O5(NE\K@K5@6OF V!?Z',:?Z*]$72''%!BYM'M\X3D $1"&@%VX
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M$$;!/((N0=E\?CI AQ:\M+](;" 5' 2Y?/W'*BR#12Y1^_QS9KTJ/ *@\0C
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MB<<73 >UL>=G"W']OL90!%1*FKRH3'S0-#*X8R:"IH^,%SB/F%VH[MA13ZK
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MHS?:,+G/$?#_BIQQ6-W*Y]=8MF3@'P2 2KH(A6Z](@HBR)DFZKC:TB2G22+
M$V9TH?@@\)*2+F!PUYN*7M8VXCSP:^L3PCP#3PY^M*5S#J$GW44BPSW*N_ES
MQ6.C3YW8!OW( ;ER*[WK/;\<16X.7,$+&00$81".)%GK^=$A--YGF\4L1'5O
M?0]L9I$M^D_3=;RP14V6. KB#S T\)5;GS2B@8DM%]A]L0B>$KP[&J$_L!P1
M2"='',M6TK'^H[S^H%/!(;@U'SCL0-!A5U^=7D[>^-9NA-/#I"I7ME+#(D+
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M@W!Z^(-)^CW>GLME493!,R$4,VU@>\SOANC(<77W)<IA6!+G_#,IT1R=#=E
MQI_/P)[;-%)-5)>:00"W7OBBC(-<Z@C8UL4\3UQ%<\:SN'L40'&<@N3_9!U0
M'-28]<OB13B?$X3M_Z'331=EU$L?WKN&KZ2$+#_P]*ND,#>+*<1GW0X+#MDC
M:,J"J("&", 3>$I1'7U$8H'N' 0]'*D%"2'*8+P\X)Y!5TEI55WRGQW6,@UD
MH<,)U-L']6,>1XAR)18L9LN8\)[B:Q,!HP<GS'I'LA2];\X>>1,#T"O$Y T&
MXU!#I_8Q E\0?PT#GD>X.JJA@ 6>L06>X0+/(D7=O.\)9 /';L1EO:EKVJ>N
MJ7/\=4T9J%[PVT$AU&.AA_TFD_0"(TK%DCAMP_.CK7/H)?&:2M$ 2")-LMQ3
MT*D@:Q%#)A76D]5/8"$RM0F!,O89D'98=!R T:&Z9K-D_)<CT;4)?YX'OZA^
M5N!215MER.7+4\F1[K4"\X/3.^% "N9X$>JD\-%Q3+E8$99I1A;$C.H)%83@
M>;CFHPG.%VR?QX4?OCF>]W&/BX?84]E#BV^HA_5&](M3B?/6!ZRT^,AR-1SQ
MD2,'!6$(&S'%' *!1A^]13=85; NX@M6>ATIGHG43O-X,CTUF[Z$B7\L-D&(
M>WZ]NV'107('W<7X7\4]BL@*!9?6)U,:<FGZ<69'@ ^)[LOJJS_+R>!4=S%8
M\6!CM*]<T4M-NOH,+N.,V +9@6#(:00973&P^5F4E*0LFTB7!A_G11PBZ7NF
M8V<KB(--U0#126^IL69"'L*(6R8-CZ4F\1*]&!:!82U8'89GSN !J*K;TA?\
MI6ELVD:8GZ]JP;SO5RQ*WO3P<!_I67CTB^PKQN!K.*HZ38#@&BWKVE&.3EV,
MC9KC?1) FX#.1CXAN;[C*9@@IJ0(-@@+T]^+W4KL3'HJG<#:37TQ6U/+%TCF
M(\4[,Y8D+E@XOZ03 7<TP<RG!(H+2)PXG%'I4.X>GE?;7LTG<&3BM&Z#PYKR
M,V#HN 'UK^9)&<Z0WHQI-\.,:3=1WRLX<I89#S#?=F" +>BH%_A>=$X$K'QO
MSG0VF2F"MK;D/$7<BA-6"</>M\X"AF>L]RF-?IIP7;)BBF$F?/RPLUT'!:\Z
M$K$E5MB<41ORRC,_B7_\;EC>:J&_?+)L4N?TI=_C#T3=_X18/L#(/+"D&)/]
M.0S(V@H+RGP7_L\0;^9_;L.?_I+^_:#3[G4[F7]2VFKF[_,>I:IM;53N4?F_
M[_1'U2VJM^E1<!K(#O^O!;+"/R/.!7C&W/Y3?R':!S&VB)P9/V0^@3,&.CWJ
MRI<HU2\)!X$/)/FD2/"W_%6<TC/VHGO>QPO?/4I]3%O]P@^F,SE),6026(V/
M-TQX>"FWE(3[R_1\^OWS]$8"!1GH,-_8CP);G.#O1T ;M!<QFNRZQQ,G4G<+
M(KV*&-[KLY\/KK.VC3.^Q]G,! -=1#><Q?2:5-LBM%(8\# 6FIE4+\:K.G+)
MJ)7;L2)E[)LZC^JP\?R:;_*XDR7?O=A\#B7IZ.[IWK*FKOBP% @%S@S'/^-O
MS:@.'W9;XZXJ:\H@52#.O,WD29;D5SH_9=O3R]<KFUZ7J9?>-;,-#\UL&9-Y
M(GS68\/K5.WW6C/:@93[G/Z_8U#N5R&HSFKMSAYUZG(.(]6=-'W&]D]+^$8U
MU/1]T/1R=Z#(VK"_KPQF\^^K*?O$ZTHK^U/GM[Y20WX;M,8]&1P,>=!7:LUO
M[\>AWXKWIJ(%AJ6] ZV/%5P\E]RX]UE"J-90"(>M\5#N=4>U=KH:[[XTKVDU
MY+41.!@#N3_JUIK9WH^'OQ7CW2%>T#Y./$_Y\0N9#IR3X:SQ>H?2?MLE!$]*
M-FMH!D8*^OX]39&5;GJ4ZVZ^6!7G?@0Q0\/>"?;6:IC%'*D8:W0[FMSM[6U]
M:LG?>UBMO]#%>7Z]9:EJC$OS><*J3Q$XQW5L!ZM+J=FJN$AQE*J4.J**MQOJ
M3%F\2!/#6>%-1T@#*4Z$&@/?7=A!(0F6C718^=#7H$TMLJ=;K!.B[MS/#K:Z
M6IZWQEW?_I NG39]^TP9U636<K0?4_K )D$/NLK'3V\Q7[D>%%EB/;>8[N!(
M(86D+Y8W6S@(A/'&XZ=CG!1.H$[\(6PZ%?WRL5)@K ]&(!ZV*9,A7.#_;V-Y
M+A_@H4N@  E$B-K#L0X=&'YAL7HF5L-(U6^\I8#0CZA26&#%<8!R6;IWG9^F
MC95T;"XV!Q9 5 GL:7-<ZMC'%@-1<1^\#<>>T0"_^=JEDN3(L^Y?!$PSOO:?
M8#,]G*'$L2-B[8385<2>@VUK6#8=6430,<0FOO'1@3*5(Q.UK !5@D]"BQ O
MWAB,S>0R5:U18QY.[A6PD-2I[ND/#P@1QJM9YR96E^(T&^QU_0L"9C&(!8&[
M1QC9+_&]6;P-GC5](.R]+RU,W?.EWF]1C%:QK,C4WIR%L6I/VWR6/*[!I&<$
M':%"-P$?S[E#U&??FZ"6J3.1>GU"':GVJ,ZNR\IH)5-W<>20(<8?8MN9[R?G
M<>G"0"3XF-HJ""IU0\MRT-8[M]#-8=V].%S."%<F*@"W;5>IKSV]X(;E.,WI
M)2I9;DZ[>YG3[IG2J9<YO14<R6]M [3$1&L$^SC_T)3#Z7P)]0/*2L3H2!]N
MU_<^V6BP V=HII.?!KE.KD'B#ZZ+S<+C$C8K+!;W"30#A_ R^QN1[Q!@F_!(
M4/M2!7Q &#8]*ISU&D$]9&B1 8:-@"P*+0YJ(-">#VN+-==:.1HOB?*]6??U
M64$^EF=9RQV^/VA+T[C:M+Q0<P90VM&5LT8^-D"99IWAQG$GBQ>.(/@2_8!K
M^M&/Q)4Q]BJ0#4=5(Z R><<!PZYF/;Q1XO'QH9OU=!3L/#S'30"P6P5;/V%+
MGVXL[R?B__X0W7MHO7.CJXQ*]E%&)?LQV0C</U$Y1H'Z&H2[1"=D=,P@,(B[
M#BLI'A;./7!3R%>P^)]F#/"$8,2Q/8!Y:;K RQ??1;_260(/>0OGV7">[;;T
M]T=K80H4!=_EVHBA+(';Q2;OSAF4-'N)B?A";*:1Z04,1#THEA>;CB20W5$*
M6<=*%DQ4X)NS68P@>M[*81TG$7S5:+\\(0[-80L(]B 6AP@3?+QP.!\1_$!$
M;(J.A66C4L32V%N]-9^]SGK:4=JS1]B #0NF$GK^VA" %,$O?7JH'$>7XDV%
M3Z;[:.I\DA,12#<(5R6D3P0_E2''(LP%;'*Y8JW(X60O'?AM'C0*TL0N.L+9
M(]#;I&Y(4E9"=1%\%3O_%TYI;/1 @%\$/Z V:03HL&;PRB3(-@V1NF?=P*X>
M&!Q^/(A>2D -YHKWI>#0*!H%@?"GBX4<Q\] <&UL,7MXC*,R"(BI>W.!$'P"
M^X6?KRP]@MR8;I*TN%).C+!K)9PN+E0VT] 9#,5&K@LXD0@NGY\U2 ]/C29!
M6X0-EN(O&SUO#A/RP23[2_R/<T4#,6(+IWY4HCM8]MG/Q<O'8 QUP '$*E'(
M%?PS#=X38(D,#25[8CS_ML&DDYC\!1G$HEE/?&XF?" &I*1[GC.S]  ]CD?0
MP+D+#%%=2PP8XCKEP716#F+Z$/NC@\= 'B,3OAW[P:$AXD ;@79TL_8\2V>J
M^B<-7PTL^S.#)L)_?K<, QAJ"O$=*!80;9,<!_[JI3YSG4"GA1"3;#)' ,K)
MD&T8.A6-Z=8?(B<755B,$0AV)'2K@$X$]9(]T0 617@[8##12D71GHN->@.Y
M402YT4T0[]@@-T:9K6XCUNJ6#],QR(3I&-:L.7\2XIAQZ$T,3IDG/.?(55GN
M;UR56DS;8^T_BV1PZFX0L#P1JI,;Z[QG%D' (+%AD@DKM5[1DJ(#?QEB>S#H
MD67+#([!3]K_"34Q>0>ZZQ)P:X!#B@_B&%#PT0A^&1@Q-LA.& ]F3QG&E>CL
MQ Q9=!E\>#&;=AS!6^/Q26"T<KR/3+2ZO:!]WIR5"N2G6%*&E$P)TY4)SO+6
M]__D.)5\-J?PB[C-I$ A8#>,O_V$*TI'S\T&@EC3\($@U@L^2A5NY$0RC#*<
M>H4(K(BIYO'WX)_7T8!$5$.S#MX50VWE-N_><E:/.@3R,X*=I\#>P*DE+\P@
MYYK[T'>)> QA/__"@@B:NU)YRTH8_T_<ZV/.:&K4N! 0^,E8X^1<;!1'^?-^
MAX4M0!43FHOK@%.XI/V%CPO=:')+9-;HC!.@V8Q</CZ">^8N/6D.AIR@XAC5
M%IP@2]U>H^?/D 'X.I$,OP<K2XX6IV#>QM@+$8,#$A!P2&1E,\01^UU C C^
M$8C\S+DF7\-^Y(ZPY>?-N:0;W,R'L;V0@X3;H2S%C!SI",VYOB.9_YWQ)QL=
M\D*'K,]$>HB@>,[8*$A:7^C)<&J(4TF<67L;Y;%+;C7+>.(749@M3>DHIC[K
M*F97[:H#51_-!MI,T>\5=3@:=+K_HVFCUL;7=>.)B$[UB8C"M$.GS<L%RHUP
MTBWW3S0TD51G1I8F8R3AJ)?.TGR=7-Q(?TZ^_9A*WZ>3VQ\WT^_3R[O;C8WZ
MNX J!"N?D&F<V,:WT#)^9YCYQI5]@Z4<R)2(;^+=(4MG[*^?RC?EV81>ID_5
MJ]T QKL8R@.+B7F@[F5D:8M-?0Y\*I],8,2'(XCAW9SN'(N0Y6,-:Q8,=5R@
M/A1.7.3KCZ!JT;8$(V*-^'17\ES"SWO2!S):SAKH97CA[?F6VN&PD ZC45OM
M]LHB.G0[[8$VJ 8\06MK?:TJ1(=!MUG4X1=5C'W1X%4TS]CU&=F\HVH-\S3/
MV)9Y-L&5O$%'P38P&FP]!H)]DF/TB48,X*<0H>7V_.;B^N[BZG(+G(TC0 R)
M0<Y@9+0ESLJ6?',$%/BO'U=WTR_2]<W%^?262# YO[OX$P*7R<U_3N_8K[Y>
MW4@77R"$N3B??&,?NKV%/TH?ODW_G'YC 9?Z\5T1[O;BC\N+KT"0RSOIZNZO
MTQNBR]7GV^G-GY//WZ;TX\7E]8\$F;2&3-N0J1,GTS$VZ^Y2P:6PG#Z$F=N@
M/>7M>G\8J)T:.O=96;.X2A=WC.V.6[8[?7=L\X47W$A4/KP/"D%F:U==MOIO
M>^WLN)K5UIZ1:I+N1#O5SCHIH'7=>YS8!O[/]%]KZTE?8%8O(Y6[73M:)\R#
M#EIC;:#( QPW46/@BU)-DXU4G(A4=-]**H:-5#1245>IZ+V*5&1@XD4$8E09
M)EXC$(U 5"P0_8,+!"RZ;@)14=Z \7FGGHQ."#"I6^JR8#U[(&'4A1#;2WRY
M/1^_+M@02+'2D?U=Q*ZB5N8BECJB-X(R:V3J'<O4AC"L.IG2&IEJ9.I]R-2&
M(&Y+F2KV43M5 YDWXM2(4SW%:4,(6(DX=8]'G':HZBI?()0$FBMYE=^\J.!%
M34EG\XR]JO+B4(HUJXG?<<QAM]M61Q5-%-3::K=<??T!QAPVBRJQJ%[QE,KR
M&K1:;7^*'WL]M^(=?ZPIHCZ:$L^L(NIMYC">3I%K4T3=%%'7D4QO4T0-#GE3
M05V3.N!F<36OH'X-86G*IYL*($S_#MZF4+2K]%KC7J\O*_VJ9GDT=7&-5%0E
M%<.WDHI^(Q6-5-15*D9O4"TZJ%NU:",0C4!P@1@H;R 0P[H)Q*'+IP\>#55:
M.UW]C,'C4P954N3HE<BF"*RZ&M%19;YEA0=8[Y*W1EH;:2T5&58FK:K22&LC
MK8VTOFK$6D5QJZJ^4G%K(ZB-H+X70=T425<BJ-JI".I6$[^3..)U MPN0 S7
MTC/6; >G6-G>',<*B'E$$1!L L?V)(/-$T"$;)RGZB4&JO)J!SY5E3"VL0:)
M#1.,#Q+A(P-,G(\K1C%ZLAA,P88-\BP (OG3"%"<ION")\+'ALQF+H[_%-]F
M,QA^T6017*+EQF"Y^<@G7+OWZ+C^&0)XBWG!P8R6;&CQC#D VZ+^Y\X#S!L!
MD"@)?;?CCGIQTD3_6V)20D<+)B74:TA27><V='>:VW"%<GO.Q)89DM14@Z[:
M24TJ@-^EIS9<WTRO)Q=?I.E_7T\O;Z>WTN3R"RNWDLY_W-Q,+^\D5K%7X1R'
M+R9H/M<TSG$\W#F;6X90_]=,0TUL@W;(MA::QHQ-=K<<W<"V7B^;<9W0QVQ&
M8X9*QC$^H#(WZ'T:HF=Y.#E'C%4()D <TY"$'1M"!IUVKUO<!K!U1X':UD;E
M'G6 -@=<5(/]?V"X\LQWCHZIBC96IUZB+G9?JA>5!-:%-M7BGA\[*;IO43;]
M%G%\:'B!]#B6[.;?]>7J]R\2C:MM(*0:+(' <\U)M]*H>\Y&4\Y%-U^8.\M<
MM]*W([W66)7[RJCV> *'2ZHV(G6"(J7E)$9?0:3Z(%(]>= =UEZF3ABX/F5L
MX\-2,TUN0 *M' DR-<)12DD9P_,]2M"XP*1E8M :=T9["T1]*D\;5BFC4 M8
MI:1N';;&/;G7[=6$DS8H4)&;@H6:^8SWFI]Z!^&4!SSB2;[^:R=UGK'?TY'1
M0G5^BW2[TW_=F#/3>L*T::90%E\%5P?*7E#,?. PH>&;0MU>P#<I_H 'C55-
MK0EO'+NVKOT"3R%@L&QO[>KVS&RB@VW-B;A?Y22\$!3,4@AJ:UQ!MJD)!.K#
M%7G&H@Q7:, 5O;W-1+WZL.JLY+SUO3=SK152>;<TR$G[/]ND06XC)"QP@#JM
M\:@[J(D#U#C'!TI\;,D<76".OE(3YCAAW^X"+[M-SZ>B)<-ZL@P3_N$& 8S4
M^'IE?;TOG(H3VQ#4#0/"+%XGF)JZY.T:Q^\ CM\&%BF7^=7P5DT>J'6!<WD'
M3N+"?, F?=N@$L_UPM?M'>_,3MH?V,99_(:D1 2+D)"E!6"  J IC2]Y0KRS
MC2^9R3MI]ABVQITC2;0>LRL)!X<PCM1H-'>=)1TH4AO<2<_4W=FCY+@/NFW]
MK[Y[<'W2;D.AON3D_;(VOP)QSSEM;SAIKZ*4W?$*61N!'NW*W>'><5?CB]:'
MJ0H5Z;Y,57@%VCG5,;QUU+[4G]6XH&6#]4A;VXY:LX.S9N7.J/$^3XAM-@7P
M%;"-AD%+M]?D. \$KI=LML]M[BQKE HA&I0BE(83K9^OGBY'KT^VK ^8,MZ,
MMUOOJF Z8)<T65.TBIROZLZSIIBXC2 W@EQ124>E@MP%0>[+FE956/ZV@KPO
MLM K(;.H6R%$9*#>; O$TFN-:PY]TML)^N3:=59PUB_7"]WV@>$1AGJUA),I
M@@D!:J2P4#J]+"R4J^OIS=T_" -E^E\_+JZ_3R_O9.ER>K<1_20+=(3>D8L-
MU>\B-E3-($D8=<E;-05I9<DV_0:$A-[<@) T("0-"$D#0G)P$)+]9_,=.9'>
M#3S)N;-<K8'JH0$F\^HY<_]9=U/M$)MVW( IG"Z80J^[*3[,\9;_<!TOJWJA
MTV^-.WL7!S88)+7@I$9L\L"9U:K%9G 48G/"MR[?]'N<.N^X+Z'9;$I^4O:B
MMQ_CETPE#EOC@=SM=&I2C]$4^%2A.[6#LA".>))'@[H@UIQPV'$UGULS4YJO
M73C]=3K.:,HT>OU#LGY7H3KSRJ8EU<#G;EAHT#DH"ZG(0NI@;P/<X'X<O8-,
M94G[>,3[E2,<I;1NKJ.I5%JUUG@H#SH55]#4MD"F8;X]:S\J9;X.QFKJL'\,
MS'?"7O@WT_,^X;"E]7*]T/$>W3!7+AP;E0[LXY.?B A]J%*!3T(Z?XF0&?Z]
M,/$?(%:3I0-[9ETIN2)76MJZK7%7[F:D##]6EBVL29Z]8=']U/R;L6@/&TU&
MW31$6+U8](1=]H)JK*9KH"DVKDVT<VF6URY]-(#:_FULM2@R;KH%&@&N@0#O
M'#'N(L #$N#.:0CP5ET"=2K4CKJ"HL=0>M8]Z=]*:?P8O_328SK#EUPZ]LIU
MC#4]-."'?L@/P]98;:?C&0GVO,!UH ]3:G':H,+5(=9$.YU8"U8'S%]VSK*,
M0",K<X;S@1<O[<34V2+N.=:>DF'M>TKZ._643/C ZVLV[WK")EU_"P=2B\:J
MR*_"=A/>9Y7N.NDIZ:Z3GI+N.IF<G]_\F!9.X/UV,?E\\>WB[F):Y1C>V]FC
M::P7YM4\O>4[I$3&GE*KS^M]H9W62VE.4B/,4SW9D2GD3<-+T_#2-+PT#2]-
MPTO3\-(TO+QFC!O:Y68>;U.XOS-D(6<C 2<'3OL7$T(SAU(<^PR[ZVEX%=+O
M[UV8T?3%U(+C&O':!;SQ]<2K@S7>:J?^HZ]/^*XQ98.;,;T5V:,RXWE[6!>B
M-5.Y3HA%MM&IE8WE[?7P5J:C-.TR!U.8,V>)V426^\2LX+UIFW.K&=!0OL!@
MNEPMG!?3O#&IW"F2C=Y5'/KH60P'=4$];5IH#G#+73T7X< /!1S4NK#1NW!#
M9Y9G[CQ,_*0]BDUJ]$[_98J[S%U9'H>8R)U!5=4=C2=: [[9I#@W\DWA^(5>
M=1/H&^=S6S793 :KJ@T$R7GM.G/3\^!I^N*KN;._T%=0>7:'3>/V";'0%FT:
MA2R4YA*U-1[N;V ;EW(CKL7.HVI.VAO8:E1-5O"4YF2\'E,;5_&$F&.K@33;
M,4>G->ZJ5745-R[AAK$S>JD2QQUOUIHFE->CR]&KCBU][?W3<OUN:ZSV9:7J
M>^.:]Y#M7[K1B&\COOO&.16(+_:7*Q5>SAQ!!]GIS9E!A+&:]P0-=NH)$F5.
MD1HG&OW-H-EO.19[T="9?C_=_M/OI]M_OEV<8]N/-/GC9CK%>3.;6WRR^FW8
MHS->6#AC1HN?3;?ZLZ'G?++ .;5F6YS6=]WS]-GCVC-]WY/^,&W3!;?VKXZW
MLJ+X9=NUT!RPM^C*EB8KUUI(/6P0 K^$>H&07W3[12*)!K?<LGT'7'*\WEJL
M/>O)E%:ZSYSR&;5PZ@^N:1+D_[/E/TIW\(PD#>"A[@JQCO'PC;_<_T67BHDF
M?<"\O*;\_OV/O]*_U-\_MJ4?-BA#6F3.N^'3T@<=(H@E:X>T;'C/"VYN0%'%
M5_/>7>LN_6;(MAN^1YJ(AXDWQ@GBW/LZT-"($4.6GAUW83Q;1K HF:T%OTH*
M6 +Z>:#5Q5_7M(L9:&5X'"<F"WI\<_9HHZJ&A3/+A/1RYK@O&1^SU'_" QYU
M.(2E;N"S//$S_,N0)<]<+/@OP%; +Q:F'GR$_@V_LY9P%C[_)?L!6\%<%G0]
MTR6F"XPUAV7R51L2[U5E"X4?9J:'L1HVH<*K)6H;P^^9NL\0/PQ+?[ =S_)D
MV.-B8875)BL7%)0M]F; ^W01]L$/9/$\?.#C>@FKH-_K-EGW-G&7.!#+DUR$
M&$$N!>+@,F;.$O3/#&1C\0)_U#W'II8T,+:P2P\_9C#MR&\@Q,=!;C;N%7]:
MKCT?(M9'"YX2G&&P"@/\BP?3GIG8I&MZOF.;7IDN6]&(I9($KX!Z^)%/+I8%
M +.%?6^_Q14DUR%*^!7]'LX?U'[N5S*T3[JGY+#ZZ.L9)EUBQ(K\]S%H5UOI
M#^;9/9SNSS-]#JO\I"^>]1</79KH!F%W<7J6( 7?^/C_WKM_&6>M*=^BU6T^
M6J@T@51+3[1\QA1>7-$EY&H%&E27%L[SV1RUOV$]6*33EI81_8UN RVP!A<,
MAFGK* 1S$XR%:V&?NL/Z3"T7Q">4.LD##QM79(&PL3]RV4-UQ"5/AK=O]R[B
MAMU?!-_4?=S]#'9NL5Y6_0'> 9]VG1=]@:&#'$C]#&A-RAKU@FL^(. 58OD'
MHH^46Y)R%ZWZ[,VYL0U?4@J -S8QY>+R:ZP>$SRN>].]FE]SI34AY01QP7>Q
MCCOG#@S1@^E^#^GUU31CT0^PUPPC(+!FAF?:H4<X:(W]1V"3- Y!H"5A<Y9M
M "GP]Z1CA8+TUK/'B"H$R_AH17\34@@<TW)0"X->-M0"T22[X#]@]W-X$K[C
MSKDV723"5\>E]+!WSL\4OG@3G&A R R4AOZP-1ZV\W+% JJ!6T?] 5;P  9?
M9M9',%+(IJ?%.Z/WQ3O!,18QS  ATH?MO Q"'L?$/1]T_L+]@UHKM_T<3/BB
M[;O@$#YL(, U6Q#\S/B(/GXUWR13V^1@E)!^$+WW%!E,99JK2N.U# ;'3 GP
M-#I*#BF ?S1%4P3F@QI'?I$#K:*'ZQ.>P4:[1ASWP?H(*FF!C3;P$W@S%Y=?
M!-<*Z[L&^C DP \6?)P>#AS,0"#I:]+U(_C^DAJ^U$>7)X%3(R7=?C@N!^(Q
M\%0);I8[*6">T64)3+4$+\$IL&C[:<UI!Q_/$K? %XY.C@<_+[BCX0D_)_9+
M)HOL-1!EP!*8#H(@[Y^P9HI%5J3*0%!_6<OU,E]MVZ2!BQ544FOOK*%NV))O
M8,7?V<)N3 Y !!]%EQ\\ZX#3P),-6 W;W=)<]AL<$_\^,=1"G_UDQ_JD8Z)R
MMM"MI2R(2T$?]['(S;)-]+HP'!?<*([8=WBTC8XG#_4I"P%_>K1<XVRE(\8D
M6J3% DB.SN!*($^ZK(A:^)RI0V?&]P$S#I136ZZ 'W$/[%PY6^&>.%^%#+4.
M?.F8^XQ7E^ M$\/IJ1>>W;^<)7_'HT\2$/R[D)5['0)FX!Z'\Z..#BU0E%[P
M(B1TH8-X14@<_#YX"T\J$+%GSA,\A,QI:AE 8?J#>#^<0V'.<;"5K=Q&14YQ
M1SIG/<LQTAZ%L7:3'@5X,V/8&8.\2J8<I;GK+(N]?]IKSMY3N85L):-+JT!4
M\)&P@#.N"LX$YP66V04.!Q5F2/<OR/.TP# 59&;J'WX#P/4/)3^DV2,2%%^'
MQ^$Z"PIW($9#A>GPZ"RJHQ*+Q&>G%Z5[$LH1T]\O0C7C5C'[(S35*GB#Y*$(
MG_$0;(ED:]<WNWF7*Z4D7AD2Y9H84.)Q"-T>T06HHM*R'8D>H^G)1'"-/R[1
M0$$ ;MG (MRW$PL+Y)US']4D#WY'?3-;HTE;HAY 1L:L![ L><V>LX#CF+W(
MC$% $2*/W+_$DY8YFB$:?[!:"[2WUMQ"9J67F-FI@J0CFK\KHI@MTG!LD^%+
M6%[@V;5\%&C;\7&0$W :O&Q;IJK=1<!?X6G.8TBK^@K'E1V A$FJ)G,7,3_]
MGY=P9SMN2V >3,KR7#K !VI/AM\ <ZY-IO.$&?#8M\[7X$>";O:8'[IT7#.6
M\<:0Q\6K3;3V7OC.HV6,._VG:>C'QA@=F8-&EN<+OF'P[N%,9^::+J ]Z4?[
MMCUIR]*%/6L'5SSLL^$MSYOP4G9:?ML;Y6[M;Y2'.]THW_K.[.>CL\ ;&43>
M]5_P3(IND-%!3%[H#GKI&^3;NZOS__SKU;<OTYM;;NZDZ7_]N+C[QTXWR>P5
M&2^N6S9^4@#0*&?Z .(NDT7CGD\>)IINL*,SM+J8U;9GD0M6?>T_.BZLRD@&
M59;G@1CE!J,>B*OI%5?'18)1P268^')LXI5;>L(D6$#IG$8?*VPHIY&=UV!+
M9)XPOA6.#5XK09BCHS.+4=':W)@1@Y"#5KK/5J]U]\J]I>/X$U\:/C.]JT%K
M3%"5:D8F%%TO_%X[HZ*E+ES[-0(U7(0TG+ 5KFZAS_F PYV8FVP:.Z0KA\6@
MRK<ZPL'2F9PCL"DH*Y*#&Q[G7-EW83R3E9$= L]UM'9ZXF  M;Q:N]Y:MWV1
M4^"62_?I)SB>GR:&46"WP-#(W)1)E-JW;9-MD:R5LW:E6TI'3>(&\YN)W_TI
M 5?Y-MY_?_MV+F.$!A$<?$;8RLG==^F*OR>L4H@NCV7)G]G]?UE1CY,Z@_\C
MM!9W!TSD+U"S&!=Q4I>4_1&;KP"2/TI?J!1*/F->5))/</@/=.LXVUT-##:I
M@0@9KO%-!;(_5%KC7K>MICOKHJ*/,16F*@,A"7(9T1./07X7RB%0!/P@?07/
M^V5A]+AXJ5;HKOE"O\(Z\>SQ7NAJ'E&/&8(V5$'0M*S;LA!QG6YP#995A VS
MU"V3 3QVB_K4JM,AE,6*G.;D@9)6P8NR=H%I]TVH\4(7A$T-F'[F=\QVN;5W
MBFZK(FNG_XBS($2>K-5WT!3EH\K7.*$#H<G?=!O+MQBO#[-,#CJFK$2+<K4B
MO["BI%MX+*":F:(LJ2"'RALJR"%-8$-'L8QK1)J '#_F0[*Z,+9[\!L7:]0B
M9<F@OB49>J!12Q(AL?^403=_8::8U;'-UXN%2'T%3 0F680ISBJX'%B[,[J_
MPD)LGQIH^0)D[I$FV&X_LS34*C1+.,P(?=*-9BFX@LXQ4,D][FMYXB)6D>5!
M.)R>VL[PO[G>DU.F)SAZ_,& D)?F+01E@\(296K[6FC1[$1 )*27;O#WGH2S
M=>JPX U5RJ.B*/G>T5V#E9.ZX' [X$%_B'CJG_'/PF%&]EKHF,32X>-/$##0
M&996@IVB2]H(0W[A[Q":D)$]%,ZB4II4#\H0HA7'SBBI8;7&(E"@=P0;CNHJ
M!T<N\ D/&)',\3=,X(762Q+7-I]!B@W3LQYL2C_<PEEB#"/]#6@$/BE&+=;,
M6NDD+-<N9O"0OK1].1*8[Z;W\@@=J@3^PK*!^7"T16 N?<#K$+QEX;2-[ __
M+L(]IAGH/IH76408,/$=+PS>T*=GESIKW_/A(>3WBN.(63%NK+Q(5@X_ PP/
M[,)G?[ *#L>C;]^O/9 GCRZFF1"AOX12%+_&H:M.W0#+1D*QL)86C?%=\XQ2
MY(V,SR"<!Z41$[&(,@DW9X)F)')(UG)I&A;9 XIK/9-NB/Q'<??)OQ^Y-C.(
MU]BV8BH@Z[T9Q?OW+QS<T'\VS=@%&_U>-,8P6M^Y6-G-_RY+EY2GAG<'CP_N
MOJ*_$1W*(!Z@WY[8!)8L$0H*ZEDL0S$_KW$1QQH/:_'>%T\%9!9V ,L'D^I@
MP8.QS;.2["9+%EWRRJPD *_M[@.O,-<90MYBFPT+'Y+DCM'D&8PIOV8-68X=
M6A\;'W@$9(K'(N$AE%U8R%>F@4^D1@3S%[OQ-A+7F7&N-1R@M^WXK)&!M6@$
M][7Y*Z9^#-/\&>-J<EA 1P4A=H2=:V'-LXWCA<T*6; . *N[Y>3:L9"!*6Y6
MPH#M'NBP@GJSZ8J;KF61=J#O\)H6MH^MBBO&*/J,ZL ]CA!*Q13.,R:H'JU5
MH<W,+FP:QLI1M3R+^3EXVY5XV35;[]TCK ;/+*M,:82UE5EE2OG3C7.6V7O5
M9:KHC68LDVO"F<YD#S/:'G5<80FZY:]YB&'93UB(YWZ4Q(47U_LI"T*JDRV8
MV6)2%O Q=E4O>)Y_G9PD)F+TS\ BI'C*)GWC\+(LY"ZZC+!979.KKRPCG <O
M$C9-'\SV?3"#(^^#J>'-6\K$HGL@,?EG=VA,JL"*/3J\-XY5IK-  92H2^QN
MV7/P*K'GA#V2%63%7>>8511ZF KH#5Y*YCH^V>M'D[\Y6H++G_(?7MS7,QBP
M/96@68X19K$L'Q3T @MYO8C@^S%;2982W(*%>&W218'EP>,]B.7)5T]O@:P[
M57R:O*CH)[STT7$,;BQ8>8#E@YN1M";41I-#+/@W?.8!/& P2F?\-B6J/@*M
MM=)?B "PCAAA=)LI,_ W,%$A7K-RS:6U7M;C9BT['(\JYSJL,K^6+IP1B&44
MDK=>+O6P@$XX=-0P"?'NPGP(F3 2J\2=W(++\+*C!ZNE1FY]3S9]OEG@)AF,
M5YGKC?KA4\!WA_4(PV)KJGD/EH8]N1Z90XN)YK/%?(7U2LX](Q)ZB!5(L!=,
M>;&("6)#_7[Q(KP6S Z"NV("%Q#$)_Q%?]*M!;71H5<-+P<%<[\6V=.X! >M
M>[Q.E1P@>+5AWOM12*C8M$N;^2:(9._-N6O'JUDC^T8]P(\$M)%N1XK#([MF
MB@@44+87M0HB*EKWV\8$)=E3)*"\-^'(V[ M(CP(+Q:(@O*&G1"G!&7^B9-(
MT#^?82FFC# K+W<.V!4LB6<&>;](9 S:B"\GR ^R)+>UI&71__)XE/G':)+H
M7B_%[A!]>FVIN-BG5%*\OR$%%AQQ' QY8AN7CCW;$ADY3(R-P'NSG712#$*3
MQY!VS$NB[$1 ,BR(UBWCJ.3C3X?RELS7>1,9F6("D*<BTG=7,7[.99LG\"@+
MIZ47I*@9!1@!1)H:?H=)[RVRTQ&^Z>1DIW%Q8:J3IS=MTO#P=,S"86/$$F]K
M#=9P0-_@#D345,C\UI*5=(*L+\Q \0?)_V@Q?NA,[U!*AVFXK&_=ORST9UA+
MS(B1K0P24L)_A7\^,09C3E);^FS.]+7'=V?QI$W4% %-_NFXEA^X5SG7FE&^
M('I9+)>321,07IO]A<C.GQS^.5"U=$S\":0>X7,OL 1GO<#K4VD&+K]G'I6$
MWX3N:>B?>6\@Z)^DO^;8+>(9FVRDN5SYA"T#POP$G^7N&@B(-W,M=OT<<;C1
M+S+)[MD.I5&7*^'A>9;]DXYTS9!,GBQ^:QDSN,G0F#<XTAODF-$NZ=_'FB)9
MWYVP^ 9N#"^'=;HB()&2HZ%$^MFA$""/>^P.*NV:,<\B&E_B.X/;JZ!)=>VO
MW207[SB+GF4#7\X7X "G:Z)'W=0 ^CH%=T5>2C S/EYE@Y<2<!1XXV$D!LCG
M:"K4*8SB=.N E_;-</G3'"Z?C0HJSL7&3O>M/]4,JM_W&7O1O1EZWPR]SQE"
MT R]SQEZ?T QW.VA=?W4H8'NR>LX(*3Q#[KF 8?IYO:'I#_K$$,G;M1V&'ZT
MQVCS^F,]Y]3=Q4![E((6K7.=P$19"<P-]U>_.NY7<D1%\6C9^N-1KS4>J'UY
MF(&(4K?IWP>>H_0>N7'XFMQ8G*3M5S:^[HT8\4"&XH@&/ZT"'+R@8#<:1[_S
MF5 Y(CAZ8X,PP.%Y(T65!TI=I@8U(Z6JX:V1\L:\-<1QX)UA5Q[T]W8W7I6W
MCL/I/R"G38+KX+ 6>7I[?1WOMWF? T]SA$U]8V$;M<:JW._"_RGI%MEF$NI1
M\Y;VIKS54[ V7=:Z WG83W<;U8FW&J=\@R(G8-V=E?C)>TR=-Q8T%;UQM=N7
ME=[>XZP;;[Q>O-5]8][26F-0WW*_YJ.#&U\\:]+L/CYWX:2^]YCW5-\VZ=)3
M.JWQ2.XJ?5E3J_+5JSCD(_#Q&UY.\++VMDF>GM)MC0=R=]25M<[P)'EY#X.4
M'E : P<M:B,]S@&EJM+MU1Y/=K03GNP=8H&OW1>2I52A9$])@\?"[]+@L7<W
MT\GMCYM_2(0BNPM@+']LQLOJUK8:=F-C%6L [<HJ9<T0U66>W?@9='=&;Y&"
MD1S8<!G 5[I!'Z9M/CB^I2=& 3!0*QJ9@*TP?#:!+X8J6#.&?K'4;9T-?Y 0
MT,&+=F:VI1V11 U03UA8S_$(6 %PL%\<E!"O7ZYO*^65+5W-?(> UWL9B$9Q
M@&U6/!OBC D,"PY^+1#\J0^ .N+F.).'3HX^,/DRN5$E;K6D[^'1?,A%JF%?
M(42?$*8F-B\@]VW7*$YS_9?T)WP$2WW%B_/?%GPE\<*V=(MLE;__$#:'\7OP
M(%QI; ]4AAY=@!34BV.CB1< R832%&"%B/6TI>L$2 H;IL@P?VR&_A;(7N:3
MV+83*^,-C$DJ,)"Z2)=&3E5UB,H!NT)<#@&8LI3A;]0J;4< W,IC7(WR!A%Y
MKL_0P<.]7KO.@ZLOXWA_(13TG?/9##]<%AFZI_01VT-6!WVY-\I W\RFD"R.
M*P#^(5B^O6#X1OU,<)!,&S=A^LJ8,%Q:1.7,AZ/J*0A3-V@/,K87HE&QL1J1
M4PUX;;MM%6\G V^/SXT!S1T>WP; O9XRQ"EW2@'4J\QF*!L,-H_@AGS]E\S[
MD7"^#1./ $ U,=8IM'U\'I>/(3[LS0M0%"+F\9D:%A FBR%*^?R0N!PA3-8#
M;X.![R]-8%K6\$6P#1PD,_T]*WML"Q"8/&K6*:8O:$"I]VB:?CV0 3=:)DW)
MLDPT4 FV@G 8A&3A,N1#UF4;T#K?+C/IHQ[2DDR;*XN#?* >KH"X!,8 ,:_L
M<[X7-ICOCG9#,,M98CG:0BQCF&3L>0RW.;1HR*71OW"D+'*B>I\415JUEVUI
MJGM@6VS6;@QDN'2>^)R6H3@49,Q(QPT:2C,8IQ57=Q -$H0/:HW0C')AV<$>
M; ((CVF_^ F4U?@JH3G)HQYH_7ZNQI>W48A[P)&.1J^@'E5$@!IUVQF@X!6I
MQRB?M27I.Z)$$?1TG0]<V^; &< LTS_D)J?VRP0$,0;7B-L8_5JV/-#8/N 0
MP@A@,_B(_O!1^F#@X1',FDW]B-1DR)ZY!H6M4S:$?$N<-\.L!3K%AJL_V[R)
M-GP0&20,:!ATA64:;V[$@#1,:>!3BBQ8 ^15 LAK>"Q 7G7R1 J2-AK+B,3'
MR.;&7,C;H4_#VUF3Z@(_%!A9^A2\FTM+EG>W<LTGRUE[V+MLV\Z:/*)R-F60
M;5/R@ZHPC)K0W$4URZAT6N/.H)<Q6CH833#C\;AK0GB.N#CT<+ /%^E1)?E$
M12+&]6W4Y; 8W$A)D@ 3OX:=[6*FLF#>!&8SMK&NH;8/%*D :Q2Z>B^E6@B%
MU4[KV)V3RUI/J7UN655V2BZ'8\F(+?#D^!P@\HQH(@8Y*)\Q_R#X*9V%5C.R
MT&K>"+.SSY/;Z1?I_.K[]?3R=G)W<76Y4SY:S<Q'JV^2C\[%UL@^+DU1!QQ=
M],)&,XN()_7&E,^&.,W="(OM6O1W_+GU$>7[JWGOXC02^IX<@I'%8,T(8C7Z
M? &@^AWG)M.OF.<7_A'=O*5#\VAG#%I:(-!$OJ8I-<XD;!QR!WJ4N<[[92=5
M9>,<DD#>HQHA,J#Z\TM*)4RP-3,OBUDZIL$Y&ZHF*Z-1J6$EK-Q0S 6.(G)'
M0=$<WBX4%I@';-26)@B(S3^ (3)UG,:^GO$U/@0Y]C&RA +(O::P/WFJ25,D
M-KCR:'3310#5KV :CIU.WC8"S<0K4D$SW9LS$('PP$@SL5%RB-FR7O@RX@3-
MUR[A*7*V$#"/2]TPL]GI3BR$WDM80H;I!7CI!*Q(UY#$PX+Q<$2Y-6>HK12%
M\L7'/_6A=7%[Y;4^4KK>!-?>>1$N6.KY($&(P05!=^!LA8^YY(]!G"ZPO7Z
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M"IN;12K_9<6O%1 Z1H)($C5:<5I$254D[&X \#]_PIM!MU[3R $UC0=KK-T
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MO=9L]O8^_I'J?H&+P8U B&B)**:,01M?/Q/<IU<C*1U5)J6-ZU\S-NO7A\W
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M<SOL.Z7"/GG?LO'4)FG'O>T[YOP^R,H]JI:W1:75Q!%D'B71>\/#EO/@M5X
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M'\<>2^@XS -\+]IH-RLR1DCVU^3L1IE<74PNE(O)^>3[E\D-9B6$NMCN XQ
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MO#M=CG!@>VL8']C^%NAR#X4A/#VR2BD%-"T[U!,L7PY!2J) G0%09P"\V0R
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M7L+U4''J#_A+5'X[K<_B(P\ ]''[\T>I;>*CT6?"K[X';5=H.>)!KAN"(NN
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M*QDC8O28_WYX(WJ*4?;9#'[(+3T3F('.0#T2,E?&"8,.SOBJL<,E+:X)-%/
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M_^ 0@?91:Y3EIN;HF@@A'S#41\&##FC&U'!P#LH>K\R/@.H%@!$(F2!(OO&
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M,XW9KOWPPXG\[]1HKI/BIB$I#23]Y7B;8(M5X%&[[WZ0_]X>WA%QU*2 <,M
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M<*4*2J.-V[*U!"'[*,MS0J6:F1(H_1,R+\$RR^)#ZOF"67X4SUH6V(?YRWV
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M(\1@N4<EM4Q/89CO!;T1+_\-:S[M)+V_9JLERG\,YY\_3T9UKO6BCKJ2![L
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M/SY83^X\&8JJ8 )OA #+N%71.REP-Q-\[:-/1M^[BG59U[X+78OSJ(R@@\=
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MKGOD!8BM!J1(&H/4W)765XX;P#HBEK3QGENK8NW!<L@0X=E@TLN]_F4M]/R
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MQ  E:$*H3$DRG033[HD!/UJB;:/ 3M.HIBG6?Y"JQN_)JYF%*V:9TUZ#D$:
M+=Y#E-G3.< X8G ^8.O*B3L!'6 R6U/]K<V?VE7X'8257Y _/OR.>*,CPE40
MJQ34449P47)0R!WX: H8+%X8ES2FUCT&UH(Y,4:T$7H'^\0M8'-(/*%@7"D0
MO*8VQUI2RXT#J=$+\JBRX*US=E? .&4&/$#0'42-=SQ;SRYJ?<ZYM;&V*V7
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M)Q]]ZC1?]SV=7+VO=1KCC:CK57 T@3:)@<42P7L9($C'F9521-6Z"GLK@*=
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M-*219SX-R*5+'17MP!$'P0,S:1VA#TZ#F@'48F>F%4TO!OY=>D#_Z7?"RDA
M@@;+$ER1\@RDO1.(EUY]W1'B*R\KN++";L :N&^&H]#[.EAX27[KI=EJ%)(Y
M37\9MN4.K) 1L Y*QTA9+*YZW!/J*Q,KNK;"D9HUL*\GMV%TX?_G?CQY/F\V
M!Q-Y YK%]&UT'JN$6(<#S=S+T%X95]!UJPQCE1AV>9L/,[X=7 W,],++YM
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M5R5'M<#]=#P]"2^OLE97&FB;>M%<Y#+?=+.2L!$$2D0&FG..13"*R&J2CR[
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M(DBJ!*51*+9<W*0 =9JQ'&LKN)BO5SA4P.85=G":<,UM76Q#5FD7>#VJXVP
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MDLEF) >31)?Q]TI T=V\QQ9"YQW"]^9_AJ/+^_%D>!=&XZ<-X+DN<.% &1*
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M5F<T-Y**EO72U[9Q)HXN:<G2MR=\'$X2F)[I/Z5:LVO&QG.!<B[I[Y]SL67
M.&@P7BG@A"")D ^NY9B_3^OG1(KJUB]]E<)ZP&GL2A&+2S_:@I>*7 R:>8B:
M1ZH)B\2U2V[W:/SG($L9VZ^_=:$X6::+.UNPQKRYPGC*@(*/.#"%M6Y75G.W
M=G\.BG2V> ,[NJW6?KC/5KJ.C:M_JS; !K1G"A1SCBH6 B+M1HW-[9R3]PM:
MM,';G=5QGT+OSMZ/QM/P)Z>\[WIWO4GP'\UH,@BC\6WOVW,HO"+-Q ),2G'!
M"NPEU1I%APJG'3L!/!/BU'=. Y4Z+X)>.)>O-QU_"B[TON=]@0]A<GD_&C6
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M2_V_QLJE\K9@3!0)R!^ZL#NUOP(B;)& IQ]$_YXV+P)_G 3\0'GX1[M5NAH
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M6^?H=%^NFT1@6FO=]DZ7#7<-UBFU9]ER45*ZG8(LV[[2+Z]@BYE8(@<//FB
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M7EM;?=;6[#[<$R4/>>T&B54.[)9<R/ ,G]UK8F25K$M"AGROBC8+&Z=7O^!
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M?%8\"'ZVKSYQM\\EO'YZZ+M[JIN5)R83?2P%I0[LF.(?$:IUYFI+5OIFY:0
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MQ=*':_"-(AUG&XEE1R[KG*4 RK'M(6GXGL=;$KL3@4X09O.XY-M5$+S[MHP
MRH+%Z8E)ZN6L+U[E#M(:U_!(,D].!P6PQ5)&7?X7?GS7N0\'40"]*CW4C#N3
M N EG(S8I*ZG9RPS=\";&BFD2]V(9.CC_7U3T10 *MD?2@&<7P8366#['SA"
M'; 4 (FV@"I=%3"VN%0\D^#..09V_[%[ZOI&\1Q\"K'+/@/]%0GX)T!.*Q'B
MY(DV+]C$_EZM0;7\W9R=8O+E?XY8\%])!6X#)<@.I.7]G5I*OU*6^2NDQLX,
MV.IG8WM2#['E?P>+[UQ'<SIFKY"_E"U2 . ^"B Z(%X3-/ZJJ(\ WPW;"TN
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MK4M6Y/Y&C\F&N:J!YT* I$:$CG!!F->VE%Z>U82)IK7TZN#PZ=0V!^&UWO8
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M+\Y-2[+5H0" @GCP(AI"Y 22E2%)6\85VV9V\[*LAG5EV[1D074,=* 5@9<
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M]M!]Z)B$L"U)('>&NU'^1@1ZO))3/07 0-3)%E5.:0X4B=AQ[9<,>@>[^R4
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M_JK'\IC3X#E=YR*=-YQ?EMR7,O4]/A_G=YU4"1]Y:/6YDQK;6B/"Q[;.=N7
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MP_B#;_:/$]Z+B/K8P-<H&/,WC<P"1[;P]&<^M'6J<)0FCPCLO.12@+997R,
M[TA [;3DM]4.R=#'HJ$\%Q6_!!Q'%1:F%#P\U=DY&PZ^N1$60K0LQ -;CR7/
MAWGJ%O(9ESOW3IDI:T,,UX 762X(."V#P\#E8LWPR,>XE#RB6?](<Z/D@(UY
MU[;SR>.5O M1+AOS(=#\A C8JX>M,T+GBFG/94:V&GYO45?9T=@,+MG5,(?M
M?776Z_XTN?2R?@0BTY/CF@.]"PFJO0]#Z4+"DU-U/ N6#F@.](U$GKO$(0Q<
M+Z$7^_!QS0%>81?DKX"E1><\4P-FVGM!,*]](E"N"L[VVK7HL>833[V].F_0
M$ZK7+<$M$)B@(,8H?LIJH@;OC)9\KN!,VQI[V6ILI$=DMK1F'"[2?Q$_V<XB
MQS"B_0Z_/'T_?H9DW([Q&;D 95UZ(5(_$N^XA'_N%J(I'0(27Z"_N@NWOBI_
MFV?4E#""[%DGPJH3K5_U*.:_V?CJ:.@2_]1%A<CJ[/%LG6IA<F5FE;XR\)E)
M$&HX:0;"2Y3%@$/EH2P+;,P<CER18N,*=4'=3*=7A.PGC./C.CXL29 '(3PR
M[WJ)/"@0Y[>*B4A^E?FH!QY&JM;15\Z,E=SSHO.GD_*CG6!8<:F7),A.7O)C
M]PF^8+)6K(&L5 ]XJ:GXR.RT<#,[$H0R&W,D?]G33T*_T4"V!@H09)^_T,Y[
M[OE$Z-I;?L#GV= C/?3%"I'/M.E9?-X1MPB%(YJ+ 3WZW 4":IIJ%A\2YL^I
M\P7/560DS'V?G%GO<BBHN3%[1<T-N]F*!'H@&1RX=%'CKFSX]*A$/_^>%9+H
MEUL"&XK>USX>!5Q/#_\H(/<).L;>%G@((V2)+S.(O(T]5I9/"FY.=CS_0,:3
M^]7[=P,7/[=S3KCWG).,C3=:*T>,EB[UZ(?C<S1U&Y1C"Q6$L;2D4K9,QDK7
MLP\!+'0/51E*BBX1E'V2V[D5()P+53NL^E62N3W%95/K5G"$G&L'X?A,XUES
MJ\)Q(ZY$! 8H(5]*OG(SC2[3N!Y96O:XLG#=4M)4P:\<;ORY&OH\4'%883U<
MT+A5J]\. V\)M\:R% N&E,H;<WT]XV3??-%;I:3G07#<(6\O)'^CB*5/_D<S
MW84T_HJ4MHB1U;MS>M+M23EOF?H_CS)\[GYX&L#<H?!:*11J2X"MNHG6H.9@
MMP 3E\>6.:;HU-INBM+N3([$]X@FU[JN=&0@S1Q7T9:"IBNKSTKNCPBG?N$^
M_BS6O]F&EI;A C]-C*3\>RT]@F;Q3CU)U6&GK/3=!Z.\B_%-0_XE#K(VJ]X"
M_3<G!UT,O/JCO/3)R@0G_Z/E>&-T]-D.C6->_:L5NMF;TJLZ46.3N<BY5NU)
M)AIAEI#'_,8)/K 6+W#%<-S"#:0^?NBNB]G8XOD86?9+O-_;CO-+=^>B$.%,
M@BH!AEB^&:Z0>H, 9S35.TO5@IKK?+[WE<-7N9G<E[F,32+,0\*CFP]G3&ZR
MIIG6T4#X?#[A4C#KS2FZ/2Q$8&6"S(2\4B!X2(B.C'K,67'Q# .T(KJCB&:N
M[K2)A<$PN22D'QC80P:E=Z38F3"\9NO>S*U!+V9U#Q4?6[<5(PW&Q0TM.PNG
M0$Y/F4XX[+B/63:)% ZRR=^\(,?A,ZG/8R)XX2!K1$16?7WUH$QV;5V:>7[>
M1)?4IK)W;%?7?>LNX1T%S@ 4WMY0D^.C>$8$X!]?514P #ZI98\EOLCQ,5WZ
MW8PE"F"#95#FN&WH>A1YM5:)(Z@IHY((F8:P$L&#F0/U!NE(//1Z'.O#Q-HH
MNE.\<E=8:%:N"&FTEX@C[S!(.K4*,@T33UFG3SF.^2?>'IM]-2B_*/ R,O)1
MFW_3TX=RAYN:</GD WA+-"*"BS=*@[-W32%IH/#+T,SESN<'+^%?3SZ-FIZV
M$Z,_$)EOX>5=\LG0,BDBD,6GITG%)2?7Z3%'Y3$SYRTSVXE5>?T2BZZC"4*J
M_-]?=3Z(BO%51E>/L1O<E1]&:7*69>.53(?5SA;@0[^VY?25>SV370L)/\@L
MR1G%*7S6!H:B%\">YQZ\P<;!I@\H0I YJ,M53$JN(VW37E?)P*IU8WTU0<BY
MLBJ6L4,*/GG[O G[(%.?1Q6C4DEGGZ4,'/.I;:\R.&?9RXIG2*;<^2+68UD5
M7_BJQ>W19Z.[6F0QJ<,?UR2U6Y&TY!-XN:_H=0A&JR;3;+P%]SR[OLS&!#V5
M5S^?L69KL74HK%#&MJ*CF\"OQV%XZWA&A#C@EXOV'082H6! _\;X1M_:6/NV
M\_ 9N?<E8_W96MRLYG ,HO$XM+=+B80/HP#""Z'!<'H^M'?8=E=[0:UKDI37
MN![B-;Q.=+U>_4S$"@+UPH8:/!>",=08&NN)1I\Q]7<\-U(EM\Y'#ANWW84<
M'6S1RJ9_?3/Q_8"A.6X.$CN'_!E!)IEKIQ6XQR-*7;"/[A_TO C&=,I!>X?A
M>  47PO^&4'/=GU^.10#PM-GDF+;$%]N4@!TQ>1KFZYX"/(H>,$FA;R_/7/_
MT&E& IJ>Q!0/189#\1%;<+P-#WC!R8 ( !,M07^/0*,JP0M&IJ4&]>#2<U6[
M[Z'30Q1 5YKS+Q# **C_>2HA<:X$+) "8+6BY@I,P6(D9@=J)$ -S2,SR3QT
M!GN\ U1 U.=<VL,;17W4P!TZ38_3/D8!*!@0>1&[9[\@?H&C391=#P=MR>E1
M ($G]D^2[H?^Q+$'M.4X-;VX9 :=IB8WZ(6]*:,Q,!Y(!) [T<BY/ H@V)@"
M$/6M^@4,=5E\1L+2DD-U$.NM8*+F8P.B'!-\2R&'# "196 _2<.\NTZ; J!"
M#P*-\IL3A\ 81PK@>X_B+R! /^NM>/^[XX5X<F@YE4NJ^-KZ?A7(LJ^Q/04P
M#<;0$H0BH<DY9&8(\?5_2?T> :X2JR B/1D M7%SW;Q% 33E4P#Q:N._ .&
M-I/Q3ZA2$T;NH$'DDPUBORCG)V$4SEIF4FFFL@%<B9$F.\+Q"M -NY1?8,12
M /; <(DH*$HX)8>(^2&"J[^(H%]I!2IT"H1)%!,"8:?_7>-*E:G"CG<DUE9,
MG/&)L(E1&LO_KME!2XK(_,7FMJ5U<7H!EZY7UU  (5G6F^9>R _Q,&)@_B\V
M8?+7.4'SYY3X<TK\-TX)V,\69DS-8G_6S*_BV/YG#-6H4':F ^:BH'ON'9;_
M"W_\R=)=UD>, .V)(@K@9YIO?B-WR=KYN;I1 $>N@A-.=E6M"-L=Y _8^]F
M&_YB9Y^S\ 0LC>U#-9W3-.&@ZK 14K?=;Y:&Q%V*_7Z?.MT*Z= &1!^J+%+^
MU.'_?QW^L;/1%EN!>O6W?\!7]G&F $7:XH."1QA:DYTX$Y2<_CKM+I<6244\
M<LDA,R%FA;[^AQYBP0F,%X5$>C)><2FLAZ+R5N>N8SL3=X3ETB@ +VJN'@;!
M#Y##BEF@TPH]% "[);GG4#\K(6D7='J3?TSF:X-N\?HG8D\J!? ?(NK!>U(
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M3]\6R]/@#1/;+GZS4""FE:#MVW8V.U&T@=/QIMN6,XC*>(N[SP[Y&?( %*4
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MF=0<)?:*'?=Y\+$0WC#X*M^5#,%S;MW[8P+^ZP)')4,=,?UMM3LU+,/\>6C
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M1ZP1T;]0"V&&VHBQDIAO$)X0M-$^F7-;R- U==23@IY?(]/9K62N''QS31V
ML]SHGT8X0Q+(TIO/^L7'Q&8,TKN<IVKL^;N7>-<"U[('RQ.]9*](,[56K^"6
M0JJ8 K;5O;-@W1=&Q$("]]FNE6I,VT8V&#2(5+#[QUB_$J!//SY0C+9 <8R2
M<M8S^_P-\T:&U=[9<:H6OS,=[A_#<$D<F6Q.N8RN8X*<RSM[JZ6HY)=W=K%*
MME4?R[MG+IH.ZEC+<%PR^:6SC#YUX!-GK$:7<S%>>U"[^T*^)(_J7,--(Z-?
MNMJ$4\*?O(E7JJM)JBXE^4PXAP3*DE+SD"?]5:M*^QS<%05O$@4R+RPQ)=O7
MEBUO"'P>BC\Y&7)3?3\V3WK1#>=\:)A$YY.[)!%PW[M0I\OIN\1K[2F+RL?>
M'!$%-]I/'EMH*-AO=G)/DQV/)4^K?O(WDJ8!823OC;'1D%V2Z?=D9Z]I!A\G
M_,C9Y#;'&(<+=/A<J5?N"IQ?4)VHL"VF4.=BU*,MNFI< _$7K712"8\<PP*R
M4L*KRU'01>E^1+8^\V>1RG<H]NZ:@V2I&I)I+EFEYBM*098I^$VO!.:8]_49
M_;COS 8GSLP1GQXZ^IA_L^#A#>NH(J$V*W0>_#./8"=2H%.]?.#R ]<.$??$
MD+]Q/(_W)2&G*466@ E;2U3@.8+=DV\>8_GXD\GSZQ]:-K5E=#<-#7?JS4P@
M*?M0($>Y!B6%SZ'O]9V!L(]-S!13;QEV;0]N-Z_DO[M:-C+MN%"PS$X6047!
M5QE!>E)[\,\5\XJ)&.HC+)A GX:050+\JM%5<#GIT@W$C.'BZ ISQZ1_R,\Z
MH#A'?W!"OO&@ =2#:CN%%<R6G)<@7R+QE(G-3K 7O73T/Z9*K1#>SCVB]AE&
M**F1W;DJ?N=F]?U\?SJ,S89MAF[1PT#:% PGLJY]7Z<2R;,CHR/0U[P=-."B
MFP^$%867)\;62;LUI9SO*3H_)>L=V,BBMFRS@NAZ2P-".TB@2A4N?1J O@DG
M5FPGUPTLS,KABT<^3T=\?-O9^JB^28<OFH3PW?IEK@2V,F5/ P*9R<*MC9*J
MFDG2Y8.JHFE=!@6;('$[FDQ$4<.EWH,-WOQVUM.*#+9.B\R&C[Z#DH8#*^%6
M_2#)BT-12#J$]&TI#-4_#[Y4!P]Q#;@'^8Q&17<O6I.;)W7(4LY-Z*US UF4
MK2 :$-FY2[3'%IZ2;$T#E S0&SAH'6)Q$+JY7 Q:<(C*\INHYWX<-.#2)O/_
M"RK(G;!EL85)WB9X>^ O-."G?K)P!TRDY0MX75,O.!Z8<SNB*OZOHF#M@=<7
M("5J3<\"C-;/4<_8V7*[R64_>3.VUP7:VPLE.8Q&PE=UBW6VU^AW3F9CX8L+
MXGVM/31@<#\-.*SSNX;"_T?MA!#ZT9PT8#;=#KDQST25AN6/]I? _RL.SE$[
M0(:.%(9M$Y XM;[3Y&=;F_0%R!5(-/2G?FH_C2IVH73=$4G>!.G;:#!H&[30
M <PF6K%4LB!)=^T)_ RUYNJ_4#C\>[O)0Q*)CR-F:[:Y.S^I2#6(TT<(,5XU
M1VY:P_(A?V7F>7AA[FYTEB"Z@ VP?Z;PPEN=)Q5I:>WSZ:U!#T\^A/;V[/8;
M#>CO^XO$W[77\H^P^*<(BW]?-_4.P@>Y)I1MI;N03Y)28V3-;SL+,>X9!2-^
M=-\RJ@_YUTY"]Z\'*#7:([;&_@I= HCN9ZO^&,0_8OV?T$U8>2+S!#2R1M3;
MLY[*S'1\V#MHD1VU#BO*M9]RCG!JZN7QC*J)V[[TUYZKN48#'B<9U3H3_.JL
MA+W-!1NX$R=N"U(X85>-]/(XM,XR')>[%6'\H'RS\4\E.#B]V.1"D<['HS,B
MFAB>)//=2Y%F_*9(U,L+P1&(R2T5VVS2UE]XS=RPSADW*WKSE_+>//:)B*Z[
M^)+[T5P*18BI2',RT;]?(;_&;*)T&27]#?O" M/6GN&5/K#D6+R&QK@M9"1:
M]MCKZ[.J:75/&;YP;N\R&M9X,&<5EZPAV5K=&SC21-T:@9W/B'Y[$W]B<DF7
MK#6XK\2^FO*2')#K+TGJ3%VH@73E25:;W_(S]F-8*"X.MTJ20O":G]JWXB+_
MZO!*CI;1?-.(]ZD7S=QCAR[2J:]BG(J&A6\A57HO>'"IZE<4IL@GWGUQ\00?
MW:VK\Y?I6:OE/,1DO@RA['T]J.@6'YG6;T8O9J\_0Q9IK*S(YXPL).17E);D
M]U4\2+B-J^9J"N0F%F%'N.Z.$1D?!3!SO1:U?#'8P9_*5W_Z]"// =?H%OH(
M;.$0V07KL13>!^5RI/+,R7F6XF3;C5;[ML)BZ3+<IBX[V2#.W'#BSUQ\*/[*
MJHJO'GY<01G'U:&ZH-ISOSO?X]"]I'%C>'1BL_2K=+Z3IA3#5&Y>(6/(4Z-I
M)(X&'+,IT'!RI_A.X+VROY*;3"X.!1\O#54 <W-;M9?SZ/RL^ Q'A&MOS2GO
M:Q-78YNDT87PT*D/U?!B3?>:LQ5B+RT]3BA<TVK-.U.V_QW'R7P(E:UW*220
MQ__JUU4P5ZE/];88UQOLL'XZ=;\HJLLB[E&RP%6TD"9W.$XLD)_T[";!A)>Y
M#+VB '7B.]:_"*CJ3GI8*GHQ"T]NG%QE 7,H_QM$^O JZ8Q9SKC&J@'M>+U%
M*>) ,Z3_<68[WSGZ(\"%0[*G>(OBH/.+3M;OR:>)] BH]2BSJ;?G3#U;X-DN
M?UN6))714)38<;SSVULL[[V_/9F.J&%TN1+H=UP'AVG482/SEQ*]@B#U23K/
M_%GY&*IUZ@:Z\X9SY5\?/QNE_^OM%7[-<AW!_1$1"(4J4MYXGF93G]*%ZMZW
M-7VY3BJ]A4.1Q&NX4G,+A0,80K@#C%GRG;_>._MM!\O*'KYCP\9#1D_S,F[>
M?&CQP"TT\J1;[4V;R9H%5S=C*[^-$*J8"BY TZR:Y$Q0KAUA))H]CF'(,[S5
MQ_G=$4IO475I2,8D=/-!^=3#&85-R$-_K??&WE7VU%,$4T3#7)5)]R_Q6Q/R
MBNW4!R_/JJH>B:&;4+S87*H-H9Z(U,HO;DLH.S%DK]O"NAIS2N#F\H6\U;.=
MVBI:622,8=?@-7O-Z'TV#UHDGUVPNRX1P;%QW_]3]%?B8S7E:R%@+KM?-C^
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M4E)*^I22LHKJ.35UW8MZ^@:&1I>N7;]QT\+REI6=O8.CD[/+?6\?WT=^</^
ML"?A$9%1T3')*<]2T]*?O\AXDYN77U#X]MW[LO**RJKJFMJZEM:V]H[.KL]?
M!H>&1T;'OHU/8'&S<_,+BS^6E@F;6]L[NWO@S_U?=E$!-%1_._[0+DZ*7=2T
MM#2T#+_LHJ+V^U6!DY;NN#S]T?-7&6P]N4XHA![AOI#TNK2944S1',]SSVN
MB5=<"2M!^&7:;Y;].<,>_Y<L^[MA_[!K F"AH:($CX83@ *'U][$2 '_%<EK
MRG\3<C3MC^]22?W!32JA]0P/V^&A%U7O)/,M'-T^G&]BT'QY92JUS:BF1.MP
M"1KUU!MV-G@H&$KHB"=D8JO#B<=+.O.0[O[XK^ZRHY:?A72\U)-KNX"9;>5,
M?$XGA+-!AC#4 6.K[./($51NC/'5$"J*A:]-]GY92V1.8"-Z/:0^&,O<^79@
MYOAFS_,@M>]C82O/RMU1^>L)'Q>O^J%/I<L$WC98"'(0XET^KSU,!CK0FD39
M QW$^=AV7D8<-(H+;M?>\_;(N@^$RP7B.#A-;?:E[#V?[C?Y"38#+>;@T&:Y
MYV^].T>K6W"O8V*?\7SP=+HE@DBX$N\B[7TFO1I7:>-<:7SYVI9@D&^..O=5
M/>#_UV(NWY+RTG.T@0^WL=:.A\U XR7PA0F:]_9/?N*6?KB+'D]/I[K:<7T]
MAD_XT)EF^@?J&12[A"R7.^1^1 ::V?+)0-<VLG60##C"]J76R,!C$6,RD/2#
M9GE?9IX=#("M=I,!/1$T7O<=<E,+@M^F*"3%:"!G(LW)P%P L%];6K&8;]""
M9[!QG8>! 1;_0_WC%'UYP5\[^<&$<3+P\2^M42UACFK3?9[=B"'1$Y)7J+_"
M'6\)CQ]F(B=4[<#J^)K.U^]7\$?:"=TVA,T5+W&KJCB?,#N1V@1#@R[-MDP_
MV@==0H$[*#4R$)D;_/53HY@JFFCH*T<R*" #K0-(1R]_,"$(C?NM?>\@FTPW
M],KK50.USFL%[Z1_O,&ZRH4W.C;BAY%V2 XP;;!3A\#05I3EUZ*2?F]-=GU[
MWG5,0-+.6H!9M*9W8C][E+V\(RJ7*9=F&Y5F0.3AVG7D)P.Q":TB\J^68<1$
MBJO8#0]?0'_D5I.._.I#4>X%;JXKI ^F&BH=CO)QG@KH,Z-&LGZ/C-R#[DB/
M;$82M61V'<C FP0,>'P8_5,T\9\]_,!?<F3;XLOO'/W[H%'M!/'\4BCW!PHG
M<1I<9.#N/T(9#1H3PEK0PII<3C@,W7+D+?S.]V0]NMG;GZD>&4C-VK^/.]LJ
M(E/UBCI&ZO\ B5G&R6C<*LR^_OA(4K:1_=WW,?1&XGA 9#DM',>JVE;WP"HA
MY:W5<AT"LURR6G#K30IM6.6SIP_/,RSI"%XW5YU23GT-IEPBG/;Z[B)8F5WL
MP5),6W;KCOB79!8'9NDFVZ3FQ0Q@],W3T9N9.#<9RV'4AP>^QAHKDPR,?FYN
M7LE&#[X3RTZ5GC)EOZ)^A;Z2.Z*L L/E8M61'V1G]_X6QN;;.>-Z5]=GR<:.
MB_-)-Z+-'P:$#H8HOWT3 TC]"Y&))#@UH2.FM4>%+ C05@P3F'C#WG+BX.:
M6TGAJ893+\0O?!.)<*UY$Z)93Q* S: .C[)3(;&*E.!VO"4#$1:@#!FX&-8$
M R^/(PGO=P2E:+K1V%02$QD8.(;G(W&IP(CW$T$'Y&/TMJ$F'1EXTI-.!@11
M5_](X3LH-K61V0\\/R-'//D #8X$I$H _GY$!50S;%]<E(8,M#A21F7\53+
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M-_7 5<.@,R^S^7(Z<P1@G=DB^-'<&0P/[+8Q=L5:#J&J?OUJ-#UWU%#7.1]
MOTVD(6SPI9M U>ZP:,7@MG8S/DZ]$A7I4Z,\"?K*WA=RGFVLJXS]'..R>V;O
M^N=3C)^9LZF*)SKQU1&KFD+83W*Z@W=O6RN:5"4,3G# $Y2H;B"/R=Q[?[.^
M5!Z\<E6/1X*.^ZK._U3D\>_]F]JUGR^KO-SN5'N7NO9J !PB W3,X [!H+6H
MF'B,L%N-10I:6M]?*G:9B(AHT2@ZDGQ3VDU3;/VE"O @6_%3>U#F 2/"'<PY
MT+_C:J-.8/N$-6S@QLMF13Y1NLDU[;(I(VRD<3AW^GVP!?3LL?#+=Q>"!W+P
M)F@FL!J;75M /-._+<+5(=A8+XKR+UHIOV2D*]:0)!XJ[CR\<1#UVI0^P*(1
MH7J8'BR$D 3#WX&3+=F\E?T->N^M9%.'+(E/>;H<[6/7Q>293/MK)U_>?)81
M)YBD'+0D"5FYAD6"TNR=T&@RP&Q/R'GL6^S=TBB)ETMP:U-W3W=OD;VF3^-*
M;R_@J#_9K3+S%3[>OXO$F\(2<KB#U:SA[@/*&TP_H&Q$H=S.W![L<VNGD<JC
M3T](=#\V[GC]3(0,2,V5C/5B5]$0]%T,'<(0O]BV9M9"$AV4)4F +>-7?8OO
M&0EJN%#I?,V1^7G[L7#9R=F:K3!K]F;(-W03E'E=DPI7E,CFTD_4[U<ZYU,?
M?^V2GZ&[(^\*=_*SXQ<3'H))*9X,DADQZI(]Z)V?;$5H.>E9&/Z*1R*40O*<
MIBZLW"P=(\H4(;3&M@L&,"T6O57[+[W4U;6&Q;,VJ1H0W;4Z_-)$7RR2XN@$
M&#<B"!+:R ]:6/\-3VN'9_Z&I_9_B*?LVM+PW/^ IV44/)V@X*G.?X*GVG_'
M4_K$?^!IF>$[F<QH^]A [OA\)@'/!4FZAXPB-J*7U#\S5;[T.=<'2AET>L1
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MPRHS80B'7.,)],5]@MG@2[(H,]OTHZ ;*LRGFFOY[*7Z"V8/%Q<N?(F/R_K
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MHEQ>,5LB136<J>^=X,K0(7JB!I\3@:IT#>(S)[#LEFY8RQA=#RQ*?,Y:&BW
M7:7V\WF0:Q/"X\#=!+^E2QH=(S$@KGTL<XTJ-K]6:&G4Z&+/V2[XWJ:<U\GA
M"J F[JD#,1V G8.K[K8-(ZQQ/6(7D2%H/B6]X3.S5>H)Q:_:Z8K+Z@''%U_'
MKU_Q$Z;680@;;$S\>UY!.\&@\Q_]R^5,&8_&_Z'WOX7U#W;0?I=6JKC"$$D:
MAPCZ;HPO[GH1_-K8V6XO[05T).Z:G<!<3S!RP_341_!.OSNA<N&+8>LCX4>H
M'@T8>'JQ8_Q9*1X9NJ VT^D0P$!*%3RDX-KCIP#TGD>,)K(["TU*.P^+#*8A
M\&85.!>S]GQI(=E*F/KSHYQ.-9MW6NS>N"]U9G6]>2#B!$K"R"MW59&2'3X'
MO\/)P!-(<PY(%TA!?Z5YBLINA+L[%,N ITSY:@T,R0B5#L6>[>\S_D8&Q RG
MSP[43@:)(J=.-G8>6G:/$3OD6F%M>Z+7PHT/L98'![M:% V9B&N'KY N9HP(
M+0(DDBA9N"18;L,X-^1V)GD!>FK0)=U5JUMN.HHF]8?K]CJ:"3GSHJXX-WBZ
MD5]&2MJ;M^ I9 -2=AFSSY1Q.(KJ7;EV_?TE3C^C'/ES;WO:-?+$1-Z;! <0
M5?#(-H\)C=F<SE@#$#.;R& )A[6A"K]]<ZX.N5!:M4D_*DQ5_:H].%QU2IF0
MOJK1UXF9*"RE&-N/E'9]X6K>5TX<4'A4,+$>YQ;8#N%!WT-&-3)FMN=P>FA+
M$T\2] M%XWU5:MVCD7G6E\S23WP)4S#H,(4W'9,2%]R&Q@K".N3B(*)"S8+T
MZ&*$$NB4OQ3M1\FM3TTK>K^?UF"YW:X8-O_$G+&I;WIE<S:&XI.7U@8X,RKB
M.=#;'@?CAA>U[TK;.J-7:#V311]XM[S@H*Q.\'V+DN"!G(H=5!/HD\CR(^ B
M20',0H7QAF%OBQU\SB0%?&T]O",=EZ;UT/.EO 7OA*E5?>7RR<J*0&OTBP4,
M ]&- M5/T)5Z>\T0;G!T Z<2AL2.$NA3BI:OGEI6T;.75[I6)L7&-GHL.WBC
M&#Y&Y"K<C0'#2XAWAALT",SM@HE12AL\5C;6/[CNJ]*?Y][U.YVB\T(\+M>]
M\TUQD.*! JDW -WZR;@-RDDZOCP 3\0MQKRAN=88<F^B@^IQVJ/6"N-*K\!4
MT50"I.50Q8.!U*5-"W86M/4$XA=Q$O/S@QW:3D..-99G<KMVS".U0P88O3Y+
M:R77[R!?Y=6F>&[X;L+>;?<1N>MG+6*UA8EJ T2U&5;'+7W"S:+=8O/;DP*7
MC#T*QW6&3 \B96H;*AD:#4NX<)B$!B0ND9K4F:&=0V"'X3]M)-RKKA[U#3HS
ME]\VO^;VK5[^W*/O;5O91CMOM<_:M!+*,+OY8 Y+42"6#+""^A[TSJJ,7[W.
MQ:[QE4EZ--KIM):-F/$@.W.(7(L)?K<H<"91?$-JJ5OV9_KWH?Y3QL:=[A;[
MHN4XU'C@;&2(C\8G[R9HA46L,H;#4G^,8TE;.D:F7F/J50HS:P-O1[_!Y=WB
M#49PJPU2A5I%BM9B38(/L!L)C@;G53*]!C*M]:EU+WXG#J@!,XM,,SL\V\A8
M3:,".+0UH*"R:*K=KL!E=_#.U)W+%][KQ]R*EOPF^).=Q-CIQQ""M(]W[125
M>.'CQGQ]M%*.D[&$=".F/]5Z\=O/RSH;'>K#L!>7Y.Q3T%E? MMWB-O'\#E$
M[A.LDKM!(QN:UH4-2 $B%-XH5(\/0&UL^-H]B^S6F^L\?M/+HF ,P-=_6MFU
MQ3LE$"7QZQHYT38G&PA\\96Q$<.^1Q8R?1M?]BI4/3SV\ZH8+4W"!Z.E:DB.
MZ/%JPD9L@Z_D6FT^>*$+=#4<L>/-%LKH#RK9,X@6E%:F-B0#M[8<+#>IUQGN
MLV(08.NL4S31  ^[0.AKHJR]$PC33$OG;"&!':D//&[C,&^^I&%W ^MP]46_
MO?O/,A^_DW#1(J*QGY/W:F]V*A_X+XNJX3N;HHDN,R+N9.#R"%$RD![E[>$D
MS1SH&!_])A49_2AK3K3+(&"7#%"#*V:$O1 ?*,]2N<Q21O$3"X+VZII!G*KD
ML!/#$'W#T,Q&M+8DP@)/!F*VT7%(9C=-.A?-$Q/3TUJ.F*O&/^P-;H7Y/W@$
MG%5;04\T:@R03KO"J,F  S(&2CWH4D!8",5QS:#9<NV-?5W?U@L9I:/WRQ6I
MSPE=N;Y9L]4,5=X:.)Q,E740\+&"?MT7VU4%XW'0."M,.S+&JO$3?)JQ<31O
MJ$&^\,Z=>Z/,0K:5)3Q&3=,/C1^=&AEN/D @J%/:[5JC"7*F@J$U*K&*S0]/
M?PTYQ%3R$Q,^$;]LF4UD-OE! .A,IOKB$\29U?@\Y[0T+A-Z["<;>-JRC=K/
MO2^=AYNND8E83">2(_A+/^B9LQM4#M[PQ+9->HH'9(CS.K*VS'69-I^(@SXW
MF*:+MQY3*JYX$)W8DGE@X500/( 4%0?-#FXAA-2KX\PBM2'?G?<_37\HFWI0
MGF./K/.#=.CR3#"(?V1.=AW5YB"-8AA)ZJ[I5JJ/$78>'^Z/EO[LLY/]U)[7
M<8QJNDC]N.^\Z3SMW1AP2Q?/X@<51=K)L8,YE@,(1)U'Y,Z]NH),S]U)F7):
MAU?):D=^MH1'S24P.54&2J[1.7E06"H=]>&+'69XLM!*?9#7A'^2CLL]8_,;
MP@F6U%]U-*G-BI62YR-OSAV=^BG>=PV4I$#Q1@<9X'\".>K+SI.E<?O$GMEP
M\5QU9&O>\9,3DD_I[ '>[X4>/.GL:UMXMMGV6&P-27RI\VI@8EE>,6M3N4N
M&Y\C5)(,0%#Q#6[O[F= 6V"3=6XB\PFSI*//9QQC-=)X4\T]6K\X]56YKF;F
MT!./51PF^AS*M=^T"D!(5N,//_5TM?K?XQ3\^%P)IKWYL#EE\720B9.9Y;M'
MU;B2HV#Q"LC/A3A/X$(VZQ9KGLA86R2>0.'!92?C6^7N8Q"W;R?'#P\;[!^5
MU.,,UFKQU[#0V)/XONB&0!>'XLFJR4S70-=85+E\9[>,KM ' P:PBRC37%&T
MPGM8M^W:1Z_1EX]L23_J'"_WDF0/<_E*^T+^>!>3U[CC7+9K#QFX>Z@ZNS/6
MQ/F62%FNP_6T<XJ650>7R^#9&'.WF[BY+[CS\(&S^K8=]-I8F[D!H4V]1Q9$
MRWEWU[TR(OL A@FL-B14A=D5_Q!,K4+E3G>43<*L+HG'V&LQ?23=J(9)4>@Z
M%$'SEJB*-XOW*>KC@:NV/5K#!19%%6NR!DJTIR6O<W<[10*=E3^/>.FX-XR-
MC!09/;ALW1(C]4[J7_W:9HM](H5DDH[;.(P11).2C&WT*+E#-86.\H)NI-U"
M,E#X_[#WWE%-O=NZ<!05D29-.E&J2!/I4J*B%!&BH" U*DJ+@#0)$!(%Z4U
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M+%G!Z\<9@)WQM)VC\(W[ECZ9"ZZK#<"H?'LV+<L3%K1$03J_<>OF ;\ZBD(
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MBLK*GG_F(;G_+G/SN]MP0?X\;A+QC#9<,*G]&P,:QCY$Q8USH33S\,!Q:,<
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MK$-7-"2 KI*]"\G?.Z X7N@6=%H7D[+\XC0/,.7C<14M>:F'Q1PT$X (38*
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M%JL9W #I@F:R,=)50]B97+I$W3-=PV(&P..X< 9KEBE.;O"%!B4+H@;_\V@
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MT4<_XW\[?))V?7+:7XI%6.(\+84N -O#(Z,P8JL8 2T,9Y\MT'P05.4UI[G
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M?__M%_]#HT[7IVD^?K0;5XEN!;&N GF0;JQ8POLH.(&\G!=3[K_T4+63EO6
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M_[%Z.(Y23(:5-)%8T3+LN!V9H[N8-&(*&(A8)'IR*2-X5KV.*^=3<&H!.FN
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M+%//:4[= QJUR@>N9",E>V3L+-( <%#VOS((^W]3_L4'L%$&A&<>@__,ADN
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MX23T;0G:#HVFTUI^![SV6A145X-$>&Z#'P] @W$R4"6>6<>]NPUBGVS9WY5
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MM;[PKR@^>Y1^:HLN0H5L+4-G88K<GK7XJ7:=0MQ,7*0"K1(.:)UM95JL/2B
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MX&#@#.N%*L:.CJJLG*Q@<8 L>LQ2X-![4ZS27B7_;+/VK.P-^(^MBDZ-#'
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M-7@*JQ>V<'06:@->;13Z[M[3XH$#^)60I]A64=B^=>:FU'_ZE*G;'<*L2+D
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M+"C=^M[C#Z?TG7-.M.F^Y43:7\H!*D6;96JB_!85-"J:TM]Q7]0M@:J@MX+
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M?>J"1MUAW=VVDL)VZ;.:()GQ>M8:<=W+U[\L,*?4=IE%H!QRYR@6L;&YU&?
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M%1^D&M?OA!U?G67!N_S*>FRRY<C%=4E,0*:4X:4V[)P?=69>-#^_BJK\J8G
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M4!--=2;A.PY!*QB=.WQ/5V2[]HVUMIR:D([_IJ. ;^Z'D$E]SOSR$?!"J6(
M#E ^D<6>D\4!3)J_UR=A'UUWY*64$Z%1>(!TTZ-FS>LM&:%,<KYL<FP)GP^4
M7*&(B% +GG1=+\.@1#\_-NGI1\6E%3$%S#@@K#+4ZV]:AUYIN9O\V(:M.].1
M[)$P(&G];5B.L/ KK5O)WS:MX .&+1"[E\H"/U(LJL5.\6)WQ)O)/H:A6)DX
M)Z'4<&<PYW[XA9\* 'V,5$(E7503.82X4YF^=IQF>%X7@<K/"S,@31RR[<0'
M>[E%Z/'1$ Q) T,WJ?Q.)*J<.NX104[+9XGK[F#E*W$@P9L%CLYO9>3+MJGI
MU<,"B(L/WTWW<;3VSRG3/WV4[?IEF^,"-8^2T#CL;\KVVX-PG:JU9,])S]HW
MEFPFCE'M_FL_A-C?67,2*#Z5SRD-BP@JL]4.>C.C&^1W]5N&_J4@OW7S7?>_
MH^>>-U"[W\F+Z_<66TC-68:="3J#'%+7ZAZJR/:?JCP/ATDRS]6_WO0I:(":
MG16)S&=\:E*N]:"X)9W,2OGB'-6Y8SL(.-L%(^2P,/=85)DCLO^D/K$F-\QY
M3$PZLRYYFV=:AMCV.C?D_[#WGF%-;>W:Z*0( @(BO:. ($5$FG05Z0("TDM4
M4)H0D!9J$$0D- $!!23T*B!=:NA%I#<)O3>!A!H@)%_6^^U]]GK7V6N]>Y]]
M]G?.M:_WQ[S@R<QXYAQC9C[W?8_RC*7=V2"%^]I3M=O.VR_JDC5$:WSH%-Y\
ML8BVL%^O54CU+'Z,#H,Y4P]&M)M7@E[*UD[Y\>Q'BR>NK=YA6:OR%?N'C_Y(
MU]U<I=WW9VW:O!-;4-I\1C*H2FE#Z[*A6[_N,!'KQFO8WV+'P.]CQ] ?'C2P
M[R3&C$G2<6#71=,4V0]_']%XTAA+U3WGT\^>J#A@^,@:$F8^RK91>NAWEMMX
M\6;DQ,W5 +A[H%Y?3;6O5^FC?]R^$K5HDW?@E_QE#1.>PA&:L$\\B3MJZD(
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MRNS40-:2[_NJH_R8FMPM_7N?E:BO+2(U:TI[>34BBVID%6XL7W)[X&6"*V;
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M6??IGE%J7]:V$V$FJ9)JA!\6(19J-F_85^(J026KD7C@BK8C6T=N_$(4Z'$
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M^?XP6(G)WWC4Y6#+;/?9J$N[]Y4';!JMV#8G+G6^-"&_ M'*K9A0.3P0R>.
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MH\5ZN;^)@)/=(X+$CH6VP0\/97#!56WF>* K5?FP#YK@K?RG(T0(\H:8])[
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M:/:CU]0_W#@RM1Z#J7KF.9;BC?/_)$CO<2.MD4ZE;] =SO1]5T>?MJKEA)^
MOI9:9^9J;7:..@JYKSIN]@5LE(YBMW M8XAU5F\\$&B!%?R](7Q@ #.&>QY#
M6\12:+$$HMZ<A >N!1(8WI/-N8-+]7@ (8IC@/[.8#R]H<KTMQ(T+Y7WM/$
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MED?=5^\X0+%VC=054ES* >GL:DYC_#9^R.=C?)L7=A%W,"Q#&;*U]9/$&EH
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M.QF8NYU[*^?:AC_D,U17+<4L2[SEMRQZW?S+UI2.(S3)1$M@]3H6-*;)2CS
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M'#7MQ*W>+X:-RFK@QV_\K\5?6,PMZ]-_JB5;0OY G+X?"X$D0M@<"DC $FR
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M35-6JIT,U#[*QLTM%SQK4L".8_#EZ,#*JH73WZKG&"I-J>?EO^B]U$F_*L#
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MJ67TP+.7_G#QU/P%R[2GPVHEX.#+!=M/"L!BXZ2N# 70U\?3HYKQRV>-Y&N
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M*%O0&B4>I[97<A<W6T5:7><R&X4S;>"+W#.#<.61"HD-Y0V>BE.7VC@-#)_
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M8[0DEI!-TM]IZ1NS3I33VHZDU-DR]^TQ[=>SB3W],^V"?;)S8&PWSKT*W%Z
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MI9BO8^,#9X&6;/X4/*+9QR$+>-S)6SUA12O)C32K/?'YB)U_1B%N8"ZVW8+
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M_>2U1X@K#%"L= N,=*H*4#)&EC'_<!'6_0@Y?VL$X4@D\9)W:6:+B'!D(P3
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M92T/&%UK>;VATG.K5Z7WW-1"A8*$B&/DW MK'80;.8]42"X#8DVC,5OS$+Y
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MPAW,P7G,:<AZABN,<K.^(8TSQ*L_5)N7# 005D7R-4><PLEEND!I)2$A1V[
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M/7%"\+:MEGI%,=6Q6FA>E,76/6LEN=.*%2&@0,G7-F?X%NP*?$9 ?#O>ZZ*
M#LAJG25=(T<P0(:_T1FN_Y^P&GP6,8/9OH>TGZ5<2$+NH-%K"YR38_3;"NM_
MFM%4H'2O/1J(C\@ 47D5Z ;>K9R4"T)C] 'T3]EY(-])P:AQ6^%@TGU5-.W;
M=;"M&:20>H-0$;S%^J,$;PW6KY&1Y(+!6IGC)0,FS=^VLZ'LK%E-AY$+8$\&
MR"KY0 C4_ LA!8>T)/XR=]:6'=@S['RK-#GAHM@K$:"L;_($*D*TEG^).MX
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MLT(P9L)VYV4D\S'Z$"E&P;NW1+3(9M]&DR*_C.+U@Q"FL-2'1!L4OM=W0V[
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M8ZS/*P_T65ZEG;KX9[/TS^#!0&3G%S^ <G[JT4=N[[NQT:_[>--\]0#]&4Y
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M,9'2NY</$4%V?,0K4(Y.,4#+/PK:__4:^G<^A/AM%:-"IARG^B#R=B ZD#F
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M4]W\*G]SSH&+DO-UFIX;)*D6DAP6[ NUW;.6;B0X89];NGDC35K:4=LR3%U
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M.Y?Q#OAQN;V061<!R"YX.PNB/_*O+>C$4W:_"3-.>-4FK".\[A)76FRAAAU
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M3N[@+X-&S0R9!:=>0*RKD:(XL)7Z]HW-0X4_.;"_^$<@\YL/N&C2!YK4HN/
MV<B-,&%\TF^W9(8/_"91AJ:CQ%[%TP%KS%HDL'2D"!1B5\ WZM9A/V'!?SZU
M.1 Y?XR"IY\PY)L=58PYW>W7/J]8M'"(W#\^XK:E)3-*MO'IC8M[P:LWZKBV
M;YMU4F4>!KM(NPSWLCS[,<+C\Q9UZA9YEY"FACCR,=1=@Z*FFIGA:Q/MRK=L
MK103N"=M/Y_^)O=S-8L>14/65B:$%^D+C9&VHW,:TE<^3NN%-Y>M;;;K.+!'
MH&VG]H)TN&J8""X#]J.4(.!&%/-@W7B%1*_5([8O'S-KMQ%ZB3Y'H9@-1SV\
M*_7Q>E3 ;O.O;0K>6V#!-D8HMRV/G!RKU>KDS&Y%;8I-3O(V,#>'L.)W!>?N
MX&:&IY$ZOPI;625&&<.29ZGI%=!Z=A&L0H#WW4OM^A 3BI##<L1Q8"<U[4,-
MB=!T@J9CVSS:!*PNA;,54HE!**H#R L-A5(I&<Y8Z@66D^S9T_]/._Y?J!T?
M8/O-:6)>6USM QKB+JX=[RV5M?/P+/4P[#B<6Q9;IY;P_<:5ES]?;_ML\E'F
M:7SI_,H2J1D?#@U?/FWH1RMZH)&PG1KF6A;GXI/CSK\E=NS;VQFM<N$P>&<J
MC\7!\VM:2=NMP[A*F,*SF:HT\;OZ)H&4D0M-Z9]P0Q]3T["J/?WULU=*[W7$
M7;6V%-/]U%8MH&ME'"+I),G<1[>X3$5&L)SS1AM>V:'=$<+?\!&W-(N.DQR'
MIV<2\SL.W/1(.-BQ5UEMCZROT^3Q+9@1)@_0=H 6P$[ 0D^L>QTU+;5>]6>$
M\P)ED2G',H8 ?.D+3QN<>AFWSLV"QK"840[><T,FKS @YKZEC0-[B*@C,18+
M@2FME'7$\2W 23C5'')@B'#BRC0T&7*3!WZ2D%\B6;M<P#\2R%[L($=@^OHR
MUZ?_<V<F0!@75@*TI=(SP'J] #!%$>NC.@(_RY;]_76ZDQ('EH9879L";-#2
M9<X0?2*N[2Y=763MY 9/6<3@5K7;-HY((.S]-6LE4A"0RL^?"1K5!EK+>4!M
M:-9F=OXFRS+R(HFVN%'$Q79!]:_!6%D'H*5ZH]0+\ILA#U#MS#X ^B*B? VR
M?RK\HIG6RY$O<%1CY H B9[9Q;.0ASM<.,.Z!<WNP](@Q%/GDW272!2$T1PP
M? \T%Z(LLF/2 ,:A@1^1?]GRK\K^@)CX FXLJU5 2/6\ ^N*^4MR9?[?DRL1
M_Y1<"3 WRC2NH(E@(R0Y<U-7:G^]]%,&\G#R"*8?&-GB+<2*1\RW82.GOT/6
M4@'O(O_E )O_TLM&T^.H(.IL34_Q713J@].H9?[FG(*+=8Q=%V?B*Q2.3%7>
M3U/KT*P<;NTVN27Q\:/(Q#Y2AH^LVN<@2YY&\"A5J6F#2VZQ)8L_(,ACU*BD
M^HK7PPT/T0V74U$>UM-S>0B%XQ,G>]85BL>^@H=N$CJI$4_R70F[NNZP]]K@
M3-^_#1O];//PC)Q(W$4M 9U;+WD,9LG(K6TOP2Y^[TP1G --+(,<[O!8H\:Y
M,48L9[/VP:DO)U[;G6FZKBPIA$*_'A-IQ]LSTVJ'',MBQFJXS[WK?O&E2.70
M[C"5PVZ;$UQCI%Z&/U;?>G!KMY',N*Z!*_?MC8S33.*_V2!2K?0O]I?LYU[O
M_G7A--AEOA2"/#](7S<[D-A2J,8I[BD\70E@9:;5XYF\1/!!*C%[!D0#OZJP
MEW\K I#&>H 0)\[ES0(?_UZLT0UHO4<+!C]ZEK.R\&_V<X\7(+X?\N' !B%^
M_RT*_P)4!]K@M %VJ!=Q^=GLC[9_\>X4-S6'C&0ELZ7!BG(PHJ]OX  5#YJ"
M<1 M@_B-D?O,+.VI%[,/24-\@AC0!Q?P%!JB<)!K/6,R@*">P:W+$@PAIMR<
ML!'W+YPB_;6V_*0J7<&"%4^" [/C)G\K$^[UUST6C'XA]E :W78"R*R&J)O\
MIP!V2,'&X:#_Z8:+"_]SPP5"\;]3#?K_];CY#@":;!,,+/1XO_(W(#>6EA_]
M/\'R_P3+_RV"!2T^;S?V3*5:VV]\Q)<"-%IP3<O!2[P,!^KTG@^K=!W6^B&_
M*RWE28IX8J]0$-3.0;'9.6!7J:/2Y7Z"AATZ@RD__Q =0(DHV#)2O>IQ$#^4
MM63K];BH5-+,TY'>HBN736,V.HG3\DI?L 3[EN-L[:MHI4]_7I8]T&AB]NY^
M 1/U\<QP&?+0/B[%*I_.3/ S0R4MG -S2Y!R-3Q$@\=6V]#D_^BZ%F/>IW_Q
MH8*XE/+9W,POQ[,M%D/M))N7SEN\S!(J_$^2^*>F$7WEW00?-@12$V^P'<#J
M,5,.+&\VG:%GL>*QG"7T/<8:\API)+8_P-[6Y_[NGZ4*+ 2 !AS2*<E#U 1V
MH#N"8:J"71X8*V?M!$ +5#UBY?M+"!452ID]Q^&_U2'_4;!7Y1\%>T57M\!^
M/?,LA49J@J^;+M9Y,7>M6+"+D-<L><94H2&?T!WW8DKZ";&E'5(BR9"E;T</
M@\V.1A F]7_'GD@'"'TKB*[X+5#'7;@@_T>Y@_MK&C\]YC?9_CG?X0L:-8@+
M]/)&B_6#)20*DG$6D1[G#)HD2 !?;T*8<;K4Q H%7])'-X -VDB&YBL]#LQT
MHT11DBTW"+&E7'7J-Q?:1#".M6L1M&@AV_8S(5_CB5I[3H1:,X8#EK (/D(Y
MB6'DBZP197E0X'^*(&#^)4-&B;H7*P+^KTI$@9W)@?71?X+-9KAIIW)DLSY$
MJ>7M0>)S1!J]$#2YA*-A'[RCRH,6PV->;)\^R/8ALG8;WTJZ"U_"DKB!V7@\
MU#NK@=D4;$,#?&E_]L\-_<3LY(%0)$:( _,"IJWX]C\G9#%WXU.(MW#W,V']
MQ>\%G1;)\7'CQ <$!>*]ALH+*-L>>X<#@X>J\M"=VZ)D(OER'S_DL6?D5>^B
MJ*X&M.!CAO+K.KP:+J;GW]>(DQIVZ//C+<Z-F)%NN^'W3BSOJ*3DJ:/OSD@(
MIW 3CA\ FQA.<62 ETYL$'/BZ69MP;OJS5Z:3962G2CW5[^<@;YAFIUDD8$R
M4D JPZS#!$.$D(;89OZKV6BE)JQ 3'T985>_OC)%.>Z83=CG58?61:7K\7Y5
M/[_O,Q5(-!-6_#QV0@:V)0C>N)A $C(4F-&3C8RKMLNG^_^T?]1T57!8YN,)
M6'*H_\M#65573\BGPY;Y?E4L ]VPR<36C4)G?\G&AV$2?Z-:D*]_U3?+,-OE
M/9"E#/Y9JA'R54YI2(:= 6"PPMX&U&E!O@T4@SQ>[@"8:G%<IN7_> 5L&(FN
M+,YZXA5%G)//A\;8=G(GNVL9W_7[R^$48-UW(TX;N6)[M^HF8@T"W-O\2$_H
M=KL1$Z?H$$MPQN 8BLJ4@[\N&%WR'J"]"L+F%_TCA60.4N%_W1GFY\&!R=&
M#X@4+.4W*21]Y:S@)G ,M&$W0%ZP&=&-FU2GIZD/P8^>_5V*?88? P*MS9";
MMX6\$6$9S]XT0\ W=Z[O)!-G%\%!>9P**+]LV/)O90OD%?^U](%& SW.'DTH
M9"7<HTFS!X1 I779C6C-&R$6SC8&(@1&<(:=U^4MOUQ"JM41E]0A[8^<P@1
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MN!+HQ&H9;E0D>R@^;#(SI3:MN)$^0L3.L"K(P0HI8XUC2$Z^>IL;1L+UY>W
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M.>[.@^=_4[?^;_]-0ZX._P%02P,$%     @ @(!D7!]ON])0[@  ?A ! !4
M  !K<F]S+3(P,C4Q,C,Q7V<Q,RYJ<&?,NP=4$]_W+SH8$!&0WDN0(DA5BB @
ML2$B(BH*2(M([R("04)"D2)50$%!"8I(!RD!I(6.B/3>0U! :D()HPG)S??W
MO^7=LMZZ__]]Z[UW,GNMS)HY9W8[>W_VG#/T23H>X+YQS?@:P,3$!*0S?@!]
M!K@"0(X<^>=@-&;&P7*,A869F>4X*^O18QS'.3C8C[.S<Y[@Y>8\P7."G9U;
MD)N'CU] 0("#2TA8D%^8EU^ _Y]!F"",/LPL;"PL;/R<[)S\_^Y&;P%XCAT1
MA" A3-+ $1XF" \3O0.  @ 3"]._&O"?&],1!H]'68^Q'6=GW(#E!HXP02!'
MF"'_<,VX&LJX#C#SL/">/'OI*-\=!U9I/W[U\)0/QV0N5[0*W!TBRFH\>A+!
M=EQ02%A$5.Z4O,)I14VM<]HZYW6O7#6\9G3=^(;YO?L6EE8/K!V=G%U<W=P]
M_)\&! 8A@I]%/H^*CHE]$9>:]NIU>L:;MYD?<S_E?<XO*"RJK*K&UM36?:UO
M:^_H[.K^UO-]>&1T;'QB<FIZD;#T\]?RRNKO-=+.[MX^^0#\\_<?N9@ "--_
M:?]+N7@8<AUA9H8PL_XC%].1H']NX&%F.7GV*.^E.ZP.?GS2ZN''^"^G?*AH
M99/1N$L4>/1DZ+B@K.:B'.D?T?XEV?^>8!'_(<G^JV#_3:YI@ /"Q# >A >
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MHP/$.YZ]B3"R.ICAYZE?4\OFSO; X4D2[O?9IS(I\#=HXJWM!(.3X!6*&=7
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M\U(C^F8%B&@SGHZ3V?-_YS6OMZ1@9'SAC49:/Q=X</B49LYQ9&@0 0,@5NQ
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MLS$*EK)7^NW^>[&<O/1U&MB!.K+J(D8TR.+[G.=Y=M_VMG6*@$W/"8'#,DE
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M& "%+(HC<M+X(G,6=:!_%N3?B<_\2S>T19!4BY S]0J!EEZ 6WLY"@_$33$
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M3T(Y5(Z?3I&__OCLF@M(WP622&3J$40A81+T*&=\G,E.?\ULHANX<?&@QPQ
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MZ'"Q!?"45XX.[V[V\Q=W>3@S.!<\8BDH!W 4# \Q=<]5H,C9GK^*R]J),M$
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M=H:"](YI'ZORS? D;ZMZCK B&%2G_.MNS 7?#?E.GIKJJMIKY6BA9[P\',\
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MY"SD=).#VA'S=DT/#\37TLG=='LP00-T);0F')+IFI75E:*&[$\@R2'(,+(
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M_&U"'M4+2'87H5@SRV1]IY 2*_3E$ZBZAQ=CYV.?G^Q>/!4T@7JM4WQGO?R
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M]#W[0*(?M1->" (/ NU MJ-C*R,"DLHV3P/@+C"NI_]JF/ 8$0O>=06IT'5
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M]?X9& 9,B3+2&&7.> JZ(BXT+]-;2WLJDN@X\VW&E*"*ON=\:T(1FCETN0Q
MDA036)Q3J\AO$^*ORLM\\I"^7VL'0X&9.60_S+OFO0"G"!H"@18_^/?SG_G@
MOKH&\'$5K7(#PMIZJ0:(#UETQ]HQ>:$+:[0=OX?/3<:4>[@49S^<2H;0K&)Q
M[TUC#+C QR%,A57G<4T)7P1=[HIOQ(V([I'[VGYTE=>RX0$_^!KO0\ZE*T\M
M_0L-:DJ51YEO6I48%J %R='7@UQ"K 3MZE<#>?^\^'X?K1(U<-:D#9[Z /)L
M_@WT.>0-;76K=+@5PC #[Y)]49>;?)#B*_PN(75W<G/E.7@^5 W T#TZG;GW
M:;&_MZDSM%(?9/JL .A8P;@PUGH$ V_\4A$R8^LT_*TW G<<=K,VV9!+QA_@
MM*L[@W6@M*IB1_8@W'L0U$9TTP1Q>B*;/-'=+$H/S2P",U)"G4QDS9)/?N2V
M2!LFU]5_-G!6;@2=2'L0SGUHNX*[UW981K*VFY#>HB[GE:?W(>7@AZK6ATH>
M!V-S,B_YW4SU>,4=:RB)Z&!RX\26Q''ME?CZV6,T2T+7Q9#7X-D!IUJ;KS6.
MAX1,+,H*GOS4?:(T+3!3G=%[V*:UFYECP WBMW"@%8HT)X@>QTD4*"<9QX\!
M.^Y3HSK)D$ +CFN%5A(/)=EN+[;S?UN\#*K-\Q#$5@O/T/B[VB3U2[9"6ILI
M/GC--:K>SIF*JU^L;F19W;^WN.3P#VHDMDC0;WFVGF:6M'@ #I:J&^;C&(0K
M[QK,]J72V$7(/74UIU+ILWSA.^F<RK',-VT^:DF(:E3ZZ8IY\'P$92C>RT]\
M#](E[MM#?_A#_VKW09-2Q.(S-CQ-#9>'\\)-2;3+"-3B$^=JH1V#@1($$5#Z
MYWF<((C%.*X(>;U7O]%Z/'"E>/9LOYW+G:!? -M%BFW/G#0FF+;=U3UJ<!(L
MZBS4&H9;*2;L<]%T9X.Y7R$<7^L4_,G4Y]S'_7/V?=[3H/@-Y@ARFMTJZQ#<
MD9E&M\ H--14C3%"[KJ,UXTZ9:W=[?Q]ZIF)1#ORD1!GK[)SWOS&M]Y.9(UV
M<HU5.N)P2U@Y1H.F57]7BKB*E9+E =W2S,)NO[%5,I27#OCX<3""L,8$V/=1
MO[HMYN>PAD_*X/7=W84_O(Z.8S]^JVDJU_?L%*-NI$,-]7^907'/IIR7=Q4(
MOF^0>Q!O;X'I7JGN[:SC]$O1AEY:?+" OBD=L6[DWU[/ M_0;A!E.# \I>BV
M[MV7#E<32WI;[5\N/&U+T)DH:Y8^D&Y>AA3$RGJV<3-X*M#-7;8J7B\\QRO#
MPDX="SU4].+UCRQ_R)_C;0B$+S\7NG?K(1@.5&XE 4]3"\\ SIF^?+7AP-#U
M'8IG/<RK2F:W9_)7TZ^;_'ER_K)27X?B4 C2*V0UJRS\[R8(_H2MZ]Z6B"A-
M757SIF"E"WT:\N38^8/\+5S*:<_Q_76[N'3668S#%YP[8<J'<F*?%D[#]:%Y
M105*PJJ- <V^+7C_.67&8\%J-7E?<M]0'49D0K4--2<MDVJ@,U[>(@)XD#^,
M#+X$34:O";:$J<OB:F::<KXE<QJU?^2PA:BC+*KK 36&\*_?3JQ)@.\Y"J!W
M;M/4$N%A4KV3?B%B(FTC+FF7UP7JH)6NOQI(!S;V@>V;(D6FLRU)W.:-&]T4
MW;,'Z;0>6IQ=JC?.MW@;M+#N)78@.PI[95ZGXT=DL;7=)/'5I..4XQLSE7F[
M(AN7KE-1D#Y=.%])?N&_UDW['Q@"T49ZP^*BX9/\L%+>0EX&\C3M#CI7,>K(
MTJQPH.J 4/&)NS'<\=##1MQ!3_PX6U:W8'6@#(I^X=O<OLK*I" /#6K^5>6-
MX&78^X5Y6U8]/*GD&_>&^]O.(U]Y?[/*UPB?_7,DW4;6 O*ZU*)G96$P\4LH
MU!M0V[I9?=);/<LL\F6<>\>I0",R]Y-D6B4G1A!DTB]B1^?X6Q4P-P';!*R8
M)XOWZ7JGUWU\!$Z!4_"QTV3T,2R-S63M@"4DH*VJ+<U U4>F#DH]M,MZ7+0B
MFA3P _U<<<PMFZZETSV7R9MK-23F?S,V597?(7$?TIY@.5B=#SSP+;S $''W
M=!A6,]L\DG/JYP+IV'.^D;+SU3N)WA5<O5+*XUCA_1]8!41L=8"CV$*N% =
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MIS("=OD'FM]I!A+$AC5>P2>0D9S(%% W%+HQV*7_(-HQF;(T9(F;W!ZCC))
MC'.\R.L(\.:C*NF\W\.I]3[(6\S2)$&M !$2$YK(\250]1RV.[:L$/!O+IRY
M,C0>:\B8#*:=^^:D?2@SBX0Q\OZZ)L$Z/GZLYP=K4E-(Z[[0.*U(]=6J@>@D
M;@F>YVX.)/.O;>"SW\8F% 4%/_:DBF>(]:1"..H'CCY=>*-G967&14]O8DFG
M!375AM%!3(WI[;3,Z!GI&.@!'GX[,RV((<R*1!NFJV_"2[I45$9*H@_E)55B
ME6*0,KL+T],7=;" R3M(*T <#"&<4%)^/A(>.RX[8S-CF)46B9VQD8DEEQTO
MZ0ES+K!]W$U/2G*"8F7(2_I ZA[)75,+& D+'0L= ZV0G;X-$RG(PP*JPR4G
M*'S* ;SC)3U5U=;6ELZ6F<[40I>>D9.3DYZ!B9Z)B1;$H+6T-['2LJ,UL23[
MQD$09@FQT#>STC<U(3F^U](VM;;B)24]90N.0(3LK+ZS/KX_86QI!:47 V]8
M0"U!!'HF!@8.6@8F6B9.^F^TX(B4U'?*O_6?L?%W;$LK(1NK?\:V5+ W@]'+
MP2Q-K2T@,"$;F(D5V3=R,R-KRY^IK2UAQUTGNAI!=>A!94YX?,,__A[M%X?I
MZAN;G6 ?8W[#@D*^XYA96QB=C$,A]# CF#$HW!+DR/BSN?^L_C$BZ!$N05.(
M]3&YF" OZ;%4+J@I1!_*==)DA3#JP" 0)EH(DQ8[+0L#$RNMM@XG,RT+!,+*
MJ<T!9='2@GSC(V9B::5E H$=\P%[Z/1!)A!6+0B,A9V!EI65 4K+PL;.1JNM
M#8/2,D)@K.R,VAQL6FP<W^AE+/3!E-4R^EF?8SY0D \K TR'@Y&)@1;&P0&C
M96$%6UJ,G%!:=C86B!:S#A.479N9E.38B5P"]\1X29GH&$YO[QEI6>F86AB#
M,T#?!&IJ:WG:KZ!O#).WTCIV$B,; S,G"R,'.S,K&RLG)_LIQGV8A268AL?,
M3K[>)"6!0KB$059:8%[H&VOIPN@-S&"Z)^ISW;6 :5F96BB8FAKQDG[_4O0X
MJT]3EDO2%*)UG-8GF##H:;[?T=*E!YOTO\<Z.R*O9VIK\C]0?\/YUB]@865K
M:F$H8R&C;0"#6/V&^J]8WT;DP,7$TLK"7NQW:O^"\#6<HF"'J87]*8$\S/RT
M9:1/<C*WN+0@5B?NM=2R@4%)3SLA>EHFNC!PO:+_UJ/_-VG%QLD*TX' (+2,
MC.S':0EEIM7B8.6@Y6!EYV1@86#A8(%I?:.W--6QLM6R@ GH@CD%Q@9,ZY/8
MD%"=)L3-;YBV>K#C:#. R<7(0,O$H7#Z'38SZ8FM/\R@/VOA\=3F$CM."7EK
M,S,C?9C%#[-/:/\6X4?G:?;\ENC'^$G?75,S>W"RZ%G)V)K\O:B_8)ST2NI#
M8":6?R_GIS'Z,POQMRYP=3\Q_MMFP4?R7_@O_!?^"_^%_\)_X?]_\..X"3,!
M:S9;\#!Y- [_3NSN78U[<C+"8I)")V_=P;\V@AA;(C( @+&)E86<R!V2!\H/
M29 G 33@&H  X !P6A!+,REY807@M[#9\_6-P4[:8UZ_Q_M;. \%JQD @",!
MV[<A9A968%L3;+/96ID=MU^!;6RP](2"[32P?<L"5!!L]QWW:W]MSQ^W=4_:
M\,<\L2T4Y.Z"[>.W($ET?VIK_]2&Z%D8@VT6L$T.-38!^<,_^-J&'K>=CMO&
M1M:0;Z_Y';_["#-1E#_N!R]"0 00 Z2 >P )H U8 _J $6 %T(*?)F"/)2 '
MCM_Y#?W5$_I[()4V2*4/0$ *0< 4, :T3NB!XQB<]:VE#C/35TX8=P#@W,C1
MT1H% " ' L"!W]'1WINCHX-8 $ 8 H!RDQ_TIJ\!@&,#[/?[T4<> P"83P$@
MK^I'GW8H .0_!P"\?C,M"ZV3KN.W..%U= !@-0D,DS( 8+4! )K*5[^=C@-Q
MO0"@ /I*LAD PL(!X(8NR%OU-W:C_.RW?\0Y]=_)ZZ!P_R&<O [Z'S.I!"ZA
MP"><BT" N_3C=5"BX[=6$1'@OK\,"@;D'!(**CP"(AP:.'X-'#EY7_3'.-+Q
M:Y7(<"BHW]Y.O(AP$?3 Z-@_39+?@I9J-C'/9]N D7R]WR/![83N9&[^H0#B
M1-\$_DL;!?PS%T-FA'+4+;LH2DS:_@$_S#7\Z#AG_P3@=O5VY5>(50(/S:/:
MZENR"BF9^B*1XQH=AE__6^W9T/EWL$;5*;A&8&@U/>FV&O;3PLLF6!N$^ND1
M1A%Q3BHZG^J6G&9KN$6*L*.RGXSBMSL;KOGFGF6#L-Z^GC3.ET^Y/\'[2;[1
MEYA,7HT[<%X:H7WJG\Q&GM:8+AMT.]L]@FNT7U*-E^GD9W.)T.+EIJJ/OWGJ
M(!MCQJ'CYC5',OD \'1K/54[X6/5DFH+O]OB925OJ\B3OW3O+*,#%N>;V[[I
M]4< 1ZN=PNI\=>.:HG!BH2WE_^@N%]BAX<&'L[WG7UG%>!B&YEI%J*"4*7/Z
MY5U"01#H*5'L?_1>307*BSN!]U&9(\L,)G<X&F6^FA(U1*N^1E]PUKXSSLK!
MO66?$O<G_OI?9B#^$EJTVJL"S3^4@ME4UNR:_V="_L;#P!^*^4,X;R*S4^-8
MF12J0_?@_YBUH85K"_,(#D\1HT7Y'[)VWRQT0HJX/7=ET>V/1,##C]3FWZWG
MINWT"0'^3 825?WX79JXRW]N'=QTBH^4U:),%@>F2,A&T>V_QZK&YQ&%66D_
M/+WM#?.OVL?0O_Z$_S: 0( 1>([$O7X>3U*H1L1/3(#MMF,Y4!/H'^#.$MD$
M;HUP;L(NX6^8WJV'R4&4 ]P0KDKKB+EA\-#+D[DAL>'?^'>:G#$0Z473 ,.#
MVHY2":'9N_&%BI(0CLL[%'C>DD^K(-=#W35>"4(?I:\FVHG#*=&MX4EFTUFP
MD&.A-3VB@)^DTF&("&!,J\KFI:@<X;\[,\70G#UR_;$@DU,"WDMYS$O\6-=-
M_,3"G[K=0<(-EN^2CN?1>'8K(SJVGA+!?.Q4&TQ6!0/#) MGCW('GOST ; '
MDORV4IC>DA)3/WSLC.H(V-"5Z\'M'J>[!((Z]*E83?3Y-_X5E-BK ]0WDIK3
M+R4S7<JBOW)=A*YCC K12%Q7O^_!LQKQ:?J S[)D<9\0\4ED6\7,L0,,2&)'
MZ2J';N7H3F-@5U9PB1%NV^#B^SRMO"?&,*X@(Z9$2O9PNKL5SC3X\@!3?&]6
M<%+Q2MC+;XH0&;SMZI6>W,-R6[<W57D/ (B7-?$I0K1X_%!SE\^FAR>3G5_#
M;-7[?TRB7P$Y/(65M;. KVJ,ETBE9^&X"_L(H'XM[["427@&%T,VL,I=29CB
M]==;)SZW8Z&BFY[\[[=+DO*K9Z06:T_&N$;L>9.ZI]0R;_^]T+]F#]QR>Y!N
M?E^0QH#[4ABLQ>K!&0IM[VARID)&VI,;OBM"=BO7A@S%#U@)%$:O9#2SY93,
M@;KPM#**<".?AQ9^(3#6?5^::\LTP!T5ZM <FGR\7V![%G\TWGJU5+SZJ38W
ML+U)#'*Y:+4'IM3H]DT(]IR)=D8AS&&X/&QU'6=WI?P?_(30/%.&J51Z(6Z-
M$W778;^^?3?8Y1E%#-]>2?ROFG_/I-5DKZ7^+/K!D"S3T?N+!Z#-6,-5O>N9
MBNAU678Z[?>J,P3:)F%0)>:;RYOLR*&W 4QW/-TO#'=<T]:-C!SH[.?MIV-3
M="B:2I\:,<N+Y!3I%X,L#+N%,W0:KPH%?BG1B!CE-DN?8>?OTN@+:NAA7C0P
M!<6CF0;+%V?V+Q3FESJ#MTBTFO7+N(IM)/N<A+FN,GEBF"1!IE_^(2&0 UNM
M[>/GN)8ZUEN03!=><VN/6D@\3GUXP7/K;65+8^: K1?%.//A?>^_M]H4.?QP
M=.[=M'[ZE(OO*^MI*TK]\/ HGU8I38 GQ7JKM$.;_V[O?3I>HLY57R>\4 J]
M$/4'M1;9I"T-,[%C #I\ZM7X"+T%?'4*EYFH5DZ>'2F%%-[9;O46/M>LNE3.
M51]O,'B&G@*ZN#.<K)&#I7LN^RN6L\OQM(II=5YC[?L9#_.CS-OMP#+=O"10
M&]L3XOAYHQ\.WU<JCV6U>YYN#%04UXSB 6-R3#_>7M%AL5%7WT<F+].6 VL5
MT CX,%-*?"M>G4>ZL*" "W>MH :G^?QK;9&8RS),)K?2TMBUO+ZF19"A7X"*
M2U0A9=0JM1(]0:,CE+=5-J6L&(%_)J5/EVD5-+6:;G897\4<XTW'F7#/V8'&
ML':$@9D;93H ?%-&39:. \> QO-[J:.E;?D+S*U0JD1U=<$<>BX+)F("35!_
MBV7K1QTL2L(-HZ4S4:5\Q?)*BM1TYYJFIR.XPU-W3)]G@0>:J_+1*DGU3(;X
M.)O;&P^W!C.SLDR,$Y-XWSK.W"F8P=7M6P>0KBZQ;U_KY()UAUDDI&0%%N==
M'\RH"M3KG&1=4$H=!7/M_)>I=EZ?)/'"9ZR.Q05?5@M\=9%*LEE!GQ"AF1I:
M8&[<TL\([3;1%NWW;_:3/I2?_#'9Z:Q;Z#\L2O6_?W-YZ8%U6OC&CI6Y2L J
M:TQ\?U+3,)]CZ@*[>%RGJ]Y>!NQ!2M^O?OJVBPP1-_=HYLMU#.%TI+9X60_T
M'<[+A"Y:XA+KK@,HB8M$:3.[,D33M38:94YK"T0J?'3&Y_?G'L^TOMK#AP?3
M!,_T7>\7VR0]D[WU;H,MW]S5U6B%'7%[T>J"\.(R6- F&U-"L1^ 4),DZHPT
MVG]!JGW*Z4NZ3% JVR99$TOI%X5MZLUGBO:VSW.F05]%.E"*QC91*$HF90_C
M(]=K!T3*"UVCGS0^(.RV!/==%%UE5I\%H\)6L=Y/4@.Y34:A@VO@8H)AV;5^
MS;+\,&V^R$,C\W*98E2JE:D/;[#RZ9Q!3VB+N$O:4GZ=N=G.P 'I-<0Y2S$Z
MQ6!"JMG+9"=Q-)['[DP*_? -=WW/&+%89]?:PMK-)6<'B9TPY %=H@MU **^
M)9:JO#-K1%:NY%#__$9-#/VK$<7N^!).?5/8--U([I0FP+BX29132.<>7)1K
M1NR<&MABM2-9G9*35!;HC]&TUKW("RZN%T)?L7_H&?,5'%"8I^Y7<K+J=-1G
M7*O$3,OLG(I3M,W%E[?V?@<@2$:1O96#=4@\3@$W614?S<E,DN>=!TFLJ[&]
MY^^[ 0A-%IU67OP#CL6974DS";@+&,8C>J(?1O-2-0&@]D!&H!<#=R[3>8C[
M\31&4@1.W]"7*=_77TVM_&QUHZTNYQV*Y++5=D](3+QAHT2G$Y]J/4]?Z3BY
MD\Y:P8NSWOFV"!FYJO.50G=?4<MZ3#7%1ND.M4SOW6JL[-=XKP' S<A[XN]&
M$D0;'ARFTSXK#&$O$$!I+GZ7,?IJ*YNHI3(!] \M5_J7',>DVI9'F8ME(F6U
MMM'VZD.,^]X>'M,=*V$KS_(_?$X#@.W;G%?KD!TM,1*Y\?E%O+@^FT\;"_/G
MU*)UL2K!\/$Q?2/!I2I BJ&ZU*,M0]674Y^1@DK!1<S#\*:Z:JOJ6S6;%+!&
M<>?0+Y3*4B0Z O17.Y5TO1P)[,VG]"S8=9$SAS^"B[-2])<:_/7BFV]GY>B,
M=#7E^<,SG4J OW@(X-JW+JG9=^Y)9W&^,YH;\^Y:&@+?II_Z$>#T&Q^9UOJ?
M;S+2;ZK^Y!"14BVG3KO_.#=B'=R7:YJB3!U:+1N>C B5KHKGAU$\;-X%R2YF
MYYI-]U[%\X<H4&WVML1.]ZK6S8:H'9C,?_&-<)('Q< W9A)5ESS"TM@LT D/
MII<?Z5PJY2ECZF\LN GN7 ^)E'R#&R9H0VI2B6+WMI!#\Z:;7AP< >KT) !P
M<;H01JR]Z+1%:V\\LD*SR3.Q4)PXN%8890,N-GS8$?;6U"M%SJ<;K995(98>
M5+D/\08X/80W<_BY5XAC:5-5,&G9D0;C>1QAW-%FOYDV7PM3^91<'25?R<U1
MO[*%*54K<*D#ME<[4[H8;2]TIXQZ5?/.*"7G>:TI1BZ)@[D()@RV1F^;8>YL
M0F.W::WRH+1DDBY[UBP G,L2VF[I:6E?NS&_03?2UD-]7(=1K4,%"@M*"DQI
MJK]T+[ ,V@=>J+S.H%-SZ/9=&[AG';-2;_QU-2^&@1L2 [(B=Z>1:=Z&O0R:
MR7+*4&=@X@%NDXOY]*\F7'5F+37NBXG_N4H] 8YB'SI()_7:J,1,= ,V=/6X
MCY!(F=V<UG/>?#5C2?^MO(UH3@2XX@/ A7.%JB?3R^YS!F'-B K>GD3(8?9\
M@0\IU."XN,OS"L*^.^1X^Z]^AO.RL^!%J^)[_J4 DN@U;/VP0;5NY  6P[_Z
M:W;%=S,FRC7P:^NPB9UX?+2>,SQ!L+Z3^3Q)S!O2#?#41QWR:(J)H:%3&NE
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ML->P[VU 9(OJ::9RY<LG"6X.-UZ.E<R$UCY7=KW%F7@$L&ISX^> &9/P?7%
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M#EY*4=9(FT\SF; I&581^!%151A]EAIR! 10[F<MO%ZMX]XJZ@K/-GM=WYB
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M/X 5(TI*^;S?61KF/IZ"%0W!6*T6N=F,HCCF<#'"<!?(,)BJNW?WE6C'C&_
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MC\PR_1^&4RFZ3"RMN&1BXO6GQ:-;",2 0#'S@F@%WM5H2V5$>\G^Q,XO:H#
M-P!EPP1M[TRL)Y/+ISZF( 0$C7"Y%CYI!]Z?3+_II?+EDH1M,]F/' N>2'B4
M31C+^K!9E>W&/Y/7D147S"UZ>V@^\1#O-6\?Q9.$[ 8>T>YXZDO&J+]GO?))
MV9,2ELK$G;9B?1B".B,J2G0S;W=LXGR?@>8<-&!*"72NQ%;(^R^5T&BHLE(F
M'WH52^*2%H'LT[9EGU\;I%C@8>C[:A;?@D8RD.0&=L%^K<"]N.3DBU?!B@TM
M:,+ 4%#]8YJ6GB;:WY!4])M#BHG'#Z),4LX'<0GH%.(CFP1#1>T7UD='/$SN
M";+7R 9/?V[;7B8^!8N9Q<<LAV-@;QQ8(1&SC&OV.; U[7&03'91/RHRV-;A
MU*CEF>5=USZ;D9,/7=XPQ/FM)^3"(=:FDY@_5Q76RDI@!R[).[3;'NY<?[EU
M$26*QX^MD6>CM]G]."/M)*2^O5!U9-F1)\"*U1DAR*WE,.H";>XE2A."U[5@
M ,PE>\=OO0/%09;;8HQ'<Q"=DC,N,?D"I20;.?&):\OM0MQ88@2>Y>-47WD!
M4LL.3G^R)"M1]23/=-#2V;Y-)W.<2&*:4/D;@.J"_+);EH=S';Y];1DHC@15
M3<325WX:0G09_R(HYRPQ$UK9,\5^@!N>P'1%3NZ*7=NLSVXM*Y<N(BN:,PFD
M"-GQ,J88I+;1=:WEH:+ZA*"L"I.!K($3F<(]KVA+2F>N##2.YY=@";#4'R8%
MCX6.900-#^."N DN7IP,)?,X:X? %W^EXS= MT)1C!J5;*KX56=/2G!HA&_!
MWRI[Q\U>TSPAE\ ;7OS-'>Z=:9CPC2=&31ZF/FT^1J2D;8O5P(2=&^1^98[N
M_!Q26JN_BX8BD_4QS+B><$M9,1[GOT/_YR'\7>TM697(M6/?J42@L-;W?B?-
MX2_><0'A7B*T0BFAPQKVDK-"I/,[[_D&+ZNN!<$/5G#/)/]%B9QS=]34%XP$
MB[T?P*9Z!3%*K,E:<K ALW2C/63_X6;V_Y=Z,ZEQ%TCTU/BB(B6W@OF4$=#V
MVQ.O9M#NA9#_4]P1OFC\AZD)CLMA^&'<7&[:W9%TUU"BMI24ZN),5EY&@*"^
MC!%[U6D5 3KN?@/D>/[N]_H2_*U-:P^RR+;WW)$=F,8"N[:.]QBU\,ZG32CB
M">I_/KL#4J"]?87^,$B?@7^3#6._-,<8H$D.]H*)5]7.-+X)-QQ20"9A80W(
M%34L7AHHO'[ZZX>5_"U1'7UF"]OY%\](RRP2U,UHCW/=\3:KAK"8T!JL(.#S
M;ZK^#^/V;T?PRZV&B:P@P^'!WV$5#=9@7NQUT;;43[I-?,$<ZPV0[:PQJF"E
MB.OB_/M1K. B[?E-*/[T/W58&^U./+-^=P,@87'W(Z$,N3X'&:5$+:51#;][
MG2F*.E>;P@P*JLY\=NSR)@G6<M=4\IX/I8I25A0HU-GRJ>\Z&,0,)>$\TVBH
MK7V4UO3SB1K>)\@(&.D-2;3(/*'?$S-[HJ:'A/2V;;(*N-=D\9T7^^+O-X]5
MKIZPVC5#/099([ LO#:\&K#.QAC!=?&S(5[^,\7#T]8Q*%+Z6^U@A+=67/<[
M-*HDLP&^F6<)^"$:@!DZXBZ/G,A3OF)X_" 1:\_FY /%KCG4^F=Z%L5ED_Z.
MQE\-)X O:'/-JK @X6.8/3WA]M^Z,=$-\JHR1U]M#FFDU=]30Y&9[M^A__.0
M@SQJO]FK] -1O CQ"1[76C2^2,]?BM#U1< G_?E;X@&3] -QR*Z'MPCQ<?2J
M,\\W. 0QLZ^XKXBW5PZ-@TYO@)-9^#&3DRJ8E--:FW%1'&$0_@FQ$)QGL0!^
M6-&:?7E_!VL*W62\N>': /EW(\1[54R@90"YBN'C=8C8EYC1T*+5D<ZED>MD
M2I_HWBN!#ROP/U7=5V-[X7G A P?FZK-DGB,9YQD5$CE":2_$"(?P$HR,+1@
MO(<L#N'@6,2JWBUWNM*..S%:VQ,8"J8E6U/YP%N_:S@4]4# Y>$-BEIDOY+B
MKLKU;!]0JAG&:)4XC."O79A/.>_]!AYN#S MILGGPY(9=4XXQO*GGOIMOV?M
M'F^ 347F2/MY0P*BW1 :B9.?9K]F( ;:RX 2H\P>E#_:T]Y)L+ \U^+N;,4Z
MN;+)4^:"+8P")EAS HU4-%:+D,W8%99,OLRN$N@[[WZ-7?HL=?_G+57A,\ A
M\BIY= _;")6N*(^6A-YJ1KT?+[C^&N1>EF-Q$IMUQ E=T:0AYPR";SNKPVC2
MM#DK*64!J<A_Y,%0197'0/:Y5HA+<0HXSL;?[@MA:'A?FU>W'VG:XU+%.XGC
M*622B$N8Z2RM0_?D(B7H?[*[:;?3]?H$\P-^PB\UCVVOQ3_PU+5%^ZRAL#Z6
MC2'+8>A:64D#2@?A82<8 ^R'VLBOW:]BE ;1V$)=T5>.1R@@$7H#%J"EE)#9
MS3\*\TGW/SB+K.)UEAHZ%:)XUCN#]BC]8#>T%4@$1$GBUUE9F+G0E;+@F,$?
MSP;_I3^*RLHHS>[K#,(Y?NCS"YUH)*(VUUL>W7("E;H$]9YA<#DL8P;7D(Z_
MQ0MZ\IA,4$/FJ'=<-E<6\0:\KOQ'2PCY;TQ)>>4U_F=C=H2") U4O1O,!P)F
M2<?:"+%L&G=Q=3H(F&,<'U>.;T;Q&O$R,&U0BO.;*'*9^R=0Q3E3S#/BZKVF
M0>U9W74BC8^6;1->W%7QO@EL[7O#)!35SU^W/.HQ-HK/FBB"T1T3N#0O'8QL
M)8-(KIYG%D%2[Q19OTB:\=/(L\5"%> <O]1P)JA8GKT!1CWA*S7)Q^$@TCEF
MDS-*9!^&ES(<YV0G*;4$2@XGXAER%>0'<8I,PF=K^JV6MNM/G;3=>2H^$*EG
M1M/_._"_':!)4.Z6Y_VC2MM_KI+)YSIX:4:.8B=+B9^JNZXY]=+G]YU-/@8Z
MG<P5FW@+/R-.//IOV[8?UR\_V?\[\-\)%"[CI)U;_W;F.W\^<\?L0F+QA8@'
MONX8P:K?+NA,2%XB5V5,Q(FTQ&T^^>,,QB<K^,[Z0 -M4>8*,KR%?P?^.X%#
M?\R2P,]?.G*B;Z7L6HA8O@3^KI^\GMQ09E)I'7]\Q^[/-J,QO+'BKBY %_PK
M/N:.,C@.VDHD%#!(#EM21B<I ;<\^'4BQ96E9&CB+IHI<;VU'+8G8@BN('P#
M6K?I?=)4'L);S8Y(ZW9Z'$ PZ>\Q-))-$JAF,+=U$BGZTDGKYM>[X'S\)HUV
M;MX[_(KTDO3W8H]DR!*48$FCCVK?8]YQ_Y!>[JK:3RY#VX4E.1++%'IFS5MU
MLOXG*CCBQZ6</^IP-_8I$;?8#?8FKCS/(#BJB;1@;"*Q5<]H(A)4-1P4F:6U
M"W/G]*2K\<3U.XE'DHEM6;0H]QDH;R$*C.^G[J4<,QNU,)%,92/D$Y=_)(J]
M^H V]!K!X#3Y7JIV><CALP(7H5R*AA.8-4]9-UW_U(K3W"PF1GG&K.G)7AK(
M.LKD"5''.^;0V-= OJ*T_:J"7$'(EAWWN.SQA4G'PPA87QB6)DI0-TQY??FN
MO9^;0P?3-$FQ;+V?7A!GUW1"C!@F"*<=*&67-UP'/31!_Q$<O<JB-[EWY\OZ
M.BUD9/ZNGK^.E2YY9^PE_EEKPW0E5>:8+3_:ZD<83W,4AXG5A*P[W@8[0:-M
MB& %]P29#.8[V>JA";UCO;2[Y]Y8!UJT&#G8.RJB2BF5SX;>_*ER(;N5!TQO
M ",9^3Q,=GG+-%,(,@+!JUGBJ\]R .D!=?<*:8:2%?N8U !GCE!T7TH-LR J
M('WA>YK3#%UAZ:,U51P0;=)ADKGTT&EV1KR]2CGH)S:!IJ?:1R9AX&0\>\',
MM<ODL/_XY!UR\F##(OM>Q:#94?[)IUQYW=AWF+#LV/DM-*+*I7T1(8S3&:6V
M]T;CD.UJVBKBXV3(2[MA,/"A:XL,=?%9<6WM(.HX.*"+XN4#IDH4J=^^IS<N
MQ8B)<U..)Y.S:VT$8>H^U^RO#XE9%OF3X)^6%!U*J_92R*1;-+8UVYL2:],O
M5L/#%0&;QI<;TCX\VKV21V46QK=?M(:>U4U,OJQ(407^<.PY?6;WZB 8#7R7
M$>[ ZRO7)>":"C5X%<TL#=;Z@DV^8?(Z5%8\(?X3[X_NS]NU,>MKO]O#?#<;
M3+5+(3=5 RF8SL3>7I3^[GR&C<N4N(ZA%[51%^02B;OD3,D=7O/^WDE9F!DX
M9.N1I[=(/(9BRFWZ]4-W5>*":-MG:)\,/[W16OY4_.'I$[^\\3< #F0B*]OJ
MV?X..8,YK3^[* V3>8(O+COV]]04U(/'I][$BMM%2NT?GX0V(@FR2 U$OE!1
MC88I.Z6D,P%! W+AEQ3L0#8EJ$CC ;;A<W8.$_<1<OZD?NVVX=<-@P_#LD-\
M%)5@SK2)[;4D]O=5-'7Y0R_;95"3'UL*8-/G"5:^9RX=,BVN;0VHCX:U%_29
M'S^9<^^*8F4JK4/6JJ)3OV?G6$>YSVB7OG5RLG92CC>'%9"H.2Z-^!J)T;86
M,<-C#D:(Q5QS-0-!FH@YYTXH=^-9*A,Z"=QO[4X2I3-QX-7F$7P"?:QWO%;?
MEEGSH#^)BA[XL,5**YO>Z)!(\=LVA&)C"-T^O9/^+*!.D,JE3:^0^@O%I[(6
M9_6"_L<NY,K7)3BD%LSUV(0W !.6A\Q40@!%YL,@MXF U?#@G>:,3B%LXO)Y
M X;!V=YU>P+5BI-.4E;JGZ7<P*^&,]I+N^B7ECFKO"B9&@>FM DO>,40I.X_
M*/]DY["FC1#M\!H+4(.A2V1/MW[(6;4$A-S>7)":-G'G>E^'A7["OGCV_#&!
M8(RM3']99[[M3W)[ZJSAI?@!DBYP3Y"$O%S%\X'M<MZ><3</5JK#?;6QA6+7
MG23V9>CR&5&S>SK2;%7]Y:2VIN-,'+LM ?U;U-?2CC-KCG)TCAQ/12]2P(XI
M!%'--R<T0D-3Q5IH'920LC_3(V3NL&LIS\_O4R25]AC0!9 MVIM=X=M;-D\4
MJ<7KGD#0,X\B]<<W0.R,JVI.T A0>#]W0":#^8_-'K9YT[/W7W8D(&W<AP7K
M5R^7(T(;^@SB/<T7BW0S$*\CJ ^E7H54+$M$A>N0%UYPAA1S_7@P1JVTG=>^
MM5D0R&S>\VKJ9G[MTOSSQ4.N\-[NQ+E6G41_53<=3:@U3@S-8F*>@-MV7.IG
M4]'E5QR^G87"I>Q$^%;'CTN@<_=+W@"'ISJ.'N,"Q@FLH,3TUZO6M_Q]Q)#N
ME\8H'J!Q"&>F9<HXF+$S6,LD*K(B (= C45 ]U"O.159)MCGNP=Y.4*Z5_IF
M[0AL'0MGQ>I%I_K X"1BJ0WD_0()2TK^8$WM8D.5"#PI0;R R?M,S?$(K"']
ME9\+4.KD*Q69)IDFB>XS%L\"-G]B0A\B6C("+ ;Q3G.$'YRQ,RQ,+#Q[T20X
M(DB:Q0;)\*QCD+!'(;5H')?5'S17VQS,_SJ T53XM#5G@HJ%2V0#]+=D2^_W
MU^.G-&"I/HJV)++ZY_AH'1A>"/J(B+OP8ZX:EDFCFGD_SR[K0I7V70O')P[!
MQ]1*&-:*)H_=THFND:=N-MZ_ <QPC$%S'U*J^X>)SW?1[S=JN^P9)S9'2F]P
M-=#(S3]_%HQYC*&TM9*BZ D'OR3_-/'Q[<2Q46NS06ZC6U:6>W*ZG?@5\&&>
MN''7L0<5,WCT/:/&(%$YN9:1W3UD8\_P=W<3^[-@-@ V;34D,M&KH8V5)%I
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M7/Z/:BSW+ZAQ#Q!1"T$4G. &@!EFV2WOI>!=T!4^;(V3[,+M\F;]^_K?A<F
MO62=QU\][@:9-A.>):'.LO&OOU[YB2QP?NU=0VV>E#I DX5$$^DZ1)P*02]<
M ZL'Y7_[W6_Z9@8$\85+SXG,B:O1NMS3^2P<^LO/Z"EBU8H7%^0G^E(=@'8K
M%5QDERKU+%@]AY70E.FNW$HXY(>9>1'WFU?*B8VFF KUY2:L9WWIU.-P _)I
ML.[YR4+,]DK*QV5E&EN&(X<#&3TKL4G]&K$WJCJ*@W27-GYU5%AFV[12J88L
MRXP!M7)X((.=B$DQ9AU<^2BP%#NL4L#+DVR310*4^<MU+N[ASSBT?-&5N9QH
M7I=_O_7G(!=X!2F>!SX!EI*@3(]QC'6Z-\ 81E9EC$+A16H0=9'F58\J-I,0
MM/2[B6(OBR*.)=\'DIL@H>UH+:51^E&$E,M>+-RKHFL??24($=$?:Y_18\C[
M]=Z%G$6+4!?I,BD):'=-8"?6E]DHI%V$!:& #]!6X9WH#Y]+"C,^S;'-@-><
M1."E%\!?A;]J6=6.!V?"VEM:NTT=3XWHWDG;DH$FX/GJ&C:F7G!")/9T&9BO
MB5O3-)Y?:._'9,%C8.;X%#NYLN)L&).!^"FI=IM_OGJK 63Y*?1#8\S 7W\U
MDOQ5F;Q7!/I$T%RLU]) W5=^6 QJ4,^38VFC3$JH+\]A:-P12]@WZ*:'WQT&
M7:AZ>9%9T2C'>2E+WWC/1_OBE&:7?+Y,B$2YKY!Y\;B+W"Q5Q9I%2A$UE,NY
MN?GX$\&MP97F,Z+1J@O6&X#UTI/,04?Y$Q7V]E<0JR\_T-057^Q@W29X?7SA
M2UD_2LL(VO<Q >]7RSG^0MSV'>C^[7UF!"VX0OQ/>E(&FL<LJR4&,?==HQ=@
M=<NK'DPOM=F7J83!=(W+W0C=DZ#&H,C-IQ5BV\;<^$M/<:H?QRRSJ3L&"C]F
M$NF[08)&,,E2S2S*^3<!0@@A2L-APT\NJ<)F7QXJ/\Q\VP/;.? K'8ZWSI@7
M#M)FL*?;Z>$>*[<."U"4(I>)<,F@^-O[!;X!$E1IKES&DDAL*0GWBY&PZ0>R
ML=5*OBH7+C*<U]_4'RA/>:%EN#T-U)/UT?[%R;6BT<:%C*LOU@(IR^?&<:*[
M8>" =5\1LSE;257JDU6A3V/I:*V !L,M,Y[T\6NS7/3)6F/ZSJIB<^'MF=9R
M6+4R$Z(ME5QE<)JN2"7)\2YI]9LCB?E!.26(T(]^..@Q3/(Y%*B&9&RC+O-F
M)?6TTCK.W_@/M(_X<ROC5G1QQTAI8MVT*+BN;L+%\RS-TGQR1)GME8*S].M<
M/(A$,]3KRGC24?0 XOU4B1PCRU[9M"D=4JS!:9J S;0=2R30_+ET<_-A<_@O
MA33WR:GOIH$TE6K]Q0?87XQGYC-4BU#+>PUQ;.@&NG^]3_0<H")44> H(!M8
M0%1-I%P*0*T6>5\(E24^CH+LUZFNM ><I^OG\EH+!;7P1=CK$D*4+BY:G_!6
M<K+PX;+C'!R_!-!6:L%0:W9^PX^M;](M@:8DH[+;QH2U%F:B5X12"U'K./X'
MA#.?FEI#*IJA=,0=D4T$G*>,P#>VC-VY\DT@LW+4HY[<%1R7XJ2\]V>YFC 2
ML([\^6/PPF3VF$RK\+&]&AX<I_*#_ND'HS2W?!4EUP\G;A+\2Q+SQSJE@WFT
M*KV<E(8?QT<W$J<^L663V_X(:J&*QT?^<U(*TL'$>Y@.6T7*79,7%!FY/MJ!
MI+[O%0R?(JS[7-TV<+>I"!?'M=W\?'QW/BX"8A=-D,O+B4YT/[8^=_GG*2;R
MWAT%EC#>-&9%7B[D+3K@UGQR3"-*D324=TA7>N6_Y RY=JO]Y1 [JF,@]4%#
M5DZZBZ%\<;7A$6>+S.!:;&:A12KON0L.M#\K_0883Z-;?,'.%P\FLPIS7_$,
M2N2*B=S5T6N VCD\"BYS/1"ZK$,+FXL]G!,):QU+@69]G>HZC*#T!"<Z"(>G
MV\T'/.4.?41>F,LTXFI12!ZJXN>;67:RXV'()R2Y?B\V(X1 3<TIQ#:7GTZ?
MDO+)"*5^J34A[PEP0D<)X(RW+#"-=MOWU&Y_M#JGH<S52VHKZ-MX&/:4&(@)
MHNI5YA4NRW*LE]\-UBSH52CG2791&:KCZ)$Q4Y?6=+IA0(\KWX,D '+#U[;3
ME$]3'ZI$@Q0:4K81QC475DONF+C*D I$^SQ/;7.$GZ/^^7(B,GM*.^O32L*J
MA.U(#+"[B7+G]>2#WK!-6OM&@%VFDZ-Z'L"M6U9_PW($!8&)Q<8.8X2C4/,3
M+I0 D ZE.1W%';XN=>".AOR.*Y) 'SMLNZ]G#5,E2:8$M%\P%^3,3,O%O9N0
MZX9\.E.=E8Z7+KY;(B7O+#KELWVDV*7L/_'^XQYTV;>Z$O$3T)W0T?3E &.Z
M^+K9'A#('X?>\]/>>:45W.!&PM3E5?/W3'=+130NUVZ,6Q;GX_2QY?:=$B+N
M95_'S!L@5DSSEPOL>#9CH"Q]CH\CM*8VJN/BL2>Y[@G%L-,QV$#@,SV:W$O&
M<D-[&/4SF>1N]Z7PG-WL1]+X:=PK;;X.R=N$+SM-)72"C[E\[&Z/;I]AW@L1
M41<M"<;DT[C=;,X=WJ+7QJ%%Y/M*E7^&_** Y7 5C=0XC0N74U9D$(GV,WBZ
M& C96[FAL%.*"#:VRSI.<C=81\>.KG1V\_=E_(;5B)B4*N*N_U!JY[/'_4*5
MY!8@Q+7_(37@.!4UOT#WR*.5*7M<(\&M-X[WG!9"A.EDO"N@ 6E94+3*9>^Z
M&X8R" G=5BKTZ_<9I4S2;/*%JC< N5 /)OD44SSD!"/_CR\+Q@7"21F&?$1D
MN\>H0.ZN6&'7-T"@PO3^T9%,-'1%(B%PX;;P%0AE'/_$WQ60G.QN;91JCI5U
MTUM1.^/+.XB-[G]9[(_/#"MCE,K1>B\V[S'M&>9?P0!EK)DL2#;5Q$D[$6T-
M GD(K@073Y*>8$04*]\^,LP@=]$+,/2LQ^BH[WTI)EC+G Q<"3H/<'/-SX]W
M9I 6H%!ZCOW_Z&2/[I2H.E$?67(7[N2\@(9BF')S&68.NCTSK1DP7HKU+V7<
ME<[7T7"WI#4=&2,;4=5"/1HF#E4FQ=J5I,C=&Z+Y8D\3:O7I'8<W@ $+VAM@
MUABG1)%T=:Z*2DN5K\@-=N1#L&D.CXN4*S QU3G>Z>[[7IW$PZ!:**677XP]
M)\8TMJS7-8VQ<C&O>JJP%18MR6>P1!VOF+&^F.4^$"X#*PVR3AD+I]R"]% Q
M5L1MCXO=0)$&7NTV8!E/+;C:I<*7N*']>-/)OCFWH3FW@%9R-WY!P:!#\^!2
MN^0Q^2>!]/?-\+FN1=^/XX_Q?'-=K%!S@J4.&?P7DU=?EL==*2:?#(-XMA3T
MVSR_"7]39YT_]LS39;/]<>D5=S@N]S@_>WK@);0GM$%^8% ,Z+I\$E#X\9@E
M+9]+430XCSDT#M+0[FK^#*$'-V;TQ?7^AZ3CJ]#@W/V6GL<)>A6"OLO+*\W1
MT2TAP<"&P7>C0D""1 .MAW(G^VL,')4=*N'#]LLG)^UX>$_F'"UV/"YB>11K
MT/6)XHWH*K!3T[5 F,'M*V:'@!,C$PEX0XE;1+KZ(CS!L_2::C&\%)*J 0F'
M*Y'&%WP,]^3_C((#PT;#19TP@8#[!CBGU]6BX>+?YE/.=!=Z[.J9]CU\-#Y^
M_9K3_VQUX^L#G/KZ//X9J/-,7II+B\58E9&H-9# ;Q@G<O70Z@L3SV?#R:#"
M8"#O;(I>LENXBZJ6GJ0J37I-!.%^R 58TQ63NXJF?!]E+705X-M#M*!P68IC
MO,W'N4;"&4G]W?4^S<,@GM5@"POW/.1L>I37X>7@2E8M/%Y:.B:&>%HSI5;'
MCG;O0WK"7% %Y,-/IIT8X[[BF(;(L;F6(,?2?&SK6Y=UG-3( \'[2I467@6D
MS"I!*P^R11$R0%(:UZ1.K#\KEFM)LJGYPC=ZWO24W+SAT7:!#0LI(67U;\98
M57H5B!!]0:1!NC! $#<TL6%^E 1U/D9Q*)(V2@+SMJ#T9)>2'T)D[@+F*LKT
MBL$FMO+-""(?3$#!B+J/E?*(WVMTW?Q/=]YG]=+/!4\#RBS<VPW,MYL;[)_S
MW@ C],6^^3P,#1];#0>_SIG!@+N4W7H!B5"7CY\R-@/B7Y@O0D3$4G<F7QV/
M'^0,;2"A/W9(HJ,,XS6I\@1&T" 1?EU]=\[I*N8UE<U=EWX(NNZMV*_0U_,=
M3../83XF44*@4PN)QAV)8YZ=LX.?"]SL1VBT;)((Z@)XH:6AU\XTN+J%@A"E
M*7+ZA[A84(N5&]QT[D]"2*3A],9L.IY?<_! @LR788:\FWX]NVU4,;_5_7,\
MDMJM*\:3X?=WD_&E=!46L_M,J"Y<GG#EM+#[&T[P2A/.PT!$B0S<.[J3^ZA(
M5@Y3U7UG]H"8_,#W#2B60GAGAR&9*A,5_>DE8.H70>;O(T4Q!76I)=9FN (>
MFBU-A>B0*@X[DV^ CX*:S5]>8_K:)LLXZ^-0ZA+GL9QO;H=*E;8SMI>%QR^N
M)R-V0M(86D_H+M*<[-)=]1!IWP!HWW='?$#&PQP5<QQS.PXC94(<%LV-B6MG
M0?3?9'Q9:0'78>,G@;S#Q<SENB2LN$*;J,V<L=.^T:\T="U=K:3Y.L5NV4*/
M ^P5#2(Y8QD'*MQ\J[6UP%S%_+8T]N01)/- H 87&7BBUDN(LE^SA",P# %B
M'2<L M@XDZ72TB(GK3W%G'5US@O+  Y#TAP;ETG10"P5D:S2$)C62IEP^1F^
M]R$^X:)EY7H_V9G8%1,=P2K/]K;E&%*D>4[<R,?AQ.M#>,E(&P/<AIXPDEM>
M5;H9+>^0>H6$[JB>@&%3&,M3"3A(7M$"8%O$\,W)FP:C..+DO8#2R1D\TN,1
MT&%BSPUM^15#:_#F@:6Q)$>>'RET3^@" BIEQ_K(T<*F-BY&^*2SY&@Y+7*T
MSD4>3]]3 JQTE148'9CO"AT!X 3 ==S_ US[VI3!WKJUX.#,^;Y^D*I,?R,'
MK[%L S-=$Z+L>2O!/.+^)15"=#"G=]Q/=9G[#0"O(@.7D\W@C/2\1*LXIRQ.
M5E!^XV.1B[YD:RW (EQ]4L_-M.VG(2PH=!5(S4DFR&Q^S#XCE?O>@4=G'36Z
M*APMP57J-.*^0^N33 CO\#BQQ31NDY2:7_!L6N!7ZA]Z<DD^ETP_J5Q ^_1Y
M0SY*Q;<]A:(X]BENMSR,4]GH)U]E?3?GWOF'F4Q0#-\CTZN<2Q&9:?<\<IXT
M:>$];\3OLNPEH5];\&!X^Q=O5D+6M<)ET:F 8I.<3/VN@M)$+A*JB%MM^;;4
M.@]CW$)4K(*H672ZM;V8M^$&R$5>Q7BUFD@_"G)$B=L<S</%I7SLQ+H+I(R3
M+Z,57>YD)IC_'.J^5I;:B>I5L=_UPVS(750U@ '?9@8=3BHF]/(^9^G^!X!_
M&TV$I<1"?:PNLFVH/DDT281"LX6N^H@Z3Y?O<E(YSB6I,H@$_K?A./O9V&?#
MV40MU FD>#*AP"G^ (+._EX %HVKQTRD# **Y=/80'OFP>^A9FHFFJN7L,Q%
MJ0&X.I7'9<8"2;.TFM3,TRBI,U;FLIP@V@]5M'[1@AM.WD6W103P&T8YZ?;=
MR/+-/#5:-<@!Z<9B+*_BZ9UX\[GJ<_?U'XZXO>-AN,<I0_LTP[TQ)NGL[<3)
MN&7KFX6\DZUW TE=/54_S80I+?A2_,\U_VFEC\4L-ACYULO(%A2("NK4VFNN
M;TS@P W$T3.%,JZ/G'8C/,:@CG^4(;T3W?Q-%G5"K7W_BFNQV=YZW;"9I\KK
M?_$458*0_*F EA(X<3@QIM=2.LX8^0,-[!+T;%)(WTSNGI9L;O;5=81+9?)=
M!B BD3%'53&A+#W3F8_?/0">$L.83^2N[A^X;FH#S!4LFLYWXX).KRQF53-1
MCO@4W5*/O;*E=YK5Q/I"WROUNC,<,ETR/S>_(MOX3\]?]N=N*'PM?6?\O(>B
M)W:A4(ZG"J?6VA71LRJ3]HB,8':[A$8B2Z R)^[Q(8MY%3Y9\$3QTC4% 4JQ
M.I"CX,;+*Y!K1*FJ0%_HZAF[ARGC)[:/[V <9L,)'HO$\]TB[B]X,WE?":%-
ME'K"JVR2'X1:HC,YX-_45^&Z$X40FY_ZW.+&]T,X18H!')ML2J]+P5\Y5^@9
MJW$SOS%+'_\@799:ST[XT23=A$8AYD!U T_&1F7>Y1M@K>]J;V]9Z0W0IU?'
MX/:P-3P<HDA(/V[INU6D>/_L&Y S#C.2ZJ;#FX@>NYA2E^G[TO<UG$A!'-C
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M'RU;.G+J,-S<#.A3DI0=%.NZ4C:U9!7DOL3IWV@:NCP1\[ (_=*=H,9QYU/
M=XT?"8D;D)N?O ^4NWB,&H6;E#IM>0*,2F<JGS<L-X\TQ_\$;5CD$C2BV)H)
MVJ?'5%TK5U[H![M M^@93)R!\&67V%JXX*R/B1VB,A-.TX[OE__H*Q\'AU_Q
M&!-Z/8/0=/<_R]D#9\N-$=*(I),7L#H"D,:=13]?=2T^ 00\:82V6_:H?'D/
MY?83D8M];]7,9=UDY%-AOWBZ3-'&T\><AU5VY2P"0BEIOX6;1Y":8/?U1W&2
M]0IBJ?1< 3$-I4NF\P)&?@V_6+**H,< QU0N1B\Z6:E]V@Q)W$C_ _$'X@_$
M_QS$C=>"Q1- Z<VQU8%/8>P<!=";^8@*V6R/!DI=@2/^LN3861HWKQ>5]/_)
MMN;$V8*59W(65UC\@ON5<Y&U7Z=SUL%K N]%VN ^F%/GH&N8<TPF.SEU^3O\
M2QB#/D&@9AK!*QO+U>.."F[2#&JHM7._R/!?=BT_'/XG!;UUOB, EF/;NSWS
M<QDX8MS2^KG Z$%UK_S'A'Z=$1/<$C%7B%^@$"!W*\H1D=DZ=O_9D+=D[<^I
MU(M<YV,:[ ],%SYJ/FGH_>"I8NLNS_'NP1>]Q.0S[=/7PHC?_0O?VKA\J^>1
MDKU\UOO%CY*NUW\@_D#\@?B?@\AT)%EP8AV5D@S(T^>*URSN0/CDIP*PL'K7
M(CX[L)BJ(*IF0^YOZ5)]^_&;!MF^Q]^RN\)SO/2O'03UTOJ_1_'EWRF.^'L4
M/_J-XFK[[-2)*,<SS@Y0WS/N.\(?&JB'UR'S3$5WK]#V'D=D9M""(G=;*S]\
M[+N#?;F\?UM1>2?<YF\:[N\Z/7LM&[XE\%08L._(4Z2?JV3PBEJ)L>N6Y?!8
MJ,,*/10FA8KHY<YJP)_[^''M!&"5+[/&;UC^:=VWR.WC8S=N"T(12'V$X^G#
MC*"H8Q/?CPK1*@=N6ZC1.\?ABAYCS0_)>78\3LJ:FZF]?T_6?+N>-(*X+VJ^
M'Z07&2(7^.!F:DCM;[8=>QA>?2^0149UAO&N7Z2MV7S#?;YT98&9L&*;Y[SS
M1B>(*86#+,_PWD2+%IY<. F,M_ (W]_7N2';V?V<L6B03V5^C=_3^[TZ[YZV
M3QQM_$XJQ5+FCO-#O12.M9E5Y183E59%LLW8EEZ^$$W&TR/Q_9 3@.3?LT<#
MV^,_-74"2%6QOT;K "*?]O\L=^A'T[63[,<R.7I_1=#K^^M[+WZWA_3$E.Q6
M\-'6C1A\6Y$)9LN3VL:>0A2L&#N6$#B8DSI25<<\*R;,Y*Z/J5.4OZRF1%$_
M&AVB$NF3Z_+$;R^V#V%<:]\!M?1N55GN?F$P_=Z)WMHT+IJ8]&+!J7BL4P?7
ML'XM=<1^,(Y<8WWZ/2751!0_HVWLMF5.<OBP=[.W3_-[GO;XUAL][+4 'E\3
MD87']C'KZ[R9%G_+?EO%@Y \O[K%<7H.GC8]8N!N8:!>#MVSW6\<@H<.W($/
M!G]3,NZ7.YA$!@2A:.;'^-1".H4ZRVG>Z)R.< TZVZ:P&I>/B,9MU1"#LL)+
M%VJR^WD;SDUWG@!$:U3[A(,6<^.8WK#N:$'R :D#S!B"QZ#F,U6_F"!>BH.%
MEUMOQ>C%Q$-[JUPBN.=LZQSUKBC7^(&R@#[I:XQ\P# N [<@YS5> S,$KTN)
MX&("60XC*A5GV/;UOH^R&7Z#+UW;RWGI[%"L8KITQ<ZOH^EP=)YI>D^BLQ?Y
M,2](=%?4J#;TF'_I>AEV=<"BAC74A/UCXEK4+Y_&A]KC:Y[OOKSV]RQ1LU*9
MT%*&.]?O]U&Y/TM<&S]=K"R7'N9W?J=M1_DP?_MW,:HDCJB5XMZT&EE<$O"9
M"WDX'K@[3ST[V]\>HGI]_1$>4W#0V;L6[&FJJOXD6*"7QTOO>_DUWX\'"[<0
M$ G!==!::XT*C>TI9<;G[9 W2Q?<VHQQ)P!TH,[AFJ#+V/Q$:S0^'Q.D,S:*
M,I:<9(.!7N9VJT2>>6%WX^I:6O!%I7XE(A/+&MFPU_7">$UA?&8&$K%8.P*N
M+L(A2,!UP8YSI7;8=\;:[F#:KG*5[T?#][7JC.XE'A1RS]&M'Z;<]6^23TR8
M,,+SW3<P_0362SKN9H"V6ZS$%@4QL:@Z7-0C/>B<&96&?C5LK9 ?"<!\5!-,
M!:XEY-\D*LX;YGO7:>"&T#$2J0$X8X<,0?\=T[@+[S4O(!QP;*=L&^T]XW0,
MG+@,Q^K,G/P;,N8V;$W 0R$C18NJ87=L;RA(RLHL+7/=C_@QP>Z;\/TPV&EE
M8?VQ]ORA_<9_[5B*_[=C5?S3L3*ZH2]Q_ZNI^3,BP)V>]_4SJNO!3ZKCKS"'
MJ.H^&/Z=-\7A]^8_#C3&AV#7D^T+Y2<!,Z<_CU=VF4^[-JA8JI7IY=-OSE*]
M)-)3ZRK-FN;RH#O": ?WM"F#UJK:EOOMS26LM6MI<;$-H_UJVL<-*2]3A*P'
M!;<9,T+3FF*'-!!JC$]"OM%7*A??+"HMO5 ^#[K8&'_%WP )^J%D+3_TP>PQ
MP$W(7BK9WW]I)T@/*V0>F+Z@W*K>O<*L%%@%:J*OO?8UU#G(H7?T8O/CJ&&>
MB&MO+BUX29L^#JRT TLI/PR>,(X*G/VQ?G$U#C01&O)MDMZTM>K>*N\2O5]L
M@.]!R/Z"19&,\+X]-LO&AR]2HN(L(X$Q4F5!5+'4B-@AV:<\?:'3E537STA\
M4#JH.QY!G5Y3K/YR]_@::Y[X[HNY2@O!3QE>.)S=PV7R"(+2=]/'"R)261!8
M0T/?C-9@,2",W>C2GLP9>" ;:V%V32H#'Q=I7@VW6N,OU"U=[L(NM'D4<S/
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M0D=[+4*XM\NPJD/-=XV/9%Y.6 AM'124-QW_S!DM*/&XB?I46!89F2YROU+
ML>>=!8X\/4_?$WPN@8]C5AP16IB5B8QV+H^OHH-" MCAF<@WV4^3GSJQRV*G
M;/88_"<O!Y7V, EN4FR2FR? I(&><C!;OA\<X3W)!<T7_V5$Z9[CIH\S)X!E
M;/SX^W/+)X ?X]L13=]"5R+\U)YT&H?^"/A)2OUI^4WH'S]X_A46V-AB\&B2
M&*@<ACDW%X5CP5VJ0P#%IX4V5)]FO,=/@3 Y !KE0G6&B8<\@+#W2=W!?%4
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M="NR:UX]K>\#%-]-,#X=T2K' /1&?RI\SQ@XEAD3+MX+EX:KM^U'UZSGP/!
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MKID>WJ4REK+'5TB-"2!81)CF/FZ!TO<W!LRV<"1GR6YH\-U6:$[?7]'Z76^
M>%?3U>N6BQJ.S45X<F9XY/( MT,++<- 99:!"761.+I\Z'[1>/%)@C45N0Q=
MMO7KD+"I?6PSL*MNA(W19_H\\J'&E^?,S%TP(^/-NU%_[=/C(!&TN)HJ<+JH
M.4P,RUD_)+@) U*DI*:6Y,\1)-G+N7:(WQ$LB9I/]4*4"(A:&SV\^Y$K39,<
MPS,)+1X9(H$T0(N:7BS&OVC)5<[V;*:56G@+&6_* H*T1HFEHQ74\53,R'[>
MV<!9<#8\TA!\J:H$C=Z:%-TFT#C!^QK\,3._BNT8R]_JBA 8C,%FBSCK5K$?
M-2053+"T;Z25G3-< ]2<N/;-PT:@_(M1['C":^ZBJPN^I&Z]TP9K+@0"RI/.
M)5@^*?9-]JL2. T9.CDWRY6[30@H=O?I<PCIO(,[MR!W"1J5@L9%(0H21))J
MDN@; YEJ146.ZU=G']J)]ZK+M\C"1[XXONCOF^V+,W\9_YZ)\<?<-Q?)^JPU
MKML6;$*.)V*6]G:[=CW5R[TN\?'!KO[-V7,CGBE_H/Y _8'Z7POE]-'%Q#T$
M AL(E)44DQ02;H@L4^YB"R"O**ET4^0G8$%!"ZW8/R=Y?[T<_FEV6J.E,EN]
ME!0@I(6%&5SRR:?#80&2BU];D8MA9C))6J1%*"4JY_E)AEZ5%0L!GBK#DO#.
MP5BH)5!_9!,,^(2WC\B+G5+_P %@>G3+,YU^JL+(7:(HZI89$$Z?JL:C)?V6
M2(3HF&U^7Z[FV/6TLN/'E-VCU8$?@QJS6?]:@%KKQ^S[N]+7 +B?8)6)>U^V
MSG1EA8;X+.;O=IW<5L+GOFPH.C7N4,Z)QI([\5%=+2;:)L5:) $8VI(7T/SL
M86><-T3+4W)T90DOE &B7R76A(7*#<H^N*E12#R'-@GQQD)0WJ$4#V[NB#<N
M!UKLS._#'GW>?6T3)+,^>*^J+3"7O+(SZD[Z(!VI49H3;Z8,,FB"[X&"G$N'
M@VC]*=%'M_G01"1SND=+>:QH<S*N87HN$N+UM#)\8]D=/H^N7V@RNKO>E:T]
M^DA>PYN!PAZ+<RJ:GG*JD]/D" 6IPU1[AI/19N[(PT%M*2@]U=TAP>H"5/+S
M="%\% I:0 >!<2/O'L<("P4(B$*GT_-4YY"-KJ6D*A"+1!Y-H+OMI])"?K)R
M4-9&"4O*:)2[3C9%:50=;>.=%[C9#O-^V;XVJ&3H0@V@&;>D A<'J\6L%.?U
M57<N*.N#)PWUF !'ZR*![$%.==0M\7Y#'#4PM"M4ST--;I?Z;7;+$MP<Z!")
M'=*1(H% VODAZH]83+Q3C9\F0]!9)<"A9).A4?/9IN:"7?Q2UT(2C26:21>T
M:O<*Q3:.,+YW(W^!<1QAEU4K^++M2=N]W%I#I& Z##/(PY+/-RBN"^+&>$,0
M*!>#*JQ](41YWRH'\W?KEDZ#,89[O%1Q 8;/\H[ET[N:C,OCPH.@-.V=#1:(
M]?A[[H5H,3*#P0$7;@+3'%THVJ%&BPBWH$:']T.:6(PZO#0 )PUGW!A_PH?]
M*M/I2\R\Y)?S\I)-*/41: !& =55A!JGU@AHD>J%J>3@&<C'UW=\L__IP+6K
MJ]%V&N(84ATX6U*TN#]2=YQS#:BYMV]N\I?92V3^9?6)+C6@OR_H[[F3V^S(
M<8-BM?#5BITT[S/=C'"M3JM11_TU U#+HU1!,F,<[^G-EV6/!71O>80#'#ZX
M]5I:Z!7JOEB(97&S*76&Z])BN+?^$N[VM(53YTGK3.-RY?[$\M;'J*9KP$GI
MZ_.7-.1Q;0X++?%5#QR]W!VVHUA)*@V'7KW2OF/N:" ]JK\EG::G; )Q):(_
M_M2XY*OF+BU#WUPQ X''QJ+UPU.-&/*^Z"\:[>E".O@7W08EA56[DW@"$(]M
MNQ3=HM1U674I#,2))$)=YXFJAZ9X.']D6U3KUJ>5&9=*!*BC/@^ ('039H18
M6IBJM7:]M-N"H$[#9:,@)ZSMD31TVX?VY=T5Z"UM!U(FX3*,+QW[9UK>"_TA
M7JA>K_+TEW<=\9V'L9H#VM"OHO%%:K2M 9:O$#!1/4,ZNC@"N1%O-Y)(+95:
M<82L"3BBL!0<*LL$=.,VL@X6KWGCJ3R5X\SV8)UV-2I"5^<N^O9SV=<Z9G40
M+>NXKG1KI!51F@=#CK;SI8RE=UX#-3 =;M(FSB6JR]8VLB"0E=VXUZ95*G,T
M&L[1A&W"]F!MF^6'AZ9'O;S:A& #,PS,NM"IDW9'YO7-4H/A-M+)^%9688 /
M9=&0/;\Q/Z $E9HW%M =!%TQ%(#5B*+T0I"S1_8!#12:S)%N5$^@! UO;^<Z
MB19OR$V \S\GRR?\#TQF_K>:C/:O38:>KC9BP>]EQ#U4R_V\)IT*:Y^<\J6-
M#;WJ=!KT*E$4AH['F3*;U4_\2^/\J$-NEG9#XNU1Y]1A/OB";,^N[,PF&55@
MM8#)=%-&1@IF8T$USA5KV=GHXWEGN+J<9RO;5.T=\[/4/$P%N%%P>U'XFSGT
M:/B0 KN9!PE0SZE"&D63#CJX\Y4L] A8+O"KWB?I6[]#&_ZA/=;24=G*/ 8'
M0>/MH%N;96'&)*!7SS *PUX(0Q;3"_NU Y##I*6.#=H.YI7:#X% DEIW\^'Q
M.QNUR30?9MUMB#XY^CYA8H#;TM?$(,RU/?DS[OL!4K(2] J25]6?1Z$_<99S
MV\]F*@OW1(G9WE-P7BC%VG-:Z7 ?]L.U+8M8/%>AFI"0]3E7_BAR8]KP+!B]
MS]YF;K.3?1M7JLB0EUXU>,7=]J$74$,RE8?8A<=!6Z]ZASNC/8V\V%Y'9PPN
M35U]*KH@Q)!M%;!7A_%H:0:C.?AA).:F4IN:-:[W'&&[8R[KU3Q5&JG40S"
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M#>I;JJ+)_KF:(->FUUP&9^KJB7_PB8-!N2.K,G7.9B4 AZ'VL&CJ8E07(D@
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M"JI>,8D$,ZR0U"C7.<HS+Y@U<Y]W">$S YGZC36F";D%0A.9UQ.=L%K[P_L
M8>[N?B[]I!2Z): 3^0YY!T'V3^XT>IFJS>N3R_JTZXIR7S]H<2D/ 8TK\RQ(
MU2(+;<9O)"6%-I*T46ZQ!',520':.7)?AXV/&.2>M2S+M$DVQA:G6[<@&])9
M=,;<UD<*_V3>]:CTU?WU^OL+&5*]^:2?'ZO'-YZXKI1(7A&IS$<P6!5 CS%
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M[> ;PX&/MDV=R/[_>(1>(TG7<O++-/.(-3_=1*^5L(:0KB!=(WZ5J:H;A_W
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M1 J<S,1:V+*!MM#5IP UJ[[3:B3'O>BC!P[6*QV"-2R 5 JN5CY/>/(/0&!
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M?U0[ 9PZ(7;\T$:-"Q3,(ILD9&\$]P92X+G\ $!YV75"AOS/*I/G=APG$PV
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MY$&=C"9XRX.@VS="4DUH/_.'4O'TG2U&GH>.FV\.5W&M\V4S!+)%SGM>@+\
M,N5V"+[WP 2>?MUP"*7WVJ;@0AM,D$?$1FTV3/PB/#D6J77JZ^Q+YK=5BI*]
M% 5PJ%9-Y %'G&0'%^WIR*RS*<,FC_1-;!EQ]SQ;!%J \,MY51^54'R=_G&Y
MS_4:C(HK(I?1;;"L-L4V8_KVLM^!'*J_L##4Z556,W^_+F9\1H#P7+AS105%
M?L*'7,3DY;X.L(B^@K^JVLJ0R?Z91,Z>^@GQI!3TTCXJ7&FP$@^N7:D?1QCK
M'7.%H[/Y2JR0)(G$-3E2.,-A8>>MZCG2H[OKAD+]"[%M'O5&0YOP"-F4O*?!
MEA?/HCLSQ?V$D.9L,@@<DVP&7\AW.'6#SU>7S1HV3MS6B.TKZ/L4"HX5D@OR
MM?DLDD*ROQZ >RHPR$M$X'G\964)D3&Y3>U@ +ZB9)@_4#O)*0<#4AAXJ=$A
M(O)=1#E1^BD7N[<\]=<]@2E?0,[L4-X"R"[^&JMD4%;W\^@,1K$.V4E*'42<
MS1.GDJ0:^9F#C! XL)<\2)[^N;P415SZ#>Q2/JQ&P'Q"E7/-05<AW33L0NGS
MQ-<_J)_7R<GUSM'XJ-RCU;Q"/$:4@YJ.IEO#*I1.?\,UH4!VBR6BRQ:0Y(2I
MCGW$>J%OTB0;Y'6Q\8EN>E;_N6F^Q.4M^^1$26P"5QPAK4".'ZL]16I&UDEJ
M%SI!H<X,MC"SS%@2:,!#!1ISLJK2C,(YY_!\JX=)YWORDI,]A45T>+LQ/B5Y
MB< >.=H9(U=[8- W!OA90UAF&/<B97_:X'7.6S4XK4IV+KV==IZULE57RJ:?
M[#2/"'96*/>5DQ9RN4J"4^*!0C*8O6PAN:RK)"-=0 )BE68?/=.7QR@DI\Q=
M.3AK:YAI>QK@<^I)U60PD*_680TJPK!FX+__S-]%C33Z*MZU/W^2R!3>[6CS
M5'M)XD>B1=.2Q2C([9 8:&_@,%-UY6@^9#ZE\RMTO87)^%EXT\)'ZE_J$8 O
M5!+:M*KX'V5*^J1IHUARRLAJ:!$!+K%1V)X(@1QYE5^H%I56,_4D\.>@UN\L
M]/E/U6&LH7P"B4*P,UGF;[6N9S8PE]P5@A=QY,WFK<L.&H*ZZB>01ESU?\D6
M;UJ%YC"*R-/KR8P861D);6"BUS/B]ZZJ5SSC+3R0CI\OK::N4\&!![J;QK5]
MK(+Z?*/G(U&46BIGKXC5QH]3\8/?/<EA(L34BX"^S(^2G7.LS"+_9?X#>H$%
MW\_]H3ITEKT,L;G*ZPQ,;^6%1Q(5X?UE.N[Y>$MM1[&7:Z<>_FK,JBS!Z?H9
M[#U?1DG*)%[;YHT^PW<GZ#?XLB"'&WLD;\4=QKQ$=!J=&4 .WOQ%6NO477=S
M)(FA^IB6_F))"E^G<H,PC_SFC0TD(WJ,&K5OT>0^VL[.YVC1!S>?CM(\?<1Z
M$P3[,7UI;7E#-?H/U5WLL^Z?SG3^,(N(.#PZ:"9/<Y!YIHK+ 2#;8S"5<B.4
M1SD""_-)^?=O"JK1&?F7><)G')^)(O -^%E/[;O3J:=)[U+FD)BJX>4,D];)
MG[NO[933G[YW JC0> Q$<84#1-B%WQ'(4*5DV9W"C)/P,EFG*]WC#(K-^5@3
M3<OU+#4SGB=)/0GE FX<*G(<BXTFL=NRD;[T!ES!:CB-3[[H'8KC+52@6ZH!
MH6\H?U1/7[/%O\(E+P;8^/O+ 85R'7(5AR(8D R"@E5?Z1=;'#*QF):$;FQR
MH@S"0*_Q]O 4HS<_PFK=8-  (P4E #29KS>G#-G%AN--8">)[S%FU%YD^*4+
M/I"C?/P9SS[<E?JK\2N/XEBY1D62.3K 0%,-C.*(EE/E%U83(+_.9I;&Q30C
M:[\)X,7N0"7(WELY1":F+L=5[_L.RB]7W#(9W^/TF@G8SFI$RG&.$ KG(;1?
M];YB;.#1_S5A/[7^\3"6\76;.:NNE'9BUVMF$9'<6'OEQ/64K>][EP>$2T4!
M&BW1'.AL*-YZ8,Z[86J,04P?,ZG^EC43)EO&.?O59[Q&]KXT'WGO9LW*E0N'
M=':^/MN<Q7QB#5?; >:7%IH2IO4:QINX%8!2*:Z;5S"R=FOG3NC \V]-1RX+
MR2['KSDD3%:"B(-DS5RS5&V%2,ZKE).+"YD3-XB$/H52?;*V+8EZ]S/QC/@V
MNRNHR8Y^KA8!X]"-@PTC6QN@JN7 OAPQ2G@$OM$8C"K/IN H-\=W3!=.:_3K
MV_'"%C347FH->Q2.V;\2*MC,5,^X(6/H9;Z0-Z[K88C>IK2^B_E8YA!]1:UK
MYF'B\P9GYK* 8&WX.>,@Z7"ZHL$D2+UV']A.HE].6FLT>P2VU)A#X@WL,8H"
M50F03C.'"Q)1:EF<WALV:S-KE).Q41MKE6-PU2?XURYSPNI,WLPTV65T99*]
MO5KXCUB9?$LXG H.;B@J;7W@7D]8V2\8.S5X1\/ILJT;4:V1R6N?2/"5@GC\
M'QP04C97%^4T^]>6P[N)4=Y7'+<BGY$*:X^E$O1A.AP[VLY.I\&&GP'Z!A>N
MF K1JQ[! _O^9G%=^ IBUF4U;2@9TYYQ]J^2.!%!1&6^DK?)9 \EM<SO9V).
M#B6H,?[%F&QK+IO+TROY6BO=5^(<KLO]>X1 =CMCH8G/T?63(RC'H4%-$ZC%
MHDI%$&R4WY7T?#I75\$@5/ZYZP9B11<07SZ@XOBZ[HOB<X;1M'IZW F<".]Q
M2#T4AOU#I*9)1+QZ@GVZ$>GN?E!=_Y;THKR[JKX"].FF=I\IZW.<QOQ4OV))
MD92B+7B3U83D1F4<H>/X)<8:!&\TT7D;J[VI'/MG<$)%VV-KD,K&G@PE]JXX
M*6US'L8C@K_VLZMT F*8CNZ*J#/<,&2."2V:Y/"H^K'%^F'O5D-J_H/F$)8B
MJMV,NI]NV\FTV_9-^!\R/C)T5Q.]I"?2F=YDXAB'GYHY.NT*?L2LZ&&C7AY:
M WR96RYN]%&Y#"_G\KJBZV /9*JK@7;MC^)IA)22?\MK@K@C=0CXWNV;4\0F
M)-&E91.AZ=4_IJ@"$]@7?[3GFA"0*TQU!SGKMX:+6F?YDO[07>WC0<DD4H<;
M6ROK+O'W;A!KE!-62+*(&OUV3U#)-VRRG>+@/QIS]ASB/VZ8@J?!B0IN'B88
M2*N3"(L8^9CV\P*M$QW;R_?M[@U=XX+:R>LGOV (\+V/@G>YS(E<C70&65O+
M%#Z*<B4R4$7(1MM%O?W.-?K,3C1W%W,C=I,.3=="]BRPIGB8I,EH)%5U:,U3
MY:3"87>&_T-,"-$WMUUJD?1??NF[NLRB8&7;KR-Z+O^(-2"_':S6*.^PG,F"
MGAM.8N2H5YA7P<625]@&49G,,O(:'$(;;C.Q8IXRC&./Z3<](1>9&V#":5-/
M3@H 0>>;_J3K^-6#9!3]PZ=68NMM<-CIBE'SY:736X9,4%?(%CB91+IW(-P/
M;H'Z!\6]+VJD%YXMJ . WNHXQI0=^<<?>PX0>$4RF$:97BJG\[Z@X28O^S99
M*A0QO'WD!)O KI=O32X55.\JKS,:$'@2[.KIWXE;'V68,U"DY*J'+U_ZBD6!
M6M_.N8<5UFRGO#:G, :4O'A>4#D]K$[9N. )%""RE,7:4$QD9=7X\(FU*4%>
MB\]MQ^RF>AJ>=BJ?#QVCTVQZZ[>?^^[=Q@]+LQP$\#51%@+(]&(/.Y4#;<Q7
M2IJ%>L2"A[0+Y)F^F;58H6ZN"S2>A@P\GSB*6^_TP+!.VP8XY'OT)'DHX>,2
M1#.'D:<V*A.%1S/5#O9\/E;1U$AI^.@OV0FJ2/GG.86(4WHVF4(FM89.-?+'
MU[$@(0G?B_XIY0RJ6,IZ6^SWEK)2 I=6;61(,9OB]R[:']S9<*,-Y7()E>UZ
MQ"+ O2(I[RGGG\ST<?F0Q;-'5W%R!+XQG_6*I '@<B1D:S=_,<#U,K#4U0<;
M\<V+O"U3!!PJ_FW4H-:<^9R0(N"+2^A\)S97.?81Q^/7-$2 &OPG^IF6DREN
M22& PU8XML2T=O [AYZ03<LOO/,Z6W>P@V'OH-V<67GK*D#D0\(=\[S.+RQ9
M0'O_0L"^*;B7/O\E'*AYW;<V]LKCG:_%CW:G+JG7XWGV74L!JWE:CDC+_D#O
M^&]Y-8W@V4YLP39EF8Z">1^6AH"GR+4F>-,V)P+(/$&Y!U$J4(?C#+ +D-N4
M^C'C;E#Z"G'[KS5MS1R97DM.F3"[:Y;K9:L2;71P-,KP,?<,"WA$:+O!I?@&
M8?>>D8RLG#.>M]C1>-,Z"2RXE;_[4LFUV;J2&T 0LB^YY*+*=,Z+!-7DWR#3
MGWV!K;PO<82X%">+!A$3>Y@4LW2 &6F=VE.!SVJ4CDP!=(3\UU\XE<N>T5H-
M0=+#RV]D?WZ##)3JK4VN:2#'X5ZB9VM31O'A+S2R7T\2)4^E"2@5"Q[#%J)W
M>'A'_O2D=R5;KFB41\4M][?F,S\))7S[?4,QG $?^99Y=8"YJ6L<1;"_J1KR
M+0D[X,/ZT6G-1]^=T)L5IYJNA]>_3RA&N"7L^^T+0IR\&LRSU7,EKUH3--24
MF8M[WP_3RN#FJB0S4"G'4(&U DI,:B9GI;G5G$^_<'A^&Z_,L(GS5A?.L(B(
M$2FOZ2C%,B48G^&);?$BNLC2=Q^,?J[!8_(;9XELAON%2IMC[=H2J>F"I/$'
M@5-9K!>>N )V*09-M);B'^0_+-@K!RPS1%*68#ZL,A:O-L5E[&3ZSFZ"',Y8
MI\A1W*7TD]B CZ6"N4\*=(7TLH9>>0[YO975?R;"!7<W>4G]\2<!0G XSU_!
MB-_14T%0%43M8$I/T*;!Z%P(P&[0=*)[/L:<4**\_CK11>Z^+$!^\8CIAFU!
M^AM!QHB*[VJXA.3(@M.<1S#WT%33@MO$]7"5A*;U2[%<,<H\]7$7YJR^E[1_
MV7<<E"3)%DRV1B22#;V9W"5U:DZM->N3>YU;R]X)"^KN^!*8<?^08;)7*I\<
MC!,8CBGZ//B1<N ;II%I#[.H=5]HZ*AS.,R=M6"!1YK=-*%C/6']]#6 U/?+
MD^+![-K$*>%$]O 4+7X3H@IT0L,N1O,5I$&R808@B.<UIE$)XH9<D7LJUZT/
M%$R'#X>K?.#23SE3M)3+O79-\19.URFF7R^=<BU>=?[U-+'1 9J!^3+]GD*)
M#,"L$M=?J*&=?+0HHL'^35NG*VW.U1EI=?/+JMDA<T'$O@PE7Q]JJ&R;KT."
M[9\O?Y41/\KWI??W4WYSMA0!,P!1;8G@EEK#D:GL0A7X6T2/<V295I$>_ VM
M7ARM538@\PG+&:%P7]);%\OO:]UOE642@$X+>@1=I'%2L?+8/8HLFZ;)EY.C
M G URH@$PHR][Q(Q;YPHWR_U,O+\YEWP5>LL5R\G3O4=*'F120ZTE2HF"Z46
M*:UZ;QM-V;45UGOFIWL=[UUQ"!+@;A +,TA2;/V*_,0]X#J:]X]*A90^%!M)
M#?LGVX0B1T#/1;$'(":%_A&@BOCA'M4=88<1-(]STW<00E/_)#!K=-"$#Z23
M@U1E]O_8MLK(""G',E-1'UG#E/L'*.M\C)JK%#^7)3S]5=U:HLE<,K6N_"]Y
MOIP<[E:+PM-;$GW](]+:&KBI]%WD6\Z$F5"#9S^9JQ8.AB-=#,D)'!!ETV/L
M<*QE0I-^2T_YN)4 <#>Q0^6*#I6U0OL4T6O7J0X+4 @9Q$RY3>19D9YF+6YN
M(=N/M(;/4?-0[!T%MDW.N>4;VH!;7QY37](M'(/QZ_E?Z3G<88QP"8&8E[&'
MVG=![!$+SM\<$F:O<Q$7:[%MCGR"IY[Y[HO"[?Z=8;EZ,]921<1F%([ WL!L
M/1N!X*L/,Y:1FGQ"H<^Z619]9_>N?A+5C$#+7/GDWP[&N&FOJ5;4LS/(6??O
M:>*12TA^C7J"E[PA2$V1EQ+'(<)1K<]PMB= \RU&J$1%;RB:&54^,SREL)'\
MBW*$DLS +@++B]05 N6#8GS9D9A#1@_!YHT%$@:Q=FPC@84N",F0^R"WQ$A_
M-"& 4J[BAWMV'529@U8A.1&;4\=N,ILD3!#NZY+RDCN%E;DUB)R]G;2KY]UP
MI:JE?@S7^&7=A@%R&0X/^+'V<[N^![*:KG+E*#5?#)IL<QU"""IP3!M.82M#
M"QC:U.W'S' ^)F69:-2-N"R 8@E>'%]WT.OR%;EK.S81BYFIZE7HHZE2>X"6
M+]0KML?QXTH9G]&?MYC,Y'?SO@A?.Q?P]\JGQB2IM9J98[OCVV;"OT2\#RU*
M[GVJ1*M!HCCC&$ N%-D O NZKCN*<@VJ:7J#=T,3!_E=/=8C]7=Q]^Y[#07R
M.* #;1JF>KA Y*IDR H6P&LDUF"F]E*2%PBO3O'W]"MVS*6LLV]Y-_@U@>..
M&4BYY![D7: 0:M!99>KQ;:M+LXWC@O,:-/SZ+#^^Q.4#(>Q58SJK-8;CT%\M
M-0N/-#Z.\?X;,FSM?!FQ4MN2:]R%J01P$^<D_Y"/:F9,E-1LC&$O9<KPSOPH
MS[Z.%*H!Z[4(58$.A<::]X76V*'PDQH\ZL5I/..]*I/D!$W@B"'C:Z=R"09Y
M@Z2 A=^ ]:+ND.=7<>ID+V/CJ.,\=&O8KY2Z_.5MWG_RE-.EOL6S^X3-[&#6
M-S<;NG^>!R65K?=5:G:-TP2=R7]#.X-5W/7VB=C)V"N2M3.;8ZA3)H?M?J3S
M"^A@SC#W)APJO)*U0SUFU&4>BQC(*N[4'H@29,8//VL9]7,2"T  %9XJA<UM
MO Z+II0B@N"63)>,R?ERM'YM7491WZT=#Y3-ZX6:$[R_QD!HQ4QZV)+"A?0_
M"15HR/3HQT]F067_:@_1F;B2 -J9#>$-/,?$<*+=LB 4O:X.]YP[)=G'81@
M3U1W051[[QQGZIL8BM%Q0:2>@,5!_R7B5SWS_+<^(,>["+F*Z66SK[UQN!\F
M!T"2,I^B<&N-/K)Z;DM$:0LH,5"?2RXQ$M/^E'8^=9)JHEXF_]U?#G*-X<7=
M4!CK2SAEZ(7KV7[)6;:S5DN%F1D2G+E@7*Q,FMMVU3QEO\;"?^U:E0Q\H!=[
M0VK_FH'9D345S4_-,&3 944L3FC2!%@*^Y'OO5B)849'&'0Z=\_P_,$W%M.I
M_860Y^(8C9XI'THM/50VLY51=,PCGX*7S#%QG%K)6"E$4Q(E)S/%$ZR?6C,J
MAN-'K1<KR>-[[.$D4_;_K?@?2OQ\.[+7+:)%V38%>KCP:=H8[J'U7E7B)6</
MED$;)_$==LO!J^6BM&L-A9\3( X:Z*%WXS^B<4I<_4V(@-'9%_>DFL&=O7#6
MO:]X$BEU/Z-4DDYR&@\[[R08MN7I_00G->IC!?5G[!#EKLW.OJDNP^#N% DC
M?8%DOCTDT#M;8'*]29WE;3+]KF<RL,?LRRK?!Y31<Z?P^<V27C\JEFD<-[D9
MNY)SSD6=?'AWA1,4J3[!#'=%/_!Q>'8^*3&9]DV+?@)AC3X" 9<*;^JWB"Q8
M+9=_;JAP*&^!M@)R_[.<6#G)@5'6 >C?6FN/A$F]LY-+8=DAC9ZD?)_EE&+7
M#41;"#%UA9(+4.H\'3QCZ,':4(A_(DCY5BF1O%8&9R%Z!M_9B7):'L(8S)C3
MZ"_)D]+$85.H8V(KQ?R\4*33*U?0*AH,,0XY8RXT+KS1LFBZ(8XK]IH737"0
MG3E:5'/\32@?6AZ@(H\62>-*5T9,4;419&W>P=JO?K;:2TYV4[DNMN9LG.>S
MJN473"+4?U=?1L85%8CK9=^,ICOE-#Q-P';X+N0XQ\(_]8B%]R[=NU[SI N'
M4E8<WI*LLC9, W]]X3NS!8^6A^=7UMBU!DDN&IT:/:A@.SHQJM;-BW')EDLV
MK*24F4X/)],(:6C6(4 ]!K*BL3N*'V49Y+X:-T(A/"^5UM. -G$I\4DNNDH#
MW@&BH#TT?L[F<;-'S"+#+DTZ_WJ=,3V3X=H3BI VE.R3UULAH9?17!XX1X)_
M]#+5*&.WABJKP:G0_\/>6P;%N79MH@0+%A*D"1YH)-!(L,8"!&V:QMNPAN#2
M2/ @,5P;;]R=QH)#@"2X0X#&);A#("20'9W]G?EJ?KQGSJFIJ?>KFIK:/U>M
M6E7W4_>2:ZUGW74!ZZ5L<SSHA_#*:6<*:15O/3FMY%20N^/Z%0".(OO*W^Q[
M\7.=2JDC2[\<B]9,/_N_-*M\BE;**YC'<LTEWG?ZFAWE9_>/\A_E_VU*&RY0
M_]:$]Z%KJ6$Z2\?J7\"43")J[(5.M#0GT:ZL#R<P[O$%FRL*:@$\W9GSURE8
M?O;OV<[ZZ0 L0>8PYAE&WV='+LU0L(AZ28*5(A5R>W XS0G4I&9_MB'EAQ6K
M;*+G_%;^3&0"J7=V-0W'L@)*P"[52V? ]J%/_Z$&9JYEN29K-U1+RV_:NZH$
MK@D(9E<SMHT6DO;05FZHDM2BQ8+=P@:#I\>X [;$>KQI\9M'?90F0^(98'36
M;7$Q0TWM#G9(<ZI,G6'ZEQ&F7][_0B/U0_O?-%>*1Z&,&9C J-7HF$E"-S03
MK]=*?(H;!1@+\>;HLS D?]<9(L2[+CM%W3_"W:#_*@)7B&/ ;-U2%30DJ-OD
MY$*##M/]F *:O'+A-4B>Y2]R;PUE:]#8K8-G20$X=!=LK+?K/MW6#<KS#SQL
ME9U1U%;5"!_,IS=$'YK*0;4>LFF4*:]DZ)WE>-9!HO7B8+G^WQ4#TE*9D\S
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M[KC2>&^%N+GL)[.?'V9Y+N=)C%+;Z W/UYV6R'77:2*)0W4N94\=PJ5SFM(
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M/S]]D_9MI@A^-$.AD3_4** :LJA#2U^" U_DVN-:9]Q!'6(Y[ZOEY;I.1R,
MZ?JR>V^.O7AZV@Z33A<OX);PM>I8WWK:2:E^R!"GZMZD!"3K%(GY0Q)>&*:;
MQ2*V;6-TB#XU-[W-G6I<<&K.#R!Q.B'R+^F1]4B2E_+[3D"5<B<P=\W<-@8O
MR\8VYO<;+#T-*]42^W=KF7744(7TG%D^A(OHY8+P7:(V,W)1T@:V/!:<F?5K
MT_^WV\([O]&?ECY_2/Z".?TA8;<2_T'35OAAW\1#H$SF9U&GJXKY9)GR7>\$
M#>84DM5D\$6Y"![&(M!)P3!9/DJ(10EJ-%EZ8>K&;S\UVWK8GU$[TB2KKP&6
MI"Q2+_,Z""F"1*I?'+FY2VFKE#LE:HXD#W?0JUK6LM98!O*U@(?3\2J=M-%C
MHL--E.*2+ :5._RO7N= G9+XQY-'UT!?@IPG+%):T"'H"GQO*GV(@3CT&EQN
M)P)XJB+93'"],=TIA7NJ4!TK=FF@Z4WBU=JO+U1:-N?ORJ8S,K\/R51KB)^0
M\1IA:U-QE!1NG==S-<_J(SBE(L0)H_>/]#!76:54 "8QFTK9<G/;^=Y=M^2F
M\T6VLJ0$CXIJ]E!M M]2[*\AOS=B,B05*51Y0R3&B@]8F;.DK385)E@S8K6A
MI\!6C99DJAN=,,736J-OU6E^W/(-#GG X6=!,7NBDE$#E8#W=)99:>4LOV@K
M8_<50*B51!M8='/O@&E='N?H[LK0(_:D;X.B:N%DU#(=@W#!N97,U:]6',"6
M9'$5\5&7F%0.H2^.LA+3!;]]=8%0Z9E],$,=%C#<_SQ@F+R0LE:VD2V&QT+]
M]"//]!:_NRLO'1"/DQX>C( L*(?[X&^&J=Q@#2"V&Q^*)<F!MQZ^UV$TV.SH
MS!WD-B.K#E+0K,-6 ][%N?_/$?O9+6AUE&R=?9R0<RZ6O ;/)B@])Z>@D#]P
MX<AM!Q(QH759BS9+S^UM;Q"(J0]X+_?NN4%FSEHC\7^Q:65!.?=G*)(<$0^;
M9PS*\AH(QFRR"GPJ>M0/V'*XK<VUGMD)Q32"P-^YTDU+S=,$ <VC,E9B7$/&
MBCJK6THS K  ,D[^#'$=74$=2I*&?9'5Z08 >T'0VKL<\*<U[W=W&;YDET$R
M+X$R]143J=0#KC[HYH1XM>II J$R88()/,89'#^\W66'NYAHD%]@7W9OGV*=
M:]GF>,S1.M>\[/T5^S&ZL7S^Z%) S7^&.0LEG'+[UO?L7UYZ"/GDM=IX_R*%
MN"J<E7^YHH7/<V7D'Y+?-:1EH 9DJG%\O)O+?J6NS.(I1_Z5#&.T"2=T*"G1
M5O(4TO')^XGW)O\<B(D 9Y>A-50QVV,K=LW=BZ'EW0FZ51>\&J\UDQ",9Y(3
M5V+:)+2%?G'[R;')EJL!J0V2SU^).U@8FVT:,Q$I6+3/]#9D5+U<&HZW)1F?
MD+*D8,J^VLO)N"]XPH/%O^F&"NT$T3R'V?>4I"KEQB?9@CFSZG337;+_NA@4
M_OMSDLO,VJ)X&G!%*(!%,^WB+U MEN"4[ISOY@9"+4^HTJ94.B'WQEC<+?4M
MLR8AWI;=<AZ6A^$^*/,] @@D#HO-F39&9"&J/ ^BVH\'8Z\J/[*V!(7P=<3&
MQ@Y1?&;&SFDAT=7>2)3AP'S&/OCF=2D&_I]3D/&?Q+:7OAK7@O\Q#3&1TDJ3
M,0"3HF'QJ6Q'.;FY4[;?FFY+X@'5$<UG_:)C!C88TY3^A2YKCH]O*_3TSY:P
MCQO3NG<8 'K,B ?O0F09!D#\11(7.S=.>?08Y1!4<FVR'778O=B"Z&]&?WM+
M'7WI!WE))7 V^TJ=/'@T32?)<8R#5S\&Z""'>XY+2WB6Z:4^8;R2#&8X:7X"
M.BE:#NM4$N96PJ:NJU+Z48-HT1P$X&T63C6I#''-P%0TD]ZM.%18NF9<=$9N
M=6LVK4?A7W851*J4[,/=4 2E:6'/UF^&=.LT"MM8)74&5%=Z!Z!CI%UL+"$'
M7JIN%Z-B 3OX36^G6>%-#)%,WIG]$E$GDB/#XWV+L*N7[,6X7&8%S#,K,'(7
M9_:<KA.@RZH7'X@'J+E0&WCF&W:,ZCQ#G0[CI'#&HP\=.X.,#^<J.C6V&(:"
M>=]IZ!97R9"(TFCDRC6<P$HS8[]XNTPIB0&W.ZJ^Q!QJ7 TU9K5QL"0TI62/
MZ*4VF-8'5HCW*LFRS9966VU > :U90^[1#DFDRC5RL:WKMF*Q_#L<4:L$(AB
M!>S<_GM2M& FOZ^&L?WP!^/4Z+PZR*.P;($A8YP)>,2CMV953ED>+#'K<EZ*
MH(2"AWV_?<DJKX2T.S7"-,*8<4HD<J[2&D@A<TN/[3>\"!YT,>GS^\["$7E&
M40*% 3N0TL%X; ,E+@4@5?H@N.371>/($NR=A8^J<ME-QU01!D;-00AO(K?0
M>],&$I>3M$:!P;L TRZ'.FDP-8,7)L1MP6;>?L6;3ZM6EGMN/#+0362[S6.S
M52GMY=VDB5+U7#<9GR&^9<\T]Q^3IS^7ZE\<XW\W+S_.)=Y;3_:"_3P.^U'<
M&2=]"5_[-7U[[;]V)@'<_*LE>V!7KSBT[4D?7J_M&"[4[)J)<&DQ %.^_1!A
MB6!6X^'DH5=EIJN\ZU+CPW#WFZ(Y$6MAIE'A6>*A>@M<PU_4FL\$033_<)#D
M!ZO.9MN4MB>"W*<$SE!\%]:>43[:N:XT>->%JH0"%IQ@-?M\?=9G.E@7\16U
MU/O1>*!V9)_4PRM7P.03 8.KE]0O&-R_:T&4,[P\7U)2B)>;7@I/O,'>.?"6
M7_/@9\\$YGINOHZGMEH\$-9SH6-41,;H PJDJGL%DD%%#A:7!RQE[]R,Q:L]
M+)%@T#-/_)S):GP,=V#14 0O' ]S&[85H3"RC?F.X!0T;3.D]@N^N8([].-8
M[@P @H]T9V[I%/UX *L;)"O]<4#_87B:/\9:7D?4@2Y+8+I'7]%CG7!TCP3Y
MK;<*Q>/FH.*@XF[+4=XE*#H09K14P(<3R)UNGXF8H0HG&FYZLVY84YR^VE^*
M=I8\M3>N^ER:H6O,43,@,FGBD+/^E:_)Q"EQ(S5X(4R*J\'9@I9EKZJ5N4I8
M"^PXUKJ)F'$S+9:9=R\=D@^4_%@:MO00V*7';P#P:"46+P+.J+<0!T^9#L Q
M/"%&J28A\IY[@SB2K^QZC8.\:XTYC K)L^V=V8DKD@6]L$\1NI5P,=W!@V8L
M2[>X@Q+QDA-YG)"$S\$GP08Y&8X'^ 3*5V\(3H+2<)I[K47]\4)>VT8NO,R>
M,476V8N\.WSL,14")J"S;[!=RZ-W0;H5X]S+_ =#44+FZ\HU+D!/ V5;'ZH)
MN^"<FB=V*_EN/I8IVR7=]9:?E'R?MAQW[R<D7'4_[;J87E^HN\Y7?+C\=?UR
M2#O8JG,]X."3ZT+P%!?7:="GP'],_C'YKS;9$E#GNFDG3I>D%_N8!JW3F,I:
M*T%=V'(7]YUJL%.-]>JA:/Z"G,R_3A/\L5H8A18??C,-S6TC ?O*$<G\JHZ1
M\:L'<1*7;,;F[18&)^KCS7N @1A1_>#!&]T_CGS[UT_3RWX(ZZZK,2![M*1^
M?&.RX807PYAN<ZMRSY#W\/E)A 7[N&;OU3E7?4NI=R;NZD?0O.:);W09<"ZC
MMANA:Q !G :L3U2R1C*P[K'"+CI]FG2]6YY[)AIW1SE.^?Y IZ\XKK5NJ0&U
M?:U%/R-(=,#W!SW&PWQTJ6,];YVQX#2>?E2OPDAWW:.:62*';,T*'*6IYIZP
M3-(%"N@-L$[.[_',0F [/MEQ,R\&VH,KN.Z?6$2]\?I'^$?X/U9@_N[>;7H>
M_F&5P8E9Y39!<Y;9]ZB2V[+TP#B\@P5J450/%^^:)LQWP/\3M_]0JP)X[LV-
M)SO<8L*IXE-*^ >#RO?O2R^^%>T;=]#";KH_;*"5FLTT8>%O ']BI;S^5#7+
M%-QJGG%2]B"07 M!P3SV:>/_>[=BF[7Q<"M&:J]6;ZL9*NVG(CXI.S['-DLJ
MS%":PNG9[K40AR_=1MBV(=CK^.QFL5$.13Y,]H\HYTHEF_^:X2YFE\*C_2<5
M\A'X$G(%##H0TT'"R%!W?\7E<9[G2U\3+S=BA46G2POM"YRB6=<#2^YYY!M?
MNV'Q<90L=?;H]4/5S)XVI<SY%@;)Z83E]N 5+M;3ZJCNAG^$?X3_8X4[AZ^U
M&B(,8[CI5(]Y98UM*5XEB!5A/K]3S9P_%EG7=LA9W0?5+^O_E\YP6*$E&&0E
M*A93JBFCT.,2_@;%.=2F8A0KUU+/$+[':NAJ)==RJM6?/431)/_!6#:A^6A(
M,VTUJ2X([DJ!Y(S_J4M&7]$0C'"^GC/8M?8ZA6_$ *MU2P[#7>';*QH%NG:4
M=50N+3>I4@H3U4@WZ'H*R&).9O@=);>E;C4K9C#6NH#REZN%;.<C&AZSJD9$
M"CE!9FI%[-4DITN" \;LN&AN_"+@_UJX>:WUE,5IKZSS1_&]=8_@U7E)G(GR
M&=+5?+[<PR>W,[DR9\[$6U"I;/'>'Y(.B^[MF#:%>D7F-P!%/5,$@5DGQJM1
MM&IR]@XEX"U>@8ZW$85U>TN&T1K!^:0(J#,8G>\/D"]&8178G6?"9U_5:I=8
M1:LIUVOZF.],!0'/KK7:/0@I\*H;$GPICP$Y<GRP%^-TT"\',[O*5K];;PP3
M)Z;0+0 OQB*JR@"?K5 WC19.G(R+NLM[=,ETO29/_D*Q0JVW4S?#T^!J_]5Z
M=!1IBS_,7I$<$*>BL0_E?Z7)P9P,S&6XDV(?SL>_-<C O0M1]K>?/2$ZF'TM
M0I?,E-<J>D6P^_K3P"6IR^)D13TD[DOZT>NY-\,K5L=/,I;,<2_J=8L1RQ!J
M)]1^?WF?>H9G?Z,C,Z\Z@[&OM%7%[HA6KWJQ57J>H]U;.AAJ2+M2QS_PDI2_
M#Q"8D=6M&^U'.]BL* H+[P^A2XQ3L<U&3^S.A%8,I#LVE-BV1_&L<&+2>,WK
M;165(1=U@\6#Z2:DXA_@N] T"% ^AIN9ZG-Y'GF";=96PMY-"]DZC]9][<ZC
M!4U3_U_O^P58+(J)T4%Q4L0ZG!X=$(4)T_+X**\S\%7Z2=/\ZN'7(_[F/!W"
MH'T[XP=M&FX%%=HK.(2-; ^S:'/KU'(2&_QF($Z_EAXUIQ8W!"*6:^7/Q7!Q
MW4IXR<F/1DR6//L6+[2M*ZEYZ<S'OI?,<0+/\T='0&&KGV["OP[F"<^4[<RA
M#T)8$/V"KH[S.LM"1?!;-(["; 7+0.0GFC[G#T[Z[HK":_1%DM226\(?8*.^
M.O;L;J':[65VI/U/A&*RG:(L"CO%4E?I).W>AK.?BN+3H:0*!C<1;,*.S3T0
M!1B8LJ$$4Z\YX@4L@F>Q%)"RY@;Z5$"9H5[J$Y]D8NX']#)(JC!07;5TNX;J
MMHDT8W\:95B[R)CG@FJ\[ND^;N MS-VV\56N7^H8_B7NVCB".&44%RDO'45Q
M2Y( QSP%1BUK4IIY./C4R+,<@]=W=L+)T2V<VH<<W'NSQ\Q]I01W-!T,KX(P
MA\CJ";_GK(QRI9G&1UL#PB')\7S&2\JU_BYGM.)NF>=;-]Y,"1I'<<N;3=24
MBV1*MH$UB== ZQ$/S/S7]PVSTF6,30:$2B;_2WZV^TL5PN]N/PC/]_VI^E^*
M[J_://V</4/3E44YN2,/?'Y5??#0;QZ<YR*I05;%>]]LM7_U.4?:7@:7:B<R
M^MDN2MY'4$SE=&-^N\S"O5-L.CN)/5K BJ2$]0.^40^:>L7@**O-PB?+4-[+
M8S73C4D_A5QW%,U8JN"HMK?#96(CU$ZB #-QW,PV(Y7Z:*5Q1!?#6-F 8\O$
M8=[C< [;=SK5#?'\-*!V )OQF'<ZT^YL%1CJE4T3H12A:3<IO$[O"=D[Q=VS
MX I9TZJ>?875E^6HUSZY#Z_R57P7%B953@ZV9(^C%\G5EV(3M[[CG/\3]#E=
M7W"N4WC./,V$[1YU+9Y%#?YH#4?G4S)@'H[VN6CG= 2UI46B/PW1XA^6;Z0$
M^(H#GO"T^GF7PR$ET]:D-Y+(E&:%JKZTZ\&3"^TB&*519ZZLL2?L4>Z67]Z4
M(6F^;&ELD_!>N2TSG+.8\C662C:E?9[]R.^F:6F@+X*?=<@OT7=_F##+<_["
MN3GN%:(Z<BLEQLI!LY'5]+VI-\F\MF\T,5(YNUFTZT/,*;? FFZJ+U:HBYU;
M E+S2KE/1I#(3E&N4GB_X0#FXRBZYQQ4\RQSU_"=/&Y%(\YXJ>$D1IG)!E7A
MZD.U&P)GR3).[F==5>.;5\)1C?!*7-K6/@T[9#PCZ,G)6G,PK%J=E3'*=E"A
M!TFI6RC(P@5PP(1/5(P:TVPP1FJZ\P_M:C&@H[)^*]'#H\J'=63J"1R13T<\
M!TSYN.=;1HSY799;$Y15ZT9B-A]"VE@(+.)9//I>1W<*LMLTEWW38^TM87-+
M2D5JT"?Q">HQQL=7L2;[F'MK@%6S@NST3V?1+P,[$EVM_H./0X%AP@>3I5"'
M/4,3/)"6HYD;[ (LLZW.%ZYWD0=?G8EO .(%W%5<+<&B[A2:DL!H'_7IT139
M!%UHOWU8"Q,PF<OT5ML3H]--6+O8%@Q GTJ:HL#/&=62^)!'FTSO"HRJ\6(8
M):(T,1F<;*MWE<NP0QM;U>SKA2?;AE6PSN*P'GU/D-1$9A7PV?(S:>(V8H!%
M-WNZ1AA>PN4?H_;:_:%YEJ_*1DN/"IV4K"O(OG:B<GXC0GYX+X%/.#E*C[-*
MGQ_=Z9@"N-RB'2(+^V'U/ ]JQ?8I"\"K$C9XA3YE48+5+'H1I.*XR^"2(8*L
M&F(EB7"@O%NNE0R8JH3]X\9^1+9 )>-: S&--G1,V:0GUTE*PK-,NU;Y<UJB
M?+KT\$3Z^'Y4*>0&QNL<U_,KSVTIQ<$<+Y609U*37TM30)]#KUDY<#Y<,I8L
M6&:4;R4D3VW@+L^#'N4O]6QN1_V5/H!SUJA9P@2O( FGZB4;'5) B0B8 TT6
MHX9@@)HF657 5XL8"G,9,P]$L62;;8^[K%F=HCTHG#?5[<YDF%% =,-P5\N-
MK,8D6;QLJ/I);NETZ_V;3_5[')=/-_;L010 VX$\1'+@8$+:(#\VOO%=')RD
MA3591Y9?%I)<Y-N7!9*$SMBN;7P, ^D#N_U79>KI:[Y?[))^+)W)YX/>V&UE
M3[!9-;T8]>.@NHM+C(YW"X,Y9QI0!QB66'P0-V->0#GC78TNUS2K*5[)M$5[
M'=4]V^P #J;OB*S/+;]/&=*V0QI:S."=EOTUCECRL,5WYUPI:_I+%?.!2<A1
M.]ZA+"!R].?7.$E+OH39JE>NI&76'SI:W_5RO4CN)UQU_2$A159*TIQ*BU!N
M'1I"#54:M>,D9Y[YKW@X"[-XU[.IXH;*/%/]S.;Y3H)2#\O$!),5F\=:,TCK
MFYXQ322+AI>)K/9*8'MN3.D(4DT*O94V)!$Q:*T5";WUEW%Y.L"C6WN[A: $
MZH9\Y'1)/R$F35'"C) K H\+#\JHG@KFSE?U9)!_L< ZP%<J$IX/6749&CNP
M\,4N3KD);98JIXRZE0VQ- =GQ%<M-BP+121U":+K7.V-Z^EICA@JOXX*J.@\
MNR?E#BG9"'*K''H(M58#JZ7(+KVQ6&*4&F:XW<KA!:O%(,]N\R^#C[!3<8J3
M!**N<3';%G,T\6@U*"2!:>R#?GCY[,=/9E2=C@W26,^&8)7A%F%AYU6-!!K+
M KWS.Z 9$!R(V()6!RQ9F F#C-+=KHH5;$N:M>?[M6>J30 /PT9D<4'935N3
M38061J)S9$ $$*S8QEUH%_[Y"Y.-<//UCWEU\:4:O>5</N.S:NWW,K3>#0-B
M[&UWJC3/OS["$=67,(XV,2QES3AV_NX6< B5_'Q_C<DAYN;E&]ROE.JP.6'T
M $N8M_'))L9W=((FCSY180YDR0LRM\^GVO9*G_!<9U)$3YMNE:97&S!T=[%9
MME1[$[NQY>V)FDEM92)]-D]#?DK<09&N-3^E>0T])^DU\!F]9OA,<]4]L-:#
ML1;(_I6'O+_QTWO%U-.H/T-OY<VG#]EO9>)C[Y$]8]5C_T.2>S1$)@FJV3AT
MU5 B6]X*'0M[KV,F7"6">N[%?Y]K2X4[X5IUB_L;S%5U._C:N3VF1RM9L]'Q
ML6]<D(#5]QKBA"D7'I9II"Z3^67X C,Z\FJ+R%<(-5&$*9HNFDXNCDK+6\#6
M*#-@F[2A 3XQBG?RI/3?&?-LCS\33E[>IL%J"!<QF<H?)4_G<?:EY=I!-0(P
MLEJ@Q)YG- "L9=!!_-9%*%'(DW\DQ5S/#(5KN_.L_>R5I)=BJ%=DNP&!=WJ+
M.?^N\)5^=BX') WE+HC\_F8]I4JU4DSF*^\(S3=^-<YP'UA]Y!:.U$Y*89O/
MX(Q*Q\F(!\/\FZG(*QFQ+UR,T@M<IP%PT^E4B7H6 CX3W.@:]6)DW,=22V =
M+DILGCGJ+7QBL[I@@X]5R_<)F3>68@-G1*_GN.M2#!L:B_&;N-M.]ZTAKQL,
M(IY0B86>W7[>'G KSEO*KLZAI8N^;UGH$ZF;-T',..RY,FG3;&SQVY+Q!'IY
M[<9?U>82<+Q'Z]-6['.^.$L_+8Y:QXN@ 1./,V6.$T+ET&ONJ=C!W8<&]S_Z
MB3P,PSYOT_6U-6BC-JE%B;\>2!:2] N ,?6H>K=\OEG;XX*/GE$NE++/W(@]
MJ$A(I"?6I2>;E6A+@K@72S#>Q6_4;AH'-%:(@92\(:PZ3!^K>?G?>>;*#-V<
M>=!I$=J9OUT0J**0O:P%K]6HT+;EVQHK#K#>R*-I:$)JC_M/AWD'-"@H5/T$
M>+IJE:#J+F?1#<C*U48!RA"-B#*H3 HH>$E%+5^,_,7(^%)I)E16QVLX^>@9
MDR=>JVC6HY+XB686E-ZSEQ)A&A]F'_7Z1E7'9?AOT:]"Z]=U;T5D'.F<HITM
MMO*<EM&2CLN [%>6"$)^ WL^%"A,85!&GTM=D27;+1>K'S2ZW?S=>GE:)IZQ
M&QR[*W,#@94D2%7..3>L7_>[?0N-N^_",##>2=:?<^= 2N$3V?"YL&'3"F,.
M;1B!HDGA\Y+85YJU)60J.QYJ5,DH\5B_O 7;5"#M[%0$)-!1LYE;[G&+K]-\
M4RWY8+.&[I;W>TEEWI]_Q+^HZ2<92%J5U$2Y>PN;:=T]-8X+_% 8?\'W^''[
M::=*[X*K:!]Q#WG;G-D\[ 9 L#59JS0RL$R1(/]6IK$"9:<JN$C*8:[I[Q5@
MHLS+6"%E<6!\H,,GM-.>;<:W5)HA.!M]$1!95:?GFP :(CNK+-55EH>TGF8_
MP^:9H@CNZHMX(W0O7Q5\98-]53%NI_(HAPWCPJ^9"7UBK<=[S#/6-$3_C']Z
M]F2($B,S<TSV-'ZLY[)N[ -C^ [[7HGHN?&WW@<"MLT'9["Z9XSG?D^@P6&]
M$P;)EKD7#^(!170V55D['F9\TX^'S',/S"4A>\7;$:$6?V-!;%(="J;/=AEA
MP-E'#WS-4*!B4#3D:(85EMYI$[W$7+@1Y37; E24:[WFP[0]3W7\]N</-54T
MKWL(AE IV/"I@OGB-/&^)[-'\ET$Y[&8\&038_>&>K"NCD=] ,=[P^?+\5?3
MKT>=(@K**]K.3;KF&'-C\N&2/8]O,FVN:.HVKFVW:5;:$!0T3,EAV6/N)(.Y
M8GER"8A?9W@JN(.B="-?)FKB]3<AJ$Q$VZY%':%F+6V*3M;"&I:3<B_12R Q
MUY=[*MI=RKOSR5Q<W4)3^Z.VX_J6LZKI^T@FW"".?C41KD1UFI)2W1"))9;B
M>$IX'&Y1)8\-'.Q! !H^"T+HMIM&[M5/>C^'TX96F5:N H[TA0T@1!O9!&CS
MXH,\FD?LS&S[&C?TWK.-HI590I[.%AD?II\:%'Y8DW!@"70%5K\G7,B+%=\1
M6N0O5]%T<4IKFN9W*[A%3A2A:_<+NBKV=/$YL3%S;SMTJ$ =,V?)!+J7D5!T
M%*'BN;KMH?JMGO&+M4E$/I3W2 !OF/N*[]+U$'7SPX T&%7NT?-NJ-NR _B3
M%T/"<F0.\Z4V-Z=C4J#6C=6_U*%OI>8; C#%YG0.)Y4TMUZ,)*.AZOGJ"1+6
MXXGF@?S,<1*%"2:)MM,UB_5W63UF17Z$Z:HO-PM"VX87$*"O60!3"9</ZK)>
M5> S,2 F-HL?EDJO)/2E\LNU),8D;Y(#==(E=*TE> MXVB#R@K*.,GV[5J8N
MT$F;S4Y6QYY3W(U@J:Z@>2B%X(D_?9"X1+.: 0N1;7@R[4%)]!C5O'O719 )
M0HRWDV'+L[T1,!RO]CH7Y4!OL1A/FJ9!6&2F0=4&:)1R"Q^*5E!&P6%>,5P.
MCJST,'=GJ.G%:I-YX^X-PL #@-?ZD%5:M<ILXSVCYF/4G;?5IF!' 5[B!7-H
M.8*-7FF$L=QDO\8L]I#3/T^/S!0@0ADQT7:;"G^DS5B]W-1%BRCL%TEN NV;
MCE?PWQ^>5]7*_$NG5<-]@H+/ *4C1K(:#+_>I)EM*EF\BQGU?<[,ALK M)Z#
M"GW;4["KSI$5^( <*C\Z+TG4*73PF<YMY[E<)L_'D#;L75$L0@2PW#TGZ".4
MYOS)6N]]-EBL+Q^NJ%3Y8)DJ$>D'$;%@.]50CCEMQ#O!^6(W."TBFCN^*I17
M"NUH/"<M>N*T5?)>@<4'*^E*.Y19&*]:XD>PI5@Q3;29K*1#AUMX)6E[Z20<
M,1\]0\O@KT9SR*=J#D>@!U)P[A;4R&'GW38J5#!-W!.C8J,JOQPV)T7-8B3<
MW4!&^QO&NB86WG#!+XMQ*YH!F-?X/.8QT*[M[HT78I8R.3JO31V. 2E=3R_"
M^DP/+5BWJBBQDEGU=[6)W#5KS5Z-']]W96N]TZE)#0](4(9EHE*$Z5.^S<]N
M]93H;1>3W^?6]PS9!I!,V;%_Z# ;>=&NQ+W:"BZ UUDBIR>:<SSF"))%%/O"
MR[6U1!#6O?VP) H\)Q#%*+(0U_)AV6N8*7U[HR+<7+F3<:,,86$6 F^A579A
M+*KF2;6M(60VKIM0%@+CO]L]'U2-NX.=5_X8E/U?N5'QO)*([_ X1MWL8;T?
M !FO":"O1 +Z7VU%9 R4N;ZRDFR6>5X@^C[A5*=IY,EW<+6!1 10B[%:J50I
M&Z=>)+;@0-($DMX=#K2' LE!GY,G/_#$F A*5B?0NUP<,=28T_V0X+0+;S*[
MW[VK3F#V@G $T;&N:$.$KW@>SB"?TEC$WTIOTWR(^*;?$XS%!PVH5WES/@&3
M?%',<VLZV,ME.VUMU0/+?TW*1(3HW/%AA-%Y@D>:)EI/DY:^8N=*=)JJ[@KP
MR"QM9"X1*6?U4671\.T0Q^&(UVY#4C?9EMU,>4[IO["(LB=_LZ[]"* %6NJI
ME6IOF.L7TS!"R[O\V)]C6^[&J%4T"87&%1MR#?^E%2]8TZCPL5<*[T&)C,WY
M9M=A\+J8EP6SF'3?2! ))%'7$AZ%%HD;4RXPPBM87+G+/G3=>[4J;2*.C4@T
MC5!H7;4BOX=]&RJI;26M7SW_?MC+Q=.A+\$\4'8J!=B":NB]K)R3-RTU^7:J
MXOX+.'55F%B.A-)L(812'AL],PN)A4;+NRNZC]O%BP:,<P7;R >4KSQCG1-Y
M*B;5$DR#VNPIF[:;PBD.F'=U,!T!+C!/0N@D(VXP&T8Q1V8GJ/$.B:,7L 4O
M16,'E(G+QQ:E<@ .)\:RE.Y$M!ZVX0)D9\G.E#BD\&H(SYLO$GM-L)1A2W5$
M6"=/ A9<O8I8>"AC>,<PK\"\A9K>U %3K&9I3P]5H6E?1<C/X?*HN(FF.V>C
M2EK?Q-CYXLQ+R=#%[3B3M_JL8D[QSDM06\F! - 7FE*:"2F#VO@CMR+=^.M;
MRU03E9B](O(O:&:#X= @$:KY#H#RVK_\M>Z6OYFA680ZNG"^QLS.[<P*S^R3
MIM^<JYEY_95TD(&-BIY9P5 #:IRHYUU7I[[U7#%$IPI]1&M6G/5:6,*>Z-BN
MCM^F&FZ@1'27:&D!FUV+NBKLB:@ARB\PY4Z+:K3P'(>"T\QAV@B>^GR%9:*F
M+^4O!EOR02:^4:&2S$1;"0<^UFM@AV2/WQ!CA$GJD]E3@P<J[32^Q3,V7(G=
MF,(,8^MT?CL'*<%DUIK@]F'?%B1N*BSAKE@L^=AKEA3N/$SAS#0U>DO0M_ZY
M*B[EK5TN>WA/97\"SZ1\+BY&S\A4SO6DNGBD\9NRBY-PO3Q9"1H$ELNC?Y7X
M=X\T*L4NPW(\?RXE[\ PR*;+*;#9VX H0AU^R:[95\Q Y!CB62CT2PG##RT-
MTVTDF"P:=SNF\Y&V(GZ')G(JG#=0A6B7R&K,TQLNZI4(074!/:T(<*@,)91J
MWAJVWU L^KQPN$[3+@,@\GS^^23^\_FKD>VB )J*S8Q>K5<#:6EOQ89:V:+S
MI6TJ=%%_'>S:CF[8*[&N-L?."5K2H3K3?9_\HG6#B2D1IPTJ%B#:=#4I??1>
MVUGQ66PU_+R#> %C"^QY@7JKJTEW(ZV>;!F6HIM-</7.MU+U/IL>0VS)3A%;
M_P[.;-AG0%QRY"[&A_$V;8L%O--AA:6LW5R DFN*T_?[J=%GOKGM#D.8]IV&
MR"EZHH'VG5@BNH\5]AP"_2DQ'&:]>EVKB)I$FIA[<< +:.J$_?+YJ5^S(U/2
MED(#T_!4FX^8 V2Z-!$-C)=E!M&+=W&S7D.=O$9T:C'F(.\P)U*-]5TWG=FL
MH74&UM$/A/?,C=K!96XN78SO-[*O2S!20QZSXJ")%YG+EA6L2)T[]BGVH([<
M+GL(WI":Z$9+Q>-.2:^D?^O!^>,*8Z&OL6OB@UE/$%B\,_(0;ML3HU5E;F>&
M5R!AZB%_@C-4PL&Y90_99 B'&,N[?\>HWU1O!,Z/2IKG[:2?WEPL&*4-B+*I
M(L;B)?:P2G"V[='D><D23J>5!"CC=\(*)PE&9O'ONLC+/=T.<L!;=A[2*=+8
M<.G4&M8(@%V2L7[4?!5*E4?5?0WSO6[YK'+W;K:"KWLR;HZ7CG&M&'23!] 1
M)@/*3X"S54T"XTF>I<7OA6A2J.1737>=6+3<S)3$O@6'8=>>)EJJ0\Q1[,%5
MG\79=8:I6H ]M]"*- $EZDF!H:ZFQ?G?5HUNVEB%<W(DAJVP_]@8"]N#.R2<
M5EB%*E&BG)00_@PNQ*64/:@\W-B:F4*'G--#U+LI#M@JFL]P>!=5ML'Q8JVZ
M5!=2VP\R5E(F^[O73VDGSJ8+Z+JP*"D$8YU[67\ZV:*KYSJD*+HA!!,GJ;W2
M$5]V338P6R[&NC(^$MI :==N%QB9Z .IG##K%-QK_T-R'VU"G@M$@%K,.76Q
M9>;=0C6M0N<\^>RJ!.B-'=W[["9#&M0%7CR+EJW#$<[;'&%Q]$NE<Q[9>/:M
M;3"J&%&.Y&ZLZ*V!%HAI<6KQ%,H^6Q=G8JNQ(WN]7(UIWU!IT/L[YS!G(_?>
M5"$B#/$@"LD2PM##/*-T!J4[.8V[+3-6_$%\S5ATISC9,?,HP*I(I\S E8"7
M1_X%+T2P*];X=,Q1VS#U4'>*6U@*;&D7/X24N3;66;494F;<H[ZZ-4TJDL02
M=\1?.RUR(\X@<O_-+<$2?;S8VPM9?>&;3'%(UE]OAL.O4B.N%W_2KZ'97-.+
M#K\<S"WY*2QPC5;1%.Y%I/\DX&U1DA>C:,E0&^:F$3XQD8&<Z"LN-/_8BQ9D
M6SW,=K!:2TE!@A]5_91:>"?GSK9;",Y"4"8*U^=BR?4S#[2#H5E_]X<D[ GU
M7< %<V-H2S9=]M$**O*-3LR=H>K^#MX9ER"2FG@M$GH!U5;=YK?J,04],:V[
M&>@82,L1$D70J$AP]^"JX@3D6!D7$ZM%719KPH4^)V,9QW.?Q#%_7R6T;\1V
MT\>@\1KETR#2RGF^V;+L#!+"PRCH'I'ROF;L]6E?4930ZE>AZ4K"U?[3]?Y&
M\1_EZUVU&[/"J>XPP_ E=DRB*WN7D)9$B"&Y"[.9A@*]O7_/9IJD<IT/6^^O
M7D4Q^"W%,OO1&(UV@=F=2!RH$KVT:IQ,H"#M3[E*9XYB"/7"Q[ N+XT@!T9(
M=S;"(A[&17)+2VFW@4((%46DK#1+!GXR)P7]QU*6=R )- $VR(]2.JFQ.L2B
M>!7*9W<]YBI0-9L?^.?%-M4?19$SESJK(/<E!6JBA^Z\=W8G*P,/33DDQ650
M?H4!PI[U\]3;BF8K&WQ,4EQE'6>"+,VQ2LP[W0DW*6GUYD\.^Q"])1^4+"%^
M5S@]S_MKJXC_L3,J,[T+6;G@XG#'+LS();J&/_U1=*_\>J+U&L$TWO3HO?#.
M>9]YRS&+0X=.6Q>%QVR=1 (@*)"&E#P<KZ^MU !145":0H#LMS2IJ/DT(V[3
M]M<;$8@VQ'I*]MSO92I(\OP;^8W[T/!&314P!U\$7!4<\0-R$+351KI=C*ID
MT@TFEL5R.>:)9PDE/U9O?3\B2CY-7I]PJ2V_Z-@"V0_'N>)-3VITI&I_S'S:
M:)07I#EL$WT*$X/I;0E/AR>34JOQ;/EPW5;CA."*Z3[(ZC'JJ*<?U:IO[.V^
M=B/@8_V-;-%+*C R%'S^R=U41(I+Y7+I%F)_[AY,]!(6#A1*E=_B6 A7=/=?
MKS4F2!-0$1&457I9I/:M;U:BN!)Q[$;A=G11KJ' 6PDV5 O@!._B+:ZNT5OH
M6Q,:W8Z8K;8C3T/]JLD$F8(;6\QFVPE(OA+DF-1##,Y,R<+^UA.AY6,/&6ZJ
M3[%.(4[]>(PYGEL#Q%@=$>X, X$%Y3\J:G%:F-U7-KT QH"U;1,4S\0?18 %
M=XOFJI!Q6YL9[!F*1?H9],HP_M&RKWCUE$!>Z_+&A_=[TZ4'O$S7:ISVQQS]
MV$]_Z=3,S@P5*LZVI#09RA@3#*H,4WF_Q#"2BC^DY[MG;,<?H2< <*AA:!62
ME8NB<6=/?-Q6MYS7*V64@G21<6DJBK](KSS2*:,#:4/+2A?/=R'^&<-\C$J1
M&;HK3BQ+&X@(FN<+!E7&\W]UU+%^+4FO>*"A+="\;&,_[-M.CB?8'165O;?G
M>64CNXT=HEP546OQT&W\6&+\&%K5WWR86(/:SN1OYTS8TN #F#J:1&YVG]UY
M?N38/N'=<#?DC,U%5G\"4P$_A+*?=NB'#9YAM<,IO85NZ\>K=U^2@KJ2N\GK
M8X73KFGT"N/[1"JO?UGUU5N@?W;:!JGS?POW[@N5!X#<9$U*PUQ)\RPR_6NB
MC+_U#N/8D9J6=9>/HF+P;P!6R8Q-_AI@H#ZL '0'^XH+?2$]9<B??*N)9%H_
M^E>7'T_S,(OAKEUX0!?PW*Q7F^INA$$97)>^@]%!+=U!BC\B:=0K#Y%H%&$8
MR7JT,>QFVVJ:1,<)?Q^^AX=RF*)_H<%3] V"A/2?WZ1X4 EW5F=@5U*<@R03
M(D7X69*A!BY^-T@(]U8<DD#'?;M^U!T;PSU<4BM8ZS%*85".-7/14;04S.7J
M.D2>GW"?27S;#&KAW+\1/63W3=$S1+-U?^&^IY>;A9&XJQ'?T@*K+-Q%1Z!A
MJUNV/D7 _@!..OU6TX66[2<F3 ?$37=<9;>6KI_3T[]O8J_7+;Q=C-Q'MN_*
M!FG&Z,,Y!]CLC3<HJ,(]DSB=ISRI&QF^V=0;%J&*C$%&R6E'781GE5^6PT9
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MM$U=4^UK%F"4:N"."XZW/V8I M^JE*?9EVQ6E?7@K@148&L!YHK#45<H<=\
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M)CTZVJ_]%AHF(HD&2*N8']S%#WMW(UZ+44@%06F0'71>87U"N7XEY1K>U!7
MPU3B9N<5E)L5$!F!8H^'(SN)WU]&84P=T7WH\H4M:S/B=B=PTR3.8&J)/+\[
M7*:6 <*=)(.A3/6&ZR;@'9P&TVCL!6A$-%^XH"K\W.@I[\JA2U/AU:N['-=&
MAC#8/ ::HK2TM*5T31^:VN+'TLD4"B%#7.K8??1[G*B(5D;^K_*"2,T8"H7G
M-L0]\OUCB,#LK0XX:)?$TC[!".,$%@RRQOZH0L9[9'I;,WD08(#%0ODUN%@+
MO8E9:$NA5AN/+A1K?R2LFNR#%ST-5K@6 NT3F83_GOTILM%_R<7E#___?#W#
M&1>$#<XQQ^MQ&#V2'!&_>DGZ#&!,H)=/XS(;_B=>(:_X<H+#)\7ZMBW#4.>_
MAB$#07^@'050-G\.K 3&^ZB3^!Z&?O__3?2Q\._C<>L?NKCD\X^X6SZAY1 ]
M X[>:1Z_-/OAY!_ARV&UCZE^'%/+A\4U@<)4!)/#X\U>Q#1YQ"1=PU<_QS^R
MS< TH2/&<;+F_PH75W23?]5P6A>D07P/A8?]YD V'P,7UR-%S! C,>D"XKOT
MC(>:(J]<KHNKJ]."&(-^9<H>>.=59%TOZ.K.]%L<S+S]T/!%M4\(\_+U_I6\
MCJ#:MQ^1F+0OSB?IDG<(S"J/D7>B)9CTL4G)/.HQ#]N];GAGAF76O[6O_,&=
M.YRCN\H3]&.-UUT7_"8O_F'O//5^V8;C+"#R6%N(8!B]@"HC#6>:-&_I1D9T
M3O4R5*E'A$60FT+G'G*=.@NYR>G5+F_Y5$=]I*K:*<?J:<E4G<8OAOJ&.&4F
M+KAR#RG>_(U*UI0V^+;R&:#BW?B9A3XHZ$%M,TC/RKE:![TY$. ,87LK(#KV
M5;P8N(^,DF=>0P=@28=!EVSU+.L)Z.RU?= ZZD&:O:36Z?<JHJ,O2+8Y'V:B
M91=5&8Y7;_9.[<FJ4S[>0,6R1'N8\(E"VT#/ "7!5\AN\Z=O%CHPNQ%,7"$<
MHPZAHE=Q*N2]S-2@H&&SA1K%'90.ZM2\)$X^\LJM=U(O![0#N5BPTD(B;FD7
M9"I1@E_K2_CP;YB,DPN,Q6](6'TPG<6N*A 6XD:UFE5%$\I-Z*AR6+O!,<W2
M(\3IXWBC4?L4LSM>DW[8XENX9DBOS1N#'*ZJ0(T 6=+>?HC2Q%T$I^K>L>6)
MOO&,K$BM;>)EJ'T&O.D2)N27QWT=Z\K+2\N#..'YDS!]P:'P<T5LS$U1KK8&
M(0H<^%,9[F@_'"Q+8O>ZY%L6^6\%CF&VO6"5T&-ES-]'J)=0:#P'2-Y(%0&K
MVJWP2*E#HWL-[46<*7YIM,K'81)?[@$37@+K%L]].28QF]) K(?Q;[<"!VM?
MHW]]LY%B)#Z^,N TX42(U&-*A" "'*4J1]MDQPE.?68A(6 DE@=*L*:<VY0C
M]'[$6Y 70DJKT4V0:AK2!/=:C[J&1.29\04BQ]E JJ1BDV+GLWAZ*GMQR1Y?
M"1<**J3N8BT@([UU8(WN .T14/$LK'88_!#..J.GS4=6A(/@3_U8 UTP^CGN
MIF!MQDKM9X4K.CNQ$.$Y0\/Z-HRQ3>='%;K_._V8[$QDS&-S1N8MC=<GC>$>
M_"1;ZU-FFIP?4B5[>M-ND*JD4EK%,M!47E6GRO6VGP,.>$KE\GR0"C"&%_#Z
M[+E/0UW<I2 \Q&].G$S35;V9*QN^:B@FXOA1A7^11=-]^DQ&KW)%MDH'58IX
M!ER1E+DCUU@)O)\'>=4YBWQ\C4^CW7-Z7,K.4.TS&;\&&76:&:MJ^K@LIFZ9
M$"!1Q/QX$7GDPK6FFT+':H+/_8!E'" MH!MJYI86;YZZ2<\18K>EHP\S@ZKB
M^43CCGB*)?-\3I7'6Z,(B 1.CZI8CLLUB("Z.NHFSM.S:/?9U]!1*K$M<UG?
MQBO3)(DR6\:!6$/CL.@&^<?$0\3>8MT@+N$*$5QCA-?W_-6B<98GEVX@<6$_
MI]FO:;V80F\].!?SMI_H6305/8] T,9&+:]4\@']58+9-JVF1=&[E_LXSL&3
MD5?H/_,BS$SWGP'.2UEO<[TNZE]^E=/\RLHA'2X8GZ'#:&.U5T3$"1[\1NH-
M3J<ZP=Z7><5-XIW(;!4,U[8DBZA8ZA1]6#Q7G3(SBKQ0U,0:(#)A"MZ/VMZH
M-ZV.,>2^1KAJ%) %> 9A3&<7.7'>M@IK+:"/(?_!/^'FPL6Y%$^9V*RE".+N
M9'W 6/WV>PQ#@%:=* MT!"$9;KWHE<3+'=###/(<._1:W%,(Y3445T4^Y?W&
MS,V"[ +\\XD'\1(X?ZPT"B%$ZY\68>B3R;-U\H3598F6M/.7S 0DWNIE<M6K
MH.6(L&BSUB8U(#;^$)"^6O@J)MJP1_\]K7P,5E*VI4Y!M[9J_5NM9?+;C61@
M.?_[H26G-]JRUCZDQ'-B)AWC \J61-7]5"ZPP*9CM9=QI; -9R%\^-?F<>SF
M7%@WE'XQJMXT2)U.^2>/&O4V*JH;2,<2FU.'NI@R/O/1)N83 XZ,2BF_Z!#Q
M!8!QA3_?55HP=(BH%3#\SL1<0^XS1[*3WPC[7S%IU3?.$P70$V@U_!.U::D#
MJ>C'Y5U8/#L\+S[QB'OG!;L[KOLP*'N-?XV1;V,A>*V6Q\+JJA9:\ T+VY"$
M7@E]U.9&4E<LE22,HUPP3JKHO;'UXB)>WVW@KZ]X-+QC.;B?CF3$YR\!PURQ
M)>.'K$!?K6? OX*V$W_Y]D3L/X@XH+,8D2L@!AB;20^7OUXK578.#QH[>.C/
MPF^UWBOX]9">FZ3]WM9%1\_N\8_<9 CZ?Z,IIX:**WXR. !(1$$\KT!J:W>/
M=LX9)<=:^QF_'BA4.:.:A%UMDSZ9FN48D77UZ0'+S O(MMWW^8FPOZ#+["SI
M="SU)" ,_BV9#J6O2H7QDVK("I;9<&[E&>%_Z6NI3X]6S0"B0M MU-9E,C?O
MH5$;0Z*OO8:8U=KT&6?:HAXA&,@E2,P_4&</@Q$\C'CZ"<\ =A'N:BP8'420
M1;C'=3&%O^B.:ET =R"FOTI^%1#W%KF*&J")VI2QDZI3U66[?N 3*O!E1D;]
ML_<O*SI&=K&JL.DA?,6?JG2LPT)QE 5ZMA20[]KG]ZD1X;^Y#R4E3F(K""<3
M E>TWD\7\5AM'A4E?8]BY R+3Y1=X2^@87JU)C4Z/#2TTO7#&1SFNF/GT%=!
MS[$EO<#%%@&-2@KQ.<>5/=\UN9&G/*-5Q0XW9@,L8._HN.KXTB3I_,FD6EE)
M@_87(<*K;G/3 T/EM%*D?A!O)V_OUF\JQQ$6O\M$H[*(+9 7X/PL>T.M+"@J
M]=]XVBO_7LNC73D#DC^B,VLH7O(!0AY#I$AD/LCY]2.<ZM'462&?,[MI0A>8
MG4*+.@Q"7O9 2K&2D3L'U")Z3BB EJ&^)OS!2&D[/*3?$E/"/K<D^5(<9,1_
M#J>+#B^XH;LK7P@ P-#T1Z8L<* ;)<,_;A<<?I(-\ZVT$GZ0YP/$2"]5D6ON
M;B,L$U#JQ''W/C4(&<ZD-KYHALH?((>DHW>YT:/+)#BMEEC,%C<I$WU$U_S*
M5XD$Q?W( 29VA?  %B/Y)WA%WH _VO!^Y3=<,7NIY $ X@2;HHD&7#^U.\,!
MY5/X4DW[."VZ)9A+5%]E?3)?]BF*.EZ^>IO8<>!L2XE%9ZA<JAORK4M(R ES
M!'ABD8O8W!NZIZ+Y/1S6IT>Z+[]LXIHOPV*^T84G9+J$?6D V@T,H4!%63D]
M'P[$Z9CRAIOF,W;=6%L5A+\>7A;?^!7Q\3V$$9^R:^;']@^7O>,;*T59JIGW
M8Q'F^LJG43+SXM.<U:TMYL^ ].EU3'RI"8@*LSVN7%]36 F9:LT>^.,8[-U0
M_'\=,/KX%"Q\1!+V*NV!J"B_[O<U(3=I.E[\%'-66H@5'/290=,>/R@U3F:>
M)\2+,L+BA0F^'%#-1/[UEZ"5)^Q8E\^XZ8R4"=&VV4U7+MYH>C^?SI\!M"',
M^@7PQ(=&+$J8F16Z49%28,.F=#%7ZQ)3C>6)+HZZ<]"]@*Z!(GF=[#)0\RN:
M^1(>!5FP'M!9RU<\>;3J[KYKH*.@=XZ6=JNMXH#]D/AD.2Q4[C$7P=AP1AV+
M(^H28!G^<Y_DHRB,5^B#R6NCW@7UET[&!5'R8-1BLUWBP\"X3)DP%, 8G9=\
M#0N;&N2^?PMW"&7+TY?(@3,:O@?KK H_>(LQH*Z.4BQP\+[R\K+(X3&]IBK7
M\?B,RT=RT,$'E[0AE RG*-S>0/8[E"9'&5N\S L96?A54\0@<C+%(87J"VWE
MZ$ZC06RP@-&ON.JYR@2<Z7!Y,ES^<'P;EZX[Y&WJ5+0!>L:9$1K*)N.$,H(^
M*2\R$)0^T4.@!!3.Q(MDMR!=V4SY(B4JL37[I9E3RUK<:AP*G06JN&:8$Y-,
M1B(MUJCXV+R;$IT[IS65*H5K.4'(YW"5%-01T8+53)\2XA<CN%M^/U,6 %6"
M >CX4C6D^09TDY:U*77=@97JSX!FCNG^9K>O2$'8/27ICM(?O)A/:Q+6))H*
M<%B)R]&5,;"R%=IYR;L0"H QYQ'A80OTKDE)6JS$SXT*DU<T']#!_[4UG,"K
M1D/[0:D8&DK8.I1S%4[>%[N_/X]_C_R-D_WEYT0*$L%1&9DG@V_\,F2&&2]F
M\I4W&6Q)OGYL+A2KQD%ZW5P6PEQ*.A^9<K%H'/C=NBF?<2@J40JQ%<;(-#0]
MPMC@(G+>6'8SA-!^UPQ]<%1!HUJ,80T;1@/VA*)@F(33T3\JFP!.1E\C$G]Q
M>SK&=,0;/>"Y!7JP/' 9]S((5A]."?X/VKX#*HIE6[MG&&#(PY"&/, 0)><H
M.><, DI.@N0HPC#D/$3)&41$0$$$125+DJ@21:(B(!(,((H_>NX)ZO&^>]Y]
M_UY#=_7NW;N^JOYVU:[NM>B'#TI1]$0J-4'YA(4D0^U9YPUH_9[?J92]1&IS
M[OJL2#6*]6&"AYI4GVDVVZV(XE8WN8@4._3J$<);H\NB95O[8#:JFDQ!K&R^
M%K/-L:=;>\<X_ZK4Y&CK%V  77AUZVH1^2S*)]/IX=KJU%"R0IR+]1ZIY9R?
MZMV:WF15^$!;@C143Z?#]'Y#]?5EFL*00+G)F/0;8W("!HC))](YO)-@K<\>
M]_W*VF?8J0F(\.KFQ 2*+[9"<7+*[]J.<4&OX%6]24ZN7$6.NZ?8)E _M;,L
M$$UG[:G"ZC WT@$N#@^(9KRQU?YF EQ-K[9U:G K>+;4&@Z[5!+K</8+X<SW
M'T8<)0]GEGXFHTK>JFT4C*86@<18FL5_ZH2(IDT8IACK^Y?'8VNP!A4=F!"A
MIV<$L^!G;UE;H!4O3DD1D+W<_P)X1\=LW<D+$!>'V0IC*6HRY/6C_YC>_<CZ
M$1/OM$3&<)AU720;<-'B%GUF$T=,:67"'.KKPL'I;F;3M#GT0*>\DY)C 1X%
M_6<_T3I^N#6K 9P$$(.UQ^IT==(7ZJZ3XJRUVDDWM:'>-W%&,MCZK#= E3<N
M,F#'3W)$DD'Z+AT.E$):$8A,C8,D9^EC)H8!]>ISG3G1%&EN#$!PJQ0IS<_-
MM:58>E> 0_Z<"[.UYF A]9I,2G0K?5*'$''INR;))DL67$'M>ATEU=<?<^<+
M _IB/ 04"]L#/C%0QY%)RL6]?%DH3+CY_&.O7V? D1K=/06,RAG=@+!-,L$W
MF/?Z+J'XFX:>EHRNCP1T7FL^1CZ"[!_O;,C@#6M\ 89/A:CUC'H+OKFL?K\I
M[-['Y90;YA<>$!<-V@9Z;W*2YR@@QH[MF>KQ6;\ ;R'AS>5=15E7H?%,JXL,
M'I?21O(D+\'7=Z4@("-9]E2+=<)^HD92(X8G-Z+@*:$JC'B".23R);04(]S^
MCHNL7*82MBJ;V[I.#"-H,A&+(8T,!0(F\X]A+A"9AG7<PT<0]VOJLHN2G-:9
MFU.2HIR5GT$D:SGIA-QR'1ZB3>'K:#UJC6)'"39J$N(YY=K2,"\6DZ;W\G6L
M@Z  .,[FY8F<\(N+RF->EK??[&2_32,D>^/2@1 H([9N7)@RX&PD;[XN;%MK
M0Q'/'1V?;P=3A4#2K^"-3B*?OZQ6/)RJ5@1K03H,V,QTTO(0MLR+0EH"BJ5C
M]3[WM*$8 E*D<GPG3MEI&8<IHB[<PBO5*F7(WB6U5*#?J4Z"*HJSTHBKZ>87
MX(PNI)K;0SK+J)-#/*%<'[,5=8W%RE=P7V:;8-S:-OOY6,&HY"!7]%"=3*A-
M'.0-KC9NRHX%E_/K2DWTZ1!61$SM4(,465Q^P^NI!YN!@NT9;8[X>O%TG?F)
MU57*KVZ;G^K,MK#N.1?\GJGG)1C!E8OW2I1X?6QX]0FK0[%/AB:X^;(W*[42
M>8O*)<5)SH:SQRM?@( >>^T+;79,8V(W?#(:GZ+45ZFAVD+(WA=? (;2.,NT
ME^ " \(KI7SG:(D2DZ7' *64M?"8B!X*_&HY^J3]#(W$&+9/,DMB]BJF3IH(
MW%?S1PF+X/?WDWR&K5NK_:*WI!LO^9JJ)LQ+"1K;54Q<C)3 (>1S.9I9J' 1
M&F10*8F( BU%]V_6&W3-9L_?AOELNS FPUIBM J#ZK@7&?"O7$L)5KI)>O\6
MAVS/\.==J/-\?23^%(RG5(SR8_S%I=K41YV9=^QVMPWR3X]GR-Q1F!G79%F/
M?YX[L,0R9,K<NT0JZA=ARVXY%W<I-^%"5JXX@ ,#" EEPQ@OL75%'<WLX!&M
M*]/P2MQZ3/ : MQ<A09E5U9DVN>2#"@,7B/A3Q]GO: 60&H^9T0:F?]^0;9#
MVH26+XG0W:-#UY00;726@[C4_(6D'<F-*(KJIWQ@6E58KKU#W!WM#XV>MD[H
MC4Q.??8NO-NI'$:QW+/2RZ[62"?>(*9I<6&5>:0^4]E8=^.F@H*;'O[YI9*G
M9XJ\V";+/0(ET.PAP0 /KC!Y(CKM&K89/<=_K9IB?=?(DAXNNY^RYJ@[?CJW
M/0'']$8?"64CZ_(+.T*BC&1OU7<C-N6.(.H/+#PCIT"[0L@.&_QF#)Q&,VA"
MM?FN&Q'-[7?>2\2-WL;@L^3=G?P:)S-]1DNK'?19K8:K2N.8W2:I^F"&>G&8
M?V>&V@9\E+8N4F I%@,JCTHZG28C3-:URFLO+JR*C^/>#ZC";X(2E#$T0;6\
M*01*%H85\YWGI6*9M W*4<N1"G3QI0R=S]A=$)2#"!654%:-8B&*=S;S%OX!
M WVVR'>>.\D<1(59\7B)Q&+O& N+YO-[G]P"TT==HQO>%)/=CI9^,?^$!W')
M,,WLP[;$\4MS0<-^$^'QE#N6BM6QJR$R#LKTV@\)IECR4@(?/5:SKJ'%?R'X
M:.O%S=F$=D4_#>R@KH)>9%X=>YNGXNF^&$J]L[16-1F7V+<93S.XN=(%,7&L
M[!MF'BL?/IQ$5BTGREHSJW-<$0Q7]_!.,PZSBZ;$& + G;:G6C7=&M#,2I]T
MPQ*@,91\6[5L&6M ON%@;=NR=^O)'D()@V!7TGBZT3AE%,7^UA1);L>RJV>\
M82BO$[6X^8J)DGEA%"UX3@G19G>OOE3_,7-AR&-O1=UH_,;TS"?=Y5/V37C4
MZ8+Y<(5#V<JD^]J2'_-F@+JG6[1&,",14T@G>S-\8O7-6#E#@DW[IP?$,&@&
MBJU_%9CL^.R:'\AK94^4JOC4I-61DMB>_GKK50L5CU5?>5!LRJ9/(6,&/3>!
MDC5-HEVMO)5@-['@-I/08QB=KYQ7#*$C50?XL[ IB11=_U7'N$AXCI%S9^=1
MBY',?"JWP5()!#=5\.)0Y03OXXC-Q,&E)&)@;0JKT _"Q065?A!1'1$DY='"
MYH#AI2F:ZW8+@"X&*8O;U+R&7Z,VE3H7_?B-\QV5\#P.?O8':;6"]NFN; 97
M^R?Z)EH-HK+F"D1X*N('*&J*-(JJ:1E56TZ[8DF4*M*QZ32^QL\D(6IQ0PX>
M6S-$0&D,K<MF1W.@W3V 4J?S#?5#0G0R%'!-P=<3J>.AL?ZXS)Y)Y?D^30HR
M\'!U5XKK[F/.^<J/#'8((G[88,+L7JW*OO4;512\,TK'['K)4P\DB^+88XM-
M3AT7*_>W(DC-4)ABWZ"%S;A Y%.*%$])9'SL626)'.L\+LT BK8+H;;ZK'O2
MZC1LMU"9M5UEDHU4]-X)KRV@2"0IF6_Z\ TN&9G$=RTO21YGOWKW(BB383(_
MR5+L)>?@%GHADK7?!H_TL>E!HWMN;E9<X7&3/:?UR809>[&23E%:(N.&1ZWI
MYK/L(&"H";]L)^"G.:<5I.(X1I"O-,BNHJ<L#W512BR.*QH_QTD5E @AX0?.
M@.#DJ#Y]PH2):%OT"CCL S%4L\9\)#Z6-WNE=$]G&(_UX*UX,XTMM_]'(*E%
MV(B'I[0JRO7:N18=XL[2RQ2"Z2R*K27^:"6%A,=N0CT; 4P)!20V#LE0DE#(
M^C,[C4[T,.LBE16Y'?\+Z&P23+R2?\Z!R@"6=4FY8_]5'_<T--=".F'B_N=5
MR0ZH&:TB24&RPIP@(\ ^VV&UO45 \5CKK422HO"BSATWVL7X&_C1D&R4*(5[
M\)!%IS>];/MRK\V&>_@\\P([%Y18UA</.L02C7_I'F8OF?*&MYM+E-JC*I@D
M*4[4,QN-J-+5,1EV%CP#L5H1&:B2OTN+G&IK=E<C3+P#JZA:A)(N$GH*#2$G
MBP@QO6OJQ&/^C,#1Z<S]S#!TJ1#$4=T,%LD_--:<\G:D$ZZ4>5OSR-ZY88QA
M>/O^G4> ZQBDK%_-F;%MJ,N^?J.UUM*\3U6.\\SRTQH?P < 2DO7PP)^F@VV
M%0IM&]P!,IZ+\>K*S($,1L5WWAM3-**SYC*L44R5*0Z7-TH,#I5?2+I/2HH$
MW<&Y(-Y<E(X:9U7K;=<9RD1[]4\:I!C&XM&.17/#T\6E)#-]GA,)$^"$%4W
M' R(T/=5=K;)+34Y90<N]'=<UX-BU5' >>=.- "@8:!2$J:WLKPIK$K.96!U
M ZMRC>JQNA7=<FMZ2V5?CAG@S!PK.1<'2X*];[JQ+R%1O_@M03T6'Q2/<L$@
M>S-^SDUIPK2UBW?/!1,=@ZB"B4L!TV32:O+Q4A*E+*8/%^@H>:N9UM@3-')W
MSR_>BY@PI"9G7CL=KBV;Y[IZU3$]24]AWW@*+T\X1!^;7;L\G8D&*"D9R7S=
M1)/TZ3+%G,[<JV'@N:*:2:A,Z[,:JG\L2/7I@/"C>@S^AZ9%8IJQ6'X+K_,U
M%,]P]$*?\B56E"N-&VN\K9310&KH"<>[1I5--5B'QF'E"S/]OP!,N6VU%JZ=
MF:VM/&.*8_ACAR(C,0;TT>0=)GBZ]=6Z&7"M%LU760^X()AHAD)&%^E\HZ!L
MVUO="?*J@V2>-[BUCKR[S&B_ -,FM+.Y!X'"BY;#PR]G4S4:9PD&!7,PM/8F
ML3K.%[*&QYLS;7T:NYI8C-KWZRF8(>MD]M56+W1:[MY4N2LK"FMH)3TZ']GB
M&$Z&-YY+Y^WWH1VZ@L4++O7/TH ),)]Q13$-4;.SV-;RNFD2G\W?NW3[88KV
MFUUNN://;H&\32PO[\R;;-LK*;QP[<]Z8YD)$-D8)YPYZO:&2LH>*>VIGZGI
ME]")C(LXY1I<6F(:93A5^ 5P6SKU(58+EUS%#HX*UF.8_H@KL.NZ)JS016&C
MN&W&KJ&O/F0",$3*:LCB%W>*=U7?O;4LWC(IVL:'3>V=$&&P'D]/] Z3?-3
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M-[&,>$H@:P 0!,"@&&2(  F5]F7- 6'+U=8.2WT\83E.G?R6,S(*/0^R=+\
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MV$#)YY*O<0TLJ<X5'-LVK!M6K+I4MW21$\D)X;* 77EX?</D<V1>'\RH$==
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MA>T%A;\<HF $2"P!!/WW,/#-NZ?;Q'_4@L2!^1]K0_U>^ D&+86UD_[BSS!
M;=\I- #L[T/H?SB&G<# ^3[JX5#D[WW\$XR_%QE; .^[P0>$_*/XGPZE9B<T
M^A4]?LJ#?B&E)ZG8+^A!@OZV R&!;VG;R5S[U5#AY ^"_CI1(O]B^QL]4.B_
M9!RPKY;3OY7AH*^=_%LZCH8BP0 $ SJ959$9! !:\?<+OM(# E/X:P]"P'_
M.*$<%/EUNB2 G.3B&5 (7 ."@7YE$: )^2/%_XD>)Q/_B</IGUN'4_?7%1KZ
M[1_%;_1 _F -@OP!XR_*:EK_/PYP!SI;_W3N"X S%8#O\R\8]%\P8) _E>9X
M%@J_E^&Q]U;_K 5OE2P"!=H,_+[>%#2+XHD&MO3G>&9CF,QE^SNDB%/Z?[F
MI)]I4H'6[_O$!SJ=C7>2[R)>]?R!#V30YF3_.PY/!][7?_%!GV["O]6" KX3
MDAAEY0X N+8M_'O-@ 3_!>V"?_E@6UK!0?[%7 (),NLD_[XEP#3G  $:!!\*
MQOE=PW'MU<$7(/"W _#G8:>_=B#(%SB_-'3P X[X[-A@@+E@R^+W=1 XE/41
M1_+B;P>PT[8)ZW\Q;P,(7CAT?^\"F+[4EW>2Q8>A;_ZAPG<-U?]7!($\_$I.
M_\7:&LU\TK+3.]_#2!S+'@/ L[51?S#1# ,G^YUA5+T8\[]8\RLP5ITHW7^
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M>5\A>) KEYZ83FK+#H$*%%/C(:A[<(!XI2<9FQ+5N5=R$-UPTP>>2,N?IZ+
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M=_4][%RBWW;ZI:3^$UE6)[FVBKQAA<Z'5/),$BP8]HN=U\H1H:/6:(X@Y3\
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MWY"2="U-7^RP#5-SC>\Q/Z7E^'A*-348=B'@A^'8_$;DH28'MF(L*,3$UB1
M_WJ\]P0?W[7@UXU(PFBC"^!E L'P&W2L# _V@[7^EMMBPYL**S3#'GDST4<
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MHL_XBY?S"B%C67UOU$.V32D[EB@%"4HHSZ[GZ05*'!,C*8.3#*VVUC6!3V'
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M8?V6?6#'(6I9I&QJVENC*?\ [TJQI3X717(B1#UY/FA5/33PBIH=(+D>$IZ
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M!I_D>WGP+,]^+8PX([&['I_V:G@/9)=]8%%7AJ5.O@1V@-=ZH]U^#MH*>@2
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M7P=BI-W;D%V6ZX !5Q:==+#P:M[4O=]8_[.B+XZ__RS&+BMKV[&F,KIB'TN
M2)4CX $T>9[/F U>WZS)B!^<#*U<OCGB=EX(\99^!-1=]C0?W,:-5>QU&^4I
MVV?[B;GVM] ^W;S_' MIBQL4LX^CLES])1'4=M01=&9B[:^KDW2V-V]<K\VH
M?4+__% <O> (<3&7KOS@=N*$AILA8OHCZ\BH^2M,7?5'Y/YJH'B:/B-G.E:Q
M=J?Z5@5'YGR"X/4A&>HMZ-.E<Z#0[,,ZPNBTY/9L H>H\D_[Y[*2VH8L0UPB
MO]"'6RTEIU$BMZC72@5,DNO?1$"=\_.K0=H<JW(5\U^D3R)5<+Z7GW]SH3=Y
M-:J+S*P?D\1<BJB%-C789OC 6L$GGT@P3177XIEO>S<AME7326;CHC>)CN8F
M#*K?(9^[!<5*J!T=P<$52]T>@]D;"U%[[C))6Z2J:CLCGS>[/;*0CL3JSR![
M]S_B9"TM3=/$U,$2-- EDA&6?4)5-/_C*^&K>]JP*B\]Q?*P??OZ7C3-])\'
ML"OVSQ*DXZKJ'[HE,L;[-@%9!0"2=.7O;ETD(1*[N?Z\RR@?"T$LJW(6(=XM
MF)EC%C^CL%B$+C%.F)PF!(R=@-XYBHH/SHDN0VLF*%5YP[6A49\X3@T9N=L:
MI>\*-]X_S4W^P;[[8F1>1M:JIY$2",8O5]$9A82XG&F^&$\(^R^*LJYG@*.W
M9G0A%5"OD\@C;?IJ;DY\]1@?;:CP)$_ZSHI$$'\PTG?3[&2/LO;X,OODX:(3
MR5YDD]=$ZP;YG8!_-,RBKFZZO2'3$B6/8VPWSS:/]X\8DHK0H]O<BSJ+ E9B
M53;YIN]VOYN_B_8[[R6/"/UPH,(WE)>%7<H64?=$YV3B]=G5[?=D7([:\:.9
MATVL456=+S):9#-&CG]4;'_:TXOOJ%1T-V4OAY)\9IFM@$X45"\)^7*OL/@]
M N*7Z U"7!("9:1L29CK ]?P;1:REYMJ_8=.@K@A\T[E^=+=B\-RJ;\&SYYQ
MT2L0B2?FEKP^ESH?D=D\&B?;T[]]8T6DBV_DS]V2%9DC7X2H<)72W*R>=!+T
M-RIW75Y1$3KJ!$QAJ+<[Y\(G]N.9,4:)9U$?R5F0$JOGK&1&]0PQF;7-C+L;
MA428+!^(;$I_A9RH0]&(<!*9D^03]P5@'PM5:PU+S(X^(A@*&Y4##!X,I45H
M=V>O]TE(9FZ'OKU4%.*:+QRY2NK3]:EY7C:6N]F=I)N9?!XTM7;^@E9G(0V#
M86Y0!^M5H1R$*+;8=T3V"@IF\5FJ_975D),&Q&X67</ <(LW[7\[(LHO.?@)
ML)23J&:GHWX+^TJ==\:V;5KOR?>S6I]!/8FU$;O54=I?2>8 4SF1>]A6COXL
M&R6D@[YU&K+I'<,/9DH68Q^:)H;1-_GQU!$?.+V:32J\#WD8LPTK2'W/H,:B
MF?E?%.P9HVXO /U8\DW7_LPD)8P.Z=^ENX:.5(F.M/>UY,C :"!_(OYP[QY'
M!"WN0^N]'2[[!HIGXF<TPH8@XZ^$ HLE)!D/0CL"C%%1) .,K$=#_FMF#7CD
M*Y/Q3<3G>8VRS2ZWS%_]Q_WB'#=^#J9@>_%<667=QL+Y&%FW13:VVSIB[43<
M:)/NYR"<N\N# U]N57VJ?XG-6#"WK.5098?%Y; IY!3+?H<%W%W]SA8_G#D^
M./Z9<K)I?_NL/+<++WDV*4!.RV$1JP^IP75D.:]%/:&>5H';8GWR""CE;%P:
M/PME[N_PIY#51Z4VZ8[I/N%='.3PR\OX*"U^ZS&>2#Q5MONP@T>4F=F-=%M-
M" S2ZF3TG'K]_+U 7\5A+&2.WD@F(=:-K:  ;10OE3)<BS+_ZS1OHCH6F0(<
M(LZ>!$WBM3W747WW%.G]8F&RYIZU/I8T*3%SWG2^0ZC&-HN5CAU!/4TO$H,?
M.C 26AEQ%_M;EO B6W+0UV*%S[>U5X1IB,1F:.7&AO&INW>D@_]5LJ2%\F?+
M9W[GQT^>3*52P>J4E9T"U\.:FZTV'+2<+YZVF5DE":=P(7+9F3BJN48(R/T+
M,EVQ/&T^KG.[FQ9$,D1O>/(_&YA53*K8B1BTB?+BY(D/\*#S>$*@C/B$U:>S
M9A;N1/S^P[;<4L/ID/U@8A&K-^NH6OL(13Y.YI\*Y@]"T4HH_ \6/4I!ED&V
MC?+:JCJ)+,EEZO_%.<L3*WX @->^Z:QDNMQBKTUJI\R0@!^+3'^42K%W/ZQ3
M$[VD;MH\>VH%Q)IY!$0NT'Z'0QGG(X#1F6CZ/OM/""QZ/KK<6E5.=?"NGIK6
M;*'A$'@WU3+G/^VDWNT?_X4U,G+W9878?4)9)0]Q^] ZFH@/6KL[?T)='HEJ
M4]8]FC_< 1$38403V&B?UZY%5M#$?N?^N;=U=H\,G]Y:Q/HYPD;=2P+Z[>.F
M==EC58/N4CTN<!3TQ P\T/H(2+P2U*>;1#>S<F5]?J^E>%:TSSBN,;C?\^<H
MBA!$KH?W943UC'I(][5(G=8LE+81J(9S1L&[T?@+?N+=/*CN%O^G*4F0*/_%
MK)8+HLLZU5EGP$39W &G*NPK*MGH.S_=<[H2QO1V5_^Z)EH++78!E[=>]:W,
M\[ALB,BG! L<^B3BK]_FUI65-K_ASPZ3AQSZ[KP[GWBJD6_1T.WQ2Y],L.FB
M5$8\4"1&[,E53\L>+A7#BD[_'ULK0$"A7V08[#7FXA#UU^KWMMH?8"#,]XJ<
MO+#:7M$4<P*)=% (,PZ-Y%2;G@5#L!*45!3!9SI[JH20DR]15>-62C[ME1R:
MHV; EE-1)$>(4?>QX+CD)6I'E,S@>7\B&B+7%E*%-Y?/?O*FB?=BEBDF4F'O
M0P\)J+E^:/^[*,&@VH=2H9+<RM4:3;2VR1'NE0O)\D]Q&+@+)Z8RVJ._[.XS
M6\8+G;_,S;>-T>=_WG[4\&5$W!37YO9 $GNM5C+,X[O0:B2?\M7DZV4#3ZF<
M)BS5PT> 2%@Y"S?,B_@^R">*_=M,BL>^Q[W&NF,SXR%M(/^P9%:[C:Y7^YPB
M812,Z^/]BS6S%&%R2JC?=RSA7\^A244<,@XQ!Q/"1N.XU(1'=;/D:37*"I:$
M34F32M]O]M?*S$ALT=Y3S036N1E_=0:XZC5TY9+GNZ#JU7SN_P1IAS"!$^-3
M@# U)O8:O&^_JE[Y]86\;!\N#=H&)*G]N AM.HLE4HWEAI#*LQGONU!QW4:X
M?)5#5U:B1II&5X5(Q^(X2ZX36(3 H!QL7LU;"&[3C5/#A 2 '!ZA?KK/2 NP
M<A3VI37%CJ8R00N2LJ[6*P19%5D2N57UM(G?D!%/K&=Q!42S.*;:+X5C-'^=
M]O:Q^P%H2S?])8?(+:&_]I@OS (FA"Q2^Z-0C(.B5(KDNRO.>._B!6*-R9)8
M-0\F5/6UC4J6-=N[V[8RV2.KA 3?[<\8DS&Z4Y_"$2'P9'O#C^BT0L1;S2HJ
M8K?[=RS)Q"$ZJ<'<:9+_K.[ WVH! (2][.1  Z@DME;DQ1$)O%UO_!$P2>($
MH=F*J+/Y\'+[]596HJC8AQJMD0#UR0W4UFY\>XOBQ4.F7G.-L+)<WMF]A8O,
MY$3+?4 !)QK/EM^&+_F;.7Y*I.LCP.G[!2A\A!I:_'4D+["=) SV;H.KY<NK
M59Q1^+B4YH3#<RV2O[)OX0/B6_-'@+%,5IO\U3SJ>DYK!K]"=YKN$6!^!  0
M/;'XBQ4T5UF36_)I5?8IHPA\O"D&=5?=O3^EC!^$[)31FML^JR]Q].T!T=]W
M$;)IG(U(T7G2&VE@[A5170SI8KL !P2@;H8R?3&XSP3$I"^&<EWYC9_.KDR:
MI#-W' 5C9\7[?NR2U<O9"J0;-PJ=P'E[P-WM<Y+?,BSC0S,ZA#N[[3IYMQ^[
ME]?2<6<M+U^]?.ITHRFH:"1GE/?AJ,UKS<@VLF9B)T5!\OV--28,YGJ'E=OC
M0QH"K>(A$>7^WGX1A%C8VMHSJA)4Q7Z?!M 5R\RFBYRDX^0 CQWC*.'QZX^\
M*"W+"<'A%^)D*;43CW%4ZQNO5B3"?A)R==P?94O<"TCBW-+$%>83AI1B0PJ.
MS/V5%#%T>B,+9TG 2=Q;*>"2HB:U+ZIIVYKNO>!BRYJ>1F-&=A8.!/&8;BF)
MS.%]\'GF,94>0N\8 /C#RM8C<MHT.&GAJ49ZL?:NUB8P#=7H'W9XI\F3RBO^
M_/9J[EUJ8=#L5;Q4(-TZ,T8OS?L40\$Z[H9"=CTSC^.+:F(\VB>ZD[$;^,0L
M*]\AAZV=MUSW_V"&:MC2E"?TTDT%I>MN/I\/=Z@&VP^N7,]B:X_A%S,3 *+G
M+5O]2'J;,FX/EX_O\C(_Z1P5V=21G4PE5B J0#=Q:Y,LO9A6&Y8L37LU/[QU
MK4('50<%:/&;0A)[8=C4Q<_%CFJ(1TAGWQ1)*4_BJ3UWW:R_O!?Y7+Y95[=I
MWX8"OV$*$ G/J"-A/PY=LP1'3N/^\BN;T&-OA_CJKQ*V$;]%6PI+0/CN[<78
MTHT&MP::;*Z!= 1=F@JFEF8NL'J3EOH*5)'9Q(V*-6T^."HOORHP6.158H09
M$1(MG_<[1I%B*[U_(;E^:*?NYT@)11$D&H=L?N3H9"C:Q3:PT:EJ&WA;X4.G
MQR8?_"$42=D+( &IT?;=+OV-LPTQ"LI8( G5LG= D78'DTL..6&# ]P*9:5[
M">G"**:7/S8*<_\$4>.R\^FQH7':1G9O]XOL42:'U8.&?,!'7NB)KMC[3UI=
M;K7I9#EP&&Y&4/1<XAB$M?:>=!:%>^6W>Y->Y[A'2WT['^&=V)RI[RZ#K#CQ
M=T&7'@U&SFQ]1+>97Q$=O?YA<GM*[ 6Y?3VR50BC(N@!2T<ZSK!Q"I_<#S"[
M3^]7SNBQ!JY1'4X%ZS0S6 ,>#J&B%]*^^6_%&D[1A#$P#ST?=F$.$GHVS0^$
M''G1!45=OOD;0#X(?+_\FZ_-U6&>^'\4G;DI_C<O.BO\1]$93WG+\CMW8BIQ
M:@FV;<7,/XO.4$X_ "#P?N4_.@*&LO^;=P06_Z,C0/;D'QV!?V_O3;I\MX-T
MA"JVJ@ZH46_OGWTB8C(I $ V]N7_"\-?CSC\KUO:MB-U#/SO5N:)^A'(< I\
MN]Y(^5^,^(\=6SJT47'>#.W#7PEXD7P9"H!UD/^?$^E ='0T$!;POR;2!0#_
MUT0Z?T/?,0-,VWUJ_<3J_YQ(1_O'1/I]0AMG[A7(;#IYN H+1:)]K1V!,B)<
MDD)GCQAOA.'!W;6=K([1G)_@$!WC N_L@H/0A5KE^GM!<#HZ!(!RT$HQFQ^M
M[P=H5H:4\0<Y^L.4MY#.D!):+ZD5FVZ5>Z?&2X>Y'KEX&#Q+:2=0CGDJ*FJC
M33J(K:G@.H'K*PVI3IA>%TZ<4 5_Y@*LOM!GHE49J/!,#HC^" #3-^EJ!#3;
MB!1JLF@]U<;68U:X/%W ?@]H/OZ@ !S6;AK_CD9="[)2&@4P?1KGH;>$#"CC
M6 ZIRL[RH\GTCF^"Q8T D:'%%0!TREAPDQ+ 2 J0'=$?)H76&_1]G!&&*,F<
M+A9K"(]RI@A)W0+6,ST"_BAX_,YP+!!JQ7%*T?AN=VB5(9X<WO.&51);13T9
MM(*=HA@G10C6<7_+4J^A0:,FM(U]\+S(W<6JU.8G(V8A832[[A!WKZ!C?14#
M0$*ZCRU. ET.SE\Y*?3+HK9JU-AVCANXA3WRRPCXQ,K>(XR6&P"7FYI% 6.5
M0,;% &YZ@(;"NCP]T$KV(*WRF6T1U3%"FZ1\=H**&8D31\$(<#;B+AYC_YH&
M?!FXJU70)?Q)S*HW"?46AT %;"7S"J1N'Q8'FN5(^['!C<&4F:HN\TE7SG3:
M^FT&PZ;V4"%7/S3[&PZ(18 ]%OP4(8OM2@C'HF10H!U'#2"\@&GO?RIO4S?A
M%%S.QIY;,9QDVD>578@"E!>H<JRQ< $0(F\?!H -))C<L1?W_P80;D!"O9!X
M/P$Y@(EA]Q<,,,R,QCV%(B<$L!8>%Q("ZI]\_&]%=:G_;TP5^-T*].8??Q/L
M7@^$8"GK # %*"'VL8!Z/Z (X5NP'P;J/BC:^#M>?P4"GHKO_="Z).W,2(S[
M"'CV/V^&_;BY<E6#HY'(ZJT7-1JX5[N(F(F)&=NA][^3A$CN$M.!\M][SN5H
M".%_HU XT7^CC$:&T .\"?[0MRAPI*1D(D @LC=&V HCM!>[/(!=H9<;ZS )
M]/<VD6'  ; 8  0OQ682KP"6UZ?@S]@3A :$;[ 3//[<N7T,7Q#2T?!F^2:$
M_E6ENB'UE^]P$@?C^O5Q*X6^>L&JS)UOC;RMUI-CMK\'3P3DCPIF_RP4!8^*
MRK+'(W&"C2=]Z(_3G(!GY@"2B5:Q8;XD%]/@$!,Q[S*%FWB/FN]++'OL9]+G
M S4YG6[(TTWFDN0S9C:5\)MRZ0M&;O[+$6-_+?,P!*,,$2?0$'D>&2NGW63S
M252LR.FK0R%%3E@A/F>.XM-=(@:@ZP0/"57[J])1&%6B=FQ(,B^21TIM5#R4
MYJMQ6'ETK3?J!VJ9C*U-[U47DSP)VZ!Z 4"USJVU2ZZ^<+>)]AU"'GF!SH,Y
M)S7^[H[- Y?82/6(25T(*RE#<PGQ2O5]%;?X &HX'6GP32LFHK#+05.Y?&0[
MM'^T%U2;(EY=3!YNRX''*#9CVBG76$;1MZ00_IO*#"^J[9;J[Z%Q7&Z'O3,O
M+Z[<*'N[MG96$9<N*4A^T;=7P>\,)6\<W,#QC:5;9;$*><><RIY5/P &\(?N
MWWJ T.J#E'T-8$Q\/E3@LQ*WWM0ZJVX_B1D.&J9Z73IZUD!B!E) <C'(1UC=
M:S@1C96=&#[#D<@0XH#L8P:!Z4S=\C)KH."QQ0Y79<TXQPY@ZVDKNG30G';6
MMWB7< S!B FT\?Y47!PFE?'-P-J-38>[M;MK\4UN7$FBX:/F9=ME +]*>/KW
M(-;Z'%L6O,8DTU89DT3Y'YQBO-=Y3Y6?69"S\6EUW[XG2U2@A1![QZQ,CVEG
M%J*-O/JEX$]>,+JH[X$:LB:-:ZJUD[>97#;L)TQ"D:7%=5U^E0HKM=\U95R(
MDLB<90(R%8'"V4?@R[7> #3 B(C._%G>8A*>"^G1B(@,>$TNG?HF8YL5.@@6
M84]NF%)5$H)Q:Y1,X\%:7)'X&[\[%!U4T["N6K1X'P'X>(4K(KQ?L(/W3\C<
M2VL2V=(=4K[/$25>(2JC5/N]PV&Q/R=K;R7?5U!C<<W,OW=NT/Z9JB-$Z!JD
M\-]\;7Y@,&";\^,2=S#(0009>DLU('U*ZF!4! 60UQN'LY@H\JU$^GB_D9,/
M$.C.TP]8O9!7D:0^YF8 1R'BM?[X)1N-NA031;-:"8 J0^15L+,HV=J3LG9T
MA8&+>X?Z7Y WAFH8^OIM!G-_);2:#.'Q[+E2]LCTW4STC&=#@XP?3Q%Y@;7I
MD8R]RL:X.08G'S^'1T7AZ(:/QY[,(=N_%$]'FHXF1HW9,BAC(UUE%JS_(-%3
MI7UPA$E'LR6BQL3+O<N[@5UR1!"S9^5]U-8;3D9K-Y+9J0Q<7/4KT3S9^3NJ
M0N_*P=\IMV1^0^E"!DD9/S! 5;5$L168&.#\*GL?Q:A"6D/"5)JS(M=69L<<
M\:W>:[(2TP@&\G^T8IL8%K-YMD/T/!F5FIR"2[:[90O_K!)3HE&4+XC&$ESK
MQISS8@U&T$ W7;8]<2'EB)N5&5)9O:!EJ:"*%B5NSP(PH* $U]I^[9Q.YN0I
MP<G:73VA9MMHP\@4UD93&<U07]@")(DD1@_P>5H+=@WE201/^UZS,B7W(XA4
MEO52'+-F80LJV,9;"22RPV'UQ:L2*R.$M ICX:7%H)^K3#8Y>WA(]2E-6#Q2
M[-81I99DE<P5ZMXM-JM>T%SFI$1EPBIZ@H1T_QPW?WU4%#*:ZGK_3EF3 AB6
MHWTLB^FSU!ABB^.2;8!L!.%02-6I,=K@?7[:_FX $U25+MC':Q..H(Z^/N!7
M@31J-)1E*J147]09HIMW$R67 +2W35\(>;W/S"+MK>Y0CPLR\8 HC>7]XA(V
M?A?'Y/.V?@:5TYSL.USL@I>=!:>1%S1SPB4BWH9FVG@16D:V#G8"O#\=H]6@
M_1*AAB"B(!]IM'4EN40\/NLKLLM1RB6Q)ED@R^FW[,(@ARQ,#^IWZ$*Q#.M6
M:$P$\24 /"0_TQ=*X#^I7G$\F7Q,D2(Q--/="O1UVJU0R9=__VBFY:$@)+>#
ML='9> B$*?:MEKBD$0Z%P]C<?Z@':)/R]X8MEEZ..[O*T5C1,;VX\2JV%>8H
MU^YY[_'YUAJD1\S, Z _HUFC9F#G8((92:ALW *9XH8@D9?+D9+ZI<(CS^,;
M=2=0 ^]0AUE[QGO=I.S75NQ,IM H<B2A!C_5LM4L$FFE$FIM&?L9_OV,K.0]
M(&XTG:4U^?6.-H,7J*B<8B^>0)AH?/B-M,=J\2. !FRKK3VIBN<P-H'"B<+V
MIM^1/71Z4AP UP,7E;B:K$_+]PJ^&Y00K9Z3HA:&]2VO3U]N.O[QCAURTE,-
M\4MI/"Q@(!;%!@ VI15RS1! ['9(@RM7]5%..).VS9UYSQF)KM$&+V)M2=4-
M9&WMAW"AD=J7,+$W?1NIF.H<+9S'YVF;*JA,W&4 C1/ F5]1K?+(*'6]$(YJ
MR&+ ;<(88&7^X5 ;#EAR]6K-2OTH<PN2C\1@"<_Q/(IO*I"C+JL^9)W9Z\:G
M%!+:V"09ZTYA-P;.W"0.KXX4A&OKH?B+T.AN9C+QDJ7'B-FRB%^T.^B:S9)\
M' ]R7[B09[8?JMYHS=P?<3KF'8F7IGZIL2)<]B1!4L_>[/.H7/A[Z'/8/PZ*
M+.E4)K)Q%2&E5J*]#%2?'2/I+EKOP1R')$8CLFB=.&?K(Y#XMBYHY*@4&'PO
MT1CV4501[J[[R65XBO<FO$P>2$4KBP%7$I)HZM6=6,0O<OFY738?S?826_^E
M/N%+5H'IP25Y"$?\FNJ9\2QEXIOB5_NT>3-E6ZYZ&,E)29FEV%V2V%#^R .9
MWUIAG1?LML>X)5598&2]D0%?Q6= AHG44]_A .H6>?7Y8OH>UR(#;7;O0;@V
M,+> P38%/S_UGU&W@A7+UA;9!\LU*7W39426!77#P]WCC5CMX9%/2;2HD+@[
MNZ8F"HM-!:!W(]"RB#48(I.%X]]UI&?@]^'(P[E8BKQQ68A(*UG2TN')CA*8
M_S@QLV#OU@FD2&W@"$Y<R9G/I21E3$ZK/XY7/RO0*0C72#ORY%OUX<$\[ B3
ME9(1EF,5_;JQ4:$RL\,B,9M&TAD1WD#)S4:!I[.^-^D:1(K]92C@$9"O@4',
M_*N$6BPJ* -F!&_4%U1G?B9HJ8%+D[8D(.1S5)Y23+!\,PLU9$G6#[8T?"%/
MS?V.,L9W1+K2V[,_?%R#+3! &5.$FWA0B,8WKWY>0U$):VWMZGI^M#X1,]G"
M9*"'&F/NE#T&)RK4^\0#43)IR)N&'V[^FTV^?BI'*!SL["!>]\<NE*9BC,Q3
MX;66N7YE^3!6 -3R5<DL6DDOOV_M/:&1"!M[)I,*"T[,QG.1$A4XQD],W::8
MVW[,F,YDNX"FBVM,S9U)%7?8L,[;M\O^V\+&FFHA]%PBUCETJ'!K+N;N?O+A
M;^/J3I2DD:L.JS+M%4ZV'T84FB\.JPUYA(B02C=U-,9$4.S%QM?>YS:*DVH1
M9.-LD9?"@E@<5YX!ZR^G66C#A/0UL1/<U!_$4^-KY^1VK/8H/"H*=-%82!HV
MW7Y3C]4KKH2]5I?^RXA&3&IDN7,C-G/3";93'@2]+HQ677+0L<[_@[:W#*IC
M;=I&!UD$S\+=%NZ:X+ @"Y?@[NX2' (LW)W@[NX27$*0X)+@[B$$#QIR]KN_
M<[[O_'B>_52=\[Y5=]543=7,]-7=<_7=5]5=/3^1)U:ORX0K9\9*U!S MS#U
MA:)ZJ[&,G;<--6X1]&"+D/DU.9[9K$[W6!.3AP<3S[%D(@8_[*J")'2M@X#7
MRS2W)<11L[0$\O)60$D>]RT1F4&;,<FAM10D\@.R!$XG5X886 &$Q;9EBDN@
M+*%*[.Y$&*V8')&C_04+%3V:2EW,9U,)]_A@V.2,Q'PJ=S:=L>*^YXP4S/'I
MQU/Q=:*^FQ&H& !L\@48KW#H+J %J'^ P9*,01Z\#PS]<V526(Q :%R&;#J#
MM,6JREYHBSI%E=CM5SP5Y:= L==_@"&6*!2' F%4N?WX0%7J"%05Q* &^G!)
MRG7WU]68(:",Q)9Q7@;W)#C/Y >J*5\[D,F/)25%XMV.7.H!9L_+UV9X-:]R
MI35/@\C#)<WTM,S5:TA@[(10EB*']P'"9?58QZO?'I2C1'!588:R:1BFCO-8
M5D)HP \/C6E!B8\$&KO@7\^>"X-<H9FHZ5''."MW"]QTR)N=(XM]0NY *8Z7
M3AJ;*T.VFX_"Q$0<#LU8BHKELH,%?;ECT<75;/#VV^$@$E 8=09EW$Z1A[>.
M#1<<KF<:J^O^!J]T3=8U)]]GH0E!XCIC6+O4.C/9:X6!)NF$L[UWL,LL<T<N
MM#63&Z?WH4W.C)#U75Q9?3[/Y=["V$>TKL*(X:JDNB+-9#H:!38<CAR=$%I/
M4Q\E\WH:?#>VWXO]Q#+A[N/TJMY5!Q"=83??2FIXM*HNOB!?9G^+(F^4T\,W
MU]Y@1'1I7(_"W9/N)0XPM;)5^,Y9Z=&O]F9T4QUMX5/L)'MCQ2^ICC@<CM]\
M V4F[[\CZG:?]GAEEE$=P-#.JE_+14V7]V<HH+ P3_,)X^RJ6\ F"*0'PU%9
M3A:(!PEE&U<_6R]JA<#J1.ZVA.V4\/!UB;WII8JNBE1:S,?%%7TO@!8SZ(1;
MWH3,EVM$!MKWMW<\TG-^=(0^L;X'* 2A5!(M]%IG9<%-^(K)J<?6>=YSC,00
M=FZ!G,LIP5Q2XK;VG U6\-54>7HG:(6YG%<[QV/F*R ?C,/7C4<1EXL\@RX(
M9YS>*@Q=6, #06Q5<(>4@SE4]E>)<G_LK12JX,#1]F,#7?U$ !)X:]>5OD_=
M5"Q-7!$HXETE#U0O\BG[7R?L7/ ;\PK6VBHG6>DY%P<I>5.8J@PM#WDTKA&M
M5*%@L%<78LJB;"E<>7\5.8@6M,QG/P3XU6E^::JM_PX#S[7NL-9Y'BBD"(4.
M\W,-KF<Q0#FP4-MI8OW>T@^[E;8&RQ=AJ+#H5*_MI2*/,8&)U<)2,+MLZSM3
MI"4.JN"NR(ZE:D%3\[_]GKE5,L7^ .LL\GBDJA8;@VD1=JA$^#.*!(T?F%VY
M.71E"6'\@"6B#-=1UB@-JH&DH9H6!4L#F+9",6QP"[-36+,,XA--**!^8D!W
MB,NV9_>QGTPH#+.?VI1E9<2_6-T@\\F50SJT)'=,)G2FH0BM#>I_;@[^0*W0
M*04F)G6F[="MU3--&I[->17:/7%::2:GUZ>:8_Z8^YH-?R6-S,RQIYJ480F9
MXVINEY-Q7!2W"1+"0F<BJ= ZW/(KE&1':8^^Q,:"6J= +O12->F8(TN0*'P3
M-()*':8T-.8GHDLD%-D\9V;.TU(#B89C(<NBAFK0\F03N\>QY&!MJ3:BA2..
MSGSS*PSGR@P&C1YK9OM=1!IT*SB5H>OWLFVV+8]Q#*> D!4+19Q;'2?T27$'
M4/E%28<-[T88<O Y!H;4'/OZ44PLZ''9]M'9/MF>5<8.<"%'X4I-O6 H8*4C
MM,U,K3Y.[PV91:>HPDPF=FDW:Q2(<V610/9J<ZND2[8.?M/D?,!'0&@;P7==
MXLGIV,IA@=<^D"NE*%R28]%1)#KL:@ZWXM+_+"+-8JW=5EOQ.#+^'M:$9QJ,
M52]J,")YO0G3?1U77T400E2@((#@!F7+/>AYA8.,:KMLTZGXV9M1A3GTTX(L
M!2+25C 03&O&EWC\*XZ 3AFSB *#> :1J22Q/TIE0N?"PIB4$R"6LF*R(<&#
MSC"DLIBO6#?"$1+&^N1 [:^V]+@ E*BKX$!NW+?XZ$#"D,J[E_X2 T=V\FEQ
M4!RZDG&$KC*:)10, K>^%I>)F34< A,^V4(X30?,1JT]9\*$&"%4T13Y"(:3
MU"BN0AV51&>KY=/RN"F#6[*M*'\PCE:I94C'+X$028!I*OBSLUQ5DVY] RT_
MU^"8*[5 KQOFZW/'G$%8RZPEKTTW3H=I*QF1*=?3^58PRK#UQ5L> [FL%47]
MCW:4[S+=,I)N:HY9='GMF-R<#.12-/7+\9%A7_N,,K(5A#DI7HC+!>"\#T+&
MP(R"*=+0'_=IE!$$:V8I2XX1E7[UUE"52W[-8(]L9R!B8O$S7M*7?;DW#/V#
M[9HT\BPD?#4K;>%#+3BUL$&R\A-K=)E.N"40Q(@0)P<&"'(C%2G35C;5+8KT
M*'+S J9#2[MG1?W\[SVX&6M"L"_RC8DS'?$15/8^I!2]P=/39(F27ZO3=(RZ
M:O8=<<M/N?WMP3\VYQ59/N*@S!\5NE;*V>Y,&ERD/;K0NA9I;KM1-&8=76Y8
M%IC<4@)&M#&N[[=:H [.(Y@ZDVS'($-V!KLC<HWWZ-CTU_U4FTWT7MA3X[#[
M19 <=U&(0"7\B=6@SZFI@>?4(\5-Y*+S#0TSX?6G7=O5;=KP4>F9EY$O.NLR
M)[[I%[;W-5H=L>(8<!_?W##*0MJUO5WGR7BU.PIP=-5@<M1V9CQJTA5*P]$F
M%D=Q&ZA3&9')YCE<HXH'C)O&RU:(]W)W]CR>5@8/_S7[!WL X9[_F+KMH!M#
M&@!FQ5S>'D#D=H*@..=HOQ+A&H0(<O;YCN0J2%H#$@3,5I@ F;:UP]E([/94
MV<>VJS'1SM/A0FH-:"S3FJS&4IS=@(@V'U[#3! 6UJ>;.512=-=54C*:%;Q#
MI)9.]G:2D<@-O]LYX@^Q(*6UOF$]]\F*W-*Z3>.P.  ZP(L<.L2&J="%VYZ+
MHR*1(]BXP0-W@-E2MU.V]IP].5<KF]<A]4X\+'I/H:X&XIU=#E1,C 3D<GFN
MYS%J<.V7&.S.0?CGU&KJ/ZE@9?8@AH+E>/UY>_PY,D)?Y\DM?8KNR/^@ ?/I
MB#LI'S?]IE/W0^D*463"(]D]L>SJY%:O$^<ZK'>QVDPH@B+E/K,VEZ5IY0D2
MK&9B:HA[YC;'%P:$(->]KDQG.UR8?<?M1(IQL/B;#PG1237Q]I0B:Q8>$E O
MCI5&]/*ED+DU U!HK7#J'<= S::!U56K5(J'U!;#QG9FD.TZ(OP= 1PEN9W7
MM0NTDA^1%&2\_LK=L0/R;V%2&*5?.#"((<MX>OQ79>>.;C(R$7.@8:B0&5-I
M(UAZ(27G*E_\6Y*Y37ZA6/Z=I?+&IR?;FB:6#,G?TFQG?P!*"2P,J$('I97%
ML>'U)&.A\^>(A!LKPPRX1#]@9<@$WYOX&-E4OHO)8]$L00V-U,F*7-D_=%BW
M84;6Y-&Z;7&=5M*%?5))N>IUAK*DG1IBC*R1FN*-W6SHK090L%5/'^S$!'V]
M?N'J^%%FLD"EM<PD!=PZ+"@X4Z2V%Y/B&77*L!*2Q8VX-V!S*)X?D(SA9-_?
M8@)@X1TB/YO1Y3'A(U"A-MX@6R##K0KQ+5G==' 29?$@='';#&.S+1NS[7%5
M;2L^7V>&R-(WZZ*LN)K5'M?%A\NY9&71F?;4^A.G3TF0Q?\5RT6:PU7P&6EM
M-$@0U&R(R.4;7C%A,D6D"*FHSMF)!F3?S'4B9T/Z^PDQ]RL6DA'>,'\ M1/6
M /6G./_Z=;$Z:6;TBJ[,<?(?:X(R>'G[8\%:82 3@#+,^W<1=<2_^F4>+DX(
M+)<+Z>C05+Y18[%_=,(M,V]0^ .HWIYM]@7\?OR?N%C2>NZ%):$A,"EVJB,?
M@4Q4X(62BP/_TNMM,@#COS+[T<(%\;_G@>(T!ZQ%1R9"(B+BC>+[X4<ZV3K*
MFZ'I&\4C4,_5J\5X[+H/3&_?7OVB^M?O?>!&*Y8L&=M;GH"N$ZV\PL#W##:&
MLL9.E3.YINP;]3YH!G6G4G!W;Q0PZ$S@L']@\WQNB96,5KGFCRCRW&>0:)]Z
M<%W]P@ [>T2#X_VKW^@W>7=#J*(<R?CO(97O3"C?K!,HN8YUV\S*RQ?_  '/
MSW^ .+:A4^*MK-[G%7J&7Y[=6HQSWXO<I4T6SC!2;&N/W&_IL%5"OBOZG3V"
M_MT7]J/%5TZ,E_60<3QTS(1Z[X9."U''N=Q0?HOG]04SQ%C7WU,Y)8+(.#JO
M RYJ!I*1D#_Y$Z\=\_JVD96BXGK%/>T4DQ:8*L2 L@.N\I?(@?R2X-6L<W9B
M  EV/R">$<48#0)DCE&P-1I>UZ'7%A+U)C/S951XIN0W\7'981XZGVS^!461
MT1U>.5VW/$)48K 7W&LO<+)A+K_')4?O&F7%N]-8.:=C9K+T!_#35K*XOH;_
MFGH?T&\22(>RFO<7&OC_&PW="@P4-6(>L^ES\(%]6!#+9-.3V]!]@(9)1R#/
M*%/P#_"I?O.Q +_EM'MZGGCR6+ZP S4C+KXCUPP74I[7ZW1[7XR\W4SV>,R*
M#!V^(JGS/5:8K*98KYT*V/H#])H9<U-0OX.#5(BD&<BW50":$GAPPERL@OB2
MP0OQ-V6)<U-;V>7 ;]_CIG6I,I&SKN0SR27?E#1W9)!RV.R['S^^(R?_&A+^
M"X9]QA&>/X,%Q5E>%HQ!%7+]&"*;28SHQ>7<Y]BV< 8K/<!\U?RJW9'9BUM]
MI=?MKTB+K>)D(\LZR+&\.#8-54RS:V(2X)+;L,C\N,%-2IQCRM1Y<+5X!!NE
M%-X1,QJ^*DV\8NV3FZ3P.JU T+4,X W\<3N/I[,J&X$7WNW_!]!+&T6,HB<(
MZ3J+XY&\K-IGL(\]N%T,7&E!2,K5)?YZ.](::!XI@F9=[Y39<TW#XD?O-#1,
M:S^SH)^>^P?H[)X&JZBEAJ:9S0E9MB?.3Z9P#T],W(4<E^EA@PBF^$_2)9M@
M%<N"9%GW(O-_@$ J[5*(&LJ&[;>?9/=%["^H42/SR^CD?9A/Q?V.5$-;B4V6
M#MKGL]*3:%X$G0]=F?"BJ@<J6(OE0CP$F[CHFF-;N;O/W(KD4(?(_+.MAU-K
M!B\>0?>^6O'A+(#=L5CH=E\69.8=$!GUX%NG^7-Z^HJ:ED&.1D/.IH+J!A$6
MA4LGFP3Y'[@PT3!$,6F@09CU?B-<!+U*D,=UP0#06 1SW@/>'/ 76$^SA"&)
MR+"WJX(IXIP%WA)\C*5H B X\@?R*3% A B*%/YL$R,QB@AA_%TR')/VDV8(
M2KJ:&-:I/X:)O9%)/\;*%TR/0J2#EZT&N,.1)U/0*_&8$SF47Y!^DUY('$2[
M /O/?!XL>8.N"=%A31'7#2ER8G$=LP'32I/PJNUUL>-C4>N6$C_,Y)34TTIP
M'[NP/D$3WW$A2^#)?; D;$ \9P#9N"!?T-A#$\%J0]_B\88&&8?JZ00"O[-8
M[U^_1&4(O2YD!!J Y.+,D?X7P4> R^8DCHT@ (/] 5HR73#*Z.9+(Z.D4,+D
MQ;:96;64%F49&"SA-9'))7P(!(281 7V@\@@_:M$(EHN U84.$J&*MP61)-!
M]<P +9(>U]*0941CIZGT\5&,7E->Z)"R;PRVL&<+!CV([C'K5^.KL7U4$.!$
MPXU>29JC(#;I+N&H"CJ$PN$VX+!Z8/&I^(8Y/WU&A#H+;RXT![$?43[>F@J@
MQ"A ^!3()U6PAX"#]SQE.1IMXN12E0%'4,$E$0Q!,%:P"'9A=_XDQRH1%5T%
MG7=814-DFT#K!&=14G>MDA24VIF"N.*!2E(YA6AY86KY<0 -KD@$N)#:9J#(
M8^ TJ+#)SV"J-=Y]HX=0O-2 -=J@XH*L<7DY3*)KFP"2DE<C%Z8LN2E8@!EU
M(ZID9AJY[BN0_:\WMTCGQ0[--X+_R=QALWF)7A82 C202KL$5!H'Z8>"TD%7
M2W2PH&)E*98B'D=;K (#JBML#NJ=%8D'])<^_A;K)E_)_@,,^7X)@J17,0U
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M<?B44UE106-,:.FAF%Q*.><JX(G1=!!Q5D\S^7Q_]74Y6L\GI'C(.2^(O,Y
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MZ#LNUT:4'ILK7*FONUQ]LW<.[%<'2N9<DZ.BH>Z*O7"2>J4X17Z(U+AM_@?
M%3,%PU+,K#PVR]FP!SP-9G[?[ E6ZSLB*0WP'QQN:8FC23W$\)L\_]LRF;R
M&*KR52:YZJT2,WWMB2]?\\8[ (*3BA#?R.%>65\_:I5UG,84@Z8^1S@K?OR*
MX?P/X)[@0C(G<OWO:NN5'MP[ +W@<H7FE'0H5?>Q3H+;,GQH  R#%3G(A/I1
M'2%-@S48D_#NQ5PL1R'F1N<H/T('00W@P7HY)6>5#YEO9!B1X<JXK\_IX]#G
MC^AP7TQEHZSB@8Q-TC[K%=%V0KC%?"6*:H"?[,\;=XG:43Q:91=818C@<Z*C
M8I"\S\LC_']GV.5*&"(<I DGKYXQT<F;07P0C(_=VA6MBJ(I#WF#WM=?02XH
M@)E^%G189$4-5$"!J@*01PA"].2W)4J8+0YFF"I1Z!&52B1\J,L& L@2P40(
MFB6&*;_ETK&!VS"18BX*F_O!#O),$CL%)!/8G]Y0?J&]S/ /:5#IX@J'S^ B
MA&3;- N;J>BJRJ0&CY.S6YY(TRB)+<1/4NM.H#Z:LPWY?$M+7C99XSB)/7EM
MS[VHQW#,4Y,DGXH8"T1SO9_+L5CZ%O2%=3[J"EUQ+]$L;(&Z!L12%DQ !JF*
MP_(XK"S29\*:&&(JA+RV+U="A#*3]DL.+&2UA/Y8@L9@@]48CNCTLF$;E\4E
M4H5XG37"WQ.'AYV6\(-FAS ;,E9,Y\B!<HZ(O"RU.H%9G$H],@29\+G6Z19;
M^K>-1?\N<Z(J,ANVS._X'\UDZ;K>+&^>GG2>3>Z)^YYLHD01:AVGO'W++=[0
M&"8]B-H42D"4JE=6"#Z#%J5S2?.&%-5F%[6EU>T_NAY6V://P1P<381E=^T;
M)E3!:-NT[S,Y<M6+H.89"(U!,^$#'E**3"Q:$#@4$3$X,@NVE*64SW#>%<BN
M+PN@L_'?L RNC+-]5&40VIHM97M3A(!-Y;\.!HTP)M=SOC9O'-"2KJ2[4OV1
M-<6B7QVVR91BD@6MS42!2GS.K2$O19!4Q/F>.V_!%2#)\*X?) &@5P$L$^]:
MV%*%:+[")5I?U"5-MD,M@#CF&%D^G;P3#\_ .$LIVKB4.G$*O+$SFUT<=('=
M\)MN(#4:1#'>TL7$OYV.J&% ^VTG=#;CW6CWI0F1>NNO$5!E,1E'_);*FWV%
M01+?'0A:[4=3[/&@O<%E27P,^ <<PYCQ.BKTN*LI4DQ0@0@Y&M6#1PQO,"*:
M8,0';T9> L%)2?0&+/H28._P&U237#]5ISKLQ/35(SB)GA\Y;&6HJ'JIQ8B*
MSN9]#R;BSB8\5P]!'MKY&5_9-+2U6ZC#_E+B9T6.HPI<'1D1-14&\X;-B;U-
MXY?HERK$)V>-'?3)UR2-8\BVHX772<ND@2N5HVK-8:F*PV-09O"XZYI+PU;R
M-O7+QG^[1?]:X2$CNK.$3ZW67:A:\$.4V_7Z4YM85'FET6?!5O>8/3HU/&0_
M;&[3\U]42H-7KXA+!EHYOM5(0I@2RK[Q^,'F0H7'@AL[!95W3@]?/7-%0A"*
M(+(YLDXI*\2=70".8AC15/GJ6]&;&'@A!H"XWZ9-4'V^3ZY2@[SPY<ZNIJJ:
M1.<F@F,R"#GG4G3#;H._V:B_:4CQ6W21NA_7VULE'0F^E8)WV(IK+[1+%Z ,
M5+A=.*XM+D(:P&5AMO-W[.A^9-R5-E)U4-Y+@.V5!D9D.IU+P;GQP1&N@1TU
MB 2SP+(SUG>@@D9U)'\-Y0^0DZUY8VL<+TGMA[DJCL2T@*<3_PEU&65 DGUW
MEMAT[$N*@C"39W21W 65J56P&%@_I>6355OK.;@<0@Z.Q1Y0(4X+44!TZT2H
M%8;KG'>"SU_GW(MHX'),/?@N>4'HNXU<(I<GT*BFXP_:[SM:]V#.O3=&?^U+
MNG(D!UZ7^J*D\2=1@IR^QJT36"4-5"6S$HK9[*C%^('0*$M&TA,=*_F,Z56Z
M;8AOY2L^,C(2]TNK#;32]GUJ[=&SR1)WVH\EZ:AKT F:$&DYE'DMJN(SHA"I
MUI;E[&9&]1A131Z3,96-!\;L2Y?\C-J6 [K':DHJQDM^'8ZNZ%IG8JB+%1-A
MZYKC 4MD:(U!C0Z[1T>L0-"<><%R3?+V)2W8(L*Z@NL4QK #WD'W@;6_+-AB
M!J! BKL$EQ^JA?177LV9Q0+,3@5)[2T5](:#'[0[ 'DT[38I\V74!^5::HY(
M$0Q.MEHCN(.;N(1\ZL@KQ'7,N>9866%D5YWE)A%>_DZ="J!@4(V("LL' U-/
M$=V6(];5]TB!YMZ]+;H!+H%]LZ?/7^8G4/@7/,#Q@GP* ./D]JRY,L>SIT;_
MII7]=WD[6_%?L[+4TVAY>UZTK2OTC(TT($1+UKX^]MU,6#GZ?2&#6/;0*_KQ
M*5 0I1'7^]L?(-"QYZ+M-_]WMO>5+\N0<* ?H6!<9"J0$9>)BK^:IR!PT;HL
MCQ@6]4:]<)6B8B**HI]N>M7R,&]I,1K'C/DG$&DSLTBG=F*,?\6"' Y!:%Q=
M\?"B'U(6\!;A>')RI1WHB$XF4J;VY#G)?QGO6ON%)T@TY7(6W0SSRO(#E.33
M[IKC[Z$?T,?T7F1IIA7L$\E.8!+UM<LGA*CR4)^+KNFKM)SC1:K.Z?,\5R21
MQYJWSN2##DV>YY7;/ZE^+YX-NS1/8L@_AE\,_>J/.KDSA@#)N)^YH?IX'DR&
M2;-05F/U]K!A!.U6R6SM':]^TD):'\P&W[E$;<0XS=?IECHW4VBO/+O)P>XQ
MH\]&+H-8=4/)J[MRS?4B)+2YGO*7TU.=N<9XX:L>=@[:T_=GAD[S=XLQWIZ$
M3H&Q.%+11QI+-PQ]RQ&C1/NWDNS,ZK[+$DW7:Q793&'RQ)1+/$>2MT _,])%
MB@CSG<<S]_SKBDF53DD!FV^-"S%@%B<IG?D-=>^="ZG++M7\%!D1BFU15:95
M =&0VDGLAED5G[.4@'5CUV\L_G4V^?"T@D_N)HVZ P .Z-""^3,;,D,EE9LI
MZ6HS'R:UE-2*,)\EH_XG&"D?P1:6IFI1SNPZHJE#&S?SQ>6;'0UQMA90<"BW
MYM#/[)^BH1E*J$A5/[1)&1*>AF*FJTM(D*-&?0C*T>% 'JZ^)W9Y44N1Q!L8
M6,#/@Z<BE%I:+I8N'_->CB*L-F&LO/VE-C(LM%U.75EP(9P1.DP)O"];6UW
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M(A) [\2C"4M9:GP1[9=EU:)YNH.+X)SH4B^0A^&,*4[O/GI^WS_B\J9EH6N
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M(6!43 (8_'^A4E3%\BS1"B%U-;EI$U^K)-0/N_3_SW#\,IED0%$H;HSW_"K
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M@=%_2NL&W:7ZF:/K;"%WGG,9OCGX+<6KZ*43RWL02IT1!NX'O9J60S]/628
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M&8F_U\WMN$<P_9X[.!SA1D8TG6TXC+)9U-'6F&V8>=G=O:YO-3KB3SNEM)/
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M$6-(V<GR=J3+/YAK,U/@ED295[3;VI2FD#D94I: 6%67^!RM@T3"01H_-A:
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M/_!O^R]O3(??&.W7@_#Q?=,O%GQQ4'V$4Y]>B:I/6/:=;E59ZB@:M)T[P9!
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ML B"U]F,Q2HLW3<R?NKLC]G*7_:=NMEJ0L1CS1.VGLFF)GU!E 6*+FW;:DG
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MOG:47VPW><5G-+QQMWH9^O#9@SGWTZ=@OT@9-,-Y:UK'0P8XG(+)T@; .T]
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MMT._[>3ZL%G4_!.5$G+)A1$S#=)ZY )%P(!F/LN@+34I"W3 Y*_\=SJPR(@
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MS[6#>>Y )7&>W:*Z.W27[#TWI]KNQZ[&>;GJ^5;^=LZV N:@\&NHDW/*._9
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M#%#O5TB8MYQ4Y<392/%*]+UUT[\7Y#PGU_3D9;*$5D]JD@X75^? LCUGZ!F
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M#)!2, 7:>I-]!M!+@*^;+RM$^D*&$=B^E)*-^YF'C L>M[(S=2.D)4:X1@
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M>_>>-L\>W0RHY@RP;;4L/:<^XH#?_CV5-5P=V* LE1>F\F'Z-M2:K2*S?Z@
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MFY^?Q3!&EG%;<L4OO?LA-,]D/^^QZ-Z'6$PM X54JEQ9%.'^.OE68N!$FO1
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M+A)Q' 9ER=[P]G\E=V"Q7<1^YCVK_C>.]^R7OH0>G H0"E6R?^V4&6[5W-A
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MK!E.%G\?*[$MXE_+E;TV_B*3=HY6LDMK%+I.(R]7^::.*71X2OOE$;0_OOR
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MO#5KSMF<K"(!(9 2$M#<$#;I;\,IB#9%Y-J0(;R81:B(N[$1Q7TG_#<[M/4
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MWSP$UT6(=VXGZ9:TZ(6NQ+":AJ=8'<N)A?(7O?$+Y?]^]A^:8 BV#>/?@J*
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M/<-EKT,^&$8B<O%/L97R*0[X;2/#L8B<ZKK/P6(]]QK[?O.Q<-VGC!S%K9$
M]_I8K!)ZEZ@FTP(YDC2"KQN.#YHK8T-0)?C.@FFG/=N&M7Y[C"6>'KX(;DF^
MO-G*Q)P@7"P4RI* >E2/V/;1BWXIJ[%SX](<>Y(3=:'Z[]6C94R0OZQ7AJ=>
M^^G,>' M7VY?G)^OLI90V\?(QQEA@A:AYN]U0@ 7T7#0:%A8<*']<HH7$[^9
MYBY7DD#.W[;UQ].,<7$*8(N]$ZY,5\=5++3TF*8I]<=_P!:^L\"&O-6,97^L
MZK%-<#MXJ_,]76DD,@(.^8##*$ C2,#Y6YC5$"('_O* @ZPD<D,>5/=S[$UE
MPN:+*A\O ]D0_:*#F^^[_9NV(71DGE26W48"PB!T$I"/AKS91;;5?:F^XM,F
M;)5Q1X?7A3LO%4Q]5*8H9;K?M!2@A6"FC1]ITW*_,1:)0JMF"BLP"PDCUQM.
M0"7#MZ.9=>S#NQ^^GIIMX'4C2PY$^Q0\="SJ7KP]9^+EG-+*8'#9W.UB<]J5
MCW0KJQ3W)Y*([@<>>/KL.7AKE%]"9>06WCG-9"TN7M10LL#%1%%"Y(;8[NWE
M&F$G/6X?O:X49D):/?\T;-C0HJ#A2JT23WB]0.3$%D3[Z]3UB-]/0-%&;V=J
MS1P$AQH'<Y\P\K_.9K$J7\>"Q5FC5UIZ5:WA@XCB$;T(XF]3WM%:$$X2NZHW
M<$@3(:A=6:;.NS?TA+V8Z1M#[.O.^WR?^R5/*M$J1Q7804)B 9:OY;2^<F&7
MV3/!Q\=7;%.SUJ?+[N$UKRP1B>2"QNQ?:J-4OWP5OP0T:;<UNV81V> 0H=Z5
MD5L91Y9;"HS80=Q#6 _B>OVYB0DL"6CS;K9QF3$6Z,FW/DT:GI[L:XR]5I/W
M@^_<!<T6+I8ERP8L'.<(-<<<MT0(SD,";U6-R=\TG2XOD[\YS;JZE?B(@N_#
MC9-2<4X&<SSJ[B:QQS6[_W%:O.(0"BQ$H')=MDU\>DH"(!ZYI\4*L+O$ 5"I
M2%O_Q-+Z[#W,LQ\)'\?'SURNS-S04I5E/L=$PQV9-Q],&\@"NKV:Z3OXY\ "
M0MHA(@)!)VG/W,8<D8/U;XE^BG#XNF*4:$WA9;>*3586B]MX-N3BHN;N0C2\
M7"<0JN3HN'DZK9G;PYU O@!D/"5H;$2O%5%)V185'@U5&80QX@7*1FY\T1Q6
M.!A/4+[JRKO.<?&DXRR#2;KPQ:0?/6>:3C9UR#+4#N\V>G!23GBB/2AR&*C^
MH&!'TCJS[EW[NUW1KSV6#=_"CPMRYF]*VQ0:AE)OCZYGM9<<6W27PU=@Y(KR
MN:$8L:VT&!4(9I$ 4WKZZX](@FAM]'HRIM>K8WI%?F=Z[(TN3BN%YW^N4CQG
MR76?:X<$3/6TLZ(^-+QUO&93SSF*E%#5X"N+$+%[:Y6EX/-1=W+3K^I<N'^*
M5>N<95 NE>F&/3?!$)++L-Q_6R%?D@10XJ.^KR');PP-<1S$Y$AD1T'EAFL?
M+=!Z0# 7TH+)]SEZQK1 X3$AY0+W3^&.)$Y_BEW68[H)O:/7V'GTHBGV V?Z
MZUSL,WN]9CWGWQM7(0JW"%4I7-2_7.Z!@I;PC?1#U0++2#J6[L*GA97)L:@3
M>M90XUP'U(R'+3%[/8#QA!+'3QSEE$?W;Y^?SU>_[CG<RMH>XNM!B/>U+-C0
MFNY@^;2E-\5U)=-<P$7FK.!A?FO"878 5";/5F^/JJ!LT\!AU<7I[*TXLQ,*
MXZ^_V'_HNGBH.H1^3%:JMK:QUH!\ IV5EX2:8L=Q:IXN?:B.65Z_*<TQV(1<
MJ(TKF[Z]3G@)WY>:MTVLL137UR'(@S<_7)KY7>LLABL/3ZE5E5U"U[A\AP^0
MC86*ZB/$6U CA+H4[%UAH>VS$1/3SE86B\17EG;TX9^3*#IL" ?P:I0RGAOK
M01;>'/-('&MAPT&A[7!G+(:^P>(DLM2YI:N(!*3+5;8AT*HD()RLZ-QDD%?T
M3:VJ6ROXW]KZ7CB%EV^;*CW$*/Y\+_[>Q;F1MQQLAIB*;^>\A%GY/ ]AV_0P
MO85.R98VI#Z\_:*2Z=J#B]%W"N-N1Y_1Y3[3V7X7KBLL?*N\,LYK23\U0J4V
MTBGONWFT#R"(%M$/]\Q?:-NP>N*R83@51B?D'<(G;TJY4#X1O\#S35G;F5H2
M57DX//A-UR^"3U-:D@"C7 ?A&<V(S_4"2<#6JR@2H+1:I$>DYB$!MSI:HT[Q
M)21@@*<(0;R840AJ!-/DLY=L#IZ%;\_:8-./K,?DA3U#.2#SR.9O%B4(2)Q,
MX3/BZ"^Q)Y<>Q0O)P]U!_5V0KTEGDK;OO\JMKO(UM-XYW<X6Q'_6CUCK,^1N
M..$Y*3VJ#\6_Q,[@Y/%:A"^'VX(&HX<0@07"1&'Y]@6B&6YY.:93AP-"*1OI
MU73_/N$FX2,)L*)56=QM:O\YOFR 5TJ;)O@=S?%#RFA3TV,^-/*H79:.Y:OS
M.OQQ,9FN0#,AQIL(^3H];9[.8[OERZ$ E<'90[6Q@[E0W6%Y>KQ ^8@0<2(K
M\^#86SFF*AX:^9&E[YQH45/<>2\'HW(H"2CX<\8S[ '*NA3K=ZPU*"D$>?VM
M8&GT;?3)[TO;LX-;0B3 7C3E,):=FT]5IU#CD5QU?7OTL47GGW>\6 ,230**
M0=OJBY S^#<#M8P+'&])@#9Z#/FNVCA..JE7T.!%;\F]X KEUYWG%<_1MS^4
M/$)NS^ 4;!"EN\UAUK+2/<PADCU?+*Q=-JX;W= <4CXS]X/M83^+W7XX_=4/
MN8\SK+-A]M\DEK>Y%PYL3PDL!\F,6!0Z^T@7VX SM99*$3>!C2V<_VGKG..9
MJ)F<D:+0]"I1\UGCM/3<.PY:7SW<-;P4=AD-63C*G@=SP*W5Y](SNH1J>]T<
M#C!B/=?5>4[V?@?"/VUSN^A],!KMF5=2DLY/%IS"<$U"]//SIS#%QT*,>XCM
M>9R!*:P?QC)\ +XD\:1=>E*FS?E6$-.]N6UQ>UDFH>;5J-B0OKLP7JP'CA=O
M3RB4T,.4CY4S5+C6T/B0 $8;<:;JIINUWW-O7J3BXA8XXA"\)$\]EK6I'1TN
M4VI03L-7LP9K'H1$PJBQ_1C'(RYL*0F@0@4+(]\.%V0^\IW'A7V1*VRK<:T_
MJT2EG)0O_.#ZZR9#@@]ZI\YB 4FW7CV6*#4I07@V*5/CI8AIWV!17U*XHTL[
MOTC&IL&X7I9<7-\UW;<1#!JFSCG_O\>=>^#HE[L1U<@_^RIJ3%DQB^EORM^J
M(?:K=!K9?7I\I:P@J/3*6;\';%WLH:?1]<KD5E^@-T?K>?!7RT?=5+Q$'&4E
MWSDN5P1;S$Y\*BA(KX+$UG_(]V9/&>,<GJ]N0(WW5&7*': @]9,@9E@;I(0V
M>ULNQ_8TL"%_UAH&&GKAW'5$B[#ZF?"P];SEI3S .%I[E6O3=!SC3Z2V]$C]
M30)L\ (8GME47[LG1?&%LLZ_MBZ[<C2?>SG13B$0=10 ;<'=)8Z:<A.^XA6\
M7+,,6PJL$B*;<JRE+K]4J90Q8:<H;G_>1W5CC^XZ 8REP5GC[V%/N%G?)>;4
MARPH4>(_2+[B^M;)?O*"VL 'G?WN@G+H:4&S_J2D;R'SCJ ]=GI__6=^7K*Z
M[<#KZHJ!@S5'(]^M=X,96T;OS"]2L!^O2E3W565A/=3C2(#NB)!;S?6JZ(T]
MBT#NT](KYRVQ^^V&\):&\YLPOE']+$3&I)+7O=E,#:5)N:Y&SB6]1;P4Y!K<
M<3>RY[7P=\:,?;Y(EN3ZMHS)VRP"Z<,"5>VK;\2\.D_P]UCUNZ._0(L-*Z=.
M\9<+^8=5MTOVP490,":^D5-XA*GE":8_\##_"%=1#4,ZRF:OY2R-FT&^0,JD
MR%RO%40!XYSQ[%#!&,L+E Y7=/E2_;!52GW<Z!6"ZZ)X_[Q?X.%JN2\]F8],
M$#(E$2&3G,@Y=0:(4NY&-;N@JYFOT_)*PDC%F*)9#\.;GWQ)]SGRO;^RNJ0+
M_+9)ZI99-WN@]M(VV:J_4C!TE"@%E483,TYAN8N[-.N5:U.&8_L&%:$Z\@$L
M391H)!FGYS(:RH7+L[#!T#OHHDSA1'O&ZI["Z<E.30/#1[&5TP\N7@E\)7^$
MI@/\&Z&TY"RSP@8M=+04@MN\.\)>H;^/+##?NP>>V/;@:F[AWP.)GG6X?H-V
M^HH:'4/.J]<"@E>#$7=,9XR(#4*J?,)*_.Z6&P&1J;9Y!FWN%JZT,P7I;JY-
M-]R<-ZX[*:A#.&&MX%+F5O!$98>I1 F&<9HYA:FFXN.$L8%)G)^7?U)EM%/G
M_'WNH@< 4P=(!M[TL,%6SJ-M5GX4QH8UTTQ41]='KPSA)SIURFD^M(9N/1#-
M[=Y:>_[&=6^1?XY0<5,C5=A\='?"ZZ-16=)!Y6'VX2 BK3J[0SUPDF-_P@9\
MI58P>S9U<NS8<+1,\_:!0!^5Y.@ZZQAB@88*65:#LU?NUOBZ8[=B8.:\U?U<
M\B1Y#HSE@83@5><258V,,<G((,G$G*<]&7!+R8[8GQ::!M"VR=GO@F8CXWY8
MCS;45?@;QXC*"FJGL>K ;R[%&ZPNW;V6.2TMEZ(6=!]?K) 2WD)[%OU>'A'H
M&DHWW#<UA$.\$+)5OADZ@SAG!2=I1'BAK#U:@$R>69\6"$F*T*G [6\EB055
M6IKZW.V?4X")X\]@HQ819[%#.Z"@38G9VQC:=*NCV>="M\I*;LZF9V'*YA,#
MNAQ&.P(:^Z]M/#Z* <NY[?VN4A)PSATD&MIB$>5D4"V>@Y_?H'Z] &+QA#^N
M=[HXN>&=P;3WR?M*T=RXDIFO?9Y!BX>E,^-,03?G@SFGM0UOQM=-(&7\3RQ9
M:YT;QC0$$:]OU-^KQ0145"V$^7A)<CQ1VN,(FV/^8M_S0$Q>S.O1EQ1?:W(5
ME)"7LN5DQK91ON>KBW:\[.GWH+9&B3W&;YU+C/H*J-I (V:Q2&] 3[EG73OS
M@49N+_]N]N&>[_-DQ7/9CNZ(?)UN;/I"I1_TJG<<[!8F\L-WDY_3%:=9N>?+
MPN4>UYRU[00[.$:-(P#B)17WM.Z;&#(?.GJ'N"?VJCLN^I6<CB)H6VQ\%;S5
M@Q/ (HY^8BY4P>_53NHFOVU"EO?\GMPQL(1^2E7)?7>?)^3UAR@-8^P+5B2U
M;JZPON(I ?Y$.5I[J'[7;)L.*W AW3H?UBM-NQPQ(E7AZADXL?"S\I,2>ZC]
MSEV=#^0;,P^>^TP",(L8<6*U/OSVYHKZI-Y<=JO(1#0/6KBPH#??DTWSI\FS
M=L_8N#'K15W-=Z+RVM^?>_#+^F7S48#(7*^)BP0L=BQ8$MQ^$+7&D:QW,^/&
MCEQ6PJRS]T-Q!W=;E:HT-75M\5,$]8'ZI(3Y0Y%(%*V;R:,M2;I@4\;B^HB*
MNO*^2GOV/-^+I7ZTT!J<DR?S(KS=,22![WTM+>-R@Y^PQ+S<\F1598GUB\@B
M85Z0YWGJX!.^!Q>]H\0<L=PI%=44+^2Y?E>4W9J^TU""V%IYX8N2Z9TA4U#F
M>*Q>A"+=HV$=P='EAJ=%. ZQ(>-\/:P-+'+=NSRRRHQQ)]G+,<>@6YRCK2"?
MVT'NR>T;H]5X""$:)N@9/T>W?35CK=]=L@+AE2\<46A=>/-NQ3HTK<TUHK/C
M9I#LU8%/< 7PW/=Q<4-B%U',RL+3(&&0.B(T.FOEAB)'<%[;*QA2,\E,L/WO
MHD0B,5=*S9!,/X,&-9]_:A]ZWAW\O52<':#45'6MOXZ-G:=C,S6>]/1H,^2M
M\[ 3EV4U3:?M:14/+TF_5HOIA?%!13&(R,.HB[-0;K3-="\)H'Z;2J-J;[,D
MBV,,BETK3MIQ;6R^E$0!,8?UH=#JJ& 0+51UP75!55%)5<H07;<34VDHMQ5Q
MAU[U!W_+LR"N<]%B]S=-)/=^OTZ7TLU6]^CK)@$I@<ZYO19CIR>"DR3@7?::
M/2-9Y4ICCTC D0\A0T)F1F&IV(A#M:S7]-;OL[QF#$UU[Y8JY0;TMA7#H.J6
M<[O4&\0;]9^$ A,MA;;Z4^[=8@)_+Y)]1[=A(Z:Y$DXN<^.=/Y7ZTC/M54,%
M,>)'\*%R1!2J/"AHA_=GDNF&],3H;A'7.UIVJQ7KNQ.=\\I1.<@I:=&OX-R<
MV\I[-MOO2(!\@U/,2#9_A\7X*;&<%>5&$$0+#[=DMR.8;PTDK$U6%!;1<+EI
M_1(]*=U"57*]D[)D83E$HA1QA0?(9O4@^)[S+"N9G^9-D0#EL3KV,..G!.85
MZ>T..MX:8O@IL@.,5B*_.^B9Y>- O(?C@IP:U>3380>)4LO55Y8VG;R?'.0^
M )8L7(6>'5O^.#4L.4-:"\65:NNKOC2-5]I:YUI+";?+^/:6];(B?FZHJ8G^
M/$OW!OSFL->EI45:<J<PST3!+-O@\?"T\:\I30F-Z%;">1@MFP&,#__:4\(S
M0\SV=)%&?P3:TI>TC:^\N-4CRB@ZE,RN7L<A;4^ !>K,7Q]T-90D0K(W8%'P
M)MW+L'-8NTA%//=5$K N.]I%?A%Y,O2A@IC;,WZW9B:8WMX'J%:6$C;@<WD:
M)^ SLG>_]<UX\_0/D65,XI$%U@@#6AQ)J&PAYY&-BS4G4W6T8.^[]9**C=PJ
ML_U[>ZMQ4YQ.S[O:9UHN,8)MXT<#MCUJ]I;AJ7_3,0;P/95]RZT+\9C$>6)5
M@?#G;,_5%L/ O-X?^I,;1WMJ1L,]>D((.STS2#BJW''+K(#8,W9Z+VORP)1G
MX)"%==JTP\8^A:5QIOB+#_HA]Q54LPLE"PY)I.[!(/6PY6C37?7Q7>X1=SCM
M3)A(>1\N,V[FDX1"U]+G(..4YQHIKL:2/R3&0)L,?+_B3HTZ71+#1\S)].8$
MI!O-<$T-*&)[B=U%#RN-<+;C%D !=Y :%>7E[62 "?6]&-\IN=>P78K&+09U
MT(6Q0M[C63B6D>^7ALU^5M4(CXW1WO[<$A:BB&JD#F[D2PJ0L^T3AL]%)TS#
M0-&>,"[]WL("A;C6=;6*;5[YW>25'0IPVS*1,8!=CE)5&ZD71[A6(Q$7O1R)
M1(\00,/N*G)ONP5[Y7=H-I6>K>T(91AP.6^P*%THU%L$;UEB7%LA%&1A9\_V
MV*>J\*!02TL5I#O,T15<TQ##7N3$P>Y?,W!U( $73[SX --BC%5$1ZD.UTIY
M\2;F>8:N;YN>7A"\<V\M,>-W2^S;.V$_7<[8N?KKA30J1SQ_3/=-W9+@2_PX
M_"4FD]IJ' _:LQQ(N85MFP-1;EQH,2470 F5^;$IC='"[640FMG)-G6PO%>F
MU1"J=ZJ6:IO[N^>7AZ[KG4'P8,PGVSVM(U/"1W>Z2;,FYGHA1+N3I_>@(^<8
M?]OGN@2]EYG?2(!W(N4OT2Z^+Q_:8:F$J 9S2#"B5+%]^XW]$^WR45E&GTPE
MT&1!MD!T'T]X._>'8(%Y:#/5-,#ML,I8:,?$&24AAZR/&]NK"R>D1Z^$5M<U
ML('L]'@6',/JSZ--=G_CGRRJ7U[3\X7UYV[\,"+G.+3&'R( ;WH&MU&%S#^+
MS\+2-TOU9]M.MM*Z^L(IWMC:&L?JD)&?Y@'M_N6'I@]N1"61 $L4E@\2 I/Q
M9*)CV907C&H>2TA9+XA6X:U-F7=13" !M:JI43>60]CGG).<L/?[XL<$^^/8
MO!HV3P<F75[:R$$."="H42'*U@3%T+*#AD%W%:$W;9%,&\WS?,$$%FK&3$@8
M:\R?C49>(:/@YI4C'ZK+]W;H)F8"LO*M6N>D.;_/QU/&OGHN2P$IAE%B[..C
MH&RIV"]J?%O2Y3%2/P(WF)Y>.G/,TG3,4*PO^?AJH9KQ0+R6)&_VUDI!;S=_
M6FW+R__ F?LSR&.C=8@?JTA08:T))J7C2:V76=G(X4')M[D;SW-Y&I\)/+_!
M+MK^Z%1OUX<P=JHW%QBVP.9(A;<L'A>Y9B DT>LK\O8Y(":FZ,3AY_>0[Z)S
MM'SY@0$SKG5W F8^UC"ZW%-' I[!R(RC);?^&@D8:%E4Q].6D8 EP\.&B<4C
M.31D:[C YC0^4)+6A;BJ]4%HF3C^,U#AJ>[,7O""FM)AO]KH$@)]B/C8<"#B
M.4P"@$+PB4!]&)8>TT/&LC*^#XJA>"G'',-U$F =/9@ZDO9\Q8#^W!)7]>(E
MJA;.\AY#?>PP;!*?!:^Q%]FL>KNZV-"B(J>I*K9(QHH;(^GQG3X/)&LLOIGW
MW6,0^32Q>+W70_)$D 2<9R4@U)M1H2AT_+KN+"0(JKDM8V=\ASG]F]84S",J
M_U0/Z<EW=* J<B14&[V EVJUYQ?^8%<T$:VY!DU$^A;G7U/7BT+4"IA2(FC8
M%2A_S7PQ]8%Y0W>+"^HFNQ,G#O%P0?QH5(7>HF5+Q7A@<+T<NFF,G,=O69W&
MA(@#;_MD&T1@VQ.+#N())_G$BS<Q.R(7\8)1RFA(*Y5$/W-'X1/:[92P?&[O
MCW=/-.,N%S=\]7>*DI..,CSI)U*7HJF)7/@7/[$!A<W#:[-L,9)57\V-(3^Z
MDU+J]67Z<0H"JW@&^B,U]<!CUHXV3_S+\<T%#G)O9/3M[K)H*E'OU[;\I&"Y
M_EO^V/3!VFGF)7GA9);^TJG"T?A?VEFK?0L5#4L[1$AR_T.R[GI'')HJ0[$]
MP2@N?(1S5Q1F(Y@V\T"?1;XME^W^C*2_P7Y9SG8WF;+54"^T+-%7Z^G(UF&$
MV!P][79 L_JEK]P<11]SF\XY>?M#(E$EX"TX":!5I0S)( $?*XE7H[9T*XWA
M;PG(OOVGB(,QN9][A/V4T5.AK/5WB!^[6]]\Z#<46_E:XH9[&5M_G)Q=6;#^
MVIXH=6^P7@%2Z]F5WYO[,N+9'($@-U+;8"*_?PDLD1#NKEHZ+,^-MT/S-=.X
M);;+WQXNX[JU&TD3XBH;-IVA$O]ZAV&<9MYQRG$.'EXN,7RP&WR/VO5F<\1C
MZJU/*8VRF+15#+)7Y#V$"JJ$<X ZC/)BF!J<\JYLL+87+/[ZQ#N7SZ#L>>Y+
MN>*,CE93.UT); R$5B/0S^TV;Z)8/46,1Y&+0]V2A,BB-Y\3>%]E/9^5>&%_
MAUKS\C.U9W<MYIQ^>[!Z)D0E'TU 3O=V4_.^Y/*QFM -![A_UHD)U&6Y=/D1
M.9__Z%P_6:X"Q8S->E$T,2SO.6-TQ\O1&W[O:(^?*SIUR/U$1I+E<SR8[5"=
MR=/6!.M;8"*W>G3)>68]6GGJF]"WT%H#XL:]H?H/G6L \AMX+CW(<=MDX98,
MN<JO?2PPBR<!%01=EZ'QAD]:\7(/5/)(@"31 ZQ%Y(,ZHT%-B?<=H)8+/ART
M;]E2 W6M^6(\;E^[\(YBY#9C/+KAZ!OV-2;A9 L*6J01TGOYTFA++=K(6"Q2
M27]9^RU%%? !PH)G(01)JD_Z*,)#0=>A6OD*/@L,S/>8JFW;2^Z<(V=\LHG.
MQ44[FPO,[.%ST%C,E_F54IP0WK-NT$[2 (9*G6[SR+;Y3"<T065P"TK1U-3$
M(49G,QL)"4J:Y=0!>];8KZ\Z?I8=BGDP5T9LH!,_EJ\=7W#<OHGNG]ON+,?
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MON),]<3Z*!!9/+\=3!!Y0TH$LH.V]K]2I7IV!^X4L"]=NXE4??4O^@U-8?Q
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M^. J?/9-N$WVTF&!$V^XZ;L;SC\-ONR,'LC]U.5:ROWO3,S\,TG @T,DNV-
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M<V#UNAY/BZ^[Y\.C V1,]30 #8!W2#5Z%ZR[M2J5C\K]D'\T'"@,?[NQ@SA
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M3"C!S@U%T*HPC@AT..R<B7IMN!(8I5749=,#Q%G+,3IZ4MD'0VRT<JZ@L9X
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M .7'P@6H%D%.>ZQ.2\YI:YK?<EI,772RZW9..D,+^[,/^<;EOF&?#D:"8/5
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M.GQN]1?YF?&+^08K'^TE9@Q"EMR"]*IEQ>=/=RE3)_[](JQLUF/O6]2:F>W
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MRDDHMMXSS48G-W<9N=#F?S\3,D2L*Y]'S#0U)PQ."7B']M^_G7C)'ZY[_SJ
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MZ7+UA:2D$H7KP\>9T<._$:Y481=E3Q(JL% Q@&&J0YE\B9SA+\4N@SJSGR-
MBW9'\(\>%:5QU;<IWXT=6W>E%6,)9CB+'AAMD,I8%U^APSI^__7XY]*2G&>"
MS.GRUV:&/XG3B ,L%SBU6 GJRUI12C ^#VO49$[>3[Z ]-XA0G':75?03EI^
MK/*LF9E41F;[RN'NA)DCDF%O<H'$/K1$-[)L*E2-0=O&?VYY1?DUJ/G".V"!
M<!A1W@.?+5Y:^&2[ZG<^%*IN=)SABLKJ:SHRE^,3<F&W,CDCU>:8A.G62Y@/
M[3@4'I9LB5]-WGW$M,6KK"Z0J%Z1'>$0AY)\!$U).O]8JY_#67L1^(^^[GU
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M_O60"3FEQ+!R-T&&M-?UPC1(K^V*FF)QGM!.UM*7]SD!YP"+9QRA[3CWI5-
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M-6:N$A1)CI:NY*-EFV";S\NKH\W\1]>S&C_>4*0!CC7F4([->QKV\.?!C/'
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M0XZN /^R7,'Q]F<^YEC">\BG5G. N+@(V0RL3/D$H]U%,)/H6R@S,;7-W=#
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MR5,Y O$A_/$D]PJ_O&>A"JF2O<*@I*C7=\CB:;\(D)'L;#@2'F;;JZ,Y#WV
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MHK1^/9ZW=]RX]MQFFU)2;-H\]L>+<[P'[S1.0T);/E 2K:<7P^C?CT"_KZ8
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M4_(73$XX?F\W)/U.VZVL.2/A9[Y+$(Z0J*@]#V=+V .GHCEVCD#.)G%.W#C
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M$6A0@01E7*"@:;XM+2I/X<@@4_6O"DT*^)"B*K-L0Q]Z& H:0H9LU5*?(;2
M5M(]%"M<T;2E9401MC6UX%&;?MKF?):TW!GCOW=30RD[$Q BNIT>L("-1@H
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MC^D_6WO!^+390>W'P(99\R#M F9^C8+E'Z>,7>B'>7L+I-L6V4P4B*<8<H-
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M\0%/=5<H:6@62$UFP)N@L]ZL80_?^#=-^_]V%$RPZ&P85J/4N?5KS%<U @
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M!S6(X,;"KK0W(3+D]0-NF$4,\@];485-\U(HE[NXDX-?E(8H3!U$">L5D_E
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M5H)>.Z]1$B=$&@3PG/;HT&WQF UP&<E=$[E9\L] W5OQ/[=9[A0M\FBY\=X
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M^PG$*1JHY'.;&#'S*N%%/+"P)FM$XWFVN8'9@T7Z7Z$6G4CF#8,59'5,[6(
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M*K6()S84 ,1EZ)VZX!?:9$QE;2;=C99DLD79;K>M\2ON*^'EBJJXM0 /,PK
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M^U@%/-T<Z-.1CI&[VAEC\#1I\!'_(J';!81OA[%8CR88GUG$H+^&W9<-?9V
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M+QM)%$]=6$ <M*?';EZ?J,-YB=V4_T?HRE5^(:L&;,PT\T[M(J:HD]'T3?&
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M&&Z'T=*WJ#$K+AC#3>C2-?R.$7AT[3/IV:J@X)UWC+<N5&PTK-<8OWO^^0(
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M.6J5@ZPLQJ%$*<+[KTE CEW.I)\!^1+6/J0 VJ<24I%I3'SS]Z(W?7,HX@P
MR4ZFB.4/D1_-N\(_GE*1>!0/C[OLEEDE#N8P3OEVN57P?*M:E+_'RW[E/PAF
M[IA\2BK>V&L_)C IO<9@;*8A*)/*3&=ID2N-)%SY7F]9[>^Z.X8EQZN,H>Z1
M 91TW^W'S#P\FH2K/Y<:;$2PVV9W!7DK?Z;/!P[L',<$,9U@CJHHV4W,A%F-
MP8B( SW]'JO*>G'AE2QW%H=?=Q[I=0E>WW=74O5RC:(DS^/Y"PGN;&V%VV>
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MYT\=NW#P]$,1]5-3[TR2:@ZSP3F-,\ U#X-!-<[E8[X3/I>?_<J+Q>)W'VG
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MX$>OB2ESX%"J3".!(>; E>+X-LMXV+1_YFZHS/7]9T\3;M$:X=7T-P<+C6<
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M=>'!0+;VWX*LH"!"B3+_B9WKRBQ1%!BN=]QF<-VUY-=O^._2R@05U:'SE\X
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M,;;[;Z0MA+6#+1..LYS<?=UG]8ZG/49+@N/_>^B5:$%T;;7E_3(AV%R7NN?
MQ_6TJ(AM\3;H ^(VD7D>AA-]AE>9A<@AK3Q9-_:JJ=#M!SXEN1W:^P,_ '<>
M\K+FLKX+J:(RL>,'3 F@<%700JS,F-5XM9&<?T5K8XRW=O47*64<TZO,"8;?
MKNW0"]#)5'@+FFZ2:+F+D2*&=PQ.X9[5_AY[-CK>* ;=QESN]?[3$8Q5,"T:
M^;O(PJXT I==B2D9V^US]; "9TVDJ_CLKZJZ:QOE_ZUWX,FO1!6J2?;5?IN<
M@'; V%&2 7&7P0OQ4?8UD5X;'NJC[XK3MV*- Y^QJ?$ ]JNQ(U19HF!N0,1<
MT@ F5I7FZ^NM7>[N0H*!7[Z&:WGN\G4S!RV=8L/)/+1^:D:H6NB(G^]3;.50
M\4N\&RBYXORF/H'+A'&ZR<WDI"8F2;6<;]/@J)22I_H:+[H@&KXX=/]5PS^G
M2F>)UTVA)_[7N"^U_E4V-7GY;W%UB5\,TS[<5Z%4I*227IYPG,/^)JGL%&PC
MIS;%_CSG<C@B/G?9$,22NS/9G(2L22VF-@#ON*#8B4B24,"OV<ZCYNN]GG=]
MQ9[K.?CE"(F]8?=8$ON *:,/:2'=I0[N$O8Q#:%!&>FFZ@)#S^W6W?>7>N,;
MW2(9A0--Z=]YMPPH >]!/"DUNU39 -;55K^9JY\UHPX7]U>#,3Y;[)\!GWOT
M<LMY]SNTFH-%MR+P^6UP!NA5XG#'S? TN9L[>8Z.%<-",2<MM^,T];I&9*M"
M9NKHL.Q;*P?+5O=]JU2\PX+S>.3]:UT/4"G#(6QLHNEW5RJROH]^7Y.;2M0?
MG&VPM<11Y$?:*15H!^ U8F<[5ET9'U8W&MM[1[+Z[]_KX1I,_%)0XKV+QI )
M7KI,U9XY^';BHD&82A\B@FR'O=G_\<(G7(#DO^A)808&5^"/;>KBZL>/-0U@
MAO],@:R7M6XWT#;#@230D\&BD[?K%?3'=P4N3?L[D;*TD(%^:;^(^4>MQ'G?
MPI8\\>]FPQU8+,<:=,#^?(%U568I,F#@_DQ&8WG \^=2>ZU.-Q;6'CF+E:JI
M;%=5AL@K>1-[Q:V?>M>K:=]_BFNZ?WBXCMK8#@+Z0<<R[\=CT%7HJ+*%%)'3
M";=Y!U!P_ZN?0/RU#A3-!C_YD=618V1W!+%LY^K=P5=QS'J8VXYI?JO\\U?B
MB7Q!HN0;!M;4+J+[/)C-:N>9!R*FY)=W)1?^%[PXOKL!/L[0ZOD+PI;X,I4C
MRMW^9?*R[MT+'5GV8,R=50(B':.[ 5&SS+7)L+ (>HO6!FK'1'=X7[P9D_Q]
ML9?B>P;8-E#[;WM1P#?3SI:@\WL#0L<#6P!C,(41?>\ ,:XU3T&$J5^:=(4^
MH_&&2/#//,&5O4&<4J+Z#U-/(C?B)\C3W6/1EGA"2;O9);!^=,5*XV;A<IH,
M+^O)# -_TNDY/!J#QH>3Y?&HJ,UE%/RW5<NM]?T2%]XSP*Q%7ES*J!*,[9&:
MB[K3"A)6 ETHKSB=O8HM&?N>G;#GIWL&2 "I@-QMG)O,2%H;1\ES?]T6:X>_
MLKYKH;L"FC.\"C:%8CGC\3U')GI,7>0* 8NUK.^P'BFT%-E4!G3SA.V/7RV0
M$^3JJCPC^E-251,[?-?0FTGGS>WFBR/M(<VD-V3E474A\E54]6#IS/[+\OKX
M%[KF';8F#UN2M-XCN^A0TK9QK];GG9+G[SVXLU<?L@G+Z.=%R4L;]4G[)"U+
MO.U$19G6PC'[ZD*4=%59 MRQ< $8>N3Z"=KBZZ<7%X C >J5^8PS<H;5Q,9\
M)2<B%H\[F3>-"&QMID<*+U#;*?YW[\2K<L0Q>R\G=Q:"2P/!6YLDPXW9JB:5
MFF0<;]#,ST#%]*,$??>\J%<*"4!77\!YIC/ I:7W<.=AF.<N.W&SK<$T8M[S
MO/GD+'BJTR/:UU=XXN3'>:]H?BF9]__.)=IVV/..VN69,3_.2!YV?B_L48K*
MC/B8;'#W--?9KGC$,'A8W[ITMM(FQ""GZ>Z<^_4C5Z)8H:7SNP<M>3AK\)3-
M0.SQ]0O"&15_2$6 +0#O(8+6YNUGS[<3'BP>I>-R[7:P!A;RP=^]OPG>YI'=
M4.U\K 6Y2;(_&B1<)_H?!1)$OS,F$-OMI,<?Q,X2UUSP9P"BR&KH]!M"RA>'
MCTE^+:\]I:TO=CE]I9O--=G_Z1#TO;+)X[5R\#ZD=A.V ?YX<%+#G_&\\URR
M46P63_>T^.H9X ,:W7L$G$QI@X^#JF80Y\LM?!]$WD\9^30_>0;@>V+[WRE0
MD_C!>&U"?B1?0&K ?0$WF+?%%&SIV1G@GA/Y1F*;?@T_\[_O"EW"F4>:VTE,
M42#"*L**$JEZC\I%@?L$BH1EU8U*B*)]?>]Y@>WX0PSE0;&OV8YL>1(W36&)
MM+6BMPE#>LLK^>0PH\U@5&V@#"U3GC3I40H)P;I#-\BIMC_J5XG+CO9G@+A0
M1*TZ/=&)>N4,\#GS\A +U+CFU/JBR<&WKZIPXKX\U!^*NPG-^TT=A K!7WP)
M]1=AW+9\Z-?%]CU*>N.<H?HO+!96!=HV*B1#"!IC7R%W.>+M\YUG0MJ7_-T5
M'&>BBBZVX[@\E;I DI9;O>5)>=]>AWQJ$JC/W:EN(/NZ\P;P.G!YLXI--NKK
M/591<W<8?%MZXW ( W/SG&@T(4[DK0?51@C%'FX+"\58],YSK(C<VC95O7C!
M.^%<UY)9%Y"-JDI^0?F!S)K?7"LS;)W8EXQ _OC[,'?IQY>31-6O+[:%5B_;
MU@:2 HD]\\=M;#?6U6_CIU$(!\^" 3YD545E76V,\J6\&BD'W+GE=^^/(]L#
M&=H14?PB%(3Z[;5_SNJ<>QY9D9.6XQ85&?B^Y$"AVYJ#G4)W7J:?8O._OY:N
M7BL144EW"'<Y=G<."0DZ&LY1[=WE_%AH:U[";O&$G;/G#;S9R5,O)<0M46O=
M#(/F-2=KXS5C%]SE9"PV3!<<X@R:N9=D@+ZOS/!E<76[GV?H: S]&M^)R>24
M*=E;'ROF'1*==M86O\T_.5&Q;1,+M?EBO&CK$M_B[ZF[3@06S-M8O%YOV)RM
M7#FL04>^U&#O]_T_^O*9_S]>@;.=\-"[!,S\%I4SQ*3:4R9@E5.7 ?XI--UM
MJKX_Q'7P3JFS20;3MV(]W$M_VX+^4J6Q_'LF[(M"PP=!LNTT$D-/-(.<HOG\
MKBY<Q"Z-O@F;Z(-/A-I)S0$44>^;CK=M)#L]/_N!>)OH0!&2$OT9DJDI'-B>
M2]];!#(;W\DP)5]XXXMXDMU09%_![@VR3C\#!/KL_M[TE(@0YKW(PQ9^FJ%D
MF9%:@] *WBVK=?I([4-73M$X>JRB9$8R>M:F9J1T2+2:.D"2"3?MKE=W7?I@
M[D?J:-I<Q&[=I#X@.!Q'DGF*)];];X:&!V> 7IJ:0X;>]<=%M9T/O&>\9Z!6
MO'53K))[3(4K/\;H&%<UZ-(T6N*M*_Q'E_%0U.#8O\$L2'U]9K4=S'(&F,LH
MM.?;HBIBQ7<E4AD%D,@A3+7TL^['W5LMW$>)7S_<^<LMY&V+)LE3>XI)JK.N
MM2!\0@WJ--=;*[Z<\N/IE8HS0&9\^L[1NNVVAJFH:N?"HI))X4XWUM1TN-8S
MF?*L=4D9ROHBXQ[T0&*X$=5\B%VM?;)B$#=;80V[216P#LBG7K\X&(-OOXZ#
M.7ZA+FS_A<D'?5P':ZV=OEL[U8C]5/_-_=4SNO*65T6<H#SK[#HQ^PJN*#G\
MH4/ $P>'_,.5(#DOI2#V(KN['<.9.[O@X1UUB[0C[H]46<FXX0[#^[HE9164
M5-Q;\;KGPGOD6<7?FK)5^2ZG; N<'WSBO\Q<&8$HESU:=3XN1-;@">7*9D83
M'UO8!P=-P%+M=B%IQ0_VG/F22M=/$I](8EYG:!N&-><TU?HWDTZ;%4 @>011
ME"U&8'1)3[#M5+@_I7$I];@_W*M^)YJG##9G33++@F$:?#3Q]U5<B-G/FC2Q
M8FH=96.V=C>8,%W/FMIQ]:]T.822^!CH:-7"%K;59VBP;[M[=+ENYI/I.O(Q
MRB;*.CI)N]/-DI/@3M]_\R@FB)3!9_AE'SBC2#:NO&)?N^DM!"'55'K[1%$!
M,!V7GQ>@U0D>?Z)/#%M@1E\AZAI'8$YC)[D][GL(B+L*121LF/WH4OT6?B'S
M$ZH\NZE;.5.2+3+Y7OJVLNVNGF=QP^3IOT-7AP 5XMNY#:-F)5R/C3@R\PSP
MY60[E]:%E)H\Y?<D"A<\V28F5E>2_PVH?@@6U/Q PZS'J#]$(!Z(09\C*XID
MY#!*>$I$->_D>3&DO?O#ZZ5DPJWT<E@T05MTZ&U9B5]@7._MK6*#Z:TDU'X\
MW=<YF8W,L5"UG>V9F8@!6+7_5@*\FB%*;MJ5>BWYWYNJ*M+MZ"V@,RM=5?C
MCQ\@Z4.$'=%_[H 8,F?#C'DY+;_A[.>-BP[7"]?+X:E96E3_*3_XTC;DN9]
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ME>MC:V5\7+/B-OKG8.;C6O2MQ9%+0"I'4Z/Q;[4;M+D/N[+ORHX)%WT. G
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M!?(A G@_VYQ-Z;T)5I5LBKC2=ZF)C.];MO:F!>;A*Y> J8FNP$@0NX(7UL!
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M@H\5A'9P5389*$'RP6TXU)<V8; )8D3PME!?%H>"J""4)*NE[)*".Z-_RX2
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M\3X8.S1HUYJ_I/02X#*[P"87_''>L6;DXXZ,DXKA1P#S#KT=R6QOWX$)-,^
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ME)W));"HM4X5WLBFNL&#R_L56=KB"8&,>,/Q&!*?IP G#XM6V7_+2]PV#5!
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M?P&=V*]2[?[+%^-Z?3+E7QQ10+P LMV@Q/O0$%NUXETVA'IH_F>.Q.W^TK?
MZ5C/P.V<2=BY*S[U$T$-\C&F5^OMK#IFQ0OVYG?6F2UT9H)J"CP73VI^,U8!
MHR@R"J,>RGJ+2>0_O4>_-I_9F)1B=(93*(*H6[&X3+K13SY>6;X%WU[;.W.L
M29Y4*FZ^!'P)A4A4-7O?+\<RK&BXBOTH#U==6%(HFCHK\0.U<T4N,.!;<WI^
M>9L;FN.S[PF$)'8_OJWZU-U9[?G7H:6E#)/N2P MD878KW03;UJH8H=F\_?J
MI+1'CYSHC)MM^3A+G]?%\$L([W5]_$G2[$A')!_-W1J%Z$]*L;G=WQ@".U&-
M7@+ZI.-RG[-> IH.ZLY(MHW">S^>U;+69CS*X%"J&-8</3,[NA_CEJK7K=?^
M-E.N*/,>/!9Q=*1CL,L5P<6A0(.!HGL7.^NW-B471!1H+]+ J6/L=.'#OR6W
MH<M$@8#)1>IFQGZPBX^/%WQA3H6CI7+DS5UU=N?L.)@?M\47ZA&OC[*(&*2+
M#MTEP!GB6UNN#OE3F<XLZHDSYOZS>/8PP&@327$)>(-=WK\5>]>;8#G^H&K>
M5&7,>")=DJ*&N[])>XW[:Z73[.B4G:9 'P8OSSSGH5HWT5>"JTZ9-78"R?T5
M688O/:0?=:U*WRQH\G=JCC"?M-FPU,&5XZU_O-XXW.:\YR^L9=PEJDH)+K:+
MU[O]5?"U:@P]K,0W/P%NYCACE)5G+3\WM:"<<N=574=<?:@QR_$-D_7)W8LE
M31TR?&1+24&'3;DE,[AL'98\'V0!LRP%"I^EX,#8JN+ \OU0J7E5-X;\U/S>
MA#_=>WD-\H$;$M##LNGWG%F6FERA3H<]\"<^LP5Q&TL5"J\.-5*=^<0]A>9!
M)O:+)<W#-<LN,RXH6#ORKLX/_-=.VJFM(:=#IXD1M%-Z$#=CC+2NZ[,NO\E\
M\W]]):#5+$<O7U/(PSVY6M V3[J/2[[(UU\[XT^>(.CZF^@:LY [1#=8XWC>
MV5R@0+]:;@*N!8D\6!?]F53T^"?_ENR"N:DO>&&M3@EL_CC3-^.7?E0)4\EB
M:5/):&'5H16,0.$M?-AIUH5$]S_7Q6HM_/23F@ZJJPIY$6,.GO**EXS:!YQ1
MG.G7 2,6Z2K%@YOIZK%DX6+!C+^CU.Y^>U>;P*[&O-?-%680)-+3BG8SY$4%
M)^AGI3F?IX!J<1+>%M+\Y.B<#)O2!G&94>?U=>1N <:E+9 , LZ>]=8G?^"T
MOS,#+K;R^JYJA N]V?-!1E&=4+4?B-%F<_Q#9,/G^U#Z?]$R,F90E E/^<N#
M$3HUZ9V)6A"[*%62T>3+JR9<J#Z]J_1*FK'(E5):UH@L82Z+]#7%!0\F-O1<
MCO#DG#?TSUQ)=72.6>6D27Q0O@EA\-XE /P=H]C" 3^ZO4VK(&:@*=ZAF559
M$H#PN]*,\+K3":VP@JB!HO?,+S_JAD9J\I_ZN!]/6)E9A"W7=#E)+@4&[57-
M[E8L(/<^// "3-+17M$%=P^;*1H+D[6:\$9)-!>[MV0'D+%1SWT%Y$ .!O-@
MG/>85W$QP]VLOY>;A^19CT7, ^\0YT$<:6"5KLRE"YE]FQNF9NLA9 690IP7
M@_=$*J]RQU<+,)$!,]B^?P/,.#P-GH"+]IIW/"P,A[.Z7:G_ +]#'>&?[/E5
M[/<G:8T60//0DSI_RZI+0*BX5.DA5 JK<S$#=0 NII\8-M'Y!K:"S:Y.Z>1M
MMX)%A%OZIOO=2B>>^9 1(Q$U\'7DE$X[$!-+'*QW&N7OD7)LB%P[[MH7"L1.
M?3YWW- XI>9&[![*C^SLGH@$V)\ULV4?0XJ@>XB3!D1;MP#6N<,!1'%N[6#B
ME9YK6<A^?&#.H;A]N(BC3'U[D?W!</T1^$1#8OLWUPI5P#?OHL7=+.;Q72Q,
M>N#=^OPM1+_XE,/[,-RWH3O7"'U^E1\N 9,-L+6;?CXDS>:QL2>!ZH%QRUB!
MAM@^NP7/2T!/-M%N'EA%UGD/ UO:JRI2$4_Y-2\P]4%N?> ;;6U@?4,ZD024
M$"^"V6-;9_LJ@_VHZG]*=H" _S,SG6,!HHWOR<63O)AWK[?)*PRAN;OP]RD/
MYB;35'(I$ZX9_PF,J>FR8L!<?./4*@ASRK$SZD[GC@<]TH'+V> GAS'SLK9'
M0JJ!'0B?P-E?8&(@D&==-B?WD&+<4H;0**]^"8!J"1!USI7L-D%?71C76WTY
M1N5W$G2^Z%^0WG;X=(3HYPJ?B3[952=H-R5_W\%-3L(+3%^2OC".2T@-2'_>
M@Y\<A[$HB<+"D.5D8075,&=$J7VUKS^<^I:X<[--;([S^<M2&B+Y(@;66SVA
MQ+WX_% S\XG6 V#PG???_+7';@1Z='JS6!B;:S*D:3FD!RNZ7 *H#NKVWB?X
MI+>NNB]V):ZOTB-11$^ECA'W?LE6*Y;*T=WS!BH>S:K7NG]:]05_ZEY[X ]8
M2<,@F (6@)00\<*FO,:S@G"-NR72<0XE=WB&<]VICBUB?0^X\(),77V#NYHN
M8?*6[<_LX_@FBFQD'U5\8G]Q=BV4ITYDTS#@SCD3_F;VN6+5>/,]/%)EPJ.A
MD-&G&#710N!4?>'(3LV107)HIX A8S]8.DBCI"@[#7M<M]C #*]9NPBPJI_:
M[5H;)U8>S-4DBU&:JL^(] 3JC&K"7D%X+HH4KF'3=5G?1_N[V18_2M&2,0A7
M>1QT.SZ8497[W9*$[(WEZTT?U1D?VWG>@CXRC0%PYB/Y&BE_ML.)PS.*!>W+
M/GQ!DS\3M.*?0L9JU)^[..-OD<OMR"%^70)<]J-3 MA&=B W<RVJ&L]R^=?U
MXZ7;_6%\QN)O.B24^F*"QVWP ;1=NNTH-JMQJY$%Q7VBY7BIMF4'73(=+8@U
M 2<V&3.R47*X/5U@,PSQ(+A"Q#!*>7Q0$,@;BN87$L ]H'Q@K^8B,<^ 7.*=
M@+4-SA!0DYW1;SGNMQWLJX\7./TVW<*$I]EL1!7_T2$\*?<C 4D$#"))F\G%
M/W-C:3H03/8U:9EH%A,UXLQKK=S -I;[;O>^?8Y_\N[V.Y-0/$)M^%@G^A$8
M2:DU/Y NG4WO*W=ZWK_N3)%\^IN+EW&=A+_)S)3:U,KCX>]U_2\33GXU1.2-
MXRWOX]JOC[.UF:<)2NI5]OQS.Y< 1%.)/%<AB+WQ%80+$]C%6I^A[I*OM7H)
M:.XU"L2N,6 6S^DFVX$SBZSB52:ONG,W/\K7Y,8_Z@)B1P560<^)"PM\\EPM
M>@4L;FYPT+,/5X%[-_^=2[L@4/[4"Q> 7[7&D*%<(CU$)!CVHZ0:"G<?.)DG
M?9']EJ  VUFSN':NXG]-JC\>5=0(N[,!'_BY:I4F/G[1;>43GGL(X75\HISV
MR6MS<O_$9*'8?Q-+APO&^V$*#".UL&H1]T9=5IYQ5[_FSWI:D&U]5WH.-R!I
MR9B I6ROG_R2@_4HA=_"S'VK:AD3(WG&''67DF.)@86LD %3L[-.$-\&<52M
M82\!'>K.Z<_KO\^%9$('BY1\U_%O=^.B8IA(XC86,;JSA%CJ<VE,8%AE;7+W
M\ZS-B9>B8[QO7D2NJGUNT:O]!ISF3%H=[WT8R: FGF?4"P\X'$T">R:G( >Q
MOKZ5DE$6F.,*BLI$^TZ9FXC'#3(E\0$P7[/CLY-S>DJ49W2ANI,39UV):AB7
MP^^*9W3^"M.T2(VCQ:] KG,A[,2H;GJ[BW?\%#-QU,6?+!F[/U^Y<K?@"5NV
MHLA*X+0 *JQE/\**7I.&KGP!OZ:>2V/K%2CU:S:AXL^M+=[3IP+[#^66;IM,
MPLB()'CS)8COWP 6S2HM_7?)>EX/$W\\5<[)(*ETMAG0?GVH(]VVZBTX2*,M
M:613X5DQ:;+I./M"52^RW^T@E/]C_D:?.\*C8-T/9.PKZM.]RX(V0(E_)CX>
M2^KX6)K)*U%&//_:!QK?'MZ^<AB\H%J$:@+&>%33@-!OHA]QZQ+P]N$(UQ@?
MA&CY?%NVU]!73N0,!&HY^^ 16(02GMQFKF[2'\4J@2ZBB#0;@<Q*? Z,67RC
M S]S7F\.NF).1U[<SALV6(M.JF=4]#,95P)>?&EF=YRAZ@A@K:S%3!07:C5B
MY_L45+ M<;;O>]<)N:S+R*7T9A8",$3!&DUJY;Q_K^SY[ETFEPMVH#"!9=Y&
MU>N>D:HF)X"SZACR+/UMX=K'&$XX-"0Y5G-F7ZO^6$DF]""#[T.Y9(=^5,:L
M;YZ?U>Q>]<9@#RR(*#W>3'GN-I+1.]&F^!2<EE?KDH1^Y/-1:,<3]MVO4.HL
M<GD_/(L#;XW"39SK_!)+RG\029,QW)CJ.4 O+/366Y',X?Q71<A5FE!6308I
M^-9$'-):!9B*E=.L? (97@):7S:^NC?4R($Z_E3O%X'(U=N TG["-P08[=AY
MRZXQ[W#(B6CD0"86>@?/!P5X.AMKR&,S.%!:A)J9O4U_XN:Q0#L,VLR(K\J=
M<["B&U<ML761F5Y-^)/,4?Y&>NYED2_M;)/=^4O\YI)+L FC)U%T,D4]"WO[
MFQH.G/]>UU6;1[5EL,1G<$<$!<.K70+LFL164SZD5<UW'OHN!R8B\3M/B5('
M8;LHM"1:?.8ZNDW@D5B*K<O[.YX?;P?3$/! X=-B,9WG#.F#)"Q .[;MO*/1
MJIH#I72ZC,FVE;*_=@R[O$G)C?4-)\CVTO6-B:_H?H&.!98J+'6Z=PVKU!@7
M&+KQD]L>FSGUYM:2%T,K/A#W P]"AQ_[/-YG?/; 3*NNOC'>'(QZN7R;R7-=
MA2KY#4!?G?=M.5'@CQ)M0*]O4K'SO10MS)&ON],E0.NVXRV@1;7CX>(24YNB
MU[)7)%?;F>7H:[ SX[I!@T@BE)=7B">Z/[FMU$= D51EM4Z)B4V3-OR77M<=
M3QVM^D4MRQ)'<WW)!]L,G[,8H^4=C(1%C1LVWU6-FL\W; 1\/1>Y*&YDP$9V
MC>)MVC$.BXXQ3)G.SB5&W'%W@C2^K8;IG22:))U[8O:O$BN6;9GV:Z>5Q+C[
M)8!)Y'E!GVT!;Y:!K*S*>^F]'^<M[ ]/$%IX<8(PWF"))KR*YLZF67*>_^,)
MX'N;PLH/]RU;YT,[K/*8-F-.$>%*-*J+#)< 1R?^XYY4%ZE3*571P1ZVQB6N
M5D#I#I+RZZ^($A")OEN!-E/3SC["HRI!5O*!E70,12:[OZQ&GNFT>(4+TGUF
M*R!NT ,5^R60AL<QPD %TQ7Q(8[LS8&/6Y3PT<WO\6IOU:4&S(@CBU0(")T7
M>@JB1S[D9">-<..E>]'_4'?!3'6#8_8V-3UGU2H2HQM[)?/>09@J1A*)A\9C
M/Y4ESVF_WKM0-AD$EKOL;,ITV\_L=WB9/,3SJ-9:<Q13_9ZWJ-7?HK&NY%_;
MCOY!.^;ZIKQ82>":0C>;7O<"80+FYZ)U/JC&D6[29K.Y6BNL81(S:[KM\C*W
M].C 6"EY&.B"")GI:F),%\ -I-+'KD:KXH89IWSO&JN^H?EE]03='!.CDBSE
M_F:C7;CWXRW%6U*GE@0KR&/,?ALL\L"^F;G:45&BV+J6(*EQ<*H]^_E:1C(/
M!0WO,:)FG\BC@_F$4QM6>/;IT"%Y@:L\]&9"YJ0XA;#=AK9.>5KCJ%!;5R@7
M;=#:Q7:YCO]5=?LZ-"C27_:Q$_VP+DQ\+T72K2E^^Z"ZZ42Z62Q@C/,:7M(#
MQ^&HEWQHW+6<OQD74:#KR]A# 5-]HV4+D;HH:V:#O*JKK:I!U@_MWXM8)RA5
MW&T;N2]D)]C[-S>(?#9SZL;R5Q!+0-\EX,:[B]SF^ULSL(A]L8*1#^'U8_DT
M$<[Y<3%3)[@!YGBYMB4;[IA#W,!%ZCD#)KVMWBY"03 >3"4U,]V3W]21P%NG
MZK1E47%=^G#@H9_77K).DF[)[?KBE>W>&42(3'G-\5;,+3NY4O[$0V%Z=*'J
M&1"J[KQ_I2A0Q6<789C%Y9K/S6)6"S/>.A:L59UIY +/'!6>T&>0I-(^6Q^5
M6ICLYL)H+=Z^2&]3$L>2B/?[^#'$2W#D**]S&3P\A^_XGEHLDJN11&>Q?G66
MJ";LI$_S;'W\8/NAG>2VEGMBGG]UU8RE:2?$ 2M^?J7/R"&6Q21A5:,"]J?=
M [I%EX#E#I-UX(X_)ET-WX2UWVSF+I<Y$\T,GO1B)#IV-GXI_/KQH?6AK (7
M"O$;Z*)#%VA]3E)7;BJM><4_[)D:!/F-+P'#-H=784.^S<6HP'\66H(9?37!
M?]A25=\PZJX':;2NOOO6M>";ZT-?DQG7/<X"G-7]/"%!#9<DZ5U'T?U#NRXW
MI?LP7!9CTNNZ+LY#=:L3/W-$.R+N9/U<0J<U]HPN\.#7E7KLAI?4-V/(=OHQ
MN!DY4P5)E)]/8^&7W!-@X[>*3T%['9ES&9< X5/X$K!#?.9)QR6 H9*-B_%9
MJ1G>*=>K.4$7L^,9Y^,0Y9FJ$,(=#V"6ZT'D!RA %'2@(/)&-=3NYSV[:K#H
M(WEMF((=\0S@3XY(ZVZG56Y24+*.P'USD@'+F5I-3FK.7-#D]]F%= S_"N_#
M+ PX;%I1R'C6S^;M^FLN4A'%O=70N]&KB\%5(>-+%=]4Y.YH4JIVO+-]9R3+
MH[#,SJ71AX\@*/\SEQVNDN]=T.$&K@\NBTB>=UK+;*,+>OTBND96=D 2E 6L
M$._NOH UJJ!%(N&FSB6(RI.PG:]1\_?^\C4!^,;.2*6FB ,PLN/ F4AT\L]E
M$'-*W="/^L/]7%?E!:UQI]'AI[,9[A8T:-*F^G.9_T#>>P<U&85_OE%4I$8%
M!*DJ(-)!0#H1D2Y5Z25*ATCO$!(5 4&*@(!217H-2*^A5P'ID-!#KPDU0!(6
M=W9VYO[NW=U[Y\[>O3/[Q_DGDSDY.><YS_-YSGN>]ZM$85IB_@+5WODH/76@
M^8NFZPIZ#)OO+@$U9$_CNZ5#QROA[*]O85E3U7A^7''.THVLW'LOQ[AH)JB]
M!MZWF1#@:AS1*RZ5-,\G?XM>6;GR[DWS#)%_ 3@=TQW \8DDXTCBQR66'=_U
MV7*72]*BK[C'[3?][*&$G5R=O&AGD.*Y/Y0+B_;C)OBZN^<K%4UUNN9,F:![
MF5'7G]#UT0NV):VW_T3<(L9> .S8@)B)E"5YI0ZCY)R$DD]EK>^\IJVU=OO^
MG-=TG;9,C[)!:GA"P6%]14O9R]^:IIV]AQ]OH#3VZCK3=40[[+Z_8[6^BW'L
M#I1T-J]"X7PLZALR?F8 85QXSZ7<C]X(JDT0*MGJS\0J_*$:TN_GG08; Y=(
M6=]2X:6\'77LR2(-9@K"7#&[V7MR./L4I&!S 0C\FN^__@=8Y<[!4"4H?"Q-
M3*.-7Y3F.??N&'!^*X\I^F/W-='_>P@@0=>]A?4QXAO<+B/4D@P?7N"4?A^?
MAF&3U?[]\9U01F"1JK-[$.]IVDP%^938N+\=3\:WM?966R;S%TX8NY7MASLL
M4'T"2*>^NREZ4-0/;!T<:7T47M30\!P4$[\U6C*B4(ZMV<%A&SJ2LPU]:8K6
MKZI0ULCD%-[T"+#-BCV.\0"P]2!^9:;+?N=,OG?7V$9WXZ$(7Y^*XC7O:T8K
MKCN*N5#>$:A!GAE!(&6@RM@8?"K6+U\;SVF?N'_'&"/=RIDK.XD&4QW1O%K,
MV/:TSX<TOS,Z\PEQ]R@0GE>615V37G]>:<U6[Y.78BOE)&5JW/CPF_ELG2W2
M @Z4__L;BF8P8S$BBW1/>HB4>[J1AUDI=-@FB)VK0J5PH4WP+$<%GH]+I#9>
M^SJ3^\E,F&BQ,&O.GR^ICV8MW9>$T5N+/L'%\I'DQA.Q+!!+QXG/;P;=W&QB
MF6+<;LI7@&F@Y'A?!-0<-TEXB))?3A39%.78T2RCH' J+5UI@KWY?F^E>K5I
MZ+B5F$*@P8(7$6'"4&E7=]K\D[81R)<O20FE2?UV BUIA8IZ)P:J\OSCZ:H)
MBZ)E;1.I.;RH7C.=I]N508QS_N('VZ-L'PLBVD<CK:FJ9X]-IP5==AH"(#DQ
M=7) 3!K=DF2HL\0%  A^E)DS2_;;X+K:_84B7D 1V1CS,DF -,Q.CA?^+7Q[
M\Y/3DT?X0[2XF/F3LQW6QX<"S^2+ND$+:;=F\MIH M0ISL6V=%9XCVXIU\:,
M[B-B)&BL7^)\=\C]@W!W-C<%'V),OCEY/*>(DVI/H 1<"S'GPSZA9_6T]&%\
MD&4FB@C[EI*G::' ,PW/(- -=[A?-S6QH#:-.$ZPJ,(;GL"2G?$;"%2 *X%>
M>#'J:$E)(N-S)7YJ8<9\^H5>4$^TH6N/$1+?;CHLCKSAE!S=X%5=?[/2VMNM
MM=G8Q$V'3+IU6VS SS#CG(- A2/%VQ?ZV=UX*CL^<9DY9Z?9H!0?SUFKD6<R
M7;,O+T"Z"M\1#B,!9J:RTU\GEVS?=2KJ>DW'"<SE)$(&2\+Z<<;)4E!J>T9>
M4_-9"=,2PI .U><_;K4!4Y'0S,==<L/NS=5:Z#Q;UU=)Q&38'2AY/6XF^>0]
M5+'(+\5PA''0V)O!*QH->RU%<RTP1O>)&5O PN1HNB N,7Q!GC;(NH,YK3D^
MM_UD5XB%3/X;;7%W&2 >S MOE6R4/ :3^R'!MJV-S1$#QF?*]SS/_H#XL" 4
MSY)AU;DRU,V"7",V=]2JF=DPUK'A=@7CE*W"]LSN=NTAPOYVPM"3@;70!!.I
M5QK[\5HY$+1-C2O./CQD@'>E3MP](M):)@HE.BSI$[]Y#(X;61M#91#H^1=#
M0K9:K^=]]F;ZMF".FE;A='7C2C [,#V"?[H <%QBZZ][\$7F<2AZ2E?]:8;G
MO8@E[HVXO#WJV+ZX&ZH2J\S ;2!VL+N--\_)YR0YO7+82LMZQT-EZP'KMRBS
M-[H!-PPQ!1(XWU;-HJ$P<"4B3+"XE"V[>G+R9>Q?ZX&HW'WSV^NODWEM_;5M
M-8K=A)R\QG=W[(G0ILNPM7;/?,.@NXN6SL=)LA&^0#QW@67Y8;J3@>VNM$.E
M^'A="S&-D 3VQ2Q_D3]N/_FN=L2O\\>D''_'.P/?=T<"PW_)T+T\'M9XD\"=
M; #XS?4R<RHR.IA,'G(94A>R+!^? ]LO #0.O(\X=)&0).V5AR_AZ_K OL:\
M8RWBCTNB\75TVVH6K:UW)=]P.4;!TNA#095USOML[5_?5U-8JF,XG?WQ<EE4
M<C7G2HQZG9Y>U06.-B4-,!_5@DOO][J".VF1MT"292N((P79EMA@L5VC\!D;
MLS.+[>Y,?U@S0N6$$JW]JLRPFO<NW,4X%6#"9?4S??L_>T#(/N0X"WLC!#N$
MT:[ZZ>?R-%@SY$&<K$]L]KYF5[&1YQVUWB&N=,B16.O763,\Z'G$86)3=-OU
MU)I7]Z.4['$#VMY);T6F I@:.9TD&+9/ID&3NKV> G:<#)];,?H>>1.R<(OJ
MH('DQ[^:7YS__Z RZ'^_AN E%DI,8$^VSS%F^?,V<<;$'VI2H";;2 S6T[+$
M\L&Y@UFO^[D4'M%O@;[>4"W[.%TN>;>E4Y-1Y<ET'RA9VMW#K=W@FZ]>O&6!
M&.,Q#7;? 5FQ$[7 %&_07-< ;R7$GKT R9S=]<=4A:KGQEJ%2@CMJ[4:O*:.
M4U\'(%B)T<:2V^B%1M8E_O?N%P#PD\D(&)IYLA-,[Q?>R+:80;UUHG!;C3-N
M":,^FI?@:A&J4?DYV]GRQKREME]WU>>V_B>#_'H>>B<Y1>OQ-80G"H'7(T+-
MXG01?2N[RM,N:"/"7'$5SA.S]QGI +RMA>U?.-37<1:R'B,\R\Z&&;JAP?B'
MV^ B+UW/@\"3%OB' )Z6C)NE";D7@!PG21:;,0D><_D_[P/@E-1I16B> JZ,
M)!@CU S_ 0MO%W5(9R&F5Z4XW&"&A OL,4.2NH4Y_4&BA/?K %:C.@(M?A%'
MMZ3S)7<4JH7M.F]C-O=!2(\)/TR_;_XD1'%5)3.\=]VSTW=5RO30;3>4F4_<
MNNCDU\JC^@90_>.E?IQ? /[[DN@KC^+#B.7D2.%A2Q TG136.&PI>F[@5[1$
M'@)C-^W%KNDT-T[L"NOSVHQN-T\*W-JQ,E:MJO^:)861F(8R)76*$82PV\T2
M=J[TZJZKEGM1UF\ZO^?;Z@+>A"@"O&\T&RS:LC[IE.:7A(#G4"<UUIND*HZ2
M(*.$^:3DXQ/?*L0\(N]5%2)L%[2T F]5RC3W3TR^<F^7L>=]V06@YP]_,RYO
M1QZGHX1S0>0Y<ESW+M%Y65D?1Q4X7SY[6X;_%M=U*T[R>TP\P6 007"RF9\@
M@2]8TF'C^ 3C'*]B<WC)S%O97VG<.&VHTGK[#FR=X>B'B@482#F^TI=:4,41
M(-LW%V#BJZ C\Z?L*$U W&7,27EH-G&XZ0SBZUP*BS5*(HU:"NE<NPRNH3]M
M;VMQQYL^#_S!39SJ)AYEM%4KT.#[.RP5L!+-%4MP&LU%>6U'&_#V]$DX T/9
MO81Q$\_@5C:1P,F!"T -^><]:! &> /Z\"_+ !)9IYE2I>^6$VX<;%W&,G,&
MH/&3AMTP$+OYMM"9<<\IN=([8*?\D&FF3=SC=&GCR'(WZNE<[/!6 YBSFO@!
MRL,3UGRM-/.)<Q!$-QGW1 1:A;Y#*B\G0#;X>K%)H>\(]Q:#^!5'1VT34YS9
MBI\=\44P\LQ@>&8FJCSLF!"E5IM6,NH- 5X$FM\SPF-N7F5[?CEPR_\LI+"6
M_OU_UGL-_R_:%57S"<%&^5_SFTF_;Y8(_ P,3SU^H=]!>HY\N-/\V!_)S-B-
MZDI']9(F2&.!=S/Z#FX&K:<<5P,>J"JU= 8=G'O[;8)O$FCJRVIF>":%[K34
MES[O[N^-1S_PN0"T%/7 W\ _!@B'$^270'3XC/9CYO'*T9R$R("<9.W@-[.<
M^=Z<<3U/0/7*L)"O,B8P,%BTM#3M5^) :?41<@'FWZ%1^C:Z?>4;6WJ%JU=-
M%5& =,"RQ+AS L'1M9S-AR(4V$X-SRXW[ ^5JMHNM5-S8$5D@I1\H%$2K!MT
M"[D(AOK^13G*-= 8I_%A1D^R_>VQ7U7Q=D@5^*(RX>D%X%?@(IAP!PW',9SV
MGIM 93DH8=*;[AL^_;D;-7;RJCIF#H3:)9IQ7=H;DX8M;%*(5SR=MK7C1D+M
M^EYC2R?.\WF&1Q,7 ,Z>P3+_4EKQ"E8M6[W1N*HXPZ/?IA;<!T<*^\0\V-68
M&,OK7[2K&J*[3<M2=IZ*_0$F&D<^49"F;&=][_9L8;+M^ 3) K)).8ZQR_RU
M,22DH?9Q3:O6U;K/Y3ZM(C!&X^P51G)'&B-, >7%FV$R:!6IS#;_5CA]G3/=
M"\F>>O^ DSK+][NBOMB',7=+59S2\6$C/A:[9H"MPQJ41"8GU-4D[VMB9/+E
M33CW)\G_)DI)R4VR:RH]R5&=DM$K4N[-3;'<TAZ":QZ=LIU.</*7&$K,FN@7
M_TJUB1^7\*Z9'9WH'IW_O;<C".S>N7O&LO7X<.CVQ@>:L5MWWB:PW%=GUW[6
M<[^ A]7#$RP!#2!&0R$+%P!FL%_%(L%S,]DK23"0VM0K1+C8O'J;[^.]]R"O
M7#-TY*3]!>#: =ZL>'T>/2<QYOSH]^_F:C/^*T\2)*EJ97NND&X9 %Q.WWF5
MVBM= #Z^]YMLE4G,RL8CVPWK#X]K[J@P29?5/F<B(#[92BVX_<3UBA<L;BV*
M:6P]TM#@M11<WZLWVB8<-C6&""A3V^DIKSF7VNUP58W:_]IL3#LY>-),1YJ9
M>XH5JKL1A;O*,W'8LWS+7-T=F !W(K^V?*4Q.EMJ!M[(WWCYR]&;H'?8FO?L
M*)VG74N!X1,O5LR68]X.#4=!-S!#='YAQQ7X7H;!F,7.ZC&$=31*5O:YS<TO
MW3\$OK.)]7\%  *,T!R50]M$?\S\^S/ML%]V!Z;8/[I5R73!'N4=G%[W2(_T
M8C>?L6T5W:-^1,86W*E-^0T-Q>DH>T,V<J/V2*H*5W.%1=JLW;X5RE2.G'"-
M-@1538)!@J70;BP#W&$%[W\%;T?O9U+*+8HYE_SA&3:4<7!T1.!S#0==N0 X
MZGR9K#:""?Z] %25"F <?L*K-KYNZWNH[LYZ#I5X@J\@G4!W2(-4^7C8EA)S
M[O?)&R;B_=T0QYW5%D-4I_;,^R<Y.O>M6==&CX;PO$]KW%V,5+#*(9^(Z6>G
MNTFDT]>1I*H-*][5;[CH4B"5AOJ.+/_6[ '/5FY>;$A!PE@KG]2,@7%55LCL
M98K(;[@3%/-+ ':M?PD^':R!]UQ2O1L0X5C^8J2K#5QA_F F[/YB=2I9\$>Q
M8#"=TSP-3!S6%S ^6)1+K._KA9%*LB\ V28O@S,3U.[3!FADH9I1Q%\*7'X5
M+1> J]8X<!CGN<+O*$>)-F+*@#'FW3TR?K*0M6M'@"/RY-,_\%8U"4@,;;^C
M_X*S0I"V6O+36LU5,P^UKI?<3+$[2!PBK8\[65O":3B/N2QU7MS,;!T]2:)%
M<^BEJO(&9ZK>-GR==U-(/1M=7<!CNP)+V2N25SI^12P3@HE 5-M@O)4U53CR
MN!'4G.G5\ME/]VP?JZ,6;&NE[DM21?N#4>ACT&2CXU(_DL6/]^$E(QE =GBS
M;_>-\(4<< KXI+Y_DAT<V^49<0":4EV,KE@2_E)-$GOJ8;8N\UR[:SW3>.4'
MQJ%#??.91_>]%C)YY0">CABT9-?\C68)O[SGX^(09XABZ#*+K/\8ZD\LO44#
MMZX2[_)*0G1@=,*H&=4KBE2)>!/UY[N2HT'6I[(6K'Y0&U%_P8.B6NG] C.+
MTIS]<<NAJO2\!#_.2S,NQ\H:?GF!>VED6I)3/1ZOB;NFQ=;W"/Y17S):YNY,
M\\?F%GP=QEER27([8\GUSH; P-L"AS@M)O=0I>%8),KPNDZM!/:D>R\&E;0C
MC_"#H8;:ON3I.#:S0" FS+NKOE\1_;4/XQ3T0JAF)B=].6B/.$(O &6K!8M%
MAX*%BK_,-=WO0#NY8E&&VF)I#;AN5F8QJ,1C)9KP(G5]!&]1IT35R:CV?%!:
M7Z^H@>UG1&BFP7A[%[-Z7M:HEO=>7L)XS/7+S7K)E+VF. [B^_D+@,8#Q-O+
MC[[PU;31W/Y\K?3W=ZF-\Q^0'M!"JOLEH;C>42]O+/_U.ZD;\&.I90A!OH^P
MOOQZ^/-]*.O(/;T?KXPCR_6^9O5]M3G3_P,FV'P+LM+6SCBK^7R8L7SID:ZM
M_--<6P*>T_9>6B;6Z"N\506Y7(SW);4470"R5OYS9U[M7/ ;1]U^TX9:'L\C
M6]ZW][RW"=B_2>#O_I<&QDKA"Q9[*44BUUN5,!]?C"S;3\:>#H==]OL+#")R
M\<T3]2V_7 "T.=?E^38#05,6CZH%>,#DU2--\#%FO/VQ+SA<"_,E'EM&MB11
M_K4WX_>RV9[6U+EJ_TFUUQIV !8)!?Y=F@39(2DV&(=_MP;^5'5^(M**PCF#
M,A%#12D<+*1N)%/<CO.Q.:JAI/% I6M2M\8%R'GOFO5]U@*RVI)]I_($<Y^[
M?$(>SCF".47#I_ ?B;XJFC1)2REQG^ZLNL])ZHW[!("2#^2_=+$#B26-08L-
ML^26%8QG6DLAZ3.]V:J--Z@5;!Z$W6>_N6&9=0XD '$9K8M+IU"+7*$$8M:Q
M0778CMY+L_X#3<G=Z?<<,M': 9,9E]-Y7:#^::8U/HAR!O.#Q8A;;*NFEYP#
MRW=&=FR$'R\F^&"%"A 0TZ#T#,'F/.Y4T6G^3Z*?,6_4[:3?U5V+I"5G6%O5
M'WC\AN]526B>1FHRDD^]QANE\WNC')VDRMMAO:$=S9=C&G&\ZIR3U8P#!RO<
MPN41TDB9%P#KSQ> D7)P ?,:X8,$\.PD_@*@*''JC]$T02Z6"UOOVQRP=%'V
M-6BK23[[2)XKC1C3<C358B>^OFOW\1D]=9Q/\NJ2SHDY(QZDEAY#M?'=&G$!
M (&.-SB^<Y3K$%+S/I&2P&=:@D'N_RJ?+E>9_ +@;@9?/MH';QM!Q.&5-:%Z
MOV(M;_NN\NI36J'TAO+DC%"@ZIK@*HY[T.OC#T=VEAOJRFM#\>VW^L4=U#S(
MH?QTW3D!T]L8UA,*7EGNRXG+J6A=K/=,5X_Z9(A(,QN:+@%*7%JARR6]?\$
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ME/^_B:K\O$6?BU*6<KZHZ\2;.>?Q':P'WBMAE1"(IV%E<<FH-'2%5RTC.8^
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M#SQWJP[!.X+G#_W0&/M.=3GEW,TSMM*$8P?G7]''CHDV!N2^?>4B(#%1#LF
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MFA@U-U'CBNA[NMCKWOHU\OV5GDWW]\ (!($N8TEAL<$<6V:Y;&$>?P'(/MI
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M?3+@[67XM4#&!>L<</O?%I6 ZS$\?VQPQ4 %0 ;0'U:V,_Y_4OR(A7<CWE\
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M_.D<QF3 >2 ZF02#OR(#T!^JR8#%1-P1&<"0AK$FO0$3"B>AF$G0?#Q$ CI
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M]D?+FF;3_C>X).)P;S#6;4#Z4OMZ#%M^DN/3X^L;>2O)O'X?5OE60S-KEOW
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M[8LEAFMD '+@J&$%<H6@.43B"#!;;>?ZDK$UYV D/4K5O=4%$!5D^A9JJQ
MW4XD P35\224%!EPH+(:HF:^\DB3+D^+\^EC:)L/CHD4RB= !GQQ@Y) ML#7
M4#=$!$2R,68065ZMM^1>J.!\V]D(O_&-HE1.7VEDP6KA=.9!,+8984\6%_"D
MH2-V@0J;DCWQ2>\ST;K\>;7O0>GL9,F<&1R=N:\[$JRVTI;O*JP[.>;"D/D
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M\S>>O_'\C>=O/'_C^2_P/$3->TX9S"5'(>VKAYOYUR-5(\XIG$GJ9EEO\-%
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MK!AN?TYF8K5S<CPRV#YG8[(,/RE5^\>);:/<'XJR<A7[0H:Y+V'G>EH>=;[
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M.C:\@?-,@*Z-PE[CI\>7M#/5# AH_9G_U*+C;SW&5%_.#3L17?G4((N#W>V
MC+C)F$?LWB09,U"L>_C%VP*<ZF/HIJ+H<%OX;=N _W7'#] B&D.+EX(WF[(@
M:R4Q >H.@<,)*=V*UDY[\*"*N9G.ZH91G%A%ML]."S ^U Z_0[PS0KL6L$AW
M.[1IS[;_FJ?69"$<-IVKZ_Z&YW<<H25 X[6JY= D$[#K^Y@)F)I#49Z"\R?<
MC.1=ZU%D,<_$<N7Q%6,#X G&+'CW*8M:O]H"*4*I^X/0&R/MMZ!<>(_$2H.
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M<H$(\['Z\NPM*^F;C%_QSZ^*\LZ7OVL2C /J4T67(TJK26Q+$&_OYZ-Q012
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MZ'S@NRYC486<ADZ&,OJAGZ.VZ*:P#^,/4I5>+G.MGO[I@+S@'^,R5%[P_O5
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MK40<3_[Y6IF<L1#L=8CH1$7YPT^K<Q:3@H<?O);N"*KB?^V4FO"4,)OW[BO
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M'.XSSWC!GYW )<<M!V%GO]:,MFNZI%G[=;2,X6AZQQ7WTCG7M!LE>1H!1WX
M5KSLR=00USUY3<[VT]E^D(RG;9?>_P"^-R-;I$I?-T594F3'MSY:8LRI\,Q,
MJ@QCJ%V(@'VW0E"*J5P9=VC*7*RK?3HO9OX@;/MQI%B#]IVX<^3E&>AIZIW
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MM2V\)&6\C>5V,92LW,D57M(V_OG'TH%K*XP/M,/AI:=?FZA37(18^_GEM[J
M[_P.?&OU\"/<-7$ZO4OS+/YFNSB^L*[9M=J73S'2.5,L/D-FP2[V*+LP(6X2
MLRV[;%!I<!<#5? 1U3N70YB;^;O^HO^;:J+[((+$544E-A)XBJ+QQE8->>8V
MN5I?&AKC\NQ:>YR^$\W%6].)IT>*E.:E)V*2  FGS3U^=M=RD0"H7"U^E?M?
MTK!X+'*-1S#OK'X(UKB+P4[\=Z*:B)6)UD6 Y0]LXSKM!X+(!# !#0<'0]!X
M*@S^,YH)\&0"J)[68Z21Z7"&/+PJ:@R+U_<D*R'.LX)CS(L)*$A+)?I!69IQ
MO(@)2 DB<-+CE8 4/5>PLV6/$W#'7,.X,K$S+.8Z4CW__[C?+<7L/_]C#\4)
M>@6Z.$=J(>:0XH-\KB15'@35[>\_:=2\_Y:D0TX.P?P5AG'"1IB W=?8B_!M
MUPG0?I4U13U)%J*TXF#FL"^[B W;9@!)LGJ_7KVP6JY[:Z%M\DXL8[#IX.:T
MPLB(5DAQ3\/*WW]]NN[]MW/(NF@/26,+3$#$0"ERD]#EO]5T\[/9S6TUX=C#
M>P>O.(-/QSDJN93G]O#L'23BVO#$3<+SM%G;VG\-^G'_&O3K\:/TB4@.4HLV
MH3V1M_RSV_E-BPNOQ</W-2;>KAI7 R:4^]U^K1OY,JXYV,=<+[W#\=\]<."X
MP<[!+@&P1+@@ZMBZF  N4IK&,2/"33[5BN1+^>\?2)9_W:ZY>&I^2IU85/4[
M25_.M:Y.YS-K):/_TZ_\OPVIG_5,P(SE8F.D0O:0E"E!L@ON?"4R,'EXZ6Z"
MLE23J*2N^FNW'%"]<V?3RA,P3XG3@F=UDPDYXPV/OG1Y@?NV&UR*FOCT2XVZ
MTA*=NU?1:>O!1,4!Q$_9N2[SY4RH(-NJ9F_]AGO3!]8%A?^W$_>D"#I]2;0[
M>/'2I:>O9NBOS#FGD^]&#*I^$OSJ-7BN]QOR#:+N*O1UME4LE;W.<BQ-$;0!
M"_R@\IS>TZM(/2B+LT5Z1+8/P] SL[]G*50T^%]OM; 8\@3\U2DQ$LLN@T_K
MK3:4R:,:!0FYO6!9>/KJ/EKY-UC+W+O=7"9NLE!E-/WF1(:)%H_X_[W*/J +
MK>[ +L2QS7G1Y!%D6N<M)L#9<LHVC>/DMI!W\ +F!)Z/^!X<?YC5UD@\YH(L
M[A/*I#KG"=T6I<;&.<SGF*7B?F&F!U-F;(RW:&B'+S$W^$_P[-4?XMZ>1?3H
MX%_CZQ*BR^".V<NP([_7@AQI*-FBH-[-0UD>4HLN7C-:$UD%UBEV_;6@/GHT
M2 ( ."*&N,M>[#Q0/))M%+<HHR=M&"SU$0_L,>:@&49N&I_9)&R^&"_)?.C]
M<"-G(=7/[-V[X=L=556162.9\F.UK'7]$/8?";,+3(37<4 YW87/A<^,;5XU
M!8W2WEXR;",J^K3L5PTN@A.729\7-.YT5S]5S&O\\FA6/>Q^A-A+4?^3VI:_
MS$P\U+<<GII]O%I\+7]JZ_J7&.U[_W_L:UHOQGDMM(!.TEXT4X\;G&@O=1?)
M7_G4F7]'59.M17N(93F1$Z"IQAXE33EZNJ:(FY(WO[.=1D5L7H'- '$+8?8^
M2F-K#T3\PW*;C07PJ7- ^O5OR!$@20)%R^)\ __+LN7%I[/V]OR@\BQ'C:[H
M:-CHI2=^*?D20]IK_?^Z=?8' 1[I#G5=U(!T'59L.)=-&SK<T7[=(78_[MY!
MEP"MG\!&XT8M)W:&!D.8@$C&93L3.0O!2@DS5;L-8YTS _GX#YA-=QY,5,^3
MSO[FT #C$H/Y1*DI&@(\94/\2&HIMTD4FA^\\*#3GI3=?94)&#0-.B4:E(U?
M %I3EXG/Z>FM&E0YDE'(646G";^6763)YIXV5['DN7'S_FF!E45O(SVQO/D1
M+4_PK4I[$;26R. #62=D0"G>&,?RK<=IDPSQP"5J'YA3HBZ9"7A\U/"!=FMZ
MO]RCBYQR?" 9FV.2W3XI>:_5:UDN^"L:QT5@?]6JL(P^[R8BB#<L%]^RH0?@
M"&6R]TZT>C>_]/]=QSF*,G4IR\^8S#<TM7!U]VLL_NR36 =%^^QA.EC:;@B_
M&,A)#!M1-RZ -%_!.Z54W L];LG'74^.5+*8&;@R9;M<\DP%+2R%2XS+8VLB
MI>*+>]HOUGZ+&=VQ&I.HB0GJN)W?S'.B>I@%9HY:/I8]YMW7RQ)H^6%/UG&B
M*#+P-*R/=9WP!$T [454#T-TD@8*<#B10]PZF2Z_.X"[#'"&Z@*$@[.HGC8C
MKZ!Z^5A7Z]R*@&:_;5E/+T^Y5;'XMQ:F&J?$D28&W.]+8Y)3[7#/[TMF>V@6
MK_'U[)#$@?&M2DLWZD&1JKGMM47LT"T;M7)$#=9&:/6)2J>FFN:JYN^M"Z!I
M,+&=X N>%A@N1]XK_*&HNCE_ZVEE ^6BWHH8_+LAK,+$KGI(JJ2D_X9-\[AI
MC,>6\8-U\%0CT6X<[@0ZN661-5P-*7>C]'3[#-\T[SY_W+2L;"B,"0B*=B^?
M<H@II+K#^@^!=8T1ON7QY_[.]/582^FZ&RY*G>TVCB?< >CGE'V84@\[=R=I
MOXVG1]WPZ22E"W:XCY+F*$I5&&A@ N[L6K*6HMH3I_.I8N9D.DO$S[BD>SNM
MS)*RKE=@/\D0NFX[+7 N2,30P:/NCM6CV[CU;!QW%X>.6!]IZOH)%/>0S9>&
M'@>W%\EF>C8U5^7'[4;(-U@TJHB725\$SW!(6QHWOY\CO3-.(.X.L0V=B7ED
M@ZX-9]NLW +KPCMN,BXEGJ-)3-)<?<[-(L_/!_'^U0$YO9-*.DAB\5K["6@M
M51\J1>HG=!&C"=IEB'/JIK_FP()J_&*C:S9^C7%D+Z \,NUBR9S1MF/T$*R,
M)H$7;NQD)5:[ #ZWZHRU8;A%83II[OK\OP>/<]CXX'I(B%!-K@QDP((LC=L=
MX7[J\T)Z!.9J0PBF)=2PG$:6XO^1"/X?#I#,_W['I0^VX7#;80D[8]PK(H*!
MRE:X-(">5T-N+$RL9,F27>R>/O)JAQ&.G[_]%J.PYTQ3S5["T,_\.T?^^RR*
MH84LZ!J.>'2T:[QTX"_+;A?]J&HJ*ZU*8UFA5[ *RT4T3N_3?" ;,8>P<J%<
M;&3+&]MIZ^"MS_!UWO4"VS.&0'ACX_=,P$F&4J!#KRKZO;HBQ2G])E(]V'&B
M"WW9)??H&_S5A33^P7-W[">HSV$]JG#<->&&I@+P@\^!P\/ *S+.]Y^UQKVL
M\,:1/X89"1V]*_:,$/?ZX/KJ5,FP@LJ7B;QLR!Z.%$5X+FEJ,7LP1M X7%R/
M]\6^GV<;43<HF+LV%%GL*OS3(S['PR05A+LQD#05)K4GR."()IPV)H![AR3N
MC:T;I"SBU/J;77Y<D4@:K L2[@Q'?U;&/?'%3JT3RTG^C:K&$<.EKD7Z*S]\
M92_V0-QOJ_->=X[+T[!4V  !4 L9S>-YHO48V$WP3&&X*?OL@^H<M,+@NII3
MNJ"Y#^;YBVEUI/5\O)", &HRM,S+LL9FJWB%"5B,&R_D\#AKMQUZA7J.)+/5
M :H!17UNB^OR*;&9VW0\U<%^YXZV\:1&% 'YTW/:AF'T;A%-C^-E BBW+'&T
MM-M,@%/]1XZO6BL9)B:O2UI> XY]%2[?0__;AA&PQ-F5&)_'3[ O7)(]:YR_
M(9 %5IT9>HVY(*FX<%1>\E,>*#$Q.(Y7#C$I-5&&&X+ 5V:@51&FV93B&NLV
M. _#^4\.:A/[!X+O(_JQ0BF#!&>QO'0QXZ,T;+WFKZF&MM0>8M&2Q@U>XGP+
M4PCTZ5&:%\6/S\BDEO>4W&I,6YC3C;[\^NBE^Y'*?=CO:#,K1X727Z4F$_[-
MX @FX.?8^9RO8^$!\!6TX;^M15"CB59!?( N?BWCT2U2%FZA+><<]/WX[;A@
MCQ=-1%,US _$";B39P285_.2:W-[.0&EAY>(L0[*;QL]<#C)]2!)I"?9)6/U
M]>S;YWL.86=#0:S:H$NJS__#8!MI/2*>Z%X&42V'NUR;Z/4I[@TO258_'U ]
MUY[]X*50#!XQC66P#Y;2O$C/BTG#3$#O!Y+36;W<"ISH&&P*?:':\.^\[W,]
MQU>RZL^HEA[@ZZ,=JLGIUU;;#S<:VN%^?>"E<-59SZT)F(C."*J6;=L';_:=
M<:-^LA+J5T0S)&BD!#5T2@WZG&A)>!CK*=@DHQKV\_OKN\>/@6U)@QT44#?G
MZ4U[8<QVNLE(_:4X/HN*[;"'&HTWSJB>NW?<<KD19T@5VP+6I*Y'52&Z&RBK
M526CH5F;,[P-63>N3AF9^3CL5%VZO3$;QV!-:H<F0V8+R]<.Z/-94LOT.VNF
MBTHW4-I+'K7]4N 1AZ,].O[60,1H+B<G:ZW7)-4-9!-O[]M:Z>Y.)O-+;#NE
M6* .&(Y84@#J.R?E/'RWM@2^JQ5LW&G\!G:,Q.-9>F\A](BO\@&O3C,3H)^W
M\./Q^=:!OW<%L]^^'0H^R[-BP&7MY?5QUG@HV[LO1 C=O4,6;[_)TD4M+",Z
MF/:2G@!?^:,IR$(R:]#*!/7ITI P36O1W4$O02MBIV*M_NFEEU=\)=E%II%O
MVEF UZ',N$R3)HTLPGG=&)?QXQ2+Q$"9W)M%WX)6 $* 2HX2"5'2MT.DF132
M*+&>F(#1QY*5R$G11KXJ#NVH&)T_J3 PO,.R5=;+F6#3J7EY"OL2-2KP2U-Y
M[TIJ9A1]3PZS>38H"G<6SW:7_H4!-%S,=<\:?0*OL]J\]<E56@+P9@'8>DI,
M;N6ER*>%1*73-IL'B^;;*'//R?6'[JY:!V \_,%*XA2"Z$;B)LPNP!"E6YI\
MB4\(=A]'9S9[_&Q^Y&@2;U?'BW,<TS8[#F!G^Z;P-RMJFXNJNL%[9QX;*",H
MI7R^7[JGMR54R*MD\V?O,B DB]3.!##862A['RI!.)-N?Z*%#SV@4QH88BT
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M!6D9BV7E+\]%&X072$%B2M?!X8VR]LL+-[93!*?>VN>;J-AS"K]F5NX^91Z
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MGG]@BWXF:P/S)S[Q%%X6:YO!^H!KD/7/:V?*&Y_$2L7&\Y51C%&=Q9#CP^Z
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M;,.FDA'<(P(G@BU^7<Y0>O6$WW:":6GG^AXMR#,N!#4)\$LLCQAFC#7 A),
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M9VJ\B@C[W_;,3W#FAD*)J(O47"[W3<R,7S#7QQ8J0E4WX>_Q^T@ZU43)B=7
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M6.G,K11$6('YG/'LK&^2H6.O2!&# -.3PDA(M@5'VB2<./AX%F](2#EQO+X
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MVTX+EN$FB92CKA_[SB>-R&8/Y6!#GZ2:8GT,J\;?O7*\"1HBZT#Y8%.</U@
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M&50U_?#\<G4MV[JV7MM&5TCFCBG6 _U#ZA1F+:&WGO-U-VX7JW/U49LC_ 7
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M+^KSV3>5TY'\A(2CR1$T'T6\%#R--8[TM;G)V#CFF6MRZ<YZ9J_?:T][P()
M$4KW-^R5710-.,+;:2:MD(*ST5B2;\TR?\OM"/>2C(\WO[[DX= KNN:67)M5
M=$@UZH,D_6@RTE,X ?13X##J]P/>8%"8>>IN@X7GM@3N8W UTQR,,"Z_\J_'
M9VPFY158\PINXOK;=J\YMJ-+4+\5#<$=1/=\;%-7=B4Z?R,@T6KYIONTM*N7
M0%"=?YYS?$M2_ %1IVW^XUT*<$<8%2]D%7-D/6,[(^+?4@"XOTJZ!V I"A[7
M#+ZEOVW^KU#YHTUW-J.6*@H=,A1Y #]2$4>0>8UI*9,3B#H6RJ=L!QI* KWO
M/1FS#JN&P[<T- 9PY_:?3VO!KL!<+@[5W6=*6CU*GT9#WTY[A)PGZX#%S4FA
M.PC385_55\UCA:F<\1P)#C,<6@Y[T@Q?U U?B9*C#;[6TS >9@4"8C+&QB2?
M;M@+&&F/@*#ZUM*>3'Z&3MGM6DNA-P;G3P#WD%!J HV-E(\-040Q1=4LC]H2
M=2_=)D8NW[FB8=S[BVF.?^/#_]MWIO1M^1J/S/S??WUG,O%O>L*?M9]1?7]T
M 9-O5&,Y33LE)Z9I+Z;7"J0PK,/.G@!Z<^GL.!D+/)9PW]MX?@)(RFL\ 535
MG #^VD##P=Y]-HH=&)N"A?,5>/NH-N53*0 UJA8$]A4ZJ '*7-R?NP[7CMLW
M)S 1W]%I.70IG?(++X56PM=77%M*O:V'1Z[$0X3R>>2O96>G+0V^)Q[6IM1L
MGYTY14Y.75< X>_&PH<- ]!5.?F,J^VJSV^^DL'86FN)Q>?&>'%3N,R="?U8
M:SO.%D:?_/-7YVB*G!RF#4=/GIT!P*:N?X(VXNUX2<X_3@"\*.;UPU0H</B@
M_[;D.3W#PD_-=4G\O/Z3<!#>C[M\K?:G&"Q@Q>-59$?W^8+%^56:\Q?:7%!<
M.6;RPV9^CF)S&&^4\$>K.]%="HFJSNX.?VU'R<)TU\.P,SE!]U;ZKY!9\MM3
M5KB *#DS@DA!Q5=2T?$:]VO'IIA?NG6([-G/DM[7&$W;*!'CH.K5]P=VIRB"
MOVL,W68]_%1A2OT7>K^_GI5MX$W^!'[Y>[SL?LS' _01>BSVZ9>UT0_\FR<
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MWR]D,QBV/$[S][^B*5-V]M2$O!DW?^#99$NBP@9L3[I+7R9.7'4*&DDY 4R
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M7W/5122_*YJEY6(YN/JQQ99OA>3PMA/YZGDA\)BG\-E[:L&AV[:W=Q2)6Z0
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M%OP\:7*FEJ3U%?:S9Y;.=']. ,?/W;S+U>\8!ESXNC[_5:0EZY;^VUE8$BC
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M>RITCOF_DT]64,)@W#P6^6_T*;AR?<Z@.82GVWVU/O+=R+G?=;^-'RUR(S_
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M[Y.;^47008S'^'(79D-##*W)/[";^QP7RW=DPC X\\Y P(HA--;,"^]!%GY
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MT=DU; ^M]!0.^9(8J<20@VWR1RJ.@5R\XJ&7$R^V!N/KZ@;_Z![87); ?3K
ML*1^H#'))]LO)3=_^N8'?.:SK2_>CW;>CC.AN.R4'_I8%L8C':Z'[\[=?!0H
M*/8WYWZ6 ,OU]S\W;#T(2<2B210WQ<J+6;/XKU?^/8]?>S,ZXH:U/ZH_/6OC
M8H(G[V\_B#%]'/Q9.W9E^5JMSNA3\VX!!>I7C9O@OO7C12PQ(< !N\%Q YDW
MBAJ_P4 JM"^//+?*M3@V^8"L AW/&(J!/'/'PC@_2[YJ[;-T,]&^"9,]\\'/
M+OE][&G *K]/EW9609SSQU(C9J_< S_V <I]PDKZSN2/  RM_)>$1[*]$HU2
M:<3..8/H3\*@U%JHI1J2D/OCQ0)7JA(GN%!>WUU57%H33-4XG7169Q@%QEEC
M,K^+Y CX.?RJL76>V3?O!EVF([@QVQI4*$:7%/JZGJ/(3B0XR8,87&8FNBT#
MN!8ZX\&$"@9^\S-TZ]<>WO(SZ/^\,(K'ROY4!:8\OI1T9)IES2G[)SK9V<@Z
MT?([GIV@$P=Z[<4-KK=5\7JW3^?OML$G\QY(#%*T.Q"C:9) N:$G4%0U2OQ"
MZEK@?\** PL\/@'<K9GPS76S"4[!1,($W/*-C$.8X:7CNVB'K6/Q&)(.P<"0
MU+Q \AM0YYD]Y*KTX'\O=_6=3,$AU_7W,ZQM?VW9RZ'CM-NC* 4][+G]UALU
M!1.<1GL\RI#=\'L?ZP,S?0:A>.'S*CE#R .:LYS+H)NA5(3/>H:8>&E<:\WW
MT,1(*Z!FQI'7 A+_$@>/G+]6,W1YW=(V@?'CW\^!J55]WXMZ9WLD!!D.WXZV
M/K)?P=C(GQM)SA6+<0PQU0(/X;G)]UC>\WBDU"'<V8FM4.Y<O9^[N;%O;-JN
MYX 9!'-7XZ%^$<0P$EZ^9#(_^MB&D^K\N>EJIB'ZX+=.5O 6Q276.F6B^_>/
ML:RG->8:.WD-+*$PUDJ:&$1QE*(9XGZY< DI]*3'TSC5@JMRF4F((3X=9+DS
M% FLTT!C@=$\J1%>>:ZC+I@0;%W2P-60O'O%EQZ<Q9Q?!=[^NI160PR!(?=D
M/G*/K9A8 2U,=.-:V2/NRQI8?/8J,;%3H0T#:Z5)SE\5(]04/1BW&J)Y5G"+
M$NQUVO<_GO&$7 E:</1;4[/TPO NYL2X<]267!P;X0JWD)*3BQ]O7U-KYUD"
M.I7%6H]/]+Q^DR*4-&Q-'HS>!4YM+RX!>>2"2[8D\K]-;I[.S 3_E.XM#KWI
M_$GFKN:@TM)*2]H#ZC>U9RQ=MR#*.'51G9K1[H+7DI;G"BWLCXB>,R.L[>T@
MJ9N(ZC20J*GP?0^]:>S,,2XZ?@6GJAKHG-[Y]N''V<POCV6,E^WN0*2I910K
M@B"N&X'=" 'JV0BL+W<?1-NI7W\\T%"?7N\_3)UQ*I+V@91\IE^RVQ4)!S;L
MBR> &B">T7W'P;B^KK8>;D*XC.,,P]Q_^/:ZTIY0C](0X)(S4T+T436-A[[P
M"F>19B<I[=A&!_G*<+C;.S\J-JY! /_0?OGK'PR795)TZN16R*H6A$!6AHY=
MA3P9&XJ //!@+&I<KDD]Y&@K#[BA;>&?Z-_ K<9WA>613R'9$!(XJ7$1%2H0
M]:IX5N&+B"L/5>A-KL*+6SIVVP)%67F+PIQC@W*B8CF#F)P-+8@>@9>N?$3R
MW0NM2!9?1D0XJG["?*];&!@]Y=3M#'VGI>88IK<=;ZR',\;$].2PD=P7;/Q>
MRV7NE5L-$6.:&X#I#LF5I_-+K"M'MWQB[1'5B>8A>&I(-_IIZ59E^?%<] **
MB?*(;MVJ=W9[;%.57J#N[-BTG_77$<MY<U[H](5O9_;=]KPPQL3D<>@5TOM'
MPS6\ABJ[6U8^/KY>(SKG"K^].^.WA'<8JC6(B6T46+FV-EB0)=BD$9[7" O7
MN#E&L5FXS&(Y(7'C^Y@4/A6GZ[%7]<"[X+0>MS7?U;<9Z[>2K:UBUNPU82%>
MA7]F;&WTOUE.=X_TBV>)B<4FAKQCWX'%@=R'(GD0D;7B:!8WQ)3EA:'EZ8=W
M7B:Y^53[J$C/M.MUAX2(3\ \6*+Q!6O$N;,CRPXAI:<DME.AKR) =R !WBI!
M4JV!\*[MCX)8N\UM['-)^_,5;CQ?FM'VRF9W47].  L,\%*'N6RY"KS Y'?R
M 0W]BWAW#,O.+A\@]5-J8T<CD?H9==T==E6#*\ZJD],@L$1B\QMWJC#<N^2)
MS+53.<::MK6V3&2ZBO[)[47^UU7@2V'PLLW39(Q.BKJH4#/Z%UV^=KY#9H,\
MX4="&3K4B!LG@)'@Z&-)E"^U";24Z HD\D70-?.6&)8@6,Q">9YM]]\'<NV)
MT\[[$ 1_V+&< +!.L!^FN#C.#CMWVB^R(A&5>QF978T/)@;&*GK,-/88=DR@
M=NA.!DXR. %HZ;3#2(\M882^(^N^K.683),0D%"(+[ I2.)_+S3^LDVBB_H/
MZ/VG$$YZ.# 6GP#XD*OY1,18A3P"8X6;R"V>?1#RT@^'MPP.+G,]DV#(:ZO?
MM];VJ4_S#&O[V9;T^R:DE#B6O][1>\C__4CY-!X05HK*#F2DKT'3]030(]::
M8KP,>U,)UT)*4?-02E:T(1@S_4.IEE'A\7)<2S3&RH5/Z(,NU^D"PJ?V(.*
MU?]A6<6T"^R$F#8->6J6E]P0"WB^(XA8@$DI#QMZ-%ZQY23&M5PGF!0Z@VMZ
M\R?0J,9!J5GAMKJ<1AP)1-:E:)!6G81WBM"7!WZ3C_UZMCR3TABD<P)9J]_F
M*"LAC9"K,<9CE?LQO5N;GD7?F^"JHO6?NC<^:78P)'S2I;AOVH7^2[B0X@7S
M]HU2?#SHYK0H69:6TJ #06SP;H=,]LLP!XF]M:T3%<T*66?>J)X9E%=%:,'^
M?PNUU]'UQ7C6!1#<KMHHXNT"U57*^7TG<<3Z^:,BU<_7IFU+G&-W3XD%<B_
M36R?_<\5W+8Y=N=-?R@-6,PL], NV$G].EZ)OE69M'+_7UEPU@G  PX$1="
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MGV7OIA)N]@ EJ]X;"['[^H4SL>MX=@<B:^D O)']C:$FB=SHX^1_D0SX89^
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M\4* 9PY-.)RT.,84@YZ._L0:3[@N_(,WCG[(?X.\]X_N.0\/%F+/.G!;>WD
M&8&M7@]>C3:+QCYM%- 9#_H6#__(=! 4=_@$7 63F"BKYF#?Q&0M?_-.]4Z:
M?30:-!P9]AGQA@D<@:TRSE")1#D#(]Y:B0_.7ZNNQ^3E?AL0@3TL0$H4JPU6
M2S:5R%".DT6XN:\H36X2R4@2K' G__(3\"TWV$W8''C/&W@1M;7)0;T1W7J
M-\%1\8;M6!:*BB,HVDU.R49%KZ8NS;AFM+RY4_+^]]Y20JE?KXA8VQ$RF*%"
MY+$Z1R3X\)"9EJP#?AFHRA@6KRA2!+G@0(5R+,16&I*E9U3;DGZYI?9%71]G
MTRE:0KWLB^5,,GK2X'&JC?9,;4I>'>D1!-[25T;=_0UOT^(EQ2T%P8G%U*]*
M0B8/1_/3S AB>S\="G7V*W4OB[J8D"7>5[WCLV]#CNYBI"SKJ:ETP,O0D8.8
MW,;\\BS((AE2/SBY+W3?0/)$*%=7.()[$\M,![S&1H#_L?]( G5^?#'?WR0V
M_OIU]N:]6?XK29<7 DO"EO-]X11N+J-T,M&U-OOJ(V]_7.GHPKMG5RH2*'Z3
MS2>D[R\B],X;*Q=DFK5X&>Y1?COK&I>4J91EM6[1(DE#1"X\L -[V7?KQ:26
MY)8_>VK:MT[^JK$:G*Z4$U+<&_JY-+;UY5=C\\0T:T+[$7@FH!U>-5F!#]^U
MQI]%+AAR\#A[= QC?%_21H3W;B0^6;YU?\J#"3I7)V*WSH_,A+]*F-;EP*3N
M=Z5&=#-U'%FJW9/LH680J]3TK3E!0<)S^7I(+/<!G*(F3ON.HEDAJ&C;;OGG
M]E&QW\W<W6NCU'TH_M0>3=[7&',Z()R&DH>21+$)2#>99O>%Z35G:=?F+.-)
M9='(Z:AX:W^FR$'->X=*^V <3D2;;.6[.O)%R*'&P>'.U9@7;^\AAU'3<D2Y
M.FJ:5QS\F99T<M>1_[=+,QRDM)@'4=PQPAI]YSG=!W5O#Z^A-%!0QM"08V!,
MM"&8*A;](\<R)7!D_-M.)G"=ZZ&[>]X3S7(4LG5] EZ)I'"AVQOI@(X,$&>@
M447]I%<+C+LY> XJ]M[B_O([QZ,W*OIMX>J59^_VG,Y&T5B9%H74VT 560D1
MBI'S,G(/6\:V<:EZLAV*;'G2_IFL)_8+0Q0&$V*"3['VT $&H\W,-%9G.N &
MRHL.L L K4VL3'29EL3&.LBH+A<:B3E\M0OZ<[-E%KSTO\$P"8Q_<@+-6@C
M;BDYII]O![[Y^D^J?OOP A=0G.;G+=0;^U7X"]1R^[_O[<8C2!*Z65H(\@O?
MO@*CDK>UR5WPYG#,;<1O?8H4IIAO2,5Z3@2>E42U4'Q7:(K<LL<E3/40-?$7
M$O#F=]&49XLV<EWSU]"X9X_3C5Z.R":=^R:8&Z_XD=OZVE-C>0.-!8"6(T.R
M>-KO>4&2^I(<AV]:AUJ@OVYRN=^/V8U)BC9[5X"^$YJD+14TTG:SC1\Y IY&
M,Q ,1QLXHHX8]DC>R0RR]\[LA:D%+.<3 R8\9-RL&F)605)H4[N7")M1SG'W
M%AFZKAA[\\Y)+TC$]HT[-ZJZ#LYEMH<V24*OF/'??&*^B=QGT#[0GB87C05)
MD-_M!E>5;)QD_E9LY6]-ZE!]I0IRG*K49:$#'#TE#EBE]M.Z+,.+R8]@HYZ*
M:6QNE&=(F6KY6T/)Y_M%8NU'1&;H@$#T+ AOB+@P!_P TVR>ZD^/_S:)3QZ)
MMBH2A<G;XY$1J-<VNB!6VBB*HQ#590!%SG3>_&AO)W^Z[Z =%"XUV=DA=1LI
M4?8TKM4?]5,DJZ_G]&P *@4)W>JEFA!XMQ7P$9:D5_.7:O%9X5_DK8[-3G M
MC7'WQ)BB+-^X?5Q/*O7._LQ]S+1D<F[.EVGI==YBQK1(^J[>A&V'Q75R_$C_
MX\1M?21V=CFY#=D!CSM)*:\BZ_EB3KJ7U)O4$[AL!M@(RBN)[ ,7^P."U=$\
M!K:E!&/Y9.<2R@X*2;+/K;[^8W1O# ]?@6TR7K4H@3I"^?XP'DM] -])6'UJ
M_DNSOQ!_-3>:\H?$('+,Q*^$GFXHSZ8PW[C75*#$4>F))<?ETHN1D<#-):ZU
MVXG#W]%FPK&0OF(CO7'7*2IO+NHF';"8#(<@3LYO@4GF'#1-/8H\]&^U\GM!
M# ;!ND@'])2@R%II%#H@X7!?_ L19":![(>3[* 81UH(^-@=11JA ]ADR(\8
M$)QQA:P* ]1IY6G3@D6H@9V,TQ_ G25&H=/8I>!&*23E^DF&7;BN3FDHL.@J
ML -U0>/F,KMG6^.L0$]$C56+X+/WP6EF3ZO=;MUK%RGJY6<.B=<)4E^&3L&7
M)^,6Y@+ !.$*R(VTW"EKL+6>5IWH]G"/H,8'WM-<-6J<"C\#4VQI5O>S)#UB
M7Q=\^303Q-&DQ0QO?Z*$99MI+PC4'P5WI;I?S]U,?_N\N>T2<K#T?D-;8E2O
MV.=WW$=#':"$;";2:GX&]BPI&OW\W=W]J23[ICH<N=>*+4_#K7M4[S1Z82)(
MA:P(^XGBT;JQ9>D8*2UPM+B3*!CUDB#637+CC1>>OS4@@M ]8T[]WBF8MNAG
M8[@' _L<7Y!/[=FVX8Y80'!@?:TZ>01L\Y!8W^R]^5M)+NE)#ZH>!>E'<<.^
MG*DX^A)O,(N,]U<7^;J'P-31C)!+CM3WLG3 P1-D_^Z42:<:*(8.<!YBW;#<
M2;$OVTC6\W:H''=-6N+]61WJIG?&^-SI5U[<)WED,SJ@K^;O>J(?9["T:"42
M@:P1^)(!5L\3'/4(=40](H,8_$+9D4VF*4/R-Q)VMP/MO6$;@U(;'J&K#QOC
M<<Y;SB\&.#/R+C>AJ-74SPSO__;ODH\'3>UPD@D&3FC$O0->V+#E'G4]:.%Z
M5#5R,/#V@;(9S\;IVRM)WKF /-'DMDTC& S>.8?:_ 1?93C3V91#V0:RMB/1
MJ(G4X&I'S=# \*/J*M--;NFHQR7FN.:]W6?=_Y X];HY4U>05_?*1'(-KM'_
M8-/ZBJ/2F:;;<"?03/+B[C8=4&R0:Z,T%-G\Z#V_8HN<,UE+5R]+Y&*1/NU2
M0\/I\G-*^X<("G=_WVZ*6ROO$'OV;OH+KY])=S7O"WJ=)KLA4_].080:_/VN
MG-KH$^58W_+CNBOXQ<?>P)DPLS,?8 U^0J<TW_8P*YWX+>].]2P"XYJY_+ZV
M+P3QWL]:O.E:[.S]9&;NW@TM\_W+9P.O</)]#$#G6X9SR3T)\VWH*VF"95S,
MQ]U89N?<HL)M"]!M)AA(&[;Z=;*[YZ+5]-.3<2:?;]BO\9NSPDS<I\.?45=%
MO>]HF,?!VQ^C5C +#&VM(FD?9&"!L$':[0FML[31;*$LA]M]SJ7L4H\?B+_Y
MV)S]J%_//5A_R(NY!L8@R?_U.L?(#FWVR!PU8\*G/&@+/%TV-'](S6-._!BT
MIY% 8Q&D X"@R_#9,7C6;[\A"K<ZS5B0$74J8 P\K6=B&\= _8Q? B(:M..,
M&EQK7J>Q9OV=9?U&!TRAH'1 7B'R/I(2SYM+!XRRX>F SC*J5]21WC;#W&_D
MX?=IS:N,ABB(U?(1[LD":+J_FVL),EWN!?F$=<US_B/:F.(9M\+)S:5Z_#EV
M85GTY0_XRZ8_U:AIYK:Z.O;:\T%J2\Z"(V9^!J"/R '3^DDX1 YC-@N>TY?3
M,"V5MNJ;(T(\9B77J]TO,).5VJ]<[[;?TC4>B7&E[F"1LSK\DK[ZXVD.QT"P
M-;S=NHR'D,H1-F;@W!3U"GU?7Z^\W4TWJ,Y\!%XUA"MC2$Z,;*7UCMEN:1,D
M[B_K3_Q3\@LPP&=C8'%+_>W4:5S;;U<+6@_\[!O*]59A((>B:MD#+8.F] G+
MP_IV:/7R;W;LM7#UER@Q+1E?,S+1F9JK%"?WH#5%-E"E^-N)U_2=((1T!4_/
MLYI/PCWIHV'2%Y3=XN[4-]F MB9XQ9YH8^3JJ5[4')0SXCSLMYIQ8I%O;H]Y
M:\2S+PL?WF7XKO[;GQ._M'?U"M Z.T@2S1CN9!U?<^)'?,M.PZ+3X7FG-^6P
M/G?7XJ[$7W'5M^[H>6'N+81,H1-@,\)""<L^VRZM$C4A7K^S:@JC9,:]GDMH
MC)#TI! D]D!&Y#A=1#@B@GZ:<)$>.BO_+',>\&)-;D\_^T>S7W^=QF0]_O9M
M<7B).$4?U(_%PYPDGU<[C\>/4N&+(T<F.':R$<F0Z#RJF$$'7&XOMH6[/,+/
M6#D_[A$M_/?,YXAWIW3-480+DD-_!=9E")R$_TVK^8_ I6ZP 7?(7X%CG_]?
M J]7((>&2)+ .%&"24\<;T=M1J$-E_&#/7O!S[/&,[T 'XEK2TAXNR3M*OPE
MY05!/+0@Z,=6^MOZ,(,MI2:N#X<&HB"\P&@\6. SLPW%'Y4$7RE7VR-Z1-N:
M'S-&9=XN$,/!$*!P&[U(53$E/%*+P[CPGIV?GS&,$OT2:?-KRN?N9;97Z_7%
M*,==C& GHCHB#-I\;S%#YFG_X.#VM'YZ]:7NM;O1E#<^I^W0+8%,=,"9)X1=
MXGJW$5,'05^ G=EH_]5C?R-UMZL,RL@I0D)/ RNP80?8#W1 )2)<5FEFP(9'
M*@.*R[J_=^(0+/%K13[-^ZKLQ>[F[(FA0Q?W-ND'M)OJ<BA*VI*I[K*9XC)F
M=X>!H1)RBI!J_^O2NDT-<0:E]R4.0E!LI(B'!.Y2N55#K>0 [E&1976+O)>G
MVIG/-J.-W<W='6R X2ANT$H+J9/6#1FB2OI3E^OH@"= <MZQ^<+Z3Y-C.=@M
MAKFG[],!#[-1OC@Z8%R/]H=F>L"?1BX0'*$]N9U&GJ4#RDOQ0S,9-"/#)0ZJ
MOP[#[)>1(:B%--">ASF<>(H!MD<^HN=!=2J4]+0NX,D!(Q[I]8 94586OK)2
M3@=L,S&P<MZU_!0ZH/%E$)"69"9">DL'\&YQ'6@3PZCY@5)D)2=_V^*E&)NG
M1)F'BV4+$0;!JJ*S)?7)K0\ I^*/U_/?9HM040PVY[.H&[7L)SK^2@W3/REP
M,1I45Q^O&_5E7/7YW5[8RRG-2E^D\%_T">\-6^ @L\S"_^0CK_U-JT0;\ =V
MQU -NVUOQ6M:W1M>Y_%NU.CZE+Y0]+$ZI-F%3ZB%KV(($!(NR'*_@!O]';/J
M/U,'S7#Z7DETXS%'':/V&!<Q[E/CY&,YJET:J-8Z5EWP1FDNNRA-0>)P+_8)
MP_,&T;R.F(,#77,I.OCRK"70!6Q/\1],J*UKRR^+S@NA%_W8SET-Z;T:\I^<
M$P:HU_!S)+EV?Y5XRK6O4R1O_5US$U3-*&[RO-^EB6B#U2+64G[OE5-9RYI2
MYC06U>69DM^\/<(7ZE.R,?TOE*0>V&=E__OJ$\>]3['+X^F-GP.U1%BD=87N
MU._4T>H:,F>+^U7\023HD/;!A09$%';/*-""#O@W!D7E/!PS5R"HTPR0,:#M
M2SYT0*YMJW=AVR &U)7P'<0'?\5^WHB@@KNYH"GW8@SG9:.\=IP4H/Z'Q\D!
M?'.0G^]BYU4OH9)#IN6(;5=\70_\@E>)(<?9/]D"$[DU258R>KH_XD>6OCQ/
MD5D-N]# )SF]0+PCLM=#M"+4QN#7EQD]2#%8DAK:IO*:-#N[E3<7I@V 9=#J
M3RP21-^=1=UMU82WZ[4*6 2J3^ TSGRW]DWK\ID<M;+BKLB>%WSM);6F_BC2
M>-CCGY DP')94+PKVX-5CI+"(._=X:5."[-FXMAA UYE.VUY@ Z(0%3K?? 2
MY$\7JQ]?'-MY8M#UT7A)_*EZK#+L.X<+M88 BE9$G/G#BYEO*+J7OZ%\^XN;
M[ [813>O ?25*4F?*9T22 VFL6V"N;5 3@+1EKWOY-AG>[Z#YW#JE_+4<Q)
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MS.B 'ZZKT,)K=NF _U9B, [NA(B1I[PB:/B7Y<?6S@-_G!T<-.!B6Z'\>G'
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M_&I+=_FH=)F"X55S]Y'T6S-\A#F_75LC,NL4UHK$;%O_67[*VH5I>S'B3 K
M6QC[#MYF]"KP.16I8;  C_9/BRA5=)5=?O2C7M]JR.+1'C[_1WO;Z97E55"<
M58CIIVLHRNV? J97"@6@KD,EQ2QM-Q(%_:7L^?E_JOWPN3/9B$C;\^V_HR4S
MM!1DU@:12"]-2YHVN-&N+"I]N5:0Z<ZV+Q_2A\",ZX0N&3$_'BUO_@?IZL<T
MTUA;5F_W*3Y;K\7/)%KFD.,]'0#,;PIX"J\Z% EP"W6UP$U'\6EM/ERO8!YM
MK1_[Z^S">=,#S;FV/*<>#:369'=X)W+D2,2BDLUU\B1OFS76_0D@9028*IED
M5#5IO:5&VZYJR2>R5H15;TQZ?/W(*ZD;I/7O352M2?!0&$T:#FD+DZDI,EN1
M/^"2ZU_>ZJBCL+96DAP)ZYU GIHR0V,&YYIY!>%+=<Q>.G7%[=ORZG&=H]97
M<WZR@Z\XC1,:)O-=6YC<PNGN<4MU+V/U8Y"J&1WP?GR\:'Q1N0S:A]K:4?TS
M";=P>8@>HZ"0"J EWNYK/F3Q3J1HFXO SUSG;R%#F=,&*)V/:'8R"TE\L!5-
ML5#TNU@TAON<L/1&(S3@_45X6US@M->RS/W]=F]AOL3]0HMYPP"!]:R=[_4G
M[*5ZY#74 QJ )$Z[" S%G/V\48E;))L.^A]7!JX "^[3 6T01^#K0BTR' R?
MU_&EV@;G-M8=R6T +\/&+;L:D3W02X)QHSH04>_>+]V7[&U/X9)>T)0V3^"X
M"==\YTDB#XHCZ;RA;RK?HI$5:]%9 %/O1O0"0PE#S/,DDV7NP<J*2HO-#O42
MO[;CP)^FYM8GP5^I?.;#K>S4BN93W__P5&ZEAV*$BT1,LS&&!ODV"QZF>69G
M##8R@2Z#65GG2L"HXA';T<=IXO)UN@<S)\? FQ21"<&GU*\'[-H/*Y4-/$NC
MG@Z*-&MS-4A_ ;PZ+>K(],'V-SD0WK,> MK*0N]'MQ1V *M[@IO]E@U![$X>
M6-NY.:E*ZZ#//><P^9%BD6\6@(M('FHK:'F_'7$XN'7\\YGX[K.X,N@>?$72
M5.P9]V\Q1^B^.G8*NTA+^$:Y74.0M))N["X=8W%[]=A"Q(#_M%. W$#RIHGF
M634XQFIQUE:!I/[=RF+F^IQS"/G^A,C=6\_$QD]MYM,!G)*@:3F:/C"\M0YT
M\DS&?U^RM[2428KMHO\EPTL^JF)CT-2>]._UYI[;V'6:WD\&=D/'HZHHAJ6^
M9DN/M(MTB$U>]CT9P O,#=H(TAF_W:B5M.4AW#6EY@NO:L>5KD$$;Y)K1RCY
M$913YV%*B00%[7$MEL!7$U]'5R JM5]6*U/T]!V>U0%U7J(>0R91=@FGJ:@N
M##K:,>'VU'T9!J?0F%9]J=D1"V_;RI4Q^DY-.SP1F?B><FZ\A)=@B44O!7V!
M0H7RFQ_?#[Z3^SBR9%B"CVGO.^SJY'7\3DBQ2U7<\-2,@<?"%8<GAI=.S,*>
M3E9GP"\ZH4\<INPA 4PS_9<7MKTDW4D""UD8[UG"M?YO#;4@4"L?:::S590T
MX;X,CL146G1>*2#>,6JN8KEQ^MS'T[H=7]O7R=]5UUJ8B)6DB86AJ&SVD>U
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M-THC )@7Z&=-M"))U9?'^'E-E:S8]ID/O%;XSZY-W:DTQ]B8K8:BY8MCG$2
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MC-'X[J#PHD\KXA+LVO 9H!+&M[BEP\T)T+X'K??#S6E92*YM^NY$D(S(N6>
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M3FIDW0=;;'@E/3Z_PKI>,,9(LSX3E=L*0,1]+X;O=$KY'5(:MP-\=J(7M0>
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M:<3B7 [.'=09H&JYFM*?M#];[<FJU<0OU^]#I>KTF0"295BZMG8/Y )&FV*
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M_41(P-\G>&'H)^N"&!\_D=2^Y^_<P[)\>B>"<,K ['0L)BK!-_RN4!%!7[Z
MEMJVP&X]^V4FS%U6PK[6U]AP ;'/_8T,G5V*MH[69Q<3:='_P_S,BT/7(&D[
M1=>8;WG7CR8&90L)HRB-":&2NI8TFU-J^^Y_$8D,X/^>*RX$=F>WJVR4(O+!
M%+&S^Y8ZKH%EBG=M= P6[KV*-59_V#Y5H5(\(Y(CXV;R?'1ZW&GPN<W=O$91
M=LWRC@@._<L<#Q< 2G2+JB(P9FQ!9\^BL_>@>E.(MWJ@ ^7E>MW@S$*0RE=>
M&TS#IABL?TG4T">R?!G"=.Z$D1=)"N.YXQ+.N]66CSAGJ4^_%PO'!QH;&WNL
M:][VOE6OPK6 "%)66J+!Z69]$VRNW]<2;2 ^&3CHS5@64-#37?KC4[894>9H
M=<SSGPG_D9""!;<A.).X)K<M=Q<>\\HG[7]=B=8:E/T3A7_E/YGI""J7;Q]0
MQ-EG6MH;1O&2,W=WJ.VW5G+DMZS(ZB*]W6_&G<+="Y6N[9#C%H#TSX;;F5)R
M';UWA)/I0C1S];1:@+$3S2($Z86 >33;DDD>9E:7C3_2-0"_E96\XCW[-9N_
M\4+6ZTWUP*$?COCZZL0)GYH_<^;/\P1K?T4INXMN7@=3!W 'J_^Y-\0X1:\B
MH%,ULB//251)I&<(B#6L?GB]Z&.=S=KD-[WB[8UG+.:H'I0ZNQ%OMR".:A$<
M0A$QZZ;Y5/5CS_S.B3S=<P_UK-WZSVX[H^C&.-1K)*"JLRL/<^GE6A^7WLXI
MHG!H"_)$7U>BV]IWHI##5H*)>3&Y%40'$R0:$N C#KLN7PR@D>'HIU[4GQ46
MW ,N6&;FY:.WN ,'HK=I/>P]>-3OR3 4YS)<#?Q4?$]?: 7G9#L@+ G=]--!
M;E=BZP?WE;Z2Q(%I/&&6Q[62=33*A9\+^3O>-%D44)VO=#-IP^6_#1(:,_K!
M7+[BCW&K,:=6J/SVPBGIV97?3,:HQI*[1L0@1M_JM6T0EK*Y^#WFV*I*0^%J
MNQ>+,9XGQ_HD]90U0NO79F2TTV>3J%@)@AOQ/D%\$5[.7YIG8?G2*4[\CH]I
M\J4I*@9>D0O^K+(1&[! ;%9;%EM2OV^:EB5X.Z Q>*V/1>?O;/_;[VM4R#RO
M*KWEY=% 6GS"ZFIS/CBD43S/5URM>KC*0KU\5"+X2K:IW732';\W6KVW]P,F
MJMGUIEVV@Q?!TQX=)MS(CBT)Q8EKE/'\J1(?4_KCE/0](]!N$#.)87(44FD:
MA%JD(:A\F]8")OOX9KG^ZFF=%;I",R/42C#A;"+>(DAUS$DWXOAS_4I?OIR=
M22LL35T%"88KB%.0WG-_9T>; FP<RG-R1(SUW^=F<[C%1W,P-2% _3L=)E%+
M5Q[;DA%?-T5R*A\\JD/QP12P>QVE]_E ':D.8Z4WDP=C9._$?8&Q?-9//!1N
M\DS4,[+![''9O?:5:CD%ML]R>,8R_V54 K/>:]:,6SY)NRZ8'N_/1"[VCA"M
MF2NQV&375[]Y";9!]$3TWAX!;2LP4Q)F3(>]#@IVAO]E(VK^RT8$G8+=3)G#
M^1X@,!V;9X"%.-"!\1E@]YR5:K^<"D,RLK":62?G6'5,>PY"O\ELR+@!T-S:
M/BGN"$O0,STP([XX)[)1F,VY,1XR.X>CC>)30^1J);[\#)"03^@]I[#,RC-
MWJAIHAE9=/B_)(;B8DD<]A2=M?9Y_+WI,\"&X"RLG7CA#-!_? 9P 1+=(&!$
MJPEB>>Y?$I^U#HH2;SG9#_H)) TA\(OG+\>!3W$E9O7OE\^W)?<=J-:= ^W/
MDW^)JE0KP&EDJY1;@8.J>)#,O)W=S[I7BN*PX83M*V[_JC-N0"H@D9.=D,OW
M?I@=O]QXCF>-61#]C5B*RL7*;5C)8D/3EH88YM<5JYP%0S!O S]>MG*_KD7#
M<(4:Z+32S$)B_D-A>%KX]!^#:<'U\RP?V;S+\PCZIO^0V'U8>O/_0K UVV?E
MA1K2_R> ]>+VMIL6@)^X1B$S&R,;J1\'ZBU*)2&WZW:??384KIM.F)G@"D-9
M \/,^3 S+Y\6;EGH/E$,&3GQ^P]_N8O/_O@O_*5F;>V<;];N:._*5UHBQBKR
M^N&G"$4 #<"4#Z>T,!32+&'>SH^R&7 #W.*9MM]?^\2?+7\CUH[:U$U==W?5
M+3%[C\NZ6_D24<27OD6QT3_=Y#BU<_L./\VXK1FG$-\UL:)"U65>?@WQPDH"
M<"$:U!6-F0ZD%<!1/3^^?+##!IQ3];G?1I1Q#_@?BBPZEH[TJ>LG["W6AE*$
M'/%X*\%1C3QG5^$,UI.1)\8_-=RC"KX=E5ETS%>ZOH?I+S8P<EKR3JD5?(L9
MP8R8F"T:='Z:FXYDB']'#-5"@G.^"QBX56=V1_NRX76Q7.^/?*L?9#=.2-U\
MA:TIENDIO[O>:FRL!=RABLE-Q9N+%+F[SR:(/G/9]U$N/C=]0PNNX?X?4Z/)
MB:?P M'^VM2W.<*?3RL^_P8WSQ GGGY$V#"'9;*-W6J"!NPX.7Q5MC;\Q1#1
MLLSWXP?/>DL$_K?(>2OG]'D5/=BO<S :]TQ3\="I&SVB=]B[4W:U^PZ;Y+*7
MBAK'XBBE$\BT.JXZ45KR^/+._.N8'5@ZPD>0?HER*<O_^+>H$&8WA+LRJ,HR
MAL:$0+\@X=%>;Q?BM_C70GM46ZZ$1>>.!?V%7TD:#!T+-N<(AGKXYZVR5,[4
MAJ)E!=H1'_<I.T3K)KMW[^VL0CEXA&2/>X*6?/D*@@UDA[I$,AIG*BQ4\WI=
M=/>B]H"B/L]O0,O,=3.M;IA]@;))6!OB _]UPGU7FS^4*94!3)&V1^!='S&F
M1]%%19?!>?Z"[&/IQG'NQ0I/OS0QBQ.^$.\1A#$QW]&9N5"WUX7-U/^:2SZ9
ME['U2V(6S/[# #\-.85$LV!!OP4-5-1YIOW7"AU0^LCRX-K7JSUYCSY2L\ID
MLVU9%:J+5]7Y,T\;5;P<>AR/96Y#T)&D+(87,T0<L]Z*V)-)%<G3&8T] U$N
M*BI0\4[@N12\5[;'B'H-V+?W^A4]-^J51]L])#ZD$BMCQ](X'8J)'B@=0 R,
MM?+1_N4<CWX 7C%=\CN*W3X7)D;9SDB,A2OS;?.1&9Z\7URR5P6%!8.XIL;6
M\OPYV!,<9UF_8](-A^,LT6H(J$1UO_2,17_>[5!CAICOKX*8J5FL;F*D_@XM
M3C3Y']]5+W1HB#&74%QYXJ<:I X+O'PI((\]*6;]EU$&*.0O-IH9+T7PRIVY
M/9I?6.Q\X]->68L5LQMW/G2VYOVO;CYI;77#A*3H!-'?_X8>M"NK M(^S^W$
M.I<F7LJY:3<OOB%[9;QWTUNF(K:%+JP-4L'<CJ*;?^HCF+=:=^?M]<O%#^(N
M\/^(*)K7H#:M'GYB*U(LY+!E=$Y;3XRCC8T?%45=TG]/D^=W!NAD_F#%2JA;
MT2HSZ^4[%*]0(LKOKQD/>L>K,8#F:*X_V+(*5@>GI-N+N>"\E9,7A[91"ZZA
M]3E.WMZ3YOEY++.,@X5BOU^K%A4591.7!,K+@MO_[:FQ++IR:F$LI1YI6SJC
MG\I#'%(H]H/['.D_!L%J<PU%8G7?9W?E#=R;YM:R8#H$MD7F2)FG;F5_>Z0P
ML;]C3B<,>8M2A/G&0[7.C9I<VSJJ'-S>)'9DGU$=:,:^MGU<^TP !)&X2JG>
M\]2__F"[S[A(\/?W;>MY2T>KB]C2SJ$O3%FY&]ZEY[!U27-)?9"=N> 9H7(!
M]'ZO69GT9DS9OEB]4K.Z67Z2%U;QW,+S7>S+=^"?9P"G9LR8Y[3.FRZH./&%
MZ]M5RXKI&8W;T=VYHM<$MO0=T)QIB],<%2.>6Y:2 UJO7>TOME\3+D1G,XS^
MA[4*-HV<]@T2;U4CXOPC1'XHQ( P7&T0.I)!=8P4BZ.CS^T;GUSTHSS4,ULG
MTP-X8YWV/8B,OC0#\^0\#*#N#&"*_W&^<N1XG$X.LQM&NOV=DRM2-]-^'$JP
MQT+:YFD-]B@L6PIO,K?%AMS<9#5WN1[P8A4SWYM"BC:\4U?3O KFI_/&OXPY
M,_SID2F+NJM&$AMGUZJ#F:=XJ+J<TY9Q['8M%J7;'+K+3*\A'-(1WKR_.'97
MX;K)Y\)3EH@C<Y'\Y;EM05&M.=U5KJA&QF^PAR,\SW&7TY@*['07*FQDY(^_
M?& HF&&QDO(B,I% OWXY"C1/ENJE?WI3_^G'.6H)'R&_.7Q/B_DQ(E>D9B[S
MYX Y=+XR.8C"N=E7M,$Y:>CT*9I[=NXEEZW)M0?Z(<L^7=!LW'$;B!:F"[V/
MN_^Y/LW\\E7YK#OJ5-8"TA5K#_@"Q9$Y84)HUV^J(["9R;$^[%"HYQ"-@W>]
M:JQ3C;EST9?02W:OLN/!=[24X_U4M@PB1)QKO>U@]$0[0D2[!:%QHN9=E]"H
MLT!-W:_GN_&/DUIW]D.I#I!E\ L$\7\Y;A3@*#](<B.;RU0 E28\V$*6X:)0
MO8R>W Y9R'C<Q4:(V=\S:ZS+W$':U*2NRM(K!'9<%6"L5:GU1+INM)2R)SJ*
M>&V1_3/^I@[_R+WR%K48%"%2$G.US+X;P=@HCY,%UU;@)%/EQ*%^RG\3!VZK
M6UP;/(>KX[+4"+JH=$O,=C_X,D%<G8#XUIV[SBD 'LWU]OJHN0_K=]==NYW5
M,3'+;NC<]*)V3"0GXA'="0^>= 9(8:/,GP'P<\UUR#B4Z]!)W+^-XS. \Y8Y
M@EOI;E97[-&?TX#_S97'*,1"XOR^J^K-<W3*7SH#:$F(;V\22MK)FP6%1^4$
M/7UUCK7$_R6#"I6G2(&"_ON-1,__Z2:4Z<+Q#O!?>2G<4TI7AN$9X-D*<HZ;
MQ/^_7-([3!'&":];&]K D\^_;1?(_O]XGVO*YH6U'^\B.Z?P'SHO:T*772TV
MIDZ,5_'%X._ CK=.0C-OT)(LJ_&Q'@O T#MP8?@(VGEET(:KOB,U^/+:RJ.1
M#X=M'R!0$KRFKH$@NW2EE"/5NJ#'&VF0>PF%^P-=ROJ[.FM'6"F0/@,DF=0R
M/=A;B2-##YDT)QRF^![G,I:4R%Q142LKPE4)Z*J@%N!AW\(+^R(,:R;. +('
M#7@+0M@WF#PA!;]W%;XZLCJ^8W!@M^BR_?OQ505 B)CF1L.HW.D%WGI05)5E
MSX3Y7)SGUR4;[//FC/$0&!*'P(MG0OLR3%L2.E=ZGD?G6MX?*"B[]1D7J_[6
MFCA;W-*HA#D#\,"NX%[&3??ZY,RW+>TH!HYDB>FOK_N^>JK!%Z.V9S(#G<Z5
M*]1X$+HYG(2:G(%_<9H<7E?D6\&T<8N+VR<^^JIGS)Z1.YHOWD&A@X_3XL*Z
M=+(1;3)H-:+LC$3W="-IY\8K9-*OK2W+KN2E8M=P"'493/UMYK,Y1]/+FAY9
MD@^CRE+V0FDRESCVP=OG_2F82UD\7TKOE6RT':3;#R.R3G@_%W"%):+'0?NJ
M X2\I0Z"[8**80?2!OV^W AD9Z;<M)*AQ_CWP4H3\S,,Y2+\3SBN3>>-U+;0
ML,UHDM 9(!:EK,G[<ZO\G<;\XXD\<C%H.<@WESR-((O$-%K@KYP!/F=%H;:B
MD90003%I0T/7@I-;38FJ/S:GYYI04@?*\_\MIG=]3HQ<6^99535*NIF+GE%S
MIGLR69_M+GCSH9*UB<'EI]3I66I6'D0(HM=[ K$5@J)$F!.?+H+;=:A:FB^4
MCVS?>>VPZQRWNYQT=\"S/[L\0>6I<,Q[-]V,IH\6E%HE:;:"*R,>T;/)RV5^
M]BU(-%KJ$_J0GQ_'F77Y2_%+'-3-:6#Y^=_!MA(MC</EM0)>^SEE?4R@?&O]
MI=W*XIG2_"R[3)L*>=66"S,)[VG<H0<)F*0OP'9@='UG<P+QZ^& EHN$L>]^
MEXFZ_F$/,"20@^CNF^J%A81X_DV)GS?(V,T#++V+YG( 1:60+K$]T_NX6"!_
M= +7D&WKWF+Y".?R.7;QX!<C-U07RM'P\V"/0IKBR^E.O_G9N/W]'/4-GN):
MZB_5PHS.043,"4*8H-SW[BLF?FXLMS2KV\]RZ#6(CF^T67/;0*<0.0A<NJ-P
M7B!KFL/R>+5X.-O.G>SZ)]%5MS);/G><+OO3X;\3$(L]C2\RA2*?UH19OD@%
MUG0T\'TISVAYUQWSG97&OU#$$)9TMU11]5" WJ)P&70=Y+1,T%H*5U:$W44C
MDQG<JX>F25G-LN^;+3Q/)QL=C]]0NM#+DJWWH#<,IV_PPJNQPCM?SH=;&Y'2
M>"YJAW3$OO\:BRS'L5U7/T_J#"_@=DJ+F(4>GP\%SBU\2^@DIIAPCV"B$2T'
MV:Z$275YK)X$D%!2^7Y=FX/D,M4'R-#_@[;WC&HRB-I%@R ("-CH)2HH" (B
M3:1$5+J ]$Y$0$I I/=$04"I B("0I0JO?<2.@("4@.AABH]H81 VHW?.O>N
M\YU[RCKKW/MC5GZ\:\U,]IZ]]_/,[-FSZPL$L'"761F/CSWYR9L9)CX<P%BQ
M1X O\$,VYNW)>M$;Y-YQ*F_TQ;'MRJ)#>9_C=9?=+;<U*QLGW=WJ.D)EJY2P
M+"L17O*21G].9'*S?W9ZE)&#!.N,-PUZU._XU9>>J"C@6;#-Y&OQE45@V$NJ
M/PYM.A\^2#!+K&9I5IB>(8GM@:(H $YQ)1=, ?EJ3 ;GV*Y@Y'+@;G>6I]J'
M"C<Y3G_FK/#2D&JJ&LS4L&;1(1H<M3G3D,MJCKP:_*0BO9\]V$]\?#R$)^3+
MF3R+7=7.E9M37]+%.C&MGR_???YAFG_%=0G@Y9U@9/629ZW>-DKNMO$\Q,JJ
M^+08>"L@!X>9S&UTQ.Q'ENSN3E94N28IE:U4BD:<@[O!2Q4[0?5^14WOM99A
M;#,Z#K]IA_)2XU;XI\6JZ<\<0B%_&/K*PQ;IZS>S^&LM4()53[(M&9DO;TNG
M'*HT9VR#Y<FCB]>4)+'VW6?0<O30_7V]%/??9G&!%SUK?O.*+@K6:=+%9@4%
M&2:(CQF,-TXR/2\,&("+[D'?6T&^I)Y=#&K]EKTU8.7I>^U#0"+3'EVH6@@6
M+3D;_GA*:)+7XD_NJ/BNN&6 A41/UUR%H\&5LIXN_IGMMS0CM+)_@33KP0DS
MR*Z=W<;(#-&-:>EW9S1@#N@PF6U<R1?K_V1,]H-N+_Q&DL4-AG.ZB=41*MT_
M1VI%QO5*T*.P#@I ,"GNX>O8(F,K@8)"Z/R"<+*QTSA1.;<C?^_4KO'0(<.C
MN?CG")&^+04OADW5Q8^@4R?<KT.H-/>RS8QBE)04-YT<O?%A^+L_9Z9LNU)H
M\9LK2Z:-0%QHBT[^HZ29"]DF! 6SY^=>A.1P<_''!23L<$N71RN97+!?J_TF
M859YXQ?#,2CS\FIZDO84O_EX%G!6U:+ 8Y X\J--)L1K%,J\>6\HF!>\Y6]!
MD,AD/N\B-9G6B,J)?Q/Z;KW-N8'4K.2 C/WSUY+/KW'YSI57;Y3E/P*HDVU(
M0 5W2RZSQ3?];0EDR8NMG+E9<$M0C;<N?"ZI;PLR>[2(&D3+I: #B(H>:%U'
M'\>8?CEW>S<#))?BNXRDX.1^F<*^$U>_9B>-RKA;[/V_%S9RB(RDG)KRV$X(
M9\U#]=;76?8S-1ECQL/,O=/<'8+78V/C6R$-^#@L4 UOA2[T+?7RBY_7^X6.
M?9T4>$'HYL6# )4N;EF,?GNK)2\;ZNHCN/K5)W8J^7^Z^%H>A#T>8*_0OV'N
ME/RK_!&IL47-,Q#+K#$:<Z^FJN)JD5.X4'P[O/^:@2$39FT\ [/E=&Q.LALG
MR"'^6B 1K_>O# 5MJ&'V4EQ<X"D>OZM_:12*_F(89Y\,D24UW)BLU0D%]?(\
MXW%]UD&?]W)H35U?%UNG"3:]Z+EI6TM0P#,\HV+ITO.[I2^M=A^/*38W9^;\
M3LRUF1:?$[E.LPN6AJ*RSH\KB:VT2AJ-N^=4\[0VMV ?-QL/Q-*$L+Z/M";$
M'M\N/% OJ*[_9&0LQ=*A/I^&\XAK,0&&MW 7XZ-^$=R"0G/F+QC@3G^8/6 )
MCSU;0GXE,I!RD2NO&@M=$)@$N5B<W_*2%FY$Z<$<)W +R1^ZS:F.O(WEW+'R
M]%=,NV7#M#Q7.:S_V5;J['JY&.D]:!6*Y22%,Y#CM W"C+Z!]?'"H.J$R3RY
MUM5=?,XF!1"[>(T3S1;F@*5U*3"957K#;">?G#2SX3?5*[5I :8ARPOW[G(:
MMO$H.H_8/^P<Y84KR9E=CT2U$5\VPF9UR)JY"-RE>@I@ICB9% Y;-<+JDZ ]
M5!(RI":3QU@_3F8X?5_88[>B"($=RJK(D9%4),06HNJ+IOZX)+JB4@IGO'U]
M5E6O9?X1/5CU7WV!'7G-1K6Q>O7FVY4>;!]"0 7ZCG>C8\\\TJXEAKVQ8AWF
M%?@6"OFM!(,4A?#B2<&%6P\=_-OT"F_GT/EK/I,WD/YBR/;G>..B<O$FF)7H
MA3?#GHK+>%S>K)QQ?3UPHV[R$LVZY[N+V[%\V$FMS>BQSV9"CI!%[[):49^4
MSQ*EB&,*X&*P1TR(KL<2!<"TE;X[IB5>!W<[D>2#!8:5O9&>0WXB7B45B:O<
M"ZBRH2&";L=YKLI@^G&5#W]Q<C.LVA0P*)_QX-R#5:NQ<E&AN>">]>F%]JE#
M=4:ZG(M\E\=:-M >.TBTY/LF(FHX62+'/P0K(XH\%/SP^9/>GY\MWUCU(%Q>
M\X=^XT@PG@'.J3\C>VL?!L;HF^:^,I],^V!BD-2]1*-C:T/0#8B&721>Q=X:
M*J[Q'N*Q%"OL.*=A[$'T21_6&WQ\YPE*]TGC*N(JPOUO3:CEBA[&+]6C,/?B
M\RVSWPO/WOM.1ZN*D4?MX'K'(WA]W-[458.X$%WT-G>)Q=M F6RL%M?>X^9[
M'OEFV[:.!,40#8Q')P5P"0P1$!GSJ-7IX,D+MU3ER[Z:W/K!WUI^'A!+C4[:
MFP@7MG@!!GQ/SK1<7,Z6:=!QR:E\ZA?,]P#MS%\60B\#4>H:?&=(IYL%CI 3
MY00[W9&9 Y>Y,V0OG*-421F3#^9WX8CJECO'M1'_(.^@/N>>=7+-;F_@BB!]
MH\=;"J FI;QW2,=H/$/]X:W=;V(/U5\3L:*O4=W\,;%76A'1C: 9@>D ) XV
MY<.O<=]"=GXH.G+C<HMS'Q!SAPLY J3SS8"_1P!E") #NX-]L'8+/SUW;. 9
M/6HQ0F3<=LIX<?",T';XT2 F1U$R2!)#3E;9QI=BKR#1X'?[1 W?UQ[GVWKB
M9\!V*3-A$?/A\8W#;  D$'-UY0C.!S2G *)]:\QKT,!]*'*C).(D!+&%I',_
MV;;5)_@'#+JI\&-J#$.741&=X9N?$T#?X"G^P&IRV"(S[!6AU#-G%N;KXEG2
MIO'@<O(E"J"-79]X84JJ*N]AU6;]\<G[GSV&8?6MPB28K2,L#EX[#,=LF#?\
M\>&EFSH.]JY;=G$0\Z"E +SC;:+>7*#-]_ZD5*U!:FXQ8=FJ*T3O"NR-@V3\
MH&Y7[&?2J%A_%<A(M$ OLA&?AH.QF2E3M8Z7 W_?ZTVJ2<XR^:8H<OV*5?($
M$VXD#E%3T(6(;J-I'5W^4^LS>:[8W,;:LCV;D89AGU$+$$L-7%-S64/B$F>9
M69W?7A7^M/%7R<5[8'DU\'EH2*B_>F)<R_O<3[\ 2=ST\H)L!HG'=#P'H1!<
MPS@1A'VYW<EYQCE3XOXZK@;5O/#V$DW2.DBR@,@,&F@ 3@L;-1#,8HX.NE$[
M]0W,6>P'6YIGL;#%FRU6*[XQKG!@BXY#R>4R60\A:9_S'[A)+@\ALR+BZ8A5
M;Z.NKO1<81P,/>(>@YN9K$WX\.6A7\J/Z?*H/0_[.M.F0Y9!P0<VA/#S1N'?
MW!\<RTYL ^N,5?CQ<=[H./U.0TM5=ZC;>AL$VV@&790?/#BS7^_=R]P>"^$E
M*.-Y.\XD,E^U 2L1S34.G[?,3+=.V$0_^>\+"B9F?E\*,AL"UYV\A54270H"
MLA?$ZU UML]V<MXIO;@(]\J [8<;9LH^Z$5:$@E01*#QY,6G<\;N^7#D<25N
MZ<;;ZZL\IS,(MPO"^%RE&W9H"\EE=TV7?A@_YOPP*:(;"GZV2MH+JPFYBLVS
MPMDD]]S_S6LPMF/9J]N7[/560R!T5JJ>R-0BC1/'6 4D+T<,([RR''AD6$3\
M-J3[4\#COT'/[W2FXZH,4:"$X[.OCS_;/_85%3>-09+Y<_8&1,KOD/+:A'4P
M"'3FY%":XZ0L X$EIYQ8_<KP&1S#3I<08J;H9\DWL=E4_=Q&/POFS,8.#@G"
M#^7CKW8=!*:'QG74F=H:Y%-Y\#C0Y!&5>;VM>XC,A(Z2N2HQX)X[-<IR((F!
MWN$IKC[O#V9W0_O[55:1%="^/P&*'6?N)]$AJLMQK(.6;;<7%A8.#2)N15Z"
MOG)\1<=IMUB58'D 1R5;C[>H8G-,VL;V=WW%A*/GQ(>^#=YU>ZK-RJW%0-^T
MU)JI:00&&<WEB$U^?MDZ72S9:DVZ. 9;9?_WY J5>:JROZX(X5W.Y.Q&/=/-
MV<+Q5-3'RWR=GLM=L'+_.ZO5L=+J87H5GW98.2HTDDF^ T5JH&'=S/LLU@&/
M=1IVGSGMPCTNI[%_EEO3%SE;V??;!3^R!'>$%G0%7WM7FO_QE98BN^!UL@F6
M MB=H4:*ZFT5 :R2UL%<]Y1T!?F OQ_^\Q75F"%5&%B//=N.OW]1S>+FF>_G
M=$VW Z%?\9)]D!]Y%( $7VHWHOR ,**7=V%PYJ'K@&4(!5 <@T;,6NEC&1)*
M:FC1!745S:T<GEOJ>*G3#%>%A$$NNI6XN5>M)[T"M^LQ3A&^[GZ[.K.;N)$W
MOUB9=[F9V H? ..@-OS4A5(3)P^>'K6<L];BK^DJ3^/H7/QR3(P+C2%HA^CK
M&N%>C[XN79V5_!C1(%KPZ4=(/\/2P#42Q+)FPJ7,9M^C92Q?0&"!B7D>EK^A
MBY''I<'B5$2:QS@[AW+[W%U?6V[O+@2@4QXGKI5)-R-K78E>I!P96+@82^I,
M?'FY7M9+\]P,#IF_ NH=[0\> *YXSI:^@5<@PZF"4F(KQD<:=S?E_8F\#3H<
MN*ZN,3F#V$\_S5EF^+BKI(8=-)UL>5S/^1",:Q;O?NXM:*5Q>SXF26'ZN^^U
M-3V)HOP:4^39:;)>G,+$S]V]OH+COR/Z";@=[*>6BV<<[Z>:$9.BSX "&<1.
MZ?UZ3'D>E)'H,TJ6V90>=&'>1)7FJTP6#*"C:4=3*N3O]%F?8S,85WE2"IT"
M,<F6,XZ@9UK$2R@ 1R5ZNEH.N0Y!KG91NL4[_*K\4K8Z!/XM;_.0-Q5A]!ZW
M#U#+W&;*QC<\X3T<A6HZ:5ZH7[[.O<8V>K:F"15DJ1#G41469X,%5]6R_3)&
M*UT5#IIUP4(ATB0WMP?T/19\;P$ZGW4O"9N.5/V#KAD9O-8ODT2SMZS&0#XM
MT\<U8:^=;?3NFJ+,/*HW*[M<KFQ$\-)6TLY_(Z=LDWE)Q6W7 NP[_<C\U9BV
MFB;K-Q]LZ:OJ'%-CI=Z\.OVXFA2T7ET G"?HV+2VLBB_=U%7V9 ./A6(P CC
MOHZ1I:RU\JQG* #[@#"9^\PPZ1#O[UN_IAD$F[+FP@+[,J$+BP>,&!C)OY$"
M^&-?3H]W*;.T(/\)8J< HG+2D;H9UD]K(U^PCS$ZSE16:*+YXO-;-W X"N"3
M/E6OVZTCY'!^]IO)!4*E?@]]4OA>QOI5$]/FH;].ILZ<=B@ )W__^U:H#MF)
MJJ$;G=E10DFA@+)@'5)U<O>"0CV&.@21T[>HQ]OK>MC&;K.0[_#%+/"7-X!!
MKSF:8;'US"?+4SD,'9G ]B]:XGG).K*3.]WVN]<'M&]F_;VP,1'KM['M,6.$
M9HU:6J2;P2<Q?_!UMS=[JWDR>E"I#EM+<G!XD9#1*#AM.A:][BM<!T\<,?UV
M1]TPO25WOJ66C"C.-.O=CP\RZ[ 16( 4^TWX*G9V3O7*,R)>RTO+L4YR\RU]
MR\KT/'Q)IJJ-X'?X_>^K$?^S3]6!7X\6U^U5"#"F>5)3BV#A4*&SBE TX^VQ
ME7J(0JZ:T&/"H,3^H]D*MB*2J'XXO-;LO7@(L"! HP?%,VTYVUZ7O\S%$6SQ
M^>+K)"6'JXLT55X!)7<TTEE-F]L6D<>%)2Z/97)NL4+V0KDQR<M*(/869OOE
M!W<7]0FJ/L'^;PC\YH4T%?<?+"V%BJUZS :K\GCTZ/!K<;IN/0R2OO2P2?H.
M!=#G9S8C !AKD<_%V\Z$"'WI_Z$WXLDPO2IY>:'G:V%_>[\2*\.SBR_;P*36
M9? ND+X_X5N/3RZ!%HB?^%NL/H BQX[040"AM_@SR=MS9T9HX(>,'OC%$*EB
M18\ORYV"8D&_."$4P$H[TL96E7!K3K:OW8/U]; ]Y#W=R;E *7)H,7)K6\PX
MZ5!IJM$JP5UE*3M:[/+Y_Z<BV']N0&;R//# ]"B!0--% >1QLI\)4@!T)Q1
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M@W7(085@G2"LCBDFKKO9W9>@?_^\,-GVQB! I3(-M)]H*>GXH5,O\QIIR)=
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M0.5+^= !5CV+AAT%V0<FACYHO3P59V6X P50+IAML.Z7%2=.M@1^5Y$9E_%
MQ>!@$^(^ND_YY;M-;^SL35]>^U7"+5]N4/>4)JJ2_;0_9VN1BP)XF< QSU8Q
ME-OCA;X=O\4&TILXMUK(^D!97[0C4O/!JMDD!7#1=_$J]#>BH@?Q(7?<T-V6
M^_R6.;@X(O[.GC&@_46807TP!_=1B2]5$DDA*EC.".%JK.2[X\ RB9M2(_E%
ML_.6.HDG.LUW1$-7B-L//3.Y)^.X#CMQD#,B,?9'H%%T>I/[+''D$>DKS-U&
M;*7WIY)\L4M.%UGT(#91@R]C=_]<+.*+OFB[PX["TA6N)>00&&,$.A7/ E(
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MTPWO%52#G6!FXVNSC>MP;H2+9!2"QGW9@PLR.K.@U[PT[CZ:W_39^U><ZHT
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M(.S@^]GL-ZQ2LILM&LQ=HQO<MZ PR:ZD6&A=8\D:P_]-JD2JF/^ D9VV*?R
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M2P-K<N]?N[FCYN-,,I#25Q4K8/F3R]7R6-OI=H@3IW^"C:&(W@#L4&KLH2)
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MR)38 K!81'0B8M <"LA)N2XK;12BT=#CB=M\0Z]E\9-16=/S>&O,_:@W!&X
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M8<?WQ&8#GC4+TKYJ787>(J#6S^";) R)BY%>%%9#[>RPT7Z+VBC),5="?@E
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MWTMM65>]V86-1MOUSK^,NP9V]'.:>V_ET1H(/FI[=+\RV^F%Q<9^7'@@.UF
MR]9;K$[<5+TAB)\>7FQ:>=E(BFVY9W.C@@&X/M^P&85VIGWT8@!8]G'++U?9
MBM+JE%K\LPG;0""!_P!"4B3 J:+($T,F24K3J\IR7OJ"^Y MD0-H$8X@M9]'
MY^.:1TPU(M9.-*93@H9(%-B'?FP7;9QZ?1T<Y.=T*Z2-+C2D$&T2'2C@O)ZX
M%,4+RGVXP,.GL)M(1XN]FE\X=GXHI+F8 0##9X.\Z3_-';4TR%]8"S3>)MX_
MEM.UGM^J]]RW+964CW[\-D,L 20<'MOBZ#@H?T+S!(WF#:YB61N#$X'W$1WT
M\Y:_1LTO\(R\CQ.EW$7-.-JWO%#Y]?J&(+$_9BE@;YUU5OW$CIL:IJ/ Q5U)
MEV]0:S2?A<EL4F)?]U "JKVB30;[.*\FZ9O%..JX^-XC <.19="@8\3J>%3O
M_._AX^EJTZR.0XWI:TW'-Q5+KZ_;W:8\M^YE[WH8C^E62F/6@86H@/(55\"
M8OKU52"GC+<'OU;9N1!!SJ(RL'RKP#4;B8WC\IXAZ8WVQ;[@RKP6"W)GUJ3M
M\BMME@BOV3:@RKH^7N/#.$F5C^6+9T8=E^I=^9#$)O1L]BDS_VOLDW</K!B
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M]*(BV',M;FX3;?_<T'^[98H/WFHVD$;R_7GB:"A1NTZK?2W%_B!J'TYB?M*
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M6+([NUWA>[Q0ZEO=KZG/VUQ:4[F'2>I5<Q8-\:=#X8G^UE7K"2[''V7JV.J
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M^DWSCXN]3!T+U'@==*9UC(WNF!56DES.>%/^2B;NLE3<XPBG'P==0LP11Q5
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M/;96&:S/V9 '&IB3 .NQ+A=O\2_N5<BZ[!D(_WE,0)A*FT N1)JP 9SQ%TB
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M]%E(11%/=9[(D(=TU_WRYE-/$9?*B'3%ANV\UL#(8.US>1*@[P /(@&\#$F
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M E_\OK OZL=/:=V%'UY!%(O"5Q+5SP&O)2Y<W84NGP,2Q=C(1N1139IS /_
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MK&D/66M058D,?_S[MEBB[^WF:BZX9TJOO/"G(RF-9#H1A$Q-7WSO_5@]JL/
M*<6F25<L<'.@L +;II]3;&--3X+ _)N(0HM VS&K6]T!S7'4Y?%Y8;0%DCJU
MN.<#'W,D9];9$0&(</ABODH3?J]KT]7#^0KS2I"@ZCF@"(V35))6LK?1CC/Q
MJY^UVLEL6 RZ[1]=$C((7'X(,S"'H>,HX$9XQP7=K%7C'W<1Y@6)H9B@EWZA
M!I\L1;A@Z_5S!P]\??KE^(4O8Q*3K9M("D3Z9;=.! O4FAVO40G37?R+-741
M-TY3'?GI2C5P*<J.RT,[R=B%2_]^RRX'\_-$S-T".VKM0_[ZAT>OLK99HV,W
M36I"9\P"6QH#RN!=7Y=^6HIQ=%8H'E2L^OK[KFU,D!5>$1UZ^/83Y\0IR*<7
M<TAZ!]X _1D\@JZ?!B+W)[EY"X:YP?%^__=C32V1A+T+7?29@F\34.< #;IC
M87BS'62I^"1'77S1ONWX@DYULYEV OFU2+)^#YIN@YYA1#S;?Z5<.@'_ELEH
M2T@G_" F%L"4[BD'6K0V_0SLOZK^_?+[83$]U<4'7%7/1P#_U(/\23SP_GHB
MD/+K'WSS1=W!.:"=Z02T]XEO;PM^JBR,^VF,/XG]9UQ>M$,8#X+%*^!37Y2)
MA"3'S0EZ(YMYY^WV.(([S,M!/$@\=5O"T76+WGJ\]%C&*JW9W%-%D^-THXWN
MW&_8#94J5&^0PW+DQR,78+>LH1-G9:C4.W$'^:17MM>KY+>&"KE=E1)C#Y(A
MVK__QWX_5/>%:.CE*#W%RS%>):F<,2[_6HHM^[KZ"U%AKI?+'_/3M+E\O$&'
MY^B]U\^A+GH1P>6B50Y@P_#NG*PO,D@[MZ%Y7!,?N%399S?+;H=^WD%2W5?>
MWD9$YZC4$JUPYP +O/KR2>(F8>U9C-R!K8JPT'(W4V^KZEEKVPH")GL.J(20
MWM==C%' T$)-ZX^W(STM=9(84NMK2I-3J4$\/WV:0=JXA_ZZE(G">!?F0'ML
MJO-1THF1VZ$2<"F]8X&3,G/3VF^PSUJL>>+PZJ]WY3L5R0]6@X]3PK!Q+)^;
MJGH^R6]F'(Y>HHS";[8Y+$1Q4OEI=M?X);>GIZORZ.LVN>3:1[4>9M*["'@S
M?)$'W R!CK79^%<4G662>0AO'R6.5-(XL#&[CF+(VVB@2)],MV'W5&>'H+9H
MC^K M#FDY72>%&&1LH1GUY9#QB''M?5@(\<!LW5(\^E])3?"1Z(6!A(#YF1-
MB(0Y46[\P3!?*,I9]O=;+_3FOM""_=B=(][+CTJOH!/(MQ"J+C):Y4H.%>*?
M /_2T^FYGD$F?UR*5#Y./JI$$;+.BNJ8PDY[$Y?XKCFZ;_,^F@JI=7PDE@AL
M[;[$$C(RQ'CU"?NZ,C"Y#J>"M:E\DIY,W.XZ!?Y^3. P%!V#_X0U@8W. 4%\
M%=97S<(91 3I< 4T@=;]@U;64?5(Z+<#IIU38F-GX373C+I)UTFO"7^!3/--
MA$%;U5Y/PBVH0G%T\Z7E%E47PP.U$^QZX^=^8>'?-FF2ZVDO9]USOO(7 =K_
MGZ?8JN!OODC30]"/EQD4FO%S3M4S<X+_\$']]]D2(^T6WUL(?=O^8WI,9BFC
M/,VY?%$$J-Q3!NGM0#FC96W&:V)099FFT";KX@2ZFI*NOU]&*-LI)L<_G?I/
MG8.BEMI.V+S:3H]BS@%/6 O^I\-O)ZN099VIW+PQ"DO039PL%A,86$3YPWNU
M:>(UR;3 S<9-M)9+QS^I8C*<C2HY#? Z '41AQD<EQ=B")&6Q$+,["JJ$CR4
MH%NKGD3/'" DVA"_]8&1:6@.FG'VLVUE$\0.;[R0Q\(*B"=X9EGBJ$K>]?K2
MSO?)NI\N@;- ;'!Q[UB[09_]EZE/3='OCUW'@]=V9V?S<)$=<"Z_+H++V;<[
M1)/E.%-=2!?J0-/%>;Q)4L/V'& @\C3J+\<GTQ<8@2-^H4T5M"_F#9$+-^UB
M.L:?:=[\V=P1/S@012O0R-/Y04\QB_'H (*%UY\#"#5$?VCQ.>#W,[&<N%H/
M[KGJ%Y0KX O6HWX0;Y1'O/V$ZS>;K'9?_7(UEOR>ZZCRZ]*FO5PYM?F8UI1^
M!AJ2CCAK?J-_TT@T[XM! ; W-4N\HC$5B]AO01S<ZE"I'D'@,Y_4XAUZQ#FW
M93F+BIGGU.Q<MW21<O^^I3,4W$E(-%$]++]NKG^;TM5V2TF9ABR0;LU/]"]K
M-*UK$KKYS8[YC:3J[[S44#%9KWM-?$S!O^=EIVNO/WY91R0M"]0WU4?[I=[+
M^J'QI)WIL/7+O7R4RFOX#;^2U[J!F/LE%6KTKL_WR@4R[0-2%[S>/]^+WHA7
MO([])_'JQT!\2==,OP#28FZL<OU6^[(UCW'7&]NR=U/ZCK=G)\![3KD.>;OG
M@-KR7'P"1<'+%6G\73*G&]S'5Y,;2A$D>^%X&L)JSP(@M&3E<;M45T1%:EAZ
M4A.;1.P-R*4(#=4/3^4%Z$A4A-@Z"[Z9B=ZT@:%MQGA\A.MW:BJA?83T_[2=
MOCFKM:ES57JKX_[D5"7"1;9F^R_A,:?XK8PWCKJU67:!BA ':(4SM@+)RX_/
M7>3[= ZP]9Z N2W"V2!:#H34$(P?[<8*<U.[HEU<U=,K =ZC?!XP"7P^3)7H
MN[1WBW::"0M\L&L;R\OOT::0\'J&+]R?";MXZ2S[Z$7L,@'%=XPS[=M93M(B
M/?1SOWME *W;KMOBZYK,3H:*N/AC]K^\K>:<C/WGYF*^VEI$Y)968O3 ^<%]
MLC9++/)AY ;POA*(!,&G8[_B+:QP:Z'+'&0)W-ZSM\G#3GK;'W^5IM%I'-PU
MO:N%+GW<OPWOS:WZ=PY@A*GX+ZM$6DM-8Z7/0+=_[:^EW,UZ()AJ_:A0"X"1
MI\G;SL#GSH@O[C;A;2C,?EZ03QFY'^VJ9-;>.3.K$3[/OZ:N'^:;$]:4)\V5
M;6B<Q<("[Z6Z);3RV[T)*:(/N8CS[<A3!CMM?SOO\(+H.+D.<=_$IHU,#T?%
M!10>Y'FEU+XV1_QF6"I8YF@]>A7\TT"WJ&*S#&7TZRR5\LB2'$S4].=%G@/P
MBC_M)Q!%H;3VIOI)KP&=U5="XV4?W@&\!ZF=_>>P+Q\3F9<8LSC*M&D>7^@/
MK6 ]6&GV&RRRO[:/?:+ NXB:6:B!["SGUHSD5LXFW "UW2\1T1MQ 0U5?^H"
M7-Z#)3>OK%<M-_,35L\!2:NXFFT^2DJ%AYU?AONH(,.5-D_%)N?L_/G1FI;X
MH4%Z4QBH\$OO4<FLZ>[4.BMRC\N2<%%&\)]N$2!J8NDZ9,S;ZNWI5J!&S;N]
M[Y]Z6;/9LT2</%-X2!DX.,VH$%D):LQK\WK0*\QV/__W9]!7JGU$X_:2/@U\
M0%-:Y73/^\+D:#3O(%@M.)2LS/?7TJMS$"L!'+VWX^DBF'-XE:I/>Y39AG;.
M 2YN,]M/)YL5E]VB]ITXD[9-ZZ<WTDKQ9U^6GR4DUOAJ".UY5U(1_,]BR/P7
M@BX6MUP!-INN$$>8>_LYKX0]DWF!C[T:FQ.M>(3X#G?6/Y$Y!W!<&"AVE<-\
MX=&S3VTKZ&;1<X"5N,IAJ?D$T]>W&ROQ7EM2& -U?\TD FD(;^;*W.I-.UF4
MD2*PD(D$*Y=I3KP=\\H4!=U.7*K]>$<CM4'>Y.6WZMWWPJLLX!YM/=V&1L)8
M=+3!?_X<_Y#E_^];Q?\+__N#M1/F.XZ0'@T%24\<DLS<W"J],C_E-7RD;XY_
M^:&41B!7>W>CXN'P1$;&QNZ+@F$VMLF3-@(3+N<_';\PA=2<EH*%C70/*/-
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M@U=K[)OV[)&?,FH<1952X\LO/A4=J%=L"WNVN]ZO4@_OR&4CAO;DW"9^7*P
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M985A(:>V\/OW]4A(98N>0J--]\MPSB/++/OB0+%LD=1RU@,$%DJ262#;UDW
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MJ6R@#?8]-_UQ:YA2)6,$9^3C.K;;S2<F=4<W6S=/P;_A5?#_3,8YWV61C'-
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MWZ$EO@Z_F]7RG/PGP_CV$A6,%N^X6[EM<Q]CD^*8]K8.7"8V)B)F\,SX=='
M?57 >@M^G?DUIY*QE6!CJG,AK^/8H*7[P,A9:Y&M:(./DZI1,E^2MJJIM7NV
M5'S3B6S\;%4;&&NY3%TTA3E+G=(K1SA)K=4]VK?G,A)6%NR\#(,]O*XI1XSJ
MDE:6]NDB5UJI%=UP(@P2/WZSZ%H5?8\5$G@2JMVC1G_/&L7=/D9\O/:0Z30S
M6KA$[$%$C?13"&Q]:L6)E./7"VY==UB3=(_B;/,N^84?*6V(UF+\P:,6B<2+
M>,.GNK?B.FTS1HG['BBSUJ\(/U>"NR[>B6:.NS.+//[T7"JLQ@- [DX?@&)1
M6N:!6YQ< >;J;UUF^CXC S37M%T!:D/JN::Y.U V#R84P%AE$X/3V9JYV79N
MQZ: *MJL[I@W\'H5_RM '9R047OM'$&UK>=/38.=!653:$@XBNKYB7SC21=#
M['+G/:"XO_8M3A-U>&XF9B+9QFZHV!SQ[R)U\M!]^:!PVUUA7CXD^#(5RFU_
MH0J%8 MC"9;NZ=WY,2&0,F$C!6V>N(Y[_1#[5S%H72X_9,)EPE[WQFXGFOE.
M6\KLVIWS^=? C>QI4YM0=&_W,"N>SCS!U9>RYUY;$D?3>ET 28QC@RE/X%Y9
M<8-J 5A.N4M[KJ5A21*IQM-@_ZE?8)+(MM:":WWTC^ >+(\-Q?EC=+MI*!8L
M;#:G:IE^=_2@]"L^/DHG(XVY1[9V8M@[<@12A+=+V1Y:KK ZRMOT>1\?[6RW
M1L%ICVG"B-3(*867<([,W[&),H=450WD=UBO '1<Q(:V=:3Q%2#$[0\O/#).
MA@KWRG%IN)SJKN9A7T646[VP%@A\!/;HV,A-,^SLE6GK%Q",';K<&\B_ K!!
M_W+-T?6R>GQN=4+00-2ZY3[-PD-\//BN2_:Q/*,8C>B<2X@6_>R'CSVZ+4%D
MF1>ZQ*%9G9!&WCR<GC-%AE)7(_VB/L<ATH0Z* G5 D'MB3H6XKEP?T847JY$
MW_9H%BFF-'>T_,/HQ/H4^3I-]:;4/%D/C8?+^?GP<FO'Y8LQMA+0#8CJ^JS=
M?14).<42[F(6JCR^V]PM?N_R/Q6F+D_:*YFR793Q#L(#3W4MO]?[QA2GK2PP
MW>(9.TWR2.F?JK+@8H528>'AQS1S0F_Q07[#RX-0#?(O%1KWBYZF2=U\?YM2
MT+,7L&Q: &]75_Z7B=<E=B"N #D6R-!1*!L&U4$4#IE3'X$"\_"9;YUSHGJ&
M9MFZH_>KBHRIF=;;%641V<K+>5R'.@3^*\!;TRO J)!A1(]AS_JTQGBT53%P
MP&0OV')GV]J5X36C<4RL!O_@(%#%')B?HX,[L!UI=0#-''0H4>#]<\!BSE/G
M0ZVEYBK!WL6@CDIUA0F:M8+=73TV=J_IOEWRX:4:Y4\^2Z'P:H\/!#5TD-EQ
M:+"$J<'<[.,X94D^BG^/VTB2/SQX'W BB?-OOP*<\2#O7 %^<\03D_*A:1>P
M*T"?'M[^V..2B^-)"9T%TF]20RI_*#L_*RN=91T2* 'Q3_]NX*F7>.(5NU32
M-'%.ARO#KBUUMGZ$<4\<GU%)'STR?R[X74RB]-[O4PJS^/R B%UEC')G+9SR
M2;-M\99?8U9#J09/PK _1;\;6LUITO"]O(;@7_5_^Z0U_J#:^'#W9OT+17R8
M$+?8X+N1)7H./]7E!@)]!0$(Q+%B<9DK\1\;'6(9_CH:C\QJ@3/<.O\:.[.L
M0GUGC2NRT@SD31G(!0,XS/47)C1-B#;62J:*[ 8Q1[.T99A?;M?F?7@0,?QU
MK_GEA0R>WPK;$[JR$RSI8^VMT:Q5H?2MY'8#\(^Y$=73(=F=.1G$]RO \@].
M!6FE)YB(C^XB_\:K!:1 V]ZJS(0RONYWN?*U@DVVY(GRJ"FD #X-C2#;L>!+
M*''Y,K?=.-AO8383TUS9Q$Y:[<4DPQ;/?H*(NP)X:/,3:0]BE$BQP6NI<\>V
M[)ZZ5!4142^IYF:E;KX)5]L,/#+]TI]OU1$QQ>8LX+74J O&P3_+$IS'!BI$
MJ!.3UM9K<6Y";N4E&$7Q#N7JB-V-93AU=XX3R@27'OA 57?7,L2^K6>+N3O5
M=KY6 W$KOC>+:O0* !Z^O=-**?PJD*_8VP,< +[5G((MT>9/%KQI#_H:4@I@
M)D\80XYB3CN&/R&!HZXGP?SM2O=:QQ'<]]L]J>-=C2>N &URYW$_L"8_,>0=
M2Y20),UPKKL0-0W4NC=?5L*T1:?/[H<*IP]Z71_N]!]W.ZL];4?_,OKZUL @
M,3'Q:Q(R?<'BG-ET #O=2+^\H?DT.CHZQJ[,H:S_K*R\%VY< ]P\'E3:/@2=
MF& E$,=Z&D1CAZ*==']<3W21F9W(;-F_4/[:-> E>%51MRZVO!S*?0'$"X_C
MDO'MJUP<^%F&J;>5B;*/*AK/<L0TA]=*1%Y$)GRAQW@I G?C&:&L&--8J+)P
M["\(6#MQ,%>T,-DEH5GAC83K#WKN"=,_H-^F464P3L(+;.J'DPUK>=/F1(F/
M#O+^@Z3JB'O#V'MGI,AQT/N=65PF.ICSP'@2\?#W>)FMV*"G_*U7^MOPPL +
MZH>9+F8G%-I%O)Q:?I6SB_Y*XN%HBGH6G4:=O'P19QAA6.VP-J)KJ4*II @J
MA]]:!87[,XDH914LYXCV?U[^PH>1N_%'QQ/E<FZJ<HVX#T)DFIG09.J3+#4L
M=0QZ=RZ7 C=:;3."XC^#JE/CE1[Q4*?K7;Q4W4NXZ%LCDSB/G*R4]]RSYB?0
M)Q%?99/#IU]X7#("IXNO -P$^=2>B8#6[OZ#<TYMMB?1C#\)D@*'\/!S2ZQ2
M/D:RE!;_\KE/N"3\]_,CP0_P243@4BGHYA7@3]H/^+32M?51*7,SW<#'K^I.
M$AV7T%> 4!J5,RY%V/RB; /&HZVI!"R03IGILJVHT/B=ZTEX .#\E]NY:"Y.
M \^$1MPA/!RI 9=Q#EU83Y69G*\<;M]*Z%"7YG$QX_AUK_S9MI>V/;S]6;.X
M9QF!-H2XP/H\;UO?JI^>+G+&0FSIHR]AI^GR*S2@$+^S[!$V.[8B*UP](',\
M]\<H=E3C_B>V"+=^4AH'1*[.^S\(E0/#Q;J"SV>PPB%MU8!C8_L:8"\JPZ3Y
MNAEQ2<,6N4@(P.46?AUL:L1NDEI#4PMCJHE)$>/B"_UOZO3O8P^75T.STG9.
M4.U<9]Q*M_ZC@JG$2,VS:"(%"Q;8>8KD&&MF T-3 X^9!@(\;_(\K7L65_]E
M(YPWG*F<3$=F>+SU)OQ?#)Z)V.8'.G\(?.VZ,\S;V;C7&C![658X4!''2/\P
MV\3H/JC)M.[(V_>HIAR:<4$%[X/B4Z\ 5@57@+&?NI>U9?F8TUX/$GQ)EYQ=
MXW#( W4#K3<9N>^2Q =HAP=2# K)#TCB/J"S?_<24H<_PT_Z/2X%&7!^!4@N
MK"$([Z]'')Q,LS5I&MNG\F90O<A?D6U3_,PP]\V6DU0J%F9C]Y/M>+1G5BGC
M^S<JUK]BC=..PI83R5GGQ=;.*+=X9<Q!I-(]V @GF[54FY/%R<]HXG.OCH3Y
M9_4]KUZ1QW,MZBG&NA <L,H$09$05F)A7L\#.9WO#RJM4F@KYNBM V2>M 0#
MUT5F-W!NF(@.Q!V1> 4V"2+CI)O'(^/JN@:W1''IQ6A^+[G+@Z^K%! .\/@)
M,!:^JK8K+SEYJ-C3$I2;ENV"WG"RGV=CWMZYI^#O#APJ#OVQ-=JM7[3 I*_2
M8UG8=!CHJZ@I\_>5)UT[JB#9GMJI7ZX X=Y8%N@"4=LMQ'(O;W0.<A[88'M^
MU-G(-#<&4*$"H2AM#TZ(8#LSN6U#-&G2%Z _K@!?@WFY@NJ\J!WU>.3!;"FF
M8?L^W0K3Q_^7M&?(%E!L,"_:]L#D8%<TGR"+/>TL*6,SQPQ'^.K2;=49*&3/
MLOK066FYXQ^C,[7$0LR#?\O9F8Y)+Y'!&+=2O!86(6P=C"F_R\_XL]5K7JEP
M:+S[1KICTV,;W?'66\.HZ%>0>@U8PV+AO@G>8A,B:\/&$MV?JY.4MS4HORCF
M?A"$](C^NWX%L ,Q+D*&<3!,S?I/H*[_32]SA7(O,Q7N1_>#,C\&E$6#;A$>
MXT61)[L$672:L'V ]G[^$V=@%?MW+7'W'MT%<M+?Y1\]JN%WH9*-$PJ\;H5P
MN]FM(QNSE_DY0B4?8E;?Q*^U*V!1DEB1W3H,7.VRL":>'E*WPED24+[->/HX
MO,OJVP"Y@;\LUU-=M+'!#S=E3:RS?IP8I-2J8,M 9T\(U+R07&T1L!N4+#A
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MM32T>WA(JK7NM6CKKDC^W%A)$O;GW+0;P43#:(9/,L2T?E:HCEFP6'G5$2-
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MM^92HH+ ,Q2 @P(XK'##[+>ER,TNTCWX?M6@/G:[9'NUC+T%)!8-Y84M>U"
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M=5P1F0M&E$CG1).JCX2/'-;=MXX@%$#&'B,3,DD!I$D'?4\\;39?S;'1DWO
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MSSE3 %@*\?%_^\5YGS4:^K,"]HY,-49D)9P"?+@;O UF^Q].B\J&KUN!OU,
MX.\Q?X_Y>\S?8_X>\[]LS J9F[!T#8MLQ9Q84\DH<G'[N()N2U\8ZIJZ?SOG
MG>!/B84T)L:6%X;WG/%/&WTIP(N7L&]9A'WR!'AWQL5JX-OCH]M'?=X_%]K\
MBN.*;^2)AD?4IT[N73_BIP ]'A2@+*\$ML%T>+[1EQ1+ 19K*,"8,16JA@6S
M0V]:S#G,5) Y.8TT'SZF?@!_B4RX'\\_^+3Z7>79]?.9U^BYFHFRA"APC'2]
M3HY3,@[M/"6$=);,C="P*=!:_OC;-FT6 T-6YV<D'?%6BC[A^6<"0^N@O$J=
M_H5%N,?5EE5NZ;84.U^_;:,(:(KZ&LQ.]9NW%?%KXO<*]1LU6_0$HE]1F\;E
M?BNN:-MC!U+5XIWQ0IROE48OH<BTMK%!,UB9ME3;B%<:"G[5ID/GOO2/0F6#
MRQ:OQ6_$RE[5:#7KS]LX=]7Z8?$J^J)Q^>U#C6@</:'T<]#C^LI!#=!*75A*
M!'J&[ZAM]$N:7U#H/4LILT9'05RUC^R'Q!7(1([3\U&ARG1=X[Q'ZD>P=T8)
MR2W]FEQ1US4Y[]#\F\302P&PAID'\F :V#@%(+^7=EZ./L"0&7<HP,6(:9DC
M& 48#.L)9K<:(8LT6*:#GP?0^V,V!*EO=W WR6TN)A1 YP+B%D*5E(.D]@-B
ML)_%GV K(I6RA'CCL8CUN5^,6"2548;*>/X?C']H'-X8SMX'A=%S&MVY\^_L
MY?P7V3E.71K<,^1P.N24QJ!5[D:5"#]J&C^_:<SF 1\RT6EX-I8=+?YO_Z[%
M+]O<<:/:1HB*6R/([Z6*_F$;)I9?MIG#'+G_LDVELS8A?D_+6X-A&52*)(Z"
MCB2LEL@_J+W9$NPGANP,)R5)>5* QQ;]G&:$GR8$JHI<\1_^D@R6D(O]#KCC
M\5))58C K&Y1O1YP]X[%3__([D.+-Q-$?D**L[!&"B[36))XV4E%OP*%>\1,
M+'+RF@-'.P9@=G]+1H_9]!(.L$A];$3H'C)2@V.'J#[;<P%<0=\6LUDZZ7(/
M<C6[M\.<=R,S  ]E6$.U"7'U[SW+@(YOG*\=?S\7$-ZQ!F&?1811 $%O?5KC
M@?$.(:'1)VY2\]7)4YM-+0.2XG3'BI[Y3R_6LC$2W7 \33!&^+&@6S_<O$:K
MRI,Q.J/GA)X8AFH87[99$F#I,GSR')*#ZFK@.J-OH+,[A5%59PWQYK4M$J9"
M:H>C_EE,5"9WD+6KW,=))P_'D0&VKV+5<$>//:F1!K;9B);8T[-5<*Z,3V7C
M4U;(=+M"-#C%TT'&(;;#X*5P%K'H&2DF"$&X$Z"=["E>5R<7L+6#N4J2G"A*
MX1(W;NV.'T_1W![<E?_XY@-BZ. EF:<Z4H,9-0<Z0=BZ$V$Z4I&N#'D<4'.=
M=\BHMY6U0:F(_;T/RTIB;\AW9+E+1Y2\LR&''R[_:_^4SY#\Y+%Y\LI\D/WB
M0_)Y=\4BAQB'. D0/$2PDM!_9$;P;$GN[Y#W48R7SCN[]-!IXU)TL(:%YN$W
MZ ,4DS5*P*C@]MR=3Q_<@3/'OJZ-'#:<.%)P--5!2D=/(HJNQ/C/;Y6I=<Q2
M/47D_5@=$W3!6P1U.U)]*^)A<U5]Y?6=R'8YSD^U$J;3<W1"E5-^UJW)$%GL
MU+OBE0'_*I6P.IN62?P7.@=,ZBSX<5]D,I*ED6,M9= E87.3H;2\NN]*]_DD
MT#->N_7*10K &J+N)S,#0R%/^FF,;*^U39TO+XT3OZ2F[CKZY&'']ZR4A>GW
MWB5G?J0[,1G%3FYLK\$,R/8E3G+E#@-O+-[ZP6:KHRNO9@??G/%!YCENS_&P
M>3@+?U"?NI#H=PCH![A?!79+Q)L'?6"IL/A/CNM2G$:6,?^]8XS_'OVK+/2O
M09 5IC6E2"X?*W/M#VEH.6D)5N%+3.MK8SOBJC0DB21_!'%(6,O^"_2R!"N'
M4QE;*, 15P62)!+=P!%%_$T8^R$[6H+IWSH=D03;_-A0T_ZHGX^YU.,B<_)L
M30(#44C1'/0<(8:]1(61;(WR4+]3J_OHQN?^>2S6AK;&/C49_:%A(C&Z&#G1
M&TH<VL4N3$$X%W7SW%K+G :<-MR%>&'6C74E!;]>53>!<&;!NB6K/ON:K"A8
M#?R\NIH;8";#%72-BD!EV@\%DS\+5__P?J/X!:K$S+5\]>[$+LT0L7%5V\/&
M<(-+>:1>&]O7DMQF?:<>1V<5 ;$+G[0<@Y?V2@X'V<X(BG9 A.K[%;J5MRK&
M\\9%C$-BV.XT;9^8YQM//A5S0:%A:Q]- 48?N(X[>BE*HNKI"S5%-_AQ=D;)
M7B]:>OL,JY(M!20DSU]^H#-]3V@OB2=& 3%6WNICQ1!=F8)C>([X\*ZBP6KG
MV.; [138V,*3V6L687:][I)]&K1$_N%&>5MGB PNK*=5@VVDDGO(0M/\9]V;
M=RWUN4\?W%$V&9K?71O38RT<+#1^NF]E'KRW_'7Y>YZ2N$AR?AV:Z!31T7BQ
MK+_^6(1-59R[M[[[+<S]RD@'L00!Q@MVSX[-TR3H!^3Y&[86D0RG]V*KHW;-
M8XD7\@\\G%*!* YEJ3*>OFH)&O/?7IC.R_;=N+K'K%> *+Y?$];Z^ON+6_=_
M%/(R;)<PE9H;O]B'%?=D3_4]=1++KGWU;T7%'RO'?\3S=20UG@,I@"OHT+VJ
M^#$%X- HZ,UO(M'BE2A *K6"/M*SH0!HKEW-H*W?]T[12'XFV*_H+)/_*T*P
MOY4Q9G!UJL;GI:#)W?@:C<'1;SO'*4#W580<Z>/"T),0CJG5NH>)'8I)OLX%
MNBZEB_Z7OW_4KZ5[*&TH+& .)<K!42 A/P-J$!@,QE@H?7F5YL9N-?$-O_&=
MEO&W\6HYAXRG&DG#3'?F30K0^N.:L&'>6M4Q8721<!OD](":2]:$(]]"J%5<
MIC(*)=O+9L_PZ<NZ]OEZX6:8H (H5.4+5JGMF\B+60X+ YS>.<71'TM, [)'
MQ7&YN+67T.MWU[CYDF)\DU.J]A43I'<SQ+GB4X9.>41+&!5&) 2K*)3OVL6\
MZ<?%+B**0]HH "=KFK-\W=+S/0]\97G\LS?2/J4F/W1K>-?G>)L1MPA11\X$
M2%]+8+W0H%,J:<@O6O650YSJ#5BT;=/#N"ZYS'R%>5B5=FL#J"-#<:!B@WM1
ME2!_]U%<8('!\O=>E%@QYK%1@FJ"JD6O;VIE1D:SJ[1P%%S3KB>X!"2='Y-O
MR!X%H0"0E W/[G1'X\10H8A!6&EF[.Y7<+306;=34\='*SLMUD?WG\C)IXWE
MZ7<0TB0\,&Z5P9JXM#F-5UB'EK["5>EJGH$7558!RFSN!!*GM]3/P->2.Q>O
MGJ\+@RA:VKG>%.\\C,:[C:4TB>/<9B>1^+VV]CR[G/%78^;;#F^[PUN-..:)
M:66M7@<>4SFRW8XJ<!YCR*H50I_#MD1%8<'-/CF_S$]X&A&%?.Q<!.,E6B!K
M(GY+E/E(\!EZ:V;G^G3R!SL<WSD?/] (QZ8\(ZI.J[([SI#X^G1>TAB.93/U
MP;>4INPV=8I_''L&-'%6XO9P9I++N]%C4BE[$[LY^MJ0AI9HL1*Y:]G18L"_
M2;1+,()H'S$5] RY0:$B% ,>A5_!3P'H#BA XDTL#PE)3=HMBXV1Q<XP#LCG
MWLRFAF/U6_@XZEM_0A8%>%!52 %R$T:S+=+)_9AM-S G>-U\&+R;8/4VZ';A
M$Q3>XQ^<T%^<U'R<&V_QB[,73.5DI@#KY@,48#=!8E=7%"<+;WD1+58@]E>K
MEN0[7/[SCIBL,*VOQ<N&/#KR@7UGJX^:"AEP7(/F;%%$[P\$A>LCWF)/?&\-
M2GQ+^/[)5/##R<3D.\!\8E-1A-*5^0F#D:&=5WW/-22,.WXC-,\6F1"/;4AM
M7CN,?94ZK::'A<[QA!.M\PBCO^&\\^.\;2]R/Y="2"7WZMRS2WFU<& MFG'W
MU+6.O$"94+**GVJ[%>['^AYOL<)G5WVP:45RKS_/46?9IV30;Z,P6PI@B;AA
M_MZB5]*MC@)$I92')L-Q&K>IT&6>$']DXN<S9SX@K7:UP'*Y6L5S9?_GI. (
MME7\[.FDWBLTLXW5"!9282/'2N,EK/Y6M,N=GWXY-U]M^*##:L?.F:I&7Q9T
MOW)]]<1<(8(+V[?1C5@)83EBS<N^6;16VE'&HI^_/1>B['CG9+(@/C[3:2.9
MVS)4V(19L,+IR']RE_A;0W;VA)-Z[QR^^2[YK%]1$XSU\XDTLX:O<CW5#)VA
M,:X:$31]T^K.*[;,6E78S5=V>6/MYRO+P\Y&,5S[!("ZD%?)/$$/:[#(]D@U
MS]F;%Q$7FA-45WP6-2T!_GC8&!HP&C]K,83A1#K#6);)_-%@.@AJUHUC5?5!
M>76U\2RW*^UM547#$_ZB"*XJ.=K(%WEA+^KT0E("2:TFQ0P]1F4=&U$X)A0*
MQ%RB!K[0H@V;/7^IP_,D?43:9:->SD#/5-\PLC)F+=4@\V.0"O9BZ:RUWET.
M^N%*#ODU#JYKG0G7+.M\K.#3U$C#L+Q_V9;)SD_FR.2;>N#(<K#SH*+O')=A
MU^V]=@;L<\CN)_8;!4R?9*D-8_UJDICQBQRNWN&],>@@K"V OUTN<3% (#/4
M&WYFRL9?XR)V*O/C.?UNCX^K]BLTY+7C<8H,RR=*JJ(E>Q*-?77;.ZGQ&1_&
M:72-_J_0K^5&?_S7<L-MD6I@*RWHQDA$.@68_H#9?ARB3@&JV4C*UN85OT[*
M'4RF0Y[_.:S7A,:&@7_A/$N^/Q?!W"U2P7'75EJO*/C*FL4[=^Z!/H>W%$!_
M_1/XM+[D5QK7PRX6W=Y O8+D0.=(M/@#CR2O^R]R T[I!\'GQA&GR9VZ)B@A
M\8%*$+.M+F00%=!KM3CNT>UO??OBY8DEVL'1$878FW/:L0+H%3ZMQ&EFAAG$
MGF12PU?FU=*.-RQ[#R3;B#)8UFX(*2]WT%O0^@[.-$2H,GK?9LC[XDGIS??)
MX:?J-Z[)ZLZ3!E3X\%CW, T'*YWV48\I_,Z83S_&)+GH:;7$:.V%OM 0>?*0
ME0"/RO=4:'B]W,6QX@W[T*PW<0EB$@,A(@5G]X^7J>D<<1 Z4(V\=2E:.#J5
M\D\I:3K55\8_$U8Y7=$;ZTWVC3. &'"2YH=9L)YQ9?_N4=K1REQE>55L7JJC
M 1>[EH[H#Z:WBY4KC5;B6NH)Y+=30FR6JN7;9A;=!TS^@08#H7:NJG:5?IC8
MS4H]'V3R %O%ZC&;$YA!C4S=_0W+/!P\QCMJ-U#R57EPH/IW1?R/\AKMUU\.
M3$__B%[R1C"C\ =GA^4/I+:R5!]&/WR<"[5G8-A!]/LWY!J[]G:\PG[=O6H8
M_M3VV\<N5Y,N$?&'#.=LX&^9#@WQ)H3G;M-LKT;L#UK-^5JA8P-='30"7QZ_
M/7+MH@!-;7[##17F[I%9L0]B R3B)/Q<'C6:W[V7/.WE)LYLMUV T%(HZ'HS
M%<MZQ2,A 6SS&/&:"A+[T-OHD?9Q%$2C]C$$.%\U*G+T.>=9.07PCM GL07Q
M'8[TXC%&E=&+(WZ;+@MWOEWZC?>N4"C["%*F[;[3C.@WHZ!#\,VI?&,%KEE#
M34X+WK\&P_^9:':0Q--+9'VV)BC^5VW*9T[]%>L4X$40!?B616 F8ZC%8\83
M>LN\$ADE8^Y@. UY#O$]TH9]JR?>H0"EUJ848$#'N5^REP(\WCI0RHP&X26=
M,@]UI'[3$#&MNG^D3/V=>J+,+U8]*NOMHG^P.H"HK%0DCI=TA!WJ< 5<.$UX
MJSUS79/3E/.O;I!QS8$KF UG6*R;*0#[^3(E?(9@;8*4K@@\L#AW6E(WA^&-
M1'Z<NWZ@@O]^*SPV@YG@2XM>LWIC8;%#R_=X)%I:.E_$[E[DPYW!Q::2]V"E
M"IO2Q>WMU5L;W46EF7-;)PD6<Z///C24C13/!3Z5\>H[9=F9MYX'N1G>1WO4
M=7L?<0Z;N1$F\U+!,4AIKM^A1"&+'<[NY_JH)OS^6#K-].'&$BD>XCD-"N5&
M5FBWL;ANCJ(RL<\(NNV&TH>]/ZO?B=3V)=\,^C3_U"=&K)U&;70X%;0^AQU$
M82_YD%D'+Z*_!G7_;!Q8PB5Z!YZ.XV=JB/59&D%#E':^4@#A=YY#0?V#>P="
M#+@U?/U D-F,)(:%H#&U"MTX02Q*UUT59LIUV)(X=_"*O?TV<"Q@M"-@*_+<
MCYQ87=Y''MOMK,I[%QO?D1 :)Y=A)RMC^4VQZ\SY/U>G'C[]>>Z"<#R@^EKH
M6?A1PW'EMJ"B.1E6P\\2W:Y*7V[R=[P7$)H>'5EXG25P)9E75>,HP]M72=4P
MR_,:[I;*G'P(-/%*[+BO*UT@WZ$D7KG_B4)F;/)6T"O)GV/ZWD]B!WOH+7R'
MCH/3@XJPF";#&:X'4P\^3%8^<N])5MM=EAPA@P@#.S.8F-U,]I\R[]1COJ8*
MS/7$8%<(\"&FU=;!]"?R*QTZ\K=$<N0/09^\+-2GP8++5,<3Y1Q+EE/T/!W<
M:YO \B[$VW/EM,W'Z_B('XT\7*^8/]X?;"SXMRK%_P[5PNB:0%^<"]'V0HS,
M#'/Q1?[A!R*O[D9K10W%G7C<:_IRW3-C^"46-O.< ,UV\ERM2UV=.C>\F7EG
MN%++]I5(?MG+?DYWACE(%(0!9\5B,N?;FDDPKPL>.O0-DZ_)^8J36JA%[_#P
M9U>:[T/?'@D%G,0;+1:DJZ)5J^>1Q3R!O%W=4ZO>&J*D_! ^/V/'>[4X_>+A
M[S;R?'[.*0P_(IN;#T=C_'+:(1=)" 5)0^HZT4?^4#N6>"DUH]0K[>2TP(8@
MO.SA_'054 3CTV B2*+(L@2SF2)!IC[M'][ZQK<::V/E1-J$CRM;W4Q&)5SG
M75+8TR_^K*A8:FU]Z[5U2Y9PM )3P8=[ ,-UV_I=V2]A5I==#?!N'ZL:4J 9
MX>;I6G.B61'3L(A#!E0QGY3<M<&S@QO]U^QCM=^)DW>JS37F1ZGII1H>4=%'
MT ZZ6G+@T?%9:J9\!Z#)#<VY3+?/9&HWZ+&'R/=.=^I H6U[\PHGV^SLGH3K
ME(C>*XA627">BU6U>85O(E CH&$L7HT]JV7_U)C0R55>+1N?*P(<JA)SM?*/
M)LACL[F82PINNWOWK28:>UR[,.5LZ^T9BG$@;D+=&/)+XUYXVD6+C<S=$0,R
M] -9.C\.Z>1XZ/(QT2EY1/'+V/C9%I3;F5B>9:"I\'ZXZF.[<,Z[V;$WLL\V
MW5$&V'03:B^_[7K;%><9X&4;*SX8J_#0/[_-<&RG!<3M,KG'#_JR6G.@H'=*
M^#T(7X."VS.,<\VELJ'Z.$+ZZ@+1=U=W5KFCW+>OM-L^,%-&3T%N7]/^J'6]
M)]C6=$_JXJAY:)OG*8^QNBLD%D^#!D<CO,#4EMW==O9,]4IEMF/$AZ6X8\65
M*]O2I;V;^9B)0'@KT^[;>9T<B]B7.2?#35X[HXB>6(/5JU8[-^AS&?QN]PYF
M&BU/S<'SC$F99(WFV1YG,^S'? ?%M$ 'R>!4QV:SM[3A-U\K=O*#9=R?JCZ/
ME? 6Y=61$D:F'*0H<;FN[Q^*9;_[YVU\:N'!>;:C^U 4(/;0-S*G?E@Z2"9W
M^5QE+'=?T+=+<A,5L,=WM2WMXN^K/NN$]PBRN.\$/<!%H%2#M;I;(<K8OE#I
M+86THS3$*;^91U\'+WVTUF-,T:UF]G ];K5J!]I2>E+Y.G+^P?</(!LCJ*C,
M!MM<L/11JR&"D-82PF&9=CM9%<SNF' 66]DPG*HGLH]<N5Q?ZC]3?%,I06V)
MUQMH5X6_!//4/\*IMHU4)=CZN>PRZRL@7"N9^?GAA+3"QB&ILS7E4AH_LY)<
MSM70'305)6G'VUX$A'8T@_)GV7C]$,V^9.4A^Y%*2>1)IT:I"+W8U)FQ7>=2
M]=0;I1F%;NXQN+)YB2[AELR*VYK,H''FMJ=^2^WF%FB?E_F/4X]G"?AF;R[V
M2'L5W1K>*+Z8,7/:*,%'JS)A=EKO0F69YL+'H(5[K;1K=9*+7\%HU38AV>&%
MS&:/98US/Z1<O#?T6=Z?MNDINGE?JL+]^F-<=[77E#\):\D3)LE__#/F)/G'
ME#SN45MR_$P?-U$=5U%]F)X4 [GT8W<M,:]I$ WM4?AZJSJ!)X.M%'7.2"79
M^HWYW3*!9\'ZFD]!C$$6!7[C,U.O/COUCVM_TN?7]L4K/'S^,1:MY#?\ZDK.
M%6XFR^@7-/;MAM _Y#K0O]P&_5>@V=F:D+!G[T6F7^;Z_49H \>_0,Q#J%E-
M/7O0'W9"J:Q_A,Q&X*C0D%_=Q_6_>O1T7"E:3?3^' MX727^ZY'TTV^.@0J%
M,/O'[W2$QMK\P5%;C0(A?3XI7Y8U!*HK<8]:3Z*#*XM?=GL'R[EG/9+0(_Z<
MW'%7&:WIMQXLF,LMF4/C+QHUCF<$8D%-IX.N$IP_.HY^0J)W-NN''M(FU[S>
M"LH@B(+"? X_%CMDK>SSH,.&S,U]EA\F^[^7.!^7FP@1_N37W4X!>(F6GY8Q
M;'NWU2[/!)\W<0R<U9%JW9Z88$,*UF6F,/^H1H0,+T*9-!@R8X4NX*2V8HA&
MQ7XY*+1B]F%PKH6O0?CJ[;X^8;$'[-K7>!@0"I@];Z.NJO,^JP,6 610%%R]
M^,S9X7J%$O)8HV**644-N1G+&K?AZ. KKSE?^X2X&?6:45D@\9GLU:L?@VQ(
M,;M;#'ZL1S;8Q?("R-1*/^]2]9!:6:)6?55/P=?;O&I+RHB277U6%"K K.I=
M'OKF_?M/7BB[3-L61*O20%2/3(/,(IH;&6$L=^&5A+169[RDWBWAISGI,?,^
M#*K:M7B%X8B.!Q>L.+^@-9_4UV%V[#WSZ'G$5_M"ZX5G]"TZK$@9K[+&*O$Y
M7B&W1Y\53?[<-1/\1O;>LXB@ />^0K^TH[>B-UG6I"'J*I/F\F[7^A)0&-H5
M2.F1:A!S.4%IQE3NLZ^02*.F\]H7N>H!$? D=&A^M'A42U6E2"5.V>%Q24-G
M3EAT[&*EAAR2P(,#XSV'\D8;04[%LX+R,R6?1T 9FJ"=@9.SAONO(_ ()X+;
MT0W4;+&<H0H^\>++0@.D6N"^=J;1ZQ-]6;Q">^MF2^!3C:?'"7E6BYB%.EHX
M],.Z=BF1Q>_NYX<X61N<@=Z&%#D8M.ACG'=&72@=?KVZ)GJ3*YG'4M@U)O]\
M'B)U%RG@A#R!R'UE^RYG8)8^0X=&V6ACB*02-[RK$?O9DO!2MV*HXBAR<[TD
MQ_)^!O=$2>[#4\[14EUJ(S_01@L^TOV:7+?^#VJ1Z.T=(0*#N]8;QMN]$YJ>
MA;W2KO/?+NH<DZ E2(@1)0VB?>_Y,VQ89L6:3#<6PTZ-%RPGW/PT=ELEM_]V
MKMW$"^TY6]]8M?L%?IXMR<8K 8[#]3<+SFQ\?J+G8OXNY4*NVTPL8&^W?'DH
M>M7MLU2EI'WUUQ>J;\\4/LZ[TW7[7/CUW;.@EH_H>L$<X7Q!R4<6$S%\#6FP
M8&1GG*VU=CLZH@7)'O2 @,[@PRF]VE+3M,MI30DY9VTJZXC?5KJ,OO9LN]7;
MY^"9:%;)."K %HX"CW/L&$2C55E46ZTX86.XUBPC*RZSGQ\"M9:PB <$:RS1
MC^%6O5Z4^=;=H:V+0][\;0S[@YVM&?4;1F%"79+O2!\:SZQJ*/;O-OBB-.UP
M\/!-37+JW;#3<_S3=C^5SU" O=1=<M4GPY_?T-P+ZPC,%M0CHGS!ICNXSS*[
M-(A_5A/G%NY%,G/Y6!X8^3QA9/%* NKLS-PC=:8O9TF23O7V[VW?#5$SXUFF
M@[4Y+3@I":%=:-WZ16<I)6G.1B[!5_(T)@8Q [TQFD;T&-#L"'5HH'U[(T)C
M/)QMB;@FD5+9<W9/I8]^30]!>-J[ OU^ ;#?-% A*]1"C+!,JX[RM(P'V<:8
M<(&Y7;+9ZMX=WQL)Y4QBV9^?9<>_%1-YSV9R5^,L;C^\7I(QS7)T=U):@5?*
MURL>/O3C.(EK 8/M)Y]L=#Q],]$$9_K)H_K:P*:,:>9^/Q.\4/Y+D"'N8^7+
MW*!+P\)1<71H?)[+ V1T8?)U"A!TAZ' R+(15#.\6=$Y/[)^:7?R6F+C5#NN
M)-MHG$/>* $V#8XJEOB_]%COQ2%#75E-^-7?.'3XSW?E7& \PT(PW;W# )Z6
MH1\+TL FIW]PG",)]:I_Q87'1W6K!B;H@*UV,L/Q,M.PN QU[+Q.M>YP=D2K
M8A<#HTAHARR>/A$<&ZC@T/;A)ZK$\/,EVB,M/^.Q)9'$A<(+I@$G2\&Q;GP(
MS.)HVDY#IP=ZDHV;T(>;@V+):27(EQ7=YA4#_.O[5IL%UIU*M\*X1_IE>M1J
ME=4YA1B5%>8:+Q'LBOQNN$7 3@6Y^'L4$M),</2UPR))'2G._'9=H6('6H,K
M[=J"DBM]IX,47K5")+ 9RV<C4 $""5!2+, L-=84%;U[[LK&WOT5*Q!WB)!U
MD#&6M7BF.THMH@XN:^,;_FA!(/@$*-RY/RLZC/5NFR4X:J\*@PV9XS5Y^A4F
M7$(G2R<0;35-13*9)J-J_%P1D2Y3?:V'JL$OC<.:>>./TT7#H@3=F^(^C,(@
MIK,KW]IV54[7U1AI<M%>A49IG!A0\Y^1),E8E%E_]>=4](BXP>HKZ4WG";'%
MJNP29"!UV(20.;W8M'7\_/RY/J.]M3V%K5O'Z=CCH:J$D3:B*LZ\%?7FDMD;
M"E#>R7 08I:NTW.!_^CK^/<!1K#)<JH$,V_J;"^CI6[YAPN&D"3UQ_9_>?=D
M!TGDY"?KLW4@\3._]GV<_F/?YY]N/?6318*-T@V?'S*L4P-9H8/<E5Q+ 2HD
M?]T<^<-Y'E>((N>_>\GI]U(M8"HX1U(SGU6RL?6%H&'CP[0V6LPJ8>XSUP1[
M)P)/CN9B(-KY8]V>,A.QOB#8=:@"(6%[;E8TCF/@RJ-(G?"QSE4ENUVC.ZLJ
M3PU4B_6%N40V RS6Q[/@+$%2I8,Q S:]"=WRY7K[[SL7FM4.94%A7A %0A@X
M=,ME?4--$N$7M^I';.,S*WB<DB [\/62D]^RM7+Q%MLR;CG QKP3./NH:_=B
MQ:>#/'! 8$.GHY1PZ4).6R:7=]MKQRFZ :)&;E "X:7E211Y;%SD&07 W C#
M0MM8'#T_$:]_Z7]3]9L&J#\<JZXV-ME\N,ZU:GI'N#N'E.GUJ@>#?>T';X.(
M39QX-*3P[ES,TH@J3/PV_NS(5D0CLQ]S2TF98\BI_F)7!F(]*5;(;B_^N1TA
M=4/L YT9TP>:9\J <?]?,^^_/'3Z1]7.!%.K]C%JU:8 )&6;T7ZN8K=9O>%W
M@P2>#W\X=-K5_?TE:Q.V*"ZIMR%_/'':08YU4!EG8%1&*#E!$Q)UBWR1_1^W
MANC_<JOQWQ#CEMY_[%W&-)N6"P!7=!!I]=[YS7,R<(C@<,ZPM%JQPL#5)^=!
M7Q\:MW)?G4]V]QCG6D-R$N\VGL$>[41=I&.#N74<T-J FS G&N8'U_8+:SK'
MX.YK&/#H=H%9/B/8GMBXH\DY/!]X+R\[NESVKQ[S_;'UL>C_XQ(;@>.$5V-6
M@]A^@.U@!R5@O&EE'RD+>NO7W:Q_NFTE5H3[DO\KJ4L*_\^<. *Y]DR,HL!3
MG3R$-*$4=U&=8WC=14!M(TECWANT&4=N4'>Z(&UJ:O>]UP[_GM#C.8VA)Z7<
M*$O XP]:TF)#.TY>B_G2<>$M,4>H=K=/&WNS24E%.V+=.]:^69[T8)7+_Q**
M1W;>_4SF;/,\:VA&93=1'$N/B?2.)%XOXO:VI.M>C$EV_9 Y2/N%*(EQUE3N
M385+%VYANN=9E+NU\^]E1XMS_+N)X?_XR/U_.]8U]$9UQ+K5XLSP-0::--X.
MD\SK%B47K0/]+[A]Y4L&7Y.#7O7+;^6#M\EPQ*IT^([1WBN+*9$C-J@;*KR?
M'XD<N+PXD55H14#,I;0'*^JIZZH:'G<L?&>NL-JP77+55XT6_H8-@M1;.0SB
MLWWO,])_X/ZAB>O5-/PXFJ"JH^=WBO$NK?#^Q3J5L2%O8:&'24E51&)GF?Y8
M&*>1\=G_/*SN#!&5B:S<BLX 83>3YB:A377.CU62\ST5XUWRNP:^<>(]LCQ]
M791/%,E',%=?G<?90**.3)QE;8)4RH:\) 7M94Y96J=MV/VFU%EJ*);2'7_'
M2N])O*YPW"V.J4MA%PZ,\(4P!UQU"XPN2"^U'<I#4$*1)9)1OF,@ZX'I>N?@
M-CU_>U.7=^C:=KF* -,Z!+73.;[6>*D2IY4W(\5V!Z>0^X _V&E-/]RZTX[N
M=92<N/<=RSB:CN_!CVG;@T!'=_RJ6^TT:QH);@X?[T*D(WP])?S@?0E3@^9O
MKMMW9=H;B11=I "*ZET%6;HZX@^B,6SD$3YDM$*L];7!($$[Q09\-W\PMTZE
MZKB^DM'_P]U[A3491>V"0454$ 2E-Y4FO4BO(M*%T'OH/4#HA(X@1:0("$B7
M)C5$2NA%Z;T%0N^]AQ9:"./_G#EGYI\Y\SQS-V?^BWWS7>WOV]]>ZWW7?M^U
MH]?-Q#^ZN AN3[,E%ZGW8XY-%#96=1+JWO(VSOV;-Z:266/;R(F_P+N20]&.
M)ES5=LGI)]Z?+ZWV/6@&_8?UO"]P@ZV J0#&"JB/,OHP=OD&Y YU$1(3-"/9
M<8(8B?!$V!\ZVT9H4242=BLQ?Y/=#!$EY)TCU)CPN@.0[ BWD0C1[GU-9-2E
ML6]IH]"L+?2RC*5+06F]_Y>(OX^+Y+!4A7=W)VW.C04(7 ZL0J)RGM<P-R"Y
M:B!/''$TS:BS:>=S\N;T3=Z:6>[F.L+UW+KOS(DN7Q@^X/<N=D'W L1N)+%2
M:$SD"KTX\(F#^$0K^=59EJ(^<KF^"?&CE\5WS3VGT?N[;V3_H_M6]AH RI[/
M08P!+,[@+LPBS2A6R,W5U%E5#UE3O%J?.? ZU8&!>>F5W1-UCT0\J3?WZ_Z7
M#Y&AF!,)0F47%M$XH?G@]MB0CN.>6%@ >:Z9V0#15+5QN[6JL5MJ0B/'UL^^
M-=;6H$ONO%U&:I39L]WK  QIE_N8^!"N9 ;(D;:1#*3G_Q:X.Q5UKKH4M<A/
MP2\1F&;-TES=H_'X8C^O-1*]&)?-.+I?<_E'-Y2OWC3[G#33CI*2WD]ZH&YP
MK.BI-H^A85?1;,&SBNE1\^!8H#RYK<7_M-H4<'[\O#.;!0WO@3S?JS7*.N^)
M$/RW;KRE]JI,@JKX7:CBJB5Y1H?<DU?>G .=B3STG]_YMJ0>Z*ZUL'5F,Z C
M<G[MS(;_07<5#FHX3@FW028+G7D/6 ^96//I!XM9;N<4Z3.;8@1RI-3U^$BJ
M[>'IL& 'F.JJR)<:$-O*,&*%6WU*JZVR$C=]LMY6%UZ(].)LZ#DL>K<?:T,3
M/L_?,!GG:Y(!G_7O*O."L6:50$7T)ZSBUGPB<FOKC8^(>U/=9,EVU=F<%\T3
M*F^*B14T5'Y^PSL'D9]2%!TWK19%>)J1+BW"P[W"?LV!47JHZZ!DGQ>I(ACA
M(\FWR_.MKY,L8N9B!Q\1L4K4<DGSW598)9[XYSR^K/OK ;7E)9W=82\[BL,N
MO,<D#+RIC3&=^UI"H?PDP>5$27C?@#4@!.^<GOPTL.U B#6K&+1+<Q$C25*T
M0Y&.1B*<*31&S2[=)_K<7GB8C; ,O^@__EM3P__SU/67ANX(?7$0<A86E[%Z
M1-U3X8#AET[(YTGGR5/V'!TI VM0"YN8&<G1*C^M\4U4_?&7_R=M?"HUX.9A
M-'IDYF+U(D::W\1HEW(OS^&:QE[<:Q^#PE1)#5[X\+^M-'QP0.?V2BZ\L[!Y
M$$(KHGSH^5_D0/8_#P,&T2F9%4;TPN32QZ=-+0(D=X"RXT*V_@K!BGU?_1Y>
MZH$*AXOLYTB7BE?^DR?6B4.AK<@)EVZ%P,KN0'#MI00:Q1B9_13)M56?H361
M^-*FJ5Y&&(@NQI'3$P2)3^&A?3K(+N,[*<4WKOEUG2I6]G:P;21^%_T:F?-B
M#%-M@PW,6:,UFO*:/_Z'_KVW;JDRHLP*O<A-V5%EWZA7Y)4[;;CWZZ%NO'%C
M7;WAHWI?&)LR$W^:E5[Z8^^R!R<85^G&O!!I[=$[@.T1XZ6^W.^QLY%]]OTC
MIYH,-160JH%MDKHQM]'A/P949;PSVB5HPX/],:KH]+M<Z=YOJC*:H_U,]+:?
MSPSV^3*0=@&Q6.E1NB/-GFX XV5MK"<S-FUNG_5.](=^__,IO[_@L+*/IIAD
M7X9*TM=MF6E%[&!\U\*W!"3/TE)3^3++<AQ^B&T0Z7K%8303//G=?$Y]-3<_
M2-OD-@]!=3XD\@%]!PB'><'T-=5X>Y7/XZO?P_V= T5/Z=YOZ/%;"KRO)D]]
MI:Q1@=?O\&_1-Q ]4>40+) B?A4%LIU54[C14O0]EQ+@)5$T'_U83L7GOVU5
M;V^81O7Z+86U+O%8$.#RJ,,-ZB-7?0?X[+?U+APKYE%L9N+H\WJ7$FD='Z#1
MA?$F*U,DLK'VU5C_S1DCY#*-&S7E/O:.]/58"7ZX#?,IW,Z9I:G:8WB9B%_;
M:%-/2'1/PI &VIDR3%3QJK\J&3\L3W,4)P5M!>[/.9S12Q]U7:_3?/1.5]VS
MI'_-7L$-=\D*[YD>W)7,$&%^\2/U332YC]([,5X2W( XYLMRDY3PWA\SXO,;
MPD"]W8-F^C*S-"X>/8,\@\,*'J2JMIL':>R8$5C?6UE5<N3E@K%XY/X=8.U6
MZWI/_=NER]*[ZGA3-?%C+\(O/!5QN24=T&Q/,SO=R'Z#-.*I5-^7L2&6B-S;
M8L1 6=@ZE&)<54UX<=C9;^T&:CE9.'$DN*,U3>B!R:HRE,BU>I9 #$R9UCN#
MA+>1(H+IS:#92*/1E^A)5$* \VHEN&2],9%^D,R7S-A>AW-?PI0RFY7S=7FY
ME1, *K2UG[P*?Q;P\3BBNJ1C!1SXW'2"VZ:^KA*Z*C(J!S,T?9CV"KGR;0 #
M]OV>5L$#3&.?/2X3"K3XY9#BQY/A4.2 ^F;@@$E@:6F!E8/I-+JCR4E)WSWY
M"0#<!P XAOX7-(+\G^>2%0 ]EF\+P^+SY'IYUE;Z[CRIMDL-",<VR(3[<4/9
M#JA]'E9B FEV\9MB5)B5UL5T7[TC@+BK)F1/%QZ".#*DNQ1N>CSTERG##WXA
M%:.8TB4&_+.=#Y]+6-]_23ZB.95]A8';5D!6AK.(XY=C&8%UX2]#Q_%#1=>H
MGI3]82ST_)[*<SSS&>[_C^=Q?/EOY;'BK?IH%$6* \6;"9NL7@")EOT]%;!X
MA0@?]4Z2Z=NUHUGP^U'I,;L5=".NB$&G2G@..K=P!_B*NY]3#$_'ZAX3=C)(
M3,C4P+W8LW<IKK@U!S7;@QM+2?J#9]=OIO"=;,3]N W/H<3T76N44D!W:?_;
MI<W *_F M1L)K&<C"OX2O=GD/J7&QVGC(W(]M(>B)O$(<?5#R\+SRWXE&Z#B
M!8&4C)_*4E&>G)"EQL-_H=;)]Z\\.="@-4=U',)S4+.79;KZR$AIGVN6)7TE
MI#>6J"(APB7,OW3]Y-UF"+\G)"J= O8KHT&(4$IL3'.SKJ&UUB?<.EOIE1V_
MTO:#1/G7)0L#G+R+>IKD\*Z<^TL@L#=J40!]VS4<>1_D^+NK]-U(4?O/E$17
M1OZ7@(T<@/E4S/92=6HTXBFERH_+"&0'@48-,A4T[N(Y4F?RIF;"1>A17K1G
M@\&:\Q3P16R5S2N%]C;HP5+0P#>U7SN_9\#>&'TCKU;XNNIM"IQV?M&QUB]=
MF2O(?(EFP/HKL^]#7>^K-<E1 E7PC7J   K!+CA" D7*'JN7)QC-WT8J31[0
M9]-^S:DNCSKBZ%XQ.^)HL/A.JZI,TZ8&.;;Z2YG>75TP=SG0<;K;^&:XR(JA
MY#[04@3_]II@@7'PW57(^B<3AC*T3">.%<6H@VHV*QCP"G0HD"WY^O2> 9D^
M$B'&:PZ];ZID252M3%M&_5C"1& YW\HQN&IA*TJP"4:H?RR<X;M2S UQ.BL3
M&GT_0J>OS9S$/?_+VSCS\URXDIR=1Z3Y(\!967 <(S%$\(!6(ZP'1YG=8=0H
M+ Z:\!NJE@]VI6*/>$CRQ7K^W72#V$O+)L?C6(]EBA*/8_)FS7QH^HBB U;V
MMMI5(4NLZ5F&E/2LJM)&W*'@S,O?BZOVOQ3LHJ[\<_6D1_[K'*?^IV$J<:.Z
MH.J['#GF?&2-+&A,%'XKE[7_XG"V-3.\#VX)?W!YP&0"[5&IM;IIZ?MTSIF>
M*J)6HNB^1L[YR\^N'41Y0[!R^-41J>SE6KMKUY!Q-,0J;0L)F#(S;*6+Z<B=
M*=G;B![_E9'8M*LZ-O/OJWV4E6=Q-^6XK%P!/MP0XK9=<'DGB@AOGHG'XKDK
MKFFSORGKFT9ET207]JGP /M,]LHD3(\I,E9BQ54/]#"TA$K='Y.$"4;]<BR&
M N#',IAE?\+<0JBQDDU+0N7FHGDC+ZC+ Z$@UL>V8\8/O@,PGM\!GH/='-.K
M;YLA)QMUB1O9UB;9FGPOB(BP/W7@SGHBN6H#)WLXX(G4+/5'*U[,;FGZ0=/.
MG'R^?NN L<$-9=<= )$_M_M(4JQ0WN,7>P?(C.*ANE\I?(%A2T861/*G+9I@
M[=^NA#_O\!%*2?[5W>C\*ZZ.P#HV<\#S#YTH]\DKII"TY22S%]#(3@<O&P=P
M[@*G:H587>SWM3ZJP<3XO,S@9GF_D?V+4L;(MF<U:M(C[M-DM98R!F8A)"7$
M^-"S2MT74S6[N+4]MZN'% :^@;J&?TTO6JYGL(BKBLCIZZV0E6."&*S$*F&+
MM@;_-B]+UZ_$;"7$C6H'%Z.]U<958:?VX*> /S\"OG.1?V8@OY1=EKE7X+#2
M]N#2IZ./KLSU:Z$#GS%^@IZ\/NTSB]"A-P3%9*(XINS&Z N206+3M16[T,-S
M9S:=G'8:HMGL1&8:K_UTZZ="W]Q5HTPJMB\H++T3,C//2V%HLY53J!&$*.<>
MU/[2Q3I.3-"CP/@V=EQ$0 %&//29LUH@5-26V1U<E1?"!PMXO%)&2UY5A\8D
M0VQK4U"$$/+OJE2U=5S.RT\H&4SDI_,\W_?84PMFOT"31$@^K-M;@1,[2-,;
MWX3Y0!O58O3R-JU0AI((VOD[ '0==?Z_J GS/\VEC2)^MI75L A]E0#'??@7
M%3BN.5I-;RN:E7W04Z;H7TTV#P2,%Y1?+_A^3106=/*^)BN\.B?W1)_SZS*I
M9!]A?]P6.!2Q,RI<VKP;=8JB6J""C*1/E!I)3<(V$^P\;+<Q[NWQSU_U)[]\
M)GNMY]VR-D)\:2HP6X&PL9ISJGYC&0@85K-!<ZKFNL64]H_J0RI;Y*&;+3=:
MEXIJ2?V_58>,+ 5:/[(*RJ#9>G;23V,],+^/\<^2C'?\0-G?Y]SC78<DK&[^
M/,V_FA(\]K3 5/C_"(CDZW0L.8%+R2SC""990F.2/IG OP1Q0/7;C:>T4#"K
M+ 6U9LCF/]83P*,6X #_![GL8JQ2N%7-FD]U3HD@&_('R1]M@"WN82)ZF_;/
MY'U)7Z5.1NI*_[R^?>HZPH=3NMU"6M0K5K#"^V4V[P"]UZI=;8C.(+6)()KQ
MJN/[&3#-9H26Q#[=&D.!?K_9LV#[(_( V9037R^R6:]2N[=9OP4_K^A\:*8[
MD67.)#HKEXF:/?,)MOY=9R?G1I+F:G4S0LU&NC;U,FD;[QPND&ZQ:3SW<8B^
M"+2HOQA\E-"42$)-4'>OI9GX(;14QJ#3,;O/NQ5CU-1"J0XO/.[2:;?QPL'"
M8@OJDNJZ()'I1IQL0YS@*I#1=OYE0JG1KEXJ+,#%A,ADIH\LS[GG%1V#[_!;
MTU2'M:<\UXMSNM&';RR_1:V3];Y(EB*1^HOS6B-[]*L9NI&-PX#Z*_&_R=?7
MY24:;*$KVE8N(IV.IDQ#3Q7KTD7Y$M2\',MUNV7ONXJR 3(9SD=^+!=WQ]=H
MKG_W\]&OLSX+G%QLFCYW;^X@Y< -9&0+[&$KIA;$V+QF9AP08TMRQ_<_H$>B
MG(_RIVHN02 7O!L5(E7:>R2F:U?Z"Z2X<4:BH!%:F7A!L@U9CM3>'E&,T.E%
M.V0F$D<V<""C/2FH"F*2"T<YP^R_<(_V+.AVO\_>]_>$__Z7D+FEWL\9R;K\
M-'^4KXM[7_];</[UG%[#*58MNBBJ3#W3.B/V")*2*CG3YG 4X5_;M1K%DS$^
M2\UR!QC5F1BZ^0"5&SA]"7(_\[YA#?-GEU&KI#F;M4:R- .Y*BJ[0ZHE,O'O
ME[#]AG^\S!] 8L*0/,3< 2QK_CE>Z)95DJ%\\DKTR-K#Y&.5/5,$<E](E3"6
M8L7996T"1G./F8/6?D0+;]V+ .8^Q<"*"I(P42ZZ5#A<^X#FX(^[Z.+#5N^*
MBMJ7>XR)A[DABS_F_/#S"0]@+[AD>X\8JY&@JCD0GG&C>Q8GME[)EF+IR^6N
MS)RH!@#_UQ1X_Q]#<\B-OL:9>9Q+LWA XAN 83.$&9YY!P"#/"\?0,&=FG.*
M[O$^ZR:/E=O?//$A\@&(;)C&KT+B%Y^@>Y/52X4DHB[Y',JV,J]=&-_(:)OQ
M!$WD,"2M L.<:FZX&?=3P %)W!.G#[]]BR/H?PC8FCB#N7IT3'1I%^KK+,#N
M $1^9 -N2_K9KP5GH_6;D*?S-Y!_VZ%Q;/]7C5?BK)+FFI<8OM(#NLE NRXC
MD4@KWE+'%&_"F'\@Z&,Q</3Y4)"[X3]6T!9R]E7JWAW :((9/5X<-SW3;W7R
M=\N>:9/I-A1ZD-!E7#V1=TSDKDP_/C]?,E\G-L#X?F9+*DJH)R;S=XEZ^N8O
M3*HB#MCH;3=JT_"D6[F]Q52Y!SJW:.IWV#PYAC%MN5&'OE71I] &@;7@M$ZY
M+^UNMV9EN*8RH%\Q]9,53 OY]JA:O:&>'*]7:5-+]K,$F^ _Z5L7I(O%LSH'
M:5+589=A6D1R@1MK?//L3M[SXCCS:'1A+(P[*Q[1@5XTDS.4[[MJ&S.D-_O2
MRG%9W?6<2LC9[U#5\%+I8*DW7F;A%7^.TV;S1:=1^[:1U'SBV@$?Z3K?FK_(
M MOYR.CD%7E<F@^IC%0)"]4=H/J4'5OV??(I/%X2Z&"M."M89C^2?=SPY(3T
MPEU\[=H?V8Z\[E+W&ZI7-/3S/O?GU1[OK%_>ON'BTLJLB5:9O:BS1@0IG:J]
MOX8>\EC[&BF[J+/5>YI[UQ+RFN)AT?Q=NIZ(\%"I-4&.$'B2TY>>R=_ O?,C
MTX1 =(>:806*L,_925L"IG\1<U 7^GA8_%H70@8U5G.64QD3O,&/\-^NG1]Y
M=:6WX-90NQ5A*1SV*1,1J.LTA\^CK\Z#F1U3EFH\%83-7/D%>'%E\/TJ*.TS
MPJB?.!?!U766WBZ4G?N#D]!ZR)OW(&^LL<KKVWD]X.O?[0^W &=<05;QFF:.
MV&>7E*6[#,S(9B#LW;5WCMU-+_<FJ&I>1%<"R)$/ETQ'.Q.#Y#H:"]QW+G)F
M+KR7I<JC/C57Q@0TK)VM-DD1KMG%>=)*I-0>TR]TN R.F>)GEC#Z.[@JG2^O
MS;9:&J1[E36>4_8%JQY*1U28Q12&7F>3@6%S+>?^W-<./MZ!,_(!#H5!XXO"
MXUZ<G!D9EPCP8UHRXZ%[/(=8@1!9)IG80*^5 _>YSEGZN#+;N8.*54.-&]+Q
M%C_1*/TV7KE3KIXWG1N9%8CT0/VS6)HW>8W %_^/OL%_=..-R#^Z$1]\T/&/
M;5!,_C?'XW]6C"'RL4K7^>(Y]\](_C.L(3]M^[_J#3BP3NS8__ M]H[^O[;=
MER^ .]/U(YW5NDN*9W?0)%<.'AP_;]5\(5]D',T>.W@?SBHU'#\(L5'+<XZZ
M _R9HV;\B-(N>Q+\O'(N\J^EF\L$>T- S0U&*K',S%$O'=0$]/5X6LXA,/YQ
M12>(M57U6/] ?K7%B/O:<G8;\\%]E#?KC=F1BT4\UKNYR60*06^TXX( O=_2
MB9,; *E8G_1MOY,$!):%_K)XA'VRA;* :C_7-ODP09D"Q[8]WVM[$31N2HB>
M%8T^4;/4%9TK^G4^<K-%&-_=JG];*BT,/&;[,)ZK]EJ"T%@U,D7,""+P?M&0
MZB4 </W<Y.0.D#O/Q6R[Z/29(*_.ZYH4>5Q!N_K@*R960M'=B#45^G=KP+*L
M;E<:\D=?73^FC,M+I$H?,L8ZL[U))Q7:;LZAPM[OQSRW.ZLJ[X*S78CLA%-!
MV8 (-*:H=&E@94,MY7CN8V]4B^N/OTPY]>J*3C%ZV1F!#B4E2ANJ]2R@L4%B
MPTA7(*@#R\FZIQ.F/>XBN'. &Z?D3V*C9DJ&P%6V*#N078\FS\36/ZUQ!*31
MYF00=GA:C"A07Y3;&3]-NYDLW-^]N!$XQ^GO%.4>:+6O5ND.1$36Y,\8JDMG
ML/." F:V^<M,>H3*X3>72G.\P1@S;#"-=:(4*IOGWD%#'4OTOQ^D60#WDG&\
M?O,8&.69]?YM<(%OE:\\<9?U(MZP+%YJS/5%T>SE]=Y@T\F96(& J&7&,"4'
MWO"+\SUDBT=S#F6SCG53B<)2VD3U( 72_>O^BN =@*FR(4'W@&<46_[!^1"&
M/!'%#LG[^A+'!W-W'FW,M30DC#32!5D_DWFRDFIPS%I2*/\4T6@TI_#"-SS(
M*O21C @3%6ZG5+PV$@92=O;RI-5[YW/@0!6QQN*]\H\JXVW%);?05>2(Q[UN
M9EK/6BJ<:FQUYX=GZNC,HZ<=^GS<'/QF;H9XWZ1Z,CZ<AJ[2WFKK1<@RUQ&A
M2\4TBA44ESVN\'21*P'2H)8A3&X&GQ7?W &U[D(B50*2SFT'Q!LN]/V8((=F
M"//Z'2N*G!H X*/"K(W7<ITUN5<;*;7M\%L]Y^=2PE%07WMBA+*9^+K'RK02
MDT+G4FZXN5K7$7NGO(0I-I?1@F6BI?&KF[6PIH6V##^IG-QXJY_;L[:E+C5S
M^ F_[M-^<OV!8];NO3^'JN.R:ZM$I?B+,1O"%NR4F6=IV$5<B$JA3+M/R09=
M!%$)T1T^CCW3$-,E!<;A$E-HW)PS8OU56BI>?;=F/1-:5"8+BBP13]S,:)+:
MU@P7O1&59YF=9<A97HK+%D8?YDWU:"7I?_R=W8^S-=\:=3L10<8['EK=PH76
M/X-JPXM&G*1M8UF]S%NN7IY(9Y5MF5TJY4?J*)YD:=G,_GD69#&*,PFZEU4"
MC>OIX/3"Y!UM*;79UGSQ4940O8EJZ1/#T._96W(J+L3$<Y)^WSCGU4*P7 7I
M29^@V[J/GH(7\9N.Y3?VC822H_ZC:N*.A_'N?C<2L.[<8Q+CT>7!M^TWU;-#
M=M3I/25.T#$868O&-L0=Z=-_2 TK=\W.(X9A P(0IW7[X2LEDFK'9(NG70G<
MHQ&31;_'!ESJJE/8\&S<QI5#;#M(PT<&]LQ\ID97=L5K)K*WUGUKB46Y3$K^
M"M%/7E3C6OQW%2$0\JQF#5DRV0<J9*+Y&J71#P$ 3X!WR;] 3$+W7TRC"!>[
M;#C>:V_#'Q_RNMH$E_WY*%Q;>>2>']OS#3!"7?(]'W^(S1KR/MQ$35XEQJ3@
MFFFL&)[N13)'>) A4^GY:%"K8KN"Y]"=$7<O[ Y@"Z>Y3+O1#-!L2&<9.W*&
M?7<Q_DHK>D^89,$FX8NY=*30 )TNN[("KUE#X&'O]2/TH4QJ=H&O_B)N>R$'
MZB@.2XEWFJ*\<#4T+AY0=7LISZBE!L6TW)@'"(V?,^[O/;6["=9@+HY7>W]\
M2!]3]/CJN5FF^%:4I-VJZA?628@73&4](F; B[.?#\B4J/#X8-KG ,0;B:.;
M!P7,=B RAJB%=Q[3Y@>L)\6U=M19<HZ5G/L)SI>B]/W=]Y9 C0XG,_MIX7UE
M>J5Y)<J%;2*-C0[^=16-%T:PV>NESB6$612"/7M*N1(Q.G:Z,<1V_:$@Z.4;
MZ6FA]>L[P%?$$I72EMZD"]PE7Z*Y88.5Z0S8B(>AT\\QNHS;4FC$]1T38*LM
MUAU5I/5$>Q>VW9:6<HQVK;]3E[MH;-C<SC#5,S&=$YS"?W1UMPBW%, IJXUE
M@+M[)=<*QG)X+W P-07-!:$CMBW_-C6G:WZ&92YE_V>S;=XZF&$9/G#L99@;
M7:HWC:>\C?(F6;/5I>]?;/<1JG&@+,KS\ERO\9N\$Z6OU9S["4&#T)8I56R
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M=L93IHRIW.*.F^DM1F3H3.PO-^O-ECX\9WJ9*RK&L+1F,)5#?.;+R_UTJ%Q
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MA$[QYC]:'BNW62#_W<(O"&92;C'RUMAC)_N@>C!^Z7MC"&X5',>*W1:M0AY
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MT4+<NG:V7,-8GE/A%[?O6MT/R?YLHQ&/MZ'TW-/6 )*&8GAT*U> SG%/I%.
M,02RUJ1&J=@P+@D=E?,ES)B!<],_K?%.-?43=&=V.:+)JYT(M4*TZD4BA2"Q
M2\\D[P>6_UVEY28$W> O_]8=<[:MY?7PLJ_:&=TTG*>?>N*L>KPI-=2$'\49
MBG>F1JZO8CPQOC^EE;CH_.%]Z*:JP:RH$2C?5][6LM18]$'B0P&@$>(=_HL9
M9H/OU;_EZ5*L0C@_309)0$6 +2GM ]K!I(Z5Z%F?R(/U"3;M[8%'SCGHU_@
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MFBJBARTLRY61$U>LVQO/*.=/]ENN;*<*Z]+A=*143P\*W@I</WV.P(*$A:5
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M+9EABAYJ_XF%IF=_[L:^PM_GYU_T_/SMW+^=^[=S_[><ZW\Y\3\ 4$L#!!0
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M])M$7M-JKI'0/1'O9)'JV8;*16)@FPVE-S!6Y<Y/2)7.,U"J3B-S4H!ZK,C
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MHJLK]*0F,;ZV((E%LFO!':] WV&D:QJN:F!D+R UCN1/U9VUM!I!># 7GRG
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MA#1@"&K[@ S0=LR*_55+TD&VSN%.R(#<RF&;' QP=IT,"(5K[$$8$#V[7&2
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M/0+SS=5$:R%@86/17]P6$O,O,@&#DEM"GA&Y=T)MX_ F\W(JG/@[[1JQJ_6
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M8 6GUOLG7_?+ZAWCL2GVLJ$F<0TM#(6S#\541ZN?;@A]8!)V0,Q6^BHA:&(
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M8K"1*0NS)F7O786()E!;'C-1[;I'7]]H^3G YQHHV3'KX]-$I%FCIK-6ZO2
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M&2&$9]X$]I42HF(Q?.!WZD!-UW7S88UP<GF.RI;:8YN]W5R,JJN(_N0=VL.
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MDVEA#X(3TN;&GY3'CMUY%YC;T_&)X;:^70F=KZXJO?RV[OGD_P!02P,$%
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M[:CIN#T5\.#0;L;7^::*T9,""JR(\B>C;BP;^XJSF#$?4C$Y X<=S=QM;[A
MD%C$Y)%]+@>O0O@])&7C\,BCI[^^O.WP5.>SH(A#O[>LEQ^ZO)TJH+=+BAIY
MK3$3X2A?06@)4MK=\B1L?(O=N!NCDWK:2= 8+O,I>:7KXAZ[&\M:NB(>"V4
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M#5VG+C,BUIM04GXDY<.$<M/4S$K2]PKG[EFU2"B2(^P#LQ$KRW*ZXA*$C3X
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MX_]]H2?&EJ2KY3B4-=3?1&G:.CE4Q2ZPD=&S)73:^7ADFJ\SFQO+]N4X*HF
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M-5?2,K3"(*.4^G1$3SP><OSW9XW83^(OK-SY+')1G1.;Z]R3?V /"8IO!AB
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M)JO.;43T1M8%9ZO49X5DJ31T>-^O;BE\7RPI:R R&22Y [H(@IQ%PX!0 ?+
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MXU?A^BQ Z*T(,"NEFPP+XC0L&<"C0__C'#-.R4S9/A0-^[>=.RAL?;_Z[!D
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MMAE+Z(;S(9>! OJ,U\%7.R!/UQ:??6%0I.I5)/T\_!%HR+^9$D:HZOXM=QF
MV@;]^@3R(&M=H3'8;14M.KO=0193TD'M]7[H)IA%@CGVCBX%V4N#@OZ8!0/O
M%9K0,\/;3NU\C)S]ZT""@?^0H E-Z(7Q@J.4'1B[S"<8 /XW#)=)/P'92UT$
M,X\ <O;;O0>:*^1%L CZ$.@^&.(2=$L9+!3(@_>"OPMF(2U,H%1#[33JP1M
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M:9VB+2S7\S=GE,RO-[\Q@D.8K-](Z:?IUN&3[T6<+7-]->ZCU7CF,!-63E#
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M2+_8Q,OM[6-OZ9GQ\N*TJU;P2"2L:OZ%RJ,T1Q:\&N4EV0)3L]6N)4Y5GPV
MLVWP=!+1Y! 9?+5H<\>[!PB/%"OCY*LB6I#'NMJ9Y]+O:,$I:G\X5$X ! M3
MM/WNGDE+:WM3W>0,PUJ,'=9.,%K57-=2/H+Y=L+1$,8F^L"4%=YS\U1O'@/U
M)MT[.E.'Y+]E!1'9>B5$)U8SO%*^IK5UT];_6?E<!BF),(27(PR.]"/YI[!3
M/E43O$XN@DT%2^H.>TPOC"^]?LMA)?^\NW:(R'/4, 2_HJ5V6K(Z-2"$T&X$
MQR0&&5,(?<SO<Q:F\J3\M<@)0-=:^W>97UNU?X<?0.SL7LXA_&<+3B]&2R%\
MC'8MMS=[$BP65V+G\?=5UHPMK*(5_WCO.N^4[_P;%1F;\9PCE?[E"]FX8"J[
M-O9IC$HBU6GEW6."5=,\&*IB21MKSV.I_1AIH*S\)S=$5&Y81PT;H5E#$CJN
M[-0FJO> KKJ2:T*+T!M Y@,[*246UOG'Z*]8]N7WMAE-0>\0(G2\AL^9(9,T
M=AIZ^3Q2"=I-=NA!@NJF#TX N2-U'N+-GJ1(AZ\*NI&. -,O#A&FA@0XNH5T
MMY'L3CE/'L&< 'J2F8GOJ[T/C#9M\ZME ^]DZ$YD:3I%%C9/\POWICP/#R0K
M*YX 4L"<6G1WE@4.:K@WG9FFJMR;"<VYA+J OB(=[N3B4[<EX^Y'5VK9/?M"
M+^XY)@@,6PI?@)^KA#V1C5XC'G^&IFL&D#WWQ^H6N6,_B+"^(URG?/R^K'+L
M#$^H13T%)PB($.$#P-2L)6%RQD<H2INP$W^Y(+]TG21O/_SA?KVC;^1OO9;7
M;H\^)]@YF[W+V_G=":$Q;&+"E'W11J2V&9F +R+35X=4E.L61Z_(2TF'! OI
MB#S_%/V8WNFSZ5UG)\)(3[@(<?94^ZU\H $)G0H&-5X"$L@4]!+[\6HWQ1BG
M<5-U.%WS"WT8;B9"ZY^/9"L?P TS*)Q^IZ0K4=LPUS;+Y7SHQWSI3R_NG/&Q
MEV,8%F0":594D$<I-C#QXX(#:143\BN<$8C%BR>"Q==C?-3OQCU]YF$VM?M?
MA$,!;?0%DGNN6,Z!FK/41\>Q,#J*%EF\%UU\ AATT"[].8)IW3?("M/:%@,W
M.0X+"]YG8Q42D1,TVENY(#RME'K-\Q3/AJC7Y$\  \M<F*[</O1R9.5^/J.S
M T/-8Z-/D4MJ'\UX%!2^$!8">./RY)7;%,]L+!-,31-OHP9\7R\W-HV.)?IV
MVF VP5RMX\[8X^VJ#PV>U4F/Y_W9]1.DH RO(B3Q7N1S- :?.@20-C'+\??R
M6,R6#]6*?;$D-01"LGN&7X6\=WE=> +(>N(:P*L>4(/Z<PX+B@;Q:-S%R:*C
M2+G$55+3YP4H/:;J]8_3:&$>"+D^-ZS(*+SP5>A[G\RF^]E[;?W=9^_@AK9!
MGF-H*_C31#@Z!\3K(8WAG*+!XR0_WA<R K4H(53B#@>HW1<4QK?'"+.?3H-3
M$X_WIGI2[*&NMDV4^UDTI8YTTG#&\_2EIZUFNZ=2WH\7EZ(#*R<J=)\ +B"%
MH +P6'!#]NOP&^2A_IR9HHO-!.GI@5\O!2)AJR'5X@FV#YENRF^[PS@63$=R
M !1A4NQQ;>#(&"],C1Q*V.M'L_2-(*YY,&"[; :=Q5@U>&3R_@S>8C.O:ZRT
M)*P!@Y.4,=LG@ :I I%6@N;J4+R6K >*!Y=%3,Y^K6C$ZV!+K:IX]][[?9%4
M5<8;_UCNFGB4)S N_ J9D>(,$R+:#-2PZ&%!43-(IJB^C(WL'(=E>_O%>:GX
M9 W#F@[U0B%]M25]>I>:!Z=%W8OL*-O/DBJ@2*A.#,&,18=?GQ'4XFQH;0[U
M*+54X!:/%1O\\B5@$, E!-TE +2:I[54H>(ZY*XBF"QR9@"5TI3(,56I6-+T
M[HBT^7O;1<)44GCX+5Z&ES'O4=(,(0Y/1Z ,%<@02V,59=FTX=50)6I7T.QP
M%JBNV9:OXX--C][YC\]8HQ*.(+1++K[^A!9;L@*1\J QZS?\+#G&^T"QI=OS
MF8Q<EX%XB5F1P"$[@=9)DSM^WTE?"#/?]=D.!*706&:VE.YR.#Q9G9[+NI&=
M%WMKA '@_X8\/ H(KST!]+G!>,#1M3#C["'E+.3%UO;TK\L6[<VMT0L/HF-3
M))SEI**]?=OC8L0_*'417$DI9&_*/4^;]M2^'0X[<LK2<*9/NF(Z]X?O0=D)
M5C8/@YH9'C)/IF0>+5/,81>)>MV@B[2OL\HYF6MQG0HKH3>$IILHF@Q*[_:-
M=9TRC()(R;NMGL$KB'8+X=]HYI;N9< 2[-$,$D2>[ %Q!:8FT,2)P(CM?8M*
M\5=C<8I'VXMF+HQB!)[ *V^Q@G?>-&^EW-$:^H'RE8W0$B3N.S--TL3656Y3
M)X]S1"S?.1C=\/[(]JLTO3\=T)>WEC3[%NJ.'6PJ/8UE8]I-CY?+B;(?"&+)
MA&,EH9+%Y=OK,TDUC\?\5J_6V3*(C.!47;]+KB 8UW] <2O@.!HS-!=G@OJX
MT<P9FH%QRN[UTRJ"!(CZOI?)+'(7J1,MT!'W8Y*<@7NQ1&K)GM8B""R T!)]
MX/"EJ97&AW:Z*'P$;[;FG$RT;]M\?4N_ASO@H8G*0_H_QBA\&B$('AV']8=.
M\(+/\0[5)EIWU;<W<UXM$RV*5;MN)Z:A\K?)95>5QC$D213&EL:= +QDYV2Q
MRG4$_Z%L;W](Z8)F2=7',;_2Q?DEAP^M^L-"HJGATQ9OY*M?1H'ER11L30\*
MS4B2(T/@U:.55(G4OI?]086'?2_5%WHPWO8SYW9'ST8N:?LRO>--><AVT6M_
MYQ1/X8FP$((ICCZ^TYL4!M:?<&L- PW)>:#F3+'JMOAE%3:]IKLWTTI'7T7T
MF-XT!@3_YZ:-EXTHG&1Q[')_<H"G\NBSG/#2,H/S#9R=*=8M3V^P*5P5'@2_
M>M516U/<2-D,,Q]$DR:L"F:P2CDW;(J* %9Q=>=MUE2VDG% .AC':=Z!?T(;
ML(A8E@2J +JJ'_\I7XMQ4H:R(Z;,:C+"W9_8(4),2H'LFVHC6Z;VG;1V)\0B
M)[!+:BZO,USN/Z&SK'E\AB_H \N;4_Q H-@T=+#'_J0X.#LTVVQ&.B"5;\D!
MS6]]L)KR=='N!! L0+JNVGUNE<LL83^?GD0]1G2:XBK@%ST15P,ZJEY@_;S/
MAJ@P^DI%QU@9927=^R><=DVY:_)/ "Y5VA;C,'7*HPT>ZR0EO//80'O_3,[]
MUVFAMT6^9?T*7NJ^ <3;#(#9M>3(N3CZ7M0Y[7+RAN1\OGA_\ZX35?5'YX5V
M)T1,=XA0<O+NA\TV2^UTAG"3AP_IMWP'Q]"A&/C6^N4HJC8QK";.F2*&7BS,
MPH;<496Z'L-/BAK$MXZ]W$.=UOSOA)U3SCR72..(BVY*EK7/M9UCB;7'+H7@
M9=>D#'1W2?48-M<]^4<E#&/T ZB5C_:ED51>8EQON'S&T)(@V8*H??^'4R/P
MBA[F<%JQ2L?9(.[GNYNU>_5 ]8@S[N;! 1Q4XS+H#LZ&RI;;;_-R-BI;E^A-
MRI0>6;_MD^<-^Y6R;^CN\%R^1'_\ZQV@W.-NEQA &"=%(GQ2@/^XE'9M/5QP
M0HDW=-0'/3$C>\4>C7:\>SFKD" \>BED9.]FW:-+#4EG]@2:)JE/R:?LDT(*
M'?<^0,0[BS41%F.^Q4KZ2[TPDMJ22^,SJU#'":M;XC2PG;,D!O(P!IRPW !^
MM:6A$JJT.A83(*V@/9UE9.=RQ5G'DV>82^:#UJ7CU2^__)UY*<%@;<(0J>L8
M$2Y)'C-M1Y(=/B960#;CO>VQTK?7HT+\6ZU$8&.,KY(0#?EMUR-D:6/P1CVJ
M3"I98B<%1T"E[&@8$::I#/S;"!?VK2H7/JP#G;M#D*">A*R@VL,^_W,S7:4V
M__GXOCUGTB]"T\[ 93%I9S78ZTL#ZNBBR+N77]2]T[VH-K(27).JQ0,6'P3-
ME^)HY81-PR["EM9-LA7\."HDL+0IRFE4V*XWNX*7[E&-O,*%1XRN?CUBK9J,
M.&#$/IPL/GH"V"*&8#0?P2!IOQNTV&@]K>G;#K.=GL+MBZOX+^;OUJ#H:V=O
M>9P[X,3.#J%.2\59JJ0O%L0/+1FY\V/;5K1SUR>SFBOY9X+J=(&)VI$E<=24
ML(8+?A4N#3W3Z8LQO6KG5<">I/]DZF<C:\]J];K&#PGK5*_=X%>OAK%(\>.B
MSJL8^!G:=U!#02[18J#@.MD?Q\*P/H[,QVG*&H:93QJB8AD#;RW>O"#N_VSN
MU5[(Y2]\/,Z\LUK2M$D$P0215#=:+%5PHQ.9J8AW,#FE=@W%1*5*7Y_=A9 S
M-@&G97H@TRR/;M!RG'X:Q +WD7T%9]<(*& F#/4[J9L3F5)<8Z<_%M"UNE#E
MC$0@?*7CPFRA-JV.CCJ0\QECU[69O)Q^I45^+N,6R1@_LX3BH?W?EUHULZ#7
M.25%A3 5HG/1)T]&[&7[,8..UH8)_F#I_6'&QN>L"^J UM,*'*&1>O<8!7+?
MN4K>6.[E<>]?E-ET;,USN%-@W#L_(B1D9;Y:=*5.).(6-6,0\@4I\T\S*PT5
M0BJIMXGL7^&58U7:-\(OA\((3G^:E"WN:I@Z ;RT/K_;PY2KT_9U$'<8]YM+
M,!Q.M20/87V3@)>HEYE+<64U/@$(MOGA8 ).E\"S'A3.>>97K++*UZCJ53-F
M?=$CM;M@+]JTL_H$\AR\QP!YC?J 6(K>'SN'H#<MAD,&W*5[&:L.A[[.\S1P
M'.\[ L+)FO)WZ!=H"N17'V":!*UBW.5P\D]RL$F32HM-)(/H+@; 1F&U&Z/_
M8 Z))X+P=H32'@0+3!R7[SY L"7;#)CK<*26*57U,6:E&8F9N<IR=:O)?.8$
M*E\.#K])V,XE\G:CFV/*!I].!"[>=I",7WQNSUTDT1VU#.&AVA)8^D"<M!^W
M^9>[^:W16XXP]@F8V8LH/]MMV1PKCKJKB*/-3AGH?)[;TPB0:Q,BV9F)<$JY
M?5FH2LB9:"WEV:HG79/[Q<WOT;;"-NYIGRSE!N6NO5L:26_EUK#)UZ:$P,ZT
MDB.0EQ*Q06_^4DQ)5@\SPMZ-=/CT!#9\$=> 5_Z:'4#5[4%1).0T\A;5LK_9
M67"2)G!W1?/";^T6GD1;&NV)VLKK6>B^0\3MW\A0PD#.QG+#*JH'P45U(=+'
M!DI"RD7@T23X);KM8E)F?KZ]9+$'6M<_*BO-=+266A@! H<KAT\M7SH!N%O7
MI6*!2<^HFGXO2XQ"M:^UJ#!'X."9E]1CONMB6[]H$""_P62);#Q?>^D6N)2\
MAZ%/]1%J[B+25=5#G/F1Z6BG#C'9J_*9 6I6"W'TK]*<12FZZTC94Q[K"X:B
M',E%<,)(7S:-LV&RL4; 8&65R 3LB+U8TB17ZWMC2?_WF_I5)"S@!>0;399\
M8:@/1# ] 7!OM(LG**5RK>?L]%>$KDXU 9F48]C[8Z>3,N8=W@-O-:@^[!9<
MY)5PE! Y=X"@<:Y%S.-XJ#=3G3D%-"E"J#"QI8D0V+NSV\M2GV,E6H>8-TQ^
MX=8<C_3P8Q1M:.F*>S25LY@L("E"#$Z&W?7]8+O!D\XMO07K57DP3'47O4.?
M8K#&I:5$$3&5W9H^9>.&9"/B!>$R<NG@K&\-&3ZD8O8;Y]!RZ=O,+NC.0\E;
M.F>TI8H^/J#XXC&%5. TDM6SAEB LY[H5&>NX9Q3&F7F+EA[T"[WQ?K18[V;
M'5:QAO*_:K@' "&IK\)OP2!D-8K=.N(<38@\\H"<HV&'.3HP/@?.T$TTNN6D
MP_?]<99ZN 9J/T0^1.2:8(IU*Q#MBP/C)2G\T"C,X>O $T#\7Y;^R[+].:\;
M.PAAJ7'7&U+$>!GU?&4>3##)/=Q:B;2Y.8=+.\Z' 3] ,TC-43A0C!(J7N 6
MV8&PTQ><X03='%(8"_2K<%2\^C%A?O2^*Y^?X9#'W<@X01]S*.(,;>:?73P>
M+&ACY"W82V(A&:Y'Z.I)[0D_[RVSBW]T#L)8OL3EQ.ASZ>>PZ)3[Q7BN<Z2S
M"54E&QQ_D?F0,$_Q7$@@VQA3KN&V[IFW*TE)D;>G<P 2A0G_87PG"N2*U6'P
MYKUBEED;,[:L"'5M>?;SN!:E56? <395"0.^N68C#I[B1"S+_+Q&$0OY6P>Z
MZSRJX^@N42%FE."SY79KR)=-YQKDFOZML@@ _8>S"!UVNO_4'@;1WD)-+CBM
M<'49IQ@X&7UPV;@"_F4.NT/A5H(?JYH^G!W!G@"6;L)?T]SW8T_#[_HWE>/0
M.%IZY&<O='%)7/'BALHA@Z>KYU53C5T^*8\/6:Y; "6?UM.D9^XBOR)4]"\!
M)]U8EY?MY>^V-<<^UZ83KWW<83K35IB1;NHZ47-CLEAMTB;=9*3C3PI(^[A"
M0[C*"_VD81TI-+&/-_?S+MU\F97C4MOQ)H\NQ;A_-^S.$,RB:0R=V_M7-@%V
M%_-EWY=U SV3@'G:.+&_TZA8T2)[W85\'^<7AH*Z:N#64(Q4F:[9+9@")C_T
M#KE+\SAFH#4+O4T2&<?;7;20,OG3?;/\V<VDE<S+2UT=*ZA8I3!Q4A2YIQSL
M:9.5$[8_4S*Q'1JD7PU@04A_Z7--6LFS@:V;)R\_61X%\L9\4Y#2:XBJ_YU9
M\W7_T&TIY]E$,Q(9)G(":)Q]M4(&0W U30O(S$"5.9<F??^ V7-J<4_]6A\=
M#M[RCY0<@F-<YZBZQW5('D?T.KHY5:DY/^3R(*+*KJFJ_X'WMJV/N7Z/^47!
M'(R& @$QB/;M =)O>&*\#7%FA-E$L 7B;L$B+@?+=S_XXL^S?7+XE:NQJCO.
M'YF6Q,BO*>94#6(BF=?IM.K&5556XV''YO-N"?>O4B=O_KK/:,BNS=?,()!9
MVE!JFIO=V)[W8A GA^RQ=D0>B/O85)>WA&>]A/<5+2.%8/?'D9SDI][!_2IP
MM[KD+"5T\:\L[?RR!*T]/@'-,^* JX[BIS3%<X<9\G*-)/T]!NM-;YNU9)2K
MSN_Z8%<4:7F/'.VC_BY&_>Z@Z;F<L5/OTM= ^WII_%,PS=+\IWMWIC%3GR;Z
M #ZN#U\ ME_Z_7$X!0#Q,B K+)P\2MBQC>JQ/XS>-[TT(KVXN!;O'5.9WA'B
MIAMO8OOTECRH\\4%M=^E)LR<V0BGCK"UMJ1![#HV_Z91I52;PV]CRG>*C-41
MI&V$-OIR(+5?-M59DJA<A3D!7#6M3C;YY?DWIM]'.J!561_U%,'2Y/9S/NC-
M0MD@B])"^#A"0.,N80W;$K'O?7W(WONVY]P!EW? SS7:U#W7?N5O"XV)>SZ7
M+)/7A\=XP/7+L8&IS!N(:[Q6$SN*TQU$D3T'I87+5PKD1^/N=?M8(#KE;[;@
MM3]"H@;!C!I.Q1ZWX^*?=:J5CT@?5&<RY*RY-HJPWQW&BI&^R^OZ.ZAPVS38
M.^QK? T@7I-W5S4H;]M3SD+Q=.$K)FU62X9TL*GHJ#YGENE&;TF+'YUZS#45
MGFD;0>@7ZYAJEG=;B3ZN+*T/#%M&DIC"-AJP0+1V'PU(&VJF]1/%2JLWK(W"
M%2^K&RN YWM#1P56KJ2\4&&3VZ^^N68PHV%&L872#PSUV5=EO8')P(9]I;D8
M#6P7$#>MN2W?T(.SU8XJ,L@_"//]/*"A18M!+;V4:@W-BI\#G&B-,ZH./T5T
MDC5:'-E<M9RW^Z28H==+%->5,_!A)X!S+W]NP6Y\KU0R]))<1"N;YNY,0H31
MCXZ+-(1"5E2I%EZ!O!TALO &W7Q?MYV7,J2L72;M(OSY@Z$N"\(:7O(#.=W[
MQ5<0"[1P!#SA?7FK -@YJ=%U#_KJG)Q>ZS9(GJ"O,1N/BH)YKB"B#VW"+TS
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MS".X/$.:6S)!=U58<&_+RPMLFS\/<4I&U=VBUB6Y'5G\-C(2+_J!7E>N*7)
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M?@>+*KF!9EK1 R=)#I_ZUVG&IM\7;3,$9_[5-E7SB,!C.[\0C^B#5"JBQ[+
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M#U67"(Z&>\I&\CC'89T<="=E=X0<1M09YP1C?_%^>?O:S):>UX#K$51\!CE
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M)@,8!:UJ&&&(1=7#.[7\B@=]#8B%J=<MIUF>R YJ:E TJ BBZL;36;OH+,C
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MBBR:LNTJM%4NM^=\H9[]TOD>VS%[V^>*^G--'0U/$6:^]EG68;PFYO_NFQN
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MEV<CXFC)'<*Z*;LHBP'J4J1H UE\2$Z%WS0AN ':_3+E9NP<EX:Y;+W@QI#
M3:G!XE?S92(70986?<B:6BH<SD0'5!1]I@,NK>6'[M>I7U5:,;B871?^G\E@
M0Z@%&-*T*<9D$"U\I-R2QD,')"*&:"QTP.=J-XNA3KSNSV>0.(C%01BOR4/O
ML/\(?7U/+_G,-M-FV5;-NV)JXL^*8T_=9/8YM_]E^1.P!/Z2R#&[M6&8NV*U
M'P<W"B(,S?'E53RR?:R;;_CET;3,QP@VD'B1O:1>%\MS=E@4'1 62AB:1290
MV8K@2D)I464^&C5U([Y]^E93GO.^K+]:V<2?L#H<O(?**7UG)[#+QE^W;'^Q
M [:=@F")ZHM1[U#*::H(S"(99$&.,#[*H-H1>>8[TR"GJV,TA-?RA[<T+QR*
M]&GT;OS1O/6<TS4O2F"IL/44ES-<ZZ@(#BE%C-I>($?-?2C4A. IF1?<58WC
M+6W]H@ W>;AYRGO<G;1NR.EX11\<CT85MN?G2>W6&O%/6HPN9'A%6\V,'"V5
MTKJR-'^A!6F_P'Q$A2A/3*6/-:@Z.'NM*\GFPX94',)RY/UBIBY@;[<4.\L(
M0B?'Q^&&!/[X:1*$B=RQ6/ILN#A[1O+=VGF?=_FJI[T$9WDX7:^&Z!V@HT?S
MQ?B$D]<\FZ<$A\ID7"0'Z8#H2G )(2$>S4WKS5"(JD8R!3#FV1PHWM=:T*>'
M#5F1]ZWF6_PM-G^>[38^T\2/LYP7)7 GBN &A W<NG=V@)#\;?]H=[CE^+L:
M\)W0LQW3CCN:?0W WM6K#9J[[0'!?+)<PCLJ$_7^NP=<<Y(>#Y/,JYN,O8_B
M:?(!07A@N^'$%N^D,31[-4.[(T5YDEOPKO"X*J?9S6=*8N#[]_0V,G:PT6 0
M(2+<EQ($.4&NL!-<03D!5?*D,B4CS_##.\HQ?:]"P$%)L(3LZH=)7U:E,9-.
MJ[5&IC#[94@$4J#*\PVR4B&J6%.M[/$8]2[Q<B&[WJCLM3.68]K=WSXX/T[^
M TRLC(KX_'7F.-*U3("L.H>-4#;F(T^T66'"D^:[A]T]]V1COC2F/8C]H^(T
M:>I' /1;1!.L9,2$/KY[EW(08QF=Z.7EMZB5.M],![!138G6'=%T (]%BRVW
M=3Y*I\$8.#E53/S9WOA9:,.9^NW68L3UN28[4BD.#81#ZVJ(EQ.(]D+Y<7CR
M[H2-,(V[![N[<L'%!@EO-M?J,&H,.:F4;'=^X %A_R.T?W>7#KB<)Z>=<W%;
M/AB)_62137WRBR:TC"$D(%OJB6<+RPY&;^[9;5SD1&AW@BXX7?NY=C1[!6QO
MZZOM\WVJ(#C>5U:JY+M%,5R6D-!BS!M@L >'S3<9-]M*6=><W99*W1]U]RQG
ME12WH>R_?$7]8>_9]%*+MX!?TF%C^7123(/%'CB%'$94PN->(:$]V# (4#EF
M2\"P>)5[5:BT[J43Z6W(AU._L^%7NJ+!=3_D=WATKL'MYLO"4()@)CBX D=U
M"<(G\ 8H&62UN5S*[?$E_?D=(_#H(?/=]V\7$X0CM93LY 8>SYA%5S[PO[<_
M>-1@N7S8F[F9DE%=O;?EO<9E. =L58A%,:-% Z"VY- O< U4"ZEC<%\_03]K
MF^NV, 2.MNAI7)?@7[;YONE*M2%W$2B/R7$$J:U6];SA+#%"'!H%\\/5#,J1
M!FZJ(XN//=]8S#=.^P[-@U=J7\2?YP]"U[O@$&&:#S.JTXQ\5VI-UR%1%C.5
MR [C&'ZTTC#<O]A9#Y>.&4)6E$H9F7";/="3,)MB=60ZW^']\5BS6H;"QFV&
M3N5%3%BIMI6XZO[2//]49-1O0X)+XNU$C'Y.;/T=@:1!_8\7K\_$SCJAC;.3
MFEO34KJ:Y)=1[B>)WG_^F!A:'U;/F"[/O+$3T@1YVA.5?HBI9FV#F,D=RY.M
M7RW;;-8+] US\S4]9/PZGA]3N\&8T0M4LUE0Z+0P 5WDG4\U11-3ZQ;#AM;=
MX!#EV&=&K?)*_8A-I9:=H3(#XJJLV4V=>R;)%E,N9?@#0?5^D\5WIC43=,![
MBY&T&7[P6<0@@G/ '2'KJAX1"G^9/5[R#G&QHA+VO0P/\N^/.^868LCW8R&I
M6)4/=&G XD%T(31(N?*.Z=>5*:N5S72&:T8V0@DY>-3Z_+Q"Q/1I8GC>?":L
M#7<V66N+9/A[HGD!*_*Q./?*B?OQJM[Q(77 2#L>N%HIHIL1#QM!CE\.IB_\
MVE)F\^6 7-#>-G^T$-"__5E8Y@<U]V^!5W!T__6 CKZ:J:V=:HRX_C-)V=PD
M\]KN?7 SN63>[A4= /*= LWQ1\%MBI<#ZUV([44!YEC#EY+U25>>ES]VWQZ2
M2/R^).XYJ58 OW]4U*AL3[$(4)W3#9-*L_Y5=20DS+',(QU&*O]H*, CLYCB
M8,ZRF92354U<Y'OWW&<DV3TWHS;Y6D!70U62>P'R6K#27(DTR6-HK\2[/35+
M;E33E&^P3RLM],*05-55K)1?<=J=B]L#'Z[;/L])6QYT1G*C!:E.9&%\ A-<
ME\BU'T*]B9=*U5*PB3$.^BU5^Y8.*'*>/Z@XGCV?\+W JX?](#H:4R0KVS7E
MMCM$J)W5'16=RB[>MZ$#A%$Z<!-RWJS"22J7\1L,YY[P%O?XS$QI00DY9'NL
M) D_?/GW7!3:43!>Z>>\\V(,C_I,)/H:69YR5S6BT6Z.8<#5EIGHV/3./+#C
MPZE$^3F; X>D7_7'3V=V<K81J_AFD[>5>8/-9?KT"TJ;?&?R,,>.G.ZMM"OG
M9UZ;*&&HXU5@.,,&^.RC+J(X?C.O8'5<N@7%]U*JXXE1>S_JFL'W] [+I/7H
M!:X)@R],@NTSK.0U/&B]*YO\P8*@&NM).T]>,BM/N_LMC2)CS0%C73B7YJ4@
M=]-,3; ?T!)B!,_3E@X+19=B?:>G#@_7OL@]3*FRL 9/9P*?CZ E _S62&H#
MFEQG/S>TJZ#EW VL01=NQMA[*AYD.4U%_/$5^'M@2S&-0=_/-FH0:CNFSX>V
MXW!"_A'PF]G&>7V^GL?>M8KS73K/SO'DV+E9,4L'K\Y0$RM-34FVFQOR=T=>
M7NJ ^03K$D#M,QPT)JKC*+2&.%F_%5$*E_=R4HZZ%A/S?#])[\V=;QM0)E?@
M>^+''4LZ@!E]B<QO298MHTJ04[[8.JO;M&^OUMLVP=QP$(>/)TX(*9^(O*YU
M[*>_H"T7?$7[[K>!E F/S?&5H06KMFX5?5G9E;4=K<WY]ADN\$ER3+-50FO<
M[?O$@DB?N+NN0A&1ES\%"4A'"!OEW@<;A#14]+()?Y>^;HOK.(NL]&Q#1?*+
M:3:00XN=_0X_+MT?ALN,2V U[G;Z1-:RLDO]D<BR9K"1J]O!O)J*[OI&,VC4
MXL'QMFO%<R43=CO@9@)DXRF^#TEJLXO,NI!J?"K@ 9>ZC<I/0XY>0HOXA2MK
MI^WKWE>*.'#][F)2;H4#&#X70=:=AX2!N)4YFICNC);:#Q=7-V@X?5?!R7X3
M7?Y4SM*=\&G!@SDV!.R?G39R:;Q[S3.E!C3ZU7;+AN8_26%J!8/)DH0/LZAV
MX,D [_:,B$CEK=,N-T^5>^=C/;EV/^F5-_-:2EWY\#[U;6PZF-C!SVC/DX!J
MW2';M9O3 ?S56\?7:F+.N-8_'93.TL^T%.01_-02B?( P DZZ[MEF<LYJX67
M@K VI V/46!QS?QFB<H,KFX%4H5LBU.:6^K \@94ZM:DXNX.2\;\C'=D7[0/
MOU[[C26DG</^Z.MLE8W>\F%[^"?Q':.2-N_(KHZ-8F'!C8]FZK+Y5^Z'A(PY
M>QMX// .:KJW-(]LVR(_1O%6SP@BG>@ !Z2KICM) 8+=KKF3.(\8Z?>#;L97
MMYIH7V^_)7-UC/V!=_*[6N@(1@SC*BN+'+_=,G,:(0+C^M*<[TP:]1>,MN2!
MZU]*G1K5?O"P2.'Z.1'N[A!N] 7X!0(=L&$TFQ"%$!R5K/BED O;\#0,$@QU
MX>?BMF!BBS"']HM/'P/&LT<?W(M>L#3PBH[VA 66*97,Y2\L#$[38@\]YUA>
MTTX&K'6B)8@*5(69;W2 VZJ_>L(8$L^%3N[:R7-1\9A4M?=3>OW1AT\7CVRC
M U@"Q$E!9.QL3YQ/7^':&9T,W4.1UHWR(GLD^YV7 !$U9J@(KO^A6; M<>'=
M!X.I^L +B'(7;YU+6D%[>]!?=I6=[1 .2ZH".9F ZPQ,']R51_RR6<&YPR1;
MK%?97A6X/:G1YQ;9/>I75,)BJTRL=3+>Y$D.=YB)S N@(Q@D%(B0H*J1PRA:
M5G Y<ERI#1D\?QN31-'!R1<[-";P\#OIB]\M/\A%7&?F6SCM;3I7UJYPC'Q[
M%@YB0PBNJJ+/5S5BA/)KYSAZG&JL"P''[..E#]XYBFO&JYRRK!0ZZ(_N7!WX
M\Z>A>LLCC<I8RCR+#=-2NTG5AQ.'V^ ZXGX<F(,V=)ILWT93)*(_ST+._OY]
M^VG1H\Z</G_1V02)JKNOWDA4/GW_D?-XH\..W1FT'%R)W$54:CGDH]9CPVEG
MR5!]=? '?W>>+A]!"PZE0DX#T2^LB]_J9LL[^WP>=G((;$CG;2PBQA'^(N4/
M4HE66TL>#)DN%VQ'P)J1SU#4R:\;O0L"]DW)B7.RK NT[D'W79>JY5%=G;O=
MVPLB)S5#.R5D1=@/(MHR]G#1C=I?URP:P!.%-H8O(:E7T [Q-M\T.,N+5V5=
M?<S4U&HF@NVH'((/BY?X>),,:ZG"#*UE_?[_*'D1KQ#_F . @:SM,OU3$L ?
M>]J)U:!TCZ$#1$']Z+^3Q-(_APS=L4L&1_^7[573Q)$R&&UXDLOH@&=9C("4
M^V* HLB0I[74BW1 N;$^'3!X_<O_37(OTP%I$,@O&V.#[$8H*8<L/#>38,LU
M6.7)"G\XBCYC]V@FIL[7Z+2!X_=8G96%VC1-:8_'JG(Z#[TF$78!?TMF".]"
M)F!WC[+H 'P^[9PQ:4"0#GB30#$X\/.H@B60]RE/^Z_6'D'A%(OKV/% V<6M
M,+0 BL1+MIO#<,.=R"NEU)L#$O6U7D6P&IRI\BOI'N[LE[4\HIMKF=]%3JEG
M;%(A%'NX,-&B#0@DB^L21U+SYN("!S4VP"W3;)-=O&]?KM2U!8G;\V/+QZR9
MO?H 0<I\A()U6<(\OO,-TL4X+B/B#>+*= "EC9^?)[_D<U_.Y*/+67\VNA3D
MWI3T%!6=\_G!Y+\?%K@? YG-MJLL"/'MNA9G/!>>@2NO8PQCY89'6;8Y"[/@
MDZBA,LK#8[ON?']J9W@:E8BFLW:1C4:S4X%8NP&/:S%8J<,6FYZZI_#"S6*@
MV77Q[V6,NV>CBOLHD "\OH1"U 23%F3@R2?@@(SL?!E9IK;-DQ>N>)32GX>7
M1YH01@N\2L?&JVG)OI+5+1WF%C(5YSGK+M8U+SCX*&]K(CF0SF4<M*Y _PVN
M;,3@M/SP@HV*EBWRU&J:A:*NB';+-Z!\6V*W1:F0,O-QK4B6M0V^'>BZ$L5H
M&O$+52F9%M_XA)3A49#?YV5?-'/54C[ST[&XYOZS5TS>U=Y@=7ORY#YR-F>F
M,H (&,#@758P,(7*7HHD;JR2#K 3LTA)""9_ N8NERITH@3A_ 0L/A/7IG :
M1B)-<]1&"Z(LJRT:(COEHD3NAO#Y/>^[ '@(:LKZB$LG5Y(.R$RS03;LP="Y
M>RB/^I%<U5&O5G=O3?2=KV*JJ=?GG-XH?A/O8W_NS+3,+HNMWDJ8 <*5">'&
MT1;H2Y6> (FK_;X]5_;OI[PTE_P1]>C]0>SI+\SA/\\]F?/D@K\@0&)HIVO;
M1<5MX[=^N#AZ?ZDI7S"(KB$MMFW:._!PA5\Z)NR]G761J2$;_8@\0EQCN&H5
M_SJ$F,98VX'*Q++ET4.IO*>2@Q/&;@]\:T[]-'?0Z1\[O21P4(1E#%PJ^O(
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M )HY0,M<6_U(3::8$(9;H 3#4S=^XG^$NXFRNMO.RS[]5+M7FQR7Y__0J*3
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M=8?'Z&?"_J,*X&O,TOK=J?P]$E-;SVJQ P:)S+ZY_3]2?A6Q_#&_L(JTV>F
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MXFX"&,=+3YJ*XPD"968)XM$%D@YT +04K*4=XD<&D_;(.\1PW/1D^O,0KN7
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M0)\0'Z1)P61)*B^*L9"H;%D4_[YV?Q&TY)T4WOG*FQ 76.R'E<9CAAHL%^B
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M;5GMD"P_MT$=,<T-OWT]G07V:K \=/@*4*$-OWCNQ^!^GS?<K.LV:PRGU>&
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M\5ES'GM@\>..;(W3K/34-T&][:6Z@CT=%&)63G_<59XK?]'I@4D,7ZZ(6[)
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MOO5=;I$F!G#KNL^YP0ZS.2E*U<ER5B_5%]G@F4%O">MX"F58V'ZTNIV20KC
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MI6"0FLWJW>7@SWM7/*AU).82?6UM5$]HUC(U_B5WTO.",T6=GQD9KGXZG5<
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M[Y/,Z WO^I"D+"L^AG6(>P._@ADE=9BD(P7WEEL1C*%3G=V8F5[G_32>[JT
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MWA6 6I'#+RF(9E2K"4O2OBZ5/OC?:RY,^>DR;*]@>2F:\:!@AM_AO!I PUI
M^B/](X4.N='3?:Y7YRSRHOWO?-XKB]K1B"?R^OYW9R7KNY4UI40YUVQS[L^V
MS3[3,Z^54P*=:CN,7+*H!EF7VGU;4?Y247FVK^%\VF!S4&?!F-5' 8:+Q9(>
MA!+O;Y_6^8K-6&2RVGTF#('3ERK#^H39=Y;8A02\8QBV3=O2!#Y)?MK6-X2Z
M=;;"NX'U!<'09P1AI,1FV>K8OHFKVL$O&RR8G]@UQ$(<(P.U4KV_$Z?#M&"Y
M*T+/%9JHWOM[PUMACWI&7>7/PTJ]RVU'8R9=SXQ%GBIYPQ5GX)VM:B?3LE6C
MN@=WXSG[W$W/2%;("/1 U!7@4ZUJI1:)[C27\>SCVMBW&8,M?BC[-Y9/U^?[
M+XRDXLQ+K.WM1DW?+PY*IQ7(6[="<C#Q1 HNS.E*[:'CX<R\7]#?/7"]&FF0
M>L&\X%Z+[X.19(;]K!R;?3DC29&CO*8*+P9N7[O+OVL!X3DKE&&U8][\"9Y5
MJFZ[(@'WQ5.PU#' .O=/1-+?[YH3G)+?KYJ_,7MV=/^<Y1!.=>UOFD1VPHLP
MW8FY5\WC>2D+?TP/GX?$Q6ALAMXK23"-7@U\"<E%U%!W*U_F?X$3>%A2MUR]
MZW<M'0_;1U\9;P%[#VX6] A_/)5Z79C8UH4KE?8A3R&DU+;5-5SF?C_\[1^K
M[MW(YLF:_N="*V<V3;,=Q[#T0<?FJ]>F@5VK2V=XE\:M J]#31PM_@NH4S@F
MUL]3]VV(89.H6BL D'(9<73K:VD89^,MXY7DWN$,<IASD(U*F^[DOEX.5Z0=
MPIK(OLUKA &&'9CL.T<\R>5%/J5B+K6Z:.PJ%J)4RK+C<E7,BAJ(Z]A\ZG0V
MP$)*ER"H2_E_4Q84C 51!" )G[RIST_CKP#/)='@RBL (>[D"E"1-DH,LQPJ
M@_7SZEX!X/Z@8UI+R0O@%6  "+X@G[\";'K_T<'3G("+1H6_GDH6O#9*,W>8
M?Y(=_O;_Z%F@TV<-6]J%Z_%#6G^' 5*&1S?WWC4H-"._$O\NT1;@P1AIBZE=
M9EB-3_'+S^B'&.?9U<<^M_;]X:-P_-.^R'*)?HAX9H=4_T&F;X(/JJ1>,+]D
MQ9K!GL>?C$!;CRI55,2O%>VD?'[^6S2H0DWE_5HU8>?8'1>-+P-U #_+GD8)
MEM$<HK65;3^]>-&FQK;2YGX=.)9XV6'H T3$RGK@-YO:A]YR:G"CR]9\+IPA
M-N(7GVC^V-(!Q6Z/BEA?H&)RI9[BR^KK:THA*E-<XF_\;G:>B&8(,?A  I8-
M+V#XIV'=E'[ZKIJH52F/@;&F_@;V<^2UQ6]5UH4?H?/A[#TMOGR7\6D3#VU&
MV6\<@/,LY?'**.#7 -A?R=9[S%FZ_XGT%OJ?WJS_S1F6]=4 S2Y!F?X: \1-
M8=Q[BS@GM98KIP?).4@.RX-N2!YKOK)YH/9#-%U]&"I,G *2V5PF0D5[9Y6[
M(VRZ+9_+OWJ1Q<M)!4V##F30/\;78GQ5I@YREXI*P6WQE7OF^%UN+FU)OMT>
MG\!7GFWDWB23' E;S)WK G(!M);JV%1<$@;6H6F4;-+XIA8@)L#U_C'_Y;("
M_WKB/Z#QH[S0VLO!A%8,%MSV>+1'-.QB>_R&O[#RR%?QT-"1CO',;$Q?_6DO
M]6F8NRDF(P18QQL,E8+NZ#1;R*YB'C7$NHWF!>AT+W&80L0Q#$4KPR\6-><L
MA&C?;Y%WT>-*UU1T?;Y/R417_A5[PETDCU4;7@_J?&[9UPKIN5" +D*9+K,(
MOL!0B5:.[<YU-5-OQ[_ 1.7 I6X=)C."(L:R=L6LWW1[\E6]<UBH$%/PE,%@
M0F."B1<[I>:D_]Q..'Z.2.&%)>E>HB:RX;7172P+T]^\/(HD/#6=+MX@'98O
MC [:=>8N.A% 1<[GRPO274U?OBQT2I0(C%"@ I 9UV!F.O,(;X:BL;;SGOJ1
MQ=&L[(O"#*_D:&L:L2U$+>%Y=+IC:"$O,,(1<STL?Z8KO9PA16SUP@W%>_(4
M%VJO* B-7*U0B^O;@*X #L)W";?QRFBYI0<6.19:D.\]3J4D#1UL4._=)C"!
M'MP>D-^((\5,Y[&]Z6BTMPA9*M"89 PI8GN9PQ0FICB74,>@-K(""IM&",*6
M<\#,!.]EG5D.5[FN-J&IF@C@;G_&;EU5XG_=GG]/X!,Q +\C=7Q4YNQ. /N\
M+T/\$_N7+HF\E?!!,)[O2!6X)_.A+]GU$3W'O*%M AU6B,:""9YU;G@AL),2
MW7HAA^?5_R.TBI@2$J!?:_RQMBHC'V^97T75HT3S=X1: WOP]Z0%,1/1KCPR
M[SCT'9I?192"_K6\@^>8>'P\5#@2T=#E_G A0P/]P5:_-(LTJ,]KP3!WOM&0
M!*'PQ,=D]8AYCJEW?**-81RQ7+H(F)9\4@;NG"W[Y<7&G!_G$P--/(%U7@$B
MH1SXUIR\_>! 6D69CQ5V-ZO\G!+0/C6<"BZ^_1?)7 4N$Y6<"(IPP=WWJPR6
M#46L!U#ZP<2\HDIL'X$.UF?)C='Y5,-,D"NWV*SN/VC35)TU"YZ^QLKEE*4'
M$#/TP=WMUWXYYHU_UJ+M3&97M/J8\F$=>K!5)<S!Q0'ABU_,+BNVJQ-V"T);
MZI1RLO+M<UG=TN\ND3ZG<U,3L.LGK_ _3%Z!?=OO(>6[1]K&1R+*$+G<ZUDV
MDK]1ZJQ^S;GN3!>X1%XH_ZX2&H5KG!^@EKH5&%>,0CA*LL%*_I0?35[.' X0
M:0\L)2I.^+I2],9RCL*(%)S8U+YT"GRCKQ7J@-Y)5B$[UT;9F4]7C#0(?B'N
M%V^()=N] A0L+2UI%3JY%C"*__;<G:,&I4$#_S7E2$M&6Y:TV#_HB^DW7H15
M#G?"=T]RS9_UAPZ;Q^@R<D,3=Y Y=Y91BJ6T4P3<.%04XMF$WW/,TRG>&7*:
MC=/AI5ZC6VCGG:0_7T/]%$:@V"J^$V!YI6^?C7@&[:P^@RUGI]^*7U&H_[*,
M4>A<'/#&>7RPCF&MCHP6![^$O,7_R2<PXO6\T7,[,N4"5G\MI\7#SIK>-?"_
MT$9^*3<64^#+C2W^T?XV8+](FCTSG0H"7P;CGZAV70%8_7B"H(?,$L^9W@FZ
MK=Z8XTALG[G^.\8MI$'E4C^!H=ZB-^N6ZI@9!\^/R[T_PA6RNWX"/=6Y2M[3
M)Q>=Y#/0BGR7?@C''-]NR/@"8I"7P<*>6[AWG<;]-J<7)9LWYL@N)ZC@X[(A
MPIC?32.-7FQ\%*LJ)GRP/-O=U>*G/E.^LA-K8<_33S"\!'K*%>.(%LHBO]M+
MG6V/VL9RFVA^&DUH?3+G$#<S1ERK7,#6^7(E^-XV#T-0ALL161), Z.#?U+0
M*WP/XE2/]RW!!^!DHIK4)N9*;"<5H@+P E0ZI7G/XGF"KI/.K7TL$8&E7>9N
MBOEZPEPK^$+AA1KD+,/KOFBO\[:RG:49<(]: []#)'<R)C(/KG*[4A->K8%
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MM%K<NO$9\F,.6O8_['46B!I4K+%/>DL4.OX3:F@-D?[T+2B*](8D-KQ1ST,
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M T%LC)Q7KJ!Q1UI27?C1/;P4(5)-&,)WG1"%8<PI<.[?Q[;]X+G37J""GK)
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M4MA\Y=*[WL"!0N$$]_O,.@:6/JSWZ!9B!E=TWG'KYV4_.1]I*:IX0V]PLOQ
MM,%50"V2K4W!55!DQ[#@U%CB9(:&F/.E.A'?;5T-@&P%]=O[5PT-<G,W/6.R
MLS0$TX_5#R8=B#Y7X,I!Z/BPJ130!?4O9&A'>FJ?#G=@ZM1Q K8NWUXS=V/Q
MI@!T/FEK6;T_FSQ)C(X=NBC6GZ5M8.5"<U*QW<438:@M!LAJOM7?IS/V\_C_
M!7I_AZ!73S"1"@>3CIU/Z3CQT.@\!S_.V"XFIS^Q!O)>SHM.O*O"JDM5G][E
M7J7K?M5X7YW+(V8=2_>[MXPN^+!)2,>X:+CX<!8M2<MH2$C<,C+P/%5-[?V*
M8S6%(H,5\JF>T=1.-:I[KN#*NB(\:.\\H:M[1]U;R]JX(+?W9*"1+\)0IT'K
M!P0R#G%INV+$X,/&/GC+*5(38:C?(&MDO/2.KA<"@43;&\'9U*+-/./$'DG*
M)T,@T)LG%7-E5T05;9ZX!=Z%#)I>Y-+5_9*2/F@?Z'U;ZWB6AGK,T'--JXKS
MPH\O1C\;R_H2F5_ZX1K[P_"+UK2&#9@4\:*MKVPB=W^>B]>]56UV-JG\O]=_
MH_^GT@F7^X>#^'SF.H-W!ZR[R/T3*\#=32%R*+0-94\![%]9I0 >*&>1F.I2
MC[(MZO]1MD40!9"@AL*S_)IML2@+*["",LX$G]N ZN>7*'WM^VJH\>OV!L#_
MI?]+_PS2/%+2(VT]8'YO\'>5<=3G;^MQ=2$%<-RV>%=Q'L>W4+[B,E <PQWV
MWR)/@XCP,>?<"4UGZF?V$_9?B_0&[Q[OT]8 2+ F_;,N6&XP:BCX<!=&^[!.
M#%;E7G+^-^CY_PGTOUE[J9H+$69ET6S@9'5E32^8T%D3EQ3.\:%+WCTFHZN7
M1U-WE_&I9L@RI :J:M; M9>CMN.:XZK\\?1A7U:@?-^7J&\T:CM.DS'EKMEK
M_^_5%J"GCOJH*[=SS7_!5>T3F4W-D*5QS3')AC^^TK+=<<UK$ZXY1FUF=/_B
MLKD'BZNDJG-/"6VA]?&45[R#Y0W_:L7[GT#_BP=/0DK"$]KEVX/%MP<SW[U(
M=]EJIQ].>^BPHM(0(L(?;P6[3:L)<V,U[Z$ @*!'4\>"F3^E\*H;;E>$T7=5
M?FDNW?02R\]04'#.N9"L:/"N\C@])[[4NQ5XCJ@P/;('M6S]\A:T7&P^I]5F
M0! !MC#S_=1C2GF98REOIBC!4^RZ!JO8AE7BI-HF!5-[AH+UX,$E/SH6Q<5^
MYB0.%B2]F>_B<GI_F!-P:!G,/P"#]O!"?/MVSEQY);-O"B8\Z@G-VC'<<3\D
MP)M0M%+YB7<3.:[)=J&A7C*KIN16=PI )76K=&J-2RV7])BT10&$?R>(4  :
M0$T* !5!%/[3 @11#*NP9D8!;'? 1=U'2BB Q02R"?Q^?4G4:OLF@BCOU&AP
M('R@0"*!9K3^Y [\%&Y720%D0O<-\6+P_3E4,G $-&EWL'^X3 &<>8,U)D>J
MQ5  < ."X9_=FT^#_U!1UN]?84QN)&\#T7%3?\3? ;PI[D_N4,=_QQYZ*^</
M+0;_)ZM,(YN$1$Z1 Y#S!H?TA]_AMJ 0T$R9&@.\3ZL/M4E]"\.?W1(9#]E0
MQ&UP9]PG*PJ@1X!8"+]/ 01$K2[^0\+1_9UP%E#)H#7@IC3)G[3SY_+_*QTB
M]2M[W7!1M=]W9Q[I&6E!"IE5GX4=S:(%+>4L3>U17Q0&_--;&"WIB#FI>:T_
M,$L!?(37MN_.[@V0N66F$236$&XR.0N;\R=WR ;4K\S)$0N.F-T"=Z;BF?=>
MU]?##N#-CL&L%$!V7 Y\:H#,^J>W; 2.WS,G]!?UH?^!^@3^M+Z0_U_"06\A
MCH0#_ =[<NO/>S*"JG0&_Y#2Y?Y>$[)^%4XM[( "^ >D<S0N?J\*1G]0\K]?
M7_WOZ\O[@^8=:<Y_2C@=?R8<$!+XUS3G! 6PE.O\)ZJ#G->/;9O(I>E4WV5%
M4;NRF:KGM< O'(TU Y^GV@_TFN&^BDSPY,?U?(35Z3B6VT;-+>R)!ZYN%<0=
MJS;9_2[->G U WJ ^ !S1G1:^T&I[=@3^/S;YX:DT/Z?[GQQ2QA%3(H<7,X&
MF'1QEW7/_BWMMUUD$SR, OC2T](3[M>G1T+(5YUV>H',%Y?>0:(H "<P040A
M@BRDRY>!R8W3&LQBR)8.F]B5F\5<JRZO_3%V_5N/]_I7S<F10M'PN$)+EV%M
M'_O'J;Y;9SIQ'Q\<F.)LE>/$/DW!7'_AA0P:WOZ7SSK_S>E_;U!#1 3"B=-^
MRB)S.K,]3TNVC3.J[(2&4?>E)<"[]BL=0M<U.6VA& ."L-!ZL-HY@C-!73U+
M:9T(A\GO)SU60>M?B"[NT.0?3(N6])KZLK>^[SZ37(4U>.)TZ%;0_/ @IH9.
MX\3]N ;T@F#=!Q<^B<'<ZD&WAU6#7"]3G.PT8<FVF"VK])?N*68IT%0)_L\A
M:XF)=S=4#K="5G?$V1E8[R=J=9J4B&A_:?7EOD7S2E0^6CL:CS"T;;*NOI*R
ML7>FW4W94(/-NN=K:*1P]MKQW^0CL42"U>9)S0O.'E8W?KN$2,4L3X9[*68;
M=<(0G@DMK]*^;J[.S[Q?<[/+DJY(]+GH*P/OD]NS*L,_8>W-HC1PJLTKMGQ?
M7]%P@:ZQ-"BJ)1^LSX X(&0E[&YF1;9-N]\#C_?/VKR8>>)*X-?7X\3)ZS8U
M+(/FHU,?I=;A!<$B./;TZ748;K%W]]0O5[FLU*Q8.O#(A.];<^.%>BY!G"KJ
M*/$WAXS<7V!NQ*?+!C^]364/YP8OZ;[N5#D?TUO]=@-L60'FQ&!V5=O%UA0+
MM734QY(,@U(D6 UOA/X;C+K_CO2_V%(@^S-N_XR\PR2&0<24D/G\Z:W0I6]I
M!];3/-XT)M*\VT,V J.G6*34)()O#]9J^W\G/_H^_*)=S8BE%[W<0V33Q9AD
MLA >Y$!\S>D4*QA3PGV,B2?\D!VTT5JOF )6P9X)#_KS5V3].3M+I9*9G21'
M52'"V?4?<;^IIF:<[G%9\->V"N.*:9RW&D[7N).=^Z&=';,1-P8B""':[7'P
M:5)%!C$+=[4W69QL__T9;\CJ*NVC4@V8# 70*%?/;S #C_6U9$U\7;Z*W>C*
M5#@&_DR^?Z\7>:F*;;\4&G%0YYCR_2"89^+>3P\5ISSM.YR."'0,FWT?@W!V
MP<W_PG3%ORU=6KZQ?(-.@Z&QFF?@=H&I/B<P,3,[\_E$B@*# D/$1@'-@MI.
M,1<7/YFU-*H?S?]3Q,]$'!?>J-(O&GSX_'G<1O]7R,]TCQR/_.UUK?D;SLI'
MEV03F G=LTKJ"]SG_W6%-DUO]HTM_%?C IUE^<7IN?(F[I9=_ORL \&F_)E;
M;9#QEHZE?E)ZX45>#0&)O[D&>.YHS7'LM=JNVK,EX[^]LHBW^7MKDJ5%\(;4
M(I)^0+!658E26OG*K.:,!JOQOSI?R=^E7+?PE/@"FBU&,D,,YI0<,#(JNUO>
M[/N'8J; AS[(E]"5'H+(VSP*P*7;E1EK:44N!HN@5[@>FWCTAO1M^5?9%E.'
MB'F^YV^=Z)W7O G%H3L-?F')5,&3?PGZ.%R3]]5;A24]^"U;WC3M6N7<VJIK
M*N<^$4W,MR/ O>9K Q@D00_E-!6A-!>W8.#SSF*_!WWM@\YG^.S*T!;/38.)
MYV2MRI0?/PQ5Q0AU9]32HS^Z#1X0FB<8_DG'FOT[T"D]A(E+=SD%<*Y;;/4^
MT#"XB.O@V&#:=YQ0I.S4R:7*ZM)"KR_#[-H+!C)O7<&KX%1@A1^1-=481SLT
M&3?-."H[<MG[;%6EFX/U;NEW>:9\0;/(J\5F5[66*F/@SE(  A-7;"'&54GL
M13LQ:'^%7VT$F:ER\^BO\ 3HS&'5I2#&P^[<IP)5M+>1W[+.0<=2HTN9WI?:
M=(0$+@IJ<RZ4=<9$5O';U=?'JG/;YB->&G.)+<$^HHALFS.1BF""YF[[WMUR
M($%LLYF- GCC9$M,00F9^GKEL&*T5VU (_?<OO>L#H#,*8"9S:G3\"4+-$H@
MA\Q'PK:3PS*"MBR)60NQSN2F9E_[@YV>869"T%XS\(#=9[/#F0*(0 5+4P#O
M?_?._9PTT,>/$Z]# IU6Z8FJAS-Q)$:EO;ER>/-4/2<5"I0A8;K@1&)?-_"H
M3K4ZF=UG?U0-Z#]J1W:0G1?BUL05'(&V;PX:*0!F&($*.6[]J-N7 &+W-L-!
M.^*K4PGH.0I UEL+S\Y=QHR\0[K_)\V)^X]V0K?@:8HYAXQG1B/0^;"/?]P<
MK?]H9L4^J)NGCQ06OM9,E<8]T/^',![L+F=]^*/&]/U)*V$&VUJR\ </:J[^
MSY.9#F@:F75Z[G[Q3(G'^<!7%?NJW5R74_'LP#6$!Y7;D0QZ,D,(%MW"\:J5
M-WG]\Z=FE19 Q0['4[(J@;X]BB?-X*6XX]=$L@T1:\TRSD;<;\L67]OW1J?U
M8Z=>RKG334EL1(1(9OB6?-5FX5FH$GTH*=U;8,^["\K5<%,M0'8QCQJ0&8R+
MEJN3X\+)5ZSE!FE#>8U\N^R7U\&(:KXJ)XR>9(_I@)O9JGYUM"YK@;^H%EV]
M,4M8Y@7KSZK5<LF_0$J4LBOO]\U;^?<8&_$EMSUFU)"##/[5,PQC[@ #,P<;
M]PIW@+?^ZL$'(?^F!Q_\G](5HWZ^P5-KL*.D:J"Y-2KK!SM?CO@.1H)-?E<F
M]\=E1?=!$Y"#*W/2P-;4 JJC.NG]6T]CM# ,%92JN@'ODF+(/&H!]Y!7B.</
M9D!X2Z(2\B<S09 "(+Z):T8=OJ  EMM6ZJ%J%(!O' &E&?@&C@,C5N+R&,AK
M4H'^^9D+&>#C(9SEAAHTO^FVIO]"NM#.X!(SU)[H)%NF],&3YLJUS$A%1:+H
MX6-D.LHM+MJ8R$;@+EBQ=.\.\*< [*7#&\>F0Z$YS-K#1>]Y1S.T"S2^!(L=
MI?X@E58POR"+IS>J\=9*$P([.KM]W$8L&E<4F"IPXBZOL(4H'KHK_ -I*Q:E
M3MH\'2=*?[#B.SIR'<>W"AMX&$A2M.$Q)PORBM3TZR#Z5M'W^^479R#!K>Y5
M8_$C'8,XK4[I"M\#]+M%(_WQ*\QWN[FRJ9/5]DD93>?L6'-B U>.K*%V:WO
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MF3*,X5XA=XEP+K(O%<>U%7(K4KC ZN.163/[];TW%B)I15S:+]^V2'X+8.(
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M]V2</RU_P>JJ/DVQ^Z[3<;FH[%*C@]NU!H^V.ET,8MWS\!+Q$>XFCCFFGHM
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M@# DP$PU&&=B+D0"P,G[]M84=^.=C?.[(:AEJ*"T_]\3[8<V3F# !!*@C02
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MFOE*\6A>VW.]-+OTLDCN,\Z:(6=I6;=._;3%!0;+?.UF%0,_E.M_&M[7?7!
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MT=&3[R3 [F5P :@)'#N#5IDY$.8F;TY?K*&'YQ##0!2B4P*TGP0W?$UDYR*
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MK)<'"D N1O)1MR3M9M<G)WP"K%Q73$]#\@*>'<41*0)N'^5(A4&!!+U!21*
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M?2>NS.BQ (V4GE8#!EY?[)IY,1FUUU;(AJ[G]=W=X.PWZ\QS?\50:$_@.$J
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MOFQ#NJ9=FI(9N9^>W[J^ =$F.<\;!'[(2U9;8/"QSH\[UU5ICC9]<1<^L][
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M/)ITA^ZLOPT%_E?Y:LL!V]>XZ;NSUG ;] ,X<BL:#.2C@&(FQDA-V=G8 L
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MF<2#_LB>V82&@,3N[)RK>=(N $KXC\\ _T>21D:Z PCW<[SDS]YZ2P8L=Q$
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M3X)IJ<E>M:)^CQ 5AM.1GT\QY_&4HG//M(D<?G 3IE"\\LRS.2LK)E450T+
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MQ)H*?'>BJ%-S0C)K0U[#9@:B,N_WKF0,EJM8]<KB,Z9J ,#6R1WUB8*IR1V
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M?!\^X(5%H'T0]X."!39N_/$U3:(8?#_L>\>'4CL^Y'<ED/:C;J" >ON!)H.
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MOP$)(?,X\ J\.BWRZ?#4RD0%9 ]1P'?K.C0RGNN)M56^S;OA^9@GX^<?E@E
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M&>2Y9AV&&T;AI7-=6T^(2JZ2PT&-TT7?LJR+3C]GLPI@5 _PJ8</Q$X*-%!
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MSZ6AN2T"+"\MVUR?;*L^'!5,TA*:>L9L?QH(O#+->45.$<8<=G4W*ST++&[
M,Y(6\O+(7);TJ5IA^_SJ,U1]KW"!RJF#-I\PW#CT.;'W4@DY/*I$DS)P2(SM
MI[6M3&C%#*1R#.7=N[C )X_\MHD70#;!\-IUEQPY":WMI,@+:)+4>TCA5>0D
MJ/EZE[]7BI$!PJ,7J!,8GAX8)%*M_90/GP=V/'3YM-I9V<<KMBY^EM!12)Y,
MN7.81.7/]R'_/W>F/92UKC& :M)\"6\Q\D#M'Z5N,NO43<9Q[S?[ \SA6#GH
M(YRZSWZ;GP42Z"Q@2X]+DC<Y^[#JQ BKBU0%&-=&?NLD4X=%CMA@U'_@OZ*:
M'U(?G)KUW^&%K@MG*K-,T!QW'@1QW2.=DD-'.Y>H144UVRV*#JHCG-CMC5A'
M5U$E\+6I628T<XMFUG)>[W)4>6?7;9L]P0I6W"U8 U L?K0&%;S=]8SMF2K]
MUM3$:E^=&!Y$T/)&X6!]N]J2#)J.Y6QM>SU7OK^9 P1 'E( #5=<5"YX5\\^
MKIT-?TX^V%1-&@WV3>1(,Q84Y)@V:5\PR#\Q3S?*UY>A\Z07"VMC>G6P5^_"
M865O-L#X8)M^S%+N/HM7RXLUI]J7#%L1"(@EM45ME4L.5O+X%M;R<)%QG?1J
ML+QA'/]PIPIS7_I0C7DZ>B6:QAGF&=]=OLA(PVU2] ;9"=;R_5CF0$"S][$/
MPGW7(O%6'WL["CDUFEV=IQ<W?8=7/D(P=X!O0C,=%+):L[WL'MA,>0D,?M/_
MMJ9SN80".%:$URZT=Y!\(^.T&@J7/A^WJ?0-YT7#VD JTV4N*GVV&;\X;S5T
MS^(5H:=*<\$\Z,Q^<]%TN<JZ/V(9A-&>>O6U1D[AV;"+I,>8  6@^78(S\S
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MC%;6X?5XOB=[;CBE.FU/AC@)-ZBO^5_R;J_M^7$X$;GVHGO^3(V@]3EJVW=
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M0-3.EK1_4 "8$R!,QF]$.IP 6IS/!DP1]*=N6?QRE8%D4@7>9(=*V.C59R@
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M1SP3%C[O4@HER*8F9B&M5[K9#LTSF6^I[V/NF5]LFZE-YO "ZNK5 .U?X+U
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MO.D^HNY!7K3D!X5^6WZ)$96GKGR[@ .3Y4BB K!1ORT0_]ZUYN-Y= I(89^
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M]_VP7<+6^0KNZ[0#.0.!D]EZ!$9R?]+BNO[TA,%8JYD65[4[Z><JX'S_4==
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M)5&J/L:19=UB3V-FH^7KI.A)G/CU%@DUJA+%1+3>,:MXZ?(&XMFAOP3Q&R:
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M;"!IJMX=&PD]A8_JX@^9T66V,]QYA'PM8T(HF^%EIKGK3];9.ZLV!$3+MI]
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M#T]0?@XEF/0#:K8=8T*5S+*PN,BW]"M_Q]DCF.5O25QTYZN5T]>;\.*MR$[
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MWU:6,@5_@@6J3(7'%UZG^*AV[-JBFD?IO[,%3:]$K0@W <C./M01;T>HZ%T
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M/?Q5#E^*/B3FP^OEJ!=\,3WC5R1VR[04'CE.:$%4&871E&2/0,YWPW[H?_.
MO=21P^)9Z2_?(5K5\JH^,B@,^T4>"FWL2L 6Y'1GZP*5&^_N<8Q#5_05!);E
MK\GC[1<37H#;4,I%L+!;56%5@^U]GX;!V+.?,J9Z5A)4MD/_LBX4$_\;CXN+
MU$:M5(;+7HP([4)WRX<;W#[$O^S#8"F<#=@>?=SEQK$7 (P5!QX,"CVU#=.R
M">FQC9%93IYI7)U?[182.>1!:BP+3YC+SKZ?3@,_,B6GL,L6V*?&\O<!W%#]
M;^[Q+\ 70V2T&S?U ID^[/>0RX4O&LJ[80P)Q8HB>(6Q,\!=K$;':(F?]C$5
M[I\0BV8+=#@"9H/=PGG@+;&&&T(BZIH M8B9\U E;RI.6W^8W?4,.RU30.=!
MRO8=0PB7=+7>QOY*;B+Y!U2X!.R>B=\ A7-_0<_[OORC(XGPO]/='GIQ"-VW
M@6:7HT@ ]!#"XR<"G.7R^B#HR&-//$Z'9I[#HOYK=K"XW[MR&]ODOW9\RV0W
MS<7%@\NV&>KC?ZAW16(Y&J^D?BUTH93+@S%9+V8"YS9M-W]XP<@(Z6 10"]@
MH7G5N$4YNT,C,FE=J4]'++K$4I]9+T7_J"(LQ^J\I;W!)*("&<2K/=4A7.CI
MQ)94 .;ZF/N#' 5=U-V0ZN(,RV:H:49))C3G:\4*5]U(*':.]8(5N!S.3,Q(
M6R$?O8Q6"/E3&;Q._QEPR[$:7/+=5"Y$H:PCKY]EP*"Y*6 .+XVB[A)YB)5;
M9^^-!LO8IL&?-*87IRX8#2+[^UF#/$&E5R35L,,;&\ H#LJ9\YPH676L+T[Q
M^<'$:TO0#$(!8&L$7EV()KRSS$78T=+T^%X:KER1H-Z[,9G[^:YY;\6UPH&8
M6#F;N>>F3$<"NZ< &YU":66Y]+)L*;0 D?QMQ8I?QA6).M:MD%UY>WQ!7O,.
M^NGDE%6%NRP(3Q^S\3#Q>69W]L-(]8;19Q+I<5\QPT[_?=\GLNUF#"[[)5TN
M"U<^LHUC[OFDHG[IB_F+]?SIE[RF$BW1$L.WJ#=1\:[^U/(FU4MBW; TLF1]
M0^O]F,(^.Z"=$VKBUGM%$MYP.9Q<.LRFR3:V>9-JQ0\V1!$.Q#I7**I&'H6C
M_@6SG.=@GPI7^;JLQQF^\[$_V)[<3L\;4:I?J=N<^(RHUX^Y/?<0"]F9S3C[
M-&<_T:T7ZU/7YZ'8^I_K ?OJC;,#=^Z[56>%UX<6/:NH+WO:C7_L0T8W-*]/
M0/O9<FZ=$78L!3A8<<43U5<D:UF74RL<6(5UB@OF) H#ORN2!9E*-[OAT)SS
M*?!"=C%.';(88-C>$I9G#Z0<:<X-24*F<=<K.&VK =9^@CAO%B)1.F^+(@;-
M),)N">QGH*]+-!9"';M:5['@E!A48=/J\$TNN*S3C@%W3R34*TBE@^8OG?'K
M!<^7W"<^L5Z5ZE._/EC=EEZNWG@Z^OV*Q.:*9!&FA>U>5\5+5/8XUPU^L5,1
MJ'[P<M?"%_<:L@RBA5#BO3([RNR**,DE5$ZW8[;Y@_8W#U]S8E\B')=]1C45
MS;,B*C;YKQ6I@907+ ^Q5H2X/U^[3-:3*56Q^>#/ -D[+IEAJC@R;9XIF2PH
MO)45?0/\"M7P#FT^V?/YJ&_IR()16IJHCQ*)#%XKY)"?)CXWQ@95>-6-;4XK
M]IR(@UKOM3"/3M3A*=&'CPA?SK\Q9E;6VJ_71;"=ABW GR6WFZ2&K<E11WWW
M-LUZE2K1:\!V7H&:NQNX,DV:B'-#BZU+%(<2V?84!8Q)7SEQG#OCB[FC__%B
MWA)JB#Q@,+:]]"]+44YQ=^YBOAK];Z5(+HX7D)1!R!B -6\:\!%ZWP'D2+/'
M4A>=/@MXD1!@:/S?$E.LQXSBK<SN-%+"4UNGH"X//</[OZ/CGNG]:B/S]3QZ
MF>?[_$G5GL F8C'L?Q#WIN%0OO'[\%1?A"1D7Z9"*B'9LDX;0LB2G2FRCB79
M)L9,6;.'$&)"0I;).A'&/B1DR3"6,6-+MADQ)K-X]'O__)[C>([G?SPOKC?W
MB_NX[\]RGN?GNJ[/=5&K*(B-W]D$<G*GF_:]LW5S%Q>'(OT':XUNX2I0PT?8
MYSE4,?TBE_FM@!#[[-&:0;6[$%K>:CU@VGQ1L8)224S-)TGZW!BW^&(Z)MM"
MY" >U>7>++S>#2:2=<W;18C<VX14*_V9-VM$+=^_)O/'F< 0Z'])UC:9:OZ.
M4&9 EK9I5_Y[C/#:Y/RI?'[<:I4Z8KS[.#JIKX7'RURE<:1Q6P\$H6+J=%=[
MQ@51U.6V3"??&7IUYXLU&FX0P7,4J66%TNWDI7TIN?'-BQ/.M7X\,4[O4J_+
MX]1DK(X,0?IYI[?-T3A@[H"Q>&13%N<X>?P6!=?K)3VY:;G>W^3MAD809_K5
M[&"ZP/GAXC&%Z,PQ;&#E458;MJMY.TR8(XCYSDJWTFEYOW^4:!V!C[D5. 0^
M= AHD,JBWX+*T\TZH^9F/B>2-#H&W3(X2@-!:(ZN(8%>,&#O:SPZX>*/:@?(
M0RYV\5)8RM'7-%+8>M$]1L&WI&7X.V6&A%T[0LHK#&*=I"O8/*)SY[&_+3__
M$56.XK ::W=E-H*\ _AAQW\L?"'W-@B M:)9;_)+^B!KTQ+/"YV28D'!![A_
MS<5W+M!"NY_DVP[2VUMQ^2]*N;*L1?9J1]8P9$L4OP_XU"[1K:2F<G&ZU+UP
M?IB'4GP(X,1KV:H1,;3+83V1'+TV:XMSIPGFXW?^!@1(UAHER(EVHFX>@8([
M3)&\"#5EV%[,!5)WIVU"E\HYHIT(#$%>XE:.7X77_(6&>YM[;"_1?=%2WG+;
MMG7EC^>EIR[MRN7B5^?UN&DO/](6N[)=SM=GJ->^8[_^Y/&-@8%-\#GX#R39
M0AQU"MJWWG4(..TK;/O3=[97(U?X;4UWBUMYC3D50DM'%+%ZM#;K.3*V[OD+
M:=9_X[^AMB/<@4C.1K QH(77?K;JP*PB.5W=Y#+,GF_;FLO#QOR<@_\(:^[V
MY1R)!6E:&Y%Y6V 1<1+AX5W5K:*0*0>T H?#A&ES)0PO\DV<:L6)MZ2Y*ZM;
M32K@?' #QR:]E!%.OO*KC@&*$&AE4>J,D]W&VH L3JM*)VS HJGFQ?1=W #?
M]=?27>].0ZX:G,A.TTZ3=V8OJWZE<(0E\XIC, 2)1QM<6Y=F5%MHY\=X^WGK
MX6>]QE&8,K.E79%QEU9?O(8@)U9C8AH- A0IU2)GWH<H@"5I<MTVR#,@;TB!
MAM5CW02<\WV_'VDJI? I+_C)49C&!_NUR7#8@QD[;!W@+*Q$8L+MUX_NKKS$
MG_$J>F>891A?GC#B=M^01K<#(K855''GJI?#]H,Z>PGE&QUN8"^:2M]O E?P
M(8#?IQ)2II2^\EWZF+1Y62G<@86OVH&/9Y\'<E6];3H$O Q!51R)A@!19R]$
M[596V4R]M(N#7U9.RI>:5A<N]=)^].G09Q@AS,*'O(/U\;5# $]#[$\'SE.F
M9S\_3^V1\'^@;2O\^,CL4C1,\>]S4$P79<V&'TBJ5V[7K7? D$T(<2W^]2%A
MI.K;TXHA)Y/N9H#D)"O7$#/=1&I*#>PX1;$Y" *<V?WJ=M56_.;E?L&!&T3O
M2:I.R5>?U4"Z-OQ''B^6P-94_[$VSB1TIRP1QM$O\5I7?O6(DN*IK'PB,D&Q
M56FA$AH0D@0_E7F1EJ#[$L5V%+\!Z_LVX<A7?DL>RBEB*PN*4-^+02[Z9-XC
MPHMMHUO\LA7+^-OBW/=A0/9KH0B[SD.F6996YIOLI =?ZW0/ 7>/WA 'NX<>
MW?N/ED,T;!A#*3R)T_XJ?SWZZA>@1BG4=L--VAG^0TOZSC?).T-2GDXJ'AA[
MO4LP!3(VX0C*P\W*/G0JYGNZ2]^1^G'\[&UKE@AJ #/5EH[Q:E,@^MYNR;R0
M]JCGF.-C'XNL*XGO_(KXVT8/+.A/8!$X/0!#.]^)S! :(P0\8/NVK+E7XT8]
MSZS0N4._NX8FD#,<'0TC??,9@ZH]AG(2$;AVZ#X1&0>76ZM;*Y0;=_M9]?;/
MJ=Q>6UH0.:P+>'+#9;S+049+YY2F7=#(*EAK5E/!S]1FU:6J^[L<[O@G'P<]
M9"7V;'AL5MM.S\P/)P.@]Y[H+Y^E3T,BEP=V/\Y>-ZC:"HT1]5 ;JLR.;4N-
MZ!/.\T@CZIKY/71-,DGD<*[BR-DWNX'J!O'8#:$83]&I T$!@=77.]';SQAP
M06K\)H7^6/_34?'#JZ, PE]P6P8/<AX";,_I*-@=&1C!&K#L'X72>R>719K\
M%-PE*J-?[^V]E=DY$"@(: AR+JRDN\*D<# CNDIO0-G?>I>UIM_UCLD93*W3
M>W_ &]+T^UZ($_!1XK:0_<BCF"S[/-WJUL(E*JKE$."#2J."CS,X=7LFUR/+
MG?KN"GU81+A"_@01#3=F2,B9$PX3(;C<W:'S!4OVQY?\AT,I!ES*%?$55[8&
MTCR+?L!Q2$%99E7[%6\7<7+JV_I!-\7^F@M)>EXR$AE:N#7AC3]D%B(.P;5;
M+49/0BDXZ)N]?ZT"SFK9CX$%TOD89I\GCO=?L%?QUCY&7][2AY?#AQ%B5UDZ
M,.U&BFZ#JQ#P2^ZMD6V >"52Q4SUL1AD[HIP>]E'_YU T67S.P0**@\$X9WA
M[Z;"7GL+G?>'W9+1>V:P^,QO7W#WJ]'9]'Y!3,P2CH3;E*QR@1DP*ZZ26@TR
MQ:*F&%B6_7;O<QH77Z7<II;XP%K1EI30D9E386Y_%/92@KHXY6(_R#0.E6;"
M*G^;PMI(YL(ST)G%X?2*VZ*NF,D+S;(M%==/)#(+R>@NU.E?R-,+Y)BF,R,?
M5(_)Q+YYW"FJ1ENE +NH4B+,CW[!<UIS?AM63N8*QX@W,U^ZK+"-YC2DW)@Q
MI;_;-IT^F*.L+O;ED'D[GOJ@*2:J];>%YMQ$!P%:N&X\FG%6>S&U- 33-7\R
MHDV3Y?XEH_,MV[X:-6!3EJ04URY,5D@A]#A&1$S9@';EC1*DW&)%3^RB,E>.
M_B0?BB R\W[-2]+\GXR%"EIQ,[ZLC4C@4N*+?UMD/OCR-R<(L8!@G 5;4813
M5;=/T:B=?@$ULGRD,84B(]:>"=V:A4<*ZK$QC,95A[1&[N7<GN HX!X4 G\;
M0=7(DQ TLVJX- R>U./@GD-UFS/[X)CVUR,(' "?(YS$]1+JFZ(7N>W@H]5K
M3;6.6Q;#XQ.XHE==HV5:WM4_FK\"'1G"M!3AWH#X ]L$OI^%Z\N/A>=.<:A1
M5C=UZ3#H.!'9ZZ4COT"/U*/8!+)U%.HN.X;*"[ X]RD##<!8^.4?<E_PP?+J
M+0E'@E=TTT6 ;-BM GO&K-JJV;*>[0P)WK]^[SE7QTI&QY5G[S[!Y .^ERGP
M[9OWH6:N@UXB3^]&;(9.(WN$/U6-=N5:-#^[@<HS9)Q56?R>>0CPO;4P5:.C
M<)YP-GVJ-@A8 _EQ))N*P0 =BT5N'A6K'ZIK:O>J?UKJI['L/]6HN)B3E:C;
M("X82/@%["$Q8%,\XH'"]++X7<B/U#=675:5)H7O_!4](X#O@?6@OE<L/9A2
M ^4I&F(OF[Z0(>=<:A]8"!+;$S@?^\1;;P7:^]Q\8YTT H"6=%Q6ZJ;P-&6/
M-8PY=K^[&I_-A/RT^_ Z8U59*JX]_,/S)Z/-JCZ"4)GH$=4#G\C1U(**GW$+
M9RTMQV_^?[W=^?^_K7WV9_LED%^MK*]?6O+MU_76!EL@"T!DZY%3O_.R"DKG
M&OA%3ERR;V*\7YPL9W4CFX Q,.X%.I@=XBVCU74,B"\!&&!_ID0> A:1Q[R0
M CH@O;1JO&'DDX78TWKK;M4P/LH@B[-$-X;_=^$)C-NS]V@JS"3J$) 2J2C,
M=[M:Z;'CG4)CVQ:];?)*$1$D=L6GY;:WP[LOL^.WRW<N'R3^ >.CJ>_&09X%
M\F9TT\:>_99B]'2V[(CT)$8%X8E,GE=F%K0K>+. V?;5U5M*-I,K0_FZCJ<@
MNQ!J$2V-'']K;-?/%FMC@^\K?@4V;7CSVJ[PGB#6D>/20XN/S9FJR5F->N;M
M1TD<RPC/\"[]3#8('G;0SAZ?2FE+4-M UFUO,D&]O((.4*L^FU$\1,.T3AUM
M^DI\OG6P!TBV#N#UUO)E23310I(XB[Q<K650TB<:89UDB)U?!!5)'B[U\_ 5
M(FV@IV\QY7$'*;_4KCC575]Q'BD&+;S_=_?!A=_H()I4I*P"3'25TZS\\16)
MBG.*K +YWD. )Q(O3BKKS)K([- 3=X:8-W.)R%:\0>F:R6]NTR[[*L_"OWTV
M^':<V20D+=D7@1,\TO&5GG[2/;^M+_%=G$U>S$L,*>\^(;-0H[WN-L^Z#/^)
M1W0B8L*EOI*\FJ"9#VI3%]8H-9+..<B<&A7P.:,CI21 6Z\R"-'E[:2X_!I3
MWLF3%_( A-VH.4&E4WH)"7K:CH/E=V=4EZ]=M2=. (TW_^=Z,</=M#@I_B;R
M9EJW4.$-6]]ZZ4 Y7&)PW?;LE42D"MP#AM^*6-V8H<-0O7[.#$V2B?MXZ[U:
ME7+EC>1KP&#Z2KLM\ZN>&G21Q)&@H*--2N%K8 J8?5&Q<W[.)N2I$[F(2Z1$
MH%X1R&]@/O&]6A=S+[X*:+2;7M#WUP!)ET:BC[[:,7V)9DZ>>QBD@>\.P,K3
M&U?>K%EU3R9;JR%>.#>,%" \$7@(:;]+4K8A@ WJ2(>8?&U-'M&8%@-?RHSN
M7^N-Y*,;LF:!0G >6MW8/(_&_;1[>2<+\DC >7]WMA>H.T>AX;%A'M/2\JG"
M+;AT1M+Q+(%V6:/3G7((Z)HQ]>B;XJY6]/CR)=?PXC5MG$RI 33+["DZ-["M
M)I*;K$$*!@OIB?Z:/S<;MP4)B<B2%/R*&T T*FW.+)K'840S.]LYH\V^1OO
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M)VOYY:%'I.W/GM)>R MC\*\2:PH6E<[0\NTGJB>]@YNMB^!A_*:1)70PE-N
M$M\E>7\>KR_3%*A:*P$P^'FCQCB]VU" RU@LA#<<IPKR!.*M;C'?ZZCG.$0\
M#X_ZZ/GR,Q>R%/X0]O#M$-VR.^ &WO"5=?0AP _R$[.0JS6.9UA/5!=[6&AG
MO7Y"O,;SW+-/,(#F ^6^N*!S\TLF"X^# WG$;N3V::N]#_**/(H<-A$_#+L?
ME4D4Q2[)?S_BO3?>Z&ZMFNUV3U?$E5TD[=)7SX6YC^*KRADE]-G_67/]/N;
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M'A1#D&,A+ETB5/W'[VN.7=&/4J?^ P1C=2'CYAO"9$/OE%9A[J*U7/%EIE?
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M)8,FVTUIF*?K="O'#OO;P#-R\SJ'@&K4# _(/+%O_I)?L:.7M A?^8G$G<@
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MAN?4/>R/?A'5Q=CU/UM(FOW<1YY.Y.OE)T]81P[&FUK5TCL3!5;6R3<$NL\
MC*T/^*^ N>BR MZFVLVNU]O==*C< EE!02O'G?$WG?N*_V4_&)<3.U:\]D3R
M-37YY"$)5'X&0.N\8L*\F$PEG'0'IC&).T^D_VR\+L)?S:5. FW4*A@R5\U;
M:LJ('M!^8XMJ:7CM&,/7\#N>\9T^X[^8JYU'][USCFF]J>+$T64INB%QKC/
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M,O/75,I6*MTS/N ,@]L]8*<'2UD%M*\OGQYL6:5&A4I!I=IE^'%G@&NS8/5
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MI@I2DY>T?!DL:KKB\F9?]3N,7'C<)U=0HOVPYO=C[#OSB^5C67VJXW7)PRQ
MG-D5S!D@CI^E6;=D_DDAM%J_M2%^U2?J)>YN]2$<K8/Q"PMUD7/G 9O6953<
M2;12V,O%;.IIU5>5!SK7K@L(\H_EU35J<9G$5+Y55&DTT6<AQNL13)/Y\@L6
M-(/LA>?3!;Y.&G79W!]3E7@WS;58Z%[8%L#Z<N;F[[5-#6>&VRZE*A[SUZ=O
M:-Q;)%56JYJEP'%:^(0B'0?"5.*8B@M =^+4!_YD5%6W"!HU,C*Z:SOAVD.+
M<8GZEZS4X_MF32.NLP+GLAXVHOU)S''=*S=T]Q$DD:") M(0:5YQN36=H]I=
MPLEUJU86.4TK(@Z_^RQB.,3HG)HRS6@>Z JFF=/__+VBX9:7G-:0L##DS_OK
M^VI]W"6:))EP V)ZM/ZTN*\$:L0 T0SLDE@WZ_D+68V?>[:B&2;9RF$-KE63
MJHXT3KE+Z.;YI/K+[+U:S5X.F<T?F_)AF5>_*Q+%=Y?+Q8RU)!Q>9'<C5&[#
M8&!55#*7!SU#H:44J]TG9F X.\U]=QDV4DYK<WER9!4$MZ_$Z;.OY52FXKYX
MDUYTEYIO^?F=OJNV>^SDVH?6.A N"Y)O*84&84<Z6GP/=+7GS,;/44>NX=/.
MXSG=T-?4 >7#GO8E=+'^GYAZ1#8N)8">80%B)<DE5S*\92QB+7/TX&.B>Y^J
M/?O=!I60345'MBIE;^[R93"A 9QYO6W#YNZQN_=S'?4;)DS_M[X+$KVY*E[P
M<T0UZMNDTZP_AZB]EU_LPL:!BV-W3EW.=N2O8+.(N6X^5JO-%-ML2]<YTV>[
M(#:R"G&%8'3D/9WQ4K_NQ=U;$.ZL ==Z_Q%M2E025B$\?ZI@C!]4R97IZ%+K
M>GN1)9>]-QA*M%P>X29RFJ9VR<L3U'E+&Q?N&RNA7_PUJPGO[O;J:':+>=O$
M9TX2H:+3'7O\J-U34\PJ701,\&<]DXR98W@2;+GDY7CHGT7^]_PG$?FT(TB+
M/:G971U=J:,B?'==>-?PU\4'L:-?6 X/X>;G^3'7LAF)4(C@Z2WU:#1T!_6D
M'U#AZO;VVW[@?]Q=IZ4=#AC*!T&5^.^4]#.  ID!J:1&!Q7N!EY7$]3%P.EM
M!@JLYZL?=4^6;B<-C P"12E\^/EVV!OS OX'7/9G@'\FA&,RFY\0L*:YJJO]
MAZN\U\ _3W/,WY*.YB9Y]0PP+R?N'NG"!I)>C;\;V\0;> 8PF!Q]F2KA&?]M
M18E^RR;C#'"ICUCR&Y)^-1\S-Y?:\D50^G=BK?G3^,9'I?-G +>-@CKBE3*>
MMP@F[AFS_B6\#E"2-Y"07"6OHC#.,^5_-*,@XE8NYNP%J]&,;=8B)!T5P  6
MSC*6KZU?I&RYC=3*C5S:M^!'F)'9>IX0!?"15-9H9COLKJGN1^C?GM3ZP_9R
MX!&\'G0]='*\[OT35^_!)S>CU\17*LJ0;+/4B3, )P*!9_FB*E,B%3D?#HFH
M;;OY3\>L\):BJ%65@>FDM%XD]<H(GJUS\3[!B_C157MGR6)TULUBD9TR$:9Z
M<7+E#%![A9,?,94/?-K8R)S52H2/Z<],'_G44W)"^=N+-[WN+59*OIR^_#!9
M-9PLM@\ZZC!Q1\L8,\R]I<[H 9?MJCIJS#A-Q\>Z]_Z%IH:.+MWB7EYJ4Q'K
M92@\//SD-[6C)P_\]D"S)9B&I$ =40#5#)>4;5)5"9 Y\-2X:^I@@_7?[+1+
M^R!M6/L+\B/_,NIP]N4@Z-]$%;,H\V;DSN>4UJ?_#>]R"-$YBAD_%)$%<6MB
M_&L\HAT%?_.Y>UQ8:_ Z]30N5#!+&I[F020TD9X'T\<?J4UM'^I?@A9!!D(V
M>P6^Z[AM?;SQ7V?^'(*A>S0_O8\.:8,I/;T-"7;YNP./K!DA"H&B#D*D U2?
M$"Q??F0WM(!@NPU" N (V%O^L%)\&":KI8 +!__LNG/=XM'3/]3-5RKP&N^U
MJTE1GCDJNQ!V[ODCW%.-,/UL)[/@WD_E(>JA,L%>!(>E+G>T^^L_S2:E-A;_
ML%OVPBIV_-MKR'<%27WAJ^EO7QL[S!Q<;%4FXDB"4+:CB"E?[EUZXL>.I>Y[
MT7H&Q]>6GEA!&;X6&Z6# KQF]GF%J5?VB_[YHX6_J'$0ART'\NS3(?Y99G'%
M[R&S,-<!RQ;@D4TS8M)O?I&2X=(T',".+XY&G $^\U<BNYIXA9:ZBB#X+;%J
M&6G9@'\7X-5G / 2JW6P!B7:J-O?#^ZI.I6Q[D2\,BP-F?R]P*.NI&VFH=J3
M?$Z9HBLO=B6IPP_Y4]HCWWC:_-<"[N4K*CU^\TWHGM8%X'NX]'D,OX:8IJ"[
MI[)C[NS?!:MY3T?A@,O%BZ*C;@?\+!L/%P2/OZJDQ'(G).BDG'P"/=EWLCG_
MS=N\3I(4<<B87.H+!!X-3K>C1HRFU!2?N>8UIYP6=J_<^SWJL3FK&@8*@+7+
ME*WHST:B?BH9>2L)4&?3B>,8LR]W\74XVQ^;C=]?(TIY7_3NWEZY51XCGLU7
M%JKK(G^@.<8G>WX49VMG&/-.LP$,O@0BUICA="_ADF\SU>J7!>QNWR$TF>-A
MW5LP1JL%G7LIN8K5''N5'<O+7\4.MKH6E48Y,;4E\(&2)Y0$B8((I6A PWT_
M^$0Z^0,E$YN!6JJ!1>RZWI5/M-A$:?8NEZ^$6<T$)G8;EN)>.86HGUOI/I%0
M^N^T-FLYGF5IX*UDDD^592VWQR.Q>"+WN::LU1#[EF\V6V,7_*B=YHV7-"KV
M>__I0<+_&RZRH8 &XFB+%N;G"R[\W7_:JW:Z\S?>F7*'DAYL7P#MQ$@F>1<.
M<6ORV%H;QW][+^U<R:#HPFKL;]=:'$_M!U;WQ+8"YHB=^E-PW;4P46U7P0#_
MA[J1MWA+E_EG\VZF'N74N?ZB@<2I(9OA,R?!)@40/XNAY)1"VLGY!]KQ3.XI
M1@B\>J@<=:1*O8 Z<=174E+#6"8C!J2A.'B]<5;^YKP <3@-2ZP\G2;IG,#P
M1>3'U<&5WVCB"T.=0]OD/7M(CR&>TK^UI&^</&(T^X?$Z6++.-6)P-\P\$)7
MQ7Q/6JJ? I,??#B>*)PS"T<Z\1H_^QK]_492MH*9QH5ZC&/(S8*=(3CQOO#V
M2'ZP"$&18)/Q<\'&!A(WKL.S;,=Z]4'K9#Z)+[2#RDKYT4Q33#P#F$[5,/)J
M+QZ@)' 3 3"A!WHAD G8\B]73TH.QO;R"9.AFTO0M/^YS5OJGY'DH_VS^#"^
M5W1^*-[Q4OJ5[)PS2TA/J;MJK0U#K&\/G>LAOS54X1D>U224@6%^R*6RE>\A
M8-<2)S,4$%%S_A\C>/D<C+7FZQ9"0_UT6=FB+QV&H?+5BTOKJE/". ))GU@U
MW7W,QXP_7'F2URF<Y&%_[L)OHM;$SP!O0+S0?,P %+V%O3;N0NUUZV[>4WM-
M.[Q8GW<]IRI6R[BNU_0!T';I2_8=/!S'G ]5!/7[#.DM=VT@5P&.A4&:9':=
M_OH(U)54P*7@N,-]X':0\QW*[^ +#(.2]RR+31,"/1ZFGT*H##]&NU(<&MY]
M>5P>%<?(2^OVD22<2AV$5<&_(,'\5V:[RXD1QWIXDQ]#-67-WQ^S&-0V[Z\<
MM\_!9P56Y%/M,0O:RW1/E+WK L,FIA>1>#UC*)46#%FCV>/M1%J<!%$9<H5G
MJ4"HR025@/C3%%+'!76.>GUB5)MB.[8^PX'D$QX[ [QE6XF>?;JI,=2<F6W>
MP_X_NV]&-,)Q602ZO3- =[90$._E5,DJ*]K;AVV7IO\@KZG*>/X*;0_E3[_G
M[6I[(W&>?0-Q.MV+K"[>)OVD_F'5 A<0L7,==9=GXI2LO]7SZR'P" R#' 1E
M&OAE_F $;7FD5TU)==V6&XE<?)#B\)UP6VLZ&+K['K(%GW4_2G>_'CJD7/?Y
M,& QX.#ZD<;W$\>09C;B]'#@.IF-O_M4-ZUY.E3D]5Q',:M6X+!!Y(^A0,T(
MF.,6,@Q8I1^+R%+H2K$1YPK?G#]!>YP8//[+U0&OZAH+R](#6_OP9J\/MO*!
MN$/1R%OE=LV3DG?&N6"2KVV3[BH>VRO"WQ&[_W.:*B((HQ6LB6%VWCDVJ[7N
M=KQC'/@5DG >[([$ZJ=X890[^[-0[$+-B_!F0^UY3N9>OL-3 =(38I(&'MYA
M;;=NUO <X=1K.!23J/BKS.)UL-7]GM>E5U6LB.?9??P\X$:)^P9X]R]2:RVU
MQGO+DMV?DQ1[QIJ+J0PLD*.<N"F";$XKZ<7>'O1)O:<>Y;WLW!#D* [95%'K
M_T%HW^;E6Y>%J20J@U0Q)7[%:^2^_;HU?>P'%!TFO:'_>H_W$Y^KKBSC9X#W
M;\X '15_DB=$+*'4W6=[TW_K>@8,D;5U,5=,1HY^G4 ?T:F'_@JF(>B=)VP&
M=\V)V&T#,'[N?@!OO>$-1R&D<*L4Q-3B#( +PL;JZWS3M_4L*97HSRPVL"*^
M*,&*:4/R10:>AT2?*R<S8>FSJ@S>K&/*0G;<_(GLM8ATUB>"Q<]P-LPDI=#>
MUHM$"L:@!&(C6U]->*Z31*,<+AG2!V^EBD*?M2%9U7C^J=TB)!^V(*IF.Z90
M9FC_;P"[UNM$"HEQ*^<B0B>>\Y^-X/!W_ETF#Q4F[VX][D0?2A9.,MO.O>3H
M'*/QH&[DI0.5!7[K";W<XH#AJ?%;=5G(SE.ST<^AKQ:,?1YM88!$84T<+=;]
M\_@\T1'43/*R:!OA2?M'_R2=5&.,NZ _8,,G>96=ZUV%VHW_FH>1 R:#.?/G
MH,\>-P19:ZR:8M#RG0&.95#X]L*Y;U#JB*O+:61/K.Z[/=3.QLL4F2<#*OX+
M&Z;G&*VLOH!$E0E8&D4K'DS&[BD^\A+;=I\!=:,UD"3E?S3ZE [T\T7GAZ3,
M;-T@/1:6C^$602U]03FI2(1[QQG@!EF &.N:#\T^A4R;G &>)6K.O[Q-.("/
MC7RDJH(B<BI]^(1<BTG*PUK?% @\!_!HY')!MLQXL"UA5SWI66O4H0M.]4MS
M=>8#8;D#F]P?(V7G-*"Z\+M.IMU!("VU='^LZ:&6W7W#9&MN)YV2/?_WLDAV
M*OH,P"U4W3I1?F?<36'PP;JS9F9F*/L6\CSE+:?++S$$LP5A09>@'X\V=_IE
MY/JR/E9]6/"TVB6SB:'0>F&$^T[H H*E,]OC5:YG'Z^JK4^U4BF%S>J%4/=E
M9'31A-3=RA1L7[+ =_S;1^_9>TQ;+'Q7-)0E:$-88H#+F3"^PX$E5ALBMU%S
MTJNT3L'>_=K7+C8?FP56UF-J@)^7$-Y.H7>GX&4'8J4?:+N8]&;LAQD!D-+S
M+?*>T0HAZ:O_MISM%S<=\[XW3:ZV8;$X;5IQW,Y89D&K='&EP#$LUV8LB-F^
M>SN"IO-TCR*#ITV<*]JP+4.R%M$9SWI3J5>F"S?DN=[5X%-1B38+S97#!-E-
MY/W;=<\V0,;4"?Z;#D0VO(3DX"=G&8OHYZG !U]O]_&=P(= M\# :TC;<U+S
MLQ#DVJXS4S",U*D:'*4=$:!K_4YIJ''5P19O%R^'>&3.]P2LZ?4KNMP?L@5E
M7+?)_#7P_<&:JLR1*R5[G5(A)9=S';K2[>Y8W"//E#A__YMC$0T7_)R(+YQK
MK]*$+,Z^;5'$]>EL(3?#O(C7@D>[OG8GY;R\<;"V/TJH;,YY3ICGXX8H7)&(
M?M&_SS8/@$PV/SOWSW;"U3"F:>H=8DGQ["QMFW)8PZN0@/+3Q6&)[JDS0)V+
M8E/^CM0L$)N)Y&AEV3"K*UMS3NC(6Q>^K3#5DI7YHAU RA=J5CG2) +Y.X 1
MHQ;J99;0*,8:4YTMX*$;O:?-\JP#]\T[(TJ[H#N@U*R]ZK>OK=A[BXU>V:HK
M-Z#^7[PI_O_QF^0&C;&S%%%M"-=+NM^V )HMT-?_&CK$P%&TKWKNAK8V1U$"
M#^"]^L3[V!UB7^;*\1E@JJ4Y-_2DU$?Z^RDCZ58)D.:@VSX[DWJQF8;*D/FA
M60;SS7X/^S+]E.9(MH\H4+B_00X/IIQ+K.&K12[\'_OPKISAFLZ@AL3QGR%)
MZ\@9TM%; A#'C.FS;YEVEW4'_"Z\Y?*7M!=_!$F@%"(=2\XS.XC7$A[AJ_(9
M)R7(_ZYIH58#)9-I-L>/URYI'ID=_G<& $P*&IR:A</:C=E7"/J1+Q,C8PO5
M#*^6CK6\L'M4Y*!2QA3@HSF30]_L&[ R,EM+,F@!Z-#%BHM[9_U]ZM6SB+Q#
M9=W@$R#0QX%>XO_NNGJ76JMJ)\@O+#W< OWBKUHVI23[>I+Y9ZO9S@"A%JVT
ME(BR,7TT]Y/4.ROQK[RY3LFH!GR-P)5I,)>/YBR,%OGFD<PR_/,R\?/IPNI:
M'6^2CJ^[FKR8O3< LNH> V,C:Y'T0O]<P>@\<MCV,2^^)KQ;V]42+QQ%<2)\
MDO+$Z'H) F539.Z37TUCW,-#^1>VECCTP\I]3?Z$3Z[D+0YV!S=7KLLI6>6;
M#QOYA?0E5JM5$Z/_FSJ.C_Q 9I-LRH>.X-3NU,4/IG#4ZX:_[VL?AEA2KYPS
MLC,Z\DL-D ZB_"G5]%J\)%IK25#>DVAZ\5QC)<BP(W,>LGE-QDO[%D''KR6@
M,G]0M=2V(9*%'%*ZT$U@?$$0*DB0R@"_\<"?<I0Y]\>4*&HC%7HMB@+H<1F$
MIB[03:I2]W+(5<IO"9_9V&^E/!GV26NK::?3[O]IN'RS0 &4(R20G_N*JBY[
M'9J+S2OCF;TBO1(\I540:GJZ?_2%H)&E5I"NG*65MR^\7"E\X<,!O.#WN82G
MJBE-EME/X%I%GWE(VC&9O_U:-"835U_^7='VG]%J27^+E(?9.]CV/4*3!1Z&
M*L1+%I=H!17U#I8/DCXFC/--GGXSS_#^52IB57)X7@&\!U:,D,6 L5PVN<)=
M6=PFR#K3?9\9KW?VH+P40EK9'UK1:Z[HD-(U;X:*]36-T9;X\W!8SL]6(+!\
M"KW9(0LNJ#7/I^P_GVD?"DX@25 '^"Y2\E6%/4N@.2A_"_?HV31QATD-%9XD
M4 &,KUEI69_720N#O+DT-Z/S4VKGTBXB,]#LG$NYD<LYZ)%.YJM;*#Y>@G1?
MD06-JOS1[_ZVN"<CGC9Q# 7.!D?!1^ZN3 N[WEO F>DC&$&S[9$*BDNOYN<9
MP!ELU'LUXV':"XL'5[WCDD]V2<^>,4_CS(NMOEW\"\J[_'DY^ P0V'J.1!]]
MJ*,V]PF30^L1-:2BK(D;GY F;7+[(-P=ID88SL!1_H=\XV+Y*NI!!O70%^-$
M8A@O-L+=7OM#"<$K)^--TZNRUK?GC^FCR$YXZT9+ZJ19F:+)5V)XK<MZO$(4
M)0@/C_8)$<"$QY5Z_NRD2TF9E5;QC F<7EGO5*AKIA25.]8P>_*@2=J)-%^-
M^]I_2V_R1+60:!(.W<GL#;G6,IA_Z;1)TEH1*&V?#1L#TH/0_E A2I[J?3/C
MZ5V?$0;QC. F_^4$G,VY ]&Z?%^I) 9SR$0&*  =-O[G+;(I0DI\"#XEA'5J
M3V&"=;FWET6Q;0BL5_#/8?[/9A]D48V/DJ=&MPFLDHJ["(6\:K0$9S)":E5L
M#!]F3O]#=N:@)=R0[UXW&T%G6JNJ.7[/#F_X>>BW0M98B*)U<8@%B"E^^(.[
M+ S-]7)[FB_?[V'Z+!X6YAM/M&6VN(Q)*,[><&.CH9KCM@[*6L*5B8&^SFYH
M23&C]7@ $=0-JS5#B<WI0@P:4@:'ODPH.<3*M,/S5+7.3WMRDLJ]J:R^?DY+
MUVWF%S1];]0]G.\5,'G55D$_SMY^'BQ2P>X%4"FL0A2BS! K7S_YL9-F/:N]
M@?W4%\M_PZF5M2[\,/8IK]JBQN7$EZ1G#Q5I"' @]^<2AOX;TXT).L_V2ZD,
M\+\2\9]P._;[;L9Y/#&K'>\A_W:)PK-Q2\N9CR6GZ!X\C<LT>P]K-Y-8CQOI
MY(RO>9.]PE%UO=W%K![6KN8+@<##I,4Y*[XO^^Q3/O.,P8'@C_&B,THU:FKG
M/I5O&9!S2](<=/6K1N^O@&':$/<BZG"C HZ=)$B\.F".;!SG6M(PE;:\D/AX
M1.G4K >(-V2YML&UCHK>PG&=BFU@/LKY?JGSRF<_52<IJUA1![-9DI-<$IW,
M!?XDRXU')>5&Y-[?N-UR .2CL@4_K"2&$>RIUTHS3GXC.H.G7$9]1;G=/+=
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M)E$IPD@M1G!N4XY$WAHMC8JRF@)((=:=S']X ',V+$3YY&K"B7.P:';$W"Z
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M*$6RV2Z GV_;/\K.P9/P^897J2B1)V%"<0$T"-GTI)*L4T:BU<4/O#Y/0'R
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MW!;;A"7Z@4D="<]:'B$LGT*/ZH%9A@Y+CF6QF&HL<^OX2\+Y\X)M*=J8B5T
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MWVIJ6UK;VCLZN[J_#PS^'AH>&1T;Q\WBY^87%I>65TB;6]L[Y%UP;_^O7RP
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M,.LI^62'1:K08J?=2"S6E4+3M4HSR_057'WE,2S<9286VLKW02\%N7IU=.G
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M4:*2! G?^0$]Z%Y]3FARS+3F\?DB@<^MM5_8Y#Z$&CP%QR@(#S0[ _#PY45
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M>8(_@U&M&=;DA;J/CDN[VG;N,:;(P:.C]D)R;;H)J#%,  .(2D7^1F_[Z$#
M(T/*O090/V8*IPXT[/3P,GES21'Y?"B4!^71.Z&+M^[,*0 %9R/>0;D1D)#
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MRH>I7@N^H()OJZW>"<IIL]G,-K]/(/8VVE+U:!+]FEMWG,COL!M_W"K>%J-
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M<-)1$=V6D3]"59YD[8%_J'SEH^*29,)>?_]56?ZY0*=SK7BV0DPA=";I5'<
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MAXNS>F\0K:-\"9"HZMJ![!3MF02KI/#F#4,Y6\IY^B2:BP%XU/6N]?*L^MN
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M#9@^PIW60.>FLH_,]2%NS,YY!XI$;T^J39EU.QFDB-[\A!I[P$^XJ]2$&I_
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M4?1WWI]8?T%GF(NYZ3&"(I^:9 !+0M:3 <0"JA"6;GY^@]XAC:4=.$GY'&J
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MF>D>(3$,D(<!*$VOG3*DQ,'$H K$N]YX*<S/N(*S+8VHM FKFH9LZK"Z%;V
ML8FTE-RE%!FZ97,A(40+_.$(Z"GD#/@Q*%Z8@/#S^7-1?:JI )/V,_N#"\\3
M_=F=KT<:/\$X&W&P"YB;!H%7V)0H(@X@W/43X"U!#$=W I3.YU+?*5Y@P.[/
M0O[3XB0;,9AWH,X)@)C=KJ,=:(8ZX9F2VKW1EI'W!5HRI:KT.X;)=Y!3K7D>
M*9K5+:*[-J>^81EKQ:^G^!=6(\@?95>;2/._J#D#EA1$"?5?@88JJ';'9'YQ
M3<&!L7)=IO7%X'2#GN],,C0*352B6;"'*(G[U4EH?8;"A$)]$>;<I&>57]34
M]%X\?N$?QR8<T[EPX"+T1&_F._PL'%T X3$X!9L0/X,OVYGXL.BT>6$[=+KN
M:2*OG6ZSO628S$NUGG/B;YYT^:>=@E7DB.EFS;? 1:"W<? >RQT"WC=)O9#=
M%'XQ>NI/\NQN9MAISBDW"8&NS8)#.CR<+'"GQ'<.U+.K&A:HE?0EN2HPCG1^
MV3A<=F<(S[N" 9'/O.TQ4&NUU%4XT[T;+BDK[GFIL?<$B-(<(\[DP[M<]A7^
M*-%^/F-39QKH23O!6I*[DZI9Z?1.G)6V1+2R\2//1JWP=#)/]L,:]HET3OMO
MS]Z))8:=H2%"VNDB+FY*'"U2@BEM>AZK^RDK0KZ(X*4+3[T9PT/S5TFN)*-J
M^1)5(^'62R6NX?3T:$H#7HW*DHMC6F6*_3GAU2[$%*M!)^3H?-<X8S6'J9]!
M-4=.8O,E^E<-4QYYFY)R CPJ3 #5NW7;ZYEBN%+2,2(BS_]ZE8Y+9JZ%J9;;
M?&4Y%VFGVF2YRK\/QFTA4BDH]S::Z;U]4<0_@!/-@@_(M_%:W2LIR_J4M^W.
M(>?7PJ5SSWAX2_%6ZZF^R-/^'5C3(Y_$Q.!9N(J8:"7C*5DH]%O8!:(@R7"6
M;#Y%/>]!E=>,7I5KQD;?U:LU%S+J6$J7>/?N((_"^?]JIS7K?-Q[SEP7_["
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M,NTKK':O"S+MAG9MD@UV*G*<[*_^U? KU44F7YKJXUAYRF#MFIIV6VLKVZ9
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MC1WTIOCAWJVO!MRXLQ,=5TR]QC]_V$,:?'WH;&R68OP*5>%:10?$5P\F5^@
MY?@'WJA%;"?+Y1JVZ  XV3<2(^>R.C1E0FHBJJZMXJ!\CC,&;>CC"/V*EO&6
MB9G4F)'U,),SREN6Y[B5(KCV0O>C^A=:1+KF2IA#^WZ-M7^+DUQ1B)35SK8O
M5'C[XW:13M3:+M_^#H9@/OXIXM$$DCE@]899<%7M?#]4;;':Z>6:UY#XSNZ?
MC,T(V<KT]^,4#OR AFUN,NN[/$4VK:1)CM NE$06\8!5#R'_@#&B#' ;^'V_
M%JE0@=UK&2[H1&#L*_V&<!F_SJ$6R^!5!4OU:9W"S<EV8<'"WHUSKEP]$R$Z
M?>];_IS3"\M!#@B,Z E3#"T?)3FX'ES*"0T8%(IO&=Z?H*91>.5(?F,2"@)=
MQD*ZFM?>/7F^,V00)QI$XV7:,>;#F\-J'5KCK^@F(^ $:QZE])K&@*B?&W)^
M_:17H$&1P4]KA"G!=BQPM@5Z;$9MZ,-?KYA^\UJHVA/EVI^]ZI8S.?%KTI1U
MSE3LBO1)KT'FH(D?93L"$TM!3GF?G^^D2',69M_6Y9?YL)%3J_&-^6/^O/X*
M V0I&3:$B.F=V716?4;4Y=!3]5=N_,CD^'_KXHI7K-_5)A?.8>T&Q&K>5;LI
M;_?.FBK?,E+4#@&^L0D0.V@G,*!9PR9%#OJ)(=G^E;"UH77Y%OU-=:T!!I/]
M@'3 QU VQNB X^:L@R&X6T"!?LYL"^]^]CITK&S)QO'KX6.2DNE*(5XGO';0
M]3!<=0OS6U37'"$:2N)_00>LP9)N>+5 A\L0>-8B3,N#+<%'%G'*!9<N[S Q
MLLM5:OJF/$3_I1I7ZN5$4@2\*FOE'*3I3^H]T"J;4.H*P[G3@2>,Q_+^.4#"
MK+UK,4C[J?JZSH,LXC+JTL6VGD>0IL5@GQ_9I ,G'#%@\6X91Z<P*GK'A@MN
MV!1U>V3WB$1#=5.M)]'DQ,='/@_:3/./!7/)ZO7X'([GO6WZWQT$]5\.GCK$
M4(PSE93;2P,B;1I<&W5+7*9#>L-KW_J]@H,O=G%>UZQ2;$7S4RMA+O$BI*N@
MK].2F(%!T^3FKF9DY6BIVSM[_3>G$/T2P9U,7J_-U25^K!C@EM?%R#8( VJ1
M"BX(;PS7\+DH=*Y:\]C#BBJ\T+4M_TM']^>JWB:_O0] ZE$N)J#<]\D^?UQV
MZ*>:)F[.IV +;2Y:\#@=./_IPA?QV1]".WIJSOL*I$!J NT\;49<)M,FNCS-
M( N/+,3#CO5+)C>Z=ZS[26U(M<)DM+WJDT0GX>33H#3)[)MQ6HR.&L(XUFSL
M0F47CL-8Y,XETOJD@))4BY0VS"];FDW^I!IZ9%Z!QOZ +.>8$=P<F4UDY^#@
M<)R0D7=#J!?I\<KD,=TV'V.]/<4.K&$>8Z90.,Q:24'>+W[8#$TNY6*:G?18
MGGGC2_\%2_)5*%ENC.ESA1 ZAS3Y!4/804W'TF(<:+=\36CZZ(_* Z98RU$W
MA77H0'5#])E(XWQW?:$[81<O'M$Z^,;:\-]URA8=Z$_2M%K>RG_S5QSMGES]
M++/:[;FL]A"EW8\[[Y[)8;GAQISQP0ZG!QY*'Y6;_2RS!FB&4:;F-,1WOR"X
M0:[%S>G95D_P:INPM]/,E1M[%X4D+PYHE>O_EO3N%V6%W\_QX=LR6),C;';#
MA734 Y9);\#D#W!'BXSPOGS01:_)(+JLC FH,&>.,+-L:^5<<+%_K;(W_G>I
MNW_<_E[._2"POIZQ[1''(*AI'1[3>]?)_HE:%O:YJ;;#5E5"YY?Q-*O6D$;N
M:69'[6OH!#3*'98 KY$?FS%9FR1\63;Z%OLFNT=<)IY?;;]-IE!1%K[Q\TD/
M@1V@-+<(CJM #RC9=$"_1C?HCGU,D+>ROVETN:D3OY5 TJ#HA@1Q0 ,S@A1Z
M:VX8UD@'TCSIP,AMXNY+4LKH1S]T"QUX%&]"ZOU,S4+(/B94&1)\ZT(E;%X6
M.EMGZKM+09TSOW(+7TU<$* QM2<B*$=G,.Z8Q0S4UB,L%_4*EC&#[3\QAXD-
MMWT\S8,?[TN,]?LG_RF;^Q'E@>5A(FW&BQ_]YM;[4\[HVO26QB6]T$4&) %-
MZ4 '-W*TY0P=2 XG54U4S\^IDLX),(MM73*&$+UF$]WE-N>KW1CP#?WCQ)P.
M,P-?F#L?[%'BL=4>B12#1JK'IICJ,L/DE6;8M>SO#=B,HA;C4:RYG\DWBY84
M1%S\SUU.+O<5\;509]C..54):AX\<%@7>NH7X\&NPZ?KC)C7Q3F;QU^P/-FV
M:1+;SI[_$I[P>L&1#GR"KNWFXM>P[%JP,TIT )JL/00_6!F Z][6%??-0P["
MCE(T[OZ&<R+$"B^^C:SY)F_OBF?Y;C"6<'33MB4]]_?!.3OS;'NW!^+ M!M[
M]P4U9H";U>Y/,N^YX=IW>H!!7:$*91L1,+HI >X3C?RR@[8#T.;WS<=[[WM(
MMK%POUL]$)$S/DZ>G" ,\3S\;"-,G++L-G7J'FFNJ7/Q4U^];9;W9>@G9LTB
M>P?23 =:#5%@ADY7(!W0)6,I+&ET(!K]V\0QSQ$]#H\7FC4G\=)^H]([J.],
M&G54&5[^SJRQ!UFF73K2QM_M*;7V1@0W1SGWD8'@Q!@3A<(:33[P_)FF"K-E
M.YN^NKVL4HNSAAS&LS??UW=+G5E0'&$\OM09["#CC7>^Z?C-]R$G>#.]&&\P
M5I@[)ZKC/L)\$/;][#L3JF;7ZD! XA9Z 29*ZT QTZ0"&DV)L&@$LU.Q2\.K
M++=Y_/Q<WO79*]^?O^(.\>%C($?N']2WF%]OIABPU7>9@;_0O[*@Q"="XE8&
M"@$&.GHNV]9T0$ZIMR34]\GR0#WHV>2+'H>!$B_^A%!U'GK&<(Y&(!WHR>?;
M0!$V3*;[85LW7%$$C6TZD&A1C#@%0A;A(3/:&R\7%2 =N'F-+?SZG3;.RE[)
M-$?;SMZOR)70MG6X=O?":8/83Q?:2E6K?J2I[*.'R_OK:T6.[@:JJWHWST[$
M8Q+=7ZW($;V'+WAHL>'*]*%G5SMFS+Y:#:6IQ-VLWVVS;F\&.0A#ILGY36 @
MSJA>T$WA4K3KFL&'ZQ;^>D @Z^9:,$'I5KPI/)QV6+=0HI>PFR^]?:VM5(0.
M3$F3$&-9!FDX6-2MW@O((>8K;(*+$D"A6+>V"]8Q!_+& [.8CJFZF?.Q$G&A
MUKB94[B,8D"451O"WV- ;PI/+,FCR>F&W;&Q<_Y4K(1-DPZ\83.Y_N!G2\O[
M$)V3?PJ-:%. IND?"C'G:L.S)<SN-.HTXCU&Q5P.K=*.U!/N5_4]7AH2MS+!
M((Q)Y$N6"=ZM9!DM5'/6VTGLV"VVY3V*!O2OT>_S>0A'(NF-X$.3G>=2&+[I
MGF5CAE[:@=LF\19ZU&*MP _*QN3$U,47W=XA_$3U/1:+7V*\3/O[C/FE4G-]
MZM\XT8%:2*R[O>]^QK["4:XAW<G$T-$D VL]:C+*U?:\VJP)]0.N/N4\GT=N
M4I%@MV6UQV?J9?0W><PR[^<<R! 6O VKVTA]9 1)1'(V/*?,HN6/U>N$7'H+
M4G[#<&*,7D8Z:4K2@>=YK=83.G<@KP]M," ;;0GV+;$ &<H*/(RO_OMICBI0
M>)4,>7KHP)'"D-VRINCGM2LV<8N0:H,>=]W"NI[$V4UC7Q<&:['CJH_XS/$X
M(*)JY?J*2>(7QD!ND7^^JRL#D$CHS":I<\3^\1CJB<Q&?FRZ<+O3D0=9,7Q8
M+:\V98;]8V6AYBK7L=VB)C;9/DW@'J]((209V':Y9D,3Y';8W,[\*0%#!V"$
MNR:B3A]OUI#E [:-%"_-)C@\$%!;F8@>JNC1"AK%X#8.^+-^^":&Z^B,&G%V
MZ@P)*:QVO"+]SJK9(V&?78H!0/XA&H<>P=R01P[# 6Y\L4MQ_U3]*#[J=K+O
MRR&R2K,]XTG"02:_TL>H$]-N:IT'UQ@6L472F6R]T<T!"HN\L:^/J%?\&CJ&
M+SS\:5-'&#0R37_<1*B-]3];WI42K"-P7YM);B1$Q^$/22A##M2Y"69V^]>>
M2I,J5S8:.9$0]<AX:%0%\X<,*E S:HY\34:8U-SBGC/Y +^"D@X1#=I!FS=3
M,Y$\SK??;.H(!)Q?N3C[90BW:L#:[&F_:JF*J2AL?7?EJB3F"((_3G_N<NYL
M.TSREM+F1,C%4HR'PC2)=ED4SH^X5&KAOUD>=W7;\W!PR;-^4A,H]E$?#>F&
M' KI<;1"Z#F).% GDH2_;V(6LS!5M;F"ADB^7U]R-L2-C(]3)G2]UD<^,53H
M#:Q*;R?E&I;+7%;4_H*+==R#@.XKL?&8 B#(+:W'(W+FU0=-V L=OL:D\TN?
M7,P'=7=;D:\Q#_ FD)4BCFF7#+>E&[/V+D&]<^J#%_)5I;4LOJAB"8:HZ9'U
MNWJX=;O>\)1O+JHLV?;-&?74J[0C> (_X>O#!J)OXIL+[[%W7^PC["40\KO+
MRDQ[ES9=Z8 &@[W F:"@A$)[XR'N1/P0U*D@4@KF5NV&KYNON_EV=\CZ,AU@
MR:0-0(F2X#Y^7:%?O8Y*0J#)N%%8I SSYOIX%X7ALU(T\1@R\,<3:TYV8PGK
MT)@&%.5/1#0&^KL8NWKX_"!^BE+W>W-299"B2XU&.6+80>9._V72QTF5 9T>
MX_H4(SFP7-&7O;-KN/\FY=6<^OS /1U)B:V#0=Y+GU)B4W*HP[_O!'KM3F&2
M/JZA\(/<J%"#WW>$Z8#1Q3@5@;1O[ARX1!-)A,_L\B,!Q9RZ-':E:A+ZEPCI
M1ALU%0E),:'$")M,TK26T,L;RS3M?#K@0P?.TD)ACS#[*MGA=( DXP0[,.!#
M*8/C-WE7[^_S5:?]"A+R]DM>];FMAU(2__9O:]/X+/Q,/&W\.ZPZK3/Q!9:#
M(OMA!<N-%#,DGMVQP]\:M6^P%)._HG[N>4I7ORNS,P:I8;$,:4?/GJ?UD-K!
MBJ7LHPAQHL(+A/=2K*:-#$+Z=8*-;(YNG;[_W2='RF,'A[/( ;Q,!_N-:%X/
M$OIMDP<Q$^\003L,JG8]<VC+6X**S%\KA!-JFG<<7?%3Y*_N0M$/VQ0CDD*N
M26A-MD/9Z8!K(QDZR[&$B4%($_P[6TX1AV+.K;OF$K+,I"HS6#A\''SU[\?\
M:EH7VJP+U86B,YL_8M?AZN L7K5[B /!]>>\PU"X0:>.:D.R#>-&-?]R(TH=
M9V?%_3?MO;J2QQ=:(* %^3%VBC8%YZ.8X6#A"U)$2 +BMH/+8\CSK2+YM]].
MVN1I%BNQ6.@M.PX%-[$#5 0D15_C3DD\:+ $X0THQ&&B=O^<+T(H+&66W#Z3
MFY]?<G:V/^ONQ:I'Q\/'\%K;MJ__ S#[OT=#S)+=D#TPPE0+A+ 1P3#J_I33
ML&F!@2!2XAJV=K\Q3[;*XYWXG(-ZWX%%#X: AQZ49>\[H_;<D,46BD2EI4M1
MA,16C<TXA)$W2?N$?HU+8SK0SR?&9^#_\,K'#4ON':;]?"SAJAWL>PWQ3XWW
M25HV0]6BA%#C#,WMOT,'&EW"_L2OLGX TXI<)J&$2-"HX]GY2-$7)\QC7/IK
M;]WD:/CRXN(E2F[ R?B>LJ=8PKY'(G2'BP"G<3"HT/<8@.3Q/^_XFE!4\Q(A
M 4%&(TW8ZDR1:VYQLWZ;4Z'^]M)"LZ-G,/P8W!96'/9+9!%#X3>A WU\9-CB
MO+6;=[O&^0*ONG6!U%OW##^YW1H2KFA=N^C([/Z?;%?]<W83KA,:/69F.X33
MUF_2 6;E9LU;X[ZSMMJ;-6*F8Q+6EI]TEV2Y_1U<3O8*<IU6N(>?$TM__=K&
MQ3ZRV]-E&3*U38*93!=H/2A;19YB>/'1GJRS8X\:QQ"7I3"OAL1)CW4Y%(6>
M.$'94N^K3WT(T4FV).T5#O\#Z;CC'W3G4?K#^'>#X[=3!EJ9)Y69I%2_0D=:
M;H ,QL!Z =0C(%>,!?YJS%PRB.W?5W2D"77V_10_U-PCHXX_VAR*=PO !]B3
MVJG5%WUG&;C2 1UE =O"N98WY!.?:?QX(BW$HJE;V" ,'#B00J@-.A#:H*R7
MQY+'"8-@=%<R U70XF-+UK'SOFRN<-)PVJS*MBKE/&IFB#1 G>R L/<0C'"[
MW7<#7MZ3M!LZ3I.9^K!A8')&B[DG<X$!Z4E_#G<'4$2HV=_KQERKH>!U+1-Q
M$7)09Y![H<5J@^1)@^.#GF97[<.Z6U*/KGCK0H4I HQ_V%&4">=+M8R(AS;(
M2WOQ4DDF.GE+^@JN(\N;@:R9R*#] :G@6/L''A^L.IP<6,Q3/WV\EA-Q2-+Y
M\*'B.( MIXAHI L]8XMJ.X]Q:.Q/+Y<B=.<_RM!/)I;-QZ6JP[9&QS)B:6*/
MR5ITX%M%,6IQBS&0"1838)Y'LW^/8G?[6<4R.?G7V/WD/K$U!&,(N*NH61JH
M=L5_^^DPE!W)!P8MUH7XH ^#-T>,Q)B->#AL I\$IJOVCJ@.?J_8?Y<HW>P+
MYKD]L.&#'_=P4Y5S\YO"\XDE5=_6\W[UWV5F^#HICOM(2, FF] W-&8GZ_IZ
M4<J5REP#IM>AK):/C@4=7\CP\V?>3Z\>*S.?D%+J2<HY_MF/3Y544$BA&-"!
M8(N=3(9 I$9C#489;,2NB,:+:I=^C_H&9>APZUTZP$X+:P?[TG&.5YY[?JLV
MM7TF?K<2-*SSWB^K'UNW/@J\.SK;<QJ3@YV6C:)<'&JC/(7ACHT$#E'5N^RB
M_[XP@_H%P^@ TQV*W'4YGS#)!!7+);,C'XL/A:@!D.L4<NSG_A-=HP5:QBH0
MAR!KJMO<2@<.']6<]9TQK,AGOA'_N@\O.MEI<G@ /\2\:B<>;CO6I'*^P)6$
M-QN>YUG!^IO'IU]CF^/<;F-C0?1[,"#)"('_]2(\JD$_JMQY08P(>\[XLEJ@
M6\-];,S]W:P/+OI+R+(@RX5;BF%'AR9W;K$IX#=9A_")3"LTD=A.C<*HY3%Y
MX4FR@Y&/4>_3"[:"14!6('#\9751&U39A@ZT*3>Q%@1 <!O)N:L9=5$($QR#
M(JVS$A/2:U1$"OWF+SQ\FJ/8S<3)RWD_S'N7RLO4#Y+;O$%\ZS-,)([(783;
MW^70KZ%-C\SS;(G&">B?U97.TF5YM'[6TV#@&*I-&<%: /ZCJU?\XZMS\O\4
MS#-/+G@L>%%'%29V\X)2SX,[_QMXP/]4=+<4*'P&QF,U"E.%W?8FAI+7SKNZ
MGQ^Y8.C(OZ+=PZPEQVL_Q3KD?+#RV20^2X:0&$;C >NLB+\BX6PV3EMTP/FJ
MEV"R0T3:@Z@'Y.XK;8>(*:U>&0"E[X^UH77!CK:H4\Y.:GG@FY7!DCM15FXZ
M8NIHJ4B.:_@86>:+G;VVV0/J<]=Q%H#8^!Z$HHDF>>%I\D_2$@_VZ^D O@:L
M( R12HCPM66B2*=&3]N _EZ'CNB8NV5Y=(F6?Y_4YX?V5J&Z0JUJ"SD76.)[
M)+.#$AF.DXB3,-- A=N&M/F-2O<'>WG% %1YAEOVH0W"=HR4,92C?U]\YTRV
M_>'7]F[V3M#7;FX\5WGMDU[DL<,  -T% 1$,AG=P&%1@N(*7#$*GAQP"5<TS
M[Q$28HONN9'U?KP2X'$5N:O47>JIR9D!S/XGJY'_G#(GY5>MP?I%AAUEN)\K
M!/W")1$1!?[5"D.=S'Q#Z<V-XTSG6KG#V:<&5=WN7[R[R/P],11;S98(<X;-
M>G=:+/!,?*@ A19M JM_YUYKB[*J]WUD(1GWO2^=-[S]2C-G%.RIVUZY=RN6
M"R%/Z#?,OD'(CMK!<CMMS_4%RI>GN2;I;^NH7C/394W@=1C6_06(R?^+3,TO
MC/65\RRHIIA;+NF=&^QATOW^\I=<#^V2:@<V'LNQN\GB##VNO'YZR"+Z=,J>
M\7C9R-+)RG/I5RQ##'4U?,YDW+21"UT+HGZ<AT<C3U-3FR#YM)D%0=#0@^A@
ME=UZD)4T.:ES4J.)%?=*SY-F^5+<LO]*.(O#\AYZ%#N-OPIZD#4HBE4$\S3B
MV2';ZIHLIZZ?Z))9K;5'3SMY\CDY%[U,4FTC?((&^.P&:5C3FLB?(P$;91\N
M2WI?P0V/Q46R>%X66WT'1A'OM,..(G0.L'%-!H4!'D9VK-VYGA51L'G=0#\Z
M\/BRBH1&_,+<.)=WIX9#I$_)NSM68_(^[RZ-(_HV/0HM3T6CFC:^LXI_GVQ;
M.,>8Y-2 V*6%1B\<;#H-5UY$9#9CLP?#[]8%N)X<]"1?S)==&]6RE'BM K_Z
M]SEO Y!:8A.02,H"\U#H5R@-A:../"_6UJF'%W-Y\3\\SEZX1@=2(T,T4#'9
MA+L>1SO*4>U2!/L.C;INF."7&UYGTCQ.3\MQ'YVO;@HU@9UVDP![K)?PU%<H
M)Y-9II1M_'(G,V&O;32IITU'X*1F[K)K"$_(WF'S]*@K[UL60 N"06LVBX]B
M?H! ^X%_9.DG!E.-XAE(B+2Z:7=UXZNQ'SF@VY&YIX6%UHMAQSC(W15G)Q24
M?2BH>I0Q/D76H]2+_GS2=RNHV U.<IGR(_^IY/+?':OT?V*SZ,40S+B@IA.P
MAQBA^$NR9VQL8D5*/N),.UOK%#?4Q-+.=NXP'54[U-* 5J 64)R<")N+;(D(
M U2N34!&>X=AEM$[?F)81Y"0+9KC7=E6907;#V6F_0Z&UVZFQK3P()Z"AJ4@
MOJ?A#EAX-]$J6$-$2.%,V,* ?8PT2^F-B&G*@G_*9W9 ]"6)#E T"TE>=."]
MU9^J#<9#=$ ,W>41 :W!Q,,<4**K#3WM0>E:LKG.+P,3<;._]?,\/CD\U-20
M?9CY@H<+G< A[KU9PC"RKT!",1O)/]RP6U7L(H+!-?0 9"JJHP'E #V0RH#3
M6.;H ''FX(1)1?CUBMJ*ZL0OM;71IV(4>_^Z'0$- 2R6HB@Z-O@>*C/B#]!E
MN)_]TQ@'BDB)<7F @=Y8^27J^ZTO'-&7N(J%\.9J8I'&@-OP?SS$_YRD()S;
M;!,MTM1T1K?$P7#21P9K[,F.FWGHU+!TS[  M# 2.*IA;1UR9\"V5%?\]I'Z
M-GO)TKO\?'-@+*FUN8E:A= F*+59LV)>O(^<,,+P.<?+0=;&MOK/YD+/6RAN
M#%Z^^-[3.['P:^"F+N3?(MK 3["E"; G>S_<#DH)V:7@K2QG,]646!Z],C6\
M39VA)2#E&$Y(GIA(#47#=JY.;J<_I@/BGJA)%0:.UT-=!=4C.I:(4Q^79(ND
M^!HP=_J^2N(%/W\B<V$HY*XL.G"2 5 3@D1\(X@>_ SCZ&E6>M<?N@*GCE)*
M#C(%7CWNAYB.G:HBRQ E3/W!Q#_Y\V U NL0HO<B-DQ'''$(=%?.-(;H5XUX
M('S1;I?Z)6^5/E6V:8U[\.HM<O=%3Z_<9(OHGT%?T[J\)$.Q)^N"R^9@_5)/
MATIIVL6>!P+!H=$\UT)VF/MO>%7Q[:#6GH73A$QP;(64TQD>4-+:ZS61@"Y4
MQKB.ZDIPF")%>K&9H_69J+!JY$Z0&-NU.L&8'N-:HX [8\]U#]_4V"T+J]^\
M^;Y*\+];P?]/;N;2<4U">8@KA-I"'.;85$^Q8\:K,PL;@U?:'L?MFMX-WQ>>
M?1^BX_GO$%OUO[<'.C' ?@=-;)2L1@>&SXW0 <*990:3G/S6@'QW^'7AK)5U
M]ZG:VO@',8HI?+Q '@$P*_X?H&P;$X^J9@N%.6".]"W!1%=)!]JID.E%^9:?
MZW1@^:TB)$/_N\\BMR&S)/",?XU$^34/'[)8-R&[@EC2<[#Y(YAY8\(WD<.1
M/=:AP.F2_\C5'S:G'I:=C ]Q$JQ2$O=*RDEZCPG6$>W=IL (G96:AA*__4H'
M>Z024^HE]Y29OFV0\E#7P5@:NRW9;05>!8WPR>8 +UJ^)VZ^L ^<( Y+T0:J
M[]0-3LT)B546O9;;NF8R#U X<!ZAJ%J!KLTH'L2]T9I-?F=^4_W)U &%%S\3
M:!M2DD(G7_0>O1UY5NT<6Z^(7!)D/A@?YWWM$3.:;_\UPYIU4%N:C(F:74:$
MS"7SCS,+A?)-+W\]^\&PEH:ONANS%IXP@$7\)Z62[,SOGH:]/:.HNLEU1]BC
MS?"BHM_);?YX,7=[^_=M.L+*]QOS/_OVGDL.4Q.SQ;/<3P%T,N<-,;._X<_I
M !=2F#:)JN6/+T9<'D:8+,F;#@J].UW?2&2J,(I^=6AXIJ?Y%E/2Q4,]+^.^
M']-^23NZ3T8@= EUW2X*X5@!7Z/UA_VWFC7TFA>JU_8.GN2(ON^0C-_6J,YN
M//O]]<//)P\=85MMYGU5_4^RT<HMZCV\*Y1]PF#1$G:6F<9^-*AH=G[%6J$=
M&^[_U.J<5^^P/.U]Z9?%A"CO\"Q,0_SEGLP,X "U:+)6^"<SM8X,$1NM[%3#
M=0=.3"@XD_O16;BZY%QQZ=H2[RG]8TH5RY(O^]2 (.U_"U)AX&6F/HJE!(T/
M%=>,JD!KTX$?X9/;R?;>D*E%<6=(LL$Y;0 ]XS&[22K/Q$$CUW6$0?%O#$ Y
M%"^PIN&7)OK0WHTSO_M)P.#E<X9WS1??OGQ]A9W&F%+"S<THU&$DK]5OFBH#
MNR.\\7)S]U;29KHSN;:NRD)73F[?6H_7>'2_HD\[C!;5U@37.8XV;Y(]^W9E
MIA$9][WS >U3BH<],6C] AT8LJ0#F[DW/M<_[Y#>O+-!!P*>6>R(_9W(W8CV
M8C,$17CS=U:8;,(7*$L#JCV+ *&=X(=1G#%WR_#FI\O4[P1(%;LL,<;'L[1>
M&ODP>PV))<:@CC"T-OW.#3HPXK@ZY1R9F#L5X&]8-;)3(N>F=*,JPFV]M!1G
M^2!,1?#N7[?X[@+ K0M R2YE7/KKK';2^_^+O?>.:ZK;UD87@B(UT@1I06DJ
M(BI-(1!4J@BQHZ!$19H(B'0)":)(D8Z*@A 4$942D2H@H4E$!*1+#0&E!Q+
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MG&*GL@)'"0+@O*9'8]HSO1>=;0H&]'-'RF]^)G]T,W42C V^TJ5 1ZNNGP"
M@YSO!FQS('Y+(<)S:X'!;-)WU1?3>GG[OYJ/UE#;*KC ^2>_)CO#D'X["6$X
M"AT/*XU-$&;IT#G0O_SMY@)F4V?+5WRM!OG[!A+ X+Y&$2>\,.<+;HMN#_+
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MR"_EI?V^$B_F3HQZ^YMM'(9]/4@H--Z"J]/";L3L298;9&_R5IP]5C? _'2
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MUY>=TS1X$E<M%OL.H=!1KMCSB\@R&F0$<X&LU"@<S98+C)M((D>+T(MN[[C
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M]8+ Y0X9>%O&_]E9;_]-!?Y'Q;GM1F%_]<6T^_]F Q]FB6F#_6[O/;<RM@"
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M"7L\OG*!R_A^_;.@KV(N/7 LI?DMRXD>[)'^AK"OT_U=\_U%DZGW^P:),H*
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M+_D;G, _7KH,>WU].8+XX]%ZI9UWK21.E-3:68B1T!P(JZHX$=R<]GI9SHW
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MRN,Z=&E0C,./0N.X0 ,/IQV]? P!478LQ--CLCDR,,9MR/).4K@ <[U [ED
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M0!K N5=L[K'Z%-((:1*Z!!E36*W_NT84_%DC+HGA_3IW/-,IBN7%IQ^L/<C
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M6E%_8(4G=7<M)4P9<<<$_NWQ']EBPO_&:G'[XFCEC;-T2]8A V_6.=P@DI8
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M>2TYWTS&7^W1XXJELT\Q94"H#0##/P!L*(P%\&Z02IF"2513+,&>:L 4M*@
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M2;QF%,I3);HZ*$+G$._\!WO5]K7QTW4MWXM,O=T#K'G;<H __KWAO_#A'\"
M_#/^&?^,?\8_X_]?P1KY7U!+ P04    " " @&1<^:RGI?CS  "+@0$ %
M &MR;W,M,C R-3$R,S%?9S<N:G!G['P).)3_VO]C*=FR5U)&"<E6UBP9DI!*
MD9VF4ME"DI Q(Y*RAA#%*$K6^<F^9+(G2791QHQ]RPP9#S/SS/_Q.^]YE_/[
MG??]G?.><YWKO:[_<_EV77V?9[[K?=^?SWT_]_=A#;'& ,%3)\U. FSP=8KM
M% "P1@ C@(.=??,/OCCAORW;MFSAY-S"P\6U=1L?#Q\?+P\O+_]V84'^[4+;
M>7D%=P@*B8B*B8GQ">S<M4-TE["HF.AF(VP<\&\XMW!OV<(MRL_++_HW7ZSW
M@- V#BG."0ZV_0"[$!N'$!NK&4   -L6ME\OX-\N-G9XC%NYMG'S\,(/E L"
M[&P<'.R<')NCAN^&P/<!3J$MPON.&&X5.7^9:[^OJ.J]A!?;I(^7-(A9=E,.
MJ%VY%<;-LV/G+O'=,K)R!^4/J6MH:AW5UC$Z87S2Q-3LE-4%:QM;.WL'EZO7
MKKNZN7OXW?:_$Q 8=#?\?L2#R(>/HA*3GB2GI#Y-2W^9G?/J=>Z;O/RWI67E
M%955U36-3<TMK6T?VC_V]/;U#PP.?1TFD<<G)J>F9V;GJ,LK/U=I:^#ZQN:\
MV  .MC]?OSLO(7A>[)R<')Q<F_-B8P_8?$"(<\N^(UN%#<]S7?85V:]Z;YOH
M\807)0W<TFJ6%+$KM[IY=AQ0)\E0-Z?VZ\S^V,3"_JZ9_?O$_F->PP ?!QN\
M>1Q" !)@6KV,.@C\Z\HIP$%>S=Q@BZCE.?9NLW0'X.#+J'])D9?WC"L'2\=&
MNAZFUG-$-Z?[!7[\S%F-,UYI_%;HK:6P12\A1E(MU/"8,7!'/%N#0EA(I9]'
M&X.Y].OH:R"6['R=E\@#NN-/9GA4G&ONWK;$Z9XF9J0I.)[H-U!?1U%I4=G&
M.)WD8,$-1I^E"M"42+\0=-!DZS"O%U$[]DANF]AS5:C?-&M[1=3!+/;_(X6S
ML+W\C>R7'TL_Z='!'[+C3MKOOTE-.=/PP'#A0OB,L3&Y4W*^67)G_\]:_K->
MPAO+/8Z!&@K^_$H%-6+V%R1YY;41IQA7J6UA+, ="<J>K,:^<4\?I+& )N;9
MZ[%+I]ZUI@5^WB509G!V1A8YRGEUC.LN0->"N+OI-P+IM&(J,EZ=N&MHQN:Q
MVV%'<X]AX\)?2M433Q7NJ2L6V*;#AO)I>N/PS=G)H<6/KU*3CIZQ-+BHU*10
M[9>0\*'+ ;K% EQ]AGG)V$9=@I ;EM<LLEE2?0=MJ[FNT;&90TOE2I'[[&/N
MN[I?;NUYY[D*]]I+W\TX#?(7>4+Z8 +YT=E*LN>ERGJ$>_V@M!DA,'UJK(3_
ML#;]5=6=];B;@/Z//[PT>__ TIRMW%R:[D$(,>>G[G/7^H=Z1^O-]R$OV0,,
MCT 4:3E ]PO75P+E;/R(2QNQ/. 1(^@UV-IVO"S<,&S8T:9'Z5I$6DZB]:7)
MR9N!AE]XZ)B]QP?(<^0!A:?7JBM'IH\GLE.]Q9T[GL?$G;P[N))*U\5\08E
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M=6SP!M*7H--9 L/IIP?)!(9^P3B6R3,*L("&D#46(&OK23&!>":IX623UG@
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M,A7K!M BY/FN2,KH:=?44SJW4,,GVO+?OS1-U^C2-3\L+@5DL<VQ@+=8AD@
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M&_0CUW?'@W>U%EI8@+$:"SBX.Y<%2-LF8YN2X2W^T@MS3L:N37]P+QIV=[?
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MB#;/!=?A4*3E##X929K!E2*8HEV,+ \<(];\/[?+<6&S76 C5\K_Z"N\(*A
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M 72-$$CW/L7.KJ'5:_0\*KCD9U5,2H38CIQ5]Y!I+A; ,^W$ G#76  A#])
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M6:=_#^E&!FC_".D^FIV: V@L-B*NZ"G0M4Z#A=R#>P5P$NTU%;(_$^T^7JS
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M"AJRU T"IO5ASY;60GI>B6TD5*+H:GVPU+T:(4#X@\,UP-NV!2"V.XB-\,N
MMM )6;#8 N(-WL ILW/PH>@W[M?.([IU2+I:"HP:7GW[#N']H1#@7#/,3H-A
M=CK.1BR;" %[L.N!X7S?(:C*A[2\9VI9@A6/^LD-'\+*."&NP\JZS49X9XR3
M% %%)U*?JS^I<3'9[J#=M%[0KW  -RN5=!9UFU!(?'B-W"RD)CO_O(8J'-=_
MGN2X8\T5_OI;GP_FKO:5H"15H\#-NXH%YQL&T.&[I.[FJ4MDW,D>OA7?_3P,
M-S2K@$W'%1XQ1H8[07P-U,Z9#5A:75! >6_ ]QG5QR6+; 3^TA"ER9]8A0<W
MJS.LW%#X"L7>JK65*755WE8*2.LD,8FZMFI<PG)Y\C:N*@!^CEW%@[K3G;)-
M ]\%35A%Q6Y3I0\8QQF""$\%D6_!MQ*B5 @'EPS^T58J_L<&93\F+*@C?ME#
M\U_86H-5A.I0<Y[8(BPK^C5I^7#[8E% /&,]#-]J<.T ;1=G=/=N:]Z.MK_;
M#8TCT'(_!)I5A5H8<\$>7UFAB< =QKW#SIWP(C!^LX0E;(!8/C6 _VLJ&]#Q
M#8:=!9[AA<M8T(#)WX=,(#Q$_ CV/B'U1RT-S]_V<BO]U;*LC UW?H79T>8
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M%JO^YA_Z/Z"&G?<SS=*3@/+6Q3U&L$1,B"V>?FDWQKSEP49,]:%9W.T]Z;G
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M/;OH-V\IQ4IV*YY:Y'G6&]NW>;<L@B7S[Z)G4S>J$RUA9:#OR/\G@3[.="+
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MK*B66A%KP_E!?Z;5GYLYVY@E=T8 T]<X[2%RLE#%((DN-@B\QX_,PM\2FZO
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M!^^:,,S[^DSMV"Y?%C]I.89Z"D$CE>%T3J^C--27=NY85FHP=/X>.&#AR%S
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M+GJ3U"/%K<FF8;GGIC"7$XEOB=],?_ W?^>EE6".6O_Y_WO][_SO&F0,[]A
MU,;I)D2FBTB:VH+7^[YFB<PXMH7-]*(SG2%Y6(X$[291Q!F.S%)\QPPAW1T]
M5:3U !>,&Q\-PN.H8,#*8OG+DBC,^U8\W&ZA7=Z4[[NN]'"AI4I2\Y5 1S#[
MT2,S4Q'<D4U&YV%]8NU)/J9"(FE  N1H)M/@SVH* 9OD<3@#7PIGG,=,SE*M
M.L +720"U0K\$IO2/_CY;,DU1"]8;FF]A&;8LX&/37@234#+4?]1Y85 O9/
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M^^%DNZHMU9GKGJ;7#<Z81(;NCF]KV2U5%BG(<ZQ#)O!H6L8]X0*ZB?1,3HF
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MRXD&G5:69P&2]ZQ:% Y%5Q3.>V8C*3KIK\2CTKN]LO';LAD7!7_Q5IXUJ<%
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M8&5E(ON:;0@S('6[%XV-H0NJV<_1G0B?L(F0;AVO]QG/'+,J^/2'#W%<YOI
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M-7GY2=/'!O42CBIMK<R;4'A)T-V<M22AG3^'B92R4L_S%S0QB$_"FK+ILXN
MT*>+'"X^IE:=\)S J5?_5+FZ.:3GM_M#QF:_^LJBP>) _HEW19AQ'%5QKA,5
MYZA'&HMDB0D@-?)6TV2;5,X.FN]3<YQY4'*&>(+R:]<4D9=F"H*O^K<&.;^P
MEX]**';TGPSK:2P.U4'4K7,.0*AR.*+&&NP ( JW(*OU=*@'^2;,S7&(8A_D
M*UJ(L475?PPEBAU*YQ(R6-@XSW _ +!3&!V[$'<H_P)"JZ_1'T^_.44D+=^W
MF;)+M,Y:/P(0 )PGAP\HXU2-D"N>M&/TAXPZG(>:N =.ZAM&[]PJ\<C3.K-Z
MYH-L]8QHJ0N#.==/V>B:CJ0U<3CL+ACH^%+EB+@!2-(*F'Z%O-]WXE3;%%(*
M)9GQ>.%>O/>=LOM"56W*-SZIC)P3 "8O) N[ODZZQJCXVX_5(4A=6/,<%T&
M;*!LU+A?V>8+P@T_GNR4<<L,"IFZ.<0>COMV.V&7/4,O<Q=$4J>$,S)8E'1<
M@*X[786K9PH$J05I5JC7VII^X(H(OAYQ>=?:*YD$$'/JO;Y2+,A&@N^RE#%[
MRQ23'6G80(U<'Q=02Z1;N41/Y4>+F,,NUB1=S/I4_YZ3)[D<%WPX(ITV^1\?
M._XS YA+W@K[J1:;!YI!JJTY:$K!C694\/CM,8*S3LKTB?).0K1D&2""BZ/C
M.B.!]7G?3(0.@T60MNO M9TJG]DUK>J/7H5+P@LFBAOO.[M'%$XJ #]+F*\K
M"ZMAW?YY(YT6@%L&H#/!!L]!84V(ABS.-D<,*F:.XCC;C/2$;[E$WIY[!=*T
M/=S<G.-Y+]VT@#,*_V&[\\V#CH861D,'^SRUGNKA&Y<GD7375B_#&*&7CB24
MH1F6)\F),[_[:,\03GT'@%H(L;" .>$H_&+9+7OF@S5ESL5\(3Z<,]W?5?IE
MA$UDM9Z+LU_S]S' 690[ABH/Z4V:E^N?6YL+1[KXK_5]W!)IW)_5O-I/LTB[
MJ'4D7CHF_FG@O<3P:&/537!@:.<!H/%&.LV*>NE)B(^GM^Z:3R9_ (_0(8V.
M!#_5?*EIDIC)HM.4N_UW\2VZT&T")$Z?PU,\<92(WYE[AIP=)] JQ!R#Y!#S
MR()59*'89Q&5Q))D;AY'*Y8QSS/"?B;MHF,@)S3:S:TB;Y^U=\!_06U;FF\-
M)ML'Q4>?J]>%9B"\YV7*Y@W )9]*_HUW>?Q_B5LW4PPX/ GC5*6Y?F+@:E)G
MHD2/'=]TA@"B^P_,?*'TI<1NRE5QTU=;TL%Z]U)FC)/62B&$(G0#)8VTUZFO
M0'U,@(MJYI(U^&J7L"\_9\SBK^I[#)Q=?;BP\1G8?M>AAUV@C RD2%-CR(\I
MG*2M,*1+!7X;+4@_.UKZ-?#0TV3S?<K\J-*ZRL;0QMX7\0L73PH8Z-]E5$"<
MX1'PN@/ +LNEO-6NM<_2H61<KZ?'GR?/'"8RB435I6^SJ["CSJ]>G/PA-LPW
M!DSY.;?;ZD08C^HX3MK:K2/']-;0+Y.3XMJ&-DG(P<8,1ZE$[]%AF%[,ZQ4N
MR<-Z%P\?2M"E:]!DF!/9:KNQY$*[Z0XU!"=+^5B_PZMF.JE,X[YFRV>TZM5'
M(-E>X<,;#[UHNHG]!"Z'.,&Y$3F4#D;]+Q0^YLX$**I-S'E/.$OB6,[0[-RN
M?[X74+5W<5S>8-72^5 YVUX+G"[@2@F>0D*%JQ@Q%4L+ UK9+1:SI7ON78.W
MSK5G7HI_LS]^C<8QUL^G.<9C;HX@5MTSE+0T"C]V%'"H5 H ++F&_4]@)O]5
MD%6,R<7Y$"76QIII%W<H:"[Y[VU&ZXSSHH8T+XHN;/3EQ_ UI^_KS0Y=-QCU
M;-\QQ*J_.U7)JNWKI1V\S+')18\\V>SUW<R6;VE'F](WMP*P)>S(?*D?3[NZ
M1%7@.@@(Y3WCW5_6%8=W2.H;HIM7?A7)<6W]B(0B??%KB\F5E#GE/>P<)QO<
MS;>M[>]U9NSAU&+22N>*P"\<#R+3-/XZ-;)**ZT($??=L#X?&!!V=R!=^NPB
MUR:TQ<\*:/;W=$XJ5H281#.F@@E;W3NB]"LA;Y?L67K-O=L0%M\<%S28&/GB
MONGY[ZZ<_/[/>3NE]NF"/!2^&FK-Z@SU-\ENR!=L76_A>O=C928$?^Y:Q,T0
MGTBF76W#EN'^=QL^6N,?#/TXG$*IH<ZO+NFNHA/W4A?63J3[G*IISJW6J$#,
M1=]ZMG@:,U:2<;/-=8N'$M@]#L3T0**81TG(0+Y <,S/X$LR]N<)PR?#3R^;
ME"V@^SLT_UY*P%XST>9.,T$\7E.+U/BJQ_,NAURZ<S?;[\R%P&/5*7(U)Q_(
MNTIN14'.1^Z[ 7?!XD@)DDBOYX[GGA!5NB=/H1WKT+ O/I;B&RAC/G=D\M1)
M5\Z(B^_+)_NE]&<E/&VDL0U1[/X]1YY?-C@K=,</L%;Y$B!5YO8?30[^2Z%H
M)^^,6S[H0Q+UC"_]>'L;C%%%1JVF1W:TL363.6.(TS4=X+X GT*T-K_C.68U
MLF>+W:P3U249*H=4(JW$:N!X/9XAGZ'ZI.Z3[U<Y:KNT-ASAKG^>K%?"6SRX
M(R^9&\>YD[&T5*WT8X^2?0"(L($A+:D[!8B]U<UFD?"W'3@8^JALD]ORTG0F
MS2%O++4&J)0,3/Z]K0#\"9:>S2C_A&=$CRTO?,A R6DDC>4VMA*<'FL]O616
M<>??I4?AO_'?^'\,MH/Y_P%02P,$%     @ @(!D7#<Z=-4=U@  1AH! !0
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M8[=L6K';@E\,2M\K+]\Q)Q[OXOX9<\5"E]V,\9,@LAET*P) N3ZGG# AME.
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M6,@$584O8S8QL5X!TR$HKU54KQG-;ZICHS3GAQLW@,S[AS 'RTCQ(CC0FUD
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M0_O6T+#C_K1A@\0D::[:]@\%7X 6'T%YEX!MM01INB(YI35[D6^U38HKXWW
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MM>Y;?$?L:WIW'NRV#,D;H*F)"PR*:G\Z (+4PGPGK!R=)5 1%@Q)!0R5V4F
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MR3O-K\JH15Z7 "BHRRR <DQ@)13=X$I5K2T;6/]2P=OKHF4FW;AZZ=8.N;C
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M;-B(XXQ$2&S1ED>1J^[$11\Y(:X^:Y[S^+3'<J+Q+7"P#*5:@W2Y&8%AC5#
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M(^XY"QA)'$UL+T>0,-YZXOT?RZM^F6'<#/(9BO]\1F80]9/P7I9&HC*JY)&
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M]S7GTXZ0Y/V'M.ZY]5<_;C1O $)_PMO^)G/_2V2._6&0$:0LQAZFNN4\P>I
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MT0<&2N8?$J9V4][01XZS )Z[5-<;6;J1G'J>3TCBF,IU*=.W4G$N(D&K5HX
M@YQ=6PE;H7CZ888J9$7EKLOBH=I?.U-,V. ]=<W2@D>/8TC"C?.,XMB7PY^Y
M=I'VF#E1)8>C(G#K(;NY^JP=/6<8Z/N]N9[;"5MX>4B\5_)>3L;R";Z7 +XN
MAAYZU4M$0,)]!MH:E< "/%K[Z$:4=XFYAK<H*8>2:7IA7-Z2+IH%=3G]YH46
M6G6;BRS$PIX,<D1\=D?[P-W$8JNHR4J*\3%J2U?AA':!<'%' ,WG_NC$GKU>
MUDYWN2Z0]%S.^,<"-*>!SI<$TB[BF=8^/Q.*,D:2,*G<6L<S:I>@=$>QY<SE
M5]$=GP^KKMQ?#WRA!/&K-1$Z6C\21AYETLW9A;H3YYM=3I3?WK]=V6&Q)+]6
MS<+ETZ477#:1U?T/#W"=!0SDAY?YG+(""AHJ+V]?Y'N9:*31V9ER7&Y]<;+N
M_:W-&E* TJP+K1 _8A]-]"!<EI&'TH7Q45@-[<1-!92QB"E4J)R:4UWF:XIU
MZ^;4Q@-&*WVLA^D$6BSS1H!UKU*CC' GPWO8R0B2K6N6Z\E:;[%?Z]B5ZZ26
M.UU=D>VRAC5B_'[RX083DH^G72PV!:9IB3NLO[)M>7WW(\([$%(HS3TI,.5*
M[3"!;/PUR<#3DU<F=Y34%_75/?:-<_OX0.'S>=4#NY=23^W:R(FY?W^WD<!W
M+#T/]L]]A;A[$WO\IOCO\9O_E?&;'_>$-9OBIA\(%J2=HM#2\X.G:1/OF@^7
M:Z6Q@-.EGI\>K#[.R&L2D_;N^C;K"/,YC"CIM4;C>1A; O5?>[NX!N9^>ECP
M-NOXG-FZ$U?#S47:IUY/FPEQS),9!G6T"RS@[L OU;*\)Z51=E>.MY\ID3Q\
MK'=V]?1FY1T7="./PUS$;882<#OQ>4]\Q4FNF#RLX)4:6I!Z]-VN!>^M61\M
M=+A<I.).<=,_N$JE;>3OF;B]F&%]M4)O2U=#U[.4>U\O1#IL]]UR-'\J?V1_
MNKM+A(F)7($.X!:^T_O[H*W*V)E8(["LS*9*E,>(%A@I&06+>Z:T*6 ]JBBH
MP4?#$LH?O&-VJ(J2E>_C[>XYK+3++<N^*/6PILGU(@TU8.O*9*,&((3[[W'W
M_ROC[HK;Y(YVW?F@^+A99)!C(NS),8@$\U8.8=8%-]/L)=PCY^,MG8AA%]^9
M%K5//7AQHS%OF\*I%1>NE)4]!(XS<W#;<"1MOD#1!DOB*BC*1CRFNY$C-'<3
MZ1/9B[] AMON4$<&XR;S_DZ!CW/U$C>C!J,B&.=RG)IUZPLF%I,,[BT5T!^?
M4W[K&*Z]3\ Z?>,5XVHT+[PE6!YR^@2W7DR_=MI^X!HA.-0NN*?OM.J&Y]_J
M.'N^)N9B^>@G<&TL@&\J@G@5=$WDA[R43\2K5DL\?.EWP?6FB.'GT7#$JR_[
M0-RTE/>P=O">T$]HTC'KVF:W6SOY?(Y93 7,B7[\S%/*<\N6JI#&$6_!325\
MF& LL]?'^[" 7M'AQ$9K7L@:48.K,'7'1.[))9&]^>Y[:;T&CDK7<!VVY3AM
MNQ1#_Q2&WNWQR[*Q5WE4^R'29 K=/OC;B'T]<7WP,17+0>;TRY!S02%YWJ(I
MGBWJ_<>+!_;[&R5,!P$6B0E<YF_&:&FS'SX=:UF=.J2^:;<<5OVTB^P <6,^
MVJNU5Q3F85+]&RYB&C)5O(<38K BDI(M+H<SE$+VNKZUZ3U@=[3C8E%(4H3R
MOKMR0G<%S)@Q:"]T'&8MZ&6)_]@ZXGSOW+ 22;VOE^R\?_MV'_<$\M3Z OR,
M)7_!]MW84B<!U X"8C.7RX)10_9U+" F QU3(?O4ZC[V>.4MU4!I50O %%A*
MIIGQ\PNF\9KVIS<.<RQE/F?&P&*($'T$GIDRIMVDED6Y4AY%\%GL?'!^+R6_
MG^A*EUN_1XHKP#Q:9;M6D;S><\PS1 %<#F6HE#,?;<>I#S@Z>>G&U2,8[H(Q
M=R\2I1?Z4CXG&S5^:&UZ<%J@7(ASSAWF(=]G[((6Z/N]) @D:=R8$[6ROMG_
MP=?>@?T2#S_(%:3MP049/1$1X; ^8/01DXLJ$9T,'?+K?3-2<Q9Z=:A313-Q
M;7_+^6Y=SZ.]<V_7)ZH\V'C#^M-<\>G(P=S1E_@X#.7 3 1&O$K3 ]R@.O6L
M^,[A[I$IB3M5J=LN&SC<X)3<9\^?\)1C^U4-_LO^D:B#',6GPM$;<:+!JGN@
M(,06LHHH/9'%>3ZB>SH>O+C<W=BF19)@BWAP@X5<RFNY9 LYO ORQA^<6E U
M**!O!=D]O=Y*]IFZ=O[32]9EB/RZ1=!Z#W[1:2]C&B 4;\)PN J)89>3<.\N
M]DQMHN]J?0B=$@P9=EH+&YQZT[3#)JA +L%\-[K^L-T)=?6F;/WWJ_RB=0U2
M\8P-\(QUA)VW$ABY;FF_N5ZIY[AMC)1@*K=L+D$/>: JV3J0K@A=WG7:/:&O
MH>?<GIS[FXJ+L (^;TD35MASN;A^O!#6BK[3F*Y!HKR9JK!=<U5W9?I!DL9
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M;A16SE%L"?^X*1%DIQ3,9D/Y%"\K2P4S^LZ>FY);+L0,S05+C7D>7Z9B#B(
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M>CJE+6DUF^2>W2.'^+T&)ITWW7I73ILI9K,WP@GB?]+5BOJN93NR0\UWX@L
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M;D:Z:-YN]GXJ:JQRE.',WI<&0;-<O=-Q60$1GR^ -V>?"=/G]ADI#[,D-#R
M/B./?T,3(WWPNS2?7[@Z!2ZH,!4HT+IA]H63$9RWIB6L9';T>A#P6+@/OMBQ
MXDWAC[#-PR(&X:S+L)2^BXV?7LF^&:J/#NV>^.VA5"_9\VKD\^JS_C:K.OK+
M:$6)DQ!TQ2U($":^_$:YI">(1?(;/\H/+&R.;O-[O?)J5/RB^-?K\$NO&)9&
M >[/C^V"O3A7HUP)H-&7*$^#?O"-/&C7?QU-^6^/"VGGJG)!S)*W?!@+">B!
MVC,4U:\.#@1XTB,TQT: NDO*N/V&,DY=*_RMMQ1?T*VK#/+1?BMHD@)+P5M*
M(#7ECRHOR<-AIM.<.^&/^-4'BC5R.[K_J-5?O,PISF,R.G9\3V.QRX)81DVD
MB)(AXQ\@I(P!&J@NVRKI0[*O=B8UDY''J3,O[;E\:IUTNH WX P)@ANF\'8,
M%C'C=]IJ8#(XXY9FR:XWC?K%S[R4W\Q<J[K[CE/<3/*5*J JYOO$E2G613#^
M)AR(S(![@!E?_W3:O01M\ID) #\R4CR=A^)I.M>*)%WP[@&F YOD<NBRARM2
M9U;9"Q\POCA8LV%RSQ]W=R%Y\S$;=;O3W7,H-LA= I0(S3NJ)TN1RHEO9@X@
M_$9XKEW;8LL9V>1]VYEJXYJ^ZJR/"F8M,PG+7Z2D_K$)2BG&UE9W<T>ABYMK
M=@?N<O<LTCFF8H"'_2SPLV.8\KE=TS8=\G1GW)%/\F6/-?QYQAVK!3#1&H_<
M*L5WZ:F6-#Z\DH;E_RW6^8L1/8E@VAYE$\O(L>:/OF6A]D"WF.4$X'4"2$ "
MPJ!\#]V8\>,MB8]Q[-G!$2 G70:I(S5OJJMT0Y_FD:$>!X#U@Z-YL&Q:Q]UA
M#H<'FAJF3/$K#CT_!).8/H7&&$Q<.8/X+P(X#E=7=H$^2(Y(X1I2[8"#W[T2
MG[DLMZ4?O(7U%?(,IK+I%P5"S &>^0 TY_;?*H+XV\4"P!?%".Z^R3BWBW,J
MCS(2KEE>W7F78)]^^7U;8<Z:QY3D.P^NT+6U[V$/9V;!T!/ 8@JNI;@:=H@%
M]HD'XX=OYAID+R]T+0WVR46H*2H(#ZG;"TIS&3X8\I,9$+N:2!'LQU[OEOEZ
M20X?,01G?MN<:\Z+LIA]&S(A)2P>=:?CJ0+B2_PKR=ZQ:&XHM1*,R85S4,+P
M0VO=HCX781I#SG?;G@HU9YDDG #<<6S?7JTB#%71K,PI',D$.$D6N8WZM)D_
ME(&W&,I<_EUOE@#FWB3(6&I6E0CMR0^9)RD4-L!9M(KSQ"^#N2BVU"Z*-M9<
MGW<8HQQ(7!^]$JDOW34M9KZ](O6)_S::&!H=! H9<(_\X?#+:NL96>,[;0+"
M$BGS;E.H_=EZJK\2*(;LE""H3CL.;\M:DNWQX!LA,;Y;%!>]Q+!#<Z1<./A/
M1@#MK9(U1R,O8\<M;&,M.N?*&A&/2V>:_MBWMGF)\@Z)QNQX](PR%IF]Y01?
MY$__<T0@"]/FBK1)M60HQ1,/35?1__S290Q:]JON,EFEF,C>$E]J$-QNRJ]Q
M*<XK&7ZF2N'((0F)J2AN@O0A^3<=]/5(,D+9V)96^+DQZYE:?Z]X=MPE\ITU
MT$H:3D]MU3T8H@WC)XY,-<%1FZKIT[^$\UD3-=ESLVV^;GNYM'GP.QUIO/R>
M\86ZH;XG@->YV@-^1 E82>/'3L:'6?&1LF\GFDTUC8CA=H@8[#G#V>/L$0#
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M\AKQ,S^'QBT!-DF>K&NYK*(UFX'H)__)6+=;,&%WY3#V!/" KN:T:>J$G!/
M@K_R"2 "ZL<EACL.83.3OF:R[G\6 V!7LV.*YD*[?I.=OF1I0F-G3[/Q<WDL
MESXT RT,^OP^*3N8O2T)X/D\2]TX2MX'C+>#IHAY;TM&K"S= ^7U[K=__P&3
M=4WQ\S-^H" #"@Y1_^(E)7R9B:FO?![26$L1W.\IYFO.+HDTFT[L_[A1=L^W
M\EGIMECP-?2Y,;EO/F].,81T<$T/9DO[K4^B9C [+\CZM*E\Z."8I1!Z$,A*
M.R>4XCJS'?ZJ<)5AW:PP2/#-^;9D@Q\6XA)8'\9-R*(%,>!_%!N6(FF448Q)
MH97.\BDK+3*6WY)0/[=7OR]7K)G=-Y!_-3KRH]HH\C?Y#&W)>7=K!5>*EU]!
M+CXJ5+U5L"4D5E01K/)"JL?E,4H/)9&6Y9G4*W%T7:3UKK@]89+"SX\KR\%E
M<$$L5I#1- W''?^=%>B/AUI?WDUIB]_OO'Z9,UK".S70EJQ!C*'F_VUQU7M#
M7^!7,4\D6\WB=UCV&)M7;5+##<:\IL[4T!S0BMZ[52_'!,!1QLH)(*/9BJ0
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M$2TA7W4\9S_)IE+J*A<)S/*@CQP=4I!RL-\N27Z[?%L6WV&6\P=61NI]MT%
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M4#J+/- !A9)PB%8AJM<K>F8[U21TAG#N)V)%N<@>0P.X]"A_]-+//41LTA>
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M^L\/U[QH0$F,U=QM8N%7$=+YRV=\G#=M5C:KQY%?;F,G+(I[[7/*Z_:KG']
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M 21+ YT'OH7*LC.+.3I]?>2">R90.JA)I#JR*!M$GQ3%=17'$=N"9L#NU="
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M2C)*&!'^O(=:\+'9Y@;1Q'J*3JBWUUG!;#U E1NCMH!_P^5)Y 8)S &QFJ1
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M!>DF_9E..E(1BKUR/[N>5CZ5RQ+P!F9]9@]-9:84]YAM1MQ6.Y:EFE!1EC1
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MZ_C5Y,YI8I[LZ]BMP6.DT"GQUMCG]G^N;I?YIAKJ&Y)X6GA^[O>_&"0Q6M.
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M32%/M9G[ZA\S(#'R5%_HAAH52@WD6*,;8N6AZR]Z*(4XRALLOM7@BQH34,R
M'+8%\ R((6Q/?PG T>LB8L0Y.-CR3? Y<!P?;3,@)X97S$&*4_1?6IB5?K"
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M[ N$$"#IXSHCE5KZHJ*88E+"URZ0-^!YW^:EA!/GS7W)WANLT]LK"-(;\F>
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MM TE<I[FW&Y6+N*G,GG<%M28G#P.,R>,$]5K,=_9=URG@S"DK$8TSSO C6*
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M??5"K&VT#7%O8_,$NGD8YTX/F%XQN)^T;(:C:QI3]<+(B$4&A"TH$T9[H,2
M !-AVU35GJ:>W9,9X-QKY 2_5!@+?LH=L4?UAWXP( CED8*+_;62[[QV+[[3
M5U90O/?S9N0,35*L-L%&'B41H==%%ZVC:*ZV4Z7W\L_Z[E49SDU$S,@\JM<+
M.=S5IL]9]]SB!T+4@9#A(,JG*/S"K[CA1K3U@"T,\, \>LN M)83(\3(3.5[
MN62'@>!F;>.'][YL=G-<*NF]][/KS-5%\N+^4Z9=1QY#!'6)LLQ7_MNQ\W\Y
MF9I5G^8ER XSG3V<8K DQH1S'V&-7I/JIQI.>P_V9M97/LVN>*;FNW'IX?$"
M'_,',:=N'3HH;C_GL;Q%84:ZT#X@E8.G<8<<O<AI J]GDJR&U@Y)K%J@0XH?
MV0<U_FYA^7[1=#]7'PZ0[VERMI^66>[Q^K3(MQ:L^7!+?> 3(<'L=*GGI%8V
M!'VW[ [,X-V3!MYU&/68,7F9!&VN<VW"[5?25>=Z4B;B[92(AU4GSBQO"UW/
M.#>OLG/5/<'42R.]\ P#HL)R/@(Y,9W@/<.Z_,R#Q#^54;:^8)<A$<TSJ' H
MXXZ5<96(DN*L=>51B9T[S3I/7]QXP82:!T"SL=_Y1SF,:7%X4I_45L#Z>,TG
M.;CT1S)O99E"U7K7UT(W2=W/H]HS\4*4J!G8<A@QAAP[M+*%>2S*&><\6+22
MW"<_6%=5\>RF79#MMS.Y!E['-Y:6Y<N 9S/IDE/HICI$Z_VWFI7:RM&;OZK2
MA$]+?PG)LFR*N2[XF56A>?P'*X%UQ9*B%E))Y@8&W\>)("?/SP7"N8#(WD-G
M5A/:#SU\6B+)]);/BOWMN@UJ"<D*).+YZP\!,FTEYU,VED:-RJG$]N1GETA1
M$G)ZY^NG5'_:$Y)6JBA.<-0HAD\M+%WR0G7_/7,-Y64:_R7$Y,2E];,*R\>@
MM4$']RD9',R\-8L9AXZT$^9ZFA 1=%!5K>(K%W:EBXJ&)NU[N*-D6?M#;T,V
M8__)1O)1G#QTJ@J_<8$!606!4P7O;M[?I#Z&[!;\G1(NF(/_W;GZ?^JI?=AP
M>KAI@F/&OKG.NU%?VG3VQU;(D'Q.Q8O6$[:!?M$B^K=XUX?WMDSO@P0^^#&4
M".H: ORVI8%8$@:<5#<0CS).[KD4("T S7#OCYJ1M5#"UT =@>2=%#]5XSP5
MQ9-:@M5OXH-%7VX%[U43^O]60S7WQQU@0.;.P$70RY<K&9!>;?5P!L1 T(67
M.(&)0BIG+0AY!O:7%9R]XY-R<;Q)]JG$OK"WLK_*/?_GM^*/QE,L)N3GUD;#
MZ$)OZ,=6H'0>-%4"M!FQ:/=V,G8%J_R=@GBC0?6=1Z3.TK4RN3YX8K]S/7;1
MIM71!0!A%Y+OE\G]YF)&I2GTE<Q$N>-&0BDW/VJ_/?S2F*#<"ANKF8$W=PNW
MU0L^;^A;<"S13>D) ,'(^:^]%389^K=N0VB*G"MF<!G4=RAQ#S"7@BB,X(=N
MDF- #MJ/Y&Q 2Y"XLM QX]2$VAFM[G#7?R?C=0:^HI*:K4D&N20VB?8%^R.-
M2J:5X^9.X$KP-"1ZI16">IBX6195I_@WV=#^P2F#_U V-/S?94,SXK%?)]%X
M*MC_]MC!LOK?)AZ:)# @.\($Z-(L=#,[9&28&N<G-I4ZV_,8_0_P8S?\'VEP
MRA&Z]7\TC\?_\I6<\I2HY[E/_HWG:M%LM.>0YRTKK/ '-S>]<ZP?)./MNQU9
MJ<=ZIH8?HC07,#Q4E6QG .'0-Y\\I[:B'4C__G)2\_*KJT[NFK,'.R$V?BYK
M)([V43&0H#$ON2B0%'\OCO(]N[,=;,_9P9YUUG+PU5M9RPX0 @U/:^ZEZF/1
M!(I(P]=J^VOE\B< UL9Z+R<S3E%#WLV%@Z/]XR<F'1@0_S/Y464Q;=-,E+S
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MO"J<E46[^Y!CSV,KZ62L7J>MTHEVM:IUV_%&2M%O9O :K#!"_T@!/TSVA^+
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M.3,TH*H"99*%/RIS(OG!T.&*I5$/94[$'HH&+D4M&5_5G%F[#UD]-&[#L/7
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M=^2WDJ [6FS _K0K&XBX^U6F/H)I_2T1!/.](*V,'TR?I[:$_*:VQ":W!$E
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M')^<7'V]O#N__!5<7UV<GYR?WO['+VM!G&$Z_R"DYF8@K>F#-0.@Y0#\+GD
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MV EV0&J<[AW#8VHG?10R!@=_QPC970 ,(>7H)L! UMX; 9UQIKL9,)!JXX;
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M$R.S8F/TL6^':EJ@%!JC>#&T(#9AT'2"V0IG>+?3R.4^K'ZG *X\8!MC3^L
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M3.KO'!1WV\\Y_()EB\8=P12J3_QV3)3G,XBR1,9WIRC+,0U9DIJHQ+V4QO:
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M >'R;!8*S&F1A!X-TBS4+Q :IN?8<G3#XTTX:&<Z*:"L1 .Z?KOA !"8M1C
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MH\0718Y#GQ:8^%F(TZ 0N A)P4A0\$BO73J(JF,#O#]D9#8%32:% :AA:%W
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M@N>!_9CS<O;^_""8/ \MW[_]Y[*N>[Q\F3_?,>T)!?VK.#^+2%%G[^I$OF8
M?:/E?XIE4_R*+E6!$R 9; "3?LME%P[H$44+"8N9%OK2&J6"#2P]6AZ8GHC=
M)##--PRO0D6^O)FK,$8].%A=Q8LT"5E.<YQ'A8=)2"*<<19B1FE"PX"%>0 :
M1'=(PK$6*X)H2]$H3^$(+GH>_WG2PI04*"C\^O"D++9N! \)C'O)=U+ @WN[
MTT\:)@QM+OFZUX"=*^%?WP_N 9N& O4LJRTO5=V/Z%&:X_:T_V51%F*Z7,E?
MG+^+Z?/+4O#)3U'29U$/OKJ2^[^:CE4/QVJ/'#G%*8D]G% 18IIX'/M)DGHI
M\5D4P?J,?PJQ'!N8EA7!T2_3.?KQ<(7>1(DJ)=>?@.E0GP(NW>RK3\'L.#D:
MNT.8.HD:JG/ZL5P.)>?%>M!<1]2V3=Q2"KL.;M836-;R7J"UQ*@5N9E/AY30
MG3%V%K/-/M5GM)7<]CF$&C>7[G/(?"IU[W-Q9[9+;];9YNUT<M)(+E@HB-PR
MLXA@$J4)SEDH#QY!4 1)&!=9""I]Z*7F>D^;W-RCOTV^_KA&WZXG#S_NK[]=
M?X?&R/OATMMEK($ ,_Z=@:$=PH[R\K1DM&09^VF-:K"TQ-ZW(WHOF38%EVN\
M+&;RC:HQ.YO[G2++2)P)ADF=N)\*(1WC*,!4I#SUBR)/8E!VSFE2CA6[3M_]
MZ^W7J^O[AW_Y7VG@)_^&KO__'S>/__A7:&OPDV!I^H]6(("I=4/G DV6RW*:
MKY;U)-_E0OIM97-BMG]A-BRFM5[A)PF-W"A\2.##+N&#;\#CS_7$W:ME/:1W
M?S#O9*X&\O*;N<GH<O#"CC5Z/8AZ[X1P>M"URB[[6Y-E(<^K9H/&X>@.![>=
M @NS$Q8QM3P!W!@DHS YG-IHD7-C(+K!=/-%C+.!C\PS 6Z<_8LXO+H^-8_'
MQ;:I)Z2]?-0^8F-GH6H(?B3W5.<MTUZ+$\[E+T;5_L_7Z5SX3SEG44%CCG.?
MR..N2*4WS*(4^YR'4>'1*(BUTE-ZJ3C>.]NNA"W%B_5?D**-;N>:5[O]./4K
MM37I@8ZPJ> &G1E[!#NC/^.Q54?NTM@CV&&OQKZ'#=+'KF?EM#?KA\ASJ9<E
M"?8SP3&)<JFHE&<XXW'@QV$8$3_5SAX;HN9:3;?DS\D=&\2L7U6M(P%4V0X(
M-A+'!M$ Y(W91,4L;:P/'4M98[I"]B:-#2XR7LZ8KCP[*6/:+]ES-8(G/^?$
MY]*"16$H,,EXA/.$4QSEOO ]+X]"+SG7U0@^TM5X_'UQOJL1G.%J@*2WZ&KT
M"6[%U0B<N!K!Q[L: <35" S5<GV\>%13L%;E>QVIJT,A$_9?JVG95+1]$\N7
M!6^31U*&@S2/<)(6 <[B@.%0*F_,DDAD(EE/UGO4#Y7KT-;Z[=T=IO=HD,,N
MWN1/7M0\N$6!EBU?J%*,7:C.TK,55U$C\4<](&5)_[A 7#+*EJ@0[0"^S30^
MN<+_SBZB*(6%W;6^A%X<P1JP1F9A3;VI]+IH FS2.K0L7-25KJCAPEY8 2*S
MI>""%LE10PP0$/8##:!W;0;)6C?CJ8BEB>$^PS%/"29%(7!:1![V8A;F$0]R
MFG+8_,Y>>@:6!6I4CL]_!Q?$]V#F>93'82$/?PF),:'2*&=Y7F#*J9?$8>P7
M.36PS+:!,S+)[M$[)RH+ <-N4+:E[#HBNR>@TX#LFM8GB,?NB:T7CMU_R<P\
M[@[5^SJE^70FG;[O4IQFK.^32*C(A8A4TU4FU9UD.$V]%/LD]'(_ENX9![4Y
M'Z3H^.ATNSL<%,U:#J8J7W(NELJ76H\T?EN4*FX T_]A2 ,JBE 4OG1KY>&3
MD#A2%C3'(4D+GD:YQX/HZ:<H\\6'@-JEK WKUWTP;8.F9SBM @$SG@=30C?4
M+]"6OCT3JBVJ)3,Z3&]44ZHM_KXYU7_1-.KTM\5L-5_2LAFI5#UE0@@:%42Z
ME4&(21C$F+* 8/F/TH=*,S_RM/*]3E(8)]JT(=H,WM+4\-.PZ :8SA#6*+BD
M+:=!3.F$+&?$D_97'#F6=$*@PSC2J0<-KJLF$@:O/C/>S%6!Z/2GN),?<GW3
MD,6,9%F!XS1)Y)G.2W#N%QQ''H^3F'E^5FC%=X=).58[11HI:H![F'YH-*ZD
MK D,4[U:UJ9-SX9N+;O)9=3 [X?^390U,,RNH4Z"8ND.2DN\W@NH_A7&NWW2
MDF3GZDGO#</4;_8B^&HFVBDXO[[7,W&VQ0I!SD*A*CIBRCQ,1!YB&D0QCDC.
MTR2+>9%K62A->H[-U)JZ.CC=R5\649;KEEO )/ !V/1. !;!@)FP+@Z-TN;O
MJ)D\]=MCG1ONI-Y#4UY;>>$#U,9-#M<3_2!#7/,U@W%5*H_W2 VL[I"JXZ\[
MUM].1C*M;Y*V-:* R50G)._764M"P_2T)NBJ$%9#(K-I4R?6'&_&5+]0.Y.E
M!AXUVU3ORH4\N"_?U2Z]G,SK4DZ3A.?!==S]YJU)7]1.W+*.LF_(.TE\UA;6
MTO8P3&_4#4);_/TM0O]%TQC1O7B>JJ7FR^_T53S%7NY[61!B$8L"$R8$SKP\
M4%'VM$CC1,09AX6(=@F,$R':TD2**#1 M(>);GS(7%*C\)"ND ;1H>.2G!$<
MVEMPY-C0<7$.0T,GGC/J@_G\LGQ<_*A$VUMSSH^'>Z>B>A)^*!7-3W!*B=2Y
M.">8\B3 :NXU3](B89$/N,@&,S#2I;;B""\*O*J4@U?W<E4;S^+T/1BH820
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MJ\7+)C5['8(EB<B]*,9,D P3(BA6+5G5Y"CB<R_-0T\K.?HT"<?:U-!$&Z*
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M'S7YNJQT27]',_I[)3%%I>2A0J+AJ?ZA=$E8>WQ[ZY]*:@%[/</@#%&8L6C
MG/X4J&$(J1YLBB3:Y4L>V6K.%)PM;YM'[5]T&H%CR?# :(]JC(Q@V3=09HN<
M43RJVKB#:T?52ZX3A"0)@\K16IQ^'3]+$IC^#M6-]@II5C;:%>B\JM%ZI?&+
M1KL"'*T9W7G@8QH:;D9/KKL<UT]7]XO9[$O3>G&_H8D?^CAEG.&0\82E:9#E
M(6A*@7N672OTIBWWC_D4?,'D_H,!L@8^S6?XN/2!C1SRKYL/V\B"?E/2H%8<
MFX>;T;#_)!T'-1C^IVHPJ/\!;/<3!%!VE&A6G<J$J/]XE%0G<Z["1IT13G[J
MI<1C/BX\0C'QO !G11I@/_=9F*8\I034=] %DXYWC9HP4I2!P[*<?AC 7O&!
M<,-V!PC2]O/ SH!BK!0P$Q8_5_;7&2"#$[_.H>5VCMAW\<?R\7<Q^RF^+>;+
ME^HI"55WUX!@GWJY*@7P<5XD!,<Q#^*0,$83[F*@V#XCCDVI_(V/W4P6.T!4
MSSZ.@1/,!AK-&KN=6TR8/1>3D8>.';#Q*:>/G0++= S9R?7@<;CK_UJ^3WXO
M>37A_U'!"O:.O.HZMM^TDZPM>(6VLWTT#_.GY!T.UYTI*C#H?DI*RX5]/4(9
M!>Z.K3=:^*Y'F&X0K^\Q@^YO\VK^Z[Q8JM4,YH&=>-VQ$MU)9TD%73;YUIW?
M,)-I8*= &-8J"_+#-$M/= >SP 8D-6OM=F+-\5JZ]0NUT\IMX%$SAWMS.[F]
MM*)+L7=Q52ZJZM=Z5?GSYHT[(7\]YLOU-7B "Y%PG,0!QS2(/!P&J<K3XSYE
MH!*Z,_D9[V)<\8#SF@FTI'_45^,PS_Q<Z/4<]!$!=78O7F/=\%<_U;QZ@5H>
M[7GNEL"RY,"?R\VH?KPEZ/;=>5O+&A9Z3"OZ_%R*YYJ.*BZIVT-^W4S[BTB:
M"I87.(U$BDGF^3CC18;3(,^2.$X%S0BHD&. H&/[MDM>V;F6@3/F)0YBJ&?'
M;"(#,U1G@@*OE="4U%8MQ!"Y<6L=-(4_J&70?0]^0NG4MRJ[\U.4[RI>"FA-
M?7H%Q_J\>T,,;#_=(_?PN<2.R#!%[=!$:Z(( @'H/#(LH=&1I&?9T4XEPZ)U
M#R8:3YN66>;+[92&SM5=')$P(2F5NVX48)+F#&>^R'&6QL2+THS1 -1I^A0A
MU[NM)-N9ZW)1IY(97I&>Q$IS=[6  '!7-1/>H/*P7S)K%84GR(Q<*=@O[&$%
MX,#S(W?LV8Q4F535ZK5)^U"%PBI?]DHE7(HYKS/ TZ3("R],L)]DD;0 "<=I
MX3$<$<X%)X*D/JQ\QC7'K@,3+4G$6YKH?2IFP"1\]Y]-SQA]JH\!LVH6TO.V
MH[E01XP+M/G$:TGJ8,DG:/,#1?VCV_UH\_NY$C]LP6^M_0^8L$%CYI.%F8^_
M2S;>FS^;.ZCV(C)E/O>*(L6\4'-^"]73+<E]'/LY"SR:TMA/M?LU@\F[-O,]
MU<FHX6;]/PT_@ ;'<*C[K;E[ ('Q9BAV)B,=X" "FD<[!=.LI[2]7TA8GVEC
M*'K;3\-7':\KM;'$.\VJS5<QF4W1! -NB^NR5'O+MH6(;O!7=QEW5F,31UH4
M2-)?S,5B5<W:S))])Z_;3,=J:!B*@^'<!PT"(PZ"T!=W=S($X#VSX^U=V3;.
MJ;6HM>.QR /A91F.6!C+$ZGJ2^.%(>8^#Q.2$98'H%JQ8T1<9[6L23;6''9X
M/ J*WGGO7%%A&KTGI8/1:'WR6#K\'"4QZGFE3\C](T;OL_"-Y=O\;:JT^G'Z
M*OB71:WE\B#R94:?=6]D>I9PK&3?OM_==#>*F@-4+,K=K:2_AR\(DN$MUA(:
M,#V$ (%^4[Q8VD@UI#7:/_O6'6W;U!"NNUOJ/ Y7T";M]E)^6/&X6), ]BGH
M6\.QBL+:%O0*.ZQ[MN2$*5^;&%V350U'U/=751%[2EDYZG2@([21#O8N/)H2
MZHC7U4*MYTVB9QK)4U+IQ?1Y_O?I\D5-!I[.G^5CHEHG&1:"!D0$%/M1$6"2
MIPG.@R+%OA>K_R5Q%,3ZX;2S^7&L^2UQ]/N6NDKN%)!!819 UPFLC0HE,-*F
MG=FYQKO#(JIY',[M= (\)!@WZ@<PC,Z-\2& @3MKL/5'\LXG,V)HSQHFN[$^
M>\NZJRUH&=AYXFHJ7U2MY*9TMBXP(%A0U6PO+$*<L2S'<<)%P5GAAPEHQI<-
MIESG!;6DF$"Y6/XNQ!PIK9K5=08EE6<EU<;[QY\?_HP*(3^'_(F:AKJ2:O?>
M/J-;?&3U4^E%>\;^ *[WKOWGNGQ^4(F"+GPCUBD,LO3IBA5T032I6-!>V\SP
M3AA3>:[5'7U7+?W;<3'K*NBIJ-:MW3O_M#WTM6,8.M,J<D8*%F<X$FF!24HS
MG!4%QWD69#Z)8L9ST+0*N^PY-L:3R\O[']=7Z/K_WEU_?[A^0)/O5^CV\:_7
M]^CRQ_W]]?=']/5F\NO-UYO'F^L'F-6U_)WT[._'H0\,4;1\HI;1B\W8HPYC
MW8D6G7_NA# N-F-%[):DNH73DF6VS-RH-MH-L/O6VA$5PXO%MCV%W!YVQACM
MCS:KN\4G48YI'L:1Y\5I6L1/<U7\(O@CX([Q!#TMI<X:I3Z@JJW@E[1Z06\M
M"\#+QE- :5XXGB.WV:5C2[&^W]BA:?':<4 J6U>/I\B,>_TX(.S!%>30\R-G
MNC<-2K:Y]U5M9!Y?Z'R_V^'?I:?X(O]W\E.>])[%7^32RRNI<IOTR_TVM0F)
M<)9Y$>8\\&*6,L%I]-1T97]8TG*I9QP^@V@0A=P74%LWNV5CM)XTG8OGZ7RN
M_EO^1[,N^F4Z1S\>KM1_HDK)_:>1DNM=_J9X M/0\W#.,L'#-,Y\P=O?E.LY
M_Y_\>[(6[XS?$I6"_S_L]T-O^_P,K+K;JBV4<+3=ISJ"MD>4I13U:/_EM;RH
M%1C5$B,E<J<@Y!,4>SCXA!]=#V)3I'^.DA$'']%:58D+WLQ\N]I/G*IJ%G52
MD63; 3=/"14%\4B!LXBEF/BAW$!%$N,L\2,A1!Y'402)AYTBY#BRM26+F*0+
MVZY.@J.WA=@0&6;6.](JDK7U;8G:,ZM#8EDR=2?)C&I^AH3=-PF#S\/4M([;
ME.]/DQ_K.\(4%T$>X41D&:;RWW#&&><DCR*?:E4#;Y=T'51>22CH;$KUE*XC
M:K]ZF0D C,O^>'B\GWR]F9RO-H?L]B1]M0\W^M'^QU8U.DN-H@2'K*]_W8_\
MQ&S_V=O?=J<>=(XC5]/9JBZY7$<EZQJ'2:Y^Q=CR*9;G_SS-.?:]@F.2%ZI9
M!I,:PA,>!MP+.0%=H-MAR_45NI@O7J=S]7OWK["-S1+J>MO@^%C"=/W@6'(P
M)V:_Y\[VCA/]MN;/XFV+7< L;<>6F!IU\[8+Y/Y6;WEU@PSTY^=E6__U?;'\
MAUA>"6E%I$50-Q7 %L,Z:[GV%]K69F);@[@;FY",(<D9VK(&2&#7P:K?GKF
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MK2FCEC12M/53;8_+W;\K61$9MJ6820M*I^V5R"B7]OB*HR72]@K4S:+M?]#
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MM; :RP]6$:LO:KLNUN I\S?B6+KZZ]?'9SR;?=BLIG.^6DVRB$99FE) &<,
M<A:#@F80B!23-,8A1)E6<O>9]3UK<44Q*$D&#4W]%^(I0/I?B!>*:::@9A(:
MO0\[Y+!Z'YY:;[#W88<P[?=AU\=LYECL2JRJ&@PURO+NC[G\)G^?OMSS.9ZM
M7Y\DFBO59:(^".,(Q#%'(!=2XPH:"X!A&,:"Y5%.$_V)%D:T/2OBCH-@T;!0
MIJ&\</G O*-LZ&)0-0[-_J RCX/M:A];F&UY"6IF@BTW_H SF8'A#4#+:1@N
M@30<D&$%1?>H#+,E!QR:827K_O@,NR4L!VG4O4;KK-']]&*:4T%2E(,"TQ!
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M7Y.P?"?N]U%[PPE9VHGYNH]=U)OF41XCN6K )3=P=MQ^!>8IY^4L4>GJRQ-
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M==HS>H;JO@5N2ZW)UI; /;: ^S( <";-A[T!:-F$V"60AMV(K:#H[DILMN2
MW8FM9-WO4FRWA-V!I=T2N1E<?R>N%\_/BWEYRSUA84PBSAC@0D"5?2U/+;QT
MD2B)\S1+P]CHZ-)+T;^GU.K&/:TY4.D:M.3!))%('T6]HXU3;(S]JA8L-RU8
M*O)5#HO+J=2:HCJ;2]U';^#)U)KB'\^FUGW0SB#\AI=3%0C9%;=F89)$*2:
M8<( )!0!)&(!6!S'*<-YA)#67,2S%#PK?$-OZW"9Z?8Q('JZ?)&89KJ[E=!+
MJ>]901QIYO'Z@VKB6?$.->_\![WTZQC_I+.-ND)0&<?R?RKY>,)H(5A8($!#
M)'41<0IP#BE(&$Q@%LM#$HK-+L(MN/!^1?ZD)C(%RXHSIZTZ3H**XBA/PU2
M,*8I@ 7$H$@Q Q@G0B*:$ :-2LL\0VHS6WM80/4,I&>8S$RH1D^4,G^W8BEH
M>%*YO(,U2.E"9)AF*2<Y>$^-4[H@,FRBTKF412SL_VUFT\WJ/^>+/^313;]Y
M[8G'_&E!12RHJ=FTICTEI4'4Y$)I[4(C^U(["GIT2-(9V3CUW'#ABPZN]V(4
M79^SZ%0XF^T24IIOC6YKPA//^KX&G<U:"30FDUE/R=EM UR(:&8##J1SF&?;
M)XM=;\!3"P[7#+!#G+WN?UV?NS QOM7A<=N)+A.($19F0![>Y3D!JZ1XA"+
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MNZ+G)+T9UF:F5GM 'U[W3T^\"D;/JKC):0&:>Q3=5:HYY&WHDC;WL)ZH??-
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MCS7^6<ZB+$/4]=W3[E<!+P5R;\7/[H@[>^T"9U^6>;<9)7>MS_.WFB_>!]>
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M!RQJV4Y'H(_-RH=#LS*:SS=E)*:<+E('YYK&U*TLCDG*<9@07( P%Z'TZ+
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M:3A7V *,[DG#)@L..'O80L[]:<0V"_@+WUY_5V[KS7P\QV5WJOUAQ DH(E&
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MJBB_([/IMY*1C_)#L\6+HO]E.N.K]6+.5[_AY52]2Y0$4U:G.DY83$/IDU/
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M_#)=XYGBL^F.6A]A##TG/QMJ>H)\HVUR?*B\>(<N.%EZ0-#Y8=,ECV]T_O0
M\_DCJ0]B%E7D=VI+_ROZ.%7):'.VJANH%8@70N0QX$RU]4 B X2' N0(93!/
M*0ZC3+ON^S0-SR;WD*A!\>T93+KMGB-)#4/\5>'9?T7!EF1_-SEM@0WJ@R\7
MW*ZB]P0 CFINNR7JK)(]\^AP=:W=O.]5HO9\U,Z1;%:39^>;N=1=OEI+Z\6G
M/TK_(8W2!.5%"HH"*=N21O)@*QU"P42<<Q$7 B(3A["3FO?TU(I@Z16PFI%@
MN25OYJ]UXZ;G=SE#P\P2-61+(+:H//0#8>P6:0GHR+WIIC6HFZ(E]J&[H??0
MQ:?%@^[\Y5E4-<M5#?[5I-"]"R@60HCB. %%G L N3H98DCD/Z.4IR%%(C::
M6V+)QX!7?B4?575XQ4GP>;%JC<"0QXD954V M=O>7KH'QD<X7\@:'M):H)Z:
M)'(,]# W?U;PN#^!&7'Q5F<L&Z@Z3E%6RPW<-[&^8AS_5&.D5HJE*HPWB6D<
M<=4M45!4 "@X!RB."H"B-$\0"1E-S1(A7'/H^XQ6D0WXCNX;]$L\NSV:5O(M
M0;</<EV:[=YBN^FB^ X:)O9A^M8-$\_R]^=HF-@'K[.&B;V$+$TX_Z9(//"7
MQ5*ES)E6OIQYW*/&5A2#+4D_-2,]<KG2FG-DAOWR]PA[]!WN^[QY+</]CY<#
MAURSHN'H0<\O:*F2P8]5,XP'2WR;!G<;Y6\_Z8<X3HO=K7872VRF:R>$]7%\
MZ)3*JCCB>+7!2B3."M(NE#C_(7/5^22Y7,RYN@SYP9>O'S?\:?';=#&K+TG^
MOGCFU^HZ;OGZ&?\Q>E[K:I;INIX5KV8G:/@)V(:KN3%;EM016#$5U%P%DJW>
M49J7H]FOL#Z!---G/Q@:Z;DM&%9FP)C88%;"%H:V$;%>8^##_J[F<;7:/%=N
M[,-T];^?EIQO8["J[11,\J3(\QC@(B< LA0!PN((<)(AQ L:(V1>5.^38\\F
M3Y$$0M(,ILWUP5*[N]=PV^8Y*.!C,P8/$K1*W%MB7 5*D$!)TKHA<M++;'#8
MWSJ.H,WOGR.N8 J_LSB#,6'+SG"+^;98M6GA7*:3;0,0"!)">1J!C!4Y@")#
M .<P C2'F2!AGO#"Z%*\EZ+OT.[3W\</P<WM]=V7<?#+^+_OQ[>/X[]>!;?C
M)\TJ>7WL]$RR4T3,3&J;=--#_I>:^E^]1'2TA775KJV7WK!=VG3%/VK.IOV@
M^6C)\7Q=%IC]O&'2_$S%M,KL:^Z"8,H%Q!1 3B( 8TY D6<Y2)(X2V)(<19K
M#=+KI>19\2O:@20>[%/ONR0PQ*M;Z9VB8*;LU@ 8C:_4$LYJG&7WRH.-M]02
ML#WN4N\!N_?W6(BJ>7]E$R01Y12HL^B<3F?3DI#\X?62L^EZ-<$Y21($$0C3
M DN%S@4@,2WD&QVQ-$XHIW'>C$AXTG^GFW&A]0W?GY[P9*[NZFM.*X)FKW5#
M2/7>\1X0LK,!#1_-VU[!I%@)]GFY*G]1L>.A_X8='(Y< D/B@_H'=L <.@N6
MJ[Q-]DFK5NR@IJR^9.7EC-%)GD"14D% @G ,8!XAE8XB0$8%$CR'B+)P\E)6
M(#RN\7+M.3AEQKV)1A_*H'^T:16E5O-@"/\VG:L\)/6/:MW+1P8/M-]1GLJO
M,4\!1B0#,,T90#B"()=<A3FGI(B+>K_'<\V!/N]VMQL)+MAKE>/\Y]MESU%+
M?_LV>.QRF^"T5S%]5&#="%2-QGX'$4R[+7CK.*8AUW^.:*;=5KC.G3(E;^>6
M[$VR&\W9 Y^ID\2NB;UAE$Y[/7]&9']*I,HFKYD(=EQX"=H9R^Y(>_7I#JI_
MQG <:I#Y F[R4>J0X9T8S\5"?L=*S;PL%>7,DF^4A5)S4Y9A[/AQDWYR#CR[
MS!,'N+E).K&$[.)LDQX G"6:G*/SICDF/<+WI9?T/3[P0?[S=,YOUOQY-1$<
M)I$\FP$$(P8@BU)Y1D<4Q DC24AP)F@\2.K(EB7/AJC=/Z7?KR?'?GWPNV(U
M*'DU;:)R^7YY/GU9[<+ !RN]#1CNN'2$V5N?A'8,_3D..4< .CN_'*]L9VBK
ML;=ED\][O+Q;EK.U69GMT90+3J(DC\,L1P#R4/XA( <H0Q@(@:."4)%'2*O/
MB0%-SZ;RNM4_[RIXP<O@1YF(=6FD2@=-/3OG&",S0U;#4X^FEO3E5RJH.*@S
MUK;UQ.ZLE('$CLR0#L5![8P!!(>&Q.31BRU%U5CO9K7:<#9A.<L132,0PB@#
M,$,$H)C'0$ L[4.$,"YR2^O0IC.H1:AJ:X-I2=F^VO8<9,8FP!:(2]2^HGD5
M5%2]Z/DIL=SK]AZ5M]+G4Z)VZ/#)CUMT+GO@/_A\PS])UJX7\S*.\X_I^OOU
M1G[1G_E2_?W[8J;"GT_X)U]-<(1%46 &5#H5@*C( 4$D!S1-.$GCB*=<OZ69
M(7'/&MXB%ZP5O4!M6+!YD?^1#KC@FEGT5KAV:[QOM$Q#NR4C@>(D:%@)%/V@
M8>8J:*-9\N,1/(,6:QY!M.N]YAA,L_9LEFAT]FTS77.XAFZ6TNYU>K-=P\ZE
MVJ;$\%6KA5D1I6DF4 **-.8 YDD!2"@X( Q3)"#$62%,'*J35'R[4YOE4H4U
MIE5FE[2WUOW>3H.DYT)=++J9Y=SEL<FWRX[@55##X<Z)ZA3,D0MUFL:@#E2G
MF(?N4_>'/0R=>^!JRD'SRR>^?(XF<0[#G HU^Q<C>1K*($!%)D"&<9S'B!)&
MM3+4;1GP[40=3B)8-BQ4X^4"N>;S$+/G3F&O9Q-\(FIF+OIGSVW9J3X1*(8&
MFCS7@<00D^=.D7\_D^<ZP#&:/->USMMDP)9C:5<W\ZI]]J_2)Y*'0IRC)&($
MJ(;7 (I4JC_F&)!"VCIITQ)A-EK% X^>S5[3@^V;HBSU<SIOYS:^22>V4QL5
MPRS**8E5%"X',,D)4%>=0&Y>CI,0H2+-)O*;1Q9_DJUJ\ZJ]6;_6F_2NML;S
M[:8;N >^[FSED5:,*[VJ6%<_D<R_@SO0?F3?^E*T@\,_QRUI/\2NTSZ[2%E$
M64?KI^_\"U[^+U_?"<%5)ET]'0 5C!"!4R R99:+-)2G>A:I0=2%8)")2*]_
M23<9SV^_T3J0A(.*<M"0-@CXG<='(R[J1&HSRW9:8)NA$><E-PAJ.D' +GQI
MN/5FX<E>N3H#D>>?'B[DV"O!7G"Q_]/^"F^OE8W[4*XJ?U\]4:553L*HH'D8
MQH!#QD$NTAP4H@@!R](PRT2&8(Q-W/O+V/%LRRI2*L.4*A8 *7DH Y0S_(>'
M\MP.X/5\PN'@-#.2^N6[)7>@8J_\5/6HN[Q>MU -6-K;P<R[*_7M!\ZF]%=C
M53NC^'E*RY8DWY:\] A5<*69V92$D(6,,0!S*,_)<9P!',((1"A&:1[B,#5+
M#>Z@Y=F<U92#+6DS ]8%DIYU<B2ZF>DYDKH,C&I,]3*V*!KB.3(7790&M04:
M(A\JNLXC=EK\M:PL6*VGS])RK"8PH3E#$ )(,_E'DE) TAB#C*0PPP(F26AT
M-;J_O&==_5I7MC3DS%3U  D][;27STPA#T6["NX7LRE]#7ZO_^MEMLQIZ1SI
MX\'B@ZK@:<$.M>[,IVQ[;MUOB-RJ3[,%ED<"AK(LX_(@$",DWY(D TAJ&\AS
M#/]_=5?6W#:.A-_G5_!QM\JHXGV\3)7&469<FY&]MF=VM_*@ DD@UI0B>D@J
M$^^O7P D)<KB@:8 VINJ^%! ]H%T VAT?QU&4>2;KE1.9^?;=>_P*VBIBJ A
M*$+AM-JJ&#:TBP4$[KD!LDU RNJ0X0)TK/;;9D;$ZA#D' 6K:Q"\MO4QQSP=
M:)'GB^^;0K9\]?0IS191$VO'Y27A)3L$'+:'RV2#&4.'6,9G3E)1_X%N.285
M@[YZU6SUGMTBM$LZ>T9,L(.LQ%L1=.<)<B2_+W> <N[NIW7;!2=JM*@:]Z3<
MYSMPB7:/[!*F<K'80).9*#',;@:%FF8_W:^<SXX&13JQI^&1$V,965'P=%1F
MJ&27;$CQZ5 URX.WKI^&**%1R/9G[%@4A8&)0BLV(]=-4A.# /+[2>F.9/!N
MGR>4+RA''E"89%A#B1J 48V)&H '-4:%4Q73Z"<T;TAC5."SB,;X$]-,^><]
M%NDII+C9I>3K[@#!6BQVZ;\PW\IPT!5Q;&;?UV:8FC2B(:(6ASVVJ(=P0 BB
ML>G3) @#QP2%*H'T-1O]D9NZ)?8I2S"CAZI6SA-H5!C,/1P9N3I3E-#>D1FC
MX49O_&6B:A0Y%RCU63W.1-6\=D-37P/?OM_LB@V_@SD<!V17S.&']9E#3=/H
M. 6J7C?E1)RTL1UX[6R;VW'1VAM<B='P".0#2?;YIGQ9?D^>^"RN\%>R]KS$
M";!/4>*X*7(CZB#LD @%=AHFL9V8ING)!B&["&A>VQJ21D/3X$3E0Y&=.AF/
M1EXJ*<P*@4*"8I)#DDP*2W:^<+;(Y) X[>#DX#A-10'%2+[DQRRG9%/N>4UZ
MG30YB*1K1B8./"M"GN.S7:MO!0B'A!EQZ ;$)$%(J-J* <4":'8-U[QOZG9+
M4HZK0BO6R PXR:JG66X'_9XG#^CM)#+>"]F4]Y94[;SW]P.BK&E:YDJ75\W^
M^\JEUS0YX$1[77Q,R,*OJ=_2F]VFW.!M=;_79-I>9T59K-FZ$P16["(K)3[;
M4T86"LTP1IYG$4("AUA>!&@Z(TM7RB5=W&:F\309%<A%HCEWPLD#$M9EE#CL
M]I7J9&J/<J&'6VK4Y)L;\T,J_[4&M0 R^A6K9UIN_\5J@F7[ V0>S/N7><]\
M%0  J4YJ 2#/3?"%=49>#6=29W1&Q*21&\0HX D]KFFZ"-,T1"1V',MF?Q(J
M7XS414'W%5&=]IE7- 'FVZD."3=VJ9# "Z!3^:;4&W4*"G!,EPH\S1/)3BS,
MX0S),NAA.A^<SZ4,\7WB0P8'3LV:Q_%F*W#_UXYO8S^F":))Z" W=GT4F;:)
M"+5#T[/CP,7FNN3WW7*'^-:[08[B0 &8YK ]TH-FQ1^5('?$G2@:U#V,RS,A
MP?V,<V4)[<<WSYS ?B;2><+Z^9!I!K/8E9MTL]WS,I<Z<L=>RF-V'S*.[;$.
M_=!+V5]DL;,'1_/R4>RSLX=%$X^D:6P33""AL#&"FM?@-GGC2/]*Q'V-SQ4/
MP&R-41W*&:%*S< L\T*E@(U65E)%ECQ*;E;SEA7^M<U+/S<1'AD_;]BJ(]IA
MI$W (^&X;^E/^W*5E?\AY1W>I.O8]-T4!RX*'&SR7H(8X8BY!B\.0X[[%UDF
M*#8N2UBS8[C+.=I7^2)2$<B?^\VS.%P^L^%/'/N+QSAQDO TP\)XQB\<G$V,
M91_F'&695(U$@&NUM-KE?(@.9<)\2<V!T6;!:'@PXGUI,"Z,%U(:G ^%L,Q
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MF3 ;:7K9VE02>PL(NMU9][D]S3GQBEE(00:43$1>O.600[)&:AZ(7I?KW.F
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MI_NFQ%IDA+(@4*K4$.(Q0FG0 =)E);4E.<;:E1#+-#3BJFZITR=O\780<#L
M^8!R*AU="@M_'\R^'%Y/9QCM38Y^A.%UR1"6AM3XOWCI?N"6P@ O4@?2$#2X
M@J#WIH($362F!N.^G&H?0EN0V2_,=L/%\R#;FY*VQN'W-/'CVCU4;X:(W8LN
M46UT%@J2(+;,#C>X4\ML7T\<#R1Q86O?"JPDII&SK8[QJB/R)JS8-"$!95+F
M>]PKP_%\0LL-5U<\<^*B]L D>G1"60+.N;();3(V\EA_9MM:@OJU3)64_G3:
M224---$MXR]IA%(:(C<'\>M@-"@2F@V^IUN&I".$)6=!2UYFN)3WU\6K) X#
M2AE53-7?[KU 4K^&:3^@JJF%)F#U1$Q7$:.3F#!N370^QLY)\,Q(2(9PC?3+
M&/<V^>V6B'XK2?<#G=TDO2M8+NOWY%U<OWP<3Z?%E0PA!PHTEFM<92@XCTX>
M=Q9] 14)IWI?F+DGH[GZXRJ>T)9B;J IQLEX-'[,Q>TTWKONUKJ,U^06@N8$
M1,H"3.8*,FX 3Z4US-8^M%XDJKGBXUU05%<%/?K5I99AA4N'?.&?> @O&+PB
M@AL?M0;/RPC$(#E8IRWPX(I?1Y6V2W>>3PLENB_7K^M<6;_CO0J[@;#L_>#[
M(*917%!_9V.O*"<AEJEVA!3+RK@$HVV &#BQTGMO4^T)%BM(Z==KW@^>:DJ_
M 1#-[^Y62NH*O4"=C7$@K:484%(#QI91>](S=!/1V3.UL;2>HG[]HOU"JJ(N
M&D#6:D:83R@3*2%J42X"C0$OE(5,610*36W.M3MF[(:GO7E(^\53'0TTX'S?
MAPVW2?K!Z!J9NJ_!?)?R>')SCE^Z'VEZ] /EA^H;C-SDY]SW+/,\2GI_/!S.
MY8%(3]/9%9<I<9<RZ%QFDWN)$;!2*!D?E><V\&QJW^GND9WFWH7MXO"WHO9F
M=@"R>+.#WZ51RJ43J4E6J: A)RU*FY12G4$X*,I#SLDY(VM?.*\@I;EW9+LC
M;S=Q-Y$2/4FS!SF7%*SE* 2@R2LT^[Q4X)3GE):3&&@RW-1^OO&(@.9>C.V4
MCMA:M W8DT?$'WQW@V$IY[D</WC&=--<])V;#L(5<D6\) *LI[&X(0G90W/)
MC0LFL$B)J7W)MR&)S;TFJX:MRNIIHARA.X/O!\-KM(97WC'T>4T %11N,"(=
MLECZYDB*)_A\3G?MJYR-B6SN2=KK8' ;%340H/X]#3Y_0;H/$-CN<SJY+E6J
MI_G)\\W%%A/(BD2OL,S@DF5X)0'O!(?@6*+1DZQE[6NAC0CLEKLE;P1\^]--
MN\"[V49/GP]3HW),PH(IK56$3B7G8RAD;Z/6RA.1PNM ;Q6)W<#W5JI.]ZF?
M!N!W.]CBMK?*8@])QXD1R8 11)>1*1D,\02BL,X22TBN_O;A64*Z0>FMU #N
M+NL& 7-[WDLO=204@<XY!8'.9CGO&6@N&%$F)DEJ-[)904HWT+R5<HD:\GYC
MK0">F>CQB)'=6@*LFA>RI]8 +S%3?]C#FI$CDJ';'3PBSZKR($\)<-0PL#QJ
M09Q1Q-2.FSH15KE]@*%$\](<(PN&L8<2"5S2$7QD+F>9K29[8[.!]@'UL?!"
M,X%-Y-W $79'_4(B&,-^&X_*;IT_F):<I"0C!J[>6Q )'3B?DD#KFJV,D4<A
M:U](KB6H$2QMH>E5H-E9[ U@:(F'F_>Q-AKK:.DHIR@!X1P'QZ*!G'Q4FKI@
M3>VROV<):00SNRMZV1G:6>H-0.=!SNSF,;1FV2@:!'!1IAK$7"8=! ;1*Z*\
MP>A U^Y'\(2(?B%30;&K>[!M(>4F\N+/] &[867>!RS+ "&*XO(3!99(!431
MB'%!SDG4/J-6$M-O75]]X-21>@-V9L4\W!MFF.>EP;>_F3H04@9KT!:GE#&(
M\MH)7KN8;RU!_=;RU8=1/>DW *7E,;@W7%C'7%0<+:K1I1T(9^ #?L5X8DI&
M*QBIW^'@.4KZ+=RK#YX*\FX -1?7?CJ( X>VU W3PTE@3&I!+4] K$'XQTC
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M)J;TN8P(PZP%&&V9SY(JQFLW0.E(VNX5/6N7>?#2*B>>I-8H IY!,,; TQ!
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M!MWGGPXO\5_L8JG6?EX->]6=X&H.%2+L.A27&^$VBC=E;S?UEP\[L"V.K&3
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M27KNP?ARY9ZH >M5!I6R9<I@/!IJO]]<24S/)<?[1%,=!;2&I!L6:$B,4"&
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MU#%NM:4T&Q"= ON=EQSX9*H$@$=Q_7[$/?2ST)*KW?5Y,2C'DU? E<[,V&#
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MJ4Z2^$1Y1&QN4^[%X8MYCCJ+?=D?^%["UMSR=/&T?-!RIE,V*10/()3"(I\
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MFN92S4Z,R4-U?TS:V).*: !5G;-^78A@I'400G1$)TQ2MY6J?>)GW$IHJJ.
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M@SQ-[E&J>7\IE31S*240*802BJ'E@[1,J%RT2_]^Q>P)%&=TEF^KK[CCD<@
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M83LWQ7^R\XH?4KIU/355P$4J[=]3!+_(P*5$T'R>,[7NL>W(!'MVJ08OL>/
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M5$WMW>!T@ X: -23CY+;C]]\PV>6(@*5WD?!"9&Z]IG5@:PFP74("/9Y)CY
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MZ[/MD"!\7; ")K>I$10M&;3GWKN1'F3U)OK;2&5#-2W41:'9ZV=L(;/D@QI
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MZ)N_L/]Y( 7]_:?_ %!+ 0(4 Q0    ( (" 9%REI$V1XPT  "#2   /
M          "  0    !E>&AI8FET,3 R-"YH=&U02P$"% ,4    " " @&1<
M_=#>L^<(   Y-@  #P              @ $0#@  97AH:6)I=#$P,C<N:'1M
M4$L! A0#%     @ @(!D7(*J]*JR"P  "EH   X              ( !)!<
M &5X:&EB:70Q,#<N:'1M4$L! A0#%     @ @(!D7+UIIMNH @  .@X  !@
M             ( ! B,  &5X:&EB:70R,3$Q,"UK9GDR,#(U+FAT;5!+ 0(4
M Q0    ( (" 9%RX$.$FNP(  (('   8              "  > E  !E>&AI
M8FET,C,Q,3 M:V9Y,C R-2YH=&U02P$"% ,4    " " @&1<['TX"_4(   0
M20  &               @ '1*   97AH:6)I=#,Q,3$P+6MF>3(P,C4N:'1M
M4$L! A0#%     @ @(!D7*#T?ACL"   F4@  !@              ( !_#$
M &5X:&EB:70S,3(Q,"UK9GDR,#(U+FAT;5!+ 0(4 Q0    ( (" 9%QBY.2%
M7P8  $PI   8              "  1X[  !E>&AI8FET,S(Q,3 M:V9Y,C R
M-2YH=&U02P$"% ,4    " " @&1<<;)CQ&8?   >G@  %P
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M+3(P,C4Q,C,Q7V<Q,"YJ<&=02P$"% ,4    " " @&1<*<:F:-6:  "CT0
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M,#(U,3(S,5]G,30N:G!G4$L! A0#%     @ @(!D7"2C"H]O704 N'4& !4
M             ( !=GT+ &MR;W,M,C R-3$R,S%?9S$U+FIP9U!+ 0(4 Q0
M   ( (" 9%SJ>(<V>[$  .SE   4              "  1C;$ !K<F]S+3(P
M,C4Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( (" 9%R3V5+VSV8  #6!   4
M          "  <6,$0!K<F]S+3(P,C4Q,C,Q7V<S+FIP9U!+ 0(4 Q0    (
M (" 9%QQW,!H/"\! #62 0 4              "  <;S$0!K<F]S+3(P,C4Q
M,C,Q7V<T+FIP9U!+ 0(4 Q0    ( (" 9%R>=XWMR;0" "ER P 4
M      "  30C$P!K<F]S+3(P,C4Q,C,Q7V<U+FIP9U!+ 0(4 Q0    ( ("
M9%R'V#F!!4(! '>C 0 4              "  2_8%0!K<F]S+3(P,C4Q,C,Q
M7V<V+FIP9U!+ 0(4 Q0    ( (" 9%SYK*>E^/,  (N! 0 4
M  "  68:%P!K<F]S+3(P,C4Q,C,Q7V<W+FIP9U!+ 0(4 Q0    ( (" 9%PW
M.G35'=8  $8: 0 4              "  9 .& !K<F]S+3(P,C4Q,C,Q7V<X
M+FIP9U!+ 0(4 Q0    ( (" 9%SLCO*2P.H  .U0 0 4              "
M =_D& !K<F]S+3(P,C4Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( (" 9%Q@X4+K
MOC$! -$@#  5              "  ='/&0!K<F]S+3(P,C4Q,C,Q7VQA8BYX
M;6Q02P$"% ,4    " " @&1<UHWE8#ZM  !ADP@ %0              @ '"
M 1L :W)O<RTR,#(U,3(S,5]P<F4N>&UL4$L%!@     > !X QP<  #.O&P
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>kros-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:kros="http://www.kerostx.com/20251231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="kros-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2026-02-27</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:KeithRegnanteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:KeithRegnanteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:LorenaLernerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:LorenaLernerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:NimaFarzanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:NimaFarzanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JuliusKnowlesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JuliusKnowlesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:AlpnaSethMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:AlpnaSethMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JeanJacquesBienaimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">kros:JeanJacquesBienaimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kros:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">kros:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:TheGeneralHospitalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:TheGeneralHospitalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-05</startDate>
            <endDate>2016-04-05</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">kros:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">kros:O2025Q1DividendsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2025-10-15</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-15</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2025-10-20</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <startDate>2025-10-20</startDate>
            <endDate>2025-10-20</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2017StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:UnvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">kros:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">kros:TermLoanCreditAgreementThreeAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:EmployeeStockPurchasePlanTwentyTwentyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">kros:EmployeeStockPurchasePlanTwentyTwentyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-15</startDate>
            <endDate>2016-04-15</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:PhaseAPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2024-07-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">kros:WalthamLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">kros:AccentTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-12</startDate>
            <endDate>2021-12-12</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:HansohShanghaiHealthtechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:HansohAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ManufacturingTechnologyTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:TechTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ManufacturingTechnologyTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:TechTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ClinicalProductSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:ClinicalProductSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">kros:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseAndKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:TransitionServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">kros:TakedaPharmaceuticalsU.S.A.Inc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:RinvaterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:RinvaterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:ElriterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:ElriterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:CiboterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:CiboterceptProgramExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:PreclinicalDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:PreclinicalDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:OtherExternalCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">kros:OtherExternalCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">kros:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001664710</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">kros:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="financialinstitution">
        <measure>kros:financialInstitution</measure>
    </unit>
    <unit id="segment">
        <measure>kros:segment</measure>
    </unit>
    <unit id="product">
        <measure>kros:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>kros:vote</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>kros:performanceObligation</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001664710</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-37">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-38">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-39">2025</dei:DocumentFiscalYearFocus>
    <ecd:TrdArrDuration contextRef="c-7" id="f-99">P385D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-9" id="f-100">P386D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-11" id="f-101">P207D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-15" id="f-102">P203D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-17" id="f-103">P269D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-13" id="f-104">P207D</ecd:TrdArrDuration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-394"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <kros:LesseeOperatingLeasePeriodForImprovement contextRef="c-139" id="f-780">P8Y4M</kros:LesseeOperatingLeasePeriodForImprovement>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-846"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-185" id="f-852">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-186" id="f-853">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39264</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">KEROS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">81-1173868</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1050 Waltham Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 302</dei:EntityAddressAddressLine2>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02421</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">Lexington,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-14">MA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-15">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">314-6297</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">KROS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">Preferred Share Purchase Rights</dei:Security12bTitle>
    <dei:NoTradingSymbolFlag contextRef="c-3" id="f-21">true</dei:NoTradingSymbolFlag>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-23">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-24">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-25">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-26">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-27">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-28">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-29">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-30">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-31">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-32">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-4" decimals="-5" id="f-33" unitRef="usd">453000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-34" unitRef="shares">19717533</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-35">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2026 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#x2019;s fiscal year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-40">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data and information related to our product candidates, preclinical studies and clinical trials, which we refer to collectively as Information Systems and Data.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Our information technology and security, or IT, management team, and legal, and risk management teams, together with our third-party service providers, help identify, assess and manage our cybersecurity threats and risks. In doing so, they identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#x2019;s risk profile using a multi-faceted approach including use of manual and automated tools,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;internal and external IT audits, and IT security, governance, risk and compliance reviews, reviewing reports and using services that identify cybersecurity threats, conducting threat and vulnerability assessments, evaluating reported threats as well as the industry&#x2019;s risk profile, and third-party-conducted red/blue team testing and tabletop incident response exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: maintaining an incident response plan and policy, incident detection and response, maintaining a vulnerability management policy, maintaining disaster recovery and business continuity plans, conducting risk assessments, implementing security standards and certifications, maintaining network security controls, access controls, and physical security measures, asset management, systems monitoring, conducting proactive privacy and cybersecurity reviews of systems and applications, performing penetration testing using external third-party tools and techniques to test security controls, conducting employee training, monitoring emerging laws and regulations related to data protection and information security and implement appropriate changes and encrypting Information Systems and Data. In addition, we maintain cybersecurity insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#x2019;s overall risk management processes.  For example, our IT team works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. Additionally, our risk committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example professional services firms, including legal counsel, threat intelligence service providers, cybersecurity consultants and software providers, managed cybersecurity service providers and penetration testing firms.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight of applicable third-party service providers when handling or processing our Information Systems and Data. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider, including completion of security questionnaires, review of the vendor&#x2019;s written security program, review of security assessments and reports, audits, and security assessment calls with the vendor&#x2019;s security personnel. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K, including under the heading &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;If our internal computer systems, or those used by our contract research organizations, or other contractors or consultants with whom we work, fail, suffer security incidents, or are or were otherwise compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-42">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#x2019;s overall risk management processes.  For example, our IT team works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. Additionally, our risk committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-45">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. Our audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-46">Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. Our audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-51">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity. These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to our audit committee on any appropriate items</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-49">Our cybersecurity risk assessment and management processes are implemented and maintained by leaders from our IT, finance and legal teams, including our Executive Director who serves as the Head of IT and Cybersecurity, who has twenty years of experience in various roles involving information technology and cybersecurity.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-54">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Financial Officer and General Counsel. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. Our Head of IT works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response plan includes reporting to our audit committee for certain cybersecurity incidents.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-53">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Financial Officer and General Counsel. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. Our Head of IT works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, our incident response plan includes reporting to our audit committee for certain cybersecurity incidents.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-6" id="f-55">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-6" id="f-56">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-6" id="f-57">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-7" id="f-59">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;On December 11, 2025, Keith Regnante, our Chief Financial Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 24,741 shares of our common stock to be acquired upon the settlement of restricted stock units, or RSUs, vesting on February 17, 2026 and August 15, 2026, owned by Mr. Regnante. The plan will expire on December 31, 2026, subject to early termination for certain specified events set forth in the plan.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-7" id="f-58">On December 11, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-7" id="f-60">Keith Regnante</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-7" id="f-61">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-7" id="f-62">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-8" decimals="INF" id="f-63" unitRef="shares">24741</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-7" id="f-64">December 31, 2026</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-9" id="f-66">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;On December 10, 2025, Lorena Lerner, our Chief Scientific Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 19,577 shares of our common stock to be acquired upon the settlement of RSUs vesting on February 17, 2026 and August 15, 2026, owned by Dr. Lerner. The plan will expire on December 31, 2026, subject to early termination for certain specified events set forth in the plan.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-9" id="f-65">On December 10, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-9" id="f-67">Lorena Lerner</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-9" id="f-68">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-9" id="f-69">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-10" decimals="INF" id="f-70" unitRef="shares">19577</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-9" id="f-71">December 31, 2026</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-11" id="f-73">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;On December 5, 2025, Nima Farzan, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 7,875 shares of our common stock to be acquired upon the exercise of stock options or settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-11" id="f-72">On December 5, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-11" id="f-74">Nima Farzan</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-11" id="f-75">member of our board of directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-11" id="f-76">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-12" decimals="INF" id="f-77" unitRef="shares">7875</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-11" id="f-78">June 30, 2026</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-13" id="f-80">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;On December 5, 2025, Julius Knowles, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 2,625 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-13" id="f-79">On December 5, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-13" id="f-81">Julius Knowles</ecd:TrdArrIndName>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-13" id="f-82">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-14" decimals="INF" id="f-83" unitRef="shares">2625</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-13" id="f-84">June 30, 2026</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-15" id="f-86">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;On December 9, 2025, Alpna Seth, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 2,625 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on June 30, 2026, subject to early termination for certain specified events set forth in the plan.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-15" id="f-85">On December 9, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-15" id="f-87">Alpna Seth</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-15" id="f-88">member of our board of directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-15" id="f-89">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-16" decimals="INF" id="f-90" unitRef="shares">2625</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-15" id="f-91">June 30, 2026</ecd:TrdArrExpirationDate>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-17" id="f-93">On December 5, 2025, Jean-Jacques Bienaim&#xe9;, a member of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the purchase of up to 7,000 shares of our common stock. The plan will expire on August 31, 2026, subject to early termination for certain specified events set forth in the plan</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-17" id="f-92">On December 5, 2025</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-17" id="f-94">Jean-Jacques Bienaim&#xe9;</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-17" id="f-95">member of our board of directors</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-17" id="f-96">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-18" decimals="INF" id="f-97" unitRef="shares">7000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-17" id="f-98">August 31, 2026</ecd:TrdArrExpirationDate>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-105">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-106">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-107">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-108">Boston, MA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-109" unitRef="usd">287415000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-110" unitRef="usd">559931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-19" decimals="-3" id="f-111" unitRef="usd">3567000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-20" decimals="-3" id="f-112" unitRef="usd">2742000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-113" unitRef="usd">22202000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-114" unitRef="usd">26220000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-19" decimals="-3" id="f-115" unitRef="usd">2250000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-20" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent contextRef="c-19" decimals="-3" id="f-117" unitRef="usd">315434000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-20" decimals="-3" id="f-118" unitRef="usd">588893000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-119" unitRef="usd">16841000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-120" unitRef="usd">19251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-3" id="f-121" unitRef="usd">4297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-20" decimals="-3" id="f-122" unitRef="usd">4237000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-19" decimals="-3" id="f-123" unitRef="usd">1449000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-20" decimals="-3" id="f-124" unitRef="usd">1449000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-19" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-20" decimals="-3" id="f-126" unitRef="usd">2056000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-19" decimals="-3" id="f-127" unitRef="usd">338021000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-20" decimals="-3" id="f-128" unitRef="usd">615886000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-19" decimals="-3" id="f-129" unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-20" decimals="-3" id="f-130" unitRef="usd">4602000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-131" unitRef="usd">2408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-20" decimals="-3" id="f-132" unitRef="usd">1978000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-133" unitRef="usd">16039000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-134" unitRef="usd">20870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-135" unitRef="usd">20414000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-136" unitRef="usd">27450000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-137" unitRef="usd">14475000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-20" decimals="-3" id="f-138" unitRef="usd">16883000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-19" decimals="-3" id="f-139" unitRef="usd">34889000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-20" decimals="-3" id="f-140" unitRef="usd">44333000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-19" id="f-141" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-20" id="f-142" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-143"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-144"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-145"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-20"
      decimals="INF"
      id="f-146"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-147"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-148"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-149"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-150"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-19" decimals="-3" id="f-151" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-20" decimals="-3" id="f-152" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-21"
      decimals="INF"
      id="f-153"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-22"
      decimals="INF"
      id="f-154"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-22"
      decimals="INF"
      id="f-155"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-21"
      decimals="INF"
      id="f-156"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-22"
      decimals="INF"
      id="f-157"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-21"
      decimals="INF"
      id="f-158"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-159"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-160"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-22" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-21" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-163"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-20"
      decimals="INF"
      id="f-164"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-165"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-20"
      decimals="INF"
      id="f-166"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-167"
      unitRef="shares">40670466</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-168"
      unitRef="shares">19543706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-169"
      unitRef="shares">40554705</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-170"
      unitRef="shares">40554705</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-19" decimals="-3" id="f-171" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-19"
      decimals="INF"
      id="f-173"
      unitRef="shares">21126760</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-20"
      decimals="INF"
      id="f-174"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-19" decimals="-3" id="f-175" unitRef="usd">384558000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-20" decimals="-3" id="f-176" unitRef="usd">0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-19" decimals="-3" id="f-177" unitRef="usd">1169451000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-20" decimals="-3" id="f-178" unitRef="usd">1140328000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-19" decimals="-3" id="f-179" unitRef="usd">-481765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-20" decimals="-3" id="f-180" unitRef="usd">-568779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-181" unitRef="usd">303132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-182" unitRef="usd">571553000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-19" decimals="-3" id="f-183" unitRef="usd">338021000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-20" decimals="-3" id="f-184" unitRef="usd">615886000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-3" id="f-185" unitRef="usd">38706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-24" decimals="-3" id="f-186" unitRef="usd">550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-25" decimals="-3" id="f-187" unitRef="usd">205355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-26" decimals="-3" id="f-188" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">244061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-27" decimals="-3" id="f-190" unitRef="usd">3550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">129643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-27" decimals="-3" id="f-192" unitRef="usd">173629000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">46849000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-27" decimals="-3" id="f-194" unitRef="usd">40754000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">176492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-27" decimals="-3" id="f-196" unitRef="usd">214383000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">67569000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-27" decimals="-3" id="f-198" unitRef="usd">-210833000</us-gaap:OperatingIncomeLoss>
    <kros:ResearchAndDevelopmentIncentiveIncome contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">0</kros:ResearchAndDevelopmentIncentiveIncome>
    <kros:ResearchAndDevelopmentIncentiveIncome contextRef="c-27" decimals="-3" id="f-200" unitRef="usd">1238000</kros:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:DividendIncomeOperating contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">24867000</us-gaap:DividendIncomeOperating>
    <us-gaap:DividendIncomeOperating contextRef="c-27" decimals="-3" id="f-202" unitRef="usd">23496000</us-gaap:DividendIncomeOperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-539000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-27" decimals="-3" id="f-204" unitRef="usd">-954000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">24328000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-27" decimals="-3" id="f-206" unitRef="usd">23780000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">91897000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-208" unitRef="usd">-187053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">4883000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-210" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-212" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">87014000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">87014000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-27" decimals="-3" id="f-215" unitRef="usd">-187353000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-27" decimals="-3" id="f-216" unitRef="usd">-187353000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-217" unitRef="shares">37221211</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-218" unitRef="shares">37437652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-219" unitRef="shares">37859106</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-220" unitRef="shares">37437652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-221"
      unitRef="usdPerShare">2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-222"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-223"
      unitRef="usdPerShare">2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-224"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-225"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-226"
      unitRef="shares">31841084</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-227" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-29"
      decimals="INF"
      id="f-228"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-229" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-230" unitRef="usd">713636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-231" unitRef="usd">-381426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-232" unitRef="usd">332213000</us-gaap:StockholdersEquity>
    <kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts contextRef="c-27" decimals="-3" id="f-233" unitRef="usd">9943000</kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-33"
      decimals="INF"
      id="f-234"
      unitRef="shares">4025000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-235" unitRef="usd">151057000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-236" unitRef="usd">151057000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts contextRef="c-35" decimals="-3" id="f-237" unitRef="usd">3655000</kros:IssuanceOfCommonStockDiscountsCommissionsAndOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-36"
      decimals="INF"
      id="f-238"
      unitRef="shares">4290096</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-3" id="f-239" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-37" decimals="-3" id="f-240" unitRef="usd">228622000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-35" decimals="-3" id="f-241" unitRef="usd">228623000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-33"
      decimals="INF"
      id="f-242"
      unitRef="shares">398525</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-243" unitRef="usd">12141000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-27" decimals="-3" id="f-244" unitRef="usd">12141000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-245" unitRef="usd">34872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-246" unitRef="usd">34872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-38" decimals="-3" id="f-247" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-248" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-249"
      unitRef="shares">40554705</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-250" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-40"
      decimals="INF"
      id="f-251"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-253" unitRef="usd">1140328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-254" unitRef="usd">-568779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-255" unitRef="usd">571553000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-43"
      decimals="INF"
      id="f-256"
      unitRef="shares">11806</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-44" decimals="-3" id="f-257" unitRef="usd">138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <kros:RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">9558000</kros:RepurchaseOfTreasuryStockExciseTaxDirectFeesAndExpenses>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-45"
      decimals="INF"
      id="f-260"
      unitRef="shares">21126760</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-45" decimals="-3" id="f-261" unitRef="usd">384558000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">384558000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <kros:ShortSwingProfitSettlement contextRef="c-44" decimals="-3" id="f-263" unitRef="usd">139000</kros:ShortSwingProfitSettlement>
    <kros:ShortSwingProfitSettlement contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">139000</kros:ShortSwingProfitSettlement>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-43"
      decimals="INF"
      id="f-265"
      unitRef="shares">73655</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="-3" id="f-266" unitRef="usd">150000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">150000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-43"
      decimals="INF"
      id="f-268"
      unitRef="shares">30300</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-44" decimals="-3" id="f-269" unitRef="usd">28696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">28696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-271" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-273"
      unitRef="shares">40670466</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-274" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-48"
      decimals="INF"
      id="f-275"
      unitRef="shares">-21126760</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-276" unitRef="usd">-384558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-277" unitRef="usd">1169451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-278" unitRef="usd">-481765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-279" unitRef="usd">303132000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-281" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">1509000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-27" decimals="-3" id="f-283" unitRef="usd">1229000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">13000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-27" decimals="-3" id="f-285" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">28696000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-27" decimals="-3" id="f-287" unitRef="usd">34872000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">2410000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-27" decimals="-3" id="f-289" unitRef="usd">1820000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">825000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-27" decimals="-3" id="f-291" unitRef="usd">2599000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-4018000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-27" decimals="-3" id="f-293" unitRef="usd">10217000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">2250000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-27" decimals="-3" id="f-295" unitRef="usd">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">-2056000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-27" decimals="-3" id="f-297" unitRef="usd">4000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">-3001000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-27" decimals="-3" id="f-299" unitRef="usd">-249000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <kros:RightToUseAssetsAndOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">1978000</kros:RightToUseAssetsAndOperatingLeaseLiabilities>
    <kros:RightToUseAssetsAndOperatingLeaseLiabilities contextRef="c-27" decimals="-3" id="f-301" unitRef="usd">1320000</kros:RightToUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">-10131000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-27" decimals="-3" id="f-303" unitRef="usd">2952000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">107505000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-27" decimals="-3" id="f-305" unitRef="usd">-160869000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">1551000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-27" decimals="-3" id="f-307" unitRef="usd">1931000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">-1551000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-27" decimals="-3" id="f-309" unitRef="usd">-1931000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-51" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-52" decimals="-3" id="f-311" unitRef="usd">151340000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <kros:PaymentOfInitialPublicOfferingCosts contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">0</kros:PaymentOfInitialPublicOfferingCosts>
    <kros:PaymentOfInitialPublicOfferingCosts contextRef="c-27" decimals="-3" id="f-313" unitRef="usd">283000</kros:PaymentOfInitialPublicOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-53" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-35" decimals="-3" id="f-315" unitRef="usd">228794000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-27" decimals="-3" id="f-317" unitRef="usd">171000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">138000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-27" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">375000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-27" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <kros:PaymentOfStockRepurchaseCosts contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">3897000</kros:PaymentOfStockRepurchaseCosts>
    <kros:PaymentOfStockRepurchaseCosts contextRef="c-27" decimals="-3" id="f-323" unitRef="usd">0</kros:PaymentOfStockRepurchaseCosts>
    <kros:ProceedsFromShortSwingSettlementProfit contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">139000</kros:ProceedsFromShortSwingSettlementProfit>
    <kros:ProceedsFromShortSwingSettlementProfit contextRef="c-27" decimals="-3" id="f-325" unitRef="usd">0</kros:ProceedsFromShortSwingSettlementProfit>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">150000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-27" decimals="-3" id="f-327" unitRef="usd">12141000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">-378470000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-27" decimals="-3" id="f-329" unitRef="usd">391821000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">-272516000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-27" decimals="-3" id="f-331" unitRef="usd">229021000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-332" unitRef="usd">561380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-333" unitRef="usd">332359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-334" unitRef="usd">288864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-335" unitRef="usd">561380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">7145000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-27" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">5000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-27" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">5661000</kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses>
    <kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses contextRef="c-27" decimals="-3" id="f-341" unitRef="usd">0</kros:TreasuryStockRepurchaseCostsStillInAccountsPayableAndAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-27" decimals="-3" id="f-343" unitRef="usd">5737000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-3" id="f-344" unitRef="usd">287415000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-20" decimals="-3" id="f-345" unitRef="usd">559931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-19" decimals="-3" id="f-346" unitRef="usd">1449000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-20" decimals="-3" id="f-347" unitRef="usd">1449000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-348" unitRef="usd">288864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-349" unitRef="usd">561380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-350">NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Keros Therapeutics, Inc. (&#x201c;Keros&#x201d; or the &#x201c;Company&#x201d;) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (&#x201c;TGF-&#xdf;&#x201d;) family of proteins. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company's lead product candidate, rinvatercept (KER-065), is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. The Company&#x2019;s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (&#x201c;cytopenias&#x201d;), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (&#x201c;MDS&#x201d;) and in patients with myelofibrosis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Since its inception in 2015, the Company has devoted the majority of its resources to business planning, research and development of its product candidates, including conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. To date, the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company&#x2019;s $287.4 million cash and cash equivalents as of December&#160;31, 2025 will allow the Company to continue its operations for at least the next 12 months from the date these consolidated financial statements are issued. In the absence of a significant source of recurring revenue, the continued viability of the Company is dependent on its ability to continue to raise additional capital to finance its operations. If the Company is unable to obtain additional funding, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries, Keros Therapeutics Australia Pty Ltd (&#x201c;Keros Australia&#x201d;) and Keros Security Corporation, a Massachusetts securities corporation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-19" decimals="-5" id="f-351" unitRef="usd">287400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries, Keros Therapeutics Australia Pty Ltd (&#x201c;Keros Australia&#x201d;) and Keros Security Corporation, a Massachusetts securities corporation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-353">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company, Keros Australia and Keros Security Corporation. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, useful lives assigned to property and equipment and accrued and prepaid research and development expenses. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company had no financial instruments measured at level 3 as of December&#160;31, 2025 or 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of standard checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company had restricted cash in the form of certificates of deposit related to its operating leases in Lexington, Massachusetts of $1.4 million as of December&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. As of December&#160;31, 2025 and 2024, the Company&#x2019;s cash and cash equivalents were held with three financial institutions. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are written off from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. To date, no impairments have been recognized for these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than 12 months are recognized on the balance sheet as right-of-use, or ROU, assets and current and non-current lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2025, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records its repurchases of shares of common stock at cost. These shares are classified as treasury stock, which is a reduction of stockholders&#x2019; equity.  Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock is included in shares authorized and issued but excluded from shares outstanding.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services with contract research organizations that conduct research, preclinical and clinical activities on the Company&#x2019;s behalf, as well as contract manufacturing organizations that manufacture drug product for use in the Company&#x2019;s preclinical studies and clinical trials, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Incentive&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development incentive income includes payments under the Research and Development Tax Incentive (the &#x201c;R&amp;amp;D Incentive&#x201d;) from the Australian government. The R&amp;amp;D Incentive is one of the key elements of the Australian government&#x2019;s support for Australia&#x2019;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development. Since July 1, 2021, the R&amp;amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#x2019;s aggregated revenue as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt"&gt;Refundable tax offset of up to 18.5% above a company&#x2019;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt"&gt;Non-refundable tax offset of up to 16.5% above a company&#x2019;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has assessed its research and development (&#x201c;R&amp;amp;D&#x201d;) activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;amp;D Incentive. The Company estimates the refundable or non-refundable tax offset available to it based on available information at the time. This estimate is also reviewed by the Company&#x2019;s external tax advisors on an annual basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimate of the cash refund it expects to receive related to the R&amp;amp;D Incentive is included in other assets in the accompanying consolidated balance sheet and such amounts are recorded as research and development incentive income in the statement of operations. The Company recognizes research and development incentive income when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The Company did not record other income from the R&amp;amp;D Incentive for the year ended December&#160;31, 2025. The Company has received payments and has recorded other income from the R&amp;amp;D Incentive of $1.2 million for the year ended December&#160;31, 2024 related to the R&amp;amp;D Incentive as defined above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC&#160;606&#x201d;). The Company enters into certain agreements that are within the scope of ASC 606, under which the Company licenses or grants an option to license rights to certain of the Company&#x2019;s product candidates and may perform research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For combined performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If performance obligations are satisfied over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and the timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The functional currency for the Company&#x2019;s wholly owned foreign subsidiary, Keros Australia, is the United States dollar. All foreign currency transaction gains and losses are recognized in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular concentration is focused on the discovery and development of novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-&#xdf; family of proteins. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#x2019;s stock-based awards include stock options and restricted stock unit ("RSU") awards. The measurement date for employee and non-employee awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Stock-based compensation expense is classified in the accompanying consolidated statement of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies weighted with its own volatility for the period in which its stock has been publicly traded. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for interest and penalties related to uncertain tax positions within the provision for income taxes. As of December&#160;31, 2025, there have been no interest or penalties recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to net income (loss) for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period, and if dilutive, the weighted-average number of potential shares of common shares. The Company&#x2019;s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,470,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,520,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,432,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU No. 2023-09&#x201d;). ASU No. 2023-09 requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The new standard was effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU No. 2023-09 for its consolidated financial statements for the fiscal year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU No. 2024-03&#x201d;), which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. While recent trends towards rising inflation have eased, prices continue to rise, which may materially affect the Company&#x2019;s business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to the Company&#x2019;s preclinical studies and clinical trials, interest rates and overhead costs may adversely affect its operating results. Implementation of tariffs present a recent challenge impacting the U.S. economy and could make it more difficult for the Company to obtain traditional financing on acceptable terms, if at all, in the future. Although the Company does not believe that inflation, higher interest rates or tariffs have had a material impact on its financial position or results of operations to date, the Company may experience increases in the near future (especially if inflation rates rise more quickly) on its operating costs, including its labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company&#x2019;s working capital resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of the Company, Keros Australia and Keros Security Corporation. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-355">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, useful lives assigned to property and equipment and accrued and prepaid research and development expenses. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of standard checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-20" decimals="-5" id="f-358" unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-19" decimals="-5" id="f-359" unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-360">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company may maintain deposits in financial institutions in excess of government insured limits. The Company believes that it is not exposed to significant credit risk as its deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits.</us-gaap:ConcentrationRiskCreditRisk>
    <kros:NumberOfFinancialInstitutions
      contextRef="c-27"
      decimals="INF"
      id="f-361"
      unitRef="financialinstitution">3</kros:NumberOfFinancialInstitutions>
    <kros:NumberOfFinancialInstitutions
      contextRef="c-1"
      decimals="INF"
      id="f-362"
      unitRef="financialinstitution">3</kros:NumberOfFinancialInstitutions>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are written off from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-364">Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets as follows:&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.329%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESTIMATED USEFUL LIFE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-54" id="f-365">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-55" id="f-366">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-56" id="f-367">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-368">The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-369">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than 12 months are recognized on the balance sheet as right-of-use, or ROU, assets and current and non-current lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For all asset classes of its leases, the Company has elected to account for the lease and non-lease components together for existing classes of underlying assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="c-1" id="f-370">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <kros:TreasuryStockPolicyTextBlock contextRef="c-1" id="f-371">The Company records its repurchases of shares of common stock at cost. These shares are classified as treasury stock, which is a reduction of stockholders&#x2019; equity.  Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock is included in shares authorized and issued but excluded from shares outstanding.</kros:TreasuryStockPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services with contract research organizations that conduct research, preclinical and clinical activities on the Company&#x2019;s behalf, as well as contract manufacturing organizations that manufacture drug product for use in the Company&#x2019;s preclinical studies and clinical trials, facilities, and other outside expenses. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development incentive income includes payments under the Research and Development Tax Incentive (the &#x201c;R&amp;amp;D Incentive&#x201d;) from the Australian government. The R&amp;amp;D Incentive is one of the key elements of the Australian government&#x2019;s support for Australia&#x2019;s innovation system and was developed to assist businesses recover some of the costs of undertaking research and development. Since July 1, 2021, the R&amp;amp;D Incentive has provided eligible companies that engage in research and development activities with either a refundable or non-refundable tax offset depending on a company&#x2019;s aggregated revenue as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt"&gt;Refundable tax offset of up to 18.5% above a company&#x2019;s underlying tax rate where aggregated revenue is less than AUD$20.0 million per annum, or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:32.68pt"&gt;Non-refundable tax offset of up to 16.5% above a company&#x2019;s underlying tax rate where aggregated revenue is equal to or greater than AUD$20.0 million per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has assessed its research and development (&#x201c;R&amp;amp;D&#x201d;) activities and expenditures to determine which activities and expenditures in Australia are likely to be eligible under the R&amp;amp;D Incentive. The Company estimates the refundable or non-refundable tax offset available to it based on available information at the time. This estimate is also reviewed by the Company&#x2019;s external tax advisors on an annual basis.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s estimate of the cash refund it expects to receive related to the R&amp;amp;D Incentive is included in other assets in the accompanying consolidated balance sheet and such amounts are recorded as research and development incentive income in the statement of operations. The Company recognizes research and development incentive income when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured.&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, an adjustment would be made to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for interest and penalties related to uncertain tax positions within the provision for income taxes. As of December&#160;31, 2025, there have been no interest or penalties recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <kros:ResearchAndDevelopmentIncentiveIncome contextRef="c-1" decimals="-5" id="f-374" unitRef="usd">0</kros:ResearchAndDevelopmentIncentiveIncome>
    <kros:ResearchAndDevelopmentIncentiveIncome contextRef="c-27" decimals="-5" id="f-375" unitRef="usd">1200000</kros:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC&#160;606&#x201d;). The Company enters into certain agreements that are within the scope of ASC 606, under which the Company licenses or grants an option to license rights to certain of the Company&#x2019;s product candidates and may perform research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;development services in connection with such arrangements. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, clinical, regulatory and commercial sales milestone payments, and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations including whether they are distinct; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. The Company provides options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i)&#160;the customer can benefit from the good or service on its own or together with other readily available resources and (ii)&#160;the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative stand-alone selling price basis. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer can use and benefit from the license. For combined performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If performance obligations are satisfied over time, the Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company generally recognizes revenue using the cost incurred to date as compared to the total estimated cost. Changes in estimates of total internal and external costs expected to be incurred and the timing of when those costs are expected to be incurred are recognized in the period of change as a cumulative catch-up adjustment. If estimates of the total estimated cost change, or if contract amendments change the scope of the performance obligations, the impacts could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The functional currency for the Company&#x2019;s wholly owned foreign subsidiary, Keros Australia, is the United States dollar. All foreign currency transaction gains and losses are recognized in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-378">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis for the purposes of making operating decisions, assessing financial performance and allocating resources. The Company has one reportable segment and manages its operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular concentration is focused on the discovery and development of novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-&#xdf; family of proteins.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-379"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-380">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company&#x2019;s stock-based awards include stock options and restricted stock unit ("RSU") awards. The measurement date for employee and non-employee awards is the date of grant. For stock-based awards that vest based on service conditions, stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. For stock options and RSUs with performance conditions, stock-based compensation costs are recognized as expense using the accelerated attribution method when it is probable that the performance condition will be achieved. Stock-based compensation expense is classified in the accompanying consolidated statement of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies weighted with its own volatility for the period in which its stock has been publicly traded. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-381">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to net income (loss) for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-382">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period, and if dilutive, the weighted-average number of potential shares of common shares. The Company&#x2019;s potentially dilutive securities, which include stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-383">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,470,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,520,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,432,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,470,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,520,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,432,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-384" unitRef="shares">41207</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-385" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-386" unitRef="shares">4470286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-387" unitRef="shares">5384760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-388" unitRef="shares">8549</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-389" unitRef="shares">47694</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-390" unitRef="shares">4520042</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-27" decimals="0" id="f-391" unitRef="shares">5432454</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU No. 2023-09&#x201d;). ASU No. 2023-09 requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. The new standard was effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU No. 2023-09 for its consolidated financial statements for the fiscal year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU No. 2024-03&#x201d;), which intends to improve financial reporting by requiring disclosure of additional information about specific expense categories. This guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the guidance is to be applied prospectively and may be applied retrospectively. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <kros:RisksAndUncertaintiesPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;There have been significant disruptions to global financial markets that have contributed to a general global economic slowdown. While recent trends towards rising inflation have eased, prices continue to rise, which may materially affect the Company&#x2019;s business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to the Company&#x2019;s preclinical studies and clinical trials, interest rates and overhead costs may adversely affect its operating results. Implementation of tariffs present a recent challenge impacting the U.S. economy and could make it more difficult for the Company to obtain traditional financing on acceptable terms, if at all, in the future. Although the Company does not believe that inflation, higher interest rates or tariffs have had a material impact on its financial position or results of operations to date, the Company may experience increases in the near future (especially if inflation rates rise more quickly) on its operating costs, including its labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in the Middle East, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company&#x2019;s working capital resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates.</kros:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-395">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.145%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;DESCRIPTION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;QUOTED PRICES&lt;br/&gt;ACTIVE MARKETS&lt;br/&gt;FOR IDENTICAL&lt;br/&gt;ASSETS (LEVEL&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;DESCRIPTION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;QUOTED PRICES&lt;br/&gt;ACTIVE MARKETS&lt;br/&gt;FOR IDENTICAL&lt;br/&gt;ASSETS (LEVEL&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;There have been no transfers between fair value levels during the years ended December&#160;31, 2025 and 2024. The carrying values of prepaid expenses, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-396">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.145%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.727%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;DESCRIPTION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;QUOTED PRICES&lt;br/&gt;ACTIVE MARKETS&lt;br/&gt;FOR IDENTICAL&lt;br/&gt;ASSETS (LEVEL&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;270,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;DESCRIPTION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;QUOTED PRICES&lt;br/&gt;ACTIVE MARKETS&lt;br/&gt;FOR IDENTICAL&lt;br/&gt;ASSETS (LEVEL&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SIGNIFICANT OTHER&lt;br/&gt;OBSERVABLE&lt;br/&gt;INPUTS (LEVEL&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;556,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-397" unitRef="usd">270713000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-398" unitRef="usd">270713000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-399" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-400" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-401" unitRef="usd">270713000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-402" unitRef="usd">270713000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-405" unitRef="usd">556064000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-406" unitRef="usd">556064000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-409" unitRef="usd">556064000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-410" unitRef="usd">556064000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-413">PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid external R&amp;amp;D costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid external manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest and dividend receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid legal and consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Refunds due from contract research organizations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-414">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid external R&amp;amp;D costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid external manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Interest and dividend receivable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid legal and consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Refunds due from contract research organizations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <kros:PrepaidExternalRDCostsCurrent contextRef="c-19" decimals="-3" id="f-415" unitRef="usd">1609000</kros:PrepaidExternalRDCostsCurrent>
    <kros:PrepaidExternalRDCostsCurrent contextRef="c-20" decimals="-3" id="f-416" unitRef="usd">15748000</kros:PrepaidExternalRDCostsCurrent>
    <kros:PrepaidExternalManufacturingCostsCurrent contextRef="c-19" decimals="-3" id="f-417" unitRef="usd">398000</kros:PrepaidExternalManufacturingCostsCurrent>
    <kros:PrepaidExternalManufacturingCostsCurrent contextRef="c-20" decimals="-3" id="f-418" unitRef="usd">5545000</kros:PrepaidExternalManufacturingCostsCurrent>
    <kros:SalesTaxReceivableCurrent contextRef="c-19" decimals="-3" id="f-419" unitRef="usd">0</kros:SalesTaxReceivableCurrent>
    <kros:SalesTaxReceivableCurrent contextRef="c-20" decimals="-3" id="f-420" unitRef="usd">121000</kros:SalesTaxReceivableCurrent>
    <us-gaap:PrepaidInsurance contextRef="c-19" decimals="-3" id="f-421" unitRef="usd">609000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-20" decimals="-3" id="f-422" unitRef="usd">651000</us-gaap:PrepaidInsurance>
    <kros:PrepaidSubscriptionCurrent contextRef="c-19" decimals="-3" id="f-423" unitRef="usd">947000</kros:PrepaidSubscriptionCurrent>
    <kros:PrepaidSubscriptionCurrent contextRef="c-20" decimals="-3" id="f-424" unitRef="usd">960000</kros:PrepaidSubscriptionCurrent>
    <us-gaap:DividendAndInterestReceivable contextRef="c-19" decimals="-3" id="f-425" unitRef="usd">555000</us-gaap:DividendAndInterestReceivable>
    <us-gaap:DividendAndInterestReceivable contextRef="c-20" decimals="-3" id="f-426" unitRef="usd">1714000</us-gaap:DividendAndInterestReceivable>
    <kros:PrepaidLegalAndConsultants contextRef="c-19" decimals="-3" id="f-427" unitRef="usd">1207000</kros:PrepaidLegalAndConsultants>
    <kros:PrepaidLegalAndConsultants contextRef="c-20" decimals="-3" id="f-428" unitRef="usd">31000</kros:PrepaidLegalAndConsultants>
    <kros:RefundsDueFromContractResearchOrganizationsCurrent contextRef="c-19" decimals="-3" id="f-429" unitRef="usd">14480000</kros:RefundsDueFromContractResearchOrganizationsCurrent>
    <kros:RefundsDueFromContractResearchOrganizationsCurrent contextRef="c-20" decimals="-3" id="f-430" unitRef="usd">0</kros:RefundsDueFromContractResearchOrganizationsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-431" unitRef="usd">2397000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-432" unitRef="usd">1450000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-19" decimals="-3" id="f-433" unitRef="usd">22202000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-20" decimals="-3" id="f-434" unitRef="usd">26220000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-435">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment, net as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $1.5 million and $1.2 million for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-54" decimals="-3" id="f-436" unitRef="usd">35000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-437" unitRef="usd">35000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-55" decimals="-3" id="f-438" unitRef="usd">7433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-72" decimals="-3" id="f-439" unitRef="usd">5978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-56" decimals="-3" id="f-440" unitRef="usd">1264000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-441" unitRef="usd">1173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-19" decimals="-3" id="f-442" unitRef="usd">8732000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-20" decimals="-3" id="f-443" unitRef="usd">7186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-19" decimals="-3" id="f-444" unitRef="usd">4435000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-20" decimals="-3" id="f-445" unitRef="usd">2949000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-19" decimals="-3" id="f-446" unitRef="usd">4297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-20" decimals="-3" id="f-447" unitRef="usd">4237000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationNonproduction contextRef="c-1" decimals="-5" id="f-448" unitRef="usd">1500000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c-27" decimals="-5" id="f-449" unitRef="usd">1200000</us-gaap:DepreciationNonproduction>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-450">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued external R&amp;amp;D costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued external manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued legal and consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;20,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-451">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued external R&amp;amp;D costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued external manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued excise tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued legal and consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;20,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <kros:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-19" decimals="-3" id="f-452" unitRef="usd">2662000</kros:AccruedResearchAndDevelopmentCostsCurrent>
    <kros:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-20" decimals="-3" id="f-453" unitRef="usd">5139000</kros:AccruedResearchAndDevelopmentCostsCurrent>
    <kros:AccruedManufacturingCostsCurrent contextRef="c-19" decimals="-3" id="f-454" unitRef="usd">429000</kros:AccruedManufacturingCostsCurrent>
    <kros:AccruedManufacturingCostsCurrent contextRef="c-20" decimals="-3" id="f-455" unitRef="usd">4308000</kros:AccruedManufacturingCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-456" unitRef="usd">5870000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-457" unitRef="usd">10130000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-19" decimals="-3" id="f-458" unitRef="usd">3377000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-20" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-19" decimals="-3" id="f-460" unitRef="usd">3484000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-20" decimals="-3" id="f-461" unitRef="usd">877000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-462" unitRef="usd">217000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-463" unitRef="usd">416000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-19" decimals="-3" id="f-464" unitRef="usd">16039000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-20" decimals="-3" id="f-465" unitRef="usd">20870000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c-1" id="f-466">LICENSE AGREEMENTS&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Massachusetts General Hospital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 5, 2016, the Company entered into an exclusive patent license agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital (&#x201c;MGH&#x201d;). Under the license agreement with MGH (as amended in May 2017 and February 2018, the &#x201c;MGH Agreement&#x201d;), the Company obtained an exclusive, worldwide license, with the right to sublicense, under certain patents and technical information of MGH, to make, have made, use, have used, sell, have sold, lease, have leased, import, have imported or otherwise transfer licensed products and processes for use in the treatment, diagnosis, palliation and prevention of diseases and disorders in humans and animals. The Company is required to use commercially reasonable efforts to develop and commercialize licensed products and processes and must achieve certain required diligence milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the terms of the MGH Agreement, the Company is required to pay a low-five digit to mid-five digit annual maintenance fee prior to the first commercial sale of its first product or process, a mid-five digit annual maintenance fee after the first commercial sale of its first product or process that is creditable against royalties, certain clinical and regulatory milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $8.6&#160;million in the aggregate, and certain commercial milestone payments for the first three products or indications to achieve such milestones, which milestone payments are $18.0&#160;million in the aggregate. The Company made payments of $50,000 and $300,000 in 2020 and 2021, respectively, for the achievement of the clinical and regulatory milestones of (i) filing of an IND in the first country and (ii) the completion of a Phase 1 clinical trial, respectively.  The Company is also obligated to pay tiered royalties on net sales of licensed products ranging in the low-single digits to mid-single digits. The royalty rates are subject to up to a maximum 50% reduction for lack of a valid claim, in the event that it is necessary for the Company to obtain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed product-by-licensed product and country-by-country basis upon the later of expiry of the last valid claim of the licensed patents that cover such licensed product in such country or ten years from the first commercial sale of such product in such country. The Company is also obligated to pay a percentage of non-royalty-related payments received by it from sublicensees ranging in the low-double digits and a change of control fee equal to a low-single digit percentage of the payments received as part of any completed transaction up to a low seven-digit amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The MGH Agreement expires upon expiry of the last remaining royalty obligation for a licensed product or process. Under the MGH Agreement, MGH may terminate the agreement upon the Company&#x2019;s uncured material breach or insolvency, a challenge by the Company of the licensed patents and certain other specified breaches of the MGH Agreement. The Company may terminate the agreement for any reason upon specified prior written notice to MGH.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hansoh Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On December 12, 2021, the Company entered into a license agreement with Hansoh. Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;). Refer to Note 15, Revenue from Contracts with Customers, for more information regarding this agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee
      contextRef="c-74"
      decimals="INF"
      id="f-467"
      unitRef="product">3</kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee>
    <kros:ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone contextRef="c-75" decimals="-5" id="f-468" unitRef="usd">8600000</kros:ResearchAndDevelopmentAgreementContractToPerformForOthersClinicalAndRegulatoryMilestone>
    <kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee
      contextRef="c-74"
      decimals="INF"
      id="f-469"
      unitRef="product">3</kros:NumberOfProductsAchievingMilestoneToTriggerMaintenanceFee>
    <kros:ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone contextRef="c-75" decimals="-5" id="f-470" unitRef="usd">18000000.0</kros:ResearchAndDevelopmentAgreementContractToPerformForOthersCommercialMilestone>
    <kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone contextRef="c-76" decimals="-3" id="f-471" unitRef="usd">50000</kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone>
    <kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone contextRef="c-77" decimals="-3" id="f-472" unitRef="usd">300000</kros:ResearchAndDevelopmentArrangementContractToPerformForOthersPaymentForAchievementOfClinicalAndRegulatoryMilestone>
    <kros:ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage
      contextRef="c-75"
      decimals="INF"
      id="f-473"
      unitRef="number">0.50</kros:ResearchAndDevelopmentAgreementContractToPerformForOthersRoyaltyRateMaximumReductionPercentage>
    <kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod contextRef="c-75" id="f-474">P10Y</kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-475">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue 200,000,000 shares of common stock at a par value of $0.0001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, the Company raised gross proceeds of $232.3 million pursuant to the &#x201c;at the market offering,&#x201d; in connection with our Sales Agreement with Leerink Partners LLC, as agent (&#x201c;ATM Offering&#x201d;), pursuant to which we sold 4,290,096 shares of common stock at a weighted average price of $54.14 per share. The net proceeds from the ATM Offering for the year ended December&#160;31, 2024 were approximately $228.6 million after deducting sales agent commissions of $3.5 million and offering expenses of less than $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On January&#160;8, 2024, the Company closed an underwritten public offering in which 4,025,000 shares of common stock were issued and sold, which included 525,000 shares of common stock issued and sold pursuant to the exercise in full of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $40.00 per share. The aggregate net proceeds from the public offering were approximately $151.1 million, after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Stockholder Rights Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 9, 2025, the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) declared a dividend of one right (&#x201c;Right&#x201d;) to purchase one-thousandth of one share of the Company&#x2019;s newly designated Series A Junior Participating Preferred Stock, par value $0.0001 per share (each, a &#x201c;Preferred Share&#x201d; and collectively, the &#x201c;Preferred Shares&#x201d;), for each outstanding share of common stock to the stockholders of record as of the close of business on April 24, 2025. The Company also adopted a limited duration stockholder rights plan (the &#x201c;Rights Plan&#x201d;), effective immediately, as set forth in the Rights Agreement, dated as of April 9, 2025 (the &#x201c;Rights Agreement&#x201d;), by and between the Company and Computershare Trust Company, N.A., as Rights Agent. The Rights Agent currently serves as the Company&#x2019;s transfer agent with respect to the common stock and also has been appointed transfer agent with respect to the Preferred Shares, if any, that may be issued pursuant to the exercise of rights under the Rights Agreement. The Rights will expire on April 9, 2026, unless the rights are earlier redeemed or exchanged by the Company. The Company does not have any obligation under the Rights Agreement to seek stockholder approval for the Rights Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In general terms, the Rights Plan is designed to impose a penalty upon any person or group that acquires beneficial ownership of 10% (15% in the case of a passive institutional investor) or more of the outstanding shares of Common Stock without the approval of the Board. The Board adopted the Rights Plan in response to significant and rapid accumulations of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;the common stock by a number of investors who have indicated a desire to influence the control of the Company. The Rights Plan is intended to protect the investment of the Company's stockholders during a period in which it believes shares of the Company do not reflect the Company&#x2019;s intrinsic value. The Rights Plan will reduce the likelihood that any entity, person or group gains control of the Company through open-market accumulation without paying all stockholders an appropriate control premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following is a summary of the rights and privileges of the holders of common stock as of December&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidation Preference: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. As of December&#160;31, 2025, no cash dividends have been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting Rights: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the Company's amended and restated certificate of incorporation and amended and restated bylaws, stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rights and Preferences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;: Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025 and 2024, the Company has reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;716,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,901,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Available under the ESPP Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,641,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,247,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Available under 2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,146,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;861,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,406,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,494,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-19"
      decimals="INF"
      id="f-476"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-19"
      decimals="INF"
      id="f-477"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-78" decimals="-5" id="f-478" unitRef="usd">232300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-78"
      decimals="INF"
      id="f-479"
      unitRef="shares">4290096</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-79"
      decimals="INF"
      id="f-480"
      unitRef="usdPerShare">54.14</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-78" decimals="-5" id="f-481" unitRef="usd">228600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <kros:SaleOfStockAgentCommissions contextRef="c-78" decimals="-5" id="f-482" unitRef="usd">3500000</kros:SaleOfStockAgentCommissions>
    <kros:SaleOfStockStockIssuanceCosts contextRef="c-35" decimals="-5" id="f-483" unitRef="usd">200000</kros:SaleOfStockStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-80"
      decimals="INF"
      id="f-484"
      unitRef="shares">4025000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-81"
      decimals="INF"
      id="f-485"
      unitRef="shares">525000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-82"
      decimals="INF"
      id="f-486"
      unitRef="usdPerShare">40.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-80" decimals="-5" id="f-487" unitRef="usd">151100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <kros:CommonStockDividendNumberOfRightsPerShare
      contextRef="c-83"
      decimals="INF"
      id="f-488"
      unitRef="shares">1000</kros:CommonStockDividendNumberOfRightsPerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-83"
      decimals="INF"
      id="f-489"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <kros:CommonStockBeneficialOwnershipPenaltyThreshold contextRef="c-84" decimals="2" id="f-490" unitRef="number">0.10</kros:CommonStockBeneficialOwnershipPenaltyThreshold>
    <kros:CommonStockBeneficialOwnershipPenaltyThreshold contextRef="c-85" decimals="2" id="f-491" unitRef="number">0.15</kros:CommonStockBeneficialOwnershipPenaltyThreshold>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-86" decimals="INF" id="f-492" unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <kros:CommonStockVotingRightsNumberOfVotes contextRef="c-1" decimals="INF" id="f-493" unitRef="vote">1</kros:CommonStockVotingRightsNumberOfVotes>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-494">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025 and 2024, the Company has reserved the following shares of common stock for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;716,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,901,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Available under the ESPP Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,641,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,247,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Available under 2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,146,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;861,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,406,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,494,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-87" decimals="0" id="f-495" unitRef="shares">716850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-88" decimals="0" id="f-496" unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-89" decimals="0" id="f-497" unitRef="shares">3901706</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-90" decimals="0" id="f-498" unitRef="shares">5384760</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-91" decimals="0" id="f-499" unitRef="shares">1641602</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-92" decimals="0" id="f-500" unitRef="shares">1247861</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-93" decimals="0" id="f-501" unitRef="shares">3146054</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-94" decimals="0" id="f-502" unitRef="shares">861617</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-19" decimals="0" id="f-503" unitRef="shares">9406212</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-20" decimals="0" id="f-504" unitRef="shares">7494238</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:TreasuryStockTextBlock contextRef="c-1" id="f-505">TREASURY STOCK&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Board may authorize the repurchase of shares of the Company&#x2019;s common stock, in the open market or through negotiated transactions, at such times and at such prices as management deems appropriate. For the year ended December&#160;31, 2024, the Company did not acquire any shares of its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 15, 2025, the Company entered into stock purchase agreements with certain entities affiliated with ADAR1 Capital Management (collectively, the &#x201c;ADAR1 Parties&#x201d;) and certain entities affiliated with Pontifax Venture Capital (collectively, the &#x201c;Pontifax Parties&#x201d;). Such stock purchase agreements for each of the Pontifax and ADAR1 Parties are collectively referred to as &#x201c;Repurchase Agreements&#x201d;. Pursuant to the terms and conditions of the Repurchase Agreements, the ADAR1 Parties and the Pontifax Parties sold all of the shares of common stock beneficially owned by them, being an aggregate of 10,176,595 shares of common stock, to the Company at a price of $17.75 per share for an aggregate purchase price of $180.6 million, excluding excise tax, direct fees and expenses related to the repurchases. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 20, 2025, the Company commenced a tender offer to repurchase shares of its common stock at a cash purchase price of $17.75 per share  (the &#x201c;Tender Offer&#x201d;). The Tender Offer expired at 5:00 p.m. Eastern time on November 18, 2025, and following such expiration the Company accepted for purchase a total of 10,950,165 shares, for an aggregate purchase price of approximately $194.4 million, excluding excise tax, direct fees and expenses related to the Tender Offer.  More than 10,950,165 shares were tendered in the Tender Offer, and as such, shares were accepted for purchase on a pro rata basis, except for conditional tenders that were automatically regarded as withdrawn if the condition was not satisfied. The total cost of the repurchase was recorded as treasury stock using the cost method and is included as treasury stock in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;The completion of the Repurchase Agreements in October 2025 and the Tender Offer in November 2025 concluded the Company&#x2019;s previously announced $375.0 million capital return program.  In connection with the Repurchase Agreements and Tender Offer, the Company incurred $9.6 million in excise tax, direct fees and expenses that were included in the cost of treasury stock in the accompanying consolidated balance sheets as of December&#160;31, 2025.</us-gaap:TreasuryStockTextBlock>
    <srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c-95"
      decimals="INF"
      id="f-506"
      unitRef="shares">10176595</srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-96"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">17.75</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-96" decimals="-5" id="f-508" unitRef="usd">180600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <kros:SharesAcquiredPricePerShareOnCommencementOfTenderOffer
      contextRef="c-97"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">17.75</kros:SharesAcquiredPricePerShareOnCommencementOfTenderOffer>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-98"
      decimals="INF"
      id="f-510"
      unitRef="shares">10950165</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-99" decimals="-5" id="f-511" unitRef="usd">194400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-98"
      decimals="INF"
      id="f-512"
      unitRef="shares">10950165</us-gaap:TreasuryStockSharesAcquired>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-97" decimals="-5" id="f-513" unitRef="usd">375000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-100" decimals="-5" id="f-514" unitRef="usd">9600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-515">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Board adopted the 2017 Stock Incentive Plan (the "2017 Plan") in February 2017, and the stockholders approved the 2017 Plan in March 2017. The 2017 Plan was most recently amended in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there were an aggregate of 412,099 shares of common stock issuable upon the exercise of outstanding options under the 2017 Plan. Any options or awards outstanding under the 2017 Plan remain outstanding and effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In April 2020, the 2020 Equity Incentive Plan (the "2020 Plan") became effective, and, as a result, no further awards will be made under the 2017 Plan. The 2020 Plan provides for the grant of stock options qualifying as incentive stock options ("ISOs"), to employees and for the grant of nonstatutory stock options ("NSOs"), restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to employees, consultants and directors. The 2020 Plan also provides for the grant of performance cash awards to employees, consultants and directors. Any previously granted awards under the 2017 Plan will remain outstanding in accordance with their respective terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the 2020 Plan, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Board. On January 1, 2024, the Company increased the number of shares available for future grant under the 2020 Plan by 1,273,643 shares. On January 1, 2025, the Company increased the number of shares available for future grant under the 2020 Plan by 1,622,188 shares. On January 1, 2026, the Company increased the number of shares available for future grant under the 2020 Plan by 781,748 shares. The awards granted under the 2020 Plan typically vest over a four-year period and have a 10-year contractual term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there were an aggregate of 3,489,607 shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan. Additionally, there were an aggregate of 3,146,054 shares reserved for future issuance under the 2020 Plan, including shares forfeited from the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity during the year ended December&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.963%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF UNITS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE GRANT-DATE FAIR VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding RSU awards as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,167,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(30,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding RSU awards as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;716,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The summary of RSU award activity includes 90,500 performance-based awards granted during the year ended December&#160;31, 2025. The weighted-average grant date fair value of RSU awards granted during the years ended December&#160;31, 2025 and 2024 was $11.71 and zero, respectively. The aggregate fair value of RSU awards that vested during the years ended December&#160;31, 2025 and 2024 was $0.5 million and zero, respectively. As of December&#160;31, 2025, there has been no expense recognized for the performance-based awards, for which the performance criteria was not deemed probable as of December&#160;31, 2025. As of December&#160;31, 2025, there was approximately $6.9 million of unrecognized stock-based compensation expense related to RSU awards that are expected to vest, including $1.4 million of unrecognized stock-based compensation expense related to performance-based awards for which the performance criteria is currently not deemed probable. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.71 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December&#160;31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;83.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;81.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A summary of option activity during the year ended December&#160;31, 2025 is as follows (in thousands except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF&lt;br/&gt;OPTIONS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED-AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;TERM (IN&#160;YEARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGGREGATE&lt;br/&gt;INTRINSIC VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;84,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(73,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(783,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(709,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,901,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,091,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;34.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span id="id1d28d2136374e9b8448ed57bce695c6_8-5-1-1-163929"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The total intrinsic value of stock options exercised was $0.7 million and $10.1 million during the years ended December&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of options granted during each of the years ended December&#160;31, 2025 and 2024 was $10.36 and $40.92, respectively. As of December&#160;31, 2025, there was $22.9 million of unrecognized stock-based compensation expense related to unvested service-based stock options and $2.9 million of unrecognized stock-based compensation expense related to performance-based stock options. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 1.49 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The summary of option activity includes 125,000 performance-based options granted during the year ended December&#160;31, 2024. The options include performance-based and service-based vesting criteria. As of December&#160;31, 2025, the performance criteria was deemed probable for 50% of the performance-based options. Accordingly, the Company recorded $2.0 million stock-based compensation expense during the year end December&#160;31, 2025. Of the $2.9 million of unrecognized stock-based compensation expense, $0.4 million is related to service-based vesting criteria that the Company expects to recognize and $2.5 million is related to performance-based vesting criteria that are not considered probable as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2020, the Board adopted and the Company's stockholders approved the 2020 Employee Stock Purchase Plan ("ESPP"). The ESPP became effective on April 7, 2020. Under the ESPP, eligible employees can purchase shares of the Company's common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of the Company's common stock on the first trading day of the twenty-four month offering period, or on the applicable purchase date. Each offering under the ESPP consists of two twelve-month purchase periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the ESPP, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by the lesser of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 455,852 shares or (iii) or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by 405,547 shares. On January 1, 2026, the Company increased the number of shares available for future grant under the ESPP by 195,437 shares.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, 11,806 shares of common stock were purchased under the ESPP. As of December&#160;31, 2025, there was an aggregate of 1,641,602 shares reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December&#160;31, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;34,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-101"
      decimals="INF"
      id="f-516"
      unitRef="shares">412099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage
      contextRef="c-102"
      decimals="INF"
      id="f-517"
      unitRef="number">0.040</kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-103"
      decimals="INF"
      id="f-518"
      unitRef="shares">1273643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-104"
      decimals="INF"
      id="f-519"
      unitRef="shares">1622188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-105"
      decimals="INF"
      id="f-520"
      unitRef="shares">781748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-102" id="f-521">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-102" id="f-522">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-102"
      decimals="INF"
      id="f-523"
      unitRef="shares">3489607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-102"
      decimals="INF"
      id="f-524"
      unitRef="shares">3146054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-525">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A summary of RSU award activity during the year ended December&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.502%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.963%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF UNITS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED AVERAGE GRANT-DATE FAIR VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding RSU awards as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,167,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(30,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(420,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding RSU awards as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;716,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-88"
      decimals="INF"
      id="f-526"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-88"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-528"
      unitRef="shares">1167325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-529"
      unitRef="usdPerShare">11.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-530"
      unitRef="shares">30300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-531"
      unitRef="usdPerShare">12.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-106"
      decimals="INF"
      id="f-532"
      unitRef="shares">420175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-87"
      decimals="INF"
      id="f-534"
      unitRef="shares">716850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-87"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">12.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-107"
      decimals="INF"
      id="f-536"
      unitRef="shares">90500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-537"
      unitRef="usdPerShare">11.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-108"
      decimals="2"
      id="f-538"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-106" decimals="-5" id="f-539" unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-108" decimals="-5" id="f-540" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-5" id="f-541" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-87" decimals="-5" id="f-542" unitRef="usd">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-107" decimals="-5" id="f-543" unitRef="usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-106" id="f-544">P1Y8M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions that the Company used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted for the years ended December&#160;31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;83.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;81.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-110" decimals="4" id="f-546" unitRef="number">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-111" decimals="4" id="f-547" unitRef="number">0.0430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-110" id="f-548">P5Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-111" id="f-549">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-110" decimals="4" id="f-550" unitRef="number">0.8359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-111" decimals="4" id="f-551" unitRef="number">0.8192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-110"
      decimals="INF"
      id="f-552"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-111"
      decimals="INF"
      id="f-553"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-554">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A summary of option activity during the year ended December&#160;31, 2025 is as follows (in thousands except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.190%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.147%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NUMBER OF&lt;br/&gt;OPTIONS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE PRICE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;WEIGHTED-AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;TERM (IN&#160;YEARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;AGGREGATE&lt;br/&gt;INTRINSIC VALUE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;84,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(73,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(783,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(709,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,901,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,091,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;34.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span id="id1d28d2136374e9b8448ed57bce695c6_8-5-1-1-163929"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-20"
      decimals="INF"
      id="f-555"
      unitRef="shares">5384760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-20"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">42.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-27" id="f-557">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-20" decimals="-3" id="f-558" unitRef="usd">7395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-559" unitRef="shares">84000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">14.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-561" unitRef="shares">73655</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-562"
      unitRef="usdPerShare">2.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-563" unitRef="usd">695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-564" unitRef="shares">783495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">54.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-566" unitRef="shares">709904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">49.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-19"
      decimals="INF"
      id="f-568"
      unitRef="shares">3901706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-19"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">38.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-570">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-19" decimals="-3" id="f-571" unitRef="usd">12209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-19"
      decimals="INF"
      id="f-572"
      unitRef="shares">3091868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-19"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">34.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-574">P5Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-19" decimals="-3" id="f-575" unitRef="usd">12035000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-576" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-27" decimals="-5" id="f-577" unitRef="usd">10100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">10.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-27"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">40.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-112" decimals="-5" id="f-580" unitRef="usd">22900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-113" decimals="-5" id="f-581" unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-110" id="f-582">P1Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-107"
      decimals="INF"
      id="f-583"
      unitRef="shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-114" decimals="-5" id="f-584" unitRef="usd">2000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-113" decimals="-5" id="f-585" unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected contextRef="c-113" decimals="-5" id="f-586" unitRef="usd">400000</kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionExpected>
    <kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable contextRef="c-113" decimals="-5" id="f-587" unitRef="usd">2500000</kros:ShareBasedPaymentArrangementNonvestedAwardCostNotYetRecognizedRecognitionNotProbable>
    <kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding contextRef="c-115" decimals="2" id="f-588" unitRef="number">0.010</kros:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreasePercentOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-116"
      decimals="INF"
      id="f-589"
      unitRef="shares">455852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-117"
      decimals="INF"
      id="f-590"
      unitRef="shares">405547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-118"
      decimals="INF"
      id="f-591"
      unitRef="shares">195437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-119"
      decimals="INF"
      id="f-592"
      unitRef="shares">11806</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-120"
      decimals="INF"
      id="f-593"
      unitRef="shares">1641602</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-594">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recorded as research and development and general and administrative expenses, respectively, for employees, directors and non-employees during the years ended December&#160;31, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;34,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-595" unitRef="usd">13288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-596" unitRef="usd">18294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-597" unitRef="usd">15408000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="-3" id="f-598" unitRef="usd">16578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-599" unitRef="usd">28696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-27" decimals="-3" id="f-600" unitRef="usd">34872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-601">INCOME (LOSS) PER SHARE&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,221,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,437,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;419,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;218,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;637,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding used to compute diluted net income (loss)&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,859,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,437,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of December&#160;31, 2025 and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Unvested RSU awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,470,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,384,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,520,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,432,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.974%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,221,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,437,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;419,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of potentially dilutive restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;218,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;637,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding used to compute diluted net income (loss)&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,859,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,437,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-603" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-604" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-605" unitRef="shares">37221211</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-27" decimals="0" id="f-606" unitRef="shares">37437652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-110" decimals="0" id="f-607" unitRef="shares">419367</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-111" decimals="0" id="f-608" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-125" decimals="0" id="f-609" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-126" decimals="0" id="f-610" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-106" decimals="0" id="f-611" unitRef="shares">218528</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-108" decimals="0" id="f-612" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="0" id="f-613" unitRef="shares">637895</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-27" decimals="0" id="f-614" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-615" unitRef="shares">37859106</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-27" decimals="0" id="f-616" unitRef="shares">37437652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-27"
      decimals="2"
      id="f-618"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-27"
      decimals="2"
      id="f-620"
      unitRef="usdPerShare">-5.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-621" unitRef="shares">41207</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-622" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-623" unitRef="shares">4470286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-624" unitRef="shares">5384760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-625" unitRef="shares">8549</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-626" unitRef="shares">47694</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-627" unitRef="shares">4520042</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-27" decimals="0" id="f-628" unitRef="shares">5432454</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-629">INCOME TAXES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Loss before income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;74,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(189,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The components of the provision for income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current income tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the Company&#x2019;s U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2025 in accordance with the guidance in the ASU No. 2023-09, which the Company has elected to prospectively adopt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;U.S Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal income tax effect&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Difference between local tax rare and U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of changes in taw laws or rates enacted in the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of cross-border tax laws&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the Company&#x2019;s U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the year ended December&#160;31, 2024 prior to adoption of ASU No. 2023-09:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income at U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign withholding taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The net deferred income tax asset balance as of December&#160;31, 2025 and 2024 related to the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;78,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;155,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(150,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $159.1 million and $27.9 million, respectively. The federal NOLs can be carried forward indefinitely. The state NOL carryforwards begin to expire in 2039.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had U.S. federal and state research and development tax credit carryforwards of $0.3 million and $0.1 million, respectively. The federal research and development tax credits expire in 2045. The state research and development tax credits expire in 2040.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the provisions of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), the NOL and tax credit carryforwards are subject to review and potential adjustments by the Internal Revenue Services and state tax authorities. Under Section 382 of the Code (&#x201c;Section 382&#x201d;), certain substantial changes in the Company&#x2019;s ownership, including the sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of NOL carryforwards or tax credits which could be used annually to offset future taxable income. Based on a previous Section 382 analysis that the Company performed, the Company determined that on April 15, 2016 and April 13, 2020, Section 382 ownership changes and limitations had occurred. Based on such analysis, the Company determined that $0.3 million and $0.3 million of its federal and state NOL carryforwards, respectively, were limited by Section 382 and therefore were previously written off. The Company had updated its analyses under Section 382 through November 21, 2025, and determined that, in addition to the previous Section 382 ownership changes and limitations on April 15, 2016 and April 13, 2020, a Section 382 ownership change occurred on November 21, 2025. As a result of the November 21, 2025 Section 382 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;ownership change and limitation, $14.0 million of federal research and development tax credit carryforwards, $169.4 million of state NOL carryforwards and $5.9 million of state research and development tax credit carryforwards have been written off. Though subject to a Section 382 limitation, federal NOL carryforwards have not been written off since they can be carried forward indefinitely. The remaining unused carryforwards remain available for future periods. The Company may also experience ownership changes in the future as a result of subsequent shifts in the Company&#x2019;s stock ownership, some of which may be outside the Company&#x2019;s control. As a result, its ability to use its pre-change NOLs or tax credits to offset U.S. federal taxable income or tax may be subject to limitations, which could potentially result in increased future tax liability. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOLs and research and development credits. Under the applicable accounting standards, management has considered the Company&#x2019;s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance was maintained as of December&#160;31, 2025 and 2024. A decrease in the Company&#x2019;s valuation allowance was recorded in 2025 in the amount of $52.0 million primarily due to the reduction of net deferred tax assets related to capitalized research and development expenses, research and development tax credits and net operating loss carryforwards. An increase in the Company&#x2019;s valuation allowance was recorded in 2024 in the amount of $50.6 million, primarily due to the generation of additional net deferred tax assets related to capitalized research and development expenses, net operating loss carryforwards and research and development tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research and development (&#x201c;R&amp;amp;D&#x201d;) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;amp;D expenditures that are paid or incurred in connection with their trade or business. Specifically, costs for U.S.-based R&amp;amp;D activities must be amortized over five years and costs for foreign R&amp;amp;D activities must be amortized over 15 years &#x2013; both using a midyear convention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, President Trump signed H.R. 1, the One Big Beautiful Bill Act into law. The legislation included several changes to the Internal Revenue Code. These changes are generally effective for tax years beginning after December 31, 2025 except for changes related to the expensing of U.S.-based R&amp;amp;D expenditures which was retroactively effective and available for tax years beginning after December 31, 2024 and the reinstatement of 100% bonus depreciation for qualified assets/property placed in service after January 19, 2025. The changes that were retroactively effective were reflected in the year ended December&#x202f;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which it operates or does business in.  ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when its judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#x2019;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal and state research credit carryforwards of $3.1 million, of which $2.0 million relate to positions taken in prior years and $1.1 million relate to current year positions. As of December&#160;31, 2025, the Company had certain gross unrecognized tax benefits related to income tax reserves primarily related to federal research credit carryforwards of $0.1 million, which relate to current year positions. The Company does not have any other material gross unrecognized tax benefits related to income tax reserves. The Company does not expect any of its unrecognized tax benefits related to income tax reserves, if recognized, to impact its effective tax rate due to full valuation allowance in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December&#160;31, 2025 and 2024, the Company had no interest or penalties related to unrecognized tax benefits. For the year ended December&#160;31, 2025, the Company paid $7.2 million of total income taxes, $4.9 million related to Australia and $2.3 million related to U.S. federal income taxes. For the year ended December&#160;31, 2024, the Company made zero payments for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to income tax examination by federal, state and foreign jurisdictions, where applicable. The Company recently closed an income tax examination with the state of Massachusetts for the tax years ended December 31, 2021 and 2022, with no material impact to the Company's financial statements. The Company&#x2019;s tax years are still open under statute for income tax examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) from December 31, 2022 to the present. There are currently no pending income tax examinations with the IRS. To the extent the Company has tax attribute &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;carryforwards, the tax years in which the tax attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state and foreign tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-630">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Loss before income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.857%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.447%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;74,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(189,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;91,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-631" unitRef="usd">74804000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-27" decimals="-3" id="f-632" unitRef="usd">-189315000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-633" unitRef="usd">17093000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-27" decimals="-3" id="f-634" unitRef="usd">2262000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">91897000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-636" unitRef="usd">-187053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-637">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The components of the provision for income taxes for the years ended December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current income tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-639" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-642" unitRef="usd">4883000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-643" unitRef="usd">300000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-644" unitRef="usd">4883000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-645" unitRef="usd">300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-648" unitRef="usd">4883000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-27" decimals="-3" id="f-649" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-650">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the Company&#x2019;s U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2025 in accordance with the guidance in the ASU No. 2023-09, which the Company has elected to prospectively adopt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;U.S Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State and local income tax, net of federal income tax effect&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Difference between local tax rare and U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of changes in taw laws or rates enacted in the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of cross-border tax laws&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(36.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the Company&#x2019;s U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the year ended December&#160;31, 2024 prior to adoption of ASU No. 2023-09:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.681%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income at U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Foreign withholding taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-651" unitRef="usd">19298000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-652" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-653" unitRef="usd">734000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-654" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-127" decimals="-3" id="f-655" unitRef="usd">1538000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-127" decimals="3" id="f-656" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-127" decimals="-3" id="f-657" unitRef="usd">-245000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-127" decimals="3" id="f-658" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-660" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount contextRef="c-1" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent contextRef="c-1" decimals="3" id="f-662" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-663" unitRef="usd">13664000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-664" unitRef="number">0.149</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-665" unitRef="usd">-33331000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-666" unitRef="number">-0.363</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount contextRef="c-1" decimals="-3" id="f-667" unitRef="usd">5048000</kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationAmount>
    <kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent contextRef="c-1" decimals="3" id="f-668" unitRef="number">0.055</kros:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-669" unitRef="usd">1263000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-670" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-671" unitRef="usd">6000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-672" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-673" unitRef="usd">-2784000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-674" unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-675" unitRef="usd">-308000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-676" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-677" unitRef="usd">4883000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-678" unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-27" decimals="3" id="f-679" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-27" decimals="3" id="f-680" unitRef="number">0.088</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-27" decimals="3" id="f-681" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-27" decimals="3" id="f-682" unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-27" decimals="3" id="f-683" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c-27" decimals="3" id="f-684" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <kros:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent contextRef="c-27" decimals="3" id="f-685" unitRef="number">-0.002</kros:EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-27" decimals="3" id="f-686" unitRef="number">-0.032</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-27" decimals="3" id="f-687" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-27" decimals="3" id="f-688" unitRef="number">-0.270</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-27" decimals="3" id="f-689" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-690">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The net deferred income tax asset balance as of December&#160;31, 2025 and 2024 related to the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;78,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;155,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(97,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(150,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-19" decimals="-3" id="f-691" unitRef="usd">35141000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-20" decimals="-3" id="f-692" unitRef="usd">45084000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-19" decimals="-3" id="f-693" unitRef="usd">409000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-20" decimals="-3" id="f-694" unitRef="usd">16184000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost contextRef="c-19" decimals="-3" id="f-695" unitRef="usd">53477000</kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost>
    <kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost contextRef="c-20" decimals="-3" id="f-696" unitRef="usd">78413000</kros:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-19" decimals="-3" id="f-697" unitRef="usd">7667000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-20" decimals="-3" id="f-698" unitRef="usd">7558000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <kros:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-19" decimals="-3" id="f-699" unitRef="usd">4620000</kros:DeferredTaxAssetsOperatingLeaseLiability>
    <kros:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-20" decimals="-3" id="f-700" unitRef="usd">5068000</kros:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-19" decimals="-3" id="f-701" unitRef="usd">1447000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-20" decimals="-3" id="f-702" unitRef="usd">2626000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-19" decimals="-3" id="f-703" unitRef="usd">79000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-20" decimals="-3" id="f-704" unitRef="usd">269000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-19" decimals="-3" id="f-705" unitRef="usd">102840000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-20" decimals="-3" id="f-706" unitRef="usd">155202000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-19" decimals="-3" id="f-707" unitRef="usd">97991000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-20" decimals="-3" id="f-708" unitRef="usd">150037000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-19" decimals="-3" id="f-709" unitRef="usd">4849000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-20" decimals="-3" id="f-710" unitRef="usd">5165000</us-gaap:DeferredTaxAssetsNet>
    <kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-19" decimals="-3" id="f-711" unitRef="usd">4608000</kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-20" decimals="-3" id="f-712" unitRef="usd">5165000</kros:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-19" decimals="-3" id="f-713" unitRef="usd">241000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-20" id="f-714" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-19" decimals="-3" id="f-715" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-20" decimals="-3" id="f-716" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-128" decimals="-5" id="f-717" unitRef="usd">159100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-129" decimals="-5" id="f-718" unitRef="usd">27900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-130" decimals="-5" id="f-719" unitRef="usd">300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-131" decimals="-5" id="f-720" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <kros:OperatingLossCarryforwardWriteOff contextRef="c-132" decimals="-5" id="f-721" unitRef="usd">300000</kros:OperatingLossCarryforwardWriteOff>
    <kros:OperatingLossCarryforwardWriteOff contextRef="c-133" decimals="-5" id="f-722" unitRef="usd">300000</kros:OperatingLossCarryforwardWriteOff>
    <kros:OperatingLossCarryforwardWriteOff contextRef="c-134" decimals="-5" id="f-723" unitRef="usd">14000000.0</kros:OperatingLossCarryforwardWriteOff>
    <kros:OperatingLossCarryforwardWriteOff contextRef="c-135" decimals="-5" id="f-724" unitRef="usd">169400000</kros:OperatingLossCarryforwardWriteOff>
    <kros:OperatingLossCarryforwardWriteOff contextRef="c-136" decimals="-5" id="f-725" unitRef="usd">5900000</kros:OperatingLossCarryforwardWriteOff>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-726" unitRef="usd">-52000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-27" decimals="-5" id="f-727" unitRef="usd">50600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-20" decimals="-5" id="f-728" unitRef="usd">3100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-729" unitRef="usd">2000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-27" decimals="-5" id="f-730" unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-731" unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-5" id="f-732" unitRef="usd">7200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-127" decimals="-5" id="f-733" unitRef="usd">4900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-137" decimals="-5" id="f-734" unitRef="usd">2300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-27" decimals="-5" id="f-735" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-736">LEASES&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 7, 2021, the Company entered into an indenture of lease (the &#x201c;1050 Waltham Lease&#x201d;) with Revolution Labs Owner LLC (the &#x201c;Landlord&#x201d;), pursuant to which the Company is leasing approximately 35,662 square feet of office, laboratory and vivarium space located at 1050 Waltham Street, Lexington, Massachusetts (the &#x201c;Premises&#x201d;) for its new principal executive office. Base rent was initially fixed at $0.2 million per month and will increase by approximately 3% per annum until the 1050 Waltham Lease expires on November&#160;30, 2031. The Company is obligated to reimburse the Landlord for certain variable costs, including its proportional share of taxes and operating expenses which are not included in the measurement of the 1050 Waltham Lease liability. In connection with its entry into the 1050 Waltham Lease, the Company has provided the Landlord a letter of credit in the amount of approximately $1.2 million, which is recognized as restricted cash within other assets on the consolidated balance sheets. The Company has the option to extend the term of the 1050 Waltham Lease for a period of an additional 5 years. As of December&#160;31, 2025, the Company has no reasonable certainty that this option to extend will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In July 2024, the Company entered into a sublease (the &#x201c;Sublease Agreement&#x201d;) with Accent Therapeutics, pursuant to which the Company has sublet approximately 20,000 square feet of office and laboratory space located at 1050 Waltham Street, Lexington, Massachusetts, expanding the Company's existing headquarters. Accordingly, the Sublease Agreement for the premises was determined to be classified as an operating lease. Upon commencement of the sublease, the Company recorded an ROU asset of $5.7 million and a lease liability of $5.7 million. The term of the sublease commenced on July 1, 2024 (the "Sublease Commencement Date"). The Sublease Agreement has a term of 5 years and 3 months, measured from the Sublease Commencement Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligation for the payment of base rent for the premises began on the Sublease Commencement Date. Base rent was initially fixed at $71.00 per rentable square foot and the Company is only required to pay base rent on 17,500 square feet for the first year of the sublease. The Sublease Agreement also provides for three months of free rent. Base rent will increase by approximately 3% per annum until the Sublease Agreement expires on September&#160;30, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In connection with its entry into the Sublease Agreement and as a security deposit, the Company provided Accent Therapeutics a letter of credit in the amount of approximately $0.2 million on the Sublease Commencement Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The components of the lease cost as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other information as of December&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate for the leases as of December&#160;31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Maturities of operating lease liabilities at December&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;MATURITY OF LEASE LIABILITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Included in the consolidated balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <kros:LesseeAreaOfSublease contextRef="c-138" decimals="0" id="f-737" unitRef="sqft">35662</kros:LesseeAreaOfSublease>
    <kros:LesseeOperatingLeaseMonthlyBaseRent contextRef="c-139" decimals="-5" id="f-738" unitRef="usd">200000</kros:LesseeOperatingLeaseMonthlyBaseRent>
    <kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage
      contextRef="c-139"
      decimals="INF"
      id="f-739"
      unitRef="number">0.03</kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-140" decimals="-5" id="f-740" unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-19" id="f-741">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <kros:LesseeAreaOfSublease contextRef="c-141" decimals="-3" id="f-742" unitRef="sqft">20000</kros:LesseeAreaOfSublease>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-140" decimals="-5" id="f-743" unitRef="usd">5700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-142" decimals="-5" id="f-744" unitRef="usd">5700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-143" id="f-745">P5Y3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <kros:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot contextRef="c-140" decimals="0" id="f-746" unitRef="sqft">71.00</kros:LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot>
    <kros:LesseeOperatingLeaseAreaOfRentalSpace contextRef="c-140" decimals="0" id="f-747" unitRef="sqft">17500</kros:LesseeOperatingLeaseAreaOfRentalSpace>
    <kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage
      contextRef="c-139"
      decimals="INF"
      id="f-748"
      unitRef="number">0.03</kros:LesseeOperatingLeaseAnnualIncreaseInMonthlyBasePaymentPercentage>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-144" decimals="-5" id="f-749" unitRef="usd">200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-750">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The components of the lease cost as of December&#160;31, 2025 and 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,554&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other information as of December&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate for the leases as of December&#160;31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-751" unitRef="usd">4231000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-27" decimals="-3" id="f-752" unitRef="usd">3521000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-753" unitRef="usd">281000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-27" decimals="-3" id="f-754" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-755" unitRef="usd">2047000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-27" decimals="-3" id="f-756" unitRef="usd">1554000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-757" unitRef="usd">6559000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-27" decimals="-3" id="f-758" unitRef="usd">5075000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-759" unitRef="usd">3800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-27" decimals="-3" id="f-760" unitRef="usd">3026000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-761" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-27" decimals="-3" id="f-762" unitRef="usd">5737000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-19" id="f-763">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-20" id="f-764">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-19" decimals="4" id="f-765" unitRef="number">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-20" decimals="4" id="f-766" unitRef="number">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-767">Maturities of operating lease liabilities at December&#160;31, 2025 are as follows (in thousands):&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;MATURITY OF LEASE LIABILITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Included in the consolidated balance sheet:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-19" decimals="-3" id="f-768" unitRef="usd">4002000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-19" decimals="-3" id="f-769" unitRef="usd">4125000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-19" decimals="-3" id="f-770" unitRef="usd">4251000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-19" decimals="-3" id="f-771" unitRef="usd">3983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-19" decimals="-3" id="f-772" unitRef="usd">2903000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <kros:LesseeOperatingLeaseLiabilityToBePaidYearSix contextRef="c-19" decimals="-3" id="f-773" unitRef="usd">2734000</kros:LesseeOperatingLeaseLiabilityToBePaidYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-19" decimals="-3" id="f-774" unitRef="usd">21998000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-19" decimals="-3" id="f-775" unitRef="usd">5115000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-19" decimals="-3" id="f-776" unitRef="usd">16883000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-19" decimals="-3" id="f-777" unitRef="usd">2408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-19" decimals="-3" id="f-778" unitRef="usd">14475000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-19" decimals="-3" id="f-779" unitRef="usd">16883000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-781">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements in the normal course of business with contract manufacturing organizations for process development, raw material purchases and manufacturing services. These contracts typically do not contain minimum purchase commitments and are generally cancellable by the Company upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including noncancellable obligations of the Company&#x2019;s service providers, up to the date of cancellation and, in the case of certain arrangements with contract manufacturing organizations, may include noncancellable fees. Under such agreements, the exact amounts owed by the Company in the event of termination will be based on the timing of the termination and the exact terms of the agreement.  As of December&#160;31, 2025, the Company has committed up to approximately $1.6 million under these agreements which are expected to be paid through 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution of Proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to distribute 25% of any net cash proceeds it receives on or before December&#160;31, 2028 from the Takeda Agreement (as defined below) to its stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation contextRef="c-19" decimals="-5" id="f-782" unitRef="usd">1600000</us-gaap:PurchaseObligation>
    <kros:LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage contextRef="c-145" decimals="2" id="f-783" unitRef="number">0.25</kros:LicensesAgreementPlannedStockholderDistributionFromProceedsPercentage>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-784">REVENUE FROM CONTRACTS WITH CUSTOMERS&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Hansoh License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a license agreement with Hansoh (the &#x201c;Hansoh Agreement&#x201d;). Under the Hansoh Agreement, the Company granted to Hansoh the exclusive right to develop, manufacture and commercialize elritercept and licensed products containing elritercept within the territories of mainland China, Hong Kong and Macau (the &#x201c;Hansoh Territory&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from the Company, and the parties will also negotiate in good faith to enter into an agreement for commercial supply prior to any anticipated commercialization in the Hansoh Territory. In addition, Hansoh will use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize licensed products in any region in the Hansoh Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pursuant to the Hansoh Agreement, the Company received a net one-time $18.0 million upfront license payment in January 2022. In addition to the upfront payment and development milestones achieved to date, the Company will also be eligible to receive up to an aggregate of (i) $23.5 million upon the achievement of specified development milestones and (ii) $144.0 million upon the achievement of specified net sales thresholds for all licensed products in the Hansoh Territory. If a licensed product is approved for marketing in the Hansoh Territory, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales in each region within the Hansoh Territory, with such percentage ranging from the low double digit to high teens, subject to specified potential royalty reductions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Hansoh&#x2019;s obligation to pay royalties for a given licensed product in a given region in the Hansoh Territory will begin on the date of the first commercial sale for such licensed product in such region and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents or joint patents, and (iii) expiration of regulatory exclusivity in such region. During the royalty term, neither party will directly or indirectly commercialize a competing product in the Hansoh Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Hansoh Agreement will continue in force on a region-by-region basis until the expiration of the royalty term. Hansoh may terminate the Agreement in its entirety for convenience, with notice. The Company may terminate the Hansoh Agreement in its entirety for a patent challenge brought by Hansoh or its affiliates or their sublicensees. Either party may terminate the Hansoh Agreement in its entirety (i) if the other party materially breaches the Hansoh Agreement and fails to cure such breach or (ii) upon the bankruptcy of the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Hansoh Agreement and concluded that it was subject to ASC 606, as the Company viewed the Hansoh Agreement as a contract with a customer. As such, the Company assessed the terms of the Hansoh Agreement and identified a single performance obligation for the Company to provide Hansoh an exclusive license to develop, manufacture and commercialize elritercept and licensed products containing elritercept in the Hansoh Territory, including the underlying know-how related to such licenses. All other promised goods/services were deemed immaterial in the context of the Hansoh Agreement. Under the Hansoh Agreement, Hansoh was obligated to pay a one-time, net $18.0 million payment to the Company, which was paid in the first quarter of 2022.  The Company recognized a gross upfront fee of $20.0 million as revenue and $2.0 million in withholding tax on its consolidated statement of operations for the year ended December 31, 2021, and a receivable, net of withholding tax on its consolidated balance sheet as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company will recognize development milestone payments as revenue at the point in time when it is determined that it is probable such milestones will be achieved as all performance obligations will have been satisfied at the point which a milestone might occur (i.e., Hansoh will have assumed all responsibility for the activities under the Hansoh Agreement). The Company will recognize royalty payments and commercial milestone payments as the associated sales of licensed products are recorded by Hansoh, as they predominantly relate to the license granted with the Hansoh Agreement. The Company recognized $3.0 million as revenue and $0.3 million in withholding tax upon the achievement of a development milestone related to the Hansoh Agreement on its consolidated statement of operations for the year ended December 31, 2024, and a receivable, net of withholding tax, on its consolidated balance sheet as of December 31, 2024. Payment was received during the year ended December&#160;31, 2025.  No milestones were achieved during the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In connection with the Hansoh Agreement, the Company entered into a manufacturing technology transfer agreement (the &#x201c;Tech Transfer Agreement&#x201d;) with Hansoh, effective in June 2023. The Tech Transfer Agreement governs the transfer to Hansoh, by the Company of all documents and information required to complete the manufacturing technology transfer. Under the Tech Transfer Agreement, Hansoh is obligated to make certain payments to the Company, at the rates set forth in the Tech Transfer Agreement, as manufacturing technology transfer services are provided over the term of the Tech Transfer Agreement. The Company recognized $0.1 million and $0.1 million of service and other revenue for the years ended December&#160;31, 2025 and 2024,  respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In connection with the Hansoh Agreement, the Company entered into a clinical product supply agreement (the &#x201c;Supply Agreement&#x201d;) with Hansoh, effective February 2024. The Company evaluated the Supply Agreement and concluded that it was subject to ASC 606, as the Company viewed the Supply Agreement as a contract with a customer. As such, the Company assessed the terms of the Supply Agreement and identified a single performance obligation for the Company to supply Hansoh with clinical product supply. The Company recognizes revenue at a point in time when control transfers, which is deemed to be at the shipping point when the clinical product supply is ready for shipment. The Company recognized $0.1 million and $0.4 million of other revenue for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Takeda License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On December 3, 2024, the Company entered into a license agreement with Takeda, which became effective on January 16, 2025. Under the terms of the license agreement with Takeda (the "Takeda Agreement"), the Company granted to Takeda the exclusive right to develop, manufacture and commercialize elritercept and certain derivative compounds globally, excluding the territories of mainland China, Hong Kong and Macau (collectively, the "Takeda Territory"). Concurrent with the Takeda Agreement, the Company entered into a separate Transition Services Agreement with Takeda (&#x201c;TSA&#x201d;), pursuant to which the Company will provide certain transitional services to Takeda, including, but not limited to, clinical trial and manufacturing services, during the term of the TSA (the "Transition Services"). In January 2026, the initial fifteen month term of the TSA was extended for six months through October 2026. The Company will receive reimbursement of certain costs incurred by the Company in connection with providing the Transition Services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Takeda Agreement, the Company received a $200.0 million upfront payment in February 2025. In July 2025, a one-time $10.0 million development milestone was achieved upon dosing of the first patient in the Phase 3 RENEW clinical trial of elritercept. In addition to the upfront and development milestone payments, the Company is entitled to receive up to an aggregate of (i) $80.0 million upon the achievement of specified development milestones; (ii) $280.0 million upon the achievement of specified commercial milestones; and (iii) $740.0 million upon the achievement of specified sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;milestones. If a licensed product is approved for marketing in the Takeda Territory, the Company will be entitled to receive royalty payments based on tiered increments of annual net sales in the Takeda Territory, with such percentage ranging from the low double-digits to high teens, subject to specified potential royalty reductions.  The Company recognized $10.0 million as revenue upon the achievement of this development milestone related to the Takeda Agreement on its consolidated statement of operations for the year ended December&#160;31, 2025. Payment was received during the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Takeda&#x2019;s obligation to pay royalties for a given licensed product in a given country in the Takeda Territory will begin on the date of the first commercial sale for such licensed product in such country and continue until the latest of (i) 10 years from the date of the first commercial sale for such licensed product in such region, (ii) the expiration of the last valid claim of certain licensed patents, and (iii) expiration of regulatory exclusivity in such region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Takeda Agreement will continue in force until the expiration of the royalty term. Takeda may terminate the Takeda Agreement (i) in its entirety or on a country-by-country basis for convenience, with notice or (ii) if Takeda reasonably determines that the development, manufacture, and commercialization of the licensed compound or licensed product pose a safety or public health risk. The Company may terminate the Takeda Agreement in its entirety in the event that Takeda or its affiliates bring a patent challenge. Either party may terminate the Takeda Agreement in its entirety (i) if the other party materially breaches the Takeda Agreement and fails to cure such breach; or (ii) upon the bankruptcy of the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded it is a contract with a customer as defined in ASC 606. As the Company entered into the Takeda Agreement and the TSA concurrently, they were evaluated as a single contract under ASC 606. The Company identified two performance obligations in the Takeda Agreement and TSA including the license to its intellectual property (&#x201c;License and Know-How&#x201d;) and the Transition Services. The Company determined that the License and Know-How were distinct from the Transition Services as Takeda is able to derive benefit from the License and Know-How upon delivery and the Transition Services do not modify the License and Know-How.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The transaction price at contract inception included fixed consideration consisting of the upfront fee of $200.0 million. The transaction price at inception also included estimated variable consideration of $51.4 million relating to the Transition Services revenue that was not constrained. The transaction price has been allocated to the License and Know-How and the Transition Services on a relative standalone selling price basis. The Company allocated $195.4 million of the transaction price to the License and Know-How, which was recognized at a point in time, when control of the License and Know-How was transferred to Takeda on the effective date of the Takeda Agreement. The remaining $56.1 million of the transaction price was allocated to the Transition Services, which will be recognized over time as services are provided using the input method, based on costs incurred to provide the Transition Services, as the level of costs incurred over-time best reflect the transfer of services. As of December&#160;31, 2025, the Company recognized $38.5 million of service revenue for the Transition Services and such services are substantially complete. Any remaining services to be performed pursuant to the TSA will be recognized as performed and based on rates agreed to in the TSA. The $10.0 million development milestone was recognized as license revenue upon achievement in July 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The remaining $80.0 million of specified development milestones, $280.0 million of specified commercial milestones and $740.0 million of specified sales milestones were considered constrained at contract inception and excluded from the transaction price since the Company could not conclude it is probable that a significant revenue reversal in the amount recognized will not occur. The sales-based milestone payments and royalties will be recognized upon occurrence based on the sales and usage-based royalty exception. The Company will reevaluate the transaction price at the end of each reporting period and will adjust the estimate of the transaction price as uncertain events are resolved or other changes in circumstances occur. The Company determined that the Takeda Agreement and TSA did not contain a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable were $3.6 million as of December&#160;31, 2025 and zero as of December&#160;31, 2024. Accounts receivable are amounts due from Takeda for the Transition Services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Revenue recognized from Takeda for the year ended December&#160;31, 2025 and  2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;205,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Takeda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;243,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-5" id="f-785" unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <kros:RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration contextRef="c-147" decimals="-5" id="f-786" unitRef="usd">23500000</kros:RevenueRemainingPerformanceObligationDevelopmentMilestonesVariableConsideration>
    <kros:RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration contextRef="c-147" decimals="-5" id="f-787" unitRef="usd">144000000.0</kros:RevenueRemainingPerformanceObligationSalesMilestonesVariableConsideration>
    <kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod contextRef="c-148" id="f-788">P10Y</kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-5" id="f-789" unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-149" decimals="-5" id="f-790" unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <kros:RevenueFromContractWithCustomerWithholdingTaxes contextRef="c-149" decimals="-5" id="f-791" unitRef="usd">2000000.0</kros:RevenueFromContractWithCustomerWithholdingTaxes>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-150" decimals="-5" id="f-792" unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <kros:RevenueFromContractWithCustomerWithholdingTaxes contextRef="c-150" decimals="-5" id="f-793" unitRef="usd">300000</kros:RevenueFromContractWithCustomerWithholdingTaxes>
    <kros:ServiceAndOtherRevenue contextRef="c-151" decimals="-5" id="f-794" unitRef="usd">100000</kros:ServiceAndOtherRevenue>
    <kros:ServiceAndOtherRevenue contextRef="c-152" decimals="-5" id="f-795" unitRef="usd">100000</kros:ServiceAndOtherRevenue>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-153" decimals="-5" id="f-796" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-154" decimals="-5" id="f-797" unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InvestmentCompanyFeeWaiverTerms contextRef="c-155" id="f-798">fifteen</us-gaap:InvestmentCompanyFeeWaiverTerms>
    <us-gaap:InvestmentCompanyFeeWaiverTerms contextRef="c-156" id="f-799">six</us-gaap:InvestmentCompanyFeeWaiverTerms>
    <kros:LicenseAgreementUpfrontFee contextRef="c-157" decimals="-5" id="f-800" unitRef="usd">200000000.0</kros:LicenseAgreementUpfrontFee>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-158" decimals="-5" id="f-801" unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <kros:PotentialMilestonePaymentsDevelopmentBasedMilestones contextRef="c-159" decimals="-5" id="f-802" unitRef="usd">80000000.0</kros:PotentialMilestonePaymentsDevelopmentBasedMilestones>
    <kros:PotentialMilestonePaymentsCommercialBasedMilestones contextRef="c-159" decimals="-5" id="f-803" unitRef="usd">280000000.0</kros:PotentialMilestonePaymentsCommercialBasedMilestones>
    <kros:PotentialMilestonePaymentsSalesBasedMilestones contextRef="c-160" decimals="-5" id="f-804" unitRef="usd">740000000.0</kros:PotentialMilestonePaymentsSalesBasedMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-5" id="f-805" unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod contextRef="c-161" id="f-806">P10Y</kros:ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod>
    <kros:NumberOfPerformanceObligations
      contextRef="c-162"
      decimals="INF"
      id="f-807"
      unitRef="performanceobligation">2</kros:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-163" decimals="-5" id="f-808" unitRef="usd">200000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ReimbursementFromLimitedPartnershipInvestment contextRef="c-163" decimals="-5" id="f-809" unitRef="usd">51400000</us-gaap:ReimbursementFromLimitedPartnershipInvestment>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-164" decimals="-5" id="f-810" unitRef="usd">195400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-165" decimals="-5" id="f-811" unitRef="usd">56100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-5" id="f-812" unitRef="usd">38500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-158" decimals="-5" id="f-813" unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <kros:PotentialMilestonePaymentsDevelopmentBasedMilestones contextRef="c-159" decimals="-5" id="f-814" unitRef="usd">80000000.0</kros:PotentialMilestonePaymentsDevelopmentBasedMilestones>
    <kros:PotentialMilestonePaymentsCommercialBasedMilestones contextRef="c-159" decimals="-5" id="f-815" unitRef="usd">280000000.0</kros:PotentialMilestonePaymentsCommercialBasedMilestones>
    <kros:PotentialMilestonePaymentsSalesBasedMilestones contextRef="c-160" decimals="-5" id="f-816" unitRef="usd">740000000.0</kros:PotentialMilestonePaymentsSalesBasedMilestones>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-159" decimals="-5" id="f-817" unitRef="usd">3600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-167" decimals="-5" id="f-818" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Revenue recognized from Takeda for the year ended December&#160;31, 2025 and  2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;205,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenue from Takeda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;243,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-168" decimals="-3" id="f-820" unitRef="usd">205355000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-169" decimals="-3" id="f-821" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-166" decimals="-3" id="f-822" unitRef="usd">38509000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-170" decimals="-3" id="f-823" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-824" unitRef="usd">243864000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-27" decimals="-3" id="f-825" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-826">SEGMENT REPORTING&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;REVENUE:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;244,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;LESS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Rinvatercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Elritercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(38,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cibotercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Preclinical &amp;amp; development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Compensation costs (excluding stock based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(48,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other external costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(35,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(26,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(13,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company manages operations on a consolidated basis as a single reportable and single operating segment focused on developing novel therapeutics. Segment revenue above is 100 percent attributed to the Company&#x2019;s agreements with Takeda and Hansoh and is equal to consolidated total revenue. All revenues are derived in the United States where the agreements originated. The Company manages expenses on a program level. The significant expense categories outlined above align with the segment-level information that is regularly provided to the CODM to allocate resources, assess performance of the reportable segment, and make key operating decisions. On a quarterly basis, the CODM reviews financial information, including consolidated net income, clinical expenses by program, other company expenses and a long-range cash flow projection, to make resource decisions for the Company&#x2019;s programs to achieve the approved corporate goals. No segment asset information is provided above as the CODM is focused on how expenses impact ending cash by period and overall cash runway.  Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. All long-lived assets are held in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-827">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents segment revenue and significant segment expenses (in thousands) for the years ended December&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.854%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;REVENUE:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;244,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;LESS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Rinvatercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Elritercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(38,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cibotercept program expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Preclinical &amp;amp; development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Compensation costs (excluding stock based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(45,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(48,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other external costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(35,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(26,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;span style="font-size:6.17pt;position:relative;top:-3.32pt;vertical-align:baseline"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(12,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(13,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;87,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(187,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-3" id="f-828" unitRef="usd">244061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-3" id="f-829" unitRef="usd">3550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-173" decimals="-3" id="f-830" unitRef="usd">7081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-174" decimals="-3" id="f-831" unitRef="usd">16090000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-175" decimals="-3" id="f-832" unitRef="usd">38030000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-176" decimals="-3" id="f-833" unitRef="usd">44319000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-177" decimals="-3" id="f-834" unitRef="usd">12562000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-178" decimals="-3" id="f-835" unitRef="usd">29777000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-179" decimals="-3" id="f-836" unitRef="usd">6847000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-180" decimals="-3" id="f-837" unitRef="usd">12008000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-171" decimals="-3" id="f-838" unitRef="usd">45331000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c-172" decimals="-3" id="f-839" unitRef="usd">48084000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-181" decimals="-3" id="f-840" unitRef="usd">35095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-182" decimals="-3" id="f-841" unitRef="usd">26708000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-171" decimals="-3" id="f-842" unitRef="usd">12101000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-172" decimals="-3" id="f-843" unitRef="usd">13917000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-171" decimals="-3" id="f-844" unitRef="usd">87014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-172" decimals="-3" id="f-845" unitRef="usd">-187353000</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-847">CORPORATE RESTRUCTURING&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2025, the Board formally approved a plan to reduce the overall workforce by approximately 45% (the "2025 Restructuring"). In connection with the 2025 Restructuring, the Company incurred one-time employee termination benefits, including severance, retention and benefits costs. The total costs associated with the 2025 Restructuring was $3.1 million, including severance, retention and benefits costs, of which $2.5 million and $0.5 million were recognized as part of total &lt;span style="-sec-ix-hidden:f-852"&gt;research and development&lt;/span&gt; and &lt;span style="-sec-ix-hidden:f-853"&gt;general and administrative expenses&lt;/span&gt;, respectively, during the year ended December&#160;31, 2025. All costs have been incurred under the Company&#x2019;s single reportable segment. The 2025 Restructuring was complete as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits costs as of December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.195%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;RESTRUCTURING LIABILITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-183" decimals="2" id="f-848" unitRef="number">0.45</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-184" decimals="-5" id="f-849" unitRef="usd">3100000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-185" decimals="-5" id="f-850" unitRef="usd">2500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-186" decimals="-5" id="f-851" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-854">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accrued compensation and benefits costs as of December&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.002%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.195%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;RESTRUCTURING LIABILITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expenses incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-187" decimals="-3" id="f-855" unitRef="usd">0</us-gaap:RestructuringReserve>
    <kros:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-856">Expenses incurred</kros:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:RestructuringCharges contextRef="c-183" decimals="-3" id="f-857" unitRef="usd">3054000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-183" decimals="-3" id="f-858" unitRef="usd">2909000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-184" decimals="-3" id="f-859" unitRef="usd">145000</us-gaap:RestructuringReserve>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
